PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Oelgeschlager, M; Kowenz-Leutz, E; Schreek, S; Leutz, A; Luscher, B				Oelgeschlager, M; Kowenz-Leutz, E; Schreek, S; Leutz, A; Luscher, B			Tumorigenic N-terminal deletions of c-Myb modulate DNA binding, transactivation, and cooperativity with C/EBP	ONCOGENE			English	Article						oncogene; transcription; hematopoiesis; differentiaion; leukemia	AVIAN MYELOMONOCYTIC CELLS; V-MYB; PROMONOCYTIC LEUKEMIAS; RAPID INDUCTION; LEUCINE-ZIPPER; MYELOID GENES; MIM-1 GENE; ACTIVATION; BETA; MUTATIONS	Oncogenic activation of c-myb by retroviral insertion has been implicated fit tumor formation in chicken and mice. These genetic alterations result in deregulated expression of the: c-myb gene and frequently in, N-terminal truncation of the c-Myb: protein. We demonstrate that truncation of the c-Myb N-terminus affects DNA binding and reporter activation. However, all three mutants, Myb Delta N20, Myb Delta N47 and Myb Delta N71 cooperated with C/EBP beta in reporter assays. In contrast to Myb Delta N20 and Myb Delta N47, however, the Myb Delta N71 mutant failed to activate the chromatin, embedded endogenous mim-1 gene together with C/EBP beta. This suggests that an N-terminal region (amino acids 47-71) within repeat 1 (R1), of the murine c-Myb DNA binding domain affects activation of chromosomal target genes in collaboration with C/EBP beta.	Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Hannover Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Luscher, B (corresponding author), Rhein Westfal TH Aachen Klinikum, Inst Biochem, Abt Biochem & Mol Biol, Pauwels Str 30, D-52057 Aachen, Germany.	luescher@rwth-aachen.de	Leutz, Achim/K-9643-2013; Luscher, Bernhard/A-7330-2011	Leutz, Achim/0000-0001-8259-927X; Luscher, Bernhard/0000-0002-9622-8709				Brendeford EM, 1997, J BIOL CHEM, V272, P4436, DOI 10.1074/jbc.272.7.4436; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; EBNETH A, 1994, FEBS LETT, V337, P265, DOI 10.1016/0014-5793(94)80205-X; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRIEG J, 1995, ONCOGENE, V10, P2221; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKANO T, 1992, ONCOGENE, V7, P527; NAZAROV V, 1995, J VIROL, V69, P3885, DOI 10.1128/JVI.69.6.3885-3888.1995; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60	35	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7420	7424		10.1038/sj.onc.1204922	http://dx.doi.org/10.1038/sj.onc.1204922			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704872				2022-12-28	WOS:000171894200015
J	Piazza, F; Gurrieri, C; Pandolfi, PP				Piazza, F; Gurrieri, C; Pandolfi, PP			The theory of APL	ONCOGENE			English	Article						APL; transgenic mice; KO mice; animal models; tumor metamorphosers	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; ZINC FINGER GENE; TRANSGENIC MICE; CELL-DIFFERENTIATION; PREMATURE SENESCENCE; HISTONE DEACETYLASE; FUSION PROTEINS; ONCOGENIC RAS	Acute promyelocytic leukemia (APL) is associated with reciprocal and balanced chromosomal translocations always involving the Retinoic Acid Receptor alpha (RAR alpha) gene on chromosome 17 and variable partner genes (X genes) on distinct chromosomes. RARa fuses to the PML gene in the vast majority of APL cases, and in a few cases to the PLZF, NPM, NuMA and STAT5b genes. As a consequence, X-RAR alpha and RAR alpha -X fusion genes are generated encoding aberrant fusion proteins that can interfere with X and/or RAR alpha function. Here we will review the relevant conclusions and the open questions that stem from a decade of in giro analysis of APL pathogenesis in the mouse in transgenic and knock-out models.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr,Mol Biol Program, Sloan Kettering Div,Dept Pathol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr,Mol Biol Program, Sloan Kettering Div,Dept Pathol, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Piazza, Francesco/K-6695-2016; Piazza, Francesco/AAD-1600-2019	Piazza, Francesco/0000-0002-2831-623X; Piazza, Francesco/0000-0002-2831-623X; gurrieri, carmela/0000-0001-8233-6007				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kogan SC, 2000, BLOOD, V95, P1541, DOI 10.1182/blood.V95.5.1541.005k28_1541_1550; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	47	88	91	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7216	7222		10.1038/sj.onc.1204855	http://dx.doi.org/10.1038/sj.onc.1204855			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704849				2022-12-28	WOS:000171891900009
J	Robinson, GW; Wagner, KU; Hennighausen, L				Robinson, GW; Wagner, KU; Hennighausen, L			Functional mammary gland development and oncogene-induced tumor formation are not affected by the absence of the retinoblastoma gene	ONCOGENE			English	Article						mammary gland; tumor suppressor gene; oncogenes; pocket proteins; breast cancer	G(1) CONTROL; EXPRESSION; MICE; DIFFERENTIATION; EPITHELIUM; PROTEIN; IMMORTALIZATION; TGF-BETA-1; MUTATION; PROSTATE	results in impaired mammary gland development and neoplasia. We investigated the consequences of the absence of pRb in mammary epithelial cells during normal development and in mice that express an oncogene in the mammary epithelium. Since pRb-deficiency results in embryonic lethality, we transplanted pRb-null mammary anlagen into wild hosts. pRb-deficient mammary epithelia were capable of functional differentiation in term animals and they regenerated a differentiated gland even after multiple pregnancies. In serial transplantations no significant differences were found in outgrowth of pRb-deficient and wild type epithelia indicating that the absence of pRb does not lead to transformation. Likewise the effect of a TGF beta1 transgene was not altered in the absence of pRb. The susceptibility of mammary epithelium to form tumors was assessed in three different models. No differences in tumor incidence were found between wild type and Rb +/- WAP-int3, MMTV-PyMT transgenic and Brcal(-/-) epithelia. These results demonstrate that the absence of pRb does not affect normal mammary gland development and tumorigenesis in three different mouse models investigated and suggest that loss of more than one member of the pRb pathway is required to induce mammary tumors.	NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Robinson, GW (corresponding author), NIDDK, LGP, NIH, 8 Ctr Dr,Bldg 8,Rm 101, Bethesda, MD 20892 USA.		Wagner, Kay-Uwe/B-6044-2009; Robinson, Gertraud/I-2136-2012	Wagner, Kay-Uwe/0000-0002-5081-0226; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DEOME KB, 1959, CANCER RES, V19, P515; Dublin EA, 1998, INT J CANCER, V79, P71, DOI 10.1002/(SICI)1097-0215(19980220)79:1<71::AID-IJC14>3.0.CO;2-K; Gallahan D, 1996, CANCER RES, V56, P1775; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HU NP, 1994, ONCOGENE, V9, P1021; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Marsh KL, 1998, BRIT J CANCER, V77, P1460, DOI 10.1038/bjc.1998.240; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; ROBINSON GW, 2000, METHODS MAMMARY GLAN, P307; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SERRA R, 1995, DEVELOPMENT, V121, P3057; TZENG YJ, 1993, ONCOGENE, V8, P1965; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang YH, 2000, CANCER RES, V60, P6008; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	30	29	29	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7115	7119		10.1038/sj.onc.1204888	http://dx.doi.org/10.1038/sj.onc.1204888			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704837				2022-12-28	WOS:000171739300016
J	Lee, SH; Zhang, W; Choi, JJ; Cho, Y; Lee, SH; Kim, JW; Hu, LM; Xu, J; Liu, JS; Lee, JH				Lee, SH; Zhang, W; Choi, JJ; Cho, Y; Lee, SH; Kim, JW; Hu, LM; Xu, J; Liu, JS; Lee, JH			Overexpression of the thymosin beta-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis	ONCOGENE			English	Article						thymosin beta-10; ovarian cancer; cDNA array	MESSENGER-RNA; BREAST-CANCER; EXPRESSION; PROSTATE; PROTEINS; P53; CARCINOMA; TUMORS; RAS	To understand the molecular changes during ovarian cancer development, we profiled differentially expressed genes in five paired normal and cancerous ovarian tissues. Among the genes that showed differential expression, thymosin beta -10 expression was decreased in four of five cancer tissues. The decreased level of expression was confirmed by Northern. To investigate the gene's functional role in ovarian cancers, we constructed an adenovirus vector expressing thymosin beta -10 and used it to infect ovarian cancer cell lines PA-I and SKOV3. The infected cells showed disrupted F-actin stress fibers, markedly decreased cell growth, and a high rate of apoptosis. Thus, because loss of thymosin beta -10 expression may contribute to the development of a subset of ovarian cancers, restoration of thymosin beta -10 expression may be a new strategy for ovarian cancer treatment.	Sungkyunkwan Univ, Coll Med, Mol Therapy Res Ctr, Samsung Med Ctr,Kangnam Ku, Seoul 135701, South Korea; Sungkyunkwan Univ, Coll Med, Dept Obstet & Gynecol, Samsung Med Ctr,Kangnam Ku, Seoul 135701, South Korea; Univ Texas, MD Anderson Canc Ctr, Canc Genom Core Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania	Lee, JH (corresponding author), Sungkyunkwan Univ, Coll Med, Mol Therapy Res Ctr, Samsung Med Ctr,Kangnam Ku, 50 Ilwon Dong, Seoul 135701, South Korea.	jeholee@samsung.co.kr		Kim, Jung-whan/0000-0002-7829-1480				Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; Caduff RF, 1999, AM J SURG PATHOL, V23, P323, DOI 10.1097/00000478-199903000-00012; Carpintero P, 1996, FEBS LETT, V394, P103, DOI 10.1016/0014-5793(96)00888-5; DeRisi J, 1996, NAT GENET, V14, P457; Eadie JS, 2000, J CELL BIOCHEM, V77, P277, DOI 10.1002/(SICI)1097-4644(20000501)77:2<277::AID-JCB10>3.0.CO;2-Q; Fuller GN, 1999, CANCER RES, V59, P4228; Gold JS, 1997, MODERN PATHOL, V10, P1106; HALL AK, 1995, CELL MOL BIOL RES, V41, P167; HALL AK, 1991, MOL CELL ENDOCRINOL, V79, P37, DOI 10.1016/0303-7207(91)90093-8; HALL AK, 1994, RENAL FAILURE, V16, P243, DOI 10.3109/08860229409044864; HALL AK, 1994, MED HYPOTHESES, V43, P125, DOI 10.1016/0306-9877(94)90135-X; HALL AK, 1990, MOL BRAIN RES, V8, P129, DOI 10.1016/0169-328X(90)90057-K; HENRIKSEN R, 1994, GYNECOL ONCOL, V53, P301, DOI 10.1006/gyno.1994.1138; Hough CD, 2000, CANCER RES, V60, P6281; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Iguchi K, 1998, EUR J BIOCHEM, V253, P766, DOI 10.1046/j.1432-1327.1998.2530766.x; MARIAN AJW, 1993, INT J CANCER, V53, P278; Marx D, 1997, ANTICANCER RES, V17, P2233; Meden H, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P167; Morita K, 2000, PATHOL INT, V50, P219, DOI 10.1046/j.1440-1827.2000.01028.x; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; *NIH, 1994, NIH CONSENSUS STATE, V12, P1; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; VELCLESCU VE, 1995, SCIENCE, V170, P484; VergheseNikolakaki S, 1996, BRIT J CANCER, V74, P1441, DOI 10.1038/bjc.1996.562; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; YU FX, 1993, J BIOL CHEM, V268, P502; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	31	44	57	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6700	6706		10.1038/sj.onc.1204683	http://dx.doi.org/10.1038/sj.onc.1204683			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709704				2022-12-28	WOS:000171551600006
J	Inohara, N; Nunez, G				Inohara, N; Nunez, G			The NOD: a signaling module that regulates apoptosis and host defense against pathogens	ONCOGENE			English	Review						apoptosis; Apaf-1/Nod1/CED4 family; programmed cell death; ATPase/GTPases; NOD domain	CLASS-II TRANSACTIVATOR; PROGRAMMED CELL-DEATH; NF-KAPPA-B; SPINAL MUSCULAR-ATROPHY; INDUCED-PROXIMITY MODEL; BARE LYMPHOCYTE SYNDROME; BCL-2 FAMILY MEMBERS; CREB BINDING-PROTEIN; WD-40 REPEAT REGION; C-ELEGANS	Nods, a growing family of proteins containing a nucleotide-binding oligomerization domain (NOD), are involved in the regulation of programmed cell death (PCD) and immune responses. Members of the family include Apaf-1, Ced-4, Nod1, Nod2, and the cytosolic products of plant disease resistance genes. The NOD module is homologous to the ATP-binding cassette (ABC) found in a large number of proteins with diverse biological function. The centrally located NOD promotes activation of effector molecules through self-association and induced proximity of binding partners. The C-terminal domain of Nods serves as a sensor for intracellular ligands, whereas the N-terminal domain mediates binding to dowstream effector molecules and activation of diverse signaling pathways. Thus, Nods activate, through the NOD module, diverse signaling pathways involved in the elimination of cells via PCD and the host defense against pathogens.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [R01 CA64556-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bontron S, 1997, HUM GENET, V99, P541, DOI 10.1007/s004390050403; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; del Peso L, 2000, J BIOL CHEM, V275, P27205; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Diez E, 2000, J IMMUNOL, V164, P1470, DOI 10.4049/jimmunol.164.3.1470; Dixon MS, 2000, P NATL ACAD SCI USA, V97, P8807, DOI 10.1073/pnas.97.16.8807; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Feys BJ, 2000, TRENDS GENET, V16, P449, DOI 10.1016/S0168-9525(00)02107-7; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Fontes JD, 1999, MOL CELL BIOL, V19, P941; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Growney JD, 2000, GENOME RES, V10, P1158, DOI 10.1101/gr.10.8.1158; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holcik M, 2000, P NATL ACAD SCI USA, V97, P2286, DOI 10.1073/pnas.040469797; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hsieh-Li HM, 2000, NAT GENET, V24, P66, DOI 10.1038/71709; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jaroszewski L, 2000, PROTEINS, V39, P197, DOI 10.1002/(SICI)1097-0134(20000515)39:3<197::AID-PROT10>3.0.CO;2-V; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newmeyer DD, 2000, CELL DEATH DIFFER, V7, P402, DOI 10.1038/sj.cdd.4400665; Nickerson K, 2001, J BIOL CHEM, V276, P19089, DOI 10.1074/jbc.M101295200; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Parrish J, 2000, P NATL ACAD SCI USA, V97, P11916, DOI 10.1073/pnas.210391597; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scharf JM, 1996, GENOMICS, V38, P405, DOI 10.1006/geno.1996.0644; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Tong ZB, 2000, NAT GENET, V26, P267, DOI 10.1038/81547; Tong ZB, 1999, ENDOCRINOLOGY, V140, P3720, DOI 10.1210/en.140.8.3720; Tong ZB, 2000, MAMM GENOME, V11, P281, DOI 10.1007/s003350010053; TRENT C, 1983, GENETICS, V104, P619; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weinrauch Y, 1999, ANNU REV MICROBIOL, V53, P155, DOI 10.1146/annurev.micro.53.1.155; Wu DY, 1999, DEVELOPMENT, V126, P2021; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yaraghi Z, 1998, GENOMICS, V51, P107, DOI 10.1006/geno.1998.5378; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	133	182	194	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6473	6481		10.1038/sj.onc.1204787	http://dx.doi.org/10.1038/sj.onc.1204787			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607846				2022-12-28	WOS:000171640600019
J	Um, JH; Kang, CD; Lee, BG; Kim, DW; Chung, BS; Kim, SH				Um, JH; Kang, CD; Lee, BG; Kim, DW; Chung, BS; Kim, SH			Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance	ONCOGENE			English	Article						multidrug resistance; NF-kappa B; Ku autoantigen; PKA inhibitor; anticancer drug	DEPENDENT PROTEIN-KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; INDUCED APOPTOSIS; CYCLIC-AMP; CROSS-RESISTANCE; GENE-EXPRESSION; CANCER-THERAPY; DNA-DAMAGE; CELL-DEATH; INDUCIBLE CHEMORESISTANCE	In this study, we investigated possible engagement of NF-kappaB and Ku autoantigen (Ku) activation in development of multidrug resistance (MDR) and circumvention of MDR by modulation of NF-kappaB and Ku. The NF-kappaB activity and NF-kappaB p65 subunit level were constitutively higher in MDR cells than in drug-sensitive parental cells. Interestingly, a faster running NF-kappaB DNA binding complex was identified as Ku, a DNA damage sensor and a key double strand break repair protein, and was positively correlated with the NF-kappaB activity in MDR cells and Ku- or both subunits of NF-kappaB-transfected cells. Also both NF-kappaB and Ku activities were activated or inhibited by treatment with etoposide (VP-16) or MG-132 (a proteasome inhibitor), respectively. Furthermore, PKA inhibitor suppressed markedly the constitutive and drug-induced activities of NF-kappaB and Ku in MDR cells and subsequently potentiated the cytotoxic activity of anticancer drugs. Our results proposed that the NF-kappaB and Ku activation could be one of multi-factorial MDR mechanism, and PKA inhibitor, likely via inhibition of NF-kappaB and Ku activities, could enhance the effectiveness of anticancer drugs against MDR cells with high activities of NF-kappaB and Ku.	Pusan Natl Univ, Coll Med, Dept Biochem, Pusan 602739, South Korea; Pusan Natl Univ, Coll Med, Res Ctr Mol Med, Pusan 602739, South Korea; Chang Won Natl Univ, Coll Nat Sci, Dept Microbiol, Chang Won 641773, South Korea	Pusan National University; Pusan National University; Changwon National University	Kim, SH (corresponding author), Pusan Natl Univ, Coll Med, Dept Biochem, Pusan 602739, South Korea.							ALBERT DA, 1995, J CLIN INVEST, V95, P1490, DOI 10.1172/JCI117820; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bjork-Eriksson T, 1999, INT J RADIAT ONCOL, V45, P1005, DOI 10.1016/S0360-3016(99)00268-0; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Chao CCK, 1996, EUR J PHARMACOL, V305, P213, DOI 10.1016/0014-2999(96)00168-9; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; Christodoulopoulos G, 1998, CANCER RES, V58, P1789; Cusack JC, 2000, CANCER RES, V60, P2323; Cvijic ME, 1997, CELL GROWTH DIFFER, V8, P1243; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Jin SF, 1997, CANCER SURV, V29, P221; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kang CD, 2000, EXP CELL RES, V256, P300, DOI 10.1006/excr.2000.4807; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KIM SH, 1993, CANCER LETT, V74, P37, DOI 10.1016/0304-3835(93)90041-7; Kim SH, 1999, CANCER RES, V59, P4012; Kim SH, 2000, LEUKEMIA RES, V24, P917, DOI 10.1016/S0145-2126(00)00061-8; Lee HJ, 2001, J NEUROCHEM, V76, P602, DOI 10.1046/j.1471-4159.2001.00076.x; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; McKenna SL, 1997, BRIT J HAEMATOL, V96, P659, DOI 10.1046/j.1365-2141.1997.d01-2095.x; MICKISCH G, 1991, UROL RES, V19, P99, DOI 10.1007/BF00368184; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; NEUMANN M, 1992, ANTICANCER RES, V12, P2297; Nueda A, 1999, J BIOL CHEM, V274, P14988, DOI 10.1074/jbc.274.21.14988; Pae HO, 1999, IMMUNOPHARM IMMUNOT, V21, P233, DOI 10.3109/08923979909052760; Pajonk F, 2000, INT J RADIAT ONCOL, V47, P1025, DOI 10.1016/S0360-3016(00)00516-2; Palissot V, 1998, BIOCHEM BIOPH RES CO, V245, P918, DOI 10.1006/bbrc.1998.8550; Pernin D, 2000, B CANCER, V87, P635; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; SATTA T, 1992, CANCER, V69, P941, DOI 10.1002/1097-0142(19920215)69:4<941::AID-CNCR2820690418>3.0.CO;2-H; Shackelford DA, 1999, J NEUROSCI, V19, P4727; Shen HX, 1998, BBA-GEN SUBJECTS, V1381, P131, DOI 10.1016/S0304-4165(98)00020-8; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stavrovskaya AA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P95; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; Watanabe K, 2000, BIOCHEM PHARMACOL, V60, P823, DOI 10.1016/S0006-2952(00)00387-7; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Zhao HJ, 2000, CLIN CANCER RES, V6, P1073; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhou DC, 1996, INT J CANCER, V65, P365, DOI 10.1002/(SICI)1097-0215(19960126)65:3<365::AID-IJC15>3.0.CO;2-9; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	61	46	52	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6048	6056		10.1038/sj.onc.1204732	http://dx.doi.org/10.1038/sj.onc.1204732			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593412				2022-12-28	WOS:000171056300012
J	Hoover, RR; Gerlach, MJ; Koh, EY; Daley, GQ				Hoover, RR; Gerlach, MJ; Koh, EY; Daley, GQ			Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells	ONCOGENE			English	Article						BCR/ABL; signal transduction; STAT5; Ras; apoptosis; DNA damage	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; BCR-ABL; INHIBITS APOPTOSIS; ACTIVATION; RECEPTOR; P210; SURVIVAL; GROWTH	The Akt, Ras and STAT5 signaling pathways have each been linked to transformation of hematopoietic cells by BCR/ABL. However the relative contributions of these signaling pathways to BCR/ABL mediated cytokine-independent survival, proliferation and resistance to DNA damage-induced apoptosis have not been systematically defined. Here we report that activation of either Akt, Ras or STAT5 confers cytokine-independent survival to IL-3 dependent BaF3 cells. Ras or STAT5, but not Akt, also drives cytokine-independent proliferation and imparts sustained resistance to DNA damage-induced apoptosis. We also show that dominant negative (DN) inhibition of STAT5, but not Ras or Akt, significantly reduces resistance to DNA damage-induced apoptosis in BCR/ABL transformed BaF3 cells. Whereas inhibition of STAT5 or Ras alone does not compromise cytokine-independent proliferation of BaF3-BCR/ABL cells, simultaneous blockade of both STAT5 and Ras reduces proliferation and maximally sensitizes BaF3-BCR/ABL cells to DNA damage induced by gamma -irradiation, suggesting a cooperative role for these two signaling pathways in BCR/ABL transformation. The anti-apoptotic properties of BCR/ABL can be partly explained by an increase in the expression of Pim-1 and Bcl-XL, as ectopic expression of these STAT5 target genes imparts both cytokine-independent survival and partial gamma -radiation resistance. These data illustrate both cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed cells, with STAT5 playing a dominant role in resistance to DNA damage-induced apoptosis.	Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Daley, GQ (corresponding author), Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA.	daley@wi.mit.edu			NATIONAL CANCER INSTITUTE [R29CA076418, R01CA086991] Funding Source: NIH RePORTER; NCI NIH HHS [CA 86991, CA 76418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Cortez D, 1996, ONCOGENE, V13, P2589; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lilly M, 1997, CANCER RES, V57, P5348; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Peters DG, 2001, BLOOD, V97, P1404, DOI 10.1182/blood.V97.5.1404; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SKORSKI T, 1995, CANCER RES, V55, P2275; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WilsonRawls J, 1996, CANCER RES, V56, P3426	47	70	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5826	5835		10.1038/sj.onc.1204549	http://dx.doi.org/10.1038/sj.onc.1204549			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593388				2022-12-28	WOS:000171037200006
J	Aspland, SE; Bendall, HH; Murre, C				Aspland, SE; Bendall, HH; Murre, C			The role of E2A-PBX1 in leukemogenesis	ONCOGENE			English	Article						E2A-Pbx1; pre-B cell acute lymphoblastic leukemia; Hox cofactor	COOPERATIVE DNA-BINDING; LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN PROTOONCOGENE PBX1; CHIMERIC ONCOPROTEIN E2A-PBX1; ACUTE MYELOID-LEUKEMIA; B-CELL DEVELOPMENT; WNT GENE FAMILY; PRE-B; HOMEODOMAIN PROTEIN		Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Aspland, SE (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.							Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Aspland SE, 1997, DEVELOPMENT, V124, P741; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Bain G, 1999, J EXP MED, V189, P289, DOI 10.1084/jem.189.2.289; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; Bayly R, 2000, MOL CELL BIOL, V20, P5789, DOI 10.1128/MCB.20.16.5789-5796.2000; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Buske C, 2000, INT J HEMATOL, V71, P301; Calvo KR, 1999, ONCOGENE, V18, P8033, DOI 10.1038/sj.onc.1203377; CARROLL AJ, 1984, BLOOD, V63, P721; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; CHU C, 2000, J BIOL CHEM, V12, P12; CRIST WM, 1990, BLOOD, V76, P117; de Lau WBM, 1998, ONCOGENE, V17, P503, DOI 10.1038/sj.onc.1201967; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Feldman BJ, 1997, ONCOGENE, V15, P2735, DOI 10.1038/sj.onc.1201670; Feldman BJ, 2000, BLOOD, V96, P1906, DOI 10.1182/blood.V96.5.1906.h8001906_1906_1913; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; Fu XY, 1999, ONCOGENE, V18, P4920, DOI 10.1038/sj.onc.1202874; Fu XY, 1999, GROWTH FACTORS, V17, P125, DOI 10.3109/08977199909103521; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; Goldfarb AN, 1996, MOL IMMUNOL, V33, P947, DOI 10.1016/S0161-5890(96)00047-8; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; HUNGER SP, 1991, BLOOD, V77, P687; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kee BL, 2000, IMMUNOL REV, V175, P138, DOI 10.1111/j.1600-065X.2000.imr017514.x; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, ONCOGENE, V14, P2521, DOI 10.1038/sj.onc.1201097; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Kurant E, 1998, DEVELOPMENT, V125, P1037; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LeBrun DP, 1997, ONCOGENE, V15, P2059, DOI 10.1038/sj.onc.1201367; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lu Q, 1996, P NATL ACAD SCI USA, V93, P470, DOI 10.1073/pnas.93.1.470; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; Massari ME, 1999, MOL CELL, V4, P63, DOI 10.1016/S1097-2765(00)80188-4; Massari ME, 1996, MOL CELL BIOL, V16, P121; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Polakis P, 2000, GENE DEV, V14, P1837; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Romanow WJ, 2000, MOL CELL, V5, P343, DOI 10.1016/S1097-2765(00)80429-3; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Shimamoto T, 1998, INT J HEMATOL, V67, P339; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; THROSTEINSDOTTI. U, 1997, MOL CELL BIOL, V17, P495; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	99	90	93	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	2001	20	40					5708	5717		10.1038/sj.onc.1204592	http://dx.doi.org/10.1038/sj.onc.1204592			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607820				2022-12-28	WOS:000170887500011
J	Bergsagel, PL; Kuehl, WM				Bergsagel, PL; Kuehl, WM			Chromosome translocations in multiple myeloma	ONCOGENE			English	Article						primary translocation; secondary translocation; MGUS; myeloma	GROWTH-FACTOR RECEPTOR-3; IN-SITU HYBRIDIZATION; PLASMA-CELL LEUKEMIA; HEAVY-CHAIN GENE; SOMATIC HYPERMUTATION; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; TUMOR PROGRESSION; DNA-REPAIR; CYCLIN D1	Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60-65% in intramedullarly MM, 70-80% in extramedullary MM, and > 90% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p2l (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3 ' enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.	Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Oncol, Ithaca, NY 14853 USA; NCI, Dept Genet, Med Branch, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bergsagel, PL (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Oncol, Ithaca, NY 14853 USA.	plbergsa@med.cornell.edu	Bergsagel, Peter Leif/A-7842-2011	Bergsagel, Peter Leif/0000-0003-1523-7388				Ahmann GJ, 1998, CANCER GENET CYTOGEN, V101, P7, DOI 10.1016/S0165-4608(97)00058-7; Avet-Loiseau H, 1999, CANCER RES, V59, P4546; Avet-Loiseau H, 1999, BLOOD, V94, P2583, DOI 10.1182/blood.V94.8.2583.420a05_2583_2589; Avet-Loiseau H, 1998, CANCER RES, V58, P5640; Avet-Loiseau H, 1999, GENE CHROMOSOME CANC, V24, P9, DOI 10.1002/(SICI)1098-2264(199901)24:1<9::AID-GCC2>3.0.CO;2-K; Avet-Loiseau H, 2001, BLOOD, V97, P822, DOI 10.1182/blood.V97.3.822; BAKKUS MHC, 1992, BLOOD, V80, P2326; Bednarek AK, 2000, CANCER RES, V60, P2140; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Brezinschek HP, 1998, J IMMUNOL, V160, P4762; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Calasanz MJ, 1997, GENE CHROMOSOME CANC, V18, P84, DOI 10.1002/(SICI)1098-2264(199702)18:2<84::AID-GCC2>3.3.CO;2-9; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 2001, CANC PRINCIPLES PRAC, P2215; DEWALD GW, 1985, BLOOD, V66, P380; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Fonseca R, 1998, BRIT J HAEMATOL, V101, P296, DOI 10.1046/j.1365-2141.1998.00700.x; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; Hatzivassiliou G, 2001, IMMUNITY, V14, P277, DOI 10.1016/S1074-7613(01)00109-1; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Jager U, 2000, BLOOD, V95, P3520, DOI 10.1182/blood.V95.11.3520.011k12_3520_3529; Janssen JWG, 2000, BLOOD, V95, P2691; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; Kovalchuk AL, 2001, GENE CHROMOSOME CANC, V30, P283, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1094>3.0.CO;2-I; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Kyle RA, 1999, HEMATOL ONCOL CLIN N, V13, P1181, DOI 10.1016/S0889-8588(05)70120-9; LAI JL, 1995, BLOOD, V85, P2490, DOI 10.1182/blood.V85.9.2490.bloodjournal8592490; MACLENNAN ICM, 1998, MYELOMA BIOL MANAGEM, P29; Malgeri U, 2000, CANCER RES, V60, P4058; Malpas JS, 1998, MULTIPLE MYELOMA BIO; MAX EE, 1999, FUNDAMENTAL IMMUNOLO, P113; Nakazawa N, 2000, CANCER GENET CYTOGEN, V117, P89, DOI 10.1016/S0165-4608(99)00155-7; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; Nishida K, 1997, BLOOD, V90, P526, DOI 10.1182/blood.V90.2.526.526_526_534; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Pratt G, 2001, BRIT J HAEMATOL, V112, P388, DOI 10.1046/j.1365-2141.2001.02588.x; Qian L, 1999, BRIT J HAEMATOL, V106, P477, DOI 10.1046/j.1365-2141.1999.01549.x; Rao PH, 1998, BLOOD, V92, P1743; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Ries L, 2000, SEER CANC STAT REV 1; Ronchetti D, 1999, BLOOD, V93, P1330, DOI 10.1182/blood.V93.4.1330.404k04_1330_1337; Sahota SS, 1996, BLOOD, V87, P746, DOI 10.1182/blood.V87.2.746.bloodjournal872746; SAWYER JR, 1995, CANCER GENET CYTOGEN, V82, P41, DOI 10.1016/0165-4608(94)00284-I; Sawyer JR, 1998, BLOOD, V92, P4269, DOI 10.1182/blood.V92.11.4269.423k31_4269_4278; SAWYER JR, 2000, BRIT J HAEMATOL, V112, P1; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Vanasse GJ, 1999, BLOOD, V94, P3997, DOI 10.1182/blood.V94.12.3997.424k44_3997_4010; Welzel N, 2001, CANCER RES, V61, P1629; Willis TG, 1997, BLOOD, V90, P2456; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; Yoshida S, 1999, LEUKEMIA, V13, P1812, DOI 10.1038/sj.leu.2401563; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408	68	348	361	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5611	5622		10.1038/sj.onc.1204641	http://dx.doi.org/10.1038/sj.onc.1204641			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607813				2022-12-28	WOS:000170887500004
J	Rizos, H; Puig, S; Badenas, C; Malvehy, J; Darmanian, AP; Jimenez, L; Mila, M; Kefford, RF				Rizos, H; Puig, S; Badenas, C; Malvehy, J; Darmanian, AP; Jimenez, L; Mila, M; Kefford, RF			A melanoma-associated germline mutation in exon 1 beta inactivates p14ARF	ONCOGENE			English	Article						p14ARF; p16(INK4a); melanoma; germline mutation	CUTANEOUS MALIGNANT-MELANOMA; NUCLEOLAR LOCALIZATION; TUMOR SUPPRESSION; CDKN2A MUTATIONS; P53; MDM2; P19(ARF); GENE; LOCUS; P14(ARF)	The INK4a/ARF locus encodes the cyclin dependent kinase inhibitor, p16(INK4a) and the p53 activator, p14ARF. These two proteins have an independent first exon (exon 1 alpha and exon 1 beta, respectively) but share exons 2 and 3 and are translated in different reading frames. Germline mutations in this locus are associated with melanoma susceptibility in 20-40% of multiple case melanoma families. Although most of these mutations specifically inactivate p16(INK4a), more than 40% of the INK4a/ARF alterations located in exon 2, affect both p16(INK4a) and p14ARF. We now report a 16 base pair exon 1 beta germline insertion specifically altering p14ARF, but not p16(INK4a), in an individual with multiple primary melanomas. This mutant p14ARF, 60ins16, was restricted to the cytoplasm, did not stabilize p53 and was unable to arrest the growth of a p53 expressing melanoma cell line. This is the first example of an exon 1 beta mutation that inactivates p14ARF, and thus implicates a role for this tumour suppressor in melanoma predisposition.	Univ Sydney, Westmead Millennium Inst, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia; Univ Barcelona, IDIBAPS, Hosp Clin, E-08036 Barcelona, Spain	University of Sydney; Westmead Institute for Medical Research; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Rizos, H (corresponding author), Univ Sydney, Westmead Millennium Inst, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.		Rizos, Helen/AAE-5010-2020; Puig, Susana/AAB-2091-2020; Badenas, Celia/ABH-5480-2020	Rizos, Helen/0000-0002-2094-9198; Puig, Susana/0000-0003-1337-9745; Badenas, Celia/0000-0002-0621-0477; Mila, Montserrat/0000-0002-7906-0916; malvehy, josep/0000-0002-6998-914X; Kefford, Richard/0000-0001-9251-9229				Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Dracopoli NC, 1996, CANCER SURV, V26, P115; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Flores JF, 1997, ONCOGENE, V15, P2999, DOI 10.1038/sj.onc.1201470; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Newcomb EW, 2000, HUM PATHOL, V31, P115, DOI 10.1016/S0046-8177(00)80207-5; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Puig S, 2000, MELANOMA RES, V10, P231, DOI 10.1097/00008390-200010030-00004; QUELLE DE, 1995, CELL, V83, P993; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 1997, ONCOGENE, V15, P515, DOI 10.1038/sj.onc.1201217; Rizos H, 1999, MELANOMA RES, V9, P10, DOI 10.1097/00008390-199902000-00003; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruiz A, 1998, INT J CANCER, V76, P312, DOI 10.1002/(SICI)1097-0215(19980504)76:3<312::AID-IJC4>3.3.CO;2-B; Ruiz A, 1999, J MED GENET, V36, P490; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	37	142	146	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5543	5547		10.1038/sj.onc.1204728	http://dx.doi.org/10.1038/sj.onc.1204728			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571653				2022-12-28	WOS:000170781100016
J	Yang, HW; Chen, YZ; Takita, JK; Soeda, EC; Piao, HY; Hayashi, YS				Yang, HW; Chen, YZ; Takita, JK; Soeda, EC; Piao, HY; Hayashi, YS			Genomic structure and mutational analysis of the human KIF1B gene which is homozygously deleted in neuroblastoma at chromosome 1p36.2	ONCOGENE			English	Article						neuroblastoma; homozygous deletion; KIF1B gene; 1p36; kinesin superfamily	MOTOR PROTEIN; MOLECULAR-BIOLOGY; MONOMERIC MOTOR; KINESIN; TRANSPORT; REGION; HETEROZYGOSITY; IDENTIFICATION; CELLS; PROGRESSION	In order to clone candidate tumor suppressor genes whose loss contributes to the pathogenesis of neuroblastoma (NB), we performed polymerase chain reaction (PCR) screening using a high-density sequence tagged site-content map within a commonly deleted region (chromosome band 1p36) in 24 NB cell lines. We found a similar to 480 kb homozygously deleted region at chromosome band 1p36.2 in one of the 24 NB cell lines, NB-1, and cloned the human homologue (KIF1B-beta) of the mouse-Kif1B-beta gene in this region. The KIF1B-beta gene had at least 47 exons, all of which had a classic exon-intron boundary structure. Mouse Kif1B is a microtubule-based putative anterograde motor protein for the transport of mitochondria in neural cells. We performed mutational analysis of the KIF1B-beta gene in 23 cell lines using 46 sets of primers and also an allelic imbalance (Al) analysis of KIF1B-beta in 50 fresh NB samples. A missense mutation at codon 1554, GTG (Gly) to ATG (Met), silent mutations at codon 409 (ACG to ACA) and codon 1721 (ACC to ACT), and polymorphisms at codon 170, GAT (Asp) to GAA (Glu), and at codon 1087, TAT (Tyr), to TGT (Cys), were all identified, although their functional significances remain to be determined. The Al for KIF1B-beta was slightly higher (38%) than those for the other two markers (D1S244, D1S1350) (35 and 32%) within the commonly deleted region (1p36). Reverse transcriptase-PCR analysis of the KIF-IB-fl gene revealed obvious expression in all NB cell lines except NB-1, although decreased expression of the KIF1B-beta gene was found in a subset of early- and advanced-stage NBs. These results suggest that the KIF1B-beta gene may not be a candidate for tumor suppressor gene of NB.	Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138655, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan	University of Tokyo; RIKEN	Hayashi, YS (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							Beltinger CP, 1996, GENOMICS, V35, P94, DOI 10.1006/geno.1996.0327; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Chen YZ, 2001, GENOMICS, V74, P55, DOI 10.1006/geno.2001.6511; CHEN YZ, 2001, IN PRESS GENES CHROM, V31; Conforti L, 1999, MAMM GENOME, V10, P617, DOI 10.1007/s003359901056; DEED RW, 1994, GENE, V151, P309, DOI 10.1016/0378-1119(94)90676-9; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; Furlong RA, 1996, GENOMICS, V33, P421, DOI 10.1006/geno.1996.0217; Gong TWL, 1999, GENE, V239, P117, DOI 10.1016/S0378-1119(99)00370-4; Greene MH, 1999, CANCER-AM CANCER SOC, V86, P2464, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2464::AID-CNCR3>3.0.CO;2-F; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; Hirokawa N, 1996, CELL STRUCT FUNCT, V21, P357, DOI 10.1247/csf.21.357; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; IMASHUKU S, 1973, J CLIN ENDOCR METAB, V36, P931, DOI 10.1210/jcem-36-5-931; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KOMURO H, 1993, CANCER RES, V53, P5284; Kong XT, 1997, CANCER RES, V57, P3772; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; Leek JP, 1997, CYTOGENET CELL GENET, V79, P212, DOI 10.1159/000134725; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nakagawa T, 1998, MOL BIOL CELL, V9, p393A; NAKAGAWA T, 1999, GENBANK ACCESSION; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Saito M, 1997, NEUROLOGY, V49, P1630, DOI 10.1212/WNL.49.6.1630; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHAPIRO DN, 1993, GENOMICS, V17, P767, DOI 10.1006/geno.1993.1404; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1998, ONCOGENE, V17, P3137, DOI 10.1038/sj.onc.1202232; Takita J, 2000, EUR J CANCER, V36, P508, DOI 10.1016/S0959-8049(99)00342-1; Yang HW, 2000, INT J MOL MED, V5, P379; Yang HW, 2001, NEOPLASIA, V3, P165, DOI 10.1038/sj.neo.7900141; Yonekawa Y, 1998, J CELL BIOL, V141, P431, DOI 10.1083/jcb.141.2.431	47	30	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					5075	5083		10.1038/sj.onc.1204456	http://dx.doi.org/10.1038/sj.onc.1204456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526494				2022-12-28	WOS:000170439800019
J	Fan, SJ; Yuan, RQ; Ma, YX; Xiong, JB; Meng, QH; Erdos, M; Zhao, JN; Goldberg, ID; Pestell, RG; Rosen, EM				Fan, SJ; Yuan, RQ; Ma, YX; Xiong, JB; Meng, QH; Erdos, M; Zhao, JN; Goldberg, ID; Pestell, RG; Rosen, EM			Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding	ONCOGENE			English	Article						BRCA1; retinoblastoma; RB; p107; p130; p300	TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; CELL-CYCLE; HISTONE DEACETYLASE; ALPHA-SUBUNIT; APOPTOSIS; P53; TRANSCRIPTION; EXPRESSION; INTERACT	The tumor suppressor activity of the BRCA1 gene product is due, in part, to functional interactions with other tumor suppressors, including p53 and the retinoblastoma (RB) protein. RB binding sites on BRCA1 were identified in the C-terminal BRCT domain (Yarden and Brody, 1999) and in the N-terminus (aa 304-394) (Aprelikova et al., 1999). The N-terminal site contains a consensus RB binding motif, LXCXE (aa 358-362), but the role of this motif in RB binding and BRCA1 functional activity is unclear. In both in vitro and in vivo assays, we found that the BRCA1:RB interaction does not require the BRCA1 LXCXE motif, nor does it require an intact A/B binding pocket of RB. In addition, nuclear co-localization of the endogenous BRCA1 and RB proteins was observed. Over-expression of wild-type BRCA1 (wtBRCA1) did not cause cell cycle arrest but did cause down-regulation of expression of RB, p107, p130, and other proteins (e.g., p300), associated with increased sensitivity to DNA-damaging agents. In contrast, expression of a full-length BRCA1 with an LXCXE inactivating mutation (LXCXE-->RXRXH) failed to down-regulate RB, blocked the down-regulation of RB by wtBRCA1, induced chemoresistance, and abrogated the ability of BRCA1 to mediate tumor growth suppression of DU-145 prostate cancer cells. wtBRCA1-induced chemosensitivity was partially reversed by expression of either Rb or p300 and fully reversed by co-expression of Rb plus p300. Our findings suggest that: (I) disruption of the LXCXE motif within the N-terminal RB binding region alters the biologic function of BRCA1; and (2) over-expression of BRCA1 inhibits the expression of RB and RB family (p107 and p130) proteins.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA; NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA	Northwell Health; Yeshiva University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Fan, SJ (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Pk, NY 11040 USA.	fan@lij.edu; erosen@lij.edu	Meng, Q./GSI-6185-2022		NATIONAL CANCER INSTITUTE [R01CA082599, R01CA080000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA82599, R01-CA80000] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEY MC, 1988, CANCER RES, V48, P589; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; FAN SJ, 1994, CANCER RES, V54, P5824; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Freundlieb S, 1997, METHOD ENZYMOL, V283, P159; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Pestell RG, 1996, CELL GROWTH DIFFER, V7, P1337; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	51	36	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4827	4841		10.1038/sj.onc.1204666	http://dx.doi.org/10.1038/sj.onc.1204666			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521194				2022-12-28	WOS:000170271800007
J	Matthews, CP; Shera, K; Kiviat, N; McDougall, JK				Matthews, CP; Shera, K; Kiviat, N; McDougall, JK			Expression of truncated FHIT transcripts in cervical cancers and in normal human cells	ONCOGENE			English	Article						cervical carcinoma; FHIT; alternative transcripts	TUMOR-SUPPRESSOR GENE; SPLICE-SITE SELECTION; FREQUENT ALLELIC LOSS; MESSENGER-RNA; CHROMOSOME 3P; HUMAN HOMOLOG; UPF1 PROTEIN; CARCINOMA; TUMORIGENICITY; ABNORMALITIES	To analyse FHIT transcription patterns in cervical cancer, a series of primary cervical tumors and normal control samples were studied using RT - PCR. Full length and truncated FHIT transcripts were detectable in all samples tested. Interestingly, the expression of truncated FHIT transcripts by primary epithelial cells in vitro was associated with confluency. The breakpoints of most transcript deletions coincided with genuine splice site sequences, suggesting that they resulted from alternative splicing. These findings demonstrate that truncated FHIT transcripts are commonly detected in both normal and tumor tissues, and suggest that these altered transcripts are not causally related to tumorigenesis in cervical cancer.	Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Matthews, CP (corresponding author), Fred Hutchinson Canc Res Ctr, Canc Biol Program, 1100 Fairview Ave N,POB 19024, Seattle, WA 98109 USA.				NCI NIH HHS [CA42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Applequist SE, 1997, NUCLEIC ACIDS RES, V25, P814, DOI 10.1093/nar/25.4.814; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Chaudhuri AR, 1999, J BIOL CHEM, V274, P24378, DOI 10.1074/jbc.274.34.24378; Chu TY, 1998, INT J CANCER, V75, P199, DOI 10.1002/(SICI)1097-0215(19980119)75:2<199::AID-IJC6>3.0.CO;2-P; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; Druck T, 1997, CANCER RES, V57, P504; Druck T, 1998, ONCOL RES, V10, P341; Ferrer M, 1999, MOL CARCINOGEN, V25, P55, DOI 10.1002/(SICI)1098-2744(199905)25:1<55::AID-MC7>3.0.CO;2-3; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ji L, 1999, CANCER RES, V59, P3333; Julicher K, 1999, J NATL CANCER I, V91, P1563, DOI 10.1093/jnci/91.18.1563; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KOHNO T, 1993, ONCOGENE, V8, P1825; Larson AA, 1997, CANCER RES, V57, P4082; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; Mao L, 1996, CANCER RES, V56, P5128; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; MATTHEWS CP, 2000, THESIS U WASHINGTON; MITRA AB, 1994, CANCER RES, V54, P4481; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Panagopoulos I, 1997, GENE CHROMOSOME CANC, V19, P215, DOI 10.1002/(SICI)1098-2264(199708)19:4<215::AID-GCC2>3.0.CO;2-#; Rader JS, 1998, GENE CHROMOSOME CANC, V22, P57, DOI 10.1002/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; Sambrook J., 2002, MOL CLONING LAB MANU; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Segawa T, 1999, CANCER, V85, P2001, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2001::AID-CNCR18>3.0.CO;2-R; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P220, DOI 10.1002/(SICI)1098-2264(199708)19:4<220::AID-GCC3>3.0.CO;2-Z; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Wang NM, 1999, INT J MOL MED, V3, P491; WHITE RA, 1990, CYTOMETRY, V11, P314, DOI 10.1002/cyto.990110214; Wistuba II, 1997, CANCER RES, V57, P3154; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; YOKOTA J, 1989, CANCER RES, V49, P3598; Zimonjic DB, 1997, CANCER RES, V57, P1166	47	10	15	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4665	4675		10.1038/sj.onc.1204622	http://dx.doi.org/10.1038/sj.onc.1204622			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498789				2022-12-28	WOS:000170208600007
J	Yin, XY; Landay, MF; Han, WP; Levitan, ES; Watkins, SC; Levenson, RM; Farkas, DL; Prochownik, EV				Yin, XY; Landay, MF; Han, WP; Levitan, ES; Watkins, SC; Levenson, RM; Farkas, DL; Prochownik, EV			Dynamic in vivo interactions among Myc network members	ONCOGENE			English	Article						Max; Mad Mxi1; green fluorescent protein (GFP); SC-35; transcription	RNA-POLYMERASE-II; C-MYC; DNA-BINDING; TRANSCRIPTIONAL REPRESSORS; HISTONE DEACETYLASE; LEUCINE-ZIPPER; LARGE SUBUNIT; CELL-GROWTH; MAD FAMILY; N-COR	Members of the Myc oncoprotein network (c-Myc, Max, and Mad) play important roles in proliferation, differentiation, and apoptosis. We expressed chimeric green fluorescent protein (GF-P) fusions of c-Myc,. Max, and three Mad proteins in fibroblasts.. Individually, c-Myc and Mad proteins localized in subnuclear speckles, whereas Max assumed a homogeneous nuclear pattern. These distributions were co-dominant and dynamic, however, as each protein assumed the pattern of its heterodimeric partner when the latter was co-expressed at a higher level. Deletion mapping of two Mad members, Mad1 and Mxi1, demonstrated that the domains responsible for nuclear localization and speckling are separable. A non-speckling Mxi1 mutant was also less effective as a transcriptional repressor than wild-type Mxi1. c-Myc nuclear speckles were distinct from SC-35 domains involved in mRNA processing. However, in the presence of co-expressed Max, c-Myc, but not Mad, co-localized to a subset of SC-35 loci. These results show that Myc network proteins comprise dynamic subnuclear structures and behave co-dominantly when co-expressed with their normal heterodimerization partners. In addition, c-Myc-Max heterodimers, but not Max-Mad heterodimers, localize to foci actively engaged in pre-mRNA transcription/processing. These findings suggest novel means by which Myc network members promote transcriptional activation or repression.	Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Ctr Light Microscope Imaging & Biotechnol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, 3705 5th Ave, Pittsburgh, PA 15213 USA.	edward_prochownik@poplar.chp.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL CANCER INSTITUTE [R01CA078259] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78259] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; Cardoso MC, 1998, J CELL BIOCHEM, V70, P222, DOI 10.1002/(SICI)1097-4644(19980801)70:2<222::AID-JCB8>3.0.CO;2-Q; Chen YM, 1996, CANCER RES, V56, P3168; Clemson CM, 1996, J CELL BIOCHEM, V62, P181, DOI 10.1002/(SICI)1097-4644(199608)62:2<181::AID-JCB6>3.0.CO;2-O; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; LARSSON LG, 1994, ONCOGENE, V9, P1247; Leonhardt H, 1995, INT REV CYTOL, V162B, P303; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MOEN PT, 1995, HUM MOL GENET, V4, P1779, DOI 10.1093/hmg/4.suppl_1.1779; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RABBITS PH, 1985, NATURE, V314, P363; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHULMAN IG, 1977, LEUKEMIA S, V3, P376; Smith KP, 1999, J CELL BIOL, V144, P617, DOI 10.1083/jcb.144.4.617; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1987, ONCOGENE, V1, P5; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	67	29	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4650	4664		10.1038/sj.onc.1204606	http://dx.doi.org/10.1038/sj.onc.1204606			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498788				2022-12-28	WOS:000170208600006
J	Del Bello, B; Valentini, MA; Zunino, F; Comporti, M; Maellaro, E				Del Bello, B; Valentini, MA; Zunino, F; Comporti, M; Maellaro, E			Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells	ONCOGENE			English	Article						Bcl-2 cleavage; hydrogen peroxide; cisplatin; apoptosis; melanoma cells	MALIGNANT-MELANOMA; PROTEIN EXPRESSION; DEATH; INHIBITION; RELEASE; FAMILY; BAX	Although the anti-apoptotic effect of Bcl-2 is well established, the role of Bcl-2 in tumour response to therapy and drug resistance is still unclear. The posttranslational modifications of Bcl-2 are likely involved in the control of the apoptotic pathway. In the present study we have investigated the role of Bcl-2 in cellular response to oxidative stress (hydrogen peroxide) and cisplatin using a clone of human metastatic melanoma, which, in spite of Bcl-2 (over)expression, exhibited a moderate chemosensitivity. With both treatments melanoma cells died through an apoptotic process, associated with detachment of cells from the monolayer. In the floating apoptotic cells generated by either hydrogen peroxide or cisplatin, along with morphological and biochemical features of apoptosis, we detected a significant Bcl-2 cleavage, yielding the Bax-like fragment of 23 kDa. Preincubation of cells with the caspase-3/-7 inhibitor DEVD-CHO completely suppressed Bcl-2 cleavage, thus confirming that such a specific proteolysis requires activation of caspase-3/-7. The oxidant- and cisplatin-induced processing of Bcl-2 documented in the present study may represent a regulatory mechanism to circumvent the survival function of Bcl-2 upon apoptosis triggering and to enhance apoptotic response. Since the Bcl-2 cleavage should be regarded as a pro-apoptotic event, Bcl-2 expression is expected to increase susceptibility to apoptosis. Thus, such a pathway could be exploited to improve the efficacy of cytotoxic therapy of melanomas expressing Bcl-2.	Univ Siena, Dept Pathophysiol & Expt Med, I-53100 Siena, Italy; Ist Nazl Tumori, I-20133 Milan, Italy	University of Siena; Fondazione IRCCS Istituto Nazionale Tumori Milan	Maellaro, E (corresponding author), Univ Siena, Dept Pathophysiol & Expt Med, Via A Moro, I-53100 Siena, Italy.	maellaro@unisi.it						Beale PJ, 2000, BRIT J CANCER, V82, P436; Brockhaus F, 1998, EXP CELL RES, V238, P33, DOI 10.1006/excr.1997.3778; CERRONI L, 1995, AM J DERMATOPATH, V17, P7, DOI 10.1097/00000372-199502000-00002; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHU G, 1994, J BIOL CHEM, V269, P787; Del Bello B, 1999, FASEB J, V13, P69; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Maellaro E, 2000, J CELL SCI, V113, P2671; Marin MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Reed JC, 1997, APOPTOSIS AND CANCER, P64; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rigel DS, 1996, J AM ACAD DERMATOL, V35, P1012, DOI 10.1016/S0190-9622(96)90139-5; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Tang LR, 1998, CLIN CANCER RES, V4, P1865; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRON VA, 1995, AM J PATHOL, V146, P643; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Yamamoto AM, 1998, LEUKEMIA, V12, P1467, DOI 10.1038/sj.leu.2401132; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	32	47	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4591	4595		10.1038/sj.onc.1204618	http://dx.doi.org/10.1038/sj.onc.1204618			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494156				2022-12-28	WOS:000170074900018
J	Javelaud, D; Besancon, F				Javelaud, D; Besancon, F			NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B	ONCOGENE			English	Article						NF-kappa B; JNK; apoptosis; TNF alpha; Ewing sarcoma	TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE ACTIVATION; C-JUN; TERMINAL KINASE; RECEPTOR SUPERFAMILY; MAP KINASES; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; DEATH; INDUCTION	We recently reported that inhibition of NF-kappaB activation as a consequence of the overexpression of a degradation-resistant form of I kappa -B alpha [I kappaB alpha (A32/36)] sensitized Ewing sarcoma cells to TNF alpha -induced killing. The c-Jun N-terminal kinases (JNK) have been shown to participate in death signaling triggered by certain stimuli and are activated by TNF. To obtain insight into the mechanism of the anti-apoptotic effect of NF-kappaB, we compared the profiles of JNK activation by TNF alpha in control cells and in cells in which NF-kappaB activation was impaired. We show here that JNK activation was transient in control cells but remained elevated in I kappa -B alpha (A32/36)-expressing cells. NF-kappaB repressed specifically the JNK pathway, since the kinetics of activation of the other TNF alpha -activated-MAP kinase p38 were identical in both cells, Prolongation of JNK activation in I kappaB alpha (A32/36)-expressing cells was not inhibited by the broad spectrum caspase inhibitor Z-VAD-FMK and thus was not the consequence of caspase activation, Pretreatment of control cells with the phosphatase inhibitor vanadate greatly prolonged JNK activation by TNF alpha and resulted in induction of apoptosis by this cytokine. Moreover, overexpression of a dominant-negative mutant of JNK1 decreased TNF alpha -induced apoptosis in cells expressing the super repressor of NF-kappaB, indicating that the sustained activation of JNK1 participated in death signaling triggered by TNF alpha, Our results provide evidence that the repression of JNK activation by NF-kappaB participates in the anti-apoptotic effect of this transcription factor in TNF alpha -treated Ewing sarcoma cells.	Inst Curie, INSERM, U365, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Besancon, F (corresponding author), Inst Curie, INSERM, U365, 26 Rue Ulm, F-75248 Paris 05, France.		Javelaud, Delphine/B-1129-2019	Javelaud, Delphine/0000-0002-7674-7739				Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Patel R, 1998, J CELL SCI, V111, P2247; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AD, 1996, SCIENCE, V274, P787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yeh WC, 1999, IMMUNOL REV, V169, P283, DOI 10.1111/j.1600-065X.1999.tb01323.x; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	46	108	112	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4365	4372		10.1038/sj.onc.1204570	http://dx.doi.org/10.1038/sj.onc.1204570			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466617				2022-12-28	WOS:000169912600010
J	Sibley, K; Stern, P; Knowles, MA				Sibley, K; Stern, P; Knowles, MA			Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours	ONCOGENE			English	Article						FGFR3; mutation; tumour	HUMAN PROSTATIC-CARCINOMA; CELL-LINE; ACTIVATING MUTATIONS; CERVICAL-CARCINOMA; MULTIPLE-MYELOMA; FGFR3; TRANSLOCATION; GENE; TRANSFORMATION; CHROMOSOME	Mutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma, In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date. We have now investigated the frequency of FGFR3 mutation in a panel of 125 tumours and 13 cell lines from various other organs. We analysed the mutation hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation in exon 7 (S249C) in 1/28 (3.5%) cervical tumours, Mutations were not detected in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours, nor were they found in any of the cell lines included in this study. We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma. Several tumour types appear not to possess any mutations in FCFR3, suggesting that these mutations are important only in the development of certain types of tumour.	St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England; Paterson Inst Canc Res, CRC, Immunol Grp, Manchester M20 4BX, Lancs, England	Saint James's University Hospital; Paterson Institute for Cancer Research	Knowles, MA (corresponding author), St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England.			Knowles, Margaret/0000-0002-9363-8657				BLOOM ET, 1972, CANCER RES, V32, P960; Brady CS, 1999, J GEN VIROL, V80, P3233, DOI 10.1099/0022-1317-80-12-3233; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; JONES PA, 1975, INT J CANCER, V16, P616, DOI 10.1002/ijc.2910160411; KAIGHN ME, 1979, INVEST UROL, V17, P16; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Wu R, 2000, ONCOGENE, V19, P5543, DOI 10.1038/sj.onc.1203934; Wuchner C, 1997, HUM GENET, V100, P215, DOI 10.1007/s004390050493; Yee CJ, 2000, JNCI-J NATL CANCER I, V92, P1848, DOI 10.1093/jnci/92.22.1848	22	71	71	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4416	4418		10.1038/sj.onc.1204543	http://dx.doi.org/10.1038/sj.onc.1204543			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466624				2022-12-28	WOS:000169912600017
J	Shigemitsu, K; Sekido, Y; Usami, N; Mori, S; Sato, M; Horio, Y; Hasegawa, Y; Bader, SA; Gazdar, AF; Minna, JD; Hida, T; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K				Shigemitsu, K; Sekido, Y; Usami, N; Mori, S; Sato, M; Horio, Y; Hasegawa, Y; Bader, SA; Gazdar, AF; Minna, JD; Hida, T; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K			Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion	ONCOGENE			English	Article						beta-catenin; lung cancer; malignant mesothelioma; chromosome 3; homozygous deletion; breakpoint cloning	CELL-LINES; HEPATOCELLULAR CARCINOMAS; GROWTH SUPPRESSION; HUMAN SEMAPHORIN; E-CADHERIN; MUTATIONS; EXPRESSION; ACTIVATION; REGION; CHROMOSOME-3	The beta -catenin gene (CTNNB1) has been shown to be genetically mutated in various human malignancies. To determine whether the beta -catenin gene is responsible for oncogenesis in thoracic malignancies, we searched for the mutation in 166 lung cancers (90 primary tumors and 76 cell lines), one blastoma and 10 malignant mesotheliomas (two primary tumors and eight cell lines). Among the lung cancers, including 43 small cell lung cancers (SCLCs) and 123 non-small cell lung cancers (NSCLCs), we identified four alterations in exon 3, which is the target region of mutation for stabilizing beta -catenin. One primary adenocarcinoma had a somatic mutation from C to G, leading to an amino acid substitution from Ser to Cys at codon 37. Among the cell lines, SCLC NCI-H1092 had a mutation from A to G, leading to an Asp to Cry substitution at codon 6, NSCLC HCC15 had a mutation from C to T, leading to a Ser to Phe substitution at codon 45, and NSCLC NCI-H358 had a mutation from A to G, leading to a Thr to Ala substitution at codon 75. One blastoma also had a somatic mutation from C to C, leading to a Ser to Cys substitution at codon 37. Among the 10 malignant mesotheliomas, we identified a homozygous deletion in the NCI-H28 cell line. Cloning of the rearranged fragment from NCI-H28 indicated that all the exons except exon 1 of the beta -catenin gene are deleted and that the deletion junction is 13 kb downstream from exon 1. Furthermore, Northern blot analysis of 26 lung cancer and eight mesothelioma cell line RNAs detected ubiquitous expression of the beta -catenin messages except NCI-H28, although Western blot analysis showed that relatively less amounts of protein products were expressed in some of lung cancer cell lines, Our findings suggest that the beta -catenin gene is infrequently mutated in lung cancer and that the NCI-H28 homozygous deletion of the beta -catenin gene might indicate the possibility of a new tumor suppressor gene residing in this region at 3p21.3, where various types of human cancers show frequent allelic loss.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol 2, Nagoya, Aichi 4668550, Japan; Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Aichi Canc Ctr, Dept Internal Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University; Aichi Cancer Center	Sekido, Y (corresponding author), Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan.		Sekido, Yoshitaka/P-9756-2015; Hasegawa, Yoshinori/I-1277-2012; Sato, MITSUO/I-7280-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Sato, MITSUO/0000-0001-5458-9576; Takahashi, Masahide/0000-0002-2803-2683; Horio, Yoshitsugu/0000-0003-4661-6399; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bell DW, 1997, CANCER RES, V57, P4057; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; CHENG JQ, 1994, CANCER RES, V54, P5547; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; Fukuchi T, 1998, CANCER RES, V58, P3526; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; GIBAS Z, 1986, CANCER GENET CYTOGEN, V20, P191, DOI 10.1016/0165-4608(86)90074-9; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; Hidaka N, 1998, MODERN PATHOL, V11, P1039; Iwao K, 1998, CANCER RES, V58, P1021; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kase S, 2000, CLIN CANCER RES, V6, P4789; LU YY, 1994, GENE CHROMOSOME CANC, V9, P76, DOI 10.1002/gcc.2870090114; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nawrocki B, 1998, AM J PATHOL, V153, P1521, DOI 10.1016/S0002-9440(10)65740-9; Palacios J, 1998, CANCER RES, V58, P1344; Park WS, 1999, CANCER RES, V59, P4257; POPESCU NC, 1988, CANCER RES, V48, P142; Retera JMAM, 1998, J CLIN PATHOL, V51, P891, DOI 10.1136/jcp.51.12.891; Roche J, 1996, ONCOGENE, V12, P1289; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sambrook J., 2002, MOL CLONING LAB MANU; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SEKIDO Y, 1994, CANCER RES, V54, P4988; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Smythe WR, 1999, LUNG CANCER-J IASLC, V24, P157, DOI 10.1016/S0169-5002(99)00032-X; Sparks AB, 1998, CANCER RES, V58, P1130; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; TAGUCHI T, 1993, CANCER RES, V53, P4349; TIAINEN M, 1989, BRIT J CANCER, V60, P618, DOI 10.1038/bjc.1989.326; Voeller HJ, 1998, CANCER RES, V58, P2520; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; YAMAKAWA K, 1993, ONCOGENE, V8, P327; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	45	85	88	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4249	4257		10.1038/sj.onc.1204557	http://dx.doi.org/10.1038/sj.onc.1204557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464291				2022-12-28	WOS:000169857200015
J	Jager, AC; Rasmussen, M; Bisgaard, HC; Singh, KK; Nielsen, FC; Rasmussen, LJ				Jager, AC; Rasmussen, M; Bisgaard, HC; Singh, KK; Nielsen, FC; Rasmussen, LJ			HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence assembly of hMutL alpha and hMLH1-hEXO1 complexes	ONCOGENE			English	Article						hEXO1; hMLH1; hPMS2; DNA mismatch repair; HNPCC	NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE EXO1; MEIOTIC CROSSING-OVER; HUMAN MUTL HOMOLOGS; MITOTIC RECOMBINATION; MLH1 MUTATIONS; EXONUCLEASE-I; TUMOR-CELLS; IDENTIFICATION; HETERODIMER	Hereditary nonpolyposis colorectal cancer (HNPCC) is common inherited form of neoplasia caused by germline mutations in DNA mismatch repair (MMR) genes, MMR proteins have been reported to associate with several proteins, including the human exonuclease 1 (hEXO1). We report here novel HNPCC-hMLH1 mutant proteins (T117M, Q426X and 1813insA) in Danish HNPCC patients, We demonstrate that these mutant HNPCC-hMLH1 proteins are unable to form complexes with hEXO1 and hPMS2 in vivo. The results indicate that mutations found in HNPCC gene carriers disrupt hMLH1 - hEXO1 complex formation and hMutL alpha heterodimer assembly essential for MMR activity.	Roskilde Univ, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA	Roskilde University; Rigshospitalet; University of Copenhagen; Johns Hopkins University; Johns Hopkins Medicine	Rasmussen, LJ (corresponding author), Roskilde Univ, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark.		Nielsen, Finn Cilius/AAA-4926-2020	Nielsen, Finn Cilius/0000-0002-9829-1031; Rasmussen, Lene Juel/0000-0001-6864-963X	PHS HHS [R01 09714-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Jager AC, 1997, AM J HUM GENET, V61, P129, DOI 10.1086/513896; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Nicholson A, 2000, GENETICS, V154, P133; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Rasmussen LJ, 2000, MUTAT RES-DNA REPAIR, V460, P41, DOI 10.1016/S0921-8777(00)00012-4; Risinger JI, 1998, CANCER RES, V58, P2978; Saparbaev M, 1996, GENETICS, V142, P727; Schmutte C, 1998, CANCER RES, V58, P4537; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762	30	59	63	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3590	3595		10.1038/sj.onc.1204467	http://dx.doi.org/10.1038/sj.onc.1204467			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429708				2022-12-28	WOS:000169478300017
J	Mukhopadhyay, A; Bueso-Ramos, C; Chatterjee, D; Pantazis, P; Aggarwal, BB				Mukhopadhyay, A; Bueso-Ramos, C; Chatterjee, D; Pantazis, P; Aggarwal, BB			Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines	ONCOGENE			English	Article						prostate; curcumin; NF-kappa B; AP-1; Bcl-2; androgen	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; CARCINOMA-CELLS; GENE-EXPRESSION; IN-VITRO; ACTIVATION; KINASE; ALPHA	While the role of nuclear transcription factor activator protein-1 (AP-1) in cell proliferation, and of nuclear factor-kappaB (NF-kappaB) in the suppression of apoptosis are known, their role in survival of prostate cancer cells is not well understood. We investigated the role of NF-kappaB and AP-1 in the survival of human androgen-independent (DU145) and -dependent (LNCaP) prostate cancer cell lines. Our results show that the faster rate of proliferation of DU145 cells when compared to LNCaP cells correlated with the constitutive expression of activated NF-kappaB and AP-1 in DU-145 cells. The lack of constitutive expression of NF-kappaB and AP-1 in LNCaP cells also correlated with their sensitivity to the antiproliferative effects of tumor necrosis factor (TNF). TNF induced NF-kappaB activation but not AP-1 activation in LNCaP cells. In DU145 cells both c-Fos and c-Jun were expressed and treatment with TNF activated c-Jun NH2-terminal kinase (JNK), needed for AP-1 activation. In LNCaP cells, however, only low levels of c-Jun was expressed and treatment with TNF minimally activated JNK. Treatment of cells with curcumin, a chemopreventive agent, suppressed both constitutive (DU145) and inducible (LNCaP) NF-kappaB activation, and potentiated TNF-induced apoptosis. Curcumin alone induced apoptosis in both cell types, which correlated with the downregulation of the expression of Bcl-2 and Bcl-xL and the activation of procaspase-3 and procaspase-8. Overall, our results suggest that NF-kappaB and AP-1 may play a role in the survival of prostate cancer cells, and curcumin abrogates their survival mechanisms.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Sect,Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Brown University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Sect,Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Adams J, 1999, CANCER RES, V59, P2615; Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Chen HW, 1998, BRIT J PHARMACOL, V124, P1029, DOI 10.1038/sj.bjp.0701914; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Craft N, 1999, CANCER RES, V59, P5030; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Davies MA, 1999, CANCER RES, V59, P2551; Degeorges A, 1999, CANCER RES, V59, P2787; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; EWING CM, 1995, CANCER RES, V55, P4813; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Haridas V, 1998, J IMMUNOL, V160, P3152; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Jiang MC, 1996, NUTR CANCER, V26, P111, DOI 10.1080/01635589609514468; Jobin C, 1999, J IMMUNOL, V163, P3474; Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kawamori T, 1999, CANCER RES, V59, P597; Kubota T, 1998, CANCER RES, V58, P3344; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kuo ML, 1996, BBA-MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925-4439(96)00032-4; LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839; Lin JQ, 1999, CANCER RES, V59, P2891; Liu XH, 1998, CANCER RES, V58, P4245; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; McConkey DJ, 1996, CANCER RES, V56, P5594; Mehta K, 1997, ANTI-CANCER DRUG, V8, P470, DOI 10.1097/00001813-199706000-00010; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; PARKER SL, 1997, CA CANC J CLIN, V46, P5; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAFFO AJ, 1995, CANCER RES, V55, P4438; Ripple MO, 1999, JNCI-J NATL CANCER I, V91, P1227, DOI 10.1093/jnci/91.14.1227; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sintich SM, 1999, PROSTATE, V39, P87; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; van Brussel JP, 1999, EUR J CANCER, V35, P664, DOI 10.1016/S0959-8049(98)00435-3; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784	54	345	358	0	25	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7597	7609		10.1038/sj.onc.1204997	http://dx.doi.org/10.1038/sj.onc.1204997			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753638				2022-12-28	WOS:000172124100003
J	Bader, AG; Schneider, ML; Bister, K; Hartl, M				Bader, AG; Schneider, ML; Bister, K; Hartl, M			TOJ3, a target of the v-jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1)	ONCOGENE			English	Article						jun oncogene; signal transduction; transcription factor AP-1; gene expression; target gene; nucleolar protein	DOXYCYCLINE-CONTROLLED EXPRESSION; CONDITIONAL CELL-TRANSFORMATION; C-JUN; FHA DOMAIN; STRUCTURAL-ANALYSIS; EMBRYO FIBROBLASTS; MOLECULAR-CLONING; GENE-EXPRESSION; AP-1 FUNCTION; FOS	Using the established quail cell line Q/d3 conditionally transformed by the v-jun oncogene, cDNA clones (TOJ2, TOJ3, TOJ5, TOJ6) were isolated by representational difference analysis (RDA) that correspond to genes which were induced immediately upon conditional activation of v-jun. One of these genes, TOJ3, is immediately and specifically activated after doxycycline-mediated v-jun induction, with kinetics similar to the induction of well characterized direct AP-I target genes. TOJ3 is neither activated upon conditional activation of v-myc, nor in cells or cell lines non-conditionally transformed by oncogenes other than v-jun. Sequence analysis revealed that the TOJ3-specific cDNA encodes a 530-amino acid protein with significant sequence similarities to the murine or human microspherule protein 1 (MCRS1, MSP58), a nucleolar protein that directly interacts with the ICP22 regulatory protein from herpes simplex virus 1 or with p120, a proliferation-related protein expressed at high levels in most human malignant tumor cells. Similar to its mammalian counterparts, the TOJ3 protein contains a bipartite nuclear localization motif and a forkhead associated domain (FHA). Using polyclonal antibodies directed against a recombinant amino-terminal TOJ3 protein segment, the activation of TOJ3 in jun-transformed fibroblasts was also demonstrated at the protein level by specific detection of a polypeptide with an apparent M-r of 65000. Retroviral expression of the TOJ3 gene in quail or chicken embryo fibroblasts induces anchor age-independent growth, indicating that the immediate activation of TOJ3 in fibroblasts transformed by the v-jun oncogene contributes to cell transformation.	Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria	University of Innsbruck	Bister, K (corresponding author), Univ Innsbruck, Inst Biochem, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	klaus.bister@uibk.ac.at; markus.hartl@uibk.ac.at	Bister, Klaus/AFA-9400-2022; Hartl, Markus/O-4655-2014	Hartl, Markus/0000-0001-7447-5920; Bister, Klaus/0000-0001-6545-5653				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BISTER K, 1987, ONCOGENE, V1, P97; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Boyd KE, 1999, P SOC EXP BIOL MED, V222, P9, DOI 10.1111/j.1525-1373.1999.09992.x; Bruni R, 1998, J VIROL, V72, P8525, DOI 10.1128/JVI.72.11.8525-8531.1998; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; CURRAN T, 1991, TRANSCRIPTIONAL REGU, P797; Dang CV, 1999, MOL CELL BIOL, V19, P1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dingwall C, 1998, CURR BIOL, V8, pR922, DOI 10.1016/S0960-9822(98)00010-4; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FREEMAN JW, 1988, CANCER RES, V48, P1244; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GROSSI M, 1991, ONCOGENE, V6, P1767; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOZAK P, 1995, EXP CELL RES, V216, P285, DOI 10.1006/excr.1995.1036; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JURDIC P, 1995, ONCOGENE, V11, P1699; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Li J, 2000, J CELL SCI, V113, P4143; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MOLDERS H, 1987, ONCOGENE, V1, P377; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Ren Y, 1998, EUR J BIOCHEM, V253, P734, DOI 10.1046/j.1432-1327.1998.2530734.x; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SU HY, 1991, ONCOGENE, V6, P1759; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang P, 2000, J MOL BIOL, V302, P927, DOI 10.1006/jmbi.2000.4095; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WONG WY, 1992, ONCOGENE, V7, P2077; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	69	50	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7524	7535		10.1038/sj.onc.1204938	http://dx.doi.org/10.1038/sj.onc.1204938			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709724				2022-12-28	WOS:000171976900009
J	De Toledo, M; Coulon, V; Schmidt, S; Fort, P; Blangy, A				De Toledo, M; Coulon, V; Schmidt, S; Fort, P; Blangy, A			The gene for a new brain specific RhoA exchange factor maps to the highly unstable chromosomal region 1p36.2-1p36.3.	ONCOGENE			English	Article						Rho GTPase; Dbl exchange factor; transformation; 1p36; chromosome 1	HETEROTRIMERIC G-PROTEINS; NEUROBLASTOMA CELL-LINE; GTP-BINDING PROTEIN; SIGNALING PATHWAYS; ACTIVATION; FAMILY; IDENTIFICATION; GTPASES; DELETION; RAC1	Guanine nucleotide exchange factors from the Dbl family are proto-oncogenic proteins that activate small GTPases of the Rho family. Here we report the characterization of GEF720, a novel Dbl-like protein related to p115Rho-GEF. GEF720 activated RhoA both in our recently developed Yeast Exchange Assay and in biochemical in vitro exchange assays. GEF720 induced RhoA dependent assembly of actin stress fibers in REF52 fibroblastic cells. In NIH3T3 cells this Dbl-like protein elicited formation of transformation foci with a morphology similar to RhoA-V14 induced foci. In the PC12 neuron-like cell line, expression of GEF720, whose mRNA is brain specific, inhibited NGF-induced neurite outgrowth. Finally, GEF720 gene is located on human chromosome 1 on band 1p36, between Tumor Protein 73 and Tumor Necrosis Factor Receptor 12, two genes rearranged in many neuroblastoma cell lines. Together, these results show that this new Dbl related protein, GEF720, is an exchange factor that can directly activate RhoA in vivo and is potentially involved in the control of neuronal cell differentiation. GEF720 is also a new candidate gene involved in the progression of neuroblastoma and developmental abnormalities associated with rearrangements in the 1p36 chromosomal region.	Ctr Rech Biochim Macromol, CNRS IFR24 UPR 1086, F-34293 Montpellier 5, France; Inst Genet Mol Montpellier, CNRS IFR24 UMR 5535, F-34293 Montpellier 5, France	Universite de Montpellier	Blangy, A (corresponding author), Ctr Rech Biochim Macromol, CNRS IFR24 UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.	blangy@crbm.cnrs-mop.fr	Coulon, Vincent/AFF-7934-2022; Coulon, Vincent/B-2437-2009; Fort, Philippe/M-9498-2015	Coulon, Vincent/0000-0002-3168-8755; Coulon, Vincent/0000-0002-3168-8755; Fort, Philippe/0000-0001-5997-8722; BLANGY, Anne/0000-0001-7043-0784				Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Aman AK, 2000, GENE CHROMOSOME CANC, V29, P292, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1038>3.0.CO;2-C; Amler LC, 2000, GENOMICS, V64, P195, DOI 10.1006/geno.1999.6097; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; Blangy A, 2000, J CELL SCI, V113, P729; Blomquist A, 2000, BIOCHEM J, V352, P319, DOI 10.1042/0264-6021:3520319; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Cho JH, 2000, HUM MOL GENET, V9, P1425, DOI 10.1093/hmg/9.9.1425; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coulon V, 1999, J BIOL CHEM, V274, P30439, DOI 10.1074/jbc.274.43.30439; De Toledo M, 2000, FEBS LETT, V480, P287, DOI 10.1016/S0014-5793(00)01953-0; Ejeskar K, 2000, CYTOGENET CELL GENET, V89, P62, DOI 10.1159/000015566; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Fukushima S, 2000, EXP HEMATOL, V28, P391, DOI 10.1016/S0301-472X(00)00129-6; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Heilstedt HA, 1999, CLIN GENET, V56, P123, DOI 10.1034/j.1399-0004.1999.560205.x; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P512, DOI 10.1002/1096-911X(20001201)35:6<512::AID-MPO2>3.0.CO;2-D; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Janssen JWG, 1999, INT J CANCER, V80, P857; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Knight-Jones E, 2000, DEV MED CHILD NEUROL, V42, P201, DOI 10.1017/S0012162200000347; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kutsche K, 2000, NAT GENET, V26, P247, DOI 10.1038/80002; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; NOGUCHI T, 1988, ONCOGENE, V3, P709; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Ridley A J, 1999, Prog Mol Subcell Biol, V22, P1; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; Singh R, 1999, J CLIN INVEST, V103, P1561, DOI 10.1172/JCI5754; Slavotinek A, 1999, J MED GENET, V36, P657; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759	66	37	38	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7307	7317		10.1038/sj.onc.1204921	http://dx.doi.org/10.1038/sj.onc.1204921			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704860				2022-12-28	WOS:000171894200003
J	Roussel, MJS; Lanotte, M				Roussel, MJS; Lanotte, M			Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes	ONCOGENE			English	Article						APL; t(15;17) cell lines; mutation; phenotypes	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; 6-<3-ADAMANTYL-4-HYDROXYPHENYL>-2-NAPHTHALENE CARBOXYLIC-ACID; ARSENIC TRIOXIDE AS2O3; RETINOIC ACID; DOWN-REGULATION; IN-VITRO; APOPTOSIS; EXPRESSION; DIFFERENTIATION	Chromosomal translocations, leading to gene rearrangements that generate chimerical proteins, represent one of the initiating events of leukemia. Preleukemia cells eventually develop into overt leukemia by occurrence of secondary genetic alterations (tumor progression). The physiopathology of leukemia has made considerable progress during the last two decades, due to molecular biology investigations on the role played by the altered genes, during neoplasic hemopoiesis. In vitro studies have been facilitated by the establishment of stable leukemia cell lines bearing these gene rearrangements and secondary gene mutations. Investigations on acute promyelocytic leukemia (APL) have benefited from maturation sensitive and resistant cell lines (NB4 and UF-I) derived from APL patient's leukemia cells and bearing the t(15;17). The information concerning the NB4 cell line (responsiveness to retinoid/rexinoid, cAMP, arsenic, mutations causing resistance) is spread in an abundant literature. In this paper, we briefly recapitulate the cellular and molecular features of this cell line and its subclones with the aim of facilitating investigators in their choice of the most appropriate tool for their studies. As redundancy of several names given to NB4 sublines has sometimes created difficulties, we propose a nomenclature for the various NB4 sublines that most investigators certainly would be agreed with.	Hop St Louis, Ctr G Hayem, INSERM U 496, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lanotte, M (corresponding author), Hop St Louis, Ctr G Hayem, INSERM U 496, 1 Ave Claude Vellefaux, F-75010 Paris, France.							Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Benoit GR, 2001, MOL ENDOCRINOL, V15, P1154, DOI 10.1210/me.15.7.1154; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; DERMIME S, 1993, BLOOD, V82, P1573; DERMIME S, 1995, LEUKEMIA LYMPHOMA, V16, P289, DOI 10.3109/10428199509049768; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Duprez E, 1996, ONCOGENE, V12, P2451; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Kizaki M, 1999, INT J MOL MED, V4, P359; LANOTTE M, 1991, BLOOD, V77, P1080; Maksumova L, 2000, LEUKEMIA, V14, P1444, DOI 10.1038/sj.leu.2401856; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Naito K, 2000, LEUKEMIA, V14, P1436, DOI 10.1038/sj.leu.2401851; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; NasonBurchenal K, 1997, DIFFERENTIATION, V61, P321, DOI 10.1046/j.1432-0436.1997.6150321.x; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Ponzanelli I, 2000, BLOOD, V95, P2672; ROBERTSON KA, 1992, BLOOD, V80, P1885; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shen Y, 2001, LEUKEMIA, V15, P735, DOI 10.1038/sj.leu.2402106	29	52	54	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7287	7291		10.1038/sj.onc.1204863	http://dx.doi.org/10.1038/sj.onc.1204863			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704857				2022-12-28	WOS:000171891900017
J	Lorimore, SA; Coates, PJ; Scobie, GE; Milne, G; Wright, EG				Lorimore, SA; Coates, PJ; Scobie, GE; Milne, G; Wright, EG			Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects?	ONCOGENE			English	Article						ionizing radiation; macrophage; inflammation; genetics; bystander	INDUCED CHROMOSOMAL INSTABILITY; BONE-MARROW TRANSPLANTATION; NITRIC-OXIDE; ALPHA-PARTICLES; UNIRRADIATED CELLS; P53 ACCUMULATION; APOPTOTIC CELLS; MAMMALIAN-CELLS; STROMAL CELLS; WHOLE-BODY	Haemopoietic tissues exposed to ionizing radiation are shown to exhibit increased macrophage activation, defined by ultrastructural characteristics and increased lysosomal and nitric oxide synthase enzyme activities. Macrophage activation post-irradiation was also associated with enhanced respiratory burst activities and an unexpected neutrophil infiltration. Examination of p53-null mice demonstrated that macrophage activation and neutrophil infiltration were not direct effects of irradiation, but were a consequence of the recognition and clearance of radiation-induced apoptotic cells. Increased phagocytic cell activity was maintained after apoptotic bodies had been removed. These findings demonstrate that, contrary to expectation, recognition and clearance of apoptotic cells after exposure to radiation produces both a persistent macrophage activation and an inflammatory-type response. We also demonstrate a complexity of macrophage activation following radiation that is genotype dependent, indicating that the in vivo macrophage responses to radiation damage are genetically modified processes. These short-term responses of macrophages to radiation-induced apoptosis and their genetic modification are likely to be important determinants of the longer-term consequences of radiation exposure. Furthermore, in addition to any effects attributable to immediate radiation-induced damage, our findings provide a mechanism for the production of damage via a 'bystander' effect which may contribute to radiation-induced genomic instability and leukaemogenesis.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	University of Dundee	Coates, PJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306				ADAMS DO, 1992, MACROPHAGE, P75; Brockhaus F, 1999, ONCOGENE, V18, P6403, DOI 10.1038/sj.onc.1203058; Brune B, 1996, BIOCHEM BIOPH RES CO, V229, P396, DOI 10.1006/bbrc.1996.1816; DUHRSEN U, 1990, BLOOD, V75, P190; Giles KM, 2000, BRIT J HAEMATOL, V109, P1, DOI 10.1046/j.1365-2141.2000.01805.x; GIRALT SA, 1994, BLOOD, V84, P3603, DOI 10.1182/blood.V84.11.3603.bloodjournal84113603; Gorbunov NV, 2000, RADIAT RES, V154, P73, DOI 10.1667/0033-7587(2000)154[0073:AOTNOS]2.0.CO;2; Greenberger JS, 1996, ACTA HAEMATOL-BASEL, V96, P1; Gregory CD, 2000, CURR OPIN IMMUNOL, V12, P27, DOI 10.1016/S0952-7915(99)00047-3; Handel-Fernandez ME, 2000, MACROPHAGES PRACTICA, P1; Iyer R, 2000, ARCH BIOCHEM BIOPHYS, V376, P14, DOI 10.1006/abbi.1999.1684; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Lehnert BE, 1997, CANCER RES, V57, P2164; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; MCCANN SR, 1993, LEUKEMIA LYMPHOMA, V10, P419, DOI 10.3109/10428199309148198; McKinney LC, 1998, J LEUKOCYTE BIOL, V64, P459, DOI 10.1002/jlb.64.4.459; MOLE RH, 1983, BRIT J CANCER, V47, P285, DOI 10.1038/bjc.1983.37; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill CE, 1999, CARCINOGENESIS, V20, P2273, DOI 10.1093/carcin/20.12.2273; Narayanan PK, 1997, CANCER RES, V57, P3963; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Necas E, 1998, STEM CELLS, V16, P107; NOMURA T, 1992, J RADIAT RES, V33, P109, DOI 10.1269/jrr.33.SUPPLEMENT_109; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; SILVER LM, 1995, MOUSE GENETICS CONCE, P195; Uchimura E, 2000, J LEUKOCYTE BIOL, V67, P780, DOI 10.1002/jlb.67.6.780; WALBURG HE, 1968, INT J CANCER, V3, P150, DOI 10.1002/ijc.2910030118; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2000, CANCER RES, V60, P5608; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Wood W, 2000, DEVELOPMENT, V127, P5245; Wright EG, 1998, INT J RADIAT BIOL, V74, P681, DOI 10.1080/095530098140943; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028; YAMAMOTO K, 1984, J EXP MED, V159, P405, DOI 10.1084/jem.159.2.405; YOSHIDA K, 1993, LEUKEMIA RES, V17, P437, DOI 10.1016/0145-2126(93)90099-7; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	42	298	314	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7085	7095		10.1038/sj.onc.1204903	http://dx.doi.org/10.1038/sj.onc.1204903			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704832				2022-12-28	WOS:000171739300011
J	Wang, BL; Xiong, QH; Shi, Q; Le, XD; Xie, KP				Wang, BL; Xiong, QH; Shi, Q; Le, XD; Xie, KP			Genetic disruption of host interferon-gamma drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase	ONCOGENE			English	Article						interferon-gamma; knockout; nitric oxide; metastasis; pancreas	CELL-LINES; CANCER; TUMORS; REGRESSION; THERAPY; MICE; MECHANISMS; BETA; P53	Synergistic induction of the inducible nitric oxide synthase (NOS II) gene requires a combination of interferon-gamma (IFN-gamma) and lipopolysaccharide (LPS). In this study, we determined whether the induction of IFN-gamma was required for NOS U-mediated antitumor activity in viro. Highly metastatic H7 murine pancreatic adenocarcinoma cells were implanted into the subcutis, footpad, and pancreas of syngeneic IFN-gamma (+/+) and IFN-gamma (-/-) mice. These cells grew and produced metastases and ascites in IFN-gamma (+/+) mice. In sharp contrast, the same tumor cells grew much more aggressively, metastasized more extensively, and produced a larger amount of malignant ascites in IFN-gamma (-/-) mice. Also, induction of IFN-gamma correlated with NOS II gene expression and NO production in IFN-gamma (+/+) injected with the tumor cells but not in IFN-gamma (-/-) mice or IFN-gamma (+/+) mice without tumor challenge. In vitro, only LPS plus IFN-gamma induced a high level of NO production and cytotoxicity against H7 cells. These data suggested that the tumor cells stimulated IFN-gamma secretion from host cells, which in turn stimulated NO production by host cells and suppressed tumor growth and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA 16672-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Chinje EC, 1997, ESSAYS BIOCHEM, V32, P61; CORBETT TH, 1984, CANCER RES, V44, P717; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JOHNS TG, 1992, J NATL CANCER I, V84, P1185, DOI 10.1093/jnci/84.15.1185; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KROWN SE, 1988, J NATL CANCER I, V80, P306, DOI 10.1093/jnci/80.5.306; Kundu N, 1998, INT J CANCER, V76, P713, DOI 10.1002/(SICI)1097-0215(19980529)76:5<713::AID-IJC17>3.0.CO;2-4; LOKSHIN A, 1995, JNCI-J NATL CANCER I, V87, P206, DOI 10.1093/jnci/87.3.206; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Onier N, 1999, INT J CANCER, V81, P755, DOI 10.1002/(SICI)1097-0215(19990531)81:5<755::AID-IJC15>3.0.CO;2-3; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shi Q, 2000, INT J ONCOL, V17, P217; Shi Q, 1999, CANCER RES, V59, P2072; SHI Q, 2000, CANCER RES, V60, P2645; Tannenbaum CS, 2000, SEMIN CANCER BIOL, V10, P113, DOI 10.1006/scbi.2000.0314; THOMAS H, 1991, PHARMACOL THERAPEUT, V52, P307, DOI 10.1016/0163-7258(91)90030-P; Tozer G M, 1997, Clin Oncol (R Coll Radiol), V9, P357, DOI 10.1016/S0936-6555(97)80128-8; Wang BL, 2001, INT J CANCER, V91, P607, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1109>3.0.CO;2-D; Wang BL, 2001, CANCER RES, V61, P71; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; XIE K, 1997, CLIN CANCER RES, V3, P2189; XIE KP, 1995, CANCER RES, V55, P3123; Xie KP, 1998, CANCER METAST REV, V17, P55, DOI 10.1023/A:1005956721457; Zhang JF, 1996, P NATL ACAD SCI USA, V93, P4513, DOI 10.1073/pnas.93.9.4513	31	19	21	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6930	6937		10.1038/sj.onc.1204871	http://dx.doi.org/10.1038/sj.onc.1204871			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687972				2022-12-28	WOS:000171641000014
J	Deneen, B; Denny, CT				Deneen, B; Denny, CT			Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation	ONCOGENE			English	Article						EWS/FLI1; P16(INK4a); p19(ARF); SV40 large T antigen; apoptosis	HUMAN-PAPILLOMAVIRUS TYPE-16; LARGE T-ANTIGEN; TUMOR-SUPPRESSOR; J DOMAIN; P53; FAMILY; GENES; DIFFERENTIATION; INACTIVATION; FIBROBLASTS	Ewings sarcoma and primitive neuroectodermal tumors (ES/PNET) are characterized by the fusion of the N-terminus of the EWS gene to the C-terminus of a member of the ETS family of transcription factors. While such fusion proteins are thought to play dominant oncogenic roles, it is unlikely that a single genetic alteration by itself will support cellular transformation. Given that EWS/FLI1 is only able to transform immortalized 3T3 fibroblasts and that 30% of ES/PNET tumors contain a homozygous deletion of the p16 focus, it is likely that other genetic events are required for EWS/FLI1 oncogenesis. Here we describe a complementary mechanism utilized in the establishment ES/PNET tumors. EWS/FLI1 has the capacity to induce apoptosis. and growth arrest in normal MEFs. Such effects prevent the establishment of stable expression of the protein in these cells. When expressed in p16, p19(ARF), or p53 deficient MEFs, the apoptotic and growth arrest effects are attenuated, creating a environment permissive for stable expression of the protein. While loss of a single tumor suppressor is sufficient to establish expression of EWS/FLI1, cellular transformation requires further genetic perturbation.	Univ Calif Los Angeles, Inst Mol Biol, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Gwynne Hazen Cherry Mem Labs, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Denny, CT (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA.	cdenny@ucla.edu		Deneen, Benjmain/0000-0002-6335-1081	NCI NIH HHS [CA 87771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; Damania B, 1998, MOL CELL BIOL, V18, P1331, DOI 10.1128/MCB.18.3.1331; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Esteller M, 2000, CANCER RES, V60, P129; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fletcher JA, 1998, J CLIN ONCOL, V16, P1241, DOI 10.1200/JCO.1998.16.4.1241; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gjoerup O, 2000, J VIROL, V74, P864, DOI 10.1128/JVI.74.2.864-874.2000; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; JEN J, 1994, CANCER RES, V54, P5523; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; KOVAR H, 1998, CURR OPIN ONCOL, V4, P334; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWRY DR, 1978, J VIROL, V26, P291; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MILLER DG, 1980, CANCER, V46, P1307, DOI 10.1002/1097-0142(19800915)46:6<1307::AID-CNCR2820460602>3.0.CO;2-6; Moens U, 1997, VIRUS GENES, V15, P135, DOI 10.1023/A:1007962908248; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Teitell MA, 1999, LAB INVEST, V79, P1535; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	38	102	108	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6731	6741		10.1038/sj.onc.1204875	http://dx.doi.org/10.1038/sj.onc.1204875			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709708				2022-12-28	WOS:000171551600010
J	Pavey, S; Russell, T; Gabrielli, B				Pavey, S; Russell, T; Gabrielli, B			G2 phase cell cycle arrest in human skin following UV irradiation	ONCOGENE			English	Article						p16; UV; skin; G2 checkpoint	ULTRAVIOLET-RADIATION; HUMAN MELANOCYTES; G(1) ARREST; HUMAN KERATINOCYTES; MSH RECEPTORS; GROWTH-FACTOR; DNA-DAMAGE; EXPRESSION; KINASE; MELANOGENESIS	The contribution of the short wavelength ultraviolet (UV) component of sunlight to the aetiology of skin cancer has been widely acknowledged, although its direct contribution to tumour initiation or progression is still poorly understood. The loss of normal cell cycle controls, particularly checkpoint controls, are a common feature of cancer. UV radiation causes both GI and G2 phase checkpoint arrest in vitro cultured cells. In this study we have investigated the cell cycle responses to suberythemal doses of UV on skin. We have utilized short-term whole organ skin cultures, and multi parameter immunohistochemical and biochemical analysis to demonstrate that basal and suprabasal layer melanocytes and keratinocytes undergo a G2 phase cell cycle arrest for up to 48 h following irradiation. The arrest is associated with increased p16 expression but no apparent p53 involvement. This type of organ culture provides a very useful model system, combining the ease of in vitro manipulation with the ability to perform detailed molecular analysis in a normal tissue environment.	Univ Queensland, Sch Med, Dept Pathol, Joint Expt Oncol Program, Brisbane, Qld 4006, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Joint Expt Oncol Program, Herston Rd, Brisbane, Qld 4006, Australia.		Pavey, Sandra/B-3662-2011; Gabrielli, Brian G/B-3655-2011	Pavey, Sandra/0000-0003-4519-5932; Gabrielli, Brian G/0000-0003-3933-1651				CAMPBELL C, 1993, CANCER RES, V53, P2697; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; CHAKRABORTY A, 1993, J CELL PHYSIOL, V157, P344, DOI 10.1002/jcp.1041570218; Chakraborty AK, 1999, ANN NY ACAD SCI, V885, P100; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; ELDER DE, 1989, J INVEST DERMATOL S, V92, P297; FREEMAN SE, 1987, J INVEST DERMATOL, V88, P430, DOI 10.1111/1523-1747.ep12469778; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; Haddad MM, 1999, EXP CELL RES, V253, P561, DOI 10.1006/excr.1999.4688; HERZINGER T, 1995, ONCOGENE, V11, P2151; HONIGSMANN H, 1987, J PHOTOCH PHOTOBIO B, V1, P33, DOI 10.1016/1011-1344(87)80004-0; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Im SB, 1998, CANCER RES, V58, P47; IYENGAR B, 1994, MELANOMA RES, V4, P293; LEY KD, 1992, CARCINOGENESIS, V13, P183, DOI 10.1093/carcin/13.2.183; LIBOW LF, 1988, PIGM CELL RES, V1, P397, DOI 10.1111/j.1600-0749.1988.tb00142.x; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCLANE JA, 1988, BIOCHEMISTRY-US, V27, P3743, DOI 10.1021/bi00410a033; MEDRANO EE, 1995, CANCER RES, V55, P4047; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; Pavey S, 1999, CANCER RES, V59, P4185; Petrocelli T, 1996, ONCOGENE, V12, P1387; QUEVEDO WC, 1969, AM ZOOL, V9, P531; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Soufir N, 1999, ONCOGENE, V18, P5477, DOI 10.1038/sj.onc.1202915; Tada A, 1998, CELL GROWTH DIFFER, V9, P575; TAM SW, 1994, CANCER RES, V54, P5816; Thody AJ, 1998, PIGM CELL RES, V11, P265, DOI 10.1111/j.1600-0749.1998.tb00735.x; Wang XQ, 1996, CANCER RES, V56, P2510; Watters D, 1998, BIOCHEM PHARMACOL, V55, P1691, DOI 10.1016/S0006-2952(97)00680-1; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	40	56	59	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6103	6110		10.1038/sj.onc.1204707	http://dx.doi.org/10.1038/sj.onc.1204707			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593418				2022-12-28	WOS:000171206300001
J	Morali, OG; Delmas, V; Moore, R; Jeanney, C; Thiery, JP; Larue, L				Morali, OG; Delmas, V; Moore, R; Jeanney, C; Thiery, JP; Larue, L			IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition	ONCOGENE			English	Article						cadherin; catenin; insulin-like growth factor; epithelium to mesenchyme transition	MOUSE EMBRYONIC-DEVELOPMENT; EPIDERMAL GROWTH-FACTOR; CELL-CELL-ADHESION; PROTEIN-KINASE-B; E-CADHERIN; TRANSCRIPTIONAL ACTIVITY; CYTOPLASMIC DOMAIN; DROSOPHILA HOMOLOG; FACTOR RECEPTOR; INSULIN	The epithelium to mesenchyme transition is thought to play a fundamental role during embryonic development and tumor progression. Loss of cell-cell adhesion and modification of both cell morphology and gene expression are the main events associated with this transition. There is a large amount of evidence suggesting that growth factors can initiate these events. Yet, the connection from growth factor induction to changes in cell adhesion and morphology is largely unknown. To elucidate this connection, we have investigated the action of IGF-II on E-eadherin/beta -catenin complex-mediated cell-cell adhesion and on beta -catenin/TCF-3 mediated gene expression. We can show that (1) IGF-II induces a rapid epithelium to mesenchymal transition; (2) IGF1R, the receptor for IGF-II, belongs to the same membrane complex as E-cadherin and beta -catenin; (3) IGF-II induces a redistribution of beta -catenin from the plasma membrane to the nucleus and an intracellular sequestration and degradation of E-cadherin; (4) IGF-II induces the transcription of beta -catenin/TCF-3 target genes. Based on the given case of IGF-II and E-eadherin/beta -catenin complex, this study reveals the backbone of a cascade connecting growth factor signaling with cell-cell adhesion during EMT.	Inst Curie, UMR 146 CNRS, F-91405 Orsay, France; Inst Curie, UMR 144 CNRS, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Larue, L (corresponding author), Inst Curie, UMR 146 CNRS, Bat 110, F-91405 Orsay, France.	lionel.larue@curie.fr	Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Delmas, veronique/0000-0001-7368-3664				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 1999, J CELL BIOCHEM, P68; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Birchmeier C, 1996, ACTA ANAT, V156, P217; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BLAKESLEY VA, 1999, CONT ENDOCRINOLOGY I, V7, P143; BOYER B, 1992, EXP CELL RES, V201, P347, DOI 10.1016/0014-4827(92)90283-E; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Butz S, 1995, CELL ADHES COMMUN, V3, P337, DOI 10.3109/15419069509081018; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delmas V, 1999, DEV BIOL, V216, P491, DOI 10.1006/dbio.1999.9517; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; Greaves S, 1999, GENETICS, V153, P1753; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; Larue L, 1996, DEVELOPMENT, V122, P3185; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morali OG, 2000, DEV BIOL, V227, P133, DOI 10.1006/dbio.2000.9875; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Redies C, 1996, DEV BIOL, V180, P413, DOI 10.1006/dbio.1996.0315; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SHIOZAKI H, 1995, BRIT J CANCER, V71, P250, DOI 10.1038/bjc.1995.52; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yagi T, 2000, GENE DEV, V14, P1169	48	212	218	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4942	4950		10.1038/sj.onc.1204660	http://dx.doi.org/10.1038/sj.onc.1204660			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526479				2022-12-28	WOS:000170439800004
J	Gan, DD; Reiss, K; Carrill, T; Del Valle, L; Croul, S; Giordano, A; Fishman, P; Khalili, K				Gan, DD; Reiss, K; Carrill, T; Del Valle, L; Croul, S; Giordano, A; Fishman, P; Khalili, K			Involvement of Wnt signaling pathway in murine medulloblastoma induced by human neurotropic JC virus	ONCOGENE			English	Article						Wnt pathway; human polyomavirus; T-antigen; JCV; medulloblastoma	CADHERIN-CATENIN COMPLEX; TRANSGENIC MICE; BETA-CATENIN; EARLY PROTEIN; CELL-CYCLE; TUMORS; POLYOMAVIRUS; TRANSDUCTION; EXPRESSION; MUTATION	By using the early genome of the human neurotropic polyomavirus, JCV, we have created transgenic animals that develop cerebellar primitive neuroectodermal tumors which model human medulloblastoma. Expression of T-antigen was found in some, but not all, tumor cells, and examination of the clonal cell lines derived from the tumor population showed enhanced tumorigenicity of cells expressing T-antigen in comparison to T-antigen negative cells. Considering the earlier notion on the potential involvement of beta -catenin with human medulloblastoma, we investigated various components of the Wnt signaling pathway including beta -catenin, its partner transcription factor, LEF-1, and their downstream target gene c-myc in these two cell populations. Immunohistochemical staining of the cells revealed enhanced nuclear appearance of beta -catenin in T-antigen positive cells. Results from Western blot showed higher levels of beta -catenin and LEF-1 in T-antigen positive cells in comparison to those in T-antigen negative cells. The enhanced level of LEF-1 expression correlated with the increase in DNA binding activity of this protein in nuclear extracts of T-antigen positive cells. Results from Northern and Western blot analyses revealed that the level of c-myc expression is augmented both at the RNA and protein levels in T-antigen positive cells. These observations corroborated results from transfection studies indicating the ability of JCV T-antigen to stimulate c-myc promoter activity. Further, co-transfection experiments revealed that the amount of c-myc and T-antigen protein in tumor cells may dictate the activity of JCV early promoter in these cells. These observations are interesting in light of recent discoveries on the association of JCV with human medulloblastoma and suggest that communication between JCV and the Wnt pathway may be an important event in the genesis of these tumors.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Rabin Med Ctr, Felsenstein Res Ctr, Lab Tumor Immunol, Petah Tiqwa, Israel	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Rabin Medical Center	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St 015-96,Room 203, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010; Del Valle, Luis/J-4085-2015	Giordano, Antonio/0000-0002-5959-016X; Del Valle, Luis/0000-0003-3894-9206; Croul, Sidney/0000-0002-2224-5485				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cogen PH, 1996, J NEURO-ONCOL, V29, P103, DOI 10.1007/BF00165523; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; FARWELL JR, 1984, J NEUROSURG, V61, P657, DOI 10.3171/jns.1984.61.4.0657; Franks RR, 1996, ONCOGENE, V12, P2573; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; Howard CM, 2000, CANCER RES, V60, P2737; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Marino S, 2000, GENE DEV, V14, P994; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; TAGUCHI F, 1982, MICROBIOL IMMUNOL, V26, P1057, DOI 10.1111/j.1348-0421.1982.tb00254.x; WALKER DL, 1983, POLYOMAVIRUSES HUMAN, P99	29	57	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4864	4870		10.1038/sj.onc.1204670	http://dx.doi.org/10.1038/sj.onc.1204670			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521197				2022-12-28	WOS:000170271800010
J	Glaser, T; Wagenknecht, B; Weller, M				Glaser, T; Wagenknecht, B; Weller, M			Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells	ONCOGENE			English	Article						glioma; apoptosis; p21; CD95; cytochrome c	CYTOCHROME-C RELEASE; 3/P21 COMPLEX-FORMATION; DEATH RECEPTORS; CASPASE CASCADE; ACTIVATION; PROTEIN; CLEAVAGE; MITOCHONDRIA; INHIBITOR; BCL-2	Human glioma cell lines differ in their requirement for the inhibition of protein synthesis to activate the CD95-dependent killing pathway. CD95 ligand (CD95L) induced mitochondrial cytochrome c release and processing of caspases 3, 7, 8 and 9 in LN-18 cells in the absence of an inhibitor of protein synthesis, cycloheximide (CHX). These biochemical changes were observed in LN-229 cells only in the presence of CHX. The viral caspase inhibitor, cytokine response modifier (crm)-A, inhibited mitochondrial cytochrome c release, caspase processing and cell death under all conditions. Ectopic expression of BCL-X-L prevented processing of caspase 8 in LN-18 cells but not in LN-229 cells. Thus, caspase 8 activation is amplified through the release of cytochrome c in LN-18 cells but occurs mainly at the receptor in LN-229 cells. In contrast to BCL-2, BCL-X-L, X-linked inhibitor-of-apoptosis protein (XIAP) and FLICE-inhibitory protein (FLIP), the levels of the cyclin-dependent kinase (CDK) inhibitor, p21(Waf/Cip1), rapidly decreased in response to CHX. P21 antisense oligonucleotides promoted caspase activation and mitochondrial cytochrome c release and induced strong sensitization to CD95-mediated apoptosis. These data place potentiating effects of CHX (i) to the activation of caspase 8 at the receptor in LN-229 cells as well as (ii) to a down-stream target at least in LN-18 cells, but probably both cell lines, that may be identical with p21(Waf/Cip1).	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Fulda S, 2000, CANCER RES, V60, P3947; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Granville DJ, 1999, AM J PATHOL, V155, P1021, DOI 10.1016/S0002-9440(10)65202-9; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hueber A, 1998, FEBS LETT, V432, P155, DOI 10.1016/S0014-5793(98)00855-2; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo S, 1998, ONCOGENE, V17, P2585, DOI 10.1038/sj.onc.1202194; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Leverkus M, 2000, CANCER RES, V60, P553; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Ruan S, 1998, CANCER RES, V58, P1538; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang ZL, 1999, CANCER RES, V59, P1259; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1998, INT J CANCER, V79, P640; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WELLER M, 1995, CANCER RES, V55, P2963; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang YK, 1999, INT J CANCER, V83, P790, DOI 10.1002/(SICI)1097-0215(19991210)83:6<790::AID-IJC15>3.0.CO;2-6; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	59	47	47	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4757	4767		10.1038/sj.onc.1204498	http://dx.doi.org/10.1038/sj.onc.1204498			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521188				2022-12-28	WOS:000170271800001
J	Borrmann, L; Wilkening, S; Bullerdiek, J				Borrmann, L; Wilkening, S; Bullerdiek, J			The expression of HMGA genes is regulated by their 3 ' UTR	ONCOGENE			English	Article						HMGA; high mobility group proteins; 3 ' UTR	BENIGN MESENCHYMAL TUMORS; GROUP PROTEIN I(Y); MESSENGER-RNA; 3'-UNTRANSLATED REGION; CHROMOSOMAL-PROTEINS; Y PROTEINS; REARRANGEMENTS; CELLS; IDENTIFICATION; SEQUENCE	Many benign mesenchymal tumors are characterized by chromosomal abnormalities of the regions 12q15 or 6p21.3 leading to aberrant expression of either HMGA2 (formerly HMGIC) or HMGA1 (formerly HMGIY). The proteins of both genes belong to the HMGA (formerly HMGI(Y)) family of architectural transcription factors. As a rule, aberrant HMGA transcripts found in a variety of benign tumors have intact coding regions at least for the DNA binding domains with a truncation of their 3' untranslated regions. Adding this to the finding that an altered HMGA protein level is not always correlated with an increased amount of corresponding mRNA indicates a posttranscriptional expression control mediated by regulatory elements within the 3'UTR. To check if HMGA expression is under control of such elements we performed luciferase assays with several HMGA2 and HMGA1 3'UTRs of different length. Experiments showed that an up to 12-fold increase in luciferase activity is obtained by the truncation of the 3'UTRs suggesting that the expression of HMGA2 and HMGA1 is controlled by negatively acting regulatory elements within their 3'UTR. Chromosomal aberrations affecting the HMGA genes may therefore influence their expression by an altered stability of the truncated transcripts as a result of the cytogenetic aberrations.	Univ Bremen, Ctr Human Genet, ZHG, D-28359 Bremen, Germany	University of Bremen	Bullerdiek, J (corresponding author), Univ Bremen, Ctr Human Genet, ZHG, Leobenerstr, D-28359 Bremen, Germany.							Abe N, 2000, CANCER RES, V60, P3117; ASHAR HR, 1995, CELL, V82, P57; Ayoubi TAY, 1999, ONCOGENE, V18, P5076, DOI 10.1038/sj.onc.1202881; Battista S, 1999, CANCER RES, V59, P4793; Beaujean N, 2000, DEV BIOL, V221, P337, DOI 10.1006/dbio.2000.9668; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; Chiappetta G, 1996, ONCOGENE, V13, P2439; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; Fajardo MA, 1997, DEV BIOL, V191, P42, DOI 10.1006/dbio.1997.8705; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; Geurts JMW, 1997, CANCER GENET CYTOGEN, V95, P198, DOI 10.1016/S0165-4608(96)00411-6; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GOODWIN GH, 1985, EUR J BIOCHEM, V149, P47, DOI 10.1111/j.1432-1033.1985.tb08891.x; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; Kazmierczak B, 1996, ONCOGENE, V12, P515; Kazmierczak B, 1996, GENOMICS, V38, P223, DOI 10.1006/geno.1996.0619; Kazmierczak B, 1998, GENE CHROMOSOME CANC, V23, P279, DOI 10.1002/(SICI)1098-2264(199812)23:4<279::AID-GCC1>3.0.CO;2-1; Klotzbucher M, 1999, AM J PATHOL, V155, P1535, DOI 10.1016/S0002-9440(10)65469-7; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; Russell JE, 1997, PROG NUCLEIC ACID RE, V57, P249, DOI 10.1016/S0079-6603(08)60283-4; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; TAMIMI Y, 1993, CANCER RES, V53, P5512; Tkachenko A, 1997, CANCER RES, V57, P2276; Xiao S, 1997, AM J PATHOL, V150, P901; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	34	60	62	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4537	4541		10.1038/sj.onc.1204577	http://dx.doi.org/10.1038/sj.onc.1204577			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494149				2022-12-28	WOS:000170074900011
J	Hu, JD; Ma, XR; Lindner, DJ; Karra, S; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV				Hu, JD; Ma, XR; Lindner, DJ; Karra, S; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV			Modulation of p53 dependent gene expression and cell death through thioredoxin-thioredoxin reductase by the interferon-retinoid combination	ONCOGENE			English	Article						cytokines; vitamin; growth suppression; apoptosis; redox state	HUMAN TUMOR-CELLS; REDOX REGULATION; DNA-BINDING; MOLECULAR-CLONING; SUPPRESSES GROWTH; INDUCED APOPTOSIS; VITAMIN-A; CANCER; RECEPTOR; PROTEIN	We have shown earlier that the IFN-P and all-trans retinoic acid (RA) combination, but not the single agents, induces death in several tumor cell lines. Employing a genetic technique we have identified several Genes associated with Retinoid-IFN induced Mortality (GRIM), One of the GRIMs was human thioredoxin reductase (TR), a redox enzyme. Since the overexpressed TR augments IFN/RA stimulated cell death, we explored the mechanisms of TR-mediated death, Here we show that TR augments cell death by upregulating the transcriptional activity of p53 tumor suppressor. This process does not involve a physical increase in levels of p53, Using redox inactive mutants of TR and its substrate, thioredoxin (Trx), we demonstrate that IFN/ RA-induced regulation of p53 dependent gene expression requires TR and Trx, In contrast-over-expression of wildtype TR or Trx augment the p53 dependent gene expression in response to IFN/RA treatment. Consistent with these results an increased DNA binding activity of p53 was noted in the presence of TR, These studies identify a novel mechanism of p53 mediated cell death regulation involving redox enzymes.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Greenebaum Canc Ctr,Mol & Cellular Biol Program, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Sci, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Greenebaum Canc Ctr,Mol & Cellular Biol Program, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 71401, CA 78282] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Di Leonardo A, 1997, CANCER RES, V57, P1013; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; FAN SJ, 1995, CANCER RES, V55, P1649; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAINAUT P, 1993, CANCER RES, V53, P4469; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MA X, 2001, IN PRESS J BIOL CHEM; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; MIYASHITA T, 1995, CELL, V80, P293; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALZ HK, 1994, GENETICS, V136, P1075; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Tanioka A, 1997, COLLOID SURFACE B, V9, P17, DOI 10.1016/S0927-7765(97)00006-4; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TSUKADA T, 1993, ONCOGENE, V8, P3313; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103	69	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4235	4248		10.1038/sj.onc.1204585	http://dx.doi.org/10.1038/sj.onc.1204585			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464290				2022-12-28	WOS:000169857200014
J	Rohn, TA; Wagenknecht, B; Roth, W; Naumann, U; Gulbins, E; Krammer, PH; Walczak, H; Weller, M				Rohn, TA; Wagenknecht, B; Roth, W; Naumann, U; Gulbins, E; Krammer, PH; Walczak, H; Weller, M			CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release	ONCOGENE			English	Article						brain; apoptosis; neuroimmunology; cytokines; immunotherapy	MALIGNANT GLIOMA; CD95 LIGAND; LETHAL WEAPON; APO2 LIGAND; IN-VIVO; DEATH; EXPRESSION; CYTOTOXICITY; MODULATION; RECEPTORS	Death ligands such as CD95 ligand (CD95L) or tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) induce apoptosis in radiochemotherapy-resistant human malignant glioma cell lines. The death-signaling TRAIL receptors 2 (TRAIL-R2/death receptor (DR) 5) and TRAIL-R1/ DR4 were expressed more abundantly than the non-death-inducing (decoy) receptors TRAIL-R3/DcR1 and TRAIL-R4/DcR2 in 12 human glioma cell lines. Four of the 12 cell lines were TRAIL/Apo2L-sensitive in the absence of a protein synthesis inhibitor, cycloheximide (CHX), Three of the 12 cell lines were still TRAIL/ Apo2L-resistant in the presence of CHX, TRAIL-R2 expression predicted sensitivity to apoptosis. Coexposure to TRAIL/Apo2L and cytotoxic drugs such as topotecan, lomustine (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, CCNU) or temozolomide resulted in synergistic killing. Synergistic killing was more often observed in cell lines retaining wild-type p53 activity (U87MG, LN-229) than in p53 mutant cell lines (LN-18, T98G, U373MG). Drug exposure resulted in enhanced TRAIL-R2 expression, but decreased TRAIL-R4 expression in U87MG cells. Ectopic expression of dominant-negative p53(V135A) abrogated the drug-induced changes in TRAIL-R2 and TRAIL-R4 expression, but had no effect on synergy. Thus, neither wildtype p53 function nor changes in TRAIL receptor expression were required for synergy, In contrast, synergy resulted possibly from drug-induced cytochrome c release from mitochondria, serving as an amplifier of the TRAIL/Apo2L-mediated cascade of caspase activation. These data provide novel insights into the role of the TRAIL/Apo2L system in malignant gliomas and illustrate that TRAIL/Apo2L-based immunochemotherapy may be an effective therapeutic strategy for these lethal neoplasms.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; Univ Tubingen, Sch Med, Inst Physiol, D-72076 Tubingen, Germany; German Canc Res Ctr, Dept Immunogenet, D-6900 Heidelberg, Germany; German Canc Res Ctr, Dept Apoptosis Regulat, D-6900 Heidelberg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Walczak, Henning/AAV-2214-2020; Gulbins, Erich/L-6989-2014	Walczak, Henning/0000-0002-6312-4591; Gulbins, Erich/0000-0002-3117-1342; Weller, Michael/0000-0002-1748-174X				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; GLASER T, 2001, IN PRESS ONCOGENE; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hermisson M, 2000, ONCOGENE, V19, P2338, DOI 10.1038/sj.onc.1203554; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Nagane M, 2000, CANCER RES, V60, P847; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schmidt F, 2001, EUR J PHARMACOL, V412, P21, DOI 10.1016/S0014-2999(00)00923-7; Sheikh MS, 1998, CANCER RES, V58, P1593; VAN MEIR EG, 1994, CANCER RES, V54, P649; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1998, INT J CANCER, V79, P640; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	27	85	90	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4128	4137		10.1038/sj.onc.1204534	http://dx.doi.org/10.1038/sj.onc.1204534			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464279				2022-12-28	WOS:000169857200003
J	Wang, JY; Del Valle, L; Gordon, J; Rubini, M; Romano, G; Croul, S; Peruzzi, F; Khalili, K; Reiss, K				Wang, JY; Del Valle, L; Gordon, J; Rubini, M; Romano, G; Croul, S; Peruzzi, F; Khalili, K; Reiss, K			Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas	ONCOGENE			English	Article						IGF-IR; medulloblastoma; IRS-1; cell proliferation; tyrosine phosphorylation	INSULIN-RECEPTOR SUBSTRATE-1; DOMINANT-NEGATIVE MUTANT; NEUROTROPIC JC VIRUS; CELL-LINE; IN-VIVO; EMBRYO FIBROBLASTS; INDUCED APOPTOSIS; TUMOR-GROWTH; C-MYC; TRANSFORMATION	Insulin-like growth factor I receptor (IGF-IR) has been implicated in the normal and malignant growth of many cell types including cells from the central nervous system. In the cerebellar cortex ICF-IR mRNA is found in granular cells and IGF-I stimulation is mitogenic and protects cells from low-potassium-induced apoptosis, Since primitive neuroectodermal tumers/medulloblastomas (PNETs/medulloblastomas) are suspected to originate from the external cerebellar granular layer, it is reasonable to postulate that IGF-IR and/or its signaling molecules may contribute to the transformation of these poorly differentiated cells. To study activation of the IGF-IR system in medulloblastomas, we have utilized an antibody (anti-pY1316) that specifically recognizes the phosphorylated (active) form of the IGF-IR, Medulloblastoma biopsy specimens were positive when examined immunohistochemically with anti-Y1316 antibody. Further analysis of the IGF-IR system was performed in three human (Daoy, TE-671, D283 Med) and four mouse (BsB8, BsB13, Bs-lb, Bs-lc) medulloblastoma cell lines. All the murine cell lines examined express IGF-IR and PI3-kinase at relatively normal levels, and grossly overexpress IRS-I, when compared with normal mouse cerebellum. Within 15 min following IGF-I stimulation both mouse and human cell lines phosphorylate the P subunit of the IGF-IR, IRS-1, Akt, and MAP kinases, They respond with cell proliferation when stimulated solely with IGF-I and are strongly inhibited when challenged with a dominant negative mutant of the IGF-IR (486/STOP), or with antisense oligonucleotides against the IGF-IR mRNA.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, I-44100 Ferrara, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Ferrara; Jefferson University	Reiss, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St,Biol Life Sci Bldg,Room 238, Philadelphia, PA 19122 USA.		Rubini, Michele/AFF-8477-2022; Peruzzi, Francesca/M-9804-2014; Del Valle, Luis/J-4085-2015	Rubini, Michele/0000-0003-1448-9516; Del Valle, Luis/0000-0003-3894-9206; Croul, Sidney/0000-0002-2224-5485	NINDS NIH HHS [P0-1 NS 36466] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BASERGA R, 1995, CANCER RES, V55, P240; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DAmbrosio C, 1996, CANCER RES, V56, P4013; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; Dunn SE, 1998, CANCER RES, V58, P3353; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; FULTS D, 1989, BRAIN RES, V503, P281, DOI 10.1016/0006-8993(89)91675-2; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; KALEBIC T, 1994, CANCER RES, V54, P5531; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MARTIN DM, 1992, MOL BRAIN RES, V15, P241, DOI 10.1016/0169-328X(92)90114-Q; MIURA M, 1995, CANCER RES, V55, P663; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Morrione A, 2000, CANCER RES, V60, P2263; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Pappas IS, 1996, CELL GROWTH DIFFER, V7, P797; Patti R, 2000, INT J ONCOL, V16, P577; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PORCU P, 1994, ONCOGENE, V9, P2125; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; REISS K, 1995, AM J PHYSIOL-HEART C, V269, pH943, DOI 10.1152/ajpheart.1995.269.3.H943; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; RESNICOFF M, 1994, CANCER RES, V54, P2218; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Rubini M, 1999, EXP CELL RES, V251, P22, DOI 10.1006/excr.1999.4562; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Steller MA, 1996, CANCER RES, V56, P5087; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; WATERS SB, 1993, J BIOL CHEM, V268, P22231	51	74	76	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3857	3868		10.1038/sj.onc.1204532	http://dx.doi.org/10.1038/sj.onc.1204532			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439349				2022-12-28	WOS:000169494700011
J	Mohanam, S; Jasti, SL; Kondraganti, SR; Chandrasekar, N; Lakka, SS; Kin, Y; Fuller, GN; Yung, AWK; Kyritsis, AP; Dinh, DH; Olivero, WC; Gujrati, M; Ali-Osman, F; Rao, JS				Mohanam, S; Jasti, SL; Kondraganti, SR; Chandrasekar, N; Lakka, SS; Kin, Y; Fuller, GN; Yung, AWK; Kyritsis, AP; Dinh, DH; Olivero, WC; Gujrati, M; Ali-Osman, F; Rao, JS			Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells	ONCOGENE			English	Article						glioblastoma; invasion; cathepsin B	HUMAN GLIOMAS; CYSTATIN-C; PROTEASE INHIBITORS; TUMOR PROGRESSION; CANCER METASTASIS; PROGNOSTIC FACTOR; BREAST-CANCER; ANGIOGENESIS; LOCALIZATION; LINES	Increases in abundance of cathepsin B transcript and protein correlate with increases in tumor grade and alterations in subcellular localization and activity of cathepsin B, The enzyme is able to degrade the components of the extracellular matrix (ECM) and activate other proteases capable of degrading ECM, To investigate the role played by this protease in the invasion of brain tumor cells, we transfected SNB19 human glioblastoma cells with a plasmid containing cathepsin B cDNA in antisense orientation. Control cells were transfected with vector alone. Clones expressing antisense cathepsin B cDNA exhibited significant reductions in cathepsin B mRNA, enzyme activity and protein compared to controls. Matrigel Invasion assay showed that the antisense-transfected cells had markedly diminished invasiveness compared with controls. When tumor spheroids containing antisense transfected SNB19 cells expressing reduced cathepsin B were co-cultured with fetal rat brain aggregates, invasion of fetal rat brain aggregates was significantly reduced. Green Fluorescent Protein (GFP) expressing parental cells and antisense transfectants were generated for detection in mouse brain tissue without any post-chemical treatment. Intracerebral injection of SNB19 stable antisense transfectants resulted in reduced tumor formation in nude mice. These results strongly support a role for cathepsin B in the invasiveness of human glioblastoma cells and suggest cathepsin B antisense may prove useful in cancer therapy.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neuropathol, Houston, TX 77030 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA.			Fuller, Gregory/0000-0001-9447-2647	NCI NIH HHS [P30 CA-16672, CA 76350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA076350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAO LQ, 1994, GENE, V139, P163, DOI 10.1016/0378-1119(94)90750-1; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Cox JL, 1999, MELANOMA RES, V9, P369, DOI 10.1097/00008390-199908000-00005; Demchik LL, 1999, INT J DEV NEUROSCI, V17, P483, DOI 10.1016/S0736-5748(99)00011-8; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; Foekens JA, 1998, J CLIN ONCOL, V16, P1013, DOI 10.1200/JCO.1998.16.3.1013; Friedrich B, 1999, EUR J CANCER, V35, P138, DOI 10.1016/S0959-8049(98)00273-1; Go Y, 1996, CANCER LETT, V110, P225, DOI 10.1016/S0304-3835(96)04515-6; Goldbrunner RH, 1998, MICROSC RES TECHNIQ, V43, P250, DOI 10.1002/(SICI)1097-0029(19981101)43:3<250::AID-JEMT7>3.0.CO;2-C; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Heidtmann HH, 1997, CLIN EXP METASTAS, V15, P368, DOI 10.1023/A:1018494020001; Hirai K, 1999, HUM PATHOL, V30, P680, DOI 10.1016/S0046-8177(99)90094-1; IacobuzioDonahue CA, 1997, J BIOL CHEM, V272, P29190, DOI 10.1074/jbc.272.46.29190; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; Kostoulas G, 1999, FEBS LETT, V455, P286, DOI 10.1016/S0014-5793(99)00897-2; Kruger S, 1999, CANCER RES, V59, P6010; Lah TT, 1998, BIOL CHEM, V379, P125; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maguire TM, 1998, INT J BIOL MARKER, V13, P139, DOI 10.1177/172460089801300303; MCCORMICK D, 1993, NEUROPATH APPL NEURO, V19, P146, DOI 10.1111/j.1365-2990.1993.tb00420.x; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Navab R, 1997, CLIN EXP METASTAS, V15, P121, DOI 10.1023/A:1018496625936; Nygaard SJT, 1995, INVAS METAST, V15, P179; PEDERSEN PH, 1993, CANCER RES, V53, P5158; REMPEL SA, 1994, CANCER RES, V54, P6027; SCHMITT M, 1992, FIBRINOLYSIS, V6, P3; Sinha AA, 1998, ANAT REC, V252, P281; SIVAPARVATHI M, 1995, CLIN EXP METASTAS, V13, P49, DOI 10.1007/BF00144018; Sivaparvathi M, 1996, CLIN EXP METASTAS, V14, P27, DOI 10.1007/BF00157683; SPIESS E, 1994, J HISTOCHEM CYTOCHEM, V42, P917, DOI 10.1177/42.7.8014475; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Van Noorden CJF, 1998, CLIN EXP METASTAS, V16, P159; Werle B, 1999, BRIT J CANCER, V81, P510, DOI 10.1038/sj.bjc.6690723	39	71	73	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3665	3673		10.1038/sj.onc.1204480	http://dx.doi.org/10.1038/sj.onc.1204480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439329				2022-12-28	WOS:000169400200007
J	Chen, F; Zhang, Z; Leonard, SS; Shi, XL				Chen, F; Zhang, Z; Leonard, SS; Shi, XL			Contrasting roles of NF-kappa B and JNK in arsenite-induced p53-independent expression of GADD45 alpha	ONCOGENE			English	Article						arsenite; GADD45 alpha; NF-kappa B; JNK; cell cycle; p53	CELL-CYCLE CHECKPOINT; GENE-EXPRESSION; EPITHELIAL-CELLS; IKK-BETA; ACTIVATION; INDUCTION; KINASE; STRESS; TRANSCRIPTION; BRCA1	Growth arrest and DNA damage-inducible protein 45 alpha (GADD45 alpha) is an important cell cycle checkpoint protein that arrests cells at G2/M phase by inhibiting the activity of G2-specific kinase, cyclin B/p34cdc2. We report here that arsenite induces GADD45 alpha expression in a p53-independent fashion and that this GADD45a induction by arsenite is regulated by NF-KB and c-Jun-N-terminal kinase (JNK) oppositely. In human bronchial epithelial cells overexpressing a kinase-mutated form of I kappaB kinase beta (IKK beta -KM), the activation of NF-kappaB was inhibited. However, the G2/M cell cycle arrest and expression of GADB45 alpha was substantially enhanced in response to arsenite in these cells. Expression of a dominant-negative mutant of SEK1 that blocks JNK activation decreased arsenite-induced GADD45a expression. Analysis of GADD45 alpha expression in both wild-type and p53-/- fibroblasts indicated that the induction of GADD45a by arsenite was independent of the status of p53 protein.	NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Chen, F (corresponding author), NIOSH, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Zhang, Zhuo/B-8601-2012; Shi, Xianglin/B-8588-2012					Barchowsky A, 1996, FREE RADICAL BIO MED, V21, P783, DOI 10.1016/0891-5849(96)00174-8; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen F, 1999, CLIN CHEM, V45, P7; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; Gebel T, 2000, TOXICOLOGY, V144, P155, DOI 10.1016/S0300-483X(99)00202-4; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hamilton JW, 1998, ENVIRON HEALTH PERSP, V106, P1005, DOI 10.2307/3434145; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Huang SC, 1998, CARCINOGENESIS, V19, P889, DOI 10.1093/carcin/19.5.889; Jaspers I, 1999, J BIOL CHEM, V274, P31025, DOI 10.1074/jbc.274.43.31025; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kayajanian GM, 2000, ECOTOX ENVIRON SAFE, V45, P195, DOI 10.1006/eesa.1999.1865; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Mazumder DNG, 1998, INT J EPIDEMIOL, V27, P871, DOI 10.1093/ije/27.5.871; O'Reilly MA, 2000, AM J PHYSIOL-LUNG C, V278, pL552, DOI 10.1152/ajplung.2000.278.3.L552; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Simeonova Petia P., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P281; Simeonova PP, 2000, CANCER RES, V60, P3445; Styblo M, 1999, CHEM RES TOXICOL, V12, P560, DOI 10.1021/tx990050l; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	36	26	27	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3585	3589		10.1038/sj.onc.1204442	http://dx.doi.org/10.1038/sj.onc.1204442			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429707				2022-12-28	WOS:000169478300016
J	Blesofsky, WA; Mowen, K; Arduini, RM; Baker, DP; Murphy, MA; Bowtell, DDL; David, M				Blesofsky, WA; Mowen, K; Arduini, RM; Baker, DP; Murphy, MA; Bowtell, DDL; David, M			Regulation of STAT protein synthesis by c-Cbl	ONCOGENE			English	Article						interferon; c-Cbl; STAT; translation	EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; TRANSCRIPTION FACTOR; FACTOR RECEPTOR; INTERFERON ACTIVATION; SIGNALING PROTEINS; NEGATIVE REGULATOR; CSF-1 RECEPTOR; V-CBL	Many cytokines and growth factors induce transcription of immediate early response genes by activating members of the Signal Transducers and Activators of Transcription (STAT) family. Although significant progress has been made in understanding the events that lead to the activation of STAT proteins, less, is known about the regulation of their expression. Here we report that murine embryonic fibroblasts derived from c-Cbl-deficient mice display significantly increased levels of STAT1 and STAT5 protein. In contrast, STAT2 and STAT3 expression, as well as the levels of the tyrosine kinases Jak1 and Tyk2, appear to be regulated independently of c-Cbl. Interestingly, the half-life of STAT1 was, unaffected by the presence of c-Cbl, indicating that c-Cbl acts independently of STAT1 degradation. Further analysis revealed similar levels of STAT1 mRNA, however, a dramatically increased rate of STAT1 protein synthesis was observed in c-Cbl-deficient cells. Thus, our findings, demonstrate an additional control mechanism over STAT1 function, and also provide a novel biological effect of the Chl protein family.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3000, Australia; Biogen Inc, Cambridge, MA 02142 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Peter Maccallum Cancer Center; Biogen	David, M (corresponding author), Univ Calif San Diego, Dept Biol, Bonner Hall 3138,9500 Gilman Dr, La Jolla, CA 92093 USA.		Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525	NATIONAL CANCER INSTITUTE [R01CA080105] Funding Source: NIH RePORTER; NCI NIH HHS [CA80105] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; BLAKE TJ, 1991, ONCOGENE, V6, P653; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; LAMER AC, 1993, SCIENCE, V261, P1730; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LOKVIST WE, 2001, BIOCHEM J, V356, P627; Luca ME, 1999, J NEUROIMMUNOL, V100, P190, DOI 10.1016/S0165-5728(99)00198-8; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Thien CBF, 1999, J IMMUNOL, V162, P7133; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	42	16	17	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7326	7333		10.1038/sj.onc.1204919	http://dx.doi.org/10.1038/sj.onc.1204919			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704862	Green Published			2022-12-28	WOS:000171894200005
J	Jackson, JG; Zhang, XH; Yoneda, T; Yee, D				Jackson, JG; Zhang, XH; Yoneda, T; Yee, D			Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines	ONCOGENE			English	Article						breast neoplasms; insulin-like growth factors; cell migration; insulin receptor substrate; adhesion	GROWTH-FACTOR-I; IGF-I; EPITHELIAL-CELLS; EXPRESSION; ADHESION; INTEGRINS; MIGRATION; CARCINOMA; PHENOTYPE; PROTEINS	Insulin-like growth factors (IGFs) regulate breast cancer cell proliferation, protect cells from apoptosis, and enhance metastasis. In this study, we examined the IGF signaling pathway in two breast cancer cell lines selected for metastatic behavior. LCC6 was, selected for growth as, an ascites tumor in athymic mice from parental MDA-MB-435 cells (435P). The MDA-231BO cell line was derived from osseous metastases that formed after intracardiac injection of the MDA-MB-231 cell line in athymic mice. Compared to the parental cell Rues, IGF-I treatment enhanced IRS-2 phosphorylation over IRS-I in the metastatic variants. IGF-I stimulated cell migration in the variant cells, but not in the parental cells. To. determine the role for IRS-2 in IGF-mediated motility, we transfected MDA-231BO cells with, an anti-sense IRS-2 construct. Transfected cells had decreased levels of IRS-2. with diminished IGF-mediated motility and anchorage independent growth when compared to control cells. However, adherence to fibronectin was. enhanced in the transfected cells compared to MD A-231BO cells. Our data show that breast cancer cells selected for metastatic behavior in vivo have increased IRS-2 activation and signaling. In these cells, IGF-I enhances cell adhesion and motility suggesting that IRS-2 may mediate these aspects of the malignant phenotype.	Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Dept Med, Minneapolis, MN 55455 USA; Univ Texas, Hlth Sci Ctr, Div Med Oncol, Dept Med, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Div Endocrinol, Dept Med, San Antonio, TX 78229 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Yee, D (corresponding author), Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Dept Med, Mayo Mail Code 806,420 Delaware St SE, Minneapolis, MN 55455 USA.			Yee, Douglas/0000-0002-3387-4009; Jackson, James Griffith/0000-0002-2640-6442	NATIONAL CANCER INSTITUTE [R01CA074285, P30CA054174] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA74285, P30CA54174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; Clemmons DR, 1999, ENDOCRINOLOGY, V140, P4616, DOI 10.1210/en.140.10.4616; CULLEN KJ, 1990, CANCER RES, V50, P48; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FIGUEROA JA, 1993, J CELL PHYSIOL, V157, P229, DOI 10.1002/jcp.1041570204; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lebrun P, 2000, J BIOL CHEM, V275, P38371, DOI 10.1074/jbc.M006162200; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; LONG L, 1995, CANCER RES, V55, P1006; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; SMITH LK, 1995, MOL CELL ENDOCRINOL, V113, P73, DOI 10.1016/0303-7207(95)03622-E; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Yu GH, 1998, AM J CLIN PATHOL, V109, P315, DOI 10.1093/ajcp/109.3.315; Zutter MM, 1998, J MAMMARY GLAND BIOL, V3, P191, DOI 10.1023/A:1018798907544	32	105	111	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7318	7325		10.1038/sj.onc.1204920	http://dx.doi.org/10.1038/sj.onc.1204920			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704861				2022-12-28	WOS:000171894200004
J	Lin, RJ; Sternsdorf, T; Tini, M; Evans, RM				Lin, RJ; Sternsdorf, T; Tini, M; Evans, RM			Transcriptional regulation in acute promyelocytic leukemia	ONCOGENE			English	Review						APL; X-RAR alpha; PML; PLZF; coreprescor; HDAC; CBP/p300; POD	PML-RAR-ALPHA; ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE COMPLEX; CREB-BINDING-PROTEIN; ACID-INDUCED DIFFERENTIATION; TRANS-RETINOIC ACID; NUCLEAR-BODIES; N-COR; MOLECULAR PATHOGENESIS; FUSION PROTEINS	It has been 10 years since the seminal discovery that a mutant form of a retinoid acid receptor (RAR alpha) is associated with acute promyelocytic leukemia (APL). This finding, coupled with the remarkable success of retinoic acid (RA), the natural ligand of RAR alpha, in the treatment of APL, has made APL a unique model system in the study of oncogenic conversion of transcription factors in hematological malignancies. Indeed, subsequent basic and clinical studies showed that chromosomal translocation involving the RAR alpha gene is the cytogenetic hallmark of APL and that these mutant forms of RARs are the oncogenes in APL that interfere with the proliferation and differentiation pathways controlled by both RAR and their fusion partners. However, it was not until recently that the role of aberrant transcriptional regulation in the pathogenesis of APL was revealed. In this review, we summarize the biochemical and biological mechanisms of transcriptional regulation by mutant RARs and their corresponding wild-type fusion partner PML and PLZF. These studies have been instrumental in our understanding of the process of leukemogenesis in general and have laid the scientific foundation for the novel concept of transcription therapy in the treatment of human cancer.	Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	evans@salk.edu	, MT/AAU-2370-2020; Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Lin, Richard/0000-0002-0834-7880				Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Doucas V, 2000, BIOCHEM PHARMACOL, V60, P1197, DOI 10.1016/S0006-2952(00)00413-5; DOUCAS V, 1996, BIOCHIM BIOPHYS ACTA, V1288, P25; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Ferbeyre G, 2000, GENE DEV, V14, P2015; Ferrara FF, 2001, CANCER RES, V61, P2; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Glass CK, 2000, GENE DEV, V14, P121; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guidez F, 2000, BLOOD, V96, P2557; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Kogan SC, 1999, ONCOGENE, V18, P5261, DOI 10.1038/sj.onc.1202996; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lawson ND, 1999, EXP HEMATOL, V27, P1355, DOI 10.1016/S0301-472X(99)00085-5; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li H, 2000, CURR OPIN CELL BIOL, V12, P641, DOI 10.1016/S0955-0674(00)00144-7; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Redner RL, 2000, BLOOD, V95, P2683; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Shao WL, 2000, BLOOD, V96, P2233; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STUURMAN N, 1997, CELL MOL BIOL LETT, V2, P137; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Trost M, 2000, J BIOL CHEM, V275, P7373, DOI 10.1074/jbc.275.10.7373; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VanLint C, 1996, GENE EXPRESSION, V5, P245; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang JW, 2000, J BIOSCIENCES, V25, P275, DOI 10.1007/BF02703936; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463	132	135	146	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7204	7215		10.1038/sj.onc.1204853	http://dx.doi.org/10.1038/sj.onc.1204853			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704848				2022-12-28	WOS:000171891900008
J	Lin, SCJ; Skapek, SX; Papermaster, DS; Hankin, M; Lee, EYHP				Lin, SCJ; Skapek, SX; Papermaster, DS; Hankin, M; Lee, EYHP			The proliferative and apoptotic activities of E2F1 in the mouse retina	ONCOGENE			English	Article						E2F1; p53; RB and retinoblastoma	S-PHASE ENTRY; RETINOBLASTOMA GENE FAMILY; TRANSCRIPTION FACTOR E2F1; SKELETAL-MUSCLE CELLS; ADIPOCYTE DIFFERENTIATION; DEREGULATED EXPRESSION; FIBROBLASTS LEADS; TRANSGENIC MICE; PROTEIN; RB	The E2F1 transcription factor controls cell proliferation and apoptosis. E2F1 activity is negatively regulated by the retinoblastoma (RB) protein. To study how inactivation of Rb and dysregulated E2F1 affects the developing retina, we analysed wild-type and Rb-/- embryonic retinas and retinal transplants and we established transgenic mice expressing human E2F1 in retinal photoreceptor cells under the regulation of the IRBP promoter (TgIRBPE2F1). A marked increase in cell proliferation and apoptosis was observed in the retinas of Rb-/- mice and TgIRBPE2F1 transgenic mice. In the transgenic mice, photoreceptor cells formed rosette-like arrangements at postnatal days 9 through 28. Complete loss of photoreceptors followed in the TgIRBPE2F1 mice but not in the Rb-/- retinal transplants. Both RB-deficient and E2F1-overexpressing photoreceptor cells expressed rhodopsin, a marker of terminal differentiation. Loss of p53 partially reduced the apoptosis and resulted in transient hyperplasia of multiple cell types in the TgIRBPE2F1 retinas at postnatal day 6. Our findings support the concept that cross-talk occurs between different retinal cell types and that multiple genetic pathways must become dysregulated for the full oncogenic transformation of neuronal retinal cells.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Connecticut, Hlth Sci Ctr, Dept Neurosci, Farmington, CT 06030 USA; Med Coll Ohio, Dept Anat & Neurobiol, Toledo, OH 43614 USA	University of Texas System; University of Texas Health San Antonio; St Jude Children's Research Hospital; University of Connecticut	Lee, EYHP (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.	Leee@uthscsa.edu			NCI NIH HHS [P30 CA 54174, CA49649] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA054174, R29CA049649, R37CA049649, R01CA049649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ALUBAIDI MR, 1992, P NATL ACAD SCI USA, V89, P1194, DOI 10.1073/pnas.89.4.1194; Belliveau MJ, 1999, DEVELOPMENT, V126, P555; Belliveau MJ, 2000, J NEUROSCI, V20, P2247; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen G, 1999, DNA CELL BIOL, V18, P305, DOI 10.1089/104454999315367; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANKIN M, 1993, DEV BRAIN RES, V75, P146, DOI 10.1016/0165-3806(93)90075-L; HANKIN MH, 1987, J COMP NEUROL, V263, P455, DOI 10.1002/cne.902630310; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HU NP, 1994, ONCOGENE, V9, P1021; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; LIOU GI, 1990, J BIOL CHEM, V265, P8373; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; McCaffrey J, 1999, MOL CELL BIOL, V19, P6458; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; NIR I, 1984, J CELL BIOL, V98, P1788, DOI 10.1083/jcb.98.5.1788; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Skapek SX, 2000, J BIOL CHEM, V275, P7212, DOI 10.1074/jbc.275.10.7212; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Udovichenko IP, 1998, J BIOL CHEM, V273, P7181, DOI 10.1074/jbc.273.13.7181; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; YOUNG RW, 1984, CELL, V85, P537; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	64	23	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7073	7084		10.1038/sj.onc.1204932	http://dx.doi.org/10.1038/sj.onc.1204932			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704831				2022-12-28	WOS:000171739300010
J	Lin, JL; Chen, HC; Fang, HI; Robinson, D; Kung, HJ; Shih, HM				Lin, JL; Chen, HC; Fang, HI; Robinson, D; Kung, HJ; Shih, HM			MST4, a new Ste20-related kinase that mediates cell growth and transformation via modulating ERK pathway	ONCOGENE			English	Article						Ste20 kinase; cell transformation; kinase signaling	N-TERMINAL KINASE; STE20-LIKE PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; SIGNALING COMPONENTS; ADAPTER PROTEINS; CARCINOMA-CELLS; FAMILY MEMBERS; OXIDANT STRESS; ACTIVATION; APOPTOSIS	In this study, we report the cloning and characterization of a novel human Ste20-related kinase that we designated MST4 (accession number AF231012). The 416 amino acid full-length MST4 contains an aminoterminal kinase domain, which is highly homologous to MST3 and SOK, and a unique carboxy-terminal domain. Northern blot analysis indicated that MST4 is highly expressed in placenta, thymus, and peripheral blood leukocytes. Wild-type but not kinase-dead MST4 can phosphorylate myelin basic protein in an in vitro kinase assay. MST4 specifically activates ERK but not JNK or p38 MAPK in transient transfected cells or in stable cell lines. Overexpression of dominant negative MEK1 or treatment with PD98059 abolishes MST4-induced ERK activity, whereas dominant-negative Ras or c-Raf-1 mutants failed to do so, indicating MST4 activates MEK1/ERK via a Ras/Raf-1 independent pathway. HeLa and Phoenix cell lines overexpressing wild-type, but not kinase-dead, MST4 exhibit increased growth rate and form aggressive soft-agar colonies. These phenotypes can be inhibited by PD98059. These results provide the first evidence that MST4 is biologically active in the activation of MEK/ERK pathway and in mediating cell growth and transformation.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	National Health Research Institutes - Taiwan; National Defense Medical Center; University of California System; University of California Davis	Shih, HM (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128,Sec2,Yen Chiu Yuan RD, Taipei 11529, Taiwan.	shihh@nhri.org.tw	Kung, Hsing-Jien/C-7651-2013; Shih, Hsiu-Ming/S-7023-2018					ARNOLD R, 2001, J BIOL CHEM, V29, P29; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BRUNET A, 1994, ONCOGENE, V9, P3379; Chen HC, 1998, J BIOMED SCI, V5, P86, DOI 10.1007/BF02258361; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Endo J, 2000, FEBS LETT, V468, P234, DOI 10.1016/S0014-5793(00)01219-9; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; GRAVES JD, 2001, J BIOL CHEM, V13, P13; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Greulich H, 1996, ONCOGENE, V12, P1689; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Kakeya H, 1998, CANCER RES, V58, P4888; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; LEE KK, 2001, J BIOL CHEM, V7, P7; LING P, 2001, J BIOL CHEM, V13, P13; Ljungdahl S, 1998, CELL GROWTH DIFFER, V9, P565; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Nakano K, 2000, J BIOL CHEM, V275, P20533, DOI 10.1074/jbc.M001009200; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; QIAN Z, 2001, J BIOL CHEM, V16, P16; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Schramek H, 1997, J BIOL CHEM, V272, P11426; Schrick K, 1997, GENETICS, V147, P19; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Tsutsumi T, 2000, J BIOL CHEM, V275, P9157, DOI 10.1074/jbc.275.13.9157; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yustein JT, 2000, ONCOGENE, V19, P710, DOI 10.1038/sj.onc.1203342; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513	65	84	87	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6559	6569		10.1038/sj.onc.1204818	http://dx.doi.org/10.1038/sj.onc.1204818			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641781				2022-12-28	WOS:000171404200009
J	Ravichandran, KS				Ravichandran, KS			Signaling via Shc family adapter proteins	ONCOGENE			English	Article						Shc; Grb2; MAPkinase; SH2; PTB; SHIP	EPIDERMAL GROWTH-FACTOR; PHOSPHOTYROSINE-BINDING-DOMAIN; TYROSINE-PHOSPHORYLATED PROTEIN; INOSITOL PHOSPHATASE SHIP; POLYOMAVIRUS MIDDLE-T; PLECKSTRIN HOMOLOGY DOMAINS; COLONY-STIMULATING FACTOR; BREAST-CANCER CELLS; PTB DOMAIN; FACTOR-RECEPTOR	The adapter protein She was initially identified as an SH2 containing proto-oncogene involved in growth factor signaling. Since then a number of studies in multiple systems have implicated a role for She in signaling via many different types of receptors, such as growth factor receptors, antigen receptors, cytokine receptors, G-protein coupled receptors, hormone receptors and integrins. In addition to the ubiquitous ShcA, two other she gene products, ShcB and ShcC, which are predominantly expressed in neuronal cells, have also been identified. ShcA knockout mice are embryonic lethal and have clearly suggested an important role for ShcA in vivo. Based on dominant negative studies and mouse embryos deficient in ShcA, a clear role for She in leading to mitogen activated protein kinase (MAPK) activation has been established. However MAPK activation may not be the sole function of She proteins. Although She has also been linked to other signaling events such as c-Myc activation and cell survival, the mechanistic understanding of these signaling events remains poorly characterized. Given the apparently central role that She plays signaling via many receptors, delineating the precise mechanism(s) of She-mediated signaling may be critical to our understanding of the effects mediated through these receptors.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Ravichandran, KS (corresponding author), Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-55761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006-2952(00)00385-3; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BUDAY L, 1995, ONCOGENE, V11, P1327; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Conti L, 1997, P NATL ACAD SCI USA, V94, P8185, DOI 10.1073/pnas.94.15.8185; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Gresham J, 1998, INT J CANCER, V77, P923, DOI 10.1002/(SICI)1097-0215(19980911)77:6<923::AID-IJC21>3.0.CO;2-0; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Harmer SL, 1999, J BIOL CHEM, V274, P12183, DOI 10.1074/jbc.274.17.12183; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Howell BW, 1999, MOL CELL BIOL, V19, P5179; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Lai KMV, 2000, GENE DEV, V14, P1132; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Liu L, 1997, LEUKEMIA, V11, P181, DOI 10.1038/sj.leu.2400559; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Lord JD, 1998, J IMMUNOL, V161, P4627; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Luschnig S, 2000, MOL CELL, V5, P231, DOI 10.1016/S1097-2765(00)80419-0; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; MIKOL V, 1995, J MOL BIOL, V254, P86, DOI 10.1006/jmbi.1995.0601; Morte C, 1998, MOL REPROD DEV, V50, P113, DOI 10.1002/(SICI)1098-2795(199805)50:1<113::AID-MRD14>3.0.CO;2-9; Mullane KP, 1998, MOL CELL BIOL, V18, P7556, DOI 10.1128/MCB.18.12.7556; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; Pratt JC, 1999, J IMMUNOL, V163, P2586; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rauh MJ, 1999, MOL CELL BIOL, V19, P8169; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; Ravichandran KS, 1995, ANN NY ACAD SCI, V766, P202, DOI 10.1111/j.1749-6632.1995.tb26663.x; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Rety S, 1996, PROTEIN SCI, V5, P405; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SAXTON TM, 1994, J IMMUNOL, V153, P623; Schmandt R, 1999, ONCOGENE, V18, P1867, DOI 10.1038/sj.onc.1202507; Shoelson SE, 1997, CURR OPIN CHEM BIOL, V1, P227, DOI 10.1016/S1367-5931(97)80014-2; SOLER C, 1994, ONCOGENE, V9, P2207; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Stevenson LE, 1998, BREAST CANCER RES TR, V49, P119, DOI 10.1023/A:1006007227747; Stevenson LE, 1999, CELL GROWTH DIFFER, V10, P61; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; TRUB T, 1995, J BIOL CHEM, V270, P18205; VAN BT, 1995, NATURE, V376, P781; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Velazquez L, 2000, BLOOD, V96, P132, DOI 10.1182/blood.V96.1.132.013k13_132_138; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zhu WJ, 1998, ONCOGENE, V17, P565, DOI 10.1038/sj.onc.1201979	97	324	336	1	16	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6322	6330		10.1038/sj.onc.1204776	http://dx.doi.org/10.1038/sj.onc.1204776			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607835	Bronze			2022-12-28	WOS:000171640600008
J	Zhou, H; Chen, WD; Qin, XS; Lee, K; Liu, LL; Markowitz, SD; Gerson, SL				Zhou, H; Chen, WD; Qin, XS; Lee, K; Liu, LL; Markowitz, SD; Gerson, SL			MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice	ONCOGENE			English	Article						c-neu transgenic mice; mammary tumor; DNA hypomethylation; MNU; MMTV promoter	METHYL-N-NITROSOUREA; DE-NOVO METHYLATION; HUMAN-BREAST-CANCER; DNA METHYLATION; FOREIGN DNA; HUMAN MGMT; RAS ONCOGENE; INDUCTION; TUMORS; ALKYLTRANSFERASE	The erbB family of receptor tyrosine kinases is frequently implicated in neoplasia. Amplification and overexpression of erbB2/neu has been found in 20 to 40% of human breast cancers. Previous studies using MMTV/c-neu transgenic mice have linked rat neu overexpression to mammary tumor development. In this study, we provide evidence that rat neu overexpression in mammary tumors of MMTV/c-neu transgenic mice is always associated with demethylation of the MMTV promoter, whereas the normal mammary glands of these transgenic mice always contain specific methylated regions of the MMTV promoter. In addition, after exposure to N-methyl-N-nitrosourea (MNU), the latency of mammary tumor development is significantly reduced and again is also associated with MMTV promoter demethylation. Thus, the transition from methylation to hypomethylation of the MMTV promoter induces high-level expression of c-neu and appears to be a prerequisite for transformation from normal to malignant mammary epithelium, either spontaneously or after carcinogen exposure. Expression of transgenic c-neu from the demethylated MMTV promoter appears to be an early event that allows outgrowth of mammary epithelium predisposed to malignant transformation.	Case Western Reserve Univ, Univ Hosp, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Howard Hughes Medical Institute	Gerson, SL (corresponding author), Case Western Reserve Univ, Univ Hosp, Div Hematol Oncol, BRB-3W,10900 Euclid Ave, Cleveland, OH 44106 USA.	slg5@po.cwru.edu	CHEN, WEI-DONG/F-4521-2014	CHEN, WEI-DONG/0000-0003-2264-5515	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NIEHS NIH HHS [5R01 ES 06288] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Asamoto M, 2000, CARCINOGENESIS, V21, P243, DOI 10.1093/carcin/21.2.243; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Betzl G, 1996, BIOL CHEM, V377, P711, DOI 10.1515/bchm3.1996.377.11.711; BOEHM TLJ, 1983, RECENT RES CANCER, V84, P212; BOEHM TLJ, 1981, CARCINOGENESIS, V2, P39, DOI 10.1093/carcin/2.1.39; BOEHM TLJ, 1983, J NATL CANCER I, V71, P429; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Cervoni N, 1999, J BIOL CHEM, V274, P8363, DOI 10.1074/jbc.274.13.8363; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; Doerfler W, 1997, TRENDS BIOTECHNOL, V15, P297, DOI 10.1016/S0167-7799(97)01061-5; DOERFLER W, 1995, GENE, V157, P241, DOI 10.1016/0378-1119(95)00080-P; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FONG LYY, 1990, CARCINOGENESIS, V11, P411, DOI 10.1093/carcin/11.3.411; FREI JV, 1980, J NATL CANCER I, V64, P845; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; GERSON SL, 1985, J CLIN INVEST, V76, P2106, DOI 10.1172/JCI112215; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HANADA M, 1993, BLOOD, V82, P1820; Hung MC, 1999, SEMIN ONCOL, V26, P51; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; LU SJ, 1992, MOL CARCINOGEN, V6, P260, DOI 10.1002/mc.2940060407; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OREND G, 1995, J VIROL, V69, P1226, DOI 10.1128/JVI.69.2.1226-1242.1995; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Qin XS, 1999, ONCOGENE, V18, P4394, DOI 10.1038/sj.onc.1202798; Qin XS, 1999, CARCINOGENESIS, V20, P1667, DOI 10.1093/carcin/20.9.1667; RAO PM, 1989, CARCINOGENESIS, V10, P933, DOI 10.1093/carcin/10.5.933; Robertson G, 1996, NUCLEIC ACIDS RES, V24, P1465, DOI 10.1093/nar/24.8.1465; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Young LH, 1996, MOL CARCINOGEN, V15, P251, DOI 10.1002/(SICI)1098-2744(199604)15:4<251::AID-MC2>3.0.CO;2-J; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	44	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6009	6017		10.1038/sj.onc.1204830	http://dx.doi.org/10.1038/sj.onc.1204830			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593408				2022-12-28	WOS:000171056300008
J	Wei, LH; Kuo, ML; Chen, CA; Chou, CH; Cheng, WF; Chang, MC; Su, JL; Hsieh, CY				Wei, LH; Kuo, ML; Chen, CA; Chou, CH; Cheng, WF; Chang, MC; Su, JL; Hsieh, CY			The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI3-K/Akt pathway	ONCOGENE			English	Article						cervical cancer; interleukin-6; apoptosis; Mcl-1; PI3-K/Akt	AUTOCRINE GROWTH-FACTOR; HUMAN MYELOMA CELLS; IMMUNOHISTOCHEMICAL ANALYSIS; BCL-2 FAMILY; IN-VITRO; IL-6 FUNCTIONS; BONE-MARROW; EXPRESSION; GENE; DIFFERENTIATION	Interleukin-6 (IL-6), a multifunctional cytokine, has recently been implicated in human cervical cancer, though the mechanism remains elusive. This study demonstrates that the anti-apoptotic protein Mcl-1 and IL-6 was concomitantly expressed in human cervical cancer tissues and cell lines, but not in normal cervix tissues. Upon IL-6 treatment, Mcl-1, but not other Bcl-2 family members, was rapidly up-regulated peaking at 4-8 h in human cervical cancer C33A cells. Supporting this observation, using anti-IL-6 or anti-IL-6 receptor antibody to interrupt the IL-6 autocrine loop in SiHa cells significantly reduced cellular level of Mcl-1. This study hypothesizes that the expression of Mcl-1 in cervical cancer cells is regulated by IL-6. The matter of which signaling pathways transduced by IL-6 is responsible for the Mcl-1 up-regulation is further investigated herein. Blocking the STAT3 or MAPK pathway with dominant-negative mutant STAT3F or the MEK inhibitor PD98059 failed to inhibit IL-6-mediated Mcl-1 expression. Meanwhile, the IL-6-induced Mcl-1 up-regulation was effectively abolished by treatment with PI 3-K inhibitors, LY294002. Additionally, overexpression of dominant-negative (dn) Akt in C33A cells could inhibit the IL-6-induced increase of Mcl-1. Finally, overexpression of IL-6 in C33A cells caused a markable resistance to apoptosis induced by doxorubicin or cisplatin. Transient transfection of IL-6-overexpressed cells with a mcl-1 antisense vector, leading to the attenuation of their apoptosis-resistant activity. In conclusion, the data herein suggest that IL-6 regulated the mcl-1 expression via a PI 3-K/Akt-dependent pathway that may facilitate the oncogenesis of human cervical cancer by modulating the apoptosis threshold.	Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei, Taiwan.		Wei, Lin-Hung/B-1188-2008; Kuo, Min-Liang/C-4872-2009	CHENG, WEN-FANG/0000-0002-3282-6304; Wei, Lin-Hung/0000-0001-8789-0859; KUO, MIN-LIANG/0000-0002-7139-0144; CHEN, CHI-AN/0000-0001-6670-7939				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cervero C, 1999, AM J HEMATOL, V60, P191, DOI 10.1002/(SICI)1096-8652(199903)60:3<191::AID-AJH4>3.0.CO;2-Y; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHOI SS, 1995, ONCOGENE, V11, P1693; Crawford RAF, 1998, BRIT J CANCER, V78, P210, DOI 10.1038/bjc.1998.466; DOLE MG, 1995, CANCER RES, V55, P2576; Elder DJE, 1996, CANCER RES, V56, P2273; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kuo ML, 1999, MOL PHARMACOL, V55, P894; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakashima K, 1999, J NEUROSCI, V19, P5429; Ogata A, 1997, J IMMUNOL, V159, P2212; Okamoto M, 1997, CANCER RES, V57, P141; PINION SB, 1991, LANCET, V337, P819, DOI 10.1016/0140-6736(91)92518-7; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Richter HE, 1999, AM J OBSTET GYNECOL, V181, P940, DOI 10.1016/S0002-9378(99)70329-7; ROBERT ME, 1990, SEMIN DIAGN PATHOL, V7, P173; SCHLAIFER D, 1995, BLOOD, V85, P2671, DOI 10.1182/blood.V85.10.2671.bloodjournal85102671; Tartour E, 1999, CANCER RES, V59, P3698; TARTOUR E, 1994, CANCER RES, V54, P6243; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tjiong MY, 1999, GYNECOL ONCOL, V73, P285, DOI 10.1006/gyno.1999.5358; Tlsty TD, 1999, NAT GENET, V21, P64, DOI 10.1038/4998; Wei LH, 2001, GYNECOL ONCOL, V82, P49, DOI 10.1006/gyno.2001.6235; WU S, 1992, AM J OBSTET GYNECOL, V166, P997, DOI 10.1016/0002-9378(92)91379-O; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	47	139	155	1	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5799	5809		10.1038/sj.onc.1204733	http://dx.doi.org/10.1038/sj.onc.1204733			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593385				2022-12-28	WOS:000171037200003
J	Licht, JD				Licht, JD			AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML	ONCOGENE			English	Review						AML1; RUNX; transcription ETO; leukemia; translocation	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; POLYMERASE-CHAIN-REACTION; MINIMAL RESIDUAL DISEASE; ACUTE PROMYELOCYTIC LEUKEMIA; BONE-MARROW TRANSPLANTATION; STIMULATING FACTOR-RECEPTOR; LONG-TERM REMISSION; BINDING-FACTOR-BETA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS		CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	jonathan.licht@mssm.edu	Licht, Jonathan/AAL-9184-2020; Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369; 	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Andrieu V, 1996, BRIT J HAEMATOL, V92, P855, DOI 10.1046/j.1365-2141.1996.415954.x; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; ASOU H, 1991, BLOOD, V77, P2031; Austin GE, 1998, LEUKEMIA RES, V22, P1037, DOI 10.1016/S0145-2126(98)00105-2; BAE SC, 1993, ONCOGENE, V8, P809; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Berardi MJ, 1999, STRUCT FOLD DES, V7, P1247, DOI 10.1016/S0969-2126(00)80058-1; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; BritosBray M, 1996, LEUKEMIA, V10, P984; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen LF, 1998, MOL CELL BIOL, V18, P4165, DOI 10.1128/MCB.18.7.4165; Corsetti MT, 1997, BLOOD, V89, P2359, DOI 10.1182/blood.V89.7.2359; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; DEGREEF GE, 1995, LEUKEMIA, V9, P282; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DOWNING JR, 1993, BLOOD, V81, P2860; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ERA T, 1995, GENE CHROMOSOME CANC, V13, P25, DOI 10.1002/gcc.2870130105; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Erickson PF, 1996, BLOOD, V88, P1813; FEINSTEIN PG, 1995, GENETICS, V140, P573; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fracchiolla NS, 1998, BLOOD, V92, P3481, DOI 10.1182/blood.V92.9.3481.splL6_3481_3484; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Fujii M, 1998, ONCOGENE, V17, P1813, DOI 10.1038/sj.onc.1202087; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Goger M, 1999, NAT STRUCT BIOL, V6, P620; GOLEMIS EA, 1990, J VIROL, V64, P534, DOI 10.1128/JVI.64.2.534-542.1990; Golling G, 1996, MOL CELL BIOL, V16, P932; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; GUERRASIO A, 1995, BRIT J HAEMATOL, V90, P364, DOI 10.1111/j.1365-2141.1995.tb05160.x; Guidez F, 2000, BLOOD, V96, P2557; Harada H, 1999, MOL CELL BIOL, V19, P3808; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; Higuchi M, 2000, BLOOD, V96, p222A; HILDEBRAND D, 2001, J BIOL CHEM, V9, P9; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Huang XM, 1999, NAT STRUCT BIOL, V6, P624; Hwang ES, 1999, FEBS LETT, V446, P86, DOI 10.1016/S0014-5793(99)00190-8; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; Kim JH, 1999, INT J BIOCHEM CELL B, V31, P933, DOI 10.1016/S1357-2725(99)00048-5; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Komori A, 1999, JPN J CANCER RES, V90, P60, DOI 10.1111/j.1349-7006.1999.tb00666.x; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kondo M, 2000, LEUKEMIA RES, V24, P951, DOI 10.1016/S0145-2126(00)00071-0; KOZU T, 1993, BLOOD, V82, P1270; Krauter J, 1999, BRIT J HAEMATOL, V107, P80, DOI 10.1046/j.1365-2141.1999.01674.x; Kurokawa M, 1996, ONCOGENE, V12, P883; KUSEC R, 1994, LEUKEMIA, V8, P735; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Langabeer SE, 1997, BRIT J HAEMATOL, V99, P925, DOI 10.1046/j.1365-2141.1997.4663270.x; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2001, GENE, V262, P23, DOI 10.1016/S0378-1119(00)00532-1; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU J, 1995, MOL CELL BIOL, V15, P1651; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Marcucci G, 1998, LEUKEMIA, V12, P1482, DOI 10.1038/sj.leu.2401128; MARUYAMA F, 1994, LEUKEMIA, V8, P40; MATOZAKI S, 1995, BRIT J HAEMATOL, V89, P805; MATSUSHITA H, 1995, BIOCHEM BIOPH RES CO, V215, P431, DOI 10.1006/bbrc.1995.2483; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; McNeil S, 2000, J CELL BIOCHEM, V79, P103, DOI 10.1002/1097-4644(2000)79:1<103::AID-JCB100>3.3.CO;2-2; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; MIYAMOTO T, 1995, BRIT J HAEMATOL, V91, P132, DOI 10.1111/j.1365-2141.1995.tb05258.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Miyoshi H, 1997, LEUKEMIA RES, V21, P45, DOI 10.1016/S0145-2126(96)00089-6; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Morii E, 1999, BIOCHEM BIOPH RES CO, V261, P53, DOI 10.1006/bbrc.1999.0996; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; Morschhauser F, 2000, J CLIN ONCOL, V18, P788, DOI 10.1200/JCO.2000.18.4.788; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; Muto A, 1996, BRIT J HAEMATOL, V95, P85, DOI 10.1046/j.1365-2141.1996.d01-1877.x; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Niitsu N, 1997, CELL GROWTH DIFFER, V8, P319; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NIWAKAWAKITA M, 1995, GENOMICS, V29, P755, DOI 10.1006/geno.1995.9941; North T, 1999, DEVELOPMENT, V126, P2563; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, BLOOD, V81, P883; NUCIFORA G, 1994, LEUKEMIA, V8, P1533; NUCIFORA G, 1993, BLOOD, V82, P712; NUCIFORA G, 1995, BLOOD, V86, P1; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 2000, MOL CELL BIOL, V20, P319, DOI 10.1128/MCB.20.1.319-328.2000; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Preudhomme C, 1996, LEUKEMIA, V10, P186; Puig-Kroger A, 2000, J BIOL CHEM, V275, P28507, DOI 10.1074/jbc.M004323200; Rhoades KL, 2000, BLOOD, V96, P2108; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Sacchi N, 1996, ONCOGENE, V12, P437; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Sakata N, 1997, LEUKEMIA LYMPHOMA, V26, P141, DOI 10.3109/10428199709109169; Salomon-Nguyen F, 2000, LEUKEMIA, V14, P1704, DOI 10.1038/sj.leu.2401885; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SATAKE N, 1995, BRIT J HAEMATOL, V91, P892, DOI 10.1111/j.1365-2141.1995.tb05406.x; Saunders, 1999, Expert Opin Investig Drugs, V8, P1611, DOI 10.1517/13543784.8.10.1611; Saunders MJ, 1997, BRIT J HAEMATOL, V99, P921, DOI 10.1046/j.1365-2141.1997.4673271.x; Saunders MJ, 1996, LEUKEMIA, V10, P1139; SAUNDERS MJ, 1994, LEUKEMIA RES, V18, P891, DOI 10.1016/0145-2126(94)90100-7; Sherr CJ, 2000, CANCER RES, V60, P3689; Shi MJ, 1998, J IMMUNOL, V161, P6751; Shikami M, 1999, LEUKEMIA, V13, P358, DOI 10.1038/sj.leu.2401343; Shimada H, 2000, BLOOD, V96, P655; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Sueoka E, 1998, BRIT J HAEMATOL, V101, P737, DOI 10.1046/j.1365-2141.1998.00757.x; Sugimoto T, 2000, AM J HEMATOL, V64, P101, DOI 10.1002/(SICI)1096-8652(200006)64:2<101::AID-AJH5>3.0.CO;2-X; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; TANAKA K, 1995, BIOCHEM BIOPH RES CO, V211, P1023, DOI 10.1006/bbrc.1995.1913; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Tang L, 1999, J BIOL CHEM, V274, P33580, DOI 10.1074/jbc.274.47.33580; TIGHE JE, 1993, BLOOD, V81, P592; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; TIGHE JE, 1995, CLIN SCI, V89, P215, DOI 10.1042/cs0890215; Tobal K, 1996, BLOOD, V88, P3704, DOI 10.1182/blood.V88.10.3704.bloodjournal88103704; Tobal K, 2000, BLOOD, V95, P815, DOI 10.1182/blood.V95.3.815.003k30_815_819; Uchida H, 1997, J IMMUNOL, V158, P2251; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592; VANDELOCHT LTF, 1994, LEUKEMIA, V8, P1780; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Wang JX, 1997, CANCER RES, V57, P2951; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Wolford JK, 1998, BIOCHEM BIOPH RES CO, V246, P624, DOI 10.1006/bbrc.1998.8683; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Zhang HT, 2000, CHEM J CHINESE U, V21, P156; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133	211	145	159	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5660	5679		10.1038/sj.onc.1204593	http://dx.doi.org/10.1038/sj.onc.1204593			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607817				2022-12-28	WOS:000170887500008
J	Jiang, M; Axe, T; Holgate, R; Rubbi, CP; Okorokov, AL; Mee, T; Milner, J				Jiang, M; Axe, T; Holgate, R; Rubbi, CP; Okorokov, AL; Mee, T; Milner, J			p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress	ONCOGENE			English	Article						p53; nuclear matrix; proline-rich domain; DNA damage; SV40 large T	LARGE T-ANTIGEN; HYDROPHOBIC AMINO-ACIDS; A MOUSE CELLS; TERMINAL DOMAIN; DNA-BINDING; TRANSCRIPTIONAL COACTIVATOR; CELLULAR PROTEIN-P53; PROTEOLYTIC CLEAVAGE; FUNCTIONAL DOMAIN; GROWTH ARREST	The tumour suppressor p53 is a multifunctional protein important for the maintenance of genomic integrity. It is able to form molecular complexes with different DNA targets and also with cellular proteins involved in DNA transcription and DNA repair. In mammalian cells the biochemical processing of DNA occurs on a nuclear substructure termed the nuclear matrix. Previously Deppert and co-workers have identified p53 in association with the nuclear matrix in viral- and non-viral transformed cell lines. In the present study we demonstrate, for the first time, that p53 is bound to the nuclear matrix in primary cultures of normal mammalian cells and that this binding increases following DNA damage. Analysis of cell lines expressing structural mutants of p53 revealed that association with the nuclear matrix is independent of the tertiary and quaternary structure of p53. However, the proline-rich domain towards the N-terminus of p53 (residues 67 to 98) appeared important for binding to the nuclear matrix. This was demonstrated by TET-ON regulated expression of p53-derived constructs in p53(-/-) murine embryonic fibroblasts (MEF p53(-/-)). The proline-rich domain of p53 has potential for SH3 protein-protein interaction, and has a role in p53-mediated apoptosis and possibly base excision repair of DNA damage. We discuss our observations in relation to the ability of p53 to facilitate DNA repair and also review evidence indicating that matrix-bound p53 in SV40-transformed cells may facilitate the transforming potential of SV40 large T antigen.	Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England	University of York - UK	Milner, J (corresponding author), Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England.			Okorokov, Andrei/0000-0003-2477-3254; Jiang, Ming/0000-0003-3361-9881				Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; Berezney R, 1995, INT REV CYTOL, V162A, P1; Boulikas T, 1995, INT REV CYTOL, V162A, P279; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cook Peter R., 2001, EMBO Reports, V2, P14, DOI 10.1093/embo-reports/kve011; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, ONCOGENE, V4, P1103; Deppert W, 2000, CRIT REV EUKAR GENE, V10, P45; Deppert W, 1995, INT REV CYTOL, V162A, P485; DEPPERT W, 1990, ONCOGENE, V5, P1701; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Jackson DA, 1995, INT REV CYTOL, V162A, P125; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN JY, 1995, ONCOGENE, V10, P2387; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mee T, 1999, BRIT J CANCER, V81, P212, DOI 10.1038/sj.bjc.6690679; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1993, ONCOGENE, V8, P2001; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Molinari M, 1996, ONCOGENE, V13, P2077; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; Offer H, 2001, CANCER RES, V61, P88; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; PARDOLL DM, 1980, EXP CELL RES, V128, P466, DOI 10.1016/0014-4827(80)90083-X; Peden KWC, 1998, VIRUS GENES, V16, P153, DOI 10.1023/A:1007941622680; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Spector D. L., 1998, CELLS LAB MANUAL; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STEINMEYER K, 1990, ONCOGENE, V5, P1691; Stenoien D, 1998, J CELL BIOCHEM, V70, P213, DOI 10.1002/(SICI)1097-4644(19980801)70:2<213::AID-JCB7>3.0.CO;2-R; Stratling WH, 1999, CRIT REV EUKAR GENE, V9, P311, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.150; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Will K, 1998, J CELL BIOCHEM, V69, P260, DOI 10.1002/(SICI)1097-4644(19980601)69:3<260::AID-JCB4>3.0.CO;2-P; ZERRAHN J, 1992, ONCOGENE, V7, P1371; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	58	31	32	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5449	5458		10.1038/sj.onc.1204705	http://dx.doi.org/10.1038/sj.onc.1204705			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571642				2022-12-28	WOS:000170781100005
J	DiNardo, DNM; Butcher, DT; Robinson, DP; Archer, TK; Rodenhiser, DI				DiNardo, DNM; Butcher, DT; Robinson, DP; Archer, TK; Rodenhiser, DI			Functional analysis of CpG methylation in the BRCA1 promoter region	ONCOGENE			English	Article						BRCA1; methylation; expression; CREB	CANCER SUSCEPTIBILITY GENE; SPORADIC BREAST-CANCER; TUMOR-SUPPRESSOR GENE; OVARIAN-CANCER; DNA METHYLATION; MESSENGER-RNA; ISLAND; ESTROGEN; BINDING; TRANSCRIPTION	Understanding the role for DNA methylation in tumorigenesis has evolved from defining the location and extent of methylation in a variety of cancer-related genes to clarifying the functional and site-specific effects of aberrant methylation on gene expression, Our objectives were to characterize the functional effects of DNA methylation in the BRCA1 promoter and to clarify the functional status of the BRCA1 CRE (cAMP response element) motif Luciferase reporter assays confirm that an intact CRE is important for BRCA1 expression in transient transfections. Luciferase activities were decreased in constructs where the CRE recognition sequence was altered and when constructs were methylated in vitro. Gel mobility shift and competition assays identified a DNA-protein complex recognizing the CRE motif that we were able to supershift using CREB-specific antibody. Furthermore this CRE is methylation sensitive, and we localized this methylation effect to a CpG dinucleotide within the BRCA1 CRE motif. The consequences of aberrant DNA methylation at specific transcription factor motifs, along with the multiple mutational events that can occur in a variety of essential genes such as BRCA1, paint a complex picture where both genetic and epigenetic changes contribute to tumour formation.	Univ Western Ontario, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Child Hlth Res Inst, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada; NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Rodenhiser, DI (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Room 4068,790 Commissioners Rd E, London, ON N6A 4L6, Canada.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Baldwin RL, 2000, CANCER RES, V60, P5329; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Dobrovic A, 1997, CANCER RES, V57, P3347; Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hwu WL, 1997, DNA CELL BIOL, V16, P449, DOI 10.1089/dna.1997.16.449; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1996, CANCER RES, V56, P3655; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Maesawa C, 1996, CANCER RES, V56, P3875; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; Mancini D, 1997, AM J HUM GENET, V61, P80, DOI 10.1086/513898; Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okuse K, 1997, MOL BRAIN RES, V46, P197, DOI 10.1016/S0169-328X(96)00302-6; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Rodenhiser D, 1996, ONCOGENE, V12, P2623; Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6; SAKAI T, 1991, AM J HUM GENET, V48, P888; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHATTUCKEIDENS E, 1995, JAMA-J AM MED ASSOC, V273, P535; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	38	45	46	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5331	5340		10.1038/sj.onc.1204697	http://dx.doi.org/10.1038/sj.onc.1204697			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536045				2022-12-28	WOS:000170575500008
J	Fardioni-Laurens, L; Bosq, J; Janot, F; Vayssade, M; Le Bihan, ML; Kaghad, M; Caput, D; Benard, J; Ahomadegbe, JC				Fardioni-Laurens, L; Bosq, J; Janot, F; Vayssade, M; Le Bihan, ML; Kaghad, M; Caput, D; Benard, J; Ahomadegbe, JC			P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63?	ONCOGENE			English	Article						p73; differentiation; carcinogenesis; head and neck tissues	TUMOR-SUPPRESSOR GENE; WILD-TYPE P73; P53-RELATED PROTEIN; BREAST CANCERS; CELL CARCINOMA; HOMOLOG; OVEREXPRESSION; NEUROBLASTOMA; HETEROZYGOSITY; INACTIVATION	P73, a p53-homologue gene, has been studied for its possible role in head and neck squamous epithelium (HNSE) differentiation and carcinogenesis. P73 RNA and protein were analysed in 50 biopsies, including well- and moderately-differentiated carcinomas, and 21 matched normal adjacent tissues. P73 immunohistochemical analyses revealed intense p73 nuclear staining in basal and parabasal cells of normal squamous epithelium, in contrast with complete absence of staining in the more superficial cell layers. Moderately-differentiated carcinomas demonstrated homogeneous and diffuse staining in all tumour cells, while only basal cells were stained in well-differentiated carcinomas as in normal tissue. No correlation was observed between p73 and p53 protein expression. Immunostaining for p63, another p53-related protein previously described as being involved in HNSE morphogenesis and overexpressed in head and neck squamous cell carcinomas (HNSCC), was found to be similar to p73 labelling in carcinomas, but spread to the more differentiated layers in normal epithelium. Biallelic expression of p73 was found in tumours as well as in matched normal tissues. Comparison of p73 transcript levels between tumours and normal tissues showed decreased mRNA expression in 5/17 (30%) tumours independently of the differentiation status. Mutation and loss of heterozygosity analyses of the p73 gene revealed wild type status and no deletion. Our results strongly suggest that: (i) p73 is associated with homeostasis and control of differentiation of head and neck squamous epithelium probably in concert with p53 and p63; (ii) down-regulation of p73 expression could participate in HNSE carcinogenesis.	Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Anat Pathol, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Chirurg Cervicofaciale, F-94805 Villejuif, France; UPJV, Fac Pharm, F-80037 Amiens, France; Sanofi Rech, F-31676 Labege, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Picardie Universites; Universite de Picardie Jules Verne (UPJV); Sanofi-Aventis; Sanofi France	Ahomadegbe, JC (corresponding author), Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, F-94805 Villejuif, France.		AMSELLEM, Sophie/B-3645-2012					Ahomadegbe JC, 2000, ONCOGENE, V19, P5413, DOI 10.1038/sj.onc.1203914; AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; Brash DE, 1998, CANCER SURV, V32, P69; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; Cai YYC, 2000, CARCINOGENESIS, V21, P683, DOI 10.1093/carcin/21.4.683; Casciano I, 1999, CELL DEATH DIFFER, V6, P391, DOI 10.1038/sj.cdd.4400522; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Liefer KM, 2000, CANCER RES, V60, P4016; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Shishikura T, 1999, INT J CANCER, V84, P321, DOI 10.1002/(SICI)1097-0215(19990621)84:3<321::AID-IJC21>3.0.CO;2-S; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	42	39	43	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5302	5312		10.1038/sj.onc.1204687	http://dx.doi.org/10.1038/sj.onc.1204687			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536043				2022-12-28	WOS:000170575500006
J	Rasmussen, SB; Kordon, E; Callahan, R; Smith, GH				Rasmussen, SB; Kordon, E; Callahan, R; Smith, GH			Evidence for the transforming activity of a truncated Int6 gene, in vitro	ONCOGENE			English	Article						Int6; eIF3-p48; transformation; mammary gland; epithelial cells	MAMMARY EPITHELIAL-CELLS; C-HA-RAS; HTLV-I TAX; RNA 5' CAP; TRANSLATION INITIATION; GROWTH-FACTOR; TUMOR VIRUS; MALIGNANT TRANSFORMATION; TRANSGENIC MICE; PROSTATE-CANCER	Int6/eIF3-p48 was first identified as a common integration site for MMTV in mouse mammary tumors. In all cases, the MMTV integration event resulted in an interruption of the normal Int6 transcript from one allele leaving the second allele intact and operative. We hypothesize that insertion of MMTV into Int6 results in a mutated allele that encodes a shortened Int6 mRNA and protein (Int6sh), which either modifies normal Int6 function or possesses a new independent function. To confirm the transforming potential of the mutation and its dominant function, we transfected two mammary epithelial cell lines, MCF10A (human), and HC11 (mouse), with Int6sh under the control of the elongation factor-la (eEF1A) promoter. Expression of Int6sh in MCF10A and HC11 mammary epithelial cells leads to anchorage-independent growth in soft agar indicative of a transformed phenotype. Colonies selected from agar exhibited high levels of mutated Int6sh and wild type Int6 RNA transcripts by RT-PCR and Northern blot analysis. In addition, Int6sh transformed MCF10A and HC11 cells formed nodular growths, in vivo, in immune compromised hosts. NIH3T3 cells, mouse embryo fibroblasts, were also transformed to anchorage-independent growth in vitro by Int6sh expression. These observations provide direct evidence that the Int6 mutations observed in MMTV-induced tumors and hyperplasia contribute to the malignant transformation of the mammary epithelial cells.	NCI, NIH, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA; Acad Nacl Med Buenos Aires, Buenos Aires, DF, Argentina	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Buenos Aires National Academy of Medicine	Smith, GH (corresponding author), NCI, NIH, Tumor Immunol & Biol Lab, 10 Center Dr,Room 8B07, Bethesda, MD 20892 USA.							Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Diella F, 1997, DNA CELL BIOL, V16, P839, DOI 10.1089/dna.1997.16.839; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Girard L, 1998, ONCOGENE, V16, P517, DOI 10.1038/sj.onc.1201562; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; Karniol B, 1998, FEBS LETT, V439, P173, DOI 10.1016/S0014-5793(98)01367-2; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Methot N, 1996, MOL CELL BIOL, V16, P5328; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; MIYAZAKI S, 1995, GENOMICS, V27, P420, DOI 10.1006/geno.1995.1072; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Neuveut C, 1997, J BIOMED SCI, V4, P229, DOI 10.1007/BF02253422; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Pauley R J, 1993, Eur J Cancer Prev, V2 Suppl 3, P67; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Sambrook J., 2002, MOL CLONING LAB MANU; SOULE HD, 1990, CANCER RES, V50, P6075; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; WEN JY, 1995, MOL REPROD DEV, V41, P399, DOI 10.1002/mrd.1080410402	41	58	58	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5291	5301		10.1038/sj.onc.1204624	http://dx.doi.org/10.1038/sj.onc.1204624			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536042				2022-12-28	WOS:000170575500005
J	Fukazawa, T; Fujiwara, T; Uno, F; Teraishi, F; Kadowaki, Y; Itoshima, T; Takata, Y; Kagawa, S; Roth, JA; Tschopp, J; Tanaka, N				Fukazawa, T; Fujiwara, T; Uno, F; Teraishi, F; Kadowaki, Y; Itoshima, T; Takata, Y; Kagawa, S; Roth, JA; Tschopp, J; Tanaka, N			Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells	ONCOGENE			English	Article						p53; apoptosis; FLIP; ubiquitin-proteasome; colon cancer	NF-KAPPA-B; DEATH RECEPTOR; P53; GENE; EXPRESSION; KILLER/DR5; SYSTEM; FADD; MODULATION; FAS	Apoptosis is a morphologically distinct form of programmed cell death that plays a major role in cancer treatments. This cellular suicide program is known to be regulated by many different signals from both intracellular and extracellular stimuli. Here we report that p53 suppressed expression of the cellular FLICE-inhibitory protein (FLIP) that potentially blocks apoptotic signaling in human colon cancer cell lines expressing mutated and wild-type p53. In contrast, the expression of the death receptor KILLER/DR5 (TRAIL-R2) had no effect on FLIP expression, although exogenous p53 is known to induce KILLER/DR5 expression. In line with these observations, FLIP-negative cancer cells were sensitive to both p53- and KILLER/DR5-mediated apoptosis, whereas cells containing high levels of FLIP underwent apoptotic cell death when triggered by ectopic p53 expression but not by KILLER/DR5 expression. Treating the cells with a specific inhibitor of the proteasome inhibited the decrease of FLIP by p53, suggesting that p53 enhances the degradation of FLIP via a ubiquitin-proteasome pathway. Thus, the data indicate that p53-mediated downregulation of FLIP may explain the potent sensitization of human cancer cells to the apoptotic suicide program induced by wild-type p53 gene transfer.	Okayama Univ, Grad Sch Med & Dent, Div Surg Oncol, Dept Surg 1, Okayama 7008558, Japan; Shiga Univ Med Sci, Dept Surg 1, Otsu, Shiga 5202192, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Okayama University; Shiga University of Medical Science; University of Texas System; UTMD Anderson Cancer Center; University of Lausanne	Fujiwara, T (corresponding author), Okayama Univ, Grad Sch Med & Dent, Div Surg Oncol, Dept Surg 1, 2-5-1 Shikata Cho, Okayama 7008558, Japan.		Fukazawa, Takuya/GLR-7099-2022; Kagawa, Shunsuke/B-2189-2011	Kagawa, Shunsuke/0000-0002-3610-8211				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kataoka T, 1998, J IMMUNOL, V161, P3936; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MEDEMA JP, 1997, EMBO J, V16, P2749; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sheikh MS, 1998, CANCER RES, V58, P1593; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	23	119	119	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5225	5231		10.1038/sj.onc.1204673	http://dx.doi.org/10.1038/sj.onc.1204673			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526513				2022-12-28	WOS:000170464000018
J	Masuoka, J; Brandner, S; Paulus, W; Soffer, D; Vital, A; Chimelli, L; Jouvet, A; Yonekawa, Y; Kleihues, P; Ohgaki, H				Masuoka, J; Brandner, S; Paulus, W; Soffer, D; Vital, A; Chimelli, L; Jouvet, A; Yonekawa, Y; Kleihues, P; Ohgaki, H			Germline SDHD mutation in paraganglioma of the spinal cord	ONCOGENE			English	Article						SDHD; germline mutation; paraganglioma; cauda equina	FAMILIAL NONCHROMAFFIN PARAGANGLIOMAS; AUTOSOMAL-DOMINANT PARAGANGLIOMA; SUCCINATE-UBIQUINONE REDUCTASE; HEREDITARY PARAGANGLIOMAS; IMPRINTED GENE; GLOMUS TUMORS; CHROMOSOME; OXIDOREDUCTASE; CLONING; DOMAIN	Hereditary paraganglioma of the head and neck is associated with germline mutations in the SDHD gene, which encodes a mitochondrial respirator), chain protein. Paragangliomas of the central nervous system are very rare, occur almost exclusively in the cauda equina of the spinal cord and are considered non-familial. In the present study, we screened 22 apparently sporadic paragangliomas of the cauda equina for SDHD mutations. One spinal paraganglioma and similar cerebellar tumours that developed 22 years later in the same patient contained a missense mutation at codon 12 (GGT --> AGT, Gly --> Ser) and a silent mutation at codon 68 (AGC --> AGT, Ser --> Ser). There was no family history of paragangliomas but DNA from white blood cells of this patient showed the same sequence alterations, indicating the presence of a germline mutation. All other cases of spinal paraganglioma had the wild-type SDHD sequence, except one case with a silent mutation at codon 68 (AGC --> AGT, Ser --> Ser). This is the first observation indicating that inherited SDHD mutations may occasionally cause the development of paragangliomas in the central nervous system.	Int Agcy Res Canc, F-69372 Lyon 08, France; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland; Univ Hosp, Neuropathol Lab, F-69003 Lyon, France; Fed Univ Rio De Janeiro, Univ Hosp, Div Pathol, BR-21941590 Rio De Janeiro, Brazil; Victor Segalen Univ, Neuropathol Lab, F-33076 Bordeaux, France; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Univ Munster, Inst Neuropathol, D-48129 Munster, Germany	World Health Organization; International Agency for Research on Cancer (IARC); University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; CHU Lyon; Universidade Federal do Rio de Janeiro; UDICE-French Research Universities; Universite de Bordeaux; Hebrew University of Jerusalem; University of Munster	Ohgaki, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342				Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 1997, AM J HUM GENET, V60, P121; BRODEUR GM, 1998, PHEOCHROMOCYTOMAS PA, P535; GRUFFERMAN S, 1980, CANCER, V46, P2116, DOI 10.1002/1097-0142(19801101)46:9<2116::AID-CNCR2820460934>3.0.CO;2-S; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HEUTINK P, 1992, HUM MOL GENET, V1, P7, DOI 10.1093/hmg/1.1.7; Heutink Peter, 1994, European Journal of Human Genetics, V2, P148; Hirawake H, 1997, CYTOGENET CELL GENET, V79, P132, DOI 10.1159/000134700; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MARIMAN ECM, 1995, HUM GENET, V95, P56, DOI 10.1007/BF00225075; Niemann S, 1999, NEUROGENETICS, V2, P167, DOI 10.1007/s100480050078; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Reis RM, 2000, AM J PATHOL, V156, P425, DOI 10.1016/S0002-9440(10)64746-3; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; SOFFER D, 2000, WHO CLASSIFICATION T, P112; SPECTOR GJ, 1975, LARYNGOSCOPE, V85, P1066, DOI 10.1288/00005537-197506000-00016; STROMMER KN, 1995, J NEUROSURG, V83, P166, DOI 10.3171/jns.1995.83.1.0166; van Schothorst EM, 1998, HUM PATHOL, V29, P1045, DOI 10.1016/S0046-8177(98)90411-7; VANBAARS F, 1982, HUM GENET, V60, P305, DOI 10.1007/BF00569208; VANDERMEY AGL, 1989, LANCET, V2, P1291; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x	24	24	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5084	5086		10.1038/sj.onc.1204579	http://dx.doi.org/10.1038/sj.onc.1204579			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526495				2022-12-28	WOS:000170439800020
J	Dang, DT; Mahatan, CS; Dang, LH; Agboola, IA; Yang, VW				Dang, DT; Mahatan, CS; Dang, LH; Agboola, IA; Yang, VW			Expression of the gut-enriched Kruppel-like factor (Kruppel-like factor 4) gene in the human colon cancer cell line RKO is dependent on CDX2	ONCOGENE			English	Article						gut-enriched Kruppel-like factor; Kruppel-like factor 4; colon cancer; CDX2; adenomatous polyposis coli; dominant negative	MULTIPLE INTESTINAL NEOPLASIA; HOMEOBOX GENE; EPITHELIAL-CELLS; COLORECTAL-CANCER; BETA-CATENIN; EMBRYONIC INTESTINE; PROMOTER ACTIVITY; CYCLIN D1; DIFFERENTIATION; IDENTIFICATION	Gut-enriched Kruppel-like factor (GKLF or KLF4) is a zinc finger-containing, epithelial-specific transcription factor, that functions as a suppressor of cell proliferation. We previously showed that GKLF expression is decreased in intestinal and colonic adenomas, respectively, from multiple intestinal neoplasia (Min) mice and familial adenomatous polyposis (FAP) patients. This study shows that GKLF is induced upon activation of the adenomatous polyposis coli (APC) gene. However, among several human colon cancer cell lines surveyed, expression of GKLF is lowest in RKO, a line with wildtype APC and beta -catenin. RKO contains a mutated allele that encodes the putative tumor suppressor homeodomain protein, CDX2. We show that wild-type CDX2 activates the GKLF promoter and that the mutated CDX2 has a dominant negative effect on wild-type function. Our results may help explain the exceedingly low levels of GKLF expression detected in this cell line, which may in turn contribute to the tumor phenotype.	Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Yang, VW (corresponding author), Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, 720 Rutland Ave,Ross 918, Baltimore, MD 21205 USA.				NCI NIH HHS [R01 CA084197-02, R01 CA084197, CA84197] Funding Source: Medline; NIDDK NIH HHS [F32 DK010020, DK10020, R01 DK052230-04, DK52230, R01 DK052230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010020, R01DK052230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Duluc I, 1997, J CELL SCI, V110, P1317; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HC, 1995, AM J PATHOL, V147, P586; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Polakis P, 2000, GENE DEV, V14, P1837; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Tamai Y, 1999, CANCER RES, V59, P2965; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	45	108	117	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4884	4890		10.1038/sj.onc.1204645	http://dx.doi.org/10.1038/sj.onc.1204645			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521200	Green Accepted			2022-12-28	WOS:000170271800013
J	Hafner, C; Knuechel, R; Zanardo, L; Dietmaier, W; Blaszyk, H; Cheville, J; Hofstaedter, F; Hartmann, A				Hafner, C; Knuechel, R; Zanardo, L; Dietmaier, W; Blaszyk, H; Cheville, J; Hofstaedter, F; Hartmann, A			Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract	ONCOGENE			English	Article						urothelial carcinoma; upper and lower urinary tract; LOH; oligoclonality; p53 mutation	TRANSITIONAL-CELL CARCINOMA; MICROSATELLITE INSTABILITY; BLADDER-CANCER; FIELD CANCERIZATION; CLONAL ORIGIN; P53 MUTATION; LOW-GRADE; DELETION	Multifocality and recurrence of urothelial carcinoma may result from either the field effect of carcinogens leading to oligoclonal tumors or monoclonal tumor spread. Previous molecular studies, favoring the monoclonality hypothesis, are mostly limited to the urinary bladder. We investigated genetic alterations in a total of 94 synchronous or metachronous multifocal tumors from 19 patients with at least one tumor both in the upper and lower urinary tract. Loss of heterozygosity (LOH) was determined using eight markers on chromosome 9 and one marker on 17p13 (p53). Microsatellite instability was investigated at six loci and protein expression of MSH2 and MLH1 was evaluated by immunohistochemistry. In addition, exons 5-9 of the p53 gene were sequenced. Deletions at chromosome 9 were found in 73% of tumors and at 17p13 in 18% of tumors. There was no significant difference in the frequency of LOH in the upper and lower urinary tract. Deletions at 9p21 were significantly correlated with invasive tumor growth. The pattern of deletion revealed monoclonality of all tumors in nine patients. In five patients there were at least two tumor clones with different genetic alterations. In four of these patients the different clones occured in the bladder and subsequently in the ureter and renal pelvis. All four patients with p53 mutations revealed identical mutations in all tumors. Thus, multifocal urothelial carcinomas are frequently monoclonal, whereas others show oligoclonality, providing molecular evidence for field cancerization. Intraluminal tumor cell seeding appears to be an important mechanism of multifocal occurence and recurrence of urothelial carcinomas.	Univ Regensburg, Inst Pathol, D-93042 Regensburg, Germany; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA	University of Regensburg; Mayo Clinic	Hartmann, A (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.	arndt.hartmann@klinik.uni-regensburg.de						Aarnio M, 1995, INT J CANCER, V64, P430, DOI 10.1002/ijc.2910640613; Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J; Bender CM, 1998, MED RAD DIA IMG, P37; Boland CR, 1998, CANCER RES, V58, P5248; Dietmaier W, 1999, AM J PATHOL, V154, P83, DOI 10.1016/S0002-9440(10)65254-6; Dietmaier W, 1997, CANCER RES, V57, P4749; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; HABUCHI T, 1993, LANCET, V342, P1087, DOI 10.1016/0140-6736(93)92066-3; HARRIS AL, 1992, NEW ENGL J MED, V326, P759, DOI 10.1056/NEJM199203123261108; Hartmann A, 2000, LAB INVEST, V80, P709, DOI 10.1038/labinvest.3780074; HENEY NM, 1978, J UROLOGY, V120, P559, DOI 10.1016/S0022-5347(17)57275-4; HERMANEK P, 1998, TNM CLASSIFICATION M; Li MM, 1999, HUM PATHOL, V30, P1197, DOI 10.1016/S0046-8177(99)90037-0; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Paiss Thomas, 1997, Journal of Urology, V157, P161; Partridge M, 1997, ORAL ONCOL, V33, P332; RADOVANOVIC Z, 1985, J CANCER RES CLIN, V110, P181, DOI 10.1007/BF00402737; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; Simon R, 2001, CANCER RES, V61, P355; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; SPRUCK CH, 1994, CANCER RES, V54, P784; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Takahashi T, 2001, J UROLOGY, V165, P672, DOI 10.1097/00005392-200102000-00092; Takahashi T, 1998, CANCER RES, V58, P5835; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Xu XH, 1996, CLIN CANCER RES, V2, P1795; Yamamoto S, 1998, CARCINOGENESIS, V19, P855, DOI 10.1093/carcin/19.5.855	28	129	136	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4910	4915		10.1038/sj.onc.1204671	http://dx.doi.org/10.1038/sj.onc.1204671			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521204				2022-12-28	WOS:000170271800017
J	Parreno, M; Garriga, J; Limon, A; Albrecht, JH; Grana, X				Parreno, M; Garriga, J; Limon, A; Albrecht, JH; Grana, X			E1A modulates phosphorylation of p130 and p107 by differentially regulating the activity of G1/S cyclin/CDK complexes	ONCOGENE			English	Article						large T antigen (TAg); cyclins; cyclin dependent kinase (CDK); adenovirus; retinoblastoma protein	CELL-CYCLE CONTROL; CDC2-RELATED KINASE PITALRE; LARGE T-ANTIGEN; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; ADENOVIRUS E1A; PRB; INHIBITOR; CDK2; GROWTH	We have previously shown that the adenoviral 12S E1A protein modulates the phosphorylation status of p130 and p107 without apparent changes in the cell cycle dependent phosphorylation of the retinoblastoma protein. Here we report on the mechanisms by which E1A modifies differentially the phosphorylation status of pocket proteins. In human U-2 OS osteosarcoma cells transiently expressing E1A, ectopic expression of D-type cyclins alone or combined, but not cyclins E and/or A, fully rescues EIA-mediated block in hyperphosphorylation of p130 to form 3. However, cyclins E and A, individually or together, induce hyperphosphorylation of p130 to species with intermediate mobility. Phosphopeptide maps indicate that E1A inhibits phosphorylation of sites phosphorylatable by CDKs. One of these sites is Ser-1044. The effects of blocking the activities of endogenous and exogenous cyclins with p16 and dominant negative CDK2 in E1A expressing cells further indicate that p130 is phosphorylated by both D-type cyclin and cyclin E/CDK complexes and that E1A modulates the activity of these G1/S CDKs by independent mechanisms. Stable expression of E1A in MC3T3-E1 cells leads to downregulation of D-type cyclins, and upregulation of cyclins E and A. This is accompanied by increased CDK2 kinase activity. Downregulation of D-type cyclins in these cells correlates with a block on both p130 hyperphosphorylation to form 3 and hyperphosphorylation of p107. This is rescued by D-type cyclins but not by cyclin E. In addition, we show that the upregulation of cyclins E and A is at least partially dependent on an intact pocket protein/E2F pathway, but downregulation of D-type cyclins is not. Moreover, we provide evidence that while the lack of a functional pRB pathway also results in a block on hyperphosphorylation of p130 to form 3, this is not sufficient to induce constitutive expression of p130 form 2b.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19140 USA; Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Hennepin County Medical Center	Grana, X (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, 3307 N Broad St, Philadelphia, PA 19140 USA.	xavier@unix.temple.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045450, K02AI001823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054894] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI45450, K02 AI01823] Funding Source: Medline; NIGMS NIH HHS [R29 GM54894] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097-4644(19980201)68:2<269::AID-JCB13>3.0.CO;2-A; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Garriga J, 1996, BIOCHEM J, V320, P983, DOI 10.1042/bj3200983; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; MAYOL X, 1997, PROGR CELL CYCLE RES, P157; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Mitra J, 1999, MOL CELL BIOL, V19, P3916; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Parreno M, 2000, J VIROL, V74, P3166, DOI 10.1128/JVI.74.7.3166-3176.2000; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Raghunath M, 2000, MOL BRAIN RES, V77, P151, DOI 10.1016/S0169-328X(00)00048-6; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; SPITKOVSKY D, 1995, ONCOGENE, V10, P2421; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; TAM SW, 1994, CANCER RES, V54, P5816; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; YEAGER T, 1995, CANCER RES, V55, P493; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	50	17	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4793	4806		10.1038/sj.onc.1204644	http://dx.doi.org/10.1038/sj.onc.1204644			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521191				2022-12-28	WOS:000170271800004
J	Satyamoorthy, K; Muyrers, J; Meier, F; Patel, D; Herlyn, M				Satyamoorthy, K; Muyrers, J; Meier, F; Patel, D; Herlyn, M			Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication	ONCOGENE			English	Article						melanoma; cell-cell adhesion; antisense MEL-CAM; MUC1	CELL-ADHESION MOLECULE; INTERCELLULAR COMMUNICATION; IMMUNOGLOBULIN SUPERFAMILY; RETROVIRAL VECTORS; MAMMALIAN-CELLS; POTENTIAL ROLE; HIGH-TITER; PROGRESSION; ANTIGEN; EXPRESSION	Normal human melanocytes are interspersed singly among keratinocytes along the basement membrane of the epidermis, whereas melanoma cells readily adhere to each other during invasion of the dermis or distant organs. The tumorigenic and metastatic phenotype of melanoma cells often correlates with increased expression of cell-cell and cell-matrix adhesion receptors. Mel-CAM (MCAM, MUC 18, CD146) is a cell-cell adhesion receptor highly expressed by melanoma cells but not normal melanocytes. We show here that inhibition of Mel-CAM expression in metastatic melanoma cells using genetic suppressor elements of Mel-CAM cDNA leads to inhibition of adhesion between melanoma cells and to downregulation of the tumorigenic phenotype. Growth was not inhibited in genetic suppressor elements-transduced melanoma cells cultured in monolayers but was inhibited when cells were maintained anchorage-independently in soft agar and greatly reduced in immunodeficient mice. A three-dimensional epidermal skin equivalent model demonstrated that Mel-CANT allows melanoma cells to separate from the epidermis and invade the basement membrane zone and dermis. However, melanoma cells with little or no Mel-CAM were poorly invasive, possibly due to their loss of gap junctional communication. These results suggest the multifunctional role of a melanoma-associated cell-cell adhesion receptor in tumor progression.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	HerlynM@wistar.upenn.edu	Satyamoorthy, Kapaettu/H-3254-2015	Satyamoorthy, Kapaettu/0000-0002-2368-5490	NCI NIH HHS [CA25874, CA74294, CA76674, CA10815, CA47159] Funding Source: Medline; NIDDK NIH HHS [DK50306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076674, R01CA047159, P30CA010815, P01CA025874, P01CA074294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Bardin N, 1996, TISSUE ANTIGENS, V48, P531, DOI 10.1111/j.1399-0039.1996.tb02666.x; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; Cochlovius B, 1998, ADV EXP MED BIOL, V451, P345; Degen WGJ, 1998, AM J PATHOL, V152, P805; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERLYN D, 1990, CANCER RES, V50, P2296; HERLYN M, 1996, MOL CELLULAR BIOL ME, P1; HOLNESS CL, 1994, J CELL SCI, V107, P2065; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; JOHNS DR, 1994, J NEURO-OPHTHALMOL, V14, P130; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Johnson JP, 1997, INT J CANCER, V73, P769; Johnson JP, 1996, CURR TOP MICROBIOL, V213, P95; KATH R, 1991, CANCER RES, V51, P2205; Kraus A, 1997, MELANOMA RES, V7, pS75; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Levenson VV, 1999, SOMAT CELL MOLEC GEN, V25, P9; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; LYNCH CM, 1991, J VIROL, V65, P3887, DOI 10.1128/JVI.65.7.3887-3890.1991; Marcusson EG, 1999, MOL BIOTECHNOL, V12, P1, DOI 10.1385/MB:12:1:1; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; MORGAN RA, 1992, NUCLEIC ACIDS RES, V20, P1293, DOI 10.1093/nar/20.6.1293; Morimoto C, 1996, Hum Cell, V9, P163; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NESBIT M, 1994, INVAS METAST, V14, P131; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; Pickl WF, 1997, J IMMUNOL, V158, P2107; RONINSON IB, 1995, CANCER RES, V55, P4023; Rummel MM, 1996, CANCER RES, V56, P2218; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; SERS C, 1994, CANCER RES, V54, P5689; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shih IM, 1997, CANCER RES, V57, P3835; SHIH IM, 1994, CANCER RES, V54, P2514; St Croix B, 2000, SCIENCE, V289, P1197; Xie SH, 1997, CANCER RES, V57, P2295; Yagi T, 2000, GENE DEV, V14, P1169; Yamasaki H, 1996, MUTAT RES-REV GENET, V365, P91, DOI 10.1016/S0165-1110(96)90014-7	46	65	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4676	4684		10.1038/sj.onc.1204616	http://dx.doi.org/10.1038/sj.onc.1204616			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498790				2022-12-28	WOS:000170208600008
J	Zhang, ZH; DuBois, RN				Zhang, ZH; DuBois, RN			Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor	ONCOGENE			English	Article						cyclo-oxygenase-2; NSAID; colon cancer; subtraction cloning	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; PROTEIN-TYROSINE-PHOSPHATASE; COLORECTAL-CANCER CELLS; CYCLOOXYGENASE-2 INHIBITOR; MOLECULAR-CLONING; MESSENGER-RNA; CDNA CLONING; TUMOR-GROWTH; MOUSE MODEL	Numerous reports suggest that use of nonsteroidal anti-inflammatory drugs (NSAIDs) decrease mortality from colorectal cancer. To better understand all of the mechanisms underlying this effect, the global pattern of gene expression in colon carcinoma cells following treatment with NS-398, a selective cyclooxygenase-2 inhibitor was evaluated. We utilized suppression subtractive hybridization combined with differential screening to identify genes whose expression was affected following treatment. Among the subtracted cDNA fragments confirmed as differentially expressed, there were two which are known to be involved in the regulation of cell adhesion (human FAT and proto-cadherin-7). We identified two other genes whose levels were decreased and these are known to be involved in the regulation of cell proliferation (cyclin K and p-100). We identified additional genes which are involved in different signaling pathways which regulate programmed cell death (Dynamin 2, Pdcd4 and LIP.1). These results provide evidence that some of the effects of NS-398 on carcinoma cells may be due to modulation of genes which regulate programmed cell death, cell proliferation and cell-cell communication. Additional studies are underway to determine the biological function of the novel genes that were identified.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NATIONAL CANCER INSTITUTE [P30CA068485, P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047297, R01DK047297] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA68485, P0 CA77839] Funding Source: Medline; NIDDK NIH HHS [DK 47297] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Deleersnijder W, 1996, J BIOL CHEM, V271, P19475, DOI 10.1074/jbc.271.32.19475; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Drmanac R, 1999, METHOD ENZYMOL, V303, P165; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUNNE J, 1995, GENOMICS, V30, P207, DOI 10.1006/geno.1995.9884; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hara A, 1997, JPN J CANCER RES, V88, P600; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Heidebrecht HJ, 1997, BLOOD, V90, P226; Jacoby RF, 2000, CANCER RES, V60, P5040; Jones MK, 1999, NAT MED, V5, P1418; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Liu XH, 1998, CANCER RES, V58, P4245; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MASER RL, 1995, SEMIN NEPHROL, V15, P29; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Nagase T, 1995, DNA Res, V2, P51, DOI 10.1093/dnares/2.1.51; Nakagawa N, 2000, BIOCHEM BIOPH RES CO, V272, P505, DOI 10.1006/bbrc.2000.2787; Nishimura G, 1999, JPN J CANCER RES, V90, P1152, DOI 10.1111/j.1349-7006.1999.tb00690.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Rioux N, 1998, CANCER RES, V58, P5354; Sawaoka H., 1998, AM J PHYSIOL, V274, P1061; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Tsuji S, 1996, PROSTAG LEUKOTR ESS, V55, P179, DOI 10.1016/S0952-3278(96)90095-2; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Wang X, 2000, ONCOGENE, V19, P2346, DOI 10.1038/sj.onc.1203558; Watanabe K, 1999, CANCER RES, V59, P5093; Wechter WJ, 1997, CANCER RES, V57, P4316; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yoshida K, 1998, GENOMICS, V49, P458, DOI 10.1006/geno.1998.5271; Yoshimi N, 1999, JPN J CANCER RES, V90, P406, DOI 10.1111/j.1349-7006.1999.tb00762.x; ZENG J, 1994, NUCLEIC ACIDS RES, V22, P4381, DOI 10.1093/nar/22.21.4381; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	60	77	92	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4450	4456		10.1038/sj.onc.1204588	http://dx.doi.org/10.1038/sj.onc.1204588			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494140				2022-12-28	WOS:000170074900002
J	Struss, AK; Romeike, BFM; Munnia, A; Nastainczyk, W; Steudel, WI; Konig, J; Ohgaki, H; Feiden, W; Fischer, U; Meese, E				Struss, AK; Romeike, BFM; Munnia, A; Nastainczyk, W; Steudel, WI; Konig, J; Ohgaki, H; Feiden, W; Fischer, U; Meese, E			PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme	ONCOGENE			English	Article						humoral immune response; SEREX; glioblastoma multiforme; polyclonal antibody; PHD finger; PHF3	HUMAN TUMOR-ANTIGENS; SEROLOGIC RESPONSES; IMMUNE-RESPONSES; PHD FINGER; CANCER; GENE; P53; AUTOANTIBODIES; IDENTIFICATION; LOCALIZATION	Glioblastoma multiforme (GBM), a malignant astrocytic tumour, represents the most frequent tumour of the human brain. Nevertheless, its molecular pathology is not well understood. We utilized the immune system, which contributes to cancer protection, to help identify new GEM-related genes. By screening a human GEM cDNA library with autologous patient serum (SEREX-approach), we isolated a gene termed PHF3 (PHD finger protein 3), The gene product of PHF3 is immunogenic in GEM as tested in an allogenic patient serum screening demonstrating antibodies in 24 of 39 (61.53%) sera, whereas none of the 14 healthy persons had antibodies against PHF3, While previous SEREX studies revealed allogenic antibody responses up to 40%, our results for PHF3 represent the highest reported rate for a specific antibody response. We show that GEM patients with an antibody response against PHF3 show significant better survival than patients without PHF3-specific antibodies. Because the amino acid sequence of PHF3 contains a PHD finger (also termed LAP motif), a TFIIS homology, a proline rich region and nuclear localization signals, it supposedly functions as a transcription factor. A polyclonal antibody generated against PHF3 shows nuclear expression in most investigated formalin-fixed, paraffin embedded tissues. In GEM, PHF3 expression is concentrated in cells surrounding necroses.	Univ Saarlandes Kliniken, Inst Humangenet, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Abt Neuropathol, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Med Biochem, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Neurochirurg Klin, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Bioinformat, D-66421 Homburg, Germany; Int Agcy Res Canc, F-69372 Lyon 8, France	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; World Health Organization; International Agency for Research on Cancer (IARC)	Meese, E (corresponding author), Univ Saarland, Sch Med, Inst Humangenet, Bldg 60, D-66421 Homburg, Germany.	hgemee@med-rz.uni-sb.de	König, Jochem/T-3500-2019; Romeike, Bernd/K-8516-2019; , PD Dr. med. Bernd FM Romeike/Q-2600-2019; Meese, Eckart Ulrich/ABD-1983-2021	König, Jochem/0000-0003-4683-0360; , PD Dr. med. Bernd FM Romeike/0000-0002-9693-3870; 				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Biernat W, 1997, ACTA NEUROPATHOL, V94, P303, DOI 10.1007/s004010050711; Blaes F, 2000, ANN THORAC SURG, V69, P254, DOI 10.1016/S0003-4975(99)01198-4; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CHINOT O, 1996, BIOL TUMEURS CEREBRA; Coulson M, 1998, GENOMICS, V48, P381, DOI 10.1006/geno.1997.5201; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; Dietrich PY, 1997, ANN NY ACAD SCI, V824, P124, DOI 10.1111/j.1749-6632.1997.tb46215.x; FOLEY EJ, 1953, CANCER RES, V13, P835; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Hampton TA, 2000, CANCER GENE THER, V7, P446, DOI 10.1038/sj.cgt.7700124; Harlow E, 1998, ANTIBODIES LAB MANUA; Hasenpusch-Theil K, 1999, MAMM GENOME, V10, P294, DOI 10.1007/s003359900989; Heckel D, 1997, HUM MOL GENET, V6, P2031, DOI 10.1093/hmg/6.12.2031; Jung V, 1999, J NEUROPATH EXP NEUR, V58, P993, DOI 10.1097/00005072-199909000-00009; Kleihues P., 2000, PATHOLOGY GENETICS T, P29; KORNBLITH PL, 1983, CANCER, V52, P2230, DOI 10.1002/1097-0142(19831215)52:12<2230::AID-CNCR2820521211>3.0.CO;2-7; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OLD LJ, 1981, CANCER RES, V41, P361; PREHN RT, 1957, J NATL CANCER I, V18, P769; Rainov NG, 1995, CLIN CANCER RES, V1, P775; Robinson C, 2000, AM J RESP CELL MOL, V22, P550, DOI 10.1165/ajrcmb.22.5.3930; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Scanlan MJ, 1999, INT J CANCER, V83, P456, DOI 10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5; Scarcella DL, 1999, CLIN CANCER RES, V5, P335; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; Shrikant P, 1996, J IMMUNOL, V157, P1819; Soussi T, 2000, CANCER RES, V60, P1777; Suresh MR, 1996, ANTICANCER RES, V16, P2273; Tureci O, 1997, MOL MED TODAY, V3, P342, DOI 10.1016/S1357-4310(97)01081-2; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WELLER RO, 1992, BRAIN PATHOL, V2, P277, DOI 10.1111/j.1750-3639.1992.tb00704.x; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	37	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4107	4114		10.1038/sj.onc.1204552	http://dx.doi.org/10.1038/sj.onc.1204552			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464277				2022-12-28	WOS:000169857200001
J	Trauzold, A; Wermann, H; Arlt, A; Schutze, S; Schafer, H; Oestern, S; Roder, C; Ungefroren, H; Lampe, E; Heinrich, M; Walczak, H; Kalthoff, H				Trauzold, A; Wermann, H; Arlt, A; Schutze, S; Schafer, H; Oestern, S; Roder, C; Ungefroren, H; Lampe, E; Heinrich, M; Walczak, H; Kalthoff, H			CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappa B contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells	ONCOGENE			English	Article						apoptosis; CD95; TRAIL; PKC; NF-kappa B; pancreatic adenocarcinoma	SIGNALING PATHWAYS; TNF-ALPHA; DEATH; FAMILY; LIGAND; INHIBITION; INDUCTION; MEMBER; FAS; MU	The molecular alterations in tumour cells leading to resistance towards apoptosis induced by CD95 and TRAIL-receptors are not fully understood. We report here that the stimulation of the CD95- and TRAIL-resistant human pancreatic adenocarcinoma cell line PancTuI with an agonistic anti-CDW antibody or TRAIL resulted in activation of protein kinase C and NF-kappaB, Inhibition of protein kinase C by Go6983 sensitized these cells to apoptotic challenges and strongly diminished activation of NF-kappaB by anti-CD95 and TRAIL. Similarly, inhibition of NF-kappaB by MG132 or by transient transfection with a dominant negative mutant of I kappaB alpha restored the responsiveness of PancTuI cells to both death ligands. In the CD95 and TRAIL-sensitive cell line Colo357 the induction of protein kinase C and NF-KB following activation of CD95 and TRAIL-R was very moderate compared with PancTuI cells. However, pre-incubation of these cells with PMA strongly reduced their apoptotic response to anti-CD95 and TRAIL. Taken together, we show that activation of protein kinase C operates directly in a death receptor-dependent manner in PancTuI cells and protect pancreatic tumour cells from anti-CD95 and TRAIL-mediated apoptosis by preventing the loss Delta Psim and Cytochrome c release as well as by induction of NF-kappaB.	Univ Kiel, Clin Gen Surg, D-24105 Kiel, Germany; Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; German Canc Res Ctr, Dept Apoptosis Regulat, D-6900 Heidelberg, Germany	University of Kiel; University of Kiel; University of Kiel; Helmholtz Association; German Cancer Research Center (DKFZ)	Kalthoff, H (corresponding author), Univ Kiel, Clin Gen Surg, Arnold Heller Str 7, D-24105 Kiel, Germany.		Kalthoff, Holger/B-1618-2010; Arlt, Alexander/G-7308-2019; Schäfer, Heiner/C-1055-2011; Walczak, Henning/AAV-2214-2020; Schütze, Stefan/C-8596-2011; Roeder, Christian/F-1068-2010; Trauzold, Anna/P-4398-2014	Arlt, Alexander/0000-0002-6160-1059; Walczak, Henning/0000-0002-6312-4591; Roeder, Christian/0000-0001-7881-9110; 				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kobayashi D, 1997, CHEMOTHERAPY, V43, P415, DOI 10.1159/000239600; Krammer P H, 1999, Adv Immunol, V71, P163; KUMUDA CD, 1997, J BIOL CHEM, V272, P14914; Leverkus M, 2000, CANCER RES, V60, P553; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Packham G, 1997, CELL DEATH DIFFER, V4, P130, DOI 10.1038/sj.cdd.4400217; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PETER ME, 1998, APOPTOSIS PROBLEMS D, P25; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Ravi R, 1998, CANCER RES, V58, P882; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sawai H, 1997, J BIOL CHEM, V272, P2452; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Ungefroren H, 1998, CANCER RES, V58, P1741; von Reyher U, 1998, CANCER RES, V58, P526; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	40	143	144	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4258	4269		10.1038/sj.onc.1204559	http://dx.doi.org/10.1038/sj.onc.1204559			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464292				2022-12-28	WOS:000169857200016
J	Bensaad, K; Rouillard, D; Soussi, T				Bensaad, K; Rouillard, D; Soussi, T			Regulation of the cell cycle by p53 after DNA damage in an amphibian cell line	ONCOGENE			English	Article						p53; DNA damage; Xenopus laevis; cell cycle	XENOPUS-LAEVIS P53; WILD-TYPE P53; HUMAN CANCER; PROTEIN; BINDING; MUTATIONS; GENE; TRANSACTIVATION; MDM2; PHOSPHORYLATION	In mammalian cells, the p53 protein is a kev regulator of the cell cycle following DNA damage. In the present study, we investigated the function of p53 in the A6 amphibian cell line. Using various specific Xenopus p53 monoclonal antibodies, we showed that Xenopus p53 accumulates after DNA damage, including gamma and UV irradiation or treatment with adriamycin, Such accumulation is accompanied by an increase in the apparent molecular weight of the protein. This change was shown to be the result of a phosphorylation event that occurs after DNA damage. Accumulation of Xenopus p53 is parallel to a drastic change in the cell cycle distribution. Brief exposure to adriamycin or gamma irradiation induces reversible growth arrest, whereas long-term exposure to adriamycin leads to apoptosis, Taken together, these results indicate that p53 has a similar behaviour in frog cells and mammalian cells, and that it conserves two activities, cell cycle arrest and apoptosis.	Inst Curie, Lab Genotoxicol Tumeurs, F-75005 Paris, France; Inst Curie, Serv Cytometrie, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Soussi, T (corresponding author), Inst Curie, Lab Genotoxicol Tumeurs, 26 Rue Ulm, F-75005 Paris, France.			soussi, thierry/0000-0001-8184-3293				Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DEQUIEDT F, 1995, VIROLOGY, V209, P676, DOI 10.1006/viro.1995.1303; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; HARDYBESSARD AC, 1998, ONCOGENE, V16, P883; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; Mayr B, 2000, RES VET SCI, V68, P63, DOI 10.1053/rvsc.1999.0339; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; RAFFERTY KA, 1969, BIOL AMPHIBIAN TUMOR, P52; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SOUSSI T, 1987, ONCOGENE, V1, P71; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; Tchang F, 1999, EXP CELL RES, V251, P46, DOI 10.1006/excr.1999.4570; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Veldhoen N, 1998, ONCOGENE, V16, P249, DOI 10.1038/sj.onc.1201489; WANG Y, 1995, ONCOGENE, V10, P779; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343	37	12	12	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3766	3775		10.1038/sj.onc.1204492	http://dx.doi.org/10.1038/sj.onc.1204492			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439340				2022-12-28	WOS:000169494700002
J	Hemenway, CS; de Erkenez, AC; Gould, GCD				Hemenway, CS; de Erkenez, AC; Gould, GCD			The polycomb protein MPc3 interacts with AF9, an MLL fusion partner in t(9;11)(p22;q23) acute leukemias	ONCOGENE			English	Article						polycomb group proteinsMLL fusion genes; fluorescent protein tagging	TRANSCRIPTIONAL REPRESSOR; DROSOPHILA-MELANOGASTER; GENE-EXPRESSION; GROUP-COMPLEXES; TRITHORAX-GROUP; GAGA-FACTOR; MOUSE; CHROMATIN; IDENTIFICATION; BINDING	Polycomb group (PcG) proteins assemble to form large multiprotein complexes involved in gene silencing, Evidence suggests that PcG complexes are heterogeneous with respect to both protein composition and specific function, MPc3 is a recently described mouse Polycomb (Pc) protein that shares structural homology with at least two other Pc proteins, M33 and MPc2, All three Pc proteins bind another PcG protein, RING1, through a conserved carboxy-terminal C-box motif, Here, data are presented demonstrating that MPc3 also interacts with AF9, a transcriptional activator implicated in the development of acute leukemias. The carboxy-terminus of AF9 is fused to the MLL protein in leukemias characterized by t(9;11)(p22;q23) chromosomal translocations, importantly, it is the carboxy-terminus of AF9 to which MPc,7 binds, The AF9 binding site of MPc3 maps to a central, non-conserved, region of the polypeptide sequence. In contrast to MPc3, data indicate that the Pc protein M33 does not interact with AF9, This finding suggests a potentially unique role for MPc3 in linking a PcG silencing complex to a transcriptional activator protein.	Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA	Tulane University; Tulane University	Hemenway, CS (corresponding author), Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA.				NATIONAL CANCER INSTITUTE [K01CA078318] Funding Source: NIH RePORTER; NCI NIH HHS [1K01 CA78318-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; Bel S, 1998, DEVELOPMENT, V125, P3543; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Hashimoto N, 1998, BIOCHEM BIOPH RES CO, V245, P356, DOI 10.1006/bbrc.1998.8438; Hemenway CS, 2000, GENE, V242, P31, DOI 10.1016/S0378-1119(99)00540-5; Hemenway CS, 1998, ONCOGENE, V16, P2541, DOI 10.1038/sj.onc.1202042; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; IIDA S, 1993, ONCOGENE, V8, P3085; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; Morgan H, 2000, FASEB J, V14, P1109, DOI 10.1096/fasebj.14.9.1109; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; RUBNITZ JE, 1994, BLOOD, V84, P1747; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; Takihara Y, 1997, DEVELOPMENT, V124, P3673; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385	38	62	66	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3798	3805		10.1038/sj.onc.1204478	http://dx.doi.org/10.1038/sj.onc.1204478			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439343				2022-12-28	WOS:000169494700005
J	Sansom, OJ; Toft, NJ; Winton, DJ; Clarke, AR				Sansom, OJ; Toft, NJ; Winton, DJ; Clarke, AR			Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner	ONCOGENE			English	Article						mismatch repair; apoptosis; mutation; heterozygosity; cisplatin; alkylation	DNA MISMATCH REPAIR; COLORECTAL-CANCER; MSH2-DEFICIENT MICE; DRUG-RESISTANCE; YEAST STRAINS; TUMOR-CELLS; MLH1; P53; HETEROZYGOSITY; PHENOTYPES	Mice deficient for the mismatch repair (MMR) gene Msh2 show accelerated tumourigenesis and a reduced apoptotic response to DNA damage of methylation type, Here we examine the effect of mutation for Msh2 on in vivo mutation frequencies in the intestine as determined by loss of function at the Dolichos biflorus (Dlb-1) locus. Spontaneous mutation frequencies were scored in cohorts of ageing mice either wild type or mutant for Msh2. In mice less than 1 year old, mutation frequencies were only elevated in Msh2 null mice. However, beyond this age heterozygous Msh2 mice showed significantly higher mutation frequencies than controls. These findings implicate a gene dose dependent requirement for Msh2 in mutation suppression and prompted an analysis of young Msh2 mutants following exposure to DNA damage. Following exposure to N-methyl-N ' -nitro-N-nitrosoguanidine (MNNG), Msh2 deficient mice show a reduced apoptotic response and an increase in mutation frequency. Heterozygotes did not differ from controls. Following exposure to cisplatin, no significant elevation was seen in mutation frequencies, even within homozygotes. This is particularly surprising given the association between cisplatin resistance and MMR deficiency, These findings therefore demonstrate a complex reliance upon functional Msh2 in mutation surveillance. We have identified three separate scenarios. First, where retention of both Msh2 alleles ol er an extended period of time appears critical to the suppression of spontaneous mutation; second, 3 weeks following exposure to MNNG, where only complete loss of Msh2 results in elevated mutation; and finally following cisplatin exposure, where induced levels of mutation are independent of Msh2 status.	Cardiff Univ, Sch Biosci, Cardiff C10 3US, S Glam, Wales; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Cambridge, Addenbrookes Hosp, Canc Res Campaign, Human Genet Res Grp, Cambridge CB2 2QQ, England	Cardiff University; University of Edinburgh; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; CRUK Cambridge Institute; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, POB 911, Cardiff C10 3US, S Glam, Wales.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; de Wind N, 1998, CANCER RES, V58, P248; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drotschmann K, 1999, P NATL ACAD SCI USA, V96, P2970, DOI 10.1073/pnas.96.6.2970; Drotschmann K, 2000, TOXICOL LETT, V112, P239, DOI 10.1016/S0378-4274(99)00276-3; Fink D, 1998, CLIN CANCER RES, V4, P1; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Reitmair AH, 1996, CANCER RES, V56, P3842; Reitmair AH, 1997, CANCER RES, V57, P3765; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; STRATHDEE G, 2001, IN PRESS ONCOGENE; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Wheeler JMD, 2000, GUT, V47, P148, DOI 10.1136/gut.47.1.148; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0	24	18	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3580	3584		10.1038/sj.onc.1204449	http://dx.doi.org/10.1038/sj.onc.1204449			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429706				2022-12-28	WOS:000169478300015
J	Everett, RD				Everett, RD			DNA viruses and viral proteins that interact with PML nuclear bodies	ONCOGENE			English	Article						PML nuclear bodies; SUMO-1; DNA viruses; ICP0; ubiquitin-proteasome pathway	HERPES-SIMPLEX-VIRUS; EPSTEIN-BARR-VIRUS; PROTEASOME-DEPENDENT DEGRADATION; UBIQUITIN-SPECIFIC PROTEASE; HUMAN CYTOMEGALOVIRUS; REPLICATION COMPARTMENTS; GENE-EXPRESSION; DOMAIN 10; ALPHAHERPESVIRUS PROTEINS; CAPSID PROTEIN	Connections between PML nuclear bodies (PML NBs) and DNA virus replication have been investigated from the earliest days of the molecular characterization of PML and associated proteins. It appears to be a general feature of nuclear-replicating DNA viruses that their parental genomes preferentially become associated with PML NBs, and that their initial sites of transcription and development of DNA replication centres are frequently juxtaposed to these domains or their remnants. In addition, regulatory proteins encoded by several DNA viruses associate with and sometimes cause catastrophic changes to PML NBs by a variety of mechanisms. These events can be correlated with the efficiency of viral infection and the functions of viral regulatory proteins, but the underlying molecular connections between PML NB function and viral infection remain poorly understood. This article reviews the latest developments in the interactions between PML NBs and herpesviruses, adenoviruses and papovaviruses.	MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland		Everett, RD (corresponding author), MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.							Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Ahn JH, 1999, J VIROL, V73, P10458, DOI 10.1128/JVI.73.12.10458-10471.1999; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Ahn JH, 2001, J VIROL, V75, P3859, DOI 10.1128/JVI.75.8.3859-3872.2001; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Bastien N, 2000, VIROLOGY, V270, P124, DOI 10.1006/viro.2000.0265; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; Burkham J, 1998, J VIROL, V72, P10100, DOI 10.1128/JVI.72.12.10100-10107.1998; Burkham J, 2001, J VIROL, V75, P2353, DOI 10.1128/JVI.75.5.2353-2367.2001; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Everett RD, 2000, J VIROL, V74, P9994, DOI 10.1128/JVI.74.21.9994-10005.2000; Everett RD, 1999, J CELL SCI, V112, P3443; Everett RD, 1999, TRENDS BIOCHEM SCI, V24, P293, DOI 10.1016/S0968-0004(99)01433-4; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1998, EMBO J, V17, P7161, DOI 10.1093/emboj/17.24.7161; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Everett RD, 1999, J CELL SCI, V112, P4581; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; EVERETT RD, 1991, CONTROL HERPES SIMPL; Fabunmi RP, 2001, J CELL SCI, V114, P29; Fields BN., 1996, VIROLOGY; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Halford WP, 2001, J VIROL, V75, P3240, DOI 10.1128/JVI.75.7.3240-3249.2001; Heino P, 2000, VIROLOGY, V276, P304, DOI 10.1006/viro.2000.0342; Hobbs WE, 2001, J VIROL, V75, P3391, DOI 10.1128/JVI.75.7.3391-3403.2001; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Hsu WL, 2001, J VIROL, V75, P3819, DOI 10.1128/JVI.75.8.3819-3831.2001; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Ishov AM, 1997, J CELL BIOL, V138, P5, DOI 10.1083/jcb.138.1.5; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jiang WQ, 1996, EXP CELL RES, V229, P289, DOI 10.1006/excr.1996.0374; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; Korioth F, 1996, EXP CELL RES, V229, P155, DOI 10.1006/excr.1996.0353; LALLEMANDBREITE.V, 2001, EXPT MED, V193, P1361; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Lomonte P, 1999, J VIROL, V73, P9456, DOI 10.1128/JVI.73.11.9456-9467.1999; Lomonte P, 2001, J BIOL CHEM, V276, P5829, DOI 10.1074/jbc.M008547200; Lukonis CJ, 1997, J VIROL, V71, P2390, DOI 10.1128/JVI.71.3.2390-2399.1997; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Maul GG, 1996, VIROLOGY, V217, P67, DOI 10.1006/viro.1996.0094; Mocarski ES, 1996, P NATL ACAD SCI USA, V93, P11321, DOI 10.1073/pnas.93.21.11321; Mossman KL, 2000, J VIROL, V74, P2052, DOI 10.1128/JVI.74.4.2052-2056.2000; Muller S, 1999, J VIROL, V73, P5137; Parkinson J, 2000, J VIROL, V74, P10006, DOI 10.1128/JVI.74.21.10006-10017.2000; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Parkinson J, 2001, J VIROL, V75, P5357, DOI 10.1128/JVI.75.11.5357-5362.2001; Plehn-Dujowich D, 2000, CHROMOSOMA, V109, P266, DOI 10.1007/s004120000073; Preston CM, 2000, J GEN VIROL, V81, P1; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; Tang QY, 2000, J VIROL, V74, P9694, DOI 10.1128/JVI.74.20.9694-9700.2000; Taylor JL, 2000, J INTERF CYTOK RES, V20, P805, DOI 10.1089/10799900050151076; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Wilkinson GWG, 1998, J GEN VIROL, V79, P1233, DOI 10.1099/0022-1317-79-5-1233; Wu FY, 2001, J VIROL, V75, P1487, DOI 10.1128/JVI.75.3.1487-1506.2001; Wu H, 2000, EMBO REP, V1, P140, DOI 10.1093/embo-reports/kvd026	79	216	217	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7266	7273		10.1038/sj.onc.1204759	http://dx.doi.org/10.1038/sj.onc.1204759			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704855				2022-12-28	WOS:000171891900015
J	Baisden, JM; Gatesman, AS; Cherezova, L; Jiang, BH; Flynn, DC				Baisden, JM; Gatesman, AS; Cherezova, L; Jiang, BH; Flynn, DC			The intrinsic ability of AFAP-110 to alter actin filament integrity is linked with its ability to also activate cellular tyrosine kinases	ONCOGENE			English	Article						AFAP-110; Src; actin filaments	PP60C-SRC PROTEIN-KINASE; TRANSFORMED FIBROBLASTS; STABLE ASSOCIATION; STRESS FIBERS; SH3 DOMAINS; V-SRC; C-SRC; COMPLEX; PP60SRC; MOTIF	The actin filament-associated protein of 110 kDa (AFAP-110) is a Src binding partner that represents a potential modulator of actin filament integrity in response to cellular signals. Previous reports have demonstrated that AFAP-110 is capable of directly binding and altering actin filaments. Deletion of the leucine zipper motif of AFAP-110 (AFAP-110(Delta lzip)) has been shown to induce a phenotype which resembles Src-transformed cells, by repositioning actin filaments into rosettes. This deletion also mimics a conformational change in AFAP-110 that is detected in Src-transformed cells. The results presented here indicate that unlike AFAP-110, AFAP-110 Delta lzip is capable of activating cellular tyrosine kinases, including Src family members, and that AFAP-110 Delta lzip itself is hyperphosphorylated. The newly tyrosine phosphorylated proteins and activated Src-family members appear to be associated with actin-rich lamellipodia. A point mutation that alters the SH3-binding motif of AFAP-110 Delta lzip prevents it from activating tyrosine kinases and altering actin filament integrity. In addition, a deletion within a pleckstrin homology (PH) domain of AFAP-110 Delta lzip will also revert its effects upon actin filaments. Lastly, dominant-positive RhoA(V14) will block the ability of AFAP-110(Delta lzip) from inducing actin filament rosettes, but does not inhibit Src activation. Thus, conformational changes in AFAP-110 enable it to activate cellular kinases in a mechanism requiring SH3 and/or PH domain interactions. We hypothesize that cellular signals which alter AFAP-110 conformation, enable it to activate cellular kinases such as cSrc, which then direct changes in actin filament integrity in a Rho-dependent fashion.	W Virginia Univ, Dept Microbiol & Immunol, Morgantown, WV 26506 USA	West Virginia University	Flynn, DC (corresponding author), W Virginia Univ, Dept Microbiol & Immunol, 2822 MBRCC, Morgantown, WV 26506 USA.	dflynn@hsc.wvu.edu	Baisden, Joseph/AAN-7747-2021	Baisden, Joseph/0000-0002-8986-407X; Jiang, Bing-Hua/0000-0003-4526-2031	NATIONAL CANCER INSTITUTE [R01CA060731, R29CA060731] Funding Source: NIH RePORTER; NCI NIH HHS [CA60731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAISDEN JM, 2001, IN PRESS ONCOGENE; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; Fincham VJ, 1999, J CELL SCI, V112, P947; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; He H, 2000, CANCER J, V6, P243; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Qian Y, 1999, HYBRIDOMA, V18, P167, DOI 10.1089/hyb.1999.18.167; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000	30	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6607	6616		10.1038/sj.onc.1204802	http://dx.doi.org/10.1038/sj.onc.1204802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641786				2022-12-28	WOS:000171404200014
J	Heit, I; Wieser, RJ; Herget, T; Faust, D; Borchert-Stuhltrager, M; Oesch, F; Dietrich, C				Heit, I; Wieser, RJ; Herget, T; Faust, D; Borchert-Stuhltrager, M; Oesch, F; Dietrich, C			Involvement of protein kinase C delta in contact-dependent inhibition of growth in human and murine fibroblasts	ONCOGENE			English	Article						contact-inhibition; PKC delta; fibroblast	HUMAN-DIPLOID FIBROBLASTS; PHORBOL ESTER; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; RAT FIBROBLASTS; PKC-DELTA; EXPRESSION; CELLS; SRC; ROTTLERIN	There is evidence that protein kinase C delta (PKC delta) is a tumor suppressor, although its physiological role has not been elucidated so far. Since important anti-proliferative signals are mediated by cell-cell contacts we studied whether PKC delta is involved in contact-dependent inhibition of growth in human (FH109) and murine (NIH3T3) fibroblasts. Cell-cell contacts were imitated by the addition of glutardialdehyde-fixed cells to sparsely seeded fibroblasts. Downregulation of the PKC isoforms alpha, delta, epsilon, and mu after prolonged treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA, 0.1 mum) resulted in a significant release from contact-inhibition in FH109 cells. Bryostatin I selectively prevented TPA-induced PKC delta -downregulation and reversed TPA-induced release from contact-inhibition arguing for a role of PKC delta in contact-inhibition. In accordance, the PKC delta specific inhibitor Rottlerin (1 mum) totally abolished contact-inhibition. Interestingly, immunofluorescence revealed a rapid translocation of PKC delta to the nucleus when cultures reached confluence with a peak in early-mid G1 phase. Nuclear translocation of PKC delta in response to cell-cell contacts could also be demonstrated after subcellular fractionation by Western blotting and by measuring PKC delta -activity after immunoprecipitation. Transient transfection of NIH3T3 cells with a dominant negative mutant of PKC delta induced a transformed phenotype. We conclude that PKC delta is involved in contact-dependent inhibition of growth.	Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Dietrich, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	cdietric@mail.uni-mainz.de	Oesch, Franz/AAA-8746-2020					Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1992, J BIOL CHEM, V267, P12892; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Dietrich C, 2001, BIOCHEM BIOPH RES CO, V282, P575, DOI 10.1006/bbrc.2001.4530; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Guay J, 1997, J CELL SCI, V110, P357; Hamada K, 1996, BBA-MOL CELL RES, V1310, P149, DOI 10.1016/0167-4889(95)00148-4; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTA CAM, 1995, CARCINOGENESIS, V16, P1233; LaPorta CAM, 1997, CARCINOGENESIS, V18, P715, DOI 10.1093/carcin/18.4.715; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LI WQ, 1994, J BIOL CHEM, V269, P2349; Lorenzo PS, 1997, J BIOL CHEM, V272, P33338, DOI 10.1074/jbc.272.52.33338; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; MORETON K, 1995, FEBS LETT, V372, P33, DOI 10.1016/0014-5793(95)00941-2; OESCH F, 1988, CARCINOGENESIS, V9, P1319, DOI 10.1093/carcin/9.7.1319; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; Parmer TG, 1997, CELL GROWTH DIFFER, V8, P327; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; WIESER RJ, 1990, ENVIRON HEALTH PERSP, V88, P251, DOI 10.2307/3431085; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	54	30	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5143	5154		10.1038/sj.onc.1204657	http://dx.doi.org/10.1038/sj.onc.1204657			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526503				2022-12-28	WOS:000170464000008
J	Karoui, M; Hofmann-Radvanyi, H; Zimmermann, U; Couvelard, A; Degott, C; Faridoni-Laurens, L; Ahomadegbe, JC; Gazzeri, S; Brambilla, E; Clerici, T; Charbonnier, P; Tresallet, C; Mitry, E; Penna, C; Rougier, P; Boileau, C; Thiery, JP; Nordlinger, B; Franc, B; Radvanyi, F				Karoui, M; Hofmann-Radvanyi, H; Zimmermann, U; Couvelard, A; Degott, C; Faridoni-Laurens, L; Ahomadegbe, JC; Gazzeri, S; Brambilla, E; Clerici, T; Charbonnier, P; Tresallet, C; Mitry, E; Penna, C; Rougier, P; Boileau, C; Thiery, JP; Nordlinger, B; Franc, B; Radvanyi, F			No evidence of somatic FGFR3 mutation in various types of carcinoma	ONCOGENE			English	Article						FGFR3; growth factor receptor; carcinoma; oncogene	GROWTH-FACTOR RECEPTOR-3; MULTIPLE-MYELOMA; ACTIVATING MUTATIONS; SKELETAL DISORDERS; FIBROBLAST; GENE; EXPRESSION; DYSPLASIA; BLADDER; CERVIX	Germline specific point mutations in the gene encoding fibroblast growth factor receptor 3 (FGFR3) are associated with autosomal dominant human skeletal dysplasia and craniosynostosis syndromes. Mutations identical to the germinal activating mutations found in severe skeletal dysplasias have been identified in certain types of cancer: at low frequency in multiple myeloma and cervix carcinoma and at high frequency in bladder carcinoma. We analysed, by SSCP and sequencing, the prevalence of FGFR3 mutations in 116 primary tumours of various types (upper aerodigestive tract, oesophagus, stomach, lung and skin). The regions analysed encompassed all FGFR3 point mutations previously described in severe skeletal dysplasia and cancers. No mutations were detected in the tumour types examined, suggesting that FGFR3 mutations are restricted to a few tumour types, the evidence to date suggesting that they are very specific to bladder carcinomas.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France; CHU Grenoble, Serv Pathol Cellulaire, F-38700 Grenoble, France; Inst Gustave Roussy, Dept Biol Clin, F-94800 Villejuif, France; Hop Beaujon, Serv Anat & Cytol Pathol, F-92110 Clichy, France; Univ Paris 05, Hop Ambroise Pare, Serv Anat & Cytol Pathol, F-92104 Boulogne, France; Univ Paris 05, Hop Ambroise Pare, Lab Biochim & Genet Mol, F-92104 Boulogne, France; CHRU Lille, Hop Claude Huriez, Serv Chirurg Digest & Transplantat, F-59037 Lille, France; Univ Paris 05, Hop Ambroise Pare, Federat Special Digest, F-92104 Boulogne, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite	Thiery, JP (corresponding author), Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France.		gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013; boileau, catherine/M-4482-2017; Brambilla, Elisabeth MP/L-8796-2013; Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; boileau, catherine/0000-0002-0371-7539; Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424; Anne, Couvelard/0000-0002-6316-1210				Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; COHEN SM, 1992, UROL CLIN N AM, V19, P421; Delezoide AL, 1998, MECH DEVELOP, V77, P19, DOI 10.1016/S0925-4773(98)00133-6; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; MURGUE B, 1994, CANCER RES, V54, P5206; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; van Rhijn BWG, 2001, CANCER RES, V61, P1265; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Wu R, 2000, ONCOGENE, V19, P5543, DOI 10.1038/sj.onc.1203934; Yee CJ, 2000, JNCI-J NATL CANCER I, V92, P1848, DOI 10.1093/jnci/92.22.1848	17	35	38	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5059	5061		10.1038/sj.onc.1204651	http://dx.doi.org/10.1038/sj.onc.1204651			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526491				2022-12-28	WOS:000170439800016
J	Kozlova, NI; Morozevich, GE; Chubukina, AN; Berman, AE				Kozlova, NI; Morozevich, GE; Chubukina, AN; Berman, AE			Integrin alpha v beta 3 promotes anchorage-dependent apoptosis in human intestinal carcinoma cells	ONCOGENE			English	Article						integrins; apoptosis; anoikis; extracellular matrix	ENDOTHELIAL-CELLS; MELANOMA-CELLS; EXPRESSION; SURVIVAL; ACTIVATION; ADHESION; MATRIX; ANGIOGENESIS; INDUCTION; COLLAGEN	A population of cells surviving during prolonged incubation in suspension (anoikis-negative cells) were selected from the original anoikis-positive human intestinal carcinoma cell line Caco-2. Anoikis-negative cells are characterized by a strong transcriptional downregulation of the alphav-integrin chain as detected by FACS analysis, RT-PCR and Northern blotting. This finding suggested that ow-integrin generates a signal stimulating apoptosis of Caco-2 cells upon their detachment from the extracellular matrix. Two lines of evidence supporting this suggestion were provided. First, activation of the alphav beta3 integrin on Caco-2 cells by their treatment with an alphav beta3-specific monoclonal antibody resulted in marked stimulation of anoikis. Second, treatment of Caco-2 cells with alphav-specific antisense oligonucleotide resulted in downregulation of the expression of alphav chain and in elevated resistance of these cells to anoikis. Thus, for the first time, our data prove that alphav beta3 integrin can be an active transducer of apoptosis-stimulating signals generated in response to disruption of the cell-matrix contacts.	Russian Acad Med Sci, Inst Biomed Chem, Moscow 119832, Russia	Russian Academy of Medical Sciences; Institute of Biomedical Chemistry	Berman, AE (corresponding author), Russian Acad Med Sci, Inst Biomed Chem, Pogodinskaya Str 10, Moscow 119832, Russia.		Kozlova, Nadezda/ABD-7878-2020; Morozevich, Galina/ABD-7858-2020; EBerman, Albert/F-5042-2017					Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; BERMAN A, 1993, BIOCHEM BIOPH RES CO, V194, P351, DOI 10.1006/bbrc.1993.1827; Berman A E, 2000, Membr Cell Biol, V13, P207; Brassard DL, 1999, EXP CELL RES, V251, P33, DOI 10.1006/excr.1999.4559; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Danen EHJ, 1996, BIOCHEM BIOPH RES CO, V226, P75, DOI 10.1006/bbrc.1996.1313; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Eble J.A., 1997, MOL B INT U, P1; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEHLSEN KR, 1992, CLIN EXP METASTAS, V10, P111, DOI 10.1007/BF00114587; Heino J, 1996, INT J CANCER, V65, P717, DOI 10.1002/(SICI)1097-0215(19960315)65:6<717::AID-IJC1>3.3.CO;2-P; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Kuzuya M, 1999, EXP CELL RES, V248, P498, DOI 10.1006/excr.1999.4422; MARSHALL JF, 1991, INT J CANCER, V49, P924, DOI 10.1002/ijc.2910490621; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miao JY, 1997, BIOCHEM BIOPH RES CO, V233, P182, DOI 10.1006/bbrc.1997.6422; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morozevich GE, 1998, VOP MED KHIM, V44, P77; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	36	51	54	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4710	4717		10.1038/sj.onc.1204619	http://dx.doi.org/10.1038/sj.onc.1204619			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498793				2022-12-28	WOS:000170208600011
J	Benaud, CM; Dickson, RB				Benaud, CM; Dickson, RB			Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc	ONCOGENE			English	Article						adhesion; c-Myc; cell cycle; p27	GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; FUNCTIONAL INACTIVATION; DEPENDENT EXPRESSION; NEGATIVE REGULATORS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CDK COMPLEXES; MESSENGER-RNA	Adhesion to the extracellular matrix is required for the expression and activation of the cyclin-cyclin-dependent kinase (CDK) complexes, and for G1 phase progression of non-transformed cells. However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the p27 cyclin-dependent kinase inhibitor (CKI), and the associated inhibition of cyclin E-CDK2. We now show that in epithelial cells the expression of c-Myc is tightly regulated by cell-substrate adhesion. When deprived of adhesion, two independently derived mammary epithelial cell lines, 184AlN4 and MCF-10A, rapidly decrease their level of c-Myc mRNA and protein. This decrease in levels of c-Myc correlates with G1 phase arrest, as indicated by hypophosphorylation of pRb and inhibition of the activity of the cyclin E-CDK2 complex. In 184AlN4 cells, cell-substrate adhesion is required for the suppression of p27, and induction of cyclin E, E2F-1, but not cyclins D1 and D3. Enforced expression of c-Myc in non-adherent 184AIN4 and MCF-10A cells reverses the adhesion-dependent inhibition of cell cycle progression. Restoration of c-Myc in non-adherent cells induces the expression of E2F-1, and hyperphosphorylation of pRb in response to EGF treatment. In addition, expression of c-Myc results in the anchorage-independent activation of the CDK2 complex, the associated upregulation of cyclin E, and the destabilization and degradation of p27 by the ubiquitin-proteasome pathway. Our study thus suggests that c-Myc is the link between cell adhesion and the regulation of p27 and cyclin ECDK2. Furthermore, we describe a role for c-Myc in adhesion-mediated regulation of E2F-1.	Georgetown Univ, Med Ctr, Dept Cell Biol, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Oncol, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University; Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Dept Cell Biol, Vincent T Lombardi Canc Ctr, 3970 Reservoir Rd NW, Washington, DC 20007 USA.	dicksonr@gunet.georgetown.edu	Benaud, Christelle/M-1178-2018		NIA NIH HHS [R01 AG1496] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Carstens CP, 1996, EXP CELL RES, V229, P86, DOI 10.1006/excr.1996.0346; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dike LE, 1996, J CELL SCI, V109, P2855; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KUMATORI A, 1991, BIOCHEM BIOPH RES CO, V178, P480, DOI 10.1016/0006-291X(91)90132-Q; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Liao DJ, 2000, ONCOGENE, V19, P1307, DOI 10.1038/sj.onc.1203430; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUHISA T, 1981, EXP CELL RES, V135, P393, DOI 10.1016/0014-4827(81)90176-2; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nass SJ, 1998, CLIN CANCER RES, V4, P1813; Nijjar T, 1999, CANCER RES, V59, P5112; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SEJERSEN T, 1985, J CELL PHYSIOL, V125, P465, DOI 10.1002/jcp.1041250315; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SOULE HD, 1990, CANCER RES, V50, P6075; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	64	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4554	4567		10.1038/sj.onc.1204609	http://dx.doi.org/10.1038/sj.onc.1204609			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494151				2022-12-28	WOS:000170074900013
J	Mende, I; Malstrom, S; Tsichlis, PN; Vogt, PK; Aoki, M				Mende, I; Malstrom, S; Tsichlis, PN; Vogt, PK; Aoki, M			Oncogenic transformation induced by membrane-targeted Akt2 and Akt3	ONCOGENE			English	Article						Akt; transformation; serine/threonine kinase	PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; MOLECULAR-CLONING; CATALYTIC SUBUNIT; TUMOR-SUPPRESSOR; B-GAMMA; ACTIVATION; EXPRESSION; OVARIAN	The kinases Akt2, Akt3 and their myristylated variants, Myr-Akt2 and Myr-Akt3 were expressed by the RCAS vector in chicken embryo fibroblasts (CEF), Myr-Akt2 and Myr-Akt3 were strongly oncogenic, inducing multilayered foci of transformed cells. In contrast, wild-type Akt2 and Akt3 were only poorly transforming, their efficiencies of focus formation were more than 100-fold lower; foci appeared later and showed less multilayering, Addition of the myristylation signal not only enhanced oncogenic potential hut also increased kinase activities. Myr-Akt2 and Myr-Akt3 also induced hemangiosarcomas in the animal, whereas wild type Akt2 and Akt3 were not oncogenic in vivo. Furthermore, Akt2, driven by the lck (lymphocyte specific kinase) promoter in transgenic mice, induced lymphomas, The oncogenic effects of Akt2 and Akt3 described here are indistinguishable from those of Akt1, The downstream targets relevant to oncogenic transformation are therefore probably shared by the three Akt kinases.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Scripps Research Institute; Jefferson University	Vogt, PK (corresponding author), 10550 N Torrey Pines Rd,BCC-239, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490	NCI NIH HHS [CA 79616, CA 42564, CA 78230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564, R01CA079616, R01CA078230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; CECI JD, 1991, ONCOGENE, V6, P323; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Liu AX, 1998, CANCER RES, V58, P2973; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; OSBORN L, 1987, MOL CELL BIOL, V7, P326, DOI 10.1128/MCB.7.1.326; PELES E, 1992, J BIOL CHEM, V267, P12266; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SIRACUSA LD, 1987, GENETICS, V117, P85; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	48	86	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4419	4423		10.1038/sj.onc.1204486	http://dx.doi.org/10.1038/sj.onc.1204486			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466625				2022-12-28	WOS:000169912600018
J	Xi, HK; Goodwin, B; Shepherd, AT; Blanck, G				Xi, HK; Goodwin, B; Shepherd, AT; Blanck, G			Impaired class II transactivator expression in mice lacking interferon regulatory factor-2	ONCOGENE			English	Article						IRF; CIITA; MHC class II; IFN-gamma; mice	BARE LYMPHOCYTE SYNDROME; CREB BINDING-PROTEIN; MHC GENE-EXPRESSION; IFN-GAMMA; DERMAL FIBROBLASTS; CIITA INTERACTS; CHAIN GENE; INDUCTION; ACTIVATION; PROMOTER	Class II transactivator (CIITA) is required for both constitutive and inducible expression of MHC class II genes. IFN-gamma induced expression of CIITA in various cell types is directed by CIITA type IV promoter. The two transactivators, STAT1 and IRF-1, mediate the IFN-gamma activation of the type IV promoter by binding to the GAS and IRF-E of the promoter, respectively. In addition to IRF-1, IRF-2, another member of the IRF family, also activates the human CIITA type IV promoter, and IRF-2 cooperates with IRF-1 to activate the promoter in transient transfection assays, IRF-1 and IRF-2 can co-occupy the IRF-E of the human CIITA type IV promoter. To understand the effect of loss of IRF-2 on the endogenous CIITA expression, we assayed for CIITA expression in IRF-2 knock-out mice. Both basal and IFN-gamma induced CIITA expression were reduced in IRF-2 knock-out mice. At least half of the amount of inducible CIITA mRNA depends on IRF-2, The reduction of IFN-gamma induced CIITA mRNA in IRF-2: knock-out mice was due to the reduction of the type IV CIITA mRNA induction. The reduction of basal CIITA mRNA was apparently due to the reduction of CIITA mRNA originating from other promoters. These data indicate that IRF-2, like IRF-1, plays a critical role in the regulation of the endogenous CIITA gene. The implications in understanding the previously described phenotypes of IRF-2 defective mice are discussed.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Blanck, G (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Blanck, George/A-5365-2012		NCI NIH HHS [R01CA81497-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASTA PV, 1987, J IMMUNOL, V138, P1275; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; Bradley MB, 1997, J IMMUNOL, V159, P1086; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOES N, 1995, J IMMUNOL, V155, P4559; Grieder FB, 1999, VIROLOGY, V257, P106, DOI 10.1006/viro.1999.9662; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; Hobart M, 1997, J IMMUNOL, V158, P4260; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Lu YM, 1996, J IMMUNOL, V156, P2495; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Merediz SAK, 2000, NUCLEIC ACIDS RES, V28, P4219, DOI 10.1093/nar/28.21.4219; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nikcevich KM, 1999, J NEUROIMMUNOL, V99, P195, DOI 10.1016/S0165-5728(99)00117-4; O'Keefe GM, 1999, EUR J IMMUNOL, V29, P1275, DOI 10.1002/(SICI)1521-4141(199904)29:04<1275::AID-IMMU1275>3.0.CO;2-T; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; Rohn WM, 1996, CRIT REV IMMUNOL, V16, P311, DOI 10.1615/CritRevImmunol.v16.i3.40; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; Schoneboom BA, 2000, J INTERF CYTOK RES, V20, P205, DOI 10.1089/107999000312621; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Xi HK, 1999, ONCOGENE, V18, P5889, DOI 10.1038/sj.onc.1202969; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000	44	16	16	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4219	4227		10.1038/sj.onc.1204556	http://dx.doi.org/10.1038/sj.onc.1204556			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464288				2022-12-28	WOS:000169857200012
J	Lee, GH; Matsushita, H; Kitagawa, T				Lee, GH; Matsushita, H; Kitagawa, T			Fine chromosomal localization of the mouse Par2 gene that confers resistance against urethane-induction of pulmonary adenomas	ONCOGENE			English	Article						mouse; lung tumor; resistance gene; fine mapping; chromosome	LUNG CARCINOGENESIS; BALB/CBYJ MICE; SUSCEPTIBILITY; LINKAGE; LOCUS; IDENTIFICATION; TRAITS; MAPS; A/J	BALB/cByJ mice are 14 times more resistant to urethane-induction of pulmonary adenomas than the susceptible Al J strain. Our previous linkage analysis of (A/J x BALB/ cByJ)F-1 x A/J backcross mice provided statistical evidence that a major resistance locus of BALB/cByJ with a dominant effect, designated Par2 (Pulmonary adenoma resistance 2), exists within an approximately 25 cM section of distal chromosome 18, To facilitate molecular identification of the Par 2 locus, the present study was conducted to finely localize its chromosomal position utilizing Par a-congenic mice. Male BALB/cByJ mice were mated with female C57BL/6J mice carrying recessive Par a alleles and their male F1 progeny were backcrossed to female BALB/cByJ mice. A male backcross mouse heterozygous within the Par 2 interval of 25 cM was randomly selected and again backcrossed to female BALB/cByJ mice. This backcross-selection cycle was simply repeated to produce semi-congenic mice with a general BALB/cByJ genetic background except for the Par 2 interval, where the mice were heterozygous with paternal C57BL/6J alleles and maternal BALB/cByJ alleles, After the 6th or 7th backcross, nine male mice possessing a recombination within the paternal Par 2 interval were retained and crossed to female A/J mice. Resultant progeny were treated with urethane and examined for lung tumor development in order to deduce the Pm 2 genotypes of the recombinants through linkage analysis. By comparing the deduced Par 2 genotype of each recombinant with its recombinational breakpoint, the Par2 locus was confined to an approximately 0.5 cM region flanked by D18Mit103 and D18Mit188 loci. Our results indicate that fully congenic mice conventionally established by at least nine simple backcrosses or by the speed congenic method are not necessarily required for fine mapping of quantitative trait loci, In the case of the Par 2 locus, we found that semi-congenic mice after as few as four simple backcrosses were useful for this purpose, The map information obtained in this study should enable subsequent positional cloning of the Par 2 gene.	Toranomon Gen Hosp, Dept Pathol, Tokyo 1058470, Japan; Okinaka Mem Inst Med Res, Tokyo 1058470, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Tokyo 1708455, Japan	Toranomon Hospital; Japanese Foundation for Cancer Research	Lee, GH (corresponding author), Toranomon Gen Hosp, Dept Pathol, Tokyo 1058470, Japan.							DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; Festing MFW, 1998, GENOMICS, V53, P129, DOI 10.1006/geno.1998.5450; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; HOSPITAL F, 1992, GENETICS, V132, P1199; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JUSTICE MJ, 1992, GENOMICS, V13, P1281, DOI 10.1016/0888-7543(92)90047-V; Karasaki H, 1997, ONCOGENE, V15, P1833, DOI 10.1038/sj.onc.1201357; LANDE R, 1990, GENETICS, V124, P743; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1995, GENETICS, V139, P387; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Manenti G, 1999, GENOME RES, V9, P639; Manenti G, 1997, CANCER RES, V57, P4164; MOEN CJA, 1992, ONCOGENE, V7, P563; Obata M, 1996, ONCOGENE, V13, P1599; PERAINO C, 1973, JNCI-J NATL CANCER I, V51, P1349, DOI 10.1093/jnci/51.4.1349; WANG M, 2000, P AM ASSOC CANC RES, V41, P279; Zhang ZQ, 2000, EXP LUNG RES, V26, P627, DOI 10.1080/01902140150216710	23	11	11	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3979	3985		10.1038/sj.onc.1204562	http://dx.doi.org/10.1038/sj.onc.1204562			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494126				2022-12-28	WOS:000169681500006
J	Thompson, DA; Zacny, V; Belinsky, GS; Classon, M; Jones, DL; Schlegel, R; Munger, K				Thompson, DA; Zacny, V; Belinsky, GS; Classon, M; Jones, DL; Schlegel, R; Munger, K			The HPV E7 oncoprotein inhibits tumor necrosis factor alpha-mediated apoptosis in normal human fibroblasts	ONCOGENE			English	Article						apoptosis; tumor necrosis factor-alpha; caspase 8; human papillomavirus	HUMAN-PAPILLOMAVIRUS TYPE-16; SIGNALING COMPLEX DISC; TNF RECEPTOR; CELL-DEATH; GROWTH ARREST; KAPPA-B; KINASE RIP; PROTEIN; ACTIVATION; PATHWAY	Tumor necrosis factor-alpha (TNF) is a cytokine that induces programmed cell death, apoptosis, in a number of cell types and is employed by cytotoxic T cells to eliminate virus infected cells. Consequently, many viruses have acquired mechanisms to undermine these host cell defense mechanisms and cause resistance to TNF-mediated apoptosis, Here we show that normal human diploid fibroblasts that express the human papillomavirus type 16 E7 oncoprotein have a decreased propensity to undergo apoptosis in response to TNF treatment. The ability of E7 to undermine TNF-mediated apoptosis correlates with cellular transformation. While E7 does not generally subvert signaling by tumor necrosis factor receptor I, pro-caspase 8 activation is decreased in E7-expressing cells, E7 also provides some protection from apoptosis caused by stimulation of the TNF receptor 1-related cytokine receptor Fas, where induction of apoptosis occurs much slower in this cell type. Hence, E7-expressing normal human fibroblasts exhibit specific defect that obstructs cytokine-mediated activation of pro-caspase 8 and apoptosis.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Ctr Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Canc Cell BIol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Munger, Karl/0000-0003-3288-9935; Thompson, David/0000-0003-2372-7766	NATIONAL CANCER INSTITUTE [T32CA072320, R01CA081135] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81135, T32 CA72320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTWERP DJV, 1996, SCIENCE, V274, P787; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baker SJ, 1996, ONCOGENE, V12, P1; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boyer SN, 1996, CANCER RES, V56, P4620; Bulfone-Paus S, 1999, FASEB J, V13, P1575, DOI 10.1096/fasebj.13.12.1575; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DARCY A, 1993, J MOL BIOL, V229, P555, DOI 10.1006/jmbi.1993.1055; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jones DL, 1999, VIROLOGY, V258, P406, DOI 10.1006/viro.1999.9733; KIRSTEIN M, 1986, J IMMUNOL, V137, P2277; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; PFIZENMAIER K, 1987, BLUT, V55, P1, DOI 10.1007/BF00319635; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ramshaw IA, 1997, IMMUNOL REV, V159, P119, DOI 10.1111/j.1600-065X.1997.tb01011.x; REID TR, 1989, J BIOL CHEM, V264, P4583; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; WAKABAYASHI T, 1990, J BIOL CHEM, V265, P7604; Wold WSM, 1999, CURR OPIN IMMUNOL, V11, P380, DOI 10.1016/S0952-7915(99)80064-8; Wong GHW, 1992, TUMOR NECROSIS FACTO, P371; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806	55	43	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3629	3640		10.1038/sj.onc.1204483	http://dx.doi.org/10.1038/sj.onc.1204483			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439326				2022-12-28	WOS:000169400200004
J	Wallace, M; Coates, PJ; Wright, EG; Ball, KL				Wallace, M; Coates, PJ; Wright, EG; Ball, KL			Differential post-translational modification of the tumour suppressor proteins Rb and p53 modulate the rates of radiation-induced apoptosis in vivo	ONCOGENE			English	Article						Rb; p21; p53; apoptosis; genetic variation; radiation	CELL-CYCLE ARREST; RETINOBLASTOMA GENE-PRODUCT; DRUG-RESISTANT CELLS; HUMAN CANCER-CELLS; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; THYMOCYTE APOPTOSIS; MEDIATED APOPTOSIS; HEPATOMA-CELLS; G(1) ARREST	Ionizing radiation induces p53-dependent apoptosis in the spleen, providing a model system to study p53 regulated events in a normal cell type. We have developed an in vivo model that identifies genetic differences in the regulation of p53-mediated apoptosis and addresses whether altered post-translational events in the p53-p21/Rb axis modulate the sensitivity of cells to radiation-induced cell death in vivo. Splenocytes from mice with distinct genetic backgrounds (DBA/2 and C57BL/6) exhibit differences in the rate of apoptosis, Whilst no obvious strain differences in protein levels of Bcl-2 or the cyclin-CDKs were observed, early posttranslational regulatory events in the p53-p21/Rb axis showed striking differences in the two mouse strains. Cells from C57BL/6 animals undergo more rapid apoptosis after irradiation resulting from elevated levels and rapid induction of p53, pronounced Rb-cleavage, and the absence of a sustained induction of p21, In contrast, cells from DBA/2 animals have a reduced rate of apoptosis following irradiation with elevated levels of hyperphosphorylated Rb and a sustained induction of the p21 protein that is coincident with the C-terminal phosphorylation of p53, These data suggest that quantitative differences in the level of p21 protein can affect the rate of apoptosis in vivo, consistent with the view that p21 is an anti-apoptotic effector of p53, However, striking differences in the Rb protein-caspase cleavage or hyperphosphorylation - in the same cell type, but in different genetic backgrounds, demonstrates that p53-dependent apoptosis can be modulated in vivo by genetic factors that impinge upon the pro- or antiapoptotic potential of Rh, In addition, we show that Rb cleavage is p53-dependent and that its phosphorylation status can be uncoupled from p21 expression. This study highlights the possibility that genetic factors can be identified that affect differential sensitivity of cells to ionizing radiation in vivo.	Univ Dundee, Sch Med, Dept Surg & Mol Oncol, CRC Labs, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Med, Dept Mol & Cellular Pharmacol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Ball, KL (corresponding author), Univ Dundee, Sch Med, Dept Surg & Mol Oncol, CRC Labs, Dundee DD1 9SY, Scotland.		Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; An B, 1996, CANCER RES, V56, P438; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; Ball KL, 1996, EUR J BIOCHEM, V237, P854, DOI 10.1111/j.1432-1033.1996.0854p.x; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Bowen C, 1998, CANCER RES, V58, P3275; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DEDEIRY WS, 1994, CANCER RES, V54, P1169; DOU QP, 1995, CANCER RES, V55, P5222; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Dou QP, 1997, J CELL BIOCHEM, V64, P586; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Esposito F, 2000, FEBS LETT, V470, P211, DOI 10.1016/S0014-5793(00)01318-1; Fan GS, 1996, ONCOGENE, V12, P1909; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HAUPT Y, 1995, ONCOGENE, V10, P1563; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MIYASHITA T, 1995, CELL, V80, P293; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Muschel RJ, 1998, ONCOGENE, V17, P3359, DOI 10.1038/sj.onc.1202580; NOMURA T, 1992, J RADIAT RES, V33, P109, DOI 10.1269/jrr.33.SUPPLEMENT_109; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; RODERICK TH, 1963, RADIAT RES, V20, P631, DOI 10.2307/3571354; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Tian H, 2000, CANCER RES, V60, P679; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang H, 1996, ONCOGENE, V13, P373; Wang J, 1997, CANCER RES, V57, P351; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Weil MM, 1997, GENOMICS, V45, P626, DOI 10.1006/geno.1997.4999; Whitaker LL, 1997, ONCOGENE, V15, P1069, DOI 10.1038/sj.onc.1201277; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	68	47	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3597	3608		10.1038/sj.onc.1204496	http://dx.doi.org/10.1038/sj.onc.1204496			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439323				2022-12-28	WOS:000169400200001
J	Niu, MY; Menard, M; Reed, JC; Krajewski, S; Pratt, MAC				Niu, MY; Menard, M; Reed, JC; Krajewski, S; Pratt, MAC			Ectopic expression of cyclin D1 amplifies a retinoic acid-induced mitochondrial death pathway in breast cancer cells	ONCOGENE			English	Article						apoptosis; cyclin D1; retinoic acid; breast cancer	INDUCED CONFORMATIONAL CHANGE; MAMMARY EPITHELIAL-CELLS; CYTOCHROME-C RELEASE; RECEPTOR-BETA; BCL-2 FAMILY; IN-VITRO; HISTONE ACETYLTRANSFERASE; CHEMOPREVENTIVE AGENTS; GROWTH-INHIBITION; GENE-EXPRESSION	All-trans retinoic acid inhibits growth associated with downregulation of cyclin D1 and can cause lon level apoptosis in estrogen receptor positive breast cancer cell lines, The cyclin D1 gene is amplified and/or the protein overexpressed in about one-third of breast cancers. Constitutive expression of cyclin D1 in estrogen receptor positive MCF-7 and ZR-75 breast cancer cells (MCF-7(cycD1) and ZR-75(cycD1)) Increased the fraction of cells in S phase and reduced the G1 accumulation following retinoic acid treatment compared with control cells, However, culture of MCF-7(cycD1) with 1 muM all-trans retinoic acid resulted in about threefold greater growth inhibition compared with vector-transfected cells. Hoechst staining of DNA and lit situ DNA end-labeling analysis indicated that MCF-7(cycD1) and ZR-75(cycD1) cultures contained 4-6-fold more retinoic acid-induced apoptotic nuclei as vector-transfected cells. Retinoic acid treatment of vector-transfected clones resulted in Bax protein activation as assessed by exposure of the NH2-terminus of Bax but the proportion of cells containing activated Bax was increased in cyclin D-expressing cells treated with retinoic acid. The latter cells also displayed both immunocytochemical and biochemical evidence of translocation of cytochrome c into the cytosol following RA-treatment, Retinoic acid markedly decreased the Bcl-2 levels in MCF-7 and ZR-75 cells. Accordingly, coexpression of Bcl-2 and cyclin D1 rendered the cells resistant to retinoic acid-induced apoptosis, We conclude that constitutive expression of cyclin D1 sensitizes ER-positive breast cancer cells to a retinoic acid-induced mitochondrial death pathway involving Bax activation, cytochrome c release and caspase-9 cleavage.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Burnham Inst Canc Res, La Jolla, CA USA	University of Ottawa; Sanford Burnham Prebys Medical Discovery Institute	Pratt, MAC (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.				NIGMS NIH HHS [GM60554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bardon S, 1998, INT J ONCOL, V12, P355; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eck KM, 1998, BRIT J CANCER, V77, P2129, DOI 10.1038/bjc.1998.357; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Gianni M, 2000, CELL DEATH DIFFER, V7, P447, DOI 10.1038/sj.cdd.4400673; Glass CK, 1997, BIOCHEM SOC T, V25, P602, DOI 10.1042/bst0250602; Green A, 1999, CARCINOGENESIS, V20, P1535, DOI 10.1093/carcin/20.8.1535; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; LAMMIE GA, 1991, ONCOGENE, V6, P439; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lippman M.E., 1985, TXB ENDOCRINOLOGY, P1309; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; Manna SK, 2000, ONCOGENE, V19, P2110, DOI 10.1038/sj.onc.1203547; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; MOON RC, 1992, CANCER DETECT PREV, V16, P73; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Oh Youngman, 1995, Progress in Growth Factor Research, V6, P503, DOI 10.1016/0955-2235(95)00025-9; OSWALD F, 1994, ONCOGENE, V9, P2029; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Raffo P, 2000, ANTICANCER RES, V20, P1535; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROMAN SD, 1992, CANCER RES, V52, P2236; SALO S, 1994, P NATL ACAD SCI USA, V91, P923; Schmidt EV, 1996, BIOESSAYS, V18, P6, DOI 10.1002/bies.950180104; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 1999, EXP CELL RES, V249, P70, DOI 10.1006/excr.1999.4462; SGAMBATO A, 1995, CARCINOGENESIS, V16, P2193, DOI 10.1093/carcin/16.9.2193; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sukumar S, 1995, MUTAT RES-FUND MOL M, V333, P37, DOI 10.1016/0027-5107(95)00129-8; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; VANDERVELDEN J, 1992, INT J GYNECOL CANCER, V2, P157, DOI 10.1046/j.1525-1438.1992.02030157.x; Wang Q, 2000, CANCER RES, V60, P2040; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	64	37	38	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3506	3518		10.1038/sj.onc.1204453	http://dx.doi.org/10.1038/sj.onc.1204453			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429697				2022-12-28	WOS:000169478300006
J	Hollmann, CA; Kittrell, FS; Medina, D; Butel, JS				Hollmann, CA; Kittrell, FS; Medina, D; Butel, JS			Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis	ONCOGENE			English	Article						mammary oncogenes; wnt-1; int-2; mammary epithelial cells; mammary tumorigenesis; mouse model for breast cancer; signal transduction pathways	FIBROBLAST-GROWTH-FACTOR; GENE-PRODUCT ACTS; E-CADHERIN; IN-VIVO; PROVIRAL ACTIVATION; TRANSGENIC MICE; CELLULAR GENE; TUMOR VIRUS; CYCLIN D1; C-MYC	Development of strategies for prevention of breast cancer development requires an understanding of the effects of mammary oncogenes on mammary cells at early stages in neoplastic transformation. As mammary oncogenes wnt-1 and int-2 affect different signal transduction pathways, we investigated their effects on established mouse mammary epithelial cell lines (MMECLs) reflecting early stages in tumorigenesis. Normal interactions between beta -catenin and E-cadherin were abrogated in all three immortalized MMECLs and the cells lacked beta -catenin-mediated transactivation activity, detectable using a reporter assay, suggesting that alterations in cell adhesion may be very early events in mammary tumorigenesis. Immortalized FSK4 and EL12 cells and hyperplastic TM3 cells were stably transfected with expression vectors encoding wnt-1 or int-2 or the control vector, and drug-selected pooled cells from each tine were confirmed by reverse transcription-polymerase chain reaction to express the transfected oncogene; this expression persisted in the cells analysed in vitro and in vivo. Resultant phenotypic changes depended both on the oncogene and the target mammary cell line. In FSK4 cells, expression of wnt-1 or int-2 resulted in proliferative changes in vitro, including reduced contact inhibition, increased beta -catenin expression, and decreased p53 transcriptional activity, but neither oncogene conferred upon those cells the ability to produce tumors in vivo. EL12 cells were highly refractory to the effects of both oncogenes, with the only measurable changes being increased E-cadherin levels induced by both oncogenes and increased proliferation of the int-2-transfected cells in the absence of serum. Parental TM3 cells were phenotypically similar to wnt-1- or int-2-transfected FSK4 cells and displayed an increased rate of proliferation in vitro and markedly increased tumorigenicity in vivo following transfection with int-2 but not with wnt-1. These results suggest that wnt-1 signaling is redundant in the hyperplastic TM3 cells and indicate that wnt-1-induced effects in the immortalized FSK4 and EL12 cells were not sufficient to mediate a tumorigenic phenotype. This study showed that the wnt-1 and int-2 oncogenes have similar but distinguishable effects on immortalized MMECLs and that the genetic background of the mammary cells greatly influences the consequences of oncogene expression at early stages of cell transformation.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Butel, JS (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Mail Stop BCM 385,1 Baylor Plaza, Houston, TX 77030 USA.	jbutel@bcm.tmc.edu		Butel, Janet/0000-0002-6876-3245	NCI NIH HHS [CA25215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Bonnette SG, 1999, CARCINOGENESIS, V20, P1715, DOI 10.1093/carcin/20.9.1715; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELYAZIDI I, 1995, ANTICANCER RES, V15, P783; Fioravanti L, 1997, INT J CANCER, V74, P620, DOI 10.1002/(SICI)1097-0215(19971219)74:6<620::AID-IJC11>3.0.CO;2-9; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Hajitou A, 1998, ONCOGENE, V17, P2059, DOI 10.1038/sj.onc.1202126; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Hollmann CA, 2000, IN VITRO CELL DEV-AN, V36, P74; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Jackson D, 1997, J CELL SCI, V110, P1261; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; Jansen LAM, 1996, CARCINOGENESIS, V17, P1527, DOI 10.1093/carcin/17.7.1527; JERRY DJ, 1993, CANCER RES, V53, P3374; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KITTRELL FS, 1992, CANCER RES, V52, P1924; KLINT P, 1999, FRONT BIOSCI, V4, P165; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; McLeskey SW, 1996, BREAST CANCER RES TR, V39, P103, DOI 10.1007/BF01806082; Medina D, 1998, MOL CARCINOGEN, V22, P199, DOI 10.1002/(SICI)1098-2744(199807)22:3<199::AID-MC8>3.0.CO;2-G; MEDINA D, 1993, CANCER RES, V53, P668; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MEDINA D, 1993, CANCER RES, V53, P663; MEDINA D, 1973, METHOD CANCER RES, V7, P353; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Naylor S, 2000, J CELL SCI, V113, P2129; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; OZBUN MA, 1993, CANCER RES, V53, P1646; Papkoff J, 1997, J BIOL CHEM, V272, P4536; PETERS G, 1984, NATURE, V309, P273, DOI 10.1038/309273a0; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Schroeder JA, 2000, ONCOGENE, V19, P3193, DOI 10.1038/sj.onc.1203652; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; UITENBROEK D. G, 1997, SISA BINOMIAL; VENESIO T, 1992, CELL GROWTH DIFFER, V3, P63; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	63	12	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2001	20	52					7645	7657		10.1038/sj.onc.1204980	http://dx.doi.org/10.1038/sj.onc.1204980			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753642				2022-12-28	WOS:000172124100007
J	Suraweera, N; Iacopetta, B; Duval, A; Compoint, A; Tubacher, E; Hamelin, R				Suraweera, N; Iacopetta, B; Duval, A; Compoint, A; Tubacher, E; Hamelin, R			Conservation of mononucleotide repeats within 3 ' and 5 ' untranslated regions and their instability in MSI-H colorectal cancer	ONCOGENE			English	Article						5 ' UTR; 3 ' UTR; MSI tumors	MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; SEQUENCE REPEATS; BINDING PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; COLON CANCERS; CELL-LINES; TRANSCRIPTION; RECEPTOR	Messenger RNA contains untranslated 3' and 5' regions (3' and 5' UTRs) with sequence elements that are essential for the regulation of gene expression. A systematic search of GenBank revealed a large number of mononucleotide repeats within these UTRs. We selected 35 such mononucleotide repeats ranging in length from 15 bp to 32 bp and analysed their size in a series of 60 normal individuals. The conservation of repeats correlated inversely to their length, with longer repeats generally being more polymorphic than shorter repeats, irrespective of 3' or 5' location. Several long repeats were identified however to be monomorphic and we postulate that their conservation may be due to selective pressures relating to a possible functional role. We analysed 19 conserved UTR repeats in 117 colorectal cancers (CRC), 43 of which had defective mismatch repair characterized by widespread microsatellite instability (MSI-H). The UTR repeats were very often deleted in MSI-H tumors, with the length of deletion being proportional to the size of the repeat. Because of the high frequency of deletion observed in the conserved UTR repeats of MSI-H tumors, these could serve as a useful model for the study of possible changes in gene expression resulting from such mutations.	Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Univ Western Australia, Dept Surg, Nedlands, WA 6009, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Western Australia	Hamelin, R (corresponding author), Ctr Etud Polymorphisme Humain, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.		Suraweera, Nirosha/E-5912-2012					AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AHARONI A, 1993, NUCLEIC ACIDS RES, V21, P5221, DOI 10.1093/nar/21.22.5221; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GOLLER M, 1994, NUCLEIC ACIDS RES, V22, P1885, DOI 10.1093/nar/22.10.1885; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; Kashi Y, 1997, TRENDS GENET, V13, P74, DOI 10.1016/S0168-9525(97)01008-1; LEVISON G, 1987, MOL BIOL EVOL, V4, P202; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NOWAK R, 1994, SCIENCE, V263, P608, DOI 10.1126/science.7508142; Percesepe A, 2000, GENE CHROMOSOME CANC, V27, P424, DOI 10.1002/(SICI)1098-2264(200004)27:4<424::AID-GCC13>3.0.CO;2-M; Pesole G, 1997, GENE, V205, P95, DOI 10.1016/S0378-1119(97)00407-1; Pesole G, 2000, BIOINFORMATICS, V16, P439, DOI 10.1093/bioinformatics/16.5.439; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sturzeneker R, 2000, HUM MOL GENET, V9, P347, DOI 10.1093/hmg/9.3.347; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; Zhang L, 2001, CANCER RES, V61, P3801; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	31	24	28	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7472	7477		10.1038/sj.onc.1204952	http://dx.doi.org/10.1038/sj.onc.1204952			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709718				2022-12-28	WOS:000171976900003
J	Sepehr, A; Taniere, P; Martel-Planche, G; Zia'ee, AA; Rastgar-Jazii, F; Yazdanbod, M; Etemad-Moghadam, G; Kamangar, F; Saidi, F; Hainaut, P				Sepehr, A; Taniere, P; Martel-Planche, G; Zia'ee, AA; Rastgar-Jazii, F; Yazdanbod, M; Etemad-Moghadam, G; Kamangar, F; Saidi, F; Hainaut, P			Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran	ONCOGENE			English	Article; Proceedings Paper	16th Meeting of the European-Association-for-Cancer-Research	JUN 02, 2000	HALKIDIKI HELLAS, GREECE	European Assoc Canc Res		esophagus; neoplasms; Iran; p53; COX-2	TUMOR-SUPPRESSOR GENE; P53 MUTATIONS; NITRIC-OXIDE; PRECANCEROUS LESIONS; CANCER; EXPRESSION; CYCLOOXYGENASE-2; CARCINOGENESIS; AMPLIFICATION; CHINA	Extremely high rates of squamous cell carcinoma of the esophagus (SCCE), are observed in Iran,, reflecting unknown, genetic and/or epidemiological risk factors. Among genetic alterations, in SCCE,: TP53: mutations are the most frequent, vary among populations, and may provide clues on etiological mechanisms. We have analysed mutations in TP53 (exons 5-8): in 98 SCCE from Iran by temporal temperature get electrophoresis and direct sequencing. We found 58, mutations, in 49 patients, (50%,), with a high prevalence of C to T transitions at CpG dinucleotides (29.3%). The TP53 mutation pattern in Iran was significantly different from that observed in SCCEs from high incidence areas of China and Western Europe (P=0.007)., Moreover, the prevalence of mutations at A:T base pairs, (transitions and transversions) was higher in men than in women (38.7%, vs 11.1%, P=0.033). COX-2 overexpression was, detected in 69% of the cases evaluated (24/35), without significant association with TP53, mutation. Accumulation of nitrotyrosine, a marker of protein damage by excess, levels of nitric oxide, was observed in tumor cells, in six of 16 cases analysed. These results are consistent with the hypothesis that several factors are involved in TP53 mutagenesis, in Iran., These factors include a baseline of chronic inflammatory stress, which may have a multiplicative impact on the sensitivity of esophageal cells to exogenous factors of risk.	IARC, Grp Mol Carcinogenesis, F-69008 Lyon, France; Univ Tehran, Inst Biochem & Biophys, Tehran, Iran; NRCGEB, Tehran, Iran; Univ Tehran Med Sci, Dept Surg, Tehran, Iran; Iran Mehr Hosp, Dept Pathol, Tehran, Iran; Iran Mehr Hosp, Dept Surg, Tehran, Iran; Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA	World Health Organization; International Agency for Research on Cancer (IARC); University of Tehran; Tehran University of Medical Sciences; Johns Hopkins University	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Ambs S, 1999, J NATL CANCER I, V91, P86, DOI 10.1093/jnci/91.1.86; AUDREZET MP, 1993, CANCER RES, V53, P5745; Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4; Biramijamal F, 2001, CANCER RES, V61, P3119; Cai YYC, 2000, CARCINOGENESIS, V21, P683, DOI 10.1093/carcin/21.4.683; Chazotte-Aubert L, 2000, BIOCHEM BIOPH RES CO, V267, P609, DOI 10.1006/bbrc.1999.2003; COOKMOZAFFARI PJ, 1979, BRIT J CANCER, V39, P293, DOI 10.1038/bjc.1979.54; *COUNC INT ORG MED, 1993, CIOMS INT ETH GUID B; ESTEVE A, 1993, MOL CARCINOGEN, V8, P306, DOI 10.1002/mc.2940080414; Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3; FRIESEN M, 1985, MUTAT RES, V150, P177, DOI 10.1016/0027-5107(85)90114-9; GAO HK, 1994, CANCER RES, V54, P4342; Hainaut P, 2000, ADV CANCER RES, V77, P81; Harsch A, 2000, CHEM RES TOXICOL, V13, P1342, DOI 10.1021/tx000140m; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HEWER T, 1978, LANCET, V2, P494; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HORMOZDIARI H, 1975, CANCER RES, V35, P3493; Kato H, 2000, CANCER LETT, V153, P121, DOI 10.1016/S0304-3835(00)00358-X; KMET J, 1972, SCIENCE, V175, P846, DOI 10.1126/science.175.4024.846; Leung WK, 2001, BRIT J CANCER, V84, P335, DOI 10.1054/bjoc.2000.1607; LIANG YY, 1995, INT J CANCER, V61, P611, DOI 10.1002/ijc.2910610505; Lung ML, 1996, CANCER EPIDEM BIOMAR, V5, P277; MAHBOUBI E, 1973, BRIT J CANCER, V28, P192, DOI 10.1038/bjc.1973.138; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; Munoz N, 1996, CANC EPIDEMIOLOGY PR, P681; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Ratnasinghe D, 1999, ANTICANCER RES, V19, P171; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Rugge M, 1997, CANCER EPIDEM BIOMAR, V6, P171; Saidi F, 2000, BRIT J CANCER, V83, P1249, DOI 10.1054/bjoc.2000.1414; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Shi ST, 1999, CARCINOGENESIS, V20, P591, DOI 10.1093/carcin/20.4.591; Shi ST, 1996, CARCINOGENESIS, V17, P2131, DOI 10.1093/carcin/17.10.2131; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Taniere P, 2000, INT J CANCER, V88, P223, DOI 10.1002/1097-0215(20001015)88:2&lt;223::AID-IJC12&gt;3.0.CO;2-G; Taniere P, 2001, BRIT J CANCER, V85, P721, DOI 10.1054/bjoc.2001.1990; Taniere P, 2001, AM J PATHOL, V158, P33, DOI 10.1016/S0002-9440(10)63941-7; Zimmermann KC, 1999, CANCER RES, V59, P198	39	49	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7368	7374		10.1038/sj.onc.1204912	http://dx.doi.org/10.1038/sj.onc.1204912			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704866				2022-12-28	WOS:000171894200009
J	Koul, D; Parthasarathy, R; Shen, RJ; Davies, MA; Jasser, SA; Chintala, SK; Rao, JS; Sun, Y; Benvenisite, EN; Liu, TJ; Yung, WKA				Koul, D; Parthasarathy, R; Shen, RJ; Davies, MA; Jasser, SA; Chintala, SK; Rao, JS; Sun, Y; Benvenisite, EN; Liu, TJ; Yung, WKA			Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN	ONCOGENE			English	Article						MMAC/PTEN; glioma; invasion; matrix metalloproteinases-2; tumor suppression	TUMOR-SUPPRESSOR; IV COLLAGENASE; PLASMINOGEN-ACTIVATOR; ADHESION MOLECULES; GERMLINE MUTATIONS; TISSUE INHIBITORS; PTEN; BREAST; PROTEINASES; PTEN/MMAC1	Human gliomas are highly invasive, and remain to be a major obstacle for any effective therapeutic remedy. Among many other factors, gliomas express elevated levels of matrix metalloproteinases (MMPs), which have been implicated to play an important role in tumor invasion as well as neovascularization. The tumor suppressor gene mutated in multiple advanced cancers/phosphatase and tensin homologue (MMAC/PTEN) has been shown to inhibit cell migration, spreading, and focal adhesion. In this study, we determined whether MMAC/PTEN inhibits tumor invasion by modulating MMP-2 activity. Our results showed that reintroduction of the MMAC/PTEN gene into human glioma U251 and U87 cells modified their phenotype and growth characteristics. The ability of MMAC/PTEN to induce anoikis in U251 cells was accompanied by a significant inhibition of in vitro invasion (70%). Expression of MMAC/PTEN in U251 and U87 cells inhibited MMP-2 enzymatic activity as determined by zymography. Furthermore, MMAC/PTEN expression strongly decreased MMP-2 mRNA levels, which correlated well with the inhibition of invasion capacity in these cells. Concomitant with MMP-2 expression and activity, MMP-2 promoter activity was also reduced in MMAC/PTEN expressing cells. Our observations suggest that MMAC/PTEN inhibits tumor cell invasion in part by regulating MMP-2 gene transcription and thereby its enzymatic activity. Further characterization of this regulation will facilitate the development of MMAC/PTEN based gene therapy for gliomas.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pfizer; University of Alabama System; University of Alabama Birmingham	Yung, WKA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Box 100, Houston, TX 77030 USA.	wyung@mdanderson.org	Davies, Michael/GWV-2527-2022		NATIONAL CANCER INSTITUTE [P30CA016672, R01CA051148] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, R01 CA 51148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL C, 1994, CANCER RES, V54, P943; ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; APODACA G, 1990, CANCER RES, V50, P2322; Barille S, 1997, BLOOD, V90, P1649, DOI 10.1182/blood.V90.4.1649.1649_1649_1655; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; BJERKVIG R, 1986, CANCER RES, V46, P4071; Cairns P, 1997, CANCER RES, V57, P4997; Cheney IW, 1998, CANCER RES, V58, P2331; Chintala S.K., 1996, FRONT BIOSCI, V1, pd324, DOI 10.2741/a135; Chintala SK, 1996, CANCER LETT, V103, P201, DOI 10.1016/0304-3835(96)04215-2; COCKETT MI, 1994, BIOCHEM SOC T, V22, P55, DOI 10.1042/bst0220055; DAVIES B, 1993, CANCER RES, V53, P5365; Davies MA, 1998, CANCER RES, V58, P5285; Deryugina EI, 1997, ANTICANCER RES, V17, P3201; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Edwards DR, 1996, INT J OBES RELAT MET, V20, P9; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Guldberg P, 1997, CANCER RES, V57, P3660; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Kim HG, 2000, BIOCHEM BIOPH RES CO, V269, P401; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MOHANAM S, 1993, CANCER RES, V53, P4143; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MOSER TL, 1994, INT J CANCER, V56, P552, DOI 10.1002/ijc.2910560415; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; NAKAJIMA M, 1993, CANCER RES, V53, P5802; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; Qin HW, 1998, J IMMUNOL, V161, P6664; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; Rhei E, 1997, CANCER RES, V57, P3657; RUCKLIDGE GJ, 1994, BIOCHEM SOC T, V22, P63, DOI 10.1042/bst0220063; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SEFTOR REB, 1993, CANCER RES, V53, P3411; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tashiro H, 1997, CANCER RES, V57, P3935; Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006; Uhm JH, 1996, CLIN EXP METASTAS, V14, P421, DOI 10.1007/BF00128958; Uhm JH, 1997, CAN J NEUROL SCI, V24, P3, DOI 10.1017/S0317167100021028; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; Wang SI, 1997, CANCER RES, V57, P4183; Xuan JW, 1998, ANTICANCER RES, V18, P743; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	60	99	113	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6669	6678		10.1038/sj.onc.1204799	http://dx.doi.org/10.1038/sj.onc.1204799			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709701				2022-12-28	WOS:000171551600003
J	Boldrini, L; Faviana, P; Pistolesi, F; Gisfredi, S; Di Quirico, D; Lucchi, M; Mussi, A; Angeletti, CA; Baldinotti, F; Fogli, A; Simi, P; Basolo, F; Fontanini, G				Boldrini, L; Faviana, P; Pistolesi, F; Gisfredi, S; Di Quirico, D; Lucchi, M; Mussi, A; Angeletti, CA; Baldinotti, F; Fogli, A; Simi, P; Basolo, F; Fontanini, G			Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer	ONCOGENE			English	Article						NSCLC; Fas (CD95/APO-1); p53; mutations	TUMOR-NECROSIS-FACTOR; LIGAND EXPRESSION; IN-VIVO; P53-MEDIATED APOPTOSIS; MEDIATED APOPTOSIS; IMMUNE PRIVILEGE; GROWTH-FACTOR; RECEPTOR; ANTIGEN; ADENOCARCINOMAS	The Fas (APO-1/CD95) system regulates a number of physiological and pathological processes of cell death. The ligand for Fas induces apoptosis by interacting with a transmembrane cell surface Fas receptor. The key role of the Fas system has been studied mostly in the immune system, but Fas mutations, one of the possible mechanisms for resistance to apoptosis signaling, may be involved in the pathogenesis of non-lymphoid malignancies as well. To better understand the potential involvement of Fas system in non-small cell lung cancer (NSCLC) we evaluated Fas and Fas-ligand mRNA expression by polymerase chain reaction in 102 tumor samples and in 44 normal surrounding tissues. Although over 60% of the human NSCLC analysed expressed both genes, they seem to be unable to induce apoptosis in vivo by autocrine suicide. In this regard, we investigated in 79 cases, the promoter and the entire coding region of the Fas gene by polymerase chain reaction, single strand conformation polymorphism and DNA sequencing for detecting putative alterations. Sixteen tumors (20.25%) were found to have Fas alterations, in promoter and/or exon region. In all cases samples carried heterozygous alterations and mostly showed simultaneous mutations of p53 gene. Moreover, the quantitative analysis of Fas mRNA expression showed high levels of Fas messenger associated with p53 wild-type status alone. Taken together, these findings point to an involvement of Fas/Fas-ligand system in the development of NSCLC, suggesting that the loss of its apoptotic function might be linked to p53 alterations which contribute to the self-maintenance of cancer cells.	Univ Pisa, Dept Oncol Transplants & Adv Technol Med, Pisa, Italy; Univ Pisa, Dept Cardiothorac Surg, Pisa, Italy; UO Cytogenet & Mol Genet, Dept Oncol, I-56100 Pisa, Italy	University of Pisa; University of Pisa	Fontanini, G (corresponding author), Dept Oncol, Div Pathol, Via Roma 57, I-56126 Pisa, Italy.		Faviana, Pinuccia/ABA-8436-2021; Basolo, Fulvio/AAC-2727-2019; Fontanini, Gabriella/O-7636-2015; Faviana, Pinuccia/L-5620-2019; FAVIANA, PINUCCIA/R-7928-2017; Lucchi, Marco/K-2140-2019	Faviana, Pinuccia/0000-0003-4283-1083; Basolo, Fulvio/0000-0003-1657-5020; Fontanini, Gabriella/0000-0003-1957-2052; FAVIANA, PINUCCIA/0000-0003-4283-1083; Boldrini, Laura/0000-0001-5904-3708; LUCCHI, MARCO/0000-0001-9909-6820				Beltinger C, 1998, BLOOD, V91, P3943; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bennett MW, 1998, J IMMUNOL, V160, P5669; Boldrini L, 1999, INT J ONCOL, V14, P161; Boussaud V, 1998, EUR RESPIR J, V12, P926, DOI 10.1183/09031936.98.12040926; Butler LM, 2000, BRIT J CANCER, V82, P131; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; Fontanini G, 1999, CLIN CANCER RES, V5, P155; GRATAS C, 1997, BRAIN PATHOL, V7, P853; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kashii Y, 1999, J IMMUNOL, V163, P5358; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P3068; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LICHTER P, 1992, GENOMICS, V14, P179, DOI 10.1016/S0888-7543(05)80302-7; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Midis GP, 1996, CANCER RES, V56, P3870; Mitra D, 1996, IMMUNOLOGY, V87, P581, DOI 10.1046/j.1365-2567.1996.510589.x; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; MUNKER R, 1995, ANN HEMATOL, V70, P15, DOI 10.1007/BF01715376; Munker R, 1996, LEUKEMIA, V10, P1531; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nambu Y, 1998, J CLIN INVEST, V101, P1102, DOI 10.1172/JCI1692; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OConnell J, 1997, MOL MED, V3, P294, DOI 10.1007/BF03401808; Rakkar ANS, 1999, CELL DEATH DIFFER, V6, P326, DOI 10.1038/sj.cdd.4400498; RHIN KJ, 2000, J INVEST DERMATOL, V114, P122; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Ungefroren H, 1998, CANCER RES, V58, P1741; Uramoto H, 1999, EUR J CANCER, V35, P1462, DOI 10.1016/S0959-8049(99)00157-4; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	39	24	25	2	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6632	6637		10.1038/sj.onc.1204727	http://dx.doi.org/10.1038/sj.onc.1204727			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641789				2022-12-28	WOS:000171404200017
J	Han, DC; Shen, TL; Guan, JL				Han, DC; Shen, TL; Guan, JL			The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions	ONCOGENE			English	Article						Grb7; protein interactions; cell migration; cell proliferation; signal transduction	GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; FACTOR-I RECEPTOR; SH2 DOMAIN PROTEINS; INSULIN-RECEPTOR; ADAPTER PROTEIN; TYROSINE KINASE; ESOPHAGEAL-CARCINOMA; PLECKSTRIN HOMOLOGY; BINDING-PROTEIN	Grb7 family adaptor molecules consist of Grb7, Grb10 and Grb14, each of which has several splicing variants. Like other adaptor molecules, Grb7 family proteins function to mediate the coupling of multiple cell surface receptors to downstream signaling pathways in the regulation of various cellular functions. They share significant sequence homology with each other and a conserved molecular architecture including an aminoterminal proline-rich region, a central segment termed the GM region (for (G) under bar rb and (M) under bar ig) which includes a PH domain and shares sequence homology with the Caenorhabditis elegans protein, Mig-10, involved in embryonic migration, and a carboxyl-terminal SH2 domain. Grb7 family proteins are differentially expressed in a variety of tissues. They are phosphorylated on serine/threonine as well as tyrosine residues, although the kinases responsible have not been well characterized. Grb7 family proteins are mainly localized in the cytoplasm, but have been observed at the plasma membrane, focal contacts, or mitochondria under certain conditions. A large number of receptor tyrosine kinases and other signaling molecules can associate with Grb7 family proteins, mostly through the SH2 domains. Various isoforms of Grb1O have been shown to regulate cell proliferation and apoptosis, whereas Grb7 has been found to regulate cell migration and also implicated in tumor progression. Future studies of interests will include identification of potential downstream effectors of Grb7 family proteins as well as understanding of the mechanisms of specificity of the different family members in signal transduction.	Cornell Univ, Dept Mol Med, Canc Biol Lab, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Canc Biol Lab, Ithaca, NY 14853 USA.		Shen, Tang-Long/C-7460-2011	Shen, Tang-Long/0000-0001-6264-3608	NIGMS NIH HHS [GM48050] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dong LQ, 1998, J BIOL CHEM, V273, P17720, DOI 10.1074/jbc.273.28.17720; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kasus-Jacobi A, 2000, ONCOGENE, V19, P2052, DOI 10.1038/sj.onc.1203469; Keegan K, 1996, ONCOGENE, V12, P1537; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Leavey SF, 1998, AM J PHYSIOL-RENAL, V275, pF770, DOI 10.1152/ajprenal.1998.275.5.F770; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Reiske HR, 2000, FEBS LETT, V486, P275, DOI 10.1016/S0014-5793(00)02295-X; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein EG, 2001, FEBS LETT, V493, P106, DOI 10.1016/S0014-5793(01)02282-7; Tanaka S, 2000, J CELL PHYSIOL, V183, P411, DOI 10.1002/(SICI)1097-4652(200006)183:3<411::AID-JCP14>3.0.CO;2-Z; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Vayssiere B, 2000, FEBS LETT, V467, P91, DOI 10.1016/S0014-5793(99)01530-6; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942	52	143	147	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6315	6321		10.1038/sj.onc.1204775	http://dx.doi.org/10.1038/sj.onc.1204775			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607834				2022-12-28	WOS:000171640600007
J	Li, W; Fan, JH; Woodley, DT				Li, W; Fan, JH; Woodley, DT			Nck/Dock: an adapter between cell surface receptors and the actin cytoskeleton	ONCOGENE			English	Review						Src-homology domains; adapters; tyrosine kinases; signal transduction; cytoskeleton	PHOTORECEPTOR AXON GUIDANCE; GUANINE-NUCLEOTIDE EXCHANGE; INTEGRIN-LINKED KINASE; SMOOTH-MUSCLE-CELLS; ONLY PROTEIN PINCH; GROWTH-FACTOR; TYROSINE KINASE; P21-ACTIVATED KINASE; SIGNAL-TRANSDUCTION; EPH RECEPTORS	In response to extracellular signals, cell surface receptors engage in connections with multiple intracellular signaling pathways, leading to the cellular responses such as survival, migration, proliferation and differentiation. The 'pY --> SH2/SH3 --> effector' connection is a frequently used scheme by many cell surface receptors, in which SH2/SH3-containing adapters connect protein tyrosine phosphorylation to a variety of downstream effector pathways. Following the initial landmark finding that Grb2 adapter links the receptors to the Ras pathway leading to DNA synthesis, recent studies have revealed that the biological function of the SH2/SH3 adapter Nck/Dock is to link cell surface receptors to the actin cytoskeleton. For example, in the evolutionarily-conserved signaling network, GEF-Rae-Nck-Pak, Nck 'fixes up' the interaction of Pak with its upstream activator, Rac. The activated Pak then regulates the cytoskeletal dynamics. The fact that the majority of the more than 20 Nck-SH3-associated effectors are regulators of the actin cytoskeleton suggests that Nck/Dock regulates, via binding to distinct effectors, various cell type-specific motogenic responses. This review focuses on our current understanding of Nck/Dock function. Due to the number and complexity of the terminologies used in this review, a 'Glossary of Terms' is provided to help reduce confusions.	Univ So Calif, Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Norris Cotton Canc Ctr, Los Angeles, CA 90033 USA; Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA	University of Southern California; Norris Cotton Cancer Center; University of Southern California; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Li, W (corresponding author), Univ So Calif, Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90033 USA.	wli@hsc.usc.edu			NCI NIH HHS [CA65567] Funding Source: Medline; NIAMS NIH HHS [AR46538] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046538] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adler CE, 2000, J BIOL CHEM, V275, P36472, DOI 10.1074/jbc.M005424200; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Desai CJ, 1999, DEVELOPMENT, V126, P1527; DEUEL TF, 1991, ANNU REV MED, V42, P567, DOI 10.1146/annurev.me.42.020191.003031; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; Ellis C, 1996, ONCOGENE, V12, P1727; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Garrity PA, 1999, NEURON, V22, P707, DOI 10.1016/S0896-6273(00)80730-8; Godwin SL, 1997, J BIOL CHEM, V272, P11307; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Hummel T, 2000, GENE DEV, V14, P863; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jones SM, 2000, ONCOGENE, V19, P5558, DOI 10.1038/sj.onc.1203858; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; Kitamura Y, 1997, BIOCHEM J, V322, P873, DOI 10.1042/bj3220873; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KROLL J, 1997, J BIOL CHEM, V252, P32421; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Mayer BJ, 1999, MOL BIOTECHNOL, V13, P201, DOI 10.1385/MB:13:3:201; Mayer BJ, 2001, J CELL SCI, V114, P1253; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Morrione A, 2000, INT J MOL MED, V5, P151; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOBES CD, 1995, J CELL SCI, V108, P225; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Park D, 1997, MOL CELLS, V7, P231; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIERCE GF, 1995, ANNU REV MED, V46, P467; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruan WJ, 1999, NEURON, V24, P595, DOI 10.1016/S0896-6273(00)81115-0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Su YC, 2000, MOL CELL BIOL, V20, P4736, DOI 10.1128/MCB.20.13.4736-4744.2000; Treisman JE, 1997, GENE, V186, P119, DOI 10.1016/S0378-1119(96)00694-4; Tu YZ, 2001, FEBS LETT, V491, P193, DOI 10.1016/S0014-5793(01)02195-0; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu CY, 1999, J CELL SCI, V112, P4485; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yamakawa K, 1998, HUM MOL GENET, V7, P227, DOI 10.1093/hmg/7.2.227; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zigmond SH, 2000, J CELL BIOL, V150, pF117, DOI 10.1083/jcb.150.6.F117	124	134	135	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6403	6417		10.1038/sj.onc.1204782	http://dx.doi.org/10.1038/sj.onc.1204782			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607841				2022-12-28	WOS:000171640600014
J	de Leeuw, WJF; van Puijenbroek, M; Merx, R; Wijnen, JT; Brocker-Vriends, AHJT; Tops, C; Vasen, H; Cornelisse, CJ; Morreau, H				de Leeuw, WJF; van Puijenbroek, M; Merx, R; Wijnen, JT; Brocker-Vriends, AHJT; Tops, C; Vasen, H; Cornelisse, CJ; Morreau, H			Bias in detection of instability of the (C)8 mononucleotide repeat of MSH6 in tumours from HNPCC patients	ONCOGENE			English	Article						HNPCC; MSI; MSH6; repeat; microsatellite	NONPOLYPOSIS COLORECTAL-CANCER; II RECEPTOR GENE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATIONS; CARCINOMAS; TUMORS	Recently, we and others reported instability in the (C)8 repeat in exon 5 of MSH6 as a preferential target for somatic mutations in tumours from MSH6 germline mutation carriers. Here, we report that in 45% of tumours from MLH1, MSH2 and MSH6 germline mutation carriers no sequence change in the (C)8 repeat of MSH6 was found upon DNA sequencing analysis of PCR products with a shift in electrophoresis mobility. Using 'standard' PCR primers a high frequency of instability (50-86%) of the (C)8 repeat was found, but using a modified PCR reverse primer, accomplishing modulation of non-templated addition of adenine during in vitro PCR amplification by the Taq polymerase, a markedly lower frequency of instability was found in turnours from MLH1, MSH2 and MSH6 mutation carriers (6, 13 and 40%, respectively). Furthermore, a significant difference of the frequency of instability of the (C)8 repeat in tumours from MSH6 mutation carriers was found compared to MLH1, MSH2 mutation carriers. These results might have important implications for the detection of instability of other short mononucleotide repeats, e.g. TGF beta RII, BAX, IGFRII, PTEN, BRCA2.	Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human & Clin Genet, MGC, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Fdt Detect Hereditary Tumours, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	de Leeuw, WJF (corresponding author), Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands.			Vasen, Hans/0000-0003-2682-2603				Akiyama Y, 1996, CANCER-AM CANCER SOC, V78, P2478, DOI 10.1002/(SICI)1097-0142(19961215)78:12<2478::AID-CNCR5>3.0.CO;2-G; Akiyama Y, 1997, CANCER RES, V57, P3920; Boland CR, 1998, CANCER RES, V58, P5248; Brownstein MJ, 1996, BIOTECHNIQUES, V20, P1004, DOI 10.2144/96206st01; de Leeuw WJF, 2000, J PATHOL, V192, P328, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH701>3.0.CO;2-2; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kolodner RD, 1999, CANCER RES, V59, P5068; Koul A, 1999, GENE CHROMOSOME CANC, V24, P207, DOI 10.1002/(SICI)1098-2264(199903)24:3<207::AID-GCC5>3.0.CO;2-3; Magnuson VL, 1996, BIOTECHNIQUES, V21, P700, DOI 10.2144/96214rr03; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; PARSONS R, 1995, CANCER RES, V55, P5548; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Planck M, 2000, GENE CHROMOSOME CANC, V29, P33, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1004>3.0.CO;2-R; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SMITH JR, 1995, GENOME RES, V5, P312, DOI 10.1101/gr.5.3.312; SOUZA RF, 1996, NAT GENET, V14, P2255; Togo G, 1996, CANCER RES, V56, P5620; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Wu Y, 1999, AM J HUM GENET, V65, P1291, DOI 10.1086/302612	23	10	10	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6241	6244		10.1038/sj.onc.1204795	http://dx.doi.org/10.1038/sj.onc.1204795			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593433				2022-12-28	WOS:000171206300016
J	Schmidt, M; Koller, R; Haviernik, P; Bies, J; Maciag, K; Wolff, L				Schmidt, M; Koller, R; Haviernik, P; Bies, J; Maciag, K; Wolff, L			Deregulated c-Myb expression in murine myeloid leukemias prevents the up-regulation of p15(INK4b) normally associated with differentiation	ONCOGENE			English	Article						c-Myb; p15(INK4b); myeloid leukemia	CELL-CYCLE INHIBITORS; TERMINAL DIFFERENTIATION; GENE FAMILY; BALB/C MICE; APOPTOSIS; INACTIVATION; METHYLATION; P16(INK4A); INDUCTION; PROTEIN	Deregulated expression of the proto-oncogene c-myb, which results from provirus integration, is thought to be responsible for transformation in a set of murine leukemia virus (MuLV)-induced myeloid leukemias (MML). We reported recently that this transcription factor promotes proliferation by directly transactivating c-myc and inhibits cell death through its up-regulation of Bcl-2 (Schmidt et al., 2000). To understand more about how these cells become transformed we looked at how they deal with cellular pathways inducing growth arrest. Specifically, we were interested in the expression of the tumor suppressor gene Cdkn2b (p15(INK4b)) in MML because this gene is expressed during myeloid differentiation and its inactivation by methylation has been shown to be important for the development of human acute myeloid leukemia. mRNA levels for p15(INK4b) and another INK4 gene p16(INK4b) were examined in monocytic Myb tumors and were compared with expression of the same genes in c-myc transformed monocytic tumors that do not express c-Myb. The Cdkn2a (p16(INK4b)) gene was generally not expressed in either tumor type, an observation explained by methylation or deletion in the promoter region. Although Cdkn2b (p15(INK4b)) mRNA was expressed in the Myc tumors, many transcripts were aberrant in size and contained only exon 1. Surprisingly, in the majority of the Myb tumors there was no p15(INK4b) transcription and neither deletion nor methylation could explain this result. Additional experiments demonstrated that, in the presence of constitutive c-Myb expression, the induction of p15(INK4b) mRNA that accompanies differentiation of MI cells to monocytes does not occur. Therefore, the transcriptional regulator c-Myb appears to prevent activation of a growth arrest pathway that normally accompanies monocyte maturation.	NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA; Canc Res Inst, Mol Virol Lab, Bratislava, Slovakia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Slovak Academy of Sciences	Wolff, L (corresponding author), NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA.	LWOLFF@helix.nih.gov		/0000-0003-0803-4312				Amanullah A, 2000, BLOOD, V96, P475; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; Batova A, 1997, CANCER RES, V57, P832; Bies J, 1996, ONCOGENE, V12, P355; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DellaRagione F, 1997, LEUKEMIA LYMPHOMA, V25, P23, DOI 10.3109/10428199709042493; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, CANCER RES, V56, P722; HIRAMA T, 1995, BLOOD, V86, P841; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; QUELLE DE, 1995, ONCOGENE, V11, P635; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; Siebert R, 1996, LEUKEMIA LYMPHOMA, V23, P505, DOI 10.3109/10428199609054859; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Teofili L, 1998, EXP HEMATOL, V26, P1133; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Wolff L, 1996, CURR TOP MICROBIOL, V211, P191; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; WOLFF L, 1988, J IMMUNOL, V141, P681; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60; Zhang B, 2000, J MOL BIOL, V299, P1121, DOI 10.1006/jmbi.2000.3803; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	45	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6205	6214		10.1038/sj.onc.1204821	http://dx.doi.org/10.1038/sj.onc.1204821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593429				2022-12-28	WOS:000171206300012
J	Liu, YZ; Hiraiwa, Y; Liu, EB; Kurata, H; Thant, AA; Matsuda, S; Hamaguchi, M				Liu, YZ; Hiraiwa, Y; Liu, EB; Kurata, H; Thant, AA; Matsuda, S; Hamaguchi, M			Suppression of cell spreading by v-Crk requires Ras-MPK-MAP kinase signaling	ONCOGENE			English	Article						v-Crk; Ras; MAP kinase; cell spreading; integrin	PROTEIN; TRANSFORMATION; PATHWAY; ACTIVATION; TRANSDUCTION; FIBROBLASTS; INTEGRINS; ADHESION	We investigated the attachment and spreading of v-Crk-transformed cells, v-Crk3Y1, on fibronectin. Transformation-by v-Crk virtually suppressed the spreading, but not the attachment, of cells on fibronectin. This suppression of cell spreading was not correlated with the suppression of integrin alpha5 and beta1 expression. However, the spreading of v-Crk3Y1 on fibronectin was dramatically restored by either expression of dominant-negative Ras or treatment with manumycin A, a Ras farnesyltransferase inhibitor. Moreover, both expression of dominant-negative MEK1 and treatment of cells with U0126, a MEK1 inhibitor, restored the cell spreading of v-Crk3Y1. In contrast, neither treatment with LY294002, a PI3K inhibitor, nor expression of dominant-negative C3G showed no effect on cell spreading on fibronectin. Taken together, our results suggest that, among multiple signaling pathways activated by v-Crk, the Ras-MEK1-MAP kinase cascade plays a pivotal role in the suppression of cell spreading on fibronectin, but C3G and the PI3 kinase do not.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.							ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Liu EB, 2000, CANCER RES, V60, P2361; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356	21	5	5	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5908	5912		10.1038/sj.onc.1204738	http://dx.doi.org/10.1038/sj.onc.1204738			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593397				2022-12-28	WOS:000171037200015
J	Ludde, T; Kubicka, S; Plumpe, J; Liedtke, C; Manns, MP; Trautwein, C				Ludde, T; Kubicka, S; Plumpe, J; Liedtke, C; Manns, MP; Trautwein, C			Ras adenoviruses modulate cyclin E protein expression and DNA synthesis after partial hepatectomy	ONCOGENE			English	Article						Ras; hepatectomy; liver regeneration; DNA synthesis; cyclin E	RETINOBLASTOMA GENE-PRODUCT; MITOGEN-ACTIVATED PROTEIN; CELL-CYCLE; LIVER-REGENERATION; DIFFERENTIAL REGULATION; DOWN-REGULATION; S PHASE; TRANSCRIPTION; BINDING; GROWTH	Ras-genes encode for proteins important for transmitting extracellular signals from the cytoplasm to the nucleus. In this study we investigated the impact of Ras on cell cycle progression after hepatectomy by using adenoviral vectors (adv) expressing beta -galactosidase (beta -gal), a dominant-negative (Ras N17) or a dominant-active (Ras 61L) form of H-Ras. Partial hepatectomy was performed in mice treated with the different adenoviruses and cell cycle progression was studied by analysing factors involved in cell cycle control during liver regeneration. After hepatectomy, adv Ras 61L increases DNA synthesis significantly in comparison to the other treatment groups. Higher Ras activity results in an early increase of transcriptional active E2F-3, which is associated with higher cyclin E, but almost unchanged cyclin D protein expression. However, Northern blot analysis and cyclin E promoter experiments indicate that, besides transcriptional mechanisms also post-transcriptional mechanisms are involved in regulating cyclin E protein expression after partial hepatectomy in mice treated with adv Ras 61L. Cyclin E phosphorylation studies demonstrate that adv Ras 61L results in hypophosphorylation of cyclin E compared to the control group at early time points after hepatectomy, when cyclin E protein expression strongly increases and there is only a minor effect on cyclin E mRNA levels. Our experiments indicate adv Ras 61L in vivo increases Cyclin E expression by higher transcription via E2F and a post-transcriptional mechanism. These mechanisms result in an earlier activation of an active CDK2/Cyclin E complex which, in turn, triggers DNA synthesis.	Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany	Hannover Medical School	Trautwein, C (corresponding author), Hannover Med Sch, Dept Gastroenterol & Hepatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Trautwein.christian@MH-Hannover.de	Liedtke, Christian/DTV-1874-2022; Luedde, Tom/AAE-9135-2022	Liedtke, Christian/0000-0003-4681-7887; Luedde, Tom/0000-0002-6288-8821				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BRENNER DA, 1998, GASTROENTEROL HEPATO, V13, P93; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DAMJANOV I, 1994, BIOCHEM BIOPH RES CO, V201, P994, DOI 10.1006/bbrc.1994.1800; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Hayder H, 1999, J IMMUNOL, V163, P1516; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Kim TH, 1997, HEPATOLOGY, V26, P896, DOI 10.1002/hep.510260415; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lozier JN, 1999, BLOOD, V94, P3968, DOI 10.1182/blood.V94.12.3968.424k43_3968_3975; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; ROEB E, 1993, HEPATOLOGY, V18, P1437, DOI 10.1016/0270-9139(93)90236-G; Rudolph KL, 1999, HEPATOLOGY, V30, P1159, DOI 10.1002/hep.510300502; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Trautwein C, 1999, ONCOGENE, V18, P6443, DOI 10.1038/sj.onc.1203045; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; Winston JT, 1996, ONCOGENE, V12, P127; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	49	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5264	5278		10.1038/sj.onc.1204690	http://dx.doi.org/10.1038/sj.onc.1204690			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536040				2022-12-28	WOS:000170575500003
J	Jeronimo, C; Nomoto, S; Caballero, OL; Usadel, H; Henrique, R; Varzim, G; Oliveira, J; Lopes, C; Fliss, MS; Sidransky, D				Jeronimo, C; Nomoto, S; Caballero, OL; Usadel, H; Henrique, R; Varzim, G; Oliveira, J; Lopes, C; Fliss, MS; Sidransky, D			Mitochondrial mutations in early stage prostate cancer and bodily fluids	ONCOGENE			English	Article						prostate cancer; prostate intraepithelial neoplasia; mitochondrial mutations; bodily fluids	MICROSATELLITE ANALYSIS; MOLECULAR-DETECTION; BLADDER-CANCER; DNA MUTATIONS; CARCINOMA; NUCLEAR; REPAIR; TUMORS; GENOME; CELLS	We recently demonstrated the existence of specific patterns of somatic mitochondrial DNA (mtDNA) mutations in several cancers. Here we sought to identify the presence of mtDNA mutations in prostate cancer an their paired PIN lesions. The D-loop region, 16S rRNA, and the NADH subunits of complex I were sequenced to identify mtDNA mutations in 16 matched PIN lesions and primary prostate cancers. Twenty mtDNA mutations were detected in the tumor tissue of three patients. Identical mutations were also identified in the PIN lesion from one patient. This patient with multiple point mutations also harbored a high frequency of microsatellite instability (MSI-H) in nuclear mononucleotide repeat markers. Remarkably, identical mutations were also detected in all (3/3) matched urine and plasma samples obtained from these patients. Although mitochondrial mutations are less common in prostate adenocareinoma, they occur early in cancer progression and they can be detected in bodily fluids of early stage disease patients. The identification of MtDNA mutations may complement other early detection approaches for prostate cancer.	Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; Inst Portugues Oncol Francisco Gentil, Ctr Reg Porto, Dept Pathol, Unit Mol Pathol, Oporto, Portugal; Inst Portugues Oncol Francisco Gentil, Ctr Reg Porto, Dept Urol, Oporto, Portugal	Johns Hopkins University; Portuguese Institute of Oncology; Portuguese Institute of Oncology	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Jerónimo, Carmen/H-3284-2013; Henrique, Rui Manuel Ferreira/I-2757-2013	Jerónimo, Carmen/0000-0003-4186-5345; Henrique, Rui Manuel Ferreira/0000-0003-3171-4666	NCI NIH HHS [R01 CA 77664, P01 CA 58184, UO1 CA 84986] Funding Source: Medline; NIDCR NIH HHS [R01 DE 012488] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058184, P01CA077664, U01CA084986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Cairns P, 1997, CANCER RES, V57, P4997; CAIRNS P, 2000, IN PRESS P AM ASS CA, V41, P241; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; ISAACS WB, 1996, PRINCIPLES PRACTICE, P403; JEN J, 1994, CANCER RES, V54, P5523; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4	20	193	208	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5195	5198		10.1038/sj.onc.1204646	http://dx.doi.org/10.1038/sj.onc.1204646			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526508				2022-12-28	WOS:000170464000013
J	Heppner, C; Bilimoria, KY; Agarwal, SK; Kester, MB; Whitty, LJ; Guru, SC; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ; Burns, AL				Heppner, C; Bilimoria, KY; Agarwal, SK; Kester, MB; Whitty, LJ; Guru, SC; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ; Burns, AL			The tumor suppressor protein menin interacts with NF-kappa B proteins and inhibits NF-kappa B-mediated transactivation	ONCOGENE			English	Article						MEN1; MEN1 gene; menin; NF-kappa B; transcriptional repression; oncogene; Rel-homology domain	JUND-ACTIVATED TRANSCRIPTION; GENE-MUTATIONS; P65; FAMILY; IDENTIFICATION; EXPRESSION; PRODUCT; SUBUNIT; CANCER; P300	Multiple endocrine neoplasia type I is an autosomal dominant tumor syndrome. Manifestations include neoplasms of the parathyroid glands, entero pancreatic neuroendocrine cells, and the anterior pituitary gland. The MEN1 tumor suppressor gene encodes menin, a 610 amino acid nuclear protein without sequence homology to other proteins. To elucidate menin function, we used immunoprecipitation to identify interacting proteins. The NF-kappaB proteins p50, p52 and p65 were found to interact specifically and directly with menin in vitro and in vivo. The region of NF-kappaB proteins sufficient for binding to menin is the N-terminus. Furthermore, amino acids 305-381 of menin are essential for this binding. Menin represses p65-mediated transcriptional activation on NF-kappaB sites in a dose-dependent and specific manner. Also, PMA (phorbol 12-myristate 13-acetate)-stimulated NF-kappaB activation is suppressed by menin. These observations suggest that menin's ability to interact with NF-kappaB proteins and its modulation of NF-kappaB transactivation contribute to menin's tumor suppressor function.	NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Metab Dis Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Burns, AL (corresponding author), Univ Klin Koln, Klin & Poliklin Innere Med 2, D-50924 Cologne, Germany.		Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIEDK043009, Z01DK043009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000062] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gilmore TD, 1996, ONCOGENE, V13, P1367; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; Goebel SU, 2000, J CLIN ENDOCR METAB, V85, P116, DOI 10.1210/jc.85.1.116; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kingston RE, 1999, NATURE, V399, P199, DOI 10.1038/20302; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Marx SJ, 2001, METABOLIC MOL BASES, P943; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Ravi R, 1998, CANCER RES, V58, P4531; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VALLE MA, 2001, IN PRESS CYTOTECHNOL; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	38	201	209	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4917	4925		10.1038/sj.onc.1204529	http://dx.doi.org/10.1038/sj.onc.1204529			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526476				2022-12-28	WOS:000170439800001
J	Ikeguchi, A; Yang, HY; Gao, GX; Goff, SP				Ikeguchi, A; Yang, HY; Gao, GX; Goff, SP			Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1	ONCOGENE			English	Article						Abelson murine leukemia virus; interacting protein	TYROSINE KINASE-ACTIVITY; LEUKEMIA-VIRUS VARIANTS; C-ABL; INDUCED ACTIVATION; BINDING; GROWTH; EPS8; RAS; ABL-INTERACTOR-1; IDENTIFICATION	The abi-1 gene encodes a protein that binds and is phosphorylated by the Abelson protein tyrosine kinase. Constructs expressing a full-length abi-1 cDNA, and a smaller cDNA arising from an alternatively spliced form, were generated and tested for their effect on transformation of NIH3T3 cells by the Abelson murine leukemia virus. Overexpression of both forms of the protein strongly inhibited transformation by the wild-type P160 strain of the virus, but not by the non-interacting mutant P90A strain. The inhibition required the SH3 domain of Abi-1, suggesting that a direct interaction was required for the effect. Rare breakthrough P160 transformants of the Abi-1 overexpressing lines were found to have downregulated Abi-1 protein levels by a post-transcriptional mechanism.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University	Goff, SP (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.		Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NCI NIH HHS [P01 CA 23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; BERGOLD PJ, 1987, J VIROL, V61, P1193, DOI 10.1128/JVI.61.4.1193-1202.1987; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GOFF SP, 1981, J VIROL, V38, P460, DOI 10.1128/JVI.38.2.460-468.1981; Juang JL, 1999, ONCOGENE, V18, P5138, DOI 10.1038/sj.onc.1202911; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Maniatis T., 1982, MOL CLONING LAB MANU; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; NICHOLS GL, 1994, BLOOD, V84, P2912; Raffel GD, 1996, J BIOL CHEM, V271, P4640; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENBERG N, 1980, J VIROL, V33, P340, DOI 10.1128/JVI.33.1.340-348.1980; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; So CW, 2000, LEUKEMIA, V14, P594, DOI 10.1038/sj.leu.2401692; Taki T, 1998, BLOOD, V92, P1125, DOI 10.1182/blood.V92.4.1125.416k40_1125_1130; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	29	21	25	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4926	4934		10.1038/sj.onc.1204502	http://dx.doi.org/10.1038/sj.onc.1204502			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526477				2022-12-28	WOS:000170439800002
J	Xirodimas, D; Saville, MK; Edling, C; Lane, DP; Lain, S				Xirodimas, D; Saville, MK; Edling, C; Lane, DP; Lain, S			Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo	ONCOGENE			English	Article						p53; p14ARF; Mdm2; ubiquitin; proteasome inhibition	RING-FINGER DOMAIN; TUMOR-SUPPRESSOR P53; IN-VIVO; NUCLEOLAR-LOCALIZATION; NUCLEAR EXPORT; STABILIZES P53; DEGRADATION; PROMOTES; P19(ARF); PROTEIN	Mdm2 has been shown to promote its own ubiquitination and the ubiquitination of the p53 tumour suppressor by virtue of its E3 ubiquitin ligase activity. This modification targets Mdm2 and p53 for degradation by the proteasome. The p14ARF tumour suppressor has been shown to inhibit degradation of p53 mediated by Mdm2. Several models have been proposed to explain this effect of p14ARF. Here we have compared the effects of p14ARF overexpression on the in vivo ubiquitination of p53 and Mdm2. We report that the inhibition of the Mdm2-mediated degradation of p53 by p14ARF is associated with a decrease in the proportion of ubiquitinated p53. The levels of polyubiquitinated p53 decreased preferentially compared to monoubiquitinated species. p14ARF overexpression increased the levels of Mdm2 but it did not reduce the overall levels of ubiquitinated Mdm2 in vivo. This is unexpected because p14ARF has been reported to inhibit the ubiquitination of Mdm2 in vitro. In addition we show that like p14ARF, the proteasome inhibitor MG132 can promote the accumulation of Mdm2 in the nucleolus and that this can occur in the absence of p14ARF expression. We also show that the mutation of the nucleolar localization signal of Mdm2 does not impair the overall ubiquitination of Mdm2 but is necessary for the effective polyubiquitination of p53. These studies reveal important differences in the regulation of the stability of p53 and of Mdm2.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Lain, S (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	s.lain@dundee.ac.uk	Lain, Sonia/B-6980-2014; Lane, David P/C-4920-2008	Lain, Sonia/0000-0001-9693-5246; Lane, David/0000-0003-0551-3545; Xirodimas, Dimitris/0000-0001-9275-1140				An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	37	149	154	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4972	4983		10.1038/sj.onc.1204656	http://dx.doi.org/10.1038/sj.onc.1204656			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526482				2022-12-28	WOS:000170439800007
J	Munnia, A; Schutz, N; Romeike, BFM; Maldener, E; Glass, B; Maas, R; Nastainczyk, W; Feiden, W; Fischer, U; Meese, E				Munnia, A; Schutz, N; Romeike, BFM; Maldener, E; Glass, B; Maas, R; Nastainczyk, W; Feiden, W; Fischer, U; Meese, E			Expression, cellular distribution and protein binding of the glioma amplified sequence (GAS41), a highly conserved putative transcription factor	ONCOGENE			English	Article						amplification; GAS41; glioma; NuMA; ENL; KIAA1009; PFDN1; TFIIF	GENE AMPLIFICATION; MITOTIC SPINDLE; MATRIX; NUMA; OVEREXPRESSION; PREFOLDIN; COMPONENT; DOMAIN	The glioma amplified sequence 41 (GAS41) was previously isolated by microdissection mediated cDNA capture from the glioblastoma multiforme cell line TX3868 and shown to be frequently amplified in human gliomas. We determined the complete cDNA sequence of the GAS41 gene, demonstrated that the GAS41 protein is evolutionarily conserved, specifically at the N-terminus, and identified the yeast transcription factor tf2f domain within the GAS41 sequence. A human multiple-tissue Northern blot revealed ubiquitous expression of GAS41 with the highest expression in human brain. After generating polyclonal antibodies we found GAS41 protein expression in the nucleus of the TX3868 cell line by Western blot analysis and immunofluorescence microscopy. The nuclear localization was confirmed for several human tumors including gliomas of different grades of malignancy. In neuroblastoma however, GAS41 was found in the nucleoli but not in the nucleoplasm. Yeast two-hybrid screening of the TX3868 cell line identified the nuclear mitotic apparatus protein (NuMA), the KIAA1009 protein, and prefoldin subunit 1 (PFDN1) as potential interacting partners of GAS41. We generated a polyclonal antibody against the KIAA1009 protein and we demonstrated that the KIAA1009 protein is a nuclear protein, which appears to be co-localized with the GAS41 protein and NuMA.	Univ Saarlandes Kliniken, Inst Human Genet, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Abt Neuropathol, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Med Biochem, D-66421 Homburg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Meese, E (corresponding author), Univ Saarland, Dept Human Genet, Bldg 60, D-66421 Homburg, Germany.	hgemee@med-rz.uni-sb.de	Romeike, Bernd/K-8516-2019; , PD Dr. med. Bernd FM Romeike/Q-2600-2019; Meese, Eckart Ulrich/ABD-1983-2021	, PD Dr. med. Bernd FM Romeike/0000-0002-9693-3870; 				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Albrecht EB, 2000, MOL BIOL CELL, V11, P873, DOI 10.1091/mbc.11.3.873; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COMPTON DA, 1995, J CELL SCI, V108, P621; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; Dionne MA, 1999, CELL MOTIL CYTOSKEL, V42, P189, DOI 10.1002/(SICI)1097-0169(1999)42:3<189::AID-CM3>3.0.CO;2-X; Fischer U, 1997, HUM MOL GENET, V6, P1817, DOI 10.1093/hmg/6.11.1817; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Gueth-Hallonet C, 1998, EXP CELL RES, V243, P434, DOI 10.1006/excr.1998.4178; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Harborth J, 2000, J BIOL CHEM, V275, P31979, DOI 10.1074/jbc.M000994200; Harlow E., 1989, ANTIBODIES LAB MANUA; Heiskanen MA, 2000, CANCER RES, V60, P799; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LYDERSON BK, 1980, CELL               2, V22, P498; MARTIN KJ, 1991, BIOESSAYS, V13, P499, DOI 10.1002/bies.950131003; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Murakami Y, 2000, J VET MED SCI, V62, P783, DOI 10.1292/jvms.62.783; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; RICHARD AW, 1997, NAT GENET, V17, P109; Sehgal A, 1998, SEMIN SURG ONCOL, V14, P3; Suzuki SO, 2000, MODERN PATHOL, V13, P548, DOI 10.1038/modpathol.3880095; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang ZH, 1999, ANTICANCER RES, V19, P5445; Zeng CQ, 2000, MICROSC RES TECHNIQ, V49, P467, DOI 10.1002/(SICI)1097-0029(20000601)49:5<467::AID-JEMT9>3.3.CO;2-M	37	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4853	4863		10.1038/sj.onc.1204650	http://dx.doi.org/10.1038/sj.onc.1204650			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521196				2022-12-28	WOS:000170271800009
J	Orelli, BJ; Logsdon, JM; Bishop, DK				Orelli, BJ; Logsdon, JM; Bishop, DK			Nine novel conserved motifs in BRCA1 identified by the chicken orthologue	ONCOGENE			English	Article						avian; DT40; breast cancer; BRCA1	DNA-DAMAGE RESPONSE; TRANSCRIPTION-COUPLED REPAIR; SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; SEQUENCE-ANALYSIS; MEIOTIC CELLS; MOUSE BRCA1; IN-VIVO; PHOSPHORYLATION; AMPLIFICATION	The breast cancer susceptibility gene BRCA1 encodes a multifunctional protein that is mutated in many hereditary breast and ovarian cancers. We have cloned a homologue of the human BRCA1 gene from chicken; the gene encodes a 1749 amino acid protein that is 33% identical to human BRCA1, Phylogenetic analyses of the chicken and mammalian proteins indicate that the chicken gene is a bona fide BRCA1 orthologue, the first to be described from a non-mammal. Most of the chicken protein has diverged considerably from its mammalian orthologues, although the RING and BRCT repeat regions are highly conserved. This marked overall sequence divergence has allowed us to identify nine additional highly-conserved motifs (ranging from 8-56 amino acids in length) which are likely important for BRCA1 function.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	University of Chicago; Emory University	Bishop, DK (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 920 E 58th St, Chicago, IL 60637 USA.		Logsdon, John M/B-7812-2009					ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Bennett LM, 1999, MAMM GENOME, V10, P19, DOI 10.1007/s003359900935; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Le Page F, 2000, CANCER RES, V60, P5548; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD DL, 2001, PAUP PHYLOGENETIC AN; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	40	35	38	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4433	4438		10.1038/sj.onc.1204485	http://dx.doi.org/10.1038/sj.onc.1204485			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466627				2022-12-28	WOS:000169912600020
J	Mattoon, D; Gupta, K; Doyon, J; Loll, PJ; DiMaio, D				Mattoon, D; Gupta, K; Doyon, J; Loll, PJ; DiMaio, D			Identification of the transmembrane dimer interface of the bovine papillomavirus E5 protein	ONCOGENE			English	Article						coiled-coil; papillomavirus; platelet-derived growth factor receptor; transmembrane domain; viral oncogene	FACTOR-BETA RECEPTOR; GROWTH-FACTOR RECEPTOR; TRANSFORMING PROTEIN; TYROSINE KINASE; C127 CELLS; ACTIVATION; DOMAIN; PHOSPHORYLATION; REQUIRES; REVEALS	We have developed a genetic method to determine the active orientation of dimeric transmembrane protein helices, The bovine papillomavirus E5 protein, a 44-amino acid homodimeric protein that appears to traverse membranes as a left-handed foiled-coil, transforms fibroblasts by binding and activating the platelet-derived growth factor (PDCF) beta receptor, A heterologous dimerization domain was used to force E5 monomers to adopt all seven possible symmetric coiled-coil registries relative to one another within the dimer, Focus formation assays demonstrated that dimerization of the E5 protein is required for transformation and identified a single preferred orientation of the monomers, The essential glutamine residue at position 17 resided in the dimer interface in this active orientation, The active chimera formed complexes with the PDGF beta receptor and induced receptor tyrosine phosphorylation, We also identified ES-like structures that underwent non-productive interactions with the receptor.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	Yale University; University of Pennsylvania	DiMaio, D (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.		Gupta, Kushol/GOE-5620-2022	Gupta, Kushol/0000-0002-7006-2667	NATIONAL CANCER INSTITUTE [R01CA037157, R37CA037157] Funding Source: NIH RePORTER; NCI NIH HHS [CA37157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Burkhard P, 2000, STRUCTURE, V8, P223, DOI 10.1016/S0969-2126(00)00100-3; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; Surti T, 1998, PROTEINS, V33, P601; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001	25	35	37	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3824	3834		10.1038/sj.onc.1204523	http://dx.doi.org/10.1038/sj.onc.1204523			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439346				2022-12-28	WOS:000169494700008
J	Crostella, L; Lidder, S; Williams, R; Skouteris, GG				Crostella, L; Lidder, S; Williams, R; Skouteris, GG			Hepatocyte Growth Factor/Scatter Factor-induces phosphorylation of cortactin in A431 cells in a Src kinase-independent manner	ONCOGENE			English	Article						tyrosine phosphorylation; MET; F-actin binding proteins	RECEPTOR TYROSINE KINASE; GRB2 BINDING-SITE; SCATTER FACTOR; MET RECEPTOR; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; CARCINOMA-CELLS; V-SRC; MOTILITY	The Hepatocyte Growth Factor receptor transduces proliferating and scattering signals in epithelial and endothelial cells. We have explored potential interactions of the HGF/SF receptor beta-subunit (p145(beta MET)) with F-actin binding partners aiming to identify novel downstream effecters implicated in HGF/SF pluripotent signalling. Cortactin, a p80/85 F-actin binding protein, was found phosphorylated on tyrosine in response to HGF-SF in A431 human epidermoid carcinoma cells, expressing the HGF/SF receptor (c-MET). The HGF/SF receptor was enriched in the detergent-insoluble fraction and was found to co-precipitate with cortactin and to associate in vitro with cortactin, The Grb2 small adapter protein known to associate via its Src homology 2 domain (SH2) with the MET C-terminus, was also associated with cortactin, Transient transfection of A431 cells with dominant-negative Grb2 constructs has revealed that the Grb2-C-SH3 domain possesses central role in cortactin phosphorylation in response to HGF/SF, Finally, tyrosine phosphorylation of cortactin was found uncoupled of endogenous c-Src kinase activity, thus further supporting the hypothesis that cortactin is a direct target of the MET kinase, We propose that cortactin may constitute a docking site for MET-derived signals within the cytoskeleton.	Royal Free & UCL, Sch Med, Dept Med, Inst Hepatol,Lab Cell Biol, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Skouteris, GG (corresponding author), Royal Free & UCL Med Sch, Dept Med, Ctr Hepatol, Lab Cellular & Mol Biol, Upper 3rd Floor,Rowland Hill St,Royal Free Campus, London NW3 2PF, England.	g.skouteris@rfc.ucl.ac.uk						BARDELLI A, 1992, ONCOGENE, V7, P1973; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAY D, 1986, J CELL SCI, P71; BRUNATI AM, 1995, EUR J BIOCHEM, V229, P164, DOI 10.1111/j.1432-1033.1995.0164l.x; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; DUGINA VB, 1995, J CELL SCI, V108, P1659; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Provenzano C, 1998, EXP CELL RES, V242, P186, DOI 10.1006/excr.1998.4095; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sabe H, 1997, ONCOGENE, V14, P1779, DOI 10.1038/sj.onc.1201022; Skouteris GG, 1996, J BIOL CHEM, V271, P27266, DOI 10.1074/jbc.271.44.27266; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VANITALLIE CM, 1995, J CELL SCI, V108, P1735; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Weed SA, 1998, J CELL SCI, V111, P2433; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221	50	35	37	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3735	3745		10.1038/sj.onc.1204474	http://dx.doi.org/10.1038/sj.onc.1204474			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439336				2022-12-28	WOS:000169400200014
J	Bakhanashvili, M				Bakhanashvili, M			p53 enhances the fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase	ONCOGENE			English	Article						p53; HIV-1 RT; 3 '-> 5 ' exonuclease; DNA replication fidelity	WILD-TYPE; IN-VITRO; EXONUCLEASE ACTIVITY; BASE-SUBSTITUTION; ESCHERICHIA-COLI; POLYMERASE-III; PROTEIN; EXPRESSION; EXTENSION; SPECIFICITY	The tumor suppressor protein p53 plays a critical role in the maintenance of genetic integrity. p53 possesses 3'-->5' exonuclease activity, however, the significance of this function in DNA replication process remains elusive. It was suggested that 3'-->5' exonuclease activity of p53 may provide a proofreading function for DNA polymerases. In order to better understand the significance of this activity, the purified wild-type recombinant p53 was further evaluated for substrate specificity and for contribution to the accuracy of DNA synthesis. p53-associated 3'-->5' exonuclease displays 3' terminal nucleotide excision from RNA/DNA template-primer using ribosomal RNA as a template. The data demonstrate that p53 is highly efficient in removing a terminal mispair. Analysis of mispair excision opposite the template adenine residue shows that p53 catalyzes 3' terminal mismatch excision with a specificity of A:G>A:A>A:C. Hence, the observed specificity of mismatch excision indicates that p53 exonucleolytic proofreading preferentially repairs transversion mutations. The influence of the p53 on the accuracy of DNA synthesis was determined with exonuclease-deficient human immunodeficiency virus-1 (HIV-1) reverse transcriptase (RT), a key enzyme in the life cycle of the virus, that contributes significantly to the low accuracy of proviral DNA synthesis. Using an in vitro biochemical assay with recombinant purified HIV-1 RT, p53 and defined RNA/DNA or DNA/DNA template-primers, two basic features related to fidelity of DNA synthesis were studied: the misinsertion and mispair extension. The misincorporation of non-complementary deoxynucleotides into nascent DNA and subsequent mispair extension by HIV-1 RT were substantially decreased in the presence of p53 with both RNA/DNA and DNA/DNA template-primers. In addition, the productive interaction between polymerization (by HIV-1 RT) and exonuclease (by p53) activities was observed; p53 preferentially hydrolyzes mispaired 3'-termini, permitting subsequent extension of the correctly paired 3'-terminus by HIV-1 RT. Taken together the data demonstrate that preferential excision of mismatched nucleotides by 3'-->5' exonuclease activity of wild-type p53 enhances the fidelity of DNA synthesis by HIV-1 RT in vitro, thus providing a biochemical mechanism to reduce mutations caused by incorporation of mismatched nucleotides. The fact that p53 is reactive with both RNA/DNA and DNA/DNA template-primers raises an interesting possibility of the existence of functional cooperation between p53 and HIV-1 RT in cytoplasm during the reverse transcription process, which may be important for maintaining HIV genomic integrity.	Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel	Chaim Sheba Medical Center	Bakhanashvili, M (corresponding author), Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel.	bakhanus@yahoo.com						Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Bakhanashvili M, 1996, ARCH BIOCHEM BIOPHYS, V334, P89, DOI 10.1006/abbi.1996.0433; BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BAKHANASHVILI M, 1993, BIOCHEMISTRY-US, V32, P7559, DOI 10.1021/bi00080a030; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; COFFIN JM, 1986, CELL, V46, P1, DOI 10.1016/0092-8674(86)90851-2; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; Genini D, 2001, FASEB J, V15, P5; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; KASTAN MB, 1991, CANCER RES, V51, P6304; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KERN SE, 1991, ONCOGENE, V6, P131; Komarova EA, 1997, CANCER RES, V57, P5217; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PERRINO FW, 1990, BIOCHEMISTRY-US, V29, P5226, DOI 10.1021/bi00474a002; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; Prives C, 1999, J PATHOL, V187, P112; RAGIMOV N, 1993, ONCOGENE, V8, P1183; SINHA NK, 1987, P NATL ACAD SCI USA, V84, P915, DOI 10.1073/pnas.84.4.915; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; SOUSSI T, 1995, MOL GENETICS CANC, P135; STEINMEYER K, 1988, ONCOGENE, V3, P501; SZEKELY L, 1995, ONCOGENE, V10, P1869; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	50	26	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2001	20	52					7635	7644		10.1038/sj.onc.1204956	http://dx.doi.org/10.1038/sj.onc.1204956			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753641				2022-12-28	WOS:000172124100006
J	Xiang, YY; Ladeda, V; Filmus, J				Xiang, YY; Ladeda, V; Filmus, J			Glypican-3 expression is silenced in human breast cancer	ONCOGENE			English	Article						glypicans; breast cancer; DNA methylation	GOLABI-BEHMEL-SYNDROME; OVERGROWTH SYNDROME; GENE; GPC3; DYSPLASIA	Glypican-3 (GPC3) is, a membrane-bound heparan sulfate proteoglycan that is mutated in the Simpson-Golabi-Behmel syndrome. This is an X-linked condition characterized by overgrowth, and various visceral and skeletal dysmorphisms. The phenotype of the Simpson-Golabi-Behmel, syndrome patients and GM-deficient mice, as well as gene transfection experiments indicate that GPC3 can act as an inhibitor of cell proliferation and survival. It has been previously shown that GPC3 expression is downregulated in mesotheliomas and ovarian cancer. Here we report that GPC3 expression is also silenced in human. breast cancer, and that this silencing is due, at least in part, to hypermethylation of the GPC3 promoter. Ectopic expression of GPC3 inhibited growth in eight out of 10 breast cancer cell lines. Collectively, these data suggest that GPC3 can act as a negative regulator of breast cancer growth.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Mol & Cell Biol Res Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Filmus, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Mol & Cell Biol Res Program, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	filmus@sten.sunnybrook.utoronto.ca						BEHMEL A, 1984, HUM GENET, V67, P409, DOI 10.1007/BF00291401; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; FILMUS J, 2000, PROTEOGLYCANS, P161; GARGANTA CL, 1992, AM J MED GENET, V44, P129, DOI 10.1002/ajmg.1320440202; GOLABI M, 1984, AM J MED GENET, V17, P345, DOI 10.1002/ajmg.1320170128; Grisaru S, 2001, DEV BIOL, V231, P31, DOI 10.1006/dbio.2000.0127; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; HUGHESBENZIE RM, 1992, AM J MED GENET, V43, P428, DOI 10.1002/ajmg.1320430165; HughesBenzie RM, 1996, AM J MED GENET, V66, P227, DOI 10.1002/(SICI)1096-8628(19961211)66:2<227::AID-AJMG20>3.0.CO;2-U; Lin HC, 1999, CANCER RES, V59, P807; Murthy SS, 2000, ONCOGENE, V19, P410, DOI 10.1038/sj.onc.1203322; Neri G, 1998, AM J MED GENET, V79, P279, DOI 10.1002/(SICI)1096-8628(19981002)79:4<279::AID-AJMG9>3.0.CO;2-H; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; XIANG YY, 1994, CANCER RES, V54, P3034	18	164	180	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7408	7412		10.1038/sj.onc.1204925	http://dx.doi.org/10.1038/sj.onc.1204925			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704870				2022-12-28	WOS:000171894200013
J	Regad, T; Chelbi-Alix, MK				Regad, T; Chelbi-Alix, MK			Role and fate of PML nuclear bodies in response to interferon and viral infections	ONCOGENE			English	Review						signalling; transcriptional repression; HFV; APL; SUMO; RBCC; TRIM	ACUTE PROMYELOCYTIC LEUKEMIA; MAMMARY-TUMOR VIRUS; PROTEIN-KINASE PKR; VESICULAR STOMATITIS-VIRUS; HEPATITIS-C VIRUS; JAK-STAT PATHWAY; RETINOIC ACID; HUMAN CYTOMEGALOVIRUS; INFLUENZA-VIRUS; GENE-PRODUCT	Interferons (IFNs) are a family of secreted proteins with antiviral, antiproliferative and immunomodulatory activities. The different biological actions of IFN are believed to be mediated by the products of specifically induced cellular genes in the target cells. The promyelocytic leukaemia (PML) protein localizes both in the nucleoplasm and in matrix-associated multi-protein complexes known as nuclear bodies (NBs). PML is essential for the proper formation and the integrity of the NBs. Modification of PML by the Small Ubiquitin MOdifier (SUMO) was shown to be required for its localization in NBs. The number and the intensity of PML NBs increase in response to interferon (IFN). Inactivation of the IFN-induced PML gene by its fusion to retinoic acid receptor alpha alters the normal localization of PML from the punctuate nuclear patterns of NBs to microdispersed tiny dots and results in uncontrolled growth in Acute Promyelocytic Leukaemia. The NBs-associated proteins, PML, Sp100, Sp140, Sp110, ISG20 and PA28 are induced by IFN suggesting that nuclear bodies could play a role in IFN response. Although the function of PML NBs is still unclear, some results indicate that they may represent preferential targets for viral infections and that PML could play a role in the mechanism of the antiviral action of IFNs. Viruses, which require the cellular machinery for their replication, have evolved different ways to counteract the action of IFN by inhibiting IFN signalling, by blocking the activities of specific antiviral mediators or by altering PML expression and/or localization on nuclear bodies.	Inst Andre Lwoff, UPR 9045 CNRS, F-94801 Villejuif, France		Chelbi-Alix, MK (corresponding author), Inst Andre Lwoff, UPR 9045 CNRS, 7 Rue Guy Moquet, F-94801 Villejuif, France.	mchelbi@infobiogen.fr	Regad, Tarik/A-6095-2012	Regad, Tarik/0000-0003-4028-6368				Adelson ME, 1999, EUR J BIOCHEM, V264, P806, DOI 10.1046/j.1432-1327.1999.00661.x; Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Ahn JH, 1999, J VIROL, V73, P10458, DOI 10.1128/JVI.73.12.10458-10471.1999; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; ARNHEITER H, 1990, New Biologist, V2, P851; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Barnard P, 1999, VIROLOGY, V259, P305, DOI 10.1006/viro.1999.9771; Bell P, 2000, J VIROL, V74, P5329, DOI 10.1128/JVI.74.11.5329-5336.2000; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Bloch DB, 2000, MOL CELL BIOL, V20, P6138, DOI 10.1128/MCB.20.16.6138-6146.2000; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1998, J VIROL, V72, P3819, DOI 10.1128/JVI.72.5.3819-3826.1998; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; Cai RR, 2000, ARCH BIOCHEM BIOPHYS, V373, P361, DOI 10.1006/abbi.1999.1583; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CAYLEY PJ, 1984, EUR J BIOCHEM, V143, P165, DOI 10.1111/j.1432-1033.1984.tb08355.x; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHELBIALIX MK, TUMOR BIOL, V99, P17; Cheng GF, 2001, J VIROL, V75, P3666, DOI 10.1128/JVI.75.8.3666-3674.2001; CHENIK M, 1995, J VIROL, V69, P707, DOI 10.1128/JVI.69.2.707-712.1995; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; DANIEL MT, 1993, BLOOD, V82, P1858; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Dent AL, 1996, BLOOD, V88, P1423, DOI 10.1182/blood.V88.4.1423.bloodjournal8841423; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DER SD, 1995, P NATL ACAD SCI USA, V92, P8841, DOI 10.1073/pnas.92.19.8841; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DiazGuerra M, 1997, VIROLOGY, V227, P220, DOI 10.1006/viro.1996.8294; Djavani M, 2001, J VIROL, V75, P6204, DOI 10.1128/JVI.75.13.6204-6208.2001; Dwyer EJC, 2000, J VIROL, V74, P3293, DOI 10.1128/JVI.74.7.3293-3300.2000; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Everett RD, 1999, TRENDS BIOCHEM SCI, V24, P293, DOI 10.1016/S0968-0004(99)01433-4; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Fabunmi RP, 2001, J CELL SCI, V114, P29; Foss GS, 1999, J BIOL CHEM, V274, P35196, DOI 10.1074/jbc.274.49.35196; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gongora C, 2000, NUCLEIC ACIDS RES, V28, P2333, DOI 10.1093/nar/28.12.2333; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; GULDNER HH, 1992, J IMMUNOL, V149, P4067; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; Hatada E, 1999, J VIROL, V73, P2425, DOI 10.1128/JVI.73.3.2425-2433.1999; He FL, 1996, J VIROL, V70, P3902, DOI 10.1128/JVI.70.6.3902-3908.1996; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; LANOTTE M, 1991, BLOOD, V77, P1080; LAVAU C, 1995, ONCOGENE, V11, P871; Lecellier CH, 2000, VIROLOGY, V271, P1, DOI 10.1006/viro.2000.0216; Leonard GT, 1997, J VIROL, V71, P5095, DOI 10.1128/JVI.71.7.5095-5101.1997; Li SY, 1999, ONCOGENE, V18, P5727, DOI 10.1038/sj.onc.1202960; Linial ML, 1999, J VIROL, V73, P1747, DOI 10.1128/JVI.73.3.1747-1755.1999; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MEIER E, 1988, J VIROL, V62, P2386, DOI 10.1128/JVI.62.7.2386-2393.1988; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; Meurs EF, 1995, VIROLOGY, V214, P653, DOI 10.1006/viro.1995.0080; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; Miller DM, 1999, J IMMUNOL, V162, P6107; Miller DM, 1998, J EXP MED, V187, P675, DOI 10.1084/jem.187.5.675; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Muller S, 1999, J VIROL, V73, P5137; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Nguyen LH, 2001, BIOCHEMISTRY-US, V40, P7174, DOI 10.1021/bi010141t; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Pfeffer LM, 1998, CANCER RES, V58, P2489; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; Poppers J, 2000, J VIROL, V74, P11215, DOI 10.1128/JVI.74.23.11215-11221.2000; Puvion-Dutilleul F, 1999, BIOL CELL, V91, P617, DOI 10.1016/S0248-4900(00)88526-3; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Rechsteiner M, 2000, BIOCHEM J, V345, P1, DOI 10.1042/0264-6021:3450001; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHRODER HC, 1990, FASEB J, V4, P3124, DOI 10.1096/fasebj.4.13.1698680; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Sharp TV, 1997, EUR J BIOCHEM, V250, P85, DOI 10.1111/j.1432-1033.1997.00085.x; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Stadler M, 1995, ONCOGENE, V11, P2565; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; TESTA U, 1994, CANCER RES, V54, P4508; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998; ZURCHER T, 1992, VIROLOGY, V187, P796, DOI 10.1016/0042-6822(92)90481-4; ZURCHER T, 1992, J VIROL, V66, P5059	119	230	242	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7274	7286		10.1038/sj.onc.1204854	http://dx.doi.org/10.1038/sj.onc.1204854			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704856	Bronze			2022-12-28	WOS:000171891900016
J	Jazaeri, AA; Nunes, KJ; Dalton, MS; Xu, MH; Shupnik, MA; Rice, LW				Jazaeri, AA; Nunes, KJ; Dalton, MS; Xu, MH; Shupnik, MA; Rice, LW			Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression	ONCOGENE			English	Article						ER-alpha; ER-beta; PR; PR-B; endometrial cancer; MMMT	ESTROGEN-RECEPTOR-BETA; PROGESTERONE-RECEPTOR; GENE-EXPRESSION; DOWN-REGULATION; MESSENGER-RNAS; CANCER-CELLS; ALPHA; ACTIVATION; REGULATOR	Both the estrogen receptor (ER) and the progesterone receptor (PR) have two subtypes: ER-alpha and beta, and PR-A and -B, respectively. These subtypes differ in function and expression, and recent reports have correlated changes in the normal proportions of these isoforms with neoplastic states. We investigated ER and PR isoform expression in normal pre- and post-menopausal endometrium, well-differentiated endometrial adenocarcinoma, and poorly differentiated malignant mixed mullerian tumors (MMMTs). Semi-quantitative RT-PCR and immunoblotting were used to measure receptor mRNA and protein expression. Estrogen receptor-alpha/beta mRNA ratios were significantly higher in postmenopausal (27.3) compared to premenopausal endometrium (4.9) mainly as a result of lower ER-beta expression in the former. Compared to age-matched postmenopausal controls, the ER-alpha/beta ratio was reduced in both grade I adenocarcinoma and MMMT specimens (3.3 and 6.8, respectively), due to a selective loss of ER-alpha. The relative abundance of PR-A and PR-B mRNA remained unchanged between all tissue subtypes. Total PR protein, however, was significantly reduced in MMMTs compared to all other groups. Thus, sex steroid receptor expression is significantly and differentially altered in well-differentiated and poorly-differentiated endometrial cancers. Both cancers exhibit decreased ER-alpha expression and the MMMTs also demonstrate a significant loss of PR protein.	Univ Virginia, Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Div Endocrinol, Charlottesville, VA 22906 USA	University of Virginia; University of Virginia	Rice, LW (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Box 800712, Charlottesville, VA 22906 USA.	Lwr9y@virginia.edu	Jazaeri, Amir/I-3458-2015; Jazaeri, Amir/A-2400-2008	Jazaeri, Amir/0000-0003-4335-4151; 	NCI NIH HHS [K08 CA73668-01] Funding Source: Medline; NICHD NIH HHS [U54 HD 28934] Funding Source: Medline; NIDDK NIH HHS [R01 DK57082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA073668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057082] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; ANTUNES CMF, 1979, NEW ENGL J MED, V300, P9, DOI 10.1056/NEJM197901043000103; Brandenberger AW, 1998, J CLIN ENDOCR METAB, V83, P1025, DOI 10.1210/jc.83.3.1025; COSTA MJ, 1994, MODERN PATHOL, V7, P619; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FECHNER RE, 1974, CANCER-AM CANCER SOC, V34, P444, DOI 10.1002/1097-0142(197408)34:2<444::AID-CNCR2820340232>3.0.CO;2-J; Foley EF, 2000, CANCER RES, V60, P245; Graham JD, 1996, J STEROID BIOCHEM, V56, P93; Gray L A Sr, 1977, Obstet Gynecol Surv, V32, P619, DOI 10.1097/00006254-197709000-00023; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GUSBERG SB, 1971, AM J OBSTET GYNECOL, V111, P633, DOI 10.1016/0002-9378(71)90965-3; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Ing NH, 1996, BIOL REPROD, V54, P591, DOI 10.1095/biolreprod54.3.591; Jazaeri O, 1999, GYNECOL ONCOL, V74, P38, DOI 10.1006/gyno.1999.5404; Kumar NS, 1998, CANCER RES, V58, P1860; Matsuzaki S, 1999, MOL HUM REPROD, V5, P559, DOI 10.1093/molehr/5.6.559; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Pujol P, 1998, CANCER RES, V58, P5367; Rutherford T, 2000, OBSTET GYNECOL, V96, P417, DOI 10.1016/S0029-7844(00)00917-0; Sherman ME, 2000, MODERN PATHOL, V13, P295, DOI 10.1038/modpathol.3880051; SOPER JT, 1984, AM J OBSTET GYNECOL, V150, P342, DOI 10.1016/S0002-9378(84)80135-0; SUTTON GP, 1986, OBSTET GYNECOL, V68, P709; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Zelmanowicz A, 1998, GYNECOL ONCOL, V69, P253, DOI 10.1006/gyno.1998.4941	31	51	55	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6965	6969		10.1038/sj.onc.1204809	http://dx.doi.org/10.1038/sj.onc.1204809			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687977				2022-12-28	WOS:000171641000019
J	Latonen, L; Taya, Y; Laiho, M				Latonen, L; Taya, Y; Laiho, M			UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts	ONCOGENE			English	Article						p53; HDM2; phosphorylation; UV-damage	TUMOR-SUPPRESSOR P53; PROTEASOME-MEDIATED DEGRADATION; DNA-DAMAGE; CELL-CYCLE; MDM2 GENE; ULTRAVIOLET-RADIATION; POTENTIAL MEDIATOR; DOUBLE MINUTE-2; GROWTH ARREST; FEEDBACK LOOP	We address here the effects of increasing fluencies of UV-radiation on stability, modifications, activity and HDM2-interactions of endogenous p53 tumor suppressor and on cellular damage response of human diploid fibroblasts. Low amounts of UVB/C-radiation induced a transient cell cycle arrest of the cells which correlated with rapid but transient increase in p53 levels. In contrast, high UV-fluency caused cell apoptosis and a slower but sustained increase in p53. Regulation of p53 target genes was highly dependent on the radiation dose used. Whereas low doses induced p21/Cip1/Waf1 and HDM2, high doses induced only GADD45 and BAX increasing the BAX:BCL-2 ratio. The levels of HDM2, a negative regulator of p53, increased only by the low dose of UVC and p53-HDM2 association was promoted. In the absence of HDM2-induction after the high dose of UV-radiation p53-HDM2-interaction was promoted, but HDM2 failed to downregulate p53. p53 site-specific modifications (Ser15, Ser33, Ser37, Lys382) varied kinetically and were dependent on the fluency of the radiation used. Maximal phosphorylation of p53 on Ser15 and Ser33 correlated with increased levels of HDM2-free p53. The results suggest that regulation of p53 and HDM2 by UV-radiation is highly dose-dependent and contributes to the outcome of the cellular response.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan	University of Helsinki; National Cancer Center - Japan	Laiho, M (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, POB 63, FIN-00014 Helsinki, Finland.	Marikki.Laiho@Helsinki.Fi	Latonen, Leena/C-8787-2016	Latonen, Leena/0000-0003-4502-2193				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barley RDC, 1998, ONCOGENE, V17, P533, DOI 10.1038/sj.onc.1202271; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Buschmann T, 2000, CANCER RES, V60, P896; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JUVEN T, 1993, ONCOGENE, V8, P3411; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Loignon M, 1997, CANCER RES, V57, P3390; Lu X, 1996, ONCOGENE, V13, P413; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; TYRRELL RM, 1994, MOL ASPECTS MED, V15, P3; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zhao RB, 2000, GENE DEV, V14, P981	54	105	109	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6784	6793		10.1038/sj.onc.1204883	http://dx.doi.org/10.1038/sj.onc.1204883			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709713				2022-12-28	WOS:000171551600015
J	Kim, SW; Kim, HJ; Jung, DJ; Lee, SK; Kim, YS; Kim, JH; Kim, TS; Lee, JW				Kim, SW; Kim, HJ; Jung, DJ; Lee, SK; Kim, YS; Kim, JH; Kim, TS; Lee, JW			Retinoid-dependent antagonism of serum response factor transactivation mediated by transcriptional coactivator proteins	ONCOGENE			English	Article						SRF; retinoids; transcription; coactivator; nuclear receptors	NUCLEAR HORMONE-RECEPTOR; THYROID-HORMONE; BINDING DOMAIN; CO-REPRESSOR; EXPRESSION; ELEMENT; GENE; ACTIVATION; INTERACTS; PROMOTER	Transcriptional coactivators SRC-1 and p300 specifically interact with liganded-nuclear receptors and also modulate other transcription factors, including serum response factor (SRF). Here, we report that retinoids repress transactivation by SRF and specific interactions exist between the DNA binding domains of SRF and retinoic acid and retinoid X receptors. We further demonstrate that the repression may involve retinoid-dependent competition for a limiting amount of SRC-I and p300 between SRF and retinoid receptors. We propose that the well-defined anti-proliferative action of retinoids could, at least in part, result from this novel transrepressive action on the mitogenic transcription factor SRF.	Pohang Univ Sci & Technol, Ctr Ligand & Transcript, Pohang 790784, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 506303, South Korea	Pohang University of Science & Technology (POSTECH); Chonnam National University; Salk Institute; Gwangju Institute of Science & Technology (GIST)	Lee, JW (corresponding author), Pohang Univ Sci & Technol, Ctr Ligand & Transcript, Pohang 790784, South Korea.		Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208; Kim, Seung-Whan/0000-0001-6983-0481				Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; BUSHEL P, 1995, ONCOGENE, V10, P1361; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; KIM JH, 1994, J BIOL CHEM, V269, P13740; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Moore DD, 1995, GLOB MOB SURV; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Slack J L, 1999, Curr Opin Hematol, V6, P236, DOI 10.1097/00062752-199907000-00007; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	27	12	12	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6638	6642		10.1038/sj.onc.1204695	http://dx.doi.org/10.1038/sj.onc.1204695			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641790				2022-12-28	WOS:000171404200018
J	Bannasch, D; Madge, B; Schwab, M				Bannasch, D; Madge, B; Schwab, M			Functional interaction of Yaf2 with the central region of MycN	ONCOGENE			English	Article						expression; immunofluorescence; MycN; protein-protein interactions; Yaf2; yeast two-hybrid	TRANSCRIPTION FACTOR YY1; C-MYC; NEUROBLASTOMA-CELLS; BINDING-PROTEIN; TRANSFORMATION; COMPLEX; GROWTH; NETWORK; VECTOR; NMI	MYCN is often amplified in advanced-stage neuroblastomas with the consequence of enhanced MycN protein expression. By employing the yeast two-hybrid system we found that Yaf2 binds to the central region of MycN. Binding was also seen in vitro and in vivo. Ectopically expressed Yaf2, like MycN, is localized in the nuclei of neuroblastoma cells. Endogenous Yaf2 is expressed in all three tested neuroblastoma cell lines, all of which also express MycN. Yaf2 was able to enhance MycN-mediated transactivation from an E-box promoter, deletion of the Yaf2 binding region in MycN abrogates this effect. Thus, the binding of Yaf2 to the central region of MycN is functional in mammalian cells.	Deutsch Krebsforschungszentrum, Div Cytogenet H0400, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Div Cytogenet H0400, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			Madge, Britta/0000-0002-5948-8552				Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bannasch D, 1999, PLASMID, V42, P139, DOI 10.1006/plas.1999.1413; Bao JX, 1996, ONCOGENE, V12, P2171; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; CHATTON B, 1995, BIOTECHNIQUES, V18, P5527; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Dang CV, 1999, MOL CELL BIOL, V19, P1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; Lutz W, 1996, ONCOGENE, V13, P803; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; SCHWAB M, 2000, PATHOLOGY GENETICS T, P153; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Tsai RYL, 1997, BIOTECHNIQUES, V23, P794, DOI 10.2144/97235bm06; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X	24	15	18	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5913	5919		10.1038/sj.onc.1204747	http://dx.doi.org/10.1038/sj.onc.1204747			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593398				2022-12-28	WOS:000171037200016
J	Falck, J; Lukas, C; Protopopova, M; Lukas, J; Selivanova, G; Bartek, J				Falck, J; Lukas, C; Protopopova, M; Lukas, J; Selivanova, G; Bartek, J			Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway	ONCOGENE			English	Article						DNA damage; cell cycle checkpoints; Chk2; p53; tumour suppressor	DNA-DAMAGE; S-PHASE; PRB/E2F PATHWAY; CELL-LINES; P53; CHECKPOINT; ATM; ACTIVATION; CANCER; PHOSPHORYLATION	Recent evidence identified a genetic and functional link between Chk2 kinase and p53 as a candidate genome integrity checkpoint and a tumour suppressor pathway. Here we report that in human cells, Chk2 and p53 form protein-protein complexes whose abundance increased upon DNA damage, and whose formation was abrogated through cancer associated mutations in the FHA domain of Chk2, or mutations in the tetramerization domain of p53. Whereas among Li-Fraumeni syndrome families mutations of Chk2 or p53 occur in a mutually exclusive manner, we document that the colon cancer cell line HCT-15 concomitantly lacks functions of both Chk2 and p53, the latter demonstrated by a non-invasive reporter assay monitoring p53-dependent transactivation in live cells. Despite the preserved ability of common cancer-derived mutant p53 proteins to bind and potentially 'titrate' activated Chk2, the integrity of the S phase checkpoint response to ionizing radiation remained largely intact and dependent on Chk2 in cells with wild-type, mutant, or no p53. These results provide new mechanistic insights into the Chk2-p53 interplay, suggest how mutations in Chk2 may abrogate its tumour suppressor function, and indicate that compared with individual defects in either Chk2 or p53, concomitant mutations in both of these cell cycle checkpoint regulators may provide some additional selective advantage to tumour cells.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Karolinska Inst, Canc Ctr Karolinska R8 04, Dept Oncol Pathol, S-17176 Stockholm, Sweden	Danish Cancer Society; Karolinska Institutet	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014	Selivanova, Galina/0000-0002-8698-4332; Lukas, Claudia/0000-0001-7169-6883; Lukas, Jiri/0000-0001-9087-506X				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; BARTEK J, 1990, ONCOGENE, V5, P893; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Haruki N, 2000, CANCER RES, V60, P4689; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meek DW, 2000, PATHOL BIOL, V48, P246; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; OConnor PM, 1997, CANCER RES, V57, P4285; Petrini JHJ, 2000, NAT GENET, V26, P257, DOI 10.1038/81529; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	31	96	97	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5503	5510		10.1038/sj.onc.1204811	http://dx.doi.org/10.1038/sj.onc.1204811			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571648				2022-12-28	WOS:000170781100011
J	Marquez, DC; Pietras, RJ				Marquez, DC; Pietras, RJ			Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells	ONCOGENE			English	Article						estrogen receptor; breast cancer; plasma membrane; MAP kinase; Akt kinase	ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; PLASMA-MEMBRANE; RECEPTOR-ALPHA; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; MCF-7 CELLS; FACTOR-I; ESTRADIOL; IDENTIFICATION	Membrane-associated binding sites for estrogen may mediate rapid effects of estradiol-17 beta that contribute to proliferation of human breast cancers. After controlled homogenization and fractionation of MCF-7 breast cancer cells, the bulk of specific estradiol binding is found in nuclear fractions. However, a significant portion of specific, high-affinity estradiol-17 beta binding-sites are also enriched in plasma membranes. These estradiol binding-sites co-purify with 5'-nucleotidase, a plasma membrane-marker enzyme, and are free from major contamination by cytosol or nuclei. Electrophoresis of membrane fractions allowed detection of a primary 67-kDa protein and a secondary 46-kDa protein recognized by estradiol-17 beta and by a monoclonal antibody directed to the ligand-binding domain of the nuclear form of estrogen receptor. Estrogen-induced growth of MCF-7 breast cancer cells in vitro was blocked by treatment with the antibody to estrogen receptor and correlated closely with acute hormonal activation of mitogen-activated protein kinase and Akt kinase signaling. Estrogen-promoted growth of human breast cancer xenografts in nude mice was also significantly reduced by treatment in vivo with the estrogen receptor antibody. Thus, membrane-associated forms of estrogen receptor may play a role in promoting intracellular signaling for hormone-mediated proliferation and survival of breast cancers and offer a new target for antitumor therapy.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pietras, RJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, 10833 Le Conte Ave,11-934 Factor Bldg, Los Angeles, CA 90095 USA.		Marquez-Garban, Diana/M-4660-2014	Marquez-Garban, Diana/0000-0002-7866-5323; Pietras, Richard/0000-0002-2846-3192				Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BERGERON JJM, 1986, BIOCHEMISTRY-US, V25, P1756, DOI 10.1021/bi00355a046; BERTHOIS Y, 1986, J STEROID BIOCHEM, V25, P963, DOI 10.1016/0022-4731(86)90330-4; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chen FH, 1999, J CELL BIOCHEM, V74, P430, DOI 10.1002/(SICI)1097-4644(19990901)74:3<430::AID-JCB11>3.0.CO;2-5; Chun TY, 1998, P NATL ACAD SCI USA, V95, P2325, DOI 10.1073/pnas.95.5.2325; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Fuqua SAW, 1999, CANCER RES, V59, P5425; GERMAIN PS, 1993, ANTICANCER RES, V13, P2347; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Gu Q, 1999, ENDOCRINOLOGY, V140, P660, DOI 10.1210/en.140.2.660; Hawkins MB, 2000, P NATL ACAD SCI USA, V97, P10751, DOI 10.1073/pnas.97.20.10751; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; HENDERSON BE, 1988, CANCER RES, V48, P246; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Levin ER, 1999, TRENDS ENDOCRIN MET, V10, P374, DOI 10.1016/S1043-2760(99)00192-7; Luconi M, 1999, J CLIN ENDOCR METAB, V84, P1670, DOI 10.1210/jc.84.5.1670; McKenna N, 2000, NAT MED, V6, P960, DOI 10.1038/79637; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Monje P, 1999, MOL CELL ENDOCRINOL, V147, P75, DOI 10.1016/S0303-7207(98)00212-3; MURDOCH FE, 1991, MOL CELL ENDOCRINOL, V78, pC103, DOI 10.1016/0303-7207(91)90114-8; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; NENCI I, 1981, J STEROID BIOCHEM, V14, P1139, DOI 10.1016/0022-4731(81)90043-1; Norfleet AM, 2000, FASEB J, V14, P157, DOI 10.1096/fasebj.14.1.157; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PIETRAS RJ, 1979, J STEROID BIOCHEM, V11, P1471, DOI 10.1016/0022-4731(79)90124-9; PIETRAS RJ, 1984, BIOCHEM BIOPH RES CO, V123, P84, DOI 10.1016/0006-291X(84)90383-8; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; PIETRAS RJ, 1975, NATURE, V253, P357, DOI 10.1038/253357a0; PIETRAS RJ, 1980, BIOCHEM J, V191, P743, DOI 10.1042/bj1910743; Ramirez VD, 1996, FRONT NEUROENDOCRIN, V17, P402, DOI 10.1006/frne.1996.0011; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Register TC, 1998, J STEROID BIOCHEM, V64, P187, DOI 10.1016/S0960-0760(97)00155-6; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; SICA V, 1973, NATURE-NEW BIOL, V244, P36, DOI 10.1038/newbio244036a0; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455; SZEGO CM, 1984, INT REV CYTOL, V88, P1, DOI 10.1016/S0074-7696(08)62759-X; SZEGO CM, 1967, P NATL ACAD SCI USA, V58, P1711, DOI 10.1073/pnas.58.4.1711; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Weiler PJ, 2000, BIOCHEM BIOPH RES CO, V272, P731, DOI 10.1006/bbrc.2000.2847; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WELSHONS WV, 1993, MOL CELL ENDOCRINOL, V94, P183, DOI 10.1016/0303-7207(93)90167-I; ZYZEK E, 1981, BIOCHEM BIOPH RES CO, V102, P1151, DOI 10.1016/S0006-291X(81)80132-5	57	138	144	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5420	5430		10.1038/sj.onc.1204729	http://dx.doi.org/10.1038/sj.onc.1204729			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571639				2022-12-28	WOS:000170781100002
J	Miralem, T; Steinberg, R; Price, D; Avraham, H				Miralem, T; Steinberg, R; Price, D; Avraham, H			VEGF(165) requires extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells	ONCOGENE			English	Article						VEGF; breast cancer; cell signaling; mitogenic response; cell migration	ENDOTHELIAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; PHOSPHATIDYLINOSITOL 3-KINASE; FIBROBLAST-GROWTH; TYROSINE KINASE; VEGF RECEPTORS; IV COLLAGEN; INHIBITING FACTORS; BINDING DOMAIN; HEPARIN	The expression of VEGF and the relapse-free survival rate of breast cancer patients are inversely related. While VEGF induces the proliferation and migration of vascular endothelial cells, its function in breast cancer cells is not well studied. We reported previously that fibronectin increased VEGF-dependent migration in breast cancer cells. Since VEGF has an extracellular matrix (ECTM)-binding domain and possesses binding affinity for heparin, we sought to determine the effects of VEGF in breast cancer cells and the role of heparin and/ or fibronectin in VEGF-induced signaling. Cells grown on plastic were compared to those grown on fibronectin or to those grown on plastic in the presence of heparin, and analysed for intracellular signaling, proliferation and migration in response to VEGF(165). Both heparin and fibronectin enhanced the binding of VEGF to T47D cells. After treatment with VEGF, [H-3]thymidine incorporation, c-fos induction, and the number of migrating cells were significantly higher (similar to twofold) in cells grown on fibronectin or in cells grown on plastic in the presence of heparin when compared to those grown on plastic only. Likewise, tyrosine phosphorylation of VEGF receptors, MAPK activity and PI3-kinase activity were all severalfold higher in cells seeded on fibronectin or in the presence of heparin as compared to cells exposed to VEGF alone. VEGF-dependent c-fos induction was found to be regulated through a MAPK-dependent, but PI3-kinase-independent pathway. In contrast, the migration of T47D cells in response to VEGF, in the presence of ECM, was regulated through PI3-kinase. Therefore, VEGF requires ECM components to induce a mitogenic response and cell migration in T47D breast cancer cells.	Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, H (corresponding author), Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	havraham@caregroup.harvard.edu	Mordwinkin, Nicholas M/A-4347-2010; Miralem, Tihomir/F-7576-2013	Avraham, Hava/0000-0002-7545-3640; Miralem, Tihomir/0000-0001-7705-0442	NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER; NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline; NIAMS NIH HHS [AR21 CA 87290-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; AHN NG, 1990, J BIOL CHEM, V265, P11487; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; BACIC M, 1995, GROWTH FACTORS, V12, P11, DOI 10.3109/08977199509003209; Blancher C, 2000, CANCER RES, V60, P7106; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; CHRISTIANSEN NO, 1992, ACTA BIOCHIM BIOPHYS, V26, P1; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; De Jong JS, 1998, J PATHOL, V184, P44; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; Derman MP, 1996, J BIOL CHEM, V271, P4251; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GRINNELL F, 1979, CELL, V17, P117, DOI 10.1016/0092-8674(79)90300-3; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HALPER J, 1990, EXP CELL RES, V187, P324, DOI 10.1016/0014-4827(90)90099-V; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; HICKS K, 1989, BIOCHEM BIOPH RES CO, V164, P1323, DOI 10.1016/0006-291X(89)91814-7; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JEANNY JC, 1987, EXP CELL RES, V171, P63, DOI 10.1016/0014-4827(87)90251-5; Joukov V, 1996, EMBO J, V15, P290; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livant DL, 2000, J CLIN INVEST, V105, P1537, DOI 10.1172/JCI8527; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Miralem T, 1996, J BIOL CHEM, V271, P17100, DOI 10.1074/jbc.271.29.17100; Miralem T, 1996, AM J PHYSIOL-RENAL, V270, pF960, DOI 10.1152/ajprenal.1996.270.6.F960; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; ORMEROD EJ, 1985, HISTOCHEM J, V17, P1155, DOI 10.1007/BF01002540; PAOLELLA G, 1988, NUCLEIC ACIDS RES, V16, P3545, DOI 10.1093/nar/16.8.3545; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1981, J BIOL CHEM, V256, P7277; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Shahan TA, 1999, CONNECT TISSUE RES, V40, P221, DOI 10.3109/03008209909005285; Shahan TA, 1999, CANCER RES, V59, P4584; SHIBUYA M, 1999, CURR TOP MICROBIOL, P237; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Speirs V, 1999, BRIT J CANCER, V80, P898, DOI 10.1038/sj.bjc.6690438; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TEMPLETON DM, 1992, CRIT REV CL LAB SCI, V29, P141, DOI 10.3109/10408369209114599; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshiji H, 1996, CANCER RES, V56, P2013; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	80	51	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5511	5524		10.1038/sj.onc.1204753	http://dx.doi.org/10.1038/sj.onc.1204753			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571649	Bronze			2022-12-28	WOS:000170781100012
J	Claudio, J; Zhu, YX; Benn, SJ; Shukla, AH; McGlade, CJ; Falcioni, N; Stewart, AK				Claudio, J; Zhu, YX; Benn, SJ; Shukla, AH; McGlade, CJ; Falcioni, N; Stewart, AK			HACS1 encodes a novel SM-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells	ONCOGENE			English	Article						myeloma; adaptor protein; hematopoietic; SAM domain; SH3 domain	TYROSINE KINASE; HUMAN LEUKEMIA; FUSION; TEL; ACTIVATION; FAMILY; DOMAIN; GENE	SH3 and SAM domains are protein interaction motifs that are predominantly seen in signaling molecules, adaptors, and scaffold proteins. We have identified a novel family of putative adaptor genes that includes HACS1. HACS1 encodes a 441 amino acid protein that is differentially expressed in hematopoietic cells and has restricted expression in human tissues. Its SH3 domain is most similar to the same motif in Crk and its SAM domain shares homology with a family of uncharacterized putative scaffold and adaptor proteins. HACS1 maps to human chromosome 21q11.2 in a region that is frequently disrupted by translocation events in hematopoietic malignancies. Polyclonal antibodies against HACS1 recognized a 49.5 kDa protein whose mRNA is expressed in human immune tissues, bone marrow, heart, lung, placenta and brain. Cell lines and primary cells from acute myeloid leukemias and multiple myeloma patients express HACS1. Immunostaining and cellular fractionation studies localized the HACS1 protein predominantly to the cytoplasm.	Toronto Gen Res Inst, Toronto, ON, Canada; Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Canadian Blood Serv, Toronto Ctr, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Canadian Blood Services	Stewart, AK (corresponding author), Princess Margaret Hosp, 610 Univ Ave,Room 5-126, Toronto, ON M5G 2M9, Canada.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Claudio JO, 1998, GENOMICS, V50, P44, DOI 10.1006/geno.1998.5308; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sheng M, 2000, J CELL SCI, V113, P1851; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876	17	48	50	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5373	5377		10.1038/sj.onc.1204698	http://dx.doi.org/10.1038/sj.onc.1204698			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536050				2022-12-28	WOS:000170575500013
J	Turenne, GA; Paul, P; Laflair, L; Price, BD				Turenne, GA; Paul, P; Laflair, L; Price, BD			Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53	ONCOGENE			English	Article						ATM; p53; chk2; phosphorylation; bleomycin	DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; PROTEIN-KINASE; DEPENDENT PHOSPHORYLATION; CHECKPOINT PATHWAY; CELLULAR-RESPONSE; IN-VITRO; CDS1	The ATM protein kinase regulates the cell's response to DNA damage by regulating cell cycle checkpoints and DNA repair. ATM phosphorylates several proteins involved in the DNA-damage response, including p53. We have examined the mechanism by which ATM regulates p53's transcriptional activity. Here, we demonstrate that reintroduction of ATM into AT cells restores the activation of p53 by the radio-mimetic agent bleomycin. Further, p53 activation is lost when a kinase inactive ATM is used. or if the N-terminal of ATM is deleted. In addition, AT cells stably expressing ATM showed decreased sensitivity to Ionizing Radiation-induced cell killing, whereas cells expressing kinase inactive ATM or N-terminally deleted ATM were indistinguishable from AT cells. Finally, single point-mutations of serines 15, 20, 33 or 37 did not individually block the ATM-dependent activation of p53 transcriptional activity by bleomycin. However, double mutations of either serines 15 and 20 or serines 33 and 37 blocked the ability of ATM to activate p53. Our results indicate that the N-terminal of ATM and ATM's kinase activity are required for activation of p53's transcriptionl activity and restoration of normal sensitivity to DNA damage. In addition, activation of p53 by ATM requires multiple serine residues in p53's transactivation domain.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St,D810A, Boston, MA 02115 USA.	brendan_price@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA064585] Funding Source: NIH RePORTER; NCI NIH HHS [CA64585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEBAB NH, 1999, P NATL ACAD SCI USA, V96, P13777; CHEBAB NH, 2000, GENE DEV, V14, P278; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hess RD, 1997, ONCOGENE, V15, P2501, DOI 10.1038/sj.onc.1201404; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jung M, 1997, INT J RADIAT ONCOL, V37, P417, DOI 10.1016/S0360-3016(96)00500-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kohli M, 1999, BIOCHEM BIOPH RES CO, V257, P168, DOI 10.1006/bbrc.1999.0389; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo CM, 1996, J BIOL CHEM, V271, P4497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; NAGASAWA H, 1994, INT J RADIAT BIOL, V66, P373, DOI 10.1080/09553009414551311; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; ONeill FJ, 1997, ONCOGENE, V14, P955, DOI 10.1038/sj.onc.1200913; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sheppard HM, 1999, ANTICANCER RES, V19, P2079; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TISHLER RB, 1993, CANCER RES, V53, P2212; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WEICHSELBAUM RR, 1978, NATURE, V271, P261, DOI 10.1038/271261a0; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	62	75	79	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5100	5110		10.1038/sj.onc.1204665	http://dx.doi.org/10.1038/sj.onc.1204665			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526498				2022-12-28	WOS:000170464000003
J	Burns, TF; Bernhard, EJ; El-Deiry, WS				Burns, TF; Bernhard, EJ; El-Deiry, WS			Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo	ONCOGENE			English	Article						p53; apoptosis; gamma irradiation; KILLER/DR5; c-FLIP-s; real-time RT-PCR	RADIATION-INDUCED APOPTOSIS; DAMAGE-INDUCED APOPTOSIS; DEFICIENT MICE; CYTOCHROME-C; DEATH; ACTIVATION; INHIBITION; PROTEIN; TRAIL; CELLS	The p53 tumor suppressor plays a key role in the cell's response to genotoxic stress and loss of this 'guardian of the genome' is an important step in carcinogenesis. The ability of p53 to induce apoptosis through transactivation of its target genes is critical for its function as tumor suppressor. We have found that overexpression of p53 in human cancer cell lines resulted in apoptosis as measured by PARP cleavage. Furthermore we observed cleavage of both caspase 9 and caspase 8 after overexpression of p53 and found that p53-dependent apoptosis was inhibited by either cellular (c-Flip-s, BCI-X-L) or pharmacological inhibitors of caspase 8 or caspase 9 respectively. These results indicate that p53 is mediating apoptosis through both the mitochondrial and death receptor pathways. To elucidate the relevant p53 target genes and examine the caspase pathways utilized in vivo, we treated p53+/+ and age matched p53-/- mice with 5 Gy ionizing radiation or 0.5 mg/animal dexamethasone and harvested tissues at 0, 6 and 24 h. We examined the mRNA expression of p21, bax, KILLER/DR5, FAS/APO1 and EI24/PIG8 using TaqMan real time quantitative RT-PCR in the spleen, thymus and small intestine. Although the basal mRNA levels of these genes did not depend on the presence of p53, we observed a p53-dependent induction of all these targets in response to gamma -radiation and a p53-independent regulation for p21 and KILLER/DR5 in response to dexamethasone. Furthermore, we have demonstrated that the relative induction of these p53 target genes is tissue specific. Despite observing otherwise similar levels of death in these tissues, our findings suggest that in some cases apoptosis mediated through p53 occurs by redundant pathways or by a 'group effect' while in other tissues one or few targets may play a key role in p53-dependent apoptosis. Surprisingly, KILLER/DR5 is the dominantly induced transcript in both the spleen and small intestine suggesting a potentially important role for this p53 target gene in vivo.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020; BERNHARD, ERIC/HIU-0025-2022	El-Deiry, Wafik/0000-0002-9577-8266; 	NATIONAL CANCER INSTITUTE [R01CA075454, P01CA075138] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75138, CA 75454] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Fuchs EJ, 1997, CANCER RES, V57, P2550; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KASTAN MB, 1991, CANCER RES, V51, P6304; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lee SH, 1999, CANCER RES, V59, P5683; Lehar SM, 1996, ONCOGENE, V12, P1181; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Meng RD, 1998, CLIN CANCER RES, V4, P251; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Ozoren N, 2000, CANCER RES, V60, P6259; Pai SI, 1998, CANCER RES, V58, P3513; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhao RB, 2000, GENE DEV, V14, P981; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	54	113	118	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4601	4612		10.1038/sj.onc.1204484	http://dx.doi.org/10.1038/sj.onc.1204484			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498783				2022-12-28	WOS:000170208600001
J	Little, NA; Jochemsen, AG				Little, NA; Jochemsen, AG			Hdmx and Mdm2 can repress transcription activation by p53 but not by p63	ONCOGENE			English	Article						p53; p63; Mdmx; Mdm2; transcriptional activation	PROTEIN; HOMOLOG; P73; DEGRADATION; ONCOPROTEIN; PRODUCTS; MUTANTS; LIGASE; LIMB	The p53 protein is involved in cell cycle arrest and apoptosis. To ensure that cells under non-stressed conditions are able to grow, p53 sets up a negative feedback loop by inducing Mdm2. Mdm2 is able to both inhibit the transcriptional regulation by p53 and to degrade it, thus maintaining p53 inactive until it is required. The Mdm2 related protein, Hdmx, has also been shown to inhibit the transcriptional activation of p53 but is unable to degrade it. A few years ago, the p53 family member, p63 was identified. Like p53, p63 is able to induce p53 target genes and it was shown to be able to cause cell cycle arrest and apoptosis. In this study we report that, despite the similarities between p53 and p63, neither Hdmx nor Mdm2 are able to interact with p63, to repress p63-induced transcription or to affect its half-life.	Leiden Univ, Med Ctr, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Dept Mol & Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.	a.g.jochemsen@lumc.nl						Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lee LA, 1999, J INVEST DERMATOL, V113, P146, DOI 10.1046/j.1523-1747.1999.00651.x; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shimada A, 1999, CANCER RES, V59, P2781; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2000, J BIOL CHEM, V275, P28039; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van der Eb A J, 1980, Methods Enzymol, V65, P826; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	36	53	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4576	4580		10.1038/sj.onc.1204615	http://dx.doi.org/10.1038/sj.onc.1204615			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494153				2022-12-28	WOS:000170074900015
J	Drynan, LF; Hamilton, TL; Rabbitts, TH				Drynan, LF; Hamilton, TL; Rabbitts, TH			T cell tumorigenesis in Lmo2 transgenic mice is independent of V-D-J recombinase activity	ONCOGENE			English	Article						chromosomal translocation; leukaemia; T cells; T-ALL	LIM-PROTEIN RBTN2; HUMAN CD2 GENE; CHROMOSOMAL TRANSLOCATIONS; RAG-1-DEFICIENT MICE; EXPRESSION; LEUKEMIA; COMPLEX; TAL1; SCL; DIFFERENTIATION	The LMO2 gene is involved in T-cell acute leukaemia (T-ALL) in children with chromosomal translocations t(11;14)(p13;q11) or (7;11)(q35;p13). Transgenic expression of Lmo2 in T cells results in clonal tumours with long latency indicating that mutations in other genes are required for the development of overt tumours, RAG V-D-J recombinase can mediate genetic transposition and thus might create the secondary mutations necessary for T-ALL. Tumour development was compared in Lmo2 transgenic mice in the presence or absence of the Rag1 gene, No difference was observed in the rate of tumour formation nor in tumour histology in Lmo2-transgenic mice with or without Rag1. We conclude that, in this model, RAG recombinase is not a major mediator of mutations needed for T cell tumorigenesis and that antigen binding to alpha-beta or to gamma-delta T cell receptor does not play a role in tumorigenesis, The driving force behind the mutational process involved in this transgenic model remains obscure.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Drynan, Lesley/V-2984-2019; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Chervinsky DS, 1999, MOL CELL BIOL, V19, P5025; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FISCH P, 1992, ONCOGENE, V7, P2389; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEALE GAM, 1995, BLOOD, V86, P3060; Neale Geoffrey A. M., 1997, Leukemia (Basingstoke), V11, P289; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Rabbitts TH, 1999, CANCER RES, V59, p1794S; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; SHINKAI Y, 1992, CELL, V68, P885; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Valge-Archer V, 1998, ONCOGENE, V17, P3199, DOI 10.1038/sj.onc.1202353; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145	31	7	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4412	4415		10.1038/sj.onc.1204538	http://dx.doi.org/10.1038/sj.onc.1204538			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466623				2022-12-28	WOS:000169912600016
J	Zhang, YW; Morita, I; Ikeda, M; Ma, KW; Murota, S				Zhang, YW; Morita, I; Ikeda, M; Ma, KW; Murota, S			Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27	ONCOGENE			English	Article						gap junction; connexin 43; tumor suppressive effect; p27; Rb; cell cycle	JUNCTIONAL INTERCELLULAR COMMUNICATION; ANTI-HYPOXIA/REOXYGENATION AGENTS; VEIN ENDOTHELIAL-CELLS; TYROSINE KINASE; GROWTH-CONTROL; TRANSFORMED-CELLS; GAP-JUNCTIONS; NEOPLASTIC PHENOTYPE; EPITHELIAL-CELLS; GENE-EXPRESSION	Many lines of evidence indicate that connexin genes expressing gap junction (GJ) proteins inhibit tumor cell proliferation. However, the precise molecular mechanisms remain unclear, In this study, we show that overexpression of connexin43 (Cx43) suppressed proliferation of human osteosarcoma U2OS cells through inhibition of the cell cycle transition from G1 to S phase. This inhibition was attributed to a significant accumulation of the hypophosphorylated retinoblastoma (Rb) protein, which was causally related to decreases in the kinase activities of cyclin-dependent kinases (CDKs) 2 and 4, Enforced Cx43 expression markedly increased the level of the CDK inhibitor p27, This increase resulted from an increased synthesis and a reduced degradation of the p27 proteins, but not influence of the p27 mRNA, Moreover, we show that the Cx43-modulated GJ function was the main contributor to the elevation in p27 levels, in which cAMP was involved. These data suggest that Cx43 appears to inhibit proliferation of U2OS cells by increasing the levels of p27 proteins via post-transcriptional regulatory mechanisms.	Tokyo Med & Dent Univ, Dept Cellular Physiol Chem, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Sect Mol Embryol, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Morita, I (corresponding author), Tokyo Med & Dent Univ, Dept Cellular Physiol Chem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRADSHAW SL, 1993, GROWTH REGULAT, V3, P26; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHEN SC, 1995, CELL GROWTH DIFFER, V6, P681; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FITZGERALD DJ, 1990, TERATOGEN CARCIN MUT, V10, P89; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Huang RP, 1998, CANCER RES, V58, P5089; Kandel ER, 2000, BRAIN RES REV, V32, P3, DOI 10.1016/S0165-0173(99)00062-4; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Koffler L, 2000, J CELL BIOCHEM, V79, P347, DOI 10.1002/1097-4644(20001201)79:3<347::AID-JCB10>3.0.CO;2-2; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MARTIN W, 1991, CANCER RES, V51, P5348; Martyn KD, 1997, CELL GROWTH DIFFER, V8, P1015; Mehta PP, 1996, MOL CARCINOGEN, V15, P18, DOI 10.1002/(SICI)1098-2744(199601)15:1<18::AID-MC4>3.0.CO;2-O; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MESNIL M, 1995, CANCER RES, V55, P629; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; Proulx AA, 1997, CELL GROWTH DIFFER, V8, P533; Rae RS, 1998, MOL CARCINOGEN, V22, P120, DOI 10.1002/(SICI)1098-2744(199806)22:2<120::AID-MC7>3.0.CO;2-Q; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Statuto M, 1997, J BIOL CHEM, V272, P24710, DOI 10.1074/jbc.272.39.24710; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; TROSKO JE, 1993, LIFE SCI, V53, P1, DOI 10.1016/0024-3205(93)90606-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamasaki H, 1999, CR ACAD SCI III-VIE, V322, P151, DOI 10.1016/S0764-4469(99)80038-9; Yamasaki H, 1995, MUTAT RES-FUND MOL M, V333, P181, DOI 10.1016/0027-5107(95)00144-1; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang YW, 2000, PLANTA MED, V66, P119, DOI 10.1055/s-2000-11126; Zhang YW, 2000, PLANTA MED, V66, P114, DOI 10.1055/s-2000-11128; Zhang YW, 1999, PROSTAG LEUKOTR ESS, V61, P33, DOI 10.1054/plef.1999.0070; Zhang YW, 1999, J CELL PHYSIOL, V180, P305, DOI 10.1002/(SICI)1097-4652(199909)180:3<305::AID-JCP1>3.0.CO;2-Z; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	45	106	113	1	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4138	4149		10.1038/sj.onc.1204563	http://dx.doi.org/10.1038/sj.onc.1204563			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464280				2022-12-28	WOS:000169857200004
J	Goodman, PA; Wood, CM; Vassilev, A; Mao, C; Uckun, FM				Goodman, PA; Wood, CM; Vassilev, A; Mao, C; Uckun, FM			Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia	ONCOGENE			English	Article; Proceedings Paper	42nd Annual Meeting of the American-Society-of-Hematology	DEC 01-05, 2000	SAN FRANCISCO, CA	Amer Soc Hematol		pro-B cell; B-cell ontogeny; SYK; exon skipping; acute lymphoblastic leukemia	CHILDRENS CANCER GROUP; SEVERE COMBINED IMMUNODEFICIENCY; MOLECULAR-CLONING; CLINICAL-SIGNIFICANCE; RECEPTOR STIMULATION; MEDIATED ACTIVATION; IKAROS ISOFORMS; MESSENGER-RNA; SH2 DOMAINS; PROTEIN	The cytoplasmic spleen tyrosine kinase (SYK) is a key regulator of signal transduction events, apoptosis and orderly cell cycle progression in B-lineage lymphoid cells, Although SYK has not been linked to a human disease, defective expression of the closely related T-cell tyrosine kinase ZAP-70 has been associated with severe combined immunodeficiency. Childhood CD19(+)CD10(-) pro-B cell acute lymphoblastic leukemia (ALL) is thought to originate from B-cell precursors with a maturational arrest at the pro-B cell stage and it is associated with poor prognosis, Since lethally irradiated mice reconstituted with SYK-deficient fetal liver-derived lymphohematopoietic progenitor cells show a block in B-cell ontogeny at the pro-B to pre-B cell transition, we examined the SYK expression profiles of primary leukemic cells from children with pro-B cell ALL, Here we report that leukemic cells from pediatric CD19(+)CD10(-) pro-B cell ALL patients (but not leukemic cells from patients with CD19(+)CD10(+) common pre-pre-B cell ALL) have markedly reduced SYK activity, Sequencing of the reverse transcriptase-polymerase chain reaction (RT-PCR) products of the Syk mRNA in these pro-B leukemia cells revealed profoundly aberrant coding sequences with deletions or insertions, These mRNA species encode abnormal SYK proteins with a missing or truncated catalytic kinase domain, In contrast to pro-B leukemia cells, pre-pre-B leukemia cells from children with CD19+CD10+ common B-lineage ALL and EBV-transformed B-cell lines from healthy volunteers expressed wild-type Syk coding sequences, Examination of the genomic structure of the Syk gene by inter-exonic PCR and genomic cloning demonstrated that the deletions and insertions in the abnormal mRNA species of pro-B leukemia cells are caused by aberrant splicing resulting in either missplicing, exon skipping or inclusion of alternative exons, consistent with an abnormal posttranscriptional regulation of alternative splicing of Syk pre-mRNA, Our findings link for the first time specific molecular defects involving the Syk gene to an immunophenotypically distinct category of childhood ALL, To our knowledge, this is the first discovery of a specific tyrosine kinase deficiency in a human hematologic malignancy.	Parker Hughes Inst, Dept Mol Oncol, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Mol Genet, St Paul, MN 55113 USA; Parker Hughes Canc Ctr, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Biochem, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Biol Struct, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Parker Hughes Inst, Dept Mol Oncol, St Paul, MN 55113 USA.	fatih_uckun@mercury.ih.org		Uckun, Fatih M./0000-0001-9334-183X				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BRUNGER AT, 1992, X PLOR VERSION 3 1; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Chen T, 1996, J BIOL CHEM, V271, P25308, DOI 10.1074/jbc.271.41.25308; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GULBINS E, 1994, J IMMUNOL, V152, P2123; HARADA H, 1994, ONCOGENE, V9, P3313; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Latour S, 1998, EMBO J, V17, P2584, DOI 10.1093/emboj/17.9.2584; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Law CL, 1996, MOL CELL BIOL, V16, P1305; LAW CL, 1994, J BIOL CHEM, V269, P12310; Li HL, 1997, J BIOL CHEM, V272, P18200, DOI 10.1074/jbc.272.29.18200; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; Owen MJ, 1996, CURR OPIN IMMUNOL, V8, P191, DOI 10.1016/S0952-7915(96)80057-4; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERLMUTTER RM, 1994, NATURE, V370, P249, DOI 10.1038/370249a0; Qin SF, 1998, FEBS LETT, V427, P139, DOI 10.1016/S0014-5793(98)00383-4; Reaman GH, 1999, J CLIN ONCOL, V17, P445, DOI 10.1200/JCO.1999.17.2.445; ROWLEY RB, 1995, J BIOL CHEM, V270, P12659, DOI 10.1074/jbc.270.21.12659; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tamiya S, 1998, BLOOD, V91, P3935; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Trigg ME, 1996, CANC MED, P2945; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; Uckun FM, 1997, LEUKEMIA LYMPHOMA, V27, P445, DOI 10.3109/10428199709058311; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; Uckun FM, 1998, BLOOD, V92, P810; Uckun FM, 1997, BLOOD, V89, P2488; Uckun FM, 1998, J CLIN ONCOL, V16, P527, DOI 10.1200/JCO.1998.16.2.527; YAGI S, 1994, BIOCHEM BIOPH RES CO, V200, P28, DOI 10.1006/bbrc.1994.1409; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7	52	50	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					3969	3978		10.1038/sj.onc.1204515	http://dx.doi.org/10.1038/sj.onc.1204515			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494125				2022-12-28	WOS:000169681500005
J	Liu, BL; Fan, Z				Liu, BL; Fan, Z			The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway	ONCOGENE			English	Article						apoptosis; caspase; TNF receptor family; EGF receptor; monoclonal antibody	EPIDERMAL GROWTH-FACTOR; FAS-MEDIATED APOPTOSIS; CYTOCHROME-C RELEASE; ANTICANCER DRUGS; CD95 FAS/APO-1; DEATH DOMAIN; CANCER-CELLS; G(1) ARREST; LIGAND; FADD	We previously reported that the anti-epidermal growth factor (EGF) receptor monoclonal antibody (mAb) 225 induces DiFi colon cancer cells to undergo apoptosis, and this apoptosis was accompanied by activation of the two apoptosis initiation caspases, caspase-8 and caspase-9, In the current study, we found that pretreatment of DiFi cells with the caspase-8-specific inhibitor z-IETD-fmk but not pretreatment with the caspase-9-specific inhibitor z-LEHD-fmk inhibited mAb 225-induced apoptosis, indicating that caspase-8 plays an essential role in initiating mAb 225-induced apoptosis, Because caspase-8 is activated primarily by the members of the tumor necrosis factor (TNF) receptor family, such as Fas, TNF receptor-1 (TNFR1), or receptors for TNF-related apoptosis-inducing ligand (TRAIL), we investigated whether mAb 225 activated caspase-8 by regulating one or more of these known pathways, Exposure of DiFi cells to TNF alpha or TRAIL activated caspase-8 and induced apoptosis in the cells. A TNFR1-antagonistic mAb or a TRAIL decoy receptor inhibited the activation of caspase-8 and the subsequent apoptosis induced by TNF alpha or TRAIL, respectively, in the cells. However, neither the TNFR1-antagonistic mAb nor the TRAIL decoy receptor inhibited mAb 225-induced activation of caspase-8 and apoptosis in DiFi cells, DiFi cells express detectable level of Fas but are not sensitive to the treatment by the Fas-agonistic mAb CH-II, A Fas-antagonistic mAb (ZB-4) inhibited the Fas-agonistic mAb CH-ll-induced caspase-8 activation and apoptosis in Jurkat T-leukemic cells (used as positive control), but had no effect on mAb 225-induced activation of caspase-8 and apoptosis in DiFi cells. Taken together, our results suggest that mAb 225 does not interact with or regulate these known death receptor pathways, An exploration is therefore warranted for a novel mechanism by which mAb 225 activates caspase-8 and triggers apoptosis in DiFi cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 36,1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Bantel H, 1999, CANCER RES, V59, P2083; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1993, CANCER RES, V53, P4637; FAN Z, 1994, J BIOL CHEM, V269, P27595; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Fellenberg J, 1997, INT J CANCER, V72, P536, DOI 10.1002/(SICI)1097-0215(19970729)72:3<536::AID-IJC25>3.0.CO;2-8; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Liu B, 2000, BRIT J CANCER, V82, P1991; Liu BL, 2001, ONCOGENE, V20, P1913, DOI 10.1038/sj.onc.1204277; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MENDELSOHN J, 1999, P AN M AM SOC CLIN, V18, pA389; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Milas L, 2000, CLIN CANCER RES, V6, P701; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Peng D, 1996, CANCER RES, V56, P3666; PEREZSOLER R, 1998, P AN M AM SOC CLIN, V17, pA393; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sato J D, 1983, Mol Biol Med, V1, P511; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ungefroren H, 1998, CANCER RES, V58, P1741; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wu XP, 1996, ONCOGENE, V12, P1397; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5	63	35	36	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3726	3734		10.1038/sj.onc.1204490	http://dx.doi.org/10.1038/sj.onc.1204490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439335				2022-12-28	WOS:000169400200013
J	Bacon, AL; Farrington, SM; Dunlop, MG				Bacon, AL; Farrington, SM; Dunlop, MG			Mutation frequency in coding and non-coding repeat sequences in mismatch repair deficient cells derived from normal human tissue	ONCOGENE			English	Article						TGFBR2; mutation rate; BAX; mismatch repair; colon cancer	GROWTH-FACTOR-BETA; II RECEPTOR GENE; MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; INACTIVATION; PROTEIN; BAX; HEREDITARY; EXPRESSION; CANCERS	Repetitive tracts within the coding regions of TGFBR2 and BAX are frequently mutated in mismatch repair deficient tumours and are implicated in tumour progression. However, there has been little study of the balance between selection pressure and inherent instability at sequences within these genes. To determine whether TGFBR2 and BAX are inherently prone to mutations in the presence of MMR defects, we studied MMR deficient cells derived from B-lymphocytes. By analysing cells derived from normal tissue we aimed to minimize the effects of selection pressures that bias the apparent frequency of mutation. We definitively show that certain sequences, usually repaired by MMR, are inherently unstable. Using a small pool PCR technique we confirmed these cells exhibit microsatellite instability. Additionally, we demonstrate that MMR deficiency results in an excess of mutations, specifically at the poly(A)(10) tract compared to other regions of the TGFBR2 gene (P < 0.001). Conversely, an excess of mutations does not appear to arise at the poly(G)(8) tract of the BAX gene. These studies provide insight into the mechanism by which TGFBR2 and BAX genes become mutated during tumorigenesis. These findings invoke the notion of 'unmasking' specific hypermutable sequences in particular genes adding further complexity to the concept of the imitator phenotype.	Western Gen Hosp, Colon Canc Genet Grp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Dept Oncol, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Dunlop, MG (corresponding author), Western Gen Hosp, Colon Canc Genet Grp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	Malcolm.Dunlop@hgu.mrc.ac.uk	Dunlop, Malcolm G/F-1973-2011; Farrington, Susan M/C-7319-2013; Farrington, Susan M/Q-2710-2019	Dunlop, Malcolm G/0000-0002-3033-5851; Farrington, Susan M/0000-0001-5955-7389				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589; Bacon AL, 2000, HUM MOL GENET, V9, P2707, DOI 10.1093/hmg/9.18.2707; BACON AL, 2001, IN PRESS NUCL ACIDS; Boland CR, 1998, CANCER RES, V58, P5248; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Carethers JM, 2000, IN VIVO, V14, P13; Dietmaier W, 1997, CANCER RES, V57, P4749; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Grady WM, 1998, CANCER RES, V58, P3101; Grady WM, 1999, CANCER RES, V59, P320; Inman GJ, 2000, J GEN VIROL, V81, P1567, DOI 10.1099/0022-1317-81-6-1567; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Lu SL, 1996, CANCER RES, V56, P4595; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mironov N, 1999, CARCINOGENESIS, V20, P2189, DOI 10.1093/carcin/20.11.2189; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; Ouyang H, 1997, CANCER RES, V57, P1851; Papadopoulos N, 1997, HUM MUTAT, V10, P89, DOI 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.3.CO;2-K; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1995, CANCER RES, V55, P5548; Pedroni M, 2001, CANCER RES, V61, P896; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; Vilkki S, 2001, CANCER RES, V61, P4541; WANG CY, 1995, CANCER RES, V55, P5101; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Zhang L, 2001, CANCER RES, V61, P3801	30	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7464	7471		10.1038/sj.onc.1204973	http://dx.doi.org/10.1038/sj.onc.1204973			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709717				2022-12-28	WOS:000171976900002
J	Werner, S; Beer, HD; Mauch, C; Luscher, B; Werner, S				Werner, S; Beer, HD; Mauch, C; Luscher, B; Werner, S			The Mad1 transcription factor is a novel target of activin and TGF-beta action in keratinocytes: possible role of Mad1 in wound repair and psoriasis	ONCOGENE			English	Article						Mad; Myc; wound; epidermis; keratinocyte; psoriasis	GROWTH-FACTOR-BETA; TRANSGENIC MICE REVEALS; MYC ANTAGONIST MAD1; C-MYC; EPIDERMAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; HISTONE DEACETYLASE; MYC/MAX/MAD NETWORK; NUCLEOTIDE-SEQUENCE; CELL-LINE	Activin A, a member of the transforming growth factor beta (TGF-beta) superfamily, affects keratinocyte proliferation and differentiation in vitro and in vivo. However, little is known about the mechanisms of activin action in keratinocytes, and its target genes have not been identified. In this study, we demonstrate that activin A and TGF-beta1 directly induce the expression and activity of Mad1, an antagonist of the c-Myc transcription factor, in the human HaCaT keratinocyte cell line. Expression and activity of Mad1 was strongly induced by both factors in keratinocytes, although the intensity of induction was different for activin A and TGF-beta1. To determine a possible role of activin and TGF-beta1 in the regulation of mad1 expression in vivo, we analysed its expression during cutaneous wound repair when high levels of these factors are present. Expression of mad1 mRNA and protein, but not of other mad genes, increased significantly after skin injury, particularly in polymorphonuclear leukocytes and in suprabasal keratinocytes of the hyperproliferative epithelium. Elevated levels of mad1 mRNA were also detected in the hyperthickened epidermis of psoriatic patients. Since Mad1 regulates proliferation and/or differentiation of various cell types, our results suggest that this transcription factor mediates at least in the part the anti-mitotic and/or differentiation-inducing activities of TGF-beta and activin in keratinocytes.	ETH Zurich Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Cologne, Dept Dermatol & Venerol, D-50924 Cologne, Germany; Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Cologne; Hannover Medical School	Werner, S (corresponding author), ETH Zurich Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland.	Sabine.werner@cell.biol.ethz.ch	Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709; Beer, Hans-Dietmar/0000-0002-8085-713X; Werner, Sabine/0000-0001-7397-8710				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK RAF, 1996, MOL BIOL WOUND REPAI, P195; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; Gehring S, 2000, J BIOL CHEM, V275, P10413, DOI 10.1074/jbc.275.14.10413; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; Hubner G, 1996, DEV BIOL, V173, P490, DOI 10.1006/dbio.1996.0042; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; LARSSON LG, 1994, ONCOGENE, V9, P1247; Lymboussaki A, 1996, BRIT J CANCER, V73, P1347, DOI 10.1038/bjc.1996.257; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MASSAGUE J, 1990, ANN REV CELL BIOL, V6, P1; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; Munz B, 1997, J INVEST DERMATOL, V108, P307, DOI 10.1111/1523-1747.ep12286470; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Queva C, 1999, CELL GROWTH DIFFER, V10, P785; Queva C, 2001, MOL CELL BIOL, V21, P703, DOI 10.1128/MCB.21.3.703-712.2001; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Seishima M, 1999, J INVEST DERMATOL, V112, P432, DOI 10.1046/j.1523-1747.1999.00558.x; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; Werner S, 2000, EXP CELL RES, V254, P80, DOI 10.1006/excr.1999.4726; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	51	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7494	7504		10.1038/sj.onc.1204937	http://dx.doi.org/10.1038/sj.onc.1204937			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709721				2022-12-28	WOS:000171976900006
J	Cassinat, B; Chomienne, C				Cassinat, B; Chomienne, C			Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management	ONCOGENE			English	Article						APL blasts; differentiation; granulopoiesis; retinoids; RARa gene rearrangements	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; PML-RAR-ALPHA; INDUCED GRANULOCYTIC DIFFERENTIATION; COLONY-STIMULATING FACTOR; HISTONE DEACETYLASE; MYELOID-LEUKEMIA; RECEPTOR-ALPHA; CELLS; GENE	In recent years, discovery of the in vitro and in giro differentiation of APL blasts by all-trans retinoic acid (ATRA) has modified the therapeutic approach of APL and lead to important advances in understanding the biology of APL. Since it became apparent that differentiation therapy of APL with ATRA was indeed a true model of targetted therapy, evidencing the molecular targets of retinoic acid efficacy became crucial. These molecular targets are closely related to the biological features of APL cells, some of which are well-known and have contributed to the morphological and cytogenetic definition of the leukemia, others have just been defined or re-discovered in the light of a better understanding of molecular controls of cell growth and differentiation. The aims of characterizing the biological features of APL cells should allow a better management of APL therapy and the identification of potential markers for differentiation therapies in other leukemias or solid tumors.	Hop St Louis, Inst Hematol, Lab Biol Cellulaire Hematopoiet, INSERM E 00 03, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chomienne, C (corresponding author), Hop St Louis, Inst Hematol, Lab Biol Cellulaire Hematopoiet, INSERM E 00 03, 1 Ave Claude Vellefaux, F-75010 Paris, France.		CASSINAT, BRUNO/N-2752-2017	CASSINAT, BRUNO/0000-0002-6514-3905; CHOMIENNE, Christine/0000-0001-5513-5752				AGADIR A, 1995, J CLIN ONCOL, V13, P2517, DOI 10.1200/JCO.1995.13.10.2517; AGADIR A, 1995, BIOCHEM BIOPH RES CO, V213, P112, DOI 10.1006/bbrc.1995.2105; Allford S, 1999, BRIT J HAEMATOL, V105, P198; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Belaaouaj A, 1999, MAMM GENOME, V10, P210; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Calabresse C, 1995, LEUKEMIA, V9, P2049; Cassinat B, 1998, BLOOD, V92, p596A; CASSINAT B, 2001, IN PRESS BLOOD; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANG KS, 1992, BLOOD, V79, P1802; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; CHOMIENNE C, 1990, BLOOD, V76, P1710; Chomienne C, 1996, FASEB J, V10, P1025, DOI 10.1096/fasebj.10.9.8801163; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; Da Silva N, 2000, Hematol J, V1, P316, DOI 10.1038/sj.thj.6200047; De Botton S, 1998, BLOOD, V92, P2712, DOI 10.1182/blood.V92.8.2712.420k03_2712_2718; de Botton S, 2000, BRIT J HAEMATOL, V111, P801, DOI 10.1046/j.1365-2141.2000.02442.x; DEGENTILE A, 1994, LEUKEMIA, V8, P1758; DELVA L, 1993, BLOOD, V82, P2175; Delva L, 1999, MOL CELL BIOL, V19, P7158; Ding W, 1998, BLOOD, V92, P1172, DOI 10.1182/blood.V92.4.1172.416k02_1172_1183; DOMBRET H, 1993, LEUKEMIA, V7, P2; Douer D, 2001, BLOOD, V97, P73, DOI 10.1182/blood.V97.1.73; DUBOIS C, 1994, LEUKEMIA, V8, P1750; DUBOIS C, 1994, BLOOD, V83, P3264; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Exner M, 2000, CYTOMETRY, V42, P106, DOI 10.1002/(SICI)1097-0320(20000415)42:2<106::AID-CYTO3>3.0.CO;2-S; Fenaux P, 1999, BLOOD, V94, P1192, DOI 10.1182/blood.V94.4.1192.416k07_1192_1200; Ferrara F, 2000, J CLIN ONCOL, V18, P1295, DOI 10.1200/JCO.2000.18.6.1295; Foley R, 2001, AM J HEMATOL, V67, P34, DOI 10.1002/ajh.1073; GALLAGHER RE, 1995, BLOOD, V86, P1540, DOI 10.1182/blood.V86.4.1540.bloodjournal8641540; Garattini E, 1996, LEUKEMIA LYMPHOMA, V23, P493, DOI 10.3109/10428199609054858; GJERTSEN MK, 1995, LANCET, V346, P1399, DOI 10.1016/S0140-6736(95)92408-6; GRIGNANI F, 1994, BLOOD, V83, P10; Grimwade D, 2000, BLOOD, V96, P1297; Guglielmi C, 1998, BRIT J HAEMATOL, V102, P1035, DOI 10.1046/j.1365-2141.1998.00871.x; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hsu HC, 1999, EUR J HAEMATOL, V63, P11; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; JURCIC JG, 1995, LEUKEMIA, V9, P244; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; Launay S, 1999, BLOOD, V93, P4395, DOI 10.1182/blood.V93.12.4395.412k06_4395_4405; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; Miyauchi J, 1997, BLOOD, V90, P803, DOI 10.1182/blood.V90.2.803.803_803_813; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; MUINDI J, 1992, BLOOD, V79, P299; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; Neame PB, 1997, AM J HEMATOL, V56, P131, DOI 10.1002/(SICI)1096-8652(199711)56:3<131::AID-AJH1>3.0.CO;2-Z; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Novick S, 1999, BLOOD, V94, p61A; PAIETTA E, 1994, LEUKEMIA, V8, P1108; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Parrado A, 2000, Hematol J, V1, P15, DOI 10.1038/sj.thj.6200012; Pollock JL, 2000, BLOOD, V96, p827A; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; Sainty D, 2000, BLOOD, V96, P1287; Seale J, 1996, LEUKEMIA, V10, P95; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Slack JL, 1997, J CLIN ONCOL, V15, P1786, DOI 10.1200/JCO.1997.15.5.1786; Slack JL, 1998, BLOOD, V91, P3347, DOI 10.1182/blood.V91.9.3347.3347_3347_3356; Thomas X, 2000, LEUKEMIA, V14, P1006, DOI 10.1038/sj.leu.2401800; TOSI P, 1994, LEUKEMIA LYMPHOMA, V14, P503, DOI 10.3109/10428199409049711; Wang ZG, 1998, SCIENCE, V279, P1547; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	83	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7154	7160		10.1038/sj.onc.1204761	http://dx.doi.org/10.1038/sj.onc.1204761			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704844				2022-12-28	WOS:000171891900004
J	Negorev, D; Maul, GG				Negorev, D; Maul, GG			Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot	ONCOGENE			English	Article						ND10; PML; Daxx; Sp100; nuclear bodies; protein interaction	ACUTE PROMYELOCYTIC LEUKEMIA; CREB-BINDING-PROTEIN; RNA-POLYMERASE-II; IMMORTALIZED HUMAN-CELLS; NEOPLASTIC HUMAN TISSUES; PML PROTEIN; SERINE/THREONINE KINASE; COVALENT MODIFICATION; VIRUS-REPLICATION; GROWTH-SUPPRESSOR	ND10, PML bodies or PODS have become the defining nuclear structure for a highly complex protein complement involved in cell activities such as aging, apoptosis, the cell cycle, stress response, hormone signaling, transcriptional regulation and development. ND10 are present in many but not all cell types and are not essential for cell survival. Here, we review the cellular proteins found in ND10, their few known interactions and their contribution to the ND10 structure per se and to functions elsewhere in the nucleus. The discrepancy between the functions of the ND10 proteins and the nonessential nature of the structure in which they are aggregated at their highest concentrations leads to the conclusion that the proteins function elsewhere. The regulated recruitment of specific proteins into ND10 as well as their controlled release upon external induced stress points to a regulated nuclear depot function for ND10. These nuclear depot functions seem important as nuclear defense against viral attack and other external insults.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Maul, GG (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.							Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Bell P, 2000, J VIROL, V74, P5329, DOI 10.1128/JVI.74.11.5329-5336.2000; BELL P, 2001, IN PRESS J VIROL; BERNHARD W, 1969, J ULTRA MOL STRUCT R, V27, P250, DOI 10.1016/S0022-5320(69)80016-X; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Boddy MN, 1996, ONCOGENE, V13, P971; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Bond U, 2000, INT J BIOCHEM CELL B, V32, P643, DOI 10.1016/S1357-2725(00)00008-X; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; Cao TY, 1998, J CELL SCI, V111, P1319; Carlile GW, 1998, BIOCHEM J, V335, P691, DOI 10.1042/bj3350691; Cho YM, 1998, INT J MOL MED, V1, P717; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; DANIEL MT, 1993, BLOOD, V82, P1858; de The G., 1960, B ASSOC FR ETUD CANC, V47, P570; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Everett RD, 1999, J CELL SCI, V112, P3443; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; Fabunmi RP, 2001, J CELL SCI, V114, P29; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gambacorta M, 1996, AM J PATHOL, V149, P2023; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; GOODSON ML, 2001, J BIOL CHEM, V15, P15; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HINGLAISGUILLAU.N, 1961, B CANCER, V48, P282; Hsu WL, 2001, J VIROL, V75, P3819, DOI 10.1128/JVI.75.8.3819-3831.2001; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Ishov AM, 1997, J CELL BIOL, V138, P5, DOI 10.1083/jcb.138.1.5; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Jiang WQ, 1996, EXP CELL RES, V229, P289, DOI 10.1006/excr.1996.0374; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Lai HK, 2000, ONCOGENE, V19, P1623, DOI 10.1038/sj.onc.1203473; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LAM YW, 1995, EXP CELL RES, V221, P344, DOI 10.1006/excr.1995.1384; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lombard DB, 2000, CANCER RES, V60, P2331; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; Maul GG, 1998, CELL GROWTH DIFFER, V9, P743; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Negorev D, 2001, J CELL SCI, V114, P59; OCHS RL, 1995, MOL BIOL CELL, V6, P345, DOI 10.1091/mbc.6.3.345; PADYKULA HA, 1981, ANAT RECORD, V201, P679, DOI 10.1002/ar.1092010412; Plehn-Dujowich D, 2000, CHROMOSOMA, V109, P266, DOI 10.1007/s004120000073; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; REGAD T, 2001, IN PRESS EMBO J; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; Ruthardt M, 1998, ONCOGENE, V16, P1945, DOI 10.1038/sj.onc.1201722; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Tang QY, 2000, J VIROL, V74, P9694, DOI 10.1128/JVI.74.20.9694-9700.2000; Tokutake Y, 1998, BIOCHEM BIOPH RES CO, V247, P765, DOI 10.1006/bbrc.1998.8876; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Trost M, 2000, J BIOL CHEM, V275, P7373, DOI 10.1074/jbc.275.10.7373; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yeager TR, 1999, CANCER RES, V59, P4175; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	95	227	230	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7234	7242		10.1038/sj.onc.1204764	http://dx.doi.org/10.1038/sj.onc.1204764			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704851				2022-12-28	WOS:000171891900011
J	Clarke, P; Meintzer, SM; Spalding, AC; Johnson, GL; Tyler, KL				Clarke, P; Meintzer, SM; Spalding, AC; Johnson, GL; Tyler, KL			Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection	ONCOGENE			English	Article						apoptosis; TRAIL; reovirus; caspase 8; chemotherapy	INFLUENZA-VIRUS INFECTION; NECROSIS-FACTOR-ALPHA; TUMORICIDAL ACTIVITY; SIGNALING PATHWAY; DEATH RECEPTORS; MOLECULAR-BASIS; LIGAND; EXPRESSION; ACTIVATION; MODULATION	TRAIL (TNF-related apoptosis-inducing ligand) induces apoptosis in susceptible cells by binding to death receptors 4 (DR4) and 5 (DR5). TRAIL preferentially induces apoptosis in transformed cells and the identification of mechanisms by which TRAIL-induced apoptosis can be enhanced may lead to novel cancer chemotherapeutic strategies. Here we show that reovirus infection induces apoptosis in cancer cell lines derived from human breast, lung and cervical cancers. Reovirus-induced apoptosis is mediated by TRAIL and is associated with the release of TRAIL from infected cells. Reovirus infection synergistically and specifically sensitizes cancer cell lines to killing by exogenous TRAIL. This sensitization both enhances the susceptibility of previously resistant cell lines to TRAIL-induced apoptosis and reduces the amount of TRAIL needed to kill already sensitive lines. Sensitization is not associated with a detectable change in the expression of TRAIL. receptors in reovirus-infected cells. Sensitization is associated with an increase in the activity of the death receptor-associated initiator caspase. caspase 8, and is inhibited by the peptide IETD-fmk, suggesting that reovirus sensitizes cancer cells to TRAIL-induced apoptosis in a caspase 8-dependent manner. Reovirus-induced sensitization of cells to TRAIL is also associated with increased cleavage of PARP, a substrate of the effector caspases 3 and 7.	Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med Microbiol & Immunol, Denver, CO 80262 USA; Denver Vet Affairs Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Tyler, KL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Neurol B 182, 4200 E 9th Ave, Denver, CO 80262 USA.		Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014071] Funding Source: NIH RePORTER; NIA NIH HHS [1RO1AG14071] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Conaldi PG, 1998, J CLIN INVEST, V102, P2041, DOI 10.1172/JCI3480; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; DeBiasi RL, 2001, J VIROL, V75, P351, DOI 10.1128/JVI.75.1.351-361.2001; Debiasi RL, 1999, J VIROL, V73, P695, DOI 10.1128/JVI.73.1.695-701.1999; DUKE RC, 1992, CURRENT PROTOCOLS IM; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Jelachich ML, 2001, J VIROL, V75, P5930, DOI 10.1128/JVI.75.13.5930-5938.2001; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kaplan D, 1998, J VIROL, V72, P6279, DOI 10.1128/JVI.72.8.6279-6282.1998; Keane MM, 1999, CANCER RES, V59, P734; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Oberhaus SM, 1997, J VIROL, V71, P2100, DOI 10.1128/JVI.71.3.2100-2106.1997; OBERHAUS SM, 1998, CURRENT TOPICS MICRO, V233; Ozoren N, 2000, CANCER RES, V60, P6259; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rayet B, 1998, J VIROL, V72, P8893, DOI 10.1128/JVI.72.11.8893-8903.1998; Sedger LM, 1999, J IMMUNOL, V163, P920; Sieg S, 1996, J VIROL, V70, P8747, DOI 10.1128/JVI.70.12.8747-8751.1996; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TAKIZAWA T, 1995, VIROLOGY, V209, P288, DOI 10.1006/viro.1995.1260; TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; TYLER KL, 1985, NEUROLOGY, V35, P88, DOI 10.1212/WNL.35.1.88; Tyler KL, 1996, J VIROL, V70, P7984, DOI 10.1128/JVI.70.11.7984-7991.1996; TYLER KL, 1995, J VIROL, V69, P6972, DOI 10.1128/JVI.69.11.6972-6979.1995; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang GH, 1997, J VIROL, V71, P8928, DOI 10.1128/JVI.71.11.8928-8932.1997; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yu R, 2000, CANCER RES, V60, P2384; Zhang XD, 1999, CANCER RES, V59, P2747	43	51	54	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6910	6919		10.1038/sj.onc.1204842	http://dx.doi.org/10.1038/sj.onc.1204842			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687970				2022-12-28	WOS:000171641000012
J	Tarapore, P; Tokuyama, Y; Horn, HF; Fukasawa, K				Tarapore, P; Tokuyama, Y; Horn, HF; Fukasawa, K			Difference in the centrosome duplication regulatory activity among p53 'hot spot' mutants: potential role of Ser 315 phosphorylation-dependent centrosome binding of p53	ONCOGENE			English	Article						centrosome duplication; cancer; p53; CDK2; phosphorylation	TRANSCRIPTIONAL ACTIVATION; GENOMIC INSTABILITY; EMBRYO FIBROBLASTS; CYCLIN-E; HYPERAMPLIFICATION; MUTATIONS; CANCER; MICE; CDK2; P21	The p53 tumor suppressor protein regulates centrosome duplication through multiple pathways, and p21(Waf1/Cip1) (Waf1), a major target of p53's transactivation function, has been shown to be one of the effectors. However, it had been unclear whether the p53's Waf1-independent centrosome duplication regulatory pathways require its transactivation function. In human cancers, specific residues of p53 are mutated at a high frequency. These 'hot spot' mutations abrogate p53's transactivation function. If p53 regulates centrosome duplication in a transactivation-independent manner, different 'hot spot' mutants may regulate centrosome duplication differently. To test this, we examined the effect of two 'hot spot' mutants (R175H and R249S) for their centrosome duplication regulatory activities. We found that R175H lost the ability to regulate centrosome duplication, while R249S partially retained it. Moreover, R249S associates with both unduplicated and duplicated centrosomes similar to wild-type p53, while R175H only associates with duplicated, but not unduplicated centrosomes. Since cyclin-dependent kinase 2 (CDK2) triggers initiation of centrosome duplication, and p53 is phosphorylated on Ser 315 by CDK2, we examined the p53 mutants with a replacement of Ser 315 to Ala (A) and Asp (D), both of which retain the transactivation function. We found that S315D retained a complete centrosome duplication activity, while S315A only partially retained it. Moreover, S315D associates with both unduplicated and duplicated centrosomes, while S315A associates with only duplicated, but not unduplicated centrosomes. Thus, p53 controls the centrosome duplication cycle both in transactivation-dependent and transactivation-independent manners, and the ability to bind to unduplicated centrosomes, which is controlled by phosphorylation on Ser 315, may be important for the overall p53-mediated regulation of centrosome duplication.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	Kenji.Fukasawa@uc.edu	Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Horn, Henning/0000-0002-5885-8996	NCI NIH HHS [CA90522] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AHNEN DJ, 1992, J CELL BIOCHEM, P143; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bates S, 1999, MOL CARCINOGEN, V24, P7, DOI 10.1002/(SICI)1098-2744(199901)24:1<7::AID-MC2>3.0.CO;2-5; BORNENS M, 1992, KALNINS, V6, P2; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge RM, 1998, BREAST CANCER RES TR, V52, P79, DOI 10.1023/A:1006163101948; FUCHS B, 1995, ONCOGENE, V10, P789; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KIKUCHIYANOSHITA R, 1995, ONCOGENE, V11, P1339; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 2000, CURR TOP DEV BIOL, V49, P235; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mowat MRA, 1998, ADV CANCER RES, V74, P25, DOI 10.1016/S0065-230X(08)60764-2; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nylander K, 2000, J ORAL PATHOL MED, V29, P413, DOI 10.1034/j.1600-0714.2000.290901.x; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ozen H, 2000, CURR OPIN ONCOL, V12, P255, DOI 10.1097/00001622-200005000-00012; PRICE BD, 1995, ONCOGENE, V11, P73; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; VET JAM, 1994, WORLD J UROL, V12, P84; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; WILLIAMS NN, 1990, SURG GYNECOL OBSTET, V171, P257; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	59	44	45	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6851	6863		10.1038/sj.onc.1204848	http://dx.doi.org/10.1038/sj.onc.1204848			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687964				2022-12-28	WOS:000171641000006
J	Marotta, A; Tan, C; Gray, V; Malik, S; Gallinger, S; Sanghera, J; Dupuis, B; Owen, D; Dedhar, S; Salh, B				Marotta, A; Tan, C; Gray, V; Malik, S; Gallinger, S; Sanghera, J; Dupuis, B; Owen, D; Dedhar, S; Salh, B			Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis	ONCOGENE			English	Article						intestinal polyposis; integrin-linked kinase (ILK); non-steroidal anti-inflammatory drugs (NSAIDs); adenomatous polyposis coli (APC); beta-catenin	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTATE-CANCER CELLS; CYCLIN D1 GENE; BETA-CATENIN; PROTEIN-KINASE; CYCLOOXYGENASE-2 INHIBITOR; ANTICANCER AGENTS; SULINDAC SULFIDE; UP-REGULATION; APC	Mutation of the adenomatous polyposis coli (APC) gene and the subsequent dysregulation of beta -catenin are well-documented abnormalities in familial adenomatous polyposis (FAP), as well as sporadic polyposis. Intriguingly, overexpression of the integrin-linked kinase (ILK) has been shown to modulate beta -catenin subcellular localization and function. However, the significance of this finding for human carcinogenesis remains unclear. Here, we report the increased biochemical activity and expression of ILK protein in polyps from FAP patients. Furthermore, dramatic increases in ILK immunoreactivity were observed in all abnormal crypts from sporadic polyps, when compared with the normal appearing crypts within the same resected specimens. As sulindac and aspirin are the two most important therapeutic/chemopreventative agents demonstrated in colorectal carcinogenesis, in both humans and animals, further investigation revealed that these non-steroidal antiinflammatory drugs (NSAIDs) target ILK and ILK-mediated events in vivo. These include inhibition of, both the biochemical activation of ILK, inhibition of serine 9 GSK3 beta phosphorylation and the enhancement of TCF-4 transcriptional activity. In conclusion, ILK protein hyperexpression appears to be an early event in colonic polyposis. Additionally, ILK signaling is shown to undergo modulation by sulindac (and aspirin) for the first time, indicating that it is likely to be one of the targets affected by these agents in vivo.	Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Thunderbay Reg Hosp, Thunder Bay, ON P7E 1G6, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6PA, Canada; Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of British Columbia	Salh, B (corresponding author), Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		Gallinger, Steven/E-4575-2013	Dedhar, Shoukat/0000-0003-4355-1657				Akashi H, 2000, INT J CANCER, V88, P873, DOI 10.1002/1097-0215(20001215)88:6<873::AID-IJC6>3.0.CO;2-B; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Barker N, 2000, ADV CANCER RES, V77, P1; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chiu CH, 1997, CANCER RES, V57, P4267; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OConnor PM, 1997, CANCER RES, V57, P4285; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Reddy BS, 1996, CANCER RES, V56, P4566; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Salh B, 1999, ANTICANCER RES, V19, P731; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sparks AB, 1998, CANCER RES, V58, P1130; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	45	68	74	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6250	6257		10.1038/sj.onc.1204791	http://dx.doi.org/10.1038/sj.onc.1204791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593435				2022-12-28	WOS:000171206300018
J	Bartkova, J; Falck, J; Rajpert-De Meyts, E; Skakkebaek, NE; Lukas, J; Bartek, J				Bartkova, J; Falck, J; Rajpert-De Meyts, E; Skakkebaek, NE; Lukas, J; Bartek, J			Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours	ONCOGENE			English	Article						cell cycle checkpoints; Chk2; spermatogenesis; carcinoma in situ; testicular germ-cell tumours	DNA-DAMAGE RESPONSE; P53 PROTEIN; MEIOTIC CHROMOSOMES; ATM; CHECKPOINT; CANCER; KINASE; LINE; MICE; DIFFERENTIATION	Chk2 is a transducer of DNA damage signals and a tumour suppressor whose germ-line mutations predispose to diverse tumour types. Unlike its downstream targets such as the p53 tumour suppressor, the expression patterns of Chk2 in tissues and tumours remain unknown. As DNA breaks occur commonly during gametogenesis, and p53 is wild-type and overexpressed in testicular cancer, we examined abundance and localisation of the Chk2 protein during normal development of human testes, and at various stages of germ-cell tumour (GCT) pathogenesis. Our results show that Chk2 is abundant in foetal germ cells and adult spermatogonia, yet only weakly expressed or lacking during the meiotic and later stages of spermatogenesis. High levels of Chk2 are detected in the majority of GCTs including all preinvasive carcinoma-in-situ lesions, contrary to variable expression and even lack of Chk2 in subsets of invasive GCTs and some teratoma structures, respectively. Together with our analyses of cell culture models, these results indicate that downmodulation or lack of Chk2 is not simply attributable to quiescence or differentiation, they suggest a role for Chk2 in mitotic rather than meiotic divisions, support the concept of foetal origin of GCTs, and have implications for protein-based screening for tumour-associated aberrations of Chk2.	Inst Canc Biol, Danish Canc Soc, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Rigshospitalet; University of Copenhagen	Bartek, J (corresponding author), Inst Canc Biol, Danish Canc Soc, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014; Rajpert-De Meyts, Ewa/H-6526-2019	Rajpert-De Meyts, Ewa/0000-0002-5946-7559; Lukas, Jiri/0000-0001-9087-506X				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; Bartkova J, 2000, ONCOGENE, V19, P4146, DOI 10.1038/sj.onc.1203769; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; Bartkova J, 2000, INT J CANCER, V85, P370, DOI 10.1002/(SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO;2-A; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chehab NH, 2000, GENE DEV, V14, P278; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; Grigor KM, 1998, APMIS, V106, P221, DOI 10.1111/j.1699-0463.1998.tb01339.x; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Shieh SY, 2000, GENE DEV, V14, P289; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603	30	57	60	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5897	5902		10.1038/sj.onc.1204746	http://dx.doi.org/10.1038/sj.onc.1204746			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593395				2022-12-28	WOS:000171037200013
J	Pandolfi, PP				Pandolfi, PP			In vivo analysis of the molecular genetics of acute promyelocytic leukemia	ONCOGENE			English	Article						APL; cancer; transgenic mice; KO mice; animal models; transcription factors	ACID RECEPTOR-ALPHA; PML-RAR-ALPHA; TRANSFORMED-CELL DIFFERENTIATION; ZINC FINGER GENE; RETINOIC ACID; TRANSGENIC MICE; HISTONE DEACETYLASE; DNA-BINDING; TRANSCRIPTIONAL REGULATION; T(15-17) TRANSLOCATION	Acute promyelocytic leukemia (APL) is a distinct and paradigmatic subtype of myeloid leukemia associated with reciprocal chromosomal translocations always involving the Retinoic Acid Receptor alpha (RAR alpha) gene on chromosome 17 and variable partner genes (X genes) on different chromosomes. As a consequence of these translocations X-RAR alpha and RAR alpha -X fusion genes are generated. RAR alpha fuses to the PML gene in the vast majority of APL cases, and in a few cases to the PLZF, NPM, NuMA and STAT5b genes respectively. In the last few years, the functions of these aberrant fusion proteins and of the normal gene products involved in these translocations have been extensively characterized in vivo in transgenic and KO animal models. Here we will review the important conclusions, the novel questions and paradoxes that stem from this analysis.	Cornell Univ, Program Mol Biol, Dept Pathol, Sloan Kettering Div,Grad Sch Med Sci, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Program Mol Biol, Dept Pathol, Sloan Kettering Div,Grad Sch Med Sci, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org						ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 1997, BLOOD, V90, P4876; Grimwade D, 1996, BRIT J HAEMATOL, V94, P557; GRISOLANO JL, 1994, P NATL ACAD SCI USA, V91, P8989, DOI 10.1073/pnas.91.19.8989; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gudas Lorraine J., 1994, P443; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kogan SC, 2000, BLOOD, V95, P1541, DOI 10.1182/blood.V95.5.1541.005k28_1541_1550; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; LAFAGEPOCHITALOFF M, 1995, BLOOD, V85, P1169, DOI 10.1182/blood.V85.5.1169.1169; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li YP, 1997, BLOOD, V90, P306; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Salomoni P, 2000, NAT MED, V6, P742, DOI 10.1038/77459; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	58	44	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5726	5735		10.1038/sj.onc.1204600	http://dx.doi.org/10.1038/sj.onc.1204600			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607822				2022-12-28	WOS:000170887500013
J	Khoo, SK; Bradley, M; Wong, FK; Hedblad, MA; Nordenskjold, M; Teh, BT				Khoo, SK; Bradley, M; Wong, FK; Hedblad, MA; Nordenskjold, M; Teh, BT			Birt-Hogg-Dube syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2	ONCOGENE			English	Article						skin tumors; renal tumors; Birt-Hogg-Dube syndrome; linkage analysis	MULTIPLE; ACROCHORDONS; FIBROFOLLICULOMAS; TRICHODISCOMAS; KINASE	Birt-Hogg-Dube syndrome (BHD) is an autosomal dominant neoplasia syndrome characterized mainly by benign skin tumors, and to a lesser extent, renal tumors and spontaneous pneumothorax. To map the BHD locus, we performed a genome-wide linkage analysis using polymorphic microsatellite markers on a large Swedish BHD family. Evidence of linkage was identified on chromosome 17p12-q11.2, with a maximum LOD score of 3.58 for marker D17S1852. Further haplotype analysis defined a similar to 35 cm candidate interval between the two flanking markers, D17S1791 and D17S798. This information will facilitate the identification of the BHD gene, leading to the understanding of its underlying molecular etiology.	Karolinska Inst, Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden; Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Karolinska Inst, Karolinska Hosp, Dept Dermatol & Venereol, S-10401 Stockholm, Sweden; Karolinska Inst, Karolinska Hosp, Dept Clin Genet, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Van Andel Institute; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Nordenskjold, M (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden.			Khoo, Sok Kean/0000-0003-3836-5497; Teh, Bin Tean/0000-0003-1514-1124; Bradley, Maria/0000-0001-7192-5041; Nordenskjold, Magnus/0000-0002-4974-425X				BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; Chung JY, 1996, INT J DERMATOL, V35, P365, DOI 10.1111/j.1365-4362.1996.tb03642.x; De la Torre C, 1999, AM J DERMATOPATH, V21, P369, DOI 10.1097/00000372-199908000-00011; FOUCAR K, 1981, CUTIS, V28, P429; Haimowitz JE, 1997, ARCH DERMATOL, V133, P1163, DOI 10.1001/archderm.133.9.1163; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MORENO A, 1985, DERMATOLOGICA, V171, P338, DOI 10.1159/000249448; RONGIOLETTI F, 1989, CLIN EXP DERMATOL, V14, P72, DOI 10.1111/j.1365-2230.1989.tb00890.x; ROTH JS, 1993, J AM ACAD DERMATOL, V29, P1055, DOI 10.1016/S0190-9622(08)82049-X; Schulz T, 1999, J CUTAN PATHOL, V26, P55, DOI 10.1111/j.1600-0560.1999.tb01792.x; STARINK TM, 1985, ARCH DERMATOL, V121, P888, DOI 10.1001/archderm.121.7.888; STARINK TM, 1987, J AM ACAD DERMATOL, V17, P493, DOI 10.1016/S0190-9622(87)70235-7; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; Toro JR, 1999, ARCH DERMATOL, V135, P1195, DOI 10.1001/archderm.135.10.1195; WEINTRAUB R, 1977, J CUTAN PATHOL, V4, P289, DOI 10.1111/j.1600-0560.1977.tb00920.x	17	120	121	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5239	5242		10.1038/sj.onc.1204703	http://dx.doi.org/10.1038/sj.onc.1204703			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526515				2022-12-28	WOS:000170464000020
J	Birch, JM; Alston, RD; McNally, RJQ; Evans, DGR; Kelsey, AM; Harris, M; Eden, OB; Varley, JM				Birch, JM; Alston, RD; McNally, RJQ; Evans, DGR; Kelsey, AM; Harris, M; Eden, OB; Varley, JM			Relative frequency and morphology of cancers in carriers of germline TP53 mutations	ONCOGENE			English	Article						germline TP53 mutations; cancer frequency; cancer predisposition	LI-FRAUMENI-SYNDROME; TUMOR-SUPPRESSOR GENE; P53 MUTATIONS; BREAST-CANCER; FAMILY SYNDROME; ADRENOCORTICAL CARCINOMA; YOUNG-CHILDREN; PRONE FAMILIES; OSTEOSARCOMA; SARCOMA	The spectrum and frequency of cancers associated with germline TP53 mutations are uncertain. To address this issue a cohort of individuals from 28 families with Li-Fraumeni syndrome, segregating germline TP53 mutations was established. Predicted cancers were estimated by applying age, morphology, site and sex-specific UK cancer statistics to person-years at risk. Observed and predicted cancers were compared and two-sided P-values calculated. Cancer types occurring to excess and showing P-values <0.02, were designated strongly associated with germline TP53 mutations. These were removed from the data and a second round of analyses performed. Cancer types with P-values <0.02 and 0.02-0.05 in the second round analyses were considered moderately and weakly associated respectively. Strongly associated cancers were: breast carcinoma, soft tissue sarcomas, osteosarcoma, brain tumours, adrenocortical carcinoma, Wilms' tumour and phyllodes tumour. Carcinoma of pancreas was moderately associated. Leukaemia and neuroblastoma were weakly associated. Other common carcinomas including lung, colon, bladder, prostate, cervix and ovary did not occur to excess. Although breast carcinoma and sarcomas were numerically most frequent, the greatest increases relative to general population rates were in adrenocortical carcinoma and phyllodes tumour. We conclude that germline TP53 mutations do not simply increase general cancer risk. There are tissue-specific effects.	Royal Manchester Childrens Hosp, CRC, Paediat & Familial Canc Res Grp, Manchester M27 4HA, Lancs, England; Royal Manchester Childrens Hosp, Dept Pathol, Manchester M27 4HA, Lancs, England; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Pathol, Acad Unit Paediat Oncol, Manchester M20 4BX, Lancs, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Canc Genet Grp, Manchester M20 4BX, Lancs, England	Royal Manchester Children's Hospital; Royal Manchester Children's Hospital; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Birch, JM (corresponding author), Royal Manchester Childrens Hosp, CRC, Paediat & Familial Canc Res Grp, Hosp Rd, Manchester M27 4HA, Lancs, England.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784; McNally, Richard/0000-0001-6685-6467				Ayan I, 1997, ONCOL REP, V4, P679; BERNSTEIN L, 1993, CANCER-AM CANCER SOC, V71, P3020, DOI 10.1002/1097-0142(19930515)71:10<3020::AID-CNCR2820711022>3.0.CO;2-G; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1994, CANCER RES, V54, P1298; BOL FJ, 1998, DIAGN MOL PATHOL, V7, P295; BORRESEN AL, 1992, CANCER RES, V52, P3234; BRUGIERES L, 1993, CANCER RES, V53, P452; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; Evans SC, 1998, HUM GENET, V102, P681, DOI 10.1007/s004390050761; FREBOURG T, 1995, AM J HUM GENET, V56, P608; Goi K, 1997, CANCER RES, V57, P1895; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; HARTLEY AL, 1993, CANCER GENET CYTOGEN, V67, P133, DOI 10.1016/0165-4608(93)90166-J; HARTLEY AL, 1987, J MED GENET, V24, P664, DOI 10.1136/jmg.24.11.664; Huusko P, 1999, CANCER GENET CYTOGEN, V112, P9, DOI 10.1016/S0165-4608(98)00258-1; JOLLY KW, 1994, ONCOGENE, V9, P97; Kleihues P, 1997, AM J PATHOL, V150, P1; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LI FP, 1988, CANCER RES, V48, P5358; Li YJ, 1995, INT J CANCER, V64, P383, DOI 10.1002/ijc.2910640606; LUBBE J, 1995, BRAIN PATHOL, V5, P15, DOI 10.1111/j.1750-3639.1995.tb00572.x; LYNCH HT, 1990, ONCOLOGY-BASEL, V47, P75; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Malkin D, 1997, NEW ENGL J MED, V336, P734, DOI 10.1056/NEJM199703063361018; MAZOYER S, 1994, ONCOGENE, V9, P1237; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; Nichols KE, 2001, CANCER EPIDEM BIOMAR, V10, P83; Pivnick EK, 1998, J MED GENET, V35, P328, DOI 10.1136/jmg.35.4.328; PORTER DE, 1992, J BONE JOINT SURG BR, V74, P883; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; Rines RD, 1998, CARCINOGENESIS, V19, P979, DOI 10.1093/carcin/19.6.979; RUSSO CL, 1994, MED PEDIATR ONCOL, V23, P354, DOI 10.1002/mpo.2950230407; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; Varley JM, 1999, AM J HUM GENET, V65, P995, DOI 10.1086/302575; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Varley JM, 2001, ONCOGENE, V20, P2647, DOI 10.1038/sj.onc.1204369; Verselis SJ, 2000, ONCOGENE, V19, P4230, DOI 10.1038/sj.onc.1203758; Vital A, 1998, J NEUROPATH EXP NEUR, V57, P1061, DOI 10.1097/00005072-199811000-00009; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707; Wang Q, 1996, INT J CANCER, V65, P554; Zhou XP, 1999, ANN NEUROL, V46, P913, DOI 10.1002/1531-8249(199912)46:6<913::AID-ANA15>3.0.CO;2-X	48	320	330	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4621	4628		10.1038/sj.onc.1204621	http://dx.doi.org/10.1038/sj.onc.1204621			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498785				2022-12-28	WOS:000170208600003
J	Galy, B; Creancier, L; Prado-Lourenco, L; Prats, AC; Prats, H				Galy, B; Creancier, L; Prado-Lourenco, L; Prats, AC; Prats, H			p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA	ONCOGENE			English	Article						FGF; p53; translational control; RNA-protein interactions; RNA structure	WILD-TYPE P53; ALTERNATIVE TRANSLATION; NUCLEIC-ACIDS; MESSENGER-RNA; PROTEIN; GROWTH-FACTOR-2; RIBOSOMES; DOMAIN; ENTRY; CELLS	Tumour suppressor p53 has been shown to inhibit fibroblast growth factor 2 expression post-transcriptionally in cultured cells. Here we have investigated the mechanism responsible for this post-transcriptional blockade. Deletion mutagenesis of the FGF-2 mRNA leader revealed the requirement of at least four RNA cis-acting elements to mediate the inhibitory effect of p53 in SK-Hep-1 transfected cells, suggesting the involvement of RNA secondary or tertiary structures. Recombinant wild-type, but not Ala(143) mutant p53, was able to specifically repress FGF-2 mRNA translation in rabbit reticulocyte lysate, in a dose dependent manner. Sucrose gradient experiments showed that p53 blocks translation initiation by preventing 80S ribosome formation on an mRNA bearing the FGF-2 mRNA leader sequence. Interaction of wild-type and mutant p53 with different RNAs showed no significant correlation between p53 RNA binding activity and its translational inhibiting effect. However, by checking the accessibility of the FGF-2 mRNA leader to complementary oligonucleotide probes, we showed that the binding to RNA of wild-type, but not mutant p53, induced RNA conformational changes that might be responsible for the translational blockade. This strongly suggests that p53 represses FGF-2 mRNA translation by a direct mechanism involving its nucleic acid unwinding-annealing activity.	CHU Rangueil, INSERM, U397, Inst Fed Rech Louis Bugnard, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, AC (corresponding author), CHU Rangueil, INSERM, U397, Inst Fed Rech Louis Bugnard, F-31403 Toulouse 04, France.		Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; Galy, Bruno/0000-0002-0501-6357; Prats, Herve/0000-0002-4861-2167				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Galy B, 1999, CANCER RES, V59, P165; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497	18	45	45	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4613	4620		10.1038/sj.onc.1204630	http://dx.doi.org/10.1038/sj.onc.1204630			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498784				2022-12-28	WOS:000170208600002
J	Deng, GR; Chen, A; Pong, E; Kim, YS				Deng, GR; Chen, A; Pong, E; Kim, YS			Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression	ONCOGENE			English	Article						colorectal cancer; hMLH1 gene; methylation; transcription factor CBF	DNA METHYLATION; NF-Y; MICROSATELLITE INSTABILITY; COLORECTAL-CARCINOMA; COLON-CANCER; HYPERMETHYLATION; INACTIVATION; TUMORS; CELLS; PROTEINS	Microsatellite instability (MSI) is caused by the dysfunction of mismatch repair genes, such as hMLH1, hMSH2. Loss of hMLH1 expression and methylation of CpG sites in hMLH1 promoter are frequently present in sporadic colorectal cancer with MSI. In this study, by transient transfection assay with constructs containing different lengths of hMLH1 promoter and a luciferase reporter gene, we located a proximal region of hMLH1 promoter, which plays a main role in regulating the gene. The fact that luciferase activities were high in all host cell lines regardless of their hMLH1 expression levels indicates that the transcription machinery is intact even in non-expressing cells. When hMLH1 promoter was in vitro methylated before transfection, the luciferase activities in the transfectants were significantly reduced. This observation indicates that methylation causes the inhibition of hMLH1 promoter activity. By electrophoretic mobility shift assay (EMSA), we identified a CCAAT box in this region, which specifically bound transcription factor CBF. Mutations in CCAAT box not only inhibited its binding to CBF factor, but also reduced its ability to drive the expression of luciferase gene. The role of CBF in activating transcription was further substantiated by inhibition of promoter activity with a plasmid expressing a dominant negative CBF-B mutant. Methylation at a CpG site two base pairs upstream of the CCAAT box inhibited the binding of CBF to CCAAT box. We conclude that methylation of an adjacent CpG site inhibits binding of the CBF transcription to the corresponding CCAAT box, and is one of the causes of hMLH1 gene silencing in colon cancer cells.	Univ Calif San Francisco, Vet Affairs Med Ctr, Gastrointestinal Res Lab, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Deng, GR (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Gastrointestinal Res Lab, San Francisco, CA 94121 USA.				NCI NIH HHS [CA 24321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Cunningham JM, 1998, CANCER RES, V58, P3455; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; Deng GR, 1999, CANCER RES, V59, P2029; Dobrovic A, 1997, CANCER RES, V57, P3347; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kanai Y, 1997, INT J CANCER, V71, P355; Kane MF, 1997, CANCER RES, V57, P808; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kominato Y, 1997, J BIOL CHEM, V272, P25890, DOI 10.1074/jbc.272.41.25890; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; Orita T, 1997, J BIOL CHEM, V272, P23216, DOI 10.1074/jbc.272.37.23216; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Qian XLC, 1997, CANCER RES, V57, P3672; Sinha S, 1996, MOL CELL BIOL, V16, P328; Stirzaker C, 1997, CANCER RES, V57, P2229; Tanaka H, 1998, CANCER RES, V58, P3429; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	32	66	74	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7120	7127		10.1038/sj.onc.1204891	http://dx.doi.org/10.1038/sj.onc.1204891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704838				2022-12-28	WOS:000171739300017
J	Glondu, M; Coopman, P; Laurent-Matha, V; Garcia, M; Rochefort, H; Liaudet-Coopman, E				Glondu, M; Coopman, P; Laurent-Matha, V; Garcia, M; Rochefort, H; Liaudet-Coopman, E			A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells	ONCOGENE			English	Article						cathepsin-D; mitogen; mutagenesis; catalytic site	HUMAN IMMUNODEFICIENCY VIRUS; PROCATHEPSIN-D ACTIVATION; BREAST-CANCER; MONOCLONAL-ANTIBODIES; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; MCF7 CELLS; IGF-II; METASTASIS; PROTEASES	Cathepsin-D, a lysosomal aspartyl proteinase, is highly secreted by breast cancer cells and its over-expression by transfection stimulates cancer cell proliferation. The mechanism by which this protease affects proliferation remains, however, unknown. In order to determine whether proteolytic activity is necessary, we abolished its enzymatic activity using site-directed mutagenesis followed by stable transfection in 3Y1-Ad12 cancer cells. Substitution of the aspartic acid residue 231 by an asparagine residue in its catalytic site abrogated the cathepsin-D proteolytic activity but did not affect its expression level, processing or secretion. However, like wild-type cathepsin-D, this mutated catalytically-inactive cathepsin-D retained its capacity to stimulate proliferation of cells embedded in Matrigel or collagen I matrices, colony formation in soft agar and tumor growth in athymic nude mice. Addition on the mock-transfected cells, of either conditioned media containing the wild-ty pe or the mutated pro-cathepsin-D, or of the purified mutated pro-cathepsin-D, partially mimicked the mitogenic activity of the transfected cathepsin-D, indicating a role of the secreted pro-enzyme. Moreover, addition of two anti-cathepsin-D antibodies on the cathepsin-D transfected cells inhibited their proliferation, suggesting an action of the secreted pro-cathepsin-D via an autocrine loop. A synthetic peptide containing the 27-44 residue moiety of the cathepsin-D pro-fragment was, however, not mitogenic suggesting that a receptor for the pro-fragment was not involved. Furthermore, the cathepsin-D mitogenicity was not blocked by inhibiting the interaction of pro-cathepsin-D with the mannose-6-phosphate receptors. Our results altogether demonstrate that a mutated cathepsin-D devoid of catalytic activity is still mitogenic and suggest that it is acting extracellularly by triggering directly or indirectly a yet unidentified cell surface receptor.	Univ Montpellier 1, INSERM, Endocrinol Mol & Cellulaire Canc U540, F-34090 Montpellier, France; Univ Montpellier 2, CNRS, UMR 5539, F-34095 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Rochefort, H (corresponding author), Univ Montpellier 1, INSERM, Endocrinol Mol & Cellulaire Canc U540, 60 Rue Navacelles, F-34090 Montpellier, France.		Coopman, Peter/G-7416-2019; Liaudet-Coopman, Emmanuelle/N-4744-2017	Coopman, Peter/0000-0003-3720-523X; Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Valerie, LAURENT-MATHA/0000-0002-3277-7397				BISSELL MJ, 1999, CANCER RES, V59, P1757; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; CAPONY F, 1989, CANCER RES, V49, P3904; CARNEY DH, 1978, CELL, V15, P1341, DOI 10.1016/0092-8674(78)90059-4; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; DeLeon DD, 1996, ENDOCRINOLOGY, V137, P1851, DOI 10.1210/en.137.5.1851; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; EMERMAN JT, 1977, P NATL ACAD SCI USA, V74, P4466, DOI 10.1073/pnas.74.10.4466; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FREISS G, 1988, CANCER RES, V48, P3709; FUSEK M, 1994, BIOCHEM J, V303, P775, DOI 10.1042/bj3030775; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; Kane S E, 1990, Semin Cancer Biol, V1, P127; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; Laurent-Matha V, 1998, J CELL SCI, V111, P2539; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; LIN XL, 1989, J BIOL CHEM, V264, P4482; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MATHIEU M, 1990, MOL ENDOCRINOL, V4, P1327, DOI 10.1210/mend-4-9-1327; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; MONTCOURRIER P, 1994, J CELL SCI, V107, P2381; Montcourrier P, 1997, CLIN EXP METASTAS, V15, P382, DOI 10.1023/A:1018446104071; Rifkin DB, 1997, FIBRINOLYSIS PROTEOL, V11, P3, DOI 10.1016/S0268-9499(97)80003-3; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612; SLOANE BF, 1984, CANCER METAST REV, V3, P249, DOI 10.1007/BF00048388; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; VEITH FO, 1983, CANCER RES, V43, P1861; Vetvicka V, 1999, BREAST CANCER RES TR, V57, P261, DOI 10.1023/A:1006238003772; VIGNON F, 1992, BREAST CANCER RES TR, V22, P47, DOI 10.1007/BF01833333; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; Wittlin S, 1999, EUR J BIOCHEM, V265, P384, DOI 10.1046/j.1432-1327.1999.00747.x	40	89	94	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6920	6929		10.1038/sj.onc.1204843	http://dx.doi.org/10.1038/sj.onc.1204843			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687971				2022-12-28	WOS:000171641000013
J	Plo, I; Lautier, D; Casteran, N; Dubreuil, P; Arock, M; Laurent, G				Plo, I; Lautier, D; Casteran, N; Dubreuil, P; Arock, M; Laurent, G			Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase C gamma	ONCOGENE			English	Article						c-Kit; daunorubicin; apoptosis; PKC; PLC gamma; ceramide	PROTEIN-KINASE-C; STEM-CELL FACTOR; CERAMIDE-INDUCED APOPTOSIS; MYELOID-LEUKEMIA CELLS; GROWTH-FACTOR; NEUTRAL SPHINGOMYELINASE; TRANSDUCTION PATHWAY; ACTIVATION; EXPRESSION; LIGAND	Previous studies have demonstrated that activation of Kit by stem cell factor (SCF), its natural ligand, or by gain-of-function point mutation in its intracellular domain, confers significant protection against apoptosis induced by growth factor deprivation or radiation. However, the effects of Kit activation on the cellular response to antitumor agents have not been so extensively documented. This study shows that daunorubicin-induced apoptosis and cytotoxicity were reduced in the murine Ba/F3 cells transfected with Kit (Ba/F3-Kit) in the presence of SCF and in Ba/F3 cells transfected with a constitutively active Kit variant (Ba/F3-Kit Delta 27), compared to either parental Ba/F3 (Ba/F3-wt) or unstimulated Ba/F3-Kit cells. In Ba/F3-wt and in Ba/F3-Kit cells, daunorubicin stimulated within 8-15 min neutral sphingomyelinase and ceramide production but not in SCF-stimulated Ba/F3-Kit or in Ba/F3-Kit Delta 27 whereas all Ba/F3 cells were equally sensitive to exogenous cell-permeant C6-ceramide. In Ba/F3-Kit, SCF-induced Kit activation resulted in a rapid phospholipase C gamma (PLC gamma) tyrosine phosphorylation followed by diacylglycerol release and protein kinase C (PKC) stimulation. U-73122, a PLC gamma inhibitor, not only blocked diacylglycerol production and PKC stimulation but also restored daunorubicin-induced sphingomyelinase stimulation, ceramide production, and apoptosis. These results suggest that Kit activation results in PLC gamma -mediated PKC-dependent sphingomyelinase inhibition which contributes to drug resistance in Kit-related malignancies.	INSERM, Inst Claudius Regaud, E9910, F-31052 Toulouse, France; Inst Natl St & Rech Med, Lab Cancerol Expt, F-13009 Marseille, France; Lab Hematol Cellulaire & Mol, UPRES, EA2509, Fac Pharm, F-75006 Paris, France; Ctr Hosp Univ Purpan, Serv Hematol, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Plo, I (corresponding author), INSERM, Inst Claudius Regaud, E9910, 20,Rue Pont St Pierre, F-31052 Toulouse, France.	plo@icr.fnclcc.fn	dubreuil, patrice/F-5346-2011; Lautier, Dominique/G-3959-2017; Plo, Isabelle/AAT-6742-2021; Dubreuil, Patrice/V-4816-2019; Plo, Isabelle/C-9056-2017	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Plo, Isabelle/0000-0002-5915-6910				Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; ASHMAN LK, 1988, LEUKEMIA RES, V12, P923, DOI 10.1016/0145-2126(88)90020-3; Bettaieb A, 1999, MOL PHARMACOL, V55, P118, DOI 10.1124/mol.55.1.118; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Burow ME, 2000, J BIOL CHEM, V275, P9628, DOI 10.1074/jbc.275.13.9628; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; CHABNER BA, 1989, CANCER PRINCIPLES PR, P349; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; Chmura SJ, 1996, CANCER RES, V56, P2711; Cole SR, 1996, LEUKEMIA, V10, P288; Come MG, 1999, INT J CANCER, V81, P580, DOI 10.1002/(SICI)1097-0215(19990517)81:4<580::AID-IJC13>3.0.CO;2-T; De Sepulveda P, 1999, EMBO J, V18, P904; FAN D, 1992, ANTICANCER RES, V12, P661; Feng HL, 1998, MOL REPROD DEV, V49, P317, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;317::AID-MRD12&gt;3.0.CO;2-T; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Haslauer M, 1999, BLOOD, V94, P114, DOI 10.1182/blood.V94.1.114.413k21_114_126; Hassan HT, 1996, ACTA HAEMATOL-BASEL, V95, P257; HERBST R, 1995, BIOCHEMISTRY-US, V34, P5971, DOI 10.1021/bi00017a026; IKEDA H, 1991, BLOOD, V78, P2962; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; KOIKE T, 1993, J IMMUNOL, V151, P359; Kozawa O, 1997, EUR J BIOCHEM, V248, P149, DOI 10.1111/j.1432-1033.1997.00149.x; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEIGH BR, 1995, RADIAT RES, V142, P12, DOI 10.2307/3578961; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; Mansat V, 1997, CANCER RES, V57, P5300; Nagata H, 1997, INT ARCH ALLERGY IMM, V113, P184, DOI 10.1159/000237541; NETA R, 1993, BLOOD, V81, P324; QuilletMary A, 1996, LEUKEMIA, V10, P417; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; REUSSBORST MA, 1994, LEUKEMIA, V8, P258; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RIZZO MT, 1991, CELL SIGNAL, V3, P311, DOI 10.1016/0898-6568(91)90060-8; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SCHUENING FG, 1993, BLOOD, V81, P20; Sette C, 1998, J CELL BIOL, V142, P1063, DOI 10.1083/jcb.142.4.1063; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Yang JM, 1997, BIOCHEM PHARMACOL, V53, P1597, DOI 10.1016/S0006-2952(97)82451-3; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x; ZSEBO KM, 1992, P NATL ACAD SCI USA, V89, P9464, DOI 10.1073/pnas.89.20.9464	51	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6752	6763		10.1038/sj.onc.1204877	http://dx.doi.org/10.1038/sj.onc.1204877			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709710				2022-12-28	WOS:000171551600012
J	Okutani, Y; Kitanaka, A; Tanaka, T; Kamano, H; Ohnishi, H; Kubota, Y; Ishida, T; Takahara, J				Okutani, Y; Kitanaka, A; Tanaka, T; Kamano, H; Ohnishi, H; Kubota, Y; Ishida, T; Takahara, J			Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway	ONCOGENE			English	Article						Src; STAT5; erythropoietin; tyrosine phosphorylation; antisense	COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; ERYTHROID-DIFFERENTIATION; RECEPTOR; EXPRESSION; KINASES; INTERLEUKIN-3; TRANSDUCTION; PROLACTIN; LEUKEMIA	Signal transducers and activators of transcription (STAT) proteins are transcription factors activated by phosphorylation on tyrosine residues after cytokine stimulation. In erythropoietin receptor (EPOR)-mediated signaling, STAT5 is tyrosine-phosphorylated by EPO stimulation. Although Janus Kinase 2 (JAK2) is reported to play a crucial role in EPO-induced activation of STAT5, it is unclear whether JAK2 alone can tyrosine-phosphorylate STAT5 after EPO stimulation. Several studies indicate that STAT activation is caused by members of other families of protein tyrosine kinases such as the Src family. We previously reported that reduction of Src by induction of antisense src RNA expression suppressed EPO-promoted erythroid differentiation in K562 cells. In the present study, we explored the function of Src downstream of the EPOR-initiated signaling. Reduction of Src diminished tyrosine phosphorylation of STAT5 in K562 cells regardless of EPO treatment. The tyrosine phosphorylation level of STAT5 induced by EPO in F-36P cells was reduced in the presence of PPI or PP2 selective Src inhibitor. In addition, the expression of dominant negative Src in F-36P cells reduced the tyrosine phosphorylation of STAT5. When Src and STAT5 were co-expressed in COS7 cells, tyrosine phosphorylation of STAT5 was observed, and tyrosine residue 694 (Tyr 694) of STAT5A was identified as the major phosphorylation site by Src. In vitro kinase assay revealed that GST-STAT5 fusion protein with the conserved C-terminal, but not the C-terminal-truncated mutant which lacks Tyr 694, was tyrosine-phosphorylated by Src. Src can thus directly tyrosine-phosphorylate the activation site of STAT5 (Tyr 694 in STAT5A), and Src may contribute to EPO-induced signal transduction via STAT5.	Kagawa Med Univ, Dept Internal Med 1, Kagawa 7610793, Japan; Kagawa Med Univ, Lab Med, Kagawa 7610793, Japan; Kagawa Univ, Hlth Sci Ctr, Kagawa 7608521, Japan	Kagawa University; Kagawa University; Kagawa University	Tanaka, T (corresponding author), Kagawa Med Univ, Dept Internal Med 1, Kagawa 7610793, Japan.	tanaka@kms.ac.jp						Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CHIBA S, 1991, BLOOD, V78, P2261; Chin H, 1998, BLOOD, V91, P3734; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kitanaka A, 1999, J IMMUNOL, V162, P1952; KITANAKA A, 1994, BIOCHEM BIOPH RES CO, V201, P1534, DOI 10.1006/bbrc.1994.1878; Kitanaka A, 1998, BLOOD, V91, P940, DOI 10.1182/blood.V91.3.940.940_940_948; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	34	73	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6643	6650		10.1038/sj.onc.1204807	http://dx.doi.org/10.1038/sj.onc.1204807			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641791				2022-12-28	WOS:000171404200019
J	Voltz, JW; Weinman, EJ; Shenolikar, S				Voltz, JW; Weinman, EJ; Shenolikar, S			Expanding the role of NHERF, a PDZ-domain containing protein adapter, to growth regulation	ONCOGENE			English	Article						NHERF; PDZ; ERM; epithelium; mitogen; cancer	TRANSMEMBRANE CONDUCTANCE REGULATOR; CAMP-MEDIATED INHIBITION; NA+/H+ EXCHANGER NHE3; KINASE-A; BETA(2)-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; ALLELIC LOSS; EZRIN; ASSOCIATION; BINDING	NHERF (Na+/H+ exchanger regulatory factor or NHERF-1) and E3KARP (NHE3 kinase A regulatory protein or NHERF-2) are structurally related protein adapters that are highly expressed in epithelial tissues. NHERF proteins contain two tandem PDZ domains and a C-terminal sequence that binds several members of the ERM (ezrin-radixin-moesin) family of membrane-cytoskeletal adapters. Although identified as a regulator of NHE3, recent evidence points to a broadening role for NHERF in the function, localization and/or turnover of G-protein coupled receptors, platelet-derived growth factor receptor and ion transporters such as CFTR, Na/Pi cotransporter, Na/HCO3 cotransporter and Trp (calcium) channels. NHERF also recruits non-membrane proteins such as the c-Yes/YAP-65 complex, members of the phospholipase Cp family and the GRK6A protein kinase to apical surface of polarized epithelial cells where they regulate or respond to membrane signals. While two distinct models have been proposed for NHERF's role in signal transduction, the common theme is NHERF's ability to bring together membrane and non-membrane proteins to regulate cell metabolism and growth. NHERF overexpression in human breast cancers and mutations in NHERF targets, such as CFTR and merlin, the product of Neurofibromatosis NF2 tumor suppressor gene, that impair NHERF binding suggest that aberrant NHERF function contributes to human disease.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Maryland, Sch Med, Div Nephrol, Dept Med, Baltimore, MD 21202 USA	Duke University; University System of Maryland; University of Maryland Baltimore	Shenolikar, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	sheno001@mc.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055881] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55881] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; BARBER DL, 1992, J BIOL CHEM, V267, P20607; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; JAY DG, 1999, BIOCHIM BIOPHYS ACTA, V1424, P39; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Lagana A, 2000, J CELL SCI, V113, P3649; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Shao ZM, 2000, ONCOGENE, V19, P4337, DOI 10.1038/sj.onc.1203785; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Shimizu K, 2000, GENOMICS, V65, P113, DOI 10.1006/geno.2000.6154; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Stokowski RP, 2000, AM J HUM GENET, V66, P873, DOI 10.1086/302812; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Szaszi K, 2000, J BIOL CHEM, V275, P28599, DOI 10.1074/jbc.M001193200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Tokunou M, 2000, LAB INVEST, V80, P1643, DOI 10.1038/labinvest.3780174; WADE JB, 2001, AM J PHYSIOL, V280, P192; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Weinman EJ, 1999, BBA-GENE STRUCT EXPR, V1447, P71, DOI 10.1016/S0167-4781(99)00100-1	44	137	141	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6309	6314		10.1038/sj.onc.1204774	http://dx.doi.org/10.1038/sj.onc.1204774			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607833				2022-12-28	WOS:000171640600006
J	Jung, MS; Yun, J; Chae, HD; Kim, JM; Kim, SC; Choi, TS; Shin, DY				Jung, MS; Yun, J; Chae, HD; Kim, JM; Kim, SC; Choi, TS; Shin, DY			p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor	ONCOGENE			English	Article						p53; p63; p73; cdk1; cyclin B; NF-Y; senescence	WILD-TYPE P53; TATA-BINDING PROTEIN; MAMMALIAN-CELLS; ONCOGENIC RAS; TUMOR-CELLS; IN-VIVO; PREMATURE SENESCENCE; GENE-EXPRESSION; PROMOTER; REPRESSION	Recent studies have identified two p53 homologues, p63 and p73. They activate p53-responsive promoters and induce apoptosis when overexpressed in certain human tumors. Here, we report that p63, like p53 and p73, induces replicative senescence when expressed in a tetracycline-regulated manner in EJ cells lacking a functional p53. In addition to transcription activation of p53-responsive genes, we found that p63 and p73 repress transcription of the cdk1 and cyclin B genes, both of which are irreversibly repressed in senescent human fibroblast. In transient transfection assay, p63 and p73 repress the cdk1 promoter regardless of the presence of a dominant negative mutant form of p53. Furthermore, we found that DNA binding activity of NF-Y transcription factor, which is essential for transcription of the cdk1 and cyclin B genes and inactivated in senescent fibroblast, is significantly decreased by expression of either of p53, p63, or p73. Since NF-Y binds to many promoters besides the cdk1 and cyclin B promoters, inactivation of NF-Y by p53 family genes may be a general mechanism for transcription repression in replicative senescence.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab Cell Cycle Regulat, Cheonan 330714, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Jongro Gu, Seoul 10300, South Korea; Korea Adv Inst Sci & Technol, Taejon 305333, South Korea; LG Chem LTD, Biotech Res Inst, Taejon 305380, South Korea	Dankook University; Seoul National University (SNU); Korea Advanced Institute of Science & Technology (KAIST); LG Chem	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab Cell Cycle Regulat, Cheonan 330714, South Korea.		Kim, Sun Chang/C-2026-2011; Kim, Sun/GSN-4867-2022; Chae, Hee-Don/D-2620-2011					AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; Chen Kuang Yu, 1997, Frontiers in Bioscience (online), V2, pD417; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Deb D, 1999, INT J ONCOL, V15, P413; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Ferbeyre G, 2000, GENE DEV, V14, P2015; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Good LF, 1996, BIOL SIGNAL, V5, P163; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park M, 2000, CANCER RES, V60, P542; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Shimada A, 1999, CANCER RES, V59, P2781; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	58	79	81	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5818	5825		10.1038/sj.onc.1204748	http://dx.doi.org/10.1038/sj.onc.1204748			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593387				2022-12-28	WOS:000171037200005
J	Sayan, AE; Sayan, BS; Findikli, N; Ozturk, M				Sayan, AE; Sayan, BS; Findikli, N; Ozturk, M			Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells	ONCOGENE			English	Article						liver cancer; p73; retinoblastoma; P16(INK4a); p14(ARF); cyclin E	P53 HOMOLOG P73; KINASE C-ABL; APOPTOTIC RESPONSE; DNA-DAMAGE; FAMILY; GENE; RETINOBLASTOMA; LINES; PROTEINS; MUTATION	p53 and p73 proteins activate similar target genes and induce apoptosis and cell cycle arrest. However, p53, but not p73 is considered a tumour-suppressor gene. Unlike p53, p73 deficiency in mice does not lead to a cancer-prone phenotype, and p73 gene is not mutated in human cancers, including hepatocellular carcinoma. Here we report that normal liver cells express only DeltaN-p73 transcript forms giving rise to the synthesis of N-terminally truncated, transcriptionally inactive and dominant negative p73 proteins. In contrast, most hepatocellular carcinoma cells express TA-p73 transcript forms encoding full-length and transcriptionally active p73 proteins, in addition to DeltaN-p73. We also show that together with the acquired expression of TA-p73, the 'retinoblastoma pathway' is inactivated, and E2F1-target genes including cyclin E and p14(ARF) are activated in hepatocellular carcinoma. However, there was no full correlation between 'retinoblastoma pathway' inactivation and TA-p73 expression. Most TA-p73-expressing hepatocellular carcinoma cells have also lost p53 function either by lack of expression or missense mutations. The p73 gene, encoding only DeltaN-p73 protein, may function as a tumour promoter rather than a tumour suppressor in liver tissue. This may be one reason why p73 is not a mutation target in hepatocellular carcinoma.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey	Ihsan Dogramaci Bilkent University	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey.		OZTURK, MEHMET/AAS-7241-2021; SAYAN, A. EMRE/H-7330-2012; Findikli, Necati/I-4924-2018; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; SAYAN, A. EMRE/0000-0002-5291-1485; Findikli, Necati/0000-0001-9362-5912; 				Agami R, 1999, NATURE, V399, P809; Baek MJ, 2000, CANCER, V89, P60, DOI 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3; BOUZAHZAH B, 1995, J CELL PHYSIOL, V165, P459, DOI 10.1002/jcp.1041650303; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gong JG, 1999, NATURE, V399, P806; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Mihara M, 1999, BRIT J CANCER, V79, P164, DOI 10.1038/sj.bjc.6690027; Morel AP, 2000, J HEPATOL, V33, P254, DOI 10.1016/S0168-8278(00)80366-9; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Suh SI, 2000, CANCER LETT, V160, P81, DOI 10.1016/S0304-3835(00)00566-8; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Tannapfel A, 1999, BRIT J CANCER, V80, P1069, DOI 10.1038/sj.bjc.6690465; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yolcu E, 2001, ONCOGENE, V20, P1398, DOI 10.1038/sj.onc.1204240; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257	33	59	60	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5111	5117		10.1038/sj.onc.1204669	http://dx.doi.org/10.1038/sj.onc.1204669			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526499	Green Submitted, Green Published			2022-12-28	WOS:000170464000004
J	Lomax, M; Fried, M				Lomax, M; Fried, M			Polyoma virus disrupts ARF signaling to p53	ONCOGENE			English	Article						ARF; MDM2; oncogene co-operation; p53; polyoma virus; polyoma virus T-antigens	T-ANTIGEN; MDM2; PROTEIN; P19(ARF); PRODUCT; PHOSPHORYLATION; TRANSFORMATION; ASSOCIATION; DEGRADATION; INHIBITION	Polyoma virus (Py) differs from other small DNA tumor viruses in not encoding a protein that inactivates p53. The complete Py early region encoding the large T-antigen (PyLT), middle T-antigen (PyMT) and small T-antigen (PyST) will transform primary rodent cells and REF52 cells, but PyMT, the main Py oncogene, by itself will only transform these cells when p53 or ARF is inactivated. We have related Py oncogene cooperation with the effects of the Py T-antigens on the ARF-p53 signaling pathway. PyMT activates an ARF-induced p53-mediated block to cell division explaining the inability of PyMT alone to generate dividing transformed cells. In contrast, in REF52 cells transformed by the whole Py early region (PyREF52), ARF is upregulated but p53 is not activated. Thus PyLT and/or PyST negates the PyMT-induced ARF-mediated block to cell division by disrupting the signaling pathway from ARF to p53. Although there is no detectable interaction or co-localization of endogenous ARF (nucleoli) and MDM2 (nucleoplasm) in PyREF52 cells, expression of transfected ectopic ARF results in an MDM2/ARF interaction and sequestration of MDM2 into the nucleoli. Sequestration of MDM2 by ARF in the nucleoli is not essential for a p53 response in REF52 cells as activation of Raf in REF52Raf-ER cells results in an ARF-induced p53-mediated cell cycle block in the absence of a detectable ARF-MDM2 interaction. Py may provide new insights into the cellular ARF-p53 signaling pathway.	Imperial Canc Res Fund, London WC2A 3PX, England; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	Cancer Research UK; University of California System; University of California San Francisco	Fried, M (corresponding author), Imperial Canc Res Fund, Lincolns Inn Fields,POB 123, London WC2A 3PX, England.							CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CUZIN F, 1984, BIOCHIM BIOPHYS ACTA, V781, P193, DOI 10.1016/0167-4781(84)90084-8; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; DURO D, 1995, ONCOGENE, V11, P21; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kannan K, 2000, INT J ONCOL, V16, P585; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MANSUR CP, 1995, ONCOGENE, V10, P457; MAO L, 1995, CANCER RES, V55, P2995; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Mor O, 1997, ONCOGENE, V15, P3113, DOI 10.1038/sj.onc.1201549; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	38	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4951	4960		10.1038/sj.onc.1204717	http://dx.doi.org/10.1038/sj.onc.1204717			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526480				2022-12-28	WOS:000170439800005
J	Naka, M; Ozaki, T; Takada, N; Takahashi, M; Shishikura, T; Sakiyama, S; Tada, M; Todo, S; Nakagawara, A				Naka, M; Ozaki, T; Takada, N; Takahashi, M; Shishikura, T; Sakiyama, S; Tada, M; Todo, S; Nakagawara, A			Functional characterization of naturally occurring mutants (P405R and P425L) of p73 alpha and p73 beta found in neuroblastoma and lung cancer	ONCOGENE			English	Article						growth suppression; missense mutation; p73; transcriptional activity	KINASE C-ABL; APOPTOTIC RESPONSE; TERMINAL REGION; P73 FUNCTION; P53; INDUCTION; VARIANTS; IDENTIFICATION; CELLS	The novel candidate tumor suppressor p73, a structural and functional homolog of p53, activates various p53 responsive promoters and induces tumor cell apoptosis, Although p73 is infrequently mutated in human cancers, we ha, e previously found two types of p73 mutation with amino acid substitution (P405R and P425L) in primary neuroblastoma and lung cancer. Here we report generations of the p73 mutants with either P405R or P425L substitution and functional analysis of these naturally occurring mutants, Indirect immunofluorescence staining revealed that nuclear accumulation of p73 alpha or p73 beta was not affected by these mutations. The P425L substitution reduced the ability of p73a to transactivate various p53 responsive promoters (p21(Waf1), Mdm2, and Bax), Moreover, this down-regulation was correlated with the reduced capability of p73 alpha (P425L) to suppress cell growth in p53-deficient SAOS-2 cells. In contrast, p73 beta (P425L) was as effective as wild-type p73 beta in transactivation and growth inhibition. On the other hand, the P405R substitution had no significant effect on both the transcriptional activity and the growth-suppressive ability of p73 alpha or p73 beta. These results suggested that, at least, one of the naturally occurring p73 mutants, p73 alpha (P425L), was a functionally defective mutant of p73.	Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan; Inst Canc Res, Div Cell Biol, Ciba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Surg 1, Sapporo, Hokkaido 0608638, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.							Agami R, 1999, NATURE, V399, P809; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gong JG, 1999, NATURE, V399, P806; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Takada N, 1999, CANCER RES, V59, P2810; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	27	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3568	3572		10.1038/sj.onc.1204470	http://dx.doi.org/10.1038/sj.onc.1204470			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429704				2022-12-28	WOS:000169478300013
J	Huang, EY; Madireddi, MT; Gopalkrishnan, RV; Leszczyniecka, M; Su, ZZ; Lebedeva, IV; Kang, DC; Jiang, HP; Lin, JJ; Alexandre, D; Chen, YM; Vozhilla, N; Mei, MX; Christiansen, KA; Sivo, F; Goldstein, NI; Mhashilkar, AB; Chada, S; Huberman, E; Pestka, S; Fisher, PB				Huang, EY; Madireddi, MT; Gopalkrishnan, RV; Leszczyniecka, M; Su, ZZ; Lebedeva, IV; Kang, DC; Jiang, HP; Lin, JJ; Alexandre, D; Chen, YM; Vozhilla, N; Mei, MX; Christiansen, KA; Sivo, F; Goldstein, NI; Mhashilkar, AB; Chada, S; Huberman, E; Pestka, S; Fisher, PB			Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties	ONCOGENE			English	Article						melanoma differentiation associated gene-7; terminal cell differentiation; gene expression; genomic structure; IL-10 cytokine family	HUMAN ADENOVIRUS TYPE-5; TERMINAL DIFFERENTIATION; IMMUNE INTERFERONS; LEUKEMIA-CELLS; IN-VITRO; PROGRESSION; DNA; ARREST; IDENTIFICATION; COMBINATION	Abnormalities in cellular differentiation are frequent occurrences in human cancers. Treatment of human melanoma cells with recombinant fibroblast interferon (IFN-beta) and the protein kinase C activator mezerein (MEZ) results in an irreversible loss in growth potential, suppression of tumorigenic properties and induction of terminal cell differentiation. Subtraction hybridization identified melanoma differentiation associated gene-7 (mda-7), as a gene induced during these physiological changes in human melanoma cells. Ectopic expression of mda-7 by means of a replication defective adenovirus results in growth suppression and induction of apoptosis in a broad spectrum of additional cancers, including melanoma, glioblastoma multiforme, osteosarcoma and carcinomas of the breast, cervix, colon, lung, nasopharynx and prostate. In contrast, no apparent harmful effects occur when mda-7 is expressed in normal epithelial or fibroblast cells. Human clones of mda-7 were isolated and its organization resolved in terms of intron/exon structure and chromosomal localization. Hu-mda-7 encompasses seven exons and six introns and encodes a protein with a predicted size of 23.8 kDa, consisting of 206 amino acids. Hu-mda-7 mRNA is stably expressed in the thymus, spleen and peripheral blood leukocytes. De novo mda-7 mRNA expression is also detected in human melanocytes and expression is inducible in cells of melanocyte/melanoma lineage and in certain normal and cancer cell types following treatment with a combination of IFN-beta plus MEZ. Mda-7 expression is also induced during megakaryocyte differentiation induced in human hematopoietic cells by treatment with TPA (12-O-tetradecanoyl phorbol-13-acetate). In contrast, de novo expression of mda-7 is not detected nor is it inducible by IFN-beta +MEZ in a spectrum of additional normal and cancer cells. No correlation was observed between induction of mda-7 mRNA expression and growth suppression following treatment with IFN-beta +MEZ and induction of endogenous mda-7 mRNA by combination treatment did not result in significant intracellular MDA-7 protein. Radiation hybrid mapping assigned the mda-7 gene to human chromosome 1q, at 1q 32.2 to 1q41, an area containing a cluster of genes associated with the IL-10 family of cytokines. Mda-7 represents a differentiation, growth and apoptosis associated gene with potential utility for the gene-based therapy of diverse human cancers.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Introgen Therapeut Inc, Houston, TX 77030 USA; Argonne Natl Lab, Ctr Mechanist Biol & Biotechnol, Argonne, IL 60439 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Columbia University; Columbia University; Columbia University; United States Department of Energy (DOE); Argonne National Laboratory; Rutgers State University New Brunswick; Rutgers State University Medical Center	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB 15-1501,630 W 168th St, New York, NY 10032 USA.	pbf@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NCI NIH HHS [CA35675, CA80826] Funding Source: Medline; NIAMS NIH HHS [P30-AR44535] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080826, R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; ARMSTRONG BK, 1994, CANCER SURV, V20, P219; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; Chaiken IM, 1996, TRENDS BIOTECHNOL, V14, P369, DOI 10.1016/0167-7799(96)10050-0; Chu XH, 1999, CELL TISSUE RES, V296, P331, DOI 10.1007/s004410051293; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; DeRisi J, 1996, NAT GENET, V14, P457; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; GUARINI L, 1990, INT J CANCER, V46, P1041, DOI 10.1002/ijc.2910460616; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; JIANG H, 2000, P NATL ACAD SCI USA, V93, P9160; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; KERBEL RS, 1984, INVAS METAST, V4, P31; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; LESZCZYNIECKA M, 2001, IN PRESS PHARM THERA; Li DQ, 1999, CURR EYE RES, V19, P154, DOI 10.1076/ceyr.19.2.154.5321; Madireddi MT, 2000, J CELL PHYSIOL, V185, P36, DOI 10.1002/1097-4652(200010)185:1<36::AID-JCP3>3.0.CO;2-V; Madireddi MT, 2000, ONCOGENE, V19, P1362, DOI 10.1038/sj.onc.1203424; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Miller M S, 1999, J Foot Ankle Surg, V38, P227; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Saito I, 2000, CRIT REV IMMUNOL, V20, P153; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Soo C, 1999, J CELL BIOCHEM, V74, P1; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; SU ZZ, 1995, INT J ONCOL, V7, P1279; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; VITA JR, 1988, ANTICANCER RES, V8, P297; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOLKERT FC, 1983, VIROLOGY, V125, P175, DOI 10.1016/0042-6822(83)90072-7; WAXMAN S, 1996, DIFFERENTIATION THER, P1; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	55	192	240	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7051	7063		10.1038/sj.onc.1204897	http://dx.doi.org/10.1038/sj.onc.1204897			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704829				2022-12-28	WOS:000171739300008
J	Hu, XT; Zhang, XH; Zhong, Q; Fisher, AB; Bryington, M; Zuckerman, KS				Hu, XT; Zhang, XH; Zhong, Q; Fisher, AB; Bryington, M; Zuckerman, KS			Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells	ONCOGENE			English	Article						cell cycle; transforming growth factor; cell line; Rb protein; cdk inhibitor	DEPENDENT-KINASE INHIBITOR; FACTOR-BETA; CDK INHIBITOR; MAMMALIAN-CELLS; TGF-BETA; G1 PHASE; PROTEIN-PHOSPHORYLATION; EPITHELIAL-CELLS; G(1) CYCLINS; P27(KIP1)	In this report we have studied the mechanism by which Transforming Growth Factor beta (TGF beta) inhibits growth of human myeloid leukemia cell lines. TGF beta1 arrested cells in G1 phase and significantly downregulated the expression of cyclin D2, cyclin D3, cdk4, cyclin A, and cdk2. The downregulation of the molecules resulted in approximately 50-90% decrease of the molecule-dependent kinase activity, varying with each molecule. Although treatment of cells with TGF beta1 upregulated accumulation of p27(kip1) in both nucleus and cytoplasm, the association of the p27(kip1) with cdk2, cyclin A, cyclin D2, cyclin D3, and cdk4 was markedly downregulated, suggesting that p27(kip1) is not responsible for the downregulation of the kinase activity. In contrast, TGF beta1 upregulated cyclin E-associated p27(kip1) with no effect on the expression of cyclin E. p27(kip1)-immunodepletion upregulated cyclin E-dependent kinase activity by more than 10-fold in TGF beta1-treated cells but not in proliferating cells; whereas immunodepletion of p27(kip1) from cdk2-immunoprecipitates markedly downregulated cdk2 kinase activity in the lysates extracted from both proliferating and TGF beta -treated cells. Consistent with this observation, TGF beta1 and p27(kip1) antisense cDNA had a synergistic or additive inhibitory effect on cdk2 but not cyclin E-dependent kinase activity. Our data suggest that (1) TGF beta1-mediated growth inhibition is accomplished through multiple pathways and (2) p27(kip1) has opposing effects on cdk2 and cyclin E activity in response to TGF beta1.	Univ S Florida, Hematol Malignancies Program, Interdisciplinary Oncol Program, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Hu, XT (corresponding author), Univ S Florida, Hematol Malignancies Program, Interdisciplinary Oncol Program, MCC 3142,12902 Magnolia Dr, Tampa, FL 33612 USA.	hu@moffitt.usf.edu						ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BATES S, 1994, ONCOGENE, V9, P71; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Drexler HG, 1998, LEUKEMIA RES, V22, P927, DOI 10.1016/S0145-2126(98)00088-5; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAUTSCH MP, 1995, J CELL BIOCHEM, V58, P517, DOI 10.1002/jcb.240580415; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hu XT, 1999, EXP HEMATOL, V27, P605, DOI 10.1016/S0301-472X(99)00004-1; Hu XT, 2000, BIOCHEM BIOPH RES CO, V276, P930, DOI 10.1006/bbrc.2000.3556; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Singh SP, 1998, CANCER RES, V58, P1730; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; Wang G, 1999, ONCOGENE, V18, P5204, DOI 10.1038/sj.onc.1202912; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	49	14	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6840	6850		10.1038/sj.onc.1204790	http://dx.doi.org/10.1038/sj.onc.1204790			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687963				2022-12-28	WOS:000171641000005
J	Jennings, R; Alsarraj, M; Wright, KL; Munoz-Antonia, T				Jennings, R; Alsarraj, M; Wright, KL; Munoz-Antonia, T			Regulation of the human transforming growth factor beta type II receptor gene promoter by novel Sp1 sites	ONCOGENE			English	Article						transforming growth factor-beta (TGF beta); TGF beta receptors; promoter; Sp1 transcription factor	THYMIDINE KINASE PROMOTER; NF-Y; TRANSCRIPTION FACTORS; CARCINOMA-CELLS; REPRESS TRANSCRIPTION; TUMOR-SUPPRESSOR; SMAD PATHWAY; MCF-7 CELLS; EXPRESSION; BINDING	The transforming growth factor-beta (TGF beta) type II receptor (T betaR-II) is responsible for transducing the growth inhibitory signals of TGF beta. The T betaR-II gene promoter lacks both a TATA box and a CAAT box near the transcription initiation site, and has been shown to contain binding sequences for several transcription factors (Sp1, AP1, NF-Y, Cut and ERT) which are important for T betaR-II gene promoter activity in vitro. However, it is still not clear which interactions are important for the regulation of T betaR-II gene promoter activity in vivo. Using in viro genomic DNA footprinting of normal human epithelial cells (HaCaT), we have identified two novel identical and strongly protected sites (ggggctgg) at positions -59 and - 102 of the T betaR-II gene promoter. Mutation of either site significantly reduced promoter activity in transient transfections. Protein binding to these sites, as determined by electrophoretic mobility shift assays (EMSA), was specifically competed with consensus Sp1 oligonucleotides. Furthermore, anti-Sp1/3 antibodies produced band shifts when incubated with the T betaR-II - 59 and - 102 DNA probes. Importantly, Sp1 protein binding was influenced by the presence of an intact NF-Y binding site at position -83. Our data suggests that both Sp1 and NF-Y may play an important role in regulating T betaR-II gene promoter basal activity in vivo.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Program Immunol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Munoz-Antonia, T (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; HUMPHRIES DE, 1994, BIOCHEM BIOPH RES CO, V203, P1020, DOI 10.1006/bbrc.1994.2284; Jackson RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P290, DOI 10.1006/abbi.1999.1459; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MunozAntonia T, 1996, CANCER RES, V56, P4831; Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sorensen P, 1999, J BIOL CHEM, V274, P30943, DOI 10.1074/jbc.274.43.30943; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978	39	21	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6899	6909		10.1038/sj.onc.1204808	http://dx.doi.org/10.1038/sj.onc.1204808			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687969	Green Published, Green Submitted			2022-12-28	WOS:000171641000011
J	David, M; Ford, D; Bertoglio, J; Maizel, AL; Pierre, J				David, M; Ford, D; Bertoglio, J; Maizel, AL; Pierre, J			Induction of the IL-13 receptor alpha 2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways	ONCOGENE			English	Article						keratinocytes; MAP kinase; inhibitors; IL-4; IL-13; cytokine receptor chain; transduction	INTERLEUKIN-13 RECEPTOR; MESSENGER-RNA; KINASE PATHWAY; CELL RESPONSE; ALPHA CHAIN; PROTEIN; GENE; INHIBITOR; CLONING; BINDING	IL-4 and IL-13 are related cytokines which induce both pro- and anti-inflammatory effects depending on the cell type they act upon and the nature of the receptors expressed. The type I receptor complex is composed of the IL-4R alpha and gammac and only binds IL-4, whereas, in the type II receptor, IL-4R alpha dimerizes with IL-13R alpha1 upon either IL-4 or IL-13 binding. Another ligand binding chain potentially implicated in the IL-4/M-13 receptor has been described, the IL-13R alpha2, but the regulation of its expression and its role in IL-4/IL-13 transduction is poorly understood. In this study we report that IL-4 and IL-13 upregulate IL-13R alpha2 at both the mRNA and protein levels in the keratinocyte cell line HaCaT. In these cells, IL-4 or IL-13 were shown to activate the Janus Kinases JAK1 and JAK2, the transcription factor STAT6, and the ERK and p38 mitogen-activated protein kinases. We show that IL-4 or IL-13-induced IL-13R alpha2 mRNA expression was inhibited by the ERK inhibitor U0126, the JAK inhibitor AG490 and, to a lesser extent, the p38 MAPK inhibitor SB203580. Moreover, expression of a constitutive active mutant of STAT6 alone did not modify IL-13R alpha2 mRNA expression, but potentiated the effects of IL-4 or 11-13 on IL-13 alpha2 expression. The constitutive active mutants of MEK1 or MKK6 increased the level of expression of IL-13R alpha2 mRNA even in absence of stimulation. Our findings demonstrate, for the first time, that IL-4 and IL-13 can induce IL-13R alpha2 expression in keratinocytes, and that the ERK and p38 MAPK together with JAK2 and STAT6 play a critical role in this process.	INSERM, Fac Pharm, U461, F-92296 Chatenay Malabry, France; Boston Univ, Sch Med, Roger Williams Med Ctr, Providence, RI 02908 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Boston University; Roger Williams Medical Center	Pierre, J (corresponding author), INSERM, Fac Pharm, U461, 5,Rue JB Clement, F-92296 Chatenay Malabry, France.		David, Muriel/F-9592-2012	David, Muriel/0000-0003-1392-2701				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRUNET A, 1994, ONCOGENE, V9, P3379; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; COLOTTA F, 1992, CYTOKINE, V4, P24, DOI 10.1016/1043-4666(92)90032-M; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Daniel C, 2000, J BIOL CHEM, V275, P14255, DOI 10.1074/jbc.C000129200; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DEROCQ JM, 1994, FEBS LETT, V343, P32, DOI 10.1016/0014-5793(94)80601-2; Ezernieks J, 1996, EUR J BIOCHEM, V240, P667, DOI 10.1111/j.1432-1033.1996.0667h.x; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feng NP, 1998, LAB INVEST, V78, P591; Ford D, 1999, J IMMUNOL, V163, P3185; GALIZZI JP, 1990, J BIOL CHEM, V265, P439; Graber P, 1998, EUR J IMMUNOL, V28, P4286, DOI 10.1002/(SICI)1521-4141(199812)28:12<4286::AID-IMMU4286>3.0.CO;2-H; HARELBELLAN A, 1986, J IMMUNOL, V136, P2463; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ogata H, 1998, J BIOL CHEM, V273, P9864, DOI 10.1074/jbc.273.16.9864; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; Wang LH, 1999, J IMMUNOL, V162, P3897; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	40	77	80	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6660	6668		10.1038/sj.onc.1204629	http://dx.doi.org/10.1038/sj.onc.1204629			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709700				2022-12-28	WOS:000171551600002
J	Reddy, KB; McGowen, R; Schuger, L; Visscher, D; Sheng, SJ				Reddy, KB; McGowen, R; Schuger, L; Visscher, D; Sheng, SJ			Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model	ONCOGENE			English	Article						hyperplasia; carcinoma in situ; invasive carcinoma; immunohistochemistry; in situ hybridization	GROWTH-FACTOR-ALPHA; TGF-ALPHA; PLASMINOGEN-ACTIVATOR; MAMMARY; CELL; CANCER; OVEREXPRESSION; HYPERPLASIA; INHIBITION; NEOPLASIA	Maspin is a novel serine protease inhibitor (serpin) with tumor suppressive activity. To date, despite the mounting evidence implicating the potential diagnostic/prognostic and therapeutic value of maspin in breast and prostate carcinoma, the lack of a suitable animal model hampers the in vivo investigation on the role of maspin at different stages of tumor progression. In this study, we used MMTV/TGF-alpha transgenic mouse model to study the expression profile of maspin in mammary tumor progression. Histopathological examinations of MMTV/TGF-alpha transgenic mice revealed TGF-alpha expression leading to hyperproliferation, hyperplasia, and occasional carcinoma in mammary gland. Interestingly, when MMTV/TGF-alpha transgenic mice were breed to homozygocity, they also developed characteristic skin papillomas. Immunohistochemistry analysis of maspin expression in the breast tissues of TGF-oc transgenic mice showed a direct correlation between down-regulation of maspin expression and tumor progression. The loss of maspin expression was concomitant with the critical transition from carcinoma in situ to invasive carcinoma. Subsequent in-situ hybridization analyses suggest that the down-regulation of maspin expression is primarily a transcriptional event. This data is consistent with the tumor suppressive role of maspin. Furthermore, our data suggests that MMTV/TGF-alpha transgenic mouse model is advantageous for in vivo evaluation of both the expression and the biological function of maspin during the slow multi-stage carcinogenesis of mammary gland.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Sheng, SJ (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	ssheng@med.wayne.edu			NCI NIH HHS [CA 64248, CA 83964, CA69845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064248, R01CA083964, R21CA069845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; McGowen R, 2000, CANCER RES, V60, P4771; REDDY KB, 1994, CELL GROWTH DIFFER, V5, P1275; Rose-Hellekant TA, 2000, ONCOGENE, V19, P1092, DOI 10.1038/sj.onc.1203350; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Wagner M, 2001, GENE DEV, V15, P286, DOI 10.1101/gad.184701; Xia WY, 2000, ONCOGENE, V19, P2398, DOI 10.1038/sj.onc.1203535; Yamada N, 2000, GENE, V241, P267, DOI 10.1016/S0378-1119(99)00484-9; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	25	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6538	6543		10.1038/sj.onc.1204796	http://dx.doi.org/10.1038/sj.onc.1204796			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641778				2022-12-28	WOS:000171404200006
J	Judd, BA; Koretzky, GA				Judd, BA; Koretzky, GA			The role of the adapter molecule SLP-76 in platelet function	ONCOGENE			English	Article						SLP-76; adapter molecule; signal transduction; platelet; GPVI; alpha IIb beta 3	RECEPTOR-GAMMA-CHAIN; T-CELL RECEPTOR; PROTEIN-TYROSINE KINASE; GUANINE-NUCLEOTIDE EXCHANGE; STIMULATED PHOSPHOPROTEIN VASP; COLLAGEN-LIKE PEPTIDES; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-VI; PHOSPHOLIPASE C-GAMMA-2; INTEGRIN ALPHA(IIB)BETA(3)	Following vascular injury, one of the most critical initial events is activation of platelets followed by formation of a hemostatic plug. Platelets are capable of responding to a diverse array of agonists resulting in adhesion and granule release. The biochemical events underlying platelet activation are just beginning to be understood. One class of molecules shown to play important roles in this process is adapters. Adapter molecules contain distinct modular domains which mediate protein-protein or protein-lipid interactions giving these proteins the ability to nucleate signal transduction complexes. In this review we will discuss the function of the hematopoietic cell specific adapter molecule, SLP-76 in both platelet activation and hemostasis. Because many parallels exist between signal transduction pathways in platelets and lymphocytes, we will also review the function of SLP-76 in coordinating signal transduction pathways following antigen bind to the T cell receptor.	Univ Penn, Abraham Family Canc Res Inst, Signal Transduct Program, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Koretzky, GA (corresponding author), Univ Penn, Abraham Family Canc Res Inst, Signal Transduct Program, Philadelphia, PA 19104 USA.		Koretzky, Gary/AAU-5381-2021					Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bearer EL, 2000, CELL MOTIL CYTOSKEL, V47, P351, DOI 10.1002/1097-0169(200012)47:4<351::AID-CM8>3.0.CO;2-8; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BRASS LF, 1985, J BIOL CHEM, V260, P5172; Brass S, 2001, NATURE, V409, P145, DOI 10.1038/35051688; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; CASTAGNA M, 1985, ADV EXP MED BIOL, V192, P249; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Ezumi Y, 2000, BIOCHEM BIOPH RES CO, V277, P27, DOI 10.1006/bbrc.2000.3624; Fang N, 1996, J IMMUNOL, V157, P3769; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; GINSBERG MH, 1995, THROMB HAEMOSTASIS, V74, P352; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Hers I, 1998, ARTERIOSCL THROM VAS, V18, P404, DOI 10.1161/01.ATV.18.3.404; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Judd BA, 2000, P NATL ACAD SCI USA, V97, P12056, DOI 10.1073/pnas.97.22.12056; Kehrel B, 1998, BLOOD, V91, P491; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; MURPHY CT, 1991, BIOCHEM J, V278, P255, DOI 10.1042/bj2780255; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Myung PS, 2000, CURR OPIN IMMUNOL, V12, P256, DOI 10.1016/S0952-7915(00)00085-6; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; Offermanns S, 2000, BIOL CHEM, V381, P389, DOI 10.1515/BC.2000.051; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Patil S, 2001, BLOOD, V97, P1727, DOI 10.1182/blood.V97.6.1727; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Quek LS, 1998, CURR BIOL, V8, P1137, DOI 10.1016/S0960-9822(98)70471-3; Quek LS, 2000, BLOOD, V96, P4246; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schneider H, 2000, J BIOL CHEM, V275, P3835, DOI 10.1074/jbc.275.6.3835; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Tomiyama Y, 2000, INT J HEMATOL, V72, P448; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Verkleij MW, 1998, BLOOD, V91, P3808; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; WERNER MH, 1992, MOL PHARMACOL, V41, P382; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; YAMAMOTO N, 1992, BRIT J HAEMATOL, V81, P86, DOI 10.1111/j.1365-2141.1992.tb08177.x; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	98	15	15	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6291	6299		10.1038/sj.onc.1204772	http://dx.doi.org/10.1038/sj.onc.1204772			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607831				2022-12-28	WOS:000171640600004
J	Wu, CJ; O'Rourke, DM; Feng, GS; Johnson, GR; Wang, Q; Greene, MI				Wu, CJ; O'Rourke, DM; Feng, GS; Johnson, GR; Wang, Q; Greene, MI			The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors	ONCOGENE			English	Article						SHP-2; phosphatidylinositol 3-kinase (PI3K); Akt; growth factors; signaling	HUMAN GLIOBLASTOMA CELLS; FACTOR RECEPTOR; PHOSPHOINOSITIDE-3-OH KINASE; PHOSPHOTYROSINE PHOSPHATASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; FOCAL ADHESION; SH2 DOMAINS; ERBB FAMILY; PROTEIN	SHP-2 is a ubiquitously expressed non-transmembrane tyrosine phosphatase with two SH2 domains. Multiple reverse-genetic studies have indicated that SHP-2 is a required component for organ and animal development. SHP-2 wild-type and homozygous mutant mouse fibroblast cells in which the N-terminal SH2 domain was target-deleted were used to examine the function of SHP-2 in regulating Phosphatidylinositol 3-Kinase (PI3K) activation by growth factors. In addition, SHP-2 and various mutants were introduced into human glioblastoma cells as well as SHP-2(-/-) mouse fibroblasts. We found that EGF stimulation and EGFR oncoprotein (Delta EGFR) expression independently induced the co-immunoprecipitation of the p85 subunit of PI3K with SHP-2. Targeted deletion of the N-terminal SH2 domain of SHP-2 severely impaired PDGF- and IGF-induced Akt phosphorylation. Ectopic expression of SHP-2 in U87MG gliobastoma cells elevated EGF-induced Akt phosphorylation, and the effect was abolished by mutation of its N-terminal SH2 domain. Likewise, the reconstitution of SHP-2 expression in the SHP-2(-/-) cells enhanced Akt phosphorylation induced by EGF while rescuing that induced by PDGF and IGF. Further lipid kinase activity assays confirmed that SHP-2 modulation of Akt phosphorylation correlated with its regulation of PI3K activation. Based on these results, we conclude that SHP-2 is required for mediating PI3K/Akt activation, and the N-terminal SH2 domain is critically important for a 'positive' role of SHP-2 in regulating PI3K pathway activation.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Burnham Inst, La Jolla, CA 92037 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Sanford Burnham Prebys Medical Discovery Institute; US Food & Drug Administration (FDA)	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 252 John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu	O'Rourke, Donald/AAC-3376-2021; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; O'Rourke, Donald/0000-0002-8479-7314				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Allard JD, 1996, DEVELOPMENT, V122, P1137; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; Manes S, 1999, MOL CELL BIOL, V19, P3125; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; Oh ES, 1999, MOL CELL BIOL, V19, P3205; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Takahashi Y, 1999, J CELL PHYSIOL, V178, P69, DOI 10.1002/(SICI)1097-4652(199901)178:1<69::AID-JCP9>3.0.CO;2-Z; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	39	119	120	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6018	6025		10.1038/sj.onc.1204699	http://dx.doi.org/10.1038/sj.onc.1204699			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593409				2022-12-28	WOS:000171056300009
J	Aouacheria, A; Arnaud, E; Venet, S; Lalle, P; Gouy, M; Rigal, D; Gillet, G				Aouacheria, A; Arnaud, E; Venet, S; Lalle, P; Gouy, M; Rigal, D; Gillet, G			Nrh, a human homologue of Nr-13 associates with Bcl-Xs and is an inhibitor of apoptosis	ONCOGENE			English	Article						apoptosis; molecular cloning; Bcl-2 family; phylogeny	CYTOCHROME-C; BH3 DOMAIN; CELL-DEATH; BCL-2-RELATED GENE; ION-CHANNEL; BAX; FAMILY; EXPRESSION; PROTEINS; RELEASE	In search of human homologues of the anti-apoptotic protein Nr-13, we have characterized a human EST clone that potentially encodes a protein, which is the closest homologue of Nr-13 among the Bcl-2 family members, to date known, in humans. Phylogenetic analyses suggest Human nrh, Mouse diva/boo and Quail nr-13 to be orthologous genes. The nrh gene has the same overall organization as nr-13 and diva/boo with one single intron interrupting the ORF at the level of the Bcl-2-homology domain BH2. RT-PCR-based analysis of nrh expression indicated that this gene is preferentially expressed in the lungs, the liver and the kidneys. Interestingly, two in frame ATG codons can lead potentially to the synthesis of two products, one of them lacking 10 aminoacids at the N-terminal end. Sequence alignment with nr-13 and Diva/Boo in addition to secondary structure prediction of the nrh transcript suggested that the shortest protein will be preferentially synthetized. Immunohistochemical analyses have revealed that Nrh is associated with mitochondria and the nuclear envelope. Moreover, Nrh preferentially associates with the apoptosis accelerator Bcl-Xs and behaves as an inhibitor of apoptosis both in yeast and vertebrate cells.	Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Univ Lyon 1, CNRS, UMR 5558, F-67622 Villeurbanne, France; Etablissement Transfus Sanguine, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup	Gillet, G (corresponding author), Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.	g.gillet@ibcp.fr	gillet, germain/A-9095-2013; LALLE, Philippe/G-7734-2018	GILLET, Germain/0000-0002-1514-327X				Afonso CL, 2001, J VIROL, V75, P971, DOI 10.1128/JVI.75.2.971-978.2001; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; DONALDSON JG, 1998, CURRENT PROTOCOLS CE, V1; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Espanel X, 1998, ONCOGENE, V17, P585, DOI 10.1038/sj.onc.1201962; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GOLEMIS EA, 1999, CURRENT PROTOCOLS MO, V4; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Mangeney M, 1996, ONCOGENE, V13, P1441; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Otter I, 1998, J BIOL CHEM, V273, P6110, DOI 10.1074/jbc.273.11.6110; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SAMBROOK J, 1989, MOL CLONING, V2, P9; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Simonen M, 1997, EUR J BIOCHEM, V249, P85, DOI 10.1111/j.1432-1033.1997.t01-1-00085.x; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Walczak H, 2000, CANCER RES, V60, P3051; WANG HG, 1994, ONCOGENE, V9, P2751; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang QF, 2000, BREAST CANCER RES TR, V61, P211, DOI 10.1023/A:1006474307180; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930	52	33	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5846	5855		10.1038/sj.onc.1204740	http://dx.doi.org/10.1038/sj.onc.1204740			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593390				2022-12-28	WOS:000171037200008
J	Bartholin, L; Maguer-Satta, W; Hayette, S; Martel, S; Gadoux, M; Bertrand, S; Corbo, L; Lamadon, C; Morera, AM; Magaud, JP; Rimokh, R				Bartholin, L; Maguer-Satta, W; Hayette, S; Martel, S; Gadoux, M; Bertrand, S; Corbo, L; Lamadon, C; Morera, AM; Magaud, JP; Rimokh, R			FLRG, an activin-binding protein, is a new target of TGF beta transcription activation through Smad proteins	ONCOGENE			English	Article						FLRG; TGF beta; Smad; activin; follistatin	GROWTH-FACTOR-BETA; ERYTHROID-DIFFERENTIATION FACTOR; MAD PROTEINS; PROMOTER; GENE; SP1; FOLLISTATIN; EXPRESSION; RECEPTORS; FAMILY	The FLRG gene encodes a secreted glycoprotein that binds to activin and is highly homologous to follistatin, an activin ligand. We cloned the promoter region of the human FLRG gene, and defined the minimal region necessary for transcription activation in a reporter-system assay. We showed that the fragment between positions -130 and +6, which consists of multiple consensus Sp1-binding sites, is required for the constitutive expression of the FLRG gene. We demonstrate here that FLRG mRNA expression is rapidly induced by TGF beta or by transfection with Smad protein expression vectors in human HepG2 cells. We investigated the transcription-regulation mechanism of FLRG expression in HepG2 cells following treatment with TGF beta. By deletion and point-mutation analysis of the FLRG promoter, we identified a Smad-binding element involved in the TGF beta -inducible expression of the FLRG gene. Moreover, transactivation of the FLRG promoter by TGF beta was compromised by dominant-negative mutants of Smad3 and Smad4 proteins. In addition, get electrophoresis mobility-shift assays demonstrated the specific interaction of Smad3 and Smad4 proteins with the Smad-binding element consensus motif found in the FLRG promoter. Taken together, our data imply that Smad proteins participate in the regulation of expression of FLRG, a new target of TGF beta transcription activation.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon, France; Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France; Hop Debrousse, INSERM, U329, F-69322 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM, U453, F-69373 Lyon, France.	rimokh@lyon.fnclcc.fr	Bartholin, Laurent/Q-6655-2017; Maguer-Satta, Veronique/U-8857-2019; Rimokh, Ruth/G-7506-2014; HAYETTE, sandrine/Z-2283-2019	Bartholin, Laurent/0000-0002-5637-3223; Maguer-Satta, Veronique/0000-0002-1556-068X; 				Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DePaolo LV, 1997, P SOC EXP BIOL MED, V214, P328; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DYBEDAL I, 1995, BLOOD, V86, P949; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Hayette S, 1998, ONCOGENE, V16, P2949, DOI 10.1038/sj.onc.1201807; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kitamura K, 2000, BLOOD, V95, P3371, DOI 10.1182/blood.V95.11.3371.011k37_3371_3379; KRYSTAL G, 1994, J EXP MED, V180, P851, DOI 10.1084/jem.180.3.851; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Maguer-Satta V, 2001, EXP HEMATOL, V29, P301, DOI 10.1016/S0301-472X(00)00675-5; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Pierelli L, 2000, BLOOD, V95, P3001; SHAO LE, 1992, BLOOD, V79, P773; SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsuchida K, 2000, J BIOL CHEM, V275, P40788, DOI 10.1074/jbc.M006114200; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; YAMASHITA T, 1992, BLOOD, V79, P304; Ying SY, 1997, P SOC EXP BIOL MED, V214, P114; Yu J, 1997, CYTOKINES CELL MOL T, V3, P169; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YQ, 1997, BBA-GENE STRUCT EXPR, V1354, P204, DOI 10.1016/S0167-4781(97)00085-7	44	34	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5409	5419		10.1038/sj.onc.1204720	http://dx.doi.org/10.1038/sj.onc.1204720			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571638				2022-12-28	WOS:000170781100001
J	VanHouten, JN; Asch, HL; Asch, BB				VanHouten, JN; Asch, HL; Asch, BB			Cloning and characterization of ectopically expressed transcripts for the actin-binding protein MIPP in mouse mammary carcinomas	ONCOGENE			English	Article						MIPP; mammary; cancer; endoplasmic reticulum; actin; kelch	ENDOPLASMIC-RETICULUM; DROSOPHILA KELCH; GENE; MICROTUBULE; CYTOSKELETON; OUTGROWTHS; FILAMENTS; COMPLEX; ENCODES; DOMAIN	Mipp is a kelch-related, placental-specific gene that is ectopically expressed in many BALB/c mouse mammary carcinomas of various etiologies. The Kelch family encompasses proteins that are emerging as key links between microfilaments and a variety of cellular structures and functions. Mouse mammary tumors express two mipp transcripts (2.2 and 5.6 kb). We cloned the 2.2 kb mipp mRNA and analysed the product of its 1.7 kb ORE The 584 residue MIPP protein has an N-terminal BTB domain and six C-terminal tandem Kelch repeats. Despite expression of two mipp RNAs, only a single MIPP protein is expressed in mammary tumors. MIPP protein binds to microfilaments in vitro and co-immunoprecipitates with actin. MIPP co-localized with concanavalin A at the endoplasmic reticulum, suggesting that MIPP might mediate interactions between microtubules and actin filaments. Because MIPP expression is widespread in mouse mammary tumors, it might contribute to tumorigenesis. Although MIPP had little effect on the growth rate of human breast cell lines following transfection, it greatly reduced the formation of duct-like structures on reconstituted basement membrane. Our results suggest that MIPP could contribute to malignant progression in the mouse mammary epithelial cells by perverting their response to cues from the extracellular matrix.	Roswell Pk Canc Inst Corp, Div Expt Pathol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	VanHouten, JN (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [R01CA062014, P30CA016056, R01CA072768] Funding Source: NIH RePORTER; NCI NIH HHS [CA62014, CA16056, CA72768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Callebaut I, 1998, CELL MOL LIFE SCI, V54, P880, DOI 10.1007/s000180050216; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; CARRAWAY KL, 1992, CYTOSKELETON PRACTIC; CHANGYEH A, 1993, P NATL ACAD SCI USA, V90, P292, DOI 10.1073/pnas.90.1.292; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; GOULD MN, 1995, SEMIN CANCER BIOL, V6, P147, DOI 10.1006/scbi.1995.0023; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Horton Paul, 1997, INTELLIGENT SYSTEMS, V5, P147; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUEDERS KK, 1977, CELL, V12, P963, DOI 10.1016/0092-8674(77)90161-1; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MEDINA D, 1993, CANCER RES, V53, P663; MEDINA D, 1988, CARCINOGENESIS, V9, P1113, DOI 10.1093/carcin/9.7.1113; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P3, DOI 10.1007/BF02096298; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Sanders MC, 1996, J BIOL CHEM, V271, P2651, DOI 10.1074/jbc.271.5.2651; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; Schmucker B, 1997, EUR J CELL BIOL, V72, P46; SELDEN SC, 1986, ANN NY ACAD SCI, V466, P803, DOI 10.1111/j.1749-6632.1986.tb38464.x; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Tabb JS, 1998, J CELL SCI, V111, P3221; TERASAKI M, 1990, CELL MOTIL CYTOSKEL, V15, P71, DOI 10.1002/cm.970150203; VanHouten JN, 1996, ONCOGENE, V12, P2241; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; WOOD JG, 1981, J NEUROCYTOL, V10, P149, DOI 10.1007/BF01181750; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	35	5	6	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5366	5372		10.1038/sj.onc.1204701	http://dx.doi.org/10.1038/sj.onc.1204701			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536049				2022-12-28	WOS:000170575500012
J	Persengiev, SP; Li, JQ; Poulin, ML; Kilpatrick, DL				Persengiev, SP; Li, JQ; Poulin, ML; Kilpatrick, DL			E2F2 converts reversibly differentiated PC12 cells to an irreversible, neurotrophin-dependent state	ONCOGENE			English	Article						terminal differentiation; neuron; apoptosis; growth arrest	NERVE GROWTH-FACTOR; ACTIVE TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN FAMILY; SUBCELLULAR-LOCALIZATION; PHEOCHROMOCYTOMA CELLS; MICE LACKING; CYCLIN D1; DEATH; NEURONS; PROLIFERATION	E2Fs play a central role in cell proliferation and growth arrest through their ability to regulate genes involved in cell cycle progression, arrest and apoptosis. Recent studies further indicate that this family of transcriptional regulators participate in cell fate/differentiation events. They are thus likely to have a prominent role in controlling the terminal differentiation process and its irreversibility. Here we have specifically examined the role of E2F2 in neuronal differentiation using a gain-of-function approach. Endogenous E2F2 increased in PC12 cells in response to nerve growth factor (NGF) and was also expressed in cerebellar granule neurons undergoing terminal differentiation. While PC12 cells normally undergo reversible dedifferentiation and cell cycle reentry upon NGF removal, forced expression of E2F2 inhibited these events and induced apoptosis. Thus, E2F2 converted PC12-derived neurons from a reversible to a 'terminally' differentiated, NGF-dependent state, analogous to postmitotic sympathetic neurons. This contrasts with the effects of E2F4, which enhances the differentiation state of PC12 cells without affecting cell cycle parameters or survival. These results indicate that E2F2 may have a unique role in maintaining the postmitotic state of terminally differentiated neurons, and may participate in apoptosis in neurons attempting to reenter the cell cycle. It may also be potentially useful in promoting the terminally arrested/differentiated state of tumor cells.	Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Kilpatrick, DL (corresponding author), Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL CANCER INSTITUTE [R01CA079999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036468] Funding Source: NIH RePORTER; NCI NIH HHS [CA-79999] Funding Source: Medline; NIDDK NIH HHS [DK36468] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Brook A, 1996, EMBO J, V15, P3676, DOI 10.1002/j.1460-2075.1996.tb00737.x; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; CAMBRAYDEAKIN MA, 1995, NEURAL CELL CULTURE, P3; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cui H, 1998, DEV BRAIN RES, V106, P129, DOI 10.1016/S0165-3806(97)00204-6; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Frade JM, 2000, J CELL SCI, V113, P1139; Francesconi CM, 2000, INVEST OPHTH VIS SCI, V41, P1054; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Gill RM, 2000, J CELL BIOL, V148, P1187, DOI 10.1083/jcb.148.6.1187; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Gollapudi L, 1999, J NEUROSCI RES, V56, P99, DOI 10.1002/(SICI)1097-4547(19990401)56:1<99::AID-JNR13>3.0.CO;2-G; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Heibein JA, 1999, J IMMUNOL, V163, P4683; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Magae J, 1996, J CELL SCI, V109, P1717; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Myster DL, 2000, DEVELOPMENT, V127, P3249; Nagy Z, 1999, J NEURAL TRANSM-SUPP, P233; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; PERSENGIEV SP, 1993, INT J BIOCHEM, V25, P441, DOI 10.1016/0020-711X(93)90637-T; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Raina AK, 2000, J NEUROSCI RES, V61, P128, DOI 10.1002/1097-4547(20000715)61:2<128::AID-JNR2>3.3.CO;2-8; Ross ME, 1996, TRENDS NEUROSCI, V19, P62, DOI 10.1016/0166-2236(96)89622-6; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; vanGrunsven LA, 1996, ONCOGENE, V12, P855; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YAN GZ, 1995, J NEUROSCI, V15, P6200; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	52	17	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5124	5131		10.1038/sj.onc.1204663	http://dx.doi.org/10.1038/sj.onc.1204663			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526501				2022-12-28	WOS:000170464000006
J	Crepieux, P; Marion, S; Martinat, N; Fafeur, V; Le Vern, Y; Kerboeuf, D; Guillou, F; Reiter, E				Crepieux, P; Marion, S; Martinat, N; Fafeur, V; Le Vern, Y; Kerboeuf, D; Guillou, F; Reiter, E			The ERK-dependent signalling is stage-specifically modulated by FSH, during primary Sertoli cell maturation	ONCOGENE			English	Article						ERK MAP kinases; cAMP/PKA; FSH; cell proliferation; cell differentiation	ACTIVATED PROTEIN-KINASE; FOLLICLE-STIMULATING-HORMONE; CYCLIN D1 EXPRESSION; OVARIAN GRANULOSA-CELLS; MAP KINASE; SIGNALING PATHWAY; COUPLED RECEPTORS; TRANSFERRIN GENE; CAMP; PHOSPHORYLATION	Primary cultures of Sertoli cells provide an interesting model to study how signalling pathways induced by a single hormone in a single cell type evolve, depending. on the developmental stage. In vivo, follicle-stimulating hormone (FSH) induces proliferation of Sertoli cells in neonate and controls the subsequent differentiation of the entire population. Molecular mechanisms underlying Sertoli cell pleiotropic responses to FSH have long been investigated. But to date, only cAMP-dependent kinase (PKA) activation has been reported to account for most FSH biological activities in male. Here, we demonstrate that FSH activates the ERK MAP kinase pathway following dual coupling of the FSH-R both to Gs and to Gi heterotrimeric proteins, in a PKA- and also Src-dependent manner. This activation is required for FSH-induced proliferation of Sertoli cells isolated 5 days after birth. Consistently, we show that the ERK-mediated FSH mitogenic effect triggers upregulation of cyclin D1. In sharp contrast, at 19 days after birth, as cells proceed through their differentiation program, the ERK pathway is dramatically inhibited by FSH treatment. Taken together, these results show that FSH can exert opposite effects on the ERK signalling cascade during the maturation process of Sertoli cells. Thus, signalling modules triggered by the FSH-R evolve dynamically throughout development of FSH natural target cells.	Univ Tours, Lab Physiol Reprod & Comportements, Inst Natl Rech Agron, CNRS,UMR 6073, Nouzilly, France; Ctr Rech Tours, Lab Pathol Aviaire & Parasitol, F-37380 Tours, France; CNRS, FRE 2353, Inst Biol Lille, Inst Pasteur Lille, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Tours; INRAE; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Crepieux, P (corresponding author), Univ Tours, Lab Physiol Reprod & Comportements, Inst Natl Rech Agron, CNRS,UMR 6073, Nouzilly, France.	crepieux@tours.inra.fr	Fafeur, Veronique/L-9072-2018; Crepieux, Pascale/X-3217-2019	Marion, Sebastien/0000-0002-3302-3845				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cameron MR, 1996, BIOL REPROD, V55, P111, DOI 10.1095/biolreprod55.1.111; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; COFFER P, 1994, ONCOGENE, V9, P911; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Fuller PJ, 1998, J CLIN ENDOCR METAB, V83, P274, DOI 10.1210/jc.83.1.274; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; GUILLOU F, 1986, BIOCHIM BIOPHYS ACTA, V887, P196, DOI 10.1016/0167-4889(86)90055-8; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANSSON V, 2000, J STEROID BIOCHEM, V72, P81; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Maizels ET, 1998, ENDOCRINOLOGY, V139, P3353, DOI 10.1210/en.139.7.3353; MONN E, 1972, ENDOCRINOLOGY, V91, P716, DOI 10.1210/endo-91-3-716; NIKULA H, 1990, MOL CELL ENDOCRINOL, V70, P247, DOI 10.1016/0303-7207(90)90215-T; ORTH JM, 1984, ENDOCRINOLOGY, V115, P1248, DOI 10.1210/endo-115-4-1248; PAULSSEN RH, 1991, BIOL REPROD, V45, P566, DOI 10.1095/biolreprod45.4.566; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; PURUSHOTHAM KR, 1994, BIOCHEM BIOPH RES CO, V202, P743, DOI 10.1006/bbrc.1994.1993; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; SAEZ JM, 1991, HORM RES, V36, P104, DOI 10.1159/000182142; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SPITERIGRECH J, 1993, J REPROD FERTIL, V98, P1; Stanislaus D, 1998, MOL CELL ENDOCRINOL, V144, P1, DOI 10.1016/S0303-7207(98)00126-9; Suire S, 1997, MOL REPROD DEV, V48, P168, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;168::AID-MRD4&gt;3.0.CO;2-Q; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Troispoux C, 1998, MOL CELL ENDOCRINOL, V142, P75, DOI 10.1016/S0303-7207(98)00115-4; Troispoux C, 1999, MOL ENDOCRINOL, V13, P1599, DOI 10.1210/me.13.9.1599; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	51	151	161	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4696	4709		10.1038/sj.onc.1204632	http://dx.doi.org/10.1038/sj.onc.1204632			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498792				2022-12-28	WOS:000170208600010
J	Wajant, H; Moosmayer, D; Wuest, T; Bartke, T; Gerlach, E; Schonherr, U; Peters, N; Scheurich, P; Pfizenmaier, K				Wajant, H; Moosmayer, D; Wuest, T; Bartke, T; Gerlach, E; Schonherr, U; Peters, N; Scheurich, P; Pfizenmaier, K			Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative	ONCOGENE			English	Article						antibody-mediated; targeting; apoptosis; tumor; TNF ligand family	APOPTOSIS-INDUCING LIGAND; TUMORICIDAL ACTIVITY; T-CELLS; EXPRESSION	TNF-related apoptosis-inducing ligand (TRAIL) is a typical member of the tumor necrosis factor (TNF) ligand family that is expressed as a type Il membrane protein (memTRAIL) and signals apoptosis via the death domain-containing receptors TRAIL-R1 and -2, Soluble recombinant derivatives of TRAIL (sTRAIL) are considered as novel tumors therapeutics because of their selective apoptosis inducing activity in a variety of human tumors but not in normal cells. Using antagonistic antigen-binding fragment (Fab) preparations of TRAIL-R1- and TRAIL-R2-specific antibodies, we demonstrate in this study that TRAIL-R1 becomes activated by both the soluble and the membrane-bound form of the ligand, whereas TRAIL-R2 becomes only activated by memTRAIL or soluble TRAIL secondarily cross-linked by antibodies. Furthermore, we show that the restricted signal capacity of sTRAIL can be readily converted into a fully signal competent memTRAIL-like molecule, i.e. a TRAIL-R2 stimulating ligand, by genetic fusion to an antibody derivative that allows antigen-dependent 'immobilization' of the fusion protein to cell surfaces. We conclude that antibody targeting-dependent activation can be used to design selective therapeutics derived of those ligands of the TNF family that are biologically inactive in their soluble form.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Rippmann JF, 2000, BIOCHEM J, V349, P805, DOI 10.1042/bj3490805; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	15	163	176	2	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4101	4106		10.1038/sj.onc.1204558	http://dx.doi.org/10.1038/sj.onc.1204558			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494138				2022-12-28	WOS:000169681500018
J	Ronchetti, D; Greco, A; Compasso, S; Colombo, G; Dell'Era, P; Otsuki, T; Lombardi, L; Neri, A				Ronchetti, D; Greco, A; Compasso, S; Colombo, G; Dell'Era, P; Otsuki, T; Lombardi, L; Neri, A			Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations	ONCOGENE			English	Article						FGFR3 mutations; multiple myeloma; t(4;14)	GROWTH-FACTOR RECEPTOR-3; T(4/14)(P16.3,Q32) CHROMOSOMAL TRANSLOCATION; LETHAL SKELETAL DYSPLASIA; CHONDROCYTE PROLIFERATION; ACTIVATING MUTATIONS; GENE; TRANSMEMBRANE; TRANSFORMATION; EXPRESSION; REGION	The t(4;14)(p16.3;q32) chromosomal translocation occurs in approximately 20%, of multiple myelomas (MM) and leads to the apparent deregulation of two genes located on 4p16.3: the fibroblast growth factor receptor 3 (FGFR3) and the putative transcription factor WHSC1/ MMSET, Interestingly, FGFR3 mutations known to be associated with autosomal dominant human skeletal disorders have also been found in some MM cell lines with t(4;14) but their pathogenetic role in MM is still controversial, Since cell lines may represent useful models for investigating the effects of deregulated FGFR3 mutants in MM, we analysed the expression, activation, signaling pathways and oncogenic potential of three mutants identified so far: the Y373C and K650E in the KMS-11 and OPM-2 cell lines respectively, and the novel G384D mutation here identified in the KMS-18 cell line, All of the cell lines present a heterozygous FGFR3 gene mutation and transcribe the mutated allele; unlike KMS-11 and OPM-2 (which express the IIIc isoform), the KMS-18 cell line expresses prevalently the isoform IIIb, We demonstrated that, under serum-starved conditions, KMS-11 and OPM-2 cells express appreciable levels of phosphorylated FGFR3 mutants indicating a constitutive activation of the Y373C and K650E receptors; the addition of the aFGF ligand further increased the level of receptor phosphorylation, Conversely, the FGFR3 mutant in KMS-18 does not seem to be constitutively activated since it was phosphorylated only in the presence of the ligand, In all three MM cell lines, ligand-stimulated FGFR3 mutants activated the MAP kinase signaling pathway but did not apparently involve either the STAT1 or STAT3 cascades, However, when transfected in 293T cells, G384D, like Y373C and K650E, was capable of activating MAPK, STAT1 and STAT3 under serum-starved condition, Finally, a focus formation assay of NIH3T3 cells transfected with FGFR3-expressing plasmid vectors showed that Y373C and K650E (albeit at different levels) but not G384D or the wild-type receptor, can induce transformed foci, Overall, our results support the idea that FGFR3 mutations are graded in terms of their activation capability, thus suggesting that they may play a critical role in the tumor progression of MM patients with t(4;14).	Univ Milan, Dipartimento Sci Med, Osped Maggiore, IRCCS,Serv Ematol, I-20122 Milan, Italy; Ist Nazl Tumori, I-20133 Milan, Italy; Osped Maggiore, IRCCS, Div Internal Med 3, Milan, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Brescia, Italy; Kawasaki Med Sch, Dept Hyg, Okayama, Japan	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Brescia; Kawasaki Medical School	Neri, A (corresponding author), Univ Milan, Dipartimento Sci Med, Osped Maggiore, IRCCS,Serv Ematol, Via Francesco Sforza 35, I-20122 Milan, Italy.		Dell'Era, Patrizia/N-6964-2019; Colombo, Gualtiero I./B-4737-2010; Neri, Antonino/I-9690-2014; Dell'Era, Patrizia/G-5294-2010; Greco, Angela/C-1953-2017; Dell'Era, Patrizia/ABD-5848-2020	Colombo, Gualtiero I./0000-0002-7348-1939; Neri, Antonino/0000-0001-9047-5912; Dell'Era, Patrizia/0000-0001-6682-6321; Greco, Angela/0000-0003-2994-0349; RONCHETTI, Domenica/0000-0002-4824-3445				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; CATLETTFALCONE R, 1999, IMMUNITY, V16, P2647; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Finelli P, 1999, BLOOD, V94, P724, DOI 10.1182/blood.V94.2.724.414k05_724_732; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; Francomano C. A., 1996, American Journal of Human Genetics, V59, pA25; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kannan K, 2000, IUBMB LIFE, V49, P197; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li Y, 1997, ONCOGENE, V14, P1397, DOI 10.1038/sj.onc.1200983; Li ZH, 1998, BLOOD, V92, p383A; LOFTS FJ, 1993, ONCOGENE, V8, P2813; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; Malgeri U, 2000, CANCER RES, V60, P4058; MUENKE M, 1997, TIG, V11, P308; MURGUE B, 1994, CANCER RES, V54, P5206; NAMBA M, 1989, IN VITRO CELL DEV B, V25, P723; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Otsuki T, 1998, INT J ONCOL, V12, P545; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Raffioni S, 1998, J BIOL CHEM, V273, P35250, DOI 10.1074/jbc.273.52.35250; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; RONCHETTI D, 2001, IN PRESS LEUKEMIA; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Webster MK, 1996, MOL CELL BIOL, V16, P4081	45	88	114	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3553	3562		10.1038/sj.onc.1204465	http://dx.doi.org/10.1038/sj.onc.1204465			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429702				2022-12-28	WOS:000169478300011
J	Takai, D; Yagi, Y; Wakazono, K; Ohishi, N; Morita, Y; Sugimura, T; Ushijima, T				Takai, D; Yagi, Y; Wakazono, K; Ohishi, N; Morita, Y; Sugimura, T; Ushijima, T			Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis	ONCOGENE			English	Article						DNA methylation; lung neoplasms; endothelin-1; serotonin IB receptor; MS-RDA	BRONCHIAL EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; PROSTATE-CANCER; GROWTH-FACTOR; CPG ISLANDS; GENE; ENDOTHELIN; HYPERMETHYLATION; AMPLIFICATION; PCR	Aberrantly hypermethylated genes in human lung cancers were searched for by a genome scanning technique, methylation-sensitive-representational difference analysis (MS-RDA). A total of 59 DNA fragments were isolated as those methylated more heavily in either/both of two lung squamous cell carcinoma cell lines, EBC-1 and LK-2, than in a primary culture of normal human bronchial epithelium, NHBE. Thirty-four DNA fragments, whose hypermethylation was confirmed in primary squamous cell carcinomas, were sequenced. By database searches, 17 of them were shown to be located within 2 kb of putative CpG islands, and five of the 17 DNA fragments had transcribed regions of known genes in their vicinities. By RT - PCR of the five genes in the carcinoma cell lines and NHBE, decreased expression of HTR1B (5-hydroxytryptamine receptor 1B) and EDN1 (endothelin-1) was observed. Sequencing after bisulfite modification showed that the CpG island in the promoter region of HTR1B was hypermethylated, while that of EDN1 was not. Demethylation and re-expression of HTR1B were observed after treatment of LK-2 cells with 5-aza-2'-deoxycytidine. In primary lung cancers, decreased mRNA expression of HTR1B was observed in 11 of 20 cases, and that of EDN1 was in 16 of 20 cases. Immunohistochemical analysis of endothelin-1 confirmed that its immunoreactivity was reduced in squamous cell carcinoma cells compared with that in normal bronchial epithelial cells. Considering that endothelin-1 induces apoptosis in melanoma cells and that silencing of endothelin receptor B is observed in prostate cancers, its reduced expression was speculated to confer a growth advantage to lung cancer cells. MS-RDA was shown to isolate DNA fragments that are hypermethylated and silenced, such as HTR1B, and those whose expressions are altered and the methylation statuses outside the promoter region are altered, such as EDN1.	Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Grad Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo 1138655, Japan	National Cancer Center - Japan; University of Tokyo	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Ushijima, Toshikazu/AAP-5742-2021	Ushijima, Toshikazu/0000-0003-3405-7817				Al Moustafa AE, 1999, CLIN CANCER RES, V5, P681; Baylin SB, 1998, ADV CANCER RES, V72, P141; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; DEMCHYSHYN L, 1992, P NATL ACAD SCI USA, V89, P5522, DOI 10.1073/pnas.89.12.5522; Eguchi K, 1997, CANCER RES, V57, P4913; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HARRIS CC, 1991, IARC SCI PUBL, V105, P294; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; Jakowlew SB, 1997, BBA-GENE STRUCT EXPR, V1353, P157, DOI 10.1016/S0167-4781(97)00068-7; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KADOKAMI Y, 1995, ANAL BIOCHEM, V226, P193, DOI 10.1006/abio.1995.1212; Kelsey G, 1999, GENOMICS, V62, P129, DOI 10.1006/geno.1999.6022; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; MARKEWITZ BA, 1995, AM J PHYSIOL-LUNG C, V268, pL192, DOI 10.1152/ajplung.1995.268.2.L192; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; McDowell DG, 1998, NUCLEIC ACIDS RES, V26, P3340, DOI 10.1093/nar/26.14.3340; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Moghal N, 1998, MOL CELL BIOL, V18, P6666, DOI 10.1128/MCB.18.11.6666; Nelson JB, 1997, CANCER RES, V57, P35; Nelson JB, 1996, CANCER RES, V56, P663; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Okazawa M, 1998, J BIOL CHEM, V273, P12584, DOI 10.1074/jbc.273.20.12584; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; Sambrook J., 2000, MOL CLONING, V3rd; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	31	50	56	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7505	7513		10.1038/sj.onc.1204940	http://dx.doi.org/10.1038/sj.onc.1204940			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709722				2022-12-28	WOS:000171976900007
J	Crnogorac-Jurcevic, T; Efthimiou, E; Capelli, P; Blaveri, E; Baron, A; Terris, B; Jones, M; Tyson, K; Bassi, C; Scarpa, A; Lemoine, NR				Crnogorac-Jurcevic, T; Efthimiou, E; Capelli, P; Blaveri, E; Baron, A; Terris, B; Jones, M; Tyson, K; Bassi, C; Scarpa, A; Lemoine, NR			Gene expression profiles of pancreatic cancer and stromal desmoplasia	ONCOGENE			English	Article						pancreatic cancer; microarray; expression profiling; desmoplasia	GROWTH-FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; BREAST-CANCER; APOPTOSIS; PROTEINS; DECORIN; TUMORS; CELLS; ADENOCARCINOMA; IDENTIFICATION	Gene expression studies were undertaken in normal pancreas and pancreatic adenocarcinomas to determine new candidate genes that can potentially be used as markers of the disease. The characteristic desmoplastic stromal reaction of pancreatic adenocarcinoma greatly hampers expression studies in this tumour type, and usually necessitates time-consuming tissue microdissection for enrichment of the tumour cell population. We show that fine needle aspiration of cancer provides a fast and efficient way of obtaining samples highly enriched in tumour cells with sufficient yields of RNA. Using Atlas cancer cDNA arrays with 588 cancer-related genes, we describe gene expression profiles of normal pancreas, bulk pancreatic tumour tissues and pancreatic tumour aspirates containing more than 95% tumour cells. Analysis of bulk tissue specimens revealed differentially expressed genes belonging predominantly to the stromal component of the tumour. This contrasted with the results obtained from tumour-cell enriched samples. Several genes already described in pancreatic cancer (caspase 8, TIMP1, CD9, IL-13) were also differentially expressed in our study. Furthermore, we found dysregulated expression of genes not previously associated with pancreatic adenocarcinoma, such as Rac 1, GLG1, NEDD5, RPL-13a, RPS9 and members of the Wnt5A gene family. In summary, we present a panel of genes newly identified in the pathogenesis of pancreatic adenocarcinoma and demonstrate that fine needle aspirates of the tumour mass are a convenient source of material for gene expression studies in tumours accompanied by desmoplastic reactions.	Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund, Dept Canc Med, Mol Oncol Unit, London W12 0NN, England; Oxford Glycosci Proteome Discovery, Abingdon, Oxon, England; Univ Verona, Dept Surg, I-37100 Verona, Italy; Univ Verona, Dept Pathol, I-37100 Verona, Italy	Cancer Research UK; Imperial College London; University of Verona; University of Verona	Lemoine, NR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund, Dept Canc Med, Mol Oncol Unit, Hammersmith Campus, London W12 0NN, England.		Terris, Benoit/P-1497-2017; scarpa, aldo/K-6832-2016; Capelli, Patrizio/AEJ-5748-2022; Capelli, Patrizio/AAD-5108-2022	scarpa, aldo/0000-0003-1678-739X; Capelli, Patrizio/0000-0001-9434-3984; SALVIA, Roberto/0000-0002-3514-8473				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Asakura S, 1999, HUM PATHOL, V30, P195, DOI 10.1016/S0046-8177(99)90275-7; Aspinall RJ, 1999, ANN ONCOL, V10, P188, DOI 10.1023/A:1008315003875; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Cardone A, 1997, PANMINERVA MED, V39, P174; Chen FW, 1998, MOL GENET METAB, V64, P271, DOI 10.1006/mgme.1998.2718; EMMERTBUCK MR, 1996, SCIENCE, V274, P988; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gress TM, 1998, DIGESTION, V59, P625, DOI 10.1159/000007567; Gress TM, 1996, ONCOGENE, V13, P1819; Gress TM, 1997, GENE CHROMOSOME CANC, V19, P97, DOI 10.1002/(SICI)1098-2264(199706)19:2<97::AID-GCC5>3.0.CO;2-V; GRESS TM, 1995, INT J CANCER, V62, P407, DOI 10.1002/ijc.2910620409; HALVORSEN TB, 1989, J CLIN PATHOL, V42, P162, DOI 10.1136/jcp.42.2.162; Hu ED, 1998, BIOCHEM BIOPH RES CO, V247, P287, DOI 10.1006/bbrc.1998.8784; IOZZO RV, 1995, CANCER RES, V55, P3495; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kohl R, 2000, J BIOL CHEM, V275, P15741, DOI 10.1074/jbc.M903271199; Kornmann M, 1999, ANTICANCER RES, V19, P125; Lemoine NR, 1997, DIGESTION, V58, P550, DOI 10.1159/000201500; Lohr M, 2001, CANCER RES, V61, P550; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ricciardelli C, 1998, CLIN CANCER RES, V4, P963; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Ryu B, 2001, CANCER RES, V61, P1833; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Sirivatanauksorn Y, 1999, J PATHOL, V189, P150, DOI 10.1002/(SICI)1096-9896(199910)189:2<150::AID-PATH451>3.0.CO;2-G; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Virkajarvi N, 1998, HISTOPATHOLOGY, V33, P432, DOI 10.1046/j.1365-2559.1998.00553.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	39	153	164	2	17	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7437	7446		10.1038/sj.onc.1204935	http://dx.doi.org/10.1038/sj.onc.1204935			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704875				2022-12-28	WOS:000171894200018
J	Atlas, E; Stramwasser, M; Mueller, CR				Atlas, E; Stramwasser, M; Mueller, CR			A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element	ONCOGENE			English	Article						BRCA1; expression; transcription; CREB; sporadic breast cancer	SPORADIC BREAST-CANCER; RESPONSE ELEMENT; BINDING PROTEIN; OVARIAN-CANCER; MESSENGER-RNA; GENE-EXPRESSION; CPG ISLAND; METHYLATION; CELLS; ACTIVATION	Transcriptional regulation of the BRCA1 proximal promoter has been suggested to play a role in the decreased expression of BRCA1 observed in sporadic breast cancer. Computer analysis of the sequence of the proximal promoter reveals the presence of a potential CREB site. We have identified CREB/ATF-1 as the factor interacting with this site in nuclear extracts from MCF-7 and T-47D cells. This site is shown to be important for the constitutive expression of the promoter in these cells, as well as in Hep G2 cells. Despite the presence of this site, the BRCA1 promoter is not responsive to cAMP induction. It appears that CREB acts as a constitutive positive element for BRCA1 expression and that any mechanism inactivating CREB function would have a dramatic effect on BRCA1 expression.	Queens Univ, Dept Biochem, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Mueller, CR (corresponding author), Queens Univ, Dept Biochem, Canc Res Labs, Botterell Hall, Kingston, ON K7L 3N6, Canada.	muellerc@post.queensu.ca						Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Cui JQ, 1998, ONCOL REP, V5, P591; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; Dobrovic A, 1997, CANCER RES, V57, P3347; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Husain A, 1998, CANCER RES, V58, P1120; Kobayashi M, 1997, BIOCHEM BIOPH RES CO, V241, P169, DOI 10.1006/bbrc.1997.7781; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Sawada J, 1999, J BIOL CHEM, V274, P35475, DOI 10.1074/jbc.274.50.35475; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	38	39	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7110	7114		10.1038/sj.onc.1204890	http://dx.doi.org/10.1038/sj.onc.1204890			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704836				2022-12-28	WOS:000171739300015
J	Itoh, T; Nichols, A; Linn, S				Itoh, T; Nichols, A; Linn, S			Abnormal regulation of DDB2 gene expression in xeroderma pigmentosum group E strains	ONCOGENE			English	Article						DDB2; xeroderma pigmentosum; damage-specific DNA binding protein unscheduled DNA synthesis; p48; skin carcinogenesis	DNA-BINDING PROTEIN; COMPLEMENTATION GROUP-E; GLOBAL GENOMIC REPAIR; ATAXIA-TELANGIECTASIA; DAMAGED DNA; EXCISION-REPAIR; UV-IRRADIATION; CELLS; P48; PHENOTYPE	A damage-specific DNA binding protein (DDB) activity is absent from a subset (DDB-) of cells from individuals initially classified as group E of xeroderma pigmentosum (XP), a hereditary, photosensitive disease with a high incidence of skin malignancies. In these cases, mutations have been identified in the DDB2 gene (DDB2(-)) that codes for the small subunit, p48, of the DDB heterodimer. In four DDB2(-) strains, neither p48 nor DDB activity were observed before or after UV-irradiation, despite an unusually strong up-regulation of DDB2 mRNA levels after UV-irradiation. In a fifth strain, XP82TO, p48 was detectable and both DDB2 mRNA and p48 levels were more up-regulated after UV-irradiation than in normal primary cells. Moreover, DDB activity also became apparent after irradiation. XP82TO showed very mild clinical manifestations compared with the other DDB- patients. These results, coupled with our findings that most, if not all DDB+ cells classified as XP-E were misclassified, suggests a direct correlation between DDB2 levels and the XP-E phenotype.	Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Itoh, T (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059424] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ES08196] Funding Source: Medline; NIGMS NIH HHS [GM59424] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOOTSMA D, 1970, MUTAT RES, V9, P507, DOI 10.1016/0027-5107(70)90035-7; Borson ND, 1998, BIOTECHNIQUES, V25, P130, DOI 10.2144/98251rr01; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver J.E., 1995, METABOLIC MOL BASIS, P4393; de Weerd-Kastelein E A, 1974, Mutat Res, V22, P87, DOI 10.1016/0165-1218(74)90056-1; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Itoh T, 1996, J INVEST DERMATOL, V107, P349, DOI 10.1111/1523-1747.ep12363303; Itoh T, 1999, J INVEST DERMATOL, V113, P251, DOI 10.1046/j.1523-1747.1999.00652.x; ITOH T, 1994, MUTAT RES, V314, P233, DOI 10.1016/0921-8777(94)90068-X; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KLEIJER WJ, 1973, MUTAT RES, V20, P417, DOI 10.1016/0027-5107(73)90062-6; KONDO S, 1988, J INVEST DERMATOL, V90, P152, DOI 10.1111/1523-1747.ep12462130; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Liu W, 2000, J BIOL CHEM, V275, P21429, DOI 10.1074/jbc.M000961200; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037	37	11	11	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7041	7050		10.1038/sj.onc.1204909	http://dx.doi.org/10.1038/sj.onc.1204909			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704828				2022-12-28	WOS:000171739300007
J	Fima, E; Shtutman, M; Libros, P; Missel, A; Shahaf, G; Kahana, G; Livneh, E				Fima, E; Shtutman, M; Libros, P; Missel, A; Shahaf, G; Kahana, G; Livneh, E			PKC eta enhances cell cycle progression, the expression of G1 cyclins and p21 in MCF-7 cells	ONCOGENE			English	Article						PKC eta; cell cycle; cyclin E; cyclin D; p21; MCF-7	PROTEIN-KINASE-C; CAPILLARY ENDOTHELIAL-CELLS; METASTATIC MELANOMA-CELLS; BREAST-CANCER CELLS; CDK INHIBITORS; PHORBOL ESTER; RETINOBLASTOMA PROTEIN; ALTERED EXPRESSION; GROWTH-INHIBITION; PHASE-TRANSITION	Protein kinase C encodes a family of enzymes implicated in cellular differentiation, growth control and tumor promotion. However, not much is known with respect to the molecular mechanisms that link protein kinase C to cell cycle control. Here we report that the expression of PKC eta in MCF-7 cells, under the control of a tetracycline-responsive inducible promoter, enhanced cell growth and affected the cell cycle at several points. The induced expression of another PKC isoform, PKC delta, in MCF-7 cells had opposite effects and inhibited their growth. PKC eta expression activated cellular pathways in these cells that resulted in the increased expression of the G1 phase cyclins, cyclin D and cyclin E. Expression of the cyclin-dependent kinase inhibitor p21(WAF1) was also specifically elevated in PKC eta expressing cells, but its overall effects were not inhibitory. Although, the protein levels of the cyclin-dependent kinase inhibitor p27(KIP1) were not altered by the induced expression of PK eta the cyclin E associated Cdk2 kinase activity was in correlation with the p27(KIP1) bound to the cyclin E complex and not by p21(WAF1) binding. PK eta expression enhanced the removal of p27(KIP1) from this complex, and its re-association with the cyclin D/Cdk4 complex. Reduced binding of p27(KIP1) to the cyclin D/Cdk4 complex at early time points of the cell cycle also enhanced the activity of this complex, while at later time points the decrease in bound p21WAF1 correlated with its increased activity in PKC eta -expressing cells. Thus, PKC eta induces altered expression of several cell cycle functions, which may contribute to its ability to affect cell growth.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel	Ben Gurion University	Livneh, E (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.							AGRAWAL D, 1995, CELL GROWTH DIFFER, V6, P1199; Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Arita Y, 1998, EXP CELL RES, V242, P381, DOI 10.1006/excr.1997.3911; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; Downward J, 1997, CURR BIOL, V7, P258; ELDAR H, 1990, J BIOL CHEM, V265, P13290; Fishman DD, 1998, INT J ONCOL, V12, P181; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; Hamada K, 1996, BBA-MOL CELL RES, V1310, P149, DOI 10.1016/0167-4889(95)00148-4; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Livneh E, 1996, ONCOGENE, V12, P1545; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MICHIELI P, 1994, CANCER RES, V54, P3391; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Nakaigawa N, 1996, BIOCHEM BIOPH RES CO, V222, P95, DOI 10.1006/bbrc.1996.0703; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Slosberg ED, 1999, ONCOGENE, V18, P6658, DOI 10.1038/sj.onc.1203083; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; Zeng YX, 1996, ONCOGENE, V12, P1557; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHOU W, 1993, J BIOL CHEM, V268, P23041	63	55	56	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6794	6804		10.1038/sj.onc.1204885	http://dx.doi.org/10.1038/sj.onc.1204885			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709714	Bronze			2022-12-28	WOS:000171551600016
J	Sugai, T; Habano, W; Uesugi, N; Jiao, YF; Nakamura, S; Yoshida, T; Higuchi, T				Sugai, T; Habano, W; Uesugi, N; Jiao, YF; Nakamura, S; Yoshida, T; Higuchi, T			Frequent allelic imbalance at the ATM locus in DNA multiploid colorectal carcinomas	ONCOGENE			English	Article						allelic imbalance; ATM; colorectal carcinogenesis; DNA multiploidy; PCR	CRYPT-ISOLATION TECHNIQUE; ATAXIA-TELANGIECTASIA GENE; TUMOR-SUPPRESSOR GENES; CHROMOSOME 11Q23; HETEROZYGOSITY; CANCER; REGION; DAMAGE; IDENTIFICATION; ANEUPLOIDY	DNA multiploidy may involve specific DNA ploidy states with respect to genetic alterations such as oncogenes, tumor suppressor gene mutation and microsatellite instability. To clarify the role of DNA multiploidy in colorectal cancer, we analysed allelic imbalance involving the ATM gene, localized to chromosome 11q22-23 and thought to be involved in genetic stability, in a series of multiploid colorectal carcinomas. In addition, p53 gene mutation (exons 5 - 8) and allelic imbalance at 11q24 loci distal to the ATM locus were also examined. The crypt isolation technique coupled with DNA cytometric sorting and polymerase chain reaction assay using 10 microsatellite markers tightly linked to the ATM gene were used to study ATM allelic imbalance in 55 colorectal carcinomas (15 diploid, 13 aneuploid, 27 multiploid). While allelic imbalance at the ATM locus was rarely observed in diploid and aneuploid carcinomas, multiploid carcinomas exhibited a high frequency of ATM allelic imbalance. In multiploid carcinoma samples, diploid subpopulations showed a smaller range of allelic imbalance at the loci tested compared to aneuploid subpopulations that demonstrated allelic imbalance over a relatively large region. Also, the frequency of AI at 11q24 showed a similar tendency to that at the ATM locus for each DNA ploidy state. An association between p53 gene mutation and ATM allelic imbalance in multiploid carcinoma was also observed. Our results suggest that ATM allelic imbalance and p53 gene mutations occur during the progression from diploid to aneuploid cell populations in multiploid colorectal carcinomas.	Iwate Med Univ, Sch Med, Cent Clin Lab, Div Pathol, Morioka, Iwate 0208505, Japan; Iwate Med Univ, Sch Med, Dept Surg 1, Morioka, Iwate 0208505, Japan	Iwate Medical University; Iwate Medical University	Sugai, T (corresponding author), Iwate Med Univ, Sch Med, Cent Clin Lab, Div Pathol, 19-1 Morioka, Morioka, Iwate 0208505, Japan.							BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; CARDER PJ, 1995, BRIT J CANCER, V71, P215, DOI 10.1038/bjc.1995.46; CARTER SL, 1994, CANCER RES, V54, P6270; Connolly KC, 1999, CANCER RES, V59, P2806; Davis M, 1996, CANCER RES, V56, P741; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; Japanese Society for Cancer of the Colon and Rectum, 1997, JAP CLASS COL CARC, P30; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; LANGE E, 1995, AM J HUM GENET, V57, P112; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; MEYN MS, 1995, CANCER RES, V55, P5991; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; NAKAMURA S, 1994, GASTROENTEROLOGY, V106, P100, DOI 10.1016/S0016-5085(94)94651-5; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1612, DOI 10.1016/0016-5085(92)91721-F; RASIO D, 1995, CANCER RES, V55, P6053; RASIO D, 1995, CANCER RES, V55, P3988; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sugai T, 2000, INT J CANCER, V88, P614, DOI 10.1002/1097-0215(20001115)88:4<614::AID-IJC15>3.3.CO;2-S; Sugai T, 2000, HUM PATHOL, V31, P925, DOI 10.1053/hupa.2000.9087; Sugai T, 2000, ARCH PATHOL LAB MED, V124, P382; Sugai T, 2000, PATHOL RES PRACT, V196, P145, DOI 10.1016/S0344-0338(00)80094-1; Takagi M, 1998, CANCER RES, V58, P4923; TURNBULL RB, 1967, ANN SURG, V166, P420; Uhrhammer N, 1999, ONCOL REP, V6, P655; VANAGAITE L, 1995, HUM GENET, V95, P451; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; ZBIERANOWSKI I, 1993, ANAL CELL PATHOL, V5, P69	33	21	21	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6095	6101		10.1038/sj.onc.1204731	http://dx.doi.org/10.1038/sj.onc.1204731			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593417				2022-12-28	WOS:000171056300017
J	Ferguson, DO; Alt, FW				Ferguson, DO; Alt, FW			DNA double strand break repair and chromosomal translocation: Lessons from animal models	ONCOGENE			English	Article						translocation; non-homologous end joining; homologous recombination; double strand break repair; loss of heterozygosity; oncogenesis	END-JOINING PATHWAY; V(D)J RECOMBINATION; NONRECIPROCAL TRANSLOCATIONS; GENOMIC STABILITY; VERTEBRATE CELLS; MAMMALIAN-CELLS; TUMOR-FORMATION; TUMORIGENESIS; PROTEINS; MICE	The maintenance of genomic stability is one of the most important defenses against neoplastic transformation. This objective must be accomplished despite a constant barrage of spontaneous DNA double strand breaks. These dangerous lesions are corrected by two primary pathways of double strand break repair; non homologous end joining and homologous recombination. Recent studies employing mouse models have shown that absence of either pathway leads to genomic instability, including potentially oncogenic translocations. Because translocations involve the union of different chromosomes, cellular machinery must exist that creates these structures in the context of unrepaired double strand breaks. Evidence is mounting that the pathways of double strand break repair that are so important for survival may themselves be the culprits that generate potentially fatal translocations. Evidence and models for the dual roles of double strand break repair in both preventing, and generating, oncogenic karyotypic changes are discussed.	Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Alt, FW (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Enders Bldg,Room 861,Mail Stop EN-334,320 Longwoo, Boston, MA 02115 USA.							Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bosco G, 1998, GENETICS, V150, P1037; Coleman AE, 1999, BLOOD, V93, P4442, DOI 10.1182/blood.V93.12.4442; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ferguson DO, 1996, P NATL ACAD SCI USA, V93, P5419, DOI 10.1073/pnas.93.11.5419; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Haber JE, 2000, CURR OPIN CELL BIOL, V12, P286, DOI 10.1016/S0955-0674(00)00090-9; Hilgenfeld E, 1999, CURR TOP MICROBIOL, V246, P169; HOLLIDAY R, 1967, MUTAT RES, V4, P275, DOI 10.1016/0027-5107(67)90022-X; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; HOWARD-FLANDERS P., 1966, Radiation Research, V6, P156, DOI 10.2307/3583555; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; McClintock B, 1941, GENETICS, V26, P234; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Pfeiffer P, 2000, MUTAGENESIS, V15, P289, DOI 10.1093/mutage/15.4.289; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sekiguchi JM, 1999, COLD SPRING HARB SYM, V64, P169, DOI 10.1101/sqb.1999.64.169; Shinohara A, 1999, MUTAT RES-DNA REPAIR, V435, P13, DOI 10.1016/S0921-8777(99)00033-6; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	52	266	279	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	2001	20	40					5572	5579		10.1038/sj.onc.1204767	http://dx.doi.org/10.1038/sj.onc.1204767			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607810				2022-12-28	WOS:000170887500001
J	Kuppers, R; Dalla-Favera, R				Kuppers, R; Dalla-Favera, R			Mechanisms of chromosomal translocations in B cell lymphomas	ONCOGENE			English	Review						chromosomal translocation; class switch recombination; germinal center; lymphomagenesis; somatic hypermutation; V(D)J recombination	C-MYC ONCOGENE; CHRONIC LYMPHOCYTIC-LEUKEMIA; HEAVY-CHAIN LOCUS; SITE-SPECIFIC RECOMBINATION; NON-HODGKINS-LYMPHOMA; REED-STERNBERG CELLS; DOUBLE-STRAND BREAKS; SOMATIC HYPERMUTATION; GERMINAL-CENTERS; MULTIPLE-MYELOMA	Reciprocal chromosomal translocations involving the immunoglobulin (Ig) loci are a hallmark of most mature B cell lymphomas and usually result in dysregulated expression of oncogenes brought under the control of the Ig enhancers. Although the precise mechanisms involved in the development of these translocations remains essentially unknown, a clear relationship has been established with the mechanisms that lead to Ig gene remodeling, including V(D)J recombination, isotype switching and somatic hypermutation. The common denominator of these three processes in the formation of Ig-associated translocations is probably represented by the fact that each of these processes intrinsically generates double-strand DNA breaks. Since isotype switching and somatic hypermutation occur in germinal center (GC) B cells, the origin of a large number of B cell lymphomas from GC B cells is likely closely related to aberrant hypermutation and isotype switching activity in these B cells.	Univ Cologne, Dept Internal Med 1, D-50931 Cologne, Germany; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; Univ Cologne, Genet Inst, D-50931 Cologne, Germany	University of Cologne; Columbia University; University of Cologne	Kuppers, R (corresponding author), Univ Cologne, Dept Internal Med 1, LFI E4 R706,Josephy Stelzmannstr 9, D-50931 Cologne, Germany.			Kuppers, Ralf/0000-0002-6691-7191				ADACHI M, 1989, ONCOGENE, V4, P1073; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Akasaka H, 2000, CANCER RES, V60, P2335; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; Bross L, 2000, IMMUNITY, V13, P589, DOI 10.1016/S1074-7613(00)00059-5; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Callanan MB, 2000, P NATL ACAD SCI USA, V97, P309, DOI 10.1073/pnas.97.1.309; Cario G, 2000, BRIT J HAEMATOL, V110, P537, DOI 10.1046/j.1365-2141.2000.02241.x; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P328, DOI 10.1002/(SICI)1098-2264(199812)23:4<328::AID-GCC8>3.0.CO;2-M; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Chirmule N, 2000, J IMMUNOL, V164, P248, DOI 10.4049/jimmunol.164.1.248; COTTER F, 1990, BLOOD, V76, P131; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 2001, CANC PRINCIPLES PRAC, P2215; de Vinuesa CG, 1999, EUR J IMMUNOL, V29, P1314; DEJONG D, 1989, J EXP MED, V169, P613, DOI 10.1084/jem.169.3.613; DENNY CT, 1985, MOL CELL BIOL, V5, P3199, DOI 10.1128/MCB.5.11.3199; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; FUSCOE JC, 1991, CANCER RES, V51, P6001; FYFE G, 1987, J IMMUNOL, V139, P2187; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; Gardby E, 2000, EUR J IMMUNOL, V30, P1861, DOI 10.1002/1521-4141(200007)30:7<1861::AID-IMMU1861>3.0.CO;2-A; Gartner F, 2000, J EXP MED, V192, P1745, DOI 10.1084/jem.192.12.1745; GELMANN EP, 1983, NATURE, V306, P799, DOI 10.1038/306799a0; Gilles F, 2000, BLOOD, V95, P2930, DOI 10.1182/blood.V95.9.2930.009k39_2930_2936; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; Goyenechea B, 1996, P NATL ACAD SCI USA, V93, P13979, DOI 10.1073/pnas.93.24.13979; Gronbaek K, 1998, BLOOD, V92, P3018; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; Harrison CJ, 2000, BEST PRACT RES CL HA, V13, P427, DOI 10.1053/beha.2000.0086; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; Hatzivassiliou G, 2001, IMMUNITY, V14, P277, DOI 10.1016/S1074-7613(01)00109-1; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; HIRSCHICK HJ, 2001, J IMMUNOL, V166, P377; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; IRSCH J, 1994, P NATL ACAD SCI USA, V91, P1323, DOI 10.1073/pnas.91.4.1323; Isaacson PG, 1996, HISTOPATHOLOGY, V28, P487, DOI 10.1046/j.1365-2559.1996.d01-473.x; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JAEGER U, 1993, BLOOD, V81, P1833; JAEGER U, 1994, LEUKEMIA LYMPHOMA, V14, P197, DOI 10.3109/10428199409049669; Jager U, 2000, BLOOD, V95, P3520, DOI 10.1182/blood.V95.11.3520.011k12_3520_3529; Janssen JWG, 2000, BLOOD, V95, P2691; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; KATO S, 1991, GENE, V97, P239; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirsch I R, 1997, Semin Immunol, V9, P207, DOI 10.1006/smim.1997.0071; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Klein U, 1998, IMMUNOL REV, V162, P261; KLOBECK HG, 1987, NUCLEIC ACIDS RES, V15, P4877, DOI 10.1093/nar/15.12.4877; KOMATSU H, 1994, BLOOD, V84, P1226; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Kuppers R, 1998, ANNU REV IMMUNOL, V16, P471, DOI 10.1146/annurev.immunol.16.1.471; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Kuppers R, 1999, CURR TOP MICROBIOL, V246, P193; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LIMPENS J, 1991, ONCOGENE, V6, P2271; Liu YJ, 1996, IMMUNITY, V4, P241, DOI 10.1016/S1074-7613(00)80432-X; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MAIZELS N, 1985, CELL, V43, P715, DOI 10.1016/0092-8674(85)90244-2; Maizels N, 1999, AM J HUM GENET, V64, P1270, DOI 10.1086/302393; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; McKeithan TW, 1997, GENE CHROMOSOME CANC, V20, P64, DOI 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.0.CO;2-F; Meffre E, 2000, NAT IMMUNOL, V1, P207, DOI 10.1038/79739; Meffre E, 1998, J EXP MED, V188, P765, DOI 10.1084/jem.188.4.765; MEIJERINK JPP, 1995, BRIT J HAEMATOL, V91, P630, DOI 10.1111/j.1365-2141.1995.tb05359.x; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MULLER JR, 1995, P NATL ACAD SCI USA, V92, P6577, DOI 10.1073/pnas.92.14.6577; Muschen M, 2000, CANCER RES, V60, P5640; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; OHNO H, 1993, LEUKEMIA, V7, P2057; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; PASQUALUCCI L, 2001, IN PRESS NATURE; Peng HZ, 1999, BLOOD, V93, P2167, DOI 10.1182/blood.V93.7.2167.407a35_2167_2172; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Roschke V, 1997, ONCOGENE, V14, P3011, DOI 10.1038/sj.onc.1201156; Roth DB, 1998, CELL, V94, P411, DOI 10.1016/S0092-8674(00)81580-9; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SIMINOVITCH KA, 1985, NATURE, V316, P260, DOI 10.1038/316260a0; Summers KE, 2001, J CLIN ONCOL, V19, P420, DOI 10.1200/JCO.2001.19.2.420; Takakuwa T, 2001, CANCER RES, V61, P1382; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TYCKO B, 1989, SCIENCE, V245, P1242, DOI 10.1126/science.2551037; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; Vaandrager JW, 2000, BLOOD, V96, P1947, DOI 10.1182/blood.V96.5.1947.h8001947_1947_1952; Vaandrager JW, 1998, BLOOD, V92, P2871, DOI 10.1182/blood.V92.8.2871.420k08_2871_2878; Weller S, 2001, P NATL ACAD SCI USA, V98, P1166, DOI 10.1073/pnas.98.3.1166; Welzel N, 2001, CANCER RES, V61, P1629; Willis TG, 1998, BLOOD, V91, P1873, DOI 10.1182/blood.V91.6.1873.1873_1873_1881; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575; YE BHH, 1993, CANCER RES, V53, P2732; Yoshida S, 1999, ONCOGENE, V18, P7994, DOI 10.1038/sj.onc.1203293; Yu W, 1999, NATURE, V400, P682, DOI 10.1038/23287; ZHANG K, 1995, J IMMUNOL, V154, P2237; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	124	442	450	0	26	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	2001	20	40					5580	5594		10.1038/sj.onc.1204640	http://dx.doi.org/10.1038/sj.onc.1204640			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607811				2022-12-28	WOS:000170887500002
J	Tanaka, S; Sugimachi, K; Saeki, H; Kinoshita, J; Ohga, T; Shimada, M; Maehara, Y; Sugimachi, K				Tanaka, S; Sugimachi, K; Saeki, H; Kinoshita, J; Ohga, T; Shimada, M; Maehara, Y; Sugimachi, K			A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma	ONCOGENE			English	Article						gastric carcinoma; scirrhous; stroma; WISP1; CCN	TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; TUMOR-GROWTH; IN-VIVO; FAMILY; CYR61; ANGIOGENESIS; ADHESION; CELLS; IDENTIFICATION	Scirrhous carcinoma of the stomach is characterized by rapid growth with a vast fibrous stroma, high invasiveness, and substantially a poor prognosis. Little is known of the molecular pathogenesis of this disease. Members of the emerging family of the CCN gene (for connective tissue growth factor, cysteine-rich 61, nephroblastoma overexpressed) encode cysteine-rich secreted proteins with roles in human fibrotic disorders and cancer progression. Using targeted differential displays, we identified a novel variant of the CCN family member WISP1 (Wnt-induced secreted protein 1), named WISP1v, as overexpressed in scirrhous. gastric carcinomas. Predicted protein of the WISP1v completely lacks a module of Von Willebrand type C that is thought to participate in protein complex formation. Ectopic expression revealed WISP1v to be a secreted oncoprotein inducing a striking cellular transformation and rapid piling-up growth. It is noteworthy that WISP1v transfectants enhanced the invasive phenotype of cocultured gastric carcinoma cells, while wild-type WISP1 had no such potential. These findings suggest that CCN protein WISP1v is involved in the aggressive progression of scirrhous gastric carcinoma.	Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan; Kyushu Univ, Stn Collaborat Res, Fukuoka, Japan	Kyushu University; Kyushu University	Tanaka, S (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Maehara, Yoshihiko/A-4867-2010					Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; CHUNG LWK, 1995, CANCER SURV, V23, P33; Hadjiargyrou M, 2000, J BONE MINER RES, V15, P1014, DOI 10.1359/jbmr.2000.15.6.1014; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; KITAMURA K, 1995, J SURG ONCOL, V58, P112, DOI 10.1002/jso.2930580208; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; Maehara Y, 1999, J CLIN ONCOL, V17, P607, DOI 10.1200/JCO.1999.17.2.607; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Scholz G, 1996, MOL CELL BIOL, V16, P481; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; SUGIMACHI K, 1993, CURR OPIN GEN SURG, V1, P216; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Tanaka S, 1998, P NATL ACAD SCI USA, V95, P10164, DOI 10.1073/pnas.95.17.10164; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Xu LF, 2000, GENE DEV, V14, P585; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	25	73	76	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5525	5532		10.1038/sj.onc.1204723	http://dx.doi.org/10.1038/sj.onc.1204723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571650				2022-12-28	WOS:000170781100013
J	Tuveson, DA; Willis, NA; Jacks, T; Griffin, JD; Singer, S; Fletcher, CDM; Fletcher, JA; Demetri, GD				Tuveson, DA; Willis, NA; Jacks, T; Griffin, JD; Singer, S; Fletcher, CDM; Fletcher, JA; Demetri, GD			STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications	ONCOGENE			English	Article						Gastrointestional Stromal Tumors (GIST); c-KIT; STI571	TYROSINE KINASE INHIBITOR; CELL-LINE; BCR-ABL; B-CELLS; MUTATIONS; GROWTH; PATHOGENESIS; EXPRESSION; PROGNOSIS; STI-571	Mutations in the c-KIT receptor occur somatically in many sporadic Gastrointestinal Stromal Tumors (GIST), and similar mutations have been identified at the germline level in kindreds with multiple GISTs. These mutations activate the tyrosine kinase activity of e-KIT and induce constitutive signaling. To investigate the function of activated c-KIT in GIST, we established a human GIST cell line, GIST882, which expresses an activating KIT mutation (K642E) in the first part of the cytoplasmic split tyrosine kinase domain. Notably, the K642E substitution is encoded by a homozygous exon 13 missense mutation, and, therefore, GIST882 cells do not express native KIT. GIST882 c-KIT protein is constitutively tyrosine phosphorylated, but tyrosine phosphorylation was rapidly and completely abolished after incubating the cells with the selective tyrosine kinase inhibitor STI571. Furthermore, GIST882 cells evidenced decreased proliferation and the onset of apoptotic cell death after prolonged incubation with STI571. Similar results were obtained after administering STI571 to a primary GIST cell culture that expressed a c-KIT exon I I juxtamembrane mutation (K558NP). These cell-culture-based studies support an important role for c-KIT signaling in GIST and suggest therapeutic potential for STI571 in patients afflicted by this chemoresistant tumor.	MIT, Ctr Canc, Cambridge, MA 02139 USA; Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute	Tuveson, DA (corresponding author), MIT, Ctr Canc, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		ravegnini, gloria/K-1330-2016	ravegnini, gloria/0000-0002-7774-402X; Singer, Samuel/0000-0001-9713-8230				Badache A, 1998, ONCOGENE, V17, P795, DOI 10.1038/sj.onc.1201978; Buchdunger E, 1996, CANCER RES, V56, P100; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chan JKC, 1999, ADV ANAT PATHOL, V6, P19, DOI 10.1097/00125480-199901000-00003; DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 1999, BLOOD, V94, p368A; EDMONSON J, 1999, P AN M AM SOC CLIN, V18, pA541; Ernst SI, 1998, LAB INVEST, V78, P1633; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lasota J, 2000, AM J PATHOL, V157, P1091, DOI 10.1016/S0002-9440(10)64623-8; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Miettinen M, 1999, HUM PATHOL, V30, P1213, DOI 10.1016/S0046-8177(99)90040-0; Moskaluk CA, 1999, ONCOGENE, V18, P1897, DOI 10.1038/sj.onc.1202496; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Nishida T, 2000, HISTOL HISTOPATHOL, V15, P1293, DOI 10.14670/HH-15.1293; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; REYNOLDS JE, 1992, HUM GENET, V90, P450; Rubin BP, 2000, INT J SURG PATHOL, V8, P5, DOI 10.1177/106689690000800105; Sarlomo-Rikala M, 1998, MODERN PATHOL, V11, P728; SOMMERHAUSEN NDA, 1998, SARCOMA, V2, P133; Taniguchi M, 1999, CANCER RES, V59, P4297; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UEYAMA T, 1992, CANCER, V69, P947, DOI 10.1002/1097-0142(19920215)69:4<947::AID-CNCR2820690419>3.0.CO;2-X; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698	30	545	584	0	18	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5054	5058		10.1038/sj.onc.1204704	http://dx.doi.org/10.1038/sj.onc.1204704			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526490				2022-12-28	WOS:000170439800015
J	Ning, ZQ; Li, J; McGuinness, M; Arceci, RJ				Ning, ZQ; Li, J; McGuinness, M; Arceci, RJ			STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity	ONCOGENE			English	Article						STAT3; c-Kit mutation; tumorigenicity	RECEPTOR TYROSINE KINASE; LIGAND-INDEPENDENT ACTIVATION; ACUTE MYELOID-LEUKEMIA; STEM-CELL FACTOR; CONSTITUTIVE ACTIVATION; SIGNALING PATHWAYS; NIH3T3 FIBROBLASTS; CATALYTIC DOMAIN; GENE-REGULATION; POINT MUTATION	Activating mutations of c-kit at codon 816 (Asp(816)) have been identified in variety of malignancies, including acute myeloid leukemia (AML), mastocytosis and germ cell tumors. The mutant c-Kit receptor confers cytokine independence and induces tumorigenicity. However, the molecular mechanisms, particularly the changes in the signal transduction pathways, responsible for these biological effects induced by mutant c-Kit are largely undefined. Using the human embryonic kidney cell line, 293, we show in the current report that constitutive activation of STAT3 and STAT1 is associated with D816H mutant c-Kit. Transfection of dominant negative STAT3, but not STAT1 inhibits mutant c-Kit mediated anchorage-independent growth in vitro and tumor formation in vivo. Expression of constitutively activated STAT3 restores the mutant c-Kit receptor's transforming ability in 293 cells. These results demonstrate that activation of STAT3 by Asp(816) mutant c-Kit is required for the anchorage-independent growth and tumorigenicity induced by Asp(816) mutant c-Kit.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA; Childrens Hosp, Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA	Johns Hopkins University; Johns Hopkins Medicine; Cincinnati Children's Hospital Medical Center	Arceci, RJ (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA.							ALEXANDER WS, 1991, EMBO J, V10, P3683, DOI 10.1002/j.1460-2075.1991.tb04936.x; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Ashman LK, 1999, LEUKEMIA LYMPHOMA, V34, P451, DOI 10.3109/10428199909058472; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caruana G, 1998, ONCOGENE, V16, P179, DOI 10.1038/sj.onc.1201494; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CROSIER PS, 1993, BLOOD, V82, P1151; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Ferrao P, 1997, BLOOD, V90, P4539; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hashimoto K, 1996, AM J PATHOL, V148, P189; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Hunter MG, 2000, BLOOD, V95, P2132, DOI 10.1182/blood.V95.6.2132; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KANAKURA Y, 1994, LEUKEMIA, V8, pS18; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Leslie NR, 1998, BLOOD, V92, P4798, DOI 10.1182/blood.V92.12.4798.424k12_4798_4807; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; NING ZQ, 2001, IN PRESS LEUK LYMPHO; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PIETRA D, 1998, GENE, V213, P119; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; Wooten DK, 2000, J BIOL CHEM, V275, P26566, DOI 10.1074/jbc.M003495200; Yajima T, 1998, HUM GENE THER, V9, P779, DOI 10.1089/hum.1998.9.6-779; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	56	70	73	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4528	4536		10.1038/sj.onc.1204590	http://dx.doi.org/10.1038/sj.onc.1204590			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494148				2022-12-28	WOS:000170074900010
J	Codony, C; Guil, S; Caudevilla, C; Serra, D; Asins, G; Graessmann, A; Hegardt, FG; Bach-Elias, M				Codony, C; Guil, S; Caudevilla, C; Serra, D; Asins, G; Graessmann, A; Hegardt, FG; Bach-Elias, M			Modulation in vitro of H-ras oncogene expression by trans-splicing	ONCOGENE			English	Article						splicing; c-H-ras; trans-splicing	MESSENGER-RNA; MAMMALIAN-CELLS; EXON; GENE; LIVER; ENHANCER	In man, activated N-, K- and H-ras oncogenes have been found in around 30% of the solid tumours tested, An exon known as IDX, which has been described previously and is located between exon 3 and exon 4A of the c-H-ras pre-mRNA, allows an alternative splicing process that results in the synthesis of the mRNA of a putative protein named p19, It has been suggested that this alternative pathway is less tumorigenic than that which results in the activation of p21, We have used the mammalian trans-splicing mechanism as a tool with which to modulate this particular pre-mRNA processing to produce mRNA similar to that of mature p19 RNA. The E4A exon of the activated H-vas gene was found to be a good target for external trans-splicing. We reprogrammed the rat carnitine octanoyltransferase exon 2 to specifically invade the terminal region of H-ras. Assays performed with this reprogrammed trans-exon showed that the trans-splicing product was obtained in competition with cis-splicing of the D intron of the H-ras gene, and was associated with concomitant downmodulation of D intron cis-splicing. We also found that the exon 4A of the human c-H-ras gene underwent successive trans-splicing rounds with an external exon.	CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, ES-08034 Barcelona, Spain; Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, E-08007 Barcelona, Spain; Free Univ Berlin, Inst Molekularbiol & Biochim, D-14195 Berlin, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Free University of Berlin	Bach-Elias, M (corresponding author), CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, C Jorge Girona Salgado 18-26, ES-08034 Barcelona, Spain.		Guil, Sonia/M-8036-2015; Serra, Dolors/L-3657-2014	Guil, Sonia/0000-0002-2257-3331; Serra, Dolors/0000-0002-4936-4206; Codony Servat, Carles/0000-0001-8928-2312				Akopian AN, 1999, FEBS LETT, V445, P177, DOI 10.1016/S0014-5793(99)00126-X; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Breen MA, 1997, FEBS LETT, V409, P375, DOI 10.1016/S0014-5793(97)00555-3; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; Cicarelli RMB, 1998, BIOCHEM BIOPH RES CO, V247, P204, DOI 10.1006/bbrc.1998.8771; COHEN JB, 1993, MOL CELL BIOL, V13, P2666, DOI 10.1128/MCB.13.5.2666; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Frantz SA, 1999, P NATL ACAD SCI USA, V96, P5400, DOI 10.1073/pnas.96.10.5400; Huang MY, 1997, ONCOL RES, V9, P611; Kawasaki T, 1999, PLANT J, V18, P625, DOI 10.1046/j.1365-313x.1999.00493.x; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mansfield SG, 2000, GENE THER, V7, P1885, DOI 10.1038/sj.gt.3301307; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; SHIMIZU A, 1993, FASEB J, V7, P149, DOI 10.1096/fasebj.7.1.7916698; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; Zaphiropoulos PG, 1999, NUCLEIC ACIDS RES, V27, P2585, DOI 10.1093/nar/27.13.2585	24	6	6	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3683	3694		10.1038/sj.onc.1204473	http://dx.doi.org/10.1038/sj.onc.1204473			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439331				2022-12-28	WOS:000169400200009
J	Landberg, G; Ostlund, H; Nielsen, NH; Roos, G; Emdin, S; Burger, AM; Seth, A				Landberg, G; Ostlund, H; Nielsen, NH; Roos, G; Emdin, S; Burger, AM; Seth, A			Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors	ONCOGENE			English	Article						IGFBP; breast cancer; proliferation; cell cycle; estrogen receptor	TISSUE MICROARRAY ANALYSIS; EXPRESSION; AMPLIFICATION; MAC25; D1	The complex insulin-like growth factor network of ligands, receptors and binding proteins has been shown to be disturbed in breast cancer, In addition to defects in proteins controling cell cycle checkpoints, this type of aberrations could affect tumor growth and survival thereby influencing both tumor aggressiveness and potential response to treatments, We have previously identified the T1A12/mac25 protein, which is identical to the IGFBP-rP1, as a differentially expressed gene product in breast cancer cells compared with normal cells, Here we compare the expression of IGFBP-rP1 in 106 tumor samples with known status of cell cycle aberrations and other clinicopathological data, This was done using a tumor tissue section array system that allows for simultaneous immunohistochemical staining of ail samples in parallel, Cytoplasmic staining of variable intensity was observed in most tumors, 15% Lacked IGFBP-rP1 staining completely, 20% had weak staining, 32% intermediate and 33% showed strong staining, Low IGFBP-rP1 was associated with high cyclin E protein content, retinoblastoma protein (pRb) inactivation, low bcl-2 protein, poorly differentiated tumors and higher stage, There was a significantly impaired prognosis for patients with low IGFBP-rP1 protein tumors, Interestingly, IGFBP-rP1 showed an inverse association with proliferation (Ki-67%) in estrogen receptor negative tumors as well as in cyclin E high tumors suggesting a separate cell cycle regulatory function for IGFBP-rP1 independent of interaction with the estrogen receptor or the pRb pathway.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Sunnbrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Univ Freiburg, Tumor Biol Ctr, Freiburg, Germany; Umea Univ, Dept Surg & Perioperat Sci, S-90187 Umea, Sweden; Umea Univ, Dept Med Biosci Pathol, S-90187 Umea, Sweden; Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, Malmo, Sweden	University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Freiburg; Umea University; Umea University; Lund University; Skane University Hospital	Seth, A (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 76 Greenville St, Toronto, ON, Canada.							Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; DEGEORGES A, 1998, CANCER RES, V50, P2787; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Kato MV, 1996, ONCOGENE, V12, P1361; Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Landberg G, 1997, APMIS, V105, P575, DOI 10.1111/j.1699-0463.1997.tb05056.x; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; LUKAS J, 1995, CANCER RES, V55, P4818; Martin JL, 1999, J BIOL CHEM, V274, P16407, DOI 10.1074/jbc.274.23.16407; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1999, BREAST CANCER RES TR, V56, P105; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Nielsen NH, 1998, ANAL CELL PATHOL, V17, P177, DOI 10.1155/1998/659712; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGE DL, 1995, AM J CLIN PATHOL, V103, P123; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sprenger CC, 1999, CANCER RES, V59, P2370; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301	25	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3497	3505		10.1038/sj.onc.1204471	http://dx.doi.org/10.1038/sj.onc.1204471			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429696				2022-12-28	WOS:000169478300005
J	Munro, J; Steeghs, K; Morrison, V; Ireland, H; Parkinson, EK				Munro, J; Steeghs, K; Morrison, V; Ireland, H; Parkinson, EK			Human fibroblast replicative senescence can occur in the absence of extensive cell division and short telomeres	ONCOGENE			English	Article						telomerase; telomeres; senescence; cell division; cell cycle inhibitors	HUMAN-DIPLOID FIBROBLASTS; TUMOR-SUPPRESSOR; LIFE-SPAN; STOCHASTIC MECHANISM; EPITHELIAL-CELLS; CDK-INHIBITOR; P53 PROTEIN; IN-VIVO; EXPRESSION; ARREST	Ectopic expression of telomerase blocks both telomeric attrition and senescence, suggesting that telomeric attrition is a mitotic counting mechanism that culminates in replicative senescence, By holding human fibroblast cultures confluent for up to 12 weeks at a time, we confirmed previous observations and showed that telomeric attrition requires cell division and also, that senescence occurs at a constant average telomere length, not at a constant time point. However, on resuming cell division, these long-term confluent (LTC) cultures completed 15-25 fewer mean population doublings (MPDs) than the controls prior to senescence. These lost divisions were mainly accounted for by slow cell turnover of the LTC cultures and by permanent cell cycle exit of 94% of the LTC cells, which resulted in many cell divisions being unmeasured by the MPD method, In the LTC cultures, p27(KIPI) accumulated and pRb became under-phosphorylated and under-expressed. Also, coincident with permanent cell cycle exit and before 1 MPD was completed, the LTC cultures upregulated the cell cycle inhibitors p21(WAF) and p16(INK4A) but not p14(ARF) developed other markers of senescence. We then tested the relationship between cell cycle re-entry and the cell cycle-inhibitory proteins following subculture of the LTC cultures. Tn these cultures, the downregulation of p27(KIPI) and the phosphorylation of pRb preceded the complete resumption of normal proliferation rate, which was accompanied by the down-regulation of p16(INK4A). Our results show that most normal human fibroblasts can accumulate p16(INK4A), p21(WAF) and p27(KIPI) and senesce by cell division-independent mechanism(s). Furthermore, this form of senescence likely requires p16(INK4A) and perhaps p27(KIPI).	CRC, Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Parkinson, EK (corresponding author), CRC, Beatson Labs, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; Dietrich C, 1997, EXP CELL RES, V232, P72, DOI 10.1006/excr.1997.3507; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; GOLDSTEIN S, 1974, EXP CELL RES, V88, P359, DOI 10.1016/0014-4827(74)90252-3; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Holliday R, 1996, BIOESSAYS, V18, P3, DOI 10.1002/bies.950180103; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Kamijo T, 1999, CANCER RES, V59, P2464; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rubelj I, 1999, J THEOR BIOL, V197, P425, DOI 10.1006/jtbi.1998.0886; SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; SMITH JR, 1980, SCIENCE, V207, P82; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tresini M, 1998, CANCER RES, V58, P1; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	49	61	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3541	3552		10.1038/sj.onc.1204460	http://dx.doi.org/10.1038/sj.onc.1204460			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429701				2022-12-28	WOS:000169478300010
J	Greenland, C; Touriol, C; Chevillard, G; Morris, SW; Bai, RY; Duyster, J; Delsol, G; Allouche, M				Greenland, C; Touriol, C; Chevillard, G; Morris, SW; Bai, RY; Duyster, J; Delsol, G; Allouche, M			Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis	ONCOGENE			English	Article						anaplastic large cell lymphoma; ALK; tyrosine kinase; chemotherapy; apoptosis	RECEPTOR TYROSINE KINASE; NON-HODGKINS-LYMPHOMA; FACTOR I RECEPTOR; ANAPLASTIC LYMPHOMA; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; POSITIVE LYMPHOMA; LEUKEMIC-CELLS; FRENCH SOCIETY	Anaplastic large cell lymphomas (ALCLs), are frequently associated with, the t(2;5)(p23;q35) translocation, leading to the expression of NPM-ALK, a fusion protein linking nucleophosmin and anaplastic lymphoma kinase, a receptor tyrosine kinase. In ALCLs, dimerization of NPM-ALK leads to constitutive autophosphorylation and activation of the kinase, necessary for NPM-ALK oncogenicity.. To investigate whether NPM-ALK, like other oncogenic tyrosine kinases, can, inhibit drug-induced apoptosis, we permanently transfected NPM-ALK into Jurkat T-cells. As, in ALCLs, NPM-ALK was expressed as, a constitutively kinase-active 80 kDa protein, and could be detected by immunocytochemistry in nucleoli, nuclei and cytoplasm. Doxorubicin-induced apoptosis (assessed by cell morphology and annexin V-FITC binding), was significantly inhibited in two independent NPM-ALK-expressing clones (5.2 +/- 1.8 and 7.5 +/- 0.8%, apoptosis), compared to control vector-transduced cells (36 +/- 6.7%). Similar results were observed with etoposide. In contrast, Fas-induced apoptosis, was not inhibited. Cytochrome c release into the cytosol was delayed in doxorubicin-, but not anti-Fas-treated transfectant cells, indicating that apoptosis inhibition occurred upstream of mitochondrial events. Using NPM-ALK mutants, we demonstrated that inhibition of drug-induced apoptosis: (1) requires functional kinase activity, (2) does not involve phospholipase C-gamma, essential for NPM-ALK-mediated mitogenicity and (3) appears to: be phosphoinositide 3-kinase independent, despite a strong Akt/PKB activation observed in wild type NPM-ALK-expressing cells. These results suggest that the NPM-ALK antiapoptotic and mitogenic pathways are distinct.	CHU Purpan, CNRS UPR2163, UPCM, F-31059 Toulouse 03, France; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-8000 Munich, Germany	CHU de Toulouse; St Jude Children's Research Hospital; Technical University of Munich; University of Munich	Allouche, M (corresponding author), CHU Purpan, CNRS UPR2163, UPCM, Ave Grande Bretagne, F-31059 Toulouse 03, France.	allouche@cict.fr	TOURIOL, Christian/O-8949-2014	TOURIOL, Christian/0000-0003-1219-4693	NCI NIH HHS [CA21765, CA69129] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA069129] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Brugieres L, 2000, ANN ONCOL, V11, P53, DOI 10.1023/A:1008352726155; Brugieres L, 1998, BLOOD, V92, P3591; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; Collins P, 2000, NAT REV NEUROSCI, V1, P156, DOI 10.1038/35044513; DELSOL G, 1988, AM J PATHOL, V130, P59; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Hernandez L, 1999, BLOOD, V94, P3265; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jain SK, 1996, BLOOD, V88, P1542; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lamant L, 1996, BLOOD, V87, P284; Lamant L, 1999, BLOOD, V93, P3088; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mason DY, 1998, CANCER RES, V58, P1057; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; McGahon AJ, 1998, BRIT J HAEMATOL, V101, P539, DOI 10.1046/j.1365-2141.1998.00745.x; MORGAN R, 1989, BLOOD, V73, P2155; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Ollendorff V, 1999, J BIOL CHEM, V274, P26922, DOI 10.1074/jbc.274.38.26922; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Ross TS, 1999, J BIOL CHEM, V274, P22328, DOI 10.1074/jbc.274.32.22328; Sanchez-Alcazar JA, 2000, CELL DEATH DIFFER, V7, P1090, DOI 10.1038/sj.cdd.4400740; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Villunger A, 1997, CANCER RES, V57, P3331; Warmuth M, 1999, ANN HEMATOL, V78, P49, DOI 10.1007/s002770050473; Wellmann A, 1997, FASEB J, V11, P965, DOI 10.1096/fasebj.11.12.9337149; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YIN DX, 1995, CANCER RES, V55, P4922	74	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7386	7397		10.1038/sj.onc.1204870	http://dx.doi.org/10.1038/sj.onc.1204870			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704868				2022-12-28	WOS:000171894200011
J	Kastner, P; Chan, S				Kastner, P; Chan, S			Function of RAR alpha during the maturation of neutrophils	ONCOGENE			English	Article						retinoids; granulocyte; differentiation	RETINOIC ACID RECEPTOR; THYROID-HORMONE RECEPTOR; BINDING-PROTEIN EPSILON; MYC ANTAGONIST MAD1; RXR-ALPHA; ERYTHROID-DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; MYELOID PROGENITORS; HISTONE DEACETYLASE; HEMATOPOIETIC-CELLS	The retinoic acid receptor alpha gene is the target of chromosomal rearrangements in all cases of acute promyelocytic leukemia (APL). This recurrent involvement of RAR alpha in the pathogenesis of APL is likely to reflect an important role played by this receptor during the differentiation of immature myeloid cells to neutrophils. RAR alpha is a negative regulator of promyelocyte differentiation when not complexed with RA, and stimulates this differentiation when bound to RA. Since RARs are dispensable for the generation of mature neutrophils, their role thus appears to be to modulatory, rather than obligatory, for the control of neutrophil differentiation. In vitro, retinoic acid is also a potent inducer of neutrophil cell fate, suggesting that it might play a role in the commitment of pluripotent hematopoietic progenitors to the neutrophil lineage. Thus, the APL translocations target an important regulator of myeloid cell differentiation.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chan, S (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP163, F-67404 Illkirch Graffenstaden, France.	scpk@igbmc.u-strasbg.fr						Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chih DY, 1997, BLOOD, V90, P2987, DOI 10.1182/blood.V90.8.2987; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; DINNEN RD, 1994, CELL GROWTH DIFFER, V5, P855; DRACH J, 1994, CANCER RES, V54, P1746; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Glass CK, 2000, GENE DEV, V14, P121; GRATAS C, 1993, LEUKEMIA, V7, P1156; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hashimoto K, 2001, P NATL ACAD SCI USA, V98, P3998, DOI 10.1073/pnas.051454698; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Imai T, 2001, P NATL ACAD SCI USA, V98, P4581, DOI 10.1073/pnas.071056098; Imai T, 2001, P NATL ACAD SCI USA, V98, P224, DOI 10.1073/pnas.011528898; JIANG HP, 1994, ONCOGENE, V9, P3397; Kastner P, 1997, DEVELOPMENT, V124, P313; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; LABBAYE C, 1994, BLOOD, V83, P651; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lawson ND, 1999, EXP HEMATOL, V27, P1682, DOI 10.1016/S0301-472X(99)00108-3; Lawson ND, 1999, EXP HEMATOL, V27, P1355, DOI 10.1016/S0301-472X(99)00085-5; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mascrez B, 1998, DEVELOPMENT, V125, P4691; Mascrez B, 2001, DEVELOPMENT, V128, P2049; Matikainen S, 1996, BLOOD, V88, P114; Mehta K, 1996, CELL GROWTH DIFFER, V7, P179; Mehta K, 1997, BLOOD, V89, P3607, DOI 10.1182/blood.V89.10.3607.3607_3607_3614; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; METZ T, 1992, ONCOGENE, V7, P597; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Monczak Y, 1997, BLOOD, V90, P3345, DOI 10.1182/blood.V90.9.3345; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; ONODERA M, 1995, ONCOGENE, V11, P1291; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; PAUL CC, 1995, BLOOD, V86, P3737, DOI 10.1182/blood.V86.10.3737.bloodjournal86103737; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Purton LE, 2000, BLOOD, V95, P470, DOI 10.1182/blood.V95.2.470; Purton LE, 1999, BLOOD, V94, P483, DOI 10.1182/blood.V94.2.483.414k12_483_495; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; Rodriguez-Pena A, 1999, J NEUROBIOL, V40, P497, DOI 10.1002/(SICI)1097-4695(19990915)40:4<497::AID-NEU7>3.0.CO;2-#; Subbarayan V, 1997, MECH DEVELOP, V66, P131, DOI 10.1016/S0925-4773(97)00098-1; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tocci A, 1996, BLOOD, V88, P2878, DOI 10.1182/blood.V88.8.2878.bloodjournal8882878; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Ueno H, 1998, LEUKEMIA RES, V22, P517, DOI 10.1016/S0145-2126(98)00026-5; VANBOCKSTAELE DR, 1993, ANN HEMATOL, V66, P61, DOI 10.1007/BF01695885; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; ZAULI G, 1995, BRIT J HAEMATOL, V90, P274, DOI 10.1111/j.1365-2141.1995.tb05147.x	85	69	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7178	7185		10.1038/sj.onc.1204757	http://dx.doi.org/10.1038/sj.onc.1204757			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704846				2022-12-28	WOS:000171891900006
J	Cabeza-Arvelaiz, Y; Thompson, TC; Sepulveda, JL; Chinault, AC				Cabeza-Arvelaiz, Y; Thompson, TC; Sepulveda, JL; Chinault, AC			LAPSER1: a novel candidate tumor suppressor gene from 10q24.3	ONCOGENE			English	Article						prostate cancer; tumor suppressor; LZTS1; LAPSER1	HUMAN PROSTATE-CANCER; FREQUENT INACTIVATION; ALLELIC LOSS; CELL-LINES; PTEN/MMAC1; CARCINOMAS; REGIONS; 8P22; PTEN; EXPRESSION	Numerous LOH and mutation analysis studies in different tumor tissues, including prostate, indicate that there are multiple tumor suppressor genes (TSGs) present within the human chromosome 8p21-22 and 10q23-24 regions. Recently, we showed that LZTS1 (or FEZ1), a putative TSG located on 8p22, has the potential to function as a cell growth modulator. We report here the cloning, gene organization, cDNA sequence characterization and expression analysis of LAPSER1, an LZTS1-related gene. This gene maps within a subregion of human chromosome 10q24.3 that has been reported to be deleted in various cancers, including prostate tumors, as frequently as the neighboring PTEN locus. The complete LAPSER1 cDNA sequence encodes a predicted protein containing various domains resembling those typically found in transcription factors (P-Box, Q-rich and multiple leucine zippers). LAPSER1 is expressed at the highest levels in normal prostate and testis, where multiple isoforms are seen, some of which are either undetectable or differentially expressed in some prostate tumor tissues and cell lines. Over-expression of LAPSER1 cDNA strongly inhibited cell growth and colony-forming efficiencies of most cancer cells assessed. Together these data suggest that LAPSER1 is another gene involved in the regulation of cell growth whose loss of function may contribute to the development of cancer.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Urol, Houston, TX 77030 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Baylor College of Medicine; Baylor College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chinault, AC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58204] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P4169, DOI 10.1038/sj.onc.1204539; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; Cairns P, 1997, CANCER RES, V57, P4997; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dong JT, 1998, ONCOGENE, V17, P1979, DOI 10.1038/sj.onc.1202119; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Foulkes NS, 1996, BBA-REV CANCER, V1288, pF101, DOI 10.1016/S0304-419X(96)00025-X; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Gotoh A, 1997, J UROLOGY, V158, P636, DOI 10.1016/S0022-5347(01)64574-9; GRAY IC, 1995, CANCER RES, V55, P4800; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; ICHIKAWA T, 1994, CANCER RES, V54, P2299; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Ittmann M, 1996, CANCER RES, V56, P2143; KAGAN J, 1995, ONCOGENE, V11, P2121; KAHN T, 1994, CANCER RES, V54, P1305; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAMPARIELLO F, 1994, CYTOMETRY, V15, P294, DOI 10.1002/cyto.990150404; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Murakami YS, 1996, CANCER RES, V56, P2157; Narahara K, 1997, J MED GENET, V34, P213, DOI 10.1136/jmg.34.3.213; Orikasa K, 1998, J HUM GENET, V43, P228, DOI 10.1007/s100380050078; Petersen S, 1998, ONCOGENE, V17, P449, DOI 10.1038/sj.onc.1201949; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Yeh JJ, 1999, GENE CHROMOSOME CANC, V26, P322, DOI 10.1002/(SICI)1098-2264(199912)26:4<322::AID-GCC6>3.0.CO;2-#; Yokomizo A, 1998, INT J ONCOL, V13, P101	41	38	40	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6707	6717		10.1038/sj.onc.1204866	http://dx.doi.org/10.1038/sj.onc.1204866			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709705				2022-12-28	WOS:000171551600007
J	Boxer, LM; Dang, CV				Boxer, LM; Dang, CV			Translocations involving c-myc and c-myc function	ONCOGENE			English	Review						c-myc; gene expression; lymphoma; apoptosis	HEAVY-CHAIN LOCUS; BURKITTS-LYMPHOMA CELLS; REVERSE-TRANSCRIPTASE GENE; UNCOUPLES DNA-REPLICATION; LUNG-CANCER CELLS; CYCLE PROGRESSION; CELLULAR GROWTH; KAPPA-B; NEOPLASTIC TRANSFORMATION; TRANSACTIVATION DOMAIN	c-MYC is the prototype for oncogene activation by chromosomal translocation. In contrast to the tightly regulated expression of c-myc in normal cells, c-myc is frequently deregulated in human cancers. Herein, aspects of c-myc gene activation and the function of the c-Myc protein are reviewed. The c-myc gene produces an oncogenic transcription factor that affects diverse cellular processes involved in cell growth, cell proliferation, apoptosis and cellular metabolism. Complete removal of c-myc results in slowed cell growth and proliferation, suggesting that while c-myc is not required for cell proliferation, it acts as an integrator and accelerator of cellular metabolism and proliferation.	Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA; Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA	Johns Hopkins University; Stanford University	Dang, CV (corresponding author), Ross Res Bldg,Room 1025,720 Rutland Ave, Baltimore, MD 21205 USA.	cvdang@jhmi.edu	Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522	NATIONAL CANCER INSTITUTE [R01CA051497, R37CA051497, R29CA051497, R01CA069322] Funding Source: NIH RePORTER; NCI NIH HHS [CA57431, CA51497, CA69322] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; ARCINAS M, 1994, ONCOGENE, V9, P2699; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; ASKEW DS, 1991, ONCOGENE, V6, P1915; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Barr LF, 1998, CANCER RES, V58, P5537; Barr LF, 2000, CANCER RES, V60, P143; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; Berridge MV, 1996, J IMMUNOL, V156, P4092; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORNKAMM GW, 1988, C MYC DEREGULATION C; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BRADLEY JF, 1993, GENE CHROMOSOME CANC, V7, P128, DOI 10.1002/gcc.2870070303; Brakebusch C, 1999, ONCOGENE, V18, P3852, DOI 10.1038/sj.onc.1202770; Butzler C, 1997, ONCOGENE, V14, P1383, DOI 10.1038/sj.onc.1200968; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Drach J, 2000, J CANCER RES CLIN, V126, P441, DOI 10.1007/s004320050011; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gandarillas A, 2000, ONCOGENE, V19, P3278, DOI 10.1038/sj.onc.1203630; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Geltinger C, 1996, GENE EXPRESSION, V6, P113; Gerbitz A, 1999, ONCOGENE, V18, P1745, DOI 10.1038/sj.onc.1202468; GIBSON AW, 1992, ONCOGENE, V7, P2363; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Guo QM, 2000, CANCER RES, V60, P5922; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; Hatton KS, 1996, MOL CELL BIOL, V16, P1794; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Janz A, 2000, NUCLEIC ACIDS RES, V28, P2268, DOI 10.1093/nar/28.11.2268; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kanda K, 2000, J BIOL CHEM, V275, P32338, DOI 10.1074/jbc.M004148200; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KESSLER DJ, 1992, ONCOGENE, V7, P2447; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Kolligs FT, 2000, GENE DEV, V14, P1319; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li Q, 1999, MOL CELL BIOL, V19, P5339; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; Malynn BA, 2000, GENE DEV, V14, P1390; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MICHAELSON JS, 1995, NUCLEIC ACIDS RES, V23, P975, DOI 10.1093/nar/23.6.975; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Mitchell KO, 2000, CANCER RES, V60, P6318; MULLER B, 1990, EUR J IMMUNOL, V20, P1409, DOI 10.1002/eji.1830200631; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Palomo C, 1999, CANCER RES, V59, P5625; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; Prochownik EV, 1998, GENE CHROMOSOME CANC, V22, P295, DOI 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.0.CO;2-Q; Pusch O, 1997, DNA CELL BIOL, V16, P737, DOI 10.1089/dna.1997.16.737; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Roussel ME, 1998, ADV CANCER RES, V74, P1, DOI 10.1016/S0065-230X(08)60763-0; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Saleque S, 1997, J IMMUNOL, V158, P4780; Saphire ACS, 1998, J BIOL CHEM, V273, P29764, DOI 10.1074/jbc.273.45.29764; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SHIRAMIZU B, 1991, BLOOD, V77, P1516; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Siebert K. J., 1981, Journal of the American Society of Brewing Chemists, V39, P1; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Wechsler DS, 1997, CANCER RES, V57, P4905; WHITEHURST C, 1992, NUCLEIC ACIDS RES, V20, P4929, DOI 10.1093/nar/20.18.4929; Wittekindt NE, 2000, NUCLEIC ACIDS RES, V28, P800, DOI 10.1093/nar/28.3.800; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; YANO T, 1993, ONCOGENE, V8, P2741; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; YU BW, 1993, J BIOL CHEM, V268, P19586; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	188	342	369	4	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5595	5610		10.1038/sj.onc.1204595	http://dx.doi.org/10.1038/sj.onc.1204595			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607812				2022-12-28	WOS:000170887500003
J	Duyster, J; Bai, RY; Morris, SW				Duyster, J; Bai, RY; Morris, SW			Translocations involving anaplastic lymphoma kinase (ALK)	ONCOGENE			English	Review						ALK; NPM-ALK; variant ALK fusions; ALCL; IMT; pleiotrophin	LARGE-CELL LYMPHOMA; GROWTH-FACTOR PLEIOTROPHIN; LEUKOCYTE TYROSINE KINASE; MAJOR NUCLEOLAR PROTEINS; ALK-POSITIVE LYMPHOMA; NON-HODGKINS-LYMPHOMA; NF-KAPPA B; NPM-ALK; KI-1 LYMPHOMA; CLINICOPATHOLOGICAL FEATURES	Anaplastic large-cell lymphoma (ALCL) comprises a group of non-Hodgkin's lymphomas (NHLs) that were first described in 1985 by Stein and co-workers and are characterized by the expression of the CD30/Ki-1 antigen (Stein et al., 1985). Approximately half of these lymphomas are associated with a typical chromosomal translocation, t(2;5)(p23;q35). Much confusion about the exact classification and clinico pathological features of this subgroup of NHL was clarified with the identification of NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) as the oncogene created by the t(2;5) (Morris et al., 1994). With the discovery of NPM-ALK as the specific lymphoma gene mutation, this NHL subtype could be redefined on the molecular level. This achievement was enhanced by the availability of specific antibodies that recognize ALK fusion proteins in paraffin-embedded lymphoma tissues. Several excellent recent reviews have summarized the histo pathological and molecular findings of ALCL and their use in the classification of this lymphoma entity (Anagnostopoulos and Stein, 2000; Benharroch et al., 1998; Drexler et al., 2000, Foss et al., 2000; Gogusev and Nezelof, 1998; Kadin and Morris, 1998; Ladanyi, 1997; Morris et al., 2001; Shiota and Mori, 1996; Skinnider et al., 1999; Stein et al., 2000). This review will focus on the molecular function and signal transduction pathways activated by ALK fusion oncogenes, with recent advances and possible clinical implications to be discussed.	Tech Univ Munich, Lab Leukemogenesis, Dept Internal Med 3, D-81675 Munich, Germany; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	Technical University of Munich; University of Munich; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Duyster, J (corresponding author), Tech Univ Munich, Lab Leukemogenesis, Dept Internal Med 3, Ismanigerstr 22, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de; steve.morris@stjude.org			NCI NIH HHS [CA69129, CA76301, CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA076301, R01CA069129] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anagnostopoulos I, 2000, PATHOLOGE, V21, P178, DOI 10.1007/s002920050384; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 1998, BLOOD, V92, p512A; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Beylot-Barry M, 1998, BLOOD, V91, P4668, DOI 10.1182/blood.V91.12.4668.412k20_4668_4676; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRUNEL V, 1995, GENE CHROMOSOME CANC, V14, P307, DOI 10.1002/gcc.2870140410; BUTTI MG, 1995, GENOMICS, V28, P15, DOI 10.1006/geno.1995.1100; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; CHAN PK, 1995, BBA-GENE STRUCT EXPR, V1262, P37, DOI 10.1016/0167-4781(95)00044-H; CHAN PK, 1990, BIOCHEM J, V270, P549, DOI 10.1042/bj2700549; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Choudhuri R, 1997, CANCER RES, V57, P1814; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cordell JL, 1999, BLOOD, V93, P632, DOI 10.1182/blood.V93.2.632; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; Falini B, 1999, BLOOD, V93, P2697; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Foss HD, 2000, PATHOLOGE, V21, P124, DOI 10.1007/s002920050380; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; Gogusev J, 1998, HEMATOL ONCOL CLIN N, V12, P445, DOI 10.1016/S0889-8588(05)70522-0; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Griffin CA, 1999, CANCER RES, V59, P2776; HARRIS NL, 1994, BLOOD, V84, P1361; Hernandez L, 1999, BLOOD, V94, P3265; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hubinger G, 1999, BLOOD, V94, p598A; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; Kadin ME, 1997, CANCER SURV, V30, P77; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kinney MC, 1999, AM J CLIN PATHOL, V111, pS56; Kinney MC, 1996, LAB INVEST, V74, P664; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Ladanyi M, 1997, CANCER SURV, V30, P59; Ladanyi M, 1996, DIAGN MOL PATHOL, V5, P154, DOI 10.1097/00019606-199609000-00002; Ladanyi M, 1996, GENE CHROMOSOME CANC, V15, P173, DOI 10.1002/(SICI)1098-2264(199603)15:3<173::AID-GCC5>3.0.CO;2-#; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lamant L, 1999, BLOOD, V93, P3088; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luthra R, 1998, HEMATOPATHOL MOL HEM, V11, P173; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mason DY, 1998, CANCER RES, V58, P1057; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; Miething C, 2000, BLOOD, V96, p93A; Mir SS, 2000, BLOOD, V96, P4307; Mitev L, 1998, LEUKEMIA LYMPHOMA, V28, P613, DOI 10.3109/10428199809058372; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nakamura S, 1997, AM J SURG PATHOL, V21, P1420, DOI 10.1097/00000478-199712000-00004; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NIEBOROWSKASKOR.M, 2000, BLOOD, V96, pA2017; OCHS R, 1983, EXP CELL RES, V146, P139, DOI 10.1016/0014-4827(83)90332-4; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Park JP, 1997, CANCER GENET CYTOGEN, V96, P118, DOI 10.1016/S0165-4608(96)00281-6; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Pfeifer W, 1999, AM J PATHOL, V155, P1353, DOI 10.1016/S0002-9440(10)65237-6; Pileri SA, 1997, AM J PATHOL, V150, P1207; Pulford K, 2000, BLOOD, V96, P1605, DOI 10.1182/blood.V96.4.1605.h8001605_1605_1607; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Pulford K, 1999, AM J PATHOL, V154, P1657, DOI 10.1016/S0002-9440(10)65421-1; RAULO E, 1994, J BIOL CHEM, V269, P12999; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SANDLUND JT, 1994, BLOOD, V84, P2467, DOI 10.1182/blood.V84.8.2467.bloodjournal8482467; SANDLUND JT, 1994, J CLIN ONCOL, V12, P895, DOI 10.1200/JCO.1994.12.5.895; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; SHIOTA M, 1994, ONCOGENE, V9, P1567; Shiota M, 1996, LEUKEMIA LYMPHOMA, V23, P25, DOI 10.3109/10428199609054798; SHIOTA M, 1994, BLOOD, V84, P3648, DOI 10.1182/blood.V84.11.3648.bloodjournal84113648; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Skinnider BF, 1999, HEMATOL ONCOL, V17, P137, DOI 10.1002/(SICI)1099-1069(199912)17:4<137::AID-HON642>3.3.CO;2-M; Slupianek A, 2001, CANCER RES, V61, P2194; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; Souttou B, 1998, J NATL CANCER I, V90, P1468, DOI 10.1093/jnci/90.19.1468; STEIN H, 1985, BLOOD, V66, P848; Stein H, 2000, BLOOD, V96, P3681; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; TIAN ZG, 1995, CANCER RES, V55, P5335; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; Trumper L, 1998, BRIT J HAEMATOL, V103, P1138; Ueno H, 1997, ONCOGENE, V14, P3067, DOI 10.1038/sj.onc.1201153; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; YonedaKato N, 1996, ONCOGENE, V12, P265; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; Zatsepina OV, 1999, J CELL SCI, V112, P455	122	205	224	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5623	5637		10.1038/sj.onc.1204594	http://dx.doi.org/10.1038/sj.onc.1204594			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607814				2022-12-28	WOS:000170887500005
J	Thomas, M; Glaunsinger, B; Pim, D; Javier, R; Banks, L				Thomas, M; Glaunsinger, B; Pim, D; Javier, R; Banks, L			HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation	ONCOGENE			English	Article						HPV; E6; DIg; MAGI-1; transformation	HUMAN PAPILLOMAVIRUS TYPE-16; LARGE TUMOR-SUPPRESSOR; CARCINOMA CELL-LINES; GUANYLATE-KINASE; PDZ DOMAINS; PHOSPHOINOSITIDE 3-KINASE; ADENOVIRUS E4-ORF1; EPITHELIAL-CELLS; PLASMA-MEMBRANE; TIGHT JUNCTIONS	It has recently been shown that the high-risk human papillomavirus (HPV) E6 proteins can target the PDZ-domain containing proteins, Dlg, MUPP-1, MAGI-1 and hScrib for proteasome-mediated degradation. However, the E6 proteins from HPV-16 and HPV-18 (the two most common high-risk virus types) differ in their ability to target these proteins in a manner that correlates with their malignant potential. To investigate the underlying mechanisms for this, we have mutated HPV-16 and HPV-18 E6s to give each protein the other's PDZ-binding motif. Analysis of these mutants shows that the greater ability of HPV-18 E6 to bind to these proteins and to target them for degradation is indeed due to a single amino acid difference. Using a number of assays, we show that the E6 proteins interact specifically with only one of the five PDZ domains of MAGI-1, and this is the first interaction described for this particular PDZ domain. We also show that the guanylate kinase homology domain and the regions of MAGI-1 down stream of amino acid 733 are pot required for the degradation of MAGI-I. Finally, in a series of comparative analyses, we show that the degradation of MAGI-1 occurs through a different mechanism from that used by the E6 protein to induce the degradation of DIg and p53.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Baylor College of Medicine	Thomas, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.				NCI NIH HHS [R01 CA58541, R01 CA058541-06, R01 CA058541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Li J, 1998, CANCER RES, V58, P5667; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; PIM D, 1994, ONCOGENE, V9, P1869; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tashiro H, 1997, CANCER RES, V57, P3935; Thomas M, 1999, J GEN VIROL, V80, P1513, DOI 10.1099/0022-1317-80-6-1513; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; THOMAS M, 1995, ONCOGENE, V10, P261; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	48	93	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5431	5439		10.1038/sj.onc.1204719	http://dx.doi.org/10.1038/sj.onc.1204719			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571640	Green Accepted			2022-12-28	WOS:000170781100003
J	Forrest, A; Gabrielli, B				Forrest, A; Gabrielli, B			Cdc25B activity is regulated by 14-3-3	ONCOGENE			English	Article						cdc25; 14-3-3; G2 checkpoint	DNA-DAMAGE CHECKPOINT; MULTIPLE SIGNALING PATHWAYS; HUMAN-CELLS; G2/M PROGRESSION; PHASE-TRANSITION; PROTEIN-KINASE; GROWTH-CONTROL; FISSION YEAST; HELA-CELLS; PHOSPHATASE	In the G2 phase cell cycle checkpoint arrest, the cdc25-dependent activation of cyclin B/cdc2, a critical step in regulating entry into mitosis, is blocked. Studies in yeast have demonstrated that the inhibition of cdc25 function involves 14-3-3 binding to cdc25, In humans, two cdc25 isoforms have roles in G2/M progression, cdc25B and cdc25C, both bind 14-3-3, Abrogating 14-3-3 binding to cdc25C attenuates the G2 checkpoint arrest, but the contribution of 14-3-3 binding to the regulation of cdc25B function is unknown. Here we demonstrate that high level over-expression of cdc25B in G2 checkpoint arrested cells can activate cyclin B/cdc2 and overcome the checkpoint arrest. Mutation of the major 14-3-3 binding site, S323, or removal of the N-terminal regulatory domain are strong activating mutations, increasing the efficiency with which the mutant forms of cdc25B not only overcome the arrest, but also initiate aberrant mitosis, We also demonstrate that 14-3-3 binding to the S323 site on cdc25B blocks access of the substrate cyclin/cdks to the catalytic site of the enzyme, thereby directly inhibiting the activity of cdc25B, This provides direct mechanistic evidence that 14-3-3 binding to cdc25B can regulate its activity, thereby controlling progression into mitosis.	Univ Queensland, Sch Med, Dept Pathol, Joint Oncol Program, Brisbane, Qld 4006, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Joint Oncol Program, Herston Rd, Brisbane, Qld 4006, Australia.		Gabrielli, Brian G/B-3655-2011; Forrest, Alistair/A-6597-2008	Gabrielli, Brian G/0000-0003-3933-1651; Forrest, Alistair/0000-0003-4543-1675				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERZINGER T, 1995, ONCOGENE, V11, P2151; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kovelman R, 1996, MOL CELL BIOL, V16, P86; Lammer C, 1998, J CELL SCI, V111, P2445; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raleigh JM, 2000, J CELL SCI, V113, P1727; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xu X, 1996, J BIOL CHEM, V271, P5118; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	43	88	95	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4393	4401		10.1038/sj.onc.1204574	http://dx.doi.org/10.1038/sj.onc.1204574			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466620				2022-12-28	WOS:000169912600013
J	Keating, KE; Gueven, N; Watters, D; Rodemann, HP; Lavin, MF				Keating, KE; Gueven, N; Watters, D; Rodemann, HP; Lavin, MF			Transcriptional downregulation of ATM by EGF is defective in ataxia-telangiectasia cells expressing mutant protein	ONCOGENE			English	Article						ataxia-telangiectasia ATM; transcriptional downregulation; EGF; Sp1 transcriptional factor	EPIDERMAL GROWTH-FACTOR; DAMAGE-INDUCED PHOSPHORYLATION; CYCLE CHECKPOINT PATHWAY; DOUBLE-STRAND BREAKS; DNA-DAMAGE; GENE-PRODUCT; DEPENDENT PHOSPHORYLATION; IONIZING-RADIATION; SP1-MEDIATED TRANSCRIPTION; SIGNAL-TRANSDUCTION	There is evidence that ATM plays a wider role in intracellular signalling in addition to DNA damage recognition and cell cycle control, In this report we show that activation of the EGF receptor is defective in ataxia-telangiectasia (A-T) cells and that sustained stimulation of cells with EGF downregulates ATM protein in control cells but not in A-T cells expressing mutant protein, Concomitant with the downregulation of ATM, DNA-binding activity of the transcription factor Spl decreased in controls after EGF treatment but increased from a lower basal level in A-T cells to that in untreated control cells, Mutation in two Spl consensus sequences in the ATM promoter reduced markedly the capacity of the promoter to support luciferase activity in a reporter assay. Overexpression of anti-sense ATM cDNA in control cells decreased the;basal level of Spl, which in turn was increased by subsequent treatment of cells with EGF, similar to that observed in,A-T cells. On the other hand full-length ATM cDNA increased the basal level of Spl binding in A-T cells, and in response to EGF Spl binding decreased, confirming that this is an ATR I-dependent process. Contrary to that observed in control cells there was no radiation-induced change in ATM protein in EGF-treated A-T cells and likewise no alteration in Spl binding activity. The results demonstrate that EGF-induced downregulation of ATM (mutant) protein in A-T cells is defective and this appears to be due to less efficient EGFR activation and abnormal Spl regulation.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Lab, Brisbane, Qld 4029, Australia; Sect Radiobiol & Mol Environm Res, D-72076 Tubingen, Germany; Univ Queensland, PO Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Royal Brisbane & Women's Hospital; University of Queensland	Lavin, MF (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Lab, Brisbane, Qld 4029, Australia.		Lavin, Martin F/F-5961-2014; Watters, Dianne J/E-6007-2010	Lavin, Martin F/0000-0002-5940-4769; Watters, Dianne J/0000-0002-2555-5825				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Clarke RA, 1998, J CLIN PATHOL-MOL PA, V51, P224, DOI 10.1136/mp.51.4.224; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dittmann KH, 1998, INT J RADIAT BIOL, V74, P225, DOI 10.1080/095530098141609; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELMORE E, 1976, J CELL PHYSIOL, V89, P429, DOI 10.1002/jcp.1040890308; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Fukao T, 1999, BLOOD, V94, P1998; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KHANNA KK, 1997, J BIOL CHEM, V271, P29335; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KONDO N, 1993, SCAND J IMMUNOL, V38, P45, DOI 10.1111/j.1365-3083.1993.tb01692.x; KWOK TT, 1992, INT J RADIAT ONCOL, V22, P525, DOI 10.1016/0360-3016(92)90867-H; KWOK TT, 1991, INT J CANCER, V19, P73; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Lynn WS, 1997, NEUROIMMUNOMODULAT, V4, P277, DOI 10.1159/000097348; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NELSON J, 1989, EUR J CANC CLIN ONCO, V12, P1851; OCONNOR RD, 1980, CLIN IMMUNOL IMMUNOP, V15, P66, DOI 10.1016/0090-1229(80)90021-5; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Rhodes N, 1998, GENE DEV, V12, P3686, DOI 10.1101/gad.12.23.3686; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Saito T, 1998, MAMM GENOME, V9, P769, DOI 10.1007/s003359900861; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHILOH Y, 1982, CARCINOGENESIS, V3, P815, DOI 10.1093/carcin/3.7.815; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WOLTMAN R, 1994, INT J RADIAT ONCOL, V30, P91; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	70	21	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4281	4290		10.1038/sj.onc.1204527	http://dx.doi.org/10.1038/sj.onc.1204527			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466608				2022-12-28	WOS:000169912600001
J	Polanowska, J; Fabbrizio, E; Le Cam, L; Trouche, D; Emiliani, S; Herrera, R; Sardet, C				Polanowska, J; Fabbrizio, E; Le Cam, L; Trouche, D; Emiliani, S; Herrera, R; Sardet, C			The periodic down regulation of Cyclin E gene expression from exit of mitosis to end of G(1) is controlled by a deacetylase- and E2F-associated bipartite repressor element	ONCOGENE			English	Article						cyclin E; E2F; promoter; transcriptional repression; cell cycle	PAPILLOMAVIRUS TYPE-16 E7; IN-VIVO STRUCTURE; CELL-CYCLE; HISTONE DEACETYLASE; TRANSCRIPTION FACTOR; S-PHASE; RETINOBLASTOMA PROTEIN; DNA-REPLICATION; E2F BINDING; PROMOTER	The expression of cyclin E and that of a few other bona fide cell cycle regulatory genes periodically oscillates every cycle in proliferating cells. Although numerous experiments have documented the role of E2F sites and E2F activities in the control of these genes as cells exit from Co to move through the initial G(1)/S phase transition, almost nothing is known on the role of E2Fs during the subsequent cell cycles. Here we show that a variant E2F-site that is part of the Cyclin E Repressor Module (CERM) (Le Cam et al,, 1999b) accounts for the periodic down regulation of the cyclin E promoter observed between the exit from mitosis until the mid/late G(1) phase in exponentially cycling cells. This cell cycle-dependent repression correlates with the periodic binding of an atypical G(1)-specific high molecular weight p107-E2F complex (Cyclin E Repressor Complex: CERC2) that differs in both size and DNA binding behaviors from known p107-E2F complexes. Notably, affinity purified CERC2 displays a TSA-sensitive histone deacetylase activity and, consistent with this, derepression of the cyclin E promoter by trichostatin A depends on the GERM element, Altogether, this shows that the cell cycle-dependent control of cyclin E promoter in cycling cells is embroiled in acetylation pathways via the GERM-like E2F element.	CNRS, IFR24, UMR 5535, Inst Genet Mol, F-34293 Montpellier 5, France; CNRS, UPR 1142, Inst Human Genet, F-34396 Montpellier, France; CNRS, IBCG, LBME, F-31062 Toulouse, France; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Baylor College of Medicine	Sardet, C (corresponding author), CNRS, IFR24, UMR 5535, Inst Genet Mol, 1919 Route Mende, F-34293 Montpellier 5, France.		Le Cam, Laurent/O-1408-2016; Polanowska, Jolanta/P-9117-2016; Trouche, Didier/B-2854-2008	Polanowska, Jolanta/0000-0001-7666-7010; LE CAM, Laurent/0000-0003-0325-878X; Trouche, Didier/0000-0003-1398-6481				ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Bennett JD, 1996, ONCOGENE, V13, P1073; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fajas L, 2000, FEBS LETT, V471, P29, DOI 10.1016/S0014-5793(00)01363-6; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Geng Y, 1996, ONCOGENE, V12, P1173; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Huet X, 1996, MOL CELL BIOL, V16, P3789; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Krude T, 2000, J BIOL CHEM, V275, P13699, DOI 10.1074/jbc.275.18.13699; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Le Cam L, 1999, BIOTECHNIQUES, V26, P840; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Li FZ, 1999, CANCER RES, V59, P3143; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Merrill GF, 1998, METHOD CELL BIOL, V57, P229; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; SARDET C, 1997, PROGR GENE EXPRESSIO, V2, P1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; Stiegler P, 1998, CANCER RES, V58, P5049; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Takahashi Y, 2000, GENE DEV, V14, P804; Tommasi S, 1999, J BIOL CHEM, V274, P27829, DOI 10.1074/jbc.274.39.27829; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Vogt B, 1999, J GEN VIROL, V80, P2103, DOI 10.1099/0022-1317-80-8-2103; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 1996, MOL CELL BIOL, V16, P634; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 2000, BIOCHEM SOC T, V28, P379, DOI 10.1042/0300-5127:0280379; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x; ZWICKER J, 1997, TRENDS GENET, V1, P3; ZWICKER J, 1996, SCIENCE, V271, P5255	66	25	25	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4115	4127		10.1038/sj.onc.1204514	http://dx.doi.org/10.1038/sj.onc.1204514			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464278				2022-12-28	WOS:000169857200002
J	Munshi, A; Pappas, G; Honda, T; McDonnell, TJ; Younes, A; Li, Y; Meyn, RE				Munshi, A; Pappas, G; Honda, T; McDonnell, TJ; Younes, A; Li, Y; Meyn, RE			TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2	ONCOGENE			English	Article						apoptosis; TRAIL; bcl-2; cycloheximide; prostate	CYTOTOXIC LIGAND TRAIL; CYTOCHROME-C RELEASE; MEDIATED APOPTOSIS; DEATH DOMAIN; PROTEIN EXPRESSION; MELANOMA-CELLS; MYELOMA CELLS; FAS; RECEPTOR; TNF	To determine if TRAIL-induced apoptosis in human prostate tumor cells was suppressed by bcl-2, we compared the levels of apoptosis induced by recombinant human TRAIL in pairs of isogenic cell lines that do or do not express bcl-2, Three human prostate tumor cell lines (PC3, DU145 and LNCaP) and their bcl-2-expressing counterparts were tested for their susceptibility to TRAIL, Cells were exposed to TRAIL in the presence of cycloheximide which acted as a sensitizer. Apoptosis was induced rapidly in PC3 and DU145 neo-control transfected cells, whereas induction in LNCaP required 24 h, All three cell line variants expressing bcl-2 were resistant to the apoptotic effects of TRAIL. Caspase 3 and 8 activation was also detected in the neo control cells after treatment with TRAIL, demonstrating the rapid activation of the caspase cascade similar to that seen with other death receptors, Bcl-2 overexpression in these cells blocked activation of these caspases, suggesting that bcl-2 expression of human cancer cells may be a critical factor in the therapeutic efficacy of TRAIL.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma & Leukemia, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 066, Houston, TX 77030 USA.				NCI NIH HHS [P30 CA16672, R01 CA69003, P01 CA06294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA069003, P01CA006294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Bonavida B, 1999, INT J ONCOL, V15, P793; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fulda S, 2000, CANCER RES, V60, P3947; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; MARIANI SM, 1997, J CELL BIOL, V37, P211; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MIYASHITA T, 1993, BLOOD, V81, P151; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; TANG C, 1994, LEUKEMIA, V8, P1960; Thomas WD, 1998, J IMMUNOL, V161, P2195; TSUCHIDA H, 1995, J IMMUNOL, V154, P2403; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; WALLACH D, 1984, J IMMUNOL, V132, P2464; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yamada K, 1999, DIABETES, V48, P478, DOI 10.2337/diabetes.48.3.478; Yu R, 2000, CANCER RES, V60, P2384; Zhang XD, 1999, CANCER RES, V59, P2747	48	96	99	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3757	3765		10.1038/sj.onc.1204504	http://dx.doi.org/10.1038/sj.onc.1204504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439339				2022-12-28	WOS:000169494700001
J	Pearson, M; Pelicci, PG				Pearson, M; Pelicci, PG			PML interaction with p53 and its role in apoptosis and replicative senescence	ONCOGENE			English	Article						PML; p53; apoptosis; senescence	PROMYELOCYTIC LEUKEMIA PROTEIN; TELOMERASE CATALYTIC SUBUNIT; CREB-BINDING-PROTEIN; NUCLEAR-BODIES; ONCOGENIC RAS; DNA-DAMAGE; PREMATURE SENESCENCE; CELLULAR SENESCENCE; TUMOR SUPPRESSION; HUMAN FIBROBLASTS	A network of control pathways has been characterized that arrest growth or induce apoptosis in response to potentially tumorogenic events such as genotoxic stress or oncogene expression. Ablation, or functional disruption, of these pathways is frequently observed during multistep carcinogenesis. Analysis of those genes most commonly compromized in tumours has led to the identification of the transcription factor p53 and the E2F binding protein Retinoblastoma (Rb), as key regulators of these processes. This review discusses recent data, demonstrating that the Promyelocytic Leukemia (PML) protein can physically and functionally interact with both p53 and Rb, suggesting that PML may be a novel regulator of these pathways.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Pearson, M (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020					ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Appella E, 2000, PATHOL BIOL, V48, P227; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1999, J CELL SCI, V112, P4581; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Ferbeyre G, 2000, GENE DEV, V14, P2015; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grobelny JV, 2000, J CELL SCI, V113, P4577; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Inoue K, 2000, GENE DEV, V14, P1797; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jiang WQ, 1997, CELL GROWTH DIFFER, V8, P513; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lansdorp P M, 1997, Ciba Found Symp, V211, P209; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Le S, 1999, GENETICS, V152, P143; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lombard DB, 2000, CANCER RES, V60, P2331; LONGO L, 1993, LEUKEMIA LYMPHOMA, V11, P405, DOI 10.3109/10428199309067933; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Maul GG, 1996, VIROLOGY, V217, P67, DOI 10.1006/viro.1996.0094; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Pluta AF, 1998, J CELL SCI, V111, P2029; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeager TR, 1999, CANCER RES, V59, P4175; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	96	104	107	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7250	7256		10.1038/sj.onc.1204856	http://dx.doi.org/10.1038/sj.onc.1204856			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704853				2022-12-28	WOS:000171891900013
J	Barone, MV; Sepe, L; Melillo, RM; Mineo, A; Santelli, G; Monaco, C; Castellone, MD; Tramontano, D; Fusco, A; Santoro, M				Barone, MV; Sepe, L; Melillo, RM; Mineo, A; Santelli, G; Monaco, C; Castellone, MD; Tramontano, D; Fusco, A; Santoro, M			RET/PTC1 oncogene signaling in PCCl 3 thyroid cells requires the small GTP-binding protein Rho	ONCOGENE			English	Article						RET; tyrosine-kinase; Rho; Ras; Rac; actin; thyroid; apoptosis	RET TYROSINE KINASE; NEOPLASTIC TRANSFORMATION; NEUROTROPHIC FACTOR; EPITHELIAL-CELLS; DOCKING SITE; FAMILY; RAS; ACTIVATION; GTPASES; SHC	Thyroid papillary carcinomas are characterized by RET/PTC rearrangements that cause the tyrosine kinase domain of the RET receptor to fuse with N-terminal sequences encoded by heterologous genes. This results in the aberrant expression of a ligand-independent and constitutively active RET kinase. We analysed actin reorganization induced by the RET/PTC1 oncogene in PC Cl 3 rat thyroid epithelial cells. Differently from oncogenes Src, Ras and Raf, RET/PTC1 caused actin filaments to form prominent stress fibers. Moreover, stress fibers were identified in human thyroid papillary carcinoma cell lines harboring RET/PTC1 rearrangements but not in thyroid carcinoma cells negative for RET/PTC rearrangements. RET/MEN 2A, a constitutively active but unrearranged membrane-bound RET oncoprotein, did not induce stress fibers in PC CI 3 cells. Induction of stress fibers by RET/PTC1 was restricted to thyroid cells; it did not occur in NIH3T3 fibroblasts or MCF7 mammary cells. RET/PTC1-mediated stress fiber formation depended on Rho but not Rac small GTPase activity. In addition, inhibition of Rho, but not of Rac, caused apoptosis of RET/PTC1-expressing thyroid cells. We conclude that Rho is implicated in the actin reorganization and cell survival mediated by the chimeric RET/PTC1 oncogene in thyroid epithelial cells, both phenotypes being cell type- and oncogene type-specific.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Fdn Senatore Pascale, I-80131 Naples, Italy; Univ Sannio, I-82100 Benevento, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Fondazione Pascale; University of Sannio	Santoro, M (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	Tramontano, Donatella/AAS-1740-2020; melillo, rosa marina/O-5255-2015	Fusco, Alfredo/0000-0003-3332-5197; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; MELILLO, Rosa Marina/0000-0002-9233-5275; Tramontano, Donatella/0000-0002-9308-034X; BARONE, Maria Vittoria/0000-0001-6190-4917				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Costello PS, 2000, J EXP MED, V192, P77, DOI 10.1084/jem.192.1.77; De Vita G, 2000, CANCER RES, V60, P3727; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Melillo RM, 1999, CANCER RES, V59, P1120; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Ponder BAJ, 1999, CANCER RES, V59, p1736S; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROGER PP, 1988, FEBS LETT, V232, P409, DOI 10.1016/0014-5793(88)80781-6; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schlumberger MJ, 1998, NEW ENGL J MED, V338, P297, DOI 10.1056/NEJM199801293380506; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; VAN AL, 1997, GENE DEV, V11, P2295; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	46	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					6973	6982		10.1038/sj.onc.1204886	http://dx.doi.org/10.1038/sj.onc.1204886			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704822				2022-12-28	WOS:000171739300001
J	Ross, J; Lemm, I; Berberet, B				Ross, J; Lemm, I; Berberet, B			Overexpression of an mRNA-binding protein in human colorectal cancer	ONCOGENE			English	Article						colorectal cancer; tumor marker; c-myc	MYC MESSENGER-RNA; CODING REGION; KH-DOMAIN; EXPRESSION; GENE; FAMILY; CELLS; PURIFICATION; CARCINOMA; ONCOGENE	A Coding Region instability Determinant-Binding Protein (CRD-BP) binds in vitro to c-myc mRNA and appears to stabilize the mRNA. The CRD-BP gene is amplified in one-third of human breast cancer cases, and the CRD-BP appears to be an oncofetal protein. To analyse CRD-BP expression in human cancer tissue, paired extracts of cancer and normal colon specimens from 21 patients were analysed by immunoblotting and/or reverse transcriptase-polymerase chain reaction. Seventeen cancer specimens out of 21 (81%) were positive for CRD-BP expression by one or both assays. With one exception, normal colon specimens were negative for CRD-BP expression; specimens of inflammatory bowel and a villous adenoma also had no detectable CRD-BP. The lack of CRD-BP expression in normal colon did not result from indiscriminate protein or RNA degradation. c-myc mRNA levels appeared to be elevated in tumor specimens. We conclude that the CRD-BP is scarce or absent from normal colon but is overexpressed in colorectal cancer. The CRD-BP might be a novel human tumor marker.	Univ Wisconsin, Mcardle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ross, J (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, Dept Oncol, 1400 Univ Ave, Madison, WI 53706 USA.	ross@oncology.wisc.edu			NCI NIH HHS [R01-CA78710] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078710] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander RJ, 1998, DIGEST DIS SCI, V43, P2652, DOI 10.1023/A:1026699126899; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Castells A, 1998, BRIT J CANCER, V78, P1368, DOI 10.1038/bjc.1998.686; Compton C, 2000, CANCER-AM CANCER SOC, V88, P1739, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO;2-T; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; Doyle GA, 2000, CANCER RES, V60, P2756; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; FINLEY GG, 1989, ONCOGENE, V4, P963; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; IMASEKI H, 1989, CANCER, V64, P704, DOI 10.1002/1097-0142(19890801)64:3<704::AID-CNCR2820640323>3.0.CO;2-S; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Mueller-Pillasch F, 1999, MECH DEVELOP, V88, P95, DOI 10.1016/S0925-4773(99)00160-4; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; Nielsen J, 2000, MECH DEVELOP, V96, P129, DOI 10.1016/S0925-4773(00)00383-X; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; NUSSBAUM NL, 1995, METABOLIC BASIS INHE, P759; PFAFF SL, 1992, DEV BIOL, V151, P306, DOI 10.1016/0012-1606(92)90235-9; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; SCHER HI, 2000, CLIN ONCOLOGY, P1823; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Zhang JY, 1999, J EXP MED, V189, P1101, DOI 10.1084/jem.189.7.1101	26	78	81	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6544	6550		10.1038/sj.onc.1204838	http://dx.doi.org/10.1038/sj.onc.1204838			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641779				2022-12-28	WOS:000171404200007
J	Suzuki, H; Tomida, A; Tsuruo, T				Suzuki, H; Tomida, A; Tsuruo, T			Dephosphorylated hypoxia-inducible factor 1 alpha as a mediator of p53-dependent apoptosis during hypoxia	ONCOGENE			English	Article						apoptosis; HIF-1 alpha; hypoxia; p53; phosphorylation	RING-FINGER DOMAIN; TRANSCRIPTION FACTOR; TUMOR ANGIOGENESIS; NUCLEAR EXPORT; SOLID TUMORS; IN-VIVO; P53; PROTEIN; MITOCHONDRIA; HIF-1-ALPHA	Under hypoxia, HIF-1 alpha binds to aryl hydrocarbon receptor nuclear translocator (ARNT, also called HIF-1 alpha) to activate expression of genes important for cell survival. Alternatively, HIF-1 alpha can bind to the tumor suppressor p53 and promote p53-dependent apoptosis. Here we show that the opposite functions of HIF-1 alpha are distinguished by its phosphorylation status. Two distinguishable forms of HIF-1 alpha, phosphorylated and dephosphorylated, were induced during hypoxia-induced apoptosis. The phosphorylated HIF-1 alpha was the major form that bound to ARNT. Ectopically expressed ARNT was consistently able to enhance HIF-1 alpha phosphorylation in a binding-dependent manner. In contrast, the dephosphorylated HIF-1 alpha was the major form that bound to p53. Depletion of the dephosphorylated HIF-1 alpha, by using the Hsp90 inhibitor geldanamycin A that had little effect on the phosphorylated HIF-1 alpha expression, suppressed p53 induction and subsequent apoptosis. Depletion of dephosphorylated HIF-1 alpha also prevented hypoxia-induced nuclear accumulation of HDM2, a negative regulator of p53. Our results indicate that the functions of HIF-1 alpha varied with its phosphorylation status and that dephosphorylated HIF-1 alpha mediated apoptosis by binding to and stabilizing p53.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1700012, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chavany C, 1996, J BIOL CHEM, V271, P4974; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shimizu S, 1996, CANCER RES, V56, P2161; Tomida A, 1996, ONCOGENE, V13, P2699; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vaupel PW, 1997, KLIN PADIATR, V209, P243, DOI 10.1055/s-2008-1043957; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 1997, BIOL CHEM, V378, P609	38	186	212	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5779	5788		10.1038/sj.onc.1204742	http://dx.doi.org/10.1038/sj.onc.1204742			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593383				2022-12-28	WOS:000171037200001
J	Xia, CZ; Ma, WB; Wang, F; Hua, SB; Liu, MY				Xia, CZ; Ma, WB; Wang, F; Hua, SB; Liu, MY			Identification of a prostate-specific G-protein coupled receptor in prostate cancer	ONCOGENE			English	Article						G-protein coupled receptor; GPCRs; prostate cancer; Galpha12; PSGR	TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; CELL-GROWTH; P115 RHOGEF; G-ALPHA-12; KINASE; PATHWAY; EXPRESSION; ONCOGENES	Membrane receptors coupled to heterotrimeric G-proteins play an essential role in the transmission of signals from the extracellular environment to the cytoplasm of the cell. A wide variety of external stimuli, including neurotransmitters, hormones, phospholipids, photons, odorants, taste ligands, and growth factors, can activate specific members of the G-protein coupled receptors (GPCRs). Besides essential functions in fully differentiated cells and tissues, GPCRs are also involved in embryogenesis, tissue regeneration, cell growth stimulation, and cell proliferation. In this study, we identified a novel prostate-specific G-protein coupled receptor that interacts with G alpha (12) in our yeast two-hybrid assays. The expression of the receptor protein is highly restricted to human prostate tissues using multiple-tissue Northern blot analysis, and tissue expression array. Furthermore, the expression of prostate-specific receptor is increased significantly in prostate tumors in comparison with the matched normal prostate tissues using PCR and Southern blot analysis, suggesting a potential role of this tissue-specific G-protein coupled receptor in prostate cancer development.	Inst Biosci & Technol Houston, Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, Houston, TX 77030 USA; Genetastix Corp, San Jose, CA 95131 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Liu, MY (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamu.edu						ABE K, 1993, J BIOL CHEM, V268, P12033; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dermott JM, 1999, ONCOGENE, V18, P7185, DOI 10.1038/sj.onc.1203345; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Xu LL, 2000, CANCER RES, V60, P6568; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	34	60	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5903	5907		10.1038/sj.onc.1204803	http://dx.doi.org/10.1038/sj.onc.1204803			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593396				2022-12-28	WOS:000171037200014
J	Arvand, A; Denny, CT				Arvand, A; Denny, CT			Biology of EWS/ETS fusions in Ewing's family tumors	ONCOGENE			English	Review						EWS/ETS; Ewing's family tumors; aberrant transcription factors	RNA-BINDING PROTEIN; PRIMITIVE NEUROECTODERMAL TUMOR; EWS CHIMERIC TRANSCRIPTS; HUMAN MYELOID-LEUKEMIA; ROUND-CELL TUMORS; ETS-FAMILY; DNA-BINDING; CHROMOSOME-TRANSLOCATION; SARCOMA TRANSLOCATION; MALIGNANT-MELANOMA	Tumor-associated chromosomal translocations lead to the formation of chimeric fusions between the EWS gene and one of five different ETS transcription factors in Ewing's family tumors (EFTs). The resultant EWS/ETS proteins promote oncogenesis in a dominant fashion in model systems and are necessary for continued growth of EFT cell lines. EWS belongs to a family of genes that encode proteins that may serve as adapters between the RNA polymerase II complex and RNA splicing factors. EWS/ETS fusions have biochemical characteristics of aberrant transcription factors and appear to promote abnormal cellular growth by transcriptionally modulating a network of target genes. Early evidence suggests that EWS/ETS proteins may also impact gene expression through alteration in RNA processing. Elucidation of EWS/ETS target gene networks in the context of other signaling pathways will hopefully lead to biology based therapeutic strategies for EFT.	Univ Calif Los Angeles, Inst Mol Biol, Gwynee Hazen Cherry Mem Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Jonsson Comprehens Ctr, Gwynee Hazen Cherry Mem Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Gwynee Hazen Cherry Mem Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Pediat, Gwynee Hazen Cherry Mem Lab, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Denny, CT (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Gwynee Hazen Cherry Mem Lab, Los Angeles, CA 90024 USA.				PHS HHS [R01-87771] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; Attwooll C, 1999, ONCOGENE, V18, P7599, DOI 10.1038/sj.onc.1203156; AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Blair DG, 2000, ONCOGENE, V19, P6472, DOI 10.1038/sj.onc.1204046; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Burchill SA, 1997, EUR J CANCER, V33, P239, DOI 10.1016/S0959-8049(96)00463-7; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Hahm KB, 1999, NAT GENET, V23, P481, DOI 10.1038/70611; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Im YH, 2000, CANCER RES, V60, P1536; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Kontny HU, 1998, CANCER RES, V58, P5842; KOVAR H, 1990, ONCOGENE, V5, P1067; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; Kwiatkowski BA, 2000, BLOOD CELL MOL DIS, V26, P84, DOI 10.1006/bcmd.2000.0282; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; Lambert G, 2000, BIOCHEM BIOPH RES CO, V279, P401, DOI 10.1006/bbrc.2000.3963; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Mager AM, 1998, INT J DEV BIOL, V42, P561; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MAO XH, 1994, J BIOL CHEM, V269, P18216; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Mastrangelo T, 2000, ONCOGENE, V19, P3799, DOI 10.1038/sj.onc.1203762; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Melet F, 1996, MOL CELL BIOL, V16, P2708; MEYER D, 1993, MECH DEVELOP, V44, P109, DOI 10.1016/0925-4773(93)90061-2; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Panagopoulos I, 1996, ONCOGENE, V12, P489; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAO VN, 1993, ONCOGENE, V8, P2167; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 2000, INT J CANCER, V87, P328, DOI 10.1002/1097-0215(20000801)87:3<328::AID-IJC4>3.0.CO;2-1; Sjogren H, 1999, CANCER RES, V59, P5064; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; SORENSEN PHB, 1995, CANCER RES, V55, P1385; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Teitell MA, 1999, LAB INVEST, V79, P1535; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Thorner P, 1996, AM J PATHOL, V148, P1125; TRICHE TJ, 1987, MAJOR PROBLEMS PATHO, V18, P145; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Watson DK, 2000, ONCOGENE, V19, P6394, DOI 10.1038/sj.onc.1204070; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, J CELL SCI, V110, P1741; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZOUBEK A, 1994, BRIT J CANCER, V70, P908, DOI 10.1038/bjc.1994.419; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	108	266	275	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5747	5754		10.1038/sj.onc.1204598	http://dx.doi.org/10.1038/sj.onc.1204598			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607824				2022-12-28	WOS:000170887500015
J	Le Scolan, E; Wendling, F; Barnache, S; Denis, N; Tulliez, M; Vainchenker, W; Moreau-Gachelin, F				Le Scolan, E; Wendling, F; Barnache, S; Denis, N; Tulliez, M; Vainchenker, W; Moreau-Gachelin, F			Germ-line deletion of p53 reveals a multistage tumor progression in spi-1/PU.1 transgenic proerythroblasts	ONCOGENE			English	Article						erythroleukemia; Spi-1/PU.1; p53; p2l(Cip1/Waf1); transgenic mice	WILD-TYPE P53; VIRUS-INDUCED ERYTHROLEUKEMIA; TRANSCRIPTION FACTOR PU.1; LONG TERMINAL REPEAT; DNA-BINDING PROTEIN; FRIEND-VIRUS; ERYTHROPOIETIN RECEPTOR; CELL-DIFFERENTIATION; HEMATOPOIETIC-CELLS; MICE DEFICIENT	Activation of the spi-1/PU.1 proto-oneogene and loss of p53 function are genetic alterations associated with the emergence of Friend malignant erythroleukemic cells. To address the role of p53 during erythroleukemogenesis, spi-1 transgenic mice (spi-1-Tg) which develop erythroleukemia were bred with p53-deficient mice. Three classes of spi-1 transgenic mice differing in their p53 functional status (p53(+/+), p53(+/-) and p53(-/-)) were generated. These mice developed a unique pattern of erythroleukemia. In wild-type p53 spi-1-Tg mice, none of the primary erythroleukemic spleen cells displayed autonomous growth in vitro and in vivo. In contrast, in p53(+/-) spi-1-Tg mice, erythroleukemic cells gave rise to growth factor-independent cell lines and generated tumors in vivo. Malignancy was associated with loss of the wild-type p53 allele. The p53(-/-) spi-1-Tg mice developed erythroleukemia with a total incidence and a reduced latency compared to the two other genotypes. Unexpectedly, 50% of p53(-/-) spi-1-Tg erythroleukemic spleens generated cell lines that were strictly dependent upon erythropoietin (Epo) for proliferation, whereas the remainder proliferated independently of cytokines. Moreover, only 70% of these spleen cells were tumorigenic. These findings indicate that p53 germ-line deletion did not confer malignancy to spi-1-transgenic proerythroblasts. Moreover Epo independence and tumorigenicity appear as separable phenotypic characteristics revealing that the spi-1-Tg proerythroblasts progress towards malignancy through multiple oncogenic events.	Inst Curie, INSERM, U528, F-75005 Paris, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Hop Cochin, Lab Anat, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75005 Paris, France.	framoreau@curie.fr		Vainchenker, William/0000-0003-4705-202X				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BLYTH K, 1995, ONCOGENE, V10, P1717; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; DAVID YB, 1988, ONCOGENE, V3, P179; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELSON A, 1995, ONCOGENE, V11, P181; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MIYASHITA T, 1995, CELL, V80, P293; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1983, BIOCHIMIE, V65, P259, DOI 10.1016/S0300-9084(83)80277-6; Mori N, 1997, BLOOD, V90, P4924, DOI 10.1182/blood.V90.12.4924.4924_4924_4932; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; PURDIE CA, 1994, ONCOGENE, V9, P603; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; Tang PP, 2000, LEUKEMIA, V14, P1292, DOI 10.1038/sj.leu.2401823; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	57	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5484	5492		10.1038/sj.onc.1204708	http://dx.doi.org/10.1038/sj.onc.1204708			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571646				2022-12-28	WOS:000170781100009
J	Miyaki, M; Iijima, T; Shiba, K; Aki, T; Kita, Y; Yasuno, M; Mori, T; Kuroki, T; Iwama, T				Miyaki, M; Iijima, T; Shiba, K; Aki, T; Kita, Y; Yasuno, M; Mori, T; Kuroki, T; Iwama, T			Alterations of repeated sequences in 5 ' upstream and coding regions in colorectal tumors from patients with hereditary nonpolyposis colorectal cancer and Turcot syndrome	ONCOGENE			English	Article						mutation; repeated sequence; 5 ' upstream region; HNPCC; Turcot; Dukes stage	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; MICROSATELLITE MUTATOR PHENOTYPE; COLON-CANCER; FRAMESHIFT MUTATIONS; BAX GENE; INSTABILITY; CASPASE-5; RECEPTOR; HOMOLOG	One of the characteristics of tumors from patients with germline mutations of DNA mismatch repair genes is instability at microsatellite regions (MSI). We analysed alterations at repeated sequences of coding regions, as well as those of 5' upstream regions, in 29 MSI-High colorectal tumors from patients with hereditary nonpolyposis colorectal cancer (HNPCC) and Turcot syndrome. We found that repeated sequences in 5' upstream regions were altered in these tumors, at considerable frequencies. The (A)(10) repeat in the promoter region (position - 178 similar to - 169) of the GAPDH gene was altered in 17% of the tumors. The (A)(10)(TA)(9) in the 5' upstream region (position -318 similar to -291) of the mitochondrial isoleucyl tRNA synthetase gene (IIeRS-A), coded in nuclear DNA, was altered in 59% of the tumors, whereas (A)(9) in the 5' upstream region (position -859 similar to -851) of cytoplasmic isoleucyl tRNA synthetase gene (IIeRS-B) was not altered. Alteration at repeated sequences in the coding regions were 72% at TGF beta RII(A)(10), 24% at IGFIIR(G)(8), 45% at BAX(G)(8), 55% at E2F4(CAG)(13), 66% at caspase-5 (A)(10), 31% at MBD4(A)(10), 55% at hMSH3(A)(8) and 34% at hMSH6(C)(8). The number of altered genes increased with the advancement of carcinoma according to Dukes categories: mean numbers of altered genes within these 10 genes were 2.6 for Dukes A, 4.7 for Dukes B and 7.8 for Dukes C. The mean number for adenomas was 2.0. These results suggest that the MSI phenotype also causes alteration of 5' upstream regions which may affect apoptosis and some mitochondrial functions in HNPCC and Turcot tumors, and that accumulation of altered genes with repeated sequences is associated with the progression of HNPCC and Turcot colorectal tumors.	Tokyo Metropolitan Inst Med Sci, Komagome Hosp, Bunkyo Ku, Tokyo 1138677, Japan; Tokyo Metropolitan Inst Med Sci, Dept Surg, Bunkyo Ku, Tokyo 1138677, Japan; Inst Canc Res, Tokyo 1708455, Japan; Yamaguchi Univ, Ube, Yamaguchi 7550805, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428666, Japan; Kyoundo Hosp, Sasaki Inst, Tokyo 1010062, Japan	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Japanese Foundation for Cancer Research; Yamaguchi University; Showa University	Miyaki, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Komagome Hosp, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.		Kuroki, Toshio/A-9500-2011; Shiba, Kiyotaka/I-9588-2014	Kuroki, Toshio/0000-0001-6369-4351; Shiba, Kiyotaka/0000-0001-6459-0204				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aki T, 1997, J BIOCHEM, V122, P271; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kamada S, 1997, CELL DEATH DIFFER, V4, P473, DOI 10.1038/sj.cdd.4400268; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIYAKI M, 1995, J MOL MED-JMM, V73, P515; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; MIYASHITA T, 1995, CELL, V80, P293; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Schwartz S, 1999, CANCER RES, V59, P2995; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544	23	18	22	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5215	5218		10.1038/sj.onc.1204578	http://dx.doi.org/10.1038/sj.onc.1204578			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526511				2022-12-28	WOS:000170464000016
J	Kanzler, S; Meyer, E; Lohse, AW; Schirmacher, P; Henninger, J; Galle, PR; Blessing, M				Kanzler, S; Meyer, E; Lohse, AW; Schirmacher, P; Henninger, J; Galle, PR; Blessing, M			Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis	ONCOGENE			English	Article						transforming growth factor-beta; hepatocarcinogenesis; transgenic mice; TGF-beta receptor; tumor suppressor	GROWTH-FACTOR-BETA; C-REACTIVE PROTEIN; TRANSGENIC MICE; TRANSFORMING GROWTH-FACTOR-BETA-1; MICROSATELLITE INSTABILITY; FACTOR (TGF)-ALPHA; MESSENGER-RNA; CANCER CELLS; RAT-LIVER; GENE	The potent growth-inhibitory activity of cytokines of the transforming growth factor-beta (TGF-beta) superfamily and their widespread expression in epithelia suggest that they may play an important role in the maintenance of epithetial homeostasis. To analyse TGF-beta mediated tumor suppressor activity in the liver, we generated transgenic mice overexpressing a dominant negative type II TGF-beta receptor in hepatocytes under control of the regulatory elements of the human C-reactive protein gene promoter. Transgenic animals exhibited constitutive and liver-specific transgene expression. The functional inactivation of the TGF-beta signaling pathway in transgenic hepatocytes was shown by reduced TGF-beta induced inhibition of DNA synthesis in primary hepatocyte cultures. Liver morphology and spontaneous tumorigenesis were unchanged in transgenic mice suggesting that interruption of the signaling of all three isoforms of TGF-beta in hepatocytes does not disturb tissue homeostasis in the liver under physiological conditions. However, following initiation with the carcinogen diethylnitrosamine and tumor-promotion with phenobarbital transgenic mice exhibited a moderate albeit significant increase in the incidence, size and multiplicity of both preneoplastic tissue lesions in the liver and of hepatocellular carcinomas. These results give in vivo evidence for a tumor suppressor activity of the endogeneous TGF-beta system in the liver during chemical hepatocarcinogenesis.	Johannes Gutenberg Univ Mainz, Dept Med, D-55131 Mainz, Germany; Univ Cologne, Dept Pathol, D-50931 Cologne, Germany	Johannes Gutenberg University of Mainz; University of Cologne	Blessing, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med, D-55131 Mainz, Germany.	Blessing@mail.uni-mainz.de	Galle, Peter R/T-5292-2018; Galle, Peter/ABE-2872-2021	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992				Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; ALEXANDROW MG, 1995, CANCER RES, V55, P3928; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; Bottinger EP, 1997, CANCER RES, V57, P5564; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BRAND T, 1993, J BIOL CHEM, V268, P11500; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Cardillo MR, 2000, ANAL QUANT CYTOL, V22, P1; Chang J, 1997, CANCER RES, V57, P2856; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CILIBERTO G, 1987, EMBO J, V6, P4017, DOI 10.1002/j.1460-2075.1987.tb02745.x; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; Dietmaier W, 1997, CANCER RES, V57, P4749; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Factor VM, 1997, CANCER RES, V57, P2089; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Gitelman SE, 1997, MAMM GENOME, V8, P212, DOI 10.1007/s003359900391; Glick AB, 1997, CANCER RES, V57, P2079; Gobbi H, 2000, HISTOPATHOLOGY, V36, P168; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Grasl-Kraupp B, 1998, HEPATOLOGY, V28, P717, DOI 10.1002/hep.510280318; HADDOW S, 1991, ONCOGENE, V6, P1465; HADDOW S, 1991, ONCOGENE, V6, P2377; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOGAN B, 1986, MANIPULATING MOUSE E; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; ITO N, 1991, CANCER RES, V51, P4080; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kanzler S, 1999, AM J PHYSIOL-GASTR L, V276, pG1059, DOI 10.1152/ajpgi.1999.276.4.G1059; Kelly DL, 1999, ANTICANCER RES, V19, P4791; Kim IY, 1996, CANCER RES, V56, P44; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KISO S, 1994, HEPATOLOGY, V20, P1303, DOI 10.1016/0270-9139(94)90772-2; Kiss A, 1997, CLIN CANCER RES, V3, P1059; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lim IK, 1999, MOL CARCINOGEN, V26, P83, DOI 10.1002/(SICI)1098-2744(199910)26:2<83::AID-MC3>3.3.CO;2-W; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lowsky R, 2000, BLOOD, V95, P1767, DOI 10.1182/blood.V95.5.1767.005k07_1767_1772; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MURPHY C, 1995, J BIOL CHEM, V270, P704, DOI 10.1074/jbc.270.2.704; MYEROFF LL, 1995, CANCER RES, V55, P5545; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; PITOT HC, 1987, NONGENOTOXIC MECH CA, P41; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Ruether Ulrich, 1993, Oncogene, V8, P87; Russell CE, 1999, MOL CELL ENDOCRINOL, V148, P129, DOI 10.1016/S0303-7207(98)00226-3; Saeki A, 2000, CANCER, V88, P1025, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1025::AID-CNCR11>3.0.CO;2-U; Salvucci M, 1999, ONCOGENE, V18, P181, DOI 10.1038/sj.onc.1202279; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Santoni-Rugiu E, 1999, AM J PATHOL, V154, P1693, DOI 10.1016/S0002-9440(10)65425-9; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Shin KH, 2000, CLIN CANCER RES, V6, P536; Sugiyama A, 1997, BIOCHEM BIOPH RES CO, V238, P539, DOI 10.1006/bbrc.1997.7338; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; THORGEIRSSON SS, 1997, ARCH TOXICOL, V19, P3359; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; WHITEHEAD AS, 1983, SCIENCE, V221, P69, DOI 10.1126/science.6857266; WU SP, 1993, CELL GROWTH DIFFER, V4, P115	71	68	72	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					5015	5024		10.1038/sj.onc.1204544	http://dx.doi.org/10.1038/sj.onc.1204544			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526486				2022-12-28	WOS:000170439800011
J	Medh, RD; Wang, AX; Zhou, F; Thompson, EB				Medh, RD; Wang, AX; Zhou, F; Thompson, EB			Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells	ONCOGENE			English	Article						cell cycle; caspase 3; TUNEL; Max; p53; p27	MESSENGER-RNA; MEDIATED APOPTOSIS; GENE-TRANSCRIPTION; INDUCED RELEASE; BINDING DOMAIN; GROWTH ARREST; OKADAIC ACID; E-BOX; PROTEIN; CYCLE	Sensitivity to glueocorticoid (GC)-evoked apoptosis in lymphoid cell lines correlates closely with GC-mediated suppression of c-Myc expression. To establish a functional role for c-Myc in GC-mediated apoptosis, we have stably expressed MycER (TM), the human c-Myc protein fused to the modified ligand-binding domain of the murine estrogen receptor a, in GC-sensitive CEM-C7-14 cells. In CEM-C7-14 cells, MycER (TM) constitutively imparts c-Myc functions. Cells expressing MycERT (TM) (C7-MycER (TM)) exhibited a marked reduction in cell death after 72 h in 100 nm dexamethasone (Dex), with 10-20-fold more viable cells when compared to the parental CEM-C7-14 clone. General GC responsiveness was not compromised, as evidenced by Dex-mediated suppression of endogenous c-Mye and cyclin D3, and induction of c-Jun and the glucocorticoid receptor. MycER (TM) also blunted Dex-mediated upregulation of p271(kipI) and suppression of the Myc target p53. In comparison to parental CEM-C7-14 cells, Dex-evoked DNA strand breaks were negligible and caspase activation was delayed, but the extent of GI cell cycle arrest was similar in C7-MycER (TM) cells. Myc-ER (TM) did not result in permanent, complete resistance to GC however, and the GC-treated cells eventually died, indicative of redundant or interactive mechanisms in the GC-evoked lytic response of lymphoid cells. Our results emphasize the importance of c-Myc suppression in GC-evoked apoptosis of CEM-C7-14 cells.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Medh, RD (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	rmedh@utmb.edu; bthompso@utmb.edu			NCI NIH HHS [R01 CA041407, 2RO1 CA41047, R01 CA041407-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041407, R01CA041047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afrakhte M, 1998, CELL GROWTH DIFFER, V9, P983; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; BRUNO S, 1992, CANCER RES, V52, P470; Casteels KM, 1998, DIABETES, V47, P1033, DOI 10.2337/diabetes.47.7.1033; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; DOWD DR, 1991, J BIOL CHEM, V266, P18423; EASTMANREKS SB, 1986, CANCER RES, V46, P2457; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gaynon PS, 1999, ADV EXP MED BIOL, V457, P593; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HOMODELARCHE F, 1984, CANCER RES, V44, P431; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG K, 1975, ENDOCRINOLOGY, V97, P744, DOI 10.1210/endo-97-3-744; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Loffler M, 1999, ONCOGENE, V18, P4626, DOI 10.1038/sj.onc.1202820; Martins TC, 1998, IMMUNOLOGY, V95, P377; Medh RD, 1998, CANCER RES, V58, P3684; Medh RD, 2000, CELL TISSUE RES, V301, P101, DOI 10.1007/s004419900159; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Montague J W, 1995, Curr Top Microbiol Immunol, V200, P51; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; REISMAN D, 1995, MOL ENDOCRINOL, V9, P1500, DOI 10.1210/me.9.11.1500; RHEE K, 1995, CANCER RES, V55, P4188; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; THOMPSON EB, 1995, ANN NY ACAD SCI, V761, P261, DOI 10.1111/j.1749-6632.1995.tb31383.x; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; THULASI R, 1993, J BIOL CHEM, V268, P18306; TOBIAS KE, 1995, ONCOGENE, V11, P1721; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WOOD KM, 1984, MOL CELL ENDOCRINOL, V37, P169, DOI 10.1016/0303-7207(84)90049-2; Yatouji S, 2000, CELL PROLIFERAT, V33, P51, DOI 10.1046/j.1365-2184.2000.00163.x; Yerly-Motta V, 1999, BIOTECH HISTOCHEM, V74, P119, DOI 10.3109/10520299909047963; YUH YS, 1989, J BIOL CHEM, V264, P10904; Zhou F, 1996, MOL ENDOCRINOL, V10, P306, DOI 10.1210/me.10.3.306	60	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4629	4639		10.1038/sj.onc.1204680	http://dx.doi.org/10.1038/sj.onc.1204680			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498786	Green Accepted			2022-12-28	WOS:000170208600004
J	Vieira, HLA; Belzacq, AS; Haouzi, D; Bernassola, F; Cohen, I; Jacotot, E; Ferri, KF; El Hamel, C; Bartle, LM; Melino, G; Brenner, C; Goldmacher, V; Kroemer, G				Vieira, HLA; Belzacq, AS; Haouzi, D; Bernassola, F; Cohen, I; Jacotot, E; Ferri, KF; El Hamel, C; Bartle, LM; Melino, G; Brenner, C; Goldmacher, V; Kroemer, G			The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal	ONCOGENE			English	Article						apoptosis; Bcl-2; (V)MIA; mitochondria; permeability transition	PERMEABILITY TRANSITION PORE; DEPENDENT ANION CHANNEL; CYTOCHROME-C RELEASE; MITOCHONDRIAL ADP/ATP CARRIER; CELL-DEATH; INDUCED APOPTOSIS; CYCLOPHILIN-D; BCL-2; BAX; PROTEINS	Nitric oxide (NO), peroxynitrite, and 4-hydroxynonenal (HNE) may be involved in the pathological demise of cells via apoptosis, Apoptosis induced by these agents is inhibited by Bcl-2, suggesting the involvement of mitochondria in the death pathway. In vitro, NO, peroxynitrite and HNE can cause direct permeabilization of mitochondrial membranes, and this effect is inhibited by cyclosporin A, indicating involvement of the permeability transition pore complex (PTPC) in the permeabilization event. NO, peroxynitrite and HNE also permeabilize proteoliposomes containing the adenine nucleotide translocator (ANT), one of the key components of the PTPC, yet have no or little effects on protein-free control liposomes, ANT-dependent, NO-, peroxynitrite- or HNE-induced permeabilization is at least partially inhibited by recombinant Bcl-2 protein, as well as the antioxidants trolox and butylated hydroxytoluene, In vitro, none of the tested agents (NO, peroxynitrite, FINE, and tert-butylhydroperoxide) causes preferential carbonylation HNE adduction, or nitrotyrosylation of ANT. How ever, all these agents induced ANT to undergo thiol oxidation/derivatization. Peroxynitrite and HNE also caused significant lipid peroxidation, which was antagonized by butylated hydroxytoluene but not by recombinant Bcl-2, Transfection-enforced expression of vMIA, a viral apoptosis inhibitor specifically targeted to ANT, largely reduces the mitochondrial and nuclear signs of apoptosis induced by NO, peroxynitrite and HNE in intact cells. Taken together these data suggest that NO, peroxynitrite, and HNE may directly act on ANT to induce mitochondrial membrane permeabilization and apoptosis.	Inst Gustave Roussy, CNRS, UMR1599, F-94805 Villejuif, France; Univ Technol Compiegne, CNRS, UMR6022, F-60205 Compiegne, France; Univ Roma Tor Vergata, Biochem Lab, I-00133 Rome, Italy; Apoptosis Technol Inc, Cambridge, MA 02139 USA	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne; University of Rome Tor Vergata	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Vieira, Helena/AAZ-9562-2021; brenner, catherine/AAE-8632-2020; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; /0000-0002-5301-1569; Vieira, Helena/0000-0001-9415-3742				Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Allione A, 1999, J IMMUNOL, V163, P4182; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; BouHamdan M, 1998, J BIOL CHEM, V273, P8009, DOI 10.1074/jbc.273.14.8009; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Buege J A, 1978, Methods Enzymol, V52, P302; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dorner A, 1999, BBA-BIOMEMBRANES, V1417, P16, DOI 10.1016/S0005-2736(98)00245-4; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Glockzin S, 1999, J BIOL CHEM, V274, P19581, DOI 10.1074/jbc.274.28.19581; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; Hashimoto M, 1999, BIOCHEMISTRY-US, V38, P1050, DOI 10.1021/bi9822978; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kristal BS, 1996, J BIOL CHEM, V271, P6033, DOI 10.1074/jbc.271.11.6033; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kruman I, 1997, J NEUROSCI, V17, P5089; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Massari P, 2000, P NATL ACAD SCI USA, V97, P9070, DOI 10.1073/pnas.97.16.9070; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Mossalayi MD, 1999, MOL MED, V5, P812, DOI 10.1007/BF03401994; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Nicotera P, 1999, CELL DEATH DIFFER, V6, P931, DOI 10.1038/sj.cdd.4400583; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	65	202	213	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4305	4316		10.1038/sj.onc.1204575	http://dx.doi.org/10.1038/sj.onc.1204575			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466611				2022-12-28	WOS:000169912600004
J	Weil, MM; Kittrell, FS; Yu, YJ; McCarthy, M; Zabriskie, RC; Ullrich, RL				Weil, MM; Kittrell, FS; Yu, YJ; McCarthy, M; Zabriskie, RC; Ullrich, RL			Radiation induces genomic instability and mammary ductal dysplasia in Atm heterozygous mice	ONCOGENE			English	Article						radiation effects; breast cancer; ataxia-telangiectasia; genomic instability	ATAXIA-TELANGIECTASIA; DEFICIENT MICE; CANCER; SENSITIVITY; BALB/C	Ataxia-telangiectasia (AT) is a genetic syndrome resulting from the inheritance of two defective copies of the ATM gene that includes among its stigmata radiosensitivity and cancer susceptibility. Epidemiological studies have demonstrated that although women with a single defective copy of ATM (AT heterozygotes) appear clinically normal, they may never the less have an increased relative risk of developing breast cancer. Whether they are at increased risk for radiation-induced breast cancer from medical exposures to ionizing radiation is unknown. We have used a murine model of AT to investigate the effect of a single defective Atm allele, the murine homologue of ATM, on the susceptibility of mammary epithelial cells to radiation-induced transformation. Here we report that mammary epithelial cells from irradiated mice with one copy of Atm truncated in the PI-3 kinase domain were susceptible to radiation-induced genomic instability and generated a 10% incidence of dysplastic mammary ducts when transplanted into syngenic recipients, whereas cells from Atm(+/+) mice were stable and formed only normal ducts. Since radiation-induced ductal dysplasia is a precursor to mammary cancer, the results indicate that AT heterozygosity increases susceptibility to radiogenic breast cancer in this murine model system.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Radiat Oncol, Div Biol, Galveston, TX 77555 USA; Colorado State Univ, Dept Radiol Hlth Sci, Ft Collins, CO 80523 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Colorado State University	Weil, MM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA073929, P01CA006294, R01CA043322] Funding Source: NIH RePORTER; NCI NIH HHS [CA43322, CA06294, CA73929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS LM, 1987, CANCER RES, V47, P4425; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; BICEHOUSE HJ, 1975, 7 ANN NATL C RAD CON, P136; BOICE JD, 1992, NEW ENGL J MED, V326, P1357; BRIDGES BA, 1992, NEW ENGL J MED, V326, P1357; CONWAY BJ, 1994, RADIOLOGY, V191, P323, DOI 10.1148/radiology.191.2.8153301; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; HALL EJ, 1992, NEW ENGL J MED, V326, P1358; KULLER LH, 1992, NEW ENGL J MED, V326, P1357; LAND CE, 1992, NEW ENGL J MED, V326, P1359; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; UPTON AC, 1977, J NATL CANCER I, V59, P480; WAGNER LK, 1992, NEW ENGL J MED, V326, P1358	18	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4409	4411		10.1038/sj.onc.1204589	http://dx.doi.org/10.1038/sj.onc.1204589			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466622				2022-12-28	WOS:000169912600015
J	Frasca, F; Vigneri, P; Vella, V; Vigneri, R; Wang, JYJ				Frasca, F; Vigneri, P; Vella, V; Vigneri, R; Wang, JYJ			Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor	ONCOGENE			English	Article						Akt; branching morphogenesis; c-Abl; cell motility; ERK; Met; PDGF receptor	C-KIT RECEPTOR; CARCINOMA CELLS; SCATTER FACTOR; RHO-GTPASES; IN-VITRO; ABL; MET; EXPRESSION; STI-571; PROTOONCOGENE	Met are physiological regulators of cell migration, HGF and Met have also been implicated in tumor progression and metastasis. We show here that the tyrosine kinase inhibitor STI571 has a stimulatory effect on HGF-induced migration and branching morphogenesis in thyroid cancer but not in primary or immortalized thyroid epithelial cells. These stimulatory effects of STI571 are observed at a concentration that is clinically relevant. The STI571-enhanced motile response can be correlated with an increase in the Met receptor tyrosine phosphorylation as well as ERK and Akt activation by HGF, Interestingly, one of the targets of STI571, namely the c-Abl tyrosine kinase, is activated by HGF and is recruited at the migrating edge of thyroid cancer cells, These data suggests that c-Abl and/or STI571-inhibited tyrosine kinases can negatively regulate the Met receptor to restrain the motile response in thyroid cancer cells.	Univ Catania, Ist Med Interna Malattie Endocrine & Metab, Osped Garibaldi, I-95123 Catania, Italy; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Catania; University of California System; University of California San Diego; University of California System; University of California San Diego; Magna Graecia University of Catanzaro	Frasca, F (corresponding author), Univ Catania, Ist Med Interna Malattie Endocrine & Metab, Osped Garibaldi, Piazza S Maria di Gesu, I-95123 Catania, Italy.		Vigneri, Paolo G/K-8504-2016; Frasca, Francesco/J-1332-2018; Vella, Veronica/AAX-5690-2020; Vella, Veronica/N-7977-2018; Vigneri, Riccardo/M-3968-2017	Vigneri, Paolo G/0000-0002-5943-6066; Frasca, Francesco/0000-0002-5556-3201; Vella, Veronica/0000-0002-4968-8550; Vigneri, Riccardo/0000-0002-4401-3140	NCI NIH HHS [R37 CA043054, R01 CA043054] Funding Source: Medline; NHLBI NIH HHS [HL57900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belfiore A, 1997, J CLIN ENDOCR METAB, V82, P2322, DOI 10.1210/jc.82.7.2322; Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; Bergstrom JD, 1999, BRIT J CANCER, V80, P650, DOI 10.1038/sj.bjc.6690406; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; DIRENZO MF, 1995, J ENDOCRINOL INVEST, V18, P134, DOI 10.1007/BF03349722; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; HELDIN NE, 1991, ENDOCRINOLOGY, V129, P2187, DOI 10.1210/endo-129-4-2187; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Kilic T, 2000, CANCER RES, V60, P5143; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; NATALI PG, 1995, CANCER RES, V55, P1787; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stuart KA, 2000, INT J EXP PATHOL, V81, P17, DOI 10.1046/j.1365-2613.2000.00138.x; TANAKA T, 1995, ENDOCR J, V42, P723, DOI 10.1507/endocrj.42.723; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698	32	55	56	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3845	3856		10.1038/sj.onc.1204531	http://dx.doi.org/10.1038/sj.onc.1204531			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439348				2022-12-28	WOS:000169494700010
J	von Lindern, M; Deiner, EM; Dolznig, H; Parren-van Amelsvoort, M; Hayman, MJ; Mullner, EW; Beug, H				von Lindern, M; Deiner, EM; Dolznig, H; Parren-van Amelsvoort, M; Hayman, MJ; Mullner, EW; Beug, H			Leukemic transformation of normal murine erythroid progenitors: v- and c-ErbB act through signaling pathways activated by the EpoR and c-Kit in stress erythropoiesis	ONCOGENE			English	Article						erythropoiesis; signal transduction; cellular transformation	STEM-CELL-FACTOR; GROWTH-FACTOR RECEPTOR; SELF-RENEWAL; IN-VITRO; GLUCOCORTICOID-RECEPTOR; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; KINASE; ROLES	Primary erythroid progenitors can be expanded by the synergistic action of erythropoietin (Epo), stem cell factor (SCF) and glucocorticoids, While Epo is required for erythropoiesis in general, glucocorticoids and SCF mainly contribute to stress erythropoiesis in hypoxic mice, This ability of normal erythroid progenitors to undergo expansion under stress conditions is targeted by the avian erythroblastosis virus (AEV), harboring the oncogenes v-ErbB and v-ErbA, We investigated the signaling pathways required for progenitor expansion under stress conditions and in leukemic transformation. Immortal strains of erythroid progenitors, able to undergo normal, terminal differentiation under appropriate conditions, were established from fetal livers of p53-/- mice. Expression and activation of the EGF-receptor (HER-1/c-ErbB) or its mutated oncogenic version (v-ErbB) in these cells abrogated the requirement for Epo and SCF in expansion of these progenitors and blocked terminal differentiation. Upon inhibition of ErbB function, differentiation into erythrocytes occurred. Signal transducing molecules important for renewal induction, i.e. Stat5- and phosphoinositide 3-kinase (PI3K), are utilized by both EpoR/c-Kit and v/c-ErbB, However, while v-ErbB transformed cells and normal progenitors depended on PI3K signaling for renewal, c-ErbB also induces progenitor expansion by PI3K-independent mechanisms.	Inst Mol Pathol, A-1030 Vienna, Austria; Erasmus MC, Inst Hematol, NL-3000 DR Rotterdam, Netherlands; Vienna Bioctr, VBC, Inst Med Biochem, A-1030 Vienna, Austria; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Erasmus University Rotterdam; Erasmus MC; Vienna Biocenter (VBC); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Beug, H (corresponding author), Inst Mol Pathol, Dr Bohrgasse 7, A-1030 Vienna, Austria.	beug@nt.imp.univie.ac.gt	von Lindern, Marieke/AAH-2350-2020; Dolznig, Helmut/L-7005-2015	Dolznig, Helmut/0000-0002-6063-3585				Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; BEUG H, 1995, METHOD ENZYMOL, V254, P41; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P284; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; Broudy VC, 1996, BLOOD, V88, P75; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; DOLZNIG H, 2001, IN PRESS FASEB J; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; KELLEY MW, 1992, DEV AUDITORY VESTIBU, V2, P139; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; Kieslinger M, 2000, GENE DEV, V14, P232; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; OZBUN MA, 1993, CELL GROWTH DIFFER, V4, P811; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; van Dijk TB, 2000, BLOOD, V96, P3406; von Lindern M, 2000, J BIOL CHEM, V275, P34719, DOI 10.1074/jbc.M007042200; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; VONRUDEN T, 1992, BLOOD, V79, P3145; Wessely O, 1997, CELL GROWTH DIFFER, V8, P481; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	49	87	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3651	3664		10.1038/sj.onc.1204494	http://dx.doi.org/10.1038/sj.onc.1204494			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439328				2022-12-28	WOS:000169400200006
J	Maurici, D; Monti, P; Campomenosi, P; North, S; Frebourg, T; Fronza, G; Hainaut, P				Maurici, D; Monti, P; Campomenosi, P; North, S; Frebourg, T; Fronza, G; Hainaut, P			Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	ONCOGENE			English	Article						amifostine; p53; yeast functional assay	TUMOR-SUPPRESSOR P53; DNA-BINDING; CELL-CYCLE; GENE-EXPRESSION; IN-VITRO; IDENTIFICATION; MUTATIONS; APOPTOSIS; SPECTRUM; LINES	Many p53 mutants found in human cancer have an altered ability to bind DNA and transactivate gene expression. Re-expression of functional p53 in cells in which the endogenous TP53 gene is inactivated has been demonstrated to restore a non-tumorigenic phenotype, Pharmacological modulation of p53 mutant conformation may therefore represent a mechanism to reactivate p53 function and consequently improve response to radio- and chemotherapy, We have recently reported that the radio- and chemoprotector Amifostine (WR2721, Ethyol(H)) activates wild-type p53 in cultured mammalian cells. In the present study, we have used a yeast functional assay to investigate the effect of WR2721 on the transcriptional activity of p53. WR2721 restored this activity in a temperature-sensitive mutant V272M (valine to methionine at codon 272) expressed at the nonpermissive temperature and it also partially restored the transcriptional activity of several other conformationally flexible p53 mutants. The results indicate that the yeast functional assay may be used to identify compounds that modulate p53 activity, with potential therapeutic implications.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France; Natl Canc Inst, Mutagenesis Lab, IST, I-16132 Genoa, Italy; Fac Med & Pharm, INSERM EPI, F-76183 Rouen, France	World Health Organization; International Agency for Research on Cancer (IARC); Institut National de la Sante et de la Recherche Medicale (Inserm)	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.		Monti, Paola/Y-1118-2019; Fronza, Gilberto/AAG-8735-2019; Campomenosi, Paola/C-9729-2011; Hainaut, Pierre/B-6018-2012; Frebourg, Thierry/AAK-8390-2020	Monti, Paola/0000-0002-1978-4998; Fronza, Gilberto/0000-0003-3722-553X; Campomenosi, Paola/0000-0002-8853-1134; Hainaut, Pierre/0000-0002-1303-1610; 				Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4; CALABROJONES PM, 1985, INT J RADIAT BIOL, V47, P23, DOI 10.1080/09553008514550041; Capizzi RL, 1999, SEMIN ONCOL, V26, P72; Capizzi RL, 1999, SEMIN ONCOL, V26, P1; Capizzi RL, 1999, SEMIN ONCOL, V26, P3; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Di Como CJ, 1998, ONCOGENE, V16, P2527; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GRDINA DJ, 1995, CARCINOGENESIS, V16, P767, DOI 10.1093/carcin/16.4.767; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kramer DL, 1998, BIOCHEM SOC T, V26, P609, DOI 10.1042/bst0260609; Kramer DL, 1999, CANCER RES, V59, P1278; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; Li L, 1999, AM J PHYSIOL-CELL PH, V276, pC946, DOI 10.1152/ajpcell.1999.276.4.C946; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Marzatico F, 2000, CANCER CHEMOTH PHARM, V45, P172, DOI 10.1007/s002800050026; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; PEGG AE, 1988, CANCER RES, V48, P759; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; ROLLEY N, 1995, ONCOGENE, V11, P763; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SHIGEMATSU N, 1994, MUTAGENESIS, V9, P355, DOI 10.1093/mutage/9.4.355; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699	44	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3533	3540		10.1038/sj.onc.1204428	http://dx.doi.org/10.1038/sj.onc.1204428			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429700				2022-12-28	WOS:000169478300009
J	Sheta, EA; Trout, H; Gildea, JJ; Harding, MA; Theodorescu, D				Sheta, EA; Trout, H; Gildea, JJ; Harding, MA; Theodorescu, D			Cell density mediated pericellular hypoxia leads to induction of HIF-1 alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways	ONCOGENE			English	Article						cell hypoxia; oxygen; nuclear proteins; nitric oxide; Ras proteins	ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; PROTEIN-TYROSINE PHOSPHORYLATION; HUMAN ERYTHROPOIETIN GENE; COLON-CARCINOMA CELLS; HUMAN PROSTATE-CANCER; SMOOTH-MUSCLE CELLS; FACTOR EXPRESSION; DEPENDENT REGULATION; TUMOR ANGIOGENESIS	Environmental signals in the cellular milieu such as hypoxia, growth factors, extracellular matrix (ECM), or cell-surface molecules on adjacent cells can activate signaling pathways that communicate the state of the environment to the nucleus. Several groups have evaluated gene expression or signaling pathways in response to increasing cell density as an in vitro surrogate for in vivo cell-cell interactions. These studies have also perhaps assumed that cells grown at various densities in standard in vitro incubator conditions do not have different pericellular oxygen levels. However, pericellular hypoxia can be induced by increasing cell density, which can exert profound influences on the target cell lines and may explain a number of findings previously attributed to normoxic cell-cell interactions. Thus, we first sought to test the hypothesis that cell-cell interactions as evaluated by the surrogate approach of increasing in vitro cell density in routine normoxic culture conditions results in pericellular hypoxia in prostate cancer cells. Second, we sought to evaluate whether such interactions affect transcription mediated by the hypoxia response element (HRE). Thirdly, we sought to elucidate the signal transduction pathways mediating the induction of HRE in response to cell density induced pericellular hypoxia in routine normoxic culture conditions. Our results indicate that paracrine cell interactions can induce nuclear localization of HIF-1a protein and this translocation is associated with strong stimulation of the HRE-reporter activity. We also make the novel observation that cell density-induced activity of the HRE is dependent on nitric oxide production, which acts as a diffusible paracrine factor secreted by densely cultured cells. These results suggest that paracrine cell interactions associated with pericellular hypoxia lead to the physiological induction of HRE activity via the cooperative action of Ras, MEK1, HIF-1a via pericellular diffusion of nitric oxide. In addition, these results highlight the importance of examining pericellular hypoxia as a possible stimulus in experiments involving in vitro cell density manipulation even in routine normoxic culture conditions.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.		Harding, Michael/C-3438-2013	Harding, Michael/0000-0001-8636-067X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AMANO F, 1995, FEBS LETT, V368, P425, DOI 10.1016/0014-5793(95)00700-J; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; Bedrin MS, 1997, J CELL PHYSIOL, V172, P126, DOI 10.1002/(SICI)1097-4652(199707)172:1<126::AID-JCP14>3.3.CO;2-N; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gioeli D, 1999, CANCER RES, V59, P279; GROEBE K, 1988, INT J RADIAT ONCOL, V15, P691, DOI 10.1016/0360-3016(88)90313-6; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319; Kharitonov VG, 1999, BIOCHEMISTRY-US, V38, P10699, DOI 10.1021/bi990277f; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kobayashi S, 1997, J BIOL CHEM, V272, P16262, DOI 10.1074/jbc.272.26.16262; Koura AN, 1996, CANCER RES, V56, P3891; Leung LK, 1998, CANCER LETT, V124, P47, DOI 10.1016/S0304-3835(97)00430-8; Li PM, 1996, J CELL BIOCHEM, V61, P31, DOI 10.1002/(SICI)1097-4644(19960401)61:1<31::AID-JCB5>3.0.CO;2-3; Lomonosova EE, 1998, FREE RADICAL BIO MED, V25, P493, DOI 10.1016/S0891-5849(98)00080-X; Mazure NM, 1996, CANCER RES, V56, P3436; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; METZEN E, 1995, RESP PHYSIOL, V100, P101, DOI 10.1016/0034-5687(94)00125-J; Minamiyama Y, 1997, ARCH BIOCHEM BIOPHYS, V341, P186, DOI 10.1006/abbi.1997.9956; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; MOULDER JE, 1984, INT J RADIAT ONCOL, V10, P695, DOI 10.1016/0360-3016(84)90301-8; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; Palmer LA, 1998, CHEST, V114, p33S, DOI 10.1378/chest.114.1_Supplement.33S; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Perkinson RA, 1996, J CELL BIOCHEM, V63, P74; POLK DB, 1995, J CELL PHYSIOL, V162, P427, DOI 10.1002/jcp.1041620315; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Prentice H, 1997, CARDIOVASC RES, V35, P567, DOI 10.1016/S0008-6363(97)00158-2; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rouquette Magali, 1997, Biochemical Society Transactions, V25, p532S; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Sheta EA, 2000, J NATL CANCER I, V92, P1065, DOI 10.1093/jnci/92.13.1065; SILVERSTEIN JL, 1988, ARCH DERMATOL, V124, P1379, DOI 10.1001/archderm.124.9.1379; Singh RK, 1996, CELL GROWTH DIFFER, V7, P397; SUN LZ, 1994, EXP CELL RES, V214, P215, DOI 10.1006/excr.1994.1251; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; THEODORESCU D, 1991, J CELL PHYSIOL, V148, P380, DOI 10.1002/jcp.1041480308; Tokuda Y, 2000, J CELL PHYSIOL, V182, P414, DOI 10.1002/(SICI)1097-4652(200003)182:3<414::AID-JCP12>3.0.CO;2-5; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; WERRLEIN RJ, 1974, NATURE, V251, P317, DOI 10.1038/251317a0; YOSHIMOTO Y, 1995, J NEUROSURG, V83, P867, DOI 10.3171/jns.1995.83.5.0867; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 2000, CANCER RES, V60, P1541	62	118	121	1	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7624	7634		10.1038/sj.onc.1204972	http://dx.doi.org/10.1038/sj.onc.1204972			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753640				2022-12-28	WOS:000172124100005
J	Astuti, D; Agathanggelou, A; Honorio, S; Dallol, A; Martinsson, T; Kogner, P; Cummins, C; Neumann, HPH; Voutilainen, R; Dahia, P; Eng, C; Maher, ER; Latif, F				Astuti, D; Agathanggelou, A; Honorio, S; Dallol, A; Martinsson, T; Kogner, P; Cummins, C; Neumann, HPH; Voutilainen, R; Dahia, P; Eng, C; Maher, ER; Latif, F			RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours	ONCOGENE			English	Article						methylation; 3p tumour suppressor gene; neuroblastoma; phaeochromocytoma	HOMOZYGOUS DELETION; LUNG-CANCER; GENE-EXPRESSION; SHORT ARM; SUPPRESSOR; PHEOCHROMOCYTOMA; HETEROZYGOSITY; IDENTIFICATION; TUMORS; CHROMOSOME-3	Deletions of chromosome 3p are frequent in many types of neoplasia including neural crest tumours such as neuroblastoma (NB) and phaeochromocytoma. Recently we isolated several candidate tumour suppressor genes (TSGs) from a 120 kb critical interval at 3p21.3 defined by overlapping homozygous deletions in lung and breast tumour lines. Although mutation analysis of candidate TSGs in lung and breast cancers revealed only rare mutations, expression of one of the genes (RASSF1A) was absent in the majority of lung tumour cell lines analysed. Subsequently methylation of a CpG island in the promoter region of RASSF1A was demonstrated in a majority of small cell lung carcinomas and to a lesser extent in non-small cell lung carcinomas. To investigate the role of 3p TSGs in neural crest tumours, we (a) analysed phaeochromocytomas for 3p allele loss (n = 41) and RASSF1A methylation (n = 23) and (b) investigated 67 neuroblastomas for RASSF1A inactivation. 46% of phaeochromocytomas showed 3p allele loss (38.5% at 3p21.3). RASSF1A promoter region hypermethylation was found in 22% (5/23) of sporadic phaeochromocytomas and in 55% (37/67) of neuroblastomas analysed but RASSF1A mutations were not identified. In two neuroblastoma cell lines, methylation of RASSF1A correlated with loss of RASSF1A expression and RASSF1A expression was restored after treatment with the demethylating agent 5-azacytidine. As frequent methylation of the CASP8 gene has also been reported in neuroblastoma, we investigated whether RASSF1A and CASP8 methylation were independent or related events. CASP8 methylation was detected in 56% of neuroblastomas with RASSF1A methylation and 17% without RASSF1A methylation (P = 0.0031). These results indicate that (a) RASSF1A inactivation by hypermethylation is a frequent event in neural crest tumorigenesis, particularly neuroblastoma, and that RASSF1A is a candidate 3p21.3 neuroblastoma TSG and (b) a subset of neuroblastomas may be characterized by a CpG island methylator phenotype.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Gothenburg, Sahlgrenska Univ Hosp Ostra, Dept Clin Genet, S-41685 Gothenburg, Sweden; Karolinska Inst, Karolinska Hosp, Dept Woman & Child Hlth, Childhood Canc Res Unit, S-17176 Stockholm, Sweden; Birmingham Childrens Hosp, Birmingham, W Midlands, England; Univ Freiburg, Med Klin, D-79106 Freiburg, Germany; Kuopio Univ Hosp, Dept Pediat, FIN-70211 Kuopio, Finland; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge, England	University of Birmingham; Sahlgrenska University Hospital; University of Gothenburg; Karolinska Institutet; Karolinska University Hospital; University of Birmingham; University of Freiburg; Kuopio University Hospital; Harvard University; Dana-Farber Cancer Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Cambridge	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.		Martinsson, Tommy/J-4140-2013; MAHER, EAMONN R/A-9507-2008; Dallol, Ashraf/H-8661-2012	Martinsson, Tommy/0000-0002-9403-3123; MAHER, EAMONN R/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X; Eng, Charis/0000-0002-3693-5145; Voutilainen, Raimo/0000-0002-7858-665X; Kogner, Per/0000-0002-2202-9694; Cummins, Carole/0000-0001-5464-1944; Astuti, Dewi/0000-0003-4205-6160				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Ejeskar K, 1998, BRIT J CANCER, V77, P1787, DOI 10.1038/bjc.1998.297; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Fullwood P, 1999, CANCER RES, V59, P4662; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; Hoehner JC, 1998, LAB INVEST, V78, P29; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; Lerman MI, 2000, CANCER RES, V60, P6116; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; Martinsson T, 1997, CANCER GENET CYTOGEN, V95, P183, DOI 10.1016/S0165-4608(96)00259-2; MOLEY JF, 1991, CANCER RES, V51, P1596; MORRISSEY C, 2001, IN PRESS CANC RES; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Tanaka T, 1998, CANCER-AM CANCER SOC, V83, P1626, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1626::AID-CNCR19>3.0.CO;2-Y; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Vargas MP, 1997, HUM PATHOL, V28, P411, DOI 10.1016/S0046-8177(97)90028-9; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Woodward ER, 1997, HUM MOL GENET, V6, P1051, DOI 10.1093/hmg/6.7.1051; ZEIGER MA, 1995, GENE CHROMOSOME CANC, V13, P151, DOI 10.1002/gcc.2870130303	27	108	115	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7573	7577		10.1038/sj.onc.1204968	http://dx.doi.org/10.1038/sj.onc.1204968			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709729				2022-12-28	WOS:000171976900014
J	Bieche, I; Parfait, B; Nogues, C; Andrieu, C; Vidaud, D; Spyratos, F; Lidereau, R; Vidaud, M				Bieche, I; Parfait, B; Nogues, C; Andrieu, C; Vidaud, D; Spyratos, F; Lidereau, R; Vidaud, M			The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients	ONCOGENE			English	Article						postmenopausal breast cancer; CGA; real-time RT-PCR quantification; endocrine therapy	OVEREXPRESSION; TAMOXIFEN	We recently identified CGA (coding for the alpha subunit of glycoprotein hormones) as a new estrogen receptor alpha (ER alpha)-responsive gene in human breast tumors. Here, we assessed the relationship between CGA status (as determined by real-time quantitative RT-PCR) and the response to tamoxifen therapy in a well-defined cohort of 125 ER alpha -positive postmenopausal breast cancer patients treated with primary surgery followed by adjuvant tamoxifen alone. CGA overexpression, observed in 37.6% of patients, was associated with good relapse-free survival (P=0.037; univariate analysis). CGA status, combined with ERBB2 status (a marker of poor outcome), was an independent predictor of the response to tamoxifen (P=0.020; multivariate analysis). CGA status, especially when combined with ERBB2 status, may thus provide useful predictive information on tamoxifen responsiveness in breast cancer.	Univ Paris 05, Fac Sci Pharmaceut & Biol, Genet Mol Lab, UPRES JE 2195, F-75006 Paris, France; Ctr Rene Huguenin, Lab Oncobiol, F-92211 St Cloud, France; INSERM, E0017, Lab Oncogenet, F-75654 Paris, France	UDICE-French Research Universities; Universite Paris Cite; Rene Huguenin Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vidaud, M (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol, Genet Mol Lab, UPRES JE 2195, 4 Ave Observ, F-75006 Paris, France.		Bièche, Ivan/O-7399-2017; PARFAIT, Beatrice/O-7392-2017; VIDAUD, Dominique/O-7357-2017; Vidaud, Michel/O-7346-2017	Bièche, Ivan/0000-0002-2430-5429; 				Bieche I, 2001, CANCER RES, V61, P1652; Bieche I, 1999, CLIN CHEM, V45, P1148; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; COX DR, 1972, J R STAT SOC B, V34, P187; Diab SG, 2000, J NATL CANCER I, V92, P550, DOI 10.1093/jnci/92.7.550; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; McGuire W L, 1980, Recent Prog Horm Res, V36, P135; Sjogren S, 1998, J CLIN ONCOL, V16, P462; TETU B, 1994, CANCER, V73, P2359, DOI 10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9	10	21	23	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6955	6959		10.1038/sj.onc.1204739	http://dx.doi.org/10.1038/sj.onc.1204739			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687975				2022-12-28	WOS:000171641000017
J	Xin, H; D'Souza, S; Fang, L; Lengyel, P; Choubey, D				Xin, H; D'Souza, S; Fang, L; Lengyel, P; Choubey, D			p202, an interferon-inducible negative regulator of cell growth, is a target of the adenovirus E1A protein	ONCOGENE			English	Article						interferon-inducible p202; cell cycle; pRb; E2Fs; adenovirus E1A	E2F TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; INHIBITION; BINDING; PRB; P53; TRANSFORMATION; PROLIFERATION	Studies have revealed that human adenovirus-encoded E1A protein promotes cell proliferation through the targeted interaction with cellular proteins that act as key negative regulators of cell growth. The targets of E1A protein include the retinoblastoma tumor suppressor protein (pRb). Because p202, an interferon (IFN)inducible murine protein (52-kDa), negatively regulates cell growth in part through the pRb/E2F pathway, we tested whether the p202 is a target of the adenovirus-encoded E1A protein for functional inactivation. Here we report that the expression of E1A protein overcame p202-mediated inhibition of cell growth and this correlated with an alleviation of p202-mediated inhibition of the transcriptional activity of E2F. Furthermore, E1A protein relieved p202-mediated inhibition of the specific DNA-binding activity of E2F complexes, including those containing the pocket proteins. Additionally, the E1A protein bound to p202 both in vitro and in vivo and a deletion of four amino acids in the conserved region 2 (CR2) of E1A protein significantly reduced the binding of E1A to p202. Interestingly, ectopic expression of p202 under reduced serum conditions significantly reduced E1A-mediated apoptosis. Taken together, our observations provide support to the idea that the p202 and adenovirus E1A protein functionally counteract each other and E1A protein targets p202 to promote cell proliferation.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Loyola University Chicago; University System of Georgia; University of Georgia; Yale University	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, 2160 S 1st Ave,Bldg 1, Maywood, IL 60153 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008		NCI NIH HHS [CA69031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Condorelli G, 1997, J CELL BIOCHEM, V67, P423, DOI 10.1002/(SICI)1097-4644(19971215)67:4<423::AID-JCB1>3.0.CO;2-U; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Geng Y, 2000, J BIOL REG HOMEOS AG, V14, P263; Geng YB, 2000, CELL GROWTH DIFFER, V11, P475; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Min W, 1996, MOL CELL BIOL, V16, P359; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; NEVINS JR, 1992, SCIENCE, V258, P424; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; Smith K, 1996, VIROLOGY, V224, P184, DOI 10.1006/viro.1996.0520; WANG H, 2000, J BIOL CHEM, V275, P27366; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; ZANTEMA A, 1995, CURR TOP MICROBIOL, V199, P1; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	54	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6828	6839		10.1038/sj.onc.1204844	http://dx.doi.org/10.1038/sj.onc.1204844			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687962				2022-12-28	WOS:000171641000004
J	Mullan, PB; Quinn, JE; Gilmore, PM; McWilliams, S; Andrews, H; Gervin, C; McCabe, N; McKenna, S; White, P; Song, YH; Maheswaran, S; Liu, E; Haber, DA; Johnston, PG; Harkin, DP				Mullan, PB; Quinn, JE; Gilmore, PM; McWilliams, S; Andrews, H; Gervin, C; McCabe, N; McKenna, S; White, P; Song, YH; Maheswaran, S; Liu, E; Haber, DA; Johnston, PG; Harkin, DP			BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents	ONCOGENE			English	Article						BRCA1; GADD45; antimicrotubule agents; G2/M arrest; cell death	TRANSCRIPTION-COUPLED REPAIR; RETRACTED ARTICLE. SEE; DNA-DAMAGE RESPONSE; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; INDUCTION; INSTABILITY; CENTROSOME; CHECKPOINT	BRCA1 is a tumour suppressor gene implicated in the predisposition to early onset breast and ovarian cancer. We have generated cell lines with inducible expression of BRCA1 to evaluate its role in mediating the cellular response to various chemotherapeutic drugs commonly used in the treatment of breast and ovarian cancer. Induction of BRCA1 in the presence of Taxol and Vincristine resulted in a dramatic increase in cell death; an effect that was preceded by an acute arrest at the G2/M phase of the cell cycle and which correlated with BRCA1 mediated induction of GADD45. A proportion of the arrested cells were blocked in mitosis suggesting activation of both a G2 and a mitotic spindle checkpoint. In contrast, no specific interaction was observed between BRCA1 induction and treatment of cells with a range of DNA damaging agents including Cisplatin and Adriamycin. Inducible expression of GADD45 in the presence of Taxol induced both G2 and mitotic arrest in these cells consistent with a role for GADD45 in contributing to these effects. Our results support a role for both BRCA1 and GADD45 in selectively regulating a G2/M checkpoint in response to antimicrotubule agents and raise the possibility that their expression levels in cells may contribute to the toxicity observed with these compounds.	Queens Univ Belfast, Canc Res Ctr, Dept Oncol, Belfast BT9 7AB, Antrim, North Ireland; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA; NIH, Div Clin Sci, Bethesda, MD 20892 USA	Queens University Belfast; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA	Harkin, DP (corresponding author), Queens Univ Belfast, Belfast City Hosp, Canc Res Ctr, Dept Oncol, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.harkin@qub.ac.uk	Liu, Edison/C-4141-2008	Song, Young-Han/0000-0002-0758-3654	Breast Cancer Now [2000:119] Funding Source: Medline	Breast Cancer Now		Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Futamura M, 2000, CANCER RES, V60, P1531; GAYTHER SA, 1998, NEOPLASIA, V4, P365; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haber D, 2000, LANCET, V355, P2090, DOI 10.1016/S0140-6736(00)02371-0; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Larson JS, 1997, CANCER RES, V57, P3351; Leadon SA, 1997, CANCER RES, V57, P3784; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang Y, 2000, GENE DEV, V14, P927; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	40	131	141	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6123	6131		10.1038/sj.onc.1204712	http://dx.doi.org/10.1038/sj.onc.1204712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593420				2022-12-28	WOS:000171206300003
J	Alcalay, M; Orleth, A; Sebastiani, C; Meani, N; Chiaradonna, F; Casciari, C; Sciurpi, MT; Gelmetti, V; Riganelli, D; Minucci, S; Fagioli, M; Pelicci, PG				Alcalay, M; Orleth, A; Sebastiani, C; Meani, N; Chiaradonna, F; Casciari, C; Sciurpi, MT; Gelmetti, V; Riganelli, D; Minucci, S; Fagioli, M; Pelicci, PG			Common themes in the pathogenesis of acute myeloid leukemia	ONCOGENE			English	Review						acute myeloid leukemia; fusion proteins; transcription factors; differentiation; cell survival	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; PLZF-RAR-ALPHA; ZINC-FINGER PROTEIN; MYOSIN HEAVY-CHAIN; CBF-BETA-SMMHC; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; HISTONE DEACETYLASE COMPLEX; FETAL LIVER HEMATOPOIESIS; INHIBITS CELL-GROWTH	The pathogenesis of acute myeloid leukemia is associated with the appearance of oncogenic fusion proteins generated as a consequence of specific chromosome translocations. Of the two components of each fusion protein, one is generally a transcription factor, whereas the other partner is mo re variable in function, but often involved in the control of cell survival and apoptosis. As a consequence, AML-associated fusion proteins function as aberrant transcriptional regulators that interfere with the process of myeloid differentiation, determine a stage-specific arrest of maturation and enhance cell survival in a cell-type specific manner. The abnormal regulation of transcriptional networks occurs through common mechanisms that include recruitment of aberrant corepressor complexes, alterations in chromatin remodeling, and disruption of specific subnuclear compartments. The identification and analysis of common and specific target genes regulated by AML fusion proteins will be of fundamental importance for the full understanding of acute myeloid leukemogenesis and for the implementation of disease-specific drug design.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Monteluce Policlin, I-06100 Perugia, Italy	IRCCS European Institute of Oncology (IEO); University of Perugia	Alcalay, M (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Minucci, Saverio/J-9669-2012; Alcalay, Myriam/B-3182-2016; Sebastiani, Carla/AAB-9817-2022; Alcalay, Myriam/AAB-4300-2019; CHIARADONNA, Ferdinando/K-4959-2016; Pelicci, Pier Giuseppe/AAL-6572-2020	Alcalay, Myriam/0000-0002-5558-4272; Sebastiani, Carla/0000-0003-3927-3279; Alcalay, Myriam/0000-0002-5558-4272; CHIARADONNA, Ferdinando/0000-0001-8529-2732; CASCIARI, CRISTINA/0000-0002-9170-370X				Adler HT, 1999, MOL CELL BIOL, V19, P7050; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Akao Y, 1998, CANCER RES, V58, P3773; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Bradbury DA, 1997, LEUKEMIA LYMPHOMA, V24, P221, DOI 10.3109/10428199709039010; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CALIGIURI MA, 1994, CANCER RES, V54, P370; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; CASTAIGNE S, 1990, BLOOD, V76, P1704; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; CHOMIENNE C, 1990, BLOOD, V76, P1710; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Corsetti MT, 1997, BLOOD, V89, P2359, DOI 10.1182/blood.V89.7.2359; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DEGOS L, 1992, BIOMED PHARMACOTHER, V46, P201, DOI 10.1016/0753-3322(92)90083-J; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; ERA T, 1995, LEUKEMIA, V9, pS26; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Faretta M, 2001, SEMIN HEMATOL, V38, P42, DOI 10.1053/shem.2001.20866; Ferhat L, 1998, J NEUROCYTOL, V27, P887, DOI 10.1023/A:1006949006728; Ferrara FF, 2001, CANCER RES, V61, P2; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Frank R, 1995, ONCOGENE, V11, P2667; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Funakoshi M, 1997, GENES CELLS, V2, P329, DOI 10.1046/j.1365-2443.1997.1230320.x; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Golling G, 1996, MOL CELL BIOL, V16, P932; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HERVI C, 2001, CANCER RES, V61, P1247; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Higuchi Y, 1998, BIOCHEM BIOPH RES CO, V248, P597, DOI 10.1006/bbrc.1998.8978; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Hwang ES, 1999, FEBS LETT, V446, P86, DOI 10.1016/S0014-5793(99)00190-8; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Johnstone RW, 2001, MOL CELL BIOL, V21, P1672, DOI 10.1128/MCB.21.5.1672-1681.2001; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kanda Y, 1998, J BIOL CHEM, V273, P5248, DOI 10.1074/jbc.273.9.5248; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; Kersey JH, 1998, LEUKEMIA, V12, P1561, DOI 10.1038/sj.leu.2401148; Kieslinger M, 2000, GENE DEV, V14, P232; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Maki K, 1999, BLOOD, V93, P3216, DOI 10.1182/blood.V93.10.3216.410k45_3216_3224; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matsushita H, 1999, BRIT J CANCER, V79, P1325, DOI 10.1038/sj.bjc.6690214; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; McNeil S, 2000, J CELL BIOCHEM, V79, P103, DOI 10.1002/1097-4644(2000)79:1<103::AID-JCB100>3.3.CO;2-2; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; MITELMAN F, 1994, CATALOGUE CHROMOSOME; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Nason-Burchenal K, 1998, ONCOGENE, V17, P1759, DOI 10.1038/sj.onc.1202075; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Paro R, 1993, CURR OPIN CELL BIOL, V5, P999, DOI 10.1016/0955-0674(93)90084-4; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Puig-Kroger A, 2000, J BIOL CHEM, V275, P28507, DOI 10.1074/jbc.M004323200; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Redner RL, 1997, LEUKEMIA, V11, P1014, DOI 10.1038/sj.leu.2400661; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2001, SEMIN HEMATOL, V38, P54, DOI 10.1053/shem.2001.20865; Rhoades KL, 2000, BLOOD, V96, P2108; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Rogaia D, 1997, CANCER RES, V57, P799; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; RUBNITZ JE, 1994, BLOOD, V84, P1747; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Ruthardt M, 1998, ONCOGENE, V16, P1945, DOI 10.1038/sj.onc.1201722; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Stein GS, 2000, J CELL SCI, V113, P2527; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Testa U, 1998, J CLIN INVEST, V101, P2278, DOI 10.1172/JCI1332; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Wang JX, 1997, CANCER RES, V57, P2951; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wells RA, 1996, LEUKEMIA, V10, P735; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; YonedaKato N, 1996, ONCOGENE, V12, P265; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; Zhang HT, 2000, CHEM J CHINESE U, V21, P156; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306	180	59	60	1	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	2001	20	40					5680	5694		10.1038/sj.onc.1204642	http://dx.doi.org/10.1038/sj.onc.1204642			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607818				2022-12-28	WOS:000170887500009
J	Aoudjit, F; Vuori, K				Aoudjit, F; Vuori, K			Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells	ONCOGENE			English	Article						apoptosis; breast cancer; chemotherapeutic agent; extracellular matrix; integrin; paclitaxel	FOCAL ADHESION KINASE; INTESTINAL EPITHELIAL-CELLS; REGULATES BCL-2 EXPRESSION; RESISTANCE CAM-DR; EXTRACELLULAR-MATRIX; CYTOCHROME-C; CARCINOMA CELLS; PROTEIN-KINASE; MICROTUBULE DAMAGE; CELLULAR-SURVIVAL	Inherent or acquired drug resistance is one of the major problems in chemotherapy. The mechanisms by which cancer cells survive and escape the cytotoxic effects of chemotherapeutic agents are essentially unknown. In the present study, we demonstrate that in the MDA-MB-231 and MDA-MB-435 breast cancer cells, ligation of beta1 integrins by their extracellular matrix ligands inhibits significantly apoptosis induced by paclitaxel and vincristine, two microtubule-directed chemotherapeutic agents that are widely used in the therapy of breast cancer. We show that beta1 integrin signaling inhibits drug-induced apoptosis by inhibiting the release of cytochrome c from the mitochondria in response to drug treatment. Further, integrin-mediated protection from drug-induced apoptosis and inhibition of cytochrome c release are dependent on the activation of the PI 3-kinase/Akt pathway. Our results identify beta1 integrin signaling as an important survival pathway in drug-induced apoptosis in breast cancer cells and suggest that activation of this pathway may contribute to the generation of drug resistance.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA.							Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoudjit F, 2000, BLOOD, V95, P2044, DOI 10.1182/blood.V95.6.2044; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Blagosklonny MV, 1997, CANCER RES, V57, P130; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chadebech P, 1999, BIOCHEM BIOPH RES CO, V262, P823, DOI 10.1006/bbrc.1999.1291; COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; FISHER B, 1997, CANC MED; Fornier M, 1999, ONCOLOGY-NY, V13, P647; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haldar S, 1997, CANCER RES, V57, P229; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; KUMAR N, 1981, J BIOL CHEM, V256, P435; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Lebwohl DE, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008318725670; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; Lundstrom A, 1998, BIOCHEM BIOPH RES CO, V250, P735, DOI 10.1006/bbrc.1998.9389; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nista A, 1997, INT J CANCER, V72, P133, DOI 10.1002/(SICI)1097-0215(19970703)72:1<133::AID-IJC19>3.0.CO;2-K; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Page C, 2000, ANTICANCER RES, V20, P407; Petitclerc E, 1999, CANCER RES, V59, P2724; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Pusztai L, 1998, ACTA ONCOL, V37, P629, DOI 10.1080/028418698429964; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seftor REB, 1998, CANCER RES, V58, P5681; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shaw LM, 1996, CANCER RES, V56, P959; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; van der Pluijm G, 1997, LAB INVEST, V77, P665; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang WG, 1999, J CELL BIOCHEM, V73, P321; Wewer UM, 1997, AM J PATHOL, V151, P1191; Wong NC, 1998, CLIN EXP METASTAS, V16, P50; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeung TK, 1999, BIOCHEM BIOPH RES CO, V263, P398, DOI 10.1006/bbrc.1999.1375; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	63	259	277	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4995	5004		10.1038/sj.onc.1204554	http://dx.doi.org/10.1038/sj.onc.1204554			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526484				2022-12-28	WOS:000170439800009
J	Luciano, F; Ricci, JE; Auberger, P				Luciano, F; Ricci, JE; Auberger, P			Cleavage of Fyn and Lyn in their N-terminal unique regions during induction of apoptosis: a new mechanism for Src kinase regulation	ONCOGENE			English	Article						apoptosis; Src kinases; caspases; T and B lymphocytes	PROTEIN-TYROSINE KINASES; FAS-MEDIATED APOPTOSIS; CELL-DEATH; HEMATOPOIETIC-CELLS; DOWN-REGULATION; DEFICIENT MICE; T-LYMPHOCYTES; B-CELLS; RECEPTOR; ACTIVATION	The members of the Src kinase family are expressed in a wide variety of tissues, but some of them such as Blk, Hck, Fgr, Lck and Lyn are found primarily in hematopoietic cells. In the present study, we have undertaken experiments to test whether Src kinase cleavage and relocation is a general mechanism during induction of apoptosis. Our results indicate that Fyn and Lyn are efficiently cleaved in their unique region in hernatopoietic cells undergoing apoptosis. Fyn cleavage occurred in Fas-stimulated Jurkat T cells but Fyn and Lyn were also processed in the SKW6.4 B cell line. Inhibition of caspases by Z-VAD-fmk or Ac-DEVD-CHO totally prevented Fyn and Lyn cleavage in both intact cells and in vitro. Fyn and Lyn but not Lek, Src and Hck were processed in vitro by human recombinant caspase 3 and by cellular extracts prepared from Fas-stimulated cells. Single mutation of Asp 19 or Asp 18 in the unique N-terminal domains of Fyn and Lyn respectively abolished their cleavage and relocation into the cytoplasm of apoptotic cells. When immunoprecipitated from COS cells N-terminal deleted Src kinases exhibited increased enzymatic kinase activity toward enolase. Thus, cleavage of Fyn and Lyn during induction of apoptosis represents a new mechanism for the regulation of Src kinases that may have important functional and physiological consequences.	Fac Med, Equipe Labellisee Ligue Natl Canc, INSERM U526, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Auberger, P (corresponding author), Fac Med, Equipe Labellisee Ligue Natl Canc, INSERM U526, IFR50,Ave Valombrose, F-06107 Nice 2, France.		luciano, frederic/P-6264-2016; Ricci, Jean Ehrland/I-7117-2016; RICCI, Jean Ehrland/AAS-4379-2020; AUBERGER, Patrick/G-1491-2013	luciano, frederic/0000-0001-9253-4998; Ricci, Jean Ehrland/0000-0003-1585-8117; RICCI, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Johnson TM, 2000, J BIOL CHEM, V275, P33353, DOI 10.1074/jbc.M002022200; Katsuta H, 1998, J IMMUNOL, V160, P1547; KAWAKAMI Y, 1989, ONCOGENE, V4, P389; KRUEGER J, 1991, ONCOGENE, V6, P933; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; Maruo A, 1999, INT IMMUNOL, V11, P1371, DOI 10.1093/intimm/11.9.1371; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; RICCI JE, 2001, IN PRESS FASEB J; RUDD CE, 1991, ADV EXP MED BIOL, V292, P85; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; Simon HU, 1998, BLOOD, V92, P547, DOI 10.1182/blood.V92.2.547.414k02_547_557; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SUDOL M, 1993, ONCOGENE, V8, P823; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WILLMAN CL, 1991, BLOOD, V77, P726; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; ZHAO YH, 1991, ONCOGENE, V6, P1725	46	51	51	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4935	4941		10.1038/sj.onc.1204661	http://dx.doi.org/10.1038/sj.onc.1204661			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526478				2022-12-28	WOS:000170439800003
J	Schuldiner, O; Benvenisty, N				Schuldiner, O; Benvenisty, N			A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors	ONCOGENE			English	Article						MYC; oncogenesis; DNA microarray; target genes	BLASTOMA CELL-LINES; EMBRYONIC LETHALITY; MURINE DEVELOPMENT; BREAST CARCINOMAS; TRANSGENIC MICE; TARGET GENES; GROWTH; EXPRESSION; PROTEIN; DIFFERENTIATION	MYC proto-oncogenes play a major role in various types of human tumors. The products of these genes are transcription factors that bind to specific sequences and activate the expression of target genes. Identifying these target genes and their downstream effectors is a crucial step in understanding and preventing MYC induced oncogenesis. Until now, most of the efforts to identify such genes were performed by analysing in vitro systems whose relevance to the malignant process in vivo remains unclear. We aimed at identifying genes that play a major role in the malignant process of MYC induced carcinogenesis. Thus, we analysed the expression profiles of human MYC induced tumors and compared them to similar, non-MYC tumors. Moreover, we looked for the common characteristics of different types of MYC induced tumors. We identified several genes, most of them involved in cell cycle regulation, that are over expressed in MYC induced lymphomas as well as MYC induced neuronal-like tumors. In order to determine whether MYC induced oncogenesis is similar in human and in the mouse model system, we analysed the expression of the identified genes in cells derived from transgenic mice tumors. We also present the distribution of MYC putative binding sites in the regulatory sequences of the genes identified in our analysis. This analysis pointed to two genes (E2F1 and TSC2) as candidates to be targets of Myc activity. We thus further analysed the expression of these genes in the tumor cell lines, and examined the plausibility that elements in their promoter bind the Myc protein. Our data points to several genes that may be involved in c-MYC and N-MYC induced tumors and to two genes that may be targets for MYC activity.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Benvenisty, N (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel.		Schuldiner, Oren/K-1353-2012	Schuldiner, Oren/0000-0002-7350-9380				Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Ben-Porath I, 1999, MOL CELL BIOL, V19, P3529; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; BENBASSAT H, 1992, LEUKEMIA LYMPHOMA, V6, P513, DOI 10.3109/10428199209053591; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DAVIS LJ, 1993, ONCOGENE, V8, P125; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GUERIN M, 1988, ONCOGENE RES, V3, P21; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Malynn BA, 2000, GENE DEV, V14, P1390; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; OSWALD F, 1994, ONCOGENE, V9, P2029; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; SADEE W, 1987, CANCER RES, V47, P5207; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STEINITZ M, 1975, P NATL ACAD SCI USA, V72, P3518, DOI 10.1073/pnas.72.9.3518; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEGER H, 1988, DIFFERENTIATION, V39, P216, DOI 10.1111/j.1432-0436.1988.tb00095.x; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	55	55	58	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4984	4994		10.1038/sj.onc.1204459	http://dx.doi.org/10.1038/sj.onc.1204459			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526483				2022-12-28	WOS:000170439800008
J	Fuhrmann, G; Leisser, C; Rosenberger, G; Grusch, M; Huettenbrenner, S; Halama, T; Mosberger, I; Sasgary, S; Cerni, C; Krupitza, G				Fuhrmann, G; Leisser, C; Rosenberger, G; Grusch, M; Huettenbrenner, S; Halama, T; Mosberger, I; Sasgary, S; Cerni, C; Krupitza, G			Cdc25A phosphatase suppresses apoptosis induced by serum deprivation	ONCOGENE			English	Article						Cdc25; apoptosis; survival; Akt; Raf1; c-myc; signal transduction	CELL-CYCLE REGULATION; S-PHASE ENTRY; C-MYC; PROTEIN-KINASES; TNF-ALPHA; ACTIVATION; INDUCTION; PHOSPHORYLATION; EXPRESSION; 14-3-3-PROTEINS	The phosphatase Cdc25A was shown to be a target of the transcription factor c-Myc. Myc-induced apoptosis appeared dependent on Cdc25A expression and Cdc25A over-expression could substitute for Myc-triggered apoptosis. These findings suggested that an important downstream component of Myc-mediated apoptosis was identified. However and in contrast, we recently reported that during TNF alpha -induced apoptosis, which required c-Myc function, Cdc25A was down-regulated in a human carcinoma cell line. We now provide evidence that Cdc25A rendered the non-transformed rat embryonic cell line 423 refractory to apoptosis, which was induced by serum deprivation and in absence of detectable c-myc levels. The survival promoting activity of cdc25A was abolished upon infection of cells with a full-length cdc25A antisense construct. To identify the signaling proteins mediating the survival function of the phosphatase, cdc25A- and akt- over-expressing pooled clones were exposed to selected chemicals, which inhibit or activate key proteins in signaling pathways. Inhibition of apoptosis by SU4984, NF023 and Rapamycin placed Cdc25A and Akt function downstream of FGF.R, PDGF.R, and compensated G-protein- and PP2A-activity. Interestingly, upon treatment with LY-294002, cdc25A- and akt- over-expressing clones exhibited similar apoptotic patterns as control cells, which indicates that neither Akt- nor Cdc25A-mediated survival functions are dependent on PI.3 kinase activity in rat 423 cells. In cdc25A-overexpressing cells increased levels of serine 473 phosphorylated Akt were found, which coprecipitated with Cdc25A and Raf1. Since activation of proteins requires dephosphorylation of particular residues in addition to site-specific phosphorylation, the antiapoptotic effect of Cdc25A might derive from its participation in a multimeric protein complex with phosphoAkt and Raf1, two prominent components of survival pathways.	Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria; Univ Vienna, Dept Gen Dermatol, A-1090 Vienna, Austria; Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Krupitza, G (corresponding author), Univ Vienna, Inst Clin Pathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Grusch, Michael/C-1183-2008	Grusch, Michael/0000-0001-5486-9340; Krupitza, Georg/0000-0003-2949-7906				CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Das G, 1999, SCAND J IMMUNOL, V49, P307, DOI 10.1046/j.1365-3083.1999.00486.x; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Grusch M, 1999, CELL DEATH DIFFER, V6, P736, DOI 10.1038/sj.cdd.4400546; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jaworowski A, 1999, IMMUNOL CELL BIOL, V77, P90, DOI 10.1046/j.1440-1711.1999.00798.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JOLLES J, 1993, DEMENTIA, V4, P81, DOI 10.1159/000107301; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Krupitza G, 1998, CELL DEATH DIFFER, V5, P758, DOI 10.1038/sj.cdd.4400417; KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Simonitsch I, 1998, BRIT J CANCER, V78, P862, DOI 10.1038/bjc.1998.594; Spitkovsky D, 1996, ONCOGENE, V12, P2549; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xia K, 1999, MOL CELL BIOL, V19, P4819	45	28	30	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4542	4553		10.1038/sj.onc.1204499	http://dx.doi.org/10.1038/sj.onc.1204499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494150				2022-12-28	WOS:000170074900012
J	Hofmann, JFX; Sykora, M; Redemann, N; Beug, H				Hofmann, JFX; Sykora, M; Redemann, N; Beug, H			G1-Cdk activity is required for both proliferation and viability of cytokine-dependent myeloid and erythroid cells	ONCOGENE			English	Article						apoptosis; caspases; cell cycle; cytokines; hematopoiesis	BCL-X-L; APOPTOSIS; DEATH; SURVIVAL; ERYTHROPOIETIN; DIFFERENTIATION; GROWTH; MICE; RECEPTOR; PHOSPHORYLATION	Hematopoietic cytokines are critically required for survival and cell proliferation of myeloid and erythroid progenitors. It is poorly understood how the apoptotic machinery of progenitor cells senses the absence of specific cytokines, Here we show that G1-Cdk activity is essential for cytokine-mediated viability of myeloid and erythroid progenitors. Cytokine deprivation is associated with rapid downregulation of G1-Cdk activity, cell cycle arrest, and apoptosis, Specific inhibition of G1-Cdk activity results in apoptotic cell death in the presence of saturating cytokine levels. In contrast, specific cell cycle arrest in G2/M does not affect viability. When cell proliferation is arrested by cytokine withdrawal, primary erythroid progenitors expressing v-ErbA maintain G1-Cdk activity and undergo delayed apoptosis, Cdk-inhibitors strongly enhance apoptosis in starved v-ErbA cells, indicating that sustained Cdk activity is required for protection from apoptosis by v-ErbA.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Boehringer Ingelheim GmbH & Co KG, Onkol Forsch A, D-88400 Biberach, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Boehringer Ingelheim	Beug, H (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	beug@nt.imp.univie.ac.at						Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; ALLEN PD, 1993, BLOOD REV, V7, P63, DOI 10.1016/0268-960X(93)90025-Y; Antoku K, 1998, LEUKEMIA, V12, P682, DOI 10.1038/sj.leu.2400992; Barge RMY, 1997, FEBS LETT, V409, P207, DOI 10.1016/S0014-5793(97)00507-3; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Colussi PA, 1999, IMMUNOL CELL BIOL, V77, P58, DOI 10.1046/j.1440-1711.1999.00788.x; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GANDRILLON O, 1994, ONCOGENE, V9, P749; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KELLEY LL, 1993, BLOOD, V82, P2340; Kieslinger M, 2000, GENE DEV, V14, P232; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Lotem J, 1996, LEUKEMIA, V10, P925; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MARVEL J, 1994, ONCOGENE, V9, P1117; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Vander Heiden MG, 1999, MOL CELL, V3, P159; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VONLINDERN M, 2001, IN PRESS ONCOGENE; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	59	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4198	4208		10.1038/sj.onc.1204550	http://dx.doi.org/10.1038/sj.onc.1204550			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464286				2022-12-28	WOS:000169857200010
J	Giorgetti-Peraldi, S; Murdaca, J; Mas, JC; Van Obberghen, E				Giorgetti-Peraldi, S; Murdaca, J; Mas, JC; Van Obberghen, E			The adapter protein, Grb10, is a positive regulator of vascular endothelial growth factor signaling	ONCOGENE			English	Article						Grb10; VEGF receptor; KDR; angiogenesis	INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE KINASE; FLK-1/KDR ACTIVATION; PLECKSTRIN HOMOLOGY; BINDING-PROTEIN; NITRIC-OXIDE; SH2 DOMAINS; I RECEPTOR; ANGIOGENESIS; CELLS	Vascular endothelial growth factor (VEGF) is an important regulator of vasculogenesis and angiogenesis. Activation of VEGF receptors leads to the recruitment of SH2 containing proteins which link the receptors to the activation of signaling pathways. Here we report that Grb10, an adapter protein of which the biological role remains unknown, is tyrosine phosphorylated in response to VEGF in endothelial cells (HUVEC) and in 293 cells expressing the VEGF receptor KDR, An intact SH2 domain is required for Grb10 tyrosine phosphorylation in response to VEGF, and this phosphorylation is mediated in part through the activation of Src, In HUVEC, VEGF increases Grb10 mRNA level. Expression of Grb10 in HUVEC or in KDR expressing 293 cells results in an increase in the amount and in the tyrosine phosphorylation of KDR, In 293 cells, this is correlated with the activation of signaling molecules, such as MAP kinase, By expressing mutants of Grb10, we found that the positive action of Grb10 is independent of its SH2 domain. Moreover, these Grb10 effects on KDR seem to be specific since Grb10 has no effect on the insulin receptor, and Grb2, another adapter protein, does not mimic the effect of Grb10 on KDR, In conclusion, we propose that VEGF up-regulates Grb10 level, which in turn increases KDR molecules, suggesting that Grb10 could be involved in a positive feedback loop in VEGF signaling.	Fac Med Nice, IFR 50, INSERM, U145, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Giorgetti-Peraldi, S (corresponding author), Fac Med Nice, IFR 50, INSERM, U145, Ave Valombrose, F-06107 Nice 2, France.			Giorgetti-Peraldi, Sophie/0000-0002-2751-2618				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; BARBIERI B, 1981, P SOC EXP BIOL MED, V168, P204; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OOI J, 1995, ONCOGENE, V10, P1621; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096	31	31	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3959	3968		10.1038/sj.onc.1204520	http://dx.doi.org/10.1038/sj.onc.1204520			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494124				2022-12-28	WOS:000169681500004
J	Matroule, JY; Carthy, CM; Granville, DJ; Jolois, O; Hunt, DWC; Piette, J				Matroule, JY; Carthy, CM; Granville, DJ; Jolois, O; Hunt, DWC; Piette, J			Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization	ONCOGENE			English	Article						photosensitization; photodynamic therapy; pyropheophorbide; apoptosis; caspase; NF-kappa B	NF-KAPPA-B; CYTOCHROME-C RELEASE; MITOCHONDRIAL PERMEABILITY TRANSITION; ACTIVATED PROTEIN-KINASE; PHOTODYNAMIC THERAPY; CASPASE ACTIVATION; SINGLET OXYGEN; HELA-CELLS; INDUCTION; NECROSIS	Pyropheophorbide-a methylester (PPME) is a second generation of photosensitizers used in photodynamic therapy (PDT), We demonstrated that PPME photosensitization triggered apoptosis of colon cancer cells as measured by using several classical parameters such as DNA laddering, PARP cleavage, caspase activation and mitochondrial release of cytochrome c, Preincubation of cells with N-acetyl cysteine (NAC) or pyrolidine dithiocarbamate (PDTC) protected against apoptosis mediated by PPME photosensitization showing that reactive oxygen species (ROS) are involved as second messengers. On the other hand, photosensitization carried out in the presence of deuterium oxide (D2O) which enhances singlet oxygen (O-1(2)) lifetime only increases necrosis without affecting apoptosis, Since PPME was localized in the endoplasmic reticulum (ER)/Golgi system and lysosomes, other messengers than ROS were tested such as calcium, Bid, Bap31, phosphorylated Bcl-2 and caspase-12 but none was clearly identified as being involved in triggering cytochrome c release from mitochondria, On the other hand, we demonstrated that the transduction pathways leading to NF-kappaB activation and apoptosis were clearly independent although NF-kappaB was shown to counteract apoptosis mediated by PPME photosensitization.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Lab Human Histol, B-4000 Liege, Belgium; QLT Inc, Vancouver, BC V5T 4T5, Canada	University of Liege; University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be						Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Granville D J, 2000, Curr Opin Drug Discov Devel, V3, P232; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Henderson BW, 1997, CANCER RES, V57, P4000; Hirpara JL, 2000, BLOOD, V95, P1773, DOI 10.1182/blood.V95.5.1773.005k17_1773_1780; Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Katschinski DM, 2000, J BIOL CHEM, V275, P21094, DOI 10.1074/jbc.M001629200; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kim DK, 2000, EXP CELL RES, V257, P82, DOI 10.1006/excr.2000.4868; Korbelik M, 1996, J Clin Laser Med Surg, V14, P329; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; LEE C, 1995, CANCER RES, V55, P2063; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lin CP, 2000, EXP CELL RES, V259, P351, DOI 10.1006/excr.2000.4979; MacDonald IJ, 1999, PHOTOCHEM PHOTOBIOL, V70, P789, DOI 10.1111/j.1751-1097.1999.tb08284.x; Matroule JY, 1999, PHOTOCHEM PHOTOBIOL, V70, P540, DOI 10.1111/j.1751-1097.1999.tb08249.x; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; MILLER GG, 1995, PHOTOCHEM PHOTOBIOL, V61, P632, DOI 10.1111/j.1751-1097.1995.tb09880.x; Monney L, 1998, EUR J BIOCHEM, V251, P295, DOI 10.1046/j.1432-1327.1998.2510295.x; Morgan J, 2000, PHOTOCHEM PHOTOBIOL, V71, P747, DOI 10.1562/0031-8655(2000)071<0747:COPTIA>2.0.CO;2; Murphree AL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1348, DOI 10.1001/archopht.1996.01100140548005; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Pandey RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P194, DOI 10.1111/j.1751-1097.1996.tb02442.x; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Plumpe J, 2000, AM J PHYSIOL-GASTR L, V278, pG173, DOI 10.1152/ajpgi.2000.278.1.G173; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Ruck A, 2000, PHOTOCHEM PHOTOBIOL, V72, P210, DOI 10.1562/0031-8655(2000)072<0210:LIAIAD>2.0.CO;2; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimura M, 2000, J LEUKOCYTE BIOL, V68, P87; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tajiri H, 1998, CANCER LETT, V128, P205, DOI 10.1016/S0304-3835(98)00066-4; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	65	113	124	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4070	4084		10.1038/sj.onc.1204546	http://dx.doi.org/10.1038/sj.onc.1204546			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494135				2022-12-28	WOS:000169681500015
J	Gurbuxani, S; Bruey, JM; Fromentin, A; Larmonier, N; Parcellier, A; Jaattela, M; Martin, F; Solary, E; Garrido, C				Gurbuxani, S; Bruey, JM; Fromentin, A; Larmonier, N; Parcellier, A; Jaattela, M; Martin, F; Solary, E; Garrido, C			Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells	ONCOGENE			English	Article						HSP70; apoptosis; immunogenicity; tumorigenicity; colon cancer cells	HEAT-SHOCK-PROTEIN; HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; IMMUNE-RESPONSE; DIFFERENTIAL EXPRESSION; TUMOR IMMUNOGENICITY; NEGATIVE REGULATION; IN-VITRO; ANTIGEN; DEATH; TUMORIGENICITY	Expression of inducible heat shock protein 70 (HSP70) in tumor cells has been proposed to enhance their immunogenicity. However, HSP70 has also been demonstrated to prevent tumor cell death, a key process for the development of tumor cell immunogenicity. In the present study, we investigated the influence of the HSP70 protein level on PRO colon cancer cell growth and immunogenicity in syngeneic BDIX rats and nude mice. These cells have a basal expression of HSP70 which can be substantially increased by heat shock. When injected subcutaneously in syngeneic animals, PRO cells do not induce any detectable immune response and give rise to progressive, metastatic and lethal tumors. Stable transfection of an anti-sense hsp70 cDNA in PRO cells (PRO-70AS cells) strongly decreased HSP70 expression and sensitized cell-free extracts to cytochrome c/dATP-mediated activation of caspases. Subcutaneous injection of PRO-70AS cells induced tumors that rapidly regressed in syngeneic rats while they grew normally in nude mice. Syngeneic rats injected with PRO-70AS cells became protected against a further challenge with PRO cells. The tumor-specific immune response induced by HSP70-depleted PRO-70AS cells was associated with an increased rate of cell death in viro. These PRO-70AS cells were also more sensitive to NO-mediated, caspase-dependent, macrophage cytotoxicity in vivo. Altogether, these results indicate that reduced level of HSP70 expression in PRO- colon cancer cells results in the generation of a specific immune response by promoting cell death in vivo.	Fac Med, INSERM, U517, IFR 100, F-21033 Dijon, France; Danish Canc Soc, DK-2100 Copenhagen, Denmark	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Danish Cancer Society	Garrido, C (corresponding author), Fac Med, INSERM, U517, IFR 100, 7 Blvd Jeanne Darc, F-21033 Dijon, France.	cgarrido@u-bourgogne.fr	Jäättelä, Marja/AAT-7932-2021; Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018	Jäättelä, Marja/0000-0001-5950-7111; Garrido, carmen/0000-0003-1368-1493; Solary, Eric/0000-0002-8629-1341				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BELL DA, 1991, CLIN IMMUNOL IMMUNOP, V60, P13, DOI 10.1016/0090-1229(91)90108-M; Blachere NE, 1995, SEMIN CANCER BIOL, V6, P349, DOI 10.1016/1044-579X(95)90004-7; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Bonnotte B, 1998, J IMMUNOL, V161, P1433; Bonnotte B, 2000, J IMMUNOL, V164, P1995, DOI 10.4049/jimmunol.164.4.1995; BONNOTTE B, 2001, IN PRESS J IMMUNOL; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CAIGNARD A, 1985, INT J CANCER, V36, P273, DOI 10.1002/ijc.2910360221; CAIGNARD A, 1988, INT J CANCER, V42, P883, DOI 10.1002/ijc.2910420616; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kaur J, 2000, INT J CANCER, V85, P1; Kaur J, 1995, INT J CANCER, V63, P774, DOI 10.1002/ijc.2910630604; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Melcher A, 1999, J MOL MED-JMM, V77, P824, DOI 10.1007/s001099900066; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Negulyaev YA, 1996, BBA-BIOMEMBRANES, V1282, P156, DOI 10.1016/0005-2736(96)00055-7; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Ralhan R, 1995, CLIN CANCER RES, V1, P1217; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Shrestha A, 1999, LAB INVEST, V79, P1629; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; Srivastava PK, 2000, NAT IMMUNOL, V1, P363, DOI 10.1038/80795; Todryk S, 1999, J IMMUNOL, V163, P1398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wells AD, 2000, IMMUNOL TODAY, V21, P129, DOI 10.1016/S0167-5699(99)01558-3; Wells AD, 1998, INT IMMUNOL, V10, P609, DOI 10.1093/intimm/10.5.609; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643	47	72	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7478	7485		10.1038/sj.onc.1204948	http://dx.doi.org/10.1038/sj.onc.1204948			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709719				2022-12-28	WOS:000171976900004
J	Piao, CQ; Zhao, YL; Hei, TK				Piao, CQ; Zhao, YL; Hei, TK			Analysis of p16 and p21(Cip1) expression in tumorigenic human bronchial epithelial cells induced by asbestos	ONCOGENE			English	Article						asbestos; transformation; human bronchial epithelial cells; p16; p21(Cip1)	P21(WAF1/CIP1) EXPRESSION; MALIGNANT-TRANSFORMATION; DIFFERENTIATION; PROTEIN; GENE; P21; CARCINOMAS; INHIBITOR; MUTATIONS; INDUCTION	Although asbestos is carcinogenic to humans, the mechanism(s) by which it induces cancer is unknown. Using tumor cell lines generated previously by asbestos treatment of immortalized human bronchial epithelial (BEP2D) cells, we examined alterations in p16 and p21(Cip1) genes together with their protein levels. Results were compared with untreated BEP2D cells, normal human bronchial epithelial cells (NHBE), as well as nontumorigenic fusion cell lines generated by fusing tumor cells with BEP2D cells. No deletion in the p16 gene was found in any of the tumor cell lines examined. Although p16 protein was expressed at a similar level in tumor and BEP2D cells, there was a fourfold decrease in its expression among NHBE cells. In contrast, both the protein and mRNA expression levels of p21(Cip1) were decreased by about threefold in tumor cell lines when compared with either BEP2D or NHBE cells, which had a similar expression level. Expression of p21(Cip1) mRNA was restored to the control level in all the fusion cell lines examined. The results suggested that down regulation of p21(Cip1) expression is linked to the tumorigenic conversion of BEP2D cells by asbestos.	Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	Columbia University	Piao, CQ (corresponding author), Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.	cp16@cp16@columbia.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007890] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05786, ES07890] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BUTZ K, 1995, ONCOGENE, V10, P927; CHENG JQ, 1994, CANCER RES, V54, P5547; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P18, DOI 10.1165/ajrcmb.19.1.3077; GABRIELLE IT, 1999, P NATL ACAD SCI USA, V96, P9089; GERWIN BI, 1994, AM J RESP CELL MOL, V11, P507, DOI 10.1165/ajrcmb.11.5.7946379; Hei TK, 1999, ADV SPACE RES-SERIES, V22, P1699; HEI TK, 1992, CANCER RES, V52, P6305; HEI TK, 1994, CARCINOGENESIS, V15, P431, DOI 10.1093/carcin/15.3.431; Hei TK, 1997, ENVIRON HEALTH PERSP, V105, P1085, DOI 10.2307/3433513; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kokunai T, 1998, INT J CANCER, V75, P643, DOI 10.1002/(SICI)1097-0215(19980209)75:4<643::AID-IJC24>3.0.CO;2-8; LECHNER JF, 1985, P NATL ACAD SCI USA, V82, P3884, DOI 10.1073/pnas.82.11.3884; LezonGeyda K, 1996, MUTAT RES-ENVIR MUTA, V361, P113, DOI 10.1016/S0165-1161(96)90245-9; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIVINGSTON GK, 1980, J ENVIRON PATHOL TOX, V4, P373; Marchetti A, 1996, ONCOGENE, V12, P1319; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Nadal A, 1997, J PATHOL, V183, P156; Nakao Y, 1997, BRIT J CANCER, V75, P1410, DOI 10.1038/bjc.1997.243; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Park SH, 1998, CANCER RES, V58, P1144; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHAPIRO GI, 1995, CANCER RES, V55, P505; STANTON MF, 1977, J NATL CANCER I, V58, P587, DOI 10.1093/jnci/58.3.587; Takeshima Y, 1998, CARCINOGENESIS, V19, P1755, DOI 10.1093/carcin/19.10.1755; WASHIMI O, 1995, CANCER RES, V55, P514; XIAO S, 1995, ONCOGENE, V11, P511; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhao YL, 2000, CARCINOGENESIS, V21, P2005, DOI 10.1093/carcin/21.11.2005	33	8	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7301	7306		10.1038/sj.onc.1204908	http://dx.doi.org/10.1038/sj.onc.1204908			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704859				2022-12-28	WOS:000171894200002
J	Degos, L; Wang, ZY				Degos, L; Wang, ZY			All trans retinoic acid in acute promyelocytic leukemia	ONCOGENE			English	Article						differentiation; promyelocytic leukemia; retinoic acid	POLYMERASE CHAIN-REACTION; RECEPTOR-ALPHA; DIFFERENTIATION THERAPY; 15-17 TRANSLOCATION; TRANSRETINOIC ACID; COMPLETE REMISSION; CD56 EXPRESSION; PML GENE; CHEMOTHERAPY; FUSION	All trans retinoic acid (ATRA) is able to induce complete remission (CR) in almost all patients with acute promyelocytic leukemia (APL) through in vivo differentiation of APL blasts. However, it cannot eliminate the leukemic clone and to be effective must be used in combination with anthracycline-based chemotherapy. Experience accumulated over the last 10 years has clearly shown that the combination of ATRA and chemotherapy gives better survival in newly diagnosed APL than chemotherapy alone because of fewer relapses and a higher CR rate experienced by these patients. It is also strongly suggested that maintenance treatment with ATRA, and possibly in combination with low-dose chemotherapy, can further reduce the incidence of relapse. Overall, more than 90% of patients with newly diagnosed APL can achieve CR and about 75% can be cured by the combination of ATRA and chemotherapy.	Hop St Louis, Inst Univ Hematol, AP HP, F-75010 Paris, France; Shanghai Med Univ 2, Rui Jin Hosp, Shanghai Inst Hematol, Shanghai, Peoples R China	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Shanghai Jiao Tong University	Degos, L (corresponding author), Hop St Louis, Inst Univ Hematol, AP HP, 1 Ave Claude Vellefaux, F-75010 Paris, France.							Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Avvisati G, 1999, BLOOD, V94, p505A; AVVISATI G, 1991, ANN ONCOL, V2, P405; AVVISATI G, 1990, HEMOSTASIS CANC, P91; Beaumont M, 2000, BLOOD, V96, p321A; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1980, ANN INTERN MED, V92, P261, DOI 10.7326/0003-4819-92-2-261; BERNARD J, 1959, Schweiz Med Wochenschr, V89, P604; BERNARD J, 1973, BLOOD, V41, P489, DOI 10.1182/blood.V41.4.489.489; BIONDI A, 1992, BLOOD, V80, P492; BREITMAN TR, 1981, BLOOD, V57, P1000; CAEN J, 1959, REV FR ETUD CLIN BIO, V4, P363; CAEN J, 1957, C EUR HEMAT KARGER, P502; CASSINAT B, 2001, SEMINARS HEMATOLOGY; CASTAIGNE S, 1990, BLOOD, V76, P1704; CASTAIGNE S, 1992, BLOOD, V79, P3110; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1986, LEUKEMIA RES, V10, P1301, DOI 10.1016/0145-2126(86)90337-1; CHOMIENNE C, 1986, LEUKEMIA RES, V10, P1079, DOI 10.1016/0145-2126(86)90052-4; CORNIC M, 1992, CANCER RES, V52, P3329; DOMBRET H, 1995, LEUKEMIA, V9, P19; Douer D, 1996, BLOOD, V87, P308, DOI 10.1182/blood.V87.1.308.bloodjournal871308; DUBOIS C, 1994, LEUKEMIA, V8, P1750; Fenaux P, 1999, BLOOD, V94, P1192, DOI 10.1182/blood.V94.4.1192.416k07_1192_1200; FENAUX P, 1993, BLOOD, V82, P3241; FENAUX P, 1992, BLOOD, V80, P2176; Fenaux P, 2000, LEUKEMIA, V14, P1371, DOI 10.1038/sj.leu.2401859; Ferrara F, 2000, J CLIN ONCOL, V18, P1295, DOI 10.1200/JCO.2000.18.6.1295; FRANKEL SR, 1992, ANN INTERN MED, V117, P293; GOLOMB HM, 1976, ARCH INTERN MED, V136, P825, DOI 10.1001/archinte.136.7.825; Guglielmi C, 1998, BRIT J HAEMATOL, V102, P1035, DOI 10.1046/j.1365-2141.1998.00871.x; HILLESTAD LK, 1957, ACTA MED SCAND, V159, P189, DOI 10.1111/j.0954-6820.1957.tb00124.x; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; KANAMARU A, 1995, BLOOD, V85, P1202, DOI 10.1182/blood.V85.5.1202.bloodjournal8551202; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; Lo Coco F, 1999, BLOOD, V94, P2225, DOI 10.1182/blood.V94.7.2225.419k03_2225_2229; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; MICLEA JM, 1994, LEUKEMIA, V8, P214; MUINDI J, 1992, BLOOD, V79, P299; Murray CK, 1999, J CLIN ONCOL, V17, P293, DOI 10.1200/JCO.1999.17.1.293; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; RODEGHIERO F, 1990, BLOOD, V75, P2112; ROWLEY JD, 1977, LANCET, V1, P549; Schoch C, 1996, BRIT J HAEMATOL, V94, P493, DOI 10.1046/j.1365-2141.1996.d01-1829.x; Slack JL, 1997, J CLIN ONCOL, V15, P1786, DOI 10.1200/JCO.1997.15.5.1786; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Wang ZY, 1999, CHINESE MED J-PEKING, V112, P963; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1994, LEUKEMIA, V8, P929; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Zhu J, 1999, LEUKEMIA, V13, P1062, DOI 10.1038/sj.leu.2401448	55	153	166	1	16	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7140	7145		10.1038/sj.onc.1204763	http://dx.doi.org/10.1038/sj.onc.1204763			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704842				2022-12-28	WOS:000171891900002
J	Coates, PJ; Lorimore, SA; Rigat, BA; Lane, DP; Wright, EG				Coates, PJ; Lorimore, SA; Rigat, BA; Lane, DP; Wright, EG			Induction of endogenous beta-galactosidase by ionizing radiation complicates the analysis of p53-LacZ transgenic mice	ONCOGENE			English	Article						lacZ; beta-galactosidase; radiation; macrophage; transgenic mice	SENSITIVITY; LACZ	Studies of the response of p53-lacZ transgenic mice have uncovered an unexpected induction of endogenous acid-beta -galactosidase activity following whole body irradiation. Strong induction of endogenous enzyme activity is seen in a variety of mouse strains commonly used in the production of transgenes. The induction of endogenous enzyme activity therefore complicates the analysis of p53-lacZ transgenes and may also influence the analysis of radiation responses in other lacZ-reporter mice.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Wright, EG (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Lane, David P/C-4920-2008; Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306; Lane, David/0000-0003-0551-3545				Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; HATTON JD, 1992, J NEUROSCI METH, V45, P147, DOI 10.1016/0165-0270(92)90070-T; HENDRIKX PJ, 1994, ANAL BIOCHEM, V222, P456, DOI 10.1006/abio.1994.1516; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; MACCALLUM DE, 1996, ONCOGENE, V13, P2576; Nowroozi N, 1998, J CRAN GENET DEV BIO, V18, P51; Weiss DJ, 1999, HISTOCHEM J, V31, P231, DOI 10.1023/A:1003642025421	8	15	17	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7096	7097		10.1038/sj.onc.1204904	http://dx.doi.org/10.1038/sj.onc.1204904			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704833				2022-12-28	WOS:000171739300012
J	Gilmore, TD; Cormier, C; Jean-Jacques, J; Gapuzan, ME				Gilmore, TD; Cormier, C; Jean-Jacques, J; Gapuzan, ME			Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel	ONCOGENE			English	Article						Rel; c-Rel; NF-kappa B; Bcl-2; v-Rel; malignant transformation	NF-KAPPA-B; ONCOPROTEIN; ONCOGENE; LYMPHOMA; VIRUS; GENES; BCL-2; PROTOONCOGENE; AMPLIFICATION; FIBROBLASTS	Rel/NF-kappaB transcription factors control a variety of cellular processes, such as cell growth and apoptosis, that are relevant to oncogenesis, and mutations in genes encoding Rel/NF-kappaB transcription factors have been found in several human lymphoid cell cancers. In this study, we have used a sensitive cell outgrowth assay to demonstrate that wild-type human c-Rel can malignantly transform primary chicken spleen cells, and that transformation by c-Rel is accelerated by co-expression of Bcl-2. Full-length mouse c-Rel can also transform chicken spleen cells. These results are the first demonstration of a lymphoid cell malignant transforming ability for mammalian Rel/NF-kappaB transcription factors, and implicate c-Rel as a molecular target for cancer therapeutics.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; Bohlander SK, 2000, CYTOGENET CELL GENET, V91, P52, DOI 10.1159/000056818; BROWNELL E, 1989, ONCOGENE, V4, P935; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1995, DNA PROVIRUS, P109; GILMORE TD, 2000, DNA ALTERATIONS CANC, P121; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; HENDERSON E, 1977, VIROLOGY, V76, P152, DOI 10.1016/0042-6822(77)90292-6; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; Houldsworth J, 1996, BLOOD, V87, P25; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huang HHT, 2000, J MANUF SYST, V19, P73, DOI 10.1016/S0278-6125(00)80001-1; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Kaye KM, 1999, J VIROL, V73, P10525, DOI 10.1128/JVI.73.12.10525-10530.1999; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LU D, 1991, ONCOGENE, V6, P1235; Mainville CA, 2001, J VIROL, V75, P1816, DOI 10.1128/JVI.75.4.1816-1823.2001; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; SIF S, 1993, ONCOGENE, V8, P2501; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1997, SCIENCE, V276, P185; White DW, 1996, ONCOGENE, V13, P891	35	73	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7098	7103		10.1038/sj.onc.1204898	http://dx.doi.org/10.1038/sj.onc.1204898			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704834				2022-12-28	WOS:000171739300013
J	King, JG; Khalili, K				King, JG; Khalili, K			Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen	ONCOGENE			English	Article						glioblastoma multiforme (GBM); non-steroidal anti-inflammatory drugs; COX-2; p53 induction	PRIMITIVE NEUROECTODERMAL TUMORS; COLON-CANCER CELLS; IN-VITRO; CYCLOOXYGENASE-2 EXPRESSION; R-FLURBIPROFEN; APOPTOSIS; SULINDAC; TOXICITY; MODELS; MOUSE	Despite many efforts to alter the relentlessly aggressive progression of tumors of neural origin, individuals bearing these tumors exhibit poor prognosis for longterm survival. In an attempt to find an effective treatment, we examined the efficacy of the non-steroidal anti-inflammatory drug, flurbiprofen, to suppress the growth of tumor cell lines derived from medulloblastoma and glioblastoma multiforme. Results from cell proliferation assays have revealed that flurbiprofen effectively inhibits the growth of various tumor cells in a dose-dependent manner and causes a noticeable change in the progression of cells through cell cycle stages. Treatment of tumor cells with flurbiprofen reduced the number of cells in G1 and G2, and significantly increased their numbers in S phase, suggesting that, flurbiprofen accelerates G1/S entry, and/or delays cell exit from S to G2/M stages. Results from RNase protection assay and Western blot analysis showed that while treatment of cells with flurbiprofen causes a minor change in the RNA level of different cyclins, there is a significant decrease in the level of cyclin B protein upon flurbiprofen treatment. Examination of tumor suppressors by RNase protection technique showed a subtle increase in the levels of several tumor suppressors upon flurbiprofen treatment. Interestingly, at the protein level, p53 tumor suppressor was substantially increased upon flurbiprofen treatment, yet the level of p21, a downstream target for p53 remained unchanged. Curiously, treatment of the cells with flurbiprofen enhanced the level of COX-2 expression. Results from co-immunoprecipitation showed association of COX-2 with p53 in tumor cells. These observations suggest that the interaction of COX-2 with p53 may cause p21-independent suppression of tumor cell growth upon flurbiprofen treatment.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Lab Canc Biol & Intervent, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Lab Canc Biol & Intervent, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.							Deininger MH, 1999, ACTA NEUROPATHOL, V98, P240, DOI 10.1007/s004010051075; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Goldberg Y, 1996, ONCOGENE, V12, P893; Gottifredi V, 1999, J CELL SCI, V112, P2397; Grubbs CJ, 2000, CANCER RES, V60, P5599; HART MN, 1973, CANCER, V32, P890, DOI 10.1002/1097-0142(197310)32:4<890::AID-CNCR2820320421>3.0.CO;2-O; Joki T, 2000, CANCER RES, V60, P4926; Keller JJ, 1999, GUT, V45, P822, DOI 10.1136/gut.45.6.822; Kleihues P, 2000, PATHOLOGY GENETICS T; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; Matsuhashi N, 1997, GUT, V40, P344, DOI 10.1136/gut.40.3.344; MOLENAAR WM, 1994, CRIT REV ONCOL HEMAT, V17, P1, DOI 10.1016/1040-8428(94)90036-1; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Souza RF, 2000, CANCER RES, V60, P5767; Taylor MT, 2000, CANCER RES, V60, P6607; Tegeder I, 2001, FASEB J, V15, P595, DOI 10.1096/fasebj.15.3.595; von Knethen A, 1999, J IMMUNOL, V163, P2858; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Wechter WJ, 2000, CANCER RES, V60, P2203; Wechter WJ, 2000, LIFE SCI, V66, P745, DOI 10.1016/S0024-3205(99)00645-1; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1996, AM J PHYSIOL, V270, P393; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	24	39	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6864	6870		10.1038/sj.onc.1204907	http://dx.doi.org/10.1038/sj.onc.1204907			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687965				2022-12-28	WOS:000171641000007
J	Konduri, SD; Rao, CN; Chandrasekar, N; Tasiou, A; Mohanam, S; Kin, Y; Lakka, SS; Dinh, D; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Rao, JS				Konduri, SD; Rao, CN; Chandrasekar, N; Tasiou, A; Mohanam, S; Kin, Y; Lakka, SS; Dinh, D; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Rao, JS			A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion	ONCOGENE			English	Article						TFPI-2; glioblastoma; invasion	MATRIX-DEGRADING METALLOPROTEINASE; SERINE PROTEINASE-INHIBITORS; ENDOTHELIAL GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; CELL-LINE; PROTEASE INHIBITOR; MELANOMA-CELLS; CDNA CLONING; FACTOR VIIA; IN-SITU	Human tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine protease inhibitor that inhibits plasmin, trypsin, chymotrypsin, cathepsin G, and plasma kallikrein but not urokinase-type plasminogen activator, tissue plasminogen activator, or thrombin. Preliminary findings in our laboratory suggested that the expression of TFPI-2 is downregulated or lost during tumor progression in human gliomas. To investigate the role of TFPI-2 in the invasiveness of brain tumors, we stably transfected the human high-grade glioma cell line SNB19 and the human low-grade glioma cell line Hs683 with a vector capable of expressing a transcript complementary to the full-length TFPI-2 mRNA in either sense (0.7 kb) or antisense (1 kb) orientations. Parental cells and stably transfected cell lines were analysed for TFPI-2 protein by Western blotting and for TFPI-2 mRNA by Northern blotting. The levels of TFPI-2 protein and mRNA were higher in the sense clones (SNB19) and decreased in the antisense (Hs683) clones than in the corresponding parental and vector controls. In spheroid and matrigel invasion assays, the SNB19 parental cells were highly invasive, but the sense-transfected SNB-19 clones were much less invasive; the antisense-transfected Hs683 clones were more invasive than their parental and vector controls. After intracerebral injection in mice, the sense-transfected SNB19 clones were less able to form tumors than were their parental and vector controls, and the antisense-Hs683 clones but not the parental or vector controls formed small tumors. This is the first study to demonstrate that down- or upregulation of TFPI-2 plays a significant role in the invasive behavior of human gliomas.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neuropathol, Div Canc Biol, Peoria, IL 61656 USA; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Ctr Prostate Dis Res, Rockville, MD USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; Zymogenet Inc.; University of New Mexico; University of New Mexico's Health Sciences Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, 1 Illini Dr, Peoria, IL 61656 USA.			Tasiou, Anastasia/0000-0002-8853-540X	NCI NIH HHS [CA-75692, CA-76350, CA-75557] Funding Source: Medline; NHLBI NIH HHS [HL-64119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557, R01CA076350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIZIK J, 1990, CELL REGUL, V1, P895, DOI 10.1091/mbc.1.12.895; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; DVORAK HF, 1987, HUM PATHOL, V18, P275, DOI 10.1016/S0046-8177(87)80010-2; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; Eitzman DT, 1996, BLOOD, V87, P4718; GLADSON CL, 1995, AM J PATHOL, V146, P1150; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Hembrough TA, 2001, J BIOL CHEM, V276, P12241, DOI 10.1074/jbc.M010395200; Kondraganti S, 2000, CANCER RES, V60, P6851; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; KOSHIKAWA N, 1994, BIOCHEM J, V303, P187, DOI 10.1042/bj3030187; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; KRAMER MD, 1994, INVAS METAST, V14, P210; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LINO M, 1998, ARTERIOSCLER THROMB, V18, P40; LUNDJOHANSEN M, 1990, SPHEROID CULTURE CAN, P3; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miyagi Y, 1996, DNA CELL BIOL, V15, P947, DOI 10.1089/dna.1996.15.947; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; MIYAZAKI K, 1990, CANCER RES, V50, P7758; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; Nakagawa K, 1998, SEMIN THROMB HEMOST, V24, P207, DOI 10.1055/s-2007-995843; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703; PEDERSEN PH, 1993, CANCER RES, V53, P5158; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; QUAX PHA, 1991, J CELL BIOL, V115, P191, DOI 10.1083/jcb.115.1.191; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V319, P55, DOI 10.1006/abbi.1995.1266; Rao CN, 1999, BIOCHEM BIOPH RES CO, V255, P94, DOI 10.1006/bbrc.1999.0153; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; RAO CN, 1995, J INVEST DERMATOL, V104, P379, DOI 10.1111/1523-1747.ep12665851; Rao CN, 2001, CLIN CANCER RES, V7, P570; REINARTZ J, 1993, EXP CELL RES, V208, P197, DOI 10.1006/excr.1993.1238; Ruf W, 1996, Curr Opin Hematol, V3, P379; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Shoji M, 1998, AM J PATHOL, V152, P399; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; Taniguchi T, 1998, CANCER RES, V58, P4461; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P43; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WAGNER SL, 1989, J BIOL CHEM, V264, P611; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	58	67	79	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6938	6945		10.1038/sj.onc.1204847	http://dx.doi.org/10.1038/sj.onc.1204847			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687973				2022-12-28	WOS:000171641000015
J	Delarue, FL; Taylor, BS; Sebti, SM				Delarue, FL; Taylor, BS; Sebti, SM			Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase-2 in human normal liver AKN-1 cells and lung cancer A-549 cells	ONCOGENE			English	Article						NOS-2; Ras; RhoA; RhoB; Erk; cytokines	SMOOTH-MUSCLE CELLS; PRIMARY ASTROCYTES; TUMOR-GROWTH; TRANSFORMATION; PROTEIN; EXPRESSION; INDUCTION; GENE; ADENOCARCINOMA; INHIBITION	While both nitric oxide synthase-2 (NOS-2) and low molecular weight GTPases, such as Ras and Rho, have been implicated in malignant transformation, the cross talk between these important proteins is ill understood. In this study we examined the ability of H-Ras, RhoA, RhoB and Rac1 to modulate cytokine-induced NOS2. In the normal human liver AKN-1 cell line and in the human non-small cell lung carcinoma cell line, A-549, the ability of the cytokines (INF-gamma, IL-1 beta and TNF-alpha) to activate NOS-2 was blocked by activated L61-H-Ras whereas dominant negative N17-H-Ras enhanced NOS-2 activation. Consistent with this dominant negative Erk2 as well as a MEK inhibitor also enhanced cytokine activation of NOS-2. Furthermore, activated L63-RhoA blocked whereas activated V14-RhoB enhanced cytokine NOS-2 activation. Activated I115-Rac1 did not affect NOS-2 activation. These results demonstrate that the Ras/Erk and the Ras/RhoA pathways negatively regulate whereas RhoB enhances cytokine-induced NOS-2. This is the first demonstration that genes that promote malignant transformation such as Ras and RhoA inhibit, whereas genes with tumor suppresser activity such as RhoB enhance NOS2 induction.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Oncol, Tampa, FL USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA-67771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; CURLEY SA, 1993, J LEUKOCYTE BIOL, V53, P715, DOI 10.1002/jlb.53.6.715; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DONG ZY, 1994, CANCER RES, V54, P789; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; HER JH, 1993, MOL CELL BIOL, V19, P7519; Juang SH, 1997, CANCER BIOTHER RADIO, V12, P167, DOI 10.1089/cbr.1997.12.167; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LEPOIVRE M, 1989, CANCER RES, V49, P1970; MORDAN LJ, 1993, CARCINOGENESIS, V14, P1555, DOI 10.1093/carcin/14.8.1555; Muniyappa R, 2000, AM J PHYSIOL-HEART C, V278, pH1762, DOI 10.1152/ajpheart.2000.278.6.H1762; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Nussler AK, 1999, IN VITRO CELL DEV-AN, V35, P190, DOI 10.1007/s11626-999-0026-4; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINI VB, 1992, EUR J PHARMACOL, V216, P379, DOI 10.1016/0014-2999(92)90434-6; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shi Q, 2000, CANCER RES, V60, P2579; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Wang BL, 2001, CANCER RES, V61, P71; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	28	27	29	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6531	6537		10.1038/sj.onc.1204801	http://dx.doi.org/10.1038/sj.onc.1204801			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641777				2022-12-28	WOS:000171404200005
J	Ono, Y; De-Meyts, ER; Guellaen, G; Bulle, F				Ono, Y; De-Meyts, ER; Guellaen, G; Bulle, F			Sporadic testicular germ cell cancers do not exhibit specific alteration in CAG/CTG repeats containing genes expressed in human testis	ONCOGENE			English	Article						human testicular germ cell tumours; CAG/CTG repeat expansion; genetic anticipation	ANDROGEN RECEPTOR GENE; TRINUCLEOTIDE REPEAT; TRIPLET REPEAT; HUNTINGTON-DISEASE; PROSTATE-CANCER; HUMAN BRAIN; CAG REPEAT; EXPANSION; CARCINOMA; TUMORS	CAG/CTG repeat expansions in genomic DNA of testicular tumour cell lines, and germline DNA from members of families predisposed to this malignancy, have been previously described. In order to identify genes possibly concerned by this alteration, we attempted to clone all possible human testis cDNA containing at least five CAG/CTG repeats. Thirty-four different transcripts were identified. By using PCR and non denaturing gel electrophoresis, we determined the size of their repeats, as well as their polymorphisms in a collection of human testicular germ cell tumours and the normal surrounding tissues. For all tested genes, we detected the presence of several species of the same mRNA for each person. Nine genes exhibited specific patterns of expression among different groups of individuals, indicative of polymorphism. None of these polymorphisms was related to human testicular tumours.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France; Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Rigshospitalet; University of Copenhagen	Bulle, F (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.		Bulle-Thomas, Frederique/L-2528-2017					BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Bulle F, 1997, GENOME RES, V7, P705, DOI 10.1101/gr.7.7.705; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Debrauwere H, 1997, BIOCHIMIE, V79, P577, DOI 10.1016/S0300-9084(97)82006-8; Dieckmann KP, 1999, INT J CANCER, V83, P815, DOI 10.1002/(SICI)1097-0215(19991210)83:6<815::AID-IJC21>3.3.CO;2-Q; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Han S, 2000, CANCER, V88, P2319, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2319::AID-CNCR16>3.0.CO;2-O; Holmes SE, 1999, NAT GENET, V23, P391, DOI 10.1038/70493; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; King BL, 1997, CANCER RES, V57, P209; Kinoshita M, 1997, MUSCLE NERVE, V20, P622, DOI 10.1002/(SICI)1097-4598(199705)20:5<622::AID-MUS16>3.0.CO;2-Y; LI SH, 1993, GENOMICS, V16, P572, DOI 10.1006/geno.1993.1232; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; Nataraj AJ, 1999, ELECTROPHORESIS, V20, P1177, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1177::AID-ELPS1177>3.0.CO;2-2; Panagopoulos I, 1999, HUM MUTAT, V13, P232, DOI 10.1002/(SICI)1098-1004(1999)13:3<232::AID-HUMU7>3.0.CO;2-N; Pawlak A, 1998, MAMM GENOME, V9, P745, DOI 10.1007/s003359900856; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Rajpert-De Meyts E, 1998, APMIS, V106, P198; Sasaki M, 2000, MOL CARCINOGEN, V27, P237, DOI 10.1002/(SICI)1098-2744(200003)27:3<237::AID-MC11>3.3.CO;2-S; Schmutte C, 1999, ANTICANCER RES, V19, P4665; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Stanford JL, 1997, CANCER RES, V57, P1194; Teh BT, 1999, J MED GENET, V36, P348; TELENIUS H, 1995, HUM MOL GENET, V4, P189, DOI 10.1093/hmg/4.2.189; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	30	3	3	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5548	5553		10.1038/sj.onc.1204714	http://dx.doi.org/10.1038/sj.onc.1204714			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571654	Bronze			2022-12-28	WOS:000170781100017
J	Morrione, A; Navarro, M; Romano, G; Dews, M; Reiss, K; Valentinis, B; Belletti, B; Baserga, R				Morrione, A; Navarro, M; Romano, G; Dews, M; Reiss, K; Valentinis, B; Belletti, B; Baserga, R			The role of the insulin receptor substrate-1 in the differentiation of rat hippocampal neuronal cells	ONCOGENE			English	Article						IGF-IR, insulin-like growth factor-1 receptor; IGF-I, insulin-like growth factor-I; IGF-II, insulin-like growth factor-II; IRS-1, insulin receptor substrate-1; PI3K, phosphatidylinositol-3 kinase	GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; RIBOSOMAL S6 KINASE; PHOSPHOTYROSINE-DEPENDENT INTERACTION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; TYROSINE PHOSPHORYLATION; PLECKSTRIN HOMOLOGY; NPEY MOTIF; APOPTOSIS	H19-7/IGF-IR cells are rat hippocampal cells expressing a human IGF-I receptor, which differentiate to a neuronal phenotype when stimulated by IGF-I at 39 degreesC. H19-7/IGF-IR cells have low levels of expression of insulin receptor substrate-1 (IRS-1), a major substrate of the IGF-IR. IGF-I induces serine-phosphorylation and down-regulation of the endogenous IRS-1 upon differentiation of H19-7/IGF-IR cells. The profound influence of IRS-1 on differentiation of H19-7/IGF-IR cells was confirmed by transfecting these cells with a plasmid expressing mouse IRS-1. Over-expression of wild type IRS-1 in H19-7/IGF-IR cells abolishes IGF-I-induced differentiation at 39 degrees C. A mutant of IRS-1 lacking the PTB domain loses the ability to inhibit the differentiation program. H19-7/IGF-IR/IRS-1 cells at 39 degrees C show a stronger and prolonged activation of Akt, when compared to H19-7/IGF-IR cells. The role of Akt in the inhibition of the differentiation program was confirmed by using the inhibitor of Class I PI3 kinases LY29400, which restores IGF-I-induced differentiation of H19-7/IGF-IR/IRS-1 cells. H19-7/IGF-IR/IRS-1 cells show a strong reduction in MAP kinases signaling, which is related to the superactivation of Akt. This was confirmed by expressing in H19-7/IGF-IR cells a constitutively active Akt, which inhibited MAP kinases activation in these cells. These experiments confirm the importance of MAPK in the mechanism of IGF-I-mediated differentiation of H19-7/IGF-IR cells.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	r_baserga@lac.jci.tju.edu	Belletti, Barbara/J-2028-2018	Belletti, Barbara/0000-0003-2249-0285	NCI NIH HHS [CA 78890] Funding Source: Medline; NIA NIH HHS [AG 16291] Funding Source: Medline; NIDDK NIH HHS [KO1 DK 02896-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Anlar B, 1999, HORM METAB RES, V31, P120, DOI 10.1055/s-2007-978708; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Baserga R, 1999, J CELL BIOCHEM, P68; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Craparo A, 1997, J BIOL CHEM, V272, P11663; DAmbrosio C, 1997, CANCER RES, V57, P3264; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EVES EM, 1994, BRAIN RES, V656, P396, DOI 10.1016/0006-8993(94)91484-2; Eves EM, 1996, J NEUROCHEM, V67, P1908; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Furlanetto RW, 1997, BIOCHEM J, V327, P765; Guan KL, 2000, J BIOL CHEM, V275, P27354; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; LEROITH D, 1993, NEUROTROPHIC FACTORS, P391; Leventhal PS, 1999, CONT ENDOCRINOL, V17, P425; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILL JF, 1985, P NATL ACAD SCI USA, V82, P7126, DOI 10.1073/pnas.82.20.7126; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 2000, CANCER RES, V60, P2263; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RECIOPINTO E, 1984, P NATL ACAD SCI-BIOL, V81, P2562, DOI 10.1073/pnas.81.8.2562; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	63	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4842	4852		10.1038/sj.onc.1204649	http://dx.doi.org/10.1038/sj.onc.1204649			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521195				2022-12-28	WOS:000170271800008
J	Sigal, A; Matas, D; Almog, N; Goldfinger, N; Rotter, V				Sigal, A; Matas, D; Almog, N; Goldfinger, N; Rotter, V			The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis	ONCOGENE			English	Article						mutant p53; gain of function; apoptosis; growth arrest; G(2)	WILD-TYPE P53; DNA-BINDING FUNCTION; GAIN-OF-FUNCTION; P53-REGULATED GENE-EXPRESSION; ALTERNATIVELY SPLICED FORM; CELL-CYCLE CONTROL; FUNCTION MUTATIONS; TYROSINE KINASE; MYELOID CELLS; PROTEIN	The ability to suppress wild type p53-independent apoptosis may play an important role in the oncogenicity of p53 mutant proteins. However, structural elements necessary for this activity are unknown. Furthermore, it is unclear whether this mutant p53 mediated inhibition is specific to the apoptotic pathway or a more general suppression of the cellular response to stress. We observed that an unmodified C-terminus was required for the suppression of apoptosis by the p53 135(Ala to Val) oncogenic p53 mutant. It was also required for the novel activity of G(2) arrest suppression, the predominant response at low levels of genotoxic stress. These observations are consistent with a model whereby mutant p53 suppressive activity is not specific to the apoptotic pathway, but rather increases the threshold of genotoxic stress needed for a DNA damage response to occur. Furthermore, these observations indicate that it may be possible to selectively kill mutant p53 expressing cells based on the lower sensitivity of their growth arrest response.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il	Sigal, Alex/GWC-7488-2022	Sigal, Alex/0000-0001-8571-2004				Agami R, 1999, NATURE, V399, P809; Almog N, 1997, MOL CELL BIOL, V17, P713, DOI 10.1128/MCB.17.2.713; Almog N, 2000, ONCOGENE, V19, P3395, DOI 10.1038/sj.onc.1203673; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 2000, CANCER RES, V60, P3425; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, V1, P261; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P427; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Goi K, 1997, CANCER RES, V57, P1895; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HSIAO M, 1994, AM J PATHOL, V145, P702; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hussain SP, 1998, CANCER RES, V58, P4023; Iwamoto KS, 1996, CANCER RES, V56, P3862; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lassus P, 1999, ONCOGENE, V18, P4699, DOI 10.1038/sj.onc.1202841; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marston NJ, 1998, ONCOGENE, V16, P3123, DOI 10.1038/sj.onc.1201856; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Peled A, 1996, CANCER RES, V56, P2148; POWELL SN, 1995, CANCER RES, V55, P1643; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Selivanova G, 1998, SEMIN CANCER BIOL, V8, P369, DOI 10.1006/scbi.1998.0099; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sigal A, 2000, CANCER RES, V60, P6788; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Wolkowicz R, 1998, CANCER DETECT PREV, V22, P1, DOI 10.1046/j.1525-1500.1998.00003.x; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhao RB, 2000, GENE DEV, V14, P981; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	61	12	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4891	4898		10.1038/sj.onc.1204724	http://dx.doi.org/10.1038/sj.onc.1204724			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521201				2022-12-28	WOS:000170271800014
J	Berquin, IM; Dziubinski, ML; Nolan, GP; Ethier, SP				Berquin, IM; Dziubinski, ML; Nolan, GP; Ethier, SP			A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin	ONCOGENE			English	Article						EGF; EGFR; amphiregulin; breast cancer; autocrine growth factor	HUMAN-BREAST-CANCER; DIFFERENTIATION FACTOR HEREGULIN; FACTOR RECEPTOR; ESTROGEN-RECEPTOR; CARCINOMA CELLS; POOR RESPONSE; FACTOR-I; EXPRESSION; HORMONE; NEU	To gain better understanding of the molecular alterations responsible for the aggressive growth potential of epidermal growth factor receptor (EGFR)-positive breast cancers, we utilized an expression cloning strategy to seek gene products that mediate the EGF-independent growth of human breast cancer cells, A retroviral cDNA expression library was constructed from the EGFR-positive SUM-149PT cell line, and transduced into growth factor-dependent human mammary epithelial (HME) cells. Recipient cells were functionally selected for their ability to proliferate in serum-free, EGF-free medium. Library cDNAs were recovered from EGF-independent colonies by PCR amplification or by biological rescue. Clone H55a#1 contained a library insert encoding amphiregulin, This EGFR ligand,vas able to confer EGF independence when transduced into HME cells. SUM-149PT and H55a#1 cells overexpressed amphiregulin transcripts, and secreted moderate EGF-like activity in conditioned media, indicating a possible autocrine loop. EGFR membrane levels and constitutive phosphorylation were consistent with this hypothesis, as well as the sensitivity of the cells to an ErbB-specific kinase inhibitor. Expression of the WT1 Wilms' tumor suppressor gene, a transcriptional activator of amphiregulin, did not parallel amphiregulin transcript levels, suggesting that another factor regulates amphiregulin in SUM-149PT, Our data confirm the importance of amphiregulin in the etiology of breast cancer.	Univ Michigan, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	University of Michigan System; University of Michigan; Stanford University	Ethier, SP (corresponding author), 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	spethier@umich.edu	Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043	NCI NIH HHS [R01 CA77416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BATTAGLIA F, 1988, EUR J CANCER CLIN ON, V24, P1685, DOI 10.1016/0277-5379(88)90068-5; Brown P, 2000, CONT ENDOCRINOL, P49; Clarke RB, 1997, CANCER RES, V57, P4987; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; ETHIER SP, 1991, CELL GROWTH DIFFER, V2, P593; ETHIER SP, 1987, J CELL PHYSIOL, V132, P161, DOI 10.1002/jcp.1041320123; Ethier SP, 1996, MOL CARCINOGEN, V15, P134; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; ETHIER SP, 1990, CANCER RES, V50, P5351; ETHIER SP, 1991, BREAST CANCER RES TR, V17, P221, DOI 10.1007/BF01806371; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; HOLDAWAY IM, 1983, CANCER, V52, P479, DOI 10.1002/1097-0142(19830801)52:3<479::AID-CNCR2820520317>3.0.CO;2-O; Ignatoski KMW, 1999, BREAST CANCER RES TR, V54, P173, DOI 10.1023/A:1006135331912; Ignatoski KMW, 1999, ENDOCRINOLOGY, V140, P3615, DOI 10.1210/en.140.8.3615; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LEJEUNE S, 1993, CANCER RES, V53, P3597; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; NICHOLSON S, 1989, LANCET, V1, P182; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; NICHOLSON S, 1988, INT J CANCER, V42, P36, DOI 10.1002/ijc.2910420108; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; OSBORNE CK, 1985, SEMIN ONCOL, V12, P317; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pfeiffer JK, 1999, J VIROL, V73, P8441, DOI 10.1128/JVI.73.10.8441-8447.1999; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Salomon DS, 2000, CONT ENDOCRINOL, P137; SCHRANK R, 1994, HARVARD BUS REV, V72, P77; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Smaill JB, 2000, J MED CHEM, V43, P1380, DOI 10.1021/jm990482t; SOULE HD, 1990, CANCER RES, V50, P6075; Tannheimer SL, 2000, BREAST CANCER RES, V2, P311, DOI 10.1186/bcr73; TOI M, 1989, INT J CANCER, V43, P220, DOI 10.1002/ijc.2910430208; Visscher DW, 1997, BREAST CANCER RES TR, V45, P75, DOI 10.1023/A:1005845512804; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	53	33	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4019	4028		10.1038/sj.onc.1204537	http://dx.doi.org/10.1038/sj.onc.1204537			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494130				2022-12-28	WOS:000169681500010
J	Macaulay, VM; Salisbury, AJ; Bohula, EA; Playford, MP; Smorodinsky, NI; Shiloh, Y				Macaulay, VM; Salisbury, AJ; Bohula, EA; Playford, MP; Smorodinsky, NI; Shiloh, Y			Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase	ONCOGENE			English	Article						insulin-like growth factors; IGF receptor; Atm; melanoma; radiosensitivity	FACTOR-I RECEPTOR; BREAST-CANCER CELLS; HUMAN SQUAMOUS CARCINOMA; IONIZING-RADIATION; ATAXIA-TELANGIECTASIA; ANTISENSE RNA; MONOCLONAL-ANTIBODY; GAMMA-IRRADIATION; DNA-DAMAGE; P53	The type 1 insulin-like growth factor receptor (IGF1R) is required for growth, tumorigenicity and protection from apoptosis, IGF1R overexpression is associated with radioresistance in breast cancer. We used antisense (AS) RNA to downregulate IGF1R expression in mouse melanoma cells. Cells expressing AS-IGF1R transcripts were more radiosensitive in vitro and in vivo than controls. Also they showed reduced radiation-induced p53 accumulation and p53 serine 18 phosphorylation, and radioresistant DNA synthesis. These changes were reminiscent of the cellular phenotype of the human genetic disorder ataxia-telangiectasia (A-T), caused by mutations in the A TM gene. Cellular Atm protein levels mere lower in AS-IGF1R-transfected cells than in control cells, although there was no difference in Atm expression at,the transcriptional level. AS-IGF1R cells had detectable basal Atm kinase activity, but failed to induce kinase activity after irradiation. This suggests that IGF1R signalling can modulate the function of Atm, and supports the concept of targeted IGF1R downregulation as a potential treatment for malignant melanoma and other radioresistant tumours.	Weatherall Inst Mol Med, Mol Oncol Labs, IGF Grp, Oxford OX3 9DS, England; Tel Aviv Univ, George S Wise Fac Life Sci, Hybridoma Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel	University of Oxford; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Macaulay, VM (corresponding author), Weatherall Inst Mol Med, Mol Oncol Labs, IGF Grp, Oxford OX3 9DS, England.	macaulay@icrf.icnet.uk	Bohula, Erin/AAW-7276-2020		NINDS NIH HHS [R01 NS31763] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Dunn SE, 1997, CANCER RES, V57, P2687; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fan ZH, 2000, CANCER GENE THER, V7, P1307, DOI 10.1038/sj.cgt.0243; Fukao T, 1999, BLOOD, V94, P1998; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016/S0167-4889(00)00018-5; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Guha C, 2000, GENE THER, V7, P852, DOI 10.1038/sj.gt.3301174; Hartmann A, 1996, INT J CANCER, V67, P313, DOI 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U; HARTMANN KKP, 1992, J CELL BIOCHEM, V48, P81, DOI 10.1002/jcb.240480112; Huang SM, 1999, CANCER RES, V59, P1935; Jenrette JM, 1996, SEMIN ONCOL, V23, P759; JONES RF, 1994, MOL CARCINOGEN, V9, P95, DOI 10.1002/mc.2940090207; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KELLAND LR, 1989, INT J RADIAT BIOL, V55, P119, DOI 10.1080/09553008914550121; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kizilian N, 1999, BIOTECHNIQUES, V27, P926, DOI 10.2144/99275bm10; KOZAK RW, 1987, CELL IMMUNOL, V109, P318, DOI 10.1016/0008-8749(87)90315-7; KWOK TT, 1989, J NATL CANCER I, V81, P1020, DOI 10.1093/jnci/81.13.1020; LAVIN MF, 2000, NATURE CELL BIOL, V2, pE1; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Lee CT, 1996, CANCER RES, V56, P3038; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu XD, 1998, CANCER RES, V58, P5432; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nakamura S, 1997, EXP CELL RES, V235, P287, DOI 10.1006/excr.1997.3683; OLIVE PL, 1991, CANCER RES, V51, P4671; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pietras RJ, 1999, CANCER RES, V59, P1347; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Ramsay J, 1998, BRIT J CANCER, V77, P11, DOI 10.1038/bjc.1998.2; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; ROFSTAD EK, 1992, INT J RADIAT ONCOL, V23, P63, DOI 10.1016/0360-3016(92)90544-R; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Savitsky K, 1997, NUCLEIC ACIDS RES, V25, P1678, DOI 10.1093/nar/25.9.1678; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SHILOH Y, 2001, IN PRESS COLD SPRING, V65; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; Tsuboi K, 1997, Brain Tumor Pathol, V14, P19, DOI 10.1007/BF02478864; Turner BC, 1997, CANCER RES, V57, P3079; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wang H, 2000, ADV EXP MED BIOL, V465, P265; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Westphal CH, 1997, CANCER RES, V57, P1664; Whitesell L, 1999, METHODS, V18, P296, DOI 10.1006/meth.1999.0787; WOLLMAN R, 1994, INT J RADIAT ONCOL, V30, P91, DOI 10.1016/0360-3016(94)90523-1; Wouters BG, 1999, ONCOGENE, V18, P6540, DOI 10.1038/sj.onc.1203053; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhang LJ, 1999, J BIOL CHEM, V274, P13118, DOI 10.1074/jbc.274.19.13118; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	76	110	114	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4029	4040		10.1038/sj.onc.1204565	http://dx.doi.org/10.1038/sj.onc.1204565			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494131				2022-12-28	WOS:000169681500011
J	Yao, Z; Flash, I; Raviv, Z; Yung, Y; Asscher, YD; Pleban, S; Seger, R				Yao, Z; Flash, I; Raviv, Z; Yung, Y; Asscher, YD; Pleban, S; Seger, R			Non-regulated and stimulated mechanisms cooperate in the nuclear accumulation of MEK1	ONCOGENE			English	Article						MAPK; MEK; leptomycin B; nuclear translocation	ACTIVATED PROTEIN-KINASE; MAP KINASE; EXPORT SIGNAL; TRANSPORT; ERK; LOCALIZATION; CELLS; PHOSPHORYLATION; TRANSLOCATION; TRANSDUCTION	MEKs, which operate within the ERK cascade, shuttle into the nucleus, but are rapidly exported from this location, forming an apparent cytosolic distribution both before and after stimulation. Two different mechanisms have been proposed for the nuclear translocation of MEKs. One of them involves a constant and nonregulated shuttling of MEKs into the nucleus operating both before and after mitogenic stimulation. The other mechanism seems to require the activity of MEKs and is facilitated in response to mitogenic stimulation. Here we show that these two mechanisms may coexist in the same cells. We found that leptomycin B (LMB), a potent inhibitor of nuclear export, induces a nuclear accumulation of MEKs, and this was significantly facilitated by stimulation of LMB-treated cells with EGF, TPA and peroxovanadate. The EGF-stimulated, but not the LMB-induced translocation was attenuated by MEK inhibitors and by using inactive forms of MEK1. We also show that LMB slightly activates the ERK cascade, but this activity only partially induces the nuclear accumulation of MEKs in cells treated by LMB alone. Thus, MEKs translocate into the nucleus by a combination of nonregulated and stimulated processes that contribute to the nuclear translocation of MEKs either in resting cells or upon mitogenic stimulation.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Sigma Aldrich Israel Ltd, Jerusalem, Israel	Weizmann Institute of Science; Merck KGaA; MilliporeSigma	Seger, R (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.							Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Akey C W, 1991, Semin Cell Biol, V2, P167; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Yung Y, 2001, J BIOL CHEM, V276, P35280, DOI 10.1074/jbc.M105995200; Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	27	37	39	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7588	7596		10.1038/sj.onc.1204963	http://dx.doi.org/10.1038/sj.onc.1204963			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753637				2022-12-28	WOS:000172124100002
J	Banerji, L; Glassford, J; Lea, NC; Thomas, NSB; Klaus, GGB; Lam, EWF				Banerji, L; Glassford, J; Lea, NC; Thomas, NSB; Klaus, GGB; Lam, EWF			BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells	ONCOGENE			English	Article						cyclin D2; p27(Kip1); proliferation; apoptosis; WEHI 231; PI3-K	ANTIGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; DEPENDENT KINASE; LYMPHOMA-CELLS; G(1) CYCLIN; IN-VITRO; ACTIVATION	Cross-linking of the B cell antigen receptor (BCR) on immature WEHI 231 B cells results in GI cell cycle arrest and apoptosis. Here we investigated the, molecular mechanisms that are necessary and sufficient for these changes to occur., We show that BCR stimulation of WEHI 231 cells results in down-regulation of cyclin D2 and up-regulation of p27(Kip1), which are associated with pocket protein hypophosphorylation and E2F inactivation. Ectopic expression of p27(Kip1) by TAT-fusion protein or retroviral transduction is sufficient to cause G1 cell cycle arrest, followed by apoptosis. In contrast, overt expression of cyclin D2 overcomes, the cell cycle arrest and apoptosis induced by anti-IgM, indicating that downregulation of cyclin D2 is necessary for the cell cycle arrest and apoptosis activated by BCR stimulation. Thus, cyclin D2 and p27(Kip1) have opposing roles in these pathways and our data also suggest that cyclin D2 functions upstream of p27(Kip1) and the pRB pathway and therefore plays an essential part in integrating the signals from BCR with the cell cycle machinery. We next investigated which signal transduction pathways triggered by the BCR regulate cell proliferation and apoptosis. via cyclin D2 and p27(Kip1). Inhibition of PI3-K signalling by LY294002 down-regulated cyclin D2 and up-regulated p27(Kip1) expression at both, protein and RNA levels, mimicking the effects of BCR-stimulation. Furthermore, ectopic expression of a constitutively active form of AKT blocked the cell cycle arrest and apoptosis triggered by anti-IgM and also, abrogated downregulation of cyclin D2 and up-regulation of p27(Kip1) expression induced by BCR-engagement. These results indicate that BCR activation targets: p27(Kip1) and cyclin D2 to mediate cell cycle arrest and apoptosis and that down-regulation of PI3-K/AKT activity post BCR stimulation is necessary for these to occur.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, CRC,Lab Canc Cell Biol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, CRC,Sect Canc Cell Biol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London W2 1PG, England; Guys Kings St Thomas Sch Med, Rayne Inst, Dept Haematol, London, England; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England	Imperial College London; Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of London; King's College London; MRC National Institute for Medical Research	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, CRC,Lab Canc Cell Biol, Du Cane Rd, London W12 0NN, England.	eric.lam@ic.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576				AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Birkeland ML, 1997, CRIT REV IMMUNOL, V17, P353, DOI 10.1615/CritRevImmunol.v17.i3-4.50; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Carey GB, 2001, J IMMUNOL, V166, P1618, DOI 10.4049/jimmunol.166.3.1618; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Craxton A, 2000, CELL IMMUNOL, V200, P56, DOI 10.1006/cimm.2000.1616; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Donjerkovic D, 1999, CELL GROWTH DIFFER, V10, P695; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GOLD MR, 1994, J IMMUNOL, V152, P42; Gold MR, 1999, J IMMUNOL, V163, P1894; Gold MR, 2000, IMMUNOL REV, V176, P47; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Klaus G G, 1997, Int Rev Immunol, V15, P5, DOI 10.3109/08830189709068169; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Kuwahara K, 1996, INT IMMUNOL, V8, P1273, DOI 10.1093/intimm/8.8.1273; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li HL, 1999, P NATL ACAD SCI USA, V96, P6890, DOI 10.1073/pnas.96.12.6890; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Monroe JG, 2000, CURR TOP MICROBIOL, V245, P1; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Padmore L, 1997, CELL IMMUNOL, V177, P119, DOI 10.1006/cimm.1997.1102; PARADA Y, 2001, J BIOL CHEM, V25, P25; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sakata A, 1999, IMMUNOL LETT, V68, P301, DOI 10.1016/S0165-2478(99)00053-X; Sakata N, 1999, EUR J IMMUNOL, V29, P2999, DOI 10.1002/(SICI)1521-4141(199909)29:09<2999::AID-IMMU2999>3.0.CO;2-L; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wu M, 1999, J IMMUNOL, V163, P6530	62	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7352	7367		10.1038/sj.onc.1204951	http://dx.doi.org/10.1038/sj.onc.1204951			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704865				2022-12-28	WOS:000171894200008
J	Benoit, G; Roussel, M; Pendino, F; Segal-Bendirdjian, E; Lanotte, M				Benoit, G; Roussel, M; Pendino, F; Segal-Bendirdjian, E; Lanotte, M			Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation	ONCOGENE			English	Review						APL; maturation; cell death; ATRA; cyclic AMP; 'rexinoids'; RXR signaling; cross-talk	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; PML-RAR-ALPHA; COLONY-STIMULATING FACTOR; ARSENIC TRIOXIDE AS2O3; ACUTE MYELOID-LEUKEMIA; ONCOGENIC TRANSCRIPTION FACTORS; LEUKOCYTE ALKALINE-PHOSPHATASE; BONE-MARROW TRANSPLANTATION; POLYMERASE CHAIN-REACTION	Despite intensive molecular biology investigations over the past 10 years, and an important breakthrough on how PML-RAR alpha, the fusion protein resulting from t(15;17), can alter RAR alpha and PML functions, no definitive views on how leukemia is generated and by what mechanism(s) the normal phenotype is restored, are yet available. 'Resistances' to pharmacological levels of all-traps-retinoic acid (ATRA) have been observed in experimental in vivo and in vitro models. In this review, we emphasize the key role played by signal cross-talk for both normal and neoplastic hemopoiesis. After an overview of reported experimental data on APL-cell maturation and apoptosis, we apply our current knowledge on signaling pathways to underline those which might generate signal cross-talks. The design of biological models suitable to decipher the integration of signal cross-talks at the transcriptional level should be our first priority today, to generate some realistic therapeutic approaches After 'Ten Years of Molecular APL', we still know very little about how the disease develops and how effective medicines work.	Hop St Louis, Ctr G Hayem, INSERM U 496, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lanotte, M (corresponding author), Hop St Louis, Ctr G Hayem, INSERM U 496, 1 Ave Claude Vellefaux, F-75010 Paris, France.	mlanotte@chu-stlouis.fr	PENDINO, Frederic/G-6630-2017	Segal-Bendirdjian, Evelyne/0000-0001-9813-4880; BENOIT, Gerard/0000-0001-9462-6570				ADAMS JM, 1992, CANCER SURV, V15, P119; AHN MJ, 1995, ONCOGENE, V10, P2307; Albanell J, 1996, CANCER RES, V56, P1503; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; Allouche Michele, 1995, Progress in Growth Factor Research, V6, P35, DOI 10.1016/0955-2235(95)00041-0; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Benoit GR, 2001, MOL ENDOCRINOL, V15, P1154, DOI 10.1210/me.15.7.1154; Bergstrom SK, 1998, J PEDIAT HEMATOL ONC, V20, P545, DOI 10.1097/00043426-199811000-00006; Berry DM, 1999, ENDOCRINOLOGY, V140, P4779, DOI 10.1210/en.140.10.4779; BHATIA M, 1994, LEUKEMIA, V8, P1744; Bhatia M, 1996, EXP CELL RES, V222, P61, DOI 10.1006/excr.1996.0008; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; BOLLAG W, 1994, J CELL BIOCHEM, V56, P427, DOI 10.1002/jcb.240560402; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Breitschopf K, 2001, FEBS LETT, V493, P21, DOI 10.1016/S0014-5793(01)02272-4; Brendel C, 2000, LEUKEMIA, V14, P1711, DOI 10.1038/sj.leu.2401907; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Brown DC, 1999, BRIT J HAEMATOL, V107, P86, DOI 10.1046/j.1365-2141.1999.01671.x; BUDEL LM, 1993, J BIOL CHEM, V268, P10154; BURGER C, 1994, J CELL SCI, V107, P2047; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; Classon M, 2000, SEMIN CANCER BIOL, V10, P393, DOI 10.1006/scbi.2000.0338; COREY SJ, 1994, LEUKEMIA, V8, P1350; Crans HN, 2001, LEUKEMIA, V15, P313, DOI 10.1038/sj.leu.2402033; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DALTON WT, 1988, BLOOD, V71, P242; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dexter T M, 1984, Prog Clin Biol Res, V148, P13; Douer D, 2000, LEUKEMIA, V14, P874, DOI 10.1038/sj.leu.2401772; DUBOIS C, 1994, LEUKEMIA, V8, P1750; DUBOIS C, 1994, BLOOD, V83, P3264; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Duprez E, 1996, ONCOGENE, V12, P2451; DUPREZ E, 1992, LEUKEMIA, V6, P1281; Edwards RH, 1999, AM J CLIN PATHOL, V112, P819; El Marjou M, 2000, LEUKEMIA, V14, P2118; Elstner E, 1997, J CLIN INVEST, V99, P349, DOI 10.1172/JCI119164; Fenaux P, 1997, SEMIN ONCOL, V24, P92; Fenaux P, 2000, LEUKEMIA, V14, P1371, DOI 10.1038/sj.leu.2401859; Fenaux P, 2001, SEMIN HEMATOL, V38, P13, DOI 10.1053/shem.2001.20862; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ferrero D, 2001, LEUKEMIA, V15, P422, DOI 10.1038/sj.leu.2402038; FONTANA JA, 1987, J NATL CANCER I, V78, P1107; GABERT J, 1989, LANCET, V2, P1125; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; GALLAGHER R, 1979, BLOOD, V54, P713; GALLAGHER RE, 1987, LEUKEMIA RES, V11, P609, DOI 10.1016/0145-2126(87)90033-6; Garattini E, 1998, LEUKEMIA LYMPHOMA, V30, P467, DOI 10.3109/10428199809057559; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; GIANNI M, 1994, BLOOD, V83, P1909; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grolleau A, 2000, LEUKEMIA, V14, P1909, DOI 10.1038/sj.leu.2401904; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Hida T, 2001, JPN J PHARMACOL, V85, P60, DOI 10.1254/jjp.85.60; HOHMANN P, 1989, INT J CANCER, V43, P863, DOI 10.1002/ijc.2910430521; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Hsu HC, 1999, EUR J HAEMATOL, V63, P11; HSU HC, 1993, LEUKEMIA, V7, P458; HSU HC, 1996, CHUNG HUA I HSUEH TS, V57, P93; HU ZB, 1993, LEUKEMIA, V7, P1817; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Idres N, 2001, CANCER RES, V61, P700; Introna M, 1999, LEUKEMIA, V13, P1301, DOI 10.1038/sj.leu.2401492; Ismair MG, 1998, LEUKEMIA, V12, P1136, DOI 10.1038/sj.leu.2401042; James SY, 1999, GEN PHARMACOL, V32, P143, DOI 10.1016/S0306-3623(98)00098-6; Jansen JH, 2001, SEMIN HEMATOL, V38, P37, DOI 10.1053/shem.2001.20864; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Katayama N, 1998, AM J HEMATOL, V58, P31, DOI 10.1002/(SICI)1096-8652(199805)58:1<31::AID-AJH6>3.0.CO;2-1; KHANNAGUPTA A, 1994, BLOOD, V84, P294; KHAZAIE K, 1994, P NATL ACAD SCI USA, V91, P7430, DOI 10.1073/pnas.91.16.7430; Kihara H, 1998, INT J ONCOL, V12, P629; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; KLEIN G, 1995, EXPERIENTIA, V51, P914, DOI 10.1007/BF01921741; Ko BS, 1999, LEUKEMIA, V13, P1406, DOI 10.1038/sj.leu.2401495; Kogan SC, 1999, ONCOGENE, V18, P5261, DOI 10.1038/sj.onc.1202996; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kosugi H, 1999, LEUKEMIA, V13, P1316, DOI 10.1038/sj.leu.2401508; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LANOTTE M, 1991, BLOOD, V77, P1080; LAZZARINO M, 1995, BRIT J HAEMATOL, V90, P928, DOI 10.1111/j.1365-2141.1995.tb05217.x; Lee HY, 1999, MOL CELL BIOL, V19, P1973; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Marchetti M, 1996, BRIT J HAEMATOL, V93, P360, DOI 10.1046/j.1365-2141.1996.4911029.x; Marill J, 2000, MOL PHARMACOL, V58, P1341, DOI 10.1124/mol.58.6.1341; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MARTINTHOUVENIN V, 1992, J CELL PHYSIOL, V153, P95, DOI 10.1002/jcp.1041530113; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; MATIKAINEN S, 1994, CELL GROWTH DIFFER, V5, P975; Matikainen S, 1996, BLOOD, V88, P114; Mayani H, 1996, LEUKEMIA, V10, P1041; MCCANN SR, 1994, LEUKEMIA, V8, pS133; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Miura D, 1999, FEBS LETT, V460, P297, DOI 10.1016/S0014-5793(99)01347-2; Moqattash S, 1998, P SOC EXP BIOL MED, V219, P8; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Nakamura M, 2001, J CELL PHYSIOL, V187, P392, DOI 10.1002/jcp.1087; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; NasonBurchenal K, 1997, DIFFERENTIATION, V61, P321, DOI 10.1046/j.1432-0436.1997.6150321.x; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NUCIFORA G, 1994, LEUKEMIA LYMPHOMA, V14, P353, DOI 10.3109/10428199409049690; Ohsawa M, 2000, LEUKEMIA, V14, P941, DOI 10.1038/sj.leu.2401755; OLSSON IL, 1982, CANCER RES, V42, P3928; Omay SB, 1996, BLOOD, V87, P2947, DOI 10.1182/blood.V87.7.2947.bloodjournal8772947; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; PAUL CC, 1995, BLOOD, V86, P3737, DOI 10.1182/blood.V86.10.3737.bloodjournal86103737; Paulson R F, 1995, Semin Immunol, V7, P267, DOI 10.1006/smim.1995.0031; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Peschel C, 1996, LEUKEMIA LYMPHOMA, V22, P129, DOI 10.3109/10428199609074370; Prosper F, 2001, J LEUKOCYTE BIOL, V69, P307; Quenech'Du N, 1998, LEUKEMIA, V12, P1829, DOI 10.1038/sj.leu.2401171; Radich J P, 1999, Rev Immunogenet, V1, P265; Redner RL, 1997, LEUKEMIA, V11, P1014, DOI 10.1038/sj.leu.2400661; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Rosenfeld C, 2000, LEUKEMIA, V14, P2, DOI 10.1038/sj.leu.2401618; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Savickiene J, 1997, ANTICANCER RES, V17, P285; Scheele JS, 2000, CELL MOL LIFE SCI, V57, P1950, DOI 10.1007/PL00000675; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SMELAND EB, 1994, BLOOD, V84, P2940, DOI 10.1182/blood.V84.9.2940.bloodjournal8492940; So CW, 2000, LEUKEMIA, V14, P77, DOI 10.1038/sj.leu.2401643; Song XD, 1999, LEUKEMIA, V13, P275, DOI 10.1038/sj.leu.2401261; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; STONE R M, 1992, Current Opinion in Oncology, V4, P33, DOI 10.1097/00001622-199202000-00006; Stone RM, 1997, LEUKEMIA RES, V21, P399, DOI 10.1016/S0145-2126(96)00123-3; STONE RM, 1988, BLOOD, V72, P208; STONE RM, 1988, BLOOD, V71, P690; TALPAZ M, 1994, J CLIN INVEST, V94, P1383, DOI 10.1172/JCI117473; TESTA NG, 1989, ENVIRON HEALTH PERSP, V82, P51, DOI 10.2307/3430761; TESTA U, 1994, CANCER RES, V54, P4508; Thomas X, 2000, LEUKEMIA, V14, P1006, DOI 10.1038/sj.leu.2401800; TKATCH LS, 1995, J LEUKOCYTE BIOL, V57, P964, DOI 10.1002/jlb.57.6.964; Toba K, 1998, EXP HEMATOL, V26, P135; Torok-Storb B, 1999, ANN NY ACAD SCI, V872, P164, DOI 10.1111/j.1749-6632.1999.tb08461.x; Touhami M, 1999, BRIT J HAEMATOL, V104, P706, DOI 10.1046/j.1365-2141.1999.01235.x; Truran L, 1998, LEUKEMIA RES, V22, P241, DOI 10.1016/S0145-2126(97)00179-3; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Verbeek W, 2001, LEUKEMIA, V15, P103, DOI 10.1038/sj.leu.2401995; Vereecque R, 2000, GENE THER, V7, P1312, DOI 10.1038/sj.gt.3301228; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Wells RA, 1996, LEUKEMIA, V10, P735; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Wiernik PH, 1996, CANCER, V78, P2510, DOI 10.1002/(SICI)1097-0142(19961215)78:12<2510::AID-CNCR10>3.0.CO;2-Z; WOLBACH SB, 1978, NUTR REV, V36, P16; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Zang CB, 2000, J CANCER RES CLIN, V126, P33, DOI 10.1007/PL00008462; ZIPORI D, 1990, CANCER CELL-MON REV, V2, P205	196	32	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7161	7177		10.1038/sj.onc.1204760	http://dx.doi.org/10.1038/sj.onc.1204760			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704845				2022-12-28	WOS:000171891900005
J	Zhang, TD; Chen, GQ; Wang, ZG; Wang, ZY; Chen, SJ; Chen, Z				Zhang, TD; Chen, GQ; Wang, ZG; Wang, ZY; Chen, SJ; Chen, Z			Arsenic trioxide, a therapeutic agent for APL	ONCOGENE			English	Article						arsenic trioxide (AS(2)O(3)); acute promyelocytic leukemia (APL); apoptosis; differentiation; PML-RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; PML/RAR-ALPHA PROTEIN; PML-RAR-ALPHA; IN-VITRO; MEDIATED APOPTOSIS; GROWTH-INHIBITION; CLINICAL-EFFICACY; CELL APOPTOSIS; RESISTANT	Acute promyelocytic leukemia (APL) is an interesting model in cancer research, because it can respond to the differentiation/apoptosis induction therapy using all-traps retinoic acid (ATRA) and arsenic trioxide (As2O3). Over the past 5 years, it has been well demonstrated that As2O3 induces a high complete remission (CR) rate in both primary and relapsed APL patients (around 85 similar to 90%). The side effects are mild to moderate in relapsed patients, while severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As2O3 as post-remission therapy has given better survival than those treated with As2O3 alone. The effect of As2O3 has been shown to be related to the expression of APL-specific PML-RAR alpha oncoprotein, and there is a synergistic effect between As2O3 and ATRA in an APL mouse model. Cell biology studies have revealed that As2O3 exerts dose-dependent dual effects on APL cells. Apoptosis is evident when cells are treated with 0.5 similar to2.0 muM of As2O3 while partial differentiation is observed using low concentrations (0.1 similar to0.5 muM) of the drug. The apoptosis-inducing effect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the mechanisms underlying APL cell differentiation induced by low dose arsenic remain to be explored. Interestingly, As2O3 over a wide range of concentration (0.1 similar to2.0 mum) induces degradation of a key leukemogenic protein, PML-RAR alpha, as well as the wild-type PML, thus setting up a good example of targeting therapy for human cancers.	Shanghai Med Univ 2, Rui Jin Hosp, Shanghai Inst Hematol, Shanghai 200025, Peoples R China; Harbin Med Univ, Hosp 1, Harbin 150001, Peoples R China	Shanghai Jiao Tong University; Harbin Medical University	Chen, Z (corresponding author), Shanghai Med Univ 2, Rui Jin Hosp, Shanghai Inst Hematol, 194 Rui Jin Rd II, Shanghai 200025, Peoples R China.	zchen@ms.stn.sh.cn		chen, guo qiang/0000-0003-4936-2363				Agis H, 1999, ANN HEMATOL, V78, P329, DOI 10.1007/s002770050523; Akao Y, 1999, FEBS LETT, V455, P59, DOI 10.1016/S0014-5793(99)00841-8; Andre C, 1996, EXP CELL RES, V229, P253, DOI 10.1006/excr.1996.0368; Barbui T, 1998, BLOOD, V91, P3093, DOI 10.1182/blood.V91.9.3093.3093_3093_3102; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Camacho LH, 2000, J CLIN ONCOL, V18, P2620, DOI 10.1200/JCO.2000.18.13.2620; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Chen Z, 2001, SEMIN HEMATOL, V38, P26, DOI 10.1053/shem.2001.20863; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Cohen MH, 2001, ONCOLOGIST, V6, P4, DOI 10.1634/theoncologist.6-1-4; Conrad ME, 1999, NEW ENGL J MED, V340, P1043; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Deaglio S, 2001, LEUKEMIA RES, V25, P227, DOI 10.1016/S0145-2126(00)00105-3; Galimberti S, 1999, BONE MARROW TRANSPL, V24, P345, DOI 10.1038/sj.bmt.1701875; Gallagher RE, 1998, NEW ENGL J MED, V339, P1389, DOI 10.1056/NEJM199811053391909; Gianni M, 1999, LEUKEMIA, V13, P739, DOI 10.1038/sj.leu.2401419; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Huang CH, 1999, PACE, V22, P965, DOI 10.1111/j.1540-8159.1999.tb06826.x; Huang CS, 1999, CANCER RES, V59, P3053; Huang SC, 2000, BIOCHEM PHARMACOL, V60, P771, DOI 10.1016/S0006-2952(00)00397-X; Huang SY, 1998, BRIT J HAEMATOL, V103, P1092, DOI 10.1046/j.1365-2141.1998.01079.x; Huff J, 2000, TOXICOL SCI, V55, P17, DOI 10.1093/toxsci/55.1.17; Jiang XH, 2001, INT J CANCER, V91, P173, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1039>3.0.CO;2-D; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Kinjo K, 2000, LEUKEMIA, V14, P431, DOI 10.1038/sj.leu.2401646; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Kitamura K, 1997, INT J HEMATOL, V65, P179; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kwong YL, 1997, BLOOD, V89, P3487, DOI 10.1182/blood.V89.9.3487; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Li YM, 1999, CANCER RES, V59, P776; Lin CP, 2000, LEUKEMIA LYMPHOMA, V38, P191, DOI 10.3109/10428190009060333; Lin CP, 2000, LEUKEMIA LYMPHOMA, V38, P195, DOI 10.3109/10428190009060334; Look AT, 1998, J NATL CANCER I, V90, P86, DOI 10.1093/jnci/90.2.86; McCabe MJ, 2000, J PHARMACOL EXP THER, V295, P724; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mervis J, 1996, SCIENCE, V273, P578, DOI 10.1126/science.273.5275.578; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Ohnishi K, 2000, ANN INTERN MED, V133, P881, DOI 10.7326/0003-4819-133-11-200012050-00012; Ohsawa M, 2000, LEUKEMIA, V14, P941, DOI 10.1038/sj.leu.2401755; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Roboz GJ, 2000, BLOOD, V96, P1525, DOI 10.1182/blood.V96.4.1525.h8001525_1525_1530; Seol JG, 2001, INT J ONCOL, V18, P249; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen Y, 2001, LEUKEMIA, V15, P735, DOI 10.1038/sj.leu.2402106; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shen ZY, 1999, INT J MOL MED, V4, P33; Slack JL, 2000, ANN HEMATOL, V79, P227, DOI 10.1007/s002770050585; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Tallman MS, 1999, SEMIN THROMB HEMOST, V25, P209, DOI 10.1055/s-2007-994922; Tamm I, 1999, NEW ENGL J MED, V340, P1043; Uslu R, 2000, CLIN CANCER RES, V6, P4957; Wang Z Y, 2000, Lancet Oncol, V1, P101, DOI 10.1016/S1470-2045(00)00017-6; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Warrell R P Jr, 1999, Haematologica, V84 Suppl EHA-4, P75; ZHANG P, 1996, CHIN J HEMATOL, V17, P58; Zhang T, 2000, MODERN PATHOL, V13, P954, DOI 10.1038/modpathol.3880174; Zhang W, 1998, LEUKEMIA, V12, P1383, DOI 10.1038/sj.leu.2401112; Zhu J, 1999, LEUKEMIA, V13, P1062, DOI 10.1038/sj.leu.2401448; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	73	181	201	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7146	7153		10.1038/sj.onc.1204762	http://dx.doi.org/10.1038/sj.onc.1204762			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704843				2022-12-28	WOS:000171891900003
J	Zhu, J; Lallemand-Breitenbach, V; de The, H				Zhu, J; Lallemand-Breitenbach, V; de The, H			Pathways of retinoic acid- or arsenic trioxide-induced PML/RAR alpha catabolism, role of oncogene degradation in disease remission	ONCOGENE			English	Article						proteasome; clinical trials; SUMO; nuclear bodies; differentiation; apoptosis	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; UBIQUITIN-PROTEASOME PATHWAY; I-TRANSFORMED-CELLS; RECEPTOR-ALPHA; FUSION PROTEIN; HISTONE DEACETYLASE; INDUCED APOPTOSIS; NUCLEAR-BODIES; NB4 CELLS	Although there is evidence to suggest that PML/RAR alpha expression is not the sole genetic event required for the development of acute promyelocytic leukemia (APL), there is little doubt that the fusion protein plays a central role in the initiation of leukemogenesis. The two therapeutic agents, retinoic acid and arsenic, that induce clinical remissions in APL, both target the oncogenic fusion protein, representing the first example of oncogene-directed cancer therapy. This review focuses on the molecular mechanisms accounting for PML/RAR alpha degradation. Each drug targets a specific moiety of the fusion protein (RAR alpha for retinoic acid, PML for arsenic) to the proteasome. Moreover, both activate a common caspase-dependent cleavage in the PML part of the fusion protein. Specific molecular determinants (the AF2 transactivator domain of RAR alpha for retinoic acid and the K160 SUMO-binding site in PML for arsenic) are respectively implicated in RA- or arsenic-triggered catabolism. The respective roles of PML/RAR alpha activation versus its catabolism are discussed with respect to differentiation or apoptosis induction in the context of single or dual therapies.	Univ Paris 07, Hop St Louis, Lab Assoc Comite Paris Ligue Francaise Contre Can, CNRS UPR 9051, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	de The, H (corresponding author), Univ Paris 07, Hop St Louis, Lab Assoc Comite Paris Ligue Francaise Contre Can, CNRS UPR 9051, 1 Av C Vellefaux, F-75475 Paris 10, France.	dethe@chu-stlouis.fr		Lallemand, Valerie/0000-0001-9852-204X				Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; DANIEL MT, 1993, BLOOD, V82, P1858; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Duprez E, 1996, ONCOGENE, V12, P2451; Duprez E, 1996, ONCOGENE, V12, P2443; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; El-Sabban ME, 2000, BLOOD, V96, P2849; Everett RD, 1998, EMBO J, V17, P7161, DOI 10.1093/emboj/17.24.7161; Everett RD, 1999, J CELL SCI, V112, P4581; Fabunmi RP, 2001, J CELL SCI, V114, P29; Ferbeyre G, 2000, GENE DEV, V14, P2015; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; Hamadeh HK, 1999, BIOCHEM BIOPH RES CO, V263, P446, DOI 10.1006/bbrc.1999.1395; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; Kinjo K, 2000, LEUKEMIA, V14, P431, DOI 10.1038/sj.leu.2401646; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Minami Y, 2000, J BIOL CHEM, V275, P9055, DOI 10.1074/jbc.275.12.9055; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NERVI C, 1992, CANCER RES, V52, P3687; Nervi C, 1998, BLOOD, V92, P2244; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Perletti L, 2001, BMC Mol Biol, V2, P4, DOI 10.1186/1471-2199-2-4; Puccetti E, 2000, CANCER RES, V60, P3409; Quenech'Du N, 1998, LEUKEMIA, V12, P1829, DOI 10.1038/sj.leu.2401171; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Quignon F, 1997, BBA-REV CANCER, V1333, pM53, DOI 10.1016/S0304-419X(97)00025-5; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Slack JL, 1998, BLOOD, V91, P3347, DOI 10.1182/blood.V91.9.3347.3347_3347_3356; Stadler M, 1995, ONCOGENE, V11, P2565; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stitzel ML, 2001, GENE DEV, V15, P128, DOI 10.1101/gad.863801; Testa U, 1998, J CLIN INVEST, V101, P2278, DOI 10.1172/JCI1332; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yih LH, 2000, CANCER RES, V60, P6346; Yoshida H, 1996, CANCER RES, V56, P2945; Zheng J, 1999, INT J CANCER, V82, P286, DOI 10.1002/(SICI)1097-0215(19990719)82:2<286::AID-IJC21>3.0.CO;2-K; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	84	134	144	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7257	7265		10.1038/sj.onc.1204852	http://dx.doi.org/10.1038/sj.onc.1204852			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704854				2022-12-28	WOS:000171891900014
J	Tonin, PN; Hudson, TJ; Rodier, F; Bossolasco, M; Lee, PD; Novak, J; Manderson, EN; Provencher, D; Mes-Masson, AM				Tonin, PN; Hudson, TJ; Rodier, F; Bossolasco, M; Lee, PD; Novak, J; Manderson, EN; Provencher, D; Mes-Masson, AM			Microarray analysis of gene expression mirrors the biology of an ovarian cancer model	ONCOGENE			English	Article						epithelial ovarian cancer; cell model; high-density microarray analysis; RNA expression analysis; signature patterns	CARCINOMA CELL-LINE; MOLECULAR CLASSIFICATION; MESSENGER-RNA; ESTABLISHMENT; ADENOCARCINOMA; PATTERNS; EPITHELIUM; SURVIVAL; ASCITES; PROTEIN	We have previously described an ovarian cancer model based on four independent spontaneously immortalized epithelial ovarian cancer cell lines (TOV-21G, TOV-81D, TOV-112D and OV-90) from patients who were never exposed to chemotherapy or radiation therapy. These cell lines are particularly interesting since they retain characteristics of the original epithelial ovarian cancers (EOC) from which they were derived. Here we report the characterization of this model system using high-density DNA microarrays in order to assess gene expression. Expression profiles were generated from total RNAs extracted from the four EOC cell lines. For comparison, expression profiling is also provided for a primary culture of normal ovarian surface epithelium (NOV-31) and a fresh EOC sample (TOV-578G). Comparison of expression profiles revealed patterns of expression that distinguish NOV-31 from that of all tumor derived samples. The expression pattern of Tov-81D, an EOC cell line that was derived from a patient with indolent disease, most closely resembles NOV-31 while profiles of samples derived from patients with more aggressive disease (TOV-21G, OV-90, TOV-112D and TOV-578G) showed more divergent patterns of expression. The microarray analysis (http://genome.mcgill.ca) results confirm the usefulness of an ovarian cancer model based on the characterization of these EOC cell lines.	McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3G 1A4, Canada; McGill Univ, Ctr Hlth, Montreal Genome Ctr, Montreal, PQ H3G 1A4, Canada; MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02139 USA; Univ Montreal, Ctr Hosp, Ctr Rech, Hop Notre Dame, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	McGill University; McGill University; McGill University; McGill University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Mes-Masson, AM (corresponding author), CHUM, ICM, Ctr Rech, 1560 Rue Sherbrooke E, Montreal, PQ H2L 4M1, Canada.	Anne-Marie.Mes-Masson@umontreal.ca		Mes-Masson, Anne-Marie/0000-0002-6498-266X; Rodier, Francis/0000-0003-2523-309X				Alama A, 1996, GYNECOL ONCOL, V62, P82, DOI 10.1006/gyno.1996.0194; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Anttila MA, 1999, BRIT J CANCER, V79, P1870, DOI 10.1038/sj.bjc.6690298; Asschert JGW, 1997, EUR J CANCER, V33, P2246, DOI 10.1016/S0959-8049(97)00240-2; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Barboule N, 1998, INT J CANCER, V76, P891, DOI 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Brown TJ, 1999, GYNECOL ONCOL, V75, P25, DOI 10.1006/gyno.1999.5552; BUICK RN, 1985, CANCER RES, V45, P3668; BULLER RE, 1995, GYNECOL ONCOL, V56, P39, DOI 10.1006/gyno.1995.1007; Chambers SK, 1998, INT J CANCER, V79, P449; Courjal F, 1996, INT J CANCER, V69, P247; CRICKARD K, 1989, GYNECOL ONCOL, V32, P163, DOI 10.1016/S0090-8258(89)80028-9; DISAIA P J, 1975, Gynecologic Oncology, V3, P215, DOI 10.1016/S0090-8258(75)80006-0; Fogh J, 1975, NEW HUMAN TUMOR CELL; GOLOMBICK T, 1991, EUR J CELL BIOL, V56, P459; GOLOMBICK T, 1990, IN VITRO CELL DEV B, V26, P447; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRUNT TW, 1993, DIFFERENTIATION, V53, P45, DOI 10.1111/j.1432-0436.1993.tb00644.x; HAMILTON TC, 1983, CANCER RES, V43, P5379; HIRTE HW, 1994, CANCER, V74, P900, DOI 10.1002/1097-0142(19940801)74:3<900::AID-CNCR2820740317>3.0.CO;2-N; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Huleihel M, 1997, EUR CYTOKINE NETW, V8, P179; KRUK PA, 1990, LAB INVEST, V63, P132; LANGDON SP, 1988, CANCER RES, V48, P6166; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mok SC, 1996, ONCOGENE, V12, P1895; Neyns B, 1996, ONCOGENE, V12, P1247; Ono K, 2000, CANCER RES, V60, P5007; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; PROVENCHER DM, 1993, GYNECOL ONCOL, V50, P78, DOI 10.1006/gyno.1993.1167; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SINNA GA, 1979, GYNECOL ONCOL, V7, P267, DOI 10.1016/0090-8258(79)90104-5; St Croix B, 2000, SCIENCE, V289, P1197; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tanner B, 1998, INT J GYNECOL PATHOL, V17, P66, DOI 10.1097/00004347-199801000-00012; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; WONG WSF, 1990, GYNECOL ONCOL, V38, P37, DOI 10.1016/0090-8258(90)90008-9; WOODS LK, 1979, CANCER RES, V39, P4449; WYSOCKI SJ, 1990, CANCER RES, V50, P1800; YAMADA T, 1991, GYNECOL ONCOL, V40, P118, DOI 10.1016/0090-8258(91)90102-B	47	61	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6617	6626		10.1038/sj.onc.1204804	http://dx.doi.org/10.1038/sj.onc.1204804			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641787				2022-12-28	WOS:000171404200015
J	Bradley, JR; Pober, JS				Bradley, JR; Pober, JS			Tumor necrosis factor receptor-associated factors (TRAFs)	ONCOGENE			English	Review						tumor necrosis factor (TNF); TRAF; interleukin-1; receptor; signaling	NF-KAPPA-B; INFECTION MEMBRANE-PROTEIN; LYMPHOTOXIN-BETA-RECEPTOR; TRAF-INTERACTING PROTEIN; FACTOR FAMILY PROTEIN; TERMINAL KINASE; CELL-DEATH; BINDING-SITES; DEFECTIVE INTERLEUKIN-1; TARGETED DISRUPTION	Tumor necrosis factor receptor-associated factors (TRAFS) were initially discovered as adaptor proteins that couple the tumor necrosis factor receptor family to signaling pathways. More recently they have also been shown to be signal transducers of Toll/interleukin-l family members. Six members of the TRAF family have been identified. All TRAF proteins share a C-terminal homology region termed the TRAF domain that is capable of binding to the cytoplasmic domain of receptors, and to other TRAF proteins. In addition, TRAFs 2-6 have RING and zinc finger motifs that are important for signaling downstream events. TRAF proteins are thought to be important regulators of cell death and cellular responses to stress, and TRAF2, TRAF5 and TRAF6 have been demonstrated to mediate activation of NF-kappaB and JNK. TRAF proteins are expressed in normal and diseased tissue in a regulated fashion, suggesting that they play an important role in physiological and pathological processes.	Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Cambridge CB2 2QQ, England; Yale Univ, Sch Med, Boyer Ctr Mol Med, New Haven, CT 06520 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Yale University	Bradley, JR (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Hills Rd, Cambridge CB2 2QQ, England.	john.bradley@addenbrookes.nhs.uk		Bradley, John/0000-0002-7774-8805				AHMAD M, 1997, NATURE, V385, P86; Aizawa S, 1997, J BIOL CHEM, V272, P2042; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Brink R, 1998, J BIOL CHEM, V273, P4129, DOI 10.1074/jbc.273.7.4129; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Dadgostar H, 2000, J BIOL CHEM, V275, P2539, DOI 10.1074/jbc.275.4.2539; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Durkop H, 1999, BLOOD, V93, P617, DOI 10.1182/blood.V93.2.617.402k14_617_623; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Hatzoglou A, 2000, J IMMUNOL, V165, P1322, DOI 10.4049/jimmunol.165.3.1322; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; Hostager BS, 1999, J IMMUNOL, V162, P6307; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Izban KF, 2000, MODERN PATHOL, V13, P1324, DOI 10.1038/modpathol.3880243; Izumi KM, 1999, J VIROL, V73, P9908, DOI 10.1128/JVI.73.12.9908-9916.1999; Jang HD, 2001, BIOCHEM BIOPH RES CO, V281, P499, DOI 10.1006/bbrc.2001.4369; Jobin C, 1999, J IMMUNOL, V162, P4447; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Krajewska M, 1998, AM J PATHOL, V152, P1549; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; LaMonica R, 2001, J BIOL CHEM, V276, P19889, DOI 10.1074/jbc.M100499200; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Ling L, 2000, P NATL ACAD SCI USA, V97, P9567, DOI 10.1073/pnas.170279097; Ling L, 2000, J BIOL CHEM, V275, P23852, DOI 10.1074/jbc.M001095200; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Luftig MA, 2001, J BIOL CHEM, V276, P14602, DOI 10.1074/jbc.C100103200; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Masson R, 1998, MECH DEVELOP, V71, P187, DOI 10.1016/S0925-4773(97)00192-5; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; McFadden G, 1997, J NEUROIMMUNOL, V72, P119, DOI 10.1016/S0165-5728(96)00177-4; Min W, 1998, J IMMUNOL, V161, P319; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shi CS, 1999, J IMMUNOL, V163, P3279; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200	105	502	530	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6482	6491		10.1038/sj.onc.1204788	http://dx.doi.org/10.1038/sj.onc.1204788			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607847				2022-12-28	WOS:000171640600020
J	Calastretti, A; Bevilacqua, A; Ceriani, C; Vigano, S; Zancai, P; Capaccioli, S; Nicolin, A				Calastretti, A; Bevilacqua, A; Ceriani, C; Vigano, S; Zancai, P; Capaccioli, S; Nicolin, A			Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase	ONCOGENE			English	Article						apoptosis; BCL-2; mTOR; microtubules; p27; rapamycin	DOWN-REGULATES BCL-2; MAMMALIAN TARGET; DEPENDENT DEGRADATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; MESSENGER-RNA; CELL-CYCLE; APOPTOSIS; RAPAMYCIN; PROTEIN	Rapamycin, a specific inhibitor of the serine/threonine mTOR kinase, markedly inhibited both cell growth and apoptosis in human B-cell lines. Besides arresting cells in G(1) by increasing p27(kip1), rapamycin tripled the cellular level of the BCL-2 protein. The activity was dose-dependent and specific for the p27(kip1) and BCL-2 proteins. Rapamycin did not affect bcl-2 mRNA although it increased cellular BCL-2 concentration by inhibiting phosphorylation, a mechanism initiating the decay process. To add new insight, we combined rapamycin treatment with treatment by taxol, which, by damaging microtubules, can phosphorylate BCL-2 and activate apoptosis. It was found that the mTOR kinase was activated in cells treated with taxol or with nocodazole although it was inhibited in cells pre-treated with rapamycin. BCL-2 phosphorylation, apoptosis and hyperdiploidy were also inhibited by rapamycin. In contrast, taxol-induced microtubule stabilization or metaphase synchronization were not inhibited by rapamycin. Taken together, these findings indicate that mTOR belongs to the enzymatic cascade that, starting from damaged microtubules, phosphorylates BCL-2. By regulating apoptosis, in addition to the control of a multitude of growth-related pathways, mTOR plays a nodal role in signaling G(1) and G(2)-M events.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy; Ctr Riferimento Oncol, Div Expt Oncol, I-33081 Aviano, Italy; Univ Florence, Inst Gen Pathol, Florence, Italy	University of Milan; IRCCS Aviano (CRO); University of Florence	Nicolin, A (corresponding author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	angelo.nicolin@unimi.it	Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424				Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AIELLO A, 1992, CYTOMETRY, V13, P502, DOI 10.1002/cyto.990130509; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Capaccioli S, 1996, ONCOGENE, V13, P105; Chadebech P, 1999, BIOCHEM BIOPH RES CO, V262, P823, DOI 10.1006/bbrc.1999.1291; Choi JH, 2000, CURR BIOL, V10, P861, DOI 10.1016/S0960-9822(00)00599-6; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; CROSSIN KL, 1981, CELL, V27, P341, DOI 10.1016/0092-8674(81)90417-7; DYER MJS, 1990, BLOOD, V75, P709; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1997, CANCER RES, V57, P229; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Itano Y, 1996, J NEUROCHEM, V67, P131; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Kitamura Y, 1997, JPN J PHARMACOL, V75, P195, DOI 10.1254/jjp.75.195; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; Koff A, 1995, Prog Cell Cycle Res, V1, P141; Konig A, 1997, BLOOD, V90, P4307; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KORSMEYER SJ, 1990, CURR TOP MICROBIOL, V166, P203; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; McDonnell TJ, 1996, EXPERIENTIA, V52, P1008, DOI 10.1007/BF01920110; Metcalfe SM, 1997, ONCOGENE, V15, P1635, DOI 10.1038/sj.onc.1201341; Migita K, 1997, CLIN EXP IMMUNOL, V108, P199, DOI 10.1046/j.1365-2249.1997.d01-1002.x; Morelli S, 1997, P NATL ACAD SCI USA, V94, P8150, DOI 10.1073/pnas.94.15.8150; Morelli S, 1996, ANTI-CANCER DRUG DES, V11, P1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pratesi G, 2000, BIOCHEM PHARMACOL, V60, P77, DOI 10.1016/S0006-2952(00)00300-2; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Saille C, 1999, NEUROSCIENCE, V92, P1455, DOI 10.1016/S0306-4522(99)00089-5; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9; Siegel DS, 1998, P NATL ACAD SCI USA, V95, P162, DOI 10.1073/pnas.95.1.162; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; STEUBE KG, 1995, LEUKEMIA, V9, P1841; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TERADA N, 1995, J IMMUNOL, V155, P3418; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	62	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6172	6180		10.1038/sj.onc.1204751	http://dx.doi.org/10.1038/sj.onc.1204751			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593425	Green Published			2022-12-28	WOS:000171206300008
J	Gozuacik, D; Murakami, Y; Saigo, K; Chami, M; Mugnier, C; Lagorce, D; Okanoue, T; Urashima, T; Brechot, C; Paterlini-Brechot, P				Gozuacik, D; Murakami, Y; Saigo, K; Chami, M; Mugnier, C; Lagorce, D; Okanoue, T; Urashima, T; Brechot, C; Paterlini-Brechot, P			Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging	ONCOGENE			English	Article						hepatitis B virus; Alu-PCR; gene trap; cancer; insertional mutagenesis; hepatocellular carcinoma	HEPATOCELLULAR-CARCINOMA; NUCLEAR RECEPTORS; CELLS; INTEGRATION; GENOME; MUTAGENESIS; REPLICATION; IDENTIFY; PROTEINS; LEUKEMIA	Proviral tagging has been used in animals as a powerful tool for cancer genetics. We show that a similar approach is possible in patients with hepatocellular carcinoma (HCC) infected by Hepatitis B Virus (HBV), a human pararetrovirus which may act by insertional mutagenesis. In this work, the HBV genome is used as a probe to identify cancer-related genes. By using HBV-Alu-PCR, we obtained 21 HBV/cellular DNA junctions from 18 different patients. In six of 21, we found the HBV DNA integrated into a cellular gene: (1) Sarco/Endoplasmic Reticulum Calcium ATPase1 Gene; (2) Thyroid Hormone Receptor Associated Protein 150 alpha Gene; (3) Human Telomerase Reverse Transcriptase Gene; (4) Minichromosome Maintenance Protein (MCM)-Related Gene; (5) FR7, a new gene expressed in human liver and cancer tissues; and (6) Nuclear Matrix Protein p84 Gene. Seven junctions contained unique cellular sequences. In the remaining eight, the HBV DNA was next to repetitive sequences, five of them of LINE1 type. The cellular genes targeted by HBV are key regulators of cell proliferation and viability. Our results show that studies on HBV-related HCCs allow to identify cellular genes involved in cancer. We therefore propose this approach as a valuable tool for functional cancer genomic studies in humans.	Necker Inst, INSERM, U370, F-75015 Paris, France; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kyoto 6020841, Japan; Chiba Univ, Dept Surg 2, Chiba 2638852, Japan; Necker Enfants Malad Hosp, Dept Biotech & Med Informat, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Kyoto Prefectural University of Medicine; Chiba University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Paterlini-Brechot, P (corresponding author), Necker Inst, INSERM, U370, F-75015 Paris, France.		Devrim, Gozuacik/C-3330-2008; Chami, Mounia/S-6471-2019	Devrim, Gozuacik/0000-0001-7739-2346; Chami, Mounia/0000-0003-1498-7187; Paterlini- Brechot, Patrizia/0000-0001-7981-6325				Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia M A, 1992, Semin Cancer Biol, V3, P309; Cecconi F, 2000, FEBS LETT, V480, P63, DOI 10.1016/S0014-5793(00)01779-8; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; CHISARI FV, 1995, HEPATOLOGY, V22, P1316, DOI 10.1016/0270-9139(95)90645-2; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Evans MJ, 1997, TRENDS GENET, V13, P370, DOI 10.1016/S0168-9525(97)01240-7; Fourel G, 1994, PRIMARY LIVER CANC E, P89; Freeman A, 1999, CLIN CANCER RES, V5, P2121; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; JOHNSON PJ, 1994, PRIMARY LIVER CANC E, P31; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Largaespada DA, 2000, LEUKEMIA, V14, P1174, DOI 10.1038/sj.leu.2401852; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Musahl C, 1998, EXP CELL RES, V241, P260, DOI 10.1006/excr.1998.4041; ROBINSON WS, 1987, HEPATOLOGY, V7, pS64, DOI 10.1002/hep.1840070712; SCHLUTER V, 1994, ONCOGENE, V9, P1; Todovov IT, 1998, LAB INVEST, V78, P73; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0	32	88	95	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6233	6240		10.1038/sj.onc.1204835	http://dx.doi.org/10.1038/sj.onc.1204835			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593432				2022-12-28	WOS:000171206300015
J	Wadle, A; Thiel, G; Mischo, A; Jung, V; Pfreundschuh, M; Renner, C				Wadle, A; Thiel, G; Mischo, A; Jung, V; Pfreundschuh, M; Renner, C			Chromosomal localization and promoter analysis of the adenomatous polyposis coli binding protein RP1	ONCOGENE			English	Article						adenomatous polyposis coli tumour-suppressor; protein; tubulin binding proteins; RP1 protein; chromosomal localization; T-cell signalling	CAMP RESPONSE ELEMENT; APC GENE-PRODUCT; BETA-CATENIN; CYCLIN D1; YEAST; IDENTIFICATION; CANCER; CELLS; MICROTUBULES; EXPRESSION	characterized by the ability of its members to serve as interacting partners for the adenomatous polyposis coli (ADC) tumour suppressor protein and tubulin. Data obtained with highly conserved yeast homologues suggest that the EB1/RP1 protein family promotes cytoplasmic microtubule dynamics and contributes to the sensor mechanism controlling the cytokinesis checkpoint during mitosis. However, the precise function of this protein family in mammalian cells has not been elucidated so far and remains unclear. Here, we report on the genomic localization of the RP1 gene and the characterization of the corresponding promoter. The RP1 gene was found to be encoded on chromosome 18q21, a locus which is altered or deleted in up to 50% of all patients with colorectal cancer. Promoter analysis revealed that the RP1 gene is under the control of a strong promoter that was 10 times more active in mammalian cells when compared to SV40 promoter. Members of the cyclic AMP response element binding protein family (CREB1 and CREB2) could be identified as transcription factors binding specifically within the RP1 promoter sequence.	Univ Saarland, Sch Med, Dept Med 1, D-66421 Homburg, Germany; Univ Saarland, Sch Med, D-66421 Homburg, Germany; Univ Saarland, Sch Med, Inst Human Genet, D-66421 Homburg, Germany	Saarland University; Saarland University; Saarland University	Renner, C (corresponding author), Univ Saarland, Sch Med, Dept Med 1, D-66421 Homburg, Germany.							Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Cibelli G, 1999, EUR J CELL BIOL, V78, P642, DOI 10.1016/S0171-9335(99)80049-1; Cibelli G, 1996, EUR J BIOCHEM, V236, P171, DOI 10.1111/j.1432-1033.1996.00171.x; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hsueh YP, 1997, J IMMUNOL, V158, P85; Jernvall P, 1999, BRIT J CANCER, V79, P903, DOI 10.1038/sj.bjc.6690144; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Ogunbiyi OA, 1998, J CLIN ONCOL, V16, P427, DOI 10.1200/JCO.1998.16.2.427; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Renner C, 1997, J IMMUNOL, V159, P1276; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sambrook J., 1989, MOL CLONING LAB MANU; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tarafa G, 2000, ONCOGENE, V19, P546, DOI 10.1038/sj.onc.1203353; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thiel G, 1996, GENE, V168, P173, DOI 10.1016/0378-1119(95)00739-3; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; VANDERVELDE G, 1994, WATER SCI TECHNOL, V29, P1; Zhang YM, 1998, HUM GENET, V103, P727	33	4	4	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5920	5929		10.1038/sj.onc.1204797	http://dx.doi.org/10.1038/sj.onc.1204797			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593399				2022-12-28	WOS:000171037200017
J	Ayton, PM; Cleary, ML				Ayton, PM; Cleary, ML			Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins	ONCOGENE			English	Review						MLL; leukemia	ACUTE MYELOID-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; DNA-BINDING DOMAIN; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTION FACTOR; HISTONE ACETYLTRANSFERASE; NUCLEAR-PROTEIN; T(10-11) TRANSLOCATION; CAENORHABDITIS-ELEGANS; GENE REARRANGEMENTS	The MLL (Mixed Lineage Leukemia) gene is a common target for chromosomal translocations associated with human acute leukemias. These translocations result in a gain of MLL function by generating novel chimeric proteins containing the amino-terminus of MLL fused in frame with one of 30 distinct partner proteins. Structure/function studies using an in vitro myeloid progenitor immortalization assay have revealed that at least four nuclear partner proteins contribute transcriptional effector properties to MLL to produce a range of chimeric transcription factors with leukemogenic potential. Mouse models suggest that expression of an MLL fusion protein is necessary but not sufficient for leukemogenesis. Interestingly, whilst all MLL fusion proteins tested so far phenocopy each other with respect to in vitro immortalization, the latency period required for the onset of acute leukemia in vivo is variable and partner protein dependent. We discuss potential mechanisms that may account for the ability of distinct MLL fusion proteins to promote short or long latency leukemogenesis.	Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Ayton, PM (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.							AYTON, 2001, TRANSCRIPTION FACTOR, P447; Bahri SM, 2001, MECH DEVELOP, V100, P291, DOI 10.1016/S0925-4773(00)00539-6; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Caligiuri MA, 1996, CANCER RES, V56, P1418; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Croce CM, 1999, CANCER RES, V59, p1778S; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Dreyling MH, 1998, BLOOD, V91, P4662; Felix C A, 1999, Oncologist, V4, P225; Galoian K, 2000, BLOOD, V96, p457A; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Isnard P, 2000, BLOOD, V96, P705; Joh T, 1996, ONCOGENE, V13, P1945; Johansson B, 1998, LEUKEMIA, V12, P779, DOI 10.1038/sj.leu.2401012; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Kuwada N, 2001, CANCER RES, V61, P2665; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lavau C, 2000, BLOOD, V96, p573A; Li QZ, 1998, BLOOD, V92, P3841, DOI 10.1182/blood.V92.10.3841.422k02_3841_3847; Lochner K, 1996, CANCER RES, V56, P2171; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Mahgoub N, 1998, GENE CHROMOSOME CANC, V21, P270, DOI 10.1002/(SICI)1098-2264(199803)21:3<270::AID-GCC14>3.0.CO;2-T; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Matsuo T, 1997, DEVELOPMENT, V124, P2671; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; Miller T, 2000, J BIOL CHEM, V275, P32052, DOI 10.1074/jbc.M005175200; MITELMAN F, 1994, CATALOGUE CHROMOSOME; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; MORRISSEY J, 1993, BLOOD, V81, P1124; Morrissey JJ, 1997, LEUKEMIA RES, V21, P911, DOI 10.1016/S0145-2126(97)00012-X; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Pegram LD, 2000, BLOOD, V96, P4360; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; RUBNITZ JE, 1994, BLOOD, V84, P1747; Sano K, 2000, BLOOD, V95, P1066, DOI 10.1182/blood.V95.3.1066.003k11_1066_1068; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Secker-Walker LM, 1998, LEUKEMIA, V12, P776, DOI 10.1038/sj.leu.2401011; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Strout MP, 1996, GENE CHROMOSOME CANC, V16, P204, DOI 10.1002/(SICI)1098-2264(199607)16:3<204::AID-GCC8>3.0.CO;2-2; Su MA, 2001, GENETICS, V157, P717; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Taki T, 1998, BLOOD, V92, P1125, DOI 10.1182/blood.V92.4.1125.416k40_1125_1130; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tang AH, 2001, DEVELOPMENT, V128, P801; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; von Bergh A, 2000, BLOOD, V96, p693A; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wittwer F, 2001, DEVELOPMENT, V128, P791; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	104	404	422	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5695	5707		10.1038/sj.onc.1204639	http://dx.doi.org/10.1038/sj.onc.1204639			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607819				2022-12-28	WOS:000170887500010
J	Yin, MB; Hapke, G; Guo, B; Azrak, RG; Frank, C; Rustum, YM				Yin, MB; Hapke, G; Guo, B; Azrak, RG; Frank, C; Rustum, YM			The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer	ONCOGENE			English	Article						BNP1350; bax; cyclin B; cdc2; chk1; cdc25C	DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; OVARIAN-CANCER; FISSION YEAST; HUMAN HEAD; THYMOCYTE APOPTOSIS; ANTITUMOR-ACTIVITY; CYCLE ARREST; DEATH; EXPRESSION	Promotion of apoptosis may potentiate the sensitivity of tumor cells to chemotherapeutic agents, thus improving the efficacy of cancer treatment. The transfection of the proapoptotic bax gene, which results in the overexpression of bax protein, augments the growth inhibition of A253 cells by BNP1350. Increased drug response was associated with the induction of DNA fragmentation in the size of 30-200 Kb, generating a cleaved fragment of 18 kDa from full-length 21 kDa bax and the cleavage of PARP. A253/vec cells treated with 0.07 muM(IC50) of BNP1350 accumulated in G(2) phase at 24 h after drug removal. In contrast, A253/Bax cells treated with an equimolar concentration of BNP1350 primarily displayed a G(1) phase accumulation with a concurrent decrease in G(2) phase. Certain cell cycle regulatory protein expression and activities were altered following drug exposure in both cell lines under similar conditions. Cdk2- and cdc2-associated HI kinase activities were markedly increased in the A253/Bax cell line with marginal increased activity in the A253/vec cell line. A chk1 activity assay was performed with GST-cdc25C (200 - 256) or GST-cdc25C(S216A) (200-256) fusion proteins as the substrate. Increased chk1 activity was observed in the A253/vec cell line, with little change in the A253/Bax cell line, when exposed to equimolar concentrations of BNP1350 (0.07 MM). A Western blot of immunoprecipitated chk1 indicated that increased chk1 phosphorylation following DNA damage induced by BNP1350 was accompanied by the observed G(2) accumulation in the A253/vec cell line, while only a slight increase in chk1 phosphorylation was seen in the A253/Bax cell line. A decreased expression of cdc25C was observed in the BNP1350-treated A253/Bax cells, but not in the A253/vec cell line. Following exposure to BNP1350, increased binding of 14-3-3 proteins to chk1 occurred in both cell lines, with more being observed in the A253/vec cell line. The data have shown that inhibition of the chk1 pathway accompanied by the abrogation of G(2) arrest is involved in sensitizing A253 cells to BNP1350 by bax gene transfer. These findings suggest that bax gene transfer sensitizes A253 cells to BNP1350 through apoptosis promoting and G(2)/M DNA damage checkpoint regulatory pathways.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Rustum, YM (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA065761, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056, CA 65761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Arafat WO, 2000, MOL THER, V1, P545, DOI 10.1006/mthe.2000.0071; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chan TA, 2000, GENE DEV, V14, P1584; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GIACCIA AJ, 1991, MUTAT RES, V263, P69, DOI 10.1016/0165-7992(91)90062-9; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Goldwasser F, 1996, CANCER RES, V56, P4430; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo B, 1999, ONCOL RES, V11, P91; Guo B, 2000, CLIN CANCER RES, V6, P718; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Hsu SL, 1999, EXP CELL RES, V252, P332, DOI 10.1006/excr.1999.4625; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jackson JR, 2000, CANCER RES, V60, P566; Jacotot E, 2000, PATHOL BIOL, V48, P271; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lind EF, 1999, J IMMUNOL, V162, P5374; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; McPake CR, 1998, ONCOL RES, V10, P235; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PANADERO A, 1995, ONCOL RES, V7, P73; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raleigh JM, 2000, J CELL SCI, V113, P1727; ROSHAK A, 1999, P AM ASSOC CANC RES, V40, P413; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; Shinoura N, 2000, CANCER GENE THER, V7, P739, DOI 10.1038/sj.cgt.7700158; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Strobel T, 1998, CANCER RES, V58, P4776; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Sugimoto C, 1999, INT J CANCER, V82, P860, DOI 10.1002/(SICI)1097-0215(19990909)82:6<860::AID-IJC15>3.0.CO;2-6; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; TSAI LH, 1993, DEVELOPMENT, V119, P1029; Vogelbaum MA, 1998, J NEUROSURG, V88, P99, DOI 10.3171/jns.1998.88.1.0099; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Xiang J, 2000, J GENE MED, V2, P97, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<97::AID-JGM99>3.0.CO;2-S; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yin MB, 2000, MOL PHARMACOL, V57, P453, DOI 10.1124/mol.57.3.453; Yin MB, 1999, INT J CANCER, V83, P341, DOI 10.1002/(SICI)1097-0215(19991029)83:3<341::AID-IJC9>3.0.CO;2-3; Yin MB, 1999, EXP CELL RES, V247, P189, DOI 10.1006/excr.1998.4346	52	8	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5249	5257		10.1038/sj.onc.1204686	http://dx.doi.org/10.1038/sj.onc.1204686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536038				2022-12-28	WOS:000170575500001
J	Ishiguro, H; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y				Ishiguro, H; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y			Identification of AXUD1, a novel human gene induced by AXIN1 and its reduced expression in human carcinomas of the lung, liver, colon and kidney	ONCOGENE			English	Article						AXIN1; chromosome 3p22; colon cancer; lung cancer	ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN MUTATIONS; WNT SIGNALING PATHWAY; NEGATIVE REGULATOR; HEPATOCELLULAR CARCINOMAS; COLORECTAL CARCINOMAS; CYCLIN D1; CANCER; ACTIVATION; APC	Axin, an important regulator of beta -catenin, is frequently mutated in human hepatocellular carcinomas (HCCs), and transduction of the wild-type Axin gene (AXIN1) induces apoptosis in HCC cells as well as in colon cancer cells. To investigate the detailed biological function of Axin, we searched on a cDNA microarray for genes whose expression was altered by transfer of wild-type AXIN1 into colon-cancer cell line LoVo. Among the genes showing altered expression, we focused on one, termed AXUD1 (AXIN1 up-regulated(1)), that revealed enhanced expression in response to exogeneously expressed AXIN1 but not to LacZ, a control gene. The AXUD1 gene consists of five exons and encodes a transcript with an open reading frame of 1767 bp. A 3.2-kb transcript of AXUD1 was expressed in all human tissues examined, most abundantly in lung, placenta, skeletal muscle, pancreas and leukocyte. By radiation-hybrid mapping we assigned its chromosomal location at 3p22, a region where frequent loss of heterozygosity has been reported in lung, renal, prostate, breast and cervical cancers. AXUD1 was frequently down-regulated in lung, kidney, liver and colon cancers compared with their corresponding normal tissues, suggesting that AXUD1 may have a tumor-suppressor function in those organs.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Minato Ku, Tokyo 1088639, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan	University of Tokyo; RIKEN; Nagoya City University	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Tsunoda, Tatsuhiko/K-2061-2014; Tanaka, Toshihiro/J-9310-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Tanaka, Toshihiro/0000-0001-6201-9784				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Fujita M, 2000, CANCER RES, V60, P6683; Fukuchi T, 1998, CANCER RES, V58, P3526; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ishiguro H, 2000, JPN J CANCER RES, V91, P597, DOI 10.1111/j.1349-7006.2000.tb00987.x; Iwao K, 1998, CANCER RES, V58, P1021; Kawasoe T, 2000, CANCER RES, V60, P3354; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Miano JM, 1997, GENE, V197, P215, DOI 10.1016/S0378-1119(97)00265-5; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakamura Y, 1997, NAT MED, V3, P499, DOI 10.1038/nm0597-499; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Ono K, 2000, CANCER RES, V60, P5007; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smits R, 2000, GASTROENTEROLOGY, V119, P1045, DOI 10.1053/gast.2000.18162; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Voeller HJ, 1998, CANCER RES, V58, P2520; Wistuba II, 1997, CANCER RES, V57, P3154; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yokota J, 1989, Princess Takamatsu Symp, V20, P43; Zurawel RH, 1998, CANCER RES, V58, P896	35	52	57	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5062	5066		10.1038/sj.onc.1204603	http://dx.doi.org/10.1038/sj.onc.1204603			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526492				2022-12-28	WOS:000170439800017
J	Unoki, M; Nakamura, Y				Unoki, M; Nakamura, Y			Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway	ONCOGENE			English	Article						EGR2; BPOZ; PTEN; tumor suppressor gene; PINK1	HUMAN OVARIAN-CANCER; ZINC FINGER PROTEIN; MOLECULAR-CLONING; PROSTATE-CANCER; BTB/POZ DOMAIN; NERVOUS-SYSTEM; CELLS; TRANSCRIPTION; MUTATIONS; DIFFERENTIATION	Defects in PTEN a tumor suppressor, have been found in cancers arising in a variety of human tissues. To elucidate the tumor-suppressive function of this gene, we have been analysing expression profiles of cancer cells after introduction of exogenous PTEN Those experiments identified 99 candidate genes that were transcriptionally transactivated. Among them, we report here the further analyses of eight genes, EGR2/Krox-20, BPOZ, APS, HCLS1/HS1, DUSP1/MKP1, NDRG1/Drg1/ RTP, NFIL3/E4BP4, and a novel gene (PINK], PTEN-induced putative kinase). Expression of six of them (PINK], EGR2, HCLS1, DUSP1, BPOZ, and NFIL3) was decreased in ovarian tumors compared with corresponding normal tissues. Colony-formation assays using plasmid clones designed to express each gene indicated that EGR2 and BPOZ were able to suppress growth of cancer cells significantly; in particular, cancer-cell lines stably expressing BPOZ grew more slowly than control cells containing mock vector. Flow cytometry suggested that over-expression of BPOZ inhibited progression of the cell cycle at the G(1)/S transition. Anti-sense oligonucleotides for BPOZ or EGR2 effectively inhibited their expression, and cell growth was accelerated. Therefore both genes appear to be novel candidates as mediators of the PTEN growth-suppressive signaling pathway.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Unoki, Motoko/X-3285-2019	Unoki, Motoko/0000-0002-9629-3818				Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Arlt MF, 1996, HUM MOL GENET, V5, P1017, DOI 10.1093/hmg/5.7.1017; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Borg A, 1996, CANCER RES, V56, P2497; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dai KS, 2000, BIOCHEM BIOPH RES CO, V273, P991, DOI 10.1006/bbrc.2000.3053; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; Dzialo-Hatton R, 2001, J IMMUNOL, V166, P4534, DOI 10.4049/jimmunol.166.7.4534; Eid MA, 1998, CANCER RES, V58, P2461; Guang RJ, 2000, CANCER RES, V60, P749; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu CT, 1998, CANCER GENE THER, V5, P3; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Maxwell GL, 1998, GYNECOL ONCOL, V70, P13, DOI 10.1006/gyno.1998.5039; Minaguchi T, 1999, CANCER RES, V59, P6063; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; Nakagawa H, 2000, ONCOGENE, V19, P210, DOI 10.1038/sj.onc.1203308; Obata K, 1998, CANCER RES, V58, P2095; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ono K, 2000, CANCER RES, V60, P5007; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Risinger JI, 1997, CANCER RES, V57, P4736; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; Yokomizo A, 1998, INT J ONCOL, V13, P101; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	35	295	312	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4457	4465		10.1038/sj.onc.1204608	http://dx.doi.org/10.1038/sj.onc.1204608			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494141				2022-12-28	WOS:000170074900003
J	Kozaki, K; Koshikawa, K; Tatematsu, Y; Miyaishi, O; Saito, H; Hida, T; Osada, H; Takahashi, T				Kozaki, K; Koshikawa, K; Tatematsu, Y; Miyaishi, O; Saito, H; Hida, T; Osada, H; Takahashi, T			Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis	ONCOGENE			English	Article						human lung cancer; metastasis; invasion; expression profiling; inflammation	EXPRESSION; ADENOCARCINOMAS; CHEMOKINES	This study established and characterized low-metastatic revertant and parental clones of a highly metastatic human lung cancer cell line, NCI-H460-LNM35 (hereafter referred to as LNM35), Expression-profiling analysis revealed that up-regulation of various proinflammatory cytokines and angiogenic chemotactic chemokines was present in LNM35, Further, while COX-2 itself is known to be inducible in inflammation, COX-2 expression levels correlated well with the capabilities of these clones for not only in vitro motility and invasion but also in vivo metastasis, and COX-2 inhibitors were shown for the first time to reduce lung cancer metastasis in vivo. These findings suggest that lung cancer cells may mimic inflammatory cells in the process of metastasis.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Internal Med, Nagoya, Aichi 4648681, Japan; Natl Inst Longev Sci, Dept Basic Gerontol, Aichi 4748522, Japan	Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Takahashi, Takashi/I-7262-2014; Kozaki, Ken-ichi/M-6281-2014	Takahashi, Takashi/0000-0003-0615-7001; Kozaki, Ken-ichi/0000-0003-3286-819X				Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; BANI MR, 1991, JNCI-J NATL CANCER I, V83, P119, DOI 10.1093/jnci/83.2.119; GAZDAR A F, 1990, Current Opinion in Oncology, V2, P321; Hida T, 1998, CANCER RES, V58, P3761; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Kozaki K, 2000, CANCER RES, V60, P2535; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; *STAT INF DEP, 1998, VIT STAT JAP, V3, P384; Sulzer MA, 1998, AM J RESP CRIT CARE, V157, P1319, DOI 10.1164/ajrccm.157.4.9703099; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VIDALVANACLOCHA F, 1994, CANCER RES, V54, P2667; Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8; Wikenheiser KA, 1997, AM J RESP CELL MOL, V16, P713, DOI 10.1165/ajrcmb.16.6.9191473	20	52	60	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4228	4234		10.1038/sj.onc.1204561	http://dx.doi.org/10.1038/sj.onc.1204561			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464289				2022-12-28	WOS:000169857200013
J	Grubb, DR; Ly, JD; Vaillant, F; Johnson, KL; Lawen, A				Grubb, DR; Ly, JD; Vaillant, F; Johnson, KL; Lawen, A			Mitochondrial cytochrome c release is caspase-dependent and does not involve mitochondrial permeability transition in didemnin B-induced apoptosis	ONCOGENE			English	Article						didemnin B; apoptosis; mitochondria; cytochrome c; permeability transition; caspases	ANTIPROLIFERATIVE AGENT DIDEMNIN; CELL-DEATH; NEURONAL APOPTOSIS; BONGKREKIC ACID; HL-60 CELLS; ACTIVATION; BCL-2; INDUCTION; DNA; REDUCTION	Permeability transition, and a subsequent drop in mitochondrial membrane potential (Delta Psi (m)), have been suggested to be mechanisms by which cytochrome c is released from the mitochondria into the cytosol during ;apoptosis, Furthermore, a drop in Delta Psi (m) has been suggested to be an obligate early step in the apoptotic pathway. Didemnin B, a branched cyclic peptolide described to have immunosuppressive, anti-tumour, and anti-viral properties, induces rapid apoptosis in a range of mammalian cell lines. Induction of apoptosis by didemnin B in cultured human pro-myeloid HL-60 cells is the fastest and most complete ever described with all cells being apoptotic after 3 h of treatment, By utilizing the system of didemnin B-induced apoptosis in HL-60 cells,;and the potent inhibitors of mitochondrial permeability transition, cyclosporin A and bongkrekic acid, we show that permeability transition as determined by changes in Delta Psi (m) and mitochondrial Ca2+ fluxing, is not a requirement for apoptosis or cytochrome c release. In this system, changes in mitochondrial membrane potential and cytochrome c release are shown to be dependent on caspase activation, and to occur concurrently with the release of caspase-9 from mitochondria, genomic DNA fragmentation and apoptotic body formation.	Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia	Monash University	Lawen, A (corresponding author), Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, POB 13D, Melbourne, Vic 3800, Australia.		Lawen, Alfons/A-6598-2008	Lawen, Alfons/0000-0001-6553-9945				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Crews CM, 1996, P NATL ACAD SCI USA, V93, P4316, DOI 10.1073/pnas.93.9.4316; CREWS CM, 1994, J BIOL CHEM, V269, P15411; de Bruijn J, 1973, TETRAHEDRON, V29, P1541; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; GAMEN S, 1995, FEBS LETT, V376, P15, DOI 10.1016/0014-5793(95)01236-1; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GRUBB DR, 1995, BIOCHEM BIOPH RES CO, V215, P1130, DOI 10.1006/bbrc.1995.2580; HENDERSON PJ, 1970, J BIOL CHEM, V245, P1319; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Johnson KL, 1999, J CELL BIOCHEM, V72, P269; Johnson KL, 1996, FEBS LETT, V383, P1, DOI 10.1016/0014-5793(96)00203-7; Johnson KL, 1999, IMMUNOL CELL BIOL, V77, P242, DOI 10.1046/j.1440-1711.1999.00821.x; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; KLINGENBERG M, 1970, BIOCHEM BIOPH RES CO, V39, P344, DOI 10.1016/0006-291X(70)90582-6; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; LARM JA, 1994, J BIOL CHEM, V269, P30097; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIJMBACH GW, 1970, TETRAHEDRON, V26, P5993; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Meng LH, 1998, BIOCHEMISTRY-US, V37, P10488, DOI 10.1021/bi9804479; MONTGOMERY DW, 1985, TRANSPLANTATION, V40, P49, DOI 10.1097/00007890-198507000-00011; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; RINEHART KL, 1983, FED PROC, V42, P87; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; RUSSEL WC, 1975, NATURE, V253, P4671; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; VAILLANT F, 1995, HUM MOL GENET, V4, P903, DOI 10.1093/hmg/4.5.903; WEED SD, 1983, ANTIVIR RES, V3, P269, DOI 10.1016/0166-3542(83)90005-0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zhai DY, 2000, FEBS LETT, V472, P293, DOI 10.1016/S0014-5793(00)01471-X; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	57	42	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4085	4094		10.1038/sj.onc.1204545	http://dx.doi.org/10.1038/sj.onc.1204545			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494136				2022-12-28	WOS:000169681500016
J	Ludwig, T; Fisher, P; Murty, V; Efstratiadis, A				Ludwig, T; Fisher, P; Murty, V; Efstratiadis, A			Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice	ONCOGENE			English	Article						Brca2; mouse mutant; mammary tumors	BREAST-CANCER; TRANSGENIC MICE; DNA-REPAIR; ADENOSQUAMOUS CARCINOMA; GENETIC INSTABILITY; TUMOR-FORMATION; MUTATION; PROTEIN; RAD51; EXPRESSION	Cre-mediated deletion of exons 3 and 4 of the mouse Brca2 gene occurring specifically in mammary epithelial cells of conditional female mutants carrying a combination of loxP-modified and null Brca2 alleles resulted in a high incidence (77%) of breast tumors that were often palpable and developed in one or more glands after long latency (time for median tumor-free survival of similar to1.4 years; total of 40 tumors in 20 animals). These invasive adenocarcinomas were histologically quite uniform, exhibiting predominantly a solid, nodular tumor pattern with very few variants, in striking contrast to the morphological heterogeneity of analogous Brca1-associated tumors. The karyotypes of tumor cells lacking Brca2 had various chromosomal aberrations and ranged from diploid to hypertetraploid, but this wide variability was incongruous with the histological appearance of carcinomas that was comparable between specimens. The implications of these observations in the context of models positing that Brca2 is involved in the maintenance of genomic stability are discussed.	Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Ludwig, T (corresponding author), Columbia Univ, Dept Anat & Cell Biol, Russ Berrie Med Sci Pavil,1150 St Nicholas Ave, New York, NY 10032 USA.	tl154@columbia.edu	Ludwig, Thomas/Q-6484-2016	Ludwig, Thomas/0000-0003-3461-2585	NATIONAL CANCER INSTITUTE [P01CA075553] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA75553] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agnarsson BA, 1998, BREAST CANCER RES TR, V47, P121, DOI 10.1023/A:1005853022804; Armes JE, 1999, CANCER RES, V59, P2011; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Chappuis PO, 2000, SEMIN SURG ONCOL, V18, P287, DOI 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.3.CO;2-X; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Denley H, 2000, HISTOPATHOLOGY, V36, P203; Dietrich P, 2000, MAMM GENOME, V11, P196, DOI 10.1007/s003350010037; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; Friedman LS, 1998, CANCER RES, V58, P1338; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Glover TW, 1998, CANCER RES, V58, P3409; Gretarsdottir S, 1998, CANCER RES, V58, P859; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Ingvarsson S, 1999, CANCER RES, V59, P2682; Kanazawa H, 2000, AM J PATHOL, V156, P1289, DOI 10.1016/S0002-9440(10)64999-1; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUDWIG T, 2001, IN PRESS GENES DEV; MEDINA D, 1996, MAMMARY TUMOR CELL C, P37; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Milner J, 2000, ONCOGENE, V19, P4441, DOI 10.1038/sj.onc.1203793; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Niho S, 1999, JPN J CANCER RES, V90, P1244, DOI 10.1111/j.1349-7006.1999.tb00703.x; Osin P, 1998, EUR J CANCER, V34, P1683, DOI 10.1016/S0959-8049(98)00248-2; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rossant J, 1999, GENE DEV, V13, P142, DOI 10.1101/gad.13.2.142; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shoker BS, 1999, HISTOPATHOLOGY, V35, P393; Tirkkonen M, 1997, CANCER RES, V57, P1222; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Wang Y, 2000, GENE DEV, V14, P927; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918	56	79	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					3937	3948		10.1038/sj.onc.1204512	http://dx.doi.org/10.1038/sj.onc.1204512			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494122				2022-12-28	WOS:000169681500002
J	Brabender, J; Usadel, H; Danenberg, KD; Metzger, R; Schneider, PM; Lord, RV; Wickramasinghe, K; Lum, CE; Park, J; Salonga, D; Singer, J; Sidransky, D; Holscher, AH; Meltzer, SJ; Danenberg, PV				Brabender, J; Usadel, H; Danenberg, KD; Metzger, R; Schneider, PM; Lord, RV; Wickramasinghe, K; Lum, CE; Park, J; Salonga, D; Singer, J; Sidransky, D; Holscher, AH; Meltzer, SJ; Danenberg, PV			Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival	ONCOGENE			English	Article						APC; methylation; neoplasia; NSCLC	CHI-SQUARE STATISTICS; DNA; METHYLATION	Methylation of 5 ' CpG islands in promoter and upstream coding regions has been identified as a mechanism for transcriptional inactivation of tumor suppressor genes. The purpose of this study was to determine whether hypermethylation of the adenomatous polyposis coli (APC) gene promoter occurs in primary non-small cell lung cancer (NSCLC), and whether hypermethylated APC has any relationship with survival. APC promoter 1A methylation was determined in normal and corresponding tumor tissue from 91 NSCLC patients and in a control group of 10 patients without cancer, using a quantitative fluorogenic real-time PCR (Taqman((R))) system. APC promoter methylation was detectable in 86 (95%) of 91 tumor samples, but also in 80 (88%) of 91 normal samples of NSCLC patients, and in only two (20%) of 10 normal lung tissues of the control group. The median level of APC promoter methylation was 4.75 in tumor compared to 1.57 in normal lung tissue (P < 0.001), Patients with low methylation status showed significantly longer survival than did patients with high methylation status (P = 0.041), In a multivariate analysis of prognostic factors, APC methylation was a significant independent prognostic factor (P = 0.044), as were pT (P = 0.050) and pN (P < 0.001) classifications. This investigation shows that APC gene promoter methylation occurs in the majority of primary NSCLCs, High APC promoter methylation is significantly associated with inferior survival, showing promise as a biomarker of biologically aggressive disease in NSCLC.	Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA; Univ Cologne, Dept Visual & Vasc Surg, D-50931 Cologne, Germany; Johns Hopkins Univ, Div Head & Neck Canc Res, Baltimore, MD 21231 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Med, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA	University of Southern California; University of Southern California; University of Southern California; University of Cologne; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Brabender, J (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, NOR 5318,1441 Eastlake Ave, Los Angeles, CA 90033 USA.			Lord, Reginald V N/0000-0001-7475-492X	NCI NIH HHS [CA78843, R01 CA71716, CA85069, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717, DK53620] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077057, R01CA078843, U01CA085069, R01CA071716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053620, R01DK047717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; EGUICHI K, 1997, CANCER RES, V57, P4913; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 1999, CANCER RES, V59, P67; Ginsberg Robert J., 1997, P858; HALPERN J, 1982, BIOMETRICS, V38, P1017, DOI 10.2307/2529882; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; PIKE MC, 1972, J R STAT SOC A, V135, P210; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704	19	112	122	2	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3528	3532		10.1038/sj.onc.1204455	http://dx.doi.org/10.1038/sj.onc.1204455			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429699				2022-12-28	WOS:000169478300008
J	Chaussade, L; Eymin, B; Brambilla, E; Gazzeri, S				Chaussade, L; Eymin, B; Brambilla, E; Gazzeri, S			Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status	ONCOGENE			English	Article						p(15INK4b); p16(INK4a); p14(ARF); expression; methylation; lung tumour	DEPENDENT KINASE INHIBITORS; CPG ISLAND METHYLATION; CELL-CYCLE ARREST; CDK INHIBITORS; BETA-TRANSCRIPT; P16(INK4) GENE; HUMAN CANCERS; TGF-BETA; INACTIVATION; SUPPRESSOR	The cell cycle inhibitor p15(INK4B) is frequently inactivated by homozygous deletions together with p16(INK4a)/14(ARF) in many tumour types. Although it is now well established that p16(INK4a) and p14(ARF) act as tumour suppressor genes, the role of p15(INK4b) remains to be well defined. In order to explore the possibility of a selective deregulation of p15(INK4b) in human lung carcinogenesis, we studied p15INK4b status in neuroendocrine (NE) lung tumours where homozygous deletions of the p16(INK4a)/p14(ARF) locus are rarely observed. Expressions of p15 and p15.5 protein isoforms were analysed in a series of eight control normal lung, 12 tumour-associated normal lung, five low grade and 15 high grade neuroendocrine (NE) lung tumours and relationship with a specific p15(INK4b) methylation status was studied. Using Western blot analysis, we showed that p15 and p15.5 isoforms displayed a high heterogeneous pattern of expression in both normal and tumour tissues. P15 and p15.5 expressions were correlated in control normal lung (P < 0.04) whereas they were not in tumours and associated normal lung. The level of p15.5 was significantly higher in associated normal lung and in tumours (P < 0.02 respectively), specially in low grade tumours (P < 0.01), than in control normal lung. Furthermore, p15.5 expression was more variable in tumours than in normal lung (P < 0.01) and in low grade than in high grade NE lung tumours (P < 0.02). Levels of p15 and p15.5 were distinct (up- or downregulated) from those observed in paired normal lung in 4/12 (33%) and 10/12 (83%) tumours respectively. Aberrant methylation at the 5 ' end of P15(INK4b) gene was observed in 15% of NE lung tumours using PCR-based assay, in a region proximal to the translation start where methylation did not occur in control and associated normal lung. However, no correlation could be assessed with protein status. MSP analysis of CpG islands proximal to the transcription start revealed methylation in all normal and tumour samples. No correlation was found between p15(INK4b) and p16(INK4a) or p14(ARF) status. These data suggest that complex deregulation of p15.5 is implicated in the carcinogenesis of human NE lung tumours independently of p16(INK4a) and p14(ARF) status.	Inst Albert Bonniot, INSERM EMI 9925, Grp Rech Canc Poumon, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM EMI 9925, Grp Rech Canc Poumon, F-38706 La Tronche, France.		Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013; Brambilla, Elisabeth MP/L-8796-2013; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810				Aggerholm A, 1999, CANCER RES, V59, P436; Anbazhagan R, 1999, CANCER RES, V59, P5119; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dosaka-Akita H, 2000, CANCER, V88, P550, DOI 10.1002/(SICI)1097-0142(20000201)88:3<550::AID-CNCR9>3.0.CO;2-D; Fuxe J, 2000, ONCOGENE, V19, P1724, DOI 10.1038/sj.onc.1203496; Gazzeri S, 1998, CANCER RES, V58, P3926; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GrayBablin J, 1997, CANCER RES, V57, P604; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Iravani M, 1997, ONCOGENE, V15, P2609, DOI 10.1038/sj.onc.1201428; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; OKAMOTO A, 1995, CANCER RES, V55, P1448; Packenham JP, 1995, CLIN CANCER RES, V1, P687; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rusin MR, 1996, INT J CANCER, V65, P734, DOI 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, ONCOGENE, V11, P987; TRAVIS WD, 1999, EMBO J, V18, P4280; Tsubari M, 1997, CANCER RES, V57, P2966; WASHIMI O, 1995, CANCER RES, V55, P514; XIAO S, 1995, CANCER RES, V55, P2968; Yuan JP, 1999, J PATHOL, V189, P358	44	18	20	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6587	6596		10.1038/sj.onc.1204798	http://dx.doi.org/10.1038/sj.onc.1204798			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641784				2022-12-28	WOS:000171404200012
J	Tsygankov, AY; Teckchandani, AM; Feshchenko, EA; Swaminathan, G				Tsygankov, AY; Teckchandani, AM; Feshchenko, EA; Swaminathan, G			Beyond the RING: CBL proteins as multivalent adapters	ONCOGENE			English	Review						Cbl; adapter; SH2; SH3; tyrosine phosphorylation; ubiquitination	GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; PROTOONCOGENE C-CBL; TYROSINE-PHOSPHORYLATED CBL; INTEGRIN SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3'-KINASE PATHWAY; ANCHORAGE-INDEPENDENT GROWTH; MEDIATED NEGATIVE REGULATION; NUCLEOTIDE-RELEASING FACTOR	Following discovery of c-Cbl, a cellular form of the transforming retroviral protein v-Cbl, multiple Cbl-related proteins have been identified in vertebrate and invertebrate organisms. c-Cbl and its homologues are capable of interacting with numerous proteins involved in cell signaling, including various molecular adapters and protein tyrosine kinases. It appears that Cbl proteins play several functional roles, acting both as multivalent adapters and inhibitors of various protein tyrosine kinases. The latter function is linked, to a substantial extent, to the E3 ubiquitin-ligase activity of Cbl proteins. Experimental evidence for these functions, interrelations between them, and their biological significance are addressed in this review, with the main accent placed on the adapter functions of Cbl proteins.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, Kresge Bldg,Room 506,3400 N Broad St, Philadelphia, PA 19140 USA.	tsygan@astro.temple.edu	Tsygankov, Alexander Y/K-6205-2017	Teckchandani, Anjali/0000-0002-2237-9598	NCI NIH HHS [CA78499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler CE, 2000, J BIOL CHEM, V275, P36472, DOI 10.1074/jbc.M005424200; Ahmed Z, 2000, FEBS LETT, V475, P31, DOI 10.1016/S0014-5793(00)01621-5; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Alsayed Y, 2000, EXP HEMATOL, V28, P826, DOI 10.1016/S0301-472X(00)00170-3; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Amsen D, 2000, EUR J IMMUNOL, V30, P2832, DOI 10.1002/1521-4141(200010)30:10<2832::AID-IMMU2832>3.0.CO;2-D; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Anzai N, 1999, BLOOD, V93, P3317, DOI 10.1182/blood.V93.10.3317.410k12_3317_3326; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Astier A, 2000, J IMMUNOL, V164, P6091, DOI 10.4049/jimmunol.164.12.6091; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Borinstein SC, 2000, CELL SIGNAL, V12, P769, DOI 10.1016/S0898-6568(00)00129-7; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Brizzi MF, 1996, ONCOGENE, V13, P2067; Brizzi MF, 1998, EXP HEMATOL, V26, P1229; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Campana D, 1996, Hum Cell, V9, P317; Cerboni C, 1998, EUR J IMMUNOL, V28, P1005, DOI 10.1002/(SICI)1521-4141(199803)28:03<1005::AID-IMMU1005>3.0.CO;2-O; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chu J, 1998, BLOOD, V92, P1697, DOI 10.1182/blood.V92.5.1697.417a06_1697_1706; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cohen S, 1999, BLOOD, V93, P2013, DOI 10.1182/blood.V93.6.2013.406k25_2013_2024; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Dennehy KM, 1998, EUR J IMMUNOL, V28, P1617, DOI 10.1002/(SICI)1521-4141(199805)28:05<1617::AID-IMMU1617>3.0.CO;2-7; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Erdreich-Epstein A, 1997, EXP CELL RES, V237, P288, DOI 10.1006/excr.1997.3795; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; Fernandez B, 1999, J BIOL CHEM, V274, P20244, DOI 10.1074/jbc.274.29.20244; Fernandez JA, 1999, J BIOL CHEM, V274, P1401, DOI 10.1074/jbc.274.3.1401; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Finkelstein LD, 2000, BIOCHEM J, V345, P385, DOI 10.1042/0264-6021:3450385; FitzerAttas CJ, 1997, J BIOL CHEM, V272, P8551, DOI 10.1074/jbc.272.13.8551; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fournier TM, 2000, MOL BIOL CELL, V11, P3397, DOI 10.1091/mbc.11.10.3397; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Graham LJ, 1998, BIOCHEM BIOPH RES CO, V249, P537, DOI 10.1006/bbrc.1998.9177; Graham LJ, 2000, FEBS LETT, V470, P273, DOI 10.1016/S0014-5793(00)01341-7; Grishin A, 2000, ONCOGENE, V19, P97, DOI 10.1038/sj.onc.1203254; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Hanazono Y, 1996, ACTA HAEMATOL-BASEL, V95, P236; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hazeki K, 1999, EUR J IMMUNOL, V29, P3302, DOI 10.1002/(SICI)1521-4141(199910)29:10<3302::AID-IMMU3302>3.0.CO;2-G; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Hunter S, 1997, MOL ENDOCRINOL, V11, P1213, DOI 10.1210/me.11.9.1213; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Izadi KD, 1998, EXP CELL RES, V245, P330, DOI 10.1006/excr.1998.4259; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kamei T, 2000, INT J ONCOL, V17, P335; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kato M, 1998, AM J RESP CELL MOL, V18, P675, DOI 10.1165/ajrcmb.18.5.2885; Kato M, 2000, INT ARCH ALLERGY IMM, V122, P33, DOI 10.1159/000053629; KAWATA M, 1988, J BIOL CHEM, V263, P18965; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Khwaja A, 1996, ONCOGENE, V12, P2491; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klapper LN, 2000, CANCER RES, V60, P3384; Kontani K, 1996, J BIOL CHEM, V271, P1534; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Lavagna-Sevenier C, 1998, LEUKEMIA, V12, P301, DOI 10.1038/sj.leu.2400921; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Lazaar AL, 2001, J IMMUNOL, V166, P155, DOI 10.4049/jimmunol.166.1.155; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Lin HM, 2001, INT IMMUNOL, V13, P13, DOI 10.1093/intimm/13.1.13; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Liu YH, 1999, J IMMUNOL, V162, P7095; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mallone R, 2001, INT IMMUNOL, V13, P397, DOI 10.1093/intimm/13.4.397; Manie SN, 1997, EXP HEMATOL, V25, P45; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Marengere LEM, 1997, J IMMUNOL, V159, P70; Matsuo T, 1996, FEBS LETT, V397, P113, DOI 10.1016/S0014-5793(96)01151-9; Matsuo T, 1996, FEBS LETT, V382, P11, DOI 10.1016/0014-5793(96)00122-6; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Michel F, 2000, J IMMUNOL, V165, P3820, DOI 10.4049/jimmunol.165.7.3820; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Naccache PH, 1997, J LEUKOCYTE BIOL, V62, P901, DOI 10.1002/jlb.62.6.901; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NOBES CD, 1995, J CELL SCI, V108, P225; Oda A, 1996, BLOOD, V88, P1330, DOI 10.1182/blood.V88.4.1330.bloodjournal8841330; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; Okuda K, 1996, ONCOGENE, V13, P1147; Osada M, 1999, MOL CELL BIOL, V19, P6333; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Pai LM, 2000, CELL, V103, P51, DOI 10.1016/S0092-8674(00)00104-5; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Park RK, 1999, BLOOD, V94, P2112; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; Pedraza-Alva G, 2001, J BIOL CHEM, V276, P729, DOI 10.1074/jbc.M008494200; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Robertson H, 2000, ONCOGENE, V19, P3299, DOI 10.1038/sj.onc.1203624; Rollet-Labelle E, 2000, J IMMUNOL, V164, P1020, DOI 10.4049/jimmunol.164.2.1020; Saci A, 2000, BIOCHEM J, V351, P669, DOI 10.1042/0264-6021:3510669; Salgia R, 1996, EXP HEMATOL, V24, P310; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Salojin K, 1997, J EXP MED, V186, P887, DOI 10.1084/jem.186.6.887; Salojin KV, 1999, J IMMUNOL, V163, P844; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Scaife RM, 2000, J CELL SCI, V113, P215; Schlottmann KE, 1996, J LEUKOCYTE BIOL, V60, P546, DOI 10.1002/jlb.60.4.546; Scholz G, 2000, J BIOL CHEM, V275, P14615, DOI 10.1074/jbc.275.19.14615; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Slavik JM, 1999, J BIOL CHEM, V274, P3116, DOI 10.1074/jbc.274.5.3116; Smit L, 1996, ONCOGENE, V13, P381; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Suzuki H, 1997, J IMMUNOL, V159, P5881; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; Teckchandani AM, 2001, ONCOGENE, V20, P1739, DOI 10.1038/sj.onc.1204246; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 1999, J IMMUNOL, V162, P7133; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, ONCOGENE, V14, P3067, DOI 10.1038/sj.onc.1201153; Umehara H, 1998, INT IMMUNOL, V10, P833, DOI 10.1093/intimm/10.6.833; van Leeuwen JEM, 1999, MOL CELL BIOL, V19, P6652; van Leeuwen JEM, 1999, J BIOL CHEM, V274, P5153, DOI 10.1074/jbc.274.8.5153; Wang BC, 2000, J BIOL CHEM, V275, P5222, DOI 10.1074/jbc.275.7.5222; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; Wang L, 2000, EXP HEMATOL, V28, P1503, DOI 10.1016/S0301-472X(00)00632-9; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wisniewski D, 1996, LEUKEMIA, V10, P1436; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Wunderlich L, 1999, CELL SIGNAL, V11, P253, DOI 10.1016/S0898-6568(98)00054-0; Yankee TM, 1999, J IMMUNOL, V163, P5827; Yasuda T, 2000, J EXP MED, V191, P641, DOI 10.1084/jem.191.4.641; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yoon CH, 2000, MOL BIOL CELL, V11, P4019, DOI 10.1091/mbc.11.11.4019; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zhang ZH, 1999, J BIOL CHEM, V274, P4883, DOI 10.1074/jbc.274.8.4883; Zhang ZH, 1999, CURR BIOL, V9, P203, DOI 10.1016/S0960-9822(99)80090-6; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	257	107	115	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6382	6402		10.1038/sj.onc.1204781	http://dx.doi.org/10.1038/sj.onc.1204781			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607840				2022-12-28	WOS:000171640600013
J	Wonerow, P; Watson, SP				Wonerow, P; Watson, SP			The transmembrane adapter LAT plays a central role in immune receptor signalling	ONCOGENE			English	Article						LAT; T cell receptor signalling; glycolipid-enriched membrane domains (GEMs); adapters; platelets; signal transduction	T-CELL RECEPTOR; PROTEIN-TYROSINE KINASE; NATURAL-KILLER-CELLS; SRC FAMILY KINASES; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; GAMMA-CHAIN; COLLAGEN RECEPTOR; MEMBRANE DOMAINS; GLYCOPROTEIN-VI	The transmembrane adapter LAT (linker for activation of T cells) plays a central role in signalling by ITAM bearing receptors expressed on T cells, natural killer cells, mast cells and platelets. Receptor engagement leads to the phosphorylation of tyrosine residues present in the intracellular domain of LAT and formation of a multiprotein complex with other adapter molecules and enzymes including Grb2, Gads/SLP-76 and PLC gamma isoforms. These signalling events predominantly take place in glycolipid-enriched membrane domains. The constitutive presence of LAT in GEMs enables its function as the main scaffolding protein for the organization of GEM-localized signalling. The study of LAT-deficient mice and LAT-deficient cell lines further emphasizes the importance of LAT for these signalling cascades but also defines the existence of LAT-independent events downstream of the Syk-family kinase-ITAM complex.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Wonerow, P (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423				Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; AZZONI L, 1992, J EXP MED, V176, P1745, DOI 10.1084/jem.176.6.1745; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; Binstadt BA, 1998, J BIOL CHEM, V273, P27518, DOI 10.1074/jbc.273.42.27518; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bonilla FA, 2000, P NATL ACAD SCI USA, V97, P1725, DOI 10.1073/pnas.040543597; Bosselut R, 1999, J EXP MED, V190, P1517, DOI 10.1084/jem.190.10.1517; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brdicka T, 1998, BIOCHEM BIOPH RES CO, V248, P356, DOI 10.1006/bbrc.1998.8857; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; CHAN AC, 1994, J IMMUNOL, V152, P4758; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Debnath J, 1999, MOL CELL BIOL, V19, P1498; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; Galandrini R, 1996, J EXP MED, V183, P179, DOI 10.1084/jem.183.1.179; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Honda ZI, 2000, MOL CELL BIOL, V20, P1759, DOI 10.1128/MCB.20.5.1759-1771.2000; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Jevremovic D, 1999, J IMMUNOL, V162, P2453; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JUNE CH, 1990, J IMMUNOL, V144, P1591; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kelly ME, 2000, CURR OPIN IMMUNOL, V12, P267, DOI 10.1016/S0952-7915(00)00086-8; Kimura T, 2001, IMMUNOL LETT, V75, P123, DOI 10.1016/S0165-2478(00)00295-9; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Lindholm CK, 1999, J BIOL CHEM, V274, P28050, DOI 10.1074/jbc.274.39.28050; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu YM, 1998, BIOCHEM BIOPH RES CO, V245, P684, DOI 10.1006/bbrc.1998.8329; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Marie-Cardine A, 1999, J EXP MED, V189, P1181, DOI 10.1084/jem.189.8.1181; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Motto DG, 1996, MOL CELL BIOL, V16, P2823; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Okada T, 2000, IMMUNITY, V13, P817, DOI 10.1016/S1074-7613(00)00079-0; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Pivniouk VI, 2000, CURR OPIN IMMUNOL, V12, P173, DOI 10.1016/S0952-7915(99)00068-0; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Sarkar S, 1998, FEBS LETT, V441, P357, DOI 10.1016/S0014-5793(98)01584-1; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schraven B, 1999, IMMUNOL TODAY, V20, P431, DOI 10.1016/S0167-5699(99)01519-4; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stoica B, 1998, J IMMUNOL, V160, P1059; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Torgersen KM, 2001, CELL SIGNAL, V13, P213, DOI 10.1016/S0898-6568(01)00131-0; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Welsh M, 1998, ONCOGENE, V16, P891, DOI 10.1038/sj.onc.1201607; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; WILDE J, 2001, CELL SIGN, V13, P1; Wong J, 2000, J BIOL CHEM, V275, P33116, DOI 10.1074/jbc.M004467200; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	99	23	24	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6273	6283		10.1038/sj.onc.1204770	http://dx.doi.org/10.1038/sj.onc.1204770			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607829				2022-12-28	WOS:000171640600002
J	Kuttler, F; Ame, P; Clark, H; Haughey, C; Mougin, C; Cahn, JY; Dang, CV; Raffeld, M; Fest, T				Kuttler, F; Ame, P; Clark, H; Haughey, C; Mougin, C; Cahn, JY; Dang, CV; Raffeld, M; Fest, T			c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli	ONCOGENE			English	Article						Burkitt's lymphoma; c-Myc; apoptosis; staurosporine; TNF alpha	TRANSCRIPTIONAL ACTIVATION DOMAIN; TRANSACTIVATION DOMAIN; CYCLE; FIBROBLASTS; PROTEIN; GENE; BINDING; ARREST; REGION; GROWTH	In addition to c-myc rearrangement, over 50% of Burkitt's lymphoma cases present clustered mutations in exon 2, where many of the functional activities of c-Myc protein are based. This report describes the functional consequences induced by tumour-derived c-myc mutations located in c-myc box II. Two mutated alleles were studied, focusing on the P138C mutation, and compared to wild-type c-myc. The c-Myc transformation, transactivation and apoptosis activities were explored based on cells over-expressing c-Myc. While the transcriptional activation activity was not affected, our experiments exploring the anchorage-independent growth capacity of c-Myc-transfected Rat1a cells showed that c-Myc box II mutants were less potent than wild-type c-Myc in promoting cell transformation. Considering the possibility that these mutations could be interfering with the ability of c-Myc to promote apoptosis, we tested c-Myc-transfected Rat1a fibroblasts under several conditions: serum deprivation-, staurosporine- and TNF alpha -induced cell death. Interestingly, the mutated alleles were characterized by an overall decrease in ability to mediate apoptosis. Our study indicates that point mutations located in c-Myc box II can decrease the ability of the protein to promote both transformation and apoptosis without modifying its transactivating activity.	Univ Hosp Jean Minjoz, Inst Etud & Transfert Genes, Dept Haematol & Cell Biol, F-25030 Besancon, France; NCI, Hematopathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA	Universite de Franche-Comte; CHU Besancon; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Fest, T (corresponding author), Univ Hosp Jean Minjoz, Inst Etud & Transfert Genes, Dept Haematol & Cell Biol, F-25030 Besancon, France.		Amé-Thomas, Patricia/C-3131-2017; Dang, Chi/Y-3375-2019	Amé-Thomas, Patricia/0000-0001-8042-9250; MOUGIN, CHRISTIANE/0000-0002-1573-8695; Dang, Chi/0000-0002-4031-2522; Kuttler, Fabien/0000-0003-2575-1989; fest, thierry/0000-0002-6437-4189				ASKEW DS, 1991, ONCOGENE, V6, P1915; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bernard B, 2001, CELL DEATH DIFFER, V8, P234, DOI 10.1038/sj.cdd.4400796; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; CLARK HM, 1994, CANCER RES, V54, P3383; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dhanaraj SN, 1996, EXP CELL RES, V224, P52, DOI 10.1006/excr.1996.0110; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; PULVERER BJ, 1994, ONCOGENE, V9, P59; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; Sakamuro D, 1995, ONCOGENE, V11, P2411; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stone B., 1987, ED RES Q, V11, P7; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; YANO T, 1993, ONCOGENE, V8, P2741; YANO T, 1992, BLOOD, V80, P758	37	19	19	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6084	6094		10.1038/sj.onc.1204827	http://dx.doi.org/10.1038/sj.onc.1204827			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593416				2022-12-28	WOS:000171056300016
J	Saadi-Kheddouci, S; Berrebi, D; Romagnolo, B; Cluzeaud, F; Peuchmaur, M; Kahn, A; Vandewalle, A; Perret, C				Saadi-Kheddouci, S; Berrebi, D; Romagnolo, B; Cluzeaud, F; Peuchmaur, M; Kahn, A; Vandewalle, A; Perret, C			Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene	ONCOGENE			English	Article						polycystic kidney disease; beta-catenin; transgenic mice	EPITHELIAL-CELLS; MOLECULAR-BASIS; ALDOLASE-B; E-CADHERIN; C-MYC; PKD1; PROTEIN; PRODUCT; TRANSCRIPTION; PROLIFERATION	Autosomal dominant polycystic kidney disease (ADPKD) is common and is a major cause of renal failure. Although the genetics of ADPKD are well known and have led to the discovery of polycystins, a new protein family, the pathogenesis of the disease remains largely unknown. Recent studies have indicated that the beta -catenin signaling pathway is one of the targets of the transduction pathway controlled by the polycystins. We have generated transgenic mice that overproduce an oncogenic form of beta -catenin in the epithelial cells of the kidney. These mice developed severe polycystic lesions soon after birth that affected the glomeruli, proximal, distal tubules and collecting ducts. The phenotype of these mice mimicked the human ADPKD phenotype. Cyst formation was associated with an increase in cell proliferation and apoptosis. The cell proliferation and apoptotic indexes was increased 4-5-fold and 3-4-fold, respectively, in cystic tubules of the transgenic mice compared to that of littermate controls. Our findings provide experimental genetic evidence that activation of the Wnt/beta -catenin signaling pathway causes polycystic kidney disease and support the view that dysregulation of the Wnt/beta -catenin signaling is involved in its pathogenesis.	ICGM, INSERM, U129, F-75014 Paris, France; Univ Paris 07, Hop Robert Debre, Serv Anatomopathol, EA3102, F-75019 Paris, France; Univ Paris 07, Inst Fed Rech 02, INSERM, U478, F-75870 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Perret, C (corresponding author), ICGM, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Perret-Mayeux, Christine/L-3297-2017; Romagnolo, Béatrice/D-5017-2017	Romagnolo, Béatrice/0000-0001-8772-3604; perret, christine/0000-0003-4710-7051				BARISONI L, 1995, AM J PATHOL, V147, P1728; Barr MM, 1999, NATURE, V401, P386, DOI 10.1038/43916; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Bieche I, 1999, CANCER RES, V59, P2759; Cadoret A, 2001, CANCER RES, V61, P3245; Calvet JP, 1998, J NEPHROL, V11, P24; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; EKBLOM P, 1992, RENAL DEV, P475; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Grantham JJ, 1996, AM J KIDNEY DIS, V28, P788, DOI 10.1016/S0272-6386(96)90378-9; Gregori C, 1998, J BIOL CHEM, V273, P25237, DOI 10.1074/jbc.273.39.25237; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lanoix J, 1996, ONCOGENE, V13, P1153; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Romagnolo B, 1999, CANCER RES, V59, P3875; Romagnolo B, 1996, J BIOL CHEM, V271, P16820, DOI 10.1074/jbc.271.28.16820; Saez DE, 2000, J CELL BIOCHEM, V78, P62, DOI 10.1002/(SICI)1097-4644(20000701)78:1<62::AID-JCB6>3.3.CO;2-N; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF184, DOI 10.1152/ajprenal.1996.271.1.F184; Sorenson CM, 1999, AM J PHYSIOL-RENAL, V276, pF210, DOI 10.1152/ajprenal.1999.276.2.F210; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vainio SJ, 1999, INT J DEV BIOL, V43, P419; van Adelsberg J, 1999, DEV GENET, V24, P299, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<299::AID-DVG13>3.0.CO;2-J; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WILSON PD, 1991, AM J PHYSIOL, V260, P420; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724	46	196	217	0	14	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5972	5981		10.1038/sj.onc.1204825	http://dx.doi.org/10.1038/sj.onc.1204825			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593404				2022-12-28	WOS:000171056300004
J	Fulda, S; Kufer, MU; Meyer, E; van Valen, F; Dockhorn-Dworniczak, B; Debatin, KM				Fulda, S; Kufer, MU; Meyer, E; van Valen, F; Dockhorn-Dworniczak, B; Debatin, KM			Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer	ONCOGENE			English	Article						caspase-8; apoptosis; drugs; methylation; gene transfer	INHIBITORY PROTEIN EXPRESSION; CD95 APO-1/FAS SYSTEM; BRAIN-TUMOR CELLS; NEUROBLASTOMA-CELLS; DEFICIENT ACTIVATION; SIGNALING COMPLEX; TRAIL RECEPTOR-2; RESISTANCE; FLICE; INDUCTION	Resistance of tumors to treatment with cytotoxic drugs, irradiation or immunotherapy may be due to disrupted apoptosis programs. Here, we report in a variety of different tumor cells including Ewing tumor, neuroblastoma, malignant brain tumors and melanoma that caspase-8 expression acts as a key determinant of sensitivity for apoptosis induced by death-inducing ligands or cytotoxic drugs. In tumor cell lines resistant to TRAIL, anti-CD95 or TNF alpha, caspase-8 protein and mRNA expression was decreased or absent without caspase-8 gene loss. Methylation-specific PCR revealed hypermethylation of caspase-8 regulatory sequences in cells with impaired caspase-8 expression. Treatment with the demethylation agent 5-Aza-2 ' -deoxycylidine (5-dAzaC) reversed hypermethylation of caspase-8 resulting in restoration of caspase-8 expression and recruitment and activation of caspase-8 at the CD95 DISC upon receptor cross-linking thereby sensitizing for death receptor-, and importantly, also for drug-induced apoptosis. Inhibition of caspase-8 activity also inhibited apoptosis sensitization by 5-dAzaC. Similar to demethylation, introduction of caspase-8 by gene transfer sensitized for apoptosis induction. Hypermethylation of caspase-8 was linked to reduced caspase-8 expression in different tumor cell lines in vitro and, most importantly, also in primary tumor samples. Thus, these findings indicate that re-expression of caspase-8, e.g. by demethylation or caspase-8 gene transfer, might be an effective strategy to restore sensitivity for chemotherapy- or death receptor-induced apoptosis in various tumors in viva.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; Univ Munster, Lab Expt Orthoped Res, D-48149 Munster, Germany; Univ Munster, Dept Pathol, D-48149 Munster, Germany	Ulm University; University of Munster; University of Munster	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.		Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DEVITA VT, 1990, MONOGR NCI, V10, P19; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2000, CANCER RES, V60, P3947; FULDA S, 2001, IN PRESS ONCOGENE; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; VANVALEN F, 1999, EWINGS SARCOMA FAMIL, P55; VANVALEN F, 2000, INT J CANCER, V88, P311; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	55	339	363	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5865	5877		10.1038/sj.onc.1204750	http://dx.doi.org/10.1038/sj.onc.1204750			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593392				2022-12-28	WOS:000171037200010
J	Pekarsky, Y; Hallas, C; Croce, CM				Pekarsky, Y; Hallas, C; Croce, CM			The role of TCL1 in human T-cell leukemia	ONCOGENE			English	Article						14q32.1; TCLI; TCLIb; Akt; T-cell leukemia	CHROMOSOME-TRANSLOCATION; TRANSGENIC MICE; GENE; EXPRESSION; RECEPTOR; PHOSPHORYLATION; ACTIVATION; ONCOGENE; LYMPHOMA; REGION	The TCL1 locus on human chromosome 14q32.1 is activated in T-cell leukemias by translocations and inversions that juxtapose it to regulatory elements of T-cell receptor genes. We isolated and characterized four genes at this locus, TCL1 and TCL1b (T-cell leukemia/lymphoma 1 and 1b), and TNG1 and TNG2 (TCL neighboring genes 1 and 2) all of which are overexpressed following rearrangements involving 14q32.1. TCL1 and TCL1b show 60% similarity and are represented in the mouse by a cluster of six homologous genes. In humans TCL1 and TCL1b show similar expression patterns: They are expressed mainly in CD4-/CD8- immature T-cells, pre B-cells and virgin B-cells. Expression decreases significantly at more mature stages of B-cell development. Activation of TCL1 and/or TCL1b in mature T-cells causes T-cell leukemia in humans. The oncogenic nature of TCL1 was confirmed by the analysis of a transgenic mouse model. Functional analysis of Tcl1 revealed its involvement in a P13-kinase dependent Akt (PKB) pro-survival pathway through its interaction with the Akt kinase which increases Akt's enzymatic activity and promotes translocation of Akt to the nucleus.	Thomas Jefferson Univ, Kimmerl Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Croce, CM (corresponding author), Thomas Jefferson Univ, Kimmerl Canc Ctr, 233 S 10th St,BLSB Room 1050, Philadelphia, PA 19107 USA.	Carlo.Croce@mail.tju.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Hallas, Cora/0000-0002-5732-4810	NATIONAL CANCER INSTITUTE [P01CA081534, P20CA081534] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81534] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariyama Y, 1999, J HUM GENET, V44, P357, DOI 10.1007/s100380050178; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CIMINO G, 1991, CANCER RES, V51, P6712; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Croce CM, 1999, CANCER RES, V59, p1778S; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; ERICSON J, 1985, P NATL ACAD SCI USA, V79, P5611; Gritti C, 1998, BLOOD, V92, P368, DOI 10.1182/blood.V92.2.368.414k39_368_373; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Madani A, 1996, BLOOD, V87, P1923; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; Narducci MG, 1997, CANCER RES, V57, P5452; Narducci MG, 2000, CANCER RES, V60, P2095; Ozes ON, 1999, NATURE, V401, P82; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; Sakashita A, 1998, LEUKEMIA, V12, P970, DOI 10.1038/sj.leu.2401023; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; STERN MH, 1993, ONCOGENE, V8, P2475; Takizawa J, 1998, JPN J CANCER RES, V89, P712, DOI 10.1111/j.1349-7006.1998.tb03275.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Thick J, 1996, ONCOGENE, V12, P379; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	43	70	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5638	5643		10.1038/sj.onc.1204596	http://dx.doi.org/10.1038/sj.onc.1204596			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607815				2022-12-28	WOS:000170887500006
J	Crisanti, P; Raguenez, G; Blancher, C; Neron, B; Mamoune, A; Omri, B				Crisanti, P; Raguenez, G; Blancher, C; Neron, B; Mamoune, A; Omri, B			Cloning and characterization of a novel transcription factor involved in cellular proliferation arrest: PATF	ONCOGENE			English	Article						PATF; retina; transcription factor; proliferation arrest	ROUS-SARCOMA VIRUS; GENE-EXPRESSION; E2F FAMILY; RETINA; CELLS; DIFFERENTIATION; RETINOBLASTOMA; MECHANISMS; PROTEINS; GROWTH	Cell cycle withdrawal involves several transcription factors such as E2Fs members that play a key role in cell growth control. Here we describe a novel putative bZIP transcription factor isolated from the retina and involved in neuronal proliferation arrest at the terminal differentiation: PATF (Proliferation Arrest Transcription Factor). We show that PATF associates with E2F4 protein and interacts with the E2F consensus site. PATF expression increases with establishment of quiescent state. Furthermore, the nuclear PATF localization like E2F4, depends on cell growth arrest. The decrease of PATF amount, using a retroviral antisense strategy, results in pursued neuroretina cell mitosis. Our results indicate that PATF could be a new molecular signal implicated in the final neuronal cell cycle withdrawal.	Assoc Claude Bernard, CNRS, INSERM, U450, F-75016 Paris, France; Univ Paris 06, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Crisanti, P (corresponding author), Assoc Claude Bernard, CNRS, INSERM, U450, 29 Rue Wilhem, F-75016 Paris, France.							BIDOU L, 1993, MECH DEVELOP, V43, P159, DOI 10.1016/0925-4773(93)90033-T; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRISANTI P, 1985, EMBO J, V4, P1467, DOI 10.1002/j.1460-2075.1985.tb03804.x; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Espanel X, 1998, ONCOGENE, V17, P585, DOI 10.1038/sj.onc.1201962; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Maniatis T., 1989, MOL CLONING LAB MANU; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Omri B, 1998, ONCOGENE, V16, P2351, DOI 10.1038/sj.onc.1201761; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; REID TW, 1974, J NATL CANCER I, V53, P347, DOI 10.1093/jnci/53.2.347; ROUET P, 1992, J BIOL CHEM, V267, P20765; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WANG SZ, 1994, P NATL ACAD SCI USA, V91, P1351, DOI 10.1073/pnas.91.4.1351; WU CL, 1995, MOL CELL BIOL, V15, P2536; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199	29	7	8	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5475	5483		10.1038/sj.onc.1204711	http://dx.doi.org/10.1038/sj.onc.1204711			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571645				2022-12-28	WOS:000170781100008
J	Kim, H; You, S; Linda, KF; Farris, J; Foster, DN				Kim, H; You, S; Linda, KF; Farris, J; Foster, DN			The rapid destabilization of p53 mRNA in immortal chicken embryo fibroblast cells	ONCOGENE			English	Article						CEF; cycloheximide; immortalization; mRNA destablization; p53 mRNA; chicken	MESSENGER-RNA DEGRADATION; TUMOR-SUPPRESSOR P53; UNTRANSLATED REGIONS; ELEMENTS; MDM2; GENE; APOPTOSIS; STABILITY; MEDIATOR; PROMOTES	The steady-state levels of p53 mRNA were dramatically lower in immortal chicken embryo fibroblast (CEF) cell lines compared to primary CEF cells. In the presence of cycloheximide (CHX), the steady-state levels of p53 mRNA markedly increased in immortal CEF cell lines, similar to levels found in primary cells. The de novo synthetic rates of p53 mRNA were relatively similar in primary and immortal cells grown in the presence or absence of CHX. Destabilization of p53 mRNA was observed in the nuclei of immortal, but not primary, CEF cells. The half-life of p53 mRNA in primary cells was found to be a relatively long 23 h compared to only 3 It in immortal cells. The expression of transfected p53 cDNA was inhibited in immortal cells, but restored upon CHX treatment. The 5'-region of the p53 mRNA was shown to be involved in the rapid p53 mRNA destabilization in immortal cells by expression analysis of 5'- and 3-deleted p53 cDNAs as well as fusion mRNA constructs of N-terminal p53 and N-terminal deleted LacZ genes. Together, it is suggestive that the downregulation of p53 mRNA in immortal CEF cells occurs through a post-transcriptional destabilizing mechanism.	Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	University of Minnesota System; University of Minnesota Twin Cities; Seoul National University (SNU)	Foster, DN (corresponding author), 495 AnSci VetMed,1988 Fitch Ave, St Paul, MN 55108 USA.		Kim, Hyunggee/F-2673-2013; You, Seungkwon/H-3067-2015; Kang, Phil Jun/F-4716-2013	Kim, Hyunggee/0000-0002-4738-0990; 				Attardi LD, 2000, GENE DEV, V14, P704; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; D'Erchia AM, 1999, GENOMICS, V58, P50, DOI 10.1006/geno.1999.5794; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JIANG D, 1993, ONCOGENE, V8, P2805; Kim H, 2001, EXP CELL RES, V265, P339, DOI 10.1006/excr.2001.5207; Kim H, 2001, ONCOGENE, V20, P3306, DOI 10.1038/sj.onc.1204423; Kim H, 2001, ONCOGENE, V20, P2671, DOI 10.1038/sj.onc.1204378; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749	26	24	25	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5118	5123		10.1038/sj.onc.1204664	http://dx.doi.org/10.1038/sj.onc.1204664			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526500				2022-12-28	WOS:000170464000005
J	Lu, Y; Jamieson, L; Brasier, AR; Fields, AP				Lu, Y; Jamieson, L; Brasier, AR; Fields, AP			NF-kappa B/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival	ONCOGENE			English	Article						protein kinase C iota; apoptosis; taxol; nuclear factor-kappa B	TUMOR-NECROSIS-FACTOR; MYELOGENOUS LEUKEMIA-CELLS; DRUG-INDUCED APOPTOSIS; ABL TYROSINE KINASE; FACTOR-ALPHA; TRANSCRIPTION FACTOR; B ACTIVATION; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; INTERLEUKIN-8 GENE	In chronic myelogenous leukemia (CML), the oncogene bcr-abl encodes a dysregulated tyrosine kinase that inhibits apoptosis. We showed previously that human erythroleukemia K562 cells are resistant to antineoplastic drug (taxol)-induced apoptosis through the atypical protein kinase C iota isozyme (PKC iota), a kinase downstream of Bcr-Abl. The mechanism(s) by which PKC iota mediates cell survival to taxol is unknown. Here we demonstrate that PKC iota requires the transcription factor nuclear factor-kappaB (NF-kappaB) to confer cell survival. At apoptosis-inducing concentrations, taxol weakly induces I kappaB alpha proteolysis and NF-kappaB translocation in K562 cells, but potently induces its transcriptional activity. Inhibition of NF-kappaB activity (by blocking l kappaB alpha degradation) significantly sensitizes cells to taxol-induced apoptosis. Likewise, K562 cells expressing antisense PKC iota mRNA or kinase dead PKC iota (PKC iota -KD) are sensitized to taxol; these cells are rescued from apoptosis by NF-kappaB overexpression. Expression of constitutively active PKC iota (PKC iota -CA) upregulates NF-kappaB transactivation and rescues cells from apoptosis in the absence of Bcr-Abl tyrosine kinase activity. Using a chimeric GAL4-RelA transactivator, we find that taxol potently activates GAL4-RelA-dependent transcription. This activation was further upregulated by expression of PKC iota -CA and inhibited by expression of PKC iota -KD. Our results indicate that RelA transactivation is an important downstream target of the PKC iota -mediated Bcr-Abl signaling pathway and is required for resistance to taxol-induced apoptosis.	Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brasier, AR (corresponding author), Univ Texas, Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.			Brasier, Allan/0000-0002-5012-4090	NCI NIH HHS [CA56869] Funding Source: Medline; NIAID NIH HHS [AI40218] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; ANAFI M, 1993, BLOOD, V82, P3524; Baichwal V. R., 1997, CURR BIOL, V7, P94; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Blobe GC, 1996, CANCER SURV, V27, P213; Bonizzi G, 1999, BIOCHEM PHARMACOL, V57, P713, DOI 10.1016/S0006-2952(98)00353-0; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Granville DJ, 1998, LAB INVEST, V78, P893; Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HUIZING MT, 1995, CANCER INVEST, V13, P381, DOI 10.3109/07357909509031919; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; Jamaluddin M, 2000, MOL ENDOCRINOL, V14, P99, DOI 10.1210/me.14.1.99; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kaur G, 1996, ANTI-CANCER DRUG, V7, P815, DOI 10.1097/00001813-199611000-00001; KURIYAN J, 1995, STRUCTURE, V3, P135, DOI 10.1016/S0969-2126(01)00143-5; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Perera PY, 1996, INFECT IMMUN, V64, P878, DOI 10.1128/IAI.64.3.878-884.1996; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rowley PT, 1996, LEUKEMIA RES, V20, P473, DOI 10.1016/0145-2126(95)00172-7; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Samali A, 1997, Adv Pharmacol, V41, P533, DOI 10.1016/S1054-3589(08)61071-6; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Torres K, 1998, CANCER RES, V58, P3620; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; WANG D, 2000, J BIOL CHEM; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	61	59	66	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4777	4792		10.1038/sj.onc.1204607	http://dx.doi.org/10.1038/sj.onc.1204607			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521190				2022-12-28	WOS:000170271800003
J	Ibarra-Sanchez, MD; Wagner, J; Ong, MT; Lampron, C; Tremblay, ML				Ibarra-Sanchez, MD; Wagner, J; Ong, MT; Lampron, C; Tremblay, ML			Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-kappa B activation	ONCOGENE			English	Article						T-cell protein tyrosine phosphatase; G1 phase; cyclin D1; NF-kappa B; IKK	PROTEIN-TYROSINE-PHOSPHATASE; CELL-CYCLE PROGRESSION; DEPENDENT KINASE; NEGATIVE REGULATORS; PROLIFERATION; P27(KIP1); EXPRESSION; GROWTH; TRANSCRIPTION; D1	Previous results suggested a potential role for T-cell protein tyrosine phosphatase (TC-PTP) in cell proliferation. However, no conclusive data has supported such a function in the modulation of this process. In order to clarify this issue, we isolated TC-PTP-/- murine embryonic fibroblasts (MEFs) as well as cell lines to characterize the role of TC-PTP in the control of cell proliferation and cell cycle. Both TC-PTP-/- primary MEFs and cell lines proliferate slower than TC-PTP+/+ cells. We also demonstrated that TC-PTP-/- cells have a slow progression through the G1 phase of the cell cycle. Further characterization of the G1 defect indicates that the kinetics of cyclin D1 induction was delayed and that p27(KIP1) remains at higher levels for an extended period of time. Moreover, cells lacking TC-PTP showed a delayed activation of CDK2. This slow progression through the early G1-phase resulted in decreased phosphorylation of the RB protein and subsequent delay into the S phase transition. In contrast, no further defects were detected in other phases of the cell cycle. Survey of the potential signaling pathways leading to this delayed cyclin D1 expression indicated that NF-kappaB activation was compromised and that IKK beta activity was also reduced following PDGF stimulation. Reintroduction of wild-type TC-PTP into the TC-PTP-/- cells rescued the defective proliferation, cyclin D1 expression, NF-kappaB, activation as well as I kappaB phosphorylation. Together, these results confirm that TC-PTP plays a positive role in the progression of early G1 phase of the cell cycle through the NF-kappaB pathway.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6G5, Canada	McGill University; McGill University	Tremblay, ML (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.		Ong, Ming Thong/R-4045-2018; Ibarra-Sánchez, María de Jesús/C-4722-2008	Ong, Ming Thong/0000-0002-6639-9718; Ibarra-Sánchez, María de Jesús/0000-0003-3623-1903				BARGOU RC, 1997, J CLIN INVEST, V100, P405; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; Ferreira V, 1999, J IMMUNOL, V162, P6442; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LORENZEN J, 1995, J BIOL CHEM, V14, P631; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NAMBIRAJAN S, 1995, J BIOSCIENCE, V20, P461, DOI 10.1007/BF02703529; Nambirajan S, 2000, J BIOSCIENCE, V25, P33, DOI 10.1007/BF02985179; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Radha V, 1997, FEBS LETT, V409, P33, DOI 10.1016/S0014-5793(97)00471-7; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Snapper CM, 1996, J IMMUNOL, V156, P183; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683	47	45	47	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4728	4739		10.1038/sj.onc.1204648	http://dx.doi.org/10.1038/sj.onc.1204648			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498795				2022-12-28	WOS:000170208600013
J	Chattopadhyay, A; Chiang, CW; Yang, E				Chattopadhyay, A; Chiang, CW; Yang, E			BAD/BCL-(xL) heterodimerization leads to bypass of G0/G1 arrest	ONCOGENE			English	Article						BAD; BCL-(xL); apoptosis; cell cycle arrest	DEATH AGONIST BAD; CELL-CYCLE ENTRY; BH3 DOMAIN; BCL-2 EXPRESSION; MICE DEFICIENT; PROTEIN; PHOSPHORYLATION; PROGRESSION; APOPTOSIS; FAMILY	The pro-apoptotic molecule BAD binds BCL-x(L) or BCL2 and inactivates their survival function. In addition to their anti-apoptotic function, BCL2 and BCL-xL also delay cell cycle entry from quiescence. We found that the BH3-only molecule BAD also exerted a cell cycle effect. BAD expression resulted in failure to cell cycle block in growth arrest conditions. In low serum and in confluence, fibroblasts constitutively or inducibly expressing BAD persisted in S phase, continued to incorporate BrdU, and exhibited sustained cyclin E/cdk2 activity. Mutation analysis indicated that the cell cycle effect of BAD was not dependent on its phosphorylation status or subcellular localization, but strictly co-segregated with BCL-xL binding. bclx(-/-) MEFs expressing BAD and bad(-/-) MEFs both arrested in G0/G1 in low serum similar to wild-type controls, suggesting that the ability to overcome the G0/G1 checkpoint resulted from the presence of BAD/BCL-x(L) heterodimers, rather than the absence of BCL-xL or BAD. These data provide evidence that in addition to regulating apoptosis, the BAD/BCLx(L) heterodimer has a novel cell cycle function.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Yang, E (corresponding author), Vanderbilt Univ Sch Med, 525 MRB 2, Nashville, TN 37232 USA.	elizabeth.yang@mcmail.vanderbilt.edu			NCI NIH HHS [CA68485, 1RO1 CA78443] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA078443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lind EF, 1999, J IMMUNOL, V162, P5374; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nagata S, 1999, NAT CELL BIOL, V1, pE143, DOI 10.1038/14094; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	45	51	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4507	4518		10.1038/sj.onc.1204584	http://dx.doi.org/10.1038/sj.onc.1204584			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494146				2022-12-28	WOS:000170074900008
J	Kim, JJ; Yang, JS; Nottingham, LK; Tang, WX; Dang, K; Manson, KH; Wyand, MS; Wilson, DM; Weiner, DB				Kim, JJ; Yang, JS; Nottingham, LK; Tang, WX; Dang, K; Manson, KH; Wyand, MS; Wilson, DM; Weiner, DB			Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen	ONCOGENE			English	Article						prostate specific antigen; DNA vaccines; prostate cancer; immune responses; rhesus macaques	RADIATION-THERAPY; CANCER; CELLS; PSA; IMMUNOTHERAPY; TRIAL	Prostate specific antigen (PSA) is a widely used marker for prostate cancer, which is secreted by normal prostate cells at low levels, but is produced more substantially by cancer cells. We have previously reported on the use of a DNA vaccine construct that encodes for human PSA gene to elicit host immune responses against cells producing PSA. DNA immunization strategy delivers DNA constructs encoding for a specific immunogen into the host, who becomes the in vivo protein source for the production of antigen. This antigen then is the focus of the resulting immune response. In this study, we examine the induction of immune responses and safety profiles in rhesus macaques immunized with DNA-based PSA vaccine. We observed induction of PSA-specific humoral response as well as positive PSA-specific lymphoproliferative (LPA) response in the vaccinated macaques. We also observed that the stimulated T cells from the PSA-immunized rhesus macaques produced higher levels of Th1 type cytokine IFN-gamma than the control vector immunized animals. On the other hand, DNA immunization did not result in any adverse effects in the immunized macaques, as indicated by complete blood counts, leukocyte differentials and hepatic and renal chemistries. The macaques appeared healthy, without any physical signs of toxicity throughout the observation period. In addition, we did not observe any adverse effect on the vaccination site. The apparent safety and immunogenecity of DNA immunization in this study suggest that further evaluation of this vaccination strategy is warranted.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Viral Genomix Inc, Philadelphia, PA 19104 USA; Inst Human Gene Therapy, Philadelphia, PA 19104 USA; Primedica Mason Labs, Worcester, MA USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; The Wistar Institute	Weiner, DB (corresponding author), Univ Penn, Dept Pathol & Lab Med, 505 Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	dbweiner@mail.med.upenn.edu	Weiner, David B/H-8579-2014					ARMBRUSTER DA, 1993, CLIN CHEM, V39, P181; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; Boyer JD, 1997, NAT MED, V3, P526, DOI 10.1038/nm0597-526; Boyer JD, 1999, CLIN IMMUNOL, V90, P100, DOI 10.1006/clim.1998.4616; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CONRY RM, 1994, CANCER RES, V54, P1164; Conry RM, 1998, CLIN CANCER RES, V4, P2903; D'Amico AV, 1998, CANCER, V82, P334, DOI 10.1002/(SICI)1097-0142(19980115)82:2<342::AID-CNCR14>3.0.CO;2-Z; Eder JP, 2000, CLIN CANCER RES, V6, P1632; Garnick MB, 1998, SCI AM, V279, P74, DOI 10.1038/scientificamerican1298-74; Godley PA, 1999, CANCER DETECT PREV, V23, P316, DOI 10.1046/j.1525-1500.1999.99033.x; HODGE JW, 1995, INT J CANCER, V63, P231, DOI 10.1002/ijc.2910630215; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; KELLEY JR, 1998, GENE THER MOL BIOL, V2, P14; Kim JJ, 1998, ONCOGENE, V17, P3125, DOI 10.1038/sj.onc.1201736; Kim JJ, 1998, J CLIN INVEST, V102, P1112, DOI 10.1172/JCI3986; LABRIE F, 1992, J UROLOGY, V151, P1283; Lekutis C, 1997, J IMMUNOL, V158, P4471; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; Lotze MT, 1997, ADV EXP MED BIOL, V417, P551; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; Malkowicz SB, 1998, HEMATOL ONCOL CLIN N, V12, P649, DOI 10.1016/S0889-8588(05)70013-7; Murphy G, 1996, PROSTATE, V29, P371; ODONNELL PD, 1989, J UROLOGY, V142, P1227, DOI 10.1016/S0022-5347(17)39038-9; Porgador A, 1996, J IMMUNOL, V156, P2918; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SANDA MG, 1994, J UROLOGY, V151, P622, DOI 10.1016/S0022-5347(17)35032-2; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Small EJ, 2000, CURR OPIN ONCOL, V12, P265, DOI 10.1097/00001622-200005000-00014; Smith BF, 1998, GENE THER, V5, P865, DOI 10.1038/sj.gt.3300675; Stenman UH, 1999, SEMIN CANCER BIOL, V9, P83, DOI 10.1006/scbi.1998.0086; Tjoa B, 1996, PROSTATE, V28, P65; Tuting T, 1997, J MOL MED-JMM, V75, P478, DOI 10.1007/s001090050133; VIEWEG J, 1994, CANCER RES, V54, P1760; WANG MC, 1982, METHOD CANCER RES, V19, P179; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; ZAGARS GK, 1995, UROLOGY, V45, P476, DOI 10.1016/S0090-4295(99)80019-3	38	32	35	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4497	4506		10.1038/sj.onc.1204542	http://dx.doi.org/10.1038/sj.onc.1204542			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494145				2022-12-28	WOS:000170074900007
J	MacGrogan, D; Alvarez, S; DeBlasio, T; Jhanwar, SC; Nimer, SD				MacGrogan, D; Alvarez, S; DeBlasio, T; Jhanwar, SC; Nimer, SD			Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines	ONCOGENE			English	Article						myeloid leukemia; 20q deletion; loss of heterozygosity	COMMONLY DELETED SEGMENT; MYELOPROLIFERATIVE DISORDERS; MYELODYSPLASTIC SYNDROMES; HEMATOLOGIC DISORDERS; DELETIONS; MAP; REGION; NEUROFIBROMATOSIS; REFINEMENT; ABNORMALITIES	Deletions of the long arm of chromosome 20 have been reported in a wide range of myeloid disorders and may reflect loss of critical tumor suppressor gene(s), To identify such candidate genes, 65 human myeloid cell line DNAs were screened by polymerase chain reaction (PCR) tor evidence of allelic loss at 39 highly polymorphic loci on the long arm of chromosome 20, A mono-allelic pattern was present in eight cell lines at multiple adjacent loci spanning the common deleted regions (CDRs) previously defined in primary hematological samples, suggesting loss of heterozygosity (LOH) at 20q, Fluorescence in situ hybridization (FISH) was then performed using a series of yeast artificial chromosomes (YACs) ordered in the CDR, and in five of eight cell lines, the deletions resulted from cytogenetically detectable whole chromosomal loss or large interstitial deletion, whereas in another cell line deletion was associated with an unbalanced translocation, LOH in the CMK megakaryocytic cell line, which has a hypotetraploid karyotype, was associated with a der(20)t(1;20)(q32;q12)x2 leading to complete deletion of the CDR, Three additional unbalanced translocations were found within the CDR and all three breakpoints mapped to a single YAC, We then used a series of P1 artificial chromosomes (PACs) spanning this YAC clone, and two PACs produced 'split' signals suggesting that they each span one of these breakpoints, Exon trapping using PACs that overlap the breakpoint regions yielded portions of six genes and evaluation of these genes as candidate tumor suppressor genes is underway. The limited information available about these genes suggests that the h-1(3)mbt gene is the most attractive candidate.	Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, Cytogenet Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	MacGrogan, D (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.		MacGrogan, Donal/E-8604-2016; MacGrogan, Donal/AAR-7392-2021	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK43025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AATOLA M, 1992, CANCER GENET CYTOGEN, V62, P75, DOI 10.1016/0165-4608(92)90043-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Asimakopoulos FA, 1996, BRIT J HAEMATOL, V95, P219; ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; Asimakopoulos FA, 1996, BLOOD, V88, P2690, DOI 10.1182/blood.V88.7.2690.bloodjournal8872690; Bench AJ, 2000, ONCOGENE, V19, P3902, DOI 10.1038/sj.onc.1203728; Bench AJ, 1998, GENOMICS, V49, P351, DOI 10.1006/geno.1998.5231; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DEWALD GW, 1995, SEMIN ONCOL, V22, P341; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FOUNTAIN JW, 1989, SCIENCE, V244, P1085, DOI 10.1126/science.2543076; HIRAMA T, 1995, BLOOD, V86, P841; HOLLINGS PE, 1994, BLOOD, V83, P305; HOLLINGS PE, 1995, CANCER GENET CYTOGEN, V79, P32, DOI 10.1016/0165-4608(94)00068-M; KNUUTILA S, 1994, GENE CHROMOSOME CANC, V10, P95, DOI 10.1002/gcc.2870100204; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; Kurtin PJ, 1996, AM J CLIN PATHOL, V106, P680; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; MERTENS F, 1991, LEUKEMIA, V5, P214; MITELMAN F, 1995, CATALOG CHROMOSOME A; Mori N, 1997, BLOOD, V90, P2010, DOI 10.1182/blood.V90.5.2010; NACHEVA E, 1995, CANCER GENET CYTOGEN, V80, P87, DOI 10.1016/0165-4608(94)00150-A; NobenTrauth K, 1996, GENOMICS, V35, P610, DOI 10.1006/geno.1996.0408; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Paige AJW, 2000, CANCER RES, V60, P1690; ROULSTON D, 1993, BLOOD, V82, P3424; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; Stoffel M, 1996, P NATL ACAD SCI USA, V93, P3937, DOI 10.1073/pnas.93.9.3937; STRACHAN T, 1996, HUM MOL GENET, P151; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Wang PW, 2000, GENOMICS, V67, P28, DOI 10.1006/geno.2000.6215; Wang PW, 1998, GENE CHROMOSOME CANC, V21, P75, DOI 10.1002/(SICI)1098-2264(199802)21:2<75::AID-GCC1>3.0.CO;2-4; WHITE NJ, 1994, BLOOD, V83, P2809, DOI 10.1182/blood.V83.10.2809.2809	38	29	31	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4150	4160		10.1038/sj.onc.1204540	http://dx.doi.org/10.1038/sj.onc.1204540			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464281				2022-12-28	WOS:000169857200005
J	Jaumot, M; Hancock, JF				Jaumot, M; Hancock, JF			Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions	ONCOGENE			English	Article						Ras; Raf; 14-3-3; phophatases; plasma membrane	CYSTEINE-RICH DOMAIN; RECEPTOR TYROSINE KINASE; DISTINCT BINDING DOMAINS; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; B-RAF; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC RAS; ZINC-FINGER; PHOSPHORYLATION	Raf-1 activation is a complex process which involves plasma membrane recruitment, phosphorylation, protein-protein and lipid-protein interactions, We now show that PP1 and PP2A serine-threonine phosphatases also have a positive role in Ras dependent Raf-1 activation, General serine-threonine phosphatase inhibitors such sodium fluoride, or beta-glycerophosphate and sodium pyrophosphate, or specific PP1 and PP2A inhibitors including microcystin-LR, protein phosphatase 2A inhibitor I-1 or protein phosphatase inhibitor 2 all abrogate H-Ras and K-Ras dependent Raf-1 activation in vitro. A critical Raf-1 target residue for PP1 and PP2A is S259. Serine phosphatase inhibitors block the dephosphorylation of S259, which accompanies Raf-1 activation, and Ras dependent activation of mutant Raf259A is relatively resistant to serine phosphatase inhibitors. Sucrose gradient analysis demonstrates that serine phosphatase inhibition increases the total amount of 14-3-3 and Raf-1 associated with the plasma membrane and significantly alters the distribution of 14-3-3 and Raf-1 across different plasma membrane microdomains, These observations suggest that dephosphorylation of S259 is a critical early step in Ras dependent Raf-1 activation which facilitates 14-3-3 displacement. Inhibition of PP1 and PP2A therefore causes plasma membrane accumulation of Raf-1/14-3-3 complexes which cannot be activated.	Univ Queensland, Sch Med, Dept Pathol, Expt Oncol Lab, Brisbane, Qld 4006, Australia	University of Queensland	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Expt Oncol Lab, Herston Rd, Brisbane, Qld 4006, Australia.		Jaumot, Montserrat/F-2640-2016	Hancock, John/0000-0003-0542-4710; Jaumot, Montserrat/0000-0003-2864-357X				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Cissel DS, 2000, J BIOL CHEM, V275, P7066, DOI 10.1074/jbc.275.10.7066; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Okada T, 1999, MOL CELL BIOL, V19, P6057; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Pol A, 2000, J BIOL CHEM, V275, P30566, DOI 10.1074/jbc.M001131200; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	69	146	148	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3949	3958		10.1038/sj.onc.1204526	http://dx.doi.org/10.1038/sj.onc.1204526			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494123				2022-12-28	WOS:000169681500003
J	Yu, HH; Zisch, AH; Dodelet, VC; Pasquale, EB				Yu, HH; Zisch, AH; Dodelet, VC; Pasquale, EB			Multiple signaling interactions of Abl and Arg kinases with the EphB2 receptor	ONCOGENE			English	Article						protein tyrosine kinase; axon guidance; actin cytoskeleton	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; CENTRAL-NERVOUS-SYSTEM; C-ABL; AUTOPHOSPHORYLATION SITE; NEURITE OUTGROWTH; LIGAND ACTIVATION; AXON GUIDANCE; VISUAL-SYSTEM	The Eph family of receptor tyrosine kinases and the Abl family of non-receptor tyrosine kinases have both been implicated in tissue morphogenesis, They regulate the organization of the actin cytoskeleton in the developing nervous system and participate in signaling pathways involved in axon growth, Both Eph receptors and Abl are localized in the neuronal growth cone, suggesting that they play a role in axon pathfinding. Two-hybrid screens identified regions of Abl and Arg that bind to the EphB2 and EphA4 receptors, suggesting a novel signaling connection involving the two kinase families. The association of full-length Abl and Arg with EphB2 was confirmed by co-immunoprecipitation and found to involve several distinct protein interactions. The SH2 domains of Abl and Arg bind to tyrosine-phosphorylated motifs in the juxtamembrane region of EphB2, A second, phosphorylation-independent interaction with EphB2 involves non-conserved sequences in the C-terminal tails of Abl and Arg, A third interaction between Abl and EphB2 is probably mediated by an intermediary protein because it requires tyrosine phosphorylation of EphB2, but not the binding sites for the Abl SH2 domain. The connection between EphB2 and Abl/Arg appears to be reciprocal. Activated EphB2 causes tyrosine phosphorylation of Abl and Arg, and vice vel sa. Interestingly, treatment of COS cells and B35 neuronal-like cells with ephrin-B1 to activate endogenous EphB2 decreased the kinase activity of endogenous Abl, These data are consistent,vith the opposite effects that Eph receptors and Abl have on neurite ougrowth and suggest that Eph receptors and Abl family kinases have shared signaling activities.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	elenap@burnham.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938, R01HD026351, R29HD026351] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26351, HD25938] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; Cong F, 1999, MOL CELL BIOL, V19, P8314; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Dottori M, 1998, P NATL ACAD SCI USA, V95, P13248, DOI 10.1073/pnas.95.22.13248; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; Ellis C, 1996, ONCOGENE, V12, P1727; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOFF SP, 1985, P SOC EXP BIOL MED, V179, P403; Helmbacher F, 2000, DEVELOPMENT, V127, P3313; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HILL KK, 1995, GENETICS, V141, P595; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MULLER AJ, 1993, P NATL ACAD SCI USA, V90, P3457, DOI 10.1073/pnas.90.8.3457; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; Nehme A, 1997, CANCER RES, V57, P3253; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PEREGO R, 1991, ONCOGENE, V6, P1899; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENBERG N, 1982, CURR TOP MICROBIOL, V101, P95; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOANS C, 1994, ONCOGENE, V9, P3353; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1996, ONCOGENE, V13, P1379; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WANG JYJ, 1984, CELL, V36, P349; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1994, ONCOGENE, V9, P1379; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	91	68	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					3995	4006		10.1038/sj.onc.1204524	http://dx.doi.org/10.1038/sj.onc.1204524			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494128				2022-12-28	WOS:000169681500008
J	Cheng, CW; Wu, PE; Yu, JC; Huang, CS; Yue, CT; Wu, CW; Shen, CY				Cheng, CW; Wu, PE; Yu, JC; Huang, CS; Yue, CT; Wu, CW; Shen, CY			Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene	ONCOGENE			English	Article						E-cadherin; breast cancer; two-hit hypothesis; loss of heterozygosity; hypermethylation; snail	TRANSCRIPTION FACTOR SNAIL; LOW-INCIDENCE AREA; HUMAN CANCER; PROMOTER HYPERMETHYLATION; SPORADIC BREAST; GASTRIC-CANCER; ALPHA-CATENIN; GAMMA-CATENIN; BETA-CATENIN; ALLELIC LOSS	Loss of heterozygosity (LOH) allows the expression of recessive mutation in tumor suppressor genes (TSG), Therefore, on the basis of Knudson's 'two-hit' hypothesis for TSG inactivation, the detection of a high LOH frequency in a chromosomal region is considered critical for TSG localization. One of these LOH regions in breast cancer is 16q22.1, which has been suggested to reflect the involvement of E-cadherin (E-cad), a cell-tell adhesion molecule, To confirm the tumorigenic role of Ecad, 81 sporadic invasive ductal carcinomas (IDCs) of the breast were tested for the 'two hits' required to inactivate this gene. A high frequency (37.3%) of LOH was detected in 67 informative tumors, but no mutation was found. To examine the possibility that transcriptional mechanisms serve as the second hit in tumors with LOH, specific pathways, including genetic variant and hypermethylation at the promoter region and abnormal expression of positive (WT1) and negative (Snail) transcription factors, were identified. Of these, promoter hypermethylation and increased expression of Snail were found to be common (> 35%), and to be strongly associated with reduced/negative E-cad expression (P <0.05), However, unexpectedly, a significantly negative association was found between the existence of LOH and promoter hypermethylation (P <0.05), which contradicts the 'two-hit' model, Instead, since they coexisted in a high frequency of tumors, hypermethylation may work in concert with increased Snail to inactivate E-cad expression, Given that Ecad is involved in diverse mechanisms, loss of which is beneficial for tumors to invade but may also trigger apoptosis, this study suggests that maintaining a reversible mechanism, either by controlling the gene at the transcriptional level or by retaining an intact allele subsequent to LOH, might be important for E-cad in IDC and may also be common in TSGs possessing diverse functions, These findings provide clues to explain why certain TSGs identified by LOH cannot fulfil the two-hit hypothesis.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Acad Sinica, Lib Sci Lib, Taipei 115, Taiwan; Natl Taiwan Univ, Sch Publ Hlth, Grad Inst Epidemiol, Taipei 100, Taiwan; Natl Hlth Res Inst, Taipei 115, Taiwan; Shin Kong Wu Ho Su Mem Hosp, Dept Pathol, Taipei 111, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Triserv Gen Hosp, Dept Surg, Taipei 11490, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University; National Health Research Institutes - Taiwan; Shin Kong Wu Ho Su Memorial Hospital; National Taiwan University; National Taiwan University Hospital; Tri-Service General Hospital	Shen, CY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.	bmcys@ccvax.sinica.edu.tw	Shen, CY/F-6271-2010	Huang, Chiun-Sheng/0000-0002-6557-211X				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bindels EMJ, 2000, CANCER RES, V60, P177; Brown MA, 1997, ADV GENET, V36, P45, DOI 10.1016/S0065-2660(08)60307-7; Bukholm IK, 2000, J PATHOL, V190, P15; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Davidson B, 2000, J PATHOL, V192, P460; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fabre A, 1999, HUM PATHOL, V30, P661, DOI 10.1016/S0046-8177(99)90091-6; Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Gonzalgo ML, 1997, CANCER RES, V57, P5336; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Healey CS, 2000, NAT GENET, V26, P362, DOI 10.1038/81691; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Huang CS, 1999, CANCER RES, V59, P4870; Ilyas M, 2000, J PATHOL, V190, P3, DOI 10.1002/(SICI)1096-9896(200001)190:1<3::AID-PATH490>3.0.CO;2-5; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ku WH, 1997, INT J CANCER, V72, P270, DOI 10.1002/(SICI)1097-0215(19970717)72:2<270::AID-IJC12>3.0.CO;2-K; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Laux DE, 1999, BREAST CANCER RES TR, V56, P35, DOI 10.1023/A:1006222803788; Li LC, 2000, CANCER RES, V60, P873; LINDBLOM A, 1993, CANCER RES, V53, P3707; Lo YL, 1998, INT J CANCER, V79, P580, DOI 10.1002/(SICI)1097-0215(19981218)79:6<580::AID-IJC5>3.0.CO;2-M; Lou MA, 1997, BRIT J CANCER, V75, P746, DOI 10.1038/bjc.1997.132; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6; Nass SJ, 2000, CANCER RES, V60, P4346; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shen CY, 2000, CANCER RES, V60, P3884; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Tan DSP, 1999, J PATHOL, V189, P20, DOI 10.1002/(SICI)1096-9896(199909)189:1<20::AID-PATH394>3.0.CO;2-2; Tseng SL, 1997, GENE CHROMOSOME CANC, V20, P377; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang PS, 1997, BRIT J CANCER, V75, P752, DOI 10.1038/bjc.1997.133	60	183	191	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 28	2001	20	29					3814	3823		10.1038/sj.onc.1204505	http://dx.doi.org/10.1038/sj.onc.1204505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439345				2022-12-28	WOS:000169494700007
J	Meyer, GE; Shelden, E; Kim, B; Feldman, EL				Meyer, GE; Shelden, E; Kim, B; Feldman, EL			Insulin-like growth factor I stimulates motility in human neuroblastoma cells	ONCOGENE			English	Article						PI3-K; MAP kinase; insulin receptor substrate; PTEN	KINASE TYROSINE PHOSPHORYLATION; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CYTOSKELETAL REORGANIZATION; DIFFERENTIAL REGULATION; RECEPTOR SUBSTRATE-2; NEURITE OUTGROWTH; SIGNALING SYSTEM; RAC	Motility is an important process that contributes to cancer cell spread. Growth factors are key regulators of motility in many cell types. Insulin-like growth factor I (IGF-I) causes SH-SY5Y human neuroblastoma cells to undergo dynamic morphological changes, leading to the extension of lamellipodia. IGF-I stimulated lamellipodia extension requires signaling through both phosphatidylinositol 3-kinase (P13-K) and MAP kinase pathways. IGF-I, over a period of hours, stimulates SH-SY5Y and SHEP neuroblastoma cells to become more motile. While SH-SY5Y and SHEP cells use different insulin receptor substrate (IRS) isoforms to transduce signals from the IGF-I receptor, IGF-I has the same relative effect on the motility of both cell lines. Blocking the P13-K and MAP kinase pathways attenuates the ability of IGF-I to increase motility. Overexpression of PTEN also attenuates IGF-I mediated motility. These results delineate some of the proximal events in the signaling mechanism utilized by IGF-I to stimulate cell motility.	Univ Michigan, Dept Neurol, Program Neurosci, Ann Arbor, MI 48109 USA; Univ Michigan, Med Sci Training Program, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, Program Neurosci, 4414 Kresge III,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.		, Eric/GWC-7636-2022	Feldman, Eva/0000-0002-9162-2694	NCI NIH HHS [5T32 CA 09676] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 07863] Funding Source: Medline; NINDS NIH HHS [R01 NS 38849] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; JACKSON JG, 1999, END SOC 81 ANN M, P479; Keller HU, 2000, CELL MOTIL CYTOSKEL, V46, P247, DOI 10.1002/1097-0169(200008)46:4<247::AID-CM2>3.0.CO;2-8; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; Kim BS, 1998, J NEUROCHEM, V71, P1333; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOHAN S, 1991, CLIN ORTHOP RELAT R, P30; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; PANAGAKOS FS, 1993, BIOCHIMIE, V75, P991, DOI 10.1016/0300-9084(93)90150-Q; Shelden EA, 2000, J NEUROSCI METH, V102, P143, DOI 10.1016/S0165-0270(00)00286-7; Singleton JR, 1996, CANCER RES, V56, P4522; SUMANTRAN VN, 1993, ENDOCRINOLOGY, V132, P2017, DOI 10.1210/en.132.5.2017; TANABE M, 1995, MED PEDIATR ONCOL, V24, P292, DOI 10.1002/mpo.2950240505; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; YAMAMOTO M, 1993, NEUROSCI LETT, V152, P37, DOI 10.1016/0304-3940(93)90477-3; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	38	53	54	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7542	7550		10.1038/sj.onc.1204927	http://dx.doi.org/10.1038/sj.onc.1204927			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709726				2022-12-28	WOS:000171976900011
J	Gilley, J; Fried, M				Gilley, J; Fried, M			One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus	ONCOGENE			English	Article						ARF; INK4A; INK4B; Fugu rubripes; tumour suppressor; evolution	INHIBITOR; CLONING; P53; EXPRESSION; P16(INK4A); SEQUENCE; PATHWAY; CDKN2	The INK4A/ARF/INK4B locus, conserved in mammals, encodes three polypeptides that regulate cell proliferation via the pRb and p53 tumour suppressor pathways. The locus is mutated in many cancers. The related, tandemly-linked INK4A and INK4B genes encode the p16(INK4A) and p15(INK4B) members of the INK4 family of cyclin-dependent kinase inhibitors which block phosphorylation of pRb, whereas the third product, ARF, derived from an alternative reading frame of INK4A, regulates p53 activity. We assessed the status of this unusual locus in the puffer fish, Fugu rubripes, and identified two INK4 genes using degenerate PCR and hybridization analyses. Sequence conservation and conservation of synteny between human and Fugu predict one gene to be an INK4A or INK4B homologue and the other an INK4D homologue. Analysis of the Fugu INK4A/B gene and the surrounding 40-kb of genomic DNA did not reveal the presence of any ARF-encoding potential or another related INK4 gene. We conclude that the gene duplication event that generated adjacent INK4A and INK4B genes and the association of ARF with the ancestral INK4A gene occurred after the divergence of the lineage leading to mammals from fish. Thus, unlike mammals, the fish p53 and pRb tumour suppressor pathways are not regulated by a single locus.	UCSF Canc Res Inst, San Francisco, CA 94115 USA; Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, London WC2A 3PX, England	University of California System; University of California San Francisco; UCSF Medical Center; Cancer Research UK	Fried, M (corresponding author), UCSF Canc Res Inst, 2340 Sutter St, San Francisco, CA 94115 USA.							Armes N, 1997, GENOME RES, V7, P1138, DOI 10.1101/gr.7.12.1138; Bhaskaran A, 1999, ENVIRON MOL MUTAGEN, V33, P177, DOI 10.1002/(SICI)1098-2280(1999)33:3<177::AID-EM1>3.0.CO;2-X; Brunelli JP, 1999, GENE, V226, P175, DOI 10.1016/S0378-1119(98)00574-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dreyling MH, 1998, GENE CHROMOSOME CANC, V22, P72, DOI 10.1002/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.3.CO;2-G; Elgar G, 1996, HUM MOL GENET, V5, P1437, DOI 10.1093/hmg/5.Supplement_1.1437; Gilley J, 1999, HUM MOL GENET, V8, P1313, DOI 10.1093/hmg/8.7.1313; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Jiang P, 1995, J MOL EVOL, V41, P795; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kazianis S, 1999, ONCOGENE, V18, P5088, DOI 10.1038/sj.onc.1202884; OKUDA T, 1995, GENOMICS, V29, P623, DOI 10.1006/geno.1995.9957; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherburn TE, 1998, DNA CELL BIOL, V17, P975, DOI 10.1089/dna.1998.17.975; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	25	40	40	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7447	7452		10.1038/sj.onc.1204933	http://dx.doi.org/10.1038/sj.onc.1204933			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704876				2022-12-28	WOS:000171894200019
J	Toomey, NL; Deyev, VV; Wood, C; Boise, LH; Scott, D; Liu, LH; Cabral, L; Podack, ER; Barber, GN; Harrington, WJ				Toomey, NL; Deyev, VV; Wood, C; Boise, LH; Scott, D; Liu, LH; Cabral, L; Podack, ER; Barber, GN; Harrington, WJ			Induction of a TRAIL mediated suicide program by interferon alpha in primary effusion lymphoma	ONCOGENE			English	Article						Human Herpes Virus Type 8; Epstein Barr virus; TRAIL; apoptosis; lymphoma; FADD	NF-KAPPA-B; APOPTOSIS-INDUCING LIGAND; SIGNALING COMPLEX DISC; EPSTEIN-BARR-VIRUS; LYMPHOPROLIFERATIVE DISORDERS; PROTEIN-KINASE; DEATH; ACTIVATION; THYMIDINE; RECEPTORS	Gammaherpes viruses are often detected in lymphomas arising in immunocompromised patients. We have found that Azidothymidine (AZT) alone induces apoptosis in Epstein Barr Virus (EBV) positive Burkitt's lymphoma (BL) cells but requires interferon alpha (IFN-alpha) to induce apoptosis in Human Herpes Virus Type 8 (HHV-8) positive Primary Effusion Lymphomas (PEL). Our analysis of a series of AIDS lymphomas revealed that IFN-alpha selectively induced very high levels of the Death Receptor (DR) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in HHV-8 positive PEL lines and primary tumor cells whereas little or no induction was observed in primary EBV+ AIDS lymphomas and ERV-Burkitt's lines. AZT and IFN-alpha mediated apoptosis in PEL was blocked by stable overexpression of dominant negative Fas Associated Death Domain (FADD), decoy receptor 2 (DcR2), soluble TRAIL receptor fusion proteins (DR-4 and DR-5) and thymidine. Trimeric TRAIL (in place of IFN-alpha) similarly synergized with AZT to induce apoptosis in HHV-8 positive PEL cells. This is the first demonstration that IFN-alpha induces functional TRAIL in a malignancy that can be exploited to effect a suicide program. This novel antiviral approach to Primary Effusion lymphomas is targeted and may represent a highly effective and relatively non-toxic therapy.	Univ Miami, Sch Med, Dept Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA	University of Miami; University of Miami; University of Nebraska System; University of Nebraska Lincoln	Harrington, WJ (corresponding author), Univ Miami, Sch Med, Dept Med, Sylvester Comprehens Canc Ctr, Room 3400 D8-4,1475 NW 12th Ave, Miami, FL 33136 USA.		Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815; Wood, Charles/0000-0002-4256-1530	NATIONAL CANCER INSTITUTE [R01CA039201, R29CA077837, R01CA082274, R01CA080228] Funding Source: NIH RePORTER; NCI NIH HHS [CA80228, CA82274, CA77837, CA39201] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNER ESJ, 1992, J BIOL CHEM, V267, P10968; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Cannon JS, 1999, J VIROL, V73, P4786, DOI 10.1128/JVI.73.6.4786-4793.1999; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; DeMario MD, 1998, SEMIN ONCOL, V25, P492; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Findenig G, 1996, ONCOL RES, V8, P189; Gaidano G, 2000, J CLIN VIROL, V16, P215, DOI 10.1016/S1386-6532(99)00082-7; GAIDANO G, 1994, ANN HEMATOL, V69, P281, DOI 10.1007/BF01696556; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Goldsby RE, 1998, J PEDIAT HEMATOL ONC, V20, P282, DOI 10.1097/00043426-199807000-00002; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Gustafson EA, 2000, J VIROL, V74, P684, DOI 10.1128/JVI.74.2.684-692.2000; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Knowles DM, 1999, MODERN PATHOL, V12, P200; Lee RK, 1999, CANCER RES, V59, P5514; Levine AM, 2000, SEMIN ONCOL, V27, P442; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mingari MC, 2000, HUM IMMUNOL, V61, P44, DOI 10.1016/S0198-8859(99)00158-5; Mullaney BP, 2000, ARCH PATHOL LAB MED, V124, P824; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Okano M, 2000, AM J MED SCI, V319, P392, DOI 10.1097/00000441-200006000-00009; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; Raez L, 1999, AIDS RES HUM RETROV, V15, P713, DOI 10.1089/088922299310809; Sarid R, 1999, J VIROL, V73, P1438, DOI 10.1128/JVI.73.2.1438-1446.1999; Swinnen LJ, 2000, ANN ONCOL, V11, P45, DOI 10.1023/A:1008396821609; Swinnen LJ, 1999, SEMIN ONCOL, V26, P21; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zavaglia C, 2000, J CLIN GASTROENTEROL, V30, P234, DOI 10.1097/00004836-200004000-00006	44	52	53	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7029	7040		10.1038/sj.onc.1204895	http://dx.doi.org/10.1038/sj.onc.1204895			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704827				2022-12-28	WOS:000171739300006
J	McKay, BC; Becerril, C; Ljungman, M				McKay, BC; Becerril, C; Ljungman, M			P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts	ONCOGENE			English	Article						apoptosis; DNA repair; p53; ultraviolet	RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; IRRADIATED HUMAN FIBROBLASTS; LIGHT-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; LI-FRAUMENI SYNDROME; ULTRAVIOLET-LIGHT; DNA-DAMAGE; HUMAN-CELLS; INHIBITION	We previously reported that transcription-coupled repair (TCR)-deficient human fibroblasts are extremely sensitive to UV-induced apoptosis and this sensitivity correlated with the induction of the p53 tumour suppressor. However, we have also found that p53 can be protective against UV-induced apoptosis. Thus, prior to this study, it was not clear whether the induction of p53 in TCR-deficient fibroblasts contributed to their death. To address this issue, we have expressed human papillomavirus E6 (HPV-E6) in primary fibroblasts derived from patients affected with xeroderma pigmentosum (complementation groups A, B and C) and Cockayne syndrome (complementation group B). We found that TCR-deficient (XP-A, XP-B and CS-B) fibroblasts were more sensitive than TCR-proficient cells (XP-C and normal) to both UV light and cisplatin treatment and this increase in sensitivity was not p53 dependent. Importantly, HPV-E6 expression increased the sensitivity of TCR-proficient normal and XP-C fibroblasts to UV- and cisplatin-induced apoptosis. This increase in sensitivity correlated with a decrease in the capacity of HPV-E6 expressing cells to recover mRNA synthesis following UV-irradiation. Therefore, we propose that p53 protects against UV- and cisplatin-induced apoptosis in a TCR-dependent manner and that p53 does not contribute strongly to the induction of apoptosis. in TCR-deficient fibroblasts.	Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada; Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Michigan System; University of Michigan	McKay, BC (corresponding author), Ottawa Reg Canc Ctr, Ctr Canc Therapeut, 503 Smyth Rd,3rd Floor, Ottawa, ON K1H 1C4, Canada.		McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331	NCI NIH HHS [CA 82376-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Barley RDC, 1998, ONCOGENE, V17, P533, DOI 10.1038/sj.onc.1202271; Conforti G, 2000, ONCOGENE, V19, P2714, DOI 10.1038/sj.onc.1203583; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; El-Mahdy MA, 2000, MUTAT RES-DNA REPAIR, V459, P135, DOI 10.1016/S0921-8777(99)00066-X; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MAY A, 1993, J BIOL CHEM, V268, P1650; McKay BC, 1997, PHOTOCHEM PHOTOBIOL, V66, P659, DOI 10.1111/j.1751-1097.1997.tb03203.x; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; McKay BC, 2001, MUTAT RES-DNA REPAIR, V485, P93, DOI 10.1016/S0921-8777(00)00064-1; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 1996, AM J PATHOL, V148, P1019; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	36	95	95	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6805	6808		10.1038/sj.onc.1204901	http://dx.doi.org/10.1038/sj.onc.1204901			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709715				2022-12-28	WOS:000171551600017
J	Mousses, S; Wagner, U; Chen, YD; Kim, JW; Bubendorf, L; Bittner, M; Pretlow, T; Elkahloun, AG; Trepel, JB; Kallioniemi, OP				Mousses, S; Wagner, U; Chen, YD; Kim, JW; Bubendorf, L; Bittner, M; Pretlow, T; Elkahloun, AG; Trepel, JB; Kallioniemi, OP			Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling	ONCOGENE			English	Article						microarray; prostate cancer; hormone-refractory; androgen-independent; CWR22	MAMMALIAN TARGET; GROWTH-FACTOR; RECEPTOR; XENOGRAFT; EXPRESSION; CWR22; MODEL; RHABDOMYOSARCOMA; INHIBITION; MECHANISM	Androgen deprivation therapy for advanced prostate cancer is often effective, but not curative. Molecular pathways mediating the therapeutic response and those contributing to the subsequent hormone-refractory cell growth remain poorly understood. Here, cDNA microarray analysis of human CWR22 prostate cancer xenografts during the course of androgen deprivation therapy revealed distinct global gene expression profiles in primary, regressing and recurrent tumors. Elucidation of the genes involved in the transition between these states implicated specific molecular mechanisms in therapy failure and tumor progression. First, we identified a set of androgen-responsive genes whose expression decreased during the therapy response, but was then systematically restored in the recurrent tumors. In addition, altered expression of genes that encode known targets of rapamycin or that converge on the PI3K/AKT/FRAP pathway was observed in the recurrent tumors. Further suggestion for the involvement of these genes in hormone-refractory prostate cancer came from the observation that cells established from the recurrent xenografts were strongly inhibited in vitro by rapamycin. The results of this functional genomic analysis suggest that the combined effect of re-expression of androgen-responsive genes as well as the activation of rapamycin-sensitive signaling may drive prostate cancer progression, and contribute to the failure of androgen-deprivation therapy.	NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; NCI, Med Branch, NIH, Bethesda, MD 20850 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Basel; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Case Western Reserve University	Kallioniemi, OP (corresponding author), NHGRI, Canc Genet Branch, NIH, Bldg 49,Rm 4A24, Bethesda, MD 20892 USA.	okalli@nhgri.nih.gov	Kallioniemi, Olli P/H-5111-2011; Bubendorf, Lukas/G-5299-2015; Bubendorfl, Lukas/H-5880-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Bubendorf, Lukas/0000-0001-5970-1803; 	NATIONAL CANCER INSTITUTE [U01CA057179, R01CA057179] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Amler LC, 2000, CANCER RES, V60, P6134; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Cheng L, 1996, J NATL CANCER I, V88, P607, DOI 10.1093/jnci/88.9.607; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; DILLING MB, 1994, CANCER RES, V54, P903; Gregory CW, 1998, CANCER RES, V58, P5718; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Khan J, 1998, CANCER RES, V58, P5009; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Mousses S, 2000, PRACT APPROACH SER, P113; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; PRETLOW TG, 1993, J NATL CANCER I, V85, P394, DOI 10.1093/jnci/85.5.394; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sekulic A, 2000, CANCER RES, V60, P3504; WAINSTEIN MA, 1994, CANCER RES, V54, P6049	22	110	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6718	6723		10.1038/sj.onc.1204889	http://dx.doi.org/10.1038/sj.onc.1204889			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709706				2022-12-28	WOS:000171551600008
J	Schmidt, M; Fan, Z				Schmidt, M; Fan, Z			Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells	ONCOGENE			English	Article						chemotherapy; chemoprotection; Rb; cell cycle; CDK	HUMAN PAPILLOMAVIRUS TYPE-16; EPIDERMAL GROWTH-FACTOR; G(1) ARREST; RETINOBLASTOMA PROTEIN; E7 ONCOPROTEIN; CDK INHIBITORS; GENE; DIFFERENTIATION; P27(KIP1); BINDING	Inactivation of the retinoblastoma (Rb) protein caused by gene mutation, association with oncoproteins from small DNA viruses, mutational inactivation of p16(Ink4a), or overexpression of cyclin D is a common feature of many human cancer cells and is causally associated with the aberrant proliferation control of cancer cells; whereas normal cells maintain an integrated cell cycle machinery and are subject to cell cycle checkpoint control by cyclin-dependent kinase (CDK) inhibitors (CKIs). To determine whether this difference can be translated into a therapeutic advantage to protect normal cells from adverse cytotoxicity caused by chemotherapy, we established cell model systems for ecdysone-inducible expression of p16(Ink4a), p21(Waf1), and p27(Kip1) in one CKI-responsive cell line (A431 human vulvar epidermoid carcinoma cells with functional Rb) and one CKI-unresponsive cell line (SiHa human cervical cancer cells with nonfunctional Rb). Expression of p16(Ink4a), p21(Waf1), or p27(Kip1) in both SiHa and A431 cells strongly inhibited CDK2 activity, indicating functional expression of the CDK inhibitors in both cell lines. However, only in A431 cells did expression of p16(Ink4a), p21(Waf1), or p27(Kip1) cause Rb dephosphorylation, arrest cell cycle traversal, and potently inhibit cell proliferation. Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) in SiHa cells failed to cause Rb dephosphorylation or to arrest cell cycle traversal, and such induction only minimally inhibited cell proliferation. We then compared the chemosensitivity of clones derived from these two cell lines when the CKIs were and were not induced. Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells. Our results support a novel chemotherapy strategy for treating patients with Rb pathway-impaired cancers by concurrent administration of chemotherapy with CKIs as chemoprotective agents for normal cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 36, Houston, TX 77030 USA.				NCI NIH HHS [CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Boyer SN, 1996, CANCER RES, V56, P4620; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; Davis ST, 2001, SCIENCE, V291, P134, DOI 10.1126/science.291.5501.134; Dellas A, 1998, ANTICANCER RES, V18, P3991; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Fueyo J, 1998, INT J ONCOL, V12, P665; Funk JO, 1998, TRENDS BIOCHEM SCI, V23, P337; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; JONES RE, 1990, J BIOL CHEM, V265, P12782; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; KWOK TT, 1994, CANCER RES, V54, P2834; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; MUNGER K, 1992, CANCER SURV, V12, P197; Ruan S, 1998, CANCER RES, V58, P1538; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; SCHMIDT M, 2001, IN PRESS MOL PHARM; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; StCroix B, 1996, NAT MED, V2, P1204; Stone S, 1996, CANCER RES, V56, P3199; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; Wu XP, 1996, ONCOGENE, V12, P1397; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	41	28	42	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6164	6171		10.1038/sj.onc.1204814	http://dx.doi.org/10.1038/sj.onc.1204814			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593424				2022-12-28	WOS:000171206300007
J	Coffin, WF; Erickson, KD; Hoedt-Miller, M; Martin, JM				Coffin, WF; Erickson, KD; Hoedt-Miller, M; Martin, JM			The cytoplasmic amino-terminus of the Latent Membrane Protein-1 of Epstein-Barr Virus: relationship between transmembrane orientation and effector functions of the carboxy-terminus and transmembrane domain	ONCOGENE			English	Article						LMP-1; EBV; transmembrane topology; signaling	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; INTERNAL SIGNAL SEQUENCE; LYMPHOCYTE TRANSFORMATION; CHARGED RESIDUES; C-TERMINUS; 1 ENGAGES; LMP1; EXPRESSION; ACTIVATION	The Latent Membrane Protein 1 (LMP-1) protein of Epstein-Barr virus (EBV) is localized in the plasma membrane of the infected cell. LMP-1 possesses a hydrophobic membrane spanning domain, and charged, intracellular amino- and carboxy-termini. Two models have been proposed for the contribution of the amino-terminus to LMP-l's function: (i) as an effector domain, interacting with cellular proteins, or (ii) as a structural domain dictating the correct orientation of transmembrane domains and thereby positioning LMP-l's critical effector domains (i.e. the carboxy-terminus). However, no studies to date have addressed directly the structural contributions of LMP-1s cytoplasmic amino-terminus to function. This study was designed to determine if LMP-1's cytoplasmic amino-terminus (N-terminus) encodes information required solely for maintenance of proper topological orientation. We have constructed LMP-1 chimeras in which the cytoplasmic N-terminus of LMP-1 is replaced with an unrelated domain of similar size and charge, but of different primary sequence. Retention of the charged amino-terminal (N-terminal) cytoplasmic domain and first predicted transmembrane domain was required for correct transmembrane topology. The absolute primary sequence of the cytoplasmic N-terminus was not critical for LMP-1's cytoskeletal association, turnover, plasma membrane patching, oligomerization, Tumor Necrosis Factor Receptor-associated factor (TRAF) binding, NF-kappaB activation, rodent cell transformation and cytostatic activity. Furthermore, our results point to the hydrophobic transmembrane domain, independent of the cytoplasmic domains, as the primary LMP-1 domain mediating oligomerization, patching and cytoskeletal association. The cytoplasmic amino-terminus provides the structural information whereby proper transmembrane orientation is achieved.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Martin, JM (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Box 347, Boulder, CO 80309 USA.	jm@stripe.colorado.edu	Erickson, Kimberly/AAR-8747-2021	Erickson, Kimberly/0000-0002-6260-282X	NATIONAL CANCER INSTITUTE [R29CA064610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001537] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64610] Funding Source: Medline; NIAID NIH HHS [AI-01537] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; BAICHWAL VR, 1989, ONCOGENE, V4, P67; Bankier A T, 1983, Mol Biol Med, V1, P425; BELTZER JP, 1991, J BIOL CHEM, V266, P973; Bloss T, 1999, J GEN VIROL, V80, P3227, DOI 10.1099/0022-1317-80-12-3227; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Clausse B, 1997, VIROLOGY, V228, P285, DOI 10.1006/viro.1996.8380; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Erickson KD, 2000, J VIROL, V74, P1057, DOI 10.1128/JVI.74.2.1057-1060.2000; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GRATAMA JW, 1991, INT J CANCER, V47, P188, DOI 10.1002/ijc.2910470205; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2276, DOI 10.1073/pnas.80.8.2276; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hatzivassiliou E, 1998, J IMMUNOL, V160, P1116; HEDGE R, 1997, CELL, V28, P575; HEDGE RS, 1999, TRENDS CELL BIOL, V9, P132; HUEN DS, 1995, ONCOGENE, V10, P549; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; KNUTSON VP, 1985, J BIOL CHEM, V260, P4180; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MARTIN J, 1991, CELL GROWTH DIFFER, V2, P653; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MILELR G, 1985, EPSTEIN BARR VIRUS; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; RABSON M, 1983, P NATL ACAD SCI-BIOL, V80, P2762, DOI 10.1073/pnas.80.9.2762; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	76	27	28	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5313	5330		10.1038/sj.onc.1204689	http://dx.doi.org/10.1038/sj.onc.1204689			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536044				2022-12-28	WOS:000170575500007
J	Azios, NG; Romero, FJ; Denton, MC; Doherty, JK; Clinton, GM				Azios, NG; Romero, FJ; Denton, MC; Doherty, JK; Clinton, GM			Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor	ONCOGENE			English	Article						herstatin; heregulin; EGF; HER-1; HER-2; HER-3; HER-2/HER-3 heterodimers	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; HER2/NEU-OVEREXPRESSING METASTATIC BREAST; TYROSINE KINASE-ACTIVITY; ERBB SIGNALING NETWORK; MONOCLONAL-ANTIBODY; EXTRACELLULAR DOMAIN; BINDING-SITE; CARCINOMA-CELLS; PHASE-II	The four members of the EGF receptor family are capable of homomeric as well as heteromeric interactions. HER-2/neu (erbB-2) dominates as the preferred coreceptor that amplifies mitogenic signaling. An alternative HER-2/neu product, herstatin, consists of a segment of the ectodomain of p185HER-2 and an intronencoded C-terminus. Recombinant herstatin was found to bind with nm affinity and inhibit p185HER-2. To further examine the impact on receptor activity, herstatin was expressed with various receptor tyrosine kinases. In CHO cells that overexpressed HER-2, herstatin caused a sevenfold inhibition of colony formation that corresponded to a reduction in the tyrosine phosphorylation of p185HER-2. Herstatin also prevented HER-2 mediated transactivation of the kinase impaired HER-3 as reflected in transphosphorylation of HER-3 and heteromers between HER-2 and HER-3. In EGF receptor-overexpressing cells, EGF induction of receptor dimerization and tyrosine phosphorylation were reduced more than 90%, and receptor down-regulation as well as colony formation were also suppressed by coexpression with herstatin. Inhibition was selective for the EGF receptor family since herstatin expression did not reduce tyrosine phosphorylation mediated by the FGF receptor-2 or by insulin-like growth factor -1. Herstatin bound to the EGF receptor as well as to p185HER-2 in pull-down assays suggesting that complex formation may be involved in receptor inhibition. Our findings indicate that herstatin has the capability to negatively regulate combinations of interactions between group I receptor tyrosine kinases that confer synergistic growth signals.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90033 USA	Oregon Health & Science University; University of Southern California	Clinton, GM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	clinton@ohsu.edu						AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1997, J MAMMARY GLAND BIOL, V2, P165, DOI 10.1023/A:1026355831693; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHOU CK, 1987, J BIOL CHEM, V262, P1842; Christianson TA, 1998, CANCER RES, V58, P5123; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENDLY BM, 1990, CANCER RES, V50, P1550; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; Klapper LN, 2000, ADV CANCER RES, V77, P25; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LIN YZJ, 1991, ONCOGENE, V6, P639; LONARDO F, 1990, New Biologist, V2, P992; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; Moscatello DK, 1996, ONCOGENE, V13, P85; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Ram TG, 2000, CELL GROWTH DIFFER, V11, P173; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Sambrook J, 1989, MOL CLONING; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINTRAUB H, 1986, CELL, V46, P115, DOI 10.1016/0092-8674(86)90865-2; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319	64	43	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5199	5209		10.1038/sj.onc.1204555	http://dx.doi.org/10.1038/sj.onc.1204555			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526509				2022-12-28	WOS:000170464000014
J	Michaelson, JS; Leder, P				Michaelson, JS; Leder, P			beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland	ONCOGENE			English	Article						beta-catenin; breast cancer; mammary gland; Wnt; adenocarcinoma; MMTV	POLYPOSIS-COLI PROTEIN; CYCLIN D1 GENE; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; FEMALE MICE; IN-VIVO; C-MYC; EXPRESSION; APC; TRANSFORMATION	The Wnt signal transduction pathway has been implicated in mammary tumorigenesis in the mouse. beta -catenin, a key downstream effector of this pathway interacts with and thus activates the Tcf/Lef family of transcription factors. Elevated levels of beta -catenin have been found in many human tumors, notably colon carcinomas. Recently, elevated levels of beta -catenin have been associated with poor prognosis in human adenocarcinoma of the breast. In order to assess the possible role of beta -catenin in mammary carcinoma, we have created transgenic mice bearing the MMTV-LTR driving an activated form of beta -catenin. These mice develop mammary gland hyperplasia and mammary adenocarcinoma, a phenotype very similar to that of transgenic mice expressing an MMTV-driven Writ gene. Indeed, the histopathology of the mammary tumors in Wnt-mediated adenocarcinoma is identical to that observed in our beta -catenin-mediated disease model. Furthermore, putative beta -catenin transcriptional targets, cyclin D1 and c-myc, are elevated in beta -catenin-mediated mammary tumors and cell lines. These observations support the notion that the oncogenic Wnt pathway operates via beta -catenin and its targets in the context of mammary hyperplasia and carcinoma.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.							Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Haertel-Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Xu LF, 2000, GENE DEV, V14, P585; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	31	145	169	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5093	5099		10.1038/sj.onc.1204586	http://dx.doi.org/10.1038/sj.onc.1204586			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526497				2022-12-28	WOS:000170464000002
J	Finzer, P; Kuntzen, C; Soto, U; Zur Hausen, H; Rosl, F				Finzer, P; Kuntzen, C; Soto, U; Zur Hausen, H; Rosl, F			Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression	ONCOGENE			English	Article						p21; p27; p45(SKP2); E7; apoptosis; therapy	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT-KINASE INHIBITOR; S-PHASE; TRANSCRIPTIONAL REGULATION; REPRESS TRANSCRIPTION; ECTOPIC EXPRESSION; POTENTIAL MEDIATOR; E7 ONCOPROTEIN; PROTEIN; DEGRADATION	Histone deacetylase (HDAC) inhibitors sodium butyrate and trichostatin A arrest human papillomavirus (HPV)positive carcinoma cells in G1 to S transition of the cell cycle, which is paralleled by an up-regulation of the cyclin-dependent kinase inhibitors (CKIs) p21(CIP1) and p27(KIP1) as well as the complete loss of cdk2 activity. Although HPV expression was hitherto thought to be required to maintain a proliferative phenotype of these cells, cdk2 suppression is achieved even in the presence of ongoing viral transcription. While CKIs normally cannot exert their cdk2-inhibitory function in the presence of the viral oncoprotein E7, co-immunoprecipitation experiments revealed that E7 binding is prevented. Increase of p27(KIP1) correlates with down-regulation of p45(SKP2), a component of the ubiquitin-protein ligase SCFSKP2 controlling the half-life of regulatory proteins during the cell cycle. HDAC inhibition also triggered an E7-dependent degradation of pRb, while the levels of E2F remained unaffected. The presence of free intracellular E2F and the concomitant up-regulation of CKIs during G1 arrest results in a 'conflicting growth situation', which finally renders the cells to undergo apoptosis. These data provide novel molecular insights into how the transforming potential of HPV can be bypassed and open new therapeutical perspectives for the treatment of cervical cancer.	Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Finzer P, 2000, ONCOGENE, V19, P3235, DOI 10.1038/sj.onc.1203643; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Janson W, 1997, ONCOGENE, V15, P1395, DOI 10.1038/sj.onc.1201304; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; NEWMARK HL, 1994, CANCER LETT, V78, P1, DOI 10.1016/0304-3835(94)90023-X; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROSL F, 1999, POSSIBLE ROLE CHEMOK, P207; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siavoshian S, 1997, BIOCHEM BIOPH RES CO, V232, P169, DOI 10.1006/bbrc.1997.6255; STOEHR M, 1978, STAIN TECHNOL, V55, P205; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TOMMASINO M, 1993, ONCOGENE, V8, P195; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	53	95	97	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4768	4776		10.1038/sj.onc.1204652	http://dx.doi.org/10.1038/sj.onc.1204652			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521189				2022-12-28	WOS:000170271800002
J	Malkin, D; Chilton-MacNeill, S; Meister, LA; Sexsmith, E; Diller, L; Garcea, RL				Malkin, D; Chilton-MacNeill, S; Meister, LA; Sexsmith, E; Diller, L; Garcea, RL			Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome	ONCOGENE			English	Article						Li-Fraumeni syndrome; p53; SV40 polyomavirus; tumor initiation	GERMLINE P53 MUTATIONS; WILD-TYPE P53; T-ANTIGEN; TRANSGENIC MICE; CHOROID-PLEXUS; BRAIN-TUMORS; CANCER; GENE; FAMILIES; SIMIAN-VIRUS-40	Inactivation of wild-type p53 tumor suppressor function is the primary mechanism of tumor initiation in Li-Fraumeni syndrome (LFS) individuals with germline p53 mutations. Tumors derived from LFS patients frequently retain the normal p53 allele, suggesting that alternative mechanisms in addition to gene deletion must be involved in inactivating wild-type p53 protein. DNA tumor viruses, such as SV40, target p53 for inactivation through the action of viral oncoproteins. We studied the probands from two unrelated LFS families, each of whom presented with multiple malignant neoplasms. Patient 1 developed an embryonal rhabdomyosarcoma (RMS) and a choroid plexus carcinoma (CPC), while patient 2 developed a CPC and subsequently presented with both an osteosarcoma (OS) and renal cell carcinoma (RCC). We utilized DNA sequence analysis and immunohistochemistry to determine p53 gene status in the germline and tumors, as well as evidence for SV40 T-antigen oncoprotein expression. Each patient harbored a heterozygous germline p53 mutation at codons 175 and 273, respectively. In patient 1, the normal p53 gene was lost while the mutant p53 allele was reduced to homozygosity in the RMS. Both normal and mutant genes were maintained in the CPC. In patient 2, normal and mutant p53 alleles were retained in both the CPC and RCC. Both specific PCR and immunostaining detected SV40 T-antigen in both CPCs and the RCC. In addition to chromosomal alterations, epigenetic mechanisms may disrupt p53 function during tumorigenesis. In two LFS patients, we found SV40 DNA sequences and viral T-antigen expression that could account for inactivation of the normal p53 protein. Inactivation of p53 or other tumor suppressors by viral proteins may contribute to tumor formation in specific tissues of genetically susceptible individuals.	Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada; Joe DiMaggio Childrens Hosp, Div Pediat Hematol, Hollywood, FL USA; Dana Farber Canc Inst, Dept Pediat, Div Oncol, Boston, MA 02115 USA; Univ Colorado, Sch Med, Childrens Hosp, Dept Pediat,Sect Hematol Oncol, Denver, CO 80218 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Dana-Farber Cancer Institute; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Malkin, D (corresponding author), Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Malkin, David/AAW-8715-2021					BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BRUGIERES L, 1993, CANCER RES, V53, P452; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Carbone M, 1996, ONCOGENE, V13, P527; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CARPENTER DB, 1982, J NEUROSURG, V56, P722, DOI 10.3171/jns.1982.56.5.0722; CHEN JD, 1992, ONCOGENE, V7, P1167; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Flaegstad T, 1999, CANCER RES, V59, P1160; FREBOURG T, 1995, AM J HUM GENET, V56, P608; JOLLY KW, 1994, ONCOGENE, V9, P97; Kleihues P, 1997, AM J PATHOL, V150, P1; KRAMER S, 1983, J NATL CANCER I, V70, P49; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; LI FP, 1988, CANCER RES, V48, P5358; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1998, GENETIC BASIS HUMAN, P393; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; Mendoza SM, 1998, ONCOGENE, V17, P2457, DOI 10.1038/sj.onc.1202179; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; PACKER RJ, 1992, CANCER, V69, P580, DOI 10.1002/1097-0142(19920115)69:2<580::AID-CNCR2820690250>3.0.CO;2-O; PENG HQ, 1993, CANCER RES, V53, P3574; Sedlacek Z, 1998, BRIT J CANCER, V77, P1034, DOI 10.1038/bjc.1998.172; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; YUASA H, 1993, NEUROSURGERY, V32, P131, DOI 10.1227/00006123-199301000-00021	36	49	50	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4441	4449		10.1038/sj.onc.1204583	http://dx.doi.org/10.1038/sj.onc.1204583			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494139				2022-12-28	WOS:000170074900001
J	Evans, SC; Viswanathan, M; Grier, JD; Narayana, M; El-Naggar, AK; Lozano, G				Evans, SC; Viswanathan, M; Grier, JD; Narayana, M; El-Naggar, AK; Lozano, G			An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2	ONCOGENE			English	Article						splicing; MDM2; cytoplasmic relocation; tumors	WILD-TYPE P53; MDM2 ONCOGENE OVEREXPRESSION; TUMOR-SUPPRESSOR; CELL-CYCLE; ENHANCED TRANSLATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; FEEDBACK LOOP; GENE; TRANSCRIPTS	The human counterpart hdm2 of the murine double-minute 2 (mdm2) gene encodes a 90-kD protein (HDM2) that inhibits the function of the p53 tumor suppressor, Hdm2 is amplified in approximately 30% of sarcomas, leading to overproduction of HDM2 and inactivation of p53, Using immunohistochemistry to screen a panel of human tumors for HDM2 overproduction, me detected high levels of HDM2 in the cytoplasm in 25% of lung tumors as opposed to its normal localization in the nucleus, These samples contained full-length hdm2 and several alternate-splice forms of hdm2 mRNA, Sequence analysis revealed deletions in the alternate-splice forms of the p53 binding domain and absence of a nuclear localization signal. In transient transfection assays, one of the alternate-splice forms, HDM2(ALT1), bound and sequestered full-length HDM2 in the cytoplasm, In addition, the binding of HDM2(ALT1) to HDM2 inhibited the interaction of HDM2 with p53, thus enhancing p53 transcriptional activity, These data suggest the existence of another level of regulation of HDM2 which increases the activity of p53.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.				NCI NIH HHS [CA34936, CA70907, CA47296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047296, P50CA070907, R29CA047296, P01CA034936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BERBERICH S, 1994, ONCOGENE, V9, P1469; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans SC, 1998, HUM GENET, V102, P681, DOI 10.1007/s004390050761; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Matsumoto R, 1998, CANCER RES, V58, P609; McMasters KM, 1996, ONCOGENE, V13, P1731; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WATANABE T, 1994, BLOOD, V84, P3158; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	41	116	121	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4041	4049		10.1038/sj.onc.1204533	http://dx.doi.org/10.1038/sj.onc.1204533			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494132				2022-12-28	WOS:000169681500012
J	Oya, M; Ohtsubo, M; Takayanagi, A; Tachibana, M; Shimizu, N; Murai, M				Oya, M; Ohtsubo, M; Takayanagi, A; Tachibana, M; Shimizu, N; Murai, M			Constitutive activation of nuclear factor-kappa B prevents TRAIL-induced apoptosis in renal cancer cells	ONCOGENE			English	Article						renal cell carcinoma; TRAIL; NF-kappa B; I kappa B alpha; apoptosis	APO2 LIGAND; FAMILY; EXPRESSION; CARCINOMA; DEATH; RECEPTORS; MEMBER; INDUCTION	TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors, However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the that some cancer cell line! -induced apoptosis despite absence of decoy receptors and the presence of death receptors, This suggested the existance of an inhibitory factor. We herein showed that NF-kappaB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-kappaB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of Ik-Ba, a specific inhibitor of NF-kappaB, in TRAIL-sensitive cell lines with a low NF-kappaB activity result in constitutive activation of NF-kappaB and resistance to TRAIL-induced apoptosis, Adenoviral expression of a stable form of I kappaB alpha in the TRAIL-resistant cell lines induced apoptosis, These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-KB activity and TRAIL-resistant RCC with constitutively activated NF kappaB, In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-kappaB appears to be a promising therapy.	Keio Univ, Sch Med, Dept Urol, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University	Oya, M (corresponding author), Keio Univ, Sch Med, Dept Urol, Shinjuku Ku, Tokyo 1608582, Japan.		Oya, Mototsugu/K-8592-2013					Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Blay JY, 1997, INT J CANCER, V72, P424, DOI 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.3.CO;2-N; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Frank S, 1999, BIOCHEM BIOPH RES CO, V257, P454, DOI 10.1006/bbrc.1999.0493; Gilmore TD, 1996, ONCOGENE, V13, P1367; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Keane MM, 1999, CANCER RES, V59, P734; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Mulders P, 1997, CANCER RES, V57, P5189; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; RITCHIE AWS, 1983, SEMIN ONCOL, V10, P390; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sumitomo M, 1999, HUM GENE THER, V10, P37, DOI 10.1089/10430349950019174; Tachibana M, 2000, CELL TISSUE RES, V301, P353, DOI 10.1007/s004410000235; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang XD, 1999, CANCER RES, V59, P2747	29	129	140	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3888	3896		10.1038/sj.onc.1204525	http://dx.doi.org/10.1038/sj.onc.1204525			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439352				2022-12-28	WOS:000169494700014
J	Hermanto, U; Zong, CS; Wang, LH				Hermanto, U; Zong, CS; Wang, LH			ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth	ONCOGENE			English	Article						ErbB2; PI3 kinase; breast cancer; cell growth	NF-KAPPA-B; PROTEIN-KINASE; INDUCED APOPTOSIS; BREAST-CANCER; UP-REGULATION; S6 KINASE; ONCOGENE; AKT; OVEREXPRESSION; AMPLIFICATION	The proto-oncogene ErbB2 is known to be amplified and to play an important role in the development of about one-third of human breast cancers. Phosphatidylinositol 3-kinase (PI3K), which is often activated in ErbB2-overexpressing breast cancer cells, is known to regulate cell proliferation and cell survival. Selective inhibitors of the PI3K pathway were used to assess the relevance of PI3K signaling in the anchorage-independent growth of a series of human mammary carcinoma cell lines. Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression. A similar growth inhibition of ErbB2-overexpressing carcinoma lines was observed when a dominant negative p85(PI3K) mutant was introduced into these cells. Forced expression of ErbB2 in breast cancer lines originally expressing low ErbB2 levels augmented receptor expression and sensitized those lines to LY294002- and rapamycin-mediated inhibition of colony formation. Furthermore, treatment with LY294002 resulted in the selective increase of cyclin-dependent kinase inhibitors p21(CIP1) or p27(Kipt) and suppression of cyclin E-associated Cdk2 kinase activity in ErbB2-overexpressing lines, which may account for their hypersensitivity toward inhibitors of the PI3K pathway in anchorage-independent growth. Our results indicate that the PI3K/Akt/p70(S6K) pathway plays an enhanced role in the anchorage-independent growth of ErbB2-overexpressing breast cancer cells, therefore providing a molecular basis for the selective targeting of this signaling pathway in the treatment of ErbB2-related human breast malignancies.	Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	1u-hai.wang@mssm.edu			NCI NIH HHS [CA 55054, CA 29339] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07280] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055054, R01CA029339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Ozes ON, 1999, NATURE, V401, P82; PIERCE JH, 1991, ONCOGENE, V6, P1189; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roh H, 2000, ONCOGENE, V19, P6138, DOI 10.1038/sj.onc.1204001; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; YANO H, 1993, J BIOL CHEM, V268, P25846; YOKOTA J, 1986, LANCET, V1, P765; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	42	55	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7551	7562		10.1038/sj.onc.1204964	http://dx.doi.org/10.1038/sj.onc.1204964			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709727				2022-12-28	WOS:000171976900012
J	Vikhanskaya, F; Bani, MR; Borsotti, P; Ghilardi, C; Ceruti, R; Ghisleni, G; Marabese, M; Giavazzi, R; Broggini, M; Taraboletti, G				Vikhanskaya, F; Bani, MR; Borsotti, P; Ghilardi, C; Ceruti, R; Ghisleni, G; Marabese, M; Giavazzi, R; Broggini, M; Taraboletti, G			p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis	ONCOGENE			English	Article						p73; angiogenesis; thrombospondin-1; VEGF; ovarian carcinoma	HUMAN BLADDER-CANCER; GROWTH-FACTOR GENE; CELL-LINES; MALIGNANT PROGRESSION; ENDOTHELIAL-CELLS; SUPPRESSOR GENE; C-JUN; EXPRESSION; P53; TRANSCRIPTION	Tumor neovascularization is controlled by a balance between positive and negative effectors, whose production can be regulated by oncogenes and tumor suppressor genes. The aim of this study was to investigate whether the angiogenic potential of tumors could also be controlled by p73, a gene homologous to the tumor suppressor p53, whose involvement in tumor angiogenesis is known. We have studied the production of proangiogenic (VEGF, FGF-2, PIGF and PDGF) and antiangiogenic (TSP-1) factors in two p73 overexpressing clones obtained from the human ovarian carcinoma cells A2780. TSP-1 was downregulated in both clones compared to mock transfected cells, both at mRNA bind protein level. Conversely, both clones showed an increased production of VEGF mRNA and protein. For both TSP-1 and VEGF, regulation of expression was partially due to modulation of the promoter activity, and was dependent on p53 status. Production of the other angiogenic factors FGF-2, PIGF and PDGF-B was also increased in p73 overexpressing clones. The two clones were more angiogenic than parental cells, as shown in vitro by their increased chemotactic activity for endothelial cells, and in vivo by the generation of more vascularized tumors. These findings suggest a potential role of p73 in tumor angiogenesis.	Mario Negri Inst Pharmacol Res, Dept Oncol, I-24125 Bergamo, Italy; Univ Milan, Ist Anat Patol Vet & Patol Aviare, I-20133 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Oncol, I-24125 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Taraboletti, G (corresponding author), Mario Negri Inst Pharmacol Res, Dept Oncol, Via Gavazzeni 11, I-24125 Bergamo, Italy.		Giavazzi, Raffaella/ABB-9768-2020; Giavazzi, Raffaella/J-7424-2018; Borsotti, Patrizia/ABF-9679-2020; Bani, Maria Rosa/AAB-3397-2020; Taraboletti, Giulia/J-4089-2018; broggini, massimo/AAA-6460-2020; Marabese, Mirko/AAA-6876-2019; Ghilardi, Carmen/AAB-1599-2020	Giavazzi, Raffaella/0000-0001-5249-8208; Borsotti, Patrizia/0000-0002-9789-528X; Bani, Maria Rosa/0000-0001-8178-1432; Taraboletti, Giulia/0000-0001-8780-5001; Marabese, Mirko/0000-0001-9379-0301; Ghilardi, Carmen/0000-0002-3036-8557; Ghisleni, Gabriele/0000-0002-8116-110X; BROGGINI, MASSIMO/0000-0002-8138-9358				Bertin N, 1997, CANCER RES, V57, P396; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Chen CL, 2000, CLIN CANCER RES, V6, P3910; Chi SG, 1999, CANCER RES, V59, P2791; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Debernardis D, 1997, CANCER RES, V57, P870; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Holmgren L, 1998, ONCOGENE, V17, P819, DOI 10.1038/sj.onc.1201993; Hsu SC, 1996, CANCER RES, V56, P5684; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Levrero M, 2000, J CELL SCI, V113, P1661; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; NAGY JA, 1995, CANCER RES, V55, P360; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Nomoto S, 1998, CANCER RES, V58, P1380; RAK J, 1995, CANCER RES, V55, P4575; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; Takahashi H, 1998, CANCER RES, V58, P2076; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; Taraboletti G, 2000, EXP CELL RES, V258, P384, DOI 10.1006/excr.2000.4936; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; Vikhanskaya F, 2001, CANCER RES, V61, P935; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOLPERT OV, 1997, ONCOGENE, V14, P1497; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; Zwahlen D, 2000, INT J CANCER, V88, P66	44	50	56	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7293	7300		10.1038/sj.onc.1204896	http://dx.doi.org/10.1038/sj.onc.1204896			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704858				2022-12-28	WOS:000171894200001
J	Wu, CH; Rastegar, M; Gordon, J; Safa, AR				Wu, CH; Rastegar, M; Gordon, J; Safa, AR			beta(2)-microglobulin induces apoptosis in HL-60 human leukemia cell line and its multidrug resistant variants overexpressing MRP1 but lacking Bax or overexpressing P-glycoprotein	ONCOGENE			English	Article						multidrug resistance; beta(2)-microglobulin; caspases; apoptosis; leukemia	PERMEABILITY TRANSITION PORE; CLASS-I MOLECULES; CYTOCHROME-C RELEASE; POLY(ADP-RIBOSE) POLYMERASE; INDEPENDENT APOPTOSIS; MELANOMA-CELLS; DEATH PATHWAY; GENE; FAS; ACTIVATION	In this study, we examined whether exogenous beta (2)-microglobulin (beta M-2) can induce apoptosis in the drug sensitive HL-60 leukemia cell line and its drug resistant variants and investigated the molecular mechanism of beta (2)m-induced apoptosis. Our data revealed that beta (2)m is very significantly down-regulated in two multidrug resistant variants of the HL-60 cells: (a) the MRP1-bearing, Bax-deficient HL-60/ADR cell line, and (b) the P-glycoprotein (P-gp) overexpressing HL-60/VCR cell line. However, exogenous beta (2)m induced similar levels of apoptosis in HL-60 cells and these drug resistant variants. beta (2)m-induced apoptosis in HL-60 and HL-60/VCR cells was associated with decreased mitochondrial membrane potential (Delta psim) but did not affect Delta psim in HL-60/ADR cells. Surprisingly, cyclosporin A (CsA), a known inhibitor of the mitochondrial permeability transition (MPT) pore, inhibited beta (2)m-induced apoptosis in HL-60/ADR cells but not in HL-60 and HL-60/VCR cells, suggesting that the pro-apoptotic effect of beta (2)m in these cells is not through MPT pore formation. Furthermore, beta (2)m induced the release of cytochrome c and the apoptosis-inducing factor (AIF) from mitochondria in HL-60 and HL-60/VCR cells, but not in HL-60/ADR cells. Additionally, z-VAD-fmk, a general inhibitor of caspases which inhibited cytochrome c release in HL-60 and HL-60/VCR cells, had no effect on AIF release in any of these cell lines, but inhibited beta (2)m-induced apoptosis in all three cell lines. However, Western blot analysis revealed that caspases-1, -3, -6, -8, and -9 are not activated during beta (2)m-induced apoptosis in these cells. Therefore, beta (2)m-induces apoptosis through an unknown caspase-dependent mitochondrial pathway in HL-60 and HL-60/VCR cells and by a Bax-independent, non-mitochodrial, caspase-dependent pathway in HL-60/ADR cells.	Indiana Univ, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Safa, AR (corresponding author), Indiana Univ, Dept Pharmacol & Toxicol, 1044 W Walnut R4-119, Indianapolis, IN 46202 USA.	asafa@iupui.edu	Rastegar, Mojgan/T-9394-2019	Rastegar, Mojgan/0000-0003-3619-6116; Gordon, John/0000-0002-9781-9842	NATIONAL CANCER INSTITUTE [R01CA080734] Funding Source: NIH RePORTER; NCI NIH HHS [CA 80734] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benitez R, 1998, TISSUE ANTIGENS, V52, P520, DOI 10.1111/j.1399-0039.1998.tb03082.x; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Castano E, 1999, BRIT J CANCER, V81, P294, DOI 10.1038/sj.bjc.6990690; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen HL, 1996, INT J CANCER, V67, P756, DOI 10.1002/(SICI)1097-0215(19960917)67:6<756::AID-IJC2>3.0.CO;2-Q; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; Christianson GJ, 1997, J IMMUNOL, V159, P4781; Chung TDK, 1998, CANCER GENE THER, V5, P344; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; DIXON B, 1993, IMMUNOGENETICS, V38, P27, DOI 10.1007/BF00216387; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FLEMING GF, 1992, CANCER CHEMOTH PHARM, V29, P445, DOI 10.1007/BF00684845; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; Genestier L, 1997, BLOOD, V90, P3629, DOI 10.1182/blood.V90.9.3629; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; Genestier L, 1997, BLOOD, V90, P726, DOI 10.1182/blood.V90.2.726.726_726_735; GRAZIOLI L, 1994, J BIOL CHEM, V269, P22304; Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.3.CO;2-X; GUSSOW D, 1987, J IMMUNOL, V139, P3132; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Hicklin DJ, 1998, J CLIN INVEST, V101, P2720, DOI 10.1172/JCI498; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Johnstone RW, 2000, LEUKEMIA LYMPHOMA, V38, P1, DOI 10.3109/10428190009060314; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; KAKLAMANIS L, 1995, CANCER RES, V55, P5191; Kollet O, 2000, BLOOD, V95, P3102, DOI 10.1182/blood.V95.10.3102.010k14_3102_3105; KRISHNAMACHARY N, 1994, ONCOL RES, V6, P119; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mori M, 1999, BLOOD, V94, P2744; Mori M, 2001, CANCER RES, V61, P4414; Munker R, 1997, HEMATOL CELL THER, V39, P75, DOI 10.1007/s00282-997-0075-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; ROWLEY DR, 1995, CANCER RES, V55, P781; Ruefli AA, 2000, BLOOD, V95, P2378, DOI 10.1182/blood.V95.7.2378.007k10_2378_2385; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Skov S, 1997, J CELL BIOL, V139, P1523, DOI 10.1083/jcb.139.6.1523; Skov S, 1997, J IMMUNOL, V158, P3189; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Takagi M, 1999, LEUKEMIA, V13, P70, DOI 10.1038/sj.leu.2401247; Takeuchi T, 1996, INT J CANCER, V67, P709, DOI 10.1002/(SICI)1097-0215(19960904)67:5<709::AID-IJC20>3.0.CO;2-Z; Ten Hagen TLM, 2000, INT J CANCER, V87, P829, DOI 10.1002/1097-0215(20000915)87:6<829::AID-IJC12>3.0.CO;2-C; Vitale M, 1998, CANCER RES, V58, P737; WallenOhman M, 1997, INT IMMUNOL, V9, P599, DOI 10.1093/intimm/9.4.599; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woodle ES, 1997, J IMMUNOL, V158, P2156; Yamamoto H, 2001, GASTROENTEROLOGY, V120, P1565, DOI 10.1053/gast.2001.24497	80	25	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7006	7020		10.1038/sj.onc.1204893	http://dx.doi.org/10.1038/sj.onc.1204893			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704825				2022-12-28	WOS:000171739300004
J	Hu, ZB; Gomes, I; Horrigan, SK; Kravarusic, J; Mar, B; Arbieva, Z; Chyna, B; Fulton, N; Edassery, S; Raza, A; Westbrook, CA				Hu, ZB; Gomes, I; Horrigan, SK; Kravarusic, J; Mar, B; Arbieva, Z; Chyna, B; Fulton, N; Edassery, S; Raza, A; Westbrook, CA			A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31	ONCOGENE			English	Article						tumor suppressor; nuclear protein; 5qNCA; leukemia; zinc finger; jmjC domain	COMMONLY DELETED REGION; MOLECULAR DELINEATION; 1A LGMD1A; HAIRLESS; MYELODYSPLASIA; ABNORMALITIES; DIAGNOSIS; DELETIONS; SEQUENCE; INTERVAL	Interstitial deletion or loss of chromosome 5, del(5q) or -5, is a frequent finding in myeloid leukemias and myelodysplasias, suggesting the presence of a tumor suppressor gene within the deleted region. In our search for this gene, we identified a candidate, 5qNCA (LOC51780), which lies within a consistently-deleted segment of 5q31. 5qNCA expresses a 7.2-kb transcript with a 5286-bp open reading frame which is present at high levels in heart, skeletal muscle, kidney, placenta, and liver as well as CD34+ cells and AML cell lines. 5qNCA encodes a 191-kD nuclear protein which contains a highly-conserved C-terminus containing a zinc finger with the unique spacing Cys-X2-Cys-X7-His-X2-Cys-X2-Cys-X4-Cys-X2-Cys and a jmjC domain, which is often found in proteins that regulate chromatin remodeling. Expression of 5qNCA in a del(5q) cell line results in suppression of clonogenic growth. Preliminary sequence results in AML and MDS samples and cell lines has revealed a possible mutation in the KG-1 cell line resulting in a THR to ALA substitution that has not been found in over 100 normal alleles to date. We propose 5qNCA is a good candidate for the del(5q) tumor suppressor gene based on its predicted function and growth suppressive activities, and suggest that further mutational and functional study of this interesting gene is warranted.	Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60607 USA; Avalon Pharmaceut, Gaithersburg, MD USA; Rush Canc Inst, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University	Westbrook, CA (corresponding author), Univ Illinois, Dept Med, Hematol Oncol Sect, M-C 734,900 S Ashland, Chicago, IL 60607 USA.	cwcw@uic.edu		Mar, Brenton/0000-0002-3857-9324	NATIONAL CANCER INSTITUTE [P01CA075606, R01CA072593] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-72593, P01-CA-75606] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartoloni L, 1998, GENOMICS, V54, P250, DOI 10.1006/geno.1998.5579; Brandt JE, 1999, BLOOD, V94, P106, DOI 10.1182/blood.V94.1.106.413k01_106_113; Christiansen H, 1996, PLANT MOL BIOL, V32, P809, DOI 10.1007/BF00020479; Cichon S, 1998, HUM MOL GENET, V7, P1671, DOI 10.1093/hmg/7.11.1671; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Fairman J, 1996, BLOOD, V88, P2259, DOI 10.1182/blood.V88.6.2259.bloodjournal8862259; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; Fenaux P, 1996, SEMIN HEMATOL, V33, P127; Frazer KA, 1997, GENOME RES, V7, P495, DOI 10.1101/gr.7.5.495; FURLEY AJ, 1986, BLOOD, V68, P1101; GALLAGHER R, 1979, BLOOD, V54, P713; HOOG C, 1991, MOL REPROD DEV, V30, P173, DOI 10.1002/mrd.1080300302; Horrigan SK, 2000, BLOOD, V95, P2372, DOI 10.1182/blood.V95.7.2372.007k20_2372_2377; Horrigan SK, 1999, GENOMICS, V57, P24, DOI 10.1006/geno.1999.5765; Horrigan SK, 1996, BLOOD, V88, P2665, DOI 10.1182/blood.V88.7.2665.bloodjournal8872665; Hu ZB, 2000, BLOOD, V95, P1047, DOI 10.1182/blood.V95.3.1047.003k43_1047_1055; Lai F, 2000, GENOMICS, V70, P123, DOI 10.1006/geno.2000.6345; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEBEAU MM, 1993, CANC SURVEYS, V15, P143; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Mao EJ, 1998, J ORAL PATHOL MED, V27, P297; NAGARAJAN L, 1995, LEUKEMIA LYMPHOMA, V17, P361, DOI 10.3109/10428199509056846; Panteleyev AA, 1998, J INVEST DERMATOL, V110, P902, DOI 10.1046/j.1523-1747.1998.00219.x; PEDERSEN B, 1993, ANTICANCER RES, V13, P1913; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; ROWLEY JD, 1981, BLOOD, V58, P759; SAMUELS BL, 1988, LEUKEMIA, V2, P79; SCHIFFER CA, 1989, BLOOD, V73, P263; Steube KG, 1997, LEUKEMIA LYMPHOMA, V25, P345, DOI 10.3109/10428199709114174; Thompson CC, 1996, J NEUROSCI, V16, P7832; Westbrook CA, 2000, BRIT J HAEMATOL, V110, P847, DOI 10.1046/j.1365-2141.2000.02285.x; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xie H, 2000, LEUKEMIA, V14, P2128, DOI 10.1038/sj.leu.2401935; Zhao ND, 1997, P NATL ACAD SCI USA, V94, P6948, DOI 10.1073/pnas.94.13.6948	34	61	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6946	6954		10.1038/sj.onc.1204850	http://dx.doi.org/10.1038/sj.onc.1204850			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687974				2022-12-28	WOS:000171641000016
J	Kiemer, AK; Takeuchi, K; Quinlan, MP				Kiemer, AK; Takeuchi, K; Quinlan, MP			Identification of genes involved in epithelial-mesenchymal transition and tumor progression	ONCOGENE			English	Article						differentiation; transformation; immortalization; gene expression	REPRESENTATIONAL DIFFERENCE ANALYSIS; ARGININE-GLYCINE AMIDINOTRANSFERASE; RENAL-CELL CARCINOMAS; GROWTH-FACTOR; ADENOVIRUS E1A; IN-VIVO; SUPPRESSOR GENE; E1A-12S PROTEIN; LYSYL OXIDASE; X-CHROMOSOME	The adenovirus E1A12S gene product (WT12S) immortalizes epithelial cells and they retain their differentiated characteristics, but certain mutants cannot do the latter. Characterization of mutant immortalized epithelial cells indicated that they had undergone epithelial mesenchymal transition (EMT). Coexpression of V12ras with WT12S leads to benign tumors, but to malignant tumors with 12S mutants. Since EMT is critical for tumor progression, identification of the molecular mechanisms involved should elucidate novel therapeutic targets. To this end, representational difference analysis (RDA) was used to identify cDNAs upregulated in the mutant cell line. Thirty-five differentially expressed mRNAs were identified and classified into several functional categories, including nine novel cDNAs. Among the 26 known cDNAs, extracellular matrix and related proteins made up the largest group of differentially expressed genes, followed by growth factors and receptors and transcription factors. There was also an ion transporter, a cytoskeletal protein, glycosylation and amidinotransferase enzymes and proteins with unknown functions. Some of the known genes have previously been associated with EMT and/or tumor progression and thus served to validate the system to obtain the desired target genes, while other cDNAs are newly linked with dedifferentiation/malignancy. Array analyses indicated that the cDNAs were specifically upregulated in invasive or metastatic tumors, especially of breast, uterus and lung, suggesting their involvement in the progression of these tumors.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan; Univ Munich, Dept Pharm, Ctr Drug Res, D-81377 Munich, Germany	Kyowa Kirin Ltd; University of Munich	Quinlan, MP (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahi Machi,Machida Shi, Tokyo 1948533, Japan.		Kiemer, Alexandra K./I-9300-2012	Kiemer, Alexandra K./0000-0002-7224-9900				Adachi E, 1997, INT REV CYTOL, V173, P73; Allgayer H, 1998, CLIN EXP METASTAS, V16, P62; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brenner W, 2000, CANCER LETT, V155, P199, DOI 10.1016/S0304-3835(00)00429-8; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Crossin KL, 2000, DEV DYNAM, V218, P260, DOI 10.1002/(SICI)1097-0177(200006)218:2<260::AID-DVDY3>3.0.CO;2-9; Daniel L, 2000, CANCER RES, V60, P80; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Eccles MR, 1998, PEDIATR NEPHROL, V12, P712, DOI 10.1007/s004670050533; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fischer RS, 2000, VIROLOGY, V269, P404, DOI 10.1006/viro.2000.0232; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P905; Friedlander A, 1999, CRIT REV ONCOGENESIS, V10, P161; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Grimm S, 1998, J EXP MED, V188, P1535, DOI 10.1084/jem.188.8.1535; GUTHMILLER P, 1994, J BIOL CHEM, V269, P17556; Haralson MA, 2000, MATRIX BIOL, V19, P47, DOI 10.1016/S0945-053X(99)00057-8; Hargrave M, 1997, DEV DYNAM, V210, P79, DOI 10.1002/(SICI)1097-0177(199710)210:2<79::AID-AJA1>3.0.CO;2-6; Hay ED, 1995, ACTA ANAT, V154, P8; He ZH, 1999, CANCER RES, V59, P3222; Hecht G, 1999, AM J PHYSIOL-CELL PH, V277, pC441, DOI 10.1152/ajpcell.1999.277.3.C441; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Huber SM, 2000, AM J PHYSIOL-RENAL, V279, pF65, DOI 10.1152/ajprenal.2000.279.1.F65; HUMM A, 1994, FEBS LETT, V339, P101, DOI 10.1016/0014-5793(94)80394-3; Isaac L, 1999, INFLAMM RES, V48, P446, DOI 10.1007/s000110050485; Kanwar YS, 1998, AM J PHYSIOL-RENAL, V275, pF710, DOI 10.1152/ajprenal.1998.275.5.F710; Kirschmann DA, 1999, BREAST CANCER RES TR, V55, P127; Komiya A, 1997, JPN J CANCER RES, V88, P389, DOI 10.1111/j.1349-7006.1997.tb00394.x; KUPPUSWAMY M, 1988, ONCOGENE, V2, P613; Lee SMY, 1998, GENE, V216, P163, DOI 10.1016/S0378-1119(98)00302-3; LINDER S, 1992, ONCOGENE, V7, P439; Lipschutz JH, 1998, AM J KIDNEY DIS, V31, P383, DOI 10.1053/ajkd.1998.v31.pm9506676; Lohi J, 1998, HISTOL HISTOPATHOL, V13, P785, DOI 10.14670/HH-13.785; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Looijenga LHJ, 1997, AM J PATHOL, V151, P581; Lyon MF, 1999, CURR BIOL, V9, pR235, DOI 10.1016/S0960-9822(99)80151-1; McDonald HL, 2000, GENE CHROMOSOME CANC, V28, P246, DOI 10.1002/1098-2264(200007)28:3<246::AID-GCC2>3.3.CO;2-S; Miner JH, 1999, KIDNEY INT, V56, P2016, DOI 10.1046/j.1523-1755.1999.00785.x; Mitchell MS, 2000, CANCER RES, V60, P6448; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; Mrowka C, 2000, J AM SOC NEPHROL, V11, pS106; Muller W, 1998, CANCER-AM CANCER SOC, V83, P2481, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2481::AID-CNCR11>3.0.CO;2-P; Mymryk JS, 1996, ONCOGENE, V13, P1581; Oivula J, 1999, J PATHOL, V187, P455, DOI 10.1002/(SICI)1096-9896(199903)187:4<455::AID-PATH271>3.0.CO;2-C; Okabe-Kado J, 1998, LEUKEMIA LYMPHOMA, V32, P19, DOI 10.3109/10428199809059243; Okada H, 1997, AM J PHYSIOL-RENAL, V273, pF563, DOI 10.1152/ajprenal.1997.273.4.F563; Panet R, 2000, J CELL PHYSIOL, V182, P109, DOI 10.1002/(SICI)1097-4652(200001)182:1<109::AID-JCP12>3.0.CO;2-A; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Plisov SY, 2000, GENESIS, V27, P22, DOI 10.1002/1526-968X(200005)27:1<22::AID-GENE40>3.3.CO;2-M; Pujuguet P, 2000, J CELL SCI, V113, P849; QUINLAN MP, 1989, ONCOGENE, V4, P1051; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1993, ONCOGENE, V8, P3289; Ramirez F, 1999, INT J BIOCHEM CELL B, V31, P255, DOI 10.1016/S1357-2725(98)00109-5; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Schneider J, 2000, BRIT J CANCER, V82, P1662; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; Sterzel RB, 2000, KIDNEY INT, V58, P1588, DOI 10.1046/j.1523-1755.2000.00320.x; Stohr H, 2000, CYTOGENET CELL GENET, V88, P211, DOI 10.1159/000015552; Stokes MB, 2000, KIDNEY INT, V57, P487, DOI 10.1046/j.1523-1755.2000.00868.x; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; van Goor H, 1999, EXP NEPHROL, V7, P35; Wada J, 1997, KIDNEY INT, V51, P1629, DOI 10.1038/ki.1997.225; WEILER SR, 1994, GENOMICS, V22, P243, DOI 10.1006/geno.1994.1374; Wilda M, 2000, J BONE MINER RES, V15, P2187, DOI 10.1359/jbmr.2000.15.11.2187; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Yang QW, 1999, DEV BIOL, V212, P229, DOI 10.1006/dbio.1999.9331; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202	81	67	68	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6679	6688		10.1038/sj.onc.1204872	http://dx.doi.org/10.1038/sj.onc.1204872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709702				2022-12-28	WOS:000171551600004
J	Bouton, AH; Riggins, RB; Bruce-Staskal, PJ				Bouton, AH; Riggins, RB; Bruce-Staskal, PJ			Functions of the adapter protein Cas: signal convergence and the determination of cellular responses	ONCOGENE			English	Review						Cas; Src; Crk; Rac1; migration; adapter	FOCAL ADHESION KINASE; CRK-ASSOCIATED SUBSTRATE; DEPENDENT TYROSINE PHOSPHORYLATION; HOMOLOGY 3 DOMAIN; GROWTH-FACTOR; C-SRC; V-CRK; DOCKING PROTEIN; BREAST-CANCER; STABLE ASSOCIATION	Since Cas was first identified as a highly phosphorylated 130 kilodalton protein that associated with the v-Src and v-Crk-oncoproteins, considerable effort has been made to determine its function. Its predicted role as a scaffolding molecule based on its domain structure has been largely confirmed. Through its ability to undergo rapid changes in phosphorylation, subcellular localization and association with heterologous proteins, Cas may spatially and temporally regulate the function of its binding partners. Numerous proteins have been identified that bind to Cas in vitro and/or in vivo, but in only a few cases is there an understanding of how Cas may function in these protein complexes. To date, Cas-Crk and Cas-Src complexes have been most frequently implicated in Cas function, particularly in regards to processes involving regulation of the actin cytoskeleton and proliferation. These and other Cas protein complexes contribute to the critical role of Cas in cell adhesion, migration, proliferation and survival of normal cycling cells. However, under conditions in which these processes are deregulated, Cas appears to play a role in oncogenic transformation and perhaps metastasis. Therefore, in its capacity as an adapter protein, Cas serves as a point of convergence for many distinct signaling inputs, ultimately contributing to the generation of specific cellular responses.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia	Bouton, AH (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 800734, Charlottesville, VA 22908 USA.	ahb8y@virginia.edu	Riggins, Rebecca/GQH-4466-2022	Riggins, Rebecca/0000-0002-1555-4431				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Andersson K, 1996, MOL MICROBIOL, V20, P1057, DOI 10.1111/j.1365-2958.1996.tb02546.x; Aplin AE, 1999, J CELL SCI, V112, P695; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Black DS, 1998, MOL MICROBIOL, V29, P1263, DOI 10.1046/j.1365-2958.1998.01014.x; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Burnham MR, 1999, MOL CARCINOGEN, V26, P20, DOI 10.1002/(SICI)1098-2744(199909)26:1<20::AID-MC3>3.0.CO;2-M; Burnham MR, 1996, ONCOGENE, V12, P2467; Cai DP, 1999, J IMMUNOL, V163, P2104; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chan YR, 1998, J BIOL CHEM, V273, P28978, DOI 10.1074/jbc.273.44.28978; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; Dersch P, 2000, INFECT IMMUN, V68, P2930, DOI 10.1128/IAI.68.5.2930-2938.2000; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Donaldson JC, 2000, EXP CELL RES, V256, P168, DOI 10.1006/excr.2000.4822; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Ferris HA, 1999, BIOCHEMISTRY-US, V38, P1497, DOI 10.1021/bi981903w; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harrington EO, 2001, AM J PHYSIOL-LUNG C, V280, pL342, DOI 10.1152/ajplung.2001.280.2.L342; Harte MT, 2000, BBA-MOL CELL RES, V1499, P34, DOI 10.1016/S0167-4889(00)00104-X; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; ILLC D, 1995, NATURE, V377, P539; Isberg RR, 2000, MICROBES INFECT, V2, P793, DOI 10.1016/S1286-4579(00)90364-2; Ishino M, 1995, ONCOGENE, V11, P2331; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; Khwaja A, 1996, ONCOGENE, V12, P2491; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kook S, 2000, MOL BIOL CELL, V11, P929, DOI 10.1091/mbc.11.3.929; Kook S, 2000, CELL BIOCHEM FUNCT, V18, P1; KOSTER A, 1991, ANTICANCER RES, V11, P193; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Larsson H, 1999, J BIOL CHEM, V274, P25726, DOI 10.1074/jbc.274.36.25726; Law SF, 1998, MOL CELL BIOL, V18, P3540, DOI 10.1128/MCB.18.6.3540; Law SF, 1999, EXP CELL RES, V252, P224, DOI 10.1006/excr.1999.4609; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Meijne AML, 1997, EXP CELL RES, V234, P477, DOI 10.1006/excr.1997.3637; Mielenz D, 2001, J BIOL CHEM, V276, P13417, DOI 10.1074/jbc.M011481200; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649-1658.2000; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PATCH LA, 1995, J CELL SCI, V108, P1371; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; Reiske HR, 2000, FEBS LETT, V486, P275, DOI 10.1016/S0014-5793(00)02295-X; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakakibara A, 2000, J BIOL CHEM, V275, P6404, DOI 10.1074/jbc.275.9.6404; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Takahashi T, 1998, AM J PHYSIOL-HEART C, V274, pH1059, DOI 10.1152/ajpheart.1998.274.4.H1059; Tamura M, 1999, CANCER RES, V59, P442; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Ueki K, 1998, FEBS LETT, V432, P197, DOI 10.1016/S0014-5793(98)00862-X; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; van der Flier S, 2000, INT J CANCER, V89, P465, DOI 10.1002/1097-0215(20000920)89:5<465::AID-IJC11>3.0.CO;2-O; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang X, 2000, ONCOGENE, V19, P2346, DOI 10.1038/sj.onc.1203558; Weidow CL, 2000, CELL MICROBIOL, V2, P549, DOI 10.1046/j.1462-5822.2000.00079.x; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; WILSON LK, 1990, ONCOGENE, V5, P1471; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; Zhou SY, 1998, METH MOL B, V87, P87; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhou SY, 2001, METHOD ENZYMOL, V332, P171; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682	136	167	167	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6448	6458		10.1038/sj.onc.1204785	http://dx.doi.org/10.1038/sj.onc.1204785			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607844	Bronze			2022-12-28	WOS:000171640600017
J	Schechtman, D; Mochly-Rosen, D				Schechtman, D; Mochly-Rosen, D			Adaptor proteins in protein kinase C-mediated signal transduction	ONCOGENE			English	Article						scaffold; PKC; RACK; isozymes; location	PLECKSTRIN HOMOLOGY DOMAINS; REGION-DERIVED PEPTIDES; CARDIAC CA2+ CHANNELS; BETA-SUBUNIT; PHORBOL ESTER; IN-VIVO; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; CELL-PROLIFERATION; EPSILON-ISOZYME	Spatial and temporal organization of signal transduction is essential in determining the speed and precision by which signaling events occur. Adaptor proteins are key to organizing signaling enzymes near their select substrates and away from others in order to optimize precision and speed of response. Here, we describe the role of adaptor proteins in determining the specific function of individual protein kinase C (PKC) isozymes. These isozyme-selective proteins were called collectively RACKs (receptors for activated C-kinase). The role of RACKs in PKC-mediated signaling was determined using isozyme-specific inhibitors and activators of the binding of each isozyme to its respective RACK. In addition to anchoring activated PKC isozymes, RACKs anchor other signaling enzymes. RACK1, the anchoring protein for activated beta IIPKC, binds for example, Src tyrosine kinase, integrin, and phosphodiesterase. RACK2, the epsilon PKC-specific RACK, is a coated-vesicle protein and thus is involved in vesicular release and cell-cell communication. Therefore, RACKs are not only adaptors for PKC, but also serve as adaptor proteins for several other signaling enzymes. Because at least some of the proteins that bind to RACKs, including PKC itself, regulate cell growth, modulating their interactions with RACKs may help elucidate signaling pathways leading to carcinogenesis and could result in the identification of novel therapeutic targets.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR 3145,269 Campus Dr, Stanford, CA 94305 USA.		schechtman, deborah/B-7572-2012	Schechtman, Deborah/0000-0002-8874-7023; Mochly-Rosen, Daria/0000-0002-6691-8733				Aley KO, 2000, J NEUROSCI, V20, P4680, DOI 10.1523/JNEUROSCI.20-12-04680.2000; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CARPENTER D, 1987, NATURE, V325, P107, DOI 10.1038/325107a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Chen CH, 2001, J MOL CELL CARDIOL, V33, P581, DOI 10.1006/jmcc.2000.1330; CHOI KY, 1994, CELL, V78, P499; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; DISATNIK MH, 1994, CELL GROWTH DIFFER, V5, P873; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; GAWLER DJ, 1995, ONCOGENE, V10, P817; Gokmen-Polar Y, 2001, CANCER RES, V61, P1375; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Hu KL, 2000, AM J PHYSIOL-HEART C, V279, pH2658, DOI 10.1152/ajpheart.2000.279.6.H2658; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; JOHNSON JA, 1995, CIRC RES, V76, P654, DOI 10.1161/01.RES.76.4.654; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Kieff E., 1996, EPSTEINBARR VIRUS IT, P2343; KILEY S, 1990, J BIOL CHEM, V265, P15704; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Koehler JA, 2001, BIOCHEM BIOPH RES CO, V283, P888, DOI 10.1006/bbrc.2001.4889; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Livneh E, 1996, ONCOGENE, V12, P1545; MAEDA T, 1993, LAB INVEST, V68, P472; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Moasser MM, 1999, CANCER RES, V59, P6145; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Myklebust JH, 1999, J CELL PHYSIOL, V180, P71; Nakaigawa N, 1996, BIOCHEM BIOPH RES CO, V222, P95, DOI 10.1006/bbrc.1996.0703; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; Pass JM, 2001, AM J PHYSIOL-HEART C, V280, pH946, DOI 10.1152/ajpheart.2001.280.3.H946; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Reinhardt J, 2000, VET MICROBIOL, V74, P87, DOI 10.1016/S0378-1135(00)00169-3; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SCHWARTZ GK, 1993, J NATL CANCER I, V85, P402, DOI 10.1093/jnci/85.5.402; Smith PR, 2000, J VIROL, V74, P3082, DOI 10.1128/JVI.74.7.3082-3092.2000; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Srivastava RK, 1999, ONCOGENE, V18, P1755, DOI 10.1038/sj.onc.1202464; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; Thompson EB, 1999, J STEROID BIOCHEM, V69, P453, DOI 10.1016/S0960-0760(99)00063-1; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Tsai JH, 2000, CANCER LETT, V161, P171, DOI 10.1016/S0304-3835(00)00597-8; VALLETE A, 1987, CANCER RES, V47, P1615; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wu HL, 1999, PEPTIDES, V20, P675, DOI 10.1016/S0196-9781(99)00049-2; WYSS R, 1987, ANTICANCER RES, V7, P721; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	91	269	286	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6339	6347		10.1038/sj.onc.1204778	http://dx.doi.org/10.1038/sj.onc.1204778			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607837				2022-12-28	WOS:000171640600010
J	Kondo, M; Ji, L; Kamibayashi, C; Tomizawa, Y; Randle, D; Sekido, Y; Yokota, J; Kashuba, V; Zabarovsky, E; Kuzmin, I; Lerman, M; Roth, J; Minna, JD				Kondo, M; Ji, L; Kamibayashi, C; Tomizawa, Y; Randle, D; Sekido, Y; Yokota, J; Kashuba, V; Zabarovsky, E; Kuzmin, I; Lerman, M; Roth, J; Minna, JD			Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells	ONCOGENE			English	Article						tumor suppressor gene; growth inhibition; lung cancer	HUMAN-CHROMOSOME 3P21.3; LOCUS; IDENTIFICATION; SEARCH	Recently we identified FUS1 as a candidate tumor suppressor gene (TSG) in the 120 kb 3p21.3 critical region contained in nested lung and breast cancer homozygous deletions. Mutation of FUS1 is infrequent in lung cancers which we have confirmed in 40 other primary lung cancers. In addition, we found no evidence for FUS1 promoter region methylation. Because haplo-insufficiency or low expression of Fus1 may play a role in lung tumorigenesis, we tested the effect of exogenously induced overexpression of Fus1 protein and found 60-80% inhibition of colony formation for non-small cell lung cancer lines NCI-H1299 (showing allele loss for FUS1) and NCI-H322 (containing only a mutated FUS1 allele) in vitro. By contrast, a similar level of expression of a tumor-acquired mutant form of FUS1 protein did not significantly suppress colony formation. Also, induced expression of Fus1 under the control of an Ecdysone regulated promoter decreased colony formation 75%, increased the doubling time twofold, and arrested H1299 cells in G1. In conclusion, our data are consistent with the hypothesis that FUS1 may function as a 3p21.3 TSG, warranting further studies of its function in the pathogenesis of human cancers.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 466, Japan; Natl Canc Ctr, Res Inst, Div Biol, Tokyo 104, Japan; Karolinska Inst, MTC, Stockholm, Sweden; Karolinska Inst, CGR, Stockholm, Sweden; Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; Nagoya University; National Cancer Center - Japan; Karolinska Institutet; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd,NB8-206, Dallas, TX 75390 USA.		Kashuba, Vladimir/AAO-7742-2020; Kondo, Masashi/I-7378-2014; Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017; Sekido, Yoshitaka/P-9756-2015	Kashuba, Vladimir I/0000-0001-9416-8282; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, CA 71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; DALY MC, 1993, ONCOGENE, V8, P1721; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; HIBI K, 1992, ONCOGENE, V7, P445; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1994, CANCER RES, V54, P4183; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lerman MI, 2000, CANCER RES, V60, P6116; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Roche J, 1996, ONCOGENE, V12, P1289; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; Wistuba II, 2000, CANCER RES, V60, P1949; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	21	68	80	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6258	6262		10.1038/sj.onc.1204832	http://dx.doi.org/10.1038/sj.onc.1204832			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593436				2022-12-28	WOS:000171206300019
J	Seidel, MG; Look, AT				Seidel, MG; Look, AT			E2A-HLF usurps control of evolutionarily conserved survival pathways	ONCOGENE			English	Article						apoptosis; acute leukemia; chromosomal translocation; circadian rhythm; hepatic leukemia factor; developmental cell fate	ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEINS; ZINC-FINGER PROTEIN; CHIMERIC TRANSCRIPTION FACTOR; LEUCINE-ZIPPER PROTEINS; PROGRAMMED CELL-DEATH; DNA-BINDING PROTEINS; FUSION MESSENGER-RNA; PRO-B LYMPHOCYTES; C-ELEGANS	E2A-HLF, the chimeric fusion protein resulting from the leukemogenic translocation t(17;19), appears to employ evolutionarily conserved signaling cascades for its transforming and antiapoptotic functions. These arise from both impairment of normal E2A function and activation of a survival pathway triggered through the HLF bZip DNA binding and dimerization domain. Recent reports identify wild-type E2A as a tumor suppressor in T lymphocytes. Moreover, E2A-HLF has been shown to activate SLUG, a mammalian homologue of the cell death specification protein CES-1 in Caenorhabditis elegans, which appears to regulate an evolutionarily conserved cell survival program. Recently, several key mouse models have been generated, enabling further elucidation of these pathways on a molecular genetic level in vivo. In this review, we discuss the characteristics of both components of the fusion protein with regard to their contribution to the regulation of cell fate and the oncogenic potential of E2A-HLF.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Look, AT (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St,M-630, Boston, MA 02115 USA.	thomas_look@dfci.harvard.edu	Seidel, Markus G/N-9951-2017	Seidel, Markus G/0000-0003-0981-8661				BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bayly R, 2000, MOL CELL BIOL, V20, P5789, DOI 10.1128/MCB.20.16.5789-5796.2000; Begbie M, 1999, DNA CELL BIOL, V18, P165, DOI 10.1089/104454999315556; Begley CG, 1999, BLOOD, V93, P2760; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; Brambillasca F, 1999, LEUKEMIA, V13, P369, DOI 10.1038/sj.leu.2401338; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chu C, 2001, J BIOL CHEM, V276, P8524, DOI 10.1074/jbc.M008371200; COWELL IG, 1994, NUCLEIC ACIDS RES, V22, P59, DOI 10.1093/nar/22.1.59; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Duncan DD, 1996, IMMUNITY, V4, P301, DOI 10.1016/S1074-7613(00)80438-0; ELLIS RE, 1991, DEVELOPMENT, V112, P591; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Ferrando AA, 2000, SEMIN HEMATOL, V37, P381, DOI 10.1016/S0037-1963(00)90018-0; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HARA E, 1994, J BIOL CHEM, V269, P2139; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hitzler JK, 1999, BRAIN RES, V820, P1, DOI 10.1016/S0006-8993(98)00999-8; Honda H, 1999, BLOOD, V93, P2780; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inoue A, 1999, BLOOD, V94, p687A; Inukai T, 1998, MOL CELL BIOL, V18, P6035, DOI 10.1128/MCB.18.10.6035; Inukai T, 1997, MOL CELL BIOL, V17, P1417, DOI 10.1128/MCB.17.3.1417; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; IZRAELI S, 1992, BLOOD, V80, P1413; Jia YW, 1997, DEVELOPMENT, V124, P2063; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Kurosawa H, 1999, BLOOD, V93, P321, DOI 10.1182/blood.V93.1.321.401k05_321_332; Lan Y, 1998, DEV BIOL, V198, P207; LAVERY DJ, 1996, PAR TRANSCRIPTION RA, P135; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Look AT, 1997, CURR TOP MICROBIOL, V220, P45; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Maloney KW, 1998, LEUKEMIA, V12, P1417, DOI 10.1038/sj.leu.2401124; McDonald JM, 1998, CANCER RES, V58, P1387; Mehenni H, 1997, AM J HUM GENET, V61, P1327, DOI 10.1086/301644; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUMATA SI, 1993, LEUKEMIA, V7, P1441; Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; Ripperger JA, 2000, GENE DEV, V14, P679; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Smith KS, 1999, MOL CELL BIOL, V19, P4443; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; TAKEDA J, 1990, MOL CELL BIOL, V10, P5027, DOI 10.1128/MCB.10.10.5027; TAKEUCHI S, 1995, CANCER RES, V55, P5377; Wang JJ, 2000, P NATL ACAD SCI USA, V97, P3497, DOI 10.1073/pnas.97.7.3497; WUARIN J, 1992, J CELL SCI, P123; Yamaguchi S, 2000, MOL CELL BIOL, V20, P4773, DOI 10.1128/MCB.20.13.4773-4781.2000; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; ZHANG W, 1995, MOL CELL BIOL, V15, P6055; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	97	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5718	5725		10.1038/sj.onc.1204591	http://dx.doi.org/10.1038/sj.onc.1204591			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607821				2022-12-28	WOS:000170887500012
J	Ma, X; Yang, K; Lindblad, P; Egevad, L; Hemminki, K				Ma, X; Yang, K; Lindblad, P; Egevad, L; Hemminki, K			VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium	ONCOGENE			English	Article						VHL gene; mutation; renal cell carcinoma; linkage disequilibrium; SSCP	TUMOR-SUPPRESSOR GENE; HIPPEL-LINDAU-DISEASE; SOMATIC MUTATIONS; CANCER; COMPLEX; DNA; IDENTIFICATION; PROTEIN; LINES	Mutations in the von Hippel-Lindau (VHL) gene are frequently detected in human sporadic renal cell carcinoma (RCC). We analysed 102 Swedish RCCs for VHL mutations by PCR-SSCP and sequencing. In 47 patients (46.1%), 70 different mutations were found, and most of them represented novel variations of the VHL gene. Mutations in the VHL gene were found in 54% of clear cell renal cell carcinomas (CCRCC) and in 18% of chromophilic cancers but in no chromophobe cancers or oncocytomas (P = 0.016). Three novel hotspot or founder mutations were detected in our study: four CCRCCs carried a missense mutation (glutamic acid to lysine) at codon 160 which is critical in the stabilization of the H1 helix of the alpha domain and the alpha-beta domain interface in the VHL protein. Five CCRCCs and one chromophilic RCC harbored a 15-nucleotide in-frame deletion (codons 41 - 45) at a duplex tandem repeat sequence site. Moreover, this deletion was in linkage disequilibrium with a C --> T transition in the promoter region. The frequency of linkage was 17 times more common than chance. Five patients with this linked mutation resided in the same hospital district and at least three of them showed the two sequence variants in the tumor-adjacent tissue. In 5/ 6 patients the wild-type allele was lost in the tumor samples, suggesting a causal role for the mutations in RCC. These linked mutations might be novel polymorphisms maintained in a relative isolated population. Multiple mutations in VHL were found in 17 tumors out of 47 tumors with the VHL mutation. A higher multiple mutation detected rate (33%) was observed in grade 3 CCRCCs than those in grade 1 (22%) and grade 2 (9%) (P=0.04). This is evidence on the association between VHL mutation and extent of nuclear atypia.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Sundsvall Hosp, Dept Urol, S-85186 Sundsvall, Sweden; Karolinska Hosp, Dept Pathol & Cytol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Hemminki, K (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.	kari.hemminki@cnt.ki.se		Egevad, Lars/0000-0001-8531-222X				Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Brauch H, 2000, CANCER RES, V60, P1942; Brauch H, 1999, JNCI-J NATL CANCER I, V91, P854, DOI 10.1093/jnci/91.10.854; Bruning T, 1997, ARCH TOXICOL, V71, P332, DOI 10.1007/s002040050394; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DAY RS, 1987, J CELL SCI, P333; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; GREENBLATT MS, 1994, CANCER RES, V54, P4855; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MANDEL JS, 1995, INT J CANCER, V61, P601, DOI 10.1002/ijc.2910610503; MCCREDIE M, 1995, INT J CANCER, V60, P345, DOI 10.1002/ijc.2910600312; McLaughlin JK, 2000, SEMIN ONCOL, V27, P115; MCLAUGHLIN JK, 1995, INT J CANCER, V60, P194, DOI 10.1002/ijc.2910600211; Meyer AJ, 2000, INT J CANCER, V87, P650, DOI 10.1002/1097-0215(20000901)87:5<650::AID-IJC5>3.0.CO;2-3; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Prowse AH, 1997, AM J HUM GENET, V60, P765; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schraml P, 1999, Verh Dtsch Ges Pathol, V83, P218; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Shiao YH, 1998, JNCI-J NATL CANCER I, V90, P1720, DOI 10.1093/jnci/90.22.1720; Siemeister G, 1996, CANCER RES, V56, P2299; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; THOENES W, 1990, KLIN WOCHENSCHR, V68, P1102, DOI 10.1007/BF01798060; THOENES W, 1990, EUR UROL, V18, P6; Yang K, 1999, CANCER LETT, V141, P1, DOI 10.1016/S0304-3835(99)00031-2; Yoshida M, 2000, JPN J CANCER RES, V91, P204, DOI 10.1111/j.1349-7006.2000.tb00933.x; Zhuang ZP, 1996, MODERN PATHOL, V9, P838	32	44	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5393	5400		10.1038/sj.onc.1204692	http://dx.doi.org/10.1038/sj.onc.1204692			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536052				2022-12-28	WOS:000170575500015
J	Schuringa, JJ; Wojtachnio, K; Hagens, W; Vellenga, E; Buys, CHCM; Hofstra, R; Kruijer, W				Schuringa, JJ; Wojtachnio, K; Hagens, W; Vellenga, E; Buys, CHCM; Hofstra, R; Kruijer, W			MEN2A-RET-induced cellular transformation by activation of STAT3	ONCOGENE			English	Article						Ret tyrosine kinase receptor; MEN2A; STAT3; cellular transformation	RECEPTOR TYROSINE KINASE; RET PROTOONCOGENE; DOCKING SITE; SIGNAL-TRANSDUCTION; GENE; MUTATIONS; ASSOCIATION; SRC; IDENTIFICATION; REQUIRES	The MEN2A oncogene encodes for a constitutive active member of the RET receptor tyrosine kinase family. Here, we report that MEN2A-RET activates Signal Transducer and Activator of Transcription 3 (STAT3) via two YxxV/Q STAT3 docking sites, Tyr752 and Tyr928. MEN2A-RET induces both Tyr705 and Ser727 phosphorylation of STAT3, and STAT3 serine phosphorylation is required for its maximal transcriptional activity. Stable NIH3T3 cell lines expressing both MEN2A-RET and STAT3 alpha but not STAT3 beta, are characterized by enhanced proliferation and cyclin-D1 promoter activity, and enhanced growth in soft agar. These data indicate that malignant cell growth induced by MEN2A-RET involves its activation of STAT3.	Univ Groningen, Biol Ctr Haren, Dept Dev Genet, NL-9751 NN Haren, Netherlands; Univ Groningen, Dept Hematol, NL-9751 NN Haren, Netherlands; Univ Groningen, Dept Med Genet, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen; University of Groningen	Kruijer, W (corresponding author), Univ Groningen, Biol Ctr Haren, Dept Dev Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.	W.Kruijer@biol.rug.nl		Hofstra, Robert/0000-0001-7498-3829				Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELELLIS RA, 1995, LAB INVEST, V72, P494; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GOODFELLOW PJ, 1995, J NATL CANCER I, V87, P1515, DOI 10.1093/jnci/87.20.1515; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HERBER B, 1994, ONCOGENE, V9, P1295; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Ponder BAJ, 1999, CANCER RES, V59, p1736S; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	51	54	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5350	5358		10.1038/sj.onc.1204715	http://dx.doi.org/10.1038/sj.onc.1204715			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536047				2022-12-28	WOS:000170575500010
J	Wang, Q; Zhang, HT; Guerrette, S; Chen, JQ; Mazurek, A; Wilson, T; Slupianek, A; Skorski, T; Fishel, R; Greene, MI				Wang, Q; Zhang, HT; Guerrette, S; Chen, JQ; Mazurek, A; Wilson, T; Slupianek, A; Skorski, T; Fishel, R; Greene, MI			Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1	ONCOGENE			English	Article						BRCA1; MSH2; DNA mismatch repair; transcription-coupled DNA damage repair	TRANSCRIPTION-COUPLED REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH-REPAIR; CELL-CYCLE; DNA-DAMAGE; NUCLEAR PHOSPHOPROTEIN; MOLECULAR SWITCH; COLON-CANCER; IN-VIVO; C-MYC	We have identified the physical interaction between the Breast Cancer susceptibility gene product BRCA1 and the Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and DNA mismatch repair (MMR) gene product hMSH2, both in vitro and in vivo. The BRCA1-hMSH2 association involved several well-defined regions of both proteins which include the adenosine nucleotide binding domain of hMSH2. Moreover, the interaction of BRCA1 with purified hMSH2-hMSH6 appears to be modulated by adenosine nucleotide much like G protein downstream interaction/signaling is modulated by guanosine nucleotide. BARD1, another BRCA1-interacting protein, was also found to interact with hMSH2. In addition, BRCA1 was found to associate with both hMSH3 and hMSH6, the heterodimeric partners of IMSH2. These observations implicate BRCA1/BARD1 as downstream effectors of the adenosine nucleotide-activated hMSH2-hMSH6 signaling complex, and suggest a global role for BRCA1 in DNA damage processing. The functional interaction between BRCA1 and hMSH2 may provide a partial explanation for the background of gynecological and colorectal cancer in both HNPCC and BRCA1 kindreds, respectively.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Genet & Mol Biol Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA	University of Pennsylvania; Pennsylvania Medicine; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Fishel, R (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.		Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049	NCI NIH HHS [R01 CA067007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; de Boer J, 1998, CANCER RES, V58, P89; Dietmaier W, 1997, CANCER RES, V57, P4749; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; EASTON DF, 1995, AM J HUM GENET, V56, P265; FISHEL R, 1994, CANCER RES, V54, P5539; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lynch HT, 1997, CANCER GENET CYTOGEN, V93, P84, DOI 10.1016/S0165-4608(96)00290-7; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Schmutte C, 1998, CANCER RES, V58, P4537; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Y, 2000, GENE DEV, V14, P927; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; WILSON TM, 1995, CANCER RES, V55, P5146; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang H, 1999, CANCER RES, V59, P3021; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang HT, 1997, ONCOGENE, V14, P2863, DOI 10.1038/sj.onc.1201140; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	55	58	58	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4640	4649		10.1038/sj.onc.1204625	http://dx.doi.org/10.1038/sj.onc.1204625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498787				2022-12-28	WOS:000170208600005
J	Turturro, F; Frist, AY; Arnold, MD; Seth, P; Pulford, K				Turturro, F; Frist, AY; Arnold, MD; Seth, P; Pulford, K			Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the anti proliferative effect of p27(Kip1)	ONCOGENE			English	Article						cell cycle; adenovirus; p27(Kip1); NPM-ALK; ALCL; PTEN	DEPENDENT KINASE INHIBITOR; NON-HODGKINS-LYMPHOMA; TYROSINE KINASE; TUMOR-CELLS; NPM-ALK; PROTEIN; GENE; EXPRESSION; RECEPTOR; FUSION	An inverse correlation between p27(Kip1) expression and proliferation has been recently established in tissues derived from human lymphomas. The nucleophosminanaplastic lymphoma kinase (NPM-ALK)/phospholipase C-gamma (PLC gamma) complex also appears to play an important role in cell proliferation and malignant transformation of anaplastic large cell lymphoma (ALCL). In this study, we report that SUDHL-1 and KARPAS 299 ALCL-derived cell lines present different sensitivity to the antiproliferative effect of recombinant adenovirus-mediated p27(Kip1) expression or to serum-starvation in culture media. The results indicate that exogenous p27(Kip1) may interact with the NPM-ALK/ PLC;, pathway in SUDHL-1 but not in KARPAS 299 cells. This interaction correlates with changes in cell cycle and cell morphology observed mainly in SUDHL-1 cells. The percentage of SUDHL-1 cells in S phase declines, whereas it is almost unchanged in KARPAS 299 cells as compared to the controls after 96 h of infection with the recombinant adenovirus. Furthermore KARPAS 299 cells are resistant to serum-starvation due to deficient p27(Kip1)-upregulation and G1 arrest, whereas SUDHL-1 cells respond with increased G1 phase and p27(Kip1)-upregulation after 48 h of serum-starvation. Both cell lines express appropriate variation of levels of cyclins E and A, and Rb-phosphorylation as expected by growing them in culture media with different FBS content. Although both cell lines express cyclin D2, SUDHL-1 cells only present high level of cyclin D3. Moreover SUDHL-1 cells express high level of PTEN and the PKB/Akt pathway is constitutively activated in both cell lines. Lastly SUDHL-1 cells show higher levels of phosphotyrosine-containing proteins that is correlated with a higher NPM-ALK-associated autophosphorylation activity compared to KARPAS 299 cells. Our study clearly identifies some of the biochemical differences that may explain the difference in sensitivity to antiproliferative stimuli shown by two cell lines derived from the same type of lymphoma.	Iowa Methodist Med Ctr, John Stoddard Canc Ctr, Human Gene Therapy Res Inst, Des Moines, IA 50309 USA; VA Cent Iowa Hlth Care Syst, Div Hematol Oncol, Des Moines, IA 50309 USA; Des Moines Univ, Univ Res, Des Moines, IA 50312 USA; John Radcliffe Hosp, Nuffield Dept, Clin Sci Lab, Oxford OX3 9DU, England	Iowa Methodist Medical Center; University of Oxford	Turturro, F (corresponding author), Iowa Methodist Med Ctr, John Stoddard Canc Ctr, Human Gene Therapy Res Inst, 1415 Woodland Ave, Des Moines, IA 50309 USA.		Pulford, Karen/B-3609-2009	Pulford, Karen/0000-0002-2989-789X				Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; FISCHER P, 1988, BLOOD, V72, P234; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; HARRIS NL, 1994, BLOOD, V84, P1361; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Izuishi K, 2000, CANCER RES, V60, P6201; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Mason DY, 1998, CANCER RES, V58, P1057; MORGAN R, 1989, BLOOD, V73, P2155; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; SanchezBeato M, 1997, AM J PATHOL, V151, P151; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sherr CJ, 2000, CANCER RES, V60, P3689; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Suzuki R, 1999, LEUKEMIA, V13, P1335, DOI 10.1038/sj.leu.2401485; Szebeni A, 1999, PROTEIN SCI, V8, P905; Turturro F, 2000, CLIN CANCER RES, V6, P185; Turturro F, 2000, GENE THER, V7, P930, DOI 10.1038/sj.gt.3301186; TURTURRO F, 2000, MOL THER, V1, pS323; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	36	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4466	4475		10.1038/sj.onc.1204582	http://dx.doi.org/10.1038/sj.onc.1204582			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494142				2022-12-28	WOS:000170074900004
J	Zhu, JH; Nozell, S; Wang, J; Jiang, JY; Zhou, WJ; Chen, XB				Zhu, JH; Nozell, S; Wang, J; Jiang, JY; Zhou, WJ; Chen, XB			p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner	ONCOGENE			English	Article						p53; p73; DNA damage; apoptosis	P53 GENE FAMILY; KINASE C-ABL; ANTICANCER AGENTS; CANCER-CELLS; MUTANT P53; IDENTIFICATION; CYTOTOXICITY; NEUROBLASTOMA; ACTIVATION; CISPLATIN	p73, a member of the p53 family, can induce apoptosis in cancer cells, Since p53-mediated apoptosis can be augmented by various cancer chemotherapeutic agents, it has been hypothesized that the status of the endogenous p53 gene in cancer cells is a key determinant in the outcome of cancer therapy. To determine whether p73 can sensitize cancer cells to apoptosis by DNA damage agents, several MCF7 adenocarcinoma cell lines that inducibly express p73 or p53 under a tetracycline-regulated promoter were generated. We found that at relevant physiological levels, p73, but not p53, is capable of sensitizing MCF? cells to apoptosis induced by chemotherapeutic agents. In addition, we found that p73 can cooperate with the DNA damaging agent camptothecin to activate the initiator caspase 2. Furthermore, me found that p73 can cooperate with DNA damaging agents or p53 to induce some p53 target genes and activate their promoters. In contrast, in MCF7E6 cells that ectopically express the human papillomavirus E6 oncogene and are functionally p53-null,, the ability of p73 to sensitize cells to apoptosis is abrogated. Taken together, these results suggest that a functional interaction between p53 and p73 in MCF7 cells leads to enhanced induction of apoptosis.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, CB-2803, Augusta, GA 30912 USA.				NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN XB, 1995, CANCER RES, V55, P4257; Chresta CM, 1996, CANCER RES, V56, P1834; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; FAN SJ, 1995, CANCER RES, V55, P1649; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gallardo D, 1996, CANCER RES, V56, P4891; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong JG, 1999, NATURE, V399, P806; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAURENZI VD, 1999, CELL DEATH DIFFER, V6, P389; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; MUNGER K, 1989, J VIROL, V63, P4417; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; OConnor PM, 1997, CANCER RES, V57, P4285; Prives C, 1999, J PATHOL, V187, P112; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1998, CANCER RES, V58, P5061	46	44	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4050	4057		10.1038/sj.onc.1204516	http://dx.doi.org/10.1038/sj.onc.1204516			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494133				2022-12-28	WOS:000169681500013
J	Damiens, E; Baratte, B; Marie, D; Eisenbrand, G; Meijer, L				Damiens, E; Baratte, B; Marie, D; Eisenbrand, G; Meijer, L			Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest	ONCOGENE			English	Article						cyclin-dependent kinase; glycogen synthase kinase; GSK-3 beta; indirubin; kinase inhibitor; cancer	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; CHEMICAL INHIBITORS; SODIUM-BUTYRATE; CANCER CELLS; DNA; STAUROSPORINE; APOPTOSIS; MEDICINE; MITOSIS	The bis-indole indirubin is the active ingredient of the Traditional Chinese Medicine recipe Danggui Longhui Wan used against chronic myelocytic leukemia, We have previously shown that indirubins are potent inhibitors of cyclin-dependent kinases and glycogen synthase kinase-3, We here investigated the anti-mitotic properties of this class of compounds using the cell permeable indirubin-3 ' -monoxime and the HBL-100 cell line. Indirubin-3 ' -monoxime reversibly arrests asynchronous HBL-100 cells in G2, This arrest is not accompanied by any significant change in expression of the major cell cycle regulators, However indirubin-3 ' -monoxime inhibits the phosphorylation of consensus CDK phosphorylation sites as well as of nucleolin at a specific CDK1/cyclin B phosphorylation site, suggesting a direct action on the mitotic CDK1/cyclin B, When indirubin-3 ' -monoxime is added to HBL-100 cells synchronized in M phase by nocodazole, cells undergo an endoreplication leading to an 8n DNA content. As soon as indirubin-3 ' -monoxime is washed away, these polyploid cells become aneuploid and later die from necrosis, This mechanism of endoreplication followed by cell death may contribute to the antitumour properties of indirubins.	CNRS, Biol Stn, Cell Cycle Grp, F-29682 Roscoff, France; Univ Kaiserslautern, Div Food Chem & Environm Toxicol, Dept Chem, D-67663 Kaiserslautern, Germany; CNRS, Phytoplankton Ocean Grp, Biol Stn, F-29682 Roscoff, France	Centre National de la Recherche Scientifique (CNRS); University of Kaiserslautern; Centre National de la Recherche Scientifique (CNRS)	Meijer, L (corresponding author), CNRS, Biol Stn, Cell Cycle Grp, BP 74, F-29682 Roscoff, France.		Eisenbrand, Gerhard/AEQ-0284-2022	Eisenbrand, Gerhard/0000-0003-4079-2463; , laurent/0000-0003-3511-4916				Akiyama T, 1999, ANTI-CANCER DRUG, V10, P67, DOI 10.1097/00001813-199901000-00009; [Anonymous], 1992, CHIN DRUGS PLANT ORI; Atienza C, 2000, INT J MOL MED, V6, P55; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bible KC, 1997, CANCER RES, V57, P3375; Borgne A, 1999, M S-MED SCI, V15, P496, DOI 10.4267/10608/1375; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; Chang CN, 1985, ADV CHINESE MED MAT, P369; CHEN DH, 1984, CHINESE TRAD HERBAL, V15, P6; Edamatsu H, 2000, ONCOGENE, V19, P3059, DOI 10.1038/sj.onc.1203625; Hall LL, 1996, CANCER RES, V56, P3551; HAN R, 1994, STEM CELLS, V12, P53, DOI 10.1002/stem.5530120110; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Ikegami Y, 1996, ARZNEIMITTEL-FORSCH, V46, P201; Institute of Haematology Chinese Academy of Medical Sciences, 1979, CHIN J INT MED, V18, P83; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lallemand F, 1999, EXP CELL RES, V247, P432, DOI 10.1006/excr.1998.4370; Ma M Z, 1983, J Tradit Chin Med, V3, P245; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; ONGKEKO W, 1995, J CELL SCI, V108, P2897; Roberge M, 1998, CANCER RES, V58, P5701; *SICH I TRAD CHIN, 1981, CHIN TRAD HERB DRUGS, V12, P27; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; WANG JH, 1981, ACTA PHARM SINICA, V2, P241; Wu K M, 1985, Yao Xue Xue Bao, V20, P821; WU LM, 1979, COMM CHINESE HERBAL, V9, P6; YAMADA K, 1985, J CELL PHYSIOL, V122, P59, DOI 10.1002/jcp.1041220110; Zhang Z N, 1985, J Tradit Chin Med, V5, P246; ZHU YP, 1995, PHARM WORLD SCI, V17, P103, DOI 10.1007/BF01872386	36	138	157	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3786	3797		10.1038/sj.onc.1204503	http://dx.doi.org/10.1038/sj.onc.1204503			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439342	Bronze			2022-12-28	WOS:000169494700004
J	Wu, CG; Salvay, DM; Forgues, M; Valerie, K; Farnsworth, J; Markin, RS; Wang, XW				Wu, CG; Salvay, DM; Forgues, M; Valerie, K; Farnsworth, J; Markin, RS; Wang, XW			Distinctive gene expression profiles associated with Hepatitis B virus x protein	ONCOGENE			English	Article						hepatitis B virus; cDNA microarray; liver cancer; chronic active hepatitis	HEPATOCELLULAR-CARCINOMA; HBX GENE; CDNA MICROARRAY; LIVER-CANCER; P53 GENE; CELL; APOPTOSIS; ETIOLOGY; TRANSFORMATION; ACCUMULATION	Hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC), HBV encodes the potentially oncogenic HBx protein, which mainly functions as a transcriptional co-activator involving in multiple gene deregulations. However, mechanisms underlying HBx-mediated oncogenicity remain unclear, To determine the role(s) of HBx in the early genesis of HCC, we utilized the NCI Oncochip microarray that contains 2208 human cDNA clones to examine the gene expression profiles in either freshly isolated normal primary adult human hepatocytes (Hhep) or an HCC cell line (SK-Hep-l) ecotopically expressing HBx via an adenoviral system. The gene expression profiles also were determined in liver samples from HBV-infected chronic active hepatitis patients when compared with normal liver samples. The microarray results were validated through Northern blot analysis of the expression of selected genes. Using reciprocally labeling hybridizations, scatterplot analysis of gene expression ratios in human primary hepatocytes expressing HBx demonstrates that microarrays are highly reproducible. The comparison of gene expression profiles between HBx-expressing primary hepatocytes and HBV-infected liver samples shows a consistent alteration of many cellular genes including a subset of oncogenes (such as c-myc and c-myb) and tumor suppressor genes (such as APC, p53, WAF1 and WT1), Furthermore, clustering algorithm analysis showed distinctive gene expression profiles in Hhep and SK-Hep-l cells. Our findings are consistent with the hypothesis that the deregulation of cellular genes by oncogenic HBx may be an early event that favors hepatocyte proliferation during liver carcinogenesis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Virginia Commonwealth University; University of Nebraska System; University of Nebraska Medical Center	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, NIH, MSC 4255,Bldg 37,Room 2C25, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009; Valerie, Kristoffer/AAL-8299-2021	Wang, Xin Wei/0000-0001-9735-606X; 				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Andrisani OM, 1999, INT J ONCOL, V15, P373; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOVA R, 1991, INT J CLIN LAB RES, V21, P190; Bradley DW, 1999, P ASSOC AM PHYSICIAN, V111, P588, DOI 10.1046/j.1525-1381.1999.t01-1-99240.x; Brechot C, 1998, J HEPATOL, V29, P173, DOI 10.1016/S0168-8278(98)80001-9; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; CASELMANN WH, 1995, J HEPATOL, V22, P34; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; DeRisi J, 1996, NAT GENET, V14, P457; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Han JS, 2000, BIOCHEM BIOPH RES CO, V272, P525, DOI 10.1006/bbrc.2000.2801; HARRIS CC, 1984, CARCINOGENESIS, V5, P697, DOI 10.1093/carcin/5.6.697; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Kew MC, 1997, HEPATOLOGY, V25, P1037, DOI 10.1002/hep.510250442; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; Kobayashi S, 1997, J SURG RES, V73, P97, DOI 10.1006/jsre.1997.5182; Koike K, 1995, INTERVIROLOGY, V38, P134, DOI 10.1159/000150424; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Ono K, 2000, CANCER RES, V60, P5007; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Robinson WS, 1999, MICROBES AND MALIGNANCY, P232; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Sluder G, 1999, BIOL CELL, V91, P413, DOI 10.1016/S0248-4900(99)80083-5; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; TAO X, 2000, CHUNG HUA KAN TSANG, V8, P161; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Valerie K, 2000, CANCER GENE THER, V7, P879, DOI 10.1038/sj.cgt.7700185; VALERIE K, 1995, MUTAT RES-DNA REPAIR, V336, P91, DOI 10.1016/0921-8777(94)00046-9; Valerie K, 1999, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, P69; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wu CG, 1997, CARCINOGENESIS, V18, P47, DOI 10.1093/carcin/18.1.47; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P339, DOI 10.1046/j.1440-1746.2000.02166.x; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	56	75	84	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3674	3682		10.1038/sj.onc.1204481	http://dx.doi.org/10.1038/sj.onc.1204481			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439330				2022-12-28	WOS:000169400200008
J	Paz, A; Haklai, R; Elad-Sfadia, G; Ballan, E; Kloog, Y				Paz, A; Haklai, R; Elad-Sfadia, G; Ballan, E; Kloog, Y			Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation	ONCOGENE			English	Article						galectin-1; oncogenic Ras; cell transformation; Ras localization	GROWTH-FACTOR; SELECTIVE-INHIBITION; CAVEOLAE MEMBRANE; PROTEIN; APOPTOSIS; EXPRESSION; ADHESION; LOCALIZATION; ACTIVATION; RECEPTOR	Ras genes, frequently mutated in human tumors, promote malignant transformation. Ras transformation requires membrane anchorage, which is promoted by Ras farnesylcysteine carboxymethylester and by a second signal. Previously we showed that the farnesylcysteine mimetic, farnesylthiosaticylic acid (FTS) disrupts Ras membrane anchorage. To understand how this disruption contributes to inhibition of cell transformation we searched, for new Ras-interacting proteins and identified galectin-1, a lectin implicated in human tumors, as a selective binding partner of oncogenic H-Ras(12V). The observed size of H-Ras(12V)-galectin-1 complex, which is equal to the sum of the molecular weights of Ras and galectin-1 indicates a direct binding interaction between the two proteins. FTS disrupted H-Ras(12V)-galectin-1 interactions. Overexpression of galectin-1 increased membrane-associated Ras, Ras-GTP, and active ERK resulting in cell transformation, which was blocked by dominant negative Ras. Galectin-1 antisense RNA inhibited transformation by H-Ras(12V) and abolished membrane anchorage of green fluorescent protein (GFP)-H-Ras(12V) but not of GFP-H-Ras wild-type (wt), GFP-K-Ras(12V), or GFP-N-Ras(13V). H-Ras(12V)galectin-1 interactions establish an essential link between two proteins associated with cell transformation and human malignancies that can be exploited to selectively target oncogenic Ras proteins.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Kloog, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	kloog@post.tau.ac.il						Allione A, 1998, J IMMUNOL, V161, P2114; Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bresalier RS, 1997, CANCER, V80, P776; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Hadari YR, 2000, J CELL SCI, V113, P2385; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Kloog, 1999, Expert Opin Investig Drugs, V8, P2121, DOI 10.1517/13543784.8.12.2121; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; OHANNESIAN DW, 1995, CANCER RES, V55, P2191; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; VANDENBRULE FA, 1995, BIOCHEM BIOPH RES CO, V209, P760, DOI 10.1006/bbrc.1995.1564; Vespa GNR, 1999, J IMMUNOL, V162, P799; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Willumsen BM, 1996, ONCOGENE, V13, P1901; Yamaoka K, 1996, J BIOCHEM-TOKYO, V119, P878; YAMAOKA K, 1991, BIOCHEM BIOPH RES CO, V179, P272, DOI 10.1016/0006-291X(91)91365-J; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H	46	320	332	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7486	7493		10.1038/sj.onc.1204950	http://dx.doi.org/10.1038/sj.onc.1204950			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709720				2022-12-28	WOS:000171976900005
J	Cheng, GJ; Meinkoth, JL				Cheng, GJ; Meinkoth, JL			Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells	ONCOGENE			English	Article						Ras; Rap1A; thyroid; apoptosis	PROTEIN-KINASE-A; EPITHELIAL-CELLS; MUTANT RAS; EXPRESSION; ONCOGENE; PROLIFERATION; GENE; DIFFERENTIATION; ACTIVATION; PATHWAYS	Ras. mutations, occur at high frequency in thyroid cancer. In vitro, the effects of Ras in thyroid cells are pleiotropic in that expression of activated Ras has been reported to, stimulate proliferation and apoptosis. An understanding of the factors that contribute to the survival versus demise of Ras-transformed cells is essential to our understanding, of the contribution of Ras to thyroid neoplasia and other cancers. Constitutive expression of oncogenic H-Ras sensitized Wistar rat thyroid (WRT) cells to apoptosis stimulated by multiple insults. When deprived of matrix attachment, Ras-transformed cells perished by apoptotic cell death at a high frequency. In contrast, parental cells were more resistant to suspension-induced cell death. Ras effects on anchorage-independent cell death were reproduced by a mutant protein that signals selectively to Raf-1, but not by mutant Ras that preferentially binds, to RalGDS. Expression of a Ras mutant that selectively activates PI3K resulted in substantial protection from detachment-induced cell death., MAPK activity was increased in, adherent Ras12V- and Rasl2V35S-expressing cells, but abolished upon detachment. Interestingly, impaired MAPK activity was sufficient to stimulate apoptosis in adherent Ras-transformed cells, but not in parental cells. Treatment with a PI3-K inhibitor also stimulated apoptosis, selectively in Ras-transformed cells. These results, demonstrate that constitutive expression of activated Ras elicits differential effects on the survival of thyroid cells., Moreover, Ras, expression results in a greater dependence of thyroid cells on MAPK and PI3K activity for their survival.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.		Meinkoth, Judy L/G-2900-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055757] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55757] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arscott PL, 1997, ENDOCRINOLOGY, V138, P5019, DOI 10.1210/en.138.11.5019; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; AVVEDIMENTO VE, 1985, EUR J BIOCHEM, V149, P467, DOI 10.1111/j.1432-1033.1985.tb08948.x; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Di Matola T, 2000, J CLIN ENDOCR METAB, V85, P1188, DOI 10.1210/jc.85.3.1188; DREMIER S, 1994, BIOCHEM BIOPH RES CO, V200, P52, DOI 10.1006/bbrc.1994.1412; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; JESO BD, 1995, BIOCHEM BIOPH RES CO, V214, P819; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Li X, 1999, ENDOCRINOLOGY, V140, P5962, DOI 10.1210/en.140.12.5962; Lin TH, 1997, J BIOL CHEM, V272, P8849; MALY FE, 1994, J BIOL CHEM, V269, P18743; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; SUAREZ HG, 1990, ONCOGENE, V5, P565; Tsygankova OM, 2000, ONCOGENE, V19, P3609, DOI 10.1038/sj.onc.1203680; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Vitale M, 1999, FEBS LETT, V462, P57, DOI 10.1016/S0014-5793(99)01512-4; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	37	19	19	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7334	7341		10.1038/sj.onc.1204928	http://dx.doi.org/10.1038/sj.onc.1204928			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704863				2022-12-28	WOS:000171894200006
J	Sayed, M; Pelech, S; Wong, C; Marotta, A; Salh, B				Sayed, M; Pelech, S; Wong, C; Marotta, A; Salh, B			Protein kinase CK2 is involved in G2 arrest and apoptosis following spindle damage in epithelial cells	ONCOGENE			English	Article						CK2; p53; spindle checkpoint; apoptosis	DNA-DAMAGE; P53 PROTEIN; NEUROBLASTOMA-CELLS; SUPPRESSOR PROTEIN; MOUSE FIBROBLASTS; CYCLE CHECKPOINT; G(2) CHECKPOINT; GAMMA-RADIATION; II SITE; PHOSPHORYLATION	p53 undergoes phosphorylation on several residues in response to cellular stresses that include UV and ionizing radiation, however the influence of spindle damage on this parameter is relatively unclear. Consequently, the effect of nocodazole on serine 392 phosphorylation was examined in two epithelial cell lines. We show that this process is dependent upon the stepwise activation of p38 mitogen-activated protein kinase (p38 MAPK) and protein kinase casein kinase 2 (CK2). Furthermore, this activation correlated with the biochemical regulation of the maturation-promoting factor (MPF, cdc2/cyclin B), as both DRB and antisense depletion of CK2, as well as SB203580 were associated with an inhibition of its activation in response to nocodazole. Strikingly, when the cell cycle characteristics of nocodazole treated cells were examined, we observed that depletion or inhibition of the catalytic subunit of CK2, in the presence of microtubule inhibitors, resulted in a compromise of the G2 arrest (spindle checkpoint). Furthermore, CK2-depleted, nocodazole treated cells demonstrated a dramatic reduction in the apoptotic cell fraction, confirming that these cells had been endowed with oncogenic properties. These changes were observed in both HeLa cells and HCT116 cells. We also show that this effect is dependent on the presence of functional wild-type p53, as this phenomenon is not apparent in HCT116 p53 /(-) cells. Collectively, our results indicate two novel roles for CK2 in the spindle checkpoint arrest, in concert with p53. Firstly, to maintain increased cyclinB/cdc2 kinase activity, as a component of G2 arrest, and secondly, a role in p53-mediated apoptosis. These findings may have implications for an improved understanding of abnormalities of the spindle checkpoint in human cancers, which is a prerequisite for defining future therapies.	Univ British Columbia, Jack Bell Res Ctr, Dept Expt Med, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of British Columbia; University of British Columbia; Memorial Sloan Kettering Cancer Center	Salh, B (corresponding author), Univ British Columbia, Dept Med, 100-2647 Willow St, Vancouver, BC V5Z 3P1, Canada.			Pelech, Steven/0000-0003-1112-903X				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1993, ONCOGENE, V8, P1519; Gotz C, 1999, MOL CELL BIOCHEM, V191, P111, DOI 10.1023/A:1006886727248; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERRMANN CPE, 1991, ONCOGENE, V6, P877; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MIYASHITA T, 1995, CELL, V80, P293; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Prives C, 1999, J PATHOL, V187, P112; ROLLEY N, 1994, ONCOGENE, V9, P3067; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHICH SY, 1997, CELL, V91, P325; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; ULLOA L, 1994, CELL MOL NEUROBIOL, V14, P407, DOI 10.1007/BF02088827; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Xu X, 1999, MOL CELL BIOCHEM, V191, P65, DOI 10.1023/A:1006866412652; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	62	53	57	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					6994	7005		10.1038/sj.onc.1204894	http://dx.doi.org/10.1038/sj.onc.1204894			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704824				2022-12-28	WOS:000171739300003
J	Pierantoni, GM; Fedele, M; Pentimalli, F; Benvenuto, G; Pero, R; Viglietto, G; Santoro, M; Chiariotti, L; Fusco, A				Pierantoni, GM; Fedele, M; Pentimalli, F; Benvenuto, G; Pero, R; Viglietto, G; Santoro, M; Chiariotti, L; Fusco, A			High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth	ONCOGENE			English	Article						HMGI(Y); HIPK2; serine-threonine kinase; growth inhibition; yeast two-hybrid screening	IFN-BETA GENE; EXPRESS HIGH-LEVELS; FACTOR HMGI-C; SERINE/THREONINE KINASE; TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; VIRUS INDUCTION; THYROID-CELLS; DNA-BINDING; SEQUENCE	The HMGI proteins (HMGI, HMGY and HMGI-C) have an important role in the chromatin organization and interact with different transcriptional factors. The HMGI genes are expressed at very low levels in normal adult tissues, whereas they are very abundant during embryonic development and in several experimental and human tumours. In order to isolate proteins interacting with the HMGI(Y) proteins, a yeast two-hybrid screening was performed using the HMGI(Y) protein as bait. This analysis led to the isolation of homeodomain-interacting protein kinase-2 (HIPK2), a serine/threonine nuclear kinase. HIPK2 co-immunoprecipitates with the HMGI(Y) protein in 293T cells. The interaction between HIPK2 and HMGI(Y) occurs through the PEST domain of HIPK2 and it is direct because in vitro translated HIPK2 binds HMGI(Y). We also show that HIPK2 is able to phosphorylate the HMGI(Y) protein by an in vitro kinase assay. In order to understand a possible role of HIPK2 gene in cell growth we performed a colony assay which showed an impressive HIPK2 inhibitory effect on normal thyroid cells. Flow cytometric analysis would indicate the block of cell growth at the G2/M phase of the cell cycle. Since normal thyroid cells do not express detectable HMGI(Y) protein levels, we assume that the HIPK2 inhibitory effect is independent from the interaction with the HMGI(Y) protein.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Fondaz Senatore Pascale, Ist Nazl Tumori, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; IRCCS Fondazione Pascale; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.		Fedele, Monica/C-1417-2015; Pero, Raffaela/L-1461-2015; Viglietto, Giuseppe/AAC-2852-2019; Pentimalli, Francesca/K-4936-2014; Pierantoni, Giovanna Maria/O-7527-2015; Chiariotti, Lorenzo/AAC-5262-2022	Fedele, Monica/0000-0002-9171-1312; Pero, Raffaela/0000-0003-2182-5530; Viglietto, Giuseppe/0000-0003-2327-7515; Pentimalli, Francesca/0000-0003-4740-6801; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; BENVENUTO, Giovanna/0000-0001-7155-2935				Abe N, 2000, CANCER RES, V60, P3117; ABE N, 1999, CANCER RES, V56, P1896; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; ASHAR HR, 1995, CELL, V82, P57; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Fedele M, 1996, CANCER RES, V56, P1896; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Li X, 2000, BIOCHEM BIOPH RES CO, V277, P513, DOI 10.1006/bbrc.2000.3700; LOVELLBADGE R, 1995, NATURE, V376, P725, DOI 10.1038/376725a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; ROGERS S, 1986, SCIENCE, V234, P3674; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; TAMIMI Y, 1993, CANCER RES, V53, P5512; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tkachenko A, 1997, CANCER RES, V57, P2276; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Xiao S, 1997, AM J PATHOL, V150, P901; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	50	76	84	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6132	6141		10.1038/sj.onc.1204635	http://dx.doi.org/10.1038/sj.onc.1204635			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593421	Bronze			2022-12-28	WOS:000171206300004
J	Waddell, S; Jenkins, JR; Proikas-Cezanne, T				Waddell, S; Jenkins, JR; Proikas-Cezanne, T			A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	ONCOGENE			English	Article						p53; p53 tumor mutant; S.pombe; functional yeast-based assay system	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTION FACTOR; DROSOPHILA P53; BINDING-SITE; AMINO-ACIDS; MDM2; ONCOPROTEIN; MUTATIONS	We have developed a functional 'no-hybrids' screen in the fission yeast Schizosaccharomyces pombe based on the transcription transactivator activity of human p53. The screen can be used to identify antagonizers and modulators of p53 activity. Expression of functional full-length human p53 is conditionally lethal to the screen reporter strains. Co-expression of specific inhibitory proteins promotes cell survival and growth. We have validated the 'no-hybrids' system by (a) successful modeling of human wild-type p53 interaction with SV40 large T antigen, Mdm2 and a panel of tumor-derived human p53 mutants, (b) demonstrating the screening system's efficiency through identification of a dominant negative fragment of p53 itself in a library screen context and (c) using Drosophila p53 to demonstrate that the system can detect evolutionarily distant p53 homologues based on their transactivator activity. The 'no-hybrids' screen will be of utility in searches for p53 function-modulators of both cellular and viral origin.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Res, Philadelphia, PA 19140 USA; MIT, Dept Biol, Dept Brain & Cognit Sci, Ctr Learning & Memory, Cambridge, MA 02139 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Massachusetts Institute of Technology (MIT)	Proikas-Cezanne, T (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Res, 3307 N Broad St, Philadelphia, PA 19140 USA.	alexandropolis@yahoo.com		Proikas-Cezanne, Prof. Dr. Tassula/0000-0001-6934-132X; Waddell, Scott/0000-0003-4503-6229				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Burch LR, 2000, FEBS LETT, V472, P93, DOI 10.1016/S0014-5793(00)01427-7; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; Di Como CJ, 1998, ONCOGENE, V16, P2527; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRIMM C, 1988, P NATL ACAD SCI USA, V78, P5445; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LENG P, 1995, ONCOGENE, V10, P1275; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Matlashewski Greg, 1999, Oncogene, V18, P7618, DOI 10.1038/sj.onc.1203157; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; RIOU G, 1990, LANCET, V335, P1171; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TARUNINA M, 1993, ONCOGENE, V8, P3165; WADDELL S, 1995, NUCLEIC ACIDS RES, V23, P1836, DOI 10.1093/nar/23.10.1836; Waddell S, 1998, ONCOGENE, V16, P1759, DOI 10.1038/sj.onc.1201848; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	41	8	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6001	6008		10.1038/sj.onc.1204702	http://dx.doi.org/10.1038/sj.onc.1204702			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593407				2022-12-28	WOS:000171056300007
J	McIlhatton, MA; Burrows, JF; Donaghy, PG; Chanduloy, S; Johnston, PG; Russell, SEH				McIlhatton, MA; Burrows, JF; Donaghy, PG; Chanduloy, S; Johnston, PG; Russell, SEH			Genomic organization, complex splicing pattern and expression of a human septin gene on chromosome 17q25.3	ONCOGENE			English	Article						septin gene; genomic organisation; complex splicing	ACUTE MYELOID-LEUKEMIA; CELL-DIVISION CYCLE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN SEPTIN; OVARIAN-TUMORS; PROTEIN-KINASE; YEAST; CYTOKINESIS; FAMILY; REGION	The Ov/Br septin gene, which is also a fusion partner of MLL in acute myeloid leukaemia, is a member of a family of novel GTP binding proteins that have been implicated in cytokinesis and exocytosis. In this study, we describe the genomic and transcriptional organization of this gene, detailing seventeen exons distributed over 240 kb of sequence. Extensive database analyses identified orthologous rodent cDNAs that corresponded to new, unidentified 5 ' splice variants of the Ov/Br septin gene, increasing the total number of such variants to six. We report that splicing events, occurring at noncanonical sites within the body of the 3 ' terminal exon, remove either 1801 by or 1849 by of non-coding sequence and facilitate access to a secondary open reading frame of 44 amino acids maintained near the end of the 3 ' UTR. These events constitute a novel coding arrangement and represent the first report of such a design being implemented by a eukaryotic gene. The various Ov/Br proteins either differ minimally at their amino and carboxy termini or are equivalent to truncated versions of larger isoforms. Northern analysis with an Ov/Br septin 3 ' UTR probe reveals three transcripts of 4.4, 4 and 3 kb, the latter being restricted to a sub-set of the tissues tested. Investigation of the identified Ov/Br septin isoforms by RT-PCR confirms a complex transcriptional pattern, with several isoforms showing tissue-specific distribution. To date, none of the other human septins have demonstrated such transcriptional complexity.	Queens Univ Belfast, Dept Oncol, Ctr Canc, Belfast City Hosp, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Russell, SEH (corresponding author), Queens Univ Belfast, Dept Oncol, Ctr Canc, Belfast City Hosp, U Floor, Belfast BT9 7AB, Antrim, North Ireland.	seh.russell@qub.ac.uk						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Bi E, 1998, J CELL BIOL, V142, P1301, DOI 10.1083/jcb.142.5.1301; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; DeVirgilio C, 1996, MICROBIOL-SGM, V142, P2897, DOI 10.1099/13500872-142-10-2897; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Fares H, 1996, J CELL BIOL, V132, P399, DOI 10.1083/jcb.132.3.399; FARES H, 1995, MOL BIOL CELL, V6, P1843, DOI 10.1091/mbc.6.12.1843; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Fung ET, 1999, FEBS LETT, V451, P203, DOI 10.1016/S0014-5793(99)00559-1; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Hanke J, 1999, TRENDS GENET, V15, P389, DOI 10.1016/S0168-9525(99)01830-2; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kilpartick GJ, 1999, TRENDS PHARMACOL SCI, V20, P294, DOI 10.1016/S0165-6147(99)01355-3; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Mori T, 1996, CYTOGENET CELL GENET, V73, P224, DOI 10.1159/000134343; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Russell SEH, 2000, CANCER RES, V60, P4729; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Sorensen AB, 2000, J VIROL, V74, P2161, DOI 10.1128/JVI.74.5.2161-2168.2000; Taki T, 1999, CANCER RES, V59, P4261; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; Yagi M, 1998, GENE, V212, P229, DOI 10.1016/S0378-1119(98)00146-2; Zhang T, 1999, P NATL ACAD SCI USA, V96, P11422, DOI 10.1073/pnas.96.20.11422	45	68	79	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5930	5939		10.1038/sj.onc.1204752	http://dx.doi.org/10.1038/sj.onc.1204752			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593400				2022-12-28	WOS:000171037200018
J	Michalowski, J; Seavey, SE; Mendrysa, SM; Perry, ME				Michalowski, J; Seavey, SE; Mendrysa, SM; Perry, ME			Defects in transcription coupled repair interfere with expression of p90(MDM2) in response to ultraviolet light	ONCOGENE			English	Article						p53; MDM2; ultraviolet; transcription	RNA-POLYMERASE-II; WILD-TYPE P53; NUCLEOTIDE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM; DNA-DAMAGE; UV IRRADIATION; MDM2 GENE; COCKAYNES-SYNDROME; PYRIMIDINE DIMERS; FEEDBACK LOOP	Ultraviolet (UV) irradiation transiently stabilizes p53 through a mechanism that may require a decrease in the activity of the ubiquitin ligase, p90(MDM2). Conversely, the recovery of low levels of p53 following UV exposure may depend on an increase in p90(MDM2). The level of p90(MDM2) is increased by UV light following the p53-dependent induction of an internal mdm2 promoter, P2. If this induction of mdm2 were critical for the recovery of low levels of p53 following UV exposure, defects in mdm2's transcription would result in a prolonged increase in p53. Cells defective in transcription coupled repair (TCR) maintain high levels of p53 for a prolonged period following UV exposure. Such cells also have defects in general transcription after UV irradiation. We investigated whether TCR-deficient cells express diminished levels of mdm2 mRNA and p90(MDM2) following UV exposure. We found that transcription of mdm2 was reduced in TCR-deficient cells. The uninducible mdm2 promoter, P1, was more sensitive to the inhibitory effects of UV irradiation than the P2 promoter. The decrease in transcription from the P1 promoter was sufficient to reduce the level of p90(MDM2) and correlated with a prolonged increase in p53. Thus, p53-independent transcription of mdm2 appears critical to p53's regulation.	Univ Wisconsin, Sch Med, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Perry, ME (corresponding author), Univ Wisconsin, Sch Med, Dept Oncol, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [CA-07175, CA-09135, CA-70781] Funding Source: Medline; NIGMS NIH HHS [GM-07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA070781, R29CA070781, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Ganesan AK, 1999, MUTAT RES-DNA REPAIR, V433, P117, DOI 10.1016/S0921-8777(98)00070-6; Geyer RK, 2000, CELL GROWTH DIFFER, V11, P149; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Huang JH, 1998, ONCOGENE, V17, P401, DOI 10.1038/sj.onc.1201951; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; JUVEN T, 1993, ONCOGENE, V8, P3411; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Landers JE, 1997, CANCER RES, V57, P3562; LI G, 1995, CANCER RES, V55, P2070; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYNE LV, 1982, CANCER RES, V42, P1473; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rockx DAP, 2000, P NATL ACAD SCI USA, V97, P10503, DOI 10.1073/pnas.180169797; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; van Hoffen A, 1999, NUCLEIC ACIDS RES, V27, P2898, DOI 10.1093/nar/27.14.2898; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Zhu QZ, 2000, MOL CARCINOGEN, V28, P215; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	46	5	5	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5856	5864		10.1038/sj.onc.1204721	http://dx.doi.org/10.1038/sj.onc.1204721			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593391				2022-12-28	WOS:000171037200009
J	Wong, S; Witte, ON				Wong, S; Witte, ON			Modeling Philadelphia chromosome positive leukemias	ONCOGENE			English	Review						BCR-ABL; mouse model; leukemia	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; SEQUENCE-BINDING-PROTEIN; P210 BCR-ABL; COLONY-STIMULATING FACTOR; CHRONIC MYELOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; MYELOPROLIFERATIVE DISEASE	The Ph chromosome has been genetically linked to CML and ALL. Its chimeric fusion gene product, BCR-ABL, can generate leukemia in mice. This review will discuss selected model systems developed to study BCR-ABL induced leukemia and focuses on what we have learned about the human disease from these models. Five main experimental approaches will be discussed including: (i) Reconstitution of mice with bone marrow cells retrovirally transduced with BCR-ABL; (ii) Transgenic mice expressing BCR-ABL; (iii) Knock-in mice with BCR-ABL expression driven from the endogenous ber locus; (iv) Development of CML-like disease in mice with loss of function mutations in heterologous genes; and (v) ES in vitro hematopoietic differentiation coupled with regulated BCR-ABL expression.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Witte, ON (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, 675 Charles E Young Dr S,Room 5-748 MRL Bldg, Los Angeles, CA 90095 USA.	owen@microbio.ucla.edu						ABELSON HT, 1970, CANCER RES, V30, P2213; Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Anderson SM, 1996, BLOOD, V87, P238; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Cambier N, 1999, ONCOGENE, V18, P343, DOI 10.1038/sj.onc.1202302; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; Chung SW, 1996, ONCOGENE, V13, P2397; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; CLARKSON B, 1993, LEUKEMIA, V7, P1683; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Colleoni GWB, 1996, AM J HEMATOL, V53, P277, DOI 10.1002/1096-8652(199612)53:4<277::AID-AJH2830530402>3.0.CO;2-Z; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; Delforge M, 1999, BLOOD, V93, P284, DOI 10.1182/blood.V93.1.284.401k31_284_292; DIEKMANN L, 1994, ACTA HAEMATOL-BASEL, V92, P169; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1084; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ENGELMAN A, 1987, P NATL ACAD SCI USA, V84, P8021, DOI 10.1073/pnas.84.22.8021; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Fabbiano F, 1998, HAEMATOLOGICA, V83, P856; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FIALKOW PJ, 1967, P NATL ACAD SCI USA, V58, P1468, DOI 10.1073/pnas.58.4.1468; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gross AW, 1999, MOL CELL BIOL, V19, P6918; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Haferlach T, 1997, BRIT J HAEMATOL, V99, P452, DOI 10.1046/j.1365-2141.1997.4203237.x; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HAWLEY RG, 1994, GENE THER, V1, P136; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Kabarowski JHS, 2000, STEM CELLS, V18, P399, DOI 10.1002/stem.180399; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KANTARJIAN HM, 1991, BLOOD, V78, P2411, DOI 10.1182/blood.V78.9.2411.bloodjournal7892411; Kasprzyk A, 1999, LEUKEMIA, V13, P2000, DOI 10.1038/sj.leu.2401580; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, BLOOD, V70, P1584; LAZARIDOU A, 1994, LEUKEMIA, V8, P454; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; LI X, 1994, LEUKEMIA LYMPHOMA, V13, P65, DOI 10.3109/10428199409052678; Lim YM, 2000, P NATL ACAD SCI USA, V97, P12233, DOI 10.1073/pnas.210253497; LIU JX, 1993, ONCOGENE, V8, P101; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; LU D, 1993, BLOOD, V82, P1257; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANO H, 1990, ONCOGENE, V5, P1781; MARTIAT P, 1990, LEUKEMIA, V4, P751; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Maru Y, 1996, FEBS LETT, V379, P244, DOI 10.1016/0014-5793(95)01518-3; McCormack MP, 1999, ONCOGENE, V18, P7190, DOI 10.1038/sj.onc.1203226; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MELO JV, 1994, LEUKEMIA, V8, P208; Melo JV, 1996, BRIT J HAEMATOL, V92, P684, DOI 10.1046/j.1365-2141.1996.00350.x; MELO JV, 1993, BLOOD, V81, P2488; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MITANI K, 1990, BRIT J HAEMATOL, V76, P221, DOI 10.1111/j.1365-2141.1990.tb07875.x; MITELMAN F, 1993, LEUKEMIA LYMPHOMA, V11, P11, DOI 10.3109/10428199309047856; MOLLINEDO F, 1991, BIOCHEM J, V273, P477, DOI 10.1042/bj2730477; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NOWELL PC, 1960, SCIENCE, V132, P1497; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pajor L, 2000, LEUKEMIA, V14, P1122, DOI 10.1038/sj.leu.2401794; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Peters DG, 2001, BLOOD, V97, P1404, DOI 10.1182/blood.V97.5.1404; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RASKIND WH, 1987, ADV CANCER RES, V49, P127, DOI 10.1016/S0065-230X(08)60796-4; Reichert A, 2001, BLOOD, V97, P1399, DOI 10.1182/blood.V97.5.1399; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; ROVIRA A, 1995, ANN HEMATOL, V70, P129; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAGLIO G, 1990, BLOOD, V76, P1819; Salloukh HF, 2000, ONCOGENE, V19, P4362, DOI 10.1038/sj.onc.1203804; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SECKERWALKER LM, 1988, BLOOD, V72, P784; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; Tauchi T, 1998, INT J ONCOL, V12, P1269; Thome KC, 1997, J VIROL, V71, P8149, DOI 10.1128/JVI.71.11.8149-8156.1997; Tiribelli M, 2000, BLOOD, V95, P4019; Unnikrishnan I, 1999, MOL CELL BIOL, V19, P4825, DOI 10.1128/mcb.19.7.4825; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Voncken JW, 1998, ONCOGENE, V16, P2029, DOI 10.1038/sj.onc.1201730; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; VONCKEN JW, 1992, CANCER RES, V52, P4534; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WILSON G, 1997, BLOOD, V88, P2410; WilsonRawls J, 1996, CANCER RES, V56, P3426; WITTE ON, 1980, P NATL ACAD SCI-BIOL, V77, P4993, DOI 10.1073/pnas.77.8.4993; WITTE ON, 1981, J VIROL, V39, P870, DOI 10.1128/JVI.39.3.870-878.1981; YOFFE G, 1987, EXP HEMATOL, V15, P725; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang XW, 2001, BLOOD, V97, P277, DOI 10.1182/blood.V97.1.277; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; Zhao RC, 2001, BLOOD, V97, P2406, DOI 10.1182/blood.V97.8.2406; Zou XM, 2000, MOL CELL BIOL, V20, P628, DOI 10.1128/MCB.20.2.628-633.2000	152	54	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5644	5659		10.1038/sj.onc.1204638	http://dx.doi.org/10.1038/sj.onc.1204638			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607816				2022-12-28	WOS:000170887500007
J	Clifford, SC; Astuti, D; Hooper, L; Maxwell, PH; Ratcliffe, PJ; Maher, ER				Clifford, SC; Astuti, D; Hooper, L; Maxwell, PH; Ratcliffe, PJ; Maher, ER			The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1 alpha in renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; elongin B; elongin C; Rbx1; HIF-1 alpha; VHL; genomic organization; chromosomal localization; mutation	TUMOR-SUPPRESSOR GENE; INDUCIBLE FACTOR 1-ALPHA; HUMAN HOMOLOG; BETA-CATENIN; ALLELE LOSS; VHL; MUTATIONS; PROTEIN; CANCER; ACTIVATION	The VHL gene product (pVHL) forms a multimeric complex with the elongin B and C, Cul2 and Rbx1 proteins (VCBCR complex), which is homologous to the SCF family of ubiquitin ligase complexes. The VCBCR complex binds HIF-1 alpha and HIF-2 alpha, transcription factors critically involved in cellular responses to hypoxia, and targets them for ubiquitin-mediated proteolysis. Germline mutations in the VHL gene cause susceptibility to haemangioblastomas, renal cell carcinoma (RCC), phaeochromocytoma and other tumours. In addition somatic inactivation of the VHL gene occurs in most sporadic clear cell RCC (CC-RCC). However, the absence of somatic VHL inactivation in 30-40% of CC-RCC implies the involvement of other gatekeeper genes in CC-RCC development. We reasoned that in CC-RCC without VHL inactivation, other pVHL-interacting proteins might be defective. To assess the role of elongin B/C, Rbx1 and HIF-1 alpha in RCC tumorigenesis we (a) mapped the genes to chromosomes 8q(cen) (elongin C), 16p13.3 (elongin B) and 22q11.2 (Rbx1) by FISH, monochromosomal somatic cell hybrid panel screening and in silico GenBank homology searching; (b) determined the genomic organisation of elongin C (by direct sequencing of PAC clones), Rbx1 and elongin B (by GenBank homology searching); and (c) performed mutation analysis of exons comprising the coding regions of elongins B, C and Rbx1 and the oxygen-dependent degradation domain of HIF-1 alpha by SSCP screening and direct sequencing in 35 sporadic clear cell RCC samples without VHL gene inactivation and in 13 individuals with familial non-VHL clear cell RCC. No coding region sequence variations were detected for the elongin 13, elongin C or Rbx1 genes. Two amino acid substitutions (Pro582Ser and Ala588Thr) were identified in the oxygen-dependent degradation/pVHL binding domain of HIF-1 alpha, however neither substitution was observed exclusively in tumour samples. Association analysis in panels of CC-RCC and non-neoplastic samples using the RFLPs generated by each variant did not reveal allelic frequency differences between RCC patients and controls (P >0.32 by chi-squared analysis). Nevertheless, the significance of these variations and their potential for modulation of HIF-1 alpha function merits further investigation in both other tumour types and in non-neoplastic disease. Taken together with our previous Cul2 mutation analysis these data suggest that development of sporadic and familial RCC is not commonly contributed to by genetic events altering the destruction domain of HIF-1 alpha, or components of the HIF-alpha destruction complex other than VHL itself. Although (a) activation of HIF could occur through mutation of another region of HIF-a, and (b) epigenetic silencing of elongin B/C, Cul2 or Rbx1 cannot be excluded, these findings suggest that pVHL may represent the sole mutational target through which the VCBR complex is disrupted in CC-RCC. HIF response is activated in CC-RCC tumorigenesis.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England	University of Oxford; Wellcome Centre for Human Genetics; University of Birmingham	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Div Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	e.r.maher@bham.ac.uk	Maxwell, Patrick H/C-5557-2008; MAHER, EAMONN R/A-9507-2008	Maxwell, Patrick H/0000-0002-0338-2679; MAHER, EAMONN R/0000-0002-6226-6918; Astuti, Dewi/0000-0003-4205-6160; Ratcliffe, Peter/0000-0002-2853-806X; Clifford, Steve/0000-0003-4893-2184				Clifford SC, 1999, GENE CHROMOSOME CANC, V26, P20, DOI 10.1002/(SICI)1098-2264(199909)26:1<20::AID-GCC3>3.3.CO;2-Y; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Duerr EM, 1999, J CLIN ENDOCR METAB, V84, P3207, DOI 10.1210/jc.84.9.3207; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ioannou P.A., 1996, CURRENT PROTOCOLS HU; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Kadota M, 2000, ONCOL REP, V7, P529; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KELSELL DP, 1995, ANN HUM GENET, V59, P233, DOI 10.1111/j.1469-1809.1995.tb00743.x; KNOWLES MA, 1993, ONCOGENE, V8, P1357; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lininger RA, 1998, HUM PATHOL, V29, P1113, DOI 10.1016/S0046-8177(98)90422-1; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Perinchery G, 1999, INT J ONCOL, V14, P495; Poli-Frederico RC, 2000, HEAD NECK-J SCI SPEC, V22, P585, DOI 10.1002/1097-0347(200009)22:6<585::AID-HED7>3.0.CO;2-4; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1996, GENOMICS, V34, P437, DOI 10.1006/geno.1996.0311; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sparks AB, 1998, CANCER RES, V58, P1130; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; THE BT, 1997, LANCET, V349, P848; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Wolter M, 1997, CANCER RES, V57, P2581; Woodward ER, 2000, J MED GENET, V37, P348, DOI 10.1136/jmg.37.5.348; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	41	124	131	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					5067	5074		10.1038/sj.onc.1204602	http://dx.doi.org/10.1038/sj.onc.1204602			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526493				2022-12-28	WOS:000170439800018
J	Yoon, DS; Li, L; Zhang, RD; Kram, A; Ro, JY; Johnston, D; Grossman, HB; Scherer, S; Czerniak, B				Yoon, DS; Li, L; Zhang, RD; Kram, A; Ro, JY; Johnston, D; Grossman, HB; Scherer, S; Czerniak, B			Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease	ONCOGENE			English	Article						tumor suppressor gene loci; chromosome 16; bladder cancer	HUMAN-BREAST-CARCINOMA; URINARY-BLADDER; MICROSATELLITE ANALYSIS; PROSTATE-CANCER; ALLELIC LOSS; E-CADHERIN; EXPRESSION; CARCINOGENESIS; HETEROZYGOSITY; ALLELOTYPE	Histologic and genetic mapping with 30 hypervariable markers mapped to chromosome 16 were performed on 234 DNA samples of five cystectomy specimens from patients with invasive bladder cancer. Allelic losses of individual markers were related to microscopically identified precursor conditions in the entire bladder mucosa and invasive cancer. Their significance for the development and progression of neoplasia from in situ preneoplastic conditions to invasive disease was analysed by the nearest neighbor algorithm and binomial maximum likelihood analysis. Using this approach we identified five distinct regions of allelic losses defined by their flanking markers and predicted size as follows. p13.3(D16S418-D16S406, 1.2 cM), p13.1(D16S748-D16S287, 12.9 cM), q12 1(D16S409-D16S514, 24.0 cM), q22.1 (D16S496-D16S515, 5.4 cM), and q24 (D16S507-D16S511, 5.9 cM and D16S402-D16S413, 17.4 cM). The regions mapping to p13.1 and q24 were involved in early intraurothelial phases of bladder neoplasia such as mild to moderate dysplasia. On the other hand the deleted region mapping to p13.3 was involved in progression of severe dysplasia/carcinoma in situ to invasive bladder cancer. Testing of markers that exhibited statistically significant LOH in relation to progression of neoplasia from precursor conditions to invasive cancer on 28 tumors and voided urine samples from 25 patients with bladder cancer revealed that q12.1 showed LOH in 46.4% of tumor and 32.0% of voided urine samples. The LOH of a single marker D16S541 could be detected in approximately 28% of tumors and 20% of voided urine samples of patients with bladder cancer. These data imply that the deleted region centered around marker D16S541 spanning approximately 10 cM and flanked by D16S409 and D16S415 contains a novel putative tumor suppressor gene or genes playing an important role in the development of human bladder cancer. To facilitate more precise positional mapping and identification of pathogenetically relevent genes, we analysed of human genome contig and sequence databases spanning the deleted regions. Multiple known candidate genes and several smaller gene-rich areas mapping to the target regions of chromosome 16 were identified Oncogene (2001) 20, 5005-5014.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Human Genome Sequencing Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Czerniak, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Kram, Andrzej/0000-0003-0621-0204	NCI NIH HHS [R29CA66723, UO-1 CA85078] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085078, R29CA066723] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, J CLIN PATHOL; Asgeirsson KS, 2000, EUR J CANCER, V36, P1098, DOI 10.1016/S0959-8049(00)00062-9; Brownlee K. A, 1965, STAT THEORY METHODOL; CAIRNS P, 1994, CANCER RES, V54, P1422; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHANG WYH, 1995, CANCER RES, V55, P3246; Chaturvedi V, 1997, ONCOGENE, V14, P2059, DOI 10.1038/sj.onc.1201044; Czerniak B, 1999, ONCOGENE, V18, P1185, DOI 10.1038/sj.onc.1202385; Czerniak B, 2000, GENE CHROMOSOME CANC, V27, P392, DOI 10.1002/(SICI)1098-2264(200004)27:4<392::AID-GCC9>3.3.CO;2-E; CZERNIAK B, 1992, HUM PATHOL, V23, P1199, DOI 10.1016/0046-8177(92)90285-B; Czerniak B, 1995, DIAGNOSTIC CYTOLOGY, P345; DEVILEE P, 1991, ONCOGENE, V6, P1705; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hartigan J., 1975, CLUSTERING ALGORITHM; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; KOSS L G, 1977, Urology, V9, P442, DOI 10.1016/0090-4295(77)90227-8; KOSS LG, 1991, NEW ENGL J MED, V324, P125; KOSS LG, 1974, JAMA-J AM MED ASSOC, V227, P281; KOSS LG, 1979, HUM PATHOL, V10, P533, DOI 10.1016/S0046-8177(79)80097-0; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; Lininger RA, 1998, HUM PATHOL, V29, P1113, DOI 10.1016/S0046-8177(98)90422-1; Lucito R, 2000, GENOME RES, V10, P1726, DOI 10.1101/gr.138300; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; Mostofi F, 1999, HISTOLOGICAL TYPING; Ott J., 1991, ANAL HUMAN GENETICS; Pan Y, 1998, PROSTATE, V36, P31, DOI 10.1002/(SICI)1097-0045(19980615)36:1<31::AID-PROS5>3.0.CO;2-E; RODGERS CS, 1984, CANCER GENET CYTOGEN, V13, P95, DOI 10.1016/0165-4608(84)90052-9; Sato M, 1998, GENE CHROMOSOME CANC, V22, P1; SATO T, 1990, CANCER RES, V50, P7184; SPRUCK CH, 1994, CANCER RES, V54, P784; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316	34	23	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5005	5014		10.1038/sj.onc.1204612	http://dx.doi.org/10.1038/sj.onc.1204612			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526485				2022-12-28	WOS:000170439800010
J	Ng, PWP; Iha, H; Iwanaga, Y; Bittner, M; Chen, YD; Jiang, Y; Gooden, G; Trent, JM; Meltzer, P; Jeang, KT; Zeichner, SL				Ng, PWP; Iha, H; Iwanaga, Y; Bittner, M; Chen, YD; Jiang, Y; Gooden, G; Trent, JM; Meltzer, P; Jeang, KT; Zeichner, SL			Genome-wide expression changes induced by HTLV-1 Tax: evidence for MLK-3 mixed lineage kinase involvement in Tax-mediated NF-kappa B activation	ONCOGENE			English	Article						HTLV-1; Tax; microarray; gene expression; MLK-3; JPX-9	T-CELL LEUKEMIA; VIRUS TYPE-I; VIRAL TRANSACTIVATOR TAX; HEPATOCYTE GROWTH-FACTOR; GENE-EXPRESSION; PROTEIN-KINASE; TYPE-1 TAX; MOLECULAR-MECHANISMS; CYCLE PROGRESSION; 1-INFECTED CELLS	The Tax protein of human T-lymphotropic virus type 1 (HTLV-1), an oncoprotein that transactivates viral and cellular genes, plays a key role in HTLV-1 replication and pathogenesis. We used cDNA microarrays to examine Tax-mediated transcriptional changes in the human Jurkat T-cell lines JPX-9 and JPX-M which express Tax and Tax-mutant protein, respectively, under the control of an inducible promoter. Approximately 300 of the over 2000 genes examined were differentially expressed in the presence of Tax. These genes were grouped according to their function and are discussed in the context of existing findings in the literature. There was strong agreement between our results and genes previously reported as being Tax-responsive. Genes that were differentially expressed in the presence of Tax included those related to apoptosis, the cell cycle and DNA repair, signaling factors, immune modulators, cytokines and growth factors, and adhesion molecules. Functionally, we provide evidence that one of these genes, the mixed-lineage kinase MLK-3, is involved in Tax-mediated NF-kappaB signaling. Our current results provide additional insights into Tax-mediated signaling.	NCI, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Zeichner, SL (corresponding author), NCI, HIV & AIDS Malignancy Branch, NIH, Bldg 10,Room 10S255, Bethesda, MD 20892 USA.	kj7e@nih.gov; zeichner@nih.gov	Jeang, Kuan-Teh/A-2424-2008	Iha, Hidekatsu/0000-0002-0999-5636	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; Baba M, 1996, INT J CANCER, V66, P124, DOI 10.1002/(SICI)1097-0215(19960328)66:1<124::AID-IJC21>3.3.CO;2-L; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chen XL, 1997, J GEN VIROL, V78, P3277, DOI 10.1099/0022-1317-78-12-3277; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLAPHAM P, 1983, SCIENCE, V222, P1125, DOI 10.1126/science.6316502; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FLORENES VA, 1992, CANCER RES, V52, P6088; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Freije JMP, 1998, BIOCHEM SOC SYMP, P261; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Khan J, 1998, CANCER RES, V58, P5009; Kibler KV, 1999, JNCI-J NATL CANCER I, V91, P903, DOI 10.1093/jnci/91.11.903; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; Miyazaki H, 1999, CLIN CANCER RES, V5, P4301; Mori N, 2000, BLOOD, V95, P3915; MULLER WA, 1995, J LEUKOCYTE BIOL, V57, P523, DOI 10.1002/jlb.57.4.523; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAGY K, 1983, INT J CANCER, V32, P321, DOI 10.1002/ijc.2910320310; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Neuveut C, 2000, Prog Cell Cycle Res, V4, P157; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; Ratajczak MZ, 1997, BRIT J HAEMATOL, V99, P228, DOI 10.1046/j.1365-2141.1997.3563170.x; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; To CTT, 1998, ONCOL REP, V5, P1013; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Watanabe T, 1997, INT J HEMATOL, V66, P257; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xu X, 1996, ONCOGENE, V13, P135; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; Yao J, 2000, FRONT BIOSCI-LANDMRK, V5, pD138, DOI 10.2741/Yao; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	75	92	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4484	4496		10.1038/sj.onc.1204513	http://dx.doi.org/10.1038/sj.onc.1204513			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494144				2022-12-28	WOS:000170074900006
J	Takita, J; Yang, HW; Chen, YY; Hanada, R; Yamamoto, K; Teitz, T; Kidd, V; Hayashi, Y				Takita, J; Yang, HW; Chen, YY; Hanada, R; Yamamoto, K; Teitz, T; Kidd, V; Hayashi, Y			Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma	ONCOGENE			English	Article						allelic imbalance; chromosome 2q; neuroblastoma; caspase 8; caspase 10	TUMOR-SUPPRESSOR GENES; CELL LUNG-CARCINOMA; N-MYC AMPLIFICATION; P16 CDKN2A GENE; P73 GENE; HETEROZYGOSITY; APOPTOSIS; EXPRESSION; DELETION; CANCER	We previously reported a high incidence of loss of heterozygosity (LOH) on chromosome 2q33 in neuroblastoma (NB), observed in various types of human cancers including lung cancer, head and neck cancer and follicular thyroid carcinoma. To better elucidate the role of chromosome 20 aberrations in NE, we examined common allelic imbalance (AI) regions on chromosome 20 in 82 NE patients using 10 polymorphic microsatellite markers. AI on 20 was detected in 26 (32%) of 82 NE cases. There was a distinct common AI region between the D2S115 and D2S307 markers on 2q33, The distance between these markers was about 2.0 cM, Recently, the caspase 8 and caspase 10 genes, both of which encode cystein protease, were mapped to chromosome 2q33, Since the common AI region on 2q33 includes the caspase 8 and caspase 10 genes, the alterations of these genes were examined further. Absent or reduced expression of caspase 8 and caspase 10 were found in 19 (70%) of 27 and two (7%) of 27 NE cell lines by reverse transcription-polymerase chain reaction, respectively. A missense mutation was detected at codon 96, GCT (Alanine) to GTT (Valine), of the caspase 8 gene in one of the NE cell lines lacking caspase 8 expression. Thirteen (68%) of 19 cell lines lacking caspase 8 expression displayed methylation of the CpG island of the caspase 8 gene, whereas only one (13%) of eight cell lines with caspase 8 expression showed caspase 8 methylation (P=0.031), Furthermore, there was significant association between Al at 2q33 and loss of caspase 8 expression (P=0.026), These results indicated that there was a tumor suppressor gene in the common AI region on chromosome 2q33 involved in the pathogenesis of a subset of NE. It is possible that the caspase 8 gene is one of the candidate tumor suppressor genes for NE and inactivation of this gene plays an important role in the tumorigenesis of NE through mainly its methylation.	Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138655, Japan; Saitama Childrens Med Ctr, Div Hematol Oncol, Iwatsuki, Saitama 3390077, Japan; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA	University of Tokyo; Saitama Children's Medical Center; St Jude Children's Research Hospital	Hayashi, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hayashiy-tky@umin.ac.jp	Chen, Yuyan/V-7279-2019	Chen, Yuyan/0000-0002-2894-1430	NCI NIH HHS [2RD1 CA67938] Funding Source: Medline; PHS HHS [21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA067938, R01CA067938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CEYNS V, 1998, GENE DEV, V12, P1551; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FERNANDESALNEMR.T, 1909, P NATL ACAD SCI USA, V93, P7464; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Herman JG, 1996, CANCER RES, V56, P722; Inoue A, 1997, INT J CANCER, V72, P1070, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1070::AID-IJC23>3.0.CO;2-7; Kaneko M, 1998, MED PEDIATR ONCOL, V31, P1, DOI 10.1002/(SICI)1096-911X(199807)31:1<1::AID-MPO1>3.0.CO;2-H; Kawano S, 1999, BLOOD, V94, P1113; KOHNO T, 1994, ONCOGENE, V9, P103; Kong XT, 1997, CANCER RES, V57, P3772; Kong XT, 1997, EUR J CANCER, V33, P1962, DOI 10.1016/S0959-8049(97)00209-8; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Muliokandov MR, 1996, CANCER RES, V56, P197; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Ransom DT, 1998, HEAD NECK-J SCI SPEC, V20, P404; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAWAGUCHI S, 1990, CANCER, V66, P1879, DOI 10.1002/1097-0142(19901101)66:9<1879::AID-CNCR2820660905>3.0.CO;2-L; Schor NF, 1999, J NEURO-ONCOL, V41, P159, DOI 10.1023/A:1006171406740; SCHWAB M, 1993, SEMIN CANCER BIOL, V4, P13; Schwemmler W, 1996, ENDOCYT CELL RES, V11, P219; SHISEKI M, 1994, CANCER RES, V54, P5643; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1997, CANCER RES, V57, P907; Takita J, 1998, ONCOGENE, V17, P3137, DOI 10.1038/sj.onc.1202232; Takita J, 2000, EUR J CANCER, V36, P508, DOI 10.1016/S0959-8049(99)00342-1; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Yang HW, 2000, INT J MOL MED, V5, P379; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	45	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4424	4432		10.1038/sj.onc.1204521	http://dx.doi.org/10.1038/sj.onc.1204521			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466626				2022-12-28	WOS:000169912600019
J	Cabeza-Arvelaiz, Y; Sepulveda, JL; Lebovitz, RM; Thompson, TC; Chinault, AC				Cabeza-Arvelaiz, Y; Sepulveda, JL; Lebovitz, RM; Thompson, TC; Chinault, AC			Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22	ONCOGENE			English	Article						prostate cancer; tumor suppressor; human; chromosome 8p; FEZ1; LZTS1	YEAST ARTIFICIAL CHROMOSOME; MAMMALIAN-CELLS; HUMAN GENOME; COLORECTAL-CANCER; BAND 8P22; EXPRESSION; P53; PROMOTER; PROTEIN; REGION	Deletions in the 8p21-22 region of the human genome are among the most common genetic alterations in prostate carcinomas. Several studies in different tumor tissues, including prostate, indicate that there are probably multiple tumor suppressor genes (TSGs) present in this region. To identify candidate TSGs on 8p22 a YAC contig spanning this region was assembled and YAC clones retrofitted with a selectable marker (neo) were transferred into rat prostate AT6,2 cells, Two overlapping YAC clones showed greatly reduced colony-forming efficiency, indicating they may carry a TSG, Two BAC clones encompassing the overlapping region also appeared to exert suppressive effects on the growth of AT6,2 cells, Database searches for genes mapped to the critical region identified a gene known as FEZ1 (LZTS1) as a potential candidate suppressor gene. Subsequent experiments showed that over-expression of LZTS1 cDNA inhibited stable colony-forming efficiencies of AT6,2, HEK-293 and LNCaP cells. In contrast, LZTS1-transfected Rat-1 and RM1 cells were growth-stimulated. Database searches also identified additional isoforms of the LZTS1 mRNA, as well as LZTS1 protein domains reminiscent of those found in transcription factors. Together these data suggest that the LZTS1 gene is involved in the regulation of cell growth and its loss of function may contribute to the development of prostatic carcinomas, as well as other cancers.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Urol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Chinault, AC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58204] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON MJ, 1993, FASEB J, V7, P826, DOI 10.1096/fasebj.7.10.8344482; Baker A, 1997, NUCLEIC ACIDS RES, V25, P1950, DOI 10.1093/nar/25.10.1950; BALEY PA, 1995, J STEROID BIOCHEM, V52, P403, DOI 10.1016/0960-0760(95)00001-G; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; BOOKSTEIN R, 1994, GENOMICS, V24, P317, DOI 10.1006/geno.1994.1622; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; CHINAULT AC, 1994, CURRENT PROTOCOLS HU, V1; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHUMAKOV IM, 1995, NATURE, V377, P175; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farrington SM, 1996, ONCOGENE, V12, P1803; FOULKES NS, 1996, BIOCHIM BIOPHYS ACTA, V1288, P101; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; Hutton FG, 2000, ONCOGENE, V19, P452, DOI 10.1038/sj.onc.1203316; ICHIKAWA T, 1994, CANCER RES, V54, P2299; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; KAGAN J, 1995, ONCOGENE, V11, P2121; Kirschner LS, 1999, BIOTECHNIQUES, V27, P72; Koreth J, 1999, ONCOGENE, V18, P1157, DOI 10.1038/sj.onc.1202372; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Murakami YS, 1996, CANCER RES, V56, P2157; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; Park BJ, 2000, CANCER RES, V60, P3031; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; Reddy DE, 2000, ONCOGENE, V19, P217, DOI 10.1038/sj.onc.1203264; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; TUCK SP, 1989, ONCOGENE RES, V4, P81; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	49	44	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4169	4179		10.1038/sj.onc.1204539	http://dx.doi.org/10.1038/sj.onc.1204539			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464283				2022-12-28	WOS:000169857200007
J	Gu, JJ; Rubin, RM; Yuan, ZM				Gu, JJ; Rubin, RM; Yuan, ZM			A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation	ONCOGENE			English	Article						p53 degradation; HPV16 E6; E1B55k/E4 34k; p73; p53; chimeras	HUMAN PAPILLOMAVIRUS TYPE-16; E6 ONCOPROTEIN; P73; MDM2; PROTEIN; INACTIVATION; ASSOCIATION; APOPTOSIS; PROMOTES; CANCER	The molecular basis that the viral oncoproteins, including HPV16 E6 and E1B55k/E4 34k complex, differentially target p53 but not its homolog p73 for degradation remains elusive, Using a series of p53/p73 chimeras, we demonstrated that despite binding to the different regions of p53, both HPV16 E6 and E1B55k/E4 34k required a very same p53 sequence, amino acid residues 92 to 112 [p53(aa.92-112)], previously identified as a necessity for Mdm2-mediated degradation, to target p53 for degradation. Removal of the p53(aa.92-112) by either substitution or deletion resulted in a p53 protein that was no longer degradable hy the viral proteins. More significantly, swapping the oncoprotein-binding motif and the p53(aa.92-112) rendered p73 susceptible to oncoprotein-mediated degradation. Collectively, our data supports a model in which the p53(aa.92-112) functions as a determinant for p53 stability while the binding of the oncoproteins directs p53 into the specific pathway for proteolysis.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,Room 209, Boston, MA 02115 USA.							ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Li XQ, 1996, J BIOL CHEM, V271, P4447; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MARSTON NJ, 1995, ONCOGENE, V10, P1709; Prabhu NS, 1998, INT J ONCOL, V13, P5; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	27	16	16	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3519	3527		10.1038/sj.onc.1204454	http://dx.doi.org/10.1038/sj.onc.1204454			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429698				2022-12-28	WOS:000169478300007
J	Brodie, SG; Xu, XL; Qiao, WH; Li, WM; Cao, L; Deng, CX				Brodie, SG; Xu, XL; Qiao, WH; Li, WM; Cao, L; Deng, CX			Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice	ONCOGENE			English	Article						Brca1; p53; ErbB2; cyclin D1; c-Myc; tumorigenesis	CANCER-SUSCEPTIBILITY GENES; DNA-DAMAGE RESPONSE; INTERACT IN-VIVO; BREAST-CANCER; CELL-CYCLE; TRANSGENIC MICE; TUMOR-FORMATION; MEIOTIC CELLS; 5 REGIONS; C-MYC	Germline mutations in the tumor suppressor gene BRCA1 predispose women to breast cancer, however somatic mutations in the gene are rarely detected in sporadic cancers. To understand this phenomenon, we examined mouse models carrying conditional disruption of Brca1 in mammary epithelium in either p53 wild type (wt) or heterozygous backgrounds. Although a p53(+/-) mutation significantly accelerated tumorigenesis, both strains developed mammary tumors in a stochastic fashion, suggesting that multiple factors, in addition to p53 mutations, may be involved in Brca1 related tumorigenesis. A unique feature of Brca1 mammary tumors is their highly diverse histopathology accompanied by severe chromosome abnormalities. The tumors also display extensive genetic/molecular alterations, including overexpression of ErbB2, c-Myc, p27 and Cyclin D1 in the majority of tumors, while they were virtually ER alpha and p16 negative. Translocations involving p53 were also identified which lead to abnormal RNA and protein products. In addition, we generated cell lines from mammary tumors and found that the cells retained many of the genetic changes found in the primary tumors, suggesting that these genes may be players in Brca1-associated tumorigenesis. Despite their distinct morphology, all cultured tumor cells were Tamoxifen resistant but highly sensitive to Doxorubicin or irradiation, suggesting that these methods would be effective in treatment of this disease.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Barbareschi M, 2000, INT J CANCER, V89, P236, DOI 10.1002/1097-0215(20000520)89:3<236::AID-IJC5>3.3.CO;2-Q; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bonsing BA, 2000, GENE CHROMOSOME CANC, V28, P173, DOI 10.1002/(SICI)1098-2264(200006)28:2<173::AID-GCC6>3.0.CO;2-1; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GATEI M, 2001, J BIOL CHEM, V13, P13; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Mueller A, 1997, CANCER RES, V57, P5542; O'Brien KA, 1999, BIOCHEM BIOPH RES CO, V260, P658, DOI 10.1006/bbrc.1999.0892; Orsetti B, 1999, ONCOGENE, V18, P6262, DOI 10.1038/sj.onc.1203006; Osborne RJ, 2000, CANCER RES, V60, P3706; Paterson JWE, 1998, DIS MARKERS, V13, P261, DOI 10.1155/1998/298530; Robson M, 1998, CANCER RES, V58, P1839; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Staff S, 2000, GENE CHROMOSOME CANC, V28, P432, DOI 10.1002/1098-2264(200008)28:4<432::AID-GCC9>3.0.CO;2-J; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Walker RA, 1999, J PATHOL, V188, P229, DOI 10.1002/(SICI)1096-9896(199907)188:3<229::AID-PATH341>3.0.CO;2-F; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1996, SEMIN CANCER BIOL, V7, P33, DOI 10.1006/scbi.1996.0005; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	63	149	153	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7514	7523		10.1038/sj.onc.1204929	http://dx.doi.org/10.1038/sj.onc.1204929			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709723				2022-12-28	WOS:000171976900008
J	Koniaras, K; Cuddihy, AR; Christopoulos, H; Hogg, A; O'Connell, MJ				Koniaras, K; Cuddihy, AR; Christopoulos, H; Hogg, A; O'Connell, MJ			Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells	ONCOGENE			English	Article						checkpoint; Chk1; p53; Cds1; DNA damage	CHK1 PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; IONIZING-RADIATION; CYCLE CHECKPOINTS; CDK INHIBITORS; HUMAN MYT1; CDC2; ATR; ACTIVATION; EXTRACTS	Cell cycle checkpoints are surveillance mechanisms that monitor and coordinate the order and fidelity of cell cycle events. When defects in the division program of a cell are detected, checkpoints prevent the pursuant cell cycle transition through regulation of the relevant cyclin-cdk complex(es). Checkpoints that respond to DNA damage have been described for the G1, S and G2 phases of the cell cycle. The p53 tumour suppressor is a key regulator of G1/S checkpoints, and can promote cell cycle delay or apoptosis in response to DNA damage. The importance of these events to cellular physiology is highlighted by the fact that tumours, in which p53 is frequently mutated, have widespread defects in the G1/S DNA damage checkpoints and a heightened level of genomic instability. G2/M DNA damage checkpoints have been defined by yeast genetics, though the genes in this response are conserved in mammals. We show here using biochemical and physiological assays that p53 is dispensable for a DNA damage checkpoint activated in the G2 phase of the cell cycle. Moreover, upregulation of p53 through serine 20 phosphorylation, does not occur in G2. Conversely, we show that the Chk1 protein kinase is essential for the human G2 DNA damage checkpoint. Importantly, inhibition of Chk1 in p53 deficient cells greatly sensitizes them to radiation, validating the hypothesis of targeting Chk1 in rational drug design and development for anti-cancer therapies.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 8006, Australia; Univ Melbourne, Dept Genet, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; University of Melbourne	O'Connell, MJ (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.			Cuddihy, Andrew/0000-0002-9898-0443				Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brown EJ, 2000, GENE DEV, V14, P397; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chehab NH, 2000, GENE DEV, V14, P278; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fattaey A, 1997, Prog Cell Cycle Res, V3, P233; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackson JR, 2000, CANCER RES, V60, P566; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KRAKER AJ, 2000, P AM ASSOC CANC RES, V41, P468; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leu JY, 1999, MOL CELL, V4, P805, DOI 10.1016/S1097-2765(00)80390-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Masui Y, 1998, BIOL CELL, V90, P537, DOI 10.1016/S0248-4900(99)80011-2; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Raleigh JM, 2000, J CELL SCI, V113, P1727; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Roberge M, 1998, CANCER RES, V58, P5701; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schmidt-Kastner PK, 1998, ONCOGENE, V16, P3003, DOI 10.1038/sj.onc.1201835; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shieh SY, 2000, GENE DEV, V14, P289; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	55	144	152	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7453	7463		10.1038/sj.onc.1204942	http://dx.doi.org/10.1038/sj.onc.1204942			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709716				2022-12-28	WOS:000171976900001
J	Lefort, K; Rouault, JP; Tondereau, L; Magaud, JP; Dore, JF				Lefort, K; Rouault, JP; Tondereau, L; Magaud, JP; Dore, JF			The specific activation of gadd45 following UVB radiation requires the POU family gene product N-oct3 in human melanoma cells	ONCOGENE			English	Article						gadd45; melanoma; UVB; UVC; N-oct3	P53-REGULATED PROTEIN GADD45; TRANSCRIPTION FACTOR-BINDING; DNA-BINDING; THYMIDINE DINUCLEOTIDES; ULTRAVIOLET-RADIATION; IONIZING-RADIATION; CYCLE CHECKPOINT; HUMAN SKIN; DOMAIN; P53	Here we report the specific regulation of gadd45 expression in human melanoma cell lines following UVB radiation. This solar wavelength is likely to be involved in melanoma aetiology. We have previously shown that gadd45 expression is strongly enhanced in a p53-independent manner following UVB irradiation, unlike the other p53 target genes studied. Furthermore, gadd45 is specifically activated in melanocytes since its induction in response to UVB, is not observed in other skin cells such as keratinocytes or fibroblasts. To investigate this particular regulation of gadd45, we analysed the UVB-induced response of different gadd45 promoter regions. Thus, a minimal promoter region of 50 bp length, responsible for gadd45 activation in melanoma cell lines following UVB irradiation, was determined. In electrophoretic mobility shift assays (EMSAs), we showed that this region (-106/-56) of the gadd45 promoter which contains two identical octamers, binds the POU family gene products oct-l and N-oct3. Given the specific expression pattern of N-oct3 in melanocyte, we invalidated the expression of this transcription factor in melanoma cells: such an abrogation of N-oct3 protein expression in melanoma cells impeded gadd45 UVB-response. Thus the response of melanocyte to UVB may use an original and previously undescribed pathway.	Ctr Leon Berard, INSERM U453, F-69373 Lyon 08, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Dore, JF (corresponding author), Ctr Leon Berard, INSERM U453, 28 Rue Laennec, F-69373 Lyon 08, France.							ANGUS J, 1995, ONCOGENE, V11, P691; Atillasoy ES, 1998, AM J PATHOL, V152, P1179; Bae I, 1996, CANCER RES, V56, P840; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Graunke DM, 1999, NUCLEIC ACIDS RES, V27, P3881, DOI 10.1093/nar/27.19.3881; Haapajarvi T, 1999, CELL GROWTH DIFFER, V10, P163; HALL PA, 1995, ONCOGENE, V10, P2427; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; JACUBOVICH R, 1985, BRIT J CANCER, V51, P335, DOI 10.1038/bjc.1985.45; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kallassy M, 1997, CANCER RES, V57, P4731; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; RONAI Z, 1994, ENVIRON MOL MUTAGEN, V23, P157, DOI 10.1002/em.2850230302; ROSFJORD E, 1995, BIOCHEM BIOPH RES CO, V212, P847, DOI 10.1006/bbrc.1995.2046; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETLOW RB, 1989, P NATL ACAD SCI USA, V86, P8922, DOI 10.1073/pnas.86.22.8922; Smith AG, 1998, MELANOMA RES, V8, P2, DOI 10.1097/00008390-199802000-00002; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; STURM RA, 1994, PIGM CELL RES, V7, P235, DOI 10.1111/j.1600-0749.1994.tb00055.x; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Takahashi S, 2001, CANCER RES, V61, P1187; THOMSON JAF, 1993, PIGM CELL RES, V6, P13, DOI 10.1111/j.1600-0749.1993.tb00576.x; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; Vigano MA, 1996, NUCLEIC ACIDS RES, V24, P2112, DOI 10.1093/nar/24.11.2112; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P837, DOI 10.1067/mjd.2001.114594; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Westerdahl J, 2000, BRIT J CANCER, V82, P1593; WOLF P, 1994, J NATL CANCER I, V86, P99, DOI 10.1093/jnci/86.2.99; Xiao G, 2000, CANCER RES, V60, P1711; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; ZHAN QM, 1994, CANCER RES, V54, P2755; Zhao HC, 2000, CANCER RES, V60, P6276	50	22	24	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7375	7385		10.1038/sj.onc.1204923	http://dx.doi.org/10.1038/sj.onc.1204923			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704867				2022-12-28	WOS:000171894200010
J	Shamay, M; Agami, R; Shaul, Y				Shamay, M; Agami, R; Shaul, Y			HBV integrants of hepatocellular carcinoma cell lines contain an active enhancer	ONCOGENE			English	Article						HBV enhancer; in vivo footprinting; onco-DNA; fetoprotein transcription factor (FTF)	HEPATITIS-B-VIRUS; COMPARATIVE GENOMIC HYBRIDIZATION; TRANSCRIPTION FACTORS; NUCLEAR RECEPTOR; GENE PROMOTER; ACTIVATION; SEQUENCES; DNA; ELEMENT; ABERRATIONS	Hepatitis B virus (HBV) infection is a major risk factor worldwide for the development of hepatocellular carcinoma (HCC). Integrated HBV DNA fragments, often highly rearranged, are frequently detected in HCC. In woodchuck, the viral enhancer plays a central role in hepatocarcinogenesis, but in humans the mechanism of HBV oncogenesis has not been established. In this study we investigated the status of the viral enhancer in two human HCC cell lines, Hep3B and PLC/PRF/5 each containing one or more integrated HBV DNA fragments. Active enhancer was defined by virtue of its protein occupancy as determined by genomic in vivo DMS footprinting. In PLC/ PRF/5 cells, the HBV DNA was integrated in a cellular gene at chromosome 11q13, at a locus reported to be amplified in many tumors. We show here that in both cell lines, the integrated HBV DNA fragments contain an active enhancer-I. In particular, the occupation of the two previously defined basic enhancer elements, E and EP, was prominent. While in both cell lines the same protein binds to the EP elements, the E element, however, is occupied in a cell-line specific manner. In PLC/PRF/5 but not Hep3B, the prominent binding of an undefined protein was detected. Our data suggest that this protein is likely to be the fetoprotein transcription factor (FTF). The finding that enhancer sequences are conserved and functional in different cell lines suggests a selection pressure for their long-term maintenance. We therefore propose that the HBV enhancer-I might play a role in hepatocellular carcinogenesis.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		agami, reuven/GOG-8289-2022	Agami, Reuven/0000-0002-2848-2473				BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BERGER I, 1987, J VIROL, V61, P1180, DOI 10.1128/JVI.61.4.1180-1186.1987; Blake M, 1996, J VIROL, V70, P6060, DOI 10.1128/JVI.70.9.6060-6066.1996; Bossard P, 1997, METHODS, V11, P180, DOI 10.1006/meth.1996.0404; BULLA GA, 1988, J VIROL, V62, P1437, DOI 10.1128/JVI.62.4.1437-1441.1988; Butel JS, 1996, TRENDS MICROBIOL, V4, P119, DOI 10.1016/0966-842X(96)81529-0; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; CHANG HK, 1987, NUCLEIC ACIDS RES, V15, P2261, DOI 10.1093/nar/15.5.2261; CHEN JY, 1994, INTERVIROLOGY, V37, P41, DOI 10.1159/000150355; Datta S, 2000, J VIROL, V74, P8277, DOI 10.1128/JVI.74.18.8277-8285.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P4427, DOI 10.1128/MCB.10.8.4427; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3682; Doitsh G, 1999, ONCOGENE, V18, P7506, DOI 10.1038/sj.onc.1203209; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FAKTOR O, 1988, VIROLOGY, V162, P362, DOI 10.1016/0042-6822(88)90476-X; Flajolet M, 1998, J VIROL, V72, P6175, DOI 10.1128/JVI.72.7.6175-6180.1998; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Gilbert S, 2000, J VIROL, V74, P5032, DOI 10.1128/JVI.74.11.5032-5039.2000; GRAEF E, 1994, ONCOGENE, V9, P81; Greenblatt MS, 1997, CANCER RES, V57, P426; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Hershkovitz M, 1997, METHODS, V11, P253, DOI 10.1006/meth.1996.0412; Hildt E, 1998, RECENT RES CANCER, V154, P315; Ishida H, 2000, J VIROL, V74, P1241, DOI 10.1128/JVI.74.3.1241-1251.2000; Kairat A, 1999, INTERVIROLOGY, V42, P228, DOI 10.1159/000024982; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; Kosovsky MJ, 1999, VIROLOGY, V259, P60, DOI 10.1006/viro.1999.9776; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Miyaki M, 2000, INT J CANCER, V85, P518, DOI 10.1002/(SICI)1097-0215(20000215)85:4<518::AID-IJC12>3.0.CO;2-7; ORI A, 1995, VIROLOGY, V207, P98, DOI 10.1006/viro.1995.1055; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; OU JH, 1987, NUCLEIC ACIDS RES, V15, P8919, DOI 10.1093/nar/15.21.8919; Paran N, 2000, MOL CELL BIOL, V20, P834, DOI 10.1128/MCB.20.3.834-841.2000; Rivkina M, 1996, CARCINOGENESIS, V17, P2689, DOI 10.1093/carcin/17.12.2689; Sakakura C, 1999, BRIT J CANCER, V80, P2034, DOI 10.1038/sj.bjc.6690638; SHAUL Y, 1986, J VIROL, V59, P731, DOI 10.1128/JVI.59.3.731-734.1986; SHAUL Y, 1984, J VIROL, V51, P776, DOI 10.1128/JVI.51.3.776-787.1984; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; Shuster MI, 2000, GENE CHROMOSOME CANC, V28, P153, DOI 10.1002/(SICI)1098-2264(200006)28:2<153::AID-GCC4>3.0.CO;2-9; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Wang PC, 2001, J VIROL METHODS, V92, P83, DOI 10.1016/S0166-0934(00)00278-0; Wong N, 2000, CLIN CANCER RES, V6, P4000; ZHOU DX, 1990, J BIOL CHEM, V265, P20731; ZIEMER M, 1985, J VIROL, V53, P885, DOI 10.1128/JVI.53.3.885-892.1985	49	34	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6811	6819		10.1038/sj.onc.1204879	http://dx.doi.org/10.1038/sj.onc.1204879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687960				2022-12-28	WOS:000171641000002
J	Zhuang, SG; Demirs, JT; Kochevar, IE				Zhuang, SG; Demirs, JT; Kochevar, IE			Protein kinase C inhibits singlet oxygen-induced apoptosis by decreasing caspase-8 activation	ONCOGENE			English	Article						protein kinase C; singlet oxygen; caspase-8; Fas; apoptosis; p38	RECEPTOR-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; RADIATION-INDUCED APOPTOSIS; PEROXIDE-INDUCED APOPTOSIS; THERAPY-INDUCED APOPTOSIS; PHOTODYNAMIC THERAPY; CYTOCHROME-C; HL-60 CELLS; HYDROGEN-PEROXIDE; MEDIATED APOPTOSIS	Although activation of protein kinase C (PKC) inhibits apoptosis induced by a variety of stimuli including singlet oxygen, the step at which PKC activation interferes with apoptotic signaling is not well defined. We have shown previously that caspase-8 and p38 mediate singlet oxygen-induced apoptosis in HL-60 cells. In this study, we investigated the influence of PKC on regulation of the caspase-8 and p38 pathways initiated by singlet oxygen. Singlet oxygen induced Fas clustering and subsequent recruitment of FADD and caspase-8. Treatment of cells with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), a PKC activator, did not affect the binding of caspase-8 to the aggregated Fas. Surprisingly, under the same conditions PKC activation was still able to prevent singlet oxygen-induced activation of caspase-8 and block its downstream signaling events including cleavage of Bid and caspase-3, decrease in mitochondrial transmembrane potential and release of cytochrome c from mitochondria. Inhibition of PKC by GF109203 or H7 counteracted the TPA-mediated effects on the cleavage of caspases -3 and -8. However, neither activation nor inhibition of PKC affected p38 phosphorylation. These data indicate that PKC inhibits singlet oxygen-induced apoptosis by blocking activation of caspase-8.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Labs Photomed, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Kochevar, IE (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Labs Photomed, WEL-224,55 Fruit St, Boston, MA 02114 USA.	kochevar@helix.mgh.harvard.edu			NIGMS NIH HHS [GM 30755] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030755] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1991, CANCER RES, V51, P5993; Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 2000, J INVEST DERMATOL, V115, P1041, DOI 10.1046/j.1523-1747.2000.00147.x; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BAKER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P523, DOI 10.1111/j.1751-1097.1992.tb04273.x; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Cook SA, 1999, CIRC RES, V85, P940; Dispersyn G, 1999, BBA-GEN SUBJECTS, V1428, P357, DOI 10.1016/S0304-4165(99)00073-2; Dong SM, 2000, CHEM RES TOXICOL, V13, P585, DOI 10.1021/tx990199x; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; Jun CD, 1999, CELL IMMUNOL, V194, P36, DOI 10.1006/cimm.1999.1480; Kessel D, 2000, PHOTOCHEM PHOTOBIOL, V71, P196, DOI 10.1562/0031-8655(2000)071<0196:DOTART>2.0.CO;2; Kitada S, 1999, BRIT J HAEMATOL, V106, P995, DOI 10.1046/j.1365-2141.1999.01642.x; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Krutmann J, 2000, J DERMATOL SCI, V23, pS22, DOI 10.1016/S0923-1811(99)00077-8; Kwon D, 2001, J NEUROIMMUNOL, V113, P1, DOI 10.1016/S0165-5728(00)00321-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOTEM J, 1991, BLOOD, V78, P953; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luo Y, 1997, PHOTOCHEM PHOTOBIOL, V66, P479, DOI 10.1111/j.1751-1097.1997.tb03176.x; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; MAY WS, 1994, J BIOL CHEM, V269, P26865; Meinhardt G, 2000, EUR J CELL BIOL, V79, P824, DOI 10.1078/0171-9335-00100; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3; Pae HO, 2000, IMMUNOPHARM IMMUNOT, V22, P61, DOI 10.3109/08923970009016406; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Ryter SW, 1998, FREE RADICAL BIO MED, V24, P1520, DOI 10.1016/S0891-5849(97)00461-9; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shen HM, 2001, FREE RADICAL BIO MED, V30, P9, DOI 10.1016/S0891-5849(00)00421-4; SOLARY E, 1993, BLOOD, V81, P1359; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; STOKA V, 2000, J BIOL CHEM, V9, P9; Suhara T, 1998, J IMMUNOL, V160, P4042; TAKAHASHI H, 1995, J INVEST DERMATOL, V105, P810, DOI 10.1111/1523-1747.ep12326577; TAKANO Y, 1993, PATHOL RES PRACT, V189, P197, DOI 10.1016/S0344-0338(11)80092-0; Umansky V, 2000, INT J ONCOL, V16, P109; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Webber J, 1996, J PHOTOCH PHOTOBIO B, V35, P209, DOI 10.1016/S1011-1344(96)07291-0; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Xue LY, 1999, CELL DEATH DIFFER, V6, P855, DOI 10.1038/sj.cdd.4400558; Yabuki M, 2000, FREE RADICAL RES, V32, P507, DOI 10.1080/10715760000300511; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200; Zhuang SG, 1998, FEBS LETT, V437, P158, DOI 10.1016/S0014-5793(98)01222-8; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V279, pC341, DOI 10.1152/ajpcell.2000.279.2.C341; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	83	43	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6764	6776		10.1038/sj.onc.1204867	http://dx.doi.org/10.1038/sj.onc.1204867			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709711				2022-12-28	WOS:000171551600013
J	Rabbitts, TH				Rabbitts, TH			Chromosomal translocation master genes, mouse models and experimental therapeutics	ONCOGENE			English	Article						cancer; therapy; chromosomal translocation; cytogenetics; leukaemia; sarcoma	T-CELL LEUKEMIA; LIM-PROTEIN RBTN2; C-MYC GENE; TRANSCRIPTION FACTORS; BURKITT-LYMPHOMA; HOMEOBOX GENE; CRE-LOXP; LMO2; FUSION; DOMAIN	Molecular biologists have elucidated general principles about chromosomal translocations by cloning oncogenes or fusion genes at chromosomal translocation junctions. These genes invariably encode intracellular proteins and in acute cancers, often involve transcription and developmental regulators, which are master regulators of cell fate (e.g. LMO2 which is involved in acute leukaemia). Chromosomal translocations are usually associated with specific cell types. The reason for this close association is under investigation using mouse models. We are trying to emulate the cell-specific consequences of chromosomal translocations in mice using homologous recombination in embryonic stem cells to generate de novo chromosomal translocations or to mimic the consequence of these translocations. In addition, chromosomal translocation genes and their products are important targets for therapy. We have designed new therapeutic strategies which include antigen-specific recruitment of endogenous cellular pathways to affect cellular viability and a novel structured form of antisense to ablate the function of fusion mRNAs. We will evaluate these procedures in the mouse models of chromosomal translocations and the long term aim is to perfect rapid procedures for characterizing patient-specific chromosomal translocations to tailor therapy to individual patients.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	thr@mrc-lmb.cam.ac.uk	Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; BENTLEY DL, 1981, CELL, V24, P613, DOI 10.1016/0092-8674(81)90088-X; BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CROCE CM, 1979, P NATL ACAD SCI USA, V76, P3416, DOI 10.1073/pnas.76.7.3416; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Delassus S, 1999, BLOOD, V94, P1495, DOI 10.1182/blood.V94.5.1495.417a08_1495_1503; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; DRYNAN LF, 2001, IN PRESS ONCOGENE; DUBE ID, 1991, BLOOD, V78, P2996; FISCH P, 1992, ONCOGENE, V7, P2389; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; HOBART MJ, 1981, ANN HUM GENET, V45, P331, DOI 10.1111/j.1469-1809.1981.tb00346.x; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; MALCOLM S, 1982, P NATL ACAD SCI-BIOL, V79, P4957, DOI 10.1073/pnas.79.16.4957; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RABBITTS TH, 1983, BIOCHEM SOC T, V11, P119, DOI 10.1042/bst0110119; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Rabbitts TH, 1999, CANCER RES, V59, p1794S; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RABBITTS TH, 1985, EMBO J, V4, P1461, DOI 10.1002/j.1460-2075.1985.tb03803.x; ROYERPOKORA B, 1995, ONCOGENE, V10, P1353; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Stocks MR, 2000, EMBO REP, V1, P59, DOI 10.1093/embo-reports/kvd003; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; Tse E, 2000, P NATL ACAD SCI USA, V97, P12266, DOI 10.1073/pnas.97.22.12266; TSE E, 2001, IN PRESS METHDOS MOL; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VAN DJ, 1995, P NATL ACAD SCI USA, V92, P7376; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320; 2001, NATURE	73	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5763	5777		10.1038/sj.onc.1204597	http://dx.doi.org/10.1038/sj.onc.1204597			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607826				2022-12-28	WOS:000170887500017
J	Sorby, M; Sandstrom, J; Ostman, A				Sorby, M; Sandstrom, J; Ostman, A			An extracellular ligand increases the specific activity of the receptor-like protein tyrosine phosphatase DEP-1	ONCOGENE			English	Article						DEP-1; Matrigel (TM); protein tyrosine phosphatase	T-CELL ACTIVATION; HOMOPHILIC BINDING; EXPRESSION; CD148; BETA; PHOSPHORYLATION; DIMERIZATION; GROWTH; ALPHA; INHIBITION	Cellular growth, differentiation and migration is regulated by protein tyrosine phosphorylation. Receptor-like protein tyrosine phosphatases are thus likely to be key regulators of vital cellular processes. The regulation of these enzymes is in general poorly understood. Ligands have been identified only for a small subset of the receptor-like protein tyrosine phosphatases and in no case has upregulation of the specific activity by extracellular ligands been demonstrated. Prompted by earlier findings of ligands for receptor-like protein tyrosine phosphatases in extracellular matrix we investigated if Matrigel (TM), a preparation of extracellular matrix proteins, contained modulators of the specific activity of the receptor-like protein tyrosine phosphatase DEP-1. Matrigel (TM) stimulation of cells increased the specific activity of immunoprecipitated DEP-1. Also, incubation of immunoprecipitated DEP-1 with Matrigel (TM) led to an increase in DEP-1 activity, which was blocked by soluble DEP-1 extracellular domain. Finally, immunoprecipitated Delta ECD-DEP-1, a mutant form of DEP-1 lacking most of the extracellular domain, failed to respond to Matrigel (TM) stimulation. These experiments identify Matrigel (TM) as a source of DEP-1 agonist(s) and provide the first evidence for upregulation of the specific activity of receptor-like protein tyrosine phosphatases by extracellular ligands.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ostman, A (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.							Autschbach F, 1999, TISSUE ANTIGENS, V54, P485, DOI 10.1034/j.1399-0039.1999.540506.x; BARNEA G, 1994, J BIOL CHEM, V269, P14349; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Keane MM, 1996, CANCER RES, V56, P4236; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Leppanen O, 2000, BIOCHEMISTRY-US, V39, P2370, DOI 10.1021/bi9919192; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Martelli ML, 1998, EXP CELL RES, V245, P195, DOI 10.1006/excr.1998.4257; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; SAP J, 1994, MOL CELL BIOL, V14, P1; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Suzuki E, 2000, J BIOL CHEM, V275, P3637, DOI 10.1074/jbc.275.5.3637; Tangye SG, 1998, J IMMUNOL, V161, P3249; Tangye SG, 1998, J IMMUNOL, V161, P3803; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; Van Vactor D, 1998, CURR OPIN CELL BIOL, V10, P174, DOI 10.1016/S0955-0674(98)80139-7; Wang Y, 1999, J BIOL CHEM, V274, P7454, DOI 10.1074/jbc.274.11.7454; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	33	32	34	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5219	5224		10.1038/sj.onc.1204581	http://dx.doi.org/10.1038/sj.onc.1204581			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526512				2022-12-28	WOS:000170464000017
J	Fruhwald, MC; O'Dorisio, MS; Dai, ZY; Tanner, SM; Balster, DA; Gao, X; Wright, FA; Plass, C				Fruhwald, MC; O'Dorisio, MS; Dai, ZY; Tanner, SM; Balster, DA; Gao, X; Wright, FA; Plass, C			Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - Implications for tumor biology and potential clinical utility	ONCOGENE			English	Article						medulloblastoma; primitive neuroectodermal tumor; DNA methylation; genome scanning	PRIMITIVE NEUROECTODERMAL TUMORS; HUMAN BRAIN-TUMORS; COMPARATIVE GENOMIC HYBRIDIZATION; CENTRAL-NERVOUS-SYSTEM; CHROMOSOME ARM 17P; CHILDHOOD MEDULLOBLASTOMA; DNA HYPERMETHYLATION; E-CADHERIN; DELETION; P16	Medulloblastomas exhibit an array of diverse cytogenetic abnormalities. To evaluate the significance of epigenetic rather than genetic lesions in medulloblastomas and other primitive neuroectodermal tumors (PNETs) of the childhood CNS we performed a systematic analysis of gene specific and global methylation. Methylation-specific PCR detected no methylation for p15(INK4B), von Hippel Lindau and TP53 and only limited methylation for E-Cadherin and p16(INK4A) in tumors. The cell lines Daoy and MHH-PNET-5 in which the p16(INK4A) promoter was methylated did not express the gene, but demonstrated abnormalities by SSCP. Immunohistochemistry for p16 was negative in all examined normal cerebella and medulloblastomas. Using the technique of Restriction Landmark Genomic Scanning we detected methylation affecting up to 1% of all CpG islands in primary MB/PNETs and 6% in MB cell lines. Methylation patterns differed between medulloblastomas and PNETs. Examination of several methylated sequences revealed homologies to known genes and expressed sequences. Analysis of survival data identified seven of 30 hypermethylated sequences significantly correlating with poor prognosis. We suggest that DNA hypermethylation has an outstanding potential for the identification of novel tumor suppressors as well as diagnostic and therapeutic targets in MBs and other PNETs of the CNS.	Univ Munster, Klin & Poliklin Kinderheilkunde, D-48149 Munster, Germany; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA	University of Munster; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Plass, C (corresponding author), Univ Munster, Klin & Poliklin Kinderheilkunde, Albert Schweitzer Str 33, D-48149 Munster, Germany.	plass-1@medctr.osu.edu	Plass, Christoph/H-7192-2014	O'Dorisio, M Sue/0000-0003-0690-1160	NCI NIH HHS [P30 CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldosari N, 2000, ACTA NEUROPATHOL, V99, P345, DOI 10.1007/s004010051134; Barker FG, 1997, J NEURO-ONCOL, V31, P17, DOI 10.1023/A:1005768910871; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burnett ME, 1997, CANCER GENET CYTOGEN, V97, P25, DOI 10.1016/S0165-4608(96)00319-6; Burns KL, 1998, J NEUROPATH EXP NEUR, V57, P122, DOI 10.1097/00005072-199802000-00003; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; David KM, 1997, J NEUROSURG, V86, P13, DOI 10.3171/jns.1997.86.1.0013; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2000, J MED GENET, V37, P501, DOI 10.1136/jmg.37.7.501; FRUHWALD MC, 1999, NEURO-ONCOLOGY, V1, P311; GRAFF JR, 1995, CANCER RES, V55, P5195; Grotzer MA, 2000, J CLIN ONCOL, V18, P1027, DOI 10.1200/JCO.2000.18.5.1027; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JEN J, 1994, CANCER RES, V54, P6353; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KLABFLEISCH JD, 1984, STAT ANAL FAILURE TI; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lescop S, 1999, J NEURO-ONCOL, V44, P119, DOI 10.1023/A:1006387518100; Liechti-Gallati S, 1999, EUR J HUM GENET, V7, P590, DOI 10.1038/sj.ejhg.5200338; LITOFSKY NS, 1994, NEUROSURGERY, V34, P967, DOI 10.1227/00006123-199406000-00003; Marino S, 2000, GENE DEV, V14, P994; Mulhern RK, 1999, ANN NEUROL, V46, P834, DOI 10.1002/1531-8249(199912)46:6<834::AID-ANA5>3.0.CO;2-M; Packer RJ, 1999, BRAIN DEV-JPN, V21, P75, DOI 10.1016/S0387-7604(98)00085-0; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Reardon DA, 1997, CANCER RES, V57, P4042; Rorke LB, 1997, BRAIN PATHOL, V7, P765, DOI 10.1111/j.1750-3639.1997.tb01063.x; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Sambrook J., 2002, MOL CLONING LAB MANU; Sato K, 1996, INT J CANCER, V66, P305, DOI 10.1002/(SICI)1097-0215(19960503)66:3<305::AID-IJC6>3.0.CO;2-2; Scheurlen WG, 1998, J CLIN ONCOL, V16, P2478, DOI 10.1200/JCO.1998.16.7.2478; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Schwechheimer K, 1998, VIRCHOWS ARCH, V432, P163, DOI 10.1007/s004280050151; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Sommer A, 1999, INT J CANCER, V82, P810, DOI 10.1002/(SICI)1097-0215(19990909)82:6<810::AID-IJC7>3.0.CO;2-V; Tanner SM, 1998, HUM MUTAT, V11, P62, DOI 10.1002/(SICI)1098-1004(1998)11:1<62::AID-HUMU10>3.3.CO;2-C; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	39	71	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5033	5042		10.1038/sj.onc.1204613	http://dx.doi.org/10.1038/sj.onc.1204613			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526488				2022-12-28	WOS:000170439800013
J	Ndisang, D; Budhram-Mahadeo, V; Pedley, B; Latchman, DS				Ndisang, D; Budhram-Mahadeo, V; Pedley, B; Latchman, DS			The Brn-3a transcription factor plays a key role in regulating the growth of cervical cancer cells in vivo	ONCOGENE			English	Article						cervical cancer; human papilloma virus; Brn-3a transcription factor; tumour growth	NEURONAL CELLS; POU-DOMAIN; INTRAEPITHELIAL NEOPLASIA; PAPILLOMAVIRUS INFECTION; GENE-EXPRESSION; DNA; POLYMORPHISM; CARCINOMA; PROMOTER; DISTINCT	The cellular Brn-3a transcription factor is known to activate transcription of the genes encoding the human papilloma virus E6 and E7 proteins and is over-expressed in women with cervical neoplasia. We show that cervical cell hues with reduced Brn-3a expression show a greatly reduced ability to form tumours in nude mice compared to control cells and also show reduced expression of the HPV E6 and cellular Bcl-2 oncogenes. These effects are also observed in cervical cells over-expressing the related Brn-3b factor, which is known to antagonize activation of HPV gene expression by Brn-3a. These results demonstrate, for the first time, that inhibition of Brn-3a expression or enhanced Brn-3b expression can inhibit cervical cell-derived tumour growth in vivo as well as in vitro. Hence they establish Brn-3a as a key factor in cervical tumorigenesis and as a potential therapeutic target in human cervical neoplasia.	Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; UCL Royal Free & Univ Coll Med Sch, Dept Oncol, London NW3, England	University of London; University College London; University of London; University College London; UCL Medical School	Latchman, DS (corresponding author), Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.							BURGHARDT E, 1984, CLIN OBSTET GYNAECOL, V11, P239; COX MF, 1986, LANCET, V2, P157; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MEANWELL CA, 1987, LANCET, V1, P703; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Ndisang D, 2000, CLIN SCI, V98, P601, DOI 10.1042/CS19990350; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; van Duin M, 2000, J GEN VIROL, V81, P317, DOI 10.1099/0022-1317-81-2-317; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8	18	18	20	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4899	4903		10.1038/sj.onc.1204634	http://dx.doi.org/10.1038/sj.onc.1204634			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521202				2022-12-28	WOS:000170271800015
J	Dhar, M; Taneja, R				Dhar, M; Taneja, R			Cross-regulatory interaction between Stra13 and USF results in functional antagonism	ONCOGENE			English	Article						yeast two hybrid; basic helix-loop-helix factors; interaction; transcriptional activity; DNA-binding	LOOP-HELIX PROTEINS; MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; UPSTREAM ELEMENT; GENE; FAMILY; BINDING; ACTIVATION; REPRESSOR; ENHANCER	Transcription factors belonging to the basic helix-loop-helix (bHLH) family are critical regulators of cellular proliferation and differentiation. The functional activity of these proteins can be regulated by heterodimerization through the HLH domain, as a result of formation of functional or non-functional heterodimers. The presence of a leucine zipper in bHLH-leucine zipper (bHLHZip) proteins, however, prevents such heterodimeric interactions via the HLH domain between bHLH and bHLHZip proteins. To identify cellular proteins that directly interact with and modulate transcriptional repression mediated by the bHLH protein Stra13, we carried out a yeast two hybrid screen. The bHLHZip protein USF (Upstream Stimulatory factor) was identified as a Stra13 interacting protein. We demonstrate a direct interaction between Stra13 and USF that is dependent upon the C-terminal repression domain of Stra13 and the DNA-binding domain of USF. Stra13 and USF also colocalize and functionally interact in mammalian cells. Co-expression of USF abrogates Stra13-mediated repression of target genes and conversely, Stra13 inhibits DNA-binding and USF-mediated transactivation. Taken together, our data demonstrate that Stra13 and USF interact physically and functionally, and identify a novel mode of cross regulatory interaction between members of the bHLH and bHLHZip families that abrogates their functional activity.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Taneja, R (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.		Taneja, Reshma/F-9658-2014	Taneja, Reshma/0000-0002-2151-2094; Reshma, Taneja/0000-0001-6214-6177				Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; Dang CV, 1999, MOL CELL BIOL, V19, P1; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; James P, 1996, GENETICS, V144, P1425; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; Sirito Mario, 1992, Gene Expression, V2, P231; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Wallin JJ, 1999, J BIOL CHEM, V274, P15959, DOI 10.1074/jbc.274.22.15959	25	22	22	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4750	4756		10.1038/sj.onc.1204637	http://dx.doi.org/10.1038/sj.onc.1204637			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498797				2022-12-28	WOS:000170208600015
J	Signori, E; Bagni, C; Papa, S; Primerano, B; Rinaldi, M; Amaldi, F; Fazio, VM				Signori, E; Bagni, C; Papa, S; Primerano, B; Rinaldi, M; Amaldi, F; Fazio, VM			A somatic mutation in the 5 ' UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency	ONCOGENE			English	Article						BRCA1; translational regulation; somatic mutation; sporadic breast cancer	OVARIAN-CANCER; MESSENGER-RNA; ALPHA-THALASSEMIA; PROMOTER REGION; AUG CODON; PROTEIN; CARCINOMAS; EXPRESSION; METHYLATION; NUCLEOTIDES	Mutations in the 5' UTR which cause increment/ decrement of translation efficiency have been recently described as a novel molecular mechanism of disease. Alterations in the consensus sequence for the translation initiation may promote context-dependent leaky scanning of ribosomes and/or initiation from a downstream AUG codon. Initiation of translation from a downstream in-frame AUG codon in BRCA1 gene was recently identified in normal cells and possibly in breast cancer. Here we present further insight into BRCA1 translational pathophysiology investigating the role of the canonical structure of the initiation consensus sequence of BRCA1. We have analysed the effect of a somatic point mutation (117 G > C) in position -3 with respect to the AUG of the BRCA1 gene, identified in a highly, aggressive sporadic breast cancer. We constructed chimeric genes encoding the luciferase reporter sequence downstream of the wild type or the mutated BRCA1 5'UTR. These transcripts were tested for their activity in in vitro and in vivo systems. In in vitro transcription/ translation assays the estimated translation efficiency of the construct with the mutated BRCA1 5'UTR was 30-50% lower than that with the wild type BRCA1 5'UTR. The same chimeric genes were analysed for their expression in vivo by transient transfection in human cells. While the two constructs were equally transcribed, the plasmid carrying the mutated sequence produced 70% less luciferase activity compared to the wild type sequence. Finally, to obtain a direct evaluation on translational efficiency in vivo, we analysed mRNA translation on translationally active and non-active ribosomes separated from transfected cells. Mutant mRNA was partially localized in subpolysomal particles analytically confirming a polysome recruitment defect. Thus, characterization of BRCA1 5'UTR and translation efficiency seems to provide new insight into BRCA1 role in breast and ovarian cancer pathogenesis.	IRCCS H Casa Solliveo Sofferenza, Lab Mol Pathol & Gene Therapy, I-71013 San Giovanni Rotondo, FG, Italy; CNR, Ist Neurobiol & Med Mol, Area Ric Tor Vergata, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Sch Med, Lab Mol Med & Biotechnol, I-00155 Rome, Italy	IRCCS Casa Sollievo Della Sofferenza; Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata; University of Rome Tor Vergata	Fazio, VM (corresponding author), IRCCS H Casa Solliveo Sofferenza, Lab Mol Pathol & Gene Therapy, I-71013 San Giovanni Rotondo, FG, Italy.	VitoM.Fazio@ims.rm.cnr.it	Signori, Emanuela/H-5134-2019; rinaldi, monica/D-2221-2016; Fazio, Vito Michele VMF/H-3007-2016	Signori, Emanuela/0000-0003-0286-7401; rinaldi, monica/0000-0002-6889-9388; Fazio, Vito Michele VMF/0000-0002-7751-1867; Bagni, Claudia/0000-0002-4419-210X				Bernard-Gallon D, 1998, ONCOL REP, V5, P995; Brown MA, 1996, ONCOGENE, V12, P2507; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Choong CS, 1996, J CLIN INVEST, V98, P1423, DOI 10.1172/JCI118930; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; ESTELLER M, 2000, JNCI, V92, P565; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gorman C., 1985, DNA CLONING, V2; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Jarvis EM, 1998, CANCER GENET CYTOGEN, V101, P109, DOI 10.1016/S0165-4608(97)00267-7; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lee WY, 1999, HISTOPATHOLOGY, V34, P106; Lida Y, 1996, NUCLEIC ACIDS RES, V24, P3313, DOI 10.1093/nar/24.17.3313; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; LORENI F, 1992, EUR J BIOCHEM, V205, P1027, DOI 10.1111/j.1432-1033.1992.tb16870.x; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MORLE F, 1986, NUCLEIC ACIDS RES, V14, P3279, DOI 10.1093/nar/14.8.3279; MORLE F, 1985, EMBO J, V4, P1245, DOI 10.1002/j.1460-2075.1985.tb03767.x; Papa S, 1998, JNCI-J NATL CANCER I, V90, P1011, DOI 10.1093/jnci/90.13.1011; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.0.CO;2-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.3.CO;2-8; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	37	70	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4596	4600		10.1038/sj.onc.1204620	http://dx.doi.org/10.1038/sj.onc.1204620			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494157	Green Published			2022-12-28	WOS:000170074900019
J	Dhakshinamoorthy, S; Jaiswal, AK				Dhakshinamoorthy, S; Jaiswal, AK			Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H : quinone oxidoreductase 1 gene	ONCOGENE			English	Article						NQO1; hARE; Nrf2; INrf2; antioxidant	TRANSCRIPTION FACTOR; NF-E2-RELATED FACTOR-2; COORDINATED INDUCTION; HEME OXYGENASE-1; ACTIN-BINDING; SUBUNIT GENE; C-FOS; NRF2; PROTEIN; ACTIVATION	Antioxidant response element (ARE) and nuclear transcription factor Nrf2 are known to regulate expression and coordinated induction of NQO1 and other detoxifying enzyme genes in response to antioxidants and xenobiotics, A cytosolic inhibitor of Nrf2, INrf2, that retains Nrf2 in the cytoplasm, was cloned and sequenced, Treatment of cells with antioxidants and xenobiotics results in the release of Nrf2 from INrf2, Nrf2 then moves in the nucleus, This leads to the induction of ARE-mediated NQO1 and other detoxifying enzyme genes expression, INrf2 after dissociation from Nrf2 remains in the cytosol, Overexpression of INrf2 repressed ARE-mediated NQO1 gene expression, Deletion mapping of INrf2 revealed the requirement of KELCH domain (amino acid residues 361-597) and C-terminal region (amino acid residues 598-624) in retention of Nrf2 in the cytosol, Both these regions of INrf2 independently retained Nrf2 in the cytosol leading to the repression of ARE-mediated NQO1 gene expression, These results may indicate that two different regions of INrf2 interact with a single molecule of Nrf2 or two or more molecules of Nrf2 interact with a single molecule of INrf2, The transcription of Nrf2 and INrf2 did not change in response to antioxidants and xenobiotics, This indicated that INrf2 and/or Nrf2 might be post-transcriptionally modified in response to antioxidants and xenobiotics leading to the release of Nrf2 from INrf2 and induction of ARE-mediated NQO1 and other detoxifying enzyme genes expression.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047466, R01GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; BERGELSON S, 1994, ONCOGENE, V9, P565; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; DELONG MJ, 1987, CARCINOGENESIS, V8, P1549, DOI 10.1093/carcin/8.10.1549; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; JAISWAL AK, 1994, J BIOL CHEM, V269, P14502; Jaiswal AK, 1999, INT CONGR SER, V1172, P103; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; Long DJ, 2000, CANCER RES, V60, P5913; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MULKAHY RT, 1997, J BIOL CHEM, V272, P7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; QIAGEN, 2000, QI AEXPRESSIONIST HD; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P597, DOI 10.1016/S0006-2952(99)00143-4; Radjendirane Venugopal, 1997, P441; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT J, 1993, MOL BIOL REP, V18, P223, DOI 10.1007/BF01674434; Schulze-Osthoff Klaus, 1997, P239; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	42	239	246	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3906	3917		10.1038/sj.onc.1204506	http://dx.doi.org/10.1038/sj.onc.1204506			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439354				2022-12-28	WOS:000169494700016
J	Shi, Q; Le, XD; Wang, BL; Abbruzzese, JL; Xiong, QH; He, YJ; Xie, KP				Shi, Q; Le, XD; Wang, BL; Abbruzzese, JL; Xiong, QH; He, YJ; Xie, KP			Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells	ONCOGENE			English	Article						angiogenesis; VEGF; regulation; acidosis; pancreatic cancer	FACTOR MESSENGER-RNA; HUMAN PANCREATIC-CANCER; TUMOR-CELLS; FACTOR GENE; TRANSCRIPTION FACTOR; HYPOXIA; PH; METASTASIS; IDENTIFICATION; ANGIOGENESIS	The influence of acidosis on the expression of the vascular endothelial growth factor (VEGF) gene was determined, FG human pancreatic adenocarcinoma cells were incubated for various time periods in media at a physiologically relevant pH level (6.7-7.4), The expression of VEGF mRNA and protein secretion was inversely correlated with pH in a pH- and time-dependent manner. Transient acidosis also activated the VEGF promoter/enhancer luciferase reporter, which was consistent with an increased VEGF gene transcription rate and VEGF mRNA half-life. These data indicated that acidosis transcriptionally and posttranscriptionally regulates VEGF expression, suggesting that an acidic tumor microenvironment contributes to tumor angiogenesis and progression.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA16672-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; BOUCHER Y, 1990, CANCER RES, V50, P4478; Brooks SE, 1998, CURR EYE RES, V17, P875, DOI 10.1076/ceyr.17.9.875.5134; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; D'Arcangelo D, 2000, CIRC RES, V86, P312, DOI 10.1161/01.RES.86.3.312; Damert A, 1997, CANCER RES, V57, P3860; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Griffiths L, 1997, CANCER RES, V57, P570; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; HUNAG S, 2000, CANCER RES, V60, P5334; INTAGLIETTA M, 1977, MED INSTRUM, V11, P149; Itakura J, 1997, CLIN CANCER RES, V3, P1309; Jang A, 1997, CLIN EXP METASTAS, V15, P469, DOI 10.1023/A:1018470709523; KALLINOWSKI F, 1988, BRIT J CANCER, V58, P314, DOI 10.1038/bjc.1988.210; LADOUX A, 1994, BIOCHEM BIOPH RES CO, V204, P794, DOI 10.1006/bbrc.1994.2529; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; ROTIN D, 1989, CANCER RES, V49, P205; Scott PAE, 1998, INT J CANCER, V75, P706, DOI 10.1002/(SICI)1097-0215(19980302)75:5<706::AID-IJC8>3.0.CO;2-2; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHI Q, 1999, CLIN CANCER RES, V5, P7234; SHI Q, 2000, J INTERFERON CYTOKIN, V20, P1544; SHUBIK P, 1982, J CANCER RES CLIN, V103, P211, DOI 10.1007/BF00409698; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Tannock IF, 1996, J CLIN ONCOL, V14, P3156, DOI 10.1200/JCO.1996.14.12.3156; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAUPEL P, 1989, CANCER RES, V49, P6449; VEZERIDIS MP, 1989, J SURG ONCOL, V40, P261, DOI 10.1002/jso.2930400412; Watanabe Y, 1998, LIFE SCI, V63, P1037, DOI 10.1016/S0024-3205(98)00365-8; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; XIE K, 2001, IN PRESS CYTOKINE GR	39	191	199	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3751	3756		10.1038/sj.onc.1204500	http://dx.doi.org/10.1038/sj.onc.1204500			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439338	Bronze			2022-12-28	WOS:000169400200016
J	Wang, LL; Hiebert, SW				Wang, LL; Hiebert, SW			TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3	ONCOGENE			English	Article						HDAC3; TEL; tumor suppressor; stromelysin-1; mSin3; N-CoR	ACUTE LYMPHOBLASTIC-LEUKEMIA; NUCLEAR RECEPTOR COREPRESSORS; TRANSCRIPTIONAL REPRESSION; N-COR; TUMOR-SUPPRESSOR; ETS-FAMILY; FREQUENT LOSS; CLASS-I; GENE; COMPLEX	TEL (Translocation-ETS-Leukemia or ETV 6) is disrupted by multiple chromosomal translocations in acute leukemia. The loss of heterozygosity at the TEL locus in leukemias and the hemizygous deletion of TEL that is observed in various tumors, suggests that TEL is tumor suppressor, Overexpression of TEL alters cellular morphology and represses the expression of the matrix metalloproteinase stromelysin-1. Based on these studies, deletion analysis was used to define the minimal repression domains of TEL, TEL-mediated repression required both the N-terminal pointed domain and a central region composed of amino acids 268-303, The mSin3A and N-CoR corepressors bind to the pointed domain and the central repression domain of TEL, respectively. Unexpectedly, histone deacetylase-3, but not other histone deacetylases, also associates with the central region of TEL, Histone deacetylase-3 interacts with a TEL mutant that cannot bind N-CoR, suggesting that this is a direct interaction with TEL, In addition, histone H3 was under-acetylated near the TEL-binding sites in the endogenous stromelysin-1 promoter when TEL was expressed. Furthermore, trichostatin A, a potent histone deacetylase inhibitor, impaired TEL-dependent repression of the stromelysin-1 promoter. Finally, while TEL-expression induced cellular aggregation of Ras-transformed cells, Trichostatin A reversed the TEL-induced cellular aggregation phenotype, Thus, the cumulative data suggests that histone deacetylase-3 activity is required for the transcriptional functions of TEL.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem, Room 512,Med Res Bldg 2, Nashville, TN 37232 USA.		Hiebert, Scott W/C-9979-2010		NCI NIH HHS [CA68465, R01-CA77274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068465, R01CA077274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guarente L, 2000, GENE DEV, V14, P1021; Guenther MG, 2000, GENE DEV, V14, P1048; Guidez F, 2000, BLOOD, V96, P2557; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Huang EY, 2000, GENE DEV, V14, P45; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Javed A, 2000, J CELL SCI, V113, P2221; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kao HY, 2000, GENE DEV, V14, P55; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mahlknecht U, 1999, CYTOGENET CELL GENET, V86, P237, DOI 10.1159/000015347; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Poirel H, 2000, ONCOGENE, V19, P4802, DOI 10.1038/sj.onc.1203830; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Rao G, 1996, ONCOGENE, V12, P1165; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Romana SP, 1996, LEUKEMIA, V10, P167; SCHOLZ H, 1993, GENETICS, V135, P455; Spirin KS, 1996, CANCER RES, V56, P2400; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wiesen JF, 1996, ENZYME PROTEIN, V49, P174, DOI 10.1159/000468624; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	70	77	79	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3716	3725		10.1038/sj.onc.1204479	http://dx.doi.org/10.1038/sj.onc.1204479			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439334				2022-12-28	WOS:000169400200012
J	de Almodovar, CR; Ruiz-Ruiz, C; Munoz-Pinedo, C; Robledo, GH; Lopez-Rivas, A				de Almodovar, CR; Ruiz-Ruiz, C; Munoz-Pinedo, C; Robledo, GH; Lopez-Rivas, A			The differential sensitivity of Bcl-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bcl-2 protein levels	ONCOGENE			English	Article						apoptosis; TRAIL; chemotherapy; mitochondria; Bcl-2	NF-KAPPA-B; CYTOCHROME-C; RECEPTOR; DEATH; LIGAND; MITOCHONDRIA; FAMILY; MEMBER; FADD; BAX	Bc1-2 protein is a potent anti-apoptotic protein that inhibits a mitochondria-operated pathway of apoptosis in many cells. DNA damaging agents and death receptor ligands can activate this mitochondrial apoptotic mechanism. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been suggested to escape from the inhibitory action of Bc1-2 protein. We show that in human breast tumor MCF-7 cells, TRAIL induced a mitochondrial pathway of apoptosis that involved cytochrome c release from mitochondria and activation of caspase 9. The DNA damaging drug doxorubicin also activated this mitochondria-regulated mechanism of apoptosis, which was inhibited in Bc1-2-overexpressing cells. We also demonstrate that in MCF-7 cells Bc1-2 might confer resistance to TRAIL-induced apoptosis, depending on the expression levels of the anti-apoptotic protein. These results indicate that enhanced expression of Bc1-2 in tumor cells can render these cells less sensitive not only to chemotherapeutic drugs but also to TRAIL.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.	alrivas@ipb.csic.es	Ruiz-Ruiz, Carmen/I-8792-2017; Munoz-Pinedo, Cristina/B-6118-2008; Lopez-Rivas, Abelardo/E-5115-2015	Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Munoz-Pinedo, Cristina/0000-0002-9120-664X; Lopez-Rivas, Abelardo/0000-0002-9351-9690				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Phillips TA, 1999, J IMMUNOL, V162, P6053; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rochaix P, 1999, J PATHOL, V187, P410, DOI 10.1002/(SICI)1096-9896(199903)187:4<410::AID-PATH266>3.0.CO;2-F; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHIYONG S, 2001, BIOCHEM BIOPH RES CO, V20, P788; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang QF, 2000, BREAST CANCER RES TR, V61, P211, DOI 10.1023/A:1006474307180; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	44	43	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7128	7133		10.1038/sj.onc.1204887	http://dx.doi.org/10.1038/sj.onc.1204887			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704839				2022-12-28	WOS:000171739300018
J	Eischen, CM; Packham, G; Nip, J; Fee, BE; Hiebert, SW; Zambetti, GP; Cleveland, JL				Eischen, CM; Packham, G; Nip, J; Fee, BE; Hiebert, SW; Zambetti, GP; Cleveland, JL			Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1	ONCOGENE			English	Article						c-Myc; E2F-1; Bcl-2; Bcl-X-L; myeloid; apoptosis	CELL-CYCLE ARREST; S-PHASE ENTRY; WILD-TYPE P53; MEDIATED APOPTOSIS; P53-DEPENDENT APOPTOSIS; ORNITHINE-DECARBOXYLASE; TRANSCRIPTION FACTORS; HEMATOPOIETIC-CELLS; SEPARABLE FUNCTIONS; RAT FIBROBLASTS	Malignant transformation occurs in cells that overexpress c-Myc or that inappropriately activate E2F-1. Transformation occurs after the selection of cells that have acquired resistance to apoptosis that is triggered by these oncogenes, and a key mediator of this cell death process is the p53 tumor suppressor. In IL-3-dependent immortal 32D.3 myeloid cells the ARF/p53 apoptotic pathway is inactivated, as these cells fail to express ARF. Nonetheless, both c-Myc and E2F-1 overexpression accelerated apoptosis when these cells were deprived of IL-3. Here we report that c-Myc or E2F-1 overexpression suppresses Bcl-2 protein and RNA levels, and that restoration of Bcl-2 protein effectively blocks the accelerated apoptosis that occurs when c-Myc- or E2F-1-overexpressing cells are deprived of IL-3. Blocking p53 activity with mutant p53 did not abrogate E2F-1-induced suppression of Bcl-2. Analysis of immortal myeloid cells engineered to overexpress c-Myc and E2F-1 DNA binding mutants revealed that DNA binding activity of these oncoproteins is required to suppress Bcl-2 expression. These results suggest that the targeting of Bcl-2 family members is an important mechanism of oncogene-induced apoptosis, and that this occurs independent of the ARF/p53 pathway.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Southampton Gen Hosp, CRC, Wessex Med Oncol Unit, Southampton SO16 6YD, Hants, England; Unilever Res US, Edgewater, NJ 07020 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Southampton; Unilever; Vanderbilt University; University of Tennessee System; University of Tennessee Health Science Center	Cleveland, JL (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.cleveland@stjude.org	Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007; Packham, Graham/0000-0002-9232-5691	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA063260, F32CA081695, R01CA077274, R01CA064140, R01CA076379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NCI NIH HHS [CA81695, CA77274, CA76379, CA64140, CA63260, CA-21765] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Dai HQ, 1999, CANCER RES, V59, P4944; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grillot DAM, 1996, J EXP MED, V183, P381, DOI 10.1084/jem.183.2.381; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HSU B, 1995, ONCOGENE, V11, P175; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; KATO J, 1993, GENE DEV, V7, P331; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lenahan MK, 1996, ONCOGENE, V12, P1847; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Mitchell KO, 2000, CANCER RES, V60, P6318; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; O'Connor L, 2000, CURR OPIN CELL BIOL, V12, P257, DOI 10.1016/S0955-0674(99)00084-8; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sakamuro D, 1995, ONCOGENE, V11, P2411; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	76	128	130	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					6983	6993		10.1038/sj.onc.1204892	http://dx.doi.org/10.1038/sj.onc.1204892			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704823				2022-12-28	WOS:000171739300002
J	Herbert, GB; Shi, B; Gartenhaus, RB				Herbert, GB; Shi, B; Gartenhaus, RB			Expression and stabilization of the MCT-1 protein by DNA damaging agents	ONCOGENE			English	Article						MCT-1 expression; stabilization; DNA damage	T-CELL MALIGNANCIES; WILD-TYPE P53; SUBCELLULAR-LOCALIZATION; CANDIDATE ONCOGENE; HTLV-I; GENE; LYMPHOMA; CYCLE; PHOSPHORYLATION; IDENTIFICATION	The contribution of oncogene amplification and/or overexpression to T-cell lymphoid neoplasms has only of late been established with the implication of the TCL1 and MTCP1 genes in T-cell malignancies. Our laboratory has recently discovered a novel oncogene, MCT-1, amplified in a T-cell lymphoma and mapped to chromosome Xq22-24. MCT-1 has been shown to decrease cell-doubling time, dramatically shortening the duration of G(1) transit time and/or G1-S transition, and transforms NIH3T3 fibroblasts. Constitutive expression of MCT-1 results in a strong proliferative signal and is associated with deregulation of protein kinase-mediated G1/S phase checkpoints. In this study we analysed the level and subcellular localization of this novel cell cycle regulatory molecule as a function of cell cycle phase. In human lymphoid tumors expression of MCT-1 is constant throughout the cell cycle and remains cytoplasmic. Cells overexpressing MCT-1 have increased expression of cyclin DI with dysregulation of the GI-S checkpoint. Both cyclin D1 and MCT-1 are involved in regulating passage of cells through the G1 phase of the cell cycle. Since prior work has shown that gamma irradiation induces cyclin DI expression we investigated the induction of MCT-1 to DNA damaging agents. We demonstrate that increases in MCT-1 protein in irradiated human lymphoid cells do not occur at the mRNA level and do not require new protein synthesis.	Northwestern Univ, Dept Med, Div Hematol Oncol, Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Gartenhaus, RB (corresponding author), Northwestern Univ, Dept Med, Div Hematol Oncol, Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.			Shi, Bo/0000-0002-0780-0372				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; BENYEHUDA D, 1994, BRIT J HAEMATOL, V86, P792, DOI 10.1111/j.1365-2141.1994.tb04831.x; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; CHUANG LT, 1994, CANCER RES, V54, P1286; Dierov J, 1999, J CELL BIOCHEM, V74, P544, DOI 10.1002/(SICI)1097-4644(19990915)74:4<544::AID-JCB4>3.3.CO;2-W; EPPERLY M, 1995, RADIAT RES, V143, P245, DOI 10.2307/3579210; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.3.CO;2-D; Monni O, 1996, BLOOD, V87, P5269, DOI 10.1182/blood.V87.12.5269.bloodjournal87125269; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Poommipanit PB, 1999, J BIOL CHEM, V274, P1033, DOI 10.1074/jbc.274.2.1033; Prosniak M, 1998, CANCER RES, V58, P4233; REID RL, 1993, ONCOGENE, V8, P3029; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Scarpa A, 1999, GENE CHROMOSOME CANC, V26, P203, DOI 10.1002/(SICI)1098-2264(199911)26:3<203::AID-GCC3>3.0.CO;2-E; Sheikh MS, 1999, J BIOL CHEM, V274, P16487, DOI 10.1074/jbc.274.23.16487; STERN MH, 1993, ONCOGENE, V8, P2475; Sugimoto J, 1999, CANCER RES, V59, P2313; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Werner CA, 1997, AM J PATHOL, V151, P335; Ye Y, 1998, INT J CANCER, V78, P62, DOI 10.1002/(SICI)1097-0215(19980925)78:1<62::AID-IJC11>3.0.CO;2-7	26	11	12	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6777	6783		10.1038/sj.onc.1204881	http://dx.doi.org/10.1038/sj.onc.1204881			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709712				2022-12-28	WOS:000171551600014
J	Skapek, SX; Lin, SCJ; Jablonski, MM; McKeller, RN; Tan, M; Hu, NP; Lee, EYHP				Skapek, SX; Lin, SCJ; Jablonski, MM; McKeller, RN; Tan, M; Hu, NP; Lee, EYHP			Persistent expression of cyclin D1 disrupts normal photoreceptor differentiation and retina development	ONCOGENE			English	Article						cyclin D1; retina; RB; photoreceptors; retinoblastoma	RETINOBLASTOMA PROTEIN; CELL-CYCLE; TARGETED DISRUPTION; ECTOPIC EXPRESSION; VERTEBRATE RETINA; MICE DEFICIENT; MOUSE RETINA; MUTANT MICE; GENE; PATHWAY	The differentiation of neuronal cells in the developing mammalian retina is closely coupled to cell cycle arrest and proceeds in a highly organized manner. Cyclin D1, which regulates cell proliferation in many cells, also drives the proliferation of photoreceptor progenitors. In the mouse retina, cyclin D1 protein normally decreases as photoreceptors mature. To study the importance of the down-regulation of cyclin D1 during photoreceptor development, we generated a transgenic mouse in which cyclin D1 was persistently expressed in developing photoreceptor cells. We observed numerous abnormalities in both photoreceptors and other nonphotoreceptor cells in the retina of these transgenic mice. In particular, we observed delayed opsin expression in developing photoreceptors and alterations in their number and morphology in the mature retina. These alterations were accompanied by disorganization of the inner nuclear and plexiform layers. The expression of cyclin D1 caused excess photoreceptor cell proliferation and apoptosis. Loss of the p53 tumor suppressor gene decreased cyclin D1-induced apoptosis and led to microscopic hyperplasia in the retina. These findings are distinct from other mouse models in which the retinoblastoma gene pathway is disrupted and suggest that the IRBP-cyclin D1 mouse model may recapitulate an early step in the development of retinoblastoma.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Tennessee, Dept Ophthalmol, Memphis, TN 38163 USA; Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Texas System; University of Texas Health San Antonio; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Skapek, SX (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	steve.skapek@stjude.org						Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; DIGGLE P, 1994, ANAL LONGITUNDINAL D, P63; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOWES KA, 1994, INVEST OPHTH VIS SCI, V35, P342; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; LIN SCJ, 2001, IN PRESS ONCOGENE; Ma CY, 1998, P NATL ACAD SCI USA, V95, P9938, DOI 10.1073/pnas.95.17.9938; Morrow EM, 1998, J NEUROSCI, V18, P3738; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; Poluha W, 1996, MOL CELL BIOL, V16, P1335; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Reh TA, 1998, J NEUROBIOL, V36, P206, DOI 10.1002/(SICI)1097-4695(199808)36:2<206::AID-NEU8>3.3.CO;2-4; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Ross ME, 1996, TRENDS NEUROSCI, V19, P62, DOI 10.1016/0166-2236(96)89622-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	44	31	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6742	6751		10.1038/sj.onc.1204876	http://dx.doi.org/10.1038/sj.onc.1204876			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709709				2022-12-28	WOS:000171551600011
J	Bustelo, XR				Bustelo, XR			Vav proteins, adaptors and cell signaling	ONCOGENE			English	Article						Vav; exchange factors; Rho/Rac proteins; tyrosine kinase; adaptor proteins; Ca2+	TYROSINE KINASE ACTIVATION; EXCHANGE FACTOR VAV; T-CELL; RHO-FAMILY; SYNERGISTIC ACTIVATION; B-LYMPHOCYTES; HIV-1 NEF; RECEPTOR; SLP-76; PHOSPHORYLATION	The Vav family is a group of signal transduction molecules with oncogenic potential that play important roles in development and cell signaling. Members of this family are distributed in all animal metazoans but not in unicellular organisms. Recent genomic studies suggest that the function of Vav proteins co-evolved with tyrosine kinase pathways, probably to assure the optimal conversion of extracellular signals into biological responses coupled to the cytoskeleton and gene transcription. To date, the best-known function of Vav proteins is their role as GDP/GTP exchange factors for Rho/Rac molecules, a function strictly controlled by tyrosine phosphorylation. Recent publications indicate that this function is highly dependent on the interaction of adaptor proteins that aid in the proper phosphorylation of Vav proteins, their interaction with other signaling molecules, and in modulating the strength of their signal outputs. In addition to the function of Vav proteins as exchange factors, there is increasing evidence suggesting that Vav proteins can mediate other cellular functions independently of their exchange activities, probably by working themselves as adaptor molecules. In this review, we will give a summary of the recent advances in this field, placing special emphasis on the non-catalytic roles of Vav and its interaction with other adaptor molecules.	Univ Salamanca, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072	NCI NIH HHS [CA7373501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; Billadeau DD, 2000, J IMMUNOL, V164, P3971, DOI 10.4049/jimmunol.164.8.3971; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Doody GM, 2000, EMBO J, V19, P6173, DOI 10.1093/emboj/19.22.6173; DOODY GM, 2001, NAT IMMUNOL, V6, P482; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Fujimoto M, 1999, J IMMUNOL, V162, P7088; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Li XL, 1997, J IMMUNOL, V158, P5649; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Manninen A, 2000, J BIOL CHEM, V275, P16513, DOI 10.1074/jbc.M910032199; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Musci MA, 1997, J IMMUNOL, V159, P1639; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Okumura K, 1997, ONCOGENE, V14, P713, DOI 10.1038/sj.onc.1200878; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Roshal M, 2001, APOPTOSIS, V6, P103, DOI 10.1023/A:1009636530839; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; Skowronski J, 1999, COLD SPRING HARB SYM, V64, P453, DOI 10.1101/sqb.1999.64.453; Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WENG WK, 1994, J BIOL CHEM, V269, P32514; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu J, 2000, CELL MOL LIFE SCI, V57, P411, DOI 10.1007/PL00000703	55	171	174	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6372	6381		10.1038/sj.onc.1204780	http://dx.doi.org/10.1038/sj.onc.1204780			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607839				2022-12-28	WOS:000171640600012
J	Liu, SKW; Berry, DM; McGlade, CJ				Liu, SKW; Berry, DM; McGlade, CJ			The role of Gads in hematopoietic cell signalling	ONCOGENE			English	Article						Gads; T cell receptor; SLP-76; LAT; RasGRP	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; ADAPTER PROTEIN SLP-76; TERMINAL SH3 DOMAIN; T-CELLS; ANTIGEN-RECEPTOR; MOLECULAR-CLONING; THYMOCYTE DEVELOPMENT; RAS ACTIVATION; NUCLEAR FACTOR	Gads is a member of the family of SH2 and SH3 domain containing adaptor proteins that is expressed specifically in hematopoietic cells and functions in the coordination of tyrosine kinase mediated signal transduction. Gads plays a critical role in signalling from the T cell receptor by promoting the formation of a complex between SLP-76 and LAT. This complex couples the T cell receptor to Ras through a novel pathway involving PLC-gamma1, Tec family kinases, and RasGRP. Studies with Gads-deficient mice have highlighted its importance for thymocyte proliferation during T cell maturation. Emerging evidence suggests that Gads may also play additional roles in antigen-receptor signalling and receptor tyrosine kinase mediated signalling in other hematopoietic lineages. Gads is a unique member of the Grb2 adaptor family, because its activity can be regulated by caspase cleavage. Gads nucleates multiprotein complexes that are required for tyrosine kinase-dependent signalling in immune cells and may also represent a point of modulation for these pathways through the activation of caspase-dependent signalling events.	Univ Toronto, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	McGlade, CJ (corresponding author), Univ Toronto, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Liu, Stanley/0000-0001-6851-0857				Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Berry DM, 2001, ONCOGENE, V20, P1203, DOI 10.1038/sj.onc.1204218; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourgin C, 2000, FEBS LETT, V480, P113, DOI 10.1016/S0014-5793(00)01906-2; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Clements JL, 1998, J IMMUNOL, V161, P3880; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 2000, BLOOD, V95, P3199; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; Ellmeier W, 1999, ANNU REV IMMUNOL, V17, P523, DOI 10.1146/annurev.immunol.17.1.523; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gobel TWF, 2000, CURR TOP MICROBIOL, V248, P303; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kikuchi K, 2001, INT IMMUNOL, V13, P777, DOI 10.1093/intimm/13.6.777; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Ma WB, 2001, ONCOGENE, V20, P1703, DOI 10.1038/sj.onc.1204224; Myung PS, 2000, CURR OPIN IMMUNOL, V12, P256, DOI 10.1016/S0952-7915(00)00085-6; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; REIF K, 1994, J BIOL CHEM, V269, P14081; Roose J, 2000, NAT IMMUNOL, V1, P275, DOI 10.1038/79713; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASTRY L, 1995, ONCOGENE, V11, P1107; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schneider H, 2000, J BIOL CHEM, V275, P3835, DOI 10.1074/jbc.275.6.3835; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Yankee TM, 2001, P NATL ACAD SCI USA, V98, P6789, DOI 10.1073/pnas.111158598; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZunigaPflucker JC, 1996, CURR OPIN IMMUNOL, V8, P215, DOI 10.1016/S0952-7915(96)80060-4	69	58	60	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6284	6290		10.1038/sj.onc.1204771	http://dx.doi.org/10.1038/sj.onc.1204771			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607830				2022-12-28	WOS:000171640600003
J	Alevizos, I; Mahadevappa, M; Zhang, X; Ohyama, H; Kohno, Y; Posner, M; Gallagher, GT; Varvares, M; Cohen, D; Kim, D; Kent, R; Donoff, RB; Todd, R; Yung, CM; Warrington, JA; Wong, DTW				Alevizos, I; Mahadevappa, M; Zhang, X; Ohyama, H; Kohno, Y; Posner, M; Gallagher, GT; Varvares, M; Cohen, D; Kim, D; Kent, R; Donoff, RB; Todd, R; Yung, CM; Warrington, JA; Wong, DTW			Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis	ONCOGENE			English	Article						oral cancer; gene expression; laser capture microdissection; microarrays	SQUAMOUS-CELL CARCINOMA; NEUROMEDIN U; PROGNOSTIC-SIGNIFICANCE; METABOLIZING-ENZYMES; HUMAN HEAD; IDENTIFICATION; TISSUE; TUMOR; OVEREXPRESSION; POLYMORPHISMS	Large scale gene expression profiling was carried out on laser capture microdissected (LCM) tumor and normal oral epithelial cells and analysed on high-density oligonucleotide microarrays. About 600 genes were found to be oral cancer associated. These oral cancer associated genes include oncogenes, tumor suppressors, transcription factors, xenobiotic enzymes, metastatic proteins, differentiation markers, and genes that have not been implicated in oral cancer. The database created provides a verifiable global profile of gene expression during oral carcinogenesis, revealing the potential role of known genes as well as genes that have not been previously implicated in oral cancer.	Harvard Univ, Sch Dent Med, Dept Oral Med & Diagnost Sci, Div Oral Biol, Boston, MA 02115 USA; Affymetrix Inc, Santa Clara, CA 95051 USA; China Med Univ, Dept Biol, Shenyang 110001, Peoples R China; Dana Farber Canc Inst, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA; Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02115 USA; Univ Nebraska, Coll Dent, Ctr Med, Lincoln, NE 68583 USA; Forsyth Inst, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA; Chung Shan Med & Dent Coll, Taichung, Taiwan	Harvard University; Harvard School of Dental Medicine; Affymetrix; China Medical University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Eye & Ear Infirmary; University of Nebraska System; University of Nebraska Lincoln; Harvard University; Forsyth Institute; Harvard University; Massachusetts General Hospital; Chung Shan Medical University	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Med & Diagnost Sci, Div Oral Biol, 188 Longwood Ave, Boston, MA 02115 USA.	dwong@warren.med.harvard.edu	Todd, Robert/GWM-4486-2022		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P30DE011814, P01DE012467, R29DE011983] Funding Source: NIH RePORTER; NIDCR NIH HHS [P01 DE12467, P30 DE11814, R29 DE11983] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; JANOT F, 1993, CARCINOGENESIS, V14, P1279, DOI 10.1093/carcin/14.7.1279; Jourenkova-Mironova N, 1999, INT J CANCER, V81, P44, DOI 10.1002/(SICI)1097-0215(19990331)81:1<44::AID-IJC9>3.0.CO;2-A; JUNIEN C, 1983, AM J HUM GENET, V35, P584; Katoh T, 1999, INT J CANCER, V83, P606, DOI 10.1002/(SICI)1097-0215(19991126)83:5<606::AID-IJC6>3.3.CO;2-G; Kawamata H, 1997, INT J CANCER, V70, P120, DOI 10.1002/(SICI)1097-0215(19970106)70:1<120::AID-IJC18>3.0.CO;2-P; Kimura Y, 2000, CANCER LETT, V155, P163, DOI 10.1016/S0304-3835(00)00423-7; Kurokawa Hideo, 1998, Fukuoka Acta Medica, V89, P321; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Leethanakul C, 2000, ORAL ONCOL, V36, P474, DOI 10.1016/S1368-8375(00)00039-7; LIN LM, 1991, J ORAL PATHOL MED, V20, P479, DOI 10.1111/j.1600-0714.1991.tb00408.x; Liu CM, 1999, BRIT J CANCER, V79, P360, DOI 10.1038/sj.bjc.6690057; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lotan R, 1997, ENVIRON HEALTH PERSP, V105, P985, DOI 10.2307/3433315; Loukinova E, 2000, ONCOGENE, V19, P3477, DOI 10.1038/sj.onc.1203687; Magary SP, 2000, OTOLARYNG HEAD NECK, V122, P712, DOI 10.1016/S0194-5998(00)70202-6; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Mighell AJ, 1997, ORAL ONCOL, V33, P155, DOI 10.1016/S0964-1955(96)00074-7; MURAMATSU H, 1995, CANCER RES, V55, P6210; MURRAY GI, 1994, GUT, V35, P599, DOI 10.1136/gut.35.5.599; Ohyama H, 2000, BIOTECHNIQUES, V29, P530, DOI 10.2144/00293st05; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Park JY, 1997, CANCER EPIDEM BIOMAR, V6, P791; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Porte H, 1998, CLIN CANCER RES, V4, P1375; Raddatz R, 2000, J BIOL CHEM, V275, P32452, DOI 10.1074/jbc.M004613200; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; Sato M, 1999, CARCINOGENESIS, V20, P1927, DOI 10.1093/carcin/20.10.1927; Sgroi DC, 1999, CANCER RES, V59, P5656; Shillitoe EJ, 2000, ORAL ONCOL, V36, P8, DOI 10.1016/S1368-8375(99)00071-8; SHIN DM, 1994, CANCER EPIDEM BIOMAR, V3, P697; SHINTANI S, 1995, CANCER LETT, V95, P79, DOI 10.1016/0304-3835(95)03866-U; Strojan P, 2000, CLIN CANCER RES, V6, P1052; SUO Z, 1993, HISTOPATHOLOGY, V23, P45, DOI 10.1111/j.1365-2559.1993.tb01182.x; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; VIAENE AI, 1995, HISTOCHEM J, V27, P69, DOI 10.1007/BF00164174; vonBiberstein SE, 1996, ARCH OTOLARYNGOL, V122, P751; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Warrington JA, 2000, MICROARRAY BIOCHIP TECHNOLOGY, P119; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yeudall WA, 1997, MOL CARCINOGEN, V18, P89, DOI 10.1002/(SICI)1098-2744(199702)18:2<89::AID-MC4>3.0.CO;2-L	47	185	210	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6196	6204		10.1038/sj.onc.1204685	http://dx.doi.org/10.1038/sj.onc.1204685			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593428				2022-12-28	WOS:000171206300011
J	Wang, RH; Liu, CWY; Avramis, VI; Berndt, N				Wang, RH; Liu, CWY; Avramis, VI; Berndt, N			Protein phosphatase 1 alpha-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein	ONCOGENE			English	Article						protein phosphatase 1; retinoblastoma protein; caspase; protein phosphorylation; cell cycle; apoptosis	CELL-CYCLE PROGRESSION; INHIBITOR OKADAIC ACID; CATALYTIC SUBUNIT; GENE-PRODUCT; MAMMALIAN-CELLS; PHOSPHORYLATION; DEATH; ACTIVATION; CLEAVAGE; ARREST	Protein phosphatase I (PPI) plays important roles in many different aspects of cellular activities including cell cycle control. One important function of PP1 is to activate the retinoblastoma protein pRB. Here we show that pRB is one of PPI's downstream targets during apoptosis. When HL-60 cells synchronized at the G1/S boundary were treated with pro-apoptotic cytosine arabinoside (araC), PP1 alpha protein increased twofold and PP1 activity about 30% within I h. This was followed by pRB dephosphorylation, pRB cleavage by caspases, DNA fragmentation, the appearance of cells with < 2n DNA content and finally, dying and dead cells. In vitro, pRB was protected from caspase-3 digestion by prior Cdk-mediated phosphorylation, whereas PP1 alpha converted phospho-pRB into an efficient substrate for caspase-3. Introduction of active PP1 alpha into HL-60 cells by electroporation was sufficient to induce characteristics of apoptosis. Similarly, araC-resistant cells, normally unable to die in response to araC, initiated apoptosis when electroporated with active PP1 alpha. This was also accompanied by pRB cleavage. In contrast, introduction of inhibitor-2 delayed the onset of araC-induced apoptosis, whereas concomitant introduction of PP1 alpha and inhibitor-2 completely prevented PP1 alpha -induced apoptosis. These results suggest that dephosphorylation of key proteins by PP1 alpha may be crucial for the initiation of apoptosis and further support the concept of PPI serving as a potential target for anti-cancer therapy.	Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Berndt, N (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.				NCI NIH HHS [CA 54167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054167] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; BAXTER GD, 1992, J IMMUNOL, V148, P1949; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berndt N., 2000, EMERGING THER TARGET, V4, P581; BERNDT N, 1995, ADV PROTEIN PHOSPHAT, V9, P63; Berndt N., 1999, FRONT BIOSCI, V4, pD22, DOI DOI 10.2741/BERNDT;PMID:9872729; Berry DE, 1996, ONCOGENE, V12, P1809; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Cheng AY, 2000, J BIOL CHEM, V275, P1846, DOI 10.1074/jbc.275.3.1846; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; Dohadwala M, 1998, METH MOL B, V93, P191; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUNIGAN DD, 1995, VIROLOGY, V207, P460, DOI 10.1006/viro.1995.1105; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fan GS, 1996, ONCOGENE, V12, P1909; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HOTZ MA, 1994, CYTOMETRY, V15, P237, DOI 10.1002/cyto.990150309; INOMATA M, 1995, J CANCER RES CLIN, V121, P729, DOI 10.1007/BF01213319; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin-Aragon S, 2000, ANTICANCER RES, V20, P139; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Morimoto Y, 1997, EXP CELL RES, V230, P181, DOI 10.1006/excr.1996.3404; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Puntoni F, 1999, BIOCHEM BIOPH RES CO, V266, P279, DOI 10.1006/bbrc.1999.1800; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Spector D. L., 1998, CELLS LAB MANUAL; Takemura M, 1997, ONCOGENE, V15, P2483, DOI 10.1038/sj.onc.1201431; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Taylor BK, 2000, AM J PHYSIOL-LUNG C, V278, pL1062, DOI 10.1152/ajplung.2000.278.5.L1062; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZHENG B, 1991, J BIOL CHEM, V266, P10031	55	65	66	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6111	6122		10.1038/sj.onc.1204829	http://dx.doi.org/10.1038/sj.onc.1204829			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593419				2022-12-28	WOS:000171206300002
J	Ladanyi, M				Ladanyi, M			Fusions of the SYT and SSX genes in synovial sarcoma	ONCOGENE			English	Article						chromosomal translocation; transcription factor; nuclear localization	HEPATOCYTE GROWTH-FACTOR; KRUPPEL-ASSOCIATED BOX; POLYMERASE CHAIN-REACTION; SOFT-TISSUE TUMORS; X-CHROMOSOME; TRANSCRIPTIONAL REPRESSION; TRANSLOCATION BREAKPOINTS; NUCLEAR-LOCALIZATION; EWINGS-SARCOMA; PROTEINS	Synovial sarcomas are high grade spindle cell tumors that are divided into two major histologic subtypes, biphasic and monophasic, according to the respective presence or absence of a well-developed glandular epithelial component. They contain in essentially all cases a t(X;18) representing the fusion of SYT (at 18q11) with either SSX1 or SSX2 (both at Xp11). Neither SYT, nor the SSX proteins contain DNA-binding domains. Instead, they appear to be transcriptional regulators whose actions are mediated primarily through protein-protein interactions, with BRM in the case of SYT, and with Polycomb group repressors in the case of SSX. Ongoing work on the SYT-SSX fusion and synovial sarcoma should yield a variety of data of broader biological interest, in areas such as BRM and Polycomb group function and dysfunction, transcriptional targets of SYT-SSX proteins and their native counterparts, differential gene regulation by SYT-SSX1 and SYT-SSX2, control of glandular morphogenesis, among others.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.	ladanyim@mskcc.org	Ladanyi, Marc/AAG-8585-2019		NCI NIH HHS [P01 CA47179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allander Susanne V., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P430; Antonescu CR, 2000, DIAGN MOL PATHOL, V9, P1, DOI 10.1097/00019606-200003000-00001; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Birdsall S, 1999, INT J CANCER, V82, P605, DOI 10.1002/(SICI)1097-0215(19990812)82:4<605::AID-IJC22>3.3.CO;2-8; BOUFFLER S, 1993, BIOESSAYS, V15, P409, DOI 10.1002/bies.950150607; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Castagnino P, 2000, ONCOGENE, V19, P640, DOI 10.1038/sj.onc.1203357; Chand A, 1995, GENOMICS, V30, P545, DOI 10.1006/geno.1995.1275; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Guillou L, 2001, HUM PATHOL, V32, P105, DOI 10.1053/hupa.2001.21130; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Hashimoto N, 2000, CANCER LETT, V149, P31, DOI 10.1016/S0304-3835(99)00336-5; Hiraga H, 1998, DIAGN MOL PATHOL, V7, P102, DOI 10.1097/00019606-199804000-00007; Illei P, 2001, MODERN PATHOL, V14, p13A; Inagaki H, 1999, AM J CLIN PATHOL, V111, P528; JANZ M, 1995, J PATHOL, V175, P391, DOI 10.1002/path.1711750405; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kasai T, 2000, J CLIN PATHOL-MOL PA, V53, P107, DOI 10.1136/mp.53.2.107; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Kuhnen C, 1998, VIRCHOWS ARCH, V432, P337, DOI 10.1007/s004280050175; Ladanyi M, 2000, HUM PATHOL, V31, P532, DOI 10.1053/hp.2000.6706; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Lewis JJ, 2000, J CLIN ONCOL, V18, P2087, DOI 10.1200/JCO.2000.18.10.2087; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Lin PP, 1999, CANCER RES, V59, P1428; Mancuso T, 2000, LAB INVEST, V80, P805, DOI 10.1038/labinvest.3780085; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MILLER AP, 1995, HUM MOL GENET, V4, P731, DOI 10.1093/hmg/4.4.731; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nielsen TO, 2001, MODERN PATHOL, V14, p16A; Nilsson G, 1999, CANCER RES, V59, P3180; Oda Y, 2000, HUM PATHOL, V31, P185, DOI 10.1016/S0046-8177(00)80218-X; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; Shipley J, 1996, AM J PATHOL, V148, P559; SHIPLEY JM, 1994, ONCOGENE, V9, P1447; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Sonobe H, 1999, INT J CANCER, V82, P459, DOI 10.1002/(SICI)1097-0215(19990730)82:3<459::AID-IJC21>3.0.CO;2-B; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; Tureci O, 1996, CANCER RES, V56, P4766; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; van de Rijn M, 1999, AM J CLIN PATHOL, V112, P43; vanKessel AG, 1997, CANCER GENET CYTOGEN, V95, P67, DOI 10.1016/S0165-4608(96)00241-5; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	63	159	171	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5755	5762		10.1038/sj.onc.1204601	http://dx.doi.org/10.1038/sj.onc.1204601			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607825				2022-12-28	WOS:000170887500016
J	Blanchette, P; Gilchrist, CA; Baker, RT; Gray, DA				Blanchette, P; Gilchrist, CA; Baker, RT; Gray, DA			Association of UNP, a ubiquitin-specific protease, with the pocket proteins pRb, p107 and p130	ONCOGENE			English	Article						ubiquitin; Ubp; deubiquitinating enzyme; retinoblastoma; pocket protein	RETINOBLASTOMA GENE-PRODUCT; RB-RELATED P107; CELL-CYCLE; REGULATED PROTEOLYSIS; MICE LACKING; C-MYC; PATHWAY; DEGRADATION; FAMILY; E2F	The murine Unp gene encodes a widely expressed ubiquitin-specific protease. The predicted sequence of the UNP protein features motifs common to viral oncoproteins through which these proteins interact with the retinoblastoma gene product pRb, as well as the related 'pocket proteins' p107 and p130. We have explored the possibility that UNP interacts with pocket proteins, and report here that such associations can be detected in vitro and in cells. Associations of UNP and pocket proteins are sensitive to site-directed mutations in a manner directly analogous to those documented in viral oncoproteins. We conclude that within cells UNP does physically associate with pRb, and can also associate with p107 and p130.	Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada; Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia	University of Ottawa; Ottawa Hospital Research Institute; Australian National University; John Curtin School of Medical Research	Gray, DA (corresponding author), Ottawa Reg Canc Ctr, Ctr Canc Therapeut, 503 Smyth Rd, Ottawa, ON K1H 1C4, Canada.		Gilchrist, Catherine/GPW-8606-2022; /U-3554-2018	Gilchrist, Catherine/0000-0002-7467-7933; /0000-0002-8634-4984				BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Boyer SN, 1996, CANCER RES, V56, P4620; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DeSalle LM, 2001, ONCOGENE, V20, P5538, DOI 10.1038/sj.onc.1204824; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GRAY DA, 1995, ONCOGENE, V10, P2179; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GUPTA K, 1994, ONCOGENE, V9, P1729; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	30	25	30	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5533	5537		10.1038/sj.onc.1204823	http://dx.doi.org/10.1038/sj.onc.1204823			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571651				2022-12-28	WOS:000170781100014
J	Roopchand, DE; Lee, JM; Shahinian, S; Paquette, D; Bussey, H; Branton, PE				Roopchand, DE; Lee, JM; Shahinian, S; Paquette, D; Bussey, H; Branton, PE			Toxicity of human adenovirus E4orf4 protein in Saccharomyces cerevisiae results from interactions with the Cdc55 regulatory B subunit of PP2A	ONCOGENE			English	Article						protein phosphatase 2A; CDC55; adenovirus; E4orf4	PHOSPHATASE 2A; P53-INDEPENDENT APOPTOSIS; TUMOR-ANTIGENS; EARLY REGION-4; A-SUBUNIT; ACTIN CYTOSKELETON; TRANSFORMED-CELLS; DNA-REPLICATION; E1A PROTEINS; YEAST	The E4orf4 protein of human adenovirus induces p53-independent apoptosis, a process that may promote cell death and viral spread. When expressed alone, E4orf4 kills transformed cells but not normal human cells. The only clear target of E4orf4 in mammalian cells is the Ba (B55) subunit of protein phosphatase 2A (PP2A), a member of one of three classes of regulatory B subunits. Here we report the effects of E4orf4 in Saccharomyces cerevisiae, which encodes two PP2A regulatory B subunits, CDC55 and RTS1, that share homology with mammalian B and B' subunits, respectively. E4orf4 expression was found to be toxic in yeast, resulting in the accumulation of cells in G2/M phase that failed to grow upon removal of E4orf4. E4orf4-expressing yeast also displayed an elongated cell morphology similar to cdc55 deletion strains. E4orf4 required CDC55 to elicit its effect, whereas RTS1 was dispensable. The recruitment of the PP2A holoenzyme by E4orf4 was entirely dependent on Cdc55. These studies indicate that E4orf4-induced apoptosis in mammalian cells and cell death in yeast require functional interactions with B-type subunits of PP2A. However, some inhibition of growth by E4orf4 was observed in the cdc55 strain and with an E4orf4 mutant that fails to interact with Cdc55, indicating that E4orf4 may possess a second Cdc55-independent function affecting cell growth.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; GeminX Biotechnol Inc, Montreal, PQ H2W 2M9, Canada	McGill University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Promenade Sir William Osle, Montreal, PQ H3G 1Y6, Canada.	branton@med.mcgill.ca						CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DIEN BS, 1994, METHOD CELL BIOL, V42, P457; Evans DRH, 1997, GENETICS, V145, P227; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Lechward K, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1373; LIN FC, 1995, EMBO J, V14, P2745, DOI 10.1002/j.1460-2075.1995.tb07275.x; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; McCright B, 1996, GENOMICS, V36, P168, DOI 10.1006/geno.1996.0438; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MULLER U, 1992, J VIROL, V66, P5867; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; TEODORO JG, 1995, ONCOGENE, V11, P467; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	59	54	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5279	5290		10.1038/sj.onc.1204693	http://dx.doi.org/10.1038/sj.onc.1204693			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536041				2022-12-28	WOS:000170575500004
J	Dennis, JH; Budhram-Mahadeo, V; Latchman, DS				Dennis, JH; Budhram-Mahadeo, V; Latchman, DS			The Brn-3b POU family transcription factor regulates the cellular growth, proliferation, and anchorage dependence of MCF7 human breast cancer cells	ONCOGENE			English	Article						Brn-3; MCF7; stable cell line; breast cancer; transcription factor	MAMMARY-CARCINOMA CELLS; CENTRAL-NERVOUS-SYSTEM; ESTROGEN-RECEPTOR; AUTOREGULATORY ELEMENT; RESPONSE ELEMENT; FACTOR SECRETION; NEURONAL CELLS; RETINOIC ACID; EXPRESSION; ACTIVATION	The Brn-3b POU domain containing transcription factor is expressed in the developing sensory nervous system as well as in epithelial cells of the breast, cervix, and testes. Brn-3b functionally interacts with the estrogen receptor (ER) and in association with the ER, regulates transcription from estrogen responsive genes. In addition, Brn-3b expression is elevated in breast tumours compared to levels in normal mammary cells. To explore the role of Brn-3b in breast cancer, we established stable cell lines derived from the MCF7 human breast cancer cell line which had been transfected with Brn-3b sense or anti-sense constructs. The Brn-3b over-expressing cell Hues exhibited increased growth rate, reached confluence at a higher saturation density, had higher proliferative activity, and an enhanced ability to form colonies in soft agar when compared to the control empty vector transfected cells. Likewise, the Brn-3b anti-sense cell lines showed reduced cellular growth and proliferation, reached confluence at a lower density, and exhibited a decreased ability to form colonies in soft agar when compared to the vector controls. Five to ten per cent of the Brn-3b over-expressing cells exhibited a severely altered morphology characterized by reduced adherence to tissue culture plastic, increased cell size, and a vacuolar cell shape. These results thus further indicate a role for the Brn-3b transcription factor in regulating mammary cell growth and suggest that its elevation in breast cancer is of functional significance.	Inst Child Hlth, London WC1N 1EH, England	University of London; University College London	Latchman, DS (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.							AWGULEWITSCH A, 1992, NATURE, V358, P341, DOI 10.1038/358341a0; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; Elledge RM, 1997, BRIT MED J, V314, P1843, DOI 10.1136/bmj.314.7098.1843; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FUQUA SA, 1992, J NATL CANCER I, V84, P554, DOI 10.1093/jnci/84.8.554; FUQUA SAW, 1992, CANCER RES, V52, P483; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Latchman DS, 1999, J CELL PHYSIOL, V179, P126; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LIPPMAN ME, 1987, J LAB CLIN MED, V109, P230; Liu YZ, 1996, J MOL NEUROSCI, V7, P77, DOI 10.1007/BF02736850; LOU L, 1995, NUCLEIC ACIDS RES, V23, P3481, DOI 10.1093/nar/23.17.3481; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; MURPHY LC, 1983, J CLIN ENDOCR METAB, V57, P373, DOI 10.1210/jcem-57-2-373; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Packer AI, 1998, DEVELOPMENT, V125, P1991; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; REDDEL RR, 1983, CANCER RES, V43, P4618; REDDEL RR, 1983, EUR J CANCER CLIN ON, V19, P1179, DOI 10.1016/0277-5379(83)90047-0; Smith MD, 1996, INT J CANCER, V67, P653; Smith MD, 1997, J BIOL CHEM, V272, P1382, DOI 10.1074/jbc.272.2.1382; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P615, DOI 10.1016/0277-5379(83)90177-3; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; TAYLOR IW, 1983, CANCER RES, V43, P4007; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	34	25	28	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4961	4971		10.1038/sj.onc.1204491	http://dx.doi.org/10.1038/sj.onc.1204491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526481				2022-12-28	WOS:000170439800006
J	Hideshima, T; Chauhan, D; Schlossman, R; Richardson, P; Anderson, KC				Hideshima, T; Chauhan, D; Schlossman, R; Richardson, P; Anderson, KC			The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications	ONCOGENE			English	Article						TNF alpha; multiple myeloma; adhesion molecule; IL-6; NF-kappa B	MARROW STROMAL CELLS; NF-KAPPA-B; ADHESION MOLECULES; INDUCED APOPTOSIS; DRUG-RESISTANCE; GROWTH-FACTOR; INTERLEUKIN-6; THALIDOMIDE; ACTIVATION; EXPRESSION	In this study we demonstrate that tumor necrosis factor alpha (TNF alpha) triggers only modest proliferation, as well as p44/p42 mitogen-activated protein kinase (MAPK) and NF-kappaB activation, in MM.1S multiple myeloma (MM) cells. TNF alpha also activates NF-kappaB and markedly upregulates (fivefold) secretion of interleukin-6 (IL-6), a myeloma growth and survival factor, in bone marrow stromal cells (BMSCs). TNF alpha in both a dose and time dependent fashion induced expression of CD11a (LFA-1), CD54 (intercellular adhesion molecule-1, ICAM-1), CD106 (vascular cell adhesion molecule-1, VCAM-1), CD49d (very late activating antigen-4, VLA-4), and/or MUC-1 on MM cell lines; as well as CD106 (VCAM-1) and CD54 (ICAM-1) expression on BMSCs. This resulted in increased (2-4-fold) per cent specific binding of MM cells to BMSCs, with related IL-6 secretion. Importantly, the proteasome inhibitor PS-341 abrogated TNF alpha -induced NF-kappaB activation, induction of ICAM-1 or VCAM-1, and increased adhesion of MM cells to BMSCs. Agents which act to inhibit TNF alpha may therefore abrogate the paracrine growth and survival advantage conferred by MM cell adhesion in the BM microenvironment.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu			PHS HHS [P01 78378] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BORSET M, 1994, EUR J HAEMATOL, V53, P31; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Corral LG, 1999, J IMMUNOL, V163, P380; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dankbar Berno, 2000, Blood, V95, P2630; Davies FE, 2000, J CLIN ONCOL, V18, P2843, DOI 10.1200/JCO.2000.18.15.2843; DAVIES FE, 2001, IN PRESS BLOOD; Filella X, 1996, CANCER DETECT PREV, V20, P52; GARRETT IR, 1987, NEW ENGL J MED, V317, P526, DOI 10.1056/NEJM198708273170902; GUPTA D, 2001, IN PRESS LEUKEMIA; Haslett PAJ, 1998, J EXP MED, V187, P1885, DOI 10.1084/jem.187.11.1885; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Jourdan M, 1999, EUR CYTOKINE NETW, V10, P65; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; KIM I, 1994, BRIT J HAEMATOL, V87, P483, DOI 10.1111/j.1365-2141.1994.tb08302.x; Li P, 2000, J IMMUNOL, V164, P5990, DOI 10.4049/jimmunol.164.11.5990; LICHTENSTEIN A, 1989, BLOOD, V74, P1266; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Marriott JB, 1998, J IMMUNOL, V161, P4236; Ogata A, 1997, J IMMUNOL, V159, P2212; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; PODAR K, 2001, IN PRESS BLOOD; Raje N, 1999, NEW ENGL J MED, V341, P1606, DOI 10.1056/NEJM199911183412110; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; Sati HIA, 1999, BRIT J HAEMATOL, V104, P350, DOI 10.1046/j.1365-2141.1999.01193.x; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Teoh G, 1997, HEMATOL ONCOL CLIN N, V11, P27, DOI 10.1016/S0889-8588(05)70413-5; TREON SP, 2001, IN PRESS J IMMUNOTHE; UCHIYAMA H, 1992, BLOOD, V80, P2306; UCHIYAMA H, 1993, BLOOD, V82, P3712; Urashima M, 1997, BLOOD, V90, P279; Urashima M, 1996, BLOOD, V87, P1928; Vacca A, 1999, BLOOD, V93, P3064	39	310	341	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4519	4527		10.1038/sj.onc.1204623	http://dx.doi.org/10.1038/sj.onc.1204623			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494147				2022-12-28	WOS:000170074900009
J	Chang, FM; McCubrey, JA				Chang, FM; McCubrey, JA			P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells	ONCOGENE			English	Article						Raf; p21(Cip1); p27(Kip1); cyclins; Cdks; cytokine independence	DEPENDENT KINASE INHIBITOR; ABROGATE CYTOKINE DEPENDENCY; ACTIVATED PROTEIN-KINASE; B-RAF; MAP KINASE; C-MYC; A-RAF; DIFFERENTIAL ABILITIES; INDUCED PROLIFERATION; TARGETED DISRUPTION		E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Member Leo Jenkins Canc Ctr, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA.	mccubreyj@mail.ecu.edu		McCubrey, James/0000-0001-6027-3156	NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA51025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrov I, 1997, FEBS LETT, V414, P465, DOI 10.1016/S0014-5793(97)00992-7; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; BOS JL, 1989, CANCER RES, V49, P4682; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHUANG CF, 1994, FEBS LETT, V346, P229, DOI 10.1016/0014-5793(94)00480-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Frank DA, 1999, MOL MED, V5, P432; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hibi M, 1998, Int Rev Immunol, V17, P75, DOI 10.3109/08830189809084488; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Isaacs JS, 1997, CANCER RES, V57, P2986; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JOHNSON DE, 1998, FRONT BIOSCI, V3, P313; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kim TK, 1997, BIOCHEM BIOPH RES CO, V234, P300, DOI 10.1006/bbrc.1997.6637; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; Kwon EM, 2000, BLOOD, V95, P2552, DOI 10.1182/blood.V95.8.2552.008k30_2552_2558; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee AW, 1999, BLOOD, V93, P537, DOI 10.1182/blood.V93.2.537.402k30_537_553; LEE JE, 1994, GENOMICS, V20, P43, DOI 10.1006/geno.1994.1125; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mangi MH, 1999, CYTOKINES CELL MOL T, V5, P87; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; May W S Jr, 1997, Adv Pharmacol, V41, P219; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Morisset J, 1999, AM J PHYSIOL-GASTR L, V277, pG953, DOI 10.1152/ajpgi.1999.277.5.G953; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Moye PW, 2000, LEUKEMIA, V14, P1060, DOI 10.1038/sj.leu.2401792; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; Nakanishi M, 1999, BIOCHEM BIOPH RES CO, V263, P35, DOI 10.1006/bbrc.1999.1296; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Ogawa M, 1999, ANN NY ACAD SCI, V872, P17, DOI 10.1111/j.1749-6632.1999.tb08449.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Papin C, 1996, ONCOGENE, V12, P2213; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Steelman LS, 1996, LEUKEMIA, V10, P528; STORM SM, 1990, ONCOGENE, V5, P345; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WADEWITZ AG, 1993, ONCOGENE, V8, P1055; Weber CK, 2000, ONCOGENE, V19, P169, DOI 10.1038/sj.onc.1203261; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zou X, 1997, CURR TOP MICROBIOL, V224, P57	99	43	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4354	4364		10.1038/sj.onc.1204564	http://dx.doi.org/10.1038/sj.onc.1204564			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466616				2022-12-28	WOS:000169912600009
J	Hamer, G; Gademan, IS; Kal, HB; de Rooij, DG				Hamer, G; Gademan, IS; Kal, HB; de Rooij, DG			Role for c-Abl and p73 in the radiation response of male germ cells	ONCOGENE			English	Article						c-Abl; p73; p63; cytoplasm; testis; ionizing radiation	TYROSINE KINASE; DNA-DAMAGE; DIFFERENTIATING SPERMATOGONIA; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; X-IRRADIATION; MOUSE TESTIS; P53; EXPRESSION; PROTEIN	p53 plays a central role in the induction of apoptosis of spermatogonia in response to ionizing radiation. In p53(-/) testes, however, spermatogonial apoptosis still can be induced by ionizing radiation, so p53 independent apoptotic pathways must exist in spermatogonia, Here we show that the p53 homologues p63 and p73 are present in the testis and that p73, but not p63, is localized in the cytoplasm of spermatogonia, Unlike p53, neither p63 nor p73 protein levels were found to increase after a dose of 4 Gy of X-rays, Although p73 protein levels did not increase, its interaction with the nonreceptor tyrosine kinase c-Abl and its phosphorylation on tyrosine residues did. c-Abl and p73 co-localize in the cytoplasm of spermatogonia and spermatocytes and in the residual bodies. Furthermore, c-Abl protein levels increase after irradiation. p63 was not found to colocalize or interact with c-Abl neither before nor after irradiation. In conclusion, in the testis ionizing radiation elevates cytoplasmic c-Abl that in turn interacts with p73, This may represent an additional, cytoplasmic, apoptotic pathway. Although less efficient than the p53 route, this pathway may cause spermatogonial apoptosis as observed in p53 deficient mice.	UMCU, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; UMCU, Dept Radiotherapy, NL-3584 CX Utrecht, Netherlands	Unilever; Utrecht University; Utrecht University Medical Center; Unilever; Utrecht University; Utrecht University Medical Center	Hamer, G (corresponding author), UMCU, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		de Rooij, D.G./AAW-1195-2021	de Rooij, Dirk/0000-0003-3932-4419; Hamer, Geert/0000-0002-9583-6796				Agami R, 1999, NATURE, V399, P809; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beumer TL, 1997, MOL REPROD DEV, V47, P240, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;240::AID-MRD2&gt;3.0.CO;2-L; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; Blanco-Rodriguez J, 1999, BIOL REPROD, V61, P1541, DOI 10.1095/biolreprod61.6.1541; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Gobe GC, 1999, INT J RADIAT BIOL, V75, P973, DOI 10.1080/095530099139737; Gong JG, 1999, NATURE, V399, P806; Hasegawa M, 1997, RADIAT RES, V147, P457, DOI 10.2307/3579503; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; Levrero M, 2000, J CELL SCI, V113, P1661; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; OAKBERG EF, 1960, INT J RADIAT BIOL RE, V2, P196, DOI 10.1080/09553006014550211; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sjoblom T, 1996, ONCOGENE, V12, P2499; Soengas MS, 2000, NAT GENET, V26, P391, DOI 10.1038/82497; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; VANDERMEER Y, 1992, RADIAT RES, V130, P296, DOI 10.2307/3578374; VANDERMEER Y, 1992, RADIAT RES, V130, P289, DOI 10.2307/3578373; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zipfel PA, 2000, J IMMUNOL, V165, P6872, DOI 10.4049/jimmunol.165.12.6872	41	49	56	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4298	4304		10.1038/sj.onc.1204568	http://dx.doi.org/10.1038/sj.onc.1204568			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466610				2022-12-28	WOS:000169912600003
J	Nanbru, C; Prats, AC; Droogmans, L; Defrance, P; Huez, G; Kruys, V				Nanbru, C; Prats, AC; Droogmans, L; Defrance, P; Huez, G; Kruys, V			Translation of the human c-myc P0 tricistronic mRNA involves two independent internal ribosome entry sites	ONCOGENE			English	Article						translation; IRES; proto-oncogene	FACTOR MESSENGER-RNA; TRACT-BINDING-PROTEIN; ALTERNATIVE TRANSLATION; GROWTH-FACTOR; POLIOVIRUS RNA; CELL-CYCLE; POLY(RC) BINDING-PROTEIN-2; INITIATION; TRANSCRIPTION; EXPRESSION	The human c-myc proto-oncogene is transcribed from four alternative promoters (P0, P1, P2, and P3) giving rise to mRNAs having 5 ' leader sequences of various length. The c-myc P0 mRNA contains three open reading frames (ORFs), the last one encoding c-Myc1 and c-Myc2 proteins generated by alternative translation initiated at CUG and AUG codons, The middle ORF (MYCHEX1) and the 5 ' ORF (ORF1) code for proteins 188 and 114 amino acids in length, respectively. We and others previously identified an internal ribosome entry site (IRES) in P0 and P2 c-myc mRNAs, promoting the cap-independent translation of c-Myc1 and c-Myc2, Here, we report the presence of a second IRES (named IRES1) promoting the cap-independent translation of MYCHEX1 in c-myc P0 mRNA, Using deletion analysis, we mapped an 80-nt region essential for IRES1 activity. c-myc P0 mRNA is thus the first eukaryotic polycistronic mRNA described for which translation initiation of two different open reading frames (MYCHEX1 and c-Myc1/c-Myc2) involves internal ribosome entry.	Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; CHU Rangueil, Inst Louis Bugnard, INSERM, Endocrinol & Commun Cellulaire U397, F-31403 Toulouse 04, France; Free Univ Brussels, Microbiol Lab, B-1070 Brussels, Belgium	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Libre de Bruxelles; Vrije Universiteit Brussel	Kruys, V (corresponding author), Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.		Kruys, Veronique I/N-6613-2018; Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; Kruys, Veronique/0000-0002-3144-5403				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; AUSUBEL FM, 1995, CURR PROTOC MOLEC BI, V31, P10; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; DEDIEU JF, 1988, ONCOGENE, V3, P523; EICK D, 1990, ONCOGENE, V5, P1397; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; Gueydan C, 1996, MOL MED, V2, P479, DOI 10.1007/BF03401907; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hoover R G, 1995, Curr Top Microbiol Immunol, V194, P257; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kaminski A, 1998, RNA, V4, P626, DOI 10.1017/S1355838298971898; KRUYS V, 1993, J EXP MED, V177, P1383, DOI 10.1084/jem.177.5.1383; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; RAY D, 1989, ONCOGENE RES, V5, P73; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sella O, 1999, MOL CELL BIOL, V19, P5429; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800	49	25	26	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4270	4280		10.1038/sj.onc.1204548	http://dx.doi.org/10.1038/sj.onc.1204548			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464293				2022-12-28	WOS:000169857200017
J	Miyoshi-Akiyama, T; Aleman, LM; Smith, JM; Adler, CE; Mayer, BJ				Miyoshi-Akiyama, T; Aleman, LM; Smith, JM; Adler, CE; Mayer, BJ			Regulation of Cbl phosphorylation by the Abl tyrosine kinase and the Nck SH2/SH3 adaptor	ONCOGENE			English	Article						signal transduction; protein binding modules	GROWTH-FACTOR RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; SRC HOMOLOGY-3 DOMAINS; PROTOONCOGENE C-CBL; SH3 DOMAINS; IN-VIVO; V-ABL; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR	The Cbl proto-oncogene product is tyrosine phosphorylated in response to a wide variety of stimuli. Cbl and the Abl nonreceptor tyrosine kinase both bind to SH3 domains from the SH2/SH3 adaptor Nck, and are candidate effecters for Nck function. Numerous additional SH2- and SH3-domain-mediated interactions are also possible between Cbl, Abl, and Nck, We find that these three signaling proteins associate when overexpressed in mammalian cells and can regulate each other's activity. Go-expression of mt Cbl together with c-Abl, the activity of which is normally repressed in vivo, led to extensive Abl-dependent phosphorylation of Cbl, The major proline-rich region of Cbl was required for ifs phosphorylation by c-Abl, but not by a constitutively activated Abl mutant, suggesting Cbl activates c-Abl by engaging its SH3 domain. Efficient phosphorylation of Cbl and its stable association with Abl required the SH2 domain of Abl, suggesting that SH2-phosphotyrosine interactions prevent dissociation of active Abl from Cbl, We also show that overexpression of Nck could repress the phosphorylation of Cbl by Abl in vivo. Studies with Nck mutants suggested that the Nck SH2 domain is responsible for inhibiting the activity of Abl toward both Cbl and Nck itself, most likely by competing with the Abl SH2 for tyrosine-phosphorylated binding sites.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	University of Connecticut; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.				NCI NIH HHS [CA82258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler CE, 2000, J BIOL CHEM, V275, P36472, DOI 10.1074/jbc.M005424200; Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; BLAKE TJ, 1991, ONCOGENE, V6, P653; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Izadi KD, 1998, EXP CELL RES, V245, P330, DOI 10.1006/excr.1998.4259; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Majidi M, 1998, J BIOL CHEM, V273, P16608, DOI 10.1074/jbc.273.26.16608; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Parrini MC, 1999, CHEM BIOL, V6, P679, DOI 10.1016/S1074-5521(00)80015-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; Raffel GD, 1996, J BIOL CHEM, V271, P4640; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sattler M, 1996, ONCOGENE, V12, P839; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1995, ONCOGENE, V10, P1977; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wunderlich L, 1999, CELL SIGNAL, V11, P253, DOI 10.1016/S0898-6568(98)00054-0; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	73	29	29	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4058	4069		10.1038/sj.onc.1204528	http://dx.doi.org/10.1038/sj.onc.1204528			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494134				2022-12-28	WOS:000169681500014
J	Scheel, C; Schaefer, KL; Jauch, A; Keller, M; Wai, D; Brinkschmidt, C; van Valen, F; Boecker, W; Dockhorn-Dworniczak, B; Poremba, C				Scheel, C; Schaefer, KL; Jauch, A; Keller, M; Wai, D; Brinkschmidt, C; van Valen, F; Boecker, W; Dockhorn-Dworniczak, B; Poremba, C			Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas	ONCOGENE			English	Article						telomere maintenance; osteosarcomas; telomerase activity; alternative lengthening of telomeres; chromosomal instability	TUMOR-CELLS; P53 GENE; CELLULAR SENESCENCE; CATALYTIC SUBUNIT; IMMORTAL CELLS; BREAST-LESIONS; CANCER; EXPRESSION; MAINTENANCE; IDENTIFICATION	Telomere maintenance is regarded as a key mechanism in overcoming cellular senescence in tumor cells and in most cases is achieved by the activation of telomerase, However there is at least one alternative mechanism of telomere lengthening (ALT) which is characterized by heterogeneous and elongated telomeres in the absence of telomerase activity (TA). We evaluated the prevalence of TA, gene expression of telomerase subunits and ALT in relation to telomere morphology and function in matrix producing bone tumors and in osteosarcoma cell lines and present evidence of a direct association of ALT with telomere dysfunction and chromosomal instability. Telomere fluorescence in situ hybridization (T-FISH) in ALT cells revealed elongated and shortened telomeres, partly in unusual configurations and loci, dicentric marker chromosomes and signal-free chromosome ends, Free ends give rise to end-to-end associations and may induce breakage-fusion-bridge cycles resulting in an increased number of complex chromosomal rearrangements, as detected by multiplex-FISH (M-FISH). We propose that ALT cannot be seen as an equivalent to telomerase activity in telomere maintenance, Its association with telomere dysfunction and chromosomal instability may have major implications for tumor progression.	Univ Munster, Gerhard Domagk Inst Pathol, D-48149 Munster, Germany; Univ Munster, Dept Expt Orthoped, D-48149 Munster, Germany; Univ Heidelberg, Dept Human Genet, Heidelberg, Germany	University of Munster; University of Munster; Ruprecht Karls University Heidelberg	Poremba, C (corresponding author), Univ Munster, Gerhard Domagk Inst Pathol, Domagkstr 17, D-48149 Munster, Germany.							Aue G, 1998, ANN SURG ONCOL, V5, P627, DOI 10.1007/BF02303833; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Avilion AA, 1996, CANCER RES, V56, P645; Biessmann H, 1997, CHROMOSOMA, V106, P63, DOI 10.1007/s004120050225; Bouffler SD, 1996, MUTAT RES-REV GENET, V366, P129, DOI 10.1016/S0165-1110(96)90033-0; Brinkschmidt C, 1998, BRIT J CANCER, V77, P2223, DOI 10.1038/bjc.1998.370; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Eils R, 1998, CYTOGENET CELL GENET, V82, P160, DOI 10.1159/000015092; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Ito H, 1998, CLIN CANCER RES, V4, P1603; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Landers JE, 1997, CANCER RES, V57, P3562; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; McClintock B, 1941, GENETICS, V26, P234; Melek M, 1996, BIOESSAYS, V18, P301, DOI 10.1002/bies.950180408; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Poremba C, 1999, J CLIN ONCOL, V17, P2020, DOI 10.1200/JCO.1999.17.7.2020; Poremba C, 1998, INT J ONCOL, V12, P641; Poremba C, 2000, J CLIN ONCOL, V18, P2582, DOI 10.1200/JCO.2000.18.13.2582; Radig K, 1998, HUM PATHOL, V29, P1310, DOI 10.1016/S0046-8177(98)90263-5; Ramakrishnan S, 1998, CANCER RES, V58, P622; ROMANO JW, 1989, ONCOGENE, V4, P1483; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Sumida T, 1999, INT J CANCER, V80, P1, DOI 10.1002/(SICI)1097-0215(19990105)80:1<1::AID-IJC1>3.0.CO;2-U; Takakura M, 1998, CANCER RES, V58, P1558; Takubo K, 1997, J SURG ONCOL, V66, P88, DOI 10.1002/(SICI)1096-9098(199710)66:2<88::AID-JSO3>3.0.CO;2-H; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Wynford-Thomas D, 1999, J PATHOL, V187, P100; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	49	135	137	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3835	3844		10.1038/sj.onc.1204493	http://dx.doi.org/10.1038/sj.onc.1204493			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439347				2022-12-28	WOS:000169494700009
J	Nakamura, T; Kanda, S; Yamamoto, K; Kohno, T; Maeda, K; Matsuyama, T; Kanetake, H				Nakamura, T; Kanda, S; Yamamoto, K; Kohno, T; Maeda, K; Matsuyama, T; Kanetake, H			Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation	ONCOGENE			English	Article						renal carcinoma cells; motility; HGF; HGF receptor; PI3-kinase	FACTOR SCATTER FACTOR; ANCHORAGE-INDEPENDENT GROWTH; SIS-TRANSFORMED-CELLS; CONSTITUTIVE ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; MET PROTOONCOGENE; C-MET; POINT MUTATION; ENDOTHELIAL-CELLS	Dysregulated cell motility is one of the major characteristics of invasion and metastatic potentials of malignant tumor cells. Here, we examined the hepatocyte growth factor (HGF)-induced cell motility of two human renal carcinoma cell lines, ACHN and VMRC-RCW. Scattering and migration was induced in ACHN in an HGF-dependent manner, whereas they were maintained in VMRC-RCW even in the absence of HGF. In VMRC-RCW, HGF receptor (HGFR) tyrosine kinase was constitutively active, and sequence analysis showed N375S, A1209G and V1290L mutations. However, transfection experiments using porcine aortic endothelial (PAE) cells demonstrated that no single mutation or combination of two or three mutations caused HGF-independent constitutive activation. Conversely, the expressed amount of receptor protein had a pivotal role in the basal kinase activity. With respect to downstream signaling molecules of HGFR in ACHN or VMRC-RCW, the Ras-MAPK pathway was downregulated, whereas phosphoinositide 3-kinase (PI3-kinase) was not further activated by HGF-treatment in VMRC-RCW cells. The PI3-kinase inhibitors, wortmannin and LY294002 strongly inhibited spontaneous migration of VMRC-RCW. One transfected PAE cell line with massive overexpression of HGFR demonstrated scattered morphology and increased PI3-kinase activity in association with increased motility, which was partially inhibited by LY294002. Taken together, our results indicate that the overexpression of HGFR causes increase in cellular motility and PI3-kinase shows the important contribution on the increased motility of renal carcinoma cells.	Nagasaki Univ, Sch Med, Dept Urol, Nagasaki 8528501, Japan; Nagasaki Univ, Grad Sch Med, Dept Mol Microbiol & Immunol, Div Cytokine Signaling, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Med, Div Endothelial Cell Biol, Nagasaki 8528501, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Kanda, S (corresponding author), Nagasaki Univ, Grad Sch Med, Dept Mol Microbiol & Immunol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Herrera R, 1998, J CELL SCI, V111, P1039; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; Inoue G, 1996, J BIOL CHEM, V271, P28206, DOI 10.1074/jbc.271.45.28206; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; Kanda S, 2000, J BIOL CHEM, V275, P10105, DOI 10.1074/jbc.275.14.10105; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Lee RCH, 1999, J BIOL CHEM, V274, P10024, DOI 10.1074/jbc.274.15.10024; Levine M D, 1995, EXS, V74, P157; LONGATI P, 1994, ONCOGENE, V9, P49; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakopoulou L, 1997, PATHOL RES PRACT, V193, P299; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; NISHIMURA N, 1992, INT J CANCER, V52, P105, DOI 10.1002/ijc.2910520119; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 1999, CANCER RES, V59, P307; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rusciano D, 1996, J BIOL CHEM, V271, P20763, DOI 10.1074/jbc.271.34.20763; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; TAKAISHI K, 1994, ONCOGENE, V9, P273; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wells A, 2000, ADV CANCER RES, V78, P31; WENNSTROM S, 1994, ONCOGENE, V234, P434; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	76	27	28	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7610	7623		10.1038/sj.onc.1204975	http://dx.doi.org/10.1038/sj.onc.1204975			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753639				2022-12-28	WOS:000172124100004
J	Forus, A; D'Angelo, A; Henriksen, J; Merla, G; Maelandsmo, GM; Florenes, VA; Olivieri, S; Bjerkehagen, B; Meza-Zepeda, LA; Blanco, FD; Muller, C; Sanvito, F; Kononen, J; Nesland, JM; Fodstad, O; Reymond, A; Kallioniemi, OP; Arrigoni, G; Ballabio, A; Myklebost, O; Zollo, M				Forus, A; D'Angelo, A; Henriksen, J; Merla, G; Maelandsmo, GM; Florenes, VA; Olivieri, S; Bjerkehagen, B; Meza-Zepeda, LA; Blanco, FD; Muller, C; Sanvito, F; Kononen, J; Nesland, JM; Fodstad, O; Reymond, A; Kallioniemi, OP; Arrigoni, G; Ballabio, A; Myklebost, O; Zollo, M			Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas - a possible mechanism for altering the nm23-H1 activity	ONCOGENE			English	Article						PRUNE; nm23; sarcoma; breast	COMPARATIVE GENOMIC HYBRIDIZATION; NUCLEOSIDE DIPHOSPHATE KINASE; HUMAN HEPATOCELLULAR-CARCINOMA; CELL-LINES; MOLECULAR CHARACTERIZATION; TISSUE MICROARRAYS; PROTEIN EXPRESSION; TUMOR PROGRESSION; GENE-EXPRESSION; DROSOPHILA	PRUNE, the human homologue of the Drosophila gene, is located in 1q21.3, a region highly amplified in human sarcomas, malignant tumours of mesenchymal origin. Prune protein interacts with the metastasis suppressor nm23-H1, but shows impaired affinity towards the nm23-H1 S120G mutant associated with advanced neuroblastoma. Based on these observations, we previously suggested that prune may act as a negative regulator of nm23-H1 activity. We found amplification of PRUNE in aggressive sarcoma subtypes, such as leiomyosarcomas and malignant fibrous histiocytomas (NIFH) as well as in the less malignant liposarcomas. PRUNE amplification was generally accompanied by high mRNA and moderate to high protein levels. The sarcoma samples expressed nm23-H1 mostly at low or moderate levels, whereas mRNA and protein levels were moderate to high in breast carcinomas. For the more aggressive sarcoma subtypes, 9/13 patients with PRUNE amplification developed metastases. A similar situation was observed in all breast carcinomas with amplification of PRUNE. Infection of NIH3T3 cells with a PRUNE recombinant retrovirus increased cell proliferation. Possibly, amplification and overexpression of PRUNE has the same effect in the tumours. We suggest that amplification and overexpression of PRUNE could be a mechanism for inhibition of nm23-H1 activity that affect the development or progression of these tumours.	Telethon Inst Genet & Med, I-80131 Naples, Italy; Norwegian Radium Hosp, Dept Tumor Biol, Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, Oslo, Norway; HSR Biomed Sci Pk, Dept Pathol, Milan, Italy; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Oslo; University of Oslo; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tampere University; Tampere University; Tampere University Hospital; University of Geneva	Zollo, M (corresponding author), Telethon Inst Genet & Med, Via Pietro Castellino 111, I-80131 Naples, Italy.	zollo@tigem.it	Kutalik, Zoltan/HHZ-5697-2022; Myklebost, Ola/E-9335-2010; merla, giuseppe/K-4627-2012; BALLABIO, Andrea/AAL-2672-2020; Kallioniemi, Olli P/H-5111-2011; Meza-Zepeda, Leonardo Andres/CAG-5229-2022	Kutalik, Zoltan/0000-0001-8285-7523; Myklebost, Ola/0000-0002-2866-3223; merla, giuseppe/0000-0001-5078-928X; BALLABIO, Andrea/0000-0003-1381-4604; Kallioniemi, Olli P/0000-0002-3231-0332; Meza-Zepeda, Leonardo Andres/0000-0003-3056-212X; Reymond, Alexandre/0000-0003-1030-8327; Kononen, Juha/0000-0002-0157-2137	Telethon [TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; Berner JM, 1997, ONCOGENE, V14, P2935, DOI 10.1038/sj.onc.1201135; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Caligo MA, 1997, INT J CANCER, V74, P102, DOI 10.1002/(SICI)1097-0215(19970220)74:1<102::AID-IJC18>3.0.CO;2-H; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; Cipollini G, 1997, INT J CANCER, V73, P297, DOI 10.1002/(SICI)1097-0215(19971009)73:2<297::AID-IJC22>3.0.CO;2-B; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3rd; FLORENES VA, 1992, CANCER RES, V52, P6088; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Forus A, 1998, BRIT J CANCER, V78, P495, DOI 10.1038/bjc.1998.521; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Forus A, 2001, CANCER GENET CYTOGEN, V125, P100, DOI 10.1016/S0165-4608(00)00369-1; Gronwald J, 1997, CANCER RES, V57, P481; Hartsough MT, 2001, CANCER RES, V61, P2320; HE J, 1995, CANCER RES, V55, P4833; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kudoh K, 1999, CLIN CANCER RES, V5, P2526; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P855; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; MARTINEZ JA, 1995, GUT, V37, P712, DOI 10.1136/gut.37.5.712; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller W, 1998, CANCER-AM CANCER SOC, V83, P2481, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2481::AID-CNCR11>3.0.CO;2-P; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREVI N, 1975, MUTAT RES, V33, P193, DOI 10.1016/0027-5107(75)90195-5; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; Pilotti S, 1998, J PATHOL, V185, P188; Qin LX, 1999, CANCER RES, V59, P5662; Reymond A, 1999, ONCOGENE, V18, P7244, DOI 10.1038/sj.onc.1203140; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; Royds JA, 1997, BRIT J CANCER, V75, P1195, DOI 10.1038/bjc.1997.204; Roymans D, 2001, EXP CELL RES, V262, P145, DOI 10.1006/excr.2000.5087; Russell RL, 1998, BRIT J CANCER, V78, P710, DOI 10.1038/bjc.1998.566; SANTORO M, 1994, ONCOGENE, V9, P509; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Srivatsa PJ, 1996, GYNECOL ONCOL, V60, P363, DOI 10.1006/gyno.1996.0056; Subramanian C, 2001, NAT MED, V7, P350, DOI 10.1038/85499; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; Tapper J, 1998, CANCER RES, V58, P2715; Tarkkanen M, 1999, INT J CANCER, V84, P114, DOI 10.1002/(SICI)1097-0215(19990420)84:2<114::AID-IJC4>3.0.CO;2-Q; Timmons L, 1996, GENETICS, V144, P1589; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Tseng YH, 2001, CANCER RES, V61, P2071; Volorio S, 1998, DNA SEQUENCE, V9, P307, DOI 10.3109/10425179809008469; Weiss SW, 1994, WHO HISTOLOGICAL CLA, V2nd; WHITE CJ, 1899, J CUTAN GENITOURIN, V17, P1; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Zimonjic DB, 1999, HEPATOLOGY, V29, P1208, DOI 10.1002/hep.510290410	61	48	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6881	6890		10.1038/sj.onc.1204874	http://dx.doi.org/10.1038/sj.onc.1204874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687967				2022-12-28	WOS:000171641000009
J	Mazurek, S; Zwerschke, W; Jansen-Durr, P; Eigenbrodt, E				Mazurek, S; Zwerschke, W; Jansen-Durr, P; Eigenbrodt, E			Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7	ONCOGENE			English	Article						metabolome; glycolysis; glutaminolysis; M2-PK; adenylate kinase; nucleotides	HUMAN-PAPILLOMAVIRUS TYPE-16; ROUS-SARCOMA VIRUS; PYRUVATE-KINASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; MALIGNANT TRANSFORMATION; MELANOMA-CELLS; C-MYC; PROLIFERATION; CYCLE	The metabolism of tumor cells (tumor metabolome) is characterized by a high concentration of glycolytic enzymes including pyruvate kinase isoenzyme type M2 (M2-PK), a high glutaminolytic capacity, high fructose 1,6-bisphosphate (FBP) levels and a low (ATP + GTP):(CTP+UTP) ratio. The sequence of events required for the establishment of the tumor metabolome is presently unknown. In non-transformed rat kidney (NRK) cells we observed a high glutaminolytic flux rate and a low (ATP + GTP):(CTP + UTP) ratio, whereas FBP levels and M2-PK activity are still extremely low. After stable expression of oncogenic ras in NRK cells a strong upregulation of FBP levels and of M2-PK activity was observed. Elevated FBP levels induce a tetramerization of M2-PK and its migration into the glycolytic enzyme complex. AMP levels increase whereas UTP and CTP levels strongly decrease. Thus, ras expression completes the glycolytic part of tumor metabolism leading to the inhibition of nucleic acid synthesis and cell proliferation. The HPV-16 E7 oncoprotein, which cooperates with ras in cell transformation, directly binds to M2-PK, induces its dimerization and restores nucleic acid synthesis as well as cell proliferation. Apparently, the combination of the different metabolic effects of ras and E7 constructs the perfect tumor metabolome as generally found in tumor cells.	Univ Giessen, Fac Vet, Inst Biochem & Endocrinol, D-35392 Giessen, Germany; Austrian Acad Sci, Inst Biomed Ageing Res, A-6020 Innsbruck, Austria; Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria	Justus Liebig University Giessen; Austrian Academy of Sciences; University of Innsbruck	Mazurek, S (corresponding author), Univ Giessen, Fac Vet, Inst Biochem & Endocrinol, Frankfurter Str 100, D-35392 Giessen, Germany.		Jansen-Dürr, Pidder/ABG-2466-2020; Mazurek, Sybille/ABH-2089-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953				AON MA, 1995, EXP CELL RES, V217, P42, DOI 10.1006/excr.1995.1061; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; Boros LG, 1997, CANCER RES, V57, P4242; Boros LG, 2000, CANCER RES, V60, P1183; Brazill DT, 1997, J BACTERIOL, V179, P4415, DOI 10.1128/jb.179.13.4415-4418.1997; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cascante M, 2000, NUTR CANCER, V36, P150, DOI 10.1207/S15327914NC3602_2; Chopade BA, 1997, J BACTERIOL, V179, P2181, DOI 10.1128/jb.179.7.2181-2188.1997; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Downes CS, 2000, J CELL SCI, V113, P1089; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; Eigenbrodt E., 1992, Critical Reviews in Oncogenesis, V3, P91; Eigenbrodt E, 1998, ANTICANCER RES, V18, P3267; EIGENBRODT E, 1998, CELL GROWTH ONCOGENE, P15; EIGENBRODT E, 1985, REGULATION CARBOHYDR, P141; Glass-Marmor L, 1999, EUR J PHARMACOL, V370, P195, DOI 10.1016/S0014-2999(99)00155-7; GLOSSMANN H, 1981, MOL CELL ENDOCRINOL, V23, P49, DOI 10.1016/0303-7207(81)90116-7; GREGORY SH, 1976, ARCH BIOCHEM BIOPHYS, V175, P644, DOI 10.1016/0003-9861(76)90555-5; HENDERSON JF, 1981, PHARMACOL THERAPEUT, V8, P539; HUNTING D, 1981, CAN J BIOCHEM CELL B, V59, P821, DOI 10.1139/o81-114; Inouye S, 1999, BIOCHEM BIOPH RES CO, V254, P618, DOI 10.1006/bbrc.1998.0116; JACKSON RC, 1980, CANCER RES, V40, P1286; Kim CY, 1997, CANCER RES, V57, P4200; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; KOLE HK, 1991, ARCH BIOCHEM BIOPHYS, V286, P586, DOI 10.1016/0003-9861(91)90084-V; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Mazurek S, 1996, J CELL PHYSIOL, V167, P238, DOI 10.1002/(SICI)1097-4652(199605)167:2<238::AID-JCP7>3.0.CO;2-Q; Mazurek S, 1997, J BIOENERG BIOMEMBR, V29, P315, DOI 10.1023/A:1022490512705; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; Mazurek S, 1998, ANTICANCER RES, V18, P3275; Mazurek S, 1997, J BIOL CHEM, V272, P4941, DOI 10.1074/jbc.272.8.4941; Mazurek S, 1999, J CELL PHYSIOL, V181, P136; MAZUREK S, 2001, IN PRESS BR J NUTR; MOYER JD, 1982, CANCER RES, V42, P4525; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Noma T, 1999, BIOCHEM BIOPH RES CO, V264, P990, DOI 10.1006/bbrc.1999.1616; Penso J, 1998, EUR J PHARMACOL, V342, P113, DOI 10.1016/S0014-2999(97)01507-0; PRESEK P, 1988, FEBS LETT, V242, P194, DOI 10.1016/0014-5793(88)81014-7; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; RYLL T, 1992, BIOTECHNOL BIOENG, V40, P934, DOI 10.1002/bit.260400810; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Thomas S, 1998, EUR J BIOCHEM, V258, P956, DOI 10.1046/j.1432-1327.1998.2580956.x; WEBER G, 1971, CANCER RES, V31, P2177; Zwerschke W, 2000, ADV CANCER RES, V78, P1; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	51	91	99	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6891	6898		10.1038/sj.onc.1204792	http://dx.doi.org/10.1038/sj.onc.1204792			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687968				2022-12-28	WOS:000171641000010
J	Lambert, S; Lopez, BS				Lambert, S; Lopez, BS			Role of RAD51 in sister-chromatid exchanges in mammalian cells	ONCOGENE			English	Article						homologous recombination; SCE; RAD51; mammalian cells; alkylating agent	DOUBLE-STRAND BREAK; HOMOLOGY-DIRECTED REPAIR; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; VERTEBRATE CELLS; GENE CONVERSION; DNA; RECOMBINATION; DISRUPTION; PROMOTES	To measure the impact of the RAD51 pathway on Sister-Chromatid Exchanges (SCE), we used hamster cells expressing either the wild-type MmRAD51, which stimulates, or the dominant negative SMRAD51, which inhibits, gene conversion without affecting cell viability of untreated as well as T-rays irradiated cells. We show that MmRAD51 did not affect the rate of spontaneous SCE while it strongly stimulated spontaneous recombination between tandem repeats. No spontaneous recombinant was detected when expressing SMRAD51 while spontaneous SCE were only slightly diminished. After treatment by an alkylating agent (MNU), MmRAD51 stimulated MNU-induced recombination whereas no recombinant was detected when expressing SMRAD51. MNU induced SCE in all cell lines, even in the SMRAD51 expressing lines, but the induction of SCE was slightly more efficient in lines expressing MmRAD51 and less efficient in lines expressing SMRAD51. Thus, in mammalian cells, the RAD51-dependent gene conversion pathway drastically affects recombination between intrachromosomal tandem repeats, whereas it only partially participates in SCE formation, measured at a chromosomal level. These results show that RAD51-gene conversion can participate in induced SCE but that alternative pathways should exist.	CEA, UMR 217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, UMR 217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, 60-68 Ave Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017; lambert, sarah/K-7750-2017	Lopez, Bernard S/0000-0001-5088-0155; lambert, sarah/0000-0002-1403-3204				BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CONNELL JR, 1982, CARCINOGENESIS, V3, P385, DOI 10.1093/carcin/3.4.385; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; KADYK LC, 1992, GENETICS, V132, P387; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Zhang H, 1996, CARCINOGENESIS, V17, P2229, DOI 10.1093/carcin/17.10.2229	19	42	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6627	6631		10.1038/sj.onc.1204813	http://dx.doi.org/10.1038/sj.onc.1204813			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641788				2022-12-28	WOS:000171404200016
J	De Rienzo, A; Balsara, BR; Apostolou, S; Jhanwar, SC; Testa, JR				De Rienzo, A; Balsara, BR; Apostolou, S; Jhanwar, SC; Testa, JR			Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma	ONCOGENE			English	Article						malignant mesothelioma; LOH; chromosome arm 15q; tumor suppressor gene	TUMOR-SUPPRESSOR GENE; COMPARATIVE GENOMIC HYBRIDIZATION; ALLELIC LOSS; DELETIONS; CANCER; CARCINOMAS; MUTATIONS; NF2; 14Q; 6Q	Previous comparative genomic hybridization and allelic loss analyses demonstrated frequent deletions from 15q11.1-15 in malignant mesothelioma. Recurrent losses of 15q11-22 have also been reported in several other tumor types such as breast and colorectal cancers. To more precisely map the commonly deleted region, we have performed a high density loss of heterozygosity analysis of 46 malignant mesotheliomas, using 26 polymorphic microsatellite markers spanning the entire long arm of chromsome 15. Allelic loss from 15q was observed in 22 of 46 (48%) cases. These analyses have defined a minimally deleted region of similar to3-cM, which was confirmed to reside at 15q15 by fluorescence in situ hybridization analysis with yeast artificial chromosome probes. No tumor suppressor genes have been reported to map to this site. The minimally deleted region identified in this investigation overlaps those observed in other kinds of cancer, and is the smallest site of recurrent 15q loss identified to date in human tumors. The identification of this commonly deleted site implicates a putative tumor suppressor gene(s) at 15q15 involved in diverse forms of human neoplasia.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA-45745, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 1996, CYTOGENET CELL GENET, V74, P248, DOI 10.1159/000134426; ANTMAN KH, 1981, SEMIN ONCOL, V8, P313; ANTMAN KH, 1989, MESOTHELIOMA; Attanoos RL, 1997, HISTOPATHOLOGY, V30, P403, DOI 10.1046/j.1365-2559.1997.5460776.x; Balsara BR, 1999, CANCER RES, V59, P450; Bell DW, 1997, CANCER RES, V57, P4057; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bisconti M, 2000, RESPIRATION, V67, P223, DOI 10.1159/000029493; Bjorkqvist AM, 1997, BRIT J CANCER, V75, P523, DOI 10.1038/bjc.1997.91; Bjorkqvist AM, 1999, BRIT J CANCER, V81, P1111, DOI 10.1038/sj.bjc.6690816; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Carbone M, 1999, J CELL PHYSIOL, V180, P167, DOI 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; CHENG JQ, 1994, CANCER RES, V54, P5547; Collins A, 1996, GENOMICS, V36, P157, DOI 10.1006/geno.1996.0436; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; De Rienzo A, 2000, GENE CHROMOSOME CANC, V28, P337, DOI 10.1002/1098-2264(200007)28:3<337::AID-GCC12>3.0.CO;2-B; DODSON MK, 1993, CANCER RES, V53, P4456; Kersemaekers AMF, 1998, INT J CANCER, V79, P411, DOI 10.1002/(SICI)1097-0215(19980821)79:4<411::AID-IJC17>3.0.CO;2-7; KNUDSON AG, 1989, CANCER, V63, P1888, DOI 10.1002/1097-0142(19890515)63:10<1888::AID-CNCR2820631004>3.0.CO;2-L; LYNCH HT, 1985, CANCER GENET CYTOGEN, V15, P25, DOI 10.1016/0165-4608(85)90128-1; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Pache JC, 1998, AM J PATHOL, V152, P333; Park WS, 2000, CANCER RES, V60, P70; POPESCU NC, 1988, CANCER RES, V48, P142; Schmutte C, 1999, CANCER RES, V59, P4564; SEEMAYER TA, 1989, LAB INVEST, V60, P585; SEKIDO Y, 1995, CANCER RES, V55, P1227; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Stanton SE, 2000, GENE CHROMOSOME CANC, V27, P323, DOI 10.1002/(SICI)1098-2264(200003)27:3<323::AID-GCC14>3.0.CO;2-P; TAGUCHI T, 1993, CANCER RES, V53, P4349; Tahara H, 1996, CANCER RES, V56, P599; Testa JR, 1998, CANCER RES, V58, P4505; Tomlinson I, 1999, GASTROENTEROLOGY, V116, P789, DOI 10.1016/S0016-5085(99)70061-2; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; Wick W, 1996, ONCOGENE, V12, P973	37	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6245	6249		10.1038/sj.onc.1204828	http://dx.doi.org/10.1038/sj.onc.1204828			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593434				2022-12-28	WOS:000171206300017
J	Kihara-Negishi, F; Yamamoto, H; Suzuki, M; Yamada, T; Sakurai, T; Tamura, T; Oikawa, T				Kihara-Negishi, F; Yamamoto, H; Suzuki, M; Yamada, T; Sakurai, T; Tamura, T; Oikawa, T			In vivo complex formation of PU.1 with HDAC1 associated with PU.1-mediated transcriptional repression	ONCOGENE			English	Article						PU.1; HDAC1; transcriptional repression	HISTONE DEACETYLASES; ACTIVATION DOMAIN; ETS FAMILY; BINDING PROTEIN; THYROID-HORMONE; EXPRESSION; RECEPTOR; P300; P53; DIFFERENTIATION	We previously reported that overexpression of PU.1, a member of the Ets family of transcription factors, induces differentiation inhibition and apoptosis associated with c-Myc down-regulation in murine erythroleukemia (MEL) cells. To understand the molecular mechanism by which c-Myc is down-regulated due to overexpression of PU.1, we performed luciferase reporter assays using the mouse c-myc promoter. PU.1 repressed the activities of not only the c-myc promoter but also several other promoters. Experiments with deletion mutants of PU.1 revealed that the C-terminal region spanning amino acids (aa) 123-272 including the PEST and ETS domains but not the activation domain was sufficient for this transcriptional repression. It was unlikely that the repression was due to sequestration of a limited amount of CBP/p300 nor pCAF, because overexpression of these co-activators did not relieve PU.1-mediated transcriptional repression. Instead, it was found that the C-terminal aa 101-272 of PU.1 formed a complex with mSin3A and HDAC1 in vivo, which was speculated to be associated with the repression. The C-terminal region of PU.1 also formed a complex with the basic transcription factor TBP in vitro and in vivo. Our results suggest that overexpression of PU.1 induces transcriptional repression in several gene promoters including the c-myc promoter which may be mediated by its complex formation with HDACs.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan; Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan	Chiba University	Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	oikawa@sasaki.or.jp						Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kihara-Negishi F, 1998, INT J CANCER, V76, P523, DOI 10.1002/(SICI)1097-0215(19980518)76:4<523::AID-IJC14>3.0.CO;2-8; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROSS IL, 1994, ONCOGENE, V9, P121; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	48	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6039	6047		10.1038/sj.onc.1204756	http://dx.doi.org/10.1038/sj.onc.1204756			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593411				2022-12-28	WOS:000171056300011
J	DeSalle, LM; Latres, E; Lin, D; Graner, E; Montagnoli, A; Baker, RT; Pagano, M; Loda, M				DeSalle, LM; Latres, E; Lin, D; Graner, E; Montagnoli, A; Baker, RT; Pagano, M; Loda, M			The de-ubiquitinating enzyme Unp interacts with the retinoblastoma protein	ONCOGENE			English	Article						Unp; retinoblastoma; isopeptidase; ubiquitin	FAT FACETS GENE; DEUBIQUITINATING ENZYME; MOUSE GENE; DEGRADATION; EXPRESSION; ENCODES; PROTOONCOGENE; ISOPEPTIDASE; PROTEASOME; SEQUENCES	The ubiquitin pathway is involved in the proteolytic turnover of many short-lived cellular regulatory proteins. Since selective degradation of substrates of this system requires the covalent attachment of a polyubiquitin chain to the substrates, degradation could be counteracted by de-ubiquitinating enzymes (or isopeptidases) which selectively remove the polyubiquitin chain. Unp is a human isopeptidase with still poorly understood biological functions. Here, we show that cellular Unp specifically interacts with the retinoblastoma gene product (pRb).	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Caplan Comprehens Canc Ctr, New York, NY 10016 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Harvard University; Dana-Farber Cancer Institute; New York University; New York University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Australian National University; John Curtin School of Medical Research	Pagano, M (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.		Graner, Edgard/K-4411-2012; Graner, Edgard/P-4651-2019	Graner, Edgard/0000-0002-4737-7935; pagano, michele/0000-0003-3210-2442; Lin, Douglas/0000-0003-0105-9760	NATIONAL CANCER INSTITUTE [R01CA076584, R01CA081755, P30CA016087, R21CA066229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1-CA81755, R21-CA66229, P30-CA16087, R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Gilchrist CA, 1997, J BIOL CHEM, V272, P32280, DOI 10.1074/jbc.272.51.32280; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Isaksson A, 1997, MECH DEVELOP, V68, P59, DOI 10.1016/S0925-4773(97)00126-3; KANAIAZUMA M, 2000, MECH DEVELOP, V68, P59; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; PAGANO M, 1992, EMBO J, V11, P761; PAGANO M, 1995, CELL CYCLE MAT METHO, P271; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wood SA, 1997, MECH DEVELOP, V63, P29, DOI 10.1016/S0925-4773(97)00672-2; Wu ZR, 1999, DEV GENET, V25, P312, DOI 10.1002/(SICI)1520-6408(1999)25:4<312::AID-DVG5>3.0.CO;2-Z	29	29	34	1	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5538	5542		10.1038/sj.onc.1204824	http://dx.doi.org/10.1038/sj.onc.1204824			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571652				2022-12-28	WOS:000170781100015
J	Lu, AP; Gupta, A; Li, C; Ahlborn, TE; Ma, YS; Shi, EY; Liu, JW				Lu, AP; Gupta, A; Li, C; Ahlborn, TE; Ma, YS; Shi, EY; Liu, JW			Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences	ONCOGENE			English	Article						breast cancer specific gene 1; DNA demethylation; transcriptional repression	ONCOSTATIN-M; SYNUCLEIN-GAMMA; IDENTIFICATION; DISEASE; POLYMORPHISM; PROMOTER; RECEPTOR; CLONING; GROWTH	Breast cancer specific gene I (BCSG1), also referred as synuclein gamma, is the third member of a neuronal protein family synuclein. BCSG1 is not expressed in normal breast tissues but highly expressed in advanced infiltrating breast carcinomas. When over expressed, BCSG1 significantly stimulates breast cancer metastasis. To elucidate the molecular mechanisms underlying the abnormal transcription of BCSG1 in breast cancer cells, in this study, we isolated a 2195 base pair fragment of human BCSG1 gene. This fragment includes I kb 5'-flanking region, exon 1, and intron 1. By analysing the promoter activity and the methylation status of the exon I region, we show that (1) Intron I plays critical roles in the control of BCSG1 gene transcription through cis-regulatory sequences that affect BCSG1 transcription in cell type-specific and cell type-nonspecific manners. (2) The activator protein-1 (AP-1) is functionally involved in BCSG1 transcription in breast cancer cells through its binding to an AP-I motif located in the intron 1. (3) The exon I region of BCSG1 gene contains a CpG island that is unmethylated in BCSG1-positive SKBR-3 and T47D cells but densely methylated in BCSG1-negative MCF-7 cells. (4) Treating MCF-7 cells with a demethylating agent 5-Aza-2'-deoxycytidine specifically activated BCSG1 transcription. Thus, our results suggest that while the cellular content of transcription activators and repressors that interact with the cis-regulatory sequences present in the intron I contribute prominently to the tissue-specific expression of BCSG1, demethylation of exon 1 is an important factor responsible for the aberrant expression of BCSG1 in breast carcinomas.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; VA Med Ctr, Idaho Falls, ID 83702 USA; Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Northwell Health	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.				NCI NIH HHS [1RO1CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Esteller M, 2000, CANCER RES, V60, P4366; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Griswold MD, 2001, BIOL REPROD, V64, P602, DOI 10.1095/biolreprod64.2.602; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Liu JW, 1997, J LIPID RES, V38, P2035; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; Ma YS, 1999, NUCLEIC ACIDS RES, V27, P4649, DOI 10.1093/nar/27.23.4649; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; SHARRARD R, 1992, ONCOGENE, V1, P670; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Xia Y, 1996, ANN NEUROL, V40, P207, DOI 10.1002/ana.410400212	20	55	62	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5173	5185		10.1038/sj.onc.1204668	http://dx.doi.org/10.1038/sj.onc.1204668			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526506				2022-12-28	WOS:000170464000011
J	Gayet, J; Zhou, XP; Duval, A; Rolland, S; Hoang, JM; Cottu, P; Hamelin, R				Gayet, J; Zhou, XP; Duval, A; Rolland, S; Hoang, JM; Cottu, P; Hamelin, R			Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines	ONCOGENE			English	Article						colorectal cancer; cell lines; genetic alterations	MICROSATELLITE MUTATOR PHENOTYPE; GRADIENT GEL-ELECTROPHORESIS; NONPOLYPOSIS COLON-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; BETA-CATENIN GENE; II RECEPTOR GENE; FRAMESHIFT MUTATIONS; SOMATIC MUTATIONS; K-RAS; INSTABILITY	A number of genetic alterations have been described in colorectal cancers. They include allelic losses on specific chromosomal arms, mutations of oncogenes, tumor suppressor genes and mismatch repair genes, microsatellite instability in coding repeat sequences of target genes and methylation defects in gene promoters. Since these alterations have been reported by different groups on different tumors and cell lines, the complete repertoire of genetic alterations for any given tumor sample remains unknown. In the present study, we analysed a series of 22 colorectal cancer cell lines for 31 different genetic alterations. We found significant correlations between mutational profiles in these colorectal cell lines associated with differences in mismatch repair status. This panel of colon cancer cell lines is representative of the genetic heterogeneity occurring in sporadic colorectal carcinoma. Our results may prove to be very useful for understanding the different biological pathways involved in the development of colon cancer, and for groups studying cellular biology and pharmacology on the same cell lines.	INSERM, U434, CEPH, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Hamelin, R (corresponding author), INSERM, U434, CEPH, 27 Rue Juliette Dodu, F-75010 Paris, France.		Cottu, Paul/ABC-8595-2020					AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; Boland CR, 1998, CANCER RES, V58, P5248; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Casares S, 1995, ONCOGENE, V11, P2303; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; Cottu PH, 1996, ONCOGENE, V13, P2727; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Deng GR, 1999, CANCER RES, V59, P2029; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Duval A, 2000, CANCER RES, V60, P3872; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMELIN R, 1993, ONCOGENE, V8, P2213; HEINEN CD, 1995, CANCER RES, V55, P4797; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoang JM, 1997, CANCER RES, V57, P300; Ilyas M, 1999, EUR J CANCER, V35, P335, DOI 10.1016/S0959-8049(98)00431-6; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Iwao K, 1998, CANCER RES, V58, P1021; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kane MF, 1997, CANCER RES, V57, P808; Kitaeva MN, 1997, CANCER RES, V57, P4478; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lerebours F, 1999, GENE CHROMOSOME CANC, V25, P147, DOI 10.1002/(SICI)1098-2264(199906)25:2<147::AID-GCC10>3.0.CO;2-Z; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LI YJ, 1995, ONCOGENE, V11, P597; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LUCE MC, 1995, GASTROENTEROLOGY, V109, P1368, DOI 10.1016/0016-5085(95)90600-2; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muzeau F, 1997, BRIT J CANCER, V75, P1336, DOI 10.1038/bjc.1997.226; Myohanen SK, 1998, CANCER RES, V58, P591; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; PEINADO MA, 1993, INT J ONCOL, V2, P123; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RIDANPAA M, 1993, HUM MOL GENET, V2, P639, DOI 10.1093/hmg/2.6.639; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; Schwartz S, 1999, CANCER RES, V59, P2995; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sparks AB, 1998, CANCER RES, V58, P1130; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	63	155	159	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5025	5032		10.1038/sj.onc.1204611	http://dx.doi.org/10.1038/sj.onc.1204611			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526487				2022-12-28	WOS:000170439800012
J	Purrello, M; Di Pietro, C; Rapisarda, A; Amico, V; Giunta, V; Engel, H; Stevens, S; Hsieh, YJ; Teichman, M; Wang, ZX; Sichel, G; Roeder, R; Grzeschik, KH				Purrello, M; Di Pietro, C; Rapisarda, A; Amico, V; Giunta, V; Engel, H; Stevens, S; Hsieh, YJ; Teichman, M; Wang, ZX; Sichel, G; Roeder, R; Grzeschik, KH			Genes for human general transcription initiation factors TFIIIB, TFIIIB-associated proteins, TFIIIC2 and PTF/SNAPC: functional and positional candidates for tumour predisposition or inherited genetic diseases?	ONCOGENE			English	Article						Cancer Genome Anatomy Project; oncogenesis; human general transcription factors; regulation of gene expression; cell proliferation, differentiation and apoptosis	RNA-POLYMERASE-III; TATA-BINDING PROTEIN; OVARIAN-TUMORS; CLONING; SUBUNIT; ACTIVATION; COMPLEX; SIMIAN-VIRUS-40; INVOLVEMENT; INTERACTS	TFIIIB, TFIIIC2, and PTF/SNAPC are heteromultimeric general transcription factors (GTFs) needed for expression of genes encoding small cytoplasmic (scRNAs) and small nuclear RNAs (snRNAs). Their activity is stimulated by viral oncogenes, such as SV40 large T antigen and Adenovirus EIA, and is repressed by specific transcription factors (STFs) acting as antioncogenes, such as p53 and pRb. GTFs role as final targets of critical signal transduction pathways, that control cell proliferation and differentiation, and their involvement in gene expression regulation suggest that the genes encoding them are potential proto-oncogenes or anti-oncogenes or may be otherwise involved in the pathogenesis of inherited genetic diseases. To test our hypothesis through the positional candidate gene approach, we have determined the physical localization in the human genome of the 11 genes, encoding the subunits of these GTFs, and of three genes for proteins associated with TFIIIB (GTF3BAPs). Our data, obtained by chromosomal in situ hybridization, radiation hybrids and somatic cell hybrids analysis, demonstrate that these genes are present in the human genome as single copy sequences and that some cluster to the same cytogenetic band, alone or in combination with class II GTFs. Intriguingly, some of them are localized within chromosomal regions where recurrent, cytogenetically detectable mutations are seen in specific neoplasias, such as neuroblastoma, uterine leyomioma, mucoepidermoid carcinoma of the salivary glands and hemangiopericytoma, or where mutations causing inherited genetic diseases map, such as Peutz-Jeghers syndrome. Their molecular function and genomic position make these GTF genes interesting candidates for causal involvement in oncogenesis or in the pathogenesis of inherited genetic diseases.	Univ Catania, Dipartimento Sci Biomed, Sez Biol Gen Cellulare & Genet Mol, I-95124 Catania, Italy; Univ Marburg, Zentrum Humangenet, D-35037 Marburg, Germany; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	University of Catania; Philipps University Marburg; Rockefeller University	Purrello, M (corresponding author), Univ Catania, Dipartimento Sci Biomed, Sez Biol Gen Cellulare & Genet Mol, I-95124 Catania, Italy.		Teichmann, Martin/M-7407-2014	Teichmann, Martin/0000-0002-5257-0510; DI PIETRO, Cinzia Santa/0000-0002-6036-4469				Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; Bai L, 1996, MOL CELL BIOL, V16, P5419; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; Damania B, 1998, MOL CELL BIOL, V18, P1331, DOI 10.1128/MCB.18.3.1331; Hemminki A, 1999, CELL MOL LIFE SCI, V55, P735, DOI 10.1007/s000180050329; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Kumar A, 1998, COLD SPRING HARB SYM, V63, P121, DOI 10.1101/sqb.1998.63.121; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; McCulloch V, 2000, EMBO J, V19, P4134, DOI 10.1093/emboj/19.15.4134; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pedeutour F, 2000, GENE CHROMOSOME CANC, V27, P209, DOI 10.1002/(SICI)1098-2264(200002)27:2<209::AID-GCC14>3.0.CO;2-U; Purrello M, 1998, ONCOGENE, V16, P1633, DOI 10.1038/sj.onc.1201673; PURRELLO M, 1995, CYTOGENET CELL GENET, V69, P75, DOI 10.1159/000133942; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; White RJ, 1998, INT J ONCOL, V12, P741; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Yoon JB, 1996, MOL CELL BIOL, V16, P1	25	6	6	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4877	4883		10.1038/sj.onc.1204604	http://dx.doi.org/10.1038/sj.onc.1204604			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521199				2022-12-28	WOS:000170271800012
J	Wang, J; Sampath, A; Raychaudhuri, P; Bagchi, S				Wang, J; Sampath, A; Raychaudhuri, P; Bagchi, S			Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells	ONCOGENE			English	Article						ubiquitination; proteasome; E7; human papilloma virus (HPV); retinoblastoma protein (Rb); E2F	HUMAN-PAPILLOMAVIRUS TYPE-16; E2F TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; E6 ONCOPROTEIN; CYCLE; DEGRADATION; LIGASE; PHOSPHORYLATION; ASSOCIATION; CARCINOMA	High-risk human papillomaviruses (HPVs) are etiologically linked to human cervical and oral cancers. The E6 and E7 oncoproteins encoded by HPV target host cell tumor suppressor proteins. E6 induces proteolysis of p53 through the ubiquitin-proteasome pathway. Recent studies showed that overexpression of E7 caused proteolytic degradation of the tumor suppressor Rb. However, unlike p53, Rb is not regulated by proteolysis in normal cells. In addition, it was unclear whether in its natural context E7 regulates Rb through the ubiquitin-proteasome pathway. Therefore, we sought to determine whether Rb is regulated by the ubiquitin-proteasome pathway in HPV-containing tumor cells. We carried out a detailed analysis in Caski cells, that are derived from HPV-containing cervical cancer tissues. Studies with various protease inhibitors revealed that Rb is regulated specifically by the ubiquitin-proteasome pathway in HPV-containing cervical tumor cells. Several inhibitors of the 26S proteasome significantly increased the level of Rb in the Caski cells. Rb controls cell growth by forming complexes with the E2F-family transcription factors. Surprisingly, in spite of a significant accumulation of the hypophosphorylated form of Rb, no Rb/E2F complex was detectable in the proteasome inhibitor treated cells. Further analysis revealed that there was an increased accumulation of the E7 oncoprotein. We showed that the proteasome inhibitors simultaneously blocked the proteolysis of E7 and Rb, suggesting that E7 is also regulated by the ubiquitin-dependent proteolysis in cervical cancer cells. Taken together, this study suggests that targeted inhibition of Rb proteolysis will be required for restoring Rb function in HPV-containing cervical cancer cells.	Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bagchi, S (corresponding author), Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, MC 860,801 S Paulina St, Chicago, IL 60612 USA.	sbagchi@uic.edu			NCI NIH HHS [CA76276] Funding Source: Medline; NIDCR NIH HHS [DE12506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BEREZUTSKAYA E, 1997, CELL GROWTH DEATH, V8, P1; Boyer SN, 1996, CANCER RES, V56, P4620; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Galloway DA, 1996, SEMIN CANCER BIOL, V7, P309, DOI 10.1006/scbi.1996.0040; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Howley Peter M., 1996, P947; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Maki CG, 1996, CANCER RES, V56, P2649; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Niv A, 2000, J LARYNGOL OTOL, V114, P41, DOI 10.1258/0022215001903870; PAGANO M, 1992, ONCOGENE, V7, P1681; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Ruesch MN, 1998, VIROLOGY, V250, P19, DOI 10.1006/viro.1998.9359; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	39	74	79	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4740	4749		10.1038/sj.onc.1204655	http://dx.doi.org/10.1038/sj.onc.1204655			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498796				2022-12-28	WOS:000170208600014
J	Coldwell, MJ; deSchoolmeester, ML; Fraser, GA; Pickering, BM; Packham, G; Willis, AE				Coldwell, MJ; deSchoolmeester, ML; Fraser, GA; Pickering, BM; Packham, G; Willis, AE			The p36 isoform of BAG-1 is translated by internal ribosome entry following heat shock	ONCOGENE			English	Article						BAG-1; IRES; translation; internal ribosome entry; heat shock	APOPTOTIC PROTEIN BAG-1; C-MYC; ALTERNATIVE TRANSLATION; NEGATIVE REGULATOR; MAMMALIAN-CELLS; INITIATION; IDENTIFICATION; LOCATION; CLONING; REGION	BAG-1 (also known as RAP46/HAP46) was originally identified as a 46 kDa protein that bound to and enhanced the anti-apoptotic properties of Bcl-2, BAG-1 exists as three major isoforms (designated p50, p46 and p36 or BAG-1L, BAG-1M and BAG-1S respectively) and one minor isoform (p29), which are translated from a common transcript. The differing amino terminus determines both the intracellular location and the repertoire of binding partners of the isoforms which play different roles in a variety of cellular processes including signal transduction, heat shock, apoptosis and transcription. Although in vitro data suggest that the four BAG-1 isoforms are translated by leaky scanning, the patterns of isoform expression in vivo, especially in transformed cells, do not support this hypothesis. We have performed in vivo analysis of the BAG-1 5' untranslated region and shown that translation initiation of the most highly expressed isoform (p36/BAG-1S) can occur by both internal ribosome entry and cap-dependent scanning. Following heat shock, when there is a downregulation of cap-dependent translation, the expression of the p36 isoform of BAG-1 is maintained by internal ribosome entry.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Southampton Gen Hosp, Oncol Unit, Southampton SO16 6YD, Hants, England	University of Leicester; University of Southampton	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	aew5@le.ac.uk		Packham, Graham/0000-0002-9232-5691; Willis, Anne/0000-0002-1470-8531				Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Cuesta R, 2000, GENE DEV, V14, P1460; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; Schneider RJ, 2000, COLD SPRING HARBOR M, V39, P581; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STONELEY M, 1998, THESIS U LEICESTER; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yueh A, 2000, GENE DEV, V14, P414; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	31	79	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4095	4100		10.1038/sj.onc.1204547	http://dx.doi.org/10.1038/sj.onc.1204547			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494137				2022-12-28	WOS:000169681500017
J	Reynolds, L; Jones, K; Winton, DJ; Cranston, A; Houghton, C; Howard, L; Ponder, BAJ; Smith, DP				Reynolds, L; Jones, K; Winton, DJ; Cranston, A; Houghton, C; Howard, L; Ponder, BAJ; Smith, DP			C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET	ONCOGENE			English	Article						RET; multiple endocrine neoplasia; MEN2A; receptor tyrosine kinase; transgenic mice	MULTIPLE ENDOCRINE NEOPLASIA; TYROSINE KINASE DOMAIN; PAPILLARY CARCINOMAS; MOLECULAR CHARACTERIZATION; MEDULLARY CARCINOMA; RET/PTC1 ONCOGENE; PROTOONCOGENE; MUTATIONS; ACTIVATION; GDNF	Gain-of-function mutations in the gene encoding the receptor tyrosine kinase RET have been identified as the aetiological factor for multiple endocrine neoplasia type 2A (MEN2A). MEN2A is a dominantly-inherited cancer predisposition syndrome characterized by medullary thyroid carcinoma, a tumour of the calcitonin-producing thyroid C-cells. There are three isoforms of RET: RET9, RET43 and RET51, and although in vitro evidence suggests they vary in cellular transformation activities, little is known about their function in tumorigenesis in vivo. To address this, we used RET51 cDNA to construct mice in which the most frequent MEN2A mutation, Cys-634-Arg, was expressed under the control of the human calcitonin promoter (CT-2A mice), These mice developed C-cell tumours resembling human MTC and follicular tumours resembling human papillary thyroid carcinoma (PTC) depending on the founder line examined, One founder line developed compound MTC/PTC at low frequency (8%) and pancreatic cystadenocarcinoma, CT-2A mice also displayed a developmental defect in thyroid follicular structure, in which much of the thyroid was occupied by large irregular cystic follicles thought to be derived from the ultimobranchial body, a developmental precursor of the thyroid gland, The CT-2A mice will provide a suitable model to further study the effects of the MEN 2A RET mutation in vivo.	Univ Cambridge, Cambridge Inst Med Res, CRC, Dept Oncol, Cambridge CB2 2XY, England	University of Cambridge	Ponder, BAJ (corresponding author), Univ Cambridge, Cambridge Inst Med Res, CRC, Dept Oncol, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.							Acton DS, 2000, ONCOGENE, V19, P3121, DOI 10.1038/sj.onc.1203648; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1995, ONCOGENE, V11, P2419; Bunone G, 2000, CANCER RES, V60, P2845; CAILLOU B, 1991, P53; DECKER RA, 1993, SURGERY, V114, P1059; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; FABBRO D, 1994, CANCER RES, V54, P4744; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARACH HR, 1994, DIS THYROID, P341; HOFSTRA RMW, 1994, NATURE, V367, P275; Jhiang SM, 1996, THYROID, V6, P115, DOI 10.1089/thy.1996.6.115; Johnston D, 1998, ONCOGENE, V16, P167, DOI 10.1038/sj.onc.1201478; KOVACS CS, 1994, CANCER-AM CANCER SOC, V74, P928, DOI 10.1002/1097-0142(19940801)74:3<928::AID-CNCR2820740321>3.0.CO;2-E; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEDOUARIN N, 1970, CR ACAD SCI D NAT, V270, P2857; LJUNGBERG O, 1983, CANCER, V52, P1053, DOI 10.1002/1097-0142(19830915)52:6<1053::AID-CNCR2820520621>3.0.CO;2-Q; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Manley NR, 1998, DEV BIOL, V195, P1, DOI 10.1006/dbio.1997.8827; MANLEY NR, 1995, DEVELOPMENT, V121, P1989; Marshall GM, 1997, CANCER RES, V57, P5399; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS SM, 1995, ONCOGENE, V11, P2039; OISHI S, 1995, ENDOCR J, V42, P527, DOI 10.1507/endocrj.42.527; Okada Y, 1999, INT J CANCER, V81, P67, DOI 10.1002/(SICI)1097-0215(19990331)81:1<67::AID-IJC13>3.0.CO;2-V; Orlandi F, 2001, J ENDOCRINOL INVEST, V24, P51, DOI 10.1007/BF03343809; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Peleg S, 1989, Henry Ford Hosp Med J, V37, P194; Ponder BAJ, 1996, ADV CANCER RES, V70, P179, DOI 10.1016/S0065-230X(08)60875-1; Portella G, 1996, ONCOGENE, V13, P2021; Powell DJ, 1998, CANCER RES, V58, P5523; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSSEL M, 1995, HUM GENET, V95, P403; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SAAD MF, 1984, MEDICINE, V63, P319, DOI 10.1097/00005792-198411000-00001; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; Santoro W, 1999, J ENDOCRINOL INVEST, V22, P811, DOI 10.1007/BF03343650; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TRUPP M, 1996, NATURE, V381, P789; WETZEL BK, 1969, ENDOCRINOLOGY, V84, P563, DOI 10.1210/endo-84-3-563; WOLLMAN SH, 1978, ANAT REC, V191, P111, DOI 10.1002/ar.1091910110	56	38	39	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3986	3994		10.1038/sj.onc.1204434	http://dx.doi.org/10.1038/sj.onc.1204434			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494127				2022-12-28	WOS:000169681500007
J	Shi, YJ; Simmons, MN; Seki, T; Oh, SP; Sugrue, SP				Shi, YJ; Simmons, MN; Seki, T; Oh, SP; Sugrue, SP			Change in gene expression subsequent to induction of Pnn/DRS/memA: increase in p21(cip1/waf1)	ONCOGENE			English	Article						Pnn; cell migration; cell cycle progression; p21(cip1/waf1); RhoA; MMP-7; MIC-1	CELL-CYCLE ARREST; METALLOPROTEINASE MATRILYSIN MMP-7; MACROPHAGE INHIBITORY CYTOKINE; TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; TGF-BETA SUPERFAMILY; C-MYC; MATRIX METALLOPROTEINASES; DESMOSOMAL PROTEIN; DNA-REPLICATION	Pnn (PNN) is a nuclear and cell adhesion-related protein. Previous work has suggested that Pnn/DRS/memA is a potential tumor suppressor involved in the regulation of cell adhesion and cell migration. Using the ecdysone-inducible mammalian expression system, a stable inducible GFP-tagged human Pnn gene (PNNGFP) expressing 293 cell line was created (EcR293-PNNGFP), Cells induced to express PNNGFP not only exhibited increased cell-cell adhesion but also exhibited changes in cell growth and cell cycle progression. cDNA array analyses, together with real time PCR, revealed that the effects of exogenously expressed Pnn on cellular behavior may be linked to the regulation of the expression of specific subset genes. This subset includes cell cycle-related genes such as p21(cip1/waf1), CDK4, CPR2; cell migration and invasion regulatory genes such as RhoA, CDK5, TIMP-1, MMP-7, and EMMPRIN; and MIC-1, Concordant with previous observations of Pnn-induced phenotype changes, genes coding for epithelial associated processes and cell division controls were elevated, while those coding for increased cell motility and cellular reorganizations were downregulated. We utilized p21 promoter-luciferase reporter constructs and demonstrated that a marked stimulation of p21 promoter activity in 293 cells correlated with increased Pnn expression, Taken together, these data indicate that Pnn may participate in the regulation of gene expression, thereby, positively promoting cell-cell adhesion, and negatively affecting cell migration and cell proliferation.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Sugrue, SP (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Archer Rd, Gainesville, FL 32610 USA.	sugrue@anatomy.med.ufl.edu			NEI NIH HHS [EY07883] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007883] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adachi Y, 1998, INT J ONCOL, V13, P1031; Adachi Y, 1999, GUT, V45, P252, DOI 10.1136/gut.45.2.252; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BISWAS C, 1995, CANCER RES, V55, P434; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.3.CO;2-R; Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Brandner JM, 1997, DIFFERENTIATION, V62, P119, DOI 10.1046/j.1432-0436.1997.6230119.x; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dang CV, 1999, MOL CELL BIOL, V19, P1; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; Degen WGJ, 1999, BBA-GENE STRUCT EXPR, V1444, P384, DOI 10.1016/S0167-4781(99)00012-3; Edwards MC, 1997, GENETICS, V147, P1063; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guo HM, 1998, GENE, V220, P99, DOI 10.1016/S0378-1119(98)00400-4; GUO K, 1995, MOL CELL BIOL, V15, P3823; Harada K, 2000, ORAL ONCOL, V36, P3, DOI 10.1016/S1368-8375(99)00049-4; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KANAI Y, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P51; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Kwon YT, 2000, CURR BIOL, V10, P363, DOI 10.1016/S0960-9822(00)00411-5; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Moll I, 1997, J INVEST DERMATOL, V108, P139, DOI 10.1111/1523-1747.ep12332388; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Mueller S, 2000, CANCER RES, V60, P156; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; OUYANG P, 1992, J CELL BIOL, V118, P1477, DOI 10.1083/jcb.118.6.1477; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Pin OY, 1999, BIOCHEM BIOPH RES CO, V263, P192, DOI 10.1006/bbrc.1999.1353; Pin OY, 1996, J CELL BIOL, V135, P1027, DOI 10.1083/jcb.135.4.1027; Rorke EA, 2000, EXP CELL RES, V259, P149, DOI 10.1006/excr.2000.4953; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sander EE, 1999, EUR J CANCER, V35, P1302, DOI 10.1016/S0959-8049(99)00145-8; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Shi YJ, 2000, ONCOGENE, V19, P289, DOI 10.1038/sj.onc.1203328; Shi YJ, 2000, INVEST OPHTH VIS SCI, V41, P1337; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tanimoto H, 1999, TUMOR BIOL, V20, P88, DOI 10.1159/000030051; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091; YAMAMOTO H, 1995, J CLIN LAB ANAL, V9, P297, DOI 10.1002/jcla.1860090504	64	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4007	4018		10.1038/sj.onc.1204507	http://dx.doi.org/10.1038/sj.onc.1204507			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494129				2022-12-28	WOS:000169681500009
J	Chen, WX; Tang, QB; Gonzales, MS; Bowden, GT				Chen, WX; Tang, QB; Gonzales, MS; Bowden, GT			Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes	ONCOGENE			English	Article						UVB; p38; ERK; COX-2; PGE(2)	ACTIVATED PROTEIN-KINASE; CYTOSOLIC PHOSPHOLIPASE A(2); COLON-CANCER CELLS; SKIN-CANCER; MULTISTAGE CARCINOGENESIS; COX-2 EXPRESSION; REGULATED KINASE; MOUSE SKIN; INHIBITION; INDUCTION	The roles of p38 MAP kinases and ERK in UVB induced cox-2 gene expression were studied in a human keratinocyte cell line, HaCaT, UVB significantly increased cox-2 gene expression at both protein and mRNA levels. As we reported previously, p38 and ERK were significantly activated after UVB irradiation in HaCaT cells. In addition, treating the cells with p38 inhibitor SB202190 or MEK inhibitor PD98059 specifically inhibited UVB induced p38 or ERK activation, respectively. In this study, we further examined the roles of p38 and ERK in UVB induced cox-2 gene expression in HaCaT cells. We found that SB202190 strongly inhibited UVB induced COX-2 protein expression at different time points and various UVB doses. Furthermore, SB202190 markedly inhibited UVB induced cox-2 mRNA. Our data indicated that ERK did not play a role in UVB induced cox-2 gene expression in human keratinocytes since suppression of ERK did not significantly alter UVB induced increase of COX-2 protein and mRNA. These results suggested, for the first time, that activation of p38 is required for UVB induced cox-2 gene expression in human keratinocytes, Since cox-2 expression plays an important role in UV carcinogenesis, p38 could be a potential molecular target for chemoprevention of skin cancer.	Univ Arizona, Coll Med, Dept Radiat Oncol, Arizona Canc Ctr, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), Univ Arizona, Coll Med, Dept Radiat Oncol, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P30CA023074, P01CA027502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [CA27502, CA23074] Funding Source: Medline; NIEHS NIH HHS [P30 ESO6694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; Barthelman M, 1998, CANCER RES, V58, P711; BENNETT A, 1982, BRIT J CANCER, V46, P888, DOI 10.1038/bjc.1982.298; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 1997, NUTR CANCER, V29, P205, DOI 10.1080/01635589709514625; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chen WX, 2000, MOL CARCINOGEN, V28, P196, DOI 10.1002/1098-2744(200008)28:4<196::AID-MC2>3.0.CO;2-C; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Chulada P. C., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P195; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; FURSTENBERGER G, 1990, EICOSANOIDS SKIN, P108; Geijsen N, 2000, FEBS LETT, V471, P83, DOI 10.1016/S0014-5793(00)01373-9; Gresham A, 1996, AM J PHYSIOL-CELL PH, V270, pC1037, DOI 10.1152/ajpcell.1996.270.4.C1037; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Higashi Y, 2000, INT J CANCER, V86, P667, DOI 10.1002/(SICI)1097-0215(20000601)86:5<667::AID-IJC10>3.3.CO;2-P; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; KANGROTONDO CH, 1993, AM J PHYSIOL, V264, P396; Marks F, 2000, EUR J CANCER, V36, P314, DOI 10.1016/S0959-8049(99)00318-4; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Parfenova H, 1998, AM J PHYSIOL-CELL PH, V274, pC72, DOI 10.1152/ajpcell.1998.274.1.C72; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Sheng HM, 1998, CANCER RES, V58, P362; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199	43	151	156	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3921	3926		10.1038/sj.onc.1204530	http://dx.doi.org/10.1038/sj.onc.1204530			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439356				2022-12-28	WOS:000169494700018
J	Rubin, E; Mittnacht, S; Villa-Moruzzi, E; Ludlow, JW				Rubin, E; Mittnacht, S; Villa-Moruzzi, E; Ludlow, JW			Site-specific and temporally-regulated retinoblastoma protein dephosphorylation by protein phosphatase type 1	ONCOGENE			English	Article						retinoblastoma protein; protein phosphatase type 1; pRB dephosphorylation; PP1 activity	CELL-CYCLE; SUSCEPTIBILITY GENE; PHOSPHORYLATION; PRODUCT; PRB; INACTIVATION; PATTERN; BINDING	pRb is dephosphorylated at mitotic exit by the type 1 serine/threonine protein phosphatases (PP1), Here we demonstrate for the first time that mitotic pRb dephosphorylation is a sequential, temporally-regulated event. We also provide evidence that the three mammalian isoforms of PP1, alpha, gamma -1, and delta, differ in their respective preferences for site-specific pRb dephosphorylation and that the mitotic and G(1) PP1-isoform counterparts exhibit differential activities towards mitotic pRb, Finally, the physiological relevance of the striking contrast between the patterns of Thr821 and Thr826 dephosphorylation, sites known to be important for disrupting binding of LXCXE-containing proteins to pRb, is addressed.	Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Pisa, Dept Expt Pathol, Pisa, Italy; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Pisa; University of Rochester	Ludlow, JW (corresponding author), Incara Pharmaceut, POB 14287, Res Triangle Pk, NC 27709 USA.	JLudlow@incara.com			NCI NIH HHS [CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Boylan JF, 1999, EXP CELL RES, V248, P110, DOI 10.1006/excr.1999.4389; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUSSOW AR, 1991, EUR J IMMUNOL, V21, P2297, DOI 10.1002/eji.1830211002; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Puntoni F, 1997, MOL CELL BIOCHEM, V171, P115, DOI 10.1023/A:1006892103306; Tamrakar S, 1999, ONCOGENE, V18, P7803, DOI 10.1038/sj.onc.1203211; Tamrakar S, 2000, J BIOL CHEM, V275, P27784; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; Tognarini M, 1998, METH MOL B, V93, P169; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMSTOTTHALL K, 1999, J BIOL CHEM, V274, P3485; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	38	57	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 28	2001	20	29					3776	3785		10.1038/sj.onc.1204518	http://dx.doi.org/10.1038/sj.onc.1204518			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439341				2022-12-28	WOS:000169494700003
J	Ganiatsas, S; Dow, R; Thompson, A; Schulman, B; Germain, D				Ganiatsas, S; Dow, R; Thompson, A; Schulman, B; Germain, D			A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT	ONCOGENE			English	Article						cyclin D1; SCF; ubiquitination; p27	F-BOX; RETINOBLASTOMA PROTEIN; TRANSGENIC MICE; LIGASE COMPLEX; BREAST-CANCER; HUMAN CUL-1; DEGRADATION; P27(KIP1); P27; ACCUMULATION	Cyclin D1 is an important regulator of the transition from G1 into S phase of the cell cycle. The level to which cyclin D1 accumulates is tightly regulated. One mechanism contributing to the control of cyclin D1 levels is the regulation of its ubiquitination, SK-UT-1B cells are deficient in the degradation of D-type cyclins, We show here that p27, a substrate of the SCFSkp2 ubiquitin Ligase complex, is coordinately stabilized in SK-UT-IB cells. Further, we show that expression of Skp2 in SK-UT-IB cells rescues the cyclin D1 and p27 degradation defect observed in this cell line. These results therefore indicate that the SCFSkp2 ubiquitin ligase complex affects the ubiquitination of cyclin D1, In addition, we show that SK-UT-LB cells express a novel splice variant of Skp2 that localizes to the cytoplasm and that cyclin D1 ubiquitination takes place in the nucleus. We propose that the translocation of Skp2 into the nucleus is required for the ubiquitination of cyclin DI and that the absence of the SCFSkp2 complex in the nucleus of SK-UT-IB cells is the mechanism underlying the ubiquitination defect observed in this cell line, Finally, our data indicates that differential splicing of F-box proteins may represent an additional level of regulation of the F-box mediated ubiquitination pathway.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Peter Maccallum Cancer Center; University of Melbourne; Memorial Sloan Kettering Cancer Center	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.							Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P104, DOI 10.1159/000134318; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1996, ONCOGENE, V13, P419; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	39	49	53	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3641	3650		10.1038/sj.onc.1204501	http://dx.doi.org/10.1038/sj.onc.1204501			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439327				2022-12-28	WOS:000169400200005
J	Mori, N; Matsumoto, Y; Okumoto, M; Suzuki, N; Yamate, J				Mori, N; Matsumoto, Y; Okumoto, M; Suzuki, N; Yamate, J			Variations in Prkdc encoding the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) and susceptibility to radiation-induced apoptosis and lymphomagenesis	ONCOGENE			English	Article						apoptosis susceptibility; susceptibility to radiation lymphomagenesis; genetic variation in DNA-PKcs; DNA double-strand breaks repair	SEVERE COMBINED IMMUNODEFICIENCY; COMBINED IMMUNE-DEFICIENCY; RECOMBINANT CONGENIC STRAINS; V(D)J RECOMBINATION; X-IRRADIATION; NONSENSE MUTATION; SCID MUTATION; BREAK REPAIR; MICE; THYMOCYTES	DNA double-strand breaks (DSBs) induced by ionizing radiation enforce cells to die, if unrepaired; while if misrepaired, DSBs may cause malignant transformation. The DSB repair system predominant in mammals requires DNA-dependent protein kinase (DNA-PK), Previously, we identified the apoptosis susceptibility gene Radiation-induced apoptosis 1 (Rapop1) on mouse chromosome 16, The STS/A (STS) allele at Rapop1 leads to decreased sensitivity to apoptosis in the BALB/cHeA (BALB/c) background. In the present study, we established Rapop1 congenic strains C,S-RI and C.S-R1L, which contain the STS genome in a 0.45 cM interval critical for Rapop1 in common in the BALB/c background. Within the segment critical for Rapop1, Prkdc encoding the catalytic subunit of DNA-PK (DNA-PKcs) was assigned. Two variations T6,418C and G11,530A, which induce amino acid substitutions C2,140R downstream from the putative leucine zipper motif and V3,844M near the kinase domain, respectively, were found between BALB/c and STS for Prkdc. The majority of inbred strains such as C57BL/6J carried the STS allele at Prkdc; a few strains including 129/SvJ and C.B17 carried the BALB/c allele. DNA-PK activity as well as DNA-PKcs expression was profoundly diminished in BALB/c and 129/SvJ mice as compared with C57BL/6 and C.S-R1 mice. In the crosses (C.S-R1 x BALB/c)F-1 x 129/SvJ and (C.S-R1 x BALB/c)F-1 x C.B17, enhanced apoptosis occurred in the absence of the wildtype allele at Prkdc. C.S-R1 and C.S-R1L were both less sensitive to radiation lymphomagenesis than BALB/ c, Our study provides strong evidence for Prkdc as a candidate for Rapop1 and a susceptibility gene for radiation lymphomagenesis as well.	Adv Sci & Technol Res Inst, Dept Appl Biosci, Osaka 5998570, Japan; Univ Osaka Prefecture, Coll Agr, Dept Vet Pathol, Osaka 5998570, Japan; Univ Tokyo, Grad Sch Med, Dept Radiat Oncol, Bunkyo Ku, Tokyo 1130033, Japan	Japan Advanced Institute of Science & Technology (JAIST); Osaka Metropolitan University; University of Tokyo	Mori, N (corresponding author), Adv Sci & Technol Res Inst, Dept Appl Biosci, Osaka 5998570, Japan.		Matsumoto, Yoshihisa/G-3430-2017	Matsumoto, Yoshihisa/0000-0002-0758-290X				Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CUSTER RP, 1985, AM J PATHOL, V120, P464; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Kamisaku H, 1997, INT J RADIAT BIOL, V72, P191, DOI 10.1080/095530097143419; Kienker LJ, 2000, NUCLEIC ACIDS RES, V28, P2752, DOI 10.1093/nar/28.14.2752; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; LIEBERMAN M, 1992, J EXP MED, V176, P399, DOI 10.1084/jem.176.2.399; Lund J, 1999, MAMM GENOME, V10, P438, DOI 10.1007/s003359901019; Matsumoto Y, 2000, FEBS LETT, V478, P67, DOI 10.1016/S0014-5793(00)01800-7; Matsumoto Y, 1999, J RADIAT RES, V40, P183, DOI 10.1269/jrr.40.183; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10792, DOI 10.1073/pnas.92.23.10792; MORI N, 1991, J RADIAT RES, V32, P277, DOI 10.1269/jrr.32.277; Mori N, 1998, MAMM GENOME, V9, P377, DOI 10.1007/s003359900773; MORI N, 1992, INT J RADIAT BIOL, V62, P153, DOI 10.1080/09553009214551961; MORI N, 1995, GENOMICS, V25, P609, DOI 10.1016/0888-7543(95)80001-3; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; Okayasu R, 2000, CANCER RES, V60, P4342; OKUMOTO M, 1989, J RADIAT RES, V30, P135, DOI 10.1269/jrr.30.135; OKUMOTO M, 1995, EXP ANIM TOKYO, V44, P43, DOI 10.1538/expanim.44.43; Park YG, 2000, CANCER LETT, V148, P95, DOI 10.1016/S0304-3835(99)00321-3; Peterson SR, 1997, J BIOL CHEM, V272, P10227; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Prise KM, 1998, INT J RADIAT BIOL, V74, P173, DOI 10.1080/095530098141564; SAKATA K, 2000, IN PRESS INT J RAD O; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Stassen APM, 1996, MAMM GENOME, V7, P55, DOI 10.1007/s003359900013; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Weil MM, 1996, RADIAT RES, V146, P646, DOI 10.2307/3579380; Weil MM, 1996, INT J RADIAT BIOL, V70, P579, DOI 10.1080/095530096144789; YAMADA T, 1988, INT J RADIAT BIOL, V53, P65, DOI 10.1080/09553008814550431; YOKORO K, 1986, RAD CARCINOG, P138	42	51	52	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3609	3619		10.1038/sj.onc.1204497	http://dx.doi.org/10.1038/sj.onc.1204497			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439324				2022-12-28	WOS:000169400200002
J	Bost, F; Caron, L; Vial, E; Montreau, N; Marchetti, I; Dejong, V; Defize, L; Castellazzi, M; Binetruy, B				Bost, F; Caron, L; Vial, E; Montreau, N; Marchetti, I; Dejong, V; Defize, L; Castellazzi, M; Binetruy, B			The defective transforming phenotype of c-Jun Ala(63/73) is rescued by mutation of the C-terminal phosphorylation site	ONCOGENE			English	Article						c-Jun transcription factor; phosphorylation sites; rat embryo fibroblasts; CBP interaction; oncogene cooperation	EMBRYO FIBROBLASTS; DNA-BINDING; IN-VITRO; RAS; ACTIVATION; CBP; COOPERATION; REQUIRES; DOMAIN; GROWTH	Cotransfection of primary rat embryo fibroblasts (REF) with c-Jun and activated Ras leads to oncogenic transformation and this process requires the phosphorylation of the N-terminal domain of c-Jun. Ras augments this phosphorylation and, consequently activates the c-Jun transactivation property of TRE (TPA Responsive Element)-dependent promoters. To analyse the role of the c-Jun C-terminal phosphorylation site in oncogenic cooperation we tested the activities of N-terminal c-Jun Ala(63/73) (named Nt), C-terminal c-Jun Ala(234/242/246/252) (named Ct) and (Nt+Ct)-with both mutations-nonphosphorylatable c-Jun mutants. In cooperation with Ras, the Ct mutant and wt c-Jun display similar oncogenic properties whereas the Nt form was defective in transforming REF cells. Unexpectedly, the Nt+Ct mutant exhibited identical oncogenic properties to wt c-Jun, demonstrating that the Ct mutation rescues in cis the Nt mutation. The transcriptional activity and the capacity to bind the c-Jun coactivator CREB Binding Protein (CBP) were enhanced by Ras for the wt and Ct proteins but not for the Nt mutant. Interestingly, the Nt+Ct mutant presents identical transactivation and CBP binding activities to wt c-Jun. Therefore the rescue in cis of the defective Nt mutation by the Ct mutation seems to be due to the recovery of CBP binding. Our results revealed that the process of oncogenic cooperation can occur between Ras and the Nt+Ct non-phosphorylatable c-Jun protein.	Univ Nice Sophia Antipolis, Fac Med, INSERM E99 11, F-06107 Nice, France; ENS Lyon, INSERM U412, F-69364 Lyon, France; Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Binetruy, B (corresponding author), Univ Nice Sophia Antipolis, Fac Med, INSERM E99 11, Av Valombrose, F-06107 Nice, France.		Binetruy, Bernard/S-2062-2019; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/A-6465-2009; Binetruy, Bernard/AFL-7188-2022; BOST, Frederic/AAN-4691-2020; Caron, Leslie/AAE-3511-2022	Binetruy, Bernard/0000-0001-8012-7092; BOST, Frederic/0000-0003-4509-4701; Caron, Leslie/0000-0003-4118-2974				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; METIVIER C, 1993, ONCOGENE, V8, P2311; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VANDEL L, 1995, ONCOGENE, V10, P495	17	7	7	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7425	7429		10.1038/sj.onc.1204924	http://dx.doi.org/10.1038/sj.onc.1204924			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704873				2022-12-28	WOS:000171894200016
J	Wang, SC; Makino, K; Xia, WY; Kim, JS; Im, SA; Peng, H; Mok, SC; Singletary, SE; Hung, MC				Wang, SC; Makino, K; Xia, WY; Kim, JS; Im, SA; Peng, H; Mok, SC; Singletary, SE; Hung, MC			DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway	ONCOGENE			English	Article						ILK; DOC-2/hDab-2; anoikis; breast cancer; HER-2; neu	INTEGRIN-LINKED KINASE; EPITHELIAL OVARIAN-CANCER; PHOSPHOINOSITIDE-3-OH KINASE; ACTIVATION; EXPRESSION; CLONING; DOMAIN; B/AKT; GENE	DOC-2/hDab-2 was identified due to the loss of its expression in primary ovarian cancer cells. It is believed that loss of DOC-2/hDab-2 expression is one of the early events of ovarian malignancy. These results suggest a function of DOC-2/hDab-2 as a tumor suppressor. However, it is not clear how DOC-2/hDab-2 negatively regulates cancer cell growth. In this report, we demonstrate that DOC-2/hDab-2 expression in breast cancer cells resulted in sensitivity to suspension-induced cell death (anoikis). This event was associated with the down-regulation of the integrin-linked kinase (ILK) activity. Since ILK is a key factor in regulating the cellular signaling in responding to the extracellular signals through adhesion molecules like integrins, our results indicate that DOC-2/hDab-2 may prevent tumor growth and invasion by modulating the anti-apoptotic ILK pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Brigham & Womens Hosp, Dana Farber Harvard Canc Ctr, Div Gynecol Oncol, Lab Gynecol Oncol, Houston, TX USA; Brigham & Womens Hosp, Dana Farber Harvard Canc Ctr, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Wang, Shao-Chun/P-9904-2019; Hung, Mien-Chie/ABD-5911-2021	Wang, Shao-Chun/0000-0002-5477-1682; Hung, Mien-Chie/0000-0003-4317-4740				Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; YU DH, 1991, ONCOGENE, V6, P1991; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	14	40	42	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6960	6964		10.1038/sj.onc.1204873	http://dx.doi.org/10.1038/sj.onc.1204873			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687976				2022-12-28	WOS:000171641000018
J	O'Bryan, JP; Mohney, RP; Oldham, CE				O'Bryan, JP; Mohney, RP; Oldham, CE			Mitogenesis and endocytosis: What's at the INTERSECTIoN?	ONCOGENE			English	Article						Eps15 homology; Src homology 3; GTPase; ubiquitination	CLATHRIN-MEDIATED ENDOCYTOSIS; ACTIVATED PROTEIN-KINASE; COATED VESICLE FORMATION; GROWTH-FACTOR RECEPTORS; FAT-FACETS GENE; SIGNAL-TRANSDUCTION; EPS15 HOMOLOGY; DEUBIQUITINATING ENZYME; ADAPTER PROTEIN; TYROSINE KINASE	Endocytosis is a regulated physiological process by which cell surface proteins are internalized along with extracellular factors such as nutrients, pathogens, peptides, toxins, etc. The process begins with the invagination of small regions of the plasma membrane which ultimately form intracellullar vesicles. These internalized vesicles may shuttle back to the plasma membrane to recycle the membrane components or they may be targeted for degradation. One role for endocytosis is in the attenuation of receptor signaling. For example, desensitization of activated membrane bound receptors such as G-protein coupled receptors (GPCRs) or receptor tyrosine kinases (RTKs) occurs, in part, through endocytosis of the activated receptor. However, accumulating evidence suggests that endocytosis also mediates intracellular signaling. In this review, we discuss the experimental data that implicate endocytosis as a critical component in cellular signal transduction, both in the initiation of a signal as well as in the termination of a signal. Furthermore, we focus our attention on a recently described adaptor protein, intersectin (ITSN), which provides a link to both the endocytic and the mitogenic machinery of a cell. Thus, ITSN functions at a crossroad in the biochemical regulation of cell function.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	O'Bryan, JP (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233,Bldg Rm 101-F336,MD F3-06, Res Triangle Pk, NC 27709 USA.	obryan@niehs.nih.gov		O'Bryan, John/0000-0001-5386-1080	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams A, 2000, J BIOL CHEM, V275, P27414; BERNARD OA, 1994, ONCOGENE, V9, P1039; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Carbone R, 1997, CANCER RES, V57, P5498; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Fernandez-Chacon R, 2000, J BIOL CHEM, V275, P12752, DOI 10.1074/jbc.275.17.12752; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Guipponi M, 1998, CYTOGENET CELL GENET, V83, P218, DOI 10.1159/000015182; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Johannessen LE, 2000, EXP CELL RES, V260, P136, DOI 10.1006/excr.2000.5004; Kadesch T, 2000, EXP CELL RES, V260, P1, DOI 10.1006/excr.2000.4921; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Munn AL, 2001, BBA-MOL BASIS DIS, V1535, P236, DOI 10.1016/S0925-4439(01)00028-X; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Parks AL, 2000, DEVELOPMENT, V127, P1373; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Pucharcos C, 1999, EUR J HUM GENET, V7, P704, DOI 10.1038/sj.ejhg.5200356; Pucharcos C, 2000, FEBS LETT, V478, P43, DOI 10.1016/S0014-5793(00)01793-2; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Robertson H, 1997, BIOCHEM BIOPH RES CO, V240, P46, DOI 10.1006/bbrc.1997.7608; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Skarpen E, 1998, EXP CELL RES, V243, P161, DOI 10.1006/excr.1998.4127; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	81	44	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6300	6308		10.1038/sj.onc.1204773	http://dx.doi.org/10.1038/sj.onc.1204773			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607832				2022-12-28	WOS:000171640600005
J	Weed, SA; Parsons, JT				Weed, SA; Parsons, JT			Cortactin: coupling, membrane dynamics to cortical actin assembly	ONCOGENE			English	Review						Rho GTPase; actin cytoskeleton; tyrosine kinase substrate; Arp2/3 complex; vesicle trafficking; invasion	PROTEIN-TYROSINE KINASE; ALDRICH-SYNDROME PROTEIN; FOCAL ADHESION KINASE; METABOTROPIC GLUTAMATE RECEPTORS; CHROMOSOME 11Q13 AMPLIFICATION; POSTSYNAPTIC DENSITY PROTEINS; JUNCTION-ASSOCIATED PROTEIN; GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR PROTEIN; SQUAMOUS-CELL CARCINOMA	Exposure of cells to a variety of external signals causes rapid changes in plasma membrane morphology. Plasma membrane dynamics, including membrane ruffle and microspike formation, fusion or fission of intracellular vesicles, and the spatial organization of transmembrane proteins, is directly controlled by the dynamic reorganization of the underlying actin cytoskeleton. Two members of the Rho family of small GTPases, Cdc42 and Rac, have been well established as mediators of extracellular signaling events that impact cortical actin organization. Actin-based signaling through Cdc42 and Rac ultimately results in activation of the actin-related protein (Arp) 2/3 complex, which promotes the formation of branched actin networks. In addition, the activity of both receptor and non-receptor protein tyrosine kinases along with numerous actin binding proteins works in concert with Arp2/3-mediated actin polymerization in regulating the formation of dynamic cortical actin-associated structures. In this review we discuss the structure and role of the cortical actin binding protein cortactin in Rho GTPase and tyrosine kinase signaling events, with the emphasis on the roles cortactin plays in tyrosine phosphorylation-based signal transduction, regulating cortical actin assembly, transmembrane receptor organization and membrane dynamics. We also consider how aberrant regulation of cortactin levels contributes to tumor cell invasion and metastasis.	Univ Colorado, Hlth Sci Ctr, Dept Craniofacial Biol, Denver, CO 80262 USA; Univ Virginia, Ctr Hlth Sci, Dept Microbiol, Charlottesville, VA 22903 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Virginia	Weed, SA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Craniofacial Biol, 4200 E 9th Ave, Denver, CO 80262 USA.	scott.weed@uchsc.edu		Weed, Scott/0000-0001-7033-9999	NCI NIH HHS [CA40042, CA29243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029243, R37CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann KJ, 2001, NAT CELL BIOL, V3, P306, DOI 10.1038/35060104; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Bear JE, 1998, J CELL BIOL, V142, P1325, DOI 10.1083/jcb.142.5.1325; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bringuier PP, 1996, ONCOGENE, V12, P1747; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Brunati AM, 1999, J BIOL CHEM, V274, P7557, DOI 10.1074/jbc.274.11.7557; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; Cameron LA, 2001, CURR BIOL, V11, P130, DOI 10.1016/S0960-9822(01)00022-7; Campbell DH, 1999, CANCER RES, V59, P5376; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; Cantarelli VV, 2000, INFECT IMMUN, V68, P382, DOI 10.1128/IAI.68.1.382-386.2000; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Dai ZS, 2000, J CELL BIOL, V150, P1321, DOI 10.1083/jcb.150.6.1321; Davidson JRT, 2000, DEPRESS ANXIETY, V11, P93; DAVIES WA, 1977, J CELL BIOL, V75, P941, DOI 10.1083/jcb.75.3.941; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; DERRY JMJ, 1995, GENOMICS, V29, P471, DOI 10.1006/geno.1995.9979; DOWNING JR, 1991, ONCOGENE, V6, P607; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FATH KR, 1993, J CELL SCI, P65; Fawaz FS, 1997, INFECT IMMUN, V65, P5301, DOI 10.1128/IAI.65.12.5301-5308.1997; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Fukuoka M, 1997, GENE, V196, P43, DOI 10.1016/S0378-1119(97)00184-4; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gallet C, 1999, J BIOL CHEM, V274, P23610, DOI 10.1074/jbc.274.33.23610; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Goldberg DJ, 2000, J NEUROSCI RES, V60, P458, DOI 10.1002/(SICI)1097-4547(20000515)60:4<458::AID-JNR4>3.3.CO;2-Q; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Hui R, 1998, ONCOGENE, V17, P1053, DOI 10.1038/sj.onc.1202023; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOHNSTON CL, 1995, BIOCHEM J, V306, P609, DOI 10.1042/bj3060609; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kaksonen M, 2000, J CELL SCI, V113, P4421; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KELLIE S, 1991, J CELL SCI, V99, P207; KELLY T, 1994, J CELL PHYSIOL, V158, P299, DOI 10.1002/jcp.1041580212; Kelly T, 1998, CLIN EXP METASTAS, V16, P501, DOI 10.1023/A:1006538200886; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; KITAMURA D, 1995, BIOCHEM BIOPH RES CO, V208, P1137, DOI 10.1006/bbrc.1995.1452; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kreienkamp HJ, 2000, J BIOL CHEM, V275, P32387, DOI 10.1074/jbc.C000490200; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Lim S, 2001, MOL CELL NEUROSCI, V17, P385, DOI 10.1006/mcne.2000.0940; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Linder S, 2000, J IMMUNOL, V165, P221, DOI 10.4049/jimmunol.165.1.221; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; LISCIA DS, 1989, ONCOGENE, V4, P1219; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Ma A, 2001, MOL BIOL CELL, V12, P1; MAA MC, 1992, ONCOGENE, V7, P2429; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Maciver SK, 1998, CURR OPIN CELL BIOL, V10, P140, DOI 10.1016/S0955-0674(98)80097-5; Mandato CA, 2000, CELL MOTIL CYTOSKEL, V45, P87, DOI 10.1002/(SICI)1097-0169(200002)45:2<87::AID-CM1>3.0.CO;2-0; Mangoura D, 1997, J NEUROSCI RES, V50, P391, DOI 10.1002/(SICI)1097-4547(19971101)50:3<391::AID-JNR5>3.0.CO;2-D; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; MIGLARESE MR, 1994, ONCOGENE, V9, P1989; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mounier J, 1999, J CELL SCI, V112, P2069; MULLER B, 1994, IMMUNOGENETICS, V39, P359; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NADA S, 1994, ONCOGENE, V9, P3571; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Ohoka Y, 1998, GENES CELLS, V3, P603, DOI 10.1046/j.1365-2443.1998.00216.x; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; Ory S, 2000, J CELL SCI, V113, P1177; OZAWA K, 1995, EXP CELL RES, V221, P197, DOI 10.1006/excr.1995.1367; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Patel AM, 1996, ONCOGENE, V12, P31; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Redecker P, 2001, J HISTOCHEM CYTOCHEM, V49, P639, DOI 10.1177/002215540104900511; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rosa JP, 1997, BLOOD, V89, P4385, DOI 10.1182/blood.V89.12.4385; Schafer DA, 2000, TRAFFIC, V1, P892; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; Sechi AS, 2000, J CELL SCI, V113, P3685; Sheng M, 2000, J CELL SCI, V113, P1851; Sheth B, 1997, DEVELOPMENT, V124, P2027; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; Soloviev MM, 2000, J MOL BIOL, V295, P1185; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Takahisa M, 1996, GENE DEV, V10, P1783, DOI 10.1101/gad.10.14.1783; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; Takenawa T, 2001, J CELL SCI, V114, P1801; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tobaben S, 2000, J BIOL CHEM, V275, P36204, DOI 10.1074/jbc.M006448200; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; Violette SM, 2001, BONE, V28, P54, DOI 10.1016/S8756-3282(00)00427-0; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang DZ, 1999, DEVELOPMENT, V126, P1281; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 1998, J CELL SCI, V111, P2433; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Wheal HV, 1998, PROG NEUROBIOL, V55, P611, DOI 10.1016/S0301-0082(98)00026-4; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wu H, 1998, J HISTOCHEM CYTOCHEM, V46, P1189, DOI 10.1177/002215549804601011; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XAIO B, 1998, NEURON, V21, P707; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zettl M, 2001, NAT CELL BIOL, V3, pE74, DOI 10.1038/35060152; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153	220	346	354	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6418	6434		10.1038/sj.onc.1204783	http://dx.doi.org/10.1038/sj.onc.1204783			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607842				2022-12-28	WOS:000171640600015
J	Dunkern, TR; Fritz, G; Kaina, B				Dunkern, TR; Fritz, G; Kaina, B			Ultraviolet light-induced DNA damage triggers apoptosis in nucleotide excision repair-deficient cells via Bcl-2 decline and caspase-3/-8 activation	ONCOGENE			English	Article						apoptosis; UV light; Bcl-2; nucleotide excision repair; DNA-damage; caspases	DRUG-INDUCED APOPTOSIS; BREAST-CANCER CELLS; CD95 FAS/APO-1; MITOCHONDRIAL CONTROL; SIGNAL-TRANSDUCTION; MUTATION-INDUCTION; ALKYLATING-AGENTS; MOLECULAR-CLONING; MISMATCH REPAIR; LEUKEMIA-CELLS	Ultraviolet (UV) light is a potent mutagenic and genotoxic agent. Whereas DNA damage induced by UV light is known to be responsible for UV-induced genotoxicity, its role in triggering apoptosis is still unclear. We addressed this issue by comparing nucleotide excision repair (NER) deficient 27-1 and 43-3B Chinese hamster (CHO) cells with the corresponding wild-type and ERCC-1 complemented cells. It is shown that NER deficient cells are dramatically hypersensitive to UV-C induced apoptosis, indicating that DNA damage is the major stimulus for the apoptotic response. Apoptosis triggered by UV-C induced DNA damage is related to caspase- and proteosome-dependent degradation of Bcl-2 protein. The expression of other members of the Bcl-2 family such as Bax, Bcl-x(L) and Bak were not affected. Bcl-2 decline is causally involved in UV-C induced apoptosis since overexpression of Bcl-2 protected NER deficient cells against apoptosis. We also demonstrate that caspase-8, caspase-9 and caspase-3 are activated and PARP is cleaved in response to unrepaired UV-C induced DNA damage. Caspase-8 activation occurred independently of CD95 receptor activation since CD95R/ FasR and CD95L/FasL were not altered in expression, and transfection of transdominant negative FADD failed to block apoptosis. Overall, the data demonstrate that UV-C induced non-repaired DNA damage triggers apoptosis in NER deficient fibroblasts involving components of the intrinsic mitochondrial damage pathway.	Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.							Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011-1344(92)85135-H; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HALDAR S, 1994, CANCER RES, V54, P2095; Hayashi T, 1998, MUTAT RES-DNA REPAIR, V407, P269, DOI 10.1016/S0921-8777(98)00013-5; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Ioannou YA, 1996, NUCLEIC ACIDS RES, V24, P992; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; Kim DK, 2000, EXP CELL RES, V257, P82, DOI 10.1006/excr.2000.4868; Kim JW, 2000, J BIOL CHEM, V275, P8121, DOI 10.1074/jbc.275.11.8121; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kurokawa H, 1999, ONCOL REP, V6, P33; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; LARMINAT F, 1994, NUCLEIC ACIDS RES, V22, P3005, DOI 10.1093/nar/22.15.3005; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; LEE KB, 1993, CARCINOGENESIS, V14, P2177, DOI 10.1093/carcin/14.10.2177; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ochs K, 2000, CANCER RES, V60, P5815; Pizer ES, 1996, CANCER RES, V56, P745; REED JC, 1989, ONCOGENE RES, V4, P271; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Richardson DS, 1999, ADV EXP MED BIOL, V457, P259; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schwarz T, 1998, J PHOTOCH PHOTOBIO B, V44, P91, DOI 10.1016/S1011-1344(98)00126-2; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; STEFANINI M, 1986, MUTAT RES, V174, P155, DOI 10.1016/0165-7992(86)90108-9; Tatsuta T, 1996, J IMMUNOL, V157, P3949; Tomicic MT, 2001, BIOCHEM BIOPH RES CO, V281, P404, DOI 10.1006/bbrc.2001.4367; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YIN DX, 1995, CANCER RES, V55, P4922; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	63	84	85	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6026	6038		10.1038/sj.onc.1204754	http://dx.doi.org/10.1038/sj.onc.1204754			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593410				2022-12-28	WOS:000171056300010
J	Zhang, XG; Steiner, MS; Rinaldy, A; Lu, Y				Zhang, XG; Steiner, MS; Rinaldy, A; Lu, Y			Apoptosis induction in prostate cancer cells by a novel gene product, pHyde, involves caspase-3	ONCOGENE			English	Article						pHyde; apoptosis; caspase-3; prostate cancer	DNA FRAGMENTATION; MAMMALIAN HOMOLOG; DEATH; CLEAVAGE; PROTEASE; ACTIVATION; INHIBITOR; PATHWAYS; CED-3; LINES	A novel gene, pHyde, was recently cloned from Dunning rat prostate cancer cells. A recombinant adenovirus containing pHyde cDNA gene (AdpHyde) was generated to investigate the biological function of pHyde protein. AdpHyde inhibited the growth of human prostate cancer cells. Apoptosis was induced in AdpHyde transduced cells as demonstrated by DAPI (4', 6-diamino-2-phenylindole), TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick and labeling) staining, and flow cytometry assays. Apoptosis was also induced in human xenograft prostate cancer tumors growing in nude mice following treatment with AdpHyde. AdpHyde transduction resulted in a dose-dependent stimulation of caspase-3 activity in DU145 cells which was blocked by DEVD (succinyl-Asp-Glu-Val-Asp-aldehyde) and VAD (benzyloxycarbonyl - Val - Ala - Asp -fluoromethylketone), inhibitors specifically against caspase-3. Moreover, cancer cells that lacked expression of endogenous caspase-3 were not or barely inhibited by pHyde. These results taken together suggest that pHyde inhibits cancer growth by inducing apoptosis through a caspase-3 dependent pathway.	Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Urol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Lu, Y (corresponding author), Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Urol, 956 Court Ave, Memphis, TN 38163 USA.							Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; CARTER HB, 1990, J UROLOGY, V143, P742, DOI 10.1016/S0022-5347(17)40078-4; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; El Etreby MF, 1998, BREAST CANCER RES TR, V51, P149, DOI 10.1023/A:1006078032287; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; HYER ML, 2000, MOL THER, V1, pS322; JACKMAN J, 1998, CURRENT PROTOCOLS CE; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu Y, 1999, CANCER GENE THER, V6, P64, DOI 10.1038/sj.cgt.7700011; Lu Yi, 1995, Molecular and Cellular Differentiation, V3, P175; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Okuma E, 2000, LEUKEMIA, V14, P612, DOI 10.1038/sj.leu.2401716; Oridate N, 1996, CLIN CANCER RES, V2, P855; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Rinaldy AR, 1999, DNA CELL BIOL, V18, P829, DOI 10.1089/104454999314827; Rokhlin OW, 1997, CANCER RES, V57, P1758; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SANDBERG AA, 1992, HUM PATHOL, V23, P368, DOI 10.1016/0046-8177(92)90083-F; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Steiner MS, 2000, CANCER RES, V60, P4419; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; WOLK A, 1998, J NATL CANCER I, V90, P876; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zhang XW, 1999, ANTI-CANCER DRUG, V10, P569, DOI 10.1097/00001813-199907000-00009	40	25	45	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5982	5990		10.1038/sj.onc.1204831	http://dx.doi.org/10.1038/sj.onc.1204831			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593405				2022-12-28	WOS:000171056300005
J	Knoepfler, PS; Sykes, DB; Pasillas, M; Kamps, MP				Knoepfler, PS; Sykes, DB; Pasillas, M; Kamps, MP			HoxB8 requires its Pbx-interaction motif to block differentiation of primary myeloid progenitors and of most cell line models of myeloid differentiation	ONCOGENE			English	Article						HoxB8; Pbx; myeloid; differentiation	COOPERATIVE DNA-BINDING; HOMEOBOX GENE; SOMATOSTATIN PROMOTER; ONCOPROTEIN E2A-PBX1; IN-VIVO; PRE-B; LEUKEMIA; PROTEINS; HOMEODOMAIN; EXPRESSION	HoxB8 was the first homeobox gene identified as a cause of leukemia. In murine WEHI3B acute myeloid leukemia (AML) cells, proviral integration leads to the expression of both HoxB8 and Interleukin (IL-3). Enforced expression of HoxB8 blocks differentiation of factor-dependent myeloid progenitors, while IL-3 co-expression induces autocrine proliferation and overt leukemogenicity. Previously, we demonstrated that HoxB8 binds DNA cooperatively with members of the Pbx family of transcription factors, and that HoxB8 makes contact with the Pbx homeodomain through a hexameric sequence designated the Pbx-interaction motif (PIM). E2a-Pbx1, an oncogenic derivative of Pbx1, both retains its ability to heterodimerize with Hox proteins and arrest myeloid differentiation. This observation prompts the question of whether E2a-Pbx1 and Hox oncoproteins use endogenous Hox and Pbx proteins, respectively, to target a common set of cellular genes. Here, we use four different models of neutrophil and macrophage differentiation to determine whether HoxB8 needs to bind DNA or Pbx cofactors in order to arrest myeloid differentiation. The ability of HoxB8 to bind DNA or to bind Pbx was essential (1) to block differentiation of factor-dependent myeloid progenitors from primary marrow; (2) to block IL-6-induced monocytic differentiation of M1-AML cells; and (3) to block granulocytic differentiation of GM-CSF-dependent ECoM-G cells. However, while DNA-binding was required, the HoxB8 Pbx-interaction motif was unnecessary for preventing macrophage differentiation of ECoM-M cells. We conclude that HoxB8 prevents differentiation by directly influencing cellular gene expression, and that the genetic context within a cell dictates whether the effect of HoxB8 is dependent on a physical interaction with Pbx proteins.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA	University of California System; University of California San Diego; Fred Hutchinson Cancer Center	Kamps, MP (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Knoepfler, Paul/0000-0001-5444-334X	NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Calvo KR, 1999, ONCOGENE, V18, P8033, DOI 10.1038/sj.onc.1203377; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; Izon DJ, 1998, BLOOD, V92, P383, DOI 10.1182/blood.V92.2.383.414k41_383_393; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1994, ONCOGENE, V9, P3159; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SYKES DB, 2001, IN PRESS BLOOD; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Yaron Y, 2001, J IMMUNOL, V166, P5058, DOI 10.4049/jimmunol.166.8.5058	47	48	52	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5440	5448		10.1038/sj.onc.1204710	http://dx.doi.org/10.1038/sj.onc.1204710			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571641				2022-12-28	WOS:000170781100004
J	Malabarba, MG; Milia, E; Faretta, M; Zamponi, R; Pelicci, PG; Di Fiore, PP				Malabarba, MG; Milia, E; Faretta, M; Zamponi, R; Pelicci, PG; Di Fiore, PP			A repertoire library that allows the selection of synthetic SH2s with altered binding specificities	ONCOGENE			English	Article						SH2; phosphotyrosine; scaffold library; scaffold engineering	AFFINITY PHOSPHOTYROSYL PEPTIDE; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; CRYSTAL-STRUCTURES; DOMAIN; PROTEIN; KINASE; BIOSENSORS; COMPLEXES; RESIDUES	Tyrosine phosphorylation is one of the major mechanisms involved in the intracellular propagation of external signals. Strategies aimed at interfering with this process might allow the control of several cellular phenotypes. SH2 domains mediate protein-protein interactions by recognizing phosphotyrosine (pY) residues in the context of specific phosphopeptides. We created an SH2-scaffolded repertoire library by randomly mutagenizing five critical amino acid positions in the specificity-determining region of the PLC gamma C-terminal SH2 domain. Synthetic SH2 domains were selected from the library using biotinylated phosphopeptides; derived from a natural PLC gamma -SH2 ligand as well as unrelated SH2 ligands. The isolated SH2s displayed high binding affinity constants for the selecting peptides and were capable of interacting with the corresponding proteins.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; IFOM, FIRC Inst Mol Oncol, I-20090 Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Di Fiore, PP (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pdifiore@ieo.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Di Fiore, Pier Paolo/K-2130-2012; Faretta, Mario/H-8946-2012; Zamponi, Raffaella/V-5683-2018; Malabarba, Maria Grazia/L-4805-2015	Di Fiore, Pier Paolo/0000-0002-2252-0950; Faretta, Mario/0000-0003-1678-5781; Malabarba, Maria Grazia/0000-0002-9457-2047; Zamponi, Raffaella/0000-0002-3313-1387				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; Bradshaw JM, 2000, J MOL BIOL, V299, P521; Breeze AL, 1996, EMBO J, V15, P3579, DOI 10.1002/j.1460-2075.1996.tb00727.x; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Ikeda M, 1996, GENE, V181, P167, DOI 10.1016/S0378-1119(96)00497-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAROSE L, 1993, ONCOGENE, V8, P2493; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morton TA, 1998, METHOD ENZYMOL, V295, P268; NARULA SS, 1995, STRUCTURE, V3, P1061, DOI 10.1016/S0969-2126(01)00242-8; Ogura K, 1999, J MOL BIOL, V289, P439, DOI 10.1006/jmbi.1999.2792; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; SALCINI AE, 1994, ONCOGENE, V9, P2827; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Shoelson SE, 1997, CURR OPIN CHEM BIOL, V1, P227, DOI 10.1016/S1367-5931(97)80014-2; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	28	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5186	5194		10.1038/sj.onc.1204654	http://dx.doi.org/10.1038/sj.onc.1204654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526507				2022-12-28	WOS:000170464000012
J	Siegrist, S; Feral, C; Chami, M; Solhonne, B; Mattei, MG; Rajpert-De Meyts, E; Guellaen, G; Bulle, F				Siegrist, S; Feral, C; Chami, M; Solhonne, B; Mattei, MG; Rajpert-De Meyts, E; Guellaen, G; Bulle, F			hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors	ONCOGENE			English	Article						hH-Rev107; tumor suppressor gene; spermatogenesis; carcinoma in situ; testicular germ cell tumors	CARCINOMA-IN-SITU; DOWN-REGULATION; HUMAN TESTIS; CANCER; IDENTIFICATION; HYBRIDIZATION; H-REV107; RNA; CHROMOSOME; CLONING	By systematic analysis of a human testis library, we have isolated the hH-Rev107-3 cDNA, identical to hH-Rev107-1 cDNA, which was previously described as a class II tumor suppressor gene. In this study, two transcripts (I and 0.8 kb) were detected by Northern blot in all human tissues, excepted in thymus. The strongest expression was found in testis, skeletal muscle and heart. These two mRNA are probably transcribed from only one gene that we mapped to the q12-q13 region of the chromosome 11. In human testis, hH-Rev107 gene expression was localized, by in situ hybridization, within the round spermatids. To investigate a possible role for hH-Rev107 protein in testicular malignant growth, we examined the expression of this gene in germ cell tumors. A strong hH-Rev107 gene expression was observed in normal testis as well as in samples with preinvasive carcinoma in situ but was completely absent in overt tumors, both seminomas and non-seminomas. By in situ hybridization, CIS was found hH-ReP107 positive and tumor negative. A semi-quantitative assessment of hH-Rev107 mRNA level in testicular germ cell tumors, by RT-PCR, exhibited a ninefold decrease in the gene expression. No gross structural aberrations of hH-Rev107 gene were detected in these human primary tumors. The results suggest that down-regulation of hH-Rev107 may be associated with invasive progression of testicular germ cell tumors.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France; Fac Med Marseille, INSERM, U491, F-13385 Marseille, France; Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Rigshospitalet; University of Copenhagen	Bulle, F (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.		Feral, Chloe C/O-5781-2016; Bulle-Thomas, Frederique/L-2528-2017; FERAL, Chloe/AAB-6111-2020; Rajpert-De Meyts, Ewa/H-6526-2019; Chami, Mounia/S-6471-2019	Feral, Chloe C/0000-0001-9756-2082; FERAL, Chloe/0000-0001-9756-2082; Rajpert-De Meyts, Ewa/0000-0002-5946-7559; Chami, Mounia/0000-0003-1498-7187				Bartkova J, 2000, INT J CANCER, V85, P370, DOI 10.1002/(SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO;2-A; BOS JL, 1989, CANCER RES, V49, P4682; Braun RE, 1998, SEMIN CELL DEV BIOL, V9, P483, DOI 10.1006/scdb.1998.0226; Bulle F, 1996, ANN GENET-PARIS, V39, P139; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Duvic M, 2000, CLIN CANCER RES, V6, P3249; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; HAJNAL A, 1994, ONCOGENE, V9, P479; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; Levy I, 1996, FEBS LETT, V382, P276, DOI 10.1016/0014-5793(96)00183-4; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MOUL JW, 1992, GENE CHROMOSOME CANC, V5, P109, DOI 10.1002/gcc.2870050204; MULDER MP, 1989, ONCOGENE, V4, P1345; PAWLAK A, 1995, GENOMICS, V26, P151, DOI 10.1016/0888-7543(95)80096-5; PECKHAM M, 1988, ACTA ONCOL, V27, P439, DOI 10.3109/02841868809093570; Rajpert-De Meyts E, 1998, APMIS, V106, P198; RICHIE JP, 1993, CA-CANCER J CLIN, V43, P151, DOI 10.3322/canjclin.43.3.151; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SCHMIDT B, 1995, J MOL MED, V73, P355; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x	28	25	27	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5155	5163		10.1038/sj.onc.1204658	http://dx.doi.org/10.1038/sj.onc.1204658			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526504	Green Submitted, Green Accepted			2022-12-28	WOS:000170464000009
J	Zhong, J; Troppmair, J; Rapp, UR				Zhong, J; Troppmair, J; Rapp, UR			Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria	ONCOGENE			English	Article						Raf; Bcl-2; apoptosis; mitochondria	NF-KAPPA-B; INDUCED APOPTOSIS; FAMILY PROTEINS; KINASE RAF-1; DEATH; EXPRESSION; MICE; PHOSPHORYLATION; TRANSFORMATION; TRANSLOCATION	Bcl-2 family proteins play a critical role in the regulation of cell survival by controlling the activation of the cell death executing caspase machinery. Recent work demonstrated that they also provide a link between growth factor signaling and cell survival control. Raf-1 has been identified initially as an essential component of the mitogenic Ras-Raf-MEK-ERK cascade. However, expression of oncogenic Raf-1 also efficiently suppresses apoptotic cell death. This process requires mitochondrial translocation of Raf-1 which can be achieved either by co-expression of the anti-apoptotic protein Bcl-2 or by fusion with the transmembrane domain of the yeast outer mitochondrial membrane protein Mas 70p. It is currently unclear how mitochondrial Raf-1 prevents apoptosis. One possible mechanism involves the phosphorylation of the pro-apoptotic protein Bad resulting in the restoration of Bcl-2 function. Alternatively, the role of Bcl-2 could be limited to the mitochondrial translocation of Raf-1 and survival signaling by Raf-1 is Bcl-2 independent. To test for the mutual requirement of Raf-1 and Bcl-2 in apoptosis suppression the individual proteins were singly tested for survival activity in a genetic background which precludes the expression of the other. The results obtained in these studies demonstrate that ablation of Raf-1 or Bcl-2 expression in fibroblast cells significantly increases the sensitivity towards doxorubicin induced cell death. Reversion of the mutant phenotype could be achieved in either case by introducing a functional bcl-2 gene or a mitochondria targeted version of oncogenic Raf-1, demonstrating that each protein by itself is sufficient to confer protection. Our data thus suggest the existence of two separate pathways of survival signaling at the mitochondria controlled either by Bcl-2 or by Raf-1.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lau QC, 1998, ONCOGENE, V16, P1899, DOI 10.1038/sj.onc.1201709; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Naumann U, 1997, Recent Results Cancer Res, V143, P237; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	44	49	52	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4807	4816		10.1038/sj.onc.1204614	http://dx.doi.org/10.1038/sj.onc.1204614			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521192				2022-12-28	WOS:000170271800005
J	Gage, BM; Alroy, D; Shin, CY; Ponomareva, ON; Dhar, S; Sharma, GG; Pandita, TK; Thayer, MJ; Turker, MS				Gage, BM; Alroy, D; Shin, CY; Ponomareva, ON; Dhar, S; Sharma, GG; Pandita, TK; Thayer, MJ; Turker, MS			Spontaneously immortalized cell lines obtained from adult Atm null mice retain sensitivity to ionizing radiation and exhibit a mutational pattern suggestive of oxidative stress	ONCOGENE			English	Article						immortalized Atm null cells; ionizing radiation; mutagenesis oxidative stress	ATAXIA-TELANGIECTASIA; DEFICIENT MICE; POSTCONFLUENCE INHIBITION; TELOMERASE ACTIVITY; MUTATOR PHENOTYPE; END ASSOCIATIONS; MOUSE APRT; RESISTANCE; DEFECTS; CANCER	The study of Ataxia-telangiectasia (A-T) has benefited significantly from mouse models with knockout mutations for the Atm (A-T mutation) locus. While these models have proven useful for in vivo studies, cell cultures from Atm null embryos have been reported to grow poorly and then senesce. In this study, we initiated primary cultures from adult ears and kidneys of Atm homozygous mice and found that these cultures immortalized readily without loss of sensitivity to ionizing radiation and other Atm related cell cycle defects. A mutational analysis for loss of expression of an autosomal locus showed that ionizing radiation had a mutagenic effect, Interestingly, some spontaneous mutants exhibited a mutational pattern that is characteristic of oxidative mutagenesis, This result is consistent with chronic oxidative stress in Atm null cells. In total, the results demonstrate that permanent cell lines can be established from the tissues of adult mice homozygous for Atm and that these cell lines will exhibit expected and novel consequences of this deficiency.	Oregon Hlth Sci Univ, CROET, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA; Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Oregon Health & Science University; Columbia University; Oregon Health & Science University; Oregon Health & Science University	Turker, MS (corresponding author), Oregon Hlth Sci Univ, CROET, Ctr Res Occupat & Environm Toxicol, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Pandita, Tej K/AAM-9188-2020		NCI NIH HHS [CA56383, CA76528] Funding Source: Medline; NIGMS NIH HHS [GM49334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076528, R01CA056383] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; COLE J, 1988, INT J RADIAT BIOL, V54, P929, DOI 10.1080/09553008814552331; COOPER GE, 1992, SOMAT CELL MOLEC GEN, V18, P215, DOI 10.1007/BF01233858; COOPER GE, 1991, SOMAT CELL MOLEC GEN, V17, P105, DOI 10.1007/BF01232969; DICKERMAN LH, 1978, MUTAT RES, V49, P83, DOI 10.1016/0027-5107(78)90080-5; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Freyer GA, 1996, MUTAT RES-FUND MOL M, V357, P237, DOI 10.1016/0027-5107(96)00130-3; Gatei M, 2001, ONCOGENE, V20, P289, DOI 10.1038/sj.onc.1204111; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HEIM RA, 1992, MUTAT RES, V284, P25, DOI 10.1016/0027-5107(92)90022-T; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HORN PL, 1984, J CELL PHYSIOL, V121, P309, DOI 10.1002/jcp.1041210207; Khattar NH, 1997, SOMAT CELL MOLEC GEN, V23, P51, DOI 10.1007/BF02679955; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Pandita TK, 1996, RADIAT RES, V145, P730, DOI 10.2307/3579364; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; ROSCHEISEN C, 1994, SOMAT CELL MOLEC GEN, V20, P493, DOI 10.1007/BF02255840; Rose JA, 2000, CANCER RES, V60, P3404; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; TURKER M, 1995, MUTAT RES-FUND MOL M, V329, P97, DOI 10.1016/0027-5107(95)00046-L; Turker MS, 1999, CANCER RES, V59, P1837; Turker MS, 1999, CANCER RES, V59, P4781; Walker KA, 1997, SOMAT CELL MOLEC GEN, V23, P111, DOI 10.1007/BF02679970; Westphal CH, 1998, CANCER RES, V58, P5637; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	34	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4291	4297		10.1038/sj.onc.1204509	http://dx.doi.org/10.1038/sj.onc.1204509			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466609				2022-12-28	WOS:000169912600002
J	Huang, SY; Pettaway, CA; Uehara, H; Bucana, CD; Fidler, IJ				Huang, SY; Pettaway, CA; Uehara, H; Bucana, CD; Fidler, IJ			Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis	ONCOGENE			English	Article						prostate cancer; NF-kappa B; angiogenesis; invasion; metastasis	PROINFLAMMATORY CYTOKINE EXPRESSION; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; CONSTITUTIVE ACTIVATION; PERMEABILITY FACTOR; ALPHA PROTEOLYSIS; MELANOMA-CELLS; INHIBITION; TUMORIGENICITY; INTERLEUKIN-8	Since the NF-kappaB/relA transcription factor is constitutively activated in human prostate cancer cells, we determined whether blocking NF-kappaB/relA activity in human prostate cancer cells affected their angiogenesis, growth, and metastasis in an orthotopic nude mouse model. Highly metastatic PC-3M human prostate cancer cells were transfected with a mutated I kappa -B alpha (I kappaB alphaM), which blocks NF-KB activity. Parental (PC3M), control vector-transfected (PC-3M-Neo), and I kappa -B alphaM-transfected (PC-3M-I kappaB alphaM) cells were injected into the prostate gland of nude mice. PC3M and PC-3M-Neo cells produced rapidly growing tumors and regional lymph node metastasis, whereas PC-3M-I kappaB alphaM cells produced slow growing tumors with low metastatic potential. NF-kappaB signaling blockade significantly inhibited in vitro and in vivo expression of three major proangiogenic molecules, VEGF, IL-8, and MMP-9, and hence decreased neoplastic angiogenesis, Inhibition of NF-kappaB activity in PC-3M cells also resulted in the downregulation of MMP-9 mRNA and collagenase activity, resulting in decreased invasion through Matrigel. Collectively, these data suggest that blockade of NF kappaB activity in PC-3M cells inhibits angiogenesis, invasion, and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fidler, IJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	ijfidler@mdanderson.org			NATIONAL CANCER INSTITUTE [R35CA042107, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA42107, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; Balbay MD, 1999, CLIN CANCER RES, V5, P783; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Borgstrom P, 1998, PROSTATE, V35, P1; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dong G, 1999, CANCER RES, V59, P3495; Duffey DC, 1999, CANCER RES, V59, P3468; Duque JLF, 1999, UROLOGY, V54, P523, DOI 10.1016/S0090-4295(99)00167-3; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; FERRER FA, 1999, J UROLOGY, V6, P2329; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Folkman J, 1992, Semin Cancer Biol, V3, P65; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Gilmore TD, 1996, ONCOGENE, V13, P1367; Giri D, 1999, CLIN CANCER RES, V5, P1063; Greene GF, 1997, AM J PATHOL, V150, P1571; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HAMDY FC, 1994, BRIT J CANCER, V69, P177, DOI 10.1038/bjc.1994.30; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang S, 2000, CLIN CANCER RES, V6, P2573; Inoue K, 2000, CLIN CANCER RES, V6, P2104; JACKSON MW, 1997, J UROLOGY, V6, P2323; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MELNYK O, 1999, J UROLOGY, V3, P960; Meyskens FL, 1999, CLIN CANCER RES, V5, P1197; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; NAKAMOTO T, 1992, CANCER RES, V52, P571; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Puyraimond A, 1999, J CELL SCI, V112, P1283; RAY JM, 1994, EUR RESPIR J, V7, P2062; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Ripple MO, 1999, JNCI-J NATL CANCER I, V91, P1227, DOI 10.1093/jnci/91.14.1227; SATO H, 1993, J BIOL CHEM, V268, P23460; Sehgal G, 1998, AM J PATHOL, V152, P591; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Veltri RW, 1999, UROLOGY, V53, P139, DOI 10.1016/S0090-4295(98)00455-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Villarete LH, 1996, AM J PATHOL, V149, P1685; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; YOKOO T, 1996, AM J PHYSIOL, V2, P123; Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624	65	488	523	0	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4188	4197		10.1038/sj.onc.1204535	http://dx.doi.org/10.1038/sj.onc.1204535			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464285				2022-12-28	WOS:000169857200009
J	Belzacq, AS; El Hamel, C; Vieira, HLA; Cohen, I; Haouzi, D; Metivier, D; Marchetti, P; Brenner, C; Kroemer, G				Belzacq, AS; El Hamel, C; Vieira, HLA; Cohen, I; Haouzi, D; Metivier, D; Marchetti, P; Brenner, C; Kroemer, G			Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437	ONCOGENE			English	Article						apoptosis; ATP; cell death; Bcl-2; vMIA; chemotherapy	PROGRAMMED CELL-DEATH; CYTOCHROME-C; TRANSITION PORE; NEUROBLASTOMA-CELLS; APOPTOSIS; BCL-2; BAX; NECROSIS; RELEASE; CHANNEL	An increasing number of experimental chemotherapeutic agents induce apoptosis by directly triggering mitochondrial membrane permeabilization (MMP). Here we examined MMP induced by lonidamine, arsenite, and the retinoid derivative CD437. Cells overexpressing the cytomegalovirus-encoded protein vMIA, a protein which interacts with the adenine nucleotide translocator, were strongly protected against the MMP-inducing and apoptogenic effects of lonidamine, arsenite, and CD437. In a cell-free system, lonidamine, arsenite, and CD437 induced the permeabilization of ANT proteoliposomes, yet had no effect on protein-free liposomes. The ANT-dependent membrane permeabilization was inhibited by the two ANT ligands ATP and ADP, as well as by recombinant Bcl-2 protein. Lonidamine, arsenite, and CD437, added to synthetic planar lipid bilayers containing ANT, elicited ANT channel activities with clearly distinct conductance levels of 20+/-7, 100+/-30, and 47+/-7 pS, respectively. Altering the ATP/ADP gradient built up on the inner mitochondrial membrane by inhibition of glycolysis and/or oxidative phosphorylation differentially modulated the cytocidal potential of lonidamine, arsenite, and CD437. Inhibition of F(0)F(1)ATPase without glycolysis inhibition sensitized to lonidamine-induced cell death. In contrast, only the combined inhibition of glycolysis plus F(0)F(1)ATPase sensitized to arsenite-induced cell death. No sensitization to cell death induction by CD437 was achieved by glucose depletion and/or oligomycin addition. These results indicate that ANT is a target of lonidamine, arsenite, and CD437 and unravel an unexpected heterogeneity in the mode of action of these three compounds.	Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Univ Technol Compiegne, CNRS, UMR 6022, F-60205 Compiegne, France; INSERM, U459, F-59045 Lille, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.		KROEMER, Guido/B-4263-2013; brenner, catherine/AAE-8632-2020; Vieira, Helena/AAZ-9562-2021; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Vieira, Helena/0000-0001-9415-3742; MARCHETTI, Philippe/0000-0002-4663-6800				Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Andre N, 2000, CANCER RES, V60, P5349; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Belzacq AS, 2001, CANCER RES, V61, P1260; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Colberg-Poley AM, 2000, J GEN VIROL, V81, P1779, DOI 10.1099/0022-1317-81-7-1779; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Genini D, 2000, BLOOD, V96, P3537; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Marchetti P, 1999, CANCER RES, V59, P6257; Martin DS, 2000, CANCER RES, V60, P6776; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watabe M, 2000, CANCER RES, V60, P5214; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	52	174	180	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7579	7587		10.1038/sj.onc.1204953	http://dx.doi.org/10.1038/sj.onc.1204953			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753636				2022-12-28	WOS:000172124100001
J	Hideshima, T; Nakamura, N; Chauhan, D; Anderson, KC				Hideshima, T; Nakamura, N; Chauhan, D; Anderson, KC			Biologic sequelae of interleukin-6 induced P13-K/Akt signaling in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; IL-6; SHP2; P13-K; Akt; apoptosis; caspase-9	PROTEIN-KINASE-B; DEXAMETHASONE-INDUCED APOPTOSIS; PLECKSTRIN-HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; CELL-GROWTH; TRANSDUCTION PATHWAY; INHIBITS APOPTOSIS; PLASMA-CELLS; PHOSPHORYLATION; ACTIVATION	Previous studies demonstrate that interleukin-6 (IL-6) mediates growth and survival in human multiple myeloma (MM) cells via the MEK/MAPK and JAK/STAT signaling pathways, respectively. IL-6 also confers protection against Dexamethasone (Dex)-induced apoptosis via activation of protein tyrosine phosphatase (SHP2). In the current study, we characterized IL-6 triggered phophatidylinositol-3 kinase/Akt kinase (PI3K/Akt) signaling in MM cells. IL-6 induces Akt/PKB phosphorylation in a time and dose dependent manner in MMAS MM cells. IL-6 also induced phosphorylation of downstream targets of Akt, including Bad, GSK-3 beta, and FKHR, confirming Akt activation. Inhibition of Akt activation by the PI3-K inhibitor LY294002 partially blocked IL-6 triggered MEK/MAPK activation and proliferation in MMAS cells, suggesting cross-talk between PI3-K and MEK signaling. We demonstrate that Dex-induced apoptosis in MM.1S cells is mediated by downstream activation of caspase-9, with resultant caspase-3 cleavage; and conversely, that IL-6 triggers activation of PI3-K and its association with SHP2, inactivates caspase-9, and protects against Dex-induced apoptosis. LY294002 completely abrogates this signaling cascade, further confirming the importance of PI3-K/Akt signaling in conferring the protective effect of IL-6 against Dex-induced apoptosis. Finally, we show that IL-6 triggered PI3-K/Akt signaling in MMAS cells inactivates forkhead transcriptional factor (FKHR), with related G1/S phase transition, whereas LY294002 blocks this signaling, resulting in upregulation of p27(KIPI) and G1 growth arrest. Our data therefore suggest that PI3-K/ Akt signaling mediates growth, survival, and cell cycle regulatory effects of IL-6 in MM.	Dana Farber Canc Inst, Dept Adult Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Jerome Lipper Multiple Myeloma Ctr, M557,44 Binney St, Boston, MA 02115 USA.				NIMH NIH HHS [R01 MH 50947, P01 MH 78378] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050947] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chung TDK, 2000, PROSTATE, V42, P1; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; DEL PL, 1997, SCIENCE, V278, P687; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Ge NL, 2000, BLOOD, V96, P2856; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2000, CLIN CANCER RES, V6, P1180; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KLEIN B, 1989, BLOOD, V73, P517; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; NISHIMOTO N, 1994, J EXP MED, V179, P1343, DOI 10.1084/jem.179.4.1343; Ogata A, 1997, J IMMUNOL, V159, P2212; Ogawa M, 2000, CANCER RES, V60, P4262; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tu YP, 2000, CANCER RES, V60, P6763; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	50	390	402	0	23	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5991	6000		10.1038/sj.onc.1204833	http://dx.doi.org/10.1038/sj.onc.1204833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593406				2022-12-28	WOS:000171056300006
J	Knight, MJ; Riffkin, CD; Muscat, AM; Ashley, DM; Hawkins, CJ				Knight, MJ; Riffkin, CD; Muscat, AM; Ashley, DM; Hawkins, CJ			Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells	ONCOGENE			English	Article						apoptosis; glioma; resistance; TRAIL; Fas; Bcl-2	INHIBITORY PROTEIN EXPRESSION; HUMAN-MELANOMA CELLS; MEDIATED APOPTOSIS; MALIGNANT GLIOMA; DECOY RECEPTOR; DEATH PATHWAY; LIGAND TRAIL; CASPASE-8; GENE; AMPLIFICATION	FasL and TNF-related apoptosis-inducing ligand (TRAIL) belong to a subgroup of the TNF superfamily which induce apoptosis by binding to their death domain containing receptors. In the present study we have utilized a panel of seven cell lines derived from human malignant gliomas to characterize molecular pathways through which FasL and TRAIL induce apoptosis in sensitive glioma cells and the mechanisms of resistance in cell lines which survive the death stimuli. Our findings indicate that FADD and Caspase-8 are essential for FasL and TRAIL mediated apoptosis in glioma cells. One sensitive cell line (D270) can be protected from FasL and TRAIL induced death by anti-apoptotic Bcl-2 family members while another (D645) cannot, implying that these lines may represent glioma examples of type II and type I cells respectively. For the first time we demonstrate resistance to FasL but not to TRAIL within the one glioma cell line. Furthermore, we report distinct mechanisms of resistance within different glioma lines, including downregulation of Caspase-8 in U373MG. Cycloheximide sensitized four of the resistant cell lines suggesting the presence of labile inhibitors. None of the known apoptosis inhibitors examined accounted for the observed resistance, suggesting novel inhibitors may exist in glioma cells.	Royal Childrens Hosp, Dept Haematol & Oncol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic, Australia	Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Royal Melbourne Hospital; University of Melbourne	Hawkins, CJ (corresponding author), Royal Childrens Hosp, Dept Haematol & Oncol, Flemington Rd, Parkville, Vic 3052, Australia.		Hawkins, Christine/B-8769-2011	Hawkins, Christine/0000-0001-8120-1071				Bai C, 2000, P NATL ACAD SCI USA, V97, P1230, DOI 10.1073/pnas.97.3.1230; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Coultas L, 2000, APOPTOSIS, V5, P491, DOI 10.1023/A:1009617727938; DELEEUW WJF, 1989, NUCLEIC ACIDS RES, V17, P10137, DOI 10.1093/nar/17.23.10137; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hao CH, 2001, CANCER RES, V61, P1162; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Hosli P, 1998, ANN ONCOL, V9, P589; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jenkins M, 2000, J BIOL CHEM, V275, P7988, DOI 10.1074/jbc.275.11.7988; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Keane MM, 1999, CANCER RES, V59, P734; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim KH, 2000, CLIN CANCER RES, V6, P335; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Leverkus M, 2000, CANCER RES, V60, P553; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Myc A, 1999, ENDOCRINOLOGY, V140, P5431, DOI 10.1210/en.140.11.5431; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1999, CELL MOL LIFE SCI, V56, P481, DOI 10.1007/s000180050447; Roth W, 2001, CANCER RES, V61, P2759; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Somia NV, 1999, P NATL ACAD SCI USA, V96, P12667, DOI 10.1073/pnas.96.22.12667; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wrone-Smith T, 2001, EXP HEMATOL, V29, P572, DOI 10.1016/S0301-472X(01)00627-0; Wu M, 2000, J NEUROSCI RES, V61, P464, DOI 10.1002/1097-4547(20000815)61:4<464::AID-JNR14>3.0.CO;2-G; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XJ, 2000, BIOCHEM BIOPH RES CO, V277, P487, DOI 10.1006/bbrc.2000.3699; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	64	84	88	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5789	5798		10.1038/sj.onc.1204810	http://dx.doi.org/10.1038/sj.onc.1204810			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593384				2022-12-28	WOS:000171037200002
J	Zhang, F; Taipale, M; Heiskanen, A; Laiho, M				Zhang, F; Taipale, M; Heiskanen, A; Laiho, M			Ectopic expression of Cdk6 circumvents transforming growth factor-beta mediated growth inhibition	ONCOGENE			English	Article						TGF-beta; cyclin-dependent kinase; cyclin-dependent kinase inhibitors; cell cycle regulation	CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITOR; TGF-BETA; EPITHELIAL-CELLS; MAMMALIAN-CELLS; P15(INK4B); PROTEIN; INK4; COMPLEXES; P27(KIP1)	Transforming growth factor-beta (TGF-beta) induced growth arrest of cells involves regulation of the activities of both D- and E-type cyclin kinase complexes thought to be mediated primarily by the regulation of p15(Ink4b) and p27(Kip1) cyclin kinase inhibitors. We show here that TGF-beta downregulates Cdk6 and that transient and stable expression of Cdk6 in Mv1Lu mink epithelial cells overrides TGF-beta mediated arrest. The main effect of the ectopic Cdk6 expression was to sequester TGF-P induced p15(Ink4b) and to maintain more p27(Kip1) in cyclin D-complexes preventing the complete shift of p27(Kip1) to Cdk2 invoked by TGF-beta. This led to the presence of an active cyclinD-Cdk6-p27(Kip1) complex and partially active cyclin E-Cdk2 complex and resulted in the failure of TGF-beta to fully arrest Mv1Lu cell growth. Though dominant negative Cdk6, expressed similarly in the cells, sequestered both p15(Ink4b) and p27(Kip1), it lacks kinase activity and was unable to override the TGF-beta arrest. The results demonstrate that downregulation of Cdk6 kinase is required for the enforcement of the G(1)-phase arrest by TGF-beta and results in changes in association of the p15(Ink4b) and p27(Kip1) inhibitors with D- and E-type cyclin kinase complexes.	Univ Helsinki, Mol Canc Biol Res Program, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland	University of Helsinki	Laiho, M (corresponding author), Univ Helsinki, Mol Canc Biol Res Program, Dept Virol, Haartman Inst, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.			Taipale, Minna/0000-0002-1905-2551				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Costello JF, 1997, CANCER RES, V57, P1250; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Easton J, 1998, CANCER RES, V58, P2624; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iavarone A, 1997, NATURE, V387, P417; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Parry D, 1999, MOL CELL BIOL, V19, P1775; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tsubari M, 1997, CANCER RES, V57, P2966; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Warner BJ, 1999, MOL CELL BIOL, V19, P5913	36	8	9	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5888	5896		10.1038/sj.onc.1204745	http://dx.doi.org/10.1038/sj.onc.1204745			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593394				2022-12-28	WOS:000171037200012
J	Jia, L; Patwari, Y; Srinivasula, SM; Newland, AC; Fernandes-Alnemri, T; Alnemri, ES; Kelsey, SM				Jia, L; Patwari, Y; Srinivasula, SM; Newland, AC; Fernandes-Alnemri, T; Alnemri, ES; Kelsey, SM			Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis	ONCOGENE			English	Article						apoptosis; Bax expression and translocation; caspases; chemotherapy; etoposide; leukaemia	CYTOCHROME-C; BCR-ABL; DEPENDENT APOPTOSIS; CASPASE ACTIVATION; BCL-2; P53; RELEASE; MITOCHONDRIA; INDUCTION; RESISTANT	Bax translocation from cytosol to mitochondria is believed to be a crucial step for triggering cytochrome c release from mitochondria. However, it is unclear whether Bax translocation is associated with Bax induction by DNA damaging agents. The induction of Bax in response to DNA damaging agents has been considered to be linked with p53. In this study, we used the p53 negative human chronic myeloid leukaemia K562 cell line. Bax up-regulation occurred at the whole cell level after DNA damage induced by etoposide. However, after incubation with etoposide, Bax failed to translocate to mitochondria and as a result, the apoptotic process was blocked. A Bax stable transfectant, the K/Bax cell line, expressed more Bax protein in the cytosol, mitochondria and nuclei. This Bax overexpression induced cytochrome c release, a reduction of cytochrome c oxidase activity and mitochondrial membrane potential (Delta Psim). However, Bax-induced apoptosis was blocked downstream of mitochondria in K562 cells. The increased levels of mitochondrial Bax sensitized cells to etoposide-induced activation of caspases-2, -3 and -9 and apoptosis. However, after transient transfection with the Apaf-1 gene, K/Bax cells were sensitized to etoposide-induced caspase activation and apoptosis to a larger extent compared with Bax or Apaf-1 transfection alone. We therefore conclude that two mechanisms contribute to the resistance of K562 cells to etoposide-induced apoptosis; firstly failure of Bax targeting to mitochondria and, secondly, deficiency of Apaf-1. Uncoupling of Bax translocation from Bax induction can occur in response to etoposide-induced DNA damage.	St Bartholomews & Royal London Sch Med & Dent, Dept Haematol, London E1 2AD, England; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA	University of London; Queen Mary University London; Jefferson University	Jia, L (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Haematol, Turner St, London E1 2AD, England.	L.Jia@mds.qmw.ac.uk	Alnemri, Emad S/B-4526-2010	Jia, Li/0000-0002-6076-8455				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fu WN, 2001, BIOCHEM BIOPH RES CO, V282, P268, DOI 10.1006/bbrc.2001.4575; Fukumi S, 2000, MOL CELL BIOCHEM, V206, P43, DOI 10.1023/A:1007056727876; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jia L, 1996, BLOOD, V87, P2401, DOI 10.1182/blood.V87.6.2401.bloodjournal8762401; Jia L, 1997, BRIT J HAEMATOL, V98, P686, DOI 10.1046/j.1365-2141.1997.2683085.x; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; KANTER PM, 1982, MOL PHARMACOL, V22, P145; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MIYASHITA T, 1995, CELL, V80, P293; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PROKOCIMER M, 1986, BLOOD, V68, P113; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Svingen PA, 2000, BLOOD, V96, P3922, DOI 10.1182/blood.V96.12.3922.h8003922_3922_3931; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZHAN QM, 1994, ONCOGENE, V9, P3743	31	69	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4817	4826		10.1038/sj.onc.1204628	http://dx.doi.org/10.1038/sj.onc.1204628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521193				2022-12-28	WOS:000170271800006
J	Furukawa, T; Adachi, Y; Fujisawa, J; Kambe, T; Yamaguchi-Iwai, Y; Sasaki, R; Kuwahara, J; Ikehara, S; Tokunaga, R; Taketani, S				Furukawa, T; Adachi, Y; Fujisawa, J; Kambe, T; Yamaguchi-Iwai, Y; Sasaki, R; Kuwahara, J; Ikehara, S; Tokunaga, R; Taketani, S			Involvement of PLAGL2 in activation of iron deficient- and hypoxia-induced gene expression in mouse cell lines	ONCOGENE			English	Article						PLAGL; PLAG; iron; hypoxia; HIF-1	ZINC-FINGER PROTEIN; LACTATE-DEHYDROGENASE-A; INDUCIBLE FACTOR-1; TRANSCRIPTIONAL ACTIVATION; PLEOMORPHIC ADENOMAS; ERYTHROPOIETIN GENE; BINDING-PROTEIN; IDENTIFICATION; ZAC1; DEFEROXAMINE	We searched iron-deficient inducible cDNA, using subtraction cloning and mRNA from desferrioxamine-treated mouse macrophage Raw264.7 cells. We identified a pleomorphic adenoma gene like 2 (PLAGL2), one of PLAG superfamily proteins exhibiting antiproliferative properties on tumor cells. Mouse PLAGL2 consists of 496 amino acids with seven C2H2 zinc-fingers. PLAGL2 mRNA was induced in RAW264.7 cells, mouse erythroleukemia cells and Balb/c 3T3 cells when they were treated with desferrioxamine. Hypoxia also increased PLAGL2 mRNA. Expression of PLAGL2 in COS-7 cells led to nuclear localization. PLAGL2 had potential binding ability to GC-rich oligonucleotide and activated transcription of a gene with the binding sequence in transient reporter assay, a finding consistent with a case seen in a PLAGL2 homolog, ZAC-1. Transient co-transfection of PLAGL2 or ZAC1 cDNA and a reporter containing a lactate dehydrogenase A (LDHA) promoter carrying the hypoxia inducible factor-1 responsive element led to an increase in the basal transcription in Balb/c 3T3 and HepG2 cells. Activation in transcription from the LDHA promoter increased by desferrioxamine treatment or hypoxia was further enhanced when PLAGL2 was expressed. We propose that PLAGL2 is involved in the cell cycle arrest and apoptosis of tumor cells by regulating iron depletion- or hypoxia-inducible gene expression.	Kansai Med Univ, Dept Hyg, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Dept Microbiol, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Dept Pathol 1, Moriguchi, Osaka 5708506, Japan; Kyoto Univ, Dept Life Sci, Kyoto 60601, Japan; Univ Tokushima, Fac Pharmaceut Sci, Inst Med Resources, Tokushima 7708505, Japan; Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan	Kansai Medical University; Kansai Medical University; Kansai Medical University; Kyoto University; Tokushima University; Kyoto Institute of Technology	Furukawa, T (corresponding author), Kansai Med Univ, Dept Hyg, Moriguchi, Osaka 5708506, Japan.	furukawa@takii.kmu.ac.jp						Abdollahi A, 1997, CANCER RES, V57, P2029; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kadota Y, 1997, MOL BRAIN RES, V46, P265, DOI 10.1016/S0169-328X(97)00023-5; Kambe T, 1998, BLOOD, V91, P1185, DOI 10.1182/blood.V91.4.1185; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kas K, 1997, GENOMICS, V43, P349, DOI 10.1006/geno.1997.4819; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Mohri T, 1999, EXP CELL RES, V253, P533, DOI 10.1006/excr.1999.4720; NOCKA KH, 1988, CANCER RES, V48, P3571; Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; SELF AJ, 1995, METHOD ENZYMOL, V258, P3; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Taketani S, 1998, J BIOL CHEM, V273, P31388, DOI 10.1074/jbc.273.47.31388; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Wang F, 1999, ANTICANCER RES, V19, P445; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Ye Z, 1999, BIOCHEM BIOPH RES CO, V264, P709, DOI 10.1006/bbrc.1999.1554; Zhang YM, 1997, GENE CHROMOSOME CANC, V18, P310, DOI 10.1002/(SICI)1098-2264(199704)18:4<310::AID-GCC10>3.0.CO;2-K	34	47	51	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4718	4727		10.1038/sj.onc.1204647	http://dx.doi.org/10.1038/sj.onc.1204647			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498794				2022-12-28	WOS:000170208600012
J	Brett, D; Kemmner, W; Koch, G; Roefzaad, C; Gross, S; Schlag, PM				Brett, D; Kemmner, W; Koch, G; Roefzaad, C; Gross, S; Schlag, PM			A rapid bioinformatic method identifies novel genes with direct clinical relevance to colon cancer	ONCOGENE			English	Article						EST; splicing variants; bioinformatic; colon cancer; metastasis; patient survival	COLORECTAL-CANCER; TUMOR	Identifying genes whose differential expression affect the survival of patients after primary tumor surgery is a major aim of clinical cancer research. To address this issue we combined rapid bioinformatic search algorithms with quantitative RT-PCR in a panel of clearly defined cases of colorectal carcinomas with detailed patient histories. Search algorithms were written that identified Expressed Sequence Tags (ESTs) from the Unigene EST collection of putative open reading frames (ORFs). Expression ratios of healthy to cancerous tissue of each Unigene ORF were calculated. The first 35 candidates arising from bioinformatic searches were examined for mRNA expression in a panel of 20 well documented cases of colon cancer. Four of these 35 genes showed significant correlations with histopathological parameters. Therefore, their expression was further analysed by quantitative RT-PCR in a larger patient cohort. Kaplan-Meier/log rank statistical tests of up to 49 patients in three of the four genes demonstrated significant association of gene expression with poor survival. All four genes demonstrated a strong association with metastatic tumor progression. Expression of the genes was localized to epithelial cells by in-situ hybridization.	Max Delbruck Ctr Mol Med, Klinikum Charite, Robert Rossle Klin, Dept Surg & Surg Oncol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Bioinformat, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kemmner, W (corresponding author), Max Delbruck Ctr Mol Med, Klinikum Charite, Robert Rossle Klin, Dept Surg & Surg Oncol, Lindenberger Weg 80, D-13125 Berlin, Germany.							BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Gazelle GS, 2000, RADIOLOGY, V215, P327, DOI 10.1148/radiology.215.2.r00ma19327; Halaschek-Wiener J, 2000, MOL MED, V6, P693, DOI 10.1007/BF03402049; Kim JC, 2000, CANCER RES, V60, P4825; Lal A, 1999, CANCER RES, V59, P5403; McLeod HL, 1999, BRIT J CANCER, V79, P191, DOI 10.1038/sj.bjc.6690033; Schmitt AO, 1999, NUCLEIC ACIDS RES, V27, P4251, DOI 10.1093/nar/27.21.4251; SCHNEIDER F, 2001, IN PRESS CANC RES; STEINBERG SM, 1986, CANCER-AM CANCER SOC, V57, P1866, DOI 10.1002/1097-0142(19860501)57:9<1866::AID-CNCR2820570928>3.0.CO;2-T; Verdecchia A, 1998, INT J CANCER, V77, P322, DOI 10.1002/(SICI)1097-0215(19980729)77:3<322::AID-IJC2>3.0.CO;2-Q	10	10	10	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4581	4585		10.1038/sj.onc.1204610	http://dx.doi.org/10.1038/sj.onc.1204610			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494154				2022-12-28	WOS:000170074900016
J	Kim, MY; Park, E; Park, JH; Park, DH; Moon, WS; Cho, BH; Shin, HS; Kim, DG				Kim, MY; Park, E; Park, JH; Park, DH; Moon, WS; Cho, BH; Shin, HS; Kim, DG			Expression profile of nine novel genes differentially expressed in hepatitis B virus-associated hepatocellular carcinomas	ONCOGENE			English	Article						HCC; HBV; genes; DD-PCR; hepatocarcinogenesis	SECRETORY-TRYPSIN-INHIBITOR; SERUM ALPHA-FETOPROTEIN; MESSENGER-RNA; FACTOR-II; TUMOR-MARKER; LIVER; H19; PROTEINS; CLONING; DNA	Chronic hepatitis B virus (HBV) infection is known to be one of the major causes in the development of hepatocellular carcinoma (HCC), although the biomolecular mechanism(s) involved remain unclear. To identify the cellular gene(s) involved in HBV-associated hepatocarcinogenesis, we used the mRNA differential display method and examined three paired tumor and nontumor tissues, all of which had chromosomally integrated HBV-DNA through chronic infection. Using 240 different combinations of three one-base anchored oligo-dT primers and 80 arbitrary 13-mers, genes decreased or increased in expression more than twofold between each tumor tissue and its paired nontumor tissue were identified. Twenty-nine known genes and four novel genes were differentially over-expressed in the HCC tumor tissues. In contrast, 27 known genes and five novel genes were under-expressed in those tumor tissues. The nucleotide sequences of the nine novel gene fragments were determined and their expression patterns were examined in 40 HCC samples. HA61T2, PT18, HG63T1, and HG57T1 were preferentially over-expressed in 32 cases (80%, P<0.001), 24 cases (60%), 23 cases (57.5%) and 22 cases (55%) of the 40 tumor tissues, respectively. There was an increased frequency of HG57T1 over-expression in HCC patients with HBV-positive serology and low serum alpha-feto protein (AFP) levels (P<0.05). DNT10, PTB, PT19, ENT25 and HA6T4 were under-expressed in 26 cases (65%), 23 cases (57.5%), 21 cases (53%), 20 cases (50%) and 18 cases (45%) of the 40 tumor samples, respectively. There was a strong correlation of DNT10 under-expression with high serum AFP level in HCC patients, irrespective of HBV serology (P<0.01). HA6T4 was preferentially under-expressed in HCC tumors in patients with HBV-positive serology and high serum AFP levels (P<0.05). Thus, the functional analyses of the known and novel genes identified in this study should prove valuable to further understand the mechanism(s) of hepatocarcinogenesis.	Chonbuk Natl Univ, Med Sch & Hosp, Res Inst Clin Med, Div GI & Hepatol,Dept Internal Med, Chonju 561712, Chonbuk, South Korea; Chonbuk Natl Univ, Med Sch & Hosp, Dept Anat Pathol, Chonju 561712, Chonbuk, South Korea; Chonbuk Natl Univ, Med Sch & Hosp, Dept Gen Surg, Chonju 561712, Chonbuk, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungpuk, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Pohang University of Science & Technology (POSTECH)	Kim, DG (corresponding author), Chonbuk Natl Univ, Med Sch & Hosp, Res Inst Clin Med, Div GI & Hepatol,Dept Internal Med, Chonju 561712, Chonbuk, South Korea.							ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; AKSOY S, 1994, J BIOL CHEM, V269, P14835; Ariel I, 1998, J CLIN PATHOL-MOL PA, V51, P21, DOI 10.1136/mp.51.1.21; BARNARD GF, 1992, CANCER RES, V52, P3067; BARNARD GF, 1993, CANCER RES, V53, P4048; Bayati N, 1998, AM J GASTROENTEROL, V93, P2452, DOI 10.1111/j.1572-0241.1998.00703.x; Buendia M A, 1992, Semin Cancer Biol, V3, P309; CAIRO G, 1993, EXP CELL RES, V206, P255, DOI 10.1006/excr.1993.1145; CARIANI E, 1988, CANCER RES, V48, P6844; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHEN DS, 1979, CANCER-AM CANCER SOC, V44, P984, DOI 10.1002/1097-0142(197909)44:3<984::AID-CNCR2820440328>3.0.CO;2-6; CHEN PJ, 1989, GASTROENTEROLOGY, V96, P527, DOI 10.1016/0016-5085(89)91581-3; DeRisi J, 1996, NAT GENET, V14, P457; HSIA CC, 1994, J MED VIROL, V44, P67, DOI 10.1002/jmv.1890440113; Hu RH, 1999, J FORMOS MED ASSOC, V98, P85; HUANG LR, 1995, CANCER RES, V55, P4717; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Kim DG, 1999, HEPATOLOGY, V29, P1091, DOI 10.1002/hep.510290414; Kim KS, 1997, CANCER LETT, V119, P143, DOI 10.1016/S0304-3835(97)00264-4; KOSHY R, 1981, J GEN VIROL, V57, P95, DOI 10.1099/0022-1317-57-1-95; LASSERRE C, 1992, CANCER RES, V52, P5089; LAURENCE C, 1994, GASTROENTEROLOGY, V106, P1312; LAWSON D, 1975, CANCER RES, V35, P156; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MATSUNO T, 1992, CANCER RES, V52, P1192; Montalto G, 1998, ONCOLOGY-BASEL, V55, P421, DOI 10.1159/000011889; MURATA A, 1988, LIFE SCI, V43, P1233, DOI 10.1016/0024-3205(88)90213-5; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OHMACHI Y, 1993, INT J CANCER, V55, P728, DOI 10.1002/ijc.2910550505; Okamura A, 1998, JPN J CANCER RES, V89, P649, DOI 10.1111/j.1349-7006.1998.tb03267.x; PENG SY, 1993, HEPATOLOGY, V17, P35, DOI 10.1016/0270-9139(93)90188-S; RAINIER S, 1995, CANCER RES, V55, P1836; Ross JA, 1999, CANCER, V85, P1389, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1389::AID-CNCR24>3.0.CO;2-V; ROTHSTEIN JL, 1993, METHOD ENZYMOL, V225, P587; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; Scuric Z, 1998, HEPATOLOGY, V27, P943, DOI 10.1002/hep.510270408; Sohda T, 1998, J HUM GENET, V43, P49, DOI 10.1007/s100380050036; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SU TS, 1989, CANCER RES, V49, P1773; TIMBLIN C, 1990, NUCLEIC ACIDS RES, V18, P1587, DOI 10.1093/nar/18.6.1587; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; Wake N, 1998, INT J GYNECOL OBSTET, V60, pS1, DOI 10.1016/S0020-7292(96)02403-4; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG X, 1994, CANCER RES, V54, P4177	48	32	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4568	4575		10.1038/sj.onc.1204626	http://dx.doi.org/10.1038/sj.onc.1204626			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494152				2022-12-28	WOS:000170074900014
J	Langa, F; Lafon, I; Vandormael-Pournin, S; Vidaud, M; Babinet, C; Morello, D				Langa, F; Lafon, I; Vandormael-Pournin, S; Vidaud, M; Babinet, C; Morello, D			Healthy mice with an altered c-myc gene: role of the 3 ' untranslated region revisited	ONCOGENE			English	Article						ARE; Cre/loxP; ES cells; mRNA stability; neomycin; targeted mutagenesis	MESSENGER-RNA STABILITY; MOUSE-LIVER REGENERATION; AU-RICH ELEMENTS; POSTTRANSCRIPTIONAL REGULATION; 3'-UNTRANSLATED REGION; PROTEIN-SYNTHESIS; BINDING PROTEIN; TRANSGENIC MICE; HALF-LIFE; DEGRADATION	c-Myc is a protooncogene involved in the control of cellular proliferation, differentiation and apoptosis, Like many other early response genes, regulation of c-myc expression is mainly controlled at the level of mRNA stability. Multiple cls-acting destabilizing elements have been described that are located both in the protein-coding region and in the 3 ' untranslated region (3 ' UTR), However, it is not known when they function during development and whether they act as partly redundant or independent elements to regulate c-myc mRNA level of expression, To begin to address these questions, we created a series of c-myc alleles modified in the 3 ' UTR, using homologous recombination and the Cre/loxP system, and analysed the consequences of these modifications in ES cells and transgenic animals. We found that deletion of the complete 3 ' UTR, including runs of Us and AU-rich elements proposed, on the basis of cell-culture assays, to be involved in the control of c-myc mRNA stability, did not alter the steady-state level of c-myc mRNA in any of the various situations analysed in vivo. Moreover, mice homozygous for the 3 ' UTR-deleted gene were perfectly healthy and fertile, Our results therefore strongly suggest that the 3 ' UTR of c-myc mRNA does not play a major role in the developmental control of c-myc expression.	Univ Toulouse 3, UMR5547, CNRS, Ctr Dev Biol, F-31062 Toulouse 04, France; Inst Pasteur, URA 1960, CNRS, Dev Biol Unit, F-75724 Paris, France; Univ Paris 05, Fac Sci Pharmaceut & Biol, Genet Mol Lab, UPRESS JE 2195, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Morello, D (corresponding author), Univ Toulouse 3, UMR5547, CNRS, Ctr Dev Biol, Batiment 4R3,118 Route Narbonne, F-31062 Toulouse 04, France.		Vidaud, Michel/O-7346-2017					AGHIB DF, 1990, ONCOGENE, V5, P707; ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P901; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Bieche I, 2000, CLIN CANCER RES, V6, P452; BONNIEU A, 1990, ONCOGENE, V5, P1585; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; COLE MD, 1990, ENZYME, V44, P167, DOI 10.1159/000468755; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GIBSON CW, 1986, MOL CELL BIOCHEM, V71, P61; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kress C, 1998, MAMM GENOME, V9, P998, DOI 10.1007/s003359900914; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; LAIRDOFFRINGA IA, 1989, NUCLEIC ACIDS RES, V17, P6499, DOI 10.1093/nar/17.16.6499; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MORELLO D, 1990, ONCOGENE, V5, P1511; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAUER B, 1990, New Biologist, V2, P441; SOBCZAK J, 1989, ONCOGENE, V4, P1503; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	45	16	17	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4344	4353		10.1038/sj.onc.1204482	http://dx.doi.org/10.1038/sj.onc.1204482			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466615				2022-12-28	WOS:000169912600008
J	Scherl-Mostageer, M; Sommergruber, W; Abseher, R; Hauptmann, R; Ambros, P; Schweifer, N				Scherl-Mostageer, M; Sommergruber, W; Abseher, R; Hauptmann, R; Ambros, P; Schweifer, N			Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer	ONCOGENE			English	Article						representational difference analysis; cDNA chip technology; laser microdissection; CUB domain; CDCP1	REPRESENTATIONAL DIFFERENCE ANALYSIS; HUMAN-CHROMOSOMES; SERIAL ANALYSIS; MESSENGER-RNA; CUB DOMAIN; EXPRESSION; HYBRIDIZATION; REARRANGEMENTS; SEQUENCES; GENOME	We report the identification of a novel human tumor associated gene, CDCP1 (Cub Domain Containing Protein), which was identified using representational difference analysis and cDNA chip technology. The gene consists of eight exons, the upstream region of which neither contains a TATA- nor a CCAAT-box, However, a CpG island is located around the transcription start, which is found in approximately 60% of known genes. The CDCP1 gene was mapped to chromosome 3p21-p23 by fluorescence in situ hybridization, For expression profiling real time quantitative RT - PCR was performed using cell lines and laser capture microdissected colon cancer biopsies. CDCP1 mRNA is approximately 6 kb and highly overexpressed in human colon cancer and lung cancer, CDCP1 represents a putative transmembrane protein, containing three CUB domains in the extracellular part most likely involved in cell adhesion or interacting with the extracellular matrix.	Boehringer Ingelheim KG, Dept Exploratory Res, Res & Dev, A-1121 Vienna, Austria; St Anna Childrens Hosp, CCRI, A-1080 Vienna, Austria	Boehringer Ingelheim; Saint Anna Children's Hospital	Schweifer, N (corresponding author), Boehringer Ingelheim KG, Dept Exploratory Res, Res & Dev, A-1121 Vienna, Austria.	norbert.schweifer@vie.boehringer-ingelheim.com	Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211				ABE K, 1992, MAMM GENOME, V2, P252, DOI 10.1007/BF00355435; Afshari CA, 1999, CANCER RES, V59, P4759; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Bornstein SR, 1998, MED KLIN, V93, P739, DOI 10.1007/BF03044814; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Cross SH, 2000, MAMM GENOME, V11, P373, DOI 10.1007/s003350010071; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; Gerstein M, 2000, CURR OPIN STRUC BIOL, V10, P574, DOI 10.1016/S0959-440X(00)00134-2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hubank M, 1999, METHOD ENZYMOL, V303, P325; Ishii M, 2000, GENOMICS, V68, P136, DOI 10.1006/geno.2000.6284; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Knight SJL, 1997, EUR J HUM GENET, V5, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kurian KM, 1999, J PATHOL, V187, P267; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Parle-McDermott A, 2000, BRIT J CANCER, V83, P725, DOI 10.1054/bjoc.2000.1330; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stollberg J, 2000, GENOME RES, V10, P1241, DOI 10.1101/gr.10.8.1241; To KY, 2000, COMB CHEM HIGH T SCR, V3, P235; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wootton JC, 1996, METHOD ENZYMOL, V266, P554	42	109	119	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4402	4408		10.1038/sj.onc.1204566	http://dx.doi.org/10.1038/sj.onc.1204566			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466621				2022-12-28	WOS:000169912600014
J	O'Neil, J; Billa, M; Oikemus, S; Kelliher, M				O'Neil, J; Billa, M; Oikemus, S; Kelliher, M			The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice	ONCOGENE			English	Article						Tal-1; E2A; leukemia	LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE II-ALPHA; IN-VIVO; TRANSCRIPTION FACTOR; VASCULAR DEVELOPMENT; ENHANCER-BINDING; TRANSGENIC MICE; ID PROTEINS	Activation of the basic helix-loop-helix (bHLH) gene TAL-1 (or SCL) is the most frequent gain-of-function mutation in pediatric T cell acute lymphoblastic leukemia (T-ALL), Similarly, mis-expression of tal-1 in the thymus of transgenic mice results in the development of clonal T cell lymphoblastic leukemia. To determine the mechanism(s) of tal-1-induced leukemogenesis, we created transgenic mice expressing a DNA binding mutant of tal-1, Surprisingly, these mice develop disease, demonstrating that the DNA binding properties of tal-1 are not required to induce leukemia/lymphoma in mice. However, wild type tal-1 and the DNA binding mutant both form stable complexes with E2A proteins. In addition, tal-1 stimulates differentiation of CDS-single positive thymocytes but inhibits the development of CD4-single positive cells: effects also observed in E2A-deficient mice. Our study suggests that the bHLH protein tal-1 contributes to leukemia by interfering with E2A protein function(s).	Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Kelliher, M (corresponding author), BioTech, 373 Plantat St, Worcester, MA 01605 USA.				NATIONAL CANCER INSTITUTE [R01CA096899] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Anderson KP, 1998, J BIOL CHEM, V273, P14347, DOI 10.1074/jbc.273.23.14347; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; Begley CG, 1999, BLOOD, V93, P2760; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; Cohen-Kaminsky S, 1998, EMBO J, V17, P5151, DOI 10.1093/emboj/17.17.5151; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; Condorelli GL, 1996, CANCER RES, V56, P5113; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DOYLE K, 1994, J BIOL CHEM, V269, P12099; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Littlewood TD., 1998, HELIX LOOP HELIX TRA; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Park ST, 1998, J BIOL CHEM, V273, P7030, DOI 10.1074/jbc.273.12.7030; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; Vyas P, 1999, DEVELOPMENT, V126, P2799; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	47	49	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3897	3905		10.1038/sj.onc.1204519	http://dx.doi.org/10.1038/sj.onc.1204519			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439353				2022-12-28	WOS:000169494700015
J	Yang, HY; Shao, RP; Hung, MC; Lee, MH				Yang, HY; Shao, RP; Hung, MC; Lee, MH			p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis	ONCOGENE			English	Article						HER2/neu; tetracycline-regulated gene expression; tumor suppression; CDK; p27	DEPENDENT KINASE INHIBITOR; HUMAN-BREAST-CANCER; TUMOR SUPPRESSION; INDUCED APOPTOSIS; GENE-EXPRESSION; NEU ONCOGENE; HER-2/NEU; P27(KIP1); ANTIBODY; TRANSFORMATION	HER2/neu, a receptor tyrosine kinase oncogene, promotes mitogenic growth and transformation of cancer cells. We previously identified that its oncogenic signals down-regulate the cyclin-dependent kinase inhibitor p27 Kip1, which is defined as a haplo-insufficient tumor suppressor. Here, we applied the human p27 gene as a novel anticancer agent for HER2/neu-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system, Overexpression of p27 inhibits HER2/neu-activated CDK2 activity, cell proliferation, and transformation. Most significantly for clinical application, p27 expression in HER2/neu-overexpressing cells can be regulated in vivo and reduce the tumor volume in a tumor model, The findings demonstrate the applicability of employing p27 in HER2/neu-associated cancer gene therapy.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Lee, Mong-Hong/0000-0001-8675-8215	NCI NIH HHS [R01 CA089266, P30 CA016672, R56 CA089266] Funding Source: Medline; NCRR NIH HHS [UL1 RR024148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089266, R56CA089266, P30CA016672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Baselga J, 1998, CANCER RES, V58, P2825; Clurman BE, 1998, P NATL ACAD SCI USA, V95, P15158, DOI 10.1073/pnas.95.26.15158; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Le XF, 2000, CANCER RES, V60, P3522; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Newman L, 2001, MOL CARCINOGEN, V30, P169, DOI 10.1002/mc.1025; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REARDON DB, 1993, J BIOL CHEM, V268, P18136; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Wen Y, 2000, CANCER RES, V60, P42; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	20	46	54	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3695	3702		10.1038/sj.onc.1204472	http://dx.doi.org/10.1038/sj.onc.1204472			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439332				2022-12-28	WOS:000169400200010
J	Campomenosi, P; Monti, P; Aprile, A; Abbondandolo, A; Frebourg, T; Gold, B; Crook, T; Inga, A; Resnick, MA; Iggo, R; Fronza, G				Campomenosi, P; Monti, P; Aprile, A; Abbondandolo, A; Frebourg, T; Gold, B; Crook, T; Inga, A; Resnick, MA; Iggo, R; Fronza, G			p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	ONCOGENE			English	Article						p53; yeast functional assay; p53 responsive elements	YEAST FUNCTIONAL ASSAY; CELL-CYCLE ARREST; DNA-BINDING; BREAST-CANCER; MUTATIONS; PROTEIN; APOPTOSIS; TUMORS; TRANSFORMATION; IDENTIFICATION	The human p53 protein acts mainly as a stress inducible transcription factor transactivating several genes involved in cell cycle arrest (e,g, p21) or apoptosis (e,g, Bax, PIG3), Roughly half of all human tumours contains p53 missense mutations. Virtually all tumour-derived p53 mutants are unable to activate Bax transcription but some retain the ability to activate p21 transcription, Identification of these mutants may have valuable clinical implications. We have determined the transactivation ability of 77 p53 mutants using reporter yeast strains containing a p53-regulated ADE2 gene whose promoter is regulated by p53 responsive elements derived from the regulatory region of the p21, BRS and PIG3 genes, We also assessed the influence of temperature on transactivation, Our results indicate that a significant proportion of mutants [16/77 (21%); 10/64 (16%) considering only tumour-derived mutants] are transcriptionally active, especially with the p21 promoter. Discriminant mutants preferentially affect less conserved (P < 0.04, Fisher's exact test), more rarely mutated (P < 0.006, Fisher's exact test) amino acids. Temperature sensitivity is frequently observed, but is more common among discriminant than non-discriminant mutants (P < 0.003, Fisher's exact test), Finally, we extended the analysis to a group of mutants isolated in BRCA-associated tumours that surprisingly were indistinguishable from wild type in standard transcription, growth suppression and apoptosis assays in human cells, but showed gain of function in transformation assays. The incidence of transcriptionally active mutations among this group was significantly higher than in the panel of mutants studied previously (P < 0.001, Fisher's exact test), Since it is not possible to predict the behaviour of a mutant from first principles, we propose that the yeast assay be used to compile a functional p53 database and fill the gap between the biophysical, pharmacological and clinical fields.	Natl Inst Canc Res, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy; IFRMP, INSERM EP19906, Fac Med & Pharm, F-76183 Rouen, France; Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA; St Marys Hosp, Sch Med, Ludwig Inst Canc Res, Sect Cell Biol & Expt Pathol, London W2 1PG, England; NIEHS, Chromosome Stabil Grp, NIH, Res Triangle Pk, NC 27709 USA; Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Nebraska System; University of Nebraska Medical Center; Imperial College London; Ludwig Institute for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Swiss Institute Experimental Cancer Research	Fronza, G (corresponding author), Natl Inst Canc Res, Mutagenesis Lab, Largo R Benzi 10, I-16132 Genoa, Italy.		Iggo, Richard/G-3546-2014; Inga, Alberto/AAC-3815-2022; Fronza, Gilberto/AAG-8735-2019; resnick, Michael/F-1668-2019; Monti, Paola/Y-1118-2019; Frebourg, Thierry/AAK-8390-2020; Campomenosi, Paola/C-9729-2011	Inga, Alberto/0000-0002-8767-1637; Fronza, Gilberto/0000-0003-3722-553X; resnick, Michael/0000-0002-8473-7506; Monti, Paola/0000-0002-1978-4998; Campomenosi, Paola/0000-0002-8853-1134	NATIONAL CANCER INSTITUTE [R01CA029088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA29088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Campomenosi P, 1997, INT J CANCER, V73, P816, DOI 10.1002/(SICI)1097-0215(19971210)73:6&lt;816::AID-IJC8&gt;3.0.CO;2-5; Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Duddy PM, 2000, J MOL DIAGN, V2, P139, DOI 10.1016/S1525-1578(10)60629-0; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Monti P, 2000, MUTAGENESIS, V15, P127, DOI 10.1093/mutage/15.2.127; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812	38	116	122	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3573	3579		10.1038/sj.onc.1204468	http://dx.doi.org/10.1038/sj.onc.1204468			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429705				2022-12-28	WOS:000169478300014
J	Catz, SD; Johnson, JL				Catz, SD; Johnson, JL			Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer	ONCOGENE			English	Article						bcl-2; NF-kappa B; prostate; cancer; transcription	TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-INDUCED APOPTOSIS; INDUCED CELL-DEATH; SUPPRESSES APOPTOSIS; HIPPOCAMPAL-NEURONS; GENE-EXPRESSION; FAMILY MEMBERS; BINDING-SITES; MICE LACKING	This work presents direct evidence that the, bcl-2 gene is transcriptionally, regulated by nuclear factor-kappaB (NF-kappaB) and directly links the TNF-alpha /NF-kappaB signaling pathway with Bcl-2 expression and its pro-survival response in human prostate carcinoma cells. DNase I footprinting, gel retardation and supershift analysis identified a NF-kappaB site in the bcl-2 p2 promoter. In the context of a minimal promoter, this bcl-2 p2 site 1 increased transcription 10-fold in the presence of the p50/p65, expression vectors, comparable to the increment observed with the consensus NF-kappaB site, while for the full p2 promoter region transcriptional activity was increased sixfold by over-expression of NF-kappaB, an effect eliminated by mutating the bcl-2 p2 site 1. The expression of Bcl-2 has been linked to the hormone-resistant phenotype of advanced prostate cancer. Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line LNCaP observed in response to hormone withdrawal is further augmented by TNF-alpha treatment, and this effect is abated by inhibitors of NF-kappaB. Concomitantly, bcl-2 p2 promoter studies in LNCaP cells, show a 40-fold increase in promoter activity after stimulation with TNF-alpha in the absence of hormone.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Johnson, JL (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jjohnson@scripps.edu		Catz, Sergio/0000-0002-1873-0277	NIAID NIH HHS [AI44434] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044434] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Apakama I, 1996, BRIT J CANCER, V74, P1258, DOI 10.1038/bjc.1996.526; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baltaci S, 2000, BJU INT, V85, P155, DOI 10.1046/j.1464-410x.2000.00388.x; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bubendorf L, 1996, AM J PATHOL, V148, P1557; Camandola S, 2000, J NEUROSCI RES, V61, P134, DOI 10.1002/1097-4547(20000715)61:2<134::AID-JNR3>3.0.CO;2-P; Chaudhary KS, 1999, ENVIRON HEALTH PERSP, V107, P49, DOI 10.2307/3434471; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; COLOMBEL M, 1993, AM J PATHOL, V143, P390; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRILLI M, 1993, INT REV CYTOL, V143, P1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; HEWITT SM, 1995, CANCER RES, V55, P5386; Huang A, 1998, UROLOGY, V51, P346, DOI 10.1016/S0090-4295(97)00636-5; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; JOHNSON JL, 1995, VIROLOGY, V208, P147, DOI 10.1006/viro.1995.1138; JOHNSON JL, 1994, NUCLEIC ACIDS RES, V22, P5085, DOI 10.1093/nar/22.23.5085; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu S, 1999, ENDOCRINOLOGY, V140, P5054, DOI 10.1210/en.140.11.5054; Mackey TJ, 1998, UROLOGY, V52, P1085, DOI 10.1016/S0090-4295(98)00360-4; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; Nakashima J, 1998, CLIN CANCER RES, V4, P1743; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perlman H, 1999, CELL DEATH DIFFER, V6, P48, DOI 10.1038/sj.cdd.4400453; PROSCH S, 1995, VIROLOGY, V208, P197, DOI 10.1006/viro.1995.1143; RAFFO AJ, 1995, CANCER RES, V55, P4438; Saeed B, 1997, PROSTATE, V31, P145; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scherr DS, 1999, J UROLOGY, V162, P12, DOI 10.1097/00005392-199907000-00003; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SINHA AA, 1977, CANCER, V40, P2836, DOI 10.1002/1097-0142(197712)40:6<2836::AID-CNCR2820400614>3.0.CO;2-N; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; SORGE J, 1984, MOL CELL BIOL, V4, P1730, DOI 10.1128/MCB.4.9.1730; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ZD, 1999, VIROLOGY, V257, P502, DOI 10.1006/viro.1999.9688; Westin P, 1998, CANCER DETECT PREV, V22, P476; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	80	424	447	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7342	7351		10.1038/sj.onc.1204926	http://dx.doi.org/10.1038/sj.onc.1204926			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704864				2022-12-28	WOS:000171894200007
J	Fujimura, Y; Siddique, H; Lee, L; Rao, VN; Reddy, ESP				Fujimura, Y; Siddique, H; Lee, L; Rao, VN; Reddy, ESP			EWS-ATF-1 chimeric protein in soft tissue clear cell sarcoma associates with CREB-binding protein and interferes with p53-mediated trans-activation function	ONCOGENE			English	Article						EWS-ATF-1; CBP; p53; Ewing's sarcoma; clear cell sarcoma	ACUTE MYELOID-LEUKEMIA; RNA-POLYMERASE-II; CHROMOSOME-TRANSLOCATION; EWINGS-SARCOMA; MALIGNANT-MELANOMA; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; GENE FUSION; EWS GENE; MYXOID LIPOSARCOMA	The recurrent t(12;22) (q13;q12) chromosomal translocation associated with soft tissue clear cell sarcoma results in a chimeric protein EWS-ATF-1 that acts as a constitutive transcriptional activator. The CBP/p300 transcriptional coactivator, which links various transcriptional factors to basal transcription apparatus, participates in transcriptional activation, growth and cell cycle control and differentiation. In this study, we show that EWS-ATF-1 associates constitutively with CBP both in vitro and in vivo. Both EWS and ATF-1 fusion domains are needed for this interaction. Here, we demonstrate that EWS-ATF-1 represses p53/CBP-mediated transactivation function. Overexpression of CBP can counteract this repressive effect of EWS-ATF-1. Taken together, these findings suggest that one of the mechanisms by which EWS-ATF-1 may cause tumors is through targeting CBP/p300 resulting in the loss of function of p53. This novel mechanism may be responsible for the development of these and other related solid tumors.	Med Coll Penn & Hahnemann Univ, Sch Med, Program Canc Genet, Canc Ctr,Dept Biochem, Philadelphia, PA 19102 USA; SAIC, Frederick, MD 21702 USA	Drexel University; Science Applications International Corporation (SAIC); SAIC-Frederick	Reddy, ESP (corresponding author), Med Coll Penn & Hahnemann Univ, Sch Med, Program Canc Genet, Canc Ctr,Dept Biochem, Broad & Vine,MS 481, Philadelphia, PA 19102 USA.				NCI NIH HHS [R01 CA58642, R01 CA 85343, CA 57322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085343, R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BROWN AD, 1995, ONCOGENE, V10, P1749; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN AL, 1984, CANCER RES, V44, P1265; Fujimura Y, 1996, ONCOGENE, V12, P159; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kung AL, 2000, GENE DEV, V14, P272; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	52	28	28	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6653	6659		10.1038/sj.onc.1204684	http://dx.doi.org/10.1038/sj.onc.1204684			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709699				2022-12-28	WOS:000171551600001
J	Lafarge, S; Sylvain, V; Ferrara, M; Bignon, YJ				Lafarge, S; Sylvain, V; Ferrara, M; Bignon, YJ			Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway	ONCOGENE			English	Article						BRCA1; microtubule-interfering agents; JNK; ribozyme	DNA-DAMAGE RESPONSE; CELL-CYCLE; TUMOR-SUPPRESSOR; CANCER-CELLS; SELF-CLEAVAGE; RNA; EXPRESSION; APOPTOSIS; PROTEIN; PHOSPHORYLATION	We have developed ribozymes (Rz) that inhibit BRCA1 expression in order to study the role of this gene in chemosensitivity. Two Rz, targeting positions 358 or 5282 of the BRCA1 mRNA, were cloned into the retroviral vector LXSN and lipofected into the breast cancer cell-line HBL100. We obtained 79-99% inhibition of BRCA1 expression, as determined by real-time quantitative PCR and by Western blotting. Decreased expression of BRCA1 led to sensitivity to the DNA damaging agents cisplatin and etoposide, resistance to the microtubule-interfering agents (MIA) taxol and vincristine. The molecular mechanism of resistance to MIA was investigated further by determining the status of the JNK pathway. We found that JNK1 expression was elevated, while JNK2 expression was decreased in Rz-expressing clones compared to controls. We have quantified the mRNA levels of BRCA1, JNK1, 2, MEK-4, -7 and c-jun after treatment with MIA. Vincristine treatment of control cells resulted in transcriptional repression of BRCA1, while the JNK1, 2, MEK-4, -7 and c-jun genes were induced. In Rz-treated cells, only JNK1 and MEK-4 were expressed and none was induced after MIA treatment. We then studied the phosphorylation of c-jun, a downstream effector of the JNK pathway. We observed a strong increase in phosphorylated c-jun after MIA treatment of the control cells but not in BRCA1-Rz treated cells, suggesting inhibition of the JNK pathway. These results show that the BRCA1-JNK pathway is involved in the cytotoxic response to MIA treatment, and inhibition of BRCA1 leads to transcriptional modifications of the JNK pathway.	Ctr Jean Perrin, Oncol Mol Lab, F-63011 Clermont Ferrand 1, France; INRA, UNCM, F-63122 St Genes Champanelle, France	UNICANCER; Centre Jean Perrin; INRAE	Bignon, YJ (corresponding author), Ctr Jean Perrin, Oncol Mol Lab, BP 392, F-63011 Clermont Ferrand 1, France.	Yves-Jean.Bignon@cjp.u-clermont1.fr	, bignon/Y-3243-2019					Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 2000, CANCER RES, V60, P5037; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; Fromes Y, 1996, J PROTEIN CHEM, V15, P377, DOI 10.1007/BF01886864; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Husain A, 1998, CANCER RES, V58, P1120; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rao VN, 1996, ONCOGENE, V12, P523; Rossi JJ, 1999, CHEM BIOL, V6, pR33, DOI 10.1016/S1074-5521(99)80001-5; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Tomlinson GE, 1998, CANCER RES, V58, P3237; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; Vaish NK, 1998, NUCLEIC ACIDS RES, V26, P5237, DOI 10.1093/nar/26.23.5237; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang CC, 1999, CANCER RES, V59, P3663; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	47	152	163	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6597	6606		10.1038/sj.onc.1204812	http://dx.doi.org/10.1038/sj.onc.1204812			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641785				2022-12-28	WOS:000171404200013
J	Tzivion, G; Shen, YH; Zhu, J				Tzivion, G; Shen, YH; Zhu, J			14-3-3 proteins; bringing new definitions to scaffolding	ONCOGENE			English	Review						14-3-3; phosphorylation; signal transduction; cell cycle	CREUTZFELDT-JAKOB-DISEASE; INSULIN-RECEPTOR SUBSTRATE-1; CELL-CYCLE PROGRESSION; IN-VIVO; SIGNALING PROTEINS; NUCLEAR-LOCALIZATION; KINASE-ACTIVITY; DNA-DAMAGE; T-CELLS; 14-3-3-PROTEINS ASSOCIATE	The 14-3-3 proteins are a part of an emerging family of proteins and protein domains that bind to serine/threonine-phosphorylated residues in a context specific manner, analogous to the Src homology 2 (SH2) and phospho-tyrosine binding (PTB) domains. 14-3-3 proteins bind and regulate key proteins involved in various physiological processes such as intracellular signaling (e.g. Raf, MLK, MEKK, PI-3 kinase, IRS-1), cell cycling (e.g. Cdc25, Wee1, CDK2, centrosome), apoptosis (e.g. BAD, ASK-1) and transcription regulation (e.g. FKHRL1, DAF-16, p53, TAZ, TLX-2, histone deacetylase). In contrast to SH2 and PTB domains, which serve mainly to mediate protein-protein interactions, 14-3-3 proteins in many cases alter the function of the target protein, thus allowing them to serve as direct regulators of their targets. This review focuses on the various mechanisms employed by the 14-3-3 proteins in the regulation of their diverse targets, the structural basis for 14-3-3-target protein interaction with emphasis on the role of 14-3-3 dimerization in target protein binding and regulation and provides an insight on 14-3-3 regulation itself.	Texas A&M Univ, Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol,Cardiovasc Res Inst, Temple, TX 76504 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Tzivion, G (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol,Cardiovasc Res Inst, Temple, TX 76504 USA.	tzivion@medicine.tamu.edu	Tzivion, Guri/D-8954-2011					AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Barinaga M, 1999, SCIENCE, V283, P1247, DOI 10.1126/science.283.5406.1247; Benzing T, 2000, J BIOL CHEM, V275, P28167; Bihn EA, 1997, PLANT J, V12, P1439, DOI 10.1046/j.1365-313x.1997.12061439.x; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Chapman T, 2000, NEUROLOGY, V55, P1396, DOI 10.1212/WNL.55.9.1396; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chung HJ, 1999, TRENDS PLANT SCI, V4, P367, DOI 10.1016/S1360-1385(99)01462-4; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Cotelle V, 2000, EMBO J, V19, P2869, DOI 10.1093/emboj/19.12.2869; Craparo A, 1997, J BIOL CHEM, V272, P11663; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Dubois T, 1997, J PROTEIN CHEM, V16, P513, DOI 10.1023/A:1026321813463; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Furlanetto RW, 1997, BIOCHEM J, V327, P765; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Green AJE, 2001, NEUROLOGY, V56, P986, DOI 10.1212/WNL.56.7.986; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Ichimura T, 1997, FEBS LETT, V413, P273, DOI 10.1016/S0014-5793(97)00910-1; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; Kosaki A, 1998, J BIOL CHEM, V273, P940, DOI 10.1074/jbc.273.2.940; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Layfield R, 1996, NEUROSCI LETT, V209, P57, DOI 10.1016/0304-3940(96)12598-2; Lee KH, 1997, ELECTROPHORESIS, V18, P502, DOI 10.1002/elps.1150180327; Li W, 1997, DEVELOPMENT, V124, P4163; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Liu YH, 1999, J IMMUNOL, V162, P7095; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MEGIDISH T, 1995, BIOCHEM BIOPH RES CO, V216, P739, DOI 10.1006/bbrc.1995.2684; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Muller WEG, 2000, MECH AGEING DEV, V116, P193, DOI 10.1016/S0047-6374(00)00112-3; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nakanishi Kozo, 1997, Human Antibodies, V8, P189; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Pan SQ, 1999, PLANT CELL, V11, P1591, DOI 10.1105/tpc.11.8.1591; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 2000, GENE DEV, V14, P1027; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Perego L, 1997, MOL REPROD DEV, V47, P370, DOI 10.1002/(SICI)1098-2795(199708)47:4&lt;370::AID-MRD3&gt;3.0.CO;2-H; Pietromonaco SF, 1996, BLOOD CELL MOL DIS, V22, P225, DOI 10.1006/bcmd.1996.0103; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Roberts MR, 2000, CURR OPIN PLANT BIOL, V3, P400, DOI 10.1016/S1369-5266(00)00103-5; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Shaw A, 2000, CURR BIOL, V10, pR400, DOI 10.1016/S0960-9822(00)00519-4; Shoji Masahiro, 1994, Human Antibodies and Hybridomas, V5, P123; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; Suzuki H, 2000, CANCER RES, V60, P4353; Tang SJ, 1998, J BIOL CHEM, V273, P25356, DOI 10.1074/jbc.273.39.25356; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tien AC, 1999, MECH DEVELOP, V81, P209, DOI 10.1016/S0925-4773(98)00238-X; Todd A, 1998, BIOCHEMISTRY-US, V37, P14317, DOI 10.1021/bi980768k; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; van Zeijl MJ, 2000, FEBS LETT, V473, P292, DOI 10.1016/S0014-5793(00)01545-3; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wang WF, 1996, J MOL EVOL, V43, P384; Wang YL, 2000, CELL GROWTH DIFFER, V11, P211; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weiner H, 1999, FEBS LETT, V455, P75, DOI 10.1016/S0014-5793(99)00868-6; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 1999, NATURE, V402, P30; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zeidler M, 2000, ANN NEUROL, V47, P683, DOI 10.1002/1531-8249(200005)47:5<683::AID-ANA25>3.0.CO;2-V; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang SS, 1999, J BIOL CHEM, V274, P24865, DOI 10.1074/jbc.274.35.24865	130	252	259	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6331	6338		10.1038/sj.onc.1204777	http://dx.doi.org/10.1038/sj.onc.1204777			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607836				2022-12-28	WOS:000171640600009
J	Barr, FG				Barr, FG			Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma	ONCOGENE			English	Review						rhabdomyosarcoma; transcription factor; translocation; paired box; fork head	TRANSCRIPTION FACTOR FKHR; MYOGENIC PRECURSOR CELLS; PAIRED BOX GENE; C-MET RECEPTOR; DNA-BINDING; CHROMOSOMAL TRANSLOCATION; IN-VIVO; GENOMIC ORGANIZATION; STRUCTURAL-ANALYSIS; DOMAIN GENE	The chromosomal translocations t(2;13)(q35;q14) and t(1;13)(p36;q14) are characteristic of alveolar rhabdomyosarcoma, a pediatric soft tissue cancer related to the striated muscle lineage. These translocations rearrange PAX3 and PAX7, members of the paired box transcription factor family, and juxtapose these genes with FKHR, a member of the fork head transcription factor family. This juxtaposition generates PAX3-FKHR and PAX7-FKHR chimeric genes that are expressed as chimeric transcripts that encode chimeric proteins. The fusion proteins, which contain the PAX3/PAX7 DNA binding domain and the FKHR transcriptional activation domain, activate transcription from PAX-binding sites with higher potency than the corresponding wild-type PAX proteins. This increased function results from the insensitivity of the FKHR activation domain to inhibitory effects of N-terminal PAX3/PAX7 domains. In addition to altered function, the fusion products are expressed in ARMS tumors at higher levels than the corresponding wild-type PAX products due to two distinct mechanisms. The PAX7-FKHR fusion is overexpressed as a result of in vivo amplification while the PAX3-FKHR fusion is overexpressed due to a copy number-independent increase in transcriptional rate. Finally, though FKHR subcellular localization is regulated by an AKT-dependent pathway, the fusion proteins are resistant to these signals and show exclusively nuclear localization. Therefore, these translocations alter biological activity at the levels of protein function, gene expression, and subcellular localization with the cumulative outcome postulated to be aberrant regulation of PAX3/PAX7 target genes. This aberrant gene expression program is then hypothesized to contribute to tumorigenic behavior by impacting on the control of growth, apoptosis, differentiation and motility.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Barr, FG (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.	barrfg@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA089461, R01CA071838, R01CA064202] Funding Source: NIH RePORTER; NCI NIH HHS [CA71838, CA64202, CA89461] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Arden KC, 1996, GENE CHROMOSOME CANC, V16, P254, DOI 10.1002/(SICI)1098-2264(199608)16:4<254::AID-GCC5>3.0.CO;2-X; Ayyanathan K, 2000, CANCER RES, V60, P5803; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; Barr FG, 1999, CANCER RES, V59, P5443; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; Barr FG, 1996, HUM MOL GENET, V5, P15, DOI 10.1093/hmg/5.1.15; Barr FG, 1998, CANCER GENET CYTOGEN, V102, P32, DOI 10.1016/S0165-4608(97)00287-2; Bendall AJ, 1999, DEVELOPMENT, V126, P4965; Bennicelli JL, 1999, ONCOGENE, V18, P4348, DOI 10.1038/sj.onc.1202812; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; BIEGEL JA, 1991, GENE CHROMOSOME CANC, V3, P483, DOI 10.1002/gcc.2870030612; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Borycki AG, 1999, DEVELOPMENT, V126, P1665; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Daston G, 1996, DEVELOPMENT, V122, P1017; DAVIS RJ, 1995, HUM MOL GENET, V4, P2355, DOI 10.1093/hmg/4.12.2355; DAVIS RJ, 1994, CANCER RES, V54, P2869; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; DEALAVA E, 1995, AM J PATHOL, V147, P1584; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; DOUGLASS EC, 1991, GENE CHROMOSOME CANC, V3, P480, DOI 10.1002/gcc.2870030611; DOWNING JR, 1995, AM J PATHOL, V146, P626; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Fitzgerald JC, 2000, CANCER GENET CYTOGEN, V117, P37, DOI 10.1016/S0165-4608(99)00130-2; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; FRANZ T, 1993, ANAT EMBRYOL, V187, P153; Frascella E, 1998, CANCER GENET CYTOGEN, V102, P104, DOI 10.1016/S0165-4608(97)00352-X; Fredericks WJ, 2000, MOL CELL BIOL, V20, P5019, DOI 10.1128/MCB.20.14.5019-5031.2000; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Galibert MD, 1999, J BIOL CHEM, V274, P26894, DOI 10.1074/jbc.274.38.26894; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Henderson DJ, 1997, MECH DEVELOP, V69, P39, DOI 10.1016/S0925-4773(97)00151-2; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; Kaestner KH, 2000, GENE DEV, V14, P142; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Khan J, 1998, CANCER RES, V58, P5009; Lagutina I, 2000, DEV BIOL, V222, P236; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lang D, 2000, J CLIN INVEST, V106, P963, DOI 10.1172/JCI10828; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MACINA RA, 1995, GENOMICS, V26, P1, DOI 10.1016/0888-7543(95)80076-X; Mackall C, 2000, CLIN ORTHOP RELAT R, P25; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; Mansouri A, 1996, DEVELOPMENT, V122, P831; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; Massuda ES, 1997, P NATL ACAD SCI USA, V94, P14701, DOI 10.1073/pnas.94.26.14701; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mennerich D, 1998, MECH DEVELOP, V73, P147, DOI 10.1016/S0925-4773(98)00046-X; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Phelan SA, 1998, J BIOL CHEM, V273, P19153, DOI 10.1074/jbc.273.30.19153; Reichmuth C, 1996, J PATHOL, V180, P50, DOI 10.1002/(SICI)1096-9896(199609)180:1<50::AID-PATH629>3.0.CO;2-C; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SUBLETT JE, 1995, ONCOGENE, V11, P545; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; TSOKOS M, 1992, ARCH PATHOL LAB MED, V116, P847; TSOKOS M, 1994, SEMIN DIAGN PATHOL, V11, P26; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; Vorobyov E, 1997, GENOMICS, V45, P168, DOI 10.1006/geno.1997.4915; Wang-Wuu S, 1988, Cancer Res, V48, P983; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wexler Leonard H., 1997, P799; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Xie E, 2001, MODERN PATHOL, V14, p4P; Yang XM, 1996, DEVELOPMENT, V122, P2163	102	258	269	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5736	5746		10.1038/sj.onc.1204599	http://dx.doi.org/10.1038/sj.onc.1204599			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607823				2022-12-28	WOS:000170887500014
J	Fukuhara, H; Kuramochi, M; Nobukuni, T; Fukami, T; Saino, M; Maruyama, T; Nomura, S; Sekiya, T; Murakami, Y				Fukuhara, H; Kuramochi, M; Nobukuni, T; Fukami, T; Saino, M; Maruyama, T; Nomura, S; Sekiya, T; Murakami, Y			Isolation of the TSLL1 and TSLL2 genes, members of the tumor suppressor TSLC1 gene family encoding transmembrane proteins	ONCOGENE			English	Article						tumor suppressor gene; TSLC1; TSLL1; TSLL2; glioma; prostate cancer	BINDING INTERFACE; CHROMOSOME 19Q; GLYCOPHORIN-C; HYBRIDIZATION; NEUREXIN; DOMAIN	We have recently identified the TSLC1 gene as a novel tumor suppressor in human non-small cell lung cancers. TSLC1 encodes a membrane glycoprotein with an extracellular domain homologous to those of immunoglobulin superfamily proteins. Truncation of TSLC1 in the cytoplasmic domain in a primary human tumor suggests that this domain is important for tumor suppressor activity. Here, we report the isolation of two TSLC1-like genes, TSLL1 and TSLL2, based on their structural homology with the sequences corresponding to the cytoplasmic domain of TSLC1. Significant similarity was also observed in the extracellular domain as well as in the overall gene structure, indicating that these three genes form a unique subfamily (the TSLC1-gene family) in the immunoglobulin superfamily genes. In contrast to the ubiquitous expression of TSLC1, TSLL1 is expressed exclusively in adult and fetal human brain, while TSLL2 is expressed in several specific tissues including prostate, brain, kidney and some other organs. Expression of TSLL1 and TSLL2 was lost or markedly reduced in many human glioma cell lines or some prostate cancer cell lines, suggesting that loss of expression of these genes might be involved in some human cancers.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; BML Inc, R&D Ctr, Kawagoe, Saitama 3501101, Japan	National Cancer Center - Japan; BML, Inc.	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Nomura, Sachio/GYU-4930-2022	Nomura, Sachio/0000-0001-9214-4041				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; DebiecRychter M, 1995, CANCER GENET CYTOGEN, V85, P61, DOI 10.1016/0165-4608(95)00129-8; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Nishizaki T, 1998, GENE CHROMOSOME CANC, V21, P340, DOI 10.1002/(SICI)1098-2264(199804)21:4<340::AID-GCC8>3.0.CO;2-Z; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Poliak S, 1999, NEURON, V24, P1037, DOI 10.1016/S0896-6273(00)81049-1; Rosenberg JE, 1996, ONCOGENE, V13, P2483; Shimura M, 1999, CANCER RES, V59, P2259; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73	17	61	71	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5401	5407		10.1038/sj.onc.1204696	http://dx.doi.org/10.1038/sj.onc.1204696			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536053				2022-12-28	WOS:000170575500016
J	Rounbehler, RJ; Schneider-Broussard, R; Conti, CJ; Johnson, DG				Rounbehler, RJ; Schneider-Broussard, R; Conti, CJ; Johnson, DG			Myc lacks E2F1's ability to suppress skin carcinogenesis	ONCOGENE			English	Article						Myc; E2F1; apoptosis; cell cycle; carcinogenesis	SQUAMOUS-CELL CARCINOMA; C-MYC; TRANSGENIC MICE; ORNITHINE DECARBOXYLASE; IN-VIVO; INDUCED APOPTOSIS; EXPRESSION; E2F-1; GENE; P53	Myc and E2F1 can each stimulate proliferation, induce apoptosis, and contribute to oncogenic transformation. However, only E2F1 has been shown to have a tumor suppressive activity under some conditions. To examine the potential of Myc to suppress tumorigenesis under one of the conditions in which E2F1 functions to suppress tumorigenesis, transgenic mice expressing Myc under the control of a keratin 5 (K5) promoter were generated. Like K5 E2F1 transgenic mice, K5 Myc transgenic mice have hyperplastic and hyperproliferative epidermis and develop spontaneous tumors in the skin and oral epithelium. In addition, K5 Myc and K5 E2F1 transgenic mice both display aberrant, p53-dependent apoptosis in the epidermis. It has been demonstrated that deregulated expression of E2F1 in the epidermis of transgenic mice inhibits tumorigenesis in a two-stage skin carcinogenesis assay. In sharp contrast to those results, deregulated expression of Myc in the epidermis of transgenic mice resulted in an enhanced response to two-stage skin carcinogenesis. We conclude that while Myc and E2F1 have similar proliferative, apoptotic and oncogenic properties in mouse epidermis, Myc lacks E2F1's tumor suppressive property. This suggests that E2F1's unique ability to inhibit skin carcinogenesis is not simply a consequence of promoting p53-dependent apoptosis.	Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Park Rd 1C, Smithville, TX 78957 USA.			Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA42157, CA16672, CA79648] Funding Source: Medline; NIEHS NIH HHS [ES007784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079648, R01CA042157, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIGIOVANNI J, 1994, CARCINOGENESIS, P265; ELSON A, 1995, ONCOGENE, V11, P181; FIELD JK, 1989, ONCOGENE, V4, P1463; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hunt KK, 1997, CANCER RES, V57, P4722; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MERRITT WD, 1990, ARCH OTOLARYNGOL, V116, P1394; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PENA A, 1993, J BIOL CHEM, V268, P27277; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	41	33	34	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5341	5349		10.1038/sj.onc.1204691	http://dx.doi.org/10.1038/sj.onc.1204691			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536046				2022-12-28	WOS:000170575500009
J	Maslyar, DJ; Aoki, M; Vogt, PK				Maslyar, DJ; Aoki, M; Vogt, PK			The growth-promoting activity of the Bad protein in chicken embryo fibroblasts requires binding to protein 14-3-3	ONCOGENE			English	Article						anchorage-independent growth; apoptosis; BH3 proteins; 14-3-3	BH3 DOMAIN; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; BCL-2; INACTIVATE; INDUCTION; DISPLACES; AKT2; DNA	Phosphorylation of the Bad protein is a key regulatory event in the prevention of apoptosis by survival factors. Phosphorylated Bad binds to the cytosolic 14-3-3 protein and is sequestered from the apoptotic machinery of the mitochondrial membrane. To examine the role of Bad in cell growth and apoptosis in primary cultures, we produced stable Bad transfectants of chicken embryo fibroblasts (CEF). As expected, serum starvation of Bad transfectants promoted apoptosis. However, Bad-transfected CEF maintained in media with a high serum concentration were capable of anchorage-independent growth and grew to a higher saturation density than control CEF transfected with the empty vector. High dilutions of the infectious retroviral vector RCAS expressing Bad led to the formation of multilayered cell foci. The growth-promoting effects of Bad were dependent on the serine 136 phosphorylation site and correlated directly with binding of Bad to 14-3-3. These results suggest that phosphorylated Bad promotes cell growth and in oncogenic transformation may contribute to the neoplastic phenotype of the cell.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,BCC 239, La Jolla, CA USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490	NATIONAL CANCER INSTITUTE [R35CA042564, R01CA078230] Funding Source: NIH RePORTER; NCI NIH HHS [CA78230, CA42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreeff M, 1999, LEUKEMIA, V13, P1881, DOI 10.1038/sj.leu.2401573; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kitada S, 1998, AM J PATHOL, V152, P51; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	24	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5087	5092		10.1038/sj.onc.1204662	http://dx.doi.org/10.1038/sj.onc.1204662			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526496				2022-12-28	WOS:000170464000001
J	Song, Y; Cohler, AN; Weinstein, DC				Song, Y; Cohler, AN; Weinstein, DC			Regulation of Laloo by the Xenopus C-terminal Src kinase (Xcsk) during early vertebrate development	ONCOGENE			English	Article						Laloo; Csk; Fyn; Src; Xenopits; mesoderm	MESODERM INDUCTION; TYROSINE KINASES; MAP KINASE; EMBRYOS; EXPRESSION; LAEVIS; FGF; CSK; INHIBITION; XWNT-8	Mesoderm formation in the frog, Xenopus laevis, is dependent on the activity of one or more members of the Src family kinases; the molecular interactions underlying this requirement are not well understood. The C-terminal Src Kinase (Csk) is a potent inhibitor of Src activity, and is required for normal mammalian development; here we report the characterization of Xenopus Csk (Xcsk). Xcsk is widely expressed during early development, physically interacts with the Src kinase Laloo, and inhibits the generation of mesoderm by the Src kinases. Xcsk activity requires a functional kinase domain; furthermore, a kinase-inactive Xcsk mutant potently synergizes with Laloo during early vertebrate development, suggesting a fundamental role for the Src kinase-Csk regulatory circuit during mesoderm induction, in vivo.	Mt Sinai Sch Med, Dept Pharmacol, New York, NY USA	Icahn School of Medicine at Mount Sinai	Weinstein, DC (corresponding author), Mt Sinai Sch Med, Dept Pharmacol, New York, NY USA.			Weinstein, Daniel/0000-0001-7832-9285				BASSEZ T, 1990, DEVELOPMENT, V110, P955; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; Curran KL, 2000, DEV BIOL, V228, P41, DOI 10.1006/dbio.2000.9917; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Honda Z, 1997, J BIOL CHEM, V272, P25753, DOI 10.1074/jbc.272.41.25753; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LaBonne C, 1997, DEV BIOL, V183, P9, DOI 10.1006/dbio.1996.8497; Miller MA, 2000, ONCOGENE, V19, P3925, DOI 10.1038/sj.onc.1203714; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; STEELE RE, 1990, ONCOGENE, V5, P369; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808; Weinstein DC, 2001, DEV DYNAM, V220, P163, DOI 10.1002/1097-0177(2000)9999:9999<1::AID-DVDY1098>3.0.CO;2-5; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0	21	6	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5210	5214		10.1038/sj.onc.1204672	http://dx.doi.org/10.1038/sj.onc.1204672			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526510				2022-12-28	WOS:000170464000015
J	Yakicier, MC; Legoix, P; Vaury, C; Gressin, L; Tubacher, E; Capron, F; Bayer, J; Degott, C; Balabaud, C; Zucman-rossi, J				Yakicier, MC; Legoix, P; Vaury, C; Gressin, L; Tubacher, E; Capron, F; Bayer, J; Degott, C; Balabaud, C; Zucman-rossi, J			Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; loss of heterozygosity; tumor suppressor gene; chromosome 16; homozygous deletion; WWOX/FOR gene	FRAGILE SITE FRA16D; BETA-CATENIN GENE; P53 GENE; MULTIPLE-MYELOMA; BREAST-CANCER; REGION; HETEROZYGOSITY; MUTATIONS; FREQUENT; CELLS	Loss of heterozygosity (LOH) represents the most frequent genetic alteration observed in hepatocellular carcinoma (HCC). Chromosome 16q is of particular interest as it exhibits LOH in 29% of HCC tumors and is frequently lost in breast, prostate, ovarian and gastric carcinomas. We genotyped 157 HCC tumors for 17 microsatellite markers distributed on chromosome 16q and determined a common region of LOH localized between the markers D16S518 and D16S504. By refining the boundaries of two interstitial LOH and two homozygous deletions, the critical region was delimited to 180 kb between D16S3096 and D16S3029. This region is located in intron 8 of the WWOX/FOR gene, but a search for mutations in all coding exons of this gene in 27 HCC tumors and cell lines did not reveal any tumor somatic alterations. Furthermore, by RT-PCR, no abnormal transcripts of this WWOX/FOR gene was detected in nine HCC cell lines. Finally, analysis of the p53 gene mutations with the clinical parameters of all tumors revealed that the two homozygous deletions have occurred in tumors presenting a R249S mutation. Our data revealed a relationship between chromosome 16q homozygous deletions and R249S p53 mutations in tumors where the patient had been exposed to Aflatoxin B1 (P = 0.002). These results are consistent with a role of Aflatoxin B1 in the instability of chromosome 16q at the fragile site FRA16D. However, the nature of the specific gene that is altered during hepato carcino genesis remains to be elucidated.	INSERM, U434, F-75010 Paris, France; Hop Antoine Beclere, Serv Anat Pathol, F-92140 Clamart, France; Hop Beaujon, F-92110 Clichy, France; Hop St Andre, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux	Zucman-rossi, J (corresponding author), INSERM, U434, CEPH 27 Rue Juliette Dodu, F-75010 Paris, France.		zucman-rossi, Jessica/B-5098-2009; j, zucman-rossi/AAV-3594-2021	zucman-rossi, Jessica/0000-0002-5687-0334; j, zucman-rossi/0000-0002-5687-0334				Autrup H., 1988, IARC SCI PUBL, V89, P63; Bando K, 2000, GENE CHROMOSOME CANC, V28, P38, DOI 10.1002/(SICI)1098-2264(200005)28:1<38::AID-GCC5>3.0.CO;2-A; Bednarek AK, 2000, CANCER RES, V60, P2140; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; Boige V, 1997, CANCER RES, V57, P1986; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Chen TP, 1996, CANCER RES, V56, P5605; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Chou YHW, 1998, CANCER LETT, V123, P1, DOI 10.1016/S0304-3835(97)00276-0; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Driouch K, 1997, GENE CHROMOSOME CANC, V19, P185, DOI 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U; ECKL PM, 1987, CARCINOGENESIS, V8, P1077, DOI 10.1093/carcin/8.8.1077; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; ELZAWAHRI M, 1977, ANN NUTR ALIMENT, V31, P859; FABRY L, 1981, TOXICOL LETT, V7, P245, DOI 10.1016/0378-4274(81)90076-X; *FAO, 1991, FAO PAHO, P3; Feo F, 2000, CRIT REV ONCOGENESIS, V11, P19; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IWABUCHI H, 1995, CANCER RES, V55, P6172; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Latil A, 1997, CANCER RES, V57, P1058; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; Miyoshi Y, 1998, CANCER RES, V58, P2524; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; ODA T, 1992, CANCER RES, V52, P6358; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Paige AJW, 2000, CANCER RES, V60, P1690; Piao Z, 1999, BRIT J CANCER, V80, P850, DOI 10.1038/sj.bjc.6690431; Preisler V, 2000, MUTAGENESIS, V15, P91, DOI 10.1093/mutage/15.1.91; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sengstag C, 1996, CANCER RES, V56, P5457; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Wong N, 2000, CLIN CANCER RES, V6, P4000; Zucman-Rossi J, 1996, GENOMICS, V38, P247, DOI 10.1006/geno.1996.0625	41	47	56	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5232	5238		10.1038/sj.onc.1204674	http://dx.doi.org/10.1038/sj.onc.1204674			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526514				2022-12-28	WOS:000170464000019
J	Soucek, T; Rosner, M; Miloloza, A; Kubista, M; Cheadle, JP; Sampson, JR; Hengstschlager, M				Soucek, T; Rosner, M; Miloloza, A; Kubista, M; Cheadle, JP; Sampson, JR; Hengstschlager, M			Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression	ONCOGENE			English	Article						tuberous sclerosis; TSC2; tuberin; proliferation; p27	EKER RAT MODEL; CELL-CYCLE; RENAL-CARCINOMA; HAMARTIN; IDENTIFICATION; SUPPRESSION; GAP	The autosomal dominant disease tuberous sclerosis (TSC) is caused by mutations in either TSC1 on chromosome 9q34, encoding hamartin, or TSC2 on chromosome 16p13.3, encoding tuberin. TSC is characterized by hamartomas that occur in many organs of affected patients and these have been considered to likely result from defects in proliferation control. Although the true biochemical functions of the two TSC proteins have not been clarified, a series of independent investigations demonstrated that modulated hamartin or tuberin expression cause deregulation of proliferation/cell cycle in human, rodent and Drosophila cells. In support of tuberin acting as a tumor suppressor, ectopic overexpression of TSC2 has been shown to decrease proliferation rates of mammalian cells. Furthermore, overexpression of TSC2 has been demonstrated to trigger upregulation of the cyclin-dependent kinase inhibitor p27. We report that three different naturally occurring and TSC causing mutations within the TSC2 gene elliminate neither the anti-proliferative capacity of tuberin nor tuberin's effects on p27 expression. For the first time these data provide strong evidence that deregulation of proliferation and/or upregulation of p27 are not likely to be the primary/only mechanisms of hamartoma development in TSC. These results demand reassessment of previous hypotheses of the pathogenesis of TSC.	Univ Vienna, A-1090 Vienna, Austria; Univ Wales Hosp, Inst Med Genet, Cardiff CF14 4XW, S Glam, Wales	University of Vienna; Cardiff University	Hengstschlager, M (corresponding author), Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Kubista, Mikael/A-5689-2008	Kubista, Mikael/0000-0002-2940-352X				AICHER LD, 2001, IN PRESS J BIOL CHEM; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; Pajak L, 1997, AM J PHYSIOL-HEART C, V273, pH1619, DOI 10.1152/ajpheart.1997.273.3.H1619; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; Plank TL, 1998, CANCER RES, V58, P4766; Sambrook J., 2002, MOL CLONING LAB MANU; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tsuchiya H, 1996, CANCER RES, V56, P429; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3	32	42	42	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4904	4909		10.1038/sj.onc.1204627	http://dx.doi.org/10.1038/sj.onc.1204627			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521203				2022-12-28	WOS:000170271800016
J	Ambartsumian, N; Klingelhofer, J; Grigorian, M; Christensen, C; Kriajevska, M; Tulchinsky, E; Georgiev, G; Berezin, V; Bock, E; Rygaard, J; Cao, RH; Cao, YH; Lukanidin, E				Ambartsumian, N; Klingelhofer, J; Grigorian, M; Christensen, C; Kriajevska, M; Tulchinsky, E; Georgiev, G; Berezin, V; Bock, E; Rygaard, J; Cao, RH; Cao, YH; Lukanidin, E			The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor	ONCOGENE			English	Article						angiogenesis; S100A4; stimulation of motility	CALCIUM-BINDING PROTEIN; ENDOTHELIAL GROWTH-FACTOR; NONMUSCLE MYOSIN; MAMMALIAN-CELLS; S100A4 P9KA; TUMOR-CELLS; MTS1 GENE; IN-VIVO; EXPRESSION; MICE	The involvement of Mts1(S100A4), a small Call-binding protein in tumor progression and metastasis had been demonstrated. However, the mechanism by which mts1(S100A4) promoted metastasis had not been identified. Here we demonstrated that Mts1(S100A4) had significant stimulatory effect on the angiogenesis. We detected high incidence of hemangiomas - benign tumors of vascular origin in aged transgenic mice ubiquitously expressing the mts1(S100A4) gene. Furthermore, the serum level of the Mts1(Sl00A4) protein increased with ageing. Tumors developed in Mts1-transgenic mice revealed an enhanced vascular density. We showed that an oligomeric, but not a dimeric form of the Mts1(S100A4) protein was capable of enhancing the endothelial cell motility in vitro and stimulate the corneal neovascularization in vivo. An oligomeric fraction of the protein was detected in the conditioned media as well as in human serum. The data obtained allowed us to conclude that mts1(S100A4) might induce tumor progression via stimulation of angiogenesis.	Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Copenhagen, Panum Inst, Prot Lab, DK-2200 Copenhagen N, Denmark; Kommune Hosp Copenhagen, Bartholin Inst, DK-1399 Copenhagen K, Denmark; Inst Gene Biol, Moscow, Russia	Danish Cancer Society; Karolinska Institutet; University of Copenhagen; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Ambartsumian, N (corresponding author), Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark.	na@cancer.dk	Klingelhöfer, Jörg/C-1676-2013; Tulchinsky, Eugene/ABD-7070-2021					Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Barraclough R, 1998, BBA-MOL CELL RES, V1448, P190, DOI 10.1016/S0167-4889(98)00143-8; BOOTH CJ, 1995, LAB ANIM SCI, V45, P497; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Duarte WR, 1999, BIOCHEM BIOPH RES CO, V255, P416, DOI 10.1006/bbrc.1999.0214; Dunn G A, 1983, Agents Actions Suppl, V12, P14; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FORD HL, 1995, ONCOGENE, V10, P1597; FRITH CH, 1982, LAB ANIM SCI, V32, P157; GESZY C, 1996, BIOCHIM BIOPHYS ACTA, V1313, P246; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Komada T, 1996, BIOCHEM BIOPH RES CO, V220, P871, DOI 10.1006/bbrc.1996.0496; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Kumar R, 1998, INT J ONCOL, V12, P749; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; LIOTTA LA, 1974, CANCER RES, V34, P997; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; PETERS RL, 1972, INT J CANCER, V10, P273, DOI 10.1002/ijc.2910100207; Polverini PJ, 1996, EUR J CANCER, V32A, P2430, DOI 10.1016/S0959-8049(96)00386-3; Rudland PS, 2000, CANCER RES, V60, P1595; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SENIN VM, 1983, EKSP ONKOL, V5, P35; SENIN VM, 1984, VESTN AKAD MED NAUK+, P85; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; Walmod PS, 1998, CELL MOTIL CYTOSKEL, V40, P220; WATANABE Y, 1992, J BIOL CHEM, V267, P17136; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WEIDNER N, 1995, AM J PATHOL, V147, P9; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	54	207	231	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4685	4695		10.1038/sj.onc.1204636	http://dx.doi.org/10.1038/sj.onc.1204636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498791				2022-12-28	WOS:000170208600009
J	Muller, C; Monferran, S; Gamp, AC; Calsou, P; Salles, B				Muller, C; Monferran, S; Gamp, AC; Calsou, P; Salles, B			Inhibition of Ku heterodimer DNA end binding activity during granulocytic differentiation of human promyelocytic cell lines	ONCOGENE			English	Article						double strand breaks; ionizing radiation; DNA repair; non homologous; end joining-differentiation	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; POLY(ADP-RIBOSE) POLYMERASE; CATALYTIC SUBUNIT; LEUKEMIA-CELLS; HL-60; AUTOANTIGEN; APOPTOSIS; RECOMBINATION; SENSITIVITY	The heterodimeric Ku protein (composed of the Ku 86 and Ku 70 sub-units) is a nuclear protein which binds to DNA termini without sequence specificity, Ku is the DNA-targeting component of the large catalytic sub-unit of the DNA-dependent protein kinase complex that is required for the repair of DNA double-strand breaks in mammalian cells. We studied the expression and function of Ku/DNA-PK during granulocytic differentiation of two human promyelocytic cell lines, HL60 and NB4, a process associated to decreased radiation resistance. After 3 days exposure to differentiating agents (either all-trans-retinoic acid or DMSO), Ku binding to double stranded (ds)-DNA ends declined dramatically whereas Ku protein levels remain unchanged, The nuclear, but not cytoplasmic, fraction of differentiated HL60 cells extracts exhibited a heat-sensitive inhibitory activity towards DNA binding of recombinant Ku heterodimer, We further demonstrate that immunoprecipitation of Ku is impaired in extracts from differentiated cells by using two antibodies that recognize epitopes within the C-terminus DNA binding domains of Ku 70 and Ku 86 proteins, These results favor the hypothesis of a protein interacting with Ku that would prevent DNA binding of heterodimerized Ku protein by steric hindrance.	Inst Pharmacol & Biol Struct, CNRS, UPR 9062, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Salles, B (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.		Monferran, Sylvie/M-3445-2014; MULLER, Catherine/M-2185-2018; MULLER, Catherine/E-2060-2011; salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020	Calsou, Patrick/0000-0001-7951-9806; Monferran, Sylvie/0000-0002-7062-7437				ANDERSON CW, 1994, J PROTEIN CHEM, V13, P500; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; BHATIA M, 1995, BIOCHEM J, V308, P131, DOI 10.1042/bj3080131; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Burgman P, 1997, CANCER RES, V57, P2847; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; COLLINS SJ, 1987, BLOOD, V70, P1233; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; FALZON M, 1993, J BIOL CHEM, V268, P10546; FARNAZEH F, 1987, NUCLEIC ACIDS RES, V15, P3493; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; GALLAGHER R, 1979, BLOOD, V54, P713; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; ISLAS AL, 1995, CANCER RES, V55, P336; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; KANAI M, 1982, BIOCHEM BIOPH RES CO, V105, P404, DOI 10.1016/0006-291X(82)91448-6; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; LANOTTE M, 1991, BLOOD, V77, P1080; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; McConnell KR, 1997, J IMMUNOL, V158, P2083; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; MINORI T, 1986, J BIOL CHEM, V261, P10375; Morio T, 1999, IMMUNITY, V11, P339, DOI 10.1016/S1074-7613(00)80109-0; Muller C, 1998, ONCOGENE, V16, P1553, DOI 10.1038/sj.onc.1201676; Muller C, 1999, BIOCHIMIE, V81, P117, DOI 10.1016/S0300-9084(99)80044-3; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; Muller C, 1997, ONCOGENE, V15, P2343, DOI 10.1038/sj.onc.1201402; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PLOEMACHER R, 1992, INT J RADIAT BIOL, V61, P488; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Romero F, 1996, MOL CELL BIOL, V16, P37; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Tai YT, 2000, J IMMUNOL, V165, P6347, DOI 10.4049/jimmunol.165.11.6347; TOFILON PJ, 1988, EXP CELL RES, V174, P502, DOI 10.1016/0014-4827(88)90319-9; Vral A, 2001, INT J RADIAT BIOL, V77, P329, DOI 10.1080/0955300001004237; WAGEMAKER G, 1995, STEM CELLS, V13, P257, DOI 10.1002/stem.5530130731; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; WANG JS, 1994, J CELL SCI, V107, P3223; WHEELER KT, 1983, RADIAT ENVIRON BIOPH, V22, P3, DOI 10.1007/BF01323757; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	63	18	18	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4373	4382		10.1038/sj.onc.1204571	http://dx.doi.org/10.1038/sj.onc.1204571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466618				2022-12-28	WOS:000169912600011
J	Soubeyran, P; Haglund, K; Garcia, S; Barth, BU; Iovanna, J; Dikic, I				Soubeyran, P; Haglund, K; Garcia, S; Barth, BU; Iovanna, J; Dikic, I			Homeobox gene Cdx1 regulates Ras, Rho and PI3 kinase pathways leading to transformation and tumorigenesis of intestinal epithelial cells	ONCOGENE			English	Article						transformation; intestinal epithelial cells; Cdx1; Ras; PI3 kinase	PROTEIN EXPRESSION; COLORECTAL-CANCER; DOWN-REGULATION; DIFFERENTIATION; ACTIVATION; INHIBITION; ELEMENT; HOMOLOG	The Cdx1 homeobox gene encodes for an intestine-specific transcription factor involved in the control of proliferation and differentiation of epithelial cells. Although it has been indicated that Cdx1 may act as a proto-oncogene in cultured fibroblasts, its direct role in the regulation of intestinal tumorigenesis has not been demonstrated. Here we show that expression of Cdx1 in an intestinal epithelial cell line (IEC-6) induces anchorage-independent growth in soft agar and promotes the formation of adenocarcinoma in vivo, The phenotype of Cdx1-induced tumors was exacerbated when IEC-6/ Cdx1 cells were injected together with matrigel containing mitogens and extracellular matrix components. These changes were correlated with an increase in the GTP-bound form of Ras, modulation of Cdc42 and Rho-A activities, and accumulation of phosphatidyl inositol 3 (PI3) kinase products. Moreover, combined inhibition of Ras/Rho and PI3 kinase signaling by syntethic inhibitors blocked colony formation of IEC-6/Cdx1 cells in soft agar, Taken together, these results demonstrate a direct involvement of Cdx1, and its collaboration with Ras, Rho and PI3 kinase pathways, in transformation and tumorigenesis of intestinal epithelial cells.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; INSERM, Lab Physiol & Pathol Digest, U315, F-13009 Marseille, France; Hop Nord Marseille, F-13915 Marseille, France	Ludwig Institute for Cancer Research; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Dikic, I (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.	Ivan.Dikic@licr.uu.se	Soubeyran, Philippe/P-1758-2018; Iovanna, Juan/M-9805-2017; Dikic, Ivan/O-4650-2015; Haglund, Kaisa/B-3927-2017	Iovanna, Juan/0000-0003-1822-2237; Dikic, Ivan/0000-0001-8156-9511; Haglund, Kaisa/0000-0002-7946-3299; Soubeyran, Philippe/0000-0002-5876-3217				Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; [Anonymous], 1988, LAB ANIM-UK, V22, P195; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; Bell E, 1999, SCIENCE, V284, P2168, DOI 10.1126/science.284.5423.2168; Bijl JJ, 1997, AM J PATHOL, V151, P1067; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Chariot A, 1999, ONCOGENE, V18, P4007, DOI 10.1038/sj.onc.1202776; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Duluc I, 1997, J CELL SCI, V110, P1317; EE HC, 1995, AM J PATHOL, V147, P586; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Isaacs HV, 1998, EMBO J, V17, P3413, DOI 10.1093/emboj/17.12.3413; JAMES R, 1994, J BIOL CHEM, V269, P15229; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1999, J BIOL CHEM, V274, P7196, DOI 10.1074/jbc.274.11.7196; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ren P, 2000, AM J PATHOL, V156, P621, DOI 10.1016/S0002-9440(10)64766-9; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971	34	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4180	4187		10.1038/sj.onc.1204551	http://dx.doi.org/10.1038/sj.onc.1204551			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464284				2022-12-28	WOS:000169857200008
J	Li, Q; Qi, B; Oka, K; Shimakage, M; Yoshioka, N; Inoue, H; Hakura, A; Kodama, K; Stanbridge, EJ; Yutsudo, M				Li, Q; Qi, B; Oka, K; Shimakage, M; Yoshioka, N; Inoue, H; Hakura, A; Kodama, K; Stanbridge, EJ; Yutsudo, M			Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer	ONCOGENE			English	Article						ASY; Nogo-B; apoptosis; cancer; endoplasmic reticulum	NEURITE OUTGROWTH; EXPRESSION; INHIBITOR; IDENTIFICATION; TRANSFORMATION; TRANSCRIPTS; CLONING; KINASE; GROWTH; DEATH	Although apoptosis plays an essential role in the embryogenesis and homeostasis of multicellular organisms, this mechanism has not yet been fully clarified. We isolated a novel human apoptosis-inducing gene, ASY, which encodes an endoplasmic reticulum-targeting protein without any known apoptosis-related motifs, This gene is identical to the Nogo-B, a splice variant of the Nogo-A which has recently been shown to be an inhibitor of neuronal regeneration in the central nervous system, Ectopic expression of the ASY gene led to extensive apoptosis, particularly in cancer cells. Furthermore, transcription of the ASY gene was suppressed in small cell lung cancer. These results suggest that a new type of apoptosis-inducing gene, namely, ASY, may be involved in the development of certain types of cancer.	Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, Suita, Osaka 5650871, Japan; Wuhan Univ, Sch Life Sci, Virus Inst, Wuhan 430072, Hubei, Peoples R China; Osaka Natl Hosp, Clin Res Inst, Osaka 5400006, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Surg, Osaka 5378511, Japan; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Osaka University; Wuhan University; Osaka National Hospital; Osaka Medical Center for Cancer & Cardiovascular Diseases; University of California System; University of California Irvine	Yutsudo, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yutsudo@biken.osaka-u.ac.jp						Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BANERJEE A, 1992, CANCER RES, V52, P6297; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Oka K, 1999, GENE CHROMOSOME CANC, V26, P47, DOI 10.1002/(SICI)1098-2264(199909)26:1<47::AID-GCC7>3.0.CO;2-8; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; ROEBROEK AJM, 1989, CANCER RES, V49, P4154; Shimakage M, 1997, HUM PATHOL, V28, P1415, DOI 10.1016/S0046-8177(97)90232-X; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	28	97	113	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					3929	3936		10.1038/sj.onc.1204536	http://dx.doi.org/10.1038/sj.onc.1204536			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494121				2022-12-28	WOS:000169681500001
J	Gross, M; Liu, B; Tan, JA; French, FS; Carey, M; Shuai, K				Gross, M; Liu, B; Tan, JA; French, FS; Carey, M; Shuai, K			Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen signaling; protein inhibitor of activated STAT	NUCLEAR-RECEPTOR; DEPENDENT TRANSCRIPTION; COACTIVATORS; BINDING; DETERMINANTS; SPECIFICITY; COREGULATOR; INHIBITION; REQUIRES; COMPLEX	Androgen signaling influences the development and growth of prostate carcinoma. The transcriptional activity of androgen receptor (AR) is regulated by positive or negative transcriptional cofactors, We report here that PIAS1, PIAS3, and PIASy of the protein inhibitor of activated STAT (PIAS) family, which are expressed in human prostate, display distinct effects on AR-mediated gene activation in prostate cancer cells. While PIAS1 and PIAS3 enhance the transcriptional activity of AR, PIASy acts as a potent inhibitor of AR in prostate cancer cells, The effects of PIAS proteins on AR are competitive. PIASy binds to AR but does not affect the DNA binding activity of AR. An NH2-terminal LXXLL signature motif of PIASy, although not required for PIASy-AR interaction, is essential for the transrepression activity of PIASy, Our results identify PIASy as a transcriptional corepressor of AR and suggest that different PIAS proteins have distinct effects on AR signaling in prostate cancer cells.	Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ N Carolina, Sch Med, Dept Pediat, Labs Reprod Biol, Chapel Hill, NC 27599 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of California System; University of California Los Angeles	Shuai, K (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, 11-934 Factor Bldg,1083 LeConte Ave, Los Angeles, CA 90095 USA.			Gross, Mitchell/0000-0002-1691-921X; Carey, Michael/0000-0003-3899-6280	NIAID NIH HHS [AI43438] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI043438, R01AI043438] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Bentel JM, 1996, J ENDOCRINOL, V151, P1, DOI 10.1677/joe.0.1510001; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 2000, GENE DEV, V14, P121; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Kokontis JM, 1999, VITAM HORM, V55, P219; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; McDonald S, 2000, CANCER RES, V60, P2317; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050	30	144	153	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 28	2001	20	29					3880	3887		10.1038/sj.onc.1204489	http://dx.doi.org/10.1038/sj.onc.1204489			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439351				2022-12-28	WOS:000169494700013
J	Soncini, C; Berdo, I; Draetta, G				Soncini, C; Berdo, I; Draetta, G			Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease	ONCOGENE			English	Article						de-ubiqitinating enzyme; G3BP; ubiquitin	FACETS DEUBIQUITINATING ENZYME; CHROMOSOMAL LOCALIZATION; SACCHAROMYCES-CEREVISIAE; ISOPEPTIDASE-T; DEGRADATION; GENE; INTERACTS; PATHWAY; UNP; PHOSPHORYLATION	Degradation of cellular proteins through ubiquitination is a fundamental strategy for regulating biological pathways. De-ubiquitination, i,e, the removal of ubiquitin from proteins and peptides to which ubiquitin is attached, is catalyzed by processing proteases known as de-ubiquitinating enzymes, We are studying the biology of a family of de-ubiquitinating enzymes, the mammalian ubiquitin-specific proteases (USPs), some of which appear to play a role in growth control. Given the fact that the modes of regulation of USPs and of their substrate specificity are poorly understood, we decided to attempt the identification of USP interacting proteins, Using the yeast two-hybrid system (2HS), we have isolated a cDNA clone whose product specifically interacts with USP10 but not with other USP baits tested. The isolated clone encodes a protein known to interact with the Ras-GTPase activating protein (G3BP), This interaction was further confirmed by performing a 2HS with G3BP, which led to the isolation of USP10 encoding cDNAs. We validated the interaction between the two proteins by performing in vitro binding assays and immunoprecipitations in human cells, G3BP does not appear to be a substrate of USP10; it rather inhibits the ability of USP10 to disassemble ubiquitin chains. The USP10/G3BP complex appears to co-immunoprecipitate with ubiquitinated species that could be substrates of USP10.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Draetta, G (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.			SONCINI, MARIACHIARA/0000-0002-2066-9751				Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; BAKER RT, 1992, J BIOL CHEM, V267, P23364; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; GRAY DA, 1995, ONCOGENE, V10, P2179; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; GUPTA K, 1993, ONCOGENE, V8, P2307; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li QH, 1997, P NATL ACAD SCI USA, V94, P12515, DOI 10.1073/pnas.94.23.12515; Lin HJ, 2000, MOL CELL BIOL, V20, P6568, DOI 10.1128/MCB.20.17.6568-6578.2000; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Parker F, 1996, MOL CELL BIOL, V16, P2561; Sloper-Mould KE, 1999, J BIOL CHEM, V274, P26878, DOI 10.1074/jbc.274.38.26878; STEIN RL, 1995, BIOCHEMISTRY-US, V34, P12616, DOI 10.1021/bi00039a017; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	39	133	142	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3869	3879		10.1038/sj.onc.1204553	http://dx.doi.org/10.1038/sj.onc.1204553			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439350				2022-12-28	WOS:000169494700012
J	Zhou, WL; Carpenter, G				Zhou, WL; Carpenter, G			Heregulin-dependent translocation and hyperphosphorylation of ErbB-2	ONCOGENE			English	Article						ErbB-2; heregulin; detergent-insoluble fraction	LIPID RAFTS; ACTIN CYTOSKELETON; SIGNALING NETWORK; MEMBRANE DOMAINS; RECEPTOR; ONCOGENESIS; TRAFFICKING; RECRUITMENT; ENGAGEMENT; CAVEOLAE	Previous data have shown that in several tumor cells lines the addition of heregulin results in the translocation of ErbB-4 to a detergent-insoluble membrane fraction where it is hypertyrosine phosphorylated, The data herein demonstrate that heregulin or betacellulin, but not EGF, promotes the rapid translocation of ErbB-2, the heterodimerization partner for ErbB-4, to the same detergent-insoluble fraction in T47 D mammary carcinoma cells. The translocation of ErbB-2 and ErbB-4, but not ErbB-3, to this detergent-insoluble fraction is readily detected 2 min after the addition of heregulin, ErbB-2 present in this detergent-insoluble membrane fraction is tyrosine phosphorylated to a level fourfold greater than the majority of cellular ErbB-2 present in the detergent-soluble membrane fraction. These results suggest the ligand-dependent formation of hyperphosphorylated ErbB-4/ErbB-2 dimers coordinate with translocation to a putative membrane microdomain,	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA024071, T32CA009582] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09582, R01 CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Dunbar AJ, 2000, INT J BIOCHEM CELL B, V32, P805, DOI 10.1016/S1357-2725(00)00028-5; Holowka D, 2000, J CELL SCI, V113, P1009; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Leupin O, 2000, CURR BIOL, V10, P277, DOI 10.1016/S0960-9822(00)00362-6; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhao YY, 1999, CIRC RES, V84, P1380; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	17	23	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3918	3920		10.1038/sj.onc.1204517	http://dx.doi.org/10.1038/sj.onc.1204517			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439355				2022-12-28	WOS:000169494700017
J	Tannapfel, A; Busse, C; Weinans, L; Benicke, M; Katalinic, A; Geissler, F; Hauss, J; Wittekind, C				Tannapfel, A; Busse, C; Weinans, L; Benicke, M; Katalinic, A; Geissler, F; Hauss, J; Wittekind, C			INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas	ONCOGENE			English	Article						hepatocellular carcinoma; P14(ARF); p16(INK4a); p53; histopathology; prognosis	METHYLATION; CELL; EXPRESSION; FREQUENCY	The INK4a-ARF (CDKN2A)- locus on chromosome 9p21 encodes for two tumour suppressor proteins, P16(INK4a) and p14(ARF), that act as upstream regulators of the Rb-CDK4 and p53 pathways. To study the contribution of each pathway in tumorigenesis of hepatocellular carcinoma (HCC), we analysed the alterations of p14(ARF), p16(INC4a) and p53. After microdissection, DNA of 71 hepatocellular carcinomas was analysed for INK4-ARF inactivation and p53 mutation by DNA sequence analysis, methylation-specific PCR (MSP), restriction-enzyme related polymerase chain reaction (RE-PCR), mRNA expression and immunohistochemistry. In addition, microdeletion of p14(ARF) and p16(INC4a) were assessed by differential PCR. Inactivation of p14(ARF) was found in 11/71 cases (15%), alterations of p16(INK4a), occurred in 47/71 carcinomas (66%), which correlated with loss of mRNA transcription. Five tumours (7%) had homozygous deletions of the INK4a-ARF locus. We failed to detect specific mutations of both exons. P16(INK4a) methylation with an unmethylated p14(ARF) promotor appeared in 39 cases. Mutations of p53 were found in 30 of 71 HCC (42%), and only one of them harboured p14(ARF) inactivation. We failed to establish alterations of the INK4a-ARF locus or p53 status as independent prognostic factor in these tumours. Our data indicate, that p14(ARF) methylation occurs independently of p16(INK4a) alterations in a subset of HCC together with wild type p53. The INK4a-ARF-/p53-pathway was disrupted in 86% of HCC, either by p53 mutations or by INK4a-ARF inactivation, and may have co-operative effects in hepatocarcinogenesis.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Med Univ Lubeck, Inst Canc Epidemiol, D-23564 Lubeck, Germany; Univ Leipzig, Dept Abdominal Vasc & Transplantat Surg 2, D-04103 Leipzig, Germany	Leipzig University; University of Lubeck; Leipzig University	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.		Katalinic, Alexander/D-2512-2010	Katalinic, Alexander/0000-0003-0490-1554				[Anonymous], 1997, J CLIN PATHOL; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664; Bradley G, 2001, ONCOGENE, V20, P654, DOI 10.1038/sj.onc.1204131; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; Esteller M, 2000, CANCER RES, V60, P129; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; HAMILTON SR, 2000, PATHOLOGY GENETICS, P173; Issa JPJ, 2001, CANCER RES, V61, P3573; Jackson PE, 2001, CANCER RES, V61, P33; Kaneto H, 2001, GUT, V48, P372, DOI 10.1136/gut.48.3.372; Kang GH, 2001, CANCER RES, V61, P2847; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; Orlow I, 1999, J NATL CANCER I, V91, P73, DOI 10.1093/jnci/91.1.73; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schraml P, 2001, AM J PATHOL, V158, P593, DOI 10.1016/S0002-9440(10)64001-1; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154	21	108	113	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7104	7109		10.1038/sj.onc.1204902	http://dx.doi.org/10.1038/sj.onc.1204902			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704835				2022-12-28	WOS:000171739300014
J	Zou, CP; Youssef, EM; Zou, CC; Carey, TE; Lotan, R				Zou, CP; Youssef, EM; Zou, CC; Carey, TE; Lotan, R			Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta and on retinoid resistance in human squamous carcinoma cells	ONCOGENE			English	Article						chromosome 3p; retinoic acid receptor beta; retinoic acid; growth inhibition; head and neck cancer	ACID RECEPTOR-BETA; HUMAN HEAD; RESPONSIVE ELEMENT; BREAST-CANCER; GROWTH; GENE; METHYLATION; PROMOTER; OVEREXPRESSION; KERATINIZATION	Retinoids' effects on cell growth and differentiation are mediated by nuclear retinoid receptors, which are ligand-activated transcription enhancing factors. Because the expression of the retinoic acid receptor beta (RAR beta) gene, which is located on chromosome 3p24, is diminished in premalignant and malignant tissues it has been proposed that it acts as a tumor suppressor. To test the hypothesis that RAR beta loss leads to retinoid resistance, we studied several karyotyped head and neck squamous carcinoma (HNSCC) cell lines (UMSCC-17A, -17B, -22A, -22B, and -38) with deletion of one chromosome 3p arm. RAR beta mRNA was neither detected nor induced by retinoic acid in these cells, whereas it was expressed and induced by retinoic acid in two other HNSCC cell lines (1483 and 183) without 3p deletion. Methylation of the RAR beta gene promoter was detected in the 17B and 22B cells that failed to express RAR beta but no methylation was found in 183A cells that did express RAR beta mRNA. Responsiveness of HNSCC cells to several retinoids in assays of growth inhibition and colony formation, was rank ordered as: 22B > 1483 > 38 > 183 > 17B. Additionally, retinoid response elements were transactivated in 22B more efficiently than in 17B cells. These results indicate that loss of RAR beta expression does not necessarily lead to loss of growth inhibition by retinoids or to a block of retinoid signaling.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Obstet Gynecol & Reprod Sci, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Michigan, Ctr Canc, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	rlotan@mdanderson.org		Carey, Thomas/0000-0002-5202-7518	NCI NIH HHS [P01 CA52051, R25 CA57730] Funding Source: Medline; NIDCR NIH HHS [P50 DE11906] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA057730, P01CA052051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Buchhagen DL, 1996, HEAD NECK-J SCI SPEC, V18, P529; Burge-Bottenbley A, 1983, Nutr Cancer, V5, P121, DOI 10.1080/01635588309513788; CAREY TE, 1989, CANCER RES, V49, P6098; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FERRARI N, 1994, EXP CELL RES, V211, P121, DOI 10.1006/excr.1994.1067; GEBERT JF, 1991, ONCOGENE, V6, P1859; GRENMAN R, 1991, CANCER, V67, P2741, DOI 10.1002/1097-0142(19910601)67:11<2741::AID-CNCR2820671105>3.0.CO;2-S; Hayashi K, 2000, CANCER LETT, V151, P199, DOI 10.1016/S0304-3835(99)00422-X; Hayashi K, 2001, JPN J CANCER RES, V92, P42, DOI 10.1111/j.1349-7006.2001.tb01046.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KRAUSE CJ, 1981, ARCH OTOLARYNGOL, V107, P703; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LATIF F, 1992, CANCER RES, V52, P1451; Le Q, 2000, ONCOGENE, V19, P1457, DOI 10.1038/sj.onc.1203436; LOTAN R, 1994, CANCER RES, V54, pS1987; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LOTAN R, 1991, METHODS ENZYMOLOGY R, P100; MAESTRO R, 1993, CANCER RES, V53, P5775; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; McGregor F, 1997, CANCER RES, V57, P3886; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; Oridate N, 1996, ONCOGENE, V12, P2019; Oridate N, 1996, IN VITRO CELL DEV-AN, V32, P192; Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059; SACKS PG, 1988, CANCER RES, V48, P2858; SCHWARTZ J L, 1985, Nutrition and Cancer, V7, P77; SHALINSKY DR, 1995, CANCER RES, V55, P3183; Shalinsky DR, 1997, CANCER RES, V57, P162; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sun SY, 2000, CLIN CANCER RES, V6, P1563; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wan HS, 1999, CANCER RES, V59, P3518; Wan HS, 1998, J BIOL CHEM, V273, P26915, DOI 10.1074/jbc.273.41.26915; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; XU XC, 1994, CANCER RES, V54, P3580; Youssef Emile M., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P550; ZOU CP, 1994, CANCER RES, V54, P5479; Zou CP, 1999, DIFFERENTIATION, V64, P123, DOI 10.1046/j.1432-0436.1999.6420123.x	55	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6820	6827		10.1038/sj.onc.1204846	http://dx.doi.org/10.1038/sj.onc.1204846			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687961				2022-12-28	WOS:000171641000003
J	Futamura, M; Kamiya, S; Tsukamoto, M; Hirano, A; Monden, Y; Arakawa, H; Nishimura, S				Futamura, M; Kamiya, S; Tsukamoto, M; Hirano, A; Monden, Y; Arakawa, H; Nishimura, S			Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells	ONCOGENE			English	Article						malolactomycin D; Ras-responsive element; MMP; tansformation	ACTIVATED PROTEIN-KINASE; FIBROBLAST-GROWTH-FACTOR; FACTOR-BINDING-SITES; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; PROMOTER ACTIVITY; HUMAN CANCER; C-FOS; INVASION; ONCOGENES	To search for anti-cancer agents, a screening system for Ras signal inhibitors was developed using a NIH3T3 cell Hue with an introduced reporter gene which is controlled by the Ras-responsive element (RRE). With this screening system, malolactomycin D was identified as a selective inhibitor of transcription from the RRE. This compound was found to preferentially inhibit the anchorage-independent growth rather than the anchorage-dependent growth of Ras-transformed NIH3T3 cells. The expression of matrix metalloproteinases MMP-1 and MMP-9, which have RRE in their promoters, were reduced by treatment with malolactomycin D at the translational and transcriptional levels. Analysis of the activity of mitogen-activated protein (MAP) kinases, which play important roles in transduction of the Ras signal, showed that malolactomycin D inhibits the activation of p38 MAP kinase and Jun N-terminal-kinase (JNK) but not extracellular signal-regulated kinase 1 or 2 (ERK1 or 2). These findings suggest that by inhibiting the pathway that leads to the activation of p38 MAP kinase and JNK, malolactomycin D suppresses the expression of MMPs. Since MMPs play important roles in metastasis and maintenance of the microenvironment of tumor cells, both of which facilitate tumor growth, the inhibition of MMPs by malolactomycin D is believed to contribute to its ability to inhibit Ras-mediated tumorigenesis.	Merck Res Labs, Banyu Tsukuba Res Inst Collaborat, Tsukuba, Ibaraki 3002611, Japan	Merck & Company	Nishimura, S (corresponding author), Merck Res Labs, Banyu Tsukuba Res Inst Collaborat, Okubo 3, Tsukuba, Ibaraki 3002611, Japan.							Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOS JL, 1989, CANCER RES, V49, P4682; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Buttice G, 1996, ONCOGENE, V13, P2297; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; COROMINAS M, 1991, ENVIRON HEALTH PERSP, V93, P19, DOI 10.2307/3431163; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GOUSTIN AS, 1986, CANCER RES, V46, P1015; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; Johansson N, 2000, J CELL SCI, V113, P227; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Simon C, 1998, CANCER RES, V58, P1135; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Tanaka Y, 1997, J ANTIBIOT, V50, P194, DOI 10.7164/antibiotics.50.194; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; White LA, 1997, CONNECT TISSUE RES, V36, P321, DOI 10.3109/03008209709160231; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Zhao A, 1999, J ANTIBIOT, V52, P1086, DOI 10.7164/antibiotics.52.1086	39	14	14	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6724	6730		10.1038/sj.onc.1204878	http://dx.doi.org/10.1038/sj.onc.1204878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709707				2022-12-28	WOS:000171551600009
J	Burek, C; Roth, J; Koch, HG; Harzer, K; Los, M; Schulze-Osthoff, K				Burek, C; Roth, J; Koch, HG; Harzer, K; Los, M; Schulze-Osthoff, K			The role of ceramide in receptor- and stress-induced apoptosis studied in acidic ceramidase-deficient Farber disease cells	ONCOGENE			English	Article						apoptosis; ceramide; ceramidase; CD95; Farber disease	NIEMANN-PICK-DISEASE; GD3 GANGLIOSIDE; SPHINGOMYELINASE; DEATH; CD95; MICE; FAS; ACTIVATION; CASPASE-3; ABSENCE	The activation of sphingomyelinases leading to the generation of ceramide has been implicated in various apoptotic pathways. However, the role of ceramide as an essential death mediator remains highly controversial. In the present study, we investigated the functional relevance of ceramide in a genetic model by using primary cells from a Farber disease patient. These cells accumulate ceramide as the result of an inherited deficiency of acidic ceramidase. We demonstrate that Farber disease lymphocytes and fibroblasts underwent apoptosis induced by various stress stimuli, including staurosporine, anticancer drugs and gamma -irradiation, equally as normal control cells. In addition, caspase activation by these proapoptotic agents occurred rather similarly in Farber disease and control fibroblasts. Interestingly, Farber disease lymphoid cells underwent apoptosis induced by the CD95 death receptor more rapidly than control cells. Our data therefore suggest that ceramide does not play an essential role as a second messenger in stress-induced apoptosis. However, in accordance with a role in lipid-rich microdomains, ceramide by altering membrane composition may function as an amplifier in CD95-mediated apoptosis.	Univ Munich, Dept Immunol & Cell Biol, D-48149 Munster, Germany; Univ Munster, Dept Pediat, D-4400 Munster, Germany; Univ Tubingen, Neurochem Lab, Tubingen, Germany	University of Munich; University of Munster; Eberhard Karls University of Tubingen	Schulze-Osthoff, K (corresponding author), Univ Munich, Dept Immunol & Cell Biol, Rontgenstr 21, D-48149 Munster, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411				Bezombes C, 2001, FASEB J, V15, P297; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Chatelut M, 1996, CLIN CHIM ACTA, V245, P61, DOI 10.1016/0009-8981(95)06173-8; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Farina F, 2000, J HISTOCHEM CYTOCHEM, V48, P57, DOI 10.1177/002215540004800106; FUJIWAKI T, 1992, Acta Paediatrica Japonica, V34, P72; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 2000, AM J PHYSIOL-RENAL, V279, pF605, DOI 10.1152/ajprenal.2000.279.4.F605; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kolodny EH, 2000, CURR OPIN HEMATOL, V7, P48, DOI 10.1097/00062752-200001000-00009; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Los M, 2000, BIOCHEMISTRY-US, V39, P7365, DOI 10.1021/bi000158w; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MOSER HW, 1969, AM J MED, V47, P869, DOI 10.1016/0002-9343(69)90202-2; Nishioka K, 1998, ARTHRITIS RHEUM, V41, P1; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; Qualman S J, 1987, Am J Med Genet Suppl, V3, P233; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Segui B, 2000, FASEB J, V14, P36, DOI 10.1096/fasebj.14.1.36; Spinedi A, 1999, BIOCHEM BIOPH RES CO, V255, P456, DOI 10.1006/bbrc.1999.0230; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	49	37	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6493	6502		10.1038/sj.onc.1204841	http://dx.doi.org/10.1038/sj.onc.1204841			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641773	Green Published			2022-12-28	WOS:000171404200001
J	Butz, K; Denk, C; Fitscher, B; Crnkovic-Mertens, I; Ullmann, A; Schroder, CH; Hoppe-Seyler, F				Butz, K; Denk, C; Fitscher, B; Crnkovic-Mertens, I; Ullmann, A; Schroder, CH; Hoppe-Seyler, F			Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity	ONCOGENE			English	Article						liver cancer; Hepatitis B virus; peptide aptamers; therapy; virus replication	TRANSIENT EXPRESSION; DNA; INHIBITION; PARTICLES; SELECTION; MUTANTS; CANCER; IDENTIFICATION; REPLICATION; 2-HYBRID	A substantial proportion of the worldwide liver cancer incidence is associated with chronic hepatitis B virus (HBV) infection. The therapeutic management of HBV infections is still problematic and novel antiviral strategies are urgently required. Using the peptide aptamer screening system, we aimed to isolate new molecules, which can block viral replication by interfering with capsid formation. Eight peptide aptamers were isolated from a randomized expression library, which specifically bound to the HBV core protein under intracellular conditions. One of them, named C1-1, efficiently inhibited viral capsid formation and, consequently, HBV replication and virion production. Hence, C1-1 is a novel model compound for inhibiting HBV replication by blocking capsid formation and provides a new basis for the development of therapeutic molecules with specific antiviral potential against HBV infections.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	hoppe-seyler@dkfz-heidelberg.de		Hoppe-Seyler, Felix/0000-0002-1864-300X				Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; Bottcher B, 1998, EMBO J, V17, P6839, DOI 10.1093/emboj/17.23.6839; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; BUTZ K, 1995, ONCOGENE, V10, P927; CALVERT J, 1994, J VIROL, V68, P2084, DOI 10.1128/JVI.68.4.2084-2090.1994; CHANG CM, 1987, EMBO J, V6, P675, DOI 10.1002/j.1460-2075.1987.tb04807.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Colas P, 2000, CURR OPIN CHEM BIOL, V4, P54, DOI 10.1016/S1367-5931(99)00051-4; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; Cunningham BC, 1997, CURR OPIN STRUC BIOL, V7, P457, DOI 10.1016/S0959-440X(97)80107-8; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; DYSON MR, 1995, P NATL ACAD SCI USA, V92, P2194, DOI 10.1073/pnas.92.6.2194; Elliott G, 1999, GENE THER, V6, P149, DOI 10.1038/sj.gt.3300850; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; GANEM D, 1996, VIROLOGY, P2703; HARLOW E, 1999, USING ANTIBODIES LAB, P221; Hoppe-Seyler F, 2000, J MOL MED, V78, P426, DOI 10.1007/s001090000140; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Konig S, 1998, J VIROL, V72, P4997; LADNER RC, 1995, TRENDS BIOTECHNOL, V13, P426, DOI 10.1016/S0167-7799(00)88997-0; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; LAMBERTS C, 1993, J VIROL, V67, P3756, DOI 10.1128/JVI.67.7.3756-3762.1993; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROINGEARD P, 1990, HEPATOLOGY, V11, P277, DOI 10.1002/hep.1840110219; Scaglioni P, 1996, HEPATOLOGY, V24, P1010; SCAGLIONI PP, 1994, VIROLOGY, V205, P112, DOI 10.1006/viro.1994.1625; Seifer M, 1995, INTERVIROLOGY, V38, P47, DOI 10.1159/000150414; SUMMERS J, 1990, J VIROL, V64, P2819, DOI 10.1128/JVI.64.6.2819-2824.1990; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; von Weizsacker F, 1999, HEPATOLOGY, V30, P308, DOI 10.1002/hep.510300139; vonWeizsacker F, 1996, HEPATOLOGY, V24, P294; vonWeizsacker F, 1997, HEPATOLOGY, V26, P251, DOI 10.1002/hep.510260237; WRIGHT TL, 1993, LANCET, V342, P1340, DOI 10.1016/0140-6736(93)92250-W; WU TT, 1990, VIROLOGY, V175, P255, DOI 10.1016/0042-6822(90)90206-7; Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; ZHOU S, 1992, P NATL ACAD SCI USA, V89, P10046, DOI 10.1073/pnas.89.21.10046	50	71	81	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6579	6586		10.1038/sj.onc.1204805	http://dx.doi.org/10.1038/sj.onc.1204805			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641783				2022-12-28	WOS:000171404200011
J	Meuwissen, R; Linn, SC; van der Valk, M; Mooi, WJ; Berns, A				Meuwissen, R; Linn, SC; van der Valk, M; Mooi, WJ; Berns, A			Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene	ONCOGENE			English	Article						somatic activation; Cre-lox; conditional K-Ras allele; lung epithelial tissue; lung tumors; non-small cell lung cancer	TRANSCRIPTION FACTOR-I; SURFACTANT PROTEIN-B; TRANSGENIC MICE; PULMONARY ADENOCARCINOMA; CLINICAL-SIGNIFICANCE; PROGNOSTIC MARKER; CELL CARCINOMAS; GENE-TRANSFER; CANCER; EXPRESSION	The onset of human lung cancer occurs through sequential mutations in oncogenes and tumor suppressor genes. Mutations in K-Ras play a prominent role in human non-small cell lung cancer. We have developed a mouse lung tumor model in which K-Ras can be sporadically activated through Cre-lox mediated somatic recombination. Adenoviral mediated delivery of Cre recombinase in lung epithelial cells gave rise to rapid onset of tumorigenesis, yielding pulmonary adenocarcinomas with 100% incidence after a short latency. The lung tumor lesions shared many features with human non-small cell lung cancer. Our data show that sporadic expression of the K-Ras oncogene is sufficient to elicit lung tumorigenesis. Therefore this model has many advantages over conventional transgenic models used thus far.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Diagnost Oncol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	tberns@nki.nl						Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOS JL, 1989, CANCER RES, V49, P4682; CAREY FA, 1992, THORAX, V47, P1041, DOI 10.1136/thx.47.12.1041; CHAN GL, 1992, THER DRUG MONIT, V14, P42, DOI 10.1097/00007691-199202000-00007; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Cooper CA, 1997, J PATHOL, V181, P401, DOI 10.1002/(SICI)1096-9896(199704)181:4<401::AID-PATH799>3.0.CO;2-Y; EDWARDS CW, 1987, J CLIN PATHOL, V40, P125, DOI 10.1136/jcp.40.2.125; FIJNEMAN RJA, 1995, IMMUNOGENETICS, V41, P106, DOI 10.1007/BF00182320; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; GAZDAR AF, 1994, ANTICANCER RES, V14, P261; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Howell JM, 1998, HUM GENE THER, V9, P629, DOI 10.1089/hum.1998.9.5-629; Huncharek M, 1999, CARCINOGENESIS, V20, P1507, DOI 10.1093/carcin/20.8.1507; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kaufmann O, 2000, HISTOPATHOLOGY, V36, P8; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Malkinson AM, 1998, EXP LUNG RES, V24, P541, DOI 10.3109/01902149809087385; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MARONPOT RR, 1991, EXP LUNG RES, V17, P305, DOI 10.3109/01902149109064420; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MILLS NE, 1995, CANCER RES, V55, P1444; Omer CA, 2000, CANCER RES, V60, P2680; OOMEN LCJM, 1991, EXP LUNG RES, V17, P283, DOI 10.3109/01902149109064419; Ordonez NG, 2000, ADV ANAT PATHOL, V7, P123, DOI 10.1097/00125480-200007020-00007; Otake K, 1998, HUM GENE THER, V9, P2207, DOI 10.1089/hum.1998.9.15-2207; OUDEJANS JJ, 1991, INT J CANCER, V49, P875, DOI 10.1002/ijc.2910490613; Park JY, 2000, LUNG CANCER-J IASLC, V30, P83, DOI 10.1016/S0169-5002(00)00189-6; PELLEGATA NS, 1994, CANCER RES, V54, P1556; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rom WN, 2000, AM J RESP CRIT CARE, V161, P1355, DOI 10.1164/ajrccm.161.4.9908012; SAITOH A, 1990, ONCOGENE, V5, P1195; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schmidt EE, 2000, P NATL ACAD SCI USA, V97, P13702, DOI 10.1073/pnas.240471297; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shimkin M B, 1975, Adv Cancer Res, V21, P1, DOI 10.1016/S0065-230X(08)60970-7; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SOZZI G, 1995, CANCER RES, V55, P135; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TenHaveOpbroek AAW, 1997, HISTOL HISTOPATHOL, V12, P319; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; World Health Organization, 1981, HIST TYP LUNG TUM; ZSENGELLER ZK, 1995, HUM GENE THER, V6, P457, DOI 10.1089/hum.1995.6.4-457	52	150	159	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6551	6558		10.1038/sj.onc.1204837	http://dx.doi.org/10.1038/sj.onc.1204837			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641780				2022-12-28	WOS:000171404200008
J	Steele, IA; Edmondson, RJ; Bulmer, JN; Bolger, BS; Leung, HY; Davies, BR				Steele, IA; Edmondson, RJ; Bulmer, JN; Bolger, BS; Leung, HY; Davies, BR			Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer	ONCOGENE			English	Article						FGF receptor 2; ovarian cancer; ovarian surface epithelium	FIBROBLAST-GROWTH-FACTOR; E-CADHERIN EXPRESSION; SURFACE EPITHELIUM; PROSTATE-CANCER; CELLS; KERATINOCYTE; FAMILY; SPECIFICITY; CARCINOMAS; TISSUES	Epithelial ovarian cancers (EOCs) arise in the Ovarian Surface Epithelium (OSE). This tissue is a simple, poorly committed mesothelium which exhibits characteristics of epithelial and mesenchymal cells when grown in culture. In contrast, EOCs frequently exhibit properties of complex epithelial tissues of the female reproductive tract, such as oviductal, endometrial and cervical epithelia, and show induction of expression of epithelial markers such as E-cadherin. Fibroblast Growth Factor Receptor 2 isoform IIIb (FGF receptor 2-IIIb) is a spliced variant of FGF receptor 2 that binds the ligands FGF-1 and FGF-7 with high affinity, and is expressed exclusively by epithelial cells. We have studied the expression of FGF receptor 2-IIIb and its ligands in primary cultures of normal human OSE, EOC cell lines and snap frozen tissue from EOCs. Expression of FGF receptor 2-IIIb mRNA is undetectable in normal OSE, but is expressed in 16/20 (80%) of EOCs. FGFs 1 and 7 mRNAs are expressed in normal OSE, whilst only 4/20 (20%) and 12/20 (60%) of EOCs demonstrated expression for these ligands respectively. However, FGF-7 protein was detected in 70% (mean level = 0.7 ng/ml) of ascitic fluids obtained from patients with EOC. FGFs 1 and 7 stimulate DNA synthesis in EOC cell lines that express FGF receptor 2-IIlb. Moreover, DNA synthesis in these cell lines can be partially blocked by blocking antisera to FGFs 1 and 7. It is suggested that induction of expression of FGF receptor 2-IIIb may play a role in the development of EOCs by rendering the OSE susceptible to paracrine and/or autocrine stimulation by its requisite FGF ligands.	Newcastle Univ, Sch Med, Dept Surg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Queen Elizabeth Hosp, No Gynaecol Oncol Ctr, Gateshead, Tyne & Wear, England; Royal Victoria Infirm, Dept Obstet & Gynaecol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Davies, BR (corresponding author), Newcastle Univ, Sch Med, Dept Surg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	B.R.Davies@ncl.ac.uk		Edmondson, Richard/0000-0003-2553-4423; Leung, Hing Y./0000-0002-3933-3975				Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bast RC, 1995, J CELL BIOCHEM, P219; BERCHUCK A, 1993, CANCER, V71, P545; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; De Medina SGD, 1999, ONCOGENE, V18, P5722, DOI 10.1038/sj.onc.1202958; DIBLASIO AM, 1993, AM J OBSTET GYNECOL, V169, P1517, DOI 10.1016/0002-9378(93)90428-L; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HERNANDEZ E, 1989, MANUAL GYNECOLOGIC C, P57; INOUE M, 1992, AM J CLIN PATHOL, V98, P76, DOI 10.1093/ajcp/98.1.76; KLUG TL, 1984, CANCER RES, V44, P1048; KRUK PA, 1990, LAB INVEST, V63, P132; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; MainesBandiera SL, 1997, INT J GYNECOL PATHOL, V16, P250, DOI 10.1097/00004347-199707000-00010; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mehta PB, 2000, J UROLOGY, V164, P2151, DOI 10.1016/S0022-5347(05)66988-1; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Ong A, 2000, INT J CANCER, V85, P430, DOI 10.1002/(SICI)1097-0215(20000201)85:3<430::AID-IJC21>3.0.CO;2-Q; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PARROTT JA, 1994, ENDOCRINOLOGY, V135, P569, DOI 10.1210/en.135.2.569; PETERS KG, 1992, DEVELOPMENT, V114, P233; RESTA L, 1993, OBSTET GYNECOL, V82, P181; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Scully RE, 1995, J CELL BIOCHEM, P208; SCULLY RE, 1977, AM J PATHOL, V87, P686; SCULLY RE, 1992, OVARIAN CANCER, V2, P199; Sundfeldt K, 1997, INT J CANCER, V74, P275, DOI 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.3.CO;2-V; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Westermann AM, 1997, CANCER TREAT REV, V23, P113, DOI 10.1016/S0305-7372(97)90024-4; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; YOUNG RH, 1989, DIAGNOSTIC SURGICAL, P1655	38	49	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5878	5887		10.1038/sj.onc.1204755	http://dx.doi.org/10.1038/sj.onc.1204755			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593393				2022-12-28	WOS:000171037200011
J	Gual, P; Giordano, S; Anguissola, S; Comoglio, PM				Gual, P; Giordano, S; Anguissola, S; Comoglio, PM			Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness	ONCOGENE			English	Article						Met; C-terminal domain; regulatory domain; kinase activity; cell transformation; invasiveness	HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; TYROSINE KINASE DOMAIN; HGF-RECEPTOR; CONSTITUTIVE ACTIVATION; FACTOR/SCATTER FACTOR; RET PROTOONCOGENE; CRYSTAL-STRUCTURE; ADAPTER PROTEINS; INSULIN-RECEPTOR	Biological responses to Hepatocyte Growth Factor are mediated by the tyrosine kinase receptor encoded by the Met oncogene. Under physiological conditions, Met triggers a multi-step genetic program called 'invasive growth' including cell-dissociation, invasion of extracellular matrices and growth. When constitutively activated, Met can induce cell transformation and metastasis. Phosphorylation of two docking tyrosines in the receptor tail is essential for all biological responses. To investigate the role of the C-terminal part of Met, we have generated mutants lacking either the last 26 or 47 amino acids. As expected, mutants lacking the docking sites fail to mediate cell transformation and invasion. Interestingly, while Met Delta 26 can mediate invasion, its transforming ability is severely impaired. Moreover, the lack of the last 26 amino acids strongly reduces Met ability to phosphorylate substrates in vitro and in vivo. These data indicate that the last 26 amino acids are required to confer the kinase its full enzymatic activity, which is critical for cell transformation but dispensable for invasive properties. Finally, we also show that upregulation of Met enzymatic activity by insertion of a point mutation in the kinase domain (M1250T) overcomes the regulatory role played by the last 26 amino acids of the tail. It is concluded that the C-terminal domain of Met is crucial not only for recruitment of transducers but also for regulation of receptor enzymatic activity.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Giordano, S (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Giordano, Silvia/J-9858-2018; Gual, Philippe/P-9833-2019; Comoglio, Paolo/G-6323-2011	Giordano, Silvia/0000-0003-1854-1086; Gual, Philippe/0000-0001-7393-8356; Comoglio, Paolo/0000-0002-7056-5328				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Borrello MG, 1995, ONCOGENE, V11, P2419; Comoglio PM, 1999, EXP CELL RES, V253, P88, DOI 10.1006/excr.1999.4684; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FERRACINI R, 1995, ONCOGENE, V10, P739; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Iwashita T, 1996, ONCOGENE, V12, P481; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; LONGATI P, 1994, ONCOGENE, V9, P49; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maritano D, 2000, ONCOGENE, V19, P1354, DOI 10.1038/sj.onc.1203431; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RONG S, 1994, COLD SPRING HARB SYM, V59, P629, DOI 10.1101/SQB.1994.059.01.072; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; Xiao ZQ, 2000, BIOCHEM BIOPH RES CO, V267, P669, DOI 10.1006/bbrc.1999.2011; ZHEN Z, 1994, ONCOGENE, V9, P1691	53	6	7	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5493	5502		10.1038/sj.onc.1204713	http://dx.doi.org/10.1038/sj.onc.1204713			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571647				2022-12-28	WOS:000170781100010
J	Hellborg, F; Qian, W; Mendez-Vidal, C; Asker, C; Kost-Alimova, M; Wilhelm, M; Imreh, S; Wiman, KG				Hellborg, F; Qian, W; Mendez-Vidal, C; Asker, C; Kost-Alimova, M; Wilhelm, M; Imreh, S; Wiman, KG			Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein	ONCOGENE			English	Article						p53; human wig-1; zinc finger; growth suppression	GENOMIC HYBRIDIZATION ANALYSIS; DOUBLE-STRANDED-RNA; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; PROMOTES APOPTOSIS; CANDIDATE MEDIATOR; CANCER; LOCALIZATION; TUMORS	We previously identified a novel p53-induced mouse gene, wig-1, that encodes a 290 amino acid zinc finger protein (Varmeh-Ziaie et al., 1997). Here we have identified and characterized the human homolog of mouse wig-1. The human wig-1 protein is 87% identical to the mouse protein and contains three zinc finger domains and a putative nuclear localization signal. Human wig-1 mRNA and protein is induced following activation of wild type p53 expression in our BL41-ts p53 Burkitt lymphoma cells. Wig-l is also induced in MCF7 cells following treatment with the DNA-damaging agent mitomycin C. Northern blotting detected low levels of wig-1 mRNA in normal human tissues. Fluorescence in situ hybridization mapped wig-1 to human chromosome 3q26.3-27. FLAG-tagged human wig-1 localizes to the nucleus. Ectopic overexpression of human wig-1 inhibits tumor cell growth in a colony formation assay. These results suggest that human wig-1 has a role in the p53-dependent growth regulatory pathway.	Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	Klas.Wiman@mtc.ki.se	IBIS, REPRODUCCION/P-3399-2015; Wiman, Klas/AAB-8399-2021; Méndez-Vidal, Cristina/F-1366-2015	Wiman, Klas/0000-0002-7113-524X; Méndez-Vidal, Cristina/0000-0002-1282-1688; Wilhelm, Margareta/0000-0002-0516-9724				Allen DG, 2000, BRIT J CANCER, V83, P1659, DOI 10.1054/bjoc.2000.1509; Attardi LD, 2000, GENE DEV, V14, P704; Balsara BR, 1997, CANCER RES, V57, P2116; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BRZOSKA PM, 1995, CANCER RES, V55, P3055; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chung DC, 1998, CANCER RES, V58, P3706; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; Fedorova L, 1997, EUR J HUM GENET, V5, P110, DOI 10.1159/000484744; Finerty PJ, 1999, BIOCHEMISTRY-US, V38, P4001, DOI 10.1021/bi9825293; Finerty PJ, 1997, J MOL BIOL, V271, P195, DOI 10.1006/jmbi.1997.1177; Forozan F, 2000, CANCER RES, V60, P4519; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; HALDAR S, 1994, CANCER RES, V54, P2095; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kruzelock RP, 1997, CANCER RES, V57, P106; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sattler HP, 2000, PROSTATE, V45, P207, DOI 10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Starostik P, 2000, BLOOD, V95, P1180, DOI 10.1182/blood.V95.4.1180.004k14_1180_1187; VarmehZiaie S, 1997, ONCOGENE, V15, P2699, DOI 10.1038/sj.onc.1201454; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yang ML, 1999, J BIOL CHEM, V274, P27399, DOI 10.1074/jbc.274.39.27399; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	38	52	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5466	5474		10.1038/sj.onc.1204722	http://dx.doi.org/10.1038/sj.onc.1204722			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571644				2022-12-28	WOS:000170781100007
J	Rahmani, M; Peron, P; Weitzman, J; Bakiri, L; Lardeux, B; Bernuau, D				Rahmani, M; Peron, P; Weitzman, J; Bakiri, L; Lardeux, B; Bernuau, D			Functional cooperation between JunD and NF-kappa B in rat hepatocytes	ONCOGENE			English	Article						NF-kappa B; p65; AP-1; JunD; hepatocytes	TUMOR-NECROSIS-FACTOR; GM-CSF PROMOTER; C-JUN; GLUCOCORTICOID RECEPTOR; LIVER-REGENERATION; TRANSCRIPTION FACTORS; AP-1 COMPLEX; DNA-BINDING; ACTIVATES TRANSCRIPTION; HEPATIC REGENERATION	AP-I and NF-kappaB are rapidly activated during liver regeneration. Whether these parallel inductions have potential functional implications is not known. Isolated rat hepatocytes were stimulated with two mitogens, epidermal growth factor or hepatocyte growth factor and with tumor necrosis factor, a cytokine involved in the liver regenerative response in vivo and a strong inducer of NF-kappaB. All three cytokines increased AP-1 and NF-kappaB binding to their cognate cis-element and induced a 2.5-fold activation of NF-kappaB-dependent transcription. Inactivation of AP-I by TAM67, a dominant negative mutant of AP-I drastically inhibited basal and cytokine-induced NF-kappaB transactivation. Overexpression of Jun D, but not of the other Jun or Fos proteins increased by threefold NF-kappaB transactivation. Functional cooperation between JunD and p65 was demonstrated in a simple Gal-hybrid system. Finally, a twofold decrease in NF-kappaB transactivation was found in hepatocytes isolated from JunD (-/-) mice compared with hepatocytes from JunD(+/+) mice. Altogether these data demonstrate a functional cooperation of p65 with JunD, a major constituent of AP-1 in normal hepatocytes.	Univ Paris 07, INSERM, U327, Biol Cellulaire Lab, F-75018 Paris, France; Univ Paris 07, F-75018 Paris, France; Inst Pasteur, Dept Biotechnol, CNRS, Unite Virus Oncogenes,URA 1644, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bernuau, D (corresponding author), Univ Paris 07, INSERM, U327, Biol Cellulaire Lab, 16 Rue Henri Huchard, F-75018 Paris, France.		Bakiri, Latifa/N-5780-2014; Bakiri, Latifa/AAP-1674-2020	Rahmani, Mohamed/0000-0002-3992-8039; bakiri, latifa/0000-0002-6300-2420; Weitzman, Jonathan/0000-0001-8445-0102				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALCORN JA, 1990, HEPATOLOGY, V11, P909, DOI 10.1002/hep.1840110602; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BALAVOINE S, 1990, EUR J BIOCHEM, V189, P617, DOI 10.1111/j.1432-1033.1990.tb15530.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; FAUSTO N, 1989, LAB INVEST, V60, P4; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Han YQ, 1997, J BIOL CHEM, V272, P9825; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HIRAI SI, 1990, ONCOGENE, V5, P39; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kaabache T, 1995, ANAL BIOCHEM, V232, P225, DOI 10.1006/abio.1995.0011; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Kirillova I, 1999, CELL GROWTH DIFFER, V10, P819; Kralova J, 1996, ONCOGENE, V12, P2595; Le Cam A, 1995, Methods Mol Biol, V48, P141; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN L, 1998, CELL, V70, P777; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; Menegazzi M, 1997, HEPATOLOGY, V25, P585, DOI 10.1002/hep.510250316; METTOUCHI A, 1997, MOL CELL BIOL, V17, P3020; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Nadori F, 1997, HEPATOLOGY, V26, P1477; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Rahmani M, 1999, J HEPATOL, V30, P916, DOI 10.1016/S0168-8278(99)80148-2; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; Thepot D, 2000, DEVELOPMENT, V127, P143; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMPSON NL, 1986, CANCER RES, V46, P3111; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG SR, 1985, IN VITRO CELL DEV B, V21, P526; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	71	39	40	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5132	5142		10.1038/sj.onc.1204678	http://dx.doi.org/10.1038/sj.onc.1204678			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526502				2022-12-28	WOS:000170464000007
J	Yamato, K; Hashimoto, S; Imamura, T; Uchida, H; Okahashi, N; Koseki, T; Ishisaki, A; Kizaki, M; Miyazono, K; Ikeda, Y; Nishihara, T				Yamato, K; Hashimoto, S; Imamura, T; Uchida, H; Okahashi, N; Koseki, T; Ishisaki, A; Kizaki, M; Miyazono, K; Ikeda, Y; Nishihara, T			Activation of the p21(CIP1/WAF1) promoter by bone morphogenetic protein-2 in mouse B lineage cells	ONCOGENE			English	Article						BMP; p21(CIP1/WAF1); transcription; promoter; Smad	GROWTH-FACTOR-BETA; SMAD-BINDING-ELEMENT; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL-ANALYSIS; INHIBITOR P21; DNA-DAMAGE; APOPTOSIS; ARREST; DIFFERENTIATION	BMPs exert a negative growth effect on various types of cells. We have previously reported that BMP-2 inhibited the growth of HS-72 mouse hybridoma cells by inducing p21(CIP1/WAF1) expression. In the present study, we demonstrated that BMP-2 activated the mouse p21(CIP1/WAF1) promoter in MS-72 cells, and that a 29-base pair (b) region of the promoter (-1928/-1900 relative to the TATA box), conserved between mice and humans, was responsive to BMP-2 as well as expression of Smad1, Smad4, and constitutively active mutants of BMP type I receptors, Furthermore, an oligonucleotide containing the 29-b region was found to be associated with Smad4 and phosphorylated Smad1 in the nuclear extract of BMP-2-stimulated HS-72 cells, These results suggested that BMP-2 might activate p21(CIP1/WAF1) transcription by inducing a binding of Smad4 and Smad1 to the 29-b region in HS-72 cells.	Tokyo Med & Dent Univ, Grad Sch, Div Oral Hlth Sci, Sect Mol Cellular Oncol & Microbiol,Bunkyo Ku, Tokyo 1138549, Japan; Natl Inst Infect Dis, Dept Oral Sci, Tokyo 1628640, Japan; JFCR, Inst Canc, Dept Biochem, Tokyo 1708455, Japan; Keio Univ, Sch Med, Div Hematol, Tokyo 1608582, Japan; Natl Inst Biosci & Human Technol, Biosignaling Dept, Tsukuba, Ibaraki 3058566, Japan; Kyushu Dent Coll, Dept Oral Microbiol, Fukuoka 8038580, Japan	Tokyo Medical & Dental University (TMDU); National Institute of Infectious Diseases (NIID); Japanese Foundation for Cancer Research; Keio University; National Institute of Advanced Industrial Science & Technology (AIST); Kyushu Dental University	Yamato, K (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Div Oral Hlth Sci, Sect Mol Cellular Oncol & Microbiol,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.		okahashi, nobuo/A-4032-2010	okahashi, nobuo/0000-0002-8045-7021; Ishisaki, Akira/0000-0001-6704-4436				Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Jernvall J, 1998, DEVELOPMENT, V125, P161; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Massague J, 2000, GENE DEV, V14, P627; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NISHIHARA T, 1995, J INTERF CYTOK RES, V15, P509, DOI 10.1089/jir.1995.15.509; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Tada K, 1999, GENES CELLS, V4, P731, DOI 10.1046/j.1365-2443.1999.00293.x; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yamato K, 2000, EXP CELL RES, V257, P198, DOI 10.1006/excr.2000.4876; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	41	18	18	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4383	4392		10.1038/sj.onc.1204572	http://dx.doi.org/10.1038/sj.onc.1204572			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466619				2022-12-28	WOS:000169912600012
J	Huo, TI; Wang, XW; Forgues, M; Wu, CG; Spillare, EA; Giannini, C; Brechot, C; Harris, CC				Huo, TI; Wang, XW; Forgues, M; Wu, CG; Spillare, EA; Giannini, C; Brechot, C; Harris, CC			Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis	ONCOGENE			English	Article						HBx; mutation; p53; apoptosis; carcinogenesis	NF-KAPPA-B; HBX PROTEIN; TRANSCRIPTION FACTOR; P53 PROTEIN; TUMOR-ANTIGEN; GENE; LIVER; EXPRESSION; TRANSACTIVATION; ACTIVATION	Chronic hepatitis B virus (HBV) infection and the integration of its X gene (HBx) are closely associated with the development of hepatocellular carcinoma (HCC), The integrated HBx frequently is truncated or contains point mutations, Previous studies indicated that these HBx mutants have a diminished co-transactivational activity. We have compared the effects of wildtype (wt) HBx and its naturally occurring mutants derived from human HCCs on transcriptional co-transactivation, apoptosis and interactive effects with p53. We demonstrated that overexpression of mutant, but not wt HBx, is defective in transcriptional co-transactivation of the NF-kappaB-driven luciferase reporter. By using a microinjection technique, the HBx mutants were shown to have an attenuated pro-apoptotic activity. This deficiency may be attributed to multiple mutations in the co-transactivation domain of HBx, that leads to decreased stability of the translated product. However, wt or mutant HBx bind to p53 in vitro and retain their ability to block p53-mediated apoptosis in vivo, which has been implicated as its major tumor suppressor function. The abrogation of p53-mediated apoptosis by integrated HBx mutants may provide a selective clonal advantage for preneoplastic or neoplastic hepatocytes acid contribute to hepatocellular carcinogenesis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Taipei Vet Gen Hosp, Taipei, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; Necker Inst, Paris, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; UDICE-French Research Universities; Universite Paris Cite	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Room 2C05, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X				AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Andrisani OM, 1999, INT J ONCOL, V15, P373; Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CASELMANN WH, 1995, J HEPATOL, V22, P34; Chen WN, 2000, BIOCHEM BIOPH RES CO, V276, P885, DOI 10.1006/bbrc.2000.3562; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; Doitsh G, 1999, ONCOGENE, V18, P7506, DOI 10.1038/sj.onc.1203209; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Gottlob K, 1998, CANCER RES, V58, P3566; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; Huang Y, 2000, CANCER RES, V60, P4426; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.3.CO;2-Q; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kew MC, 1996, CLIN LAB MED, V16, P395, DOI 10.1016/S0272-2712(18)30276-2; Kew MC, 1997, HEPATOLOGY, V25, P1037, DOI 10.1002/hep.510250442; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin Y, 1997, CANCER RES, V57, P5137; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAHE Y, 1991, J BIOL CHEM, V266, P13759; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Ogden SK, 2000, J BIOL CHEM, V275, P27806; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Park US, 2000, ONCOGENE, V19, P3384, DOI 10.1038/sj.onc.1203674; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SEIFER M, 1991, J HEPATOL, V13, pS61, DOI 10.1016/0168-8278(91)90026-8; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sohn S, 2000, MUTAT RES-DNA REPAIR, V460, P17, DOI 10.1016/S0921-8777(00)00010-0; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 2000, MUTAT RES-REV MUTAT, V462, P365, DOI 10.1016/S1383-5742(00)00026-0; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang XW, 1999, ANTICANCER RES, V19, P4759; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yun CW, 2000, ONCOGENE, V19, P5163, DOI 10.1038/sj.onc.1203896	92	66	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3620	3628		10.1038/sj.onc.1204495	http://dx.doi.org/10.1038/sj.onc.1204495			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439325				2022-12-28	WOS:000169400200003
J	Wert, M; Kennedy, S; Palfrey, HC; Hay, N				Wert, M; Kennedy, S; Palfrey, HC; Hay, N			Myc drives apoptosis in PC12 cells in the absence of Max	ONCOGENE			English	Article						c-Myc; apoptosis; growth factors; Akt	NERVE GROWTH-FACTOR; C-MYC; MEDIATED APOPTOSIS; CYCLE PROGRESSION; DIFFERENTIATION; TRANSCRIPTION; FIBROBLASTS; PROTEIN; DIMERIZATION; MECHANISMS	A conditionally active chimeric form of the c-Myc protein fused to the ligand-binding domain of the estrogen receptor (MycER) was expressed in PC12 cells, Induction of Myc activity resulted in a threefold increase in apoptosis after 5 days when cells were maintained in 1% serum, The effect of Myc overexpression was dependent on its DNA-binding domain but not on its heterodimeric binding protein Max, which is absent in PC12 cells, Preincubation of the c-Myc overexpressing cells with either NGF or bFGF, but not EGF, prevented the Myc-mediated increase in apoptosis, although the signaling pathways used by NGF and bFGF to block cell death differed, NGF-mediated rescue was mediated by the phosphatidylinositol 3 ' -OH (P13) kinase/Akt pathway white rescue by bFGF was not affected by P13 kinase inhibitors, These results show that Myc can induce apoptosis in PC12 cells in a Max-independent manner and that alternate signaling pathways exist to mediate cell survival.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Hay, N (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA.			Kennedy, Scott/0000-0002-7974-8155	NCI NIH HHS [CA71874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Bao JX, 1996, ONCOGENE, V12, P2171; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Crowder RJ, 1998, J NEUROSCI, V18, P2933; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; MARUYAMA K, 1987, ONCOGENE, V1, P361; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RIBON V, 1994, MOL CELL NEUROSCI, V5, P277, DOI 10.1006/mcne.1994.1032; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SPANDIDOS DA, 1989, INT J DEV NEUROSCI, V7, P1, DOI 10.1016/0736-5748(89)90039-7; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	27	9	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3746	3750		10.1038/sj.onc.1204466	http://dx.doi.org/10.1038/sj.onc.1204466			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439337				2022-12-28	WOS:000169400200015
J	Acquaviva, C; Brockly, F; Ferrara, P; Bossis, G; Salvat, C; Jariel-Encontre, I; Piechaczyk, M				Acquaviva, C; Brockly, F; Ferrara, P; Bossis, G; Salvat, C; Jariel-Encontre, I; Piechaczyk, M			Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G(0)-to-S phase transition	ONCOGENE			English	Article						c-Fos; oncogene; protein degradation; proteasome; PEST motif	KAPPA-B-ALPHA; IN-VIVO; TRANSCRIPTION FACTORS; INSTABILITY DETERMINANTS; TRANSFORMING ACTIVITY; MEDIATED PROTEOLYSIS; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; PEST SEQUENCES; 26S PROTEASOME	c-Fos proto-oncoprotein is rapidly and transiently expressed in cells undergoing the G(0)-to-S phase transition in response to stimulation for growth by serum. Under these conditions, the rapid decay of the protein occurring after induction is accounted for by efficient recognition and degradation by the proteasome. PEST motifs are sequences rich in Pro, Glu, Asp, Ser and Thr which have been proposed to constitute protein instability determinants. c-Fos contains three such motifs, one of which comprises the C-terminal 20 amino acids and has already been proposed to be the major determinant of c-Fos instability. Using site-directed mutagenesis and an expression system reproducing c-fos gene transient expression in transfected cells, we have analysed the turnover of c-Fos mutants deleted of the various PEST sequences in synchronized mouse embryo fibroblasts. Our data showed no role for the two internal PEST motifs in c-Fos instability. However, deletion of the C-terminal PEST region led to only a twofold stabilization of the protein. Taken together, these data indicate that c-Fos instability during the G0-to-S phase transition is governed by a major non-PEST destabilizer and a C-terminal degradation-accelerating element. Further dissection of c-Fos C-terminal region showed that the degradation-accelerating effect is not contributed by the whole PEST sequence but by a short PTL tripeptide which cannot be considered as a PEST motif and which can act in the absence of any PEST environment. Interestingly, the PTL motif is conserved in other members of the fos multigene family. Nevertheless, its contribution to protein instability is restricted to c-Fos suggesting that the mechanisms whereby the various Fos proteins are broken down are, at least partially, different. MAP kinases-mediated phosphorylation of two serines close to PTL, which are both phosphorylated all over the G(0)-to-S phase transition, have been proposed by others to stabilize c-Fos protein significantly. We, however, showed that the PTL motif does not exert its effect by counteracting a stabilizing effect of these phosphorylations under our experimental conditions.	Inst Genet Mol, CNRS, UMR 5535, IFR 24, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piechaczyk, M (corresponding author), Inst Genet Mol, CNRS, UMR 5535, IFR 24, 1919 route de Mende, F-34293 Montpellier 05, France.	piechaczyk@igm.cnrs-mop.fr	Acquaviva, Claire/N-4306-2017; PIECHACZYK, Marc/E-7896-2013	Acquaviva, Claire/0000-0002-0227-9813; PIECHACZYK, Marc/0000-0003-1367-2597; bossis, guillaume/0000-0002-3349-8250				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Acquaviva C, 2001, ONCOGENE, V20, P942, DOI 10.1038/sj.onc.1204155; Angel P. E., 1994, FOS JUN FAMILIES TRA; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Bies J, 1999, J VIROL, V73, P2038, DOI 10.1128/JVI.73.3.2038-2044.1999; Boudjelal M, 2000, CANCER RES, V60, P2247; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; CARILLO S, 1994, ONCOGENE, V9, P1679; Chen RH, 1996, ONCOGENE, V12, P1493; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 2000, J CELL BIOCHEM, P40; Coffino P, 1998, UBIQUITIN BIOL CELL, P411; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; Fleming JV, 2000, MOL CELL BIOL, V20, P4932, DOI 10.1128/MCB.20.13.4932-4947.2000; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; Harlow E., 1999, USING ANTIBODIES LAB; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOCHSTRASSER M, 1988, UBIQUITIN BIOL CELL; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LAEMMLI EK, 1971, NATURE, V227, P6800; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; MATSUI M, 1990, ONCOGENE, V5, P249; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Penrose KJ, 2000, J VIROL, V74, P6031, DOI 10.1128/JVI.74.13.6031-6038.2000; PETERS JM, 1998, UBIQUITIN BIOL CELL; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RECH J, 1989, NUCLEIC ACIDS RES, V17, P2874, DOI 10.1093/nar/17.7.2874; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROUX P, 1994, C FOS C JUN FAMILIES, P87; Salvat C, 1999, MOL BIOL REP, V26, P45, DOI 10.1023/A:1006960021281; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x; Sambrook J, 1989, MOL CLONING; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCHUERMANN M, 1991, ONCOGENE, V6, P567; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; VEYRUNE JL, 1995, ONCOGENE, V11, P2127; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803	64	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7563	7572		10.1038/sj.onc.1204880	http://dx.doi.org/10.1038/sj.onc.1204880			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709728				2022-12-28	WOS:000171976900013
J	Kato, M; Takeda, K; Kawamoto, Y; Tsuzuki, T; Dai, Y; Nakayama, S; Toriyama, K; Tamada, Y; Takahashi, M; Nakashima, I				Kato, M; Takeda, K; Kawamoto, Y; Tsuzuki, T; Dai, Y; Nakayama, S; Toriyama, K; Tamada, Y; Takahashi, M; Nakashima, I			RET tyrosine kinase enhances hair growth in association with promotion of melanogenesis	ONCOGENE			English	Article						anagen; kit; melanogenesis; RET	MELANOCYTIC TUMOR-DEVELOPMENT; NEUROTROPHIC FACTOR; MALIGNANT-MELANOMA; TRANSGENIC MICE; C-KIT; CYCLE; FOLLICLE; RECEPTOR; INVOLVEMENT; EXPRESSION	We first demonstrated that c-Ret protein is transiently expressed mainly in the inner and outer root sheaths of hair follicles soon after birth in the skin of normal C57BL/6 and BALB/c mice. A longer-lasting expression of activated RET protein overlapped the c-Ret expression with some preferential expression in the outer root sheath in close association with increase in the number of S-100 protein-containing cells in the area and excess melanogenesis in and around hair bulbs in the skin of RFP-RET-transgenic mice on a C57BL/6 background (RFP-RET/B6). Hair follicles in the skin of the transgenic mice continuously showed histology of the anagen phase, and the recovery period for the hair of the transgenic mice after shaving was shortened. Such growth promotion was not observed in the case of white hairs of RFP-RET-transgenic mice on a BALB/c background. These results suggest that RET works to extend the anagen phase in association with upregulation of melanin production.	Nagoya Univ, Grad Sch Med, Grad Dept Immunol, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Pathol, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Nagoya, Aichi 4668550, Japan; Aichi Med Univ, Dept Dermatol, Nagakute, Aichi 48011, Japan	Nagoya University; Nagoya University; Nagoya University; Aichi Medical University	Nakashima, I (corresponding author), Nagoya Univ, Grad Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 466, Japan.		KATO, Masashi/I-7250-2014; 善之, 川本/GPT-3802-2022; TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683; Tsuzuki, Toyonori/0000-0002-4855-4366				Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkareva NV, 2000, AM J PATHOL, V156, P1041, DOI 10.1016/S0002-9440(10)64972-3; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; Hansen LA, 1997, AM J PATHOL, V150, P1959; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; IWAMOTO T, 1992, EXP CELL RES, V200, P410, DOI 10.1016/0014-4827(92)90189-F; Jindo T, 1998, J INVEST DERMATOL, V110, P338, DOI 10.1046/j.1523-1747.1998.00144.x; Kato M, 1998, J INVEST DERMATOL, V111, P640, DOI 10.1046/j.1523-1747.1998.00341.x; Kato M, 1998, ONCOGENE, V17, P1885, DOI 10.1038/sj.onc.1202077; Kato M, 1999, ONCOGENE, V18, P837, DOI 10.1038/sj.onc.1202329; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; ORTONNE JP, 1993, J INVEST DERMATOL, V101, pS82, DOI 10.1111/1523-1747.ep12362884; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Peus D, 1996, DERMATOL CLIN, V14, P559, DOI 10.1016/S0733-8635(05)70384-3; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; Takahashi M, 1999, HUM MUTAT, V13, P331, DOI 10.1002/(SICI)1098-1004(1999)13:4<331::AID-HUMU11>3.3.CO;2-R; TAKAHASHI M, 1993, ONCOGENE, V8, P2925	25	22	24	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7536	7541		10.1038/sj.onc.1204918	http://dx.doi.org/10.1038/sj.onc.1204918			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709725				2022-12-28	WOS:000171976900010
J	Stoppler, H; Malerczyk, C; Block, K; Aigner, A; Czubayko, F				Stoppler, H; Malerczyk, C; Block, K; Aigner, A; Czubayko, F			The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes	ONCOGENE			English	Article						fibroblast growth factor binding protein; HPV16; E6 oncogene; E7 oncogene; promoter	FIBROBLAST GROWTH-FACTOR; K14-HPV16 TRANSGENIC MICE; TUMOR-SUPPRESSOR PROTEIN; FACTOR-BINDING PROTEIN; TYPE-16 E6; HISTONE DEACETYLASE; TELOMERASE ACTIVITY; E7 ONCOPROTEIN; WILD-TYPE; P53	Fibroblast growth, factor binding protein (FGF-BP) is a secreted protein that binds, FGF-1 and FGF-2 and is involved in mobilization and activation of FGFs from the extracellular matrix. FGF-BP overexpression as, well as ribozyme-mediated reduction of endogenous FGF-BP revealed that FGF-BP can be rate-limiting for tumor growth and angiogenesis. Recent studies showed that FGF-BP expression is up-regulated during early phases of tumorigenesis, indicating that the role of FGF-BP in angiogenesis is a critical early step in the development and progression of tumors.. Human papillomavirus type, 16 (HPV 16) is highly associated with the development of anogenital cancers. Here we demonstrate that the stable expression of the E6 oncogene of HPV 16 leads to an activation of the FGF-BP promoter in primary human foreskin keratinocytes (one of the natural host cells of these viruses). This is associated with, an increase in the steady state levels, of FGF-BP mRNA and FGF-BP protein in cells stably expressing E6. Transient E6 expression revealed that the observed activation of the FGF-BP promoter by the viral oncogene is, an early process which is. independent from immortalization/transformation, events in the cells.	Univ Marburg, Dept Pharmacol, D-35033 Marburg, Germany	Philipps University Marburg	Czubayko, F (corresponding author), Univ Marburg, Dept Pharmacol, Karl Von Frisch Str 1, D-35033 Marburg, Germany.	czubayko@mailer.uni-marburg.de	Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256				Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Arbeit JM, 1996, ONCOGENE, V13, P1847; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Coussens LM, 1996, AM J PATHOL, V149, P1899; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ETSCHEID BG, 1994, VIROLOGY, V205, P583, DOI 10.1006/viro.1994.1684; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Harris VK, 2000, J BIOL CHEM, V275, P39801; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; Nair P, 1999, PATHOL RES PRACT, V195, P163, DOI 10.1016/S0344-0338(99)80029-6; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Shino Y, 1997, J VIROL, V71, P4310, DOI 10.1128/JVI.71.6.4310-4318.1997; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WU DQ, 1991, J BIOL CHEM, V266, P16778; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	53	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7430	7436		10.1038/sj.onc.1204957	http://dx.doi.org/10.1038/sj.onc.1204957			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704874				2022-12-28	WOS:000171894200017
J	Jensen, K; Shiels, C; Freemont, PS				Jensen, K; Shiels, C; Freemont, PS			PML protein isoforms and the RBCC/TRIM motif	ONCOGENE			English	Review						PML isoforms; splice variants; RBCC; SUMO; TRIM	RING FINGER PROTEIN; PROMYELOCYTIC LEUKEMIA-CELLS; RIBOSYLATION FACTOR DOMAIN; ZINC-BINDING PROTEIN; COILED-COIL PROTEIN; CLASS-I REGION; RAR-ALPHA; RETINOIC ACID; NUCLEAR-BODIES; MOLECULAR-CLONING	PML is a component of a multiprotein complex, termed nuclear bodies, and the PML protein was originally discovered in patients suffering from acute promyelocytic leukaemia (APL). APL is associated with a reciprocal chromosomal translocation of chromosomes 15 and 17, which results in a fusion protein comprising PML and the retinoic acid receptor alpha. The PML genomic locus is approximately 35 kb and is subdivided into nine exons. A large number of alternative spliced transcripts are synthesized from the PML gene, resulting in a variety of PML proteins ranging in molecular weight from 48-97 kDa. In this review we summarize the data on the known PML isoforms and splice variants and present a new unifying nomenclature. Although, the function/s of the PML variants are unclear, all PML isoforms contain an identical N-terminal region, suggesting that these sequences are indispensable for function, but differ in their C-terminal sequences. The N-terminal region harbours a (R) under bar ING-finger, two (B) under bar -boxes and a predicted alpha -helical (C) under bar oiled-(C) under bar oil domain, that together form the RBCC/TRIM motif found in a large family of proteins. In PML this motif is essential for PML nuclear body formation in vivo and PML-homo and hetero interactions conferring growth suppressor, apoptotic and antiviral activities. In APL oligomerization mediated by the RBCC/TRIM motif is essential for the transformation potential of the PML-RAR alpha fusion protein.	Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, London SW7 2AZ, England	Imperial College London; University of London; Institute of Cancer Research - UK	Freemont, PS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, Flowers Bldg,Armstrong Rd, London SW7 2AZ, England.	p.freemont@ic.ac.uk		Freemont, Paul/0000-0002-5658-8486				Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; AHN MJ, 1995, ONCOGENE, V10, P2307; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Avela K, 2000, NAT GENET, V25, P298, DOI 10.1038/77053; BELLINI M, 1995, J CELL BIOL, V131, P563, DOI 10.1083/jcb.131.3.563; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; Boddy MN, 1996, ONCOGENE, V13, P971; Boddy MN, 1997, J CELL SCI, V110, P2197; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; BORDEN KLB, 1995, EMBO J, V14, P5947, DOI 10.1002/j.1460-2075.1995.tb00283.x; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1998, J VIROL, V72, P3819, DOI 10.1128/JVI.72.5.3819-3826.1998; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Buchner G, 1999, HUM MOL GENET, V8, P1397, DOI 10.1093/hmg/8.8.1397; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; Cao TY, 1998, J CELL SCI, V111, P1319; Cao TY, 1997, J CELL SCI, V110, P1563; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen GQ, 1996, BLOOD, V88, P1052; CHU TW, 1995, GENOMICS, V29, P229, DOI 10.1006/geno.1995.1236; Cox TC, 2000, HUM MOL GENET, V9, P2553, DOI 10.1093/hmg/9.17.2553; DANIEL MT, 1993, BLOOD, V82, P1858; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Duprez E, 1999, J CELL SCI, V112, P381; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; El-Husseini AE, 2001, GENOMICS, V71, P363, DOI 10.1006/geno.2000.6452; El-Husseini AED, 2000, BIOCHEM BIOPH RES CO, V267, P906, DOI 10.1006/bbrc.1999.2045; Everett RD, 1998, EMBO J, V17, P7161, DOI 10.1093/emboj/17.24.7161; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Harada H, 1999, MOL CELL BIOL, V19, P3808; Hasegawa N, 1996, BIOCHEM BIOPH RES CO, V225, P627, DOI 10.1006/bbrc.1996.1221; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; Inoue S, 1999, BIOCHEM BIOPH RES CO, V261, P412, DOI 10.1006/bbrc.1999.0874; ISHOV AM, 1999, J CELL BIOL, V147, P221, DOI [10.1083/jcb.147.2.221, DOI 10.1083/JCB.147.2.221]; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kapanadze B, 1998, FEBS LETT, V426, P266, DOI 10.1016/S0014-5793(98)00357-3; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kentsis A, 2000, CURR PROTEIN PEPT SC, V1, P49, DOI 10.2174/1389203003381478; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lai HK, 2000, ONCOGENE, V19, P1623, DOI 10.1038/sj.onc.1203473; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li YP, 1997, BLOOD, V90, P306; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nervi C, 1998, BLOOD, V92, P2244; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V251, P515, DOI 10.1006/bbrc.1998.9502; Orimo A, 2000, GENOMICS, V69, P143, DOI 10.1006/geno.2000.6318; Orimo A, 2000, BIOCHEM BIOPH RES CO, V276, P45, DOI 10.1006/bbrc.2000.3380; Palmer S, 1997, P NATL ACAD SCI USA, V94, P12030, DOI 10.1073/pnas.94.22.12030; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Perrin K, 1998, GENE, V210, P127, DOI 10.1016/S0378-1119(98)00052-3; Perry J, 1999, GENOMICS, V62, P385, DOI 10.1006/geno.1999.6043; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; RASKA I, 1992, CELL BIOL INT REP, V16, P771, DOI 10.1016/S0309-1651(05)80021-9; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Saha V, 1998, J CELL BIOCHEM, P264, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<264::AID-JCB32>3.0.CO;2-U; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Shou WN, 1996, MOL CELL BIOL, V16, P990; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STUURMAN N, 1992, J CELL SCI, V101, P773; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Tissot C, 1996, GENOMICS, V34, P151, DOI 10.1006/geno.1996.0258; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; Topcu Z, 1999, ONCOGENE, V18, P7091, DOI 10.1038/sj.onc.1203201; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Vincent SR, 2000, BIOCHEM BIOPH RES CO, V279, P482, DOI 10.1006/bbrc.2000.3984; Vitale N, 1998, J BIOL CHEM, V273, P2553, DOI 10.1074/jbc.273.5.2553; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	132	367	388	1	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7223	7233		10.1038/sj.onc.1204765	http://dx.doi.org/10.1038/sj.onc.1204765			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704850				2022-12-28	WOS:000171891900010
J	Baisden, JM; Qian, Y; Zot, HM; Flynn, DC				Baisden, JM; Qian, Y; Zot, HM; Flynn, DC			The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity	ONCOGENE			English	Article						adaptor protein; Src; actin; AFAP-110	PLECKSTRIN HOMOLOGY DOMAIN; TYROSINE KINASE; CROSS-LINKING; FOCAL ADHESIONS; SH2 DOMAIN; PH DOMAIN; V-SRC; MONOCLONAL-ANTIBODIES; MECHANICAL-PROPERTIES; INOSITOL PHOSPHATES	The actin filament-associated protein of 110 kDa (AFAP-110) was first identified as an SH3/SH2 binding partner for the nonreceptor tyrosine kinase, Src. Subsequent data have demonstrated that AFAP-110 can interact with other Src family members. AFAP-110 contains additional protein binding modules including two pleckstrin homology domains, a leucine zipper motif and a target sequence for serine/threonine phosphorylation. AFAP-110 interacts with actin filaments directly via a carboxy terminal actin-binding domain. Thus AFAP-110 may function as an adaptor protein by linking Src family members and/or other signaling proteins to actin filaments. AFAP-110 also has an intrinsic capability to alter actin filament integrity that can be revealed upon conformational changes associated with phosphorylation or mutagenesis. Recent data has indicated that AFAP-110 may also serve to activate cSrc in response to this conformational change as well. Thus, AFAP-110 may function in several ways by (1) acting as an adaptor protein that links signaling molecules to actin filaments, (2) serving as a platform for the construction of larger signaling complexes, (3) serving as an activator of Src family kinases in response to cellular signals that alter its conformation and (4) directly effecting actin filament organization as an actin filament cross-linking protein. Here, we will review the structure and function of AFAP-110 as well as potential binding partners and effectors of AFAP-110's ability to alter actin filament integrity.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Dept Microbiol & Immunol, Morgantown, WV 26506 USA; Eastern Michigan Univ, Dept Biol, Ypsilanti, MI 48197 USA	West Virginia University; Eastern Michigan University	Flynn, DC (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, Dept Microbiol & Immunol, Morgantown, WV 26506 USA.	dflynn@hsc.wvu.edu	Baisden, Joseph/AAN-7747-2021	Baisden, Joseph/0000-0002-8986-407X	NCI NIH HHS [CA60731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060731, R01CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Cramer Louise P., 1997, Frontiers in Bioscience (online), V2, pD260; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1999, J CELL SCI, V112, P947; FLYNN DC, 1995, J BIOL CHEM, V270, P3894, DOI 10.1074/jbc.270.8.3894; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FLYNN DC, 1992, ONCOGENE, V7, P579; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Keshavjee S, 2000, TRANSPLANTATION, V70, P525, DOI 10.1097/00007890-200008150-00022; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; LIU XQ, 1993, ONCOGENE, V8, P1119; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Morris GE, 1998, BIOCHEMISTRY-US, V37, P11117, DOI 10.1021/bi9805137; Murray RC, 1999, SEMIN CELL DEV BIOL, V10, P421, DOI 10.1006/scdb.1999.0329; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Oldenbourg R, 2000, BIOPHYS J, V78, P1176, DOI 10.1016/S0006-3495(00)76675-6; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Qian Y, 1999, HYBRIDOMA, V18, P167, DOI 10.1089/hyb.1999.18.167; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Scholler JK, 1997, DNA CELL BIOL, V16, P515, DOI 10.1089/dna.1997.16.515; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shiraishi Y, 1999, J NEUROSCI, V19, P8389; Small J. Victor, 1994, Seminars in Cell Biology, V5, P157, DOI 10.1006/scel.1994.1020; Summy JM, 2000, ONCOGENE, V19, P155, DOI 10.1038/sj.onc.1203265; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Verkhusha VV, 1999, FEBS LETT, V445, P395, DOI 10.1016/S0014-5793(99)00124-6; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; Yamakita Y, 1996, J BIOL CHEM, V271, P12632, DOI 10.1074/jbc.271.21.12632; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	76	55	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6435	6447		10.1038/sj.onc.1204784	http://dx.doi.org/10.1038/sj.onc.1204784			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607843				2022-12-28	WOS:000171640600016
J	Bosc, DG; Goueli, BS; Janknecht, R				Bosc, DG; Goueli, BS; Janknecht, R			HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1	ONCOGENE			English	Article						ER81; gene transcription; HER2/Neu; MAP kinase; matrix metalloproteinase-1; protein phosphorylation	PROTEIN-KINASE; MAP-KINASE; MATRIX-METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; BREAST-CANCER; PEA3 GROUP; EXPRESSION; CELL; PHOSPHORYLATION; BINDING	In this study, we show that the ETS transcription factor ER81 directly binds to and activates the promoter of the matrix metalloproteinase gene, MMP-1. Further, the oncoprotein HER2/Neu synergizes with ER81 to stimulate MMP-1 transcription, The activation of ER81 by HER2/Neu is mediated by MAP kinases, which phosphorylate ER81 in its N-terminal activation domain. Four respective phosphorylation sites have been identified. Blocking phosphorylation at these sites decreases ER81 transcriptional activity, which can be further diminished by abolishment of phosphorylation at two non-MAP kinase sites, Altogether, our results reveal mechanisms of how phosphorylation of ER81 regulates the expression of target genes such as MMP-1, which may be important for many physiological processes from embryogenesis to adulthood as well as for tumor metastasis.	Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Guggenheim Bldg 1501A,200 1st St SW, Rochester, MN 55905 USA.	janknecht.ralf@mayo.edu		Janknecht, Ralf/0000-0003-1741-1562	NCI NIH HHS [CA 85257, R01 CA085257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Benbow U, 1999, CLIN CANCER RES, V5, P203; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Brummer O, 1999, VIRCHOWS ARCH, V435, P566, DOI 10.1007/s004280050442; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Buttice G, 1996, ONCOGENE, V13, P2297; Buzard GS, 1999, J CANCER RES CLIN, V125, P653, DOI 10.1007/s004320050330; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; Durko M, 1997, BBA-MOL CELL RES, V1356, P271, DOI 10.1016/S0167-4889(97)00004-9; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fini ME, 1998, BIOL EXTRAC, P299; Garbett EA, 2000, J CLIN PATHOL-MOL PA, V53, P99, DOI 10.1136/mp.53.2.99; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hung MC, 1999, SEMIN ONCOL, V26, P51; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Johansson N, 2000, J CELL SCI, V113, P227; Kindler-Rohrborn A, 2000, CANCER RES, V60, P4756; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MOLL UM, 1990, HISTOCHEMISTRY, V94, P555, DOI 10.1007/BF00272621; MONTE D, 1995, ONCOGENE, V11, P771; MUIR D, 1995, CLIN EXP METASTAS, V13, P303, DOI 10.1007/BF00133486; Nakopoulou L, 1999, HUM PATHOL, V30, P436, DOI 10.1016/S0046-8177(99)90120-X; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Shingleton WD, 1996, BIOCHEM CELL BIOL, V74, P759, DOI 10.1139/o96-083; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Sunami E, 2000, Oncologist, V5, P108, DOI 10.1634/theoncologist.5-2-108; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; White LA, 1997, CONNECT TISSUE RES, V36, P321, DOI 10.3109/03008209709160231; Yang BS, 1996, MOL CELL BIOL, V16, P538	56	94	94	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6215	6224		10.1038/sj.onc.1204820	http://dx.doi.org/10.1038/sj.onc.1204820			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593430				2022-12-28	WOS:000171206300013
J	Chen, XF; Thakkar, H; Tyan, F; Gim, S; Robinson, H; Lee, C; Pandey, SK; Nwokorie, C; Onwudiwe, N; Srivastava, RK				Chen, XF; Thakkar, H; Tyan, F; Gim, S; Robinson, H; Lee, C; Pandey, SK; Nwokorie, C; Onwudiwe, N; Srivastava, RK			Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer	ONCOGENE			English	Article						TRAIL; apoptosis; prostate cancer; mitochondria; Akt; PTEN	PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTORS; INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; CYTOCHROME-C; CELL-DEATH; FREQUENT INACTIVATION; TUMORICIDAL ACTIVITY; NEGATIVE REGULATION; SURVIVAL SIGNALS	TRAIL/Apo-2L is a member of the tumor necrosis factor superfamily and has recently been shown to induce apoptosis in cancer cells, but not in normal cells. In nude mice injected with human tumors, TRAIL reduces the size of these tumors without side effects. Akt promotes cell survival and block apoptosis. Some prostate cancer cells express high levels of Akt due to lack of active lipid phosphatase PTEN, a negative regulator of PI-3 kinase pathway, which may be responsible for drug resistance. The objective of this paper is to investigate the intracellular molecules that regulate TRAIL resistance. We have examined caspase-8 activity, BID cleavage, Akt activity, mitochondrial membrane potential (AT.) and apoptosis in prostate cancer (LNCap, PC-3, PC-3M and DU145) cells treated with or without TRAIL. PC-3, PC-3M and DU145 cells are sensitive to TRAIL, whereas LNCap cells are resistant. LNCap cells express the highest level of constitutively active Akt, which is directly correlated with TRAIL resistance. TRAIL activates caspase-8 in all the cell lines. Downregulation of constitutively active Akt by PI-3 kinase inhibitors (wortmannin and LY-294002), dominant negative Akt or PTEN, renders LNCap cells sensitive to TRAIL. Inhibition of TRAIL sensitivity occurs at the level of BID cleavage. Inhibition of protein synthesis by cycloheximide also causes LNCap cells sensitive to TRAIL. Overexpression of Bcl-2 or Bcl-X-L inhibits TRAIL-induced Delta Psi (m) and apoptosis. Overexpression of constitutively active Akt in PC-3M cells (express very low levels of constitutively active Akt) restores TRAIL resistance. These data suggest that elevated Akt activity protects LNCap cells from TRAIL-induced apoptosis, and the PI-3 kinase/Akt pathway may inhibit apoptotic signals by inhibiting processing of BID. Thus, constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; NIA, Clin Invest Lab, NIH, Baltimore, MD 21224 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Srivastava, RK (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Greenebaum Canc Ctr, 20 N Pine St, Baltimore, MD 21201 USA.							Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cairns P, 1997, CANCER RES, V57, P4997; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheney IW, 1998, CANCER RES, V58, P2331; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Green D R, 1998, Results Probl Cell Differ, V24, P45; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Guldberg P, 1997, CANCER RES, V57, P3660; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Ittmann MM, 1998, ONCOL REP, V5, P1329; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Keane MM, 1999, CANCER RES, V59, P734; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim JH, 2000, INTELL AUTOM SOFT CO, V6, P3, DOI 10.1080/10798587.2000.10768155; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; Long RJ, 1997, J ANDROL, V18, P15; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mori S, 1999, J IMMUNOL, V162, P5616; Muzio M, 1998, INT J CLIN LAB RES, V28, P141, DOI 10.1007/s005990050035; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Okami K, 1998, CANCER RES, V58, P509; Orlinick J R, 1999, Int Rev Immunol, V18, P293, DOI 10.3109/08830189909088485; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Petrylak DP, 1999, UROLOGY, V54, P30, DOI 10.1016/S0090-4295(99)00452-5; Pisters LL, 1999, SEMIN ONCOL, V26, P202; Rasheed BKA, 1997, CANCER RES, V57, P4187; Richie JP, 1999, UROLOGY, V54, P15, DOI 10.1016/S0090-4295(99)00449-5; Rieger J, 1999, ACTA NEUROPATHOL, V97, P1, DOI 10.1007/s004010050948; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sekulic A, 2000, CANCER RES, V60, P3504; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srivastava Rakesh K., 2000, Molecular Cell Biology Research Communications, V4, P67, DOI 10.1006/mcbr.2001.0265; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Tonks NK, 1999, SCIENCE, V286, P2096, DOI 10.1126/science.286.5447.2096; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	87	252	262	1	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6073	6083		10.1038/sj.onc.1204736	http://dx.doi.org/10.1038/sj.onc.1204736			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593415				2022-12-28	WOS:000171056300015
J	Ugolini, F; Charafe-Jauffret, E; Bardou, VJ; Geneix, J; Adelaide, J; Labat-Moleur, F; Penault-Llorca, F; Longy, M; Jacquemier, J; Birnbaum, D; Pebusque, MJ				Ugolini, F; Charafe-Jauffret, E; Bardou, VJ; Geneix, J; Adelaide, J; Labat-Moleur, F; Penault-Llorca, F; Longy, M; Jacquemier, J; Birnbaum, D; Pebusque, MJ			WNT pathway and mammary carcinogenesis: Loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type	ONCOGENE			English	Article						breast cancer; tumor suppressor gene; in situ hybridization; chromosome 8	BREAST-CANCER; CYCLIN D1; ESTROGEN-RECEPTOR; DIFFERENTIAL EXPRESSION; SPEMANN ORGANIZER; TISSUE-SECTIONS; BETA-CATENIN; FOLLOW-UP; IN-SITU; GROWTH	Secreted Frizzled-related protein 1 (SFRP1) encodes a member of a protein family that contains a cysteine-rich domain similar to the WNT-binding site of Frizzled receptors and regulates the WNT pathway. The WNT pathway is frequently altered in human cancers. We have defined the pattern of SFRP1 mRNA expression in the progression of breast cancer. We show that SFRP1 is expressed in the epithelial component of normal breast, in the in situ component of ductal carcinomas and is lost in more than 80% of invasive breast carcinomas except the medullary type. Loss of SFRP1 expression is correlated with the presence of hormonal receptors. Conversely, the maintenance of SFRP1 in carcinomas is correlated with the presence of lymphoplasmocytic stroma. No significant association was observed between SFRP1 status and the level of apoptosis in tumoral cells.	INSERM, U119, IFR 57, Oncol Mol Lab, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Anat Pathol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, F-13009 Marseille, France; CHRU, Pathol Cellulaire Lab, Grenoble, France; Ctr Jean Perrin, Anat Pathol Lab, Clermont Ferrand, France; Inst Bergonie, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); CHU Grenoble Alpes; UNICANCER; Centre Jean Perrin; UNICANCER; Institut Bergonie	Pebusque, MJ (corresponding author), INSERM, U119, IFR 57, Oncol Mol Lab, 27 Bd Lei Roure, F-13009 Marseille, France.	pebusque@marseille.inserm.fr	ADELAIDE, José JA/O-4390-2017; Charafe-Jauffret, emmanuelle/P-6009-2017	ADELAIDE, José JA/0000-0003-4364-9857; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299; Birnbaum, Daniel/0000-0001-7920-9883				Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; CHURCH GM, 1984, P NATL ACAD SCI USA, V81, P945; Dale TC, 1996, CANCER RES, V56, P4320; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GOLD R, 1993, J HISTOCHEM CYTOCHEM, V41, P1023, DOI 10.1177/41.7.8515045; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HUGUET EL, 1994, CANCER RES, V54, P2615; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; Jacquemier JD, 1998, J PATHOL, V184, P130; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Labat-Moleur F, 1998, J HISTOCHEM CYTOCHEM, V46, P327, DOI 10.1177/002215549804600306; Lakhani SR, 1999, J PATHOL, V187, P272, DOI 10.1002/(SICI)1096-9896(199902)187:3<272::AID-PATH265>3.0.CO;2-2; Leach RJ, 1996, CYTOGENET CELL GENET, V75, P71, DOI 10.1159/000134460; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Pedersen L, 1997, APMIS, V105, P4; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; PHILIPPE JM, 1998, TECHNICAL TIPS LINE; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; RIDOLFI RL, 1977, CANCER, V40, P1365, DOI 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N; Ross JS, 1999, AM J CLIN PATHOL, V112, pS53; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shoker BS, 1999, HISTOPATHOLOGY, V35, P393; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simpson JF, 2000, AM J PATHOL, V156, P5, DOI 10.1016/S0002-9440(10)64698-6; Takano Y, 1999, J CANCER RES CLIN, V125, P505, DOI 10.1007/s004320050309; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THEILLET C, 1990, ONCOGENE, V5, P147; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; vanDiest PJ, 1997, AM J PATHOL, V150, P705; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vos CBJ, 1999, J PATHOL, V187, P279; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zorn AM, 1997, CURR BIOL, V7, pR501, DOI 10.1016/S0960-9822(06)00248-X; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	155	165	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5810	5817		10.1038/sj.onc.1204706	http://dx.doi.org/10.1038/sj.onc.1204706			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593386				2022-12-28	WOS:000171037200004
J	Saito, Y; Ochiai, Y; Kodama, Y; Tamura, Y; Togashi, T; Kosugi-Okano, H; Miyazawa, T; Wakabayashi, Y; Hatakeyama, K; Wakana, S; Niwa, O; Kominami, R				Saito, Y; Ochiai, Y; Kodama, Y; Tamura, Y; Togashi, T; Kosugi-Okano, H; Miyazawa, T; Wakabayashi, Y; Hatakeyama, K; Wakana, S; Niwa, O; Kominami, R			Genetic loci controlling susceptibility to gamma-ray-induced thymic lymphoma	ONCOGENE			English	Article						susceptibility gene; genetic mapping; gamma-ray radiation; mouse thymic lymphoma; congenic mouse	INTESTINAL NEOPLASIA; CANCER SUSCEPTIBILITY; SUPPRESSOR GENE; DEFICIENT MICE; COMPLEX TRAITS; MAJOR MODIFIER; COLON-CANCER; MOUSE; RESISTANCE; TUMORS	BALB/c is a susceptible strain for the development of gamma -ray induced mouse thymic lymphoma whereas MSM shows resistance. Association analysis of 220 backcross mice between the two strains using 67 markers was carried out to identify loci involved in the control of susceptibility. The genotype of mice with lymphoma showed excess heterozygosity relative to MSM homozygosity at D2Mit15 and D4Mit12 and was skewed toward MSM-derived alleles at D5Mit5. The P values in Mantel-Cox test were 0.0048 (D2Mit15), 0.0034 (D4Mit12) and 0.0048 (D5Mit5), suggesting association at the three loci in the susceptibility. Cooperative effect on lymphomagenesis was also observed among the three loci. To obtain independent evidence for linkage at D4Mit12, we made partially congenic mice in which a D4Mit12 region in BALB/c was replaced by MSM-derived homolog. Examination for the lymphoma susceptibility in 78 progeny of the congenic mice confirmed the effect of the locus near D4Mit12 (P=0.0037). The result, together with the linkage analysis, shows that the locus near D4Mit12 is regarded as a confirmed linkage but the other two loci as marginally suggestive.	Niigata Univ, Sch Med, Dept Biochem 1, Niigata 9518122, Japan; Niigata Univ, Sch Med, Dept Surg 1, Niigata 9518122, Japan; Kyoto Univ, Inst Phys, Kyoto, Japan; Kyoto Univ, Chem Res Genome Sci Ctr, Kyoto, Japan; Kyoto Univ, Ctr Radiat Biol, Kyoto 606, Japan	Niigata University; Niigata University; Kyoto University; Kyoto University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem 1, Asahimachi 1-757, Niigata 9518122, Japan.							Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; Baross-Francis A, 2000, CARCINOGENESIS, V21, P1259, DOI 10.1093/carcin/21.6.1259; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Demant P, 1992, Semin Cancer Biol, V3, P159; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; MERUELO D, 1981, J EXP MED, V154, P1201, DOI 10.1084/jem.154.4.1201; Moen CJA, 1996, P NATL ACAD SCI USA, V93, P1082, DOI 10.1073/pnas.93.3.1082; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; OKUMOTO M, 1990, CANCER RES, V50, P3848; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; Shisa H, 1996, JPN J CANCER RES, V87, P258, DOI 10.1111/j.1349-7006.1996.tb00214.x; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; van Wezel T, 1999, CANCER RES, V59, P4216; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590	28	27	29	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5243	5247		10.1038/sj.onc.1204675	http://dx.doi.org/10.1038/sj.onc.1204675			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526516				2022-12-28	WOS:000170464000021
J	Low, W; Olmos-Centenera, G; Madsen, C; Leverrier, Y; Collins, M				Low, W; Olmos-Centenera, G; Madsen, C; Leverrier, Y; Collins, M			Role of Bax in apoptosis of IL-3-dependent cells	ONCOGENE			English	Article						apoptosis; IL-3; Bax	COLONY-STIMULATING FACTOR; ACTIVATED PROTEIN-KINASE; COMMON BETA-SUBUNIT; CYTOCHROME-C; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC MALIGNANCIES; INTERLEUKIN-3 STIMULATION; CONFORMATIONAL-CHANGE; SIGNAL-TRANSDUCTION; FACTOR DEPRIVATION	IL-3 removal was reported to induce membrane association of the apoptotic effector Bax. This report demonstrates that IL-3-dependent cells from Bax-null mice failed to activate caspases after IL-3 removal and survived in an 10-fold lower concentration of IL-3. As IL-3 removal also down-regulates expression of Bcl-X, we examined the relationship between Bcl-X decrease and Bax membrane association. IL-3 removal from BAF-3 cells, followed by sorting caspase-active and caspase-inactive populations, showed that both expressed similar levels of Bcl-X. Inhibition of IL-3 signalling via PI-3 kinase and MEK1/2 resulted in cells with minimal Bcl-X, which remained viable with soluble Bax. However BAF-3-derived cells, which maintained Bcl-X expression without IL-3, also remained viable with soluble Bax on IL-3 removal. Therefore a decrease in Bcl-X is necessary, though not sufficient, for Bax membrane association on IL-3 removal. In contrast, treatment of BAF-3 cells with hydroxyurea induced apoptosis in the absence of a Bcl-X decrease. Furthermore, IL-3-dependent cells from Bax-null mice activated caspases after hydroxyurea treatment and show the same sensitivity to a variety of cytotoxic drugs. Thus, apoptosis after IL-3 removal requires a decrease in Bcl-X and Bax membrane association, whereas that induced by cytotoxic drugs does not.	UCL, Dept Immunol & Mol Pathol, Windeyer Inst Med Sci, London W1P 6DB, England; Ecole Normale Super Lyon, CNRS,INRA, UMR 49, Biol Cellulaire & Mol Lab, F-69364 Lyon 07, France	University of London; University College London; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE	Collins, M (corresponding author), UCL, Dept Immunol & Mol Pathol, Windeyer Inst Med Sci, 46 Cleveland St, London W1P 6DB, England.	mary.collins@ucl.ac.uk	LEVERRIER, Yann/M-3767-2014	LEVERRIER, Yann/0000-0002-4227-5446; Olmos Centenera, Gemma/0000-0003-4835-0846				Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Furlong IJ, 1997, J CELL SCI, V110, P653; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hara T, 1996, STEM CELLS, V14, P605, DOI 10.1002/stem.140605; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; JUCKER M, 1995, J BIOL CHEM, V270, P27817; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Maurer M, 2000, J INVEST DERMATOL, V114, P1205, DOI 10.1046/j.1523-1747.2000.00005.x; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Oliver FJ, 1997, J BIOL CHEM, V272, P10624; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Palacios C, 2000, ONCOGENE, V19, P3556, DOI 10.1038/sj.onc.1203683; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; Sanz C, 2000, BLOOD, V95, P2742, DOI 10.1182/blood.V95.9.2742.009k24_2742_2747; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	59	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4476	4483		10.1038/sj.onc.1204580	http://dx.doi.org/10.1038/sj.onc.1204580			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494143				2022-12-28	WOS:000170074900005
J	Giannakakou, P; Robey, R; Fojo, T; Blagosklonny, MV				Giannakakou, P; Robey, R; Fojo, T; Blagosklonny, MV			Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity	ONCOGENE			English	Article						paclitaxel; G1 arrest; mitosis; p53; p21; Bcl-2	HUMAN CANCER-CELLS; INHIBITOR-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; SV40-TRANSFORMED CELLS; ANTICANCER AGENTS; G(1) ARREST; G2/M ARREST; HUMAN HEAD; TAXOL; OVARIAN	Paclitaxel (PTX), a microtubule-active agent, blocks cell proliferation by inhibiting mitotic progression leading to mitotic and postmitotic arrest and cell death. Here we demonstrate for the first time that very low concentrations of PTX (3-6 nM) can completely inhibit cell proliferation without arresting cells at mitosis, At these low concentrations that are insufficient to inhibit mitotic progression, PTX induced both p53 and p21 causing CI and G2 arrest in A549. In contrast, low PTX concentrations failed to induce G1 and G2 arrest in A549/E6 cells, that do not express p53, Furthermore, we observed that the levels of p53 and p21 induced by adriamycin and by low concentrations of PTX in A549 cells were comparable. This observation led us to conclude that tow concentrations of PTX can induce p53 and p21 sufficiently to cause G1 and G2, Many other cell lines, including HCT116 cells, do not readily upregulate p53 in response to PTX, and therefore undergo exclusively mitotic and postmitotic arrest after PTX treatment. At low concentrations that do not cause mitotic arrest, PTX did not significantly inhibit proliferation of these cells. In HCT116 cells, loss of p53 (HCT/p53(-/-)) or p21 (HCT/p21(-/-)) affects both Bax and Bcl-2 expression. In cells lacking p53, levels of Bax and p21 were decreased. In cells lacking p21, levels of wt p53 were highly increased to compensate for the loss of p21, This in turn results in upregulation of Bax and downregulation of Bcl-2 resulting in an increase of the apoptotic Bax/Bcl2 ratio consistent with increased sensitivity of these cells to apoptotic stimuli, High levels of p53 and Bax/Bcl-2 ratio can also explain why loss of p21 is rarely found in human cancer.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; Emory Univ, Atlanta, GA 30322 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Emory University	Blagosklonny, MV (corresponding author), NCI, Med Branch, NIH, Bldg 10,R 12N226, Bethesda, MD 20892 USA.			Giannakakou, Paraskevi/0000-0001-7378-262X; Robey, Rob/0000-0002-0857-3650				An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; BHALLA K, 1993, LEUKEMIA, V7, P563; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; De Feudis P, 2000, NEOPLASIA, V2, P202, DOI 10.1038/sj.neo.7900086; Debernardis D, 1997, CANCER RES, V57, P870; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1998, CLIN CANCER RES, V4, P1047; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gan YB, 1996, CANCER RES, V56, P2086; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Giannakakou P, 2000, ONCOGENE, V19, P3078, DOI 10.1038/sj.onc.1203642; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Khan SH, 1998, CANCER RES, V58, P396; Koutcher JA, 2000, CLIN CANCER RES, V6, P1498; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LONG BH, 1994, CANCER RES, V54, P4355; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Maurer BJ, 1999, MOL PHARMACOL, V55, P938; MIYASHITA T, 1995, CELL, V80, P293; Motwani M, 2000, CLIN CANCER RES, V6, P924; Nielsen LL, 1998, CLIN CANCER RES, V4, P835; OConnor PM, 1997, CANCER RES, V57, P4285; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Safran H, 1996, CANCER, V78, P1203, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1203::AID-CNCR6>3.0.CO;2-A; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stewart ZA, 1999, CANCER RES, V59, P3831; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Torres K, 1998, CANCER RES, V58, P3620; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Vikhanskaya F, 1998, EXP CELL RES, V241, P96, DOI 10.1006/excr.1998.4018; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WALDMAN T, 1995, CANCER RES, V55, P5187; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zaffaroni N, 1998, BRIT J CANCER, V77, P1378, DOI 10.1038/bjc.1998.230; Zeng S, 2000, CLIN CANCER RES, V6, P3766; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	56	185	203	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3806	3813		10.1038/sj.onc.1204487	http://dx.doi.org/10.1038/sj.onc.1204487			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439344				2022-12-28	WOS:000169494700006
J	Besson, A; Davy, A; Robbins, SM; Yong, VW				Besson, A; Davy, A; Robbins, SM; Yong, VW			Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells	ONCOGENE			English	Article						ERK; MAPK; glioma; integrin; migration; PKC	PROTEIN-KINASE-C; IN-VITRO; PATHWAY UPSTREAM; GROWTH-FACTOR; INTEGRIN; INVASION; MOTILITY; TRANSDUCTION; INHIBITION; DOWNSTREAM	Protein kinase C (PKC) is. a family of serine/threonine kinases. involved in. the transduction of a variety of signals. There is increasing evidence to indicate that specific PKC isoforms are involved in the regulation of distinct cellular processes. In glioma, cells, PKC alpha was found to be a critical regulator of proliferation and cell cycle progression, white PKC epsilon was found to regulate adhesion and migration. Herein, we. report that specific PKC isoforms are able to differentially activate extracellular-signal regulated kinase (ERK)! in distinct cellular locations: while PKC alpha induces the activation of nuclear ERK, PKC epsilon induces, the activation of ERK at focal adhesions. Inhibition of the ERK pathway completely abolished the PKC-induced integrin-mediated adhesion and migration. Thus, we present the first evidence that PKC epsilon is able to, activate ERK at focal adhesions to mediate glioma cell adhesion and motility, providing a molecular mechanism to. explain the different biological functions of PKC alpha and epsilon in glioma cells.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Yong, VW (corresponding author), 3300 Hosp Dr NW,HMRB 191, Calgary, AB T2N 4N1, Canada.		Besson, Arnaud/J-6254-2014	Besson, Arnaud/0000-0002-9599-3943; Yong, V. Wee/0000-0002-2600-3563; Robbins, Stephen/0000-0001-7475-1665				Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; El-Obeid A, 1997, CANCER RES, V57, P5598; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Friedlander DR, 1996, CANCER RES, V56, P1939; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gillespie GY, 1999, CANCER RES, V59, P2076; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Rigot V, 1998, J CELL SCI, V111, P3119; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Sieg DJ, 1999, J CELL SCI, V112, P2677; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; TYSNES OB, 1993, ANTICANCER RES, V13, P1325; Zhang W, 1997, CANCER LETT, V120, P31, DOI 10.1016/S0304-3835(97)00287-5	26	79	83	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7398	7407		10.1038/sj.onc.1204899	http://dx.doi.org/10.1038/sj.onc.1204899			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704869				2022-12-28	WOS:000171894200012
J	Kucharczak, J; Pannequin, J; Camby, I; Decaestecker, C; Kiss, R; Martinez, J				Kucharczak, J; Pannequin, J; Camby, I; Decaestecker, C; Kiss, R; Martinez, J			Gastrin induces over-expression of genes involved in human U373 glioblastoma cell migration	ONCOGENE			English	Article						glioblastoma; proliferation; migration; gastrin; gene overexpression	CALCIUM-BINDING PROTEINS; GLIOMA-CELLS; EXTRACELLULAR-MATRIX; ASTROCYTIC TUMORS; RHO; MODULATION; KINASE; FIBROBLASTS; INCREASES; INVASION	Astrocytic tumors are the most common and the most malignant primary tumors of the central nervous system. We had previously observed that gastrin could significantly modulate both cell proliferation and migration of astrocytoma cells. We have investigated in the present study which genes could be targeted by gastrin in tumor astrocyte migration. Using a subtractive hybridization PCR technique we have cloned genes differentially overexpressed in human astrocytoma U373 cells treated or not with gastrin. We found about 70 genes overexpressed by gastrin. Among the genes overexpressed by gastrin, we paid particular attention to tenascin-C, S100A6 and MLCK genes because their direct involvement in cell migration features. Their gastrin-induced overexpression was quantitatively determined by competitive RT-PCR technique. We also showed by means of a reporter gene system that S100A6 and tenascin-C respective promoters were upregulated after gastrin treatment. These data show that gastrin-mediated effects in glioblastoma cells occur through activation of a number of genes involved in cell migration and suggest that gastrin could be a target in new therapeutic strategies against malignant gliomas.	Univ Montpellier I, Fac Pharm, LAPP, CNRS,UMR 5810, F-34060 Montpellier, France; Univ Montpellier 2, Fac Pharm, LAPP, CNRS,UMR 5810, F-34060 Montpellier, France; Free Univ Brussels, Fac Med, Lab Histopathol, B-1050 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Martinez, J (corresponding author), Univ Montpellier I, Fac Pharm, LAPP, CNRS,UMR 5810, 15 Av C Flahault, F-34060 Montpellier, France.	martinez@colombes.pharma.univ-montpl.fr	Martinez, Jean/R-9421-2019	Martinez, Jean/0000-0002-9267-4621; Decaestecker, Christine/0000-0002-5495-1931; pannequin, julie/0000-0002-9956-373X; KUCHARCZAK, Jerome/0000-0001-7722-8490				Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; ASTRUC ME, 1995, ENDOCRINOLOGY, V136, P824, DOI 10.1210/en.136.3.824; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; Camby I, 1996, J NATL CANCER I, V88, P594, DOI 10.1093/jnci/88.9.594; Camby I, 1999, BRAIN PATHOL, V9, P1; CAMBY I, 1994, J NEURO-ONCOL, V20, P67, DOI 10.1007/BF01057963; Camby I, 2001, BRAIN PATHOL, V11, P12; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; De Hauwer C, 1998, J NEUROBIOL, V37, P373, DOI 10.1002/(SICI)1097-4695(19981115)37:3<373::AID-NEU3>3.0.CO;2-H; De la Fuente M, 1998, NEUROPEPTIDES, V32, P225, DOI 10.1016/S0143-4179(98)90041-5; Decaestecker C, 1998, BRAIN PATHOL, V8, P29; DelaFuente M, 1997, J ENDOCRINOL, V153, P475, DOI 10.1677/joe.0.1530475; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Enam SA, 1998, NEUROSURGERY, V42, P599, DOI 10.1097/00006123-199803000-00030; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; Giese A, 1996, J CELL SCI, V109, P2161; Giese A, 1996, NEUROSURGERY, V38, P755, DOI 10.1227/00006123-199604000-00026; GIESE A, 1994, CANCER RES, V54, P3897; Gillespie GY, 1999, CANCER RES, V59, P2076; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Golitsina NL, 1996, BIOCHEM BIOPH RES CO, V220, P360, DOI 10.1006/bbrc.1996.0410; Kleihues P, 2000, PATHOLOGY GENETICS T; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KRUCZYNSKI A, 1995, INT J ONCOL, V6, P473; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; Sasaki H, 1998, CANCER, V82, P1921, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1921::AID-CNCR16>3.0.CO;2-V; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; Taniguchi T, 1996, ONCOGENE, V12, P1357; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Treasurywala S, 1998, GLIA, V24, P236, DOI 10.1002/(SICI)1098-1136(199810)24:2<236::AID-GLIA8>3.3.CO;2-1; VANDENHEUVEL JP, 1993, BIOTECHNIQUES, V14, P395; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Zhang H, 1998, J NEUROSCI, V18, P2370; [No title captured]	44	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7021	7028		10.1038/sj.onc.1204882	http://dx.doi.org/10.1038/sj.onc.1204882			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704826				2022-12-28	WOS:000171739300005
J	Steinman, RA; Lu, YL; Yaroslavskiy, B; Stehle, C				Steinman, RA; Lu, YL; Yaroslavskiy, B; Stehle, C			Cell cycle-independent upregulation of p27Kip1 by p21Waf1 in K562 cells	ONCOGENE			English	Article						p21Waf1; p27Kip1; differentiation; cell cycle	DEPENDENT-KINASE INHIBITOR; CDK-INHIBITOR; MYELOID CELLS; IN-VITRO; P27(KIP1); P27; DIFFERENTIATION; PHOSPHORYLATION; P21(WAF1/CIP1); EXPRESSION	Cellular differentiation frequently involves sequential peaks in the expression of cyclin-dependent kinase inhibitors (cdki's). For example, an increase in levels of the cdki p27Kip1 follows upregulation of p21Waf1 in several cell types induced to differentiate by diverse stimuli. In this study, we have investigated whether p21Waf1 expression itself, rather than the differentiating agent, could be increasing p27Kip1 protein levels. We used an inducible p21Waf1 expression vector in a K562 leukemic cell model which we had previously shown to initiate differentiation following p21Waf1 upregulation. The current study reports that p21Waf1 upregulated p27Kip1 protein without altering p27Kip1 mRNA levels. This effect did not depend on Gl-phase arrest-the increase in p27Kip1 occurred at all phases of the cell cycle. p21Waf1-expressing extracts inhibited phosphorylation of p27Kip1 on threonine-187, leading to decreased ubiquitination and decreased proteasomal destruction of p27Kip1. In K562 cells, upregulation of p27Kip1 by p21Waf1 during differentiation facilitated an ordered transition between these two cdki's, each of which may distinctly influence the differentiation process.	Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Steinman, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, E1052 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.	Steinman@imap.pitt.edu						Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Chen YJ, 1999, EUR J CELL BIOL, V78, P824, DOI 10.1016/S0171-9335(99)80033-8; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Ghiani CA, 1999, DEVELOPMENT, V126, P1077; Harvat BL, 1998, J CELL SCI, V111, P1185; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Huss R, 1999, BRIT J CANCER, V81, P808, DOI 10.1038/sj.bjc.6690768; Kawa S, 1997, BRIT J CANCER, V76, P884, DOI 10.1038/bjc.1997.479; Liu JB, 2000, ONCOGENE, V19, P661, DOI 10.1038/sj.onc.1203373; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Muto A, 1999, BLOOD, V93, P2225, DOI 10.1182/blood.V93.7.2225.407a05_2225_2233; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; Steinman RA, 2000, LEUKEMIA RES, V24, P601, DOI 10.1016/S0145-2126(00)00020-5; Tam S. W., 1997, Leukemia (Basingstoke), V11, P363; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Tian JQ, 1999, AM J PHYSIOL-CELL PH, V276, pC1245, DOI 10.1152/ajpcell.1999.276.6.C1245; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Urashima M, 1997, BLOOD, V90, P279; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Wagner EF, 1998, J IMMUNOL, V161, P1123; Xu X, 1999, BIOCHEMISTRY-US, V38, P8713; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	46	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6524	6530		10.1038/sj.onc.1204800	http://dx.doi.org/10.1038/sj.onc.1204800			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641776				2022-12-28	WOS:000171404200004
J	Schaller, MD				Schaller, MD			Paxillin: a focal adhesion-associated adaptor protein	ONCOGENE			English	Review						paxillin; integrin signaling; phosphotyrosine; cytoskeleton; cell motility; FAK	TYROSINE-PHOSPHATASE-PEST; SMOOTH-MUSCLE CELLS; SWISS 3T3 CELLS; PAPILLOMAVIRUS TYPE-1 E6; CRK-ASSOCIATED SUBSTRATE; STRESS FIBER FORMATION; LIM DOMAINS; SERINE PHOSPHORYLATION; KINASE FAK; PTP-PEST	Paxillin is a focal adhesion-associated, phosphotyrosine-containing protein that may play a role in several signaling pathways. Paxillin contains a number of motifs that mediate protein-protein interactions, including LD motifs, LIM domains, an SH3 domain-binding site and SH2 domain-binding sites. These motifs serve as docking sites for cytoskeletal proteins, tyrosine kinases, serine/threonine kinases, GTPase activating proteins and other adaptor proteins that recruit additional enzymes into complex with paxillin. Thus paxillin itself serves as a docking protein to recruit signaling molecules to a specific cellular compartment, the focal adhesions, and/or to recruit specific combinations of signaling molecules into a complex to coordinate downstream signaling. The biological function of paxillin coordinated signaling is likely to regulate cell spreading and motility.	Univ N Carolina, Dept Cell & Dev Biol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Comprehens Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Schaller, MD (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Lineberger Comprehens Canc Ctr, 534 Taylor Hall,CB 7090, Chapel Hill, NC 27599 USA.	crispy4@med.unc.edu			NCI NIH HHS [CA90901] Funding Source: Medline; NIGMS NIH HHS [GM57943] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057943] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Andreev J, 1999, MOL CELL BIOL, V19, P2338; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Berg MM, 1997, J NEUROSCI RES, V50, P979; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen LM, 2000, J NEUROSCI, V20, P3776, DOI 10.1523/JNEUROSCI.20-10-03776.2000; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Das K, 2000, J VIROL, V74, P812, DOI 10.1128/JVI.74.2.812-816.2000; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Fernandez R, 1997, J IMMUNOL, V159, P5568; Flinn HM, 1996, J CELL SCI, V109, P1133; Fox GL, 1999, P NATL ACAD SCI USA, V96, P14978, DOI 10.1073/pnas.96.26.14978; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Fujimoto J, 1999, J BIOL CHEM, V274, P29196, DOI 10.1074/jbc.274.41.29196; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; Grgurevich S, 1999, BIOCHEM BIOPH RES CO, V256, P668, DOI 10.1006/bbrc.1999.0398; Hagmann J, 1998, J CELL SCI, V111, P2181; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; Hashimoto S, 2001, J BIOL CHEM, V276, P6037, DOI 10.1074/jbc.M005854200; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; ILLC D, 1995, NATURE, V377, P539; Ishino K, 2000, J CELL BIOCHEM, V76, P411, DOI 10.1002/(SICI)1097-4644(20000301)76:3<411::AID-JCB9>3.0.CO;2-J; Ishino M, 2000, FEBS LETT, V474, P179, DOI 10.1016/S0014-5793(00)01597-0; KHAN MA, 1995, FEBS LETT, V362, P201, DOI 10.1016/0014-5793(95)00250-D; Kintscher U, 2001, HYPERTENSION, V37, P587, DOI 10.1161/01.HYP.37.2.587; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Ku H, 2000, J BIOL CHEM, V275, P11333, DOI 10.1074/jbc.275.15.11333; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Litvak V, 2000, J BIOL CHEM, V275, P32736, DOI 10.1074/jbc.M004200200; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2000, J BIOL CHEM, V275, P22736, DOI 10.1074/jbc.M000388200; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Nishiya N, 1998, NUCLEIC ACIDS RES, V26, P4267, DOI 10.1093/nar/26.18.4267; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Palmer RH, 1999, J BIOL CHEM, V274, P35621, DOI 10.1074/jbc.274.50.35621; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Pixley FJ, 2001, MOL CELL BIOL, V21, P1795, DOI 10.1128/MCB.21.5.1795-1809.2001; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; RANKIN S, 1994, J BIOL CHEM, V269, P704; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ryu H, 2000, J IMMUNOL, V165, P2116, DOI 10.4049/jimmunol.165.4.2116; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seko Y, 1999, BIOCHEM BIOPH RES CO, V262, P290, DOI 10.1006/bbrc.1999.1185; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Suen PW, 1999, J CELL SCI, V112, P4067; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Takayama Y, 1999, J BIOL CHEM, V274, P2291, DOI 10.1074/jbc.274.4.2291; Tang D, 1999, AM J PHYSIOL-CELL PH, V276, pC250, DOI 10.1152/ajpcell.1999.276.1.C250; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Thomas SM, 1999, J CELL SCI, V112, P181; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TURNER CE, 1995, J CELL SCI, V108, P333; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Wang F, 1999, EXP CELL RES, V247, P17, DOI 10.1006/excr.1998.4327; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Wheeler GN, 2001, GENE, V262, P291, DOI 10.1016/S0378-1119(00)00512-6; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; WOOD CK, 1994, J CELL SCI, V107, P709; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; YANG Q, 1993, J BIOL CHEM, V268, P6622; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682	124	436	452	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6459	6472		10.1038/sj.onc.1204786	http://dx.doi.org/10.1038/sj.onc.1204786			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607845				2022-12-28	WOS:000171640600018
J	Peace, BE; Hughes, MJ; Degen, SJF; Waltz, SE				Peace, BE; Hughes, MJ; Degen, SJF; Waltz, SE			Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis	ONCOGENE			English	Article						Ron; Stk; hepatocyte growth factor-like protein; tumorigenesis; metastasis	MACROPHAGE-STIMULATING PROTEIN; RECEPTOR TYROSINE KINASE; HEPATOCYTE GROWTH-FACTOR; MET PROTOONCOGENE; C-KIT; PHOSPHATIDYLINOSITOL-3 KINASE; ACTIVATING MUTATIONS; RET PROTOONCOGENE; SOMATIC MUTATIONS; CATALYTIC DOMAIN	The receptor tyrosine kinase Ron is a member of the receptor family that includes the proto-oncogene Met and the avian oncogene Sea. The interaction of Ron with its ligand, known as hepatocyte growth factor-like protein (HGFL) or macrophage stimulating protein (MSP), induces crucial cellular responses including invasive growth, proliferation, cell scattering, and branching morphogenesis. Based on the homology and functional similarities between Met and Ron it was hypothesized that Ron may be important in tumor formation and metastasis. To test this hypothesis, wildtype mouse Ron and three mutant forms of Ron containing mutations similar to those found in the Met gene in human hereditary papillary renal carcinoma (HPRC), were expressed in NIH3T3 cells. A transformed phenotype was produced in cell lines expressing either wild-type Ron or the mutated Ron proteins. Further, these cell lines displayed oncogenic potential by exhibiting increased proliferation and constitutive phosphorylation of Ron. These cell lines were also tested for the ability to form solid tumors. Cells expressing wild-type Ron and the three proteins with single amino acid substitutions were highly tumorigenic in vivo. In a model of experimental metastasis, two of the cell lines with altered Ron protein formed highly aggressive tumors in the lungs. These results suggest that Ron may be an aggressive oncogene when either overexpressed or when activated by mutation.	Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Waltz, SE (corresponding author), Childrens Hosp Res Fdn, Div Dev Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Waltz, Susan/0000-0003-3572-4642	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036888] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058182] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL-07752] Funding Source: Medline; NICHD NIH HHS [HD-36888] Funding Source: Medline; NIDDK NIH HHS [DK-58182, DK-47003] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZERRA JA, 1993, PROTEIN SCI, V2, P666; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Chen QY, 1997, HEPATOLOGY, V26, P59; Chen YQ, 1998, J IMMUNOL, V161, P4950; Cirafici AM, 1997, ENDOCRINOLOGY, V138, P1450, DOI 10.1210/en.138.4.1450; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LONGATI P, 1994, ONCOGENE, V9, P49; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Mera A, 1999, J BIOL CHEM, V274, P15766, DOI 10.1074/jbc.274.22.15766; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Okino T, 1999, INT J ONCOL, V15, P709; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; QUANTIN B, 1995, DEV DYNAM, V204, P383, DOI 10.1002/aja.1002040405; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; Waltz SE, 1997, J BIOL CHEM, V272, P30526, DOI 10.1074/jbc.272.48.30526; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	45	75	83	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6142	6151		10.1038/sj.onc.1204836	http://dx.doi.org/10.1038/sj.onc.1204836			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593422				2022-12-28	WOS:000171206300005
J	Xie, SH; Wang, Y; Liu, JX; Sun, T; Wilson, MB; Smithgall, TE; Arlinghaus, RB				Xie, SH; Wang, Y; Liu, JX; Sun, T; Wilson, MB; Smithgall, TE; Arlinghaus, RB			Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation	ONCOGENE			English	Article						Jak2; Bcr-Abl; Philadelphia chromosome; chronic myelogenous leukemia	CHRONIC MYELOGENOUS LEUKEMIA; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; MYELOID-LEUKEMIA; CELLS; KINASE; RECEPTOR; PATHWAY; HEMATOPOIESIS; ONCOPROTEIN	We have previously reported that the Jak2 tyrosine kinase but not Jak1 is tyrosine phosphorylated in the absence of IL-3 in Bcr-Abl positive M3.16 cells, which are rendered IL-3 independent by BCR-ABL gene expression. We have explored the involvement of Jak2 tyrosine phosphorylation in Ber-Abl oncogenic effects. Our results indicate that Jak2 became tyrosine-phosphorylated in a number of cell tines expressing Bcr-Abl, when maintained in medium lacking IL-3, whereas Bcr-Abl negative cells lacked Jak2 tyrosine phosphorylation. Jak2 was poorly tyrosine-phosphorylated in cells expressing the SH2 deletion mutant of Bcr-Abl compared to either wild-type Ber-Abl or its SH3 deletion mutant. Moreover, tyrosine phosphorylation of Jak2 by Bcr-Abl was inhibited by the Abl tyrosine kinase inhibitor, STI 571, in a dose-dependent manner. This inhibition of Bcr-Abl kinase by the drug did not interfere with the ability of Jak2 and Bcr-Abl to form a complex. Studies with deletion mutants of Ber-Abl indicated that the C-terminal domain of Abl within Bcr-Abl was involved in complex formation with Jak2. Similarly, GST-Abl pull-down assays confirmed the strong binding to Jak2 by the C-terminus of Abl. Jak2 peptide substrate studies indicated that the Bcr-Abl and Abl tyrosine kinases specifically phosphorylated Y1007 of Jak2 but only poorly phosphorylated Y1008. Phosphorylation of Y1007 of Jak2 is known to be critical for its tyrosine kinase activation. Tyrosine residue 1007 of Jak2 was phosphorylated in 32Dp210 cells as measured by Western blotting with a phosphotyrosine 1007 sequence-specific antibody. A kinase-inactive Jak2 mutant blocked the colony forming ability of K562 cells. Tumor formation of K562 cells in nude mice was similarly inhibited by this kinase-inactive Jak2 mutant. This inhibition was independent of Stat5 tyrosine phosphorylation. Furthermore, tyrosine-phosphorylated Jak2 was detected in blood cells from CML patients in blast crisis but not in a normal marrow sample. In summary, these findings provide strong evidence that the Jak2 tyrosine kinase is a critical factor in Bcr-Abl malignant transformation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.				NCI NIH HHS [CA 81398, CA 16672, CA 49639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049639, R01CA081398, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; GUO JQ, 1993, HEMATOL PATHOL, V7, P91; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Liu JX, 1996, CANCER RES, V56, P5120; LIU JX, 1993, ONCOGENE, V8, P101; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SIRARD C, 1994, BLOOD, V83, P1575; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TENHOEVE J, 1994, BLOOD, V84, P1731; Ward AC, 2000, BLOOD, V95, P19; Watanabe Sumiko, 1997, Leukemia (Basingstoke), V11, P76; WilsonRawls J, 1996, CANCER RES, V56, P3426; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828	29	110	113	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6188	6195		10.1038/sj.onc.1204834	http://dx.doi.org/10.1038/sj.onc.1204834			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593427				2022-12-28	WOS:000171206300010
J	David-Pfeuty, T; Nouvian-Dooghe, Y; Sirri, V; Roussel, P; Hernandez-Verdun, D				David-Pfeuty, T; Nouvian-Dooghe, Y; Sirri, V; Roussel, P; Hernandez-Verdun, D			Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells	ONCOGENE			English	Article						cyclin-dependent kinase 2; casein kinase II; wt p53; p21(WAFI CIPI); ribosomal RNA processing; untransformed and tumor-derived cells	CYCLIN-DEPENDENT KINASES; POLYMERASE-II TRANSCRIPTION; DNA-REPLICATION; S-PHASE; MAMMALIAN FIBROBLASTS; EPITHELIAL-CELLS; NUCLEAR-PROTEIN; PURINE ANALOGS; CDC28 MUTATION; CDK INHIBITORS	Two specific inhibitors of cyclin-dependent kinase 2 (Cdk2), roscovitine and olomoucine, have been shown recently to induce nuclear accumulation of wt p53 and nucleolar unravelling in interphase human untransformed IMR-90 and breast tumor-derived MCF-7 cells. Here, we show that the early response of MCF-7 cells to roscovitine is fully reversible since a rapid restoration of nucleolar organization followed by an induction of p21(WAF1/CIP1), a downregulation of nuclear wt p53 and normal cell cycle resumption occurs if the compound is removed after 4 h. Interestingly, similar reversible effects are also induced by the casein kinase II (CKII) inhibitor, 5,6-dichloro-1-beta -D-ribofuranosylbenzimidazole. Upon short-term treatment also, both compounds significantly, but reversibly, reduce the level of 45S precursor ribosomal RNA. Cells exposed to the two types of protein kinase inhibitors for longer times keep exhibiting altered nucleolar and wt p53 features, yet they strikingly differentiate in that most roscovitine-treated bells fail to ever accumulate high levels of p21(WAF1/CIP1) in contrast with DRB-treated ones. In both cases, however, the cells eventually fall into an irreversible state and die. Moreover, we found that constitutive overexpression of p21(WAF1/CIP1) alters the nucleolar unravelling process in the presence of DRB, but not of roscovitine, suggesting a role for this physiological Cdk inhibitor in the regulation of nucleolar function. Our data also support the notion that both roscovitine- and DRB-sensitive protein kinases, probably including Cdk2 and CKII, via their dual implication in the p53-Rb pathway and in ribosomal biogenesis, would participate in coupling cell growth with cell division.	Ctr Univ Orsay, CNRS, UMR 146, Inst Curie Rech, F-91405 Orsay, France; Inst Jacques Monod, UMR 7592, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	David-Pfeuty, T (corresponding author), Ctr Univ Orsay, CNRS, UMR 146, Inst Curie Rech, Batiment 110, F-91405 Orsay, France.	Therese.Pfeuty@curie.u-psud.fr						Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DavidPfeuty T, 1996, ONCOGENE, V13, P1447; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRANICK D, 1975, J CELL BIOL, V65, P418, DOI 10.1083/jcb.65.2.418; GRANICK D, 1975, J CELL BIOL, V65, P398, DOI 10.1083/jcb.65.2.398; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; HADJIOLOVA KV, 1993, EUR J BIOCHEM, V212, P211, DOI 10.1111/j.1432-1033.1993.tb17652.x; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1993, CELL, V75, P805; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Le Panse S, 1999, J CELL SCI, V112, P2145; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1994, ONCOGENE, V9, P2261; Linke SP, 1997, CANCER RES, V57, P1171; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Maniatis T., 1982, MOL CLONING; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NISHI K, 1994, J BIOL CHEM, V269, P6320; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Prives C, 1999, J PATHOL, V187, P112; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; ROUSSEL P, 1993, J CELL SCI, V104, P327; SCHEER U, 1984, J CELL BIOL, V99, P672, DOI 10.1083/jcb.99.2.672; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; WILSON GN, 1982, AM J HUM GENET, V34, P32; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	81	50	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					5951	5963		10.1038/sj.onc.1204741	http://dx.doi.org/10.1038/sj.onc.1204741			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593402				2022-12-28	WOS:000171056300002
J	Chernova, OB; Hunyadi, A; Malaj, E; Pan, HQ; Crooks, C; Roe, B; Cowell, JK				Chernova, OB; Hunyadi, A; Malaj, E; Pan, HQ; Crooks, C; Roe, B; Cowell, JK			A novel member of the WD-repeat gene family, WDR11, maps to the 10q26 region and is disrupted by a chromosome translocation in human glioblastoma cells	ONCOGENE			English	Article						brain tumors; gene cloning; WD40 repeat; translocation; chromosome 10	TUMOR-SUPPRESSOR GENE; MARINER TRANSPOSON; PROTEIN FAMILY; HUMAN GLIOMAS; LOW-GRADE; DELETION; BRAIN; SEQUENCE; 19Q; ASTROCYTOMAS	Allelic deletions of 10q25-26 and 19q13.3-13.4 are the most common genetic alterations in glial tumors. We have identified a balanced t(10;19) reciprocal translocation in the A172 glioblastoma cell line which involves both critical regions on chromosomes 10 and 19. In addition, loss of an entire copy of chromosome 10 has occurred in this cell line suggesting that the translocation event may provide a highly specific critical inactivating event in a gene responsible for tumorigenesis. Positional cloning of this translocation breakpoint resulted in the identification of a novel chromosome 10 gene, WDR11, which is a member of the WD-repeat gene family. The WDR11 gene is ubiquitously expressed, including normal brain and glial tumors. WDR11 is composed of 29 exons distributed over 58 kilobases and oriented towards the telomere. The translocation resulted in deletion of exon 5 and consequently fusion of intron 4 of WDR11 to the 3' untranslated region of a novel member, ZNF320, of the Kruppel-like zinc finger gene family. Since ZNF320 is oriented toward the centromere of chromosome 19, both genes appeared on the same derivative chromosome der(10). The chimeric transcript encodes the WDR11 polypeptide, which is truncated after the second of six WD-repeats. ZNF320 is also expressed in A172 cells, although it is not clear if the translocation affects the expression of the altered gene because of the presence of another unrearranged gene on chromosome 19. We suggest that, because of its localization in a region frequently showing LOH and the observation of inactivation of this gene in glioblastoma cells, WDR11 is a candidate gene for the frequently proposed tumor suppressor gene in 10q25-26 which is involved in tumorigenesis of glial and other tumors showing frequent alterations in the distal 10q region.	Cleveland Clin Fdn, Lerner Res Inst, Ctr Mol Genet, Cleveland, OH 44195 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	Cleveland Clinic Foundation; University of Oklahoma System; University of Oklahoma - Norman	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Koculi, Eda/0000-0001-9477-555X; Cowell, John/0000-0002-2079-5950; Pan, Huaqin/0000-0002-7166-108X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELLO MJ, 1995, INT J CANCER, V64, P207; Bodenteich A, 1993, AUTOMATED DNA SEQUEN, P42; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Carver EA, 1997, GENOME RES, V7, P1123, DOI 10.1101/gr.7.12.1123; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; Cheng Y, 1999, HUM PATHOL, V30, P1284, DOI 10.1016/S0046-8177(99)90057-6; Chernova O, 1998, CANCER GENET CYTOGEN, V105, P60, DOI 10.1016/S0165-4608(97)00479-2; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041; Dong JT, 1998, ONCOGENE, V17, P1979, DOI 10.1038/sj.onc.1202119; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Fujiwara Y, 2000, JPN J CANCER RES, V91, P287, DOI 10.1111/j.1349-7006.2000.tb00943.x; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; Herbst RA, 1999, ARCH DERMATOL RES, V291, P567, DOI 10.1007/s004030050456; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; KARLBOM AE, 1993, HUM GENET, V92, P169; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Kiyosawa H, 1996, HUM MOL GENET, V5, P745, DOI 10.1093/hmg/5.6.745; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu WG, 1997, CANCER RES, V57, P5254; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nagane Motoo, 1997, Current Opinion in Oncology, V9, P215, DOI 10.1097/00001622-199709030-00001; Nakamura M, 2000, J NEUROPATH EXP NEUR, V59, P539, DOI 10.1093/jnen/59.6.539; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; OHGAKI H, 1995, VIRCHOWS ARCH, V427, P113, DOI 10.1007/BF00196514; OOSUMI T, 1995, NATURE, V378, P672, DOI 10.1038/378672a0; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; Petersen S, 2000, INT J CANCER, V88, P71, DOI 10.1002/1097-0215(20001001)88:1<71::AID-IJC11>3.0.CO;2-X; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raff T, 1997, BIOTECHNIQUES, V23, P456, DOI 10.2144/97233st02; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Reiter LT, 1996, NAT GENET, V12, P288, DOI 10.1038/ng0396-288; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Robertson HM, 1997, GENE, V205, P219, DOI 10.1016/S0378-1119(97)00471-X; ROE BA, 1996, DNA ISOLATION SEQUEN; Rosenberg JE, 1996, ONCOGENE, V13, P2483; Saxena A, 1999, ONCOGENE, V18, P1385, DOI 10.1038/sj.onc.1202440; Shannon M, 1998, DNA SEQUENCE, V8, P303, DOI 10.3109/10425179809034075; SIPKINS SB, 1998, GYNECOL ONCOL, V3, P391; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Smith JS, 2000, GENE CHROMOSOME CANC, V29, P16, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1007>3.3.CO;2-9; Smith JS, 2000, FRONT BIOSCI-LANDMRK, V5, pD213, DOI 10.2741/Smith; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; Suminaga R, 2000, J HUM GENET, V45, P331, DOI 10.1007/s100380070003; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1994, CANCER RES, V54, P1397; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; Xu Y, 1994, Genet Eng (N Y), V16, P241; Yeh KT, 2000, CANCER INVEST, V18, P123, DOI 10.3109/07357900009038243	75	42	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5378	5392		10.1038/sj.onc.1204694	http://dx.doi.org/10.1038/sj.onc.1204694			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536051				2022-12-28	WOS:000170575500014
J	Reese, JS; Allay, E; Gerson, SL				Reese, JS; Allay, E; Gerson, SL			Overexpression of human O-6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice	ONCOGENE			English	Article						MGMT; p53; MNU; lymphomagenesis	TRANSGENIC MICE; N-METHYLNITROSOUREA; THYMIC LYMPHOMAS; KNOCKOUT MICE; HUMAN MGMT; GENE; MUTATIONS; EXPRESSION; REPAIR; TUMORS	O-6-alkylguanine DNA alkyltransferase (AGT) is a key mechanism in the prevention against MNU induced malignant transformation by removal of O-6 methyl guanine (O(6)mG) adducts. We asked whether heterozygous p53 deficient mice (p53+/-) would be more susceptible to MNU induced lymphomas than wild type mice, and whether O(6)mG adducts were responsible for this susceptibility. To determine whether MGMT overexpression would be protective, p53+/- mice were bred to human MGMT transgenic mice (MGMT+) and treated with 50 mg/kg MNU. MNU increased the incidence of thymic lymphomas in non-transgenic p53 + / - mice from 23% (n = 13) to 68% (n = 22) and decreased the mean latency from 433 to 106 days (P=0.01 compared to untreated mice). Wild type mice had an incidence of 30% (n = 38) and a mean latency of 135 days after MNU. Overexpression of MGMT in the thymus of p53 + / - mice significantly reduced the lymphoma incidence from 68 to 28% (n = 17) and increased the latency from 106 to 167 days (P=0.003). Similarly, the lymphoma incidence in MGMT + /wild type mice decreased from 30 to 8% (n = 12) and the latency increased to 297 days (P=0.2). Loss of the wild type allele was found in only 2/17 lymphomas occurring in p53 + / - mice and there were no significant point mutations in exons 5-8 of p53. Furthermore, there was no loss of p53 function in these mice. These data demonstrate that unrepaired O(6)mG lesions act cooperatively with the reduced p53 dose and lead to lymphomagenesis in p53+/- mice, but AGT overexpression and rapid removal of O(6)mG adducts is protective.	Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Div Hematol Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	Gerson, SL (corresponding author), Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, BRB-3,10900 Euclid Ave, Cleveland, OH 44106 USA.				NCI NIH HHS [CA63193] Funding Source: Medline; NIEHS NIH HHS [ES06288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allay E, 1999, ONCOGENE, V18, P3783, DOI 10.1038/sj.onc.1202697; Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; GOODROW TL, 1992, MOL CARCINOGEN, V5, P9; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LIU LL, 1994, CANCER RES, V54, P4648; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; NEALE GAM, 1995, BLOOD, V86, P3060; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Offer H, 2001, CANCER RES, V61, P88; Ohgaki H, 2000, MOL CARCINOGEN, V28, P97, DOI 10.1002/1098-2744(200006)28:2<97::AID-MC5>3.0.CO;2-O; PEGG AE, 1990, CANCER RES, V50, P6119; Qin XS, 1999, ONCOGENE, V18, P4394, DOI 10.1038/sj.onc.1202798; Qin XS, 1999, CARCINOGENESIS, V20, P1667, DOI 10.1093/carcin/20.9.1667; SAYLORS RL, 1991, CANCER RES, V51, P4721; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215	23	23	27	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5258	5263		10.1038/sj.onc.1204700	http://dx.doi.org/10.1038/sj.onc.1204700			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536039				2022-12-28	WOS:000170575500002
J	Tang, QB; Chen, WX; Gonzales, MS; Finch, J; Inoue, H; Bowden, GT				Tang, QB; Chen, WX; Gonzales, MS; Finch, J; Inoue, H; Bowden, GT			Role of cyclic AMP responsive element in the UVB induction of cyclooxygenase-2 transcription in human keratinocytes	ONCOGENE			English	Article						UVB; CREB; p38; COX-2; transcription	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATOR PROTEIN-1 ACTIVATION; SYNTHASE-2 GENE-EXPRESSION; MESSENGER-RNA STABILITY; GROWTH-FACTOR-ALPHA; COLON-CANCER CELLS; P38 MAP KINASE; NUCLEAR FACTOR; PHORBOL ESTER; ENDOTHELIAL-CELLS	It has been shown that UVB irradiation induces expression of COX-2 and up-regulation of COX-2 plays a functional role in UVB tumor promotion. In this study, we examined the cis-elements in the human COX-2 promoter that may be responsible for the UVB induction of COX-2. Analyses with the COX-2 promoter region revealed that the cyclic AMP responsive element near the TATA box was essential for both basal and UVB induced COX-2 expression. This was further supported by studies using a dominant negative mutant of CREB, which strongly inhibited the activity of COX-2 promoter. Electrophoretic mobility shift assays indicated that CREB and ATF-I were the major proteins binding to the COX-2 CRE. CREB and ATF-I were phosphorylated upon UVB treatment, and SB202190, a p38 MAPK inhibitor, decreased the phosphorylation of CREB/ATF-1 and suppressed COX-2 promoter activity. In contrast, treatment with forskolin, an activator of adenylyl cyclase, led to phosphorylation of CREB and ATF-I and activation of COX-2 promoter. Finally, enhanced binding of phospho-CREB/ATF-1 to the COX-2 CRE was observed after UVB induction. Thus, one signaling pathway for UVB induction of human COX-2 involves activation of p38, subsequent phosphorylation of CREB/ATF-1, and activation of the COX-2 CRE through enhanced binding of phosphorylated CREB/ATF-1.	Univ Arizona, Coll Med, Ctr Canc, Dept Radiat Oncol, Tucson, AZ 85724 USA; Natl Cardiovasc Ctr, Dept Pharmacol, Inst Res, Suita, Osaka 5658565, Japan	University of Arizona; National Cerebral & Cardiovascular Center - Japan	Bowden, GT (corresponding author), Univ Arizona, Coll Med, Ctr Canc, Dept Radiat Oncol, 1515 N Campbell Ave, Tucson, AZ 85724 USA.				NCI NIH HHS [CA27502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Boolbol SK, 1996, CANCER RES, V56, P2556; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; CHEN W, 2001, IN PRESS ONCOGENE; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 2000, MOL CARCINOGEN, V28, P196, DOI 10.1002/1098-2744(200008)28:4<196::AID-MC2>3.0.CO;2-C; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Harris RE, 1996, EPIDEMIOLOGY, V7, P203, DOI 10.1097/00001648-199603000-00017; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang M, 1998, CANCER RES, V58, P1208; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Isoherranen K, 1999, BRIT J DERMATOL, V140, P1017; Kam PCA, 2000, ANAESTHESIA, V55, P442, DOI 10.1046/j.1365-2044.2000.01271.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006-2952(99)00158-6; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; MOATTER T, 1992, J CELL PHYSIOL, V151, P571, DOI 10.1002/jcp.1041510317; Nusing RM, 1996, BIOCHEM J, V313, P617, DOI 10.1042/bj3130617; OBanion MK, 1996, J NEUROCHEM, V66, P2532; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA T, 1991, J BIOL CHEM, V266, P13621; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; Reddy BS, 1996, CANCER RES, V56, P4566; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Sheng HM, 1998, CANCER RES, V58, P362; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SMITH W, 1997, ADV EXP MED BIOL, P989; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Subbaramaiah K, 2000, CANCER RES, V60, P2399; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424	49	72	74	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5164	5172		10.1038/sj.onc.1204667	http://dx.doi.org/10.1038/sj.onc.1204667			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526505				2022-12-28	WOS:000170464000010
J	Ma, XR; Karra, S; Lindner, DJ; Hu, JB; Reddy, SPM; Kimchi, A; Yodoi, J; Kalvakolanu, DD				Ma, XR; Karra, S; Lindner, DJ; Hu, JB; Reddy, SPM; Kimchi, A; Yodoi, J; Kalvakolanu, DD			Thioredoxin participates in a cell death pathway induced by interferon and retinoid combination	ONCOGENE			English	Article						cytokines; vitamin-A; apoptosis; redox control; tumor growth	ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT PROTEIN-KINASE; MOLECULAR-CLONING; INDUCED APOPTOSIS; REDOX REGULATION; MAMMALIAN THIOREDOXIN; MEDIATED APOPTOSIS; CYTOCHROME-C; CYCLE ARREST; VITAMIN-A	Interferons (IFNs) and retinoids are potent tumor growth suppressors, We have shown earlier that the IFN-P and all-trans retinoic acid combination, but not the single agents, induces death in several tumor cell lines. Employing a genetic approach we have recently identified several Genes associated with Retinoid-IFN induced Mortality (GRIM) that mediate the cell death effect of IFN/RA combination. One of the GRIMs, GRIM-12, was identical to human thioredoxin reductase (TR), an enzyme that controls intracellular redox state. To define the participants of TR mediated death pathway we have examined the role of thioredoxin (Trx), its downstream substrate, and its influence on IFN/RA-induced death regulation. Inhibition of the thioredoxin expression by antisense RNA suppressed cell death. Similarly, a mutant Trx1 lacking the critical cysteine residues blocked cell death. In contrast, overexpression of wildtype thioredoxin augmented cell death. This effect of Trx1 was in part due to its ability to augment cell death via caspase-8, The redox inactive Trx1 mutant inhibits the cell death induced by caspase-8 but not caspase-3, These studies identify a novel mechanism of cell death regulation by IFN/RA combination involving redox enzymes.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Mol & Cellular Biol Program,Greenebaun Canc Ctr, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Sci, Baltimore, MD 21218 USA; Weizmann Inst Sci, Dept Mol Genet & Virol, IL-76100 Rehovot, Israel; Inst Virus Res, Dept Biol Responses, Shogin, Japan	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Weizmann Institute of Science	Kalvakolanu, DD (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Mol & Cellular Biol Program,Greenebaun Canc Ctr, Baltimore, MD 21201 USA.		Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 71401, CA 78282] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071401, R01CA078282] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; Gallegos A, 1996, CANCER RES, V56, P5765; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; PellicenaPalle A, 1997, MECH DEVELOP, V62, P61, DOI 10.1016/S0925-4773(96)00650-8; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SALZ HK, 1994, GENETICS, V136, P1075; Sen CK, 1999, CELL DEATH DIFFER, V6, P481, DOI 10.1038/sj.cdd.4400514; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun SY, 2000, CLIN CANCER RES, V6, P1563; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Ueda S, 1998, J IMMUNOL, V161, P6689; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang ZG, 1998, SCIENCE, V279, P1547; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	84	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3703	3715		10.1038/sj.onc.1204477	http://dx.doi.org/10.1038/sj.onc.1204477			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439333				2022-12-28	WOS:000169400200011
J	Dammann, R; Takahashi, T; Pfeifer, GP				Dammann, R; Takahashi, T; Pfeifer, GP			The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas	ONCOGENE			English	Article						RASSF1; methylation; CpG island; tumor suppressor gene; small cell lung cancer; 3p21	HUMAN-CHROMOSOME 3P21.3; ONCOGENIC RAS; DNA HYPERMETHYLATION; HOMOZYGOUS DELETIONS; DENOVO METHYLATION; ALLELIC LOSS; CANCER; LINES; 3P; APOPTOSIS	Loss of heterozygosity at 3p21.3 occurs in more than 90% of small cell lung carcinomas (SCLCs). The Ras association domain family 1 (RASSF1) gene cloned from the lung tumor suppressor locus 3p21.3 consists of two major alternative transcripts, RASSF1A and RASSF1C. Epigenetic inactivation of isoform A (RASSF1A) was observed in 40% of primary non-small cell lung carcinomas and in several tumor cell lines. Transfection of RASSF1A suppressed the growth of lung cancer cells in vitro and in nude mice. Here we have analysed the methylation status of the CPG island promoters of RASSF1A and RASSF1C in primary SCLCs. In 22 of 28 SCLCs (=79%) the promoter of RASSF1A was highly methylated at all CpG sites analysed, None of the SCLCs showed evidence for methylation of the CpG island of RASSF1C. The results suggest that hypermethylation of the CpG island promoter of the RASSF1A gene is associated with SCLC pathogenesis.	City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Aichi Canc Ctr, Inst Res, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	City of Hope; Beckman Research Institute of City of Hope; Aichi Cancer Center	Pfeifer, GP (corresponding author), City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.		Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Girard L, 2000, CANCER RES, V60, P4894; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lerman MI, 2000, CANCER RES, V60, P6116; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Palmisano WA, 2000, CANCER RES, V60, P5954; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; THIBERVILLE L, 1995, CANCER RES, V55, P5133; Todd S, 1997, CANCER RES, V57, P1344; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WAGNER SN, 1993, VIRCHOWS ARCH B, V63, P325, DOI 10.1007/BF02899279; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Wu WG, 1999, CANCER RES, V59, P1846; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; YAMAKAWA K, 1993, ONCOGENE, V8, P327; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	46	141	157	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3563	3567		10.1038/sj.onc.1204469	http://dx.doi.org/10.1038/sj.onc.1204469			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429703				2022-12-28	WOS:000169478300012
J	Kuppumbatti, YS; Rexer, B; Nakajo, S; Nakaya, K; Mira-y-Lopez, R				Kuppumbatti, YS; Rexer, B; Nakajo, S; Nakaya, K; Mira-y-Lopez, R			CRBP suppresses breast cancer cell survival and anchorage-independent growth	ONCOGENE			English	Article						FABP; soft agar; anoikis; retinol; retinoic acid	RETINOL-BINDING PROTEIN; EPITHELIAL-CELLS; CARCINOMA CELLS; LIPID BODIES; ACID; APOPTOSIS; GENE; EXPRESSION; INHIBITION; TISSUE	We showed earlier that cellular retinol-binding protein (CRBP) expression is downregulated in a subset of human breast cancers. We have now investigated the outcome of ectopic CRBP expression in MTSV1-7 cells, a SV40 T antigen-transformed human breast epithelial cell line devoid of endogenous CRBP expression. We found that: (i) CRBP did not inhibit adherent cell growth but suppressed foci formation in post-confluent cultures and colony formation in soft agar; (ii) this effect was due to CRBP inhibition of cell survival, as demonstrated by viability and TUNEL assays of cells in soft-agar or plated on polyHEMA-coated dishes; (iii) CRBP inhibited protein kinase B/Akt activation in cells in suspension but not in adherent cells and the CRBP suppression of anchorage-independent growth was mimicked by cell treatment with the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002; (iv) CRBP enhanced retinyl ester formation and storage but did not regulate retinoic acid synthesis or retinoic acid receptor activity. Ectopic CRBP-mediated inhibition of anchorage-independent cell survival and colony formation in the absence of significantly altered responses to either retinol or retinoic acid was also documented in T47D human breast cancer cells. In conclusion, the data suggest two novel and linked CRBP functions in mammary epithelial cells: inhibition of the PI3K/Akt survival pathway and suppression of anchorage-independent growth.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Tokyo 142, Japan	Icahn School of Medicine at Mount Sinai; Vanderbilt University; Showa University	Kuppumbatti, YS (corresponding author), Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [CA54273] Funding Source: Medline; NICHD NIH HHS [5T32HD07043] Funding Source: Medline; NIDDK NIH HHS [R01DK32642] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007043] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA054273, R29CA054273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; BUSCH C, 1990, METHOD ENZYMOL, V189, P315; Chang TH, 2000, CANCER RES, V60, P1129; DAWSON MI, 1995, CANCER RES, V55, P4446; Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; HUYNH HT, 1995, CANCER RES, V55, P2225; Jing YK, 1997, CANCER RES, V57, P1668; Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475; Li GY, 1999, CANCER RES, V59, P6267; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; PAPPAS RS, 1993, BIOL REPROD, V48, P235, DOI 10.1095/biolreprod48.2.235; Ruff SJ, 2000, FEBS LETT, V487, P282, DOI 10.1016/S0014-5793(00)02366-8; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sapi E, 1999, CANCER RES, V59, P5578; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Shi YE, 1997, CANCER RES, V57, P3084; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; Wang HL, 2000, ONCOGENE, V19, P2455, DOI 10.1038/sj.onc.1203575; Yamamoto M, 1998, EUR J BIOCHEM, V257, P344, DOI 10.1046/j.1432-1327.1998.2570344.x; Yu WG, 1998, AM J PATHOL, V152, P759; Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085	31	39	40	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7413	7419		10.1038/sj.onc.1204749	http://dx.doi.org/10.1038/sj.onc.1204749			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704871				2022-12-28	WOS:000171894200014
J	de The, H; Chelbi-Alix, MK				de The, H; Chelbi-Alix, MK			APL, a model disease for cancer therapies?	ONCOGENE			English	Article						leukemia; PML/RAR alpha; differentiation; apoptosis; arsenic; retinoic acid	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID; RAR-ALPHA; HISTONE DEACETYLASE; INTERACTING PROTEIN; NUCLEAR-BODIES; PML; APOPTOSIS; DAXX; NB4		Hop St Louis, CNRS UPR 9051, F-75475 Paris 10, France; Inst Andre Lwoff, CNRS UPR 9045, F-94801 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	de The, H (corresponding author), Hop St Louis, CNRS UPR 9051, 1 Ave C Vellefaux, F-75475 Paris 10, France.	dethe@jupiter.chu-stlouis.fr; mchelbi@infobiogen.fr						Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; de The G., 1960, B ASSOC FR ETUD CANC, V47, P570; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LANOTTE M, 1991, BLOOD, V77, P1080; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Quignon F, 1997, BBA-REV CANCER, V1333, pM53, DOI 10.1016/S0304-419X(97)00025-5; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; TERRIS B, 1995, CANCER RES, V55, P1590; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	26	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7136	7139		10.1038/sj.onc.1204851	http://dx.doi.org/10.1038/sj.onc.1204851			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704841				2022-12-28	WOS:000171891900001
J	Seeler, JS; Dejean, A				Seeler, JS; Dejean, A			SUMO: of branched proteins and nuclear bodies	ONCOGENE			English	Article						SUMO/Sentrin; ubiquitin; PML; SP100; Ubc9	UBIQUITIN-LIKE PROTEIN; GTPASE-ACTIVATING PROTEIN; ACUTE PROMYELOCYTIC LEUKEMIA; COVALENT MODIFICATION; MODIFIER SUMO-1; PORE COMPLEX; UBC9 INTERACTS; GENE ENCODES; PML; CONJUGATION	SUMO belongs to a growing number of ubiquitin-like proteins that covalently modify their target proteins. Although some evidence supports a role of SUMO modification in regulating protein stability, most studied examples support a model by which SUMO alters the interaction properties of its targets, often affecting their subcellular localization behavior. Examination of the PML nuclear bodies, whose principal components are SUMO-modified, has revealed this modification to be essential for their structural and functional integrity. This and other examples thus support the view that SUMO regulates the stability not of individual proteins, but rather that of entire multiprotein complexes.	Inst Pasteur, INSERM U 163, Unite Recombust & Express Genet, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Dejean, A (corresponding author), Inst Pasteur, INSERM U 163, Unite Recombust & Express Genet, 28 Rue Dr Roux, F-75724 Paris 15, France.		Dejean, Anne/L-5145-2018	Seeler, Jacob-Sebastian/0000-0001-8209-8555				Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; Ahn JH, 2001, J VIROL, V75, P3859, DOI 10.1128/JVI.75.8.3859-3872.2001; ALKHODAIRY F, 1995, J CELL SCI, V108, P475; Apionishev S, 2001, GENES CELLS, V6, P215, DOI 10.1046/j.1365-2443.2001.00413.x; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bhaskar V, 2000, J BIOL CHEM, V275, P4033, DOI 10.1074/jbc.275.6.4033; Boddy MN, 1996, ONCOGENE, V13, P971; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; GOODSON ML, 2001, J BIOL CHEM, V15, P15; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Guldner HH, 1999, J CELL SCI, V112, P733; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Long XM, 2000, J BIOL CHEM, V275, P40765, DOI 10.1074/jbc.M003949200; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muller S, 1999, J VIROL, V73, P5137; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Okura T, 1996, J IMMUNOL, V157, P4277; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rangasamy D, 2000, J BIOL CHEM, V275, P37999, DOI 10.1074/jbc.M007777200; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; RODRIGUEZ MS, 2000, J BIOL CHEM, V21, P21; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	84	133	133	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7243	7249		10.1038/sj.onc.1204758	http://dx.doi.org/10.1038/sj.onc.1204758			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704852				2022-12-28	WOS:000171891900012
J	Zelent, A; Guidez, F; Melnick, A; Waxman, S; Licht, JD				Zelent, A; Guidez, F; Melnick, A; Waxman, S; Licht, JD			Translocations of the RAR alpha gene in acute promyelocytic leukemia	ONCOGENE			English	Review						PLZF; NuMA; NPM; STAT; differentiation; retinoic acid	ACID RECEPTOR-ALPHA; MITOTIC APPARATUS PROTEIN; PML-RETINOIC ACID; POLYMERASE-CHAIN-REACTION; ZINC-FINGER GENE; MINIMAL RESIDUAL DISEASE; NUCLEAR-MATRIX PROTEINS; FUSION PROTEIN; DNA-BINDING; TRANSCRIPTIONAL REPRESSION	Acute promyelocytic leukemia (APL) has been recognized as a distinct clinical entity for over 40 years. Although relatively rare among hematopoietic malignancies (approximately 10% of AML cases), this disease has attracted a particularly good share of attention by becoming the first human cancer in which all-trans-retinoic acid (ATRA), a physiologically active derivative of vitamin A, was able to induce complete remission (CR). ATRA induced remission is not associated with rapid cell death, as in the case of conventional chemotherapy, but with a restoration of the 'normal' granulocytic differentiation pathway. With this remarkable medical success story APL has overnight become a paradigm for the differentiation therapy of cancer. A few years later, excitement with APL was further enhanced by the discovery that a cytogenetic marker for this disease, the t(15:17) reciprocal chromosomal translocation, involves a fusion between the retinoic acid receptor alpha (RAR alpha) gene and a previously unknown locus named promyelocytic leukemia (PML). Consequence of this gene rearrangement is expression of the PML-RAR alpha chimeric oncoprotein, which is responsible for the cellular transformation as well as ATRA response that is observed in APL. Since this initial discovery, a number of different translocation partner genes of RAR alpha have been reported in rarer cases of APL, strongly suggesting that disruption of RAR alpha underlies its pathogenesis. This article reviews various rearrangements of the RAR alpha gene that have so far been described in literature, functions of the proteins encoded by the different RAR alpha partner loci, and implications that these may have for the molecular pathogenesis of APL.	Inst Canc Res, Leukaemia Res Fund Ctr, Chester Beatty Labs, London SW3 6JB, England; Mt Sinai Med Ctr, Dept Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Mt Sinai Med Ctr, Dept Med, Div Med Oncol, New York, NY 10029 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Zelent, A (corresponding author), Inst Canc Res, Leukaemia Res Fund Ctr, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.	a.zelent@icr.ac.uk	Melnick, Ari/AAA-5763-2020; Licht, Jonathan/AAL-9184-2020; Guidez, Fabien/B-3750-2009; Licht, Jonathan/L-4239-2019; Guidez, Fabien/P-4220-2019; Zelent, Arthur/B-3532-2009	Licht, Jonathan/0000-0002-3942-1369; Guidez, Fabien/0000-0003-1380-4473; Zelent, Arthur/0000-0002-7968-9888	NATIONAL CANCER INSTITUTE [R01CA059936, K08CA073762] Funding Source: NIH RePORTER; NCI NIH HHS [KO8 CA73762, CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Al-Omar H. M., 1997, Blood, V90, p207B; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORROW J, 1994, GENE CHROMOSOME CANC, V9, P234, DOI 10.1002/gcc.2870090403; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; CHAN PK, 1995, BBA-GENE STRUCT EXPR, V1262, P37, DOI 10.1016/0167-4781(95)00044-H; Chan PK, 1999, BIOCHEM PHARMACOL, V57, P1265, DOI 10.1016/S0006-2952(99)00043-X; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHAN PK, 1987, CANCER RES, V47, P3798; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; CHEN SJ, 1992, ONCOGENE, V7, P1223; CHEN SJ, 1991, BLOOD, V78, P2696; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Chou CC, 2001, MOL PHARMACOL, V59, P38, DOI 10.1124/mol.59.1.38; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; COMPTON DA, 1994, CURR OPIN CELL BIOL, V6, P343, DOI 10.1016/0955-0674(94)90024-8; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; COREY SJ, 1994, LEUKEMIA, V8, P1350; Culligan DJ, 1998, BRIT J HAEMATOL, V100, P328, DOI 10.1046/j.1365-2141.1998.00575.x; DANIEL MT, 1993, BLOOD, V82, P1858; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DERENZINI M, 1995, LAB INVEST, V73, P497; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dionne MA, 1999, CELL MOTIL CYTOSKEL, V42, P189, DOI 10.1002/(SICI)1097-0169(1999)42:3<189::AID-CM3>3.0.CO;2-X; DIVERIO D, 1992, BLOOD, V79, P3331; Diverio D, 1998, BLOOD, V92, P784; Dong F, 1998, J IMMUNOL, V161, P6503; Dong S, 2000, BLOOD, V96, p457A; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fenaux Pierre, 1996, Current Opinion in Oncology, V8, P3, DOI 10.1097/00001622-199601000-00002; Ferbeyre G, 2000, GENE DEV, V14, P2015; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; FUKUTANI H, 1995, LEUKEMIA, V9, P1478; GALLAGHER RE, 1995, BLOOD, V86, P1540, DOI 10.1182/blood.V86.4.1540.bloodjournal8641540; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Glass CK, 2000, GENE DEV, V14, P121; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gordon MB, 2001, J CELL BIOL, V152, P425, DOI 10.1083/jcb.152.3.425; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 2000, BLOOD, V96, P1297; Grimwade D, 1997, BLOOD, V90, P4876; GuethHallonet C, 1997, EXP CELL RES, V233, P21, DOI 10.1006/excr.1997.3557; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Harborth J, 2000, J BIOL CHEM, V275, P31979, DOI 10.1074/jbc.M000994200; Harborth J, 1999, EMBO J, V18, P1689, DOI 10.1093/emboj/18.6.1689; HARBORTH J, 1995, EMBO J, V14, P2447, DOI 10.1002/j.1460-2075.1995.tb07242.x; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; He D, 1995, INT REV CYTOL, V162B, P1; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HERNANDEZVERDUN D, 1982, CHROMOSOMA, V85, P461, DOI 10.1007/BF00327343; HIORNS LR, 1994, BLOOD, V83, P2946, DOI 10.1182/blood.V83.10.2946.2946; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hsu CY, 1998, ONCOGENE, V16, P915, DOI 10.1038/sj.onc.1201615; Hsu CY, 2000, INT J CANCER, V88, P392, DOI 10.1002/1097-0215(20001101)88:3<392::AID-IJC11>3.0.CO;2-7; Hsu HL, 1996, J CELL SCI, V109, P277; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Ivins S, 1998, BLOOD, V92, p308A; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; Jiang PS, 1999, BIOCHEM BIOPH RES CO, V257, P865, DOI 10.1006/bbrc.1999.0551; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kane JR, 1996, LEUKEMIA, V10, P1296; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; KEMPF T, 1994, FEBS LETT, V354, P307, DOI 10.1016/0014-5793(94)01151-6; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kieslinger M, 2000, GENE DEV, V14, P232; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li XM, 1999, CANCER RES, V59, P5275; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Li YP, 1997, BLOOD, V90, P306; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Liu WH, 1999, INT J CANCER, V83, P765, DOI 10.1002/(SICI)1097-0215(19991210)83:6<765::AID-IJC12>3.0.CO;2-J; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; MAEKAWA T, 1993, J CELL SCI, V105, P589; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matikainen S, 1996, BLOOD, V88, P114; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; McConnell MJ, 2000, BLOOD, V96, p457A; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MILLER WH, 1993, BLOOD, V82, P1689; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAKAMAKI T, 1994, ANTICANCER RES, V14, P817; Neves H, 1999, BLOOD, V93, P1197, DOI 10.1182/blood.V93.4.1197.404k33_1197_1207; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; OLSON MOJ, 1974, J BIOL CHEM, V249, P2823; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; REDNER R, 1996, BLOOD, V10, pA551; Redner RL, 2000, BLOOD, V95, P2683; Redner RL, 1997, LEUKEMIA, V11, P1014, DOI 10.1038/sj.leu.2400661; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; ROWLEY JD, 1977, LANCET, V1, P549; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Ruthardt M, 1998, ONCOGENE, V16, P1945, DOI 10.1038/sj.onc.1201722; Sainty D, 2000, BLOOD, V96, P1287; Saredi A, 1997, J CELL SCI, V110, P1287; Saredi A, 1996, J CELL SCI, V109, P619; SCOTT AA, 1994, BLOOD, V84, P244; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Sirri V, 1997, CYTOMETRY, V28, P147, DOI 10.1002/(SICI)1097-0320(19970601)28:2<147::AID-CYTO8>3.3.CO;2-G; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Slack JL, 1997, J CLIN ONCOL, V15, P1786, DOI 10.1200/JCO.1997.15.5.1786; SMETANA K, 1984, EXP CELL RES, V152, P195, DOI 10.1016/0014-4827(84)90244-1; So CW, 2000, LEUKEMIA, V14, P77, DOI 10.1038/sj.leu.2401643; SPARKS CA, 1993, GENOMICS, V17, P222, DOI 10.1006/geno.1993.1307; Stadler M, 1995, ONCOGENE, V11, P2565; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; TANG TK, 1994, J CELL SCI, V107, P1389; TANG TK, 1993, J CELL SCI, V104, P249; TASHIRO S, 1994, ONCOGENE, V9, P1939; TAWFIC S, 1995, J BIOL CHEM, V270, P21009, DOI 10.1074/jbc.270.36.21009; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TERRIS B, 1995, CANCER RES, V55, P1590; TSUTSUI K, 1993, J BIOL CHEM, V268, P12886; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Waxman S, 1999, BLOOD, V94, p61A; WAXMAN S, 1978, LEUKEMIA CELL, P169; Wells RA, 1996, LEUKEMIA, V10, P735; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YANG CH, 1992, MOL BIOL CELL, V3, P1259, DOI 10.1091/mbc.3.11.1259; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; YonedaKato N, 1996, ONCOGENE, V12, P265; YOSHIDA H, 1995, GENE CHROMOSOME CANC, V12, P37, DOI 10.1002/gcc.2870120107; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1985, BIOCHEM PHARMACOL, V34, P4059, DOI 10.1016/0006-2952(85)90387-9; Zatsepina OV, 1999, J CELL SCI, V112, P455; Zelent A, 2001, NAT MED, V7, P662, DOI 10.1038/89031; ZENG CQ, 1994, CELL MOTIL CYTOSKEL, V29, P167, DOI 10.1002/cm.970290208; ZHU J, 2001, IN PRESS BLOOD; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Zweyer M, 1997, EXP CELL RES, V230, P325, DOI 10.1006/excr.1996.3415	211	162	168	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7186	7203		10.1038/sj.onc.1204766	http://dx.doi.org/10.1038/sj.onc.1204766			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704847				2022-12-28	WOS:000171891900007
J	Bhandari, P; Shashidhara, LS				Bhandari, P; Shashidhara, LS			Studies on human colon cancer gene APC by targeted expression in Drosophila	ONCOGENE			English	Article						colorectal cancer; APC; beta-catenin; drug screening; transgenic Drosophila	LONG-RANGE ACTION; BETA-CATENIN; ADENOMATOUS POLYPOSIS; MORPHOGENETIC FURROW; ADULT ABDOMEN; CELL FATES; WINGLESS; EYE; PROTEIN; ARMADILLO	Mutations in human Adenomatous Polyposis Coli (APC) gene are associated with both familial and sporadic colorectal tumors. APC is known to down regulate beta -catenin levels, a transducer of Wnt signaling. The aim of this study is to provide transgenic Drosophila expressing either full-length or truncated forms of human APC (hAPC) protein and methods for using them in functional,genomics and drug screening. Consistent with its biochemical properties, targeted expression of either full-length hAPC or its beta -catenin binding domain alone negatively regulated the function of the beta -catenin homologue, Armadillo (Arm) and thereby, inhibited Wnt/Wg signaling during fly development. hAPC inhibited Arm function even in the absence of GSK-3 beta activity, although the latter was required to mediate the degradation of Arm. Consistent with this, hAPC suppressed the phenotypes induced by the over-expression of degradation-resistant forms of Arm. Subsequently, using hAPC-induced eye phenotypes as the assay in a suppressor-enhancer screen, we have identified two new loci in Drosophila, which modulate Wnt/Wg signaling. In addition, an anti-colon cancer drug, indomethacin, specifically enhanced hAPC-induced phenotypes.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Shashidhara, LS (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	shashi@gene.ccmbindia.org						Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; Deshpande N, 1997, J BIOL CHEM, V272, P10664; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fossgreen A, 1998, P NATL ACAD SCI USA, V95, P13703, DOI 10.1073/pnas.95.23.13703; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Friedl W, 1996, HUM GENET, V97, P579; GHYSEN A, 1989, DEVELOPMENT, V105, P35; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; Hazelett DJ, 1998, DEVELOPMENT, V125, P3741; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kopp A, 1999, DEVELOPMENT, V126, P3495; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARDON G, 1994, DEVELOPMENT, V120, P3473; Morimura S, 1996, DEV BIOL, V177, P136, DOI 10.1006/dbio.1996.0151; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Pai LM, 1997, DEVELOPMENT, V124, P2255; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Pignoni F, 1997, DEVELOPMENT, V124, P271; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Scott RJ, 1996, HUM MOL GENET, V5, P1921, DOI 10.1093/hmg/5.12.1921; Shashidhara LS, 1999, DEV BIOL, V212, P491, DOI 10.1006/dbio.1999.9341; Shih IM, 2000, CANCER RES, V60, P1671; Shirras AD, 1996, DEV BIOL, V175, P24, DOI 10.1006/dbio.1996.0092; SIMMONDS AJ, 1995, NATURE, V376, P424, DOI 10.1038/376424a0; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Steitz MC, 1998, DEV BIOL, V197, P218, DOI 10.1006/dbio.1998.8884; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thomas BI, 1999, TRENDS GENET, V15, P184, DOI 10.1016/S0168-9525(99)01720-5; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu J, 1999, DEVELOPMENT, V126, P109; Yamaguchi M, 1999, ONCOGENE, V18, P6767, DOI 10.1038/sj.onc.1203113; YOFFE KB, 1995, DEV BIOL, V170, P636, DOI 10.1006/dbio.1995.1243; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	57	16	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6871	6880		10.1038/sj.onc.1204849	http://dx.doi.org/10.1038/sj.onc.1204849			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687966				2022-12-28	WOS:000171641000008
J	Kim, KC; Kim, TS; Kang, KH; Choi, KH				Kim, KC; Kim, TS; Kang, KH; Choi, KH			Amphiphysin IIb-1, a novel splicing variant of amphiphysin II, regulates p73 beta function through protein-protein interactions	ONCOGENE			English	Article						p73; amphiphysin IIb-1; SH3 domain; NLS; yeast two-hybrid; splicing variants	KINASE C-ABL; TYROSINE KINASE; DNA-DAMAGE; APOPTOTIC RESPONSE; ADENOVIRUS TYPE-5; INDUCE APOPTOSIS; MAMMALIAN-CELLS; 3-HYBRID SYSTEM; E4ORF6 PROTEINS; BREAST-CANCER	p73 is a nuclear protein that is similar in structure and function to p53. Notably, the C-terminal region of p73 has a regulatory function, through interactions with a positive or negative regulator. In this study, we use the yeast two-hybrid technique to identify a novel p73 beta binding protein, designated amphiphysin IIb-1. Amphiphysin IIb-1 is one of the splicing variants of amphiphysin II, and has a shorter protein product than amphiphysin IIb, which has been previously reported. We confirmed that amphiphysin IIb-1 binds full-length p73 beta, both in vitro and in vivo. This association is mediated via the SH3 domain of amphiphysin IIb-1 and C-terminal amino acids 321-376 of p73 beta. Double immunofluorescence patterns revealed that p73 beta is relocalized to the cytoplasm in the presence of amphiphysin IIb-1. Overexpression of amphiphysin IIb-1 was found to significantly inhibit the transcriptional activity of p73 beta in a dose-dependent manner. In addition, the cell death function of p73 beta was inhibited by amphiphysin IIb-1. These findings offer a new insight into the regulation mechanism of p73 beta, and suggest that amphiphysin IIb-1 modulates p73 beta function by direct binding.	Chung Ang Univ, Coll Nat Sci, Dept Biol, Mol Biol Lab,Dongjak Ku, Seoul 156756, South Korea	Chung Ang University	Choi, KH (corresponding author), Chung Ang Univ, Coll Nat Sci, Dept Biol, Mol Biol Lab,Dongjak Ku, Heuksuk Dong, Seoul 156756, South Korea.							Agami R, 1999, NATURE, V399, P809; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Ge K, 2000, GENOMICS, V67, P210, DOI 10.1006/geno.2000.6216; Gong JG, 1999, NATURE, V399, P806; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; Kleihues P, 1997, AM J PATHOL, V150, P1; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; MARTIN MC, 1998, MOL CELL BIOL, V18, P6316; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Ozaki T, 1999, CANCER RES, V59, P5902; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	44	12	12	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6689	6699		10.1038/sj.onc.1204839	http://dx.doi.org/10.1038/sj.onc.1204839			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709703				2022-12-28	WOS:000171551600005
J	Feller, SM				Feller, SM			Crk family adaptors - signalling complex formation and biological roles	ONCOGENE			English	Review						v-Crk; c-Crk; CRKL; SH2; SH3	EPIDERMAL-GROWTH-FACTOR; ABL TYROSINE KINASE; T-CELL-RECEPTOR; NUCLEOTIDE EXCHANGE FACTOR; TERMINAL SH3 DOMAIN; HEMATOPOIETIC PROGENITOR KINASE-1; FOCAL ADHESION KINASE; SRC HOMOLOGY-3 DOMAIN; DNA-BINDING DOMAIN; SMALL GTPASE RAP1	Crk family adaptors are widely expressed and mediate the timely formation of signal transduction protein complexes upon a variety of extracellular stimuli, including various growth and differentiation factors. Selective formation of multi-protein complexes by the Crk and Crk-like (CRKL) proteins depends on specific motifs recognized by their SH2 and SH3 domains. In the case of the first SH3 domains [SH3(1)] a P-x-x-P-x-K motif is crucial for highly selective binding, while the SH2 domains prefer motifs which conform to the consensus pY-x-x-P. Crk family proteins are involved in the relocalization and activation of several different effector proteins which include guanine nucleotide releasing proteins like C3G, protein kinases of the Abl- and GCK-families and small GTPases like Rap1 and Rac. Crk-type proteins have been found not only in vertebrates but also in flies and nematodes. Major insight into the function of Crk within organisms came from the genetic model organism C. elegans, where the Crk-homologue CED-2 regulates cell engulfment and phagocytosis. Other biological outcomes of the Crk-activated signal transduction cascades include the modulation of cell adhesion, cell migration and immune cell responses. Crk family adaptors also appear to play a role in mediating the action of human oncogenes like the leukaemia-inducing Bcr-Abl protein. This review summarizes some key findings and highlights recent insights and open questions.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund,Cell Signalling Lab, Oxford OX3 9DS, England	University of Oxford	Feller, SM (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund,Cell Signalling Lab, Oxford OX3 9DS, England.	S.Feller@icrf.icnet.uk						Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; Andoniou CE, 1996, ONCOGENE, V12, P1981; Anneren C, 2000, J BIOL CHEM, V275, P29153, DOI 10.1074/jbc.M003926200; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; Bevan P, 2001, J CELL SCI, V114, P1429; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Blelloch R, 1999, CURR OPIN CELL BIOL, V11, P608, DOI 10.1016/S0955-0674(99)00028-9; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Bork P, 1997, TRENDS BIOCHEM SCI, V22, P296, DOI 10.1016/S0968-0004(97)01084-0; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brauweiler AM, 2000, IMMUNOL REV, V176, P69; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Brown A, 2000, ONCOGENE, V19, P3032, DOI 10.1038/sj.onc.1203619; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Buensuceso CS, 2000, J BIOL CHEM, V275, P13118, DOI 10.1074/jbc.275.17.13118; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Butler AA, 1997, J BIOL CHEM, V272, P27660, DOI 10.1074/jbc.272.44.27660; Cai DP, 1999, J IMMUNOL, V163, P2104; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CARY LA, 1999, FRONT BIOSCI, V4, P102; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; Chung SB, 2000, NAT CELL BIOL, V2, P931, DOI 10.1038/35046585; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Cody WL, 2000, CURR PHARM DESIGN, V6, P59, DOI 10.2174/1381612003401532; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; Czyzyk J, 2000, MOL CELL BIOL, V20, P8740, DOI 10.1128/MCB.20.23.8740-8747.2000; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Di Cunto F, 2000, NEURON, V28, P115, DOI 10.1016/S0896-6273(00)00090-8; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Du J, 2000, J BIOL CHEM, V275, P33167, DOI 10.1074/jbc.M003655200; Dubiel W, 1999, CURR BIOL, V9, pR554, DOI 10.1016/S0960-9822(99)80353-4; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Erdreich-Epstein A, 1997, EXP CELL RES, V237, P288, DOI 10.1006/excr.1997.3795; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; FUKUI Y, 1989, ONCOGENE RES, V4, P283; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Galletta BJ, 1999, GENE, V228, P243, DOI 10.1016/S0378-1119(99)00010-4; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; Gelkop S, 1999, J BIOL CHEM, V274, P21519, DOI 10.1074/jbc.274.31.21519; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; Grumbach IM, 2001, BRIT J HAEMATOL, V112, P327, DOI 10.1046/j.1365-2141.2001.02556.x; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; Gupta N, 1999, J BIOL CHEM, V274, P7489, DOI 10.1074/jbc.274.11.7489; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hansen K, 1997, FEBS LETT, V409, P195, DOI 10.1016/S0014-5793(97)00495-X; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Hemmeryckx B, 2001, CANCER RES, V61, P1398; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hunter AJ, 1997, J IMMUNOL, V159, P4806; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; Imaizumi T, 1999, BIOCHEM BIOPH RES CO, V266, P569, DOI 10.1006/bbrc.1999.1869; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Ito Y, 2001, J BIOL CHEM, V276, P18130, DOI 10.1074/jbc.M007294200; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Izadi KD, 1998, EXP CELL RES, V245, P330, DOI 10.1006/excr.1998.4259; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jin SH, 2000, J BIOL CHEM, V275, P34344, DOI 10.1074/jbc.M004927200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; KARDINAL C, 2001, IN PRESS BLOOD; Katayama H, 1999, JPN J CANCER RES, V90, P1096, DOI 10.1111/j.1349-7006.1999.tb00683.x; Khwaja A, 1996, ONCOGENE, V12, P2491; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kobayashi S, 2001, BIOCHEM J, V354, P73, DOI 10.1042/0264-6021:3540073; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kolibaba KS, 1999, LEUKEMIA LYMPHOMA, V33, P119, DOI 10.3109/10428199909093732; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Koval AP, 1998, BIOCHEM J, V330, P923; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Larsson H, 1999, J BIOL CHEM, V274, P25726, DOI 10.1074/jbc.274.36.25726; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Lin HM, 2001, INT IMMUNOL, V13, P13, DOI 10.1093/intimm/13.1.13; Ling P, 1999, MOL CELL BIOL, V19, P1359; Ling P, 2001, J BIOL CHEM, V276, P18908, DOI 10.1074/jbc.M101485200; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu EB, 2000, CANCER RES, V60, P2361; Liu QA, 1999, ANN NY ACAD SCI, V887, P92, DOI 10.1111/j.1749-6632.1999.tb07925.x; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; Liu SKW, 2001, ONCOGENE, V20, P6284, DOI 10.1038/sj.onc.1204771; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Lu LG, 2000, EXP CELL RES, V259, P370, DOI 10.1006/excr.2000.4984; Lucas DM, 1999, BLOOD, V93, P1922, DOI 10.1182/blood.V93.6.1922.406k21_1922_1933; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Madaule P, 2000, MICROSC RES TECHNIQ, V49, P123, DOI 10.1002/(SICI)1097-0029(20000415)49:2<123::AID-JEMT3>3.0.CO;2-R; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maru Y, 1996, EXP CELL RES, V229, P438, DOI 10.1006/excr.1996.0389; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; May RC, 2001, TRENDS CELL BIOL, V11, P55, DOI 10.1016/S0962-8924(00)01915-2; Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; Nagata Y, 1999, BLOOD, V93, P3347, DOI 10.1182/blood.V93.10.3347.410k06_3347_3354; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Nguyen JT, 2000, CHEM BIOL, V7, P463, DOI 10.1016/S1074-5521(00)00130-7; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; NICHOLS GL, 1994, BLOOD, V84, P2912; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Nishihara H, 1999, BBA-MOL CELL RES, V1452, P179, DOI 10.1016/S0167-4889(99)00133-0; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Norian LA, 2000, SEMIN IMMUNOL, V12, P43; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Oda A, 2000, BIOCHEM BIOPH RES CO, V278, P299, DOI 10.1006/bbrc.2000.3803; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; ODA T, 1994, J BIOL CHEM, V269, P22925; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; OEHRL W, 1997, THESIS U WURZBURG GE; OGAWA S, 1994, ONCOGENE, V9, P1669; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Okada S, 1997, J BIOL CHEM, V272, P28179, DOI 10.1074/jbc.272.45.28179; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Ota J, 1998, BIOCHEM BIOPH RES CO, V252, P779, DOI 10.1006/bbrc.1998.9445; Ozaki K, 1998, BLOOD, V92, P4652; Park RK, 1999, BLOOD, V94, P2112; Parrini MC, 1999, CHEM BIOL, V6, P679, DOI 10.1016/S1074-5521(00)80015-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 2000, GENE DEV, V14, P1027; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Pohl E, 1999, J MOL BIOL, V292, P653, DOI 10.1006/jmbi.1999.3073; Posern G, 2000, ONCOGENE, V19, P6361, DOI 10.1038/sj.onc.1204027; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Riordan SM, 2000, BIOCHEM J, V350, P925, DOI 10.1042/0264-6021:3500925; Rohrschneider LR, 2000, GENE DEV, V14, P505; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAKAI R, 1994, J BIOL CHEM, V269, P32740; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; SAKKAB D, 2001, SIGNAL TRANSDUCT, V1, pS25; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1996, ONCOGENE, V12, P839; SATTLER M, 2001, J BIOL CHEM, V104, P517; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Sawasdikosol S, 2000, BBA-REV CANCER, V1471, pM1, DOI 10.1016/S0304-419X(00)00013-5; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Shivakrupa, 1999, DNA CELL BIOL, V18, P701, DOI 10.1089/104454999314980; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Smit L, 1996, ONCOGENE, V13, P381; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Smith JJ, 2000, J CELL BIOL, V151, P1391, DOI 10.1083/jcb.151.7.1391; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sorokin A, 1998, ONCOGENE, V16, P2425, DOI 10.1038/sj.onc.1201781; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Stoll R, 2001, EMBO J, V20, P340, DOI 10.1093/emboj/20.3.340; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Takahashi T, 1998, AM J PHYSIOL-HEART C, V274, pH1059, DOI 10.1152/ajpheart.1998.274.4.H1059; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Thomas SM, 1999, J CELL SCI, V112, P181; Torres M, 1996, ONCOGENE, V12, P77; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; TSUCHIE H, 1989, ONCOGENE, V4, P1281; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Tu YZ, 2001, FEBS LETT, V491, P193, DOI 10.1016/S0014-5793(01)02195-0; TUCHSCHERER G, 2001, IN PRESS ANGEW CHEM; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; van der Flier S, 2000, INT J CANCER, V89, P465, DOI 10.1002/1097-0215(20000920)89:5<465::AID-IJC11>3.0.CO;2-O; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; van Dijk TB, 2000, BLOOD, V96, P3406; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; VOSS J, 2001, SIGNAL TRANSDUCTION, V1, P1; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weidow CL, 2000, CELL MICROBIOL, V2, P549, DOI 10.1046/j.1462-5822.2000.00079.x; Whisstock JC, 1999, TRENDS BIOCHEM SCI, V24, P132, DOI 10.1016/S0968-0004(99)01366-3; White MF, 1998, RECENT PROG HORM RES, V53, P119; Whitehead JP, 2000, CURR OPIN CELL BIOL, V12, P222, DOI 10.1016/S0955-0674(99)00079-4; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Wolthuis RMF, 1996, ONCOGENE, V13, P353; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamabhai M, 1997, ANAL BIOCHEM, V247, P143, DOI 10.1006/abio.1997.2040; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864; Zvara A, 2001, ONCOGENE, V20, P951, DOI 10.1038/sj.onc.1204173; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	367	393	411	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6348	6371		10.1038/sj.onc.1204779	http://dx.doi.org/10.1038/sj.onc.1204779			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607838				2022-12-28	WOS:000171640600011
J	Bergoglio, V; Canitrot, Y; Hogarth, L; Minto, L; Howell, SB; Cazaux, C; Hoffmann, JS				Bergoglio, V; Canitrot, Y; Hogarth, L; Minto, L; Howell, SB; Cazaux, C; Hoffmann, JS			Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents	ONCOGENE			English	Article						DNA polymerase beta; cisplatin resistance; translesion synthesis; 6-thioguanine	ACQUIRED-RESISTANCE; REVERSE-TRANSCRIPTASE; BYPASS REPLICATION; MUTATOR PHENOTYPE; MISMATCH REPAIR; EXCISION-REPAIR; CANCER-CELLS; IN-VITRO; CISPLATIN; LINES	DNA polymerase beta, one of the most inaccurate DNA synthesizing enzymes, has been shown to confer genetic instability when up-regulated in cells, a situation found in several human cancers. Here, we demonstrated that enhanced activity and expression of this enzyme occur in the human ovarian tumor 2008/CI3*5.25 cells, which are resistant to the antitumor agent cisplatin and hypersensitive to 6-thioguanine. We found that translesion synthesis across platinated DNA crosslinks as well as increased incorporation into DNA of 6-thioguanine took place in the 2008/CI3*5.25 cells compared to the parental 2008 cells. Such features being molecular signatures of DNA polymerase beta, these findings suggest that deregulation of its expression in cancer cells may contribute to the modulation of the response to antitumor treatments and therefore to tumor progression.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France; CRU, Sch Med, LRF Mol Pharmacol Grp, Newcastle Upon Tyne, Tyne & Wear, England; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Newcastle University - UK; University of California System; University of California San Diego; University of California System; University of California San Diego	Cazaux, C (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.		Bergoglio, Valérie VB/P-1624-2014; Hoffmann, Jean-Sebastien/O-9183-2014	Bergoglio, Valérie VB/0000-0003-2773-3178; Hoffmann, Jean-Sebastien/0000-0003-2222-354X	NCI NIH HHS [CA 78648] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebi S, 1996, CANCER RES, V56, P3087; ANDREWS PA, 1985, CANCER RES, V45, P6250; ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; Bouayadi K, 1997, CANCER RES, V57, P110; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DIWAN BA, 1995, TOXICOL APPL PHARM, V132, P115, DOI 10.1006/taap.1995.1092; Gomi A, 1996, BIOCHEM BIOPH RES CO, V227, P558, DOI 10.1006/bbrc.1996.1545; GRINDEY GB, 1979, CANCER TREAT REV, V6, P19, DOI 10.1016/S0305-7372(79)80006-7; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; Hoffmann JS, 1996, J BIOL CHEM, V271, P15386, DOI 10.1074/jbc.271.26.15831; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; Johnson SW, 1997, CANCER RES, V57, P850; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; Kornberg A., 1992, DNA REPLICATION; MAMENTA EL, 1994, CANCER RES, V54, P3500; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; NELSON J, 1975, CANCER RES, P2872; OHNO Y, 1988, CANCER RES, V48, P1494; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PIL P, 1997, ENCY CANC, V1, P392; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Vaisman A, 2000, J BIOL CHEM, V275, P13017, DOI 10.1074/jbc.275.17.13017; Vaisman A, 1999, BIOCHEMISTRY-US, V38, P11026, DOI 10.1021/bi9909187; WARREN DJ, 1995, CANCER RES, V55, P1670; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9589	37	75	81	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6181	6187		10.1038/sj.onc.1204743	http://dx.doi.org/10.1038/sj.onc.1204743			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593426	Bronze			2022-12-28	WOS:000171206300009
J	Chan, HM; Smith, L; La Thangue, NB				Chan, HM; Smith, L; La Thangue, NB			Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein	ONCOGENE			English	Article						pRb; E2F; HDAC; LXCXE; tumour suppressor	CELL-CYCLE ARREST; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; BINDING-SITE; E2F SITE; IN-VIVO; E GENE; RB; DOMAIN; CHROMATIN	Cell cycle control by pRb requires the integrity of the pocket domain, which is a region necessary for interactions with a variety of proteins, including E2F and LXCXE-motif containing proteins. Through knowledge of the crystal structure of pRb we have prepared a panel of pRb mutant derivatives in which a cluster of lysine residues that demark the LXCXE peptide binding domain were systematically mutated. One of the mutant derivatives, Rb6A, exhibits significantly reduced LXCXE-dependent interactions with HPV E7, cyclinD1 and HDAC2, but retained LXCXE-independent binding to E2F. Consistent with these results, Rb6A could down-regulate E2F-1-dependent activation of different E2F responsive promoters, but was compromised in Rb-dependent repression. Most importantly, Rb6A retained wild-type growth arrest activity, and colony forming activity similar to wild-type pRb. It is compatible with these results that directly targeting HDAC2 to E2F responsive promoters as an E2F/HDAC hybrid protein failed to effect cell cycle arrest. These results suggest that LXCXE-dependent interactions are not essential for pRb to exert growth arrest.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Blvd, Glasgow G12 8QQ, Lanark, Scotland.				MRC [G9400953] Funding Source: UKRI; Medical Research Council [G9400953] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALBERT L, 1999, MOL CELL BIOL, V19, P6632; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Goodman RH, 2000, GENE DEV, V14, P1553; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Han JW, 2000, CANCER RES, V60, P6068; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Woitach JT, 1998, NAT GENET, V19, P371, DOI 10.1038/1258; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	44	60	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6152	6163		10.1038/sj.onc.1204793	http://dx.doi.org/10.1038/sj.onc.1204793			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593423				2022-12-28	WOS:000171206300006
J	Fukuyama, T; Sueoka, E; Sugio, Y; Otsuka, T; Niho, Y; Akagi, K; Kozu, T				Fukuyama, T; Sueoka, E; Sugio, Y; Otsuka, T; Niho, Y; Akagi, K; Kozu, T			MTG8 proto-oncoprotein interacts with the regulatory subunit of type II cyclic AMP-dependent protein kinase in lymphocytes	ONCOGENE			English	Article						AKAP; AML1 (RUNX-1); lymphocyte; MTG8 (ETO); PKA RII alpha	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; TRANSCRIPTION FACTOR; FUSION PARTNER; SIGNALING ENZYMES; MOLECULAR-BASIS; RUNT DOMAIN; AML1 GENE; T(8-21); ETO	AML1-MTG8 chimeric oncogene is generated in acute myelogenous leukemia with t(8;21), and seems to be responsible for the pathogenesis of the disease. However, the role of MTG8 is ambiguous. Here we found that MTG8 interacted with the regulatory subunit of type II cyclic AMP-dependent protein kinase (PKA RII alpha). The binding site of MTG8 was NHR3 domain, and that of RII alpha was the N-terminus for interacting with PKA anchoring proteins (AKAPs). NHR3 contains a putative alpha -amphipathic helix which is characteristic in binding of AKAPs with RII. Indirect immunofluorescence microscopy showed that MTG8 and RII alpha were overlapped at the centrosome-Golgi area in lymphocytes. These findings suggest that MTG8 may function as an AKAP at the Centrosome-Golgi area in lymphocytes.	Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan; Kyushu Univ Hosp, Ctr Canc, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Fac Med, Dept Med & Biosyst Sci, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Kozu, T (corresponding author), Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan.		Kozu, Tomoko/R-3087-2019	Fukuyama, Tomofusa/0000-0002-0709-3188				Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; CARR DW, 1991, J BIOL CHEM, V266, P14188; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FEINSTEIN PG, 1995, GENETICS, V140, P573; Fracchiolla NS, 1998, BLOOD, V92, P3481, DOI 10.1182/blood.V92.9.3481.splL6_3481_3484; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Keryer G, 1999, EXP CELL RES, V249, P131, DOI 10.1006/excr.1999.4447; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Komori A, 1999, JPN J CANCER RES, V90, P60, DOI 10.1111/j.1349-7006.1999.tb00666.x; KOZU T, 1993, BLOOD, V82, P1270; Le XF, 1998, EUR J HAEMATOL, V60, P217; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sacchi N, 1998, ONCOGENE, V16, P2609, DOI 10.1038/sj.onc.1201824; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sueoka E, 1998, BRIT J HAEMATOL, V101, P737, DOI 10.1046/j.1365-2141.1998.00757.x; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1997, CANCER RES, V57, P2951; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3	48	45	47	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6225	6232		10.1038/sj.onc.1204794	http://dx.doi.org/10.1038/sj.onc.1204794			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593431				2022-12-28	WOS:000171206300014
J	Pervaiz, S; Cao, J; Chao, OSP; Chin, YY; Clement, MV				Pervaiz, S; Cao, J; Chao, OSP; Chin, YY; Clement, MV			Activation of the RacGTPase inhibits apoptosis in human tumor cells	ONCOGENE			English	Article						superoxide anion; NADPH oxidase; Ha-Ras; anti-cancer drugs	SIGNAL-TRANSDUCTION; SUPEROXIDE ANION; RAS; PROTEINS; FAMILY; GENE	The small GTP-binding protein Rac is a downstream effector of the oncogene product p21-ras. Rac is involved in actin polymerization, Jun kinase activation, and intracellular superoxide anion production, through distinct pathways in tumor cells. Here we investigated the role of activated Rac in the response of tumor cells to apoptosis triggered by anti-cancer drugs or the cell surface death receptor CD95. Using M14 melanoma cells stably transfected with a constitutively active form of Rac1, we show that activated Rac inhibits tumor cell response to apoptosis. The inhibitory effect of activated Rac on apoptotic signaling is mediated by the interaction of Rac with intracellular oxidase and the subsequent production of superoxide, which is supported by experiments performed with M14 and NIH3T3 cells transiently transfected with the loss-of-function mutants of Rac in an activated RacV12 background. Consistent with these findings, we also demonstrate that inhibition of the Rac pathway in the HaRas-expressing T24 bladder carcinoma cell line induces a decrease in superoxide anion concentration, and results in a significant increase in tumor cell sensitivity to apoptosis. These findings demonstrate the existence of a novel Rac-dependent survival pathway mediated by intracellular superoxide in tumor cells.	Natl Univ Singapore, Inst Med, Oncol Res Inst, Clin Res Ctr, Singapore 117597, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore; Natl Univ Singapore, Dept Physiol, Singapore 119260, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Clement, MV (corresponding author), Natl Univ Singapore, Inst Med, Oncol Res Inst, Clin Res Ctr, Block MD11,12-01, Singapore 117597, Singapore.		Pervaiz, Shazib/C-4188-2015					Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Clement MV, 1999, FREE RADICAL RES, V30, P247, DOI 10.1080/10715769900300271; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Clement MV, 1998, FEBS LETT, V440, P13, DOI 10.1016/S0014-5793(98)01410-0; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; Finkel T, 1999, J LEUKOCYTE BIOL, V65, P337, DOI 10.1002/jlb.65.3.337; Hirpara JL, 2001, J BIOL CHEM, V276, P514, DOI 10.1074/jbc.M004687200; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MUSLEH W, 1994, NEUROPHARMACOLOGY, V33, P929, DOI 10.1016/0028-3908(94)90191-0; Pervaiz S, 1998, CANCER LETT, V128, P11, DOI 10.1016/S0304-3835(98)00021-4; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; Pervaiz S, 1999, FEBS LETT, V459, P343, DOI 10.1016/S0014-5793(99)01258-2; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; WALKER PR, 1991, CANCER RES, V51, P1078	28	107	119	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6263	6268		10.1038/sj.onc.1204840	http://dx.doi.org/10.1038/sj.onc.1204840			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593437				2022-12-28	WOS:000171206300020
J	Yokoyama, N; Miller, WT				Yokoyama, N; Miller, WT			Protein phosphatase 2A interacts with the Src kinase substrate p130(CAS)	ONCOGENE			English	Article						Src; PP2A; Cas; serine dephosphorylation	POLYOMAVIRUS MIDDLE-T; ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; V-SRC; SACCHAROMYCES-CEREVISIAE; CELL-TRANSFORMATION; COMPLEX-FORMATION; STABLE COMPLEXES; OKADAIC ACID; ANTIGEN	In this study, we report that the Src substrate Cas (p130 Crk-associated substrate) associates with protein phosphatase 2A (PP2A), a serine/threonine phosphatase. We investigated this interaction in cells expressing a temperature-sensitive mutant form of v-Src. v-Src activation (by shifting cells from the nonpermissive to the permissive temperature) led to an increase in the tyrosine phosphorylation of v-Src and Cas, as well as in the association between v-Src and Cas. v-Src has previously been shown to bind to PP2A and to phosphorylate the catalytic subunit of PP2A, resulting in inhibition of phosphatase activity. We found that the association between v-Src and PP2A decreased as cells were shifted to the permissive temperature. In contrast, the levels of PP2A that co-immunoprecipitated with Cas increased when v-Src was activated. We obtained similar results in pull-down experiments with immobilized Microcystin, a PP2A inhibitor. Serine/threonine phosphorylation of Cas has previously been shown to occur in a cell cycle regulated matter. Treatment of NIH3T3 cells with okadaic acid, a PP2A inhibitor, augments the serine/threonine phosphorylation of Cas that occurs at mitosis. Furthermore, PP2A dephosphorylates serine residues on Cas in vitro. Taken together, our results suggest that PP2A may be involved in the cell cycle-specific dephosphorylation of Cas.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NCI NIH HHS [CA 58530, CA 28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058530, P01CA028146, R29CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; Chaudhuri Sadhan K., 1997, Indian Journal of Experimental Biology, V35, P1044; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; Evans DRH, 2000, MOL GEN GENET, V264, P425; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; Glover HR, 1999, ONCOGENE, V18, P4364, DOI 10.1038/sj.onc.1202816; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LIN FC, 1995, EMBO J, V14, P2745, DOI 10.1002/j.1460-2075.1995.tb07275.x; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ogris E, 1999, J VIROL, V73, P7390, DOI 10.1128/JVI.73.9.7390-7398.1999; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; YANAGIDA M, 1992, CIBA F SYMP, V170, P130; YOKOYAMA N, 1995, MOL CELL BIOCHEM, V148, P123, DOI 10.1007/BF00928149; Yokoyama N, 1999, FEBS LETT, V456, P403, DOI 10.1016/S0014-5793(99)00992-8; ZHENG B, 1991, J BIOL CHEM, V266, P10031	39	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6057	6065		10.1038/sj.onc.1204735	http://dx.doi.org/10.1038/sj.onc.1204735			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593413				2022-12-28	WOS:000171056300013
J	Zhang, SL; Lloyd, R; Bowden, G; Glickman, BW; de Boer, JG				Zhang, SL; Lloyd, R; Bowden, G; Glickman, BW; de Boer, JG			Msh2 DNA mismatch repair gene deficiency and the food-borne mutagen 2-amino-1-methyl-6-phenolimidazo [4,5-b] pyridine (PhIP) synergistically affect mutagenesis in mouse colon	ONCOGENE			English	Article						mismatch repair; dietary mutagen; mutational spectra; lacI; cancer	NONPOLYPOSIS COLORECTAL-CANCER; HETEROCYCLIC AMINES; TRANSGENIC MICE; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; MAMMALIAN-CELLS; MUTATION; LACI; RATS; SPECIFICITY; RODENTS	Msh2 deficiency and food-borne carcinogen PhIP have been implicated as genetic and environmental factors, respectively, in human colon carcinogenesis. It is not clear whether loss of one or both alleles of Msh2 gene increases the mutational sensitivity in colon when exposed to environmental carcinogens. In the current study, Msh2(+/-)/lacI and Msh2(-/-)/lacI double transgenic mice were treated with PhIP and mutations in the lacI gene were studied in the colon. The spontaneous mutation frequency (MF) is approximately eightfold higher in Msh2(-/-) mice than in Msh2(+/+) mice, while Msh2(+/-) mice display similar levels of spontaneous mutation as the Msh2 wild type mice. PhIP induced a significant increase in MF in all genotypes of mice. However, induced MF is much higher in Msh2-/- mice compared to Msh2(+/+) and Msh2(+/-) mice. Msh2(+/-) mice ;displayed an increased level of G:C >T:A transversions and -1 frameshifts upon PhIP treatment. In contrast, loss of both Msh2 alleles mainly results in increased frequency of G:C >A:T transitions when exposed to PhIP. These results suggest that a defect in mismatch repair may result in an enhanced sensitivity from exposure to a dietary carcinogen. It also provides insight into interaction between genetic and environmental factors in human carcinogenesis.	Univ Victoria, Dept Biol, Ctr Environm Hlth, Victoria, BC V8W 3N5, Canada	University of Victoria	de Boer, JG (corresponding author), Univ Victoria, Dept Biol, Ctr Environm Hlth, POB 1700, Victoria, BC V8W 3N5, Canada.							Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Cariello NF, 1996, ENVIRON MOL MUTAGEN, V28, P397, DOI 10.1002/(SICI)1098-2280(1996)28:4<397::AID-EM14>3.0.CO;2-A; CAROTHRS AM, 1994, CHEM RES TOXICOL, V7, P209, DOI 10.1021/tx00038a015; de Boer JG, 1998, GENETICS, V148, P1441; DOHET C, 1986, P NATL ACAD SCI USA, V83, P3395, DOI 10.1073/pnas.83.10.3395; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; ENDO H, 1994, CANCER RES, V54, P3745; Erfle HL, 1996, ENVIRON MOL MUTAGEN, V28, P393; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081; Felton JS, 1997, MUTAT RES-FUND MOL M, V376, P37, DOI 10.1016/S0027-5107(97)00023-7; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FISHEL R, 1994, CELL, V77, P167; Fornasarig M, 2000, ONCOL REP, V7, P39; FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Glaab WE, 2000, CANCER RES, V60, P4921; Glaab WE, 1999, CARCINOGENESIS, V20, P391, DOI 10.1093/carcin/20.3.391; Godard V, 1999, ANN DERMATOL VENER, V126, P600; Gooderham NJ, 1997, MUTAT RES-FUND MOL M, V376, P53, DOI 10.1016/S0027-5107(97)00025-0; ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1991, CANCER RES, V51, P3075; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; Marra G, 1996, GASTROENTEROL CLIN N, V25, P755, DOI 10.1016/S0889-8553(05)70273-9; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Okonogi H, 1997, CARCINOGENESIS, V18, P745, DOI 10.1093/carcin/18.4.745; Okonogi H, 1997, MUTAT RES-GEN TOX EN, V395, P93, DOI 10.1016/S1383-5718(97)00146-0; Planck M, 2000, GENE CHROMOSOME CANC, V29, P33, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1004>3.0.CO;2-R; RADMAN M, 1985, BIOCHIMIE, V67, P745, DOI 10.1016/S0300-9084(85)80162-0; ROGERS BJ, 1995, MUTAT RES-FUND MOL M, V327, P57, DOI 10.1016/0027-5107(94)00081-F; Sorensen IK, 1997, CARCINOGENESIS, V18, P777, DOI 10.1093/carcin/18.4.777; Stuart GR, 2000, MUTAT RES-FUND MOL M, V452, P101, DOI 10.1016/S0027-5107(00)00058-0; Suri A, 1996, MUTAT RES-FUND MOL M, V372, P23, DOI 10.1016/S0027-5107(96)00105-4; TAKAHASHI S, 1991, JPN J CANCER RES, V82, P135, DOI 10.1111/j.1349-7006.1991.tb01819.x; Toft NJ, 1998, J PATHOL, V185, P123; TUDEK B, 1989, CANCER RES, V49, P1236; TURTELTAUB KW, 1989, FOOD CHEM TOXICOL, V27, P667, DOI 10.1016/0278-6915(89)90121-X; Zhang XB, 1996, CARCINOGENESIS, V17, P2259, DOI 10.1093/carcin/17.10.2259	47	16	16	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6066	6072		10.1038/sj.onc.1204730	http://dx.doi.org/10.1038/sj.onc.1204730			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593414				2022-12-28	WOS:000171056300014
J	Delhem, N; Sabile, A; Gajardo, R; Podevin, P; Abadie, A; Blaton, MA; Kremsdorf, D; Beretta, L; Brechot, C				Delhem, N; Sabile, A; Gajardo, R; Podevin, P; Abadie, A; Blaton, MA; Kremsdorf, D; Beretta, L; Brechot, C			Activation of the interferon-inducible protein kinase PKR by Hepatocellular carcinoma derived-Hepatitis C virus core protein	ONCOGENE			English	Article						HCV; core; PKR; eIF2 alpha; apoptosis	NF-KAPPA-B; SIGNAL-TRANSDUCTION; MEDIATED APOPTOSIS; NS5A PROTEIN; EXPRESSION; PATHWAY; CELLS; BINDS; PATHOGENESIS; REPLICATION	Hepatitis C virus (HCV) is a major etiological agent of chronic liver disease and hepatocellular carcinoma (HCC). We demonstrate herewith that HCV core proteins encoded by sequences isolated from HCC tumor tissues, but not those derived from their non-tumor counterparts in the same liver, co-localise in vitro and in vivo and co-immunoprecipitate with PKR in hepatocytic Huh7 cells. We show that this association in fact augments the autophosphorylation of PKR and the phosphorylation of the translation initiation factor eIF2 alpha, which are two markers of PKR activity. The present study therefore identifies a novel model of virus-cell interactions whereby a viral protein, the HCV core, activates PKR activity.	CHU Necker, INSERM, U370, Dept Liver Canc & Mol Virol, F-75015 Paris, France; Inst Curie, Dept Cytokines & Interferon, Paris, France; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Michigan System; University of Michigan	Brechot, C (corresponding author), CHU Necker, INSERM, U370, Dept Liver Canc & Mol Virol, 156 Rue Vaugirard, F-75015 Paris, France.		Kremsdorf, Dina/O-9797-2017	Laura, Beretta/0000-0002-2054-684X				Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Gale MJ, 1998, CLIN DIAGN VIROL, V10, P157; Gil J, 1999, MOL CELL BIOL, V19, P4653; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Lee JH, 1997, J MED VIROL, V53, P245, DOI 10.1002/(SICI)1096-9071(199711)53:3<245::AID-JMV11>3.0.CO;2-G; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; Lu JF, 1999, J BIOL CHEM, V274, P32198, DOI 10.1074/jbc.274.45.32198; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; McHutchison JG, 1999, SEMIN LIVER DIS, V19, P57; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Naganuma A, 2000, J VIROL, V74, P8744, DOI 10.1128/JVI.74.18.8744-8750.2000; Neddermann P, 1997, BIOL CHEM, V378, P469; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Podevin P, 2001, HEPATOLOGY, V33, P1503, DOI 10.1053/jhep.2001.24749; Polyak SJ, 1999, HEPATOLOGY, V29, P1262, DOI 10.1002/hep.510290438; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Sarrazin C, 1999, Z Gastroenterol, V37, P669; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Shimada A, 1998, CANCER RES, V58, P4434; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Shimotohno K, 1995, INTERVIROLOGY, V38, P162, DOI 10.1159/000150427; Song J, 1999, J GEN VIROL, V80, P879, DOI 10.1099/0022-1317-80-4-879; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Yeung MC, 1999, P NATL ACAD SCI USA, V96, P11860, DOI 10.1073/pnas.96.21.11860; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	44	66	73	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5836	5845		10.1038/sj.onc.1204744	http://dx.doi.org/10.1038/sj.onc.1204744			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593389				2022-12-28	WOS:000171037200007
J	Verissimo, F; Jordan, P				Verissimo, F; Jordan, P			WNK kinases, a novel protein kinase subfamily in multi-cellular organisms	ONCOGENE			English	Article						protein kinases; catalytic domain; MAP kinases; chromosome 12; gene cloning; alternative splicing	CATALYTIC SUBUNIT; ORGANIZATION	We have cloned and characterized a novel human serine/ threonine protein kinase gene from chromosome 12p13.3 encoding 2382 amino acids. Remarkably, the catalytic domain sequence contains a cysteine in place of a lysine residue conserved in subdomain II of most kinases. The same amino acid alteration was recently described for rat WNK1 (with no K=lysine) in which another nearby lysine residue was shown to confer kinase activity to the protein. Rat WNK1 is 85% identical to a splice variant lacking exons 11 and 12 of the described human kinase which we have called human WNK1. The WNK1 catalytic domain has closest homology with human PAK2, MEKK3, and Raf-1. Three additional, partial human protein kinase sequences, WNK2, WNK3 and WNK4, are also reported here with catalytic domains that are 95% homologous to WNK1. These genes differ both in chromosomal location and tissue-specific expression. Moreover, we have identified in the database a total of 18 WNK-related genes, all exclusively from multicellular organisms, which share a WNK kinase sequence signature within subdomains I and II of the catalytic domain. We suggest that they constitute a novel subfamily of protein kinases that evolved together with cell adhesion and tissue-formation.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Human Genet, P-1649016 Lisbon, Portugal	Instituto Nacional de Saude Dr. Ricardo Jorge	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Human Genet, Ave Padre Cruz, P-1649016 Lisbon, Portugal.		Jordan, Peter/G-9335-2012	Jordan, Peter/0000-0002-1425-9211				BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dhanasekaran N, 1998, ONCOGENE, V17, P1329, DOI 10.1038/sj.onc.1202170; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jordan P, 2000, BIOCHEM BIOPH RES CO, V279, P741, DOI 10.1006/bbrc.2000.3901; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795	17	209	222	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5562	5569		10.1038/sj.onc.1204726	http://dx.doi.org/10.1038/sj.onc.1204726			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571656				2022-12-28	WOS:000170781100019
J	Chan, TL; Curtis, LC; Leung, SY; Farrington, SM; Ho, JWC; Chan, ASY; Lam, PWY; Tse, CW; Dunlop, MG; Wyllie, AH; Yuen, ST				Chan, TL; Curtis, LC; Leung, SY; Farrington, SM; Ho, JWC; Chan, ASY; Lam, PWY; Tse, CW; Dunlop, MG; Wyllie, AH; Yuen, ST			Early-onset colorectal cancer with stable microsatellite DNA and near-diploid chromosomes	ONCOGENE			English	Article						early-onset colorectal cancer; chromosomal instability; DNA ploidy; microsatellite instability	COMPARATIVE GENOMIC HYBRIDIZATION; YOUNG-PATIENTS; GENETIC INSTABILITY; COLON-CANCER; TUMORS; P53; MUTATIONS; CARCINOGENESIS; CHECKPOINT; CARCINOMAS	Colorectal cancer has been described in terms of genetic instability selectively affecting either microsatellite sequences (MIN) or chromosome number and structure (CIN). A subgroup with apparently stable, near-diploid chromosomes and stable microsatellites (MACS) also exists. These distinctions are important, partly because of their value in highlighting different pathways of carcinogenesis, and partly because of their direct relevance to prognosis. Study of early-onset cancer has often proved a fruitful resource for the identification of the nature and function of cancer susceptibility genes. In a study of colorectal cancer with stable microsatellite DNA, we describe 22 early-onset tumours (mean age = 33), compared with 16 late-onset tumours (mean age = 68). Both groups contained carcinomas with the MACS phenotype, characterized by near diploid DNA content, as defined by flow cytometry, and minimal chromosome arm deletion or amplification (six or less events per genome), determined by comparative genomic hybridization (CGH). Minimal chromosome imbalance correlated strongly with diploid DNA content (P<0.001). The proportion of MACS cancers was significantly greater in early-onset as compared to late-onset tumours (64 vs 13%, P=0.005). Of the chromosome arm imbalances commonly observed in late-onset tumours, only 18q- was observed more than twice amongst the 14 early-onset MACS tumours. Seventy-nine per cent of these MACS tumours were located in the distal colon, and 69% were at advanced clinico-pathological stages (with lymph node or distant metastasis). A positive family history of colorectal or other cancers was elicited in seven patients in the MACS early-onset group, and one additional patient in this group had a metachronous ovarian cancer. The results suggest that MACS cancer may have a genetic basis different from either MIN or CIN, and further studies of these cancers may lead to discovery of new mechanisms of colorectal carcinogenesis and cancer susceptibility.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Oncol, Colon Canc Genet Grp, Edinburgh EH4 2XU, Midlothian, Scotland; Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Surg, Kowloon, Hong Kong, Peoples R China	University of Cambridge; University of Hong Kong; University of Hong Kong; University of Edinburgh; University of Edinburgh	Wyllie, AH (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.		Yuen, Siu/K-6311-2014; Dunlop, Malcolm G/F-1973-2011; Leung, Suet Yi/C-4340-2009; Farrington, Susan M/Q-2710-2019; Farrington, Susan M/C-7319-2013; Leung, Suet Yi/T-9620-2019	Dunlop, Malcolm G/0000-0002-3033-5851; Farrington, Susan M/0000-0001-5955-7389; Leung, Suet Yi/0000-0001-8614-4619				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bubb VJ, 1996, ONCOGENE, V12, P2641; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARDER P, 1993, ONCOGENE, V8, P1397; Chan TL, 1999, JNCI-J NATL CANCER I, V91, P1221, DOI 10.1093/jnci/91.14.1221; CLARKE AR, 1994, ONCOGENE, V9, P1767; Cottu PH, 1996, ONCOGENE, V13, P2727; Curtis LJ, 2000, J PATHOL, V192, P440; De Angelis PM, 1999, BRIT J CANCER, V80, P526; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; HAWN MT, 1995, CANCER RES, V55, P3721; Ho JWC, 2000, INT J CANCER, V89, P356, DOI 10.1002/1097-0215(20000720)89:4<356::AID-IJC7>3.0.CO;2-J; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung SY, 2000, ONCOGENE, V19, P4079, DOI 10.1038/sj.onc.1203740; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LOTHE RA, 1993, CANCER RES, V53, P5849; MERRITT AJ, 1994, CANCER RES, V54, P614; Miyazaki M, 1999, CANCER RES, V59, P5283; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PELTOMAKI P, 1993, CANCER RES, V53, P5853; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; SCHLEGEL J, 1995, CANCER RES, V55, P6002; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	35	62	65	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4871	4876		10.1038/sj.onc.1204653	http://dx.doi.org/10.1038/sj.onc.1204653			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521198				2022-12-28	WOS:000170271800011
J	Silva, J; Dominguez, G; Silva, JM; Garcia, JM; Gallego, I; Corbacho, C; Provencio, M; Espana, P; Bonilla, F				Silva, J; Dominguez, G; Silva, JM; Garcia, JM; Gallego, I; Corbacho, C; Provencio, M; Espana, P; Bonilla, F			Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer	ONCOGENE			English	Article						allelic losses; p14ARF; breast cancer; hypermethylation; overexpression; mutations	CELL LUNG-CANCER; TUMOR-SUPPRESSOR GENE; INK4A/ARF LOCUS; STABILIZES P53; CYCLE ARREST; P19(ARF); METHYLATION; P16(INK4A); INACTIVATION; MUTATIONS	The INK4a/ARF locus encodes two unrelated cell cycle-regulatory proteins that both function in tumor suppression, p16INK4a and p14ARF. In human tumors including breast cancer, alterations affecting selectively p14ARF have been poorly analysed. We have performed a comprehensive analysis of the inactivation mechanisms (mutation, homozygous and hemizygous deletion, and promoter hypermethylation) in a large series of 100 primary breast carcinomas. RT-PCR showed expression variable of the p14ARF transcript, with 17% demonstrating overexpression and 26% demonstrating decreased expression. No detectable alterations were observed in the majority of cases with overexpressed p14ARF mRNA, but 77% of tumors with decreased expression presented at least one of these genetic/ epigenetic alterations. Nevertheless, a statistically significant correlation was observed between decreased p14ARF expression and several poor prognostic parameters.	Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain; Clin Puerta Hierro, Dept Pathol, E-28035 Madrid, Spain; Hosp Santa Cristina, Dept Pathol, E-28009 Madrid, Spain	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Bonilla, F (corresponding author), Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain.		Gallego, Ignacio/GZK-5910-2022; Provencio, Mariano/ABE-8586-2020	Provencio, Mariano/0000-0001-9053-9197; Provencio Pulla, Mariano/0000-0001-6315-7919				Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Esteller M, 2000, CANCER RES, V60, P129; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Gazzeri S, 1998, CANCER RES, V58, P3926; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Iwato M, 2000, CANCER RES, V60, P2113; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Markl IDC, 1998, CANCER RES, V58, P5348; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, CANCER RES, V55, P2988; Takemoto S, 2000, BLOOD, V95, P3939; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	26	44	45	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4586	4590		10.1038/sj.onc.1204617	http://dx.doi.org/10.1038/sj.onc.1204617			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494155				2022-12-28	WOS:000170074900017
J	Yui, D; Yoneda, T; Oono, K; Katayama, T; Imaizumi, K; Tohyama, M				Yui, D; Yoneda, T; Oono, K; Katayama, T; Imaizumi, K; Tohyama, M			Interchangeable binding of Bcl10 to TRAF2 and cIAPs regulates apoptosis signaling	ONCOGENE			English	Article						Bcl10; TRAF2; cIAPs; phosphorylation; apoptosis	NECROSIS-FACTOR-ALPHA; CELL-DEATH; PROTEINS; GENE; LYMPHOMA; CASPASES; KINASE; RECRUITMENT; ACTIVATION; MUTATIONS	Bcl10 was identified as a candidate gene responsible for low grade B cell lymphomas of mucosa-associated lymphoid tissue. Overexpression of Bcl10 in cultured cells was reported to promote apoptosis, however, the mechanism of regulation of apoptosis mediated by Bcl10 has not been demonstrated. In the present study, we analysed the apoptosis signaling pathway mediated by Bcl10, focusing on phosphorylation of Bcl10 and the dynamic interaction with its binding partners during apoptosis, Previously, we have demonstrated that Bcl10 potentially interacts with the other apoptosis regulator, TNF receptor associated factor-2 (TRAF2) and inhibitor of apoptosis proteins (cIAPs), The present results showed that the complex formation of these molecules was regulated by phosphorylation of Bcl10, that is, phosphorylation of Bcl10 resulted in binding of Bcl10 to cIAPs and the dissociation of it from TRAFZ. Moreover, hyperphosphorylation of Bcl10 enhanced apoptosis, suggesting that changes in the binding partners of Bcl10 were correlated to the promotion of apoptosis as mediated by Bcl10, Indeed, the mutant which was deleted from the binding site of Bcl10 for cIAPs, could not induce apoptosis, These findings indicate that Bcl10 is a mediator of apoptosis signaling, by switching over binding to cIAPs from TRAFZ through the events of Bcl10 phosphorylation.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cellular & Struct Biol, Nara 6300101, Japan; JST, Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; Nara Institute of Science & Technology; Japan Science & Technology Agency (JST)	Yui, D (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; Bertoni F, 1999, ANN ONCOL, V10, P1259, DOI 10.1023/A:1008309631480; Cecconi F, 1999, CELL DEATH DIFFER, V6, P1087, DOI 10.1038/sj.cdd.4400602; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Du MQ, 2000, BLOOD, V95, P3885; HOFFMAN K, 1997, TRENDS BIOCHEM SCI, V22, P155; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; KIZAKI H, 1989, J BIOCHEM-TOKYO, V105, P673, DOI 10.1093/oxfordjournals.jbchem.a122724; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Laouar A, 1999, J BIOL CHEM, V274, P23526, DOI 10.1074/jbc.274.33.23526; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Simms LA, 2000, CELL DEATH DIFFER, V7, P236, DOI 10.1038/sj.cdd.4400650; Takada Y, 1999, J BIOL CHEM, V274, P28286, DOI 10.1074/jbc.274.40.28286; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yamamoto H, 2000, CELL DEATH DIFFER, V7, P238, DOI 10.1038/sj.cdd.4400651; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yoneda T, 2000, J BIOL CHEM, V275, P11114, DOI 10.1074/jbc.275.15.11114; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	27	21	26	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4317	4323		10.1038/sj.onc.1204576	http://dx.doi.org/10.1038/sj.onc.1204576			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466612				2022-12-28	WOS:000169912600005
J	Feng, L; Lee, KAW				Feng, L; Lee, KAW			A repetitive element containing a critical tyrosine residue is required for transcriptional activation by the EWS/ATF1 oncogene	ONCOGENE			English	Article						EWS/ATF1 oncogene; transcription; activation domain; tyrosine	TUMOR-SUPPRESSOR GENE; EWS/FLI-1 FUSION GENE; RNA-POLYMERASE-II; EWINGS-SARCOMA; CHROMOSOME-TRANSLOCATION; MALIGNANT-MELANOMA; CHIMERIC PROTEIN; BINDING DOMAIN; SOFT PARTS; EWS	Chromosomal fusion of the N-terminal region of the Ewings Sarcoma Oncogene (EWS-activation-domain, EAD) to the DNA-binding domains of a variety of cellular transcription factors produce oncogenic proteins (EWS-fusion proteins (EFPs)) that cause distinct malignancies. In EFPs, the EAD acts as a potent transcriptional activation domain and this ability is repressed in the context of normal, non-tumorigenic, EWS, Trans-activation by the EAD is therefore a specific characteristic of EFPs and it is thought that EFPs induce tumorigenesis via improper transcriptional activation of cellular genes. Functional elements required for transcriptional activation are dispersed throughout the EAD, as are thirty-one copies of a Degenerate Hexapeptide Repeat (DHR, consensus SYCQQS), This suggests that the EAD contains a highly reiterated functional element related to DHRs. Here we show that in the context of EWS/ATF1, the EFP that causes malignant melanoma of soft parts, trans-cooperation by small regions of the EAD (similar to 30 residues) results in potent transcriptional activation dependent on the conserved tyrosine residues present in DHRs, These findings provide the first evidence for a role of DHRs in EAD-mediated trans-activation and demonstrate that the EAD represents a novel tyrosine-dependent transcriptional activation domain.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.	bokaw@usthk.ust.hk						Benuck ML, 1999, J BIOL CHEM, V274, P25419, DOI 10.1074/jbc.274.36.25419; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BROWN AD, 1995, ONCOGENE, V10, P1749; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; Fujimura Y, 1996, ONCOGENE, V12, P159; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Kim J, 1999, P NATL ACAD SCI USA, V96, P14300, DOI 10.1073/pnas.96.25.14300; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; KIM TK, 1994, NUCLEIC ACIDS RES, V22, P251, DOI 10.1093/nar/22.2.251; Kovar Heinrich, 1999, Current Opinion in Oncology, V11, P275, DOI 10.1097/00001622-199907000-00007; KRAJEWSKI W, 1994, MOL CELL BIOL, V14, P7204, DOI 10.1128/MCB.14.11.7204; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Nyanguile O, 1997, P NATL ACAD SCI USA, V94, P13402, DOI 10.1073/pnas.94.25.13402; OHNO T, 1993, CANCER RES, V53, P5859; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Pollock R, 1997, P NATL ACAD SCI USA, V94, P13388, DOI 10.1073/pnas.94.25.13388; PRASAD DDK, 1994, ONCOGENE, V9, P3717; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RIBEIRO A, 1994, J BIOL CHEM, V269, P31124; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; Zhou HQ, 2001, ONCOGENE, V20, P1519, DOI 10.1038/sj.onc.1204135; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	45	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4161	4168		10.1038/sj.onc.1204522	http://dx.doi.org/10.1038/sj.onc.1204522			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464282				2022-12-28	WOS:000169857200006
J	Kao, GD; McKenna, WG; Yen, TJ				Kao, GD; McKenna, WG; Yen, TJ			Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells	ONCOGENE			English	Article						DNA damage; G2; DNA repair; BrdU	HUMAN-DIPLOID FIBROBLASTS; STRAND BREAK REPAIR; HAMSTER OVARY CELLS; HELA-CELLS; NUCLEAR-LOCALIZATION; KINASE ACTIVATION; NITROGEN-MUSTARD; MAMMALIAN-CELLS; EXCISION-REPAIR; UV IRRADIATION	All eukaryotic cells manifest cell cycle delay after exposure to DNA damaging agents. It has been proposed that such cell cycle checkpoints may allow DNA repair but direct evidence of such activity during the radiation-induced G2 delay has been lacking. We report here that cells arrested in G2 by radiation (2-3 Gy) and etoposide incorporate bromodeoxyuridine (BrdU) at discrete foci in the nucleus. We detected G2 cells with CENP-F, a nuclear protein maximally expressed in G2, Caffeine and okadaic acid, both established radiosensitizers, inhibit the incorporation of BrdU in G2 cells. Radioresistant HT29 and OVCAR cells demonstrate BrdU foci formation more frequently during the G2 delay when compared to the more radiosensitive A2780 cell line. The repair foci formed during G2 may be followed through mitosis and observed in daughter cells in G1, Taken together, these observations are consistent with the detection of DNA repair activity during the radiation-induced G2 delay after relatively low doses of radiation.	Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	University of Pennsylvania; Pennsylvania Medicine; Fox Chase Cancer Center	Yen, TJ (corresponding author), Hosp Univ Penn, Dept Radiat Oncol, 3400 Spruce St, Philadelphia, PA 19104 USA.			Yen, Tim/0000-0003-2159-0997	NCI NIH HHS [P01 CA06927] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED FE, 1977, CANCER RES, V37, P3414; Balajee AS, 1998, MUTAT RES-FUND MOL M, V404, P3, DOI 10.1016/S0027-5107(98)00088-8; Barratt RA, 1998, CANCER RES, V58, P2639; BEETHAM KL, 1982, J CELL PHYSIOL, V113, P385, DOI 10.1002/jcp.1041130306; BEISKER W, 1988, EXP CELL RES, V174, P156, DOI 10.1016/0014-4827(88)90151-6; Biade S, 1997, RADIAT RES, V147, P416, DOI 10.2307/3579497; COHN SM, 1984, J BIOL CHEM, V259, P2463; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; FOX MH, 1991, J CELL SCI, V99, P247; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOY CA, 1993, MUTAT RES, V290, P217, DOI 10.1016/0027-5107(93)90162-9; JACQUET P, 1995, INT J RADIAT BIOL, V67, P347, DOI 10.1080/09553009514550401; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Juan G, 1997, CANCER RES, V57, P803; JUNG T, 1992, INT J RADIAT BIOL, V62, P161, DOI 10.1080/09553009214551971; KALLE WHJ, 1993, ANAL BIOCHEM, V208, P228, DOI 10.1006/abio.1993.1037; Kao GD, 1999, J BIOL CHEM, V274, P34779, DOI 10.1074/jbc.274.49.34779; Kao GD, 1997, CANCER RES, V57, P753; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; KILL IR, 1991, J CELL SCI, V100, P869; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; LOCK RB, 1992, CANCER RES, V52, P1817; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NAGASAWA H, 1994, INT J RADIAT BIOL, V66, P373, DOI 10.1080/09553009414551311; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Nishii K, 1996, ONCOGENE, V13, P2225; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; RICHOLD M, 1972, INT J RADIAT BIOL RE, V21, P127, DOI 10.1080/09553007214550151; Rieber MS, 1997, DNA CELL BIOL, V16, P121, DOI 10.1089/dna.1997.16.121; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SELDEN JR, 1993, CYTOMETRY, V14, P154, DOI 10.1002/cyto.990140207; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; STEFANINI M, 1982, SOMAT CELL GENET, V8, P635, DOI 10.1007/BF01542856; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; TSAO YP, 1992, CANCER RES, V52, P1823; VANDIERENDONCK JH, 1989, CYTOMETRY, V10, P143, DOI 10.1002/cyto.990100205; VIJG J, 1984, MUTAT RES, V132, P129, DOI 10.1016/0167-8817(84)90007-5; WANG XQ, 1994, EXP CELL RES, V212, P176, DOI 10.1006/excr.1994.1133; Wang Y, 2000, GENE DEV, V14, P927; ZELLE B, 1980, MUTAT RES, V73, P157, DOI 10.1016/0027-5107(80)90144-X; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	51	67	70	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3486	3496		10.1038/sj.onc.1204445	http://dx.doi.org/10.1038/sj.onc.1204445			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429695				2022-12-28	WOS:000169478300004
J	White, DE; Cardiff, RD; Dedhar, S; Muller, WJ				White, DE; Cardiff, RD; Dedhar, S; Muller, WJ			Mammary epithelial-specific expression of the integrin linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice	ONCOGENE			English	Article						integrin linked kinase; ILK; transgenic mice; mammary epithelium; breast cancer; tumorigenesis	AP-1 TRANSCRIPTION FACTOR; GLYCOGEN-SYNTHASE KINASE; PROTEIN-KINASE; CELL-ADHESION; BETA-CATENIN; PHENOTYPE; OVEREXPRESSION; INHIBITION; ACTIVATION; B/AKT	The integrin linked kinase (ILK) is a cytoplasmic effector of integrin receptors, involved in the regulation of integrin binding properties as well as the activation of cell survival and proliferative pathways, including those involving MAP kinase, PKB/Akt and GSK-3 beta. Overexpression of ILK in cultured intestinal and mammary epithelial cells has been previously shown to induce changes characteristic of oncogenic transformation, including anchorage-independent growth, invasiveness, suppression of anoikis and tumorigenicity in nude mice. In order to determine if ILK overexpression can result in the formation of mammary tumors in vivo, we generated transgenic mice expressing ILK in the mammary epithelium, under the transcriptional control of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR). By the age of 6 months, female MMTV/ILK mice developed a hyperplastic mammary phenotype, which was accompanied by the constitutive phosphorylation of PKB/Akt, GSK-3 beta and MAP kinase. Focal mammary tumors subsequently appeared in 34% of the animals at an average age of 18 months. Given the focal nature and long latency of the tumors, however, additional genetic events are likely required for tumor induction in the MMTV/ILK mice. These results provide the first direct demonstration of a potential oncogenic role for ILK, which is upregulated in human tumors and tumor cell lines.	McMaster Univ, MOBIX, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6H 3Z6, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University; University of California System; University of California Davis; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; McMaster University	Muller, WJ (corresponding author), McMaster Univ, MOBIX, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	mullerw@mcmaster.ca		Dedhar, Shoukat/0000-0003-4355-1657				Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Schmeichel KL, 1998, J MAMMARY GLAND BIOL, V3, P201, DOI 10.1023/A:1018751124382; Seger D, 2001, J BIOL CHEM, V276, P16998, DOI 10.1074/jbc.M003766200; Shaw LM, 1999, J MAMMARY GLAND BIOL, V4, P367, DOI 10.1023/A:1018766317055; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Somasiri A, 2001, J CELL SCI, V114, P1125; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Streuli CH, 1998, J MAMMARY GLAND BIOL, V3, P151, DOI 10.1023/A:1018742822565; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zutter MM, 1998, J MAMMARY GLAND BIOL, V3, P191, DOI 10.1023/A:1018798907544	37	106	114	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7064	7072		10.1038/sj.onc.1204910	http://dx.doi.org/10.1038/sj.onc.1204910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704830				2022-12-28	WOS:000171739300009
J	Dohn, M; Jiang, JY; Chen, XB				Dohn, M; Jiang, JY; Chen, XB			Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis	ONCOGENE			English	Article						EphA2; apoptosis; p53; p73; p63	FOCAL-ADHESION-KINASE; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL ACTIVITIES; P53-RELATED PROTEIN; NEURAL DEVELOPMENT; MAMMALIAN-CELLS; HUMAN CANCERS; P73; GENE; EPHRINS	The p53 tumor suppressor protein is mutated in more than 50% of all human cancers, which makes the study of its functions and activities critical for the understanding and management of cancer. In response to cellular stresses, p53 is activated and can mediate cell cycle arrest and/or apoptosis via the upregulation of numerous target genes. Here, we have identified EphA2 as a target gene of the p53 family, that is, p53, p73, and p63. We also found that an increase of EphA2 transcript levels correlated with an increase of EphA2 protein expression, and induction of EphA2 in response to DNA damage corresponded with p53 activation. Furthermore, we identified a p53 response element located within the EphA2 promoter that is responsive to wild-type p53, p73, and p63, but not mutant p53. Interestingly, the ligand for EphA2, ephrin-A1, is also regulated by p53. EphA2 and ephrin-A1 are members of the Eph family of receptor tyrosine kinases and ligands, which are implicated in a number of developmental processes. To analyse the role of EphA2 in p53-mediated tumor suppression, we generated stable cell lines capable of expressing exogenous EphA2 in a tetracycline-repressible system. We found that EphA2 expression resulted in an increase in apoptosis. Thus, we hypothesize that the activated EphA2 may serve to impair anti-apoptotic signaling, perhaps by disrupting focal adhesions and thereby sensitize cells to pro-apoptotic stimuli.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NCI NIH HHS [R01 CA81237, R29 CA76069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARPER JW, 1993, CELL, V75, P805; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holder N, 1999, DEVELOPMENT, V126, P2033; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MIYASHITA T, 1995, CELL, V80, P293; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ozaki T, 1999, CANCER RES, V59, P5902; Prives C, 1999, J PATHOL, V187, P112; Rodriguez-Fernandez JL, 1999, BIOESSAYS, V21, P1069, DOI 10.1002/(SICI)1521-1878(199912)22:1<1069::AID-BIES13>3.0.CO;2-C; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Shimada A, 1999, CANCER RES, V59, P2781; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zaika AI, 1999, CANCER RES, V59, P3257; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	64	118	130	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6503	6515		10.1038/sj.onc.1204816	http://dx.doi.org/10.1038/sj.onc.1204816			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641774				2022-12-28	WOS:000171404200002
J	Liang, Y; Yan, CH; Schor, NF				Liang, Y; Yan, CH; Schor, NF			Apoptosis in the absence of caspase 3	ONCOGENE			English	Article						breast cancer; programmed cell death; caspases	CYTOCHROME-C; CELL-DEATH; NEUROBLASTOMA-CELLS; DNA FRAGMENTATION; PROTEASE CASCADE; GRANZYME-B; BCL-2; ACTIVATION; RELEASE; MITOCHONDRIA	MCF-7 human breast cancer cells do not express caspase 3, thought by some to be a critical component of the apoptosis cascade. Nonetheless, both mock- and bcl-2-transfected MCF-7 cells undergo apoptosis after treatment with a variety of stimuli, including the DNA-cleaving antimitotic agent, neocarzinostatin (NCS). Transfection with bcl-2 shifts the concentration-response curve to NCS but does not change the phenomenology of apoptosis when it occurs. In both cases, NCS treatment results in condensation and fragmentation of MCF-7 cell nuclei and release of cytochrome c from the mitochondria to the cytosol. This apoptosis is accompanied by decreased levels of Bcl-2 and increased levels of Bax. Using a series of caspase inhibitors with overlapping specificities, enzyme-specific chromogenic substrates, and an antibody specific for activated caspase 7, we have determined that apoptosis in MCF-7 cells proceeds via sequential activation of caspases 9, 7 and 6. P21 is detected only after activation of caspase 7, and P53 is neither expressed at baseline nor upregulated with apoptosis induction. This pathway bypasses the need for activated caspase 3 in these cells.	Childrens Hosp Pittsburgh, Pediat Ctr Neurosci, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schor, NF (corresponding author), Childrens Hosp Pittsburgh, Range Res Ctr, 3460 5th Ave, Pittsburgh, PA 15213 USA.			Schor, Nina/0000-0002-3817-7376	NCI NIH HHS [R01-CA74289] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cortazzo M, 1996, CANCER RES, V56, P1199; Eck-Enriquez K, 2000, BREAST CANCER RES TR, V61, P229, DOI 10.1023/A:1006442017658; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Hartsell TL, 1996, J PHARMACOL EXP THER, V277, P1158; HARTSELL TL, 1995, J PHARMACOL EXP THER, V275, P479; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lecoeur H, 1996, J IMMUNOL METHODS, V198, P87, DOI 10.1016/0022-1759(96)00148-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang Ye, 2001, Pediatric Research, V49, p211A; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PARK J, 2001, BIOCHEM BIOPH RES CO, V199, P93; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samali A, 1999, CELL DEATH DIFFER, V6, P495, DOI 10.1038/sj.cdd.4400520; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHOR NF, 1992, J CLIN INVEST, V89, P774, DOI 10.1172/JCI115655; Schor NF, 2000, ONCOGENE, V19, P472, DOI 10.1038/sj.onc.1203324; Shimizu S, 1996, ONCOGENE, V12, P2251; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	190	198	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6570	6578		10.1038/sj.onc.1204815	http://dx.doi.org/10.1038/sj.onc.1204815			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641782				2022-12-28	WOS:000171404200010
J	Yang, XL; Li, DM; Chen, WL; Xu, T				Yang, XL; Li, DM; Chen, WL; Xu, T			Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G(2)/M arrest or apoptosis	ONCOGENE			English	Article						Lats1 tumor suppressor; growth inhibition; regulation of G(2)/M	CELL-CYCLE CHECKPOINTS; TUMOR-SUPPRESSOR GENE; POTENTIAL MEDIATOR; CANCER-CELLS; DNA-DAMAGE; P53; EXPRESSION; PROTEIN; 14-3-3-SIGMA; GADD45	The lats gene encodes a family of proteins conserved from insects to humans. Drosophila carrying lats mutant cells or mice deficient for Lats1 develop tumors in various tissues. The mammalian LATS1 protein was previously shown to bind to CDC2, suggesting that LATS1 may modulate G(2)/M cell cycle progression by affecting CDC2 activity. In this study, we introduced human LATS1 into LATS(-/-) MEF cells by adenovirus-mediated gene transfer. Overexpression of LATS1 causes G(2)/M arrest through inhibition of CDC2 kinase activity. Furthermore, overexpression of LATS1 significantly suppressed the human tumor cell growth in vitro and tumorigenicity in vivo by inducing either cell cycle arrest in G(2)/M or apoptosis. These observations suggest that LATS1 is a potent growth suppressor and, like other tumor suppressors, it suppresses growth by inducing cell cycle arrest or apoptosis.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet,Howard Hughes Med Inst, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet,Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06536 USA.	tian.xu@yale.edu						AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; He LS, 1998, CANCER RES, V58, P4238; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; QUELLE DE, 1995, ONCOGENE, V11, P635; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wechsler DS, 1997, CANCER RES, V57, P4905; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yang XL, 1996, INT J CANCER, V65, P338, DOI 10.1002/(SICI)1097-0215(19960126)65:3<338::AID-IJC11>3.0.CO;2-6; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yang XL, 2000, EXP CELL RES, V256, P491, DOI 10.1006/excr.2000.4829; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	24	107	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6516	6523		10.1038/sj.onc.1204817	http://dx.doi.org/10.1038/sj.onc.1204817			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641775				2022-12-28	WOS:000171404200003
J	Ljungman, M; O'Hagan, HM; Paulsen, MT				Ljungman, M; O'Hagan, HM; Paulsen, MT			Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation	ONCOGENE			English	Article						RNA polymerase II; inhibitors; DNA damage; UV light; Xeroderma pigmentosum; Cockayne's syndrome	RNA-POLYMERASE-II; DAMAGE-INDUCED PHOSPHORYLATION; CARBOXYL-TERMINAL DOMAIN; LIGHT-INDUCED APOPTOSIS; RING-FINGER DOMAIN; DNA-DAMAGE; ULTRAVIOLET-RADIATION; NUCLEAR EXPORT; UV-RADIATION; CELL-CYCLE	Blockage of transcription has been shown to induce the tumor suppressor p53 in human cells. We here show that RNA synthesis inhibitors blocking the phosphorylation of the carboxyl terminal domain (CTD) of RNA polymerase II, such as DRB and H7, induced rapid nuclear accumulation of p53 proteins that were not phosphorylated at ser15 or acetylated at lys382. In contrast, agents that inhibit the elongation phase of transcription, such as UV light, camptothecin or actinomycin D, induced the accumulation of nuclear p53 proteins that were modified at both of these sites. Furthermore, using a panel of DNA repair-deficient cells we show that persistent DNA lesions in the transcribed strand of active genes are responsible for the induction of the ser15 and lys382 modifications following UV-irradiation. We conclude that inhibition of transcription is sufficient for the accumulation of p53 in the nucleus regardless of whether the ser15 site of p53 is phosphorylated or not. Importantly, blockage of the elongation phase of transcription triggers a distinct signaling pathway leading to p53 modifications on ser15 and lys382. We propose that the elongating RNA polymerase complex may act as a sensor of DNA damage and as an integrator of cellular stress signals.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ljungman, M (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, 4306 CCGC,150 E Med Ctr Dr, Ann Arbor, MI 48109 USA.			O'Hagan, Heather/0000-0001-9750-5088	NCI NIH HHS [CA 82376-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; FISCELLA M, 1993, ONCOGENE, V8, P1519; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Groulx I, 2000, J BIOL CHEM, V275, P8991, DOI 10.1074/jbc.275.12.8991; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hirose Y, 2000, GENE DEV, V14, P1415; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Ljungman M, 1996, CARCINOGENESIS, V17, P31, DOI 10.1093/carcin/17.1.31; Lu X, 1996, ONCOGENE, V13, P413; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 2001, MUTAT RES-DNA REPAIR, V485, P93, DOI 10.1016/S0921-8777(00)00064-1; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Poele RHT, 1999, ONCOGENE, V18, P5765, DOI 10.1038/sj.onc.1202961; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883	56	54	54	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5964	5971		10.1038/sj.onc.1204734	http://dx.doi.org/10.1038/sj.onc.1204734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593403				2022-12-28	WOS:000171056300003
J	Riley, D; Carragher, N; Frame, MC; Wyke, JA				Riley, D; Carragher, N; Frame, MC; Wyke, JA			The mechanism of cell cycle regulation by v-Src	ONCOGENE			English	Article						v-Src; ERK; P13-K; p27; cell cycle	PROTEIN-KINASE KINASE; D-DEPENDENT KINASES; CDK INHIBITORS; EXPRESSION; P21; PHOSPHORYLATION; ONCOPROTEIN; BINDING; GENE; MITOGENESIS	The tyrosine kinase oncoprotein v-Src can overcome the requirements for serum growth factors and anchorage which restrain normal cell growth. Here we investigated the biochemical mechanisms whereby v-Src induces quiescent cells to enter S phase in the absence of serum mitogens. Activating a temperature sensitive v-Src in quiescent cells sequentially induced cyclins D1, E and A and also down regulated p27. We addressed whether p27 down regulation was required to activate cyclin D1/ CDK4/6 or cyclin E/CDK2 by engineering cells with inducible p27. Both S phase entry and activation of cyclin/CDKs were inhibited by over expression of p27. Using cells engineered with inducible p16 we showed that Cyclin D/CDK4/6 activity was required for v-Src to increase expression of cyclin A but not cyclin E. To determine which downstream kinases mediated these effects of v-Src we added pharmacological inhibitors of phosphatidylinositol 3-kinase (PI3-K), LY294002 or mitogen activated protein kinase kinase (MEK), U0126. PI3-K was required for v-Src to activate MEK and MEK was required for v-Src to increase expression of cyclins DI and E. However, the MEK inhibitor prevented p27 protein down regulation whereas the PI3K inhibitor did not. This was because reduced PI3-K activity lead to proteolytic degradation of p27.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Wyke, JA (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Carragher, Neil/0000-0001-5541-9747				Adachi M, 1997, BLOOD, V90, P126; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Botz J, 1996, MOL CELL BIOL, V16, P3401; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fotedar R, 1996, ONCOGENE, V12, P2155; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; HALL M, 1995, ONCOGENE, V11, P1581; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Lee KM, 1999, CURR BIOL, V9, P441, DOI 10.1016/S0960-9822(99)80194-8; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; Nishiwaki E, 2000, MOL CELL BIOL, V20, P7726, DOI 10.1128/MCB.20.20.7726-7734.2000; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; WYKE AW, 1995, CELL GROWTH DIFFER, V6, P1225	47	41	45	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5941	5950		10.1038/sj.onc.1204826	http://dx.doi.org/10.1038/sj.onc.1204826			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593401				2022-12-28	WOS:000171056300001
J	Brandt, R; Wong, AML; Hynes, NE				Brandt, R; Wong, AML; Hynes, NE			Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents	ONCOGENE			English	Article						HC11 mammary cells; cleared fat pad; ErbB2; NeuT; PKI166; Taxol (R)	TYROSINE KINASE INHIBITOR; METASTATIC BREAST-CANCER; GROWTH-FACTOR RECEPTOR; BETA-CASEIN GENE; IN-VIVO MODEL; TRANSGENIC MICE; NEU ONCOGENE; EPITHELIAL-CELLS; EXPRESSION; INDUCTION	The ErbB2 receptor tyrosine kinase (RTK) has been intensely pursued as a cancer therapy target due to its association with breast cancer. In this study we used the HC11 mammary epithelial cell line to develop an orthotopic, ErbB2-driven tumor model for testing efficacy of anti-cancer compounds. HC11 cells were infected with a retrovirus encoding oncogenic NeuT, the rat homolog of ErbB2. Drug-selected populations were introduced into mammary fat pads of Balb/c syngeneic mice cleared of host tissue. The majority of glands injected with HC11-NeuT cells developed mammary tumors which appeared after a 3-4 week latency period and grew rapidly. HC11 cells infected with the control retrovirus showed no tumor growth after injection. Tumor-bearing mice were used to compare the in vivo efficacy of two anti-cancer agents: PKI166, a kinase inhibitor selective for EGF receptor and ErbB2, and Taxol(R), a microtubule assembly blocker. PKI166 inhibited NeuT-induced mammary tumor growth in a dose-dependent manner and at a dose below the maximum tolerated dose (MTD) was significantly more inhibitory than Taxol(R) at its MTD (57% vs 25% tumor regression). Importantly, there was a dose-dependent decrease in the phosphotyrosine content of NeuT isolated from PKI166-treated, tumor-bearing mice, providing a mechanistic link between kinase inhibition and its antitumor activity. Thus, implantation of genetically manipulated HC11 cells into mammary glands appears to be an excellent model for studying effects of anti-cancer agents in an orthotopic site.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Novartis Pharma AG, Oncol Dept In Vivo Pharmacol, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Hynes, NE (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66,R-1066-206, CH-4058 Basel, Switzerland.							BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BERGER MS, 1988, CANCER RES, V48, P1238; BRADBURY JM, 1993, ONCOGENE, V8, P1551; Bruns CJ, 2000, CANCER RES, V60, P2926; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; CHAMMAS R, 1994, J CELL SCI, V107, P1031; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cuny M, 2000, CANCER RES, V60, P1077; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DEOME KB, 1959, CANCER RES, V19, P515; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; GIANNI L, 1997, SEM ONCOLOGY, V24; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; MERLO GR, 1994, ONCOGENE, V9, P443; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rees CN, 1996, EUR J CANCER, V32A, P2354, DOI 10.1016/S0959-8049(96)00348-6; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; SEIDMAN AD, 1995, J CLIN ONCOL, V13, P2575, DOI 10.1200/JCO.1995.13.10.2575; Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075	37	34	34	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5459	5465		10.1038/sj.onc.1204709	http://dx.doi.org/10.1038/sj.onc.1204709			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571643				2022-12-28	WOS:000170781100006
J	Yu, WP; Pallen, CJ; Tay, A; Jirik, FR; Brenner, S; Tan, YH; Venkatesh, B				Yu, WP; Pallen, CJ; Tay, A; Jirik, FR; Brenner, S; Tan, YH; Venkatesh, B			Conserved synteny between the Fugu and human PTEN locus and the evolutionary conservation of vertebrate PTEN function	ONCOGENE			English	Article						PTEN; phosphatase; tumor suppressor; Fugu	INOSITOL POLYPHOSPHATE PHOSPHATASE; RILEY-RUVALCABA-SYNDROME; TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; MOLECULAR-CLONING; FAMILY; BREAST; 10Q23; IDENTIFICATION; PTEN/MMAC1	Mutations of PTEN, which encodes a protein-tyrosine and lipid phosphatase, are prevalent in a variety of human cancers. The human genome 'draft' sequence still lacks organization and much of the PTEN and adjacent loci remain undefined. The pufferfish, Fugu rubripes, by virtue of having a compact genome represents an excellent template for rapid vertebrate gene discovery. Sequencing of 56 kb from the Fugu pten (fpten) locus identified four complete genes and one partial gene homologous to human genes. Genes neighboring fpten include a PAPS synthase (fpapss2) differentially expressed between non-metastatic/metastatic human carcinoma cell lines, an inositol phosphatase (fminpp1) and an omega class glutathione-S-transferase (fgsto). We have determined the order of human BAC clones at the hPTEN locus and that the locus contains hPAPSS2 and hMINPP1 genes oriented as are their Fugu orthologs. Although the human genes span 500 kb, the Fugu genes lie within only 22 kb due to the compressed intronic and intergenic regions that typify this genome. Interestingly, and providing striking evidence of regulatory element conservation between widely divergent vertebrate species, the compact 2.1 kb fpten promoter is active in human cells. Also, like hPTEN, fpten has a growth and tumor suppressor activity in human glioblastoma cells, demonstrating conservation of protein function.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of British Columbia	Pallen, CJ (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbcp@imcb.nus.edu.sg		Venkatesh, Byrappa/0000-0003-3620-0277; Pallen, Catherine/0000-0002-3576-5295				AUSABEL FM, 1995, CURRENT PROTOCOLS MO, V2; Bostrom J, 1998, CANCER RES, V58, P29; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chi HB, 2000, MOL CELL BIOL, V20, P6496, DOI 10.1128/MCB.20.17.6496-6507.2000; Chi HB, 1999, GENOMICS, V56, P324, DOI 10.1006/geno.1998.5736; Craxton A, 1997, BIOCHEM J, V328, P75, DOI 10.1042/bj3280075; Dahia PM, 2000, J MED GENET, V37, P715, DOI 10.1136/jmg.37.9.715; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Feilotter HE, 1999, BRIT J CANCER, V79, P718, DOI 10.1038/sj.bjc.6690115; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Franzon VL, 1999, INT J BIOCHEM CELL B, V31, P613, DOI 10.1016/S1357-2725(98)00155-1; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Huang H, 1999, DEVELOPMENT, V126, P5365; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; Kurima K, 1999, J BIOL CHEM, V274, P33306, DOI 10.1074/jbc.274.47.33306; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; MUTTER GL, 2000, JNCI-J NATL CANCER I, V92, P861; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Reynolds SD, 1996, EXP CELL RES, V226, P197, DOI 10.1006/excr.1996.0219; Romano PR, 1998, J CELL SCI, V111, P803; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Simpkins SB, 1998, GYNECOL ONCOL, V71, P391, DOI 10.1006/gyno.1998.5208; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Venkatesh B, 2000, FEBS LETT, V476, P3, DOI 10.1016/S0014-5793(00)01659-8; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	46	15	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5554	5561		10.1038/sj.onc.1204679	http://dx.doi.org/10.1038/sj.onc.1204679			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571655				2022-12-28	WOS:000170781100018
J	Mehta, PB; Robson, CN; Neal, DE; Leung, HY				Mehta, PB; Robson, CN; Neal, DE; Leung, HY			Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells	ONCOGENE			English	Article						fibroblast growth factor; mitogen-activated protein kinase; Elk-1; MEF2A; actin; prostate	SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; KINASE PATHWAYS; PROTEIN-KINASES; POINT MUTATION; FGF RECEPTORS; EXPRESSION; TRANSCRIPTION; CANCER; PROLIFERATION	FGF7/Keratinocyte growth factor (KGF) regulates the differentiation and development of the prostate epithelium, while over-expression of FGF8 and FGF1 are implicated in carcinogenesis of the prostate. We tested the hypothesis that different members of the FGF family function through different signalling molecules. In prostate DU145 cells, both FGF1 and FGF2 activated ERK1/2 potently and p38 moderately. KGF was however most efficient in inducing p38 activities but had no effect on ERK1/2 function. JNK and STAT activities were not induced by FGFs in prostate cells. fn vitro expression of the transcription factors Elk-1 and MEF2A (substrates for ERK1/2 and p38, respectively) for functional quantification, confirmed the pattern of FGF-induced MAPK activations in COS-7 cells. Furthermore, KGF was more efficient than FGF1 and FGF2 in inducing actin stress fibres, and the specific p38 inhibitor SB202190 completely abolished this in a dose-dependent manner. The MEK1/2 inhibitor, U0126, had no effect on FGF-induced stress fibre formation. This study demonstrates the selective activation of MAPK family members by FGFs resulting in activation of transcription factors and stress fibre formation. As multiple FGFs are overexpressed in human prostate cancer, characterization of the distinct signalling pathway by FGFs may reveal new specific targets for therapy.	Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Leung, Hing Y./0000-0002-3933-3975; Neal, David/0000-0002-6033-5086				BRUNK U, 1976, EXP CELL RES, V103, P295, DOI 10.1016/0014-4827(76)90266-4; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; Carstens RP, 1997, J AM SOC NEPHROL, V8, pA1849; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Dieckgraefe BK, 1997, BIOCHEM BIOPH RES CO, V233, P389, DOI 10.1006/bbrc.1997.6469; Dorkin TJ, 1999, J PATHOL, V189, P564, DOI 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Feng SJ, 1997, CANCER RES, V57, P5369; Foster BA, 1999, PROSTATE CANCER P D, V2, P76; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Landgren E, 1998, ONCOGENE, V17, P283, DOI 10.1038/sj.onc.1201936; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Ling Y, 1997, EMBO J, V16, P2431, DOI 10.1093/emboj/16.9.2431; Matsubara A, 1998, CANCER RES, V58, P1509; McGarvey TW, 1995, EXP MOL PATHOL, V63, P52, DOI 10.1006/exmp.1995.1030; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Velmuri GS, 1996, BIOCHEM J, V314, P805, DOI 10.1042/bj3140805; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	36	37	37	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5359	5365		10.1038/sj.onc.1204688	http://dx.doi.org/10.1038/sj.onc.1204688			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536048				2022-12-28	WOS:000170575500011
J	Janicke, RU; Engels, IH; Dunkern, T; Kaina, B; Schulze-Osthoff, K; Porter, AG				Janicke, RU; Engels, IH; Dunkern, T; Kaina, B; Schulze-Osthoff, K; Porter, AG			Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells	ONCOGENE			English	Article						apoptosis; intrinsic death pathway; DNA; damage; cell cycle arrest	CYTOCHROME-C RELEASE; ETOPOSIDE-INDUCED APOPTOSIS; HUMAN LYMPHOMA-CELLS; CASPASE ACTIVATION; TUMOR-CELLS; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; THYMOCYTE APOPTOSIS; DEPENDENT APOPTOSIS; SIGNALING COMPLEX	There is considerable evidence that ionizing radiation (IR) and chemotherapeutic drugs mediate apoptosis through the intrinsic death pathway via the release of mitochondrial cytochrome c and activation of caspases-9 and -3. Here we show that MCF-7 cells that lack caspase-3 undergo a caspase-dependent apoptotic cell death in the absence of DNA fragmentation and x-fodrin cleavage following treatment with etoposide or doxorubicin, but not after exposure to IR. Re-expression of caspase-3 restored DNA fragmentation and a-fodrin cleavage following drug treatment, but it did not alter the radiation-resistant phenotype of these cells. In contrast to the anticancer drugs, IR failed to induce the intrinsic death pathway in MCF-7/casp-3 cells, an event readily observed in IR-induced apoptosis of HeLa cells. Although IR-induced DNA double-strand breaks were repaired with similar efficiencies in all cell lines, cell cycle analyses revealed a persistent G2/M arrest in the two MCF-7 cell lines, but not in HeLa cells. Together, our data demonstrate that caspase-3 is required for DNA fragmentation and a-fodrin cleavage in drug-induced apoptosis and that the intrinsic death pathway is fully functional in MCF-7 cells. Furthermore, they show that the radiation-resistant phenotype of MCF-7 cells is not due to the lack of caspase-3, but is caused by the failure of IR to activate the intrinsic death pathway. We propose (1) different signaling pathways are induced by anticancer drugs and IR, and (2) IR-induced G2/M arrest prevents the generation of an apoptotic signal required for the activation of the intrinsic death pathway.	Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany; Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Munster; Johannes Gutenberg University of Mainz; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Janicke, RU (corresponding author), Univ Munster, Dept Immunol & Cell Biol, Rontgenstr 21, D-48149 Munster, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fuchs EJ, 1997, CANCER RES, V57, P2550; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Heenan M, 1996, CYTOTECHNOLOGY, V19, P237, DOI 10.1007/BF00744218; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; LEHNERT S, 1989, RADIAT RES, V118, P568, DOI 10.2307/3577414; Levenson AS, 1997, CANCER RES, V57, P3071; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OSHITA F, 1992, J CANCER RES CLIN, V119, P28, DOI 10.1007/BF01209484; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Schmitt CA, 1999, J PATHOL, V187, P127; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Van de Craen M, 1998, CELL DEATH DIFFER, V5, P838, DOI 10.1038/sj.cdd.4400444; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yu YJ, 1998, CANCER RES, V58, P4277; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	64	69	72	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5043	5053		10.1038/sj.onc.1204659	http://dx.doi.org/10.1038/sj.onc.1204659			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526489				2022-12-28	WOS:000170439800014
J	Celiker, MY; Wang, M; Atsidaftos, E; Liu, X; Liu, YE; Jiang, Y; Valderrama, E; Goldberg, ID; Shi, YE				Celiker, MY; Wang, M; Atsidaftos, E; Liu, X; Liu, YE; Jiang, Y; Valderrama, E; Goldberg, ID; Shi, YE			Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA	ONCOGENE			English	Article						TIMP-4; Wilms' tumor; gene therapy; growth inhibition; tumorigenesis	IN-VIVO; PROGELATINASE-A; GENE-TRANSFER; PROMOTING ACTIVITY; STROMAL CELLS; EXPRESSION; CANCER; METASTASIS; OVEREXPRESSION; SUPPRESSION	Extracellular matrix (ECM) degrading matrix metalloproteinases (MMPs) lead to ECM turnover, a key event in cancer growth and progression. The tissue inhibitors of matrix metalloproteinases (TIMPs) Limit the activity of MMPs, which suggests their use for cancer gene therapy. Here we report that systemic administration of naked TIMP-4 DNA significantly inhibited Wilms' tumor growth in nude mice. TIMP-4, whose expression was lost in Wilms' tumor, inhibited the growth of G401 Wilms' tumor tells at a concentration lower than those required for MMP inhibition. This inhibition was associated with internalization of exogenous recombinant TIMP-4, Electroporation-mediated intramuscular injection of TIMP-4 expression plasmid resulted in sustained plasma TIMP-4 levels and significant tumor suppression. Our data demonstrate a tumor suppressive effect of TIMP-4 against Wilms' tumor and the potential utility of intramuscular delivery of TIMP gene for treatment of kidney derived cancers.	Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Schneider Childrens Hosp, Long Isl Jewish Med Ctr, Div Pediat Hematol Oncol, New Hyde Park, NY 11040 USA; Long Isl Jewish Med Ctr, Dept Med, New Hyde Park, NY 11040 USA; Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Long Isl Jewish Med Ctr, Dept Pathol, New Hyde Park, NY 11040 USA	Northwell Health; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Northwell Health; Northwell Health; Northwell Health	Shi, YE (corresponding author), Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, New Hyde Park, NY 11040 USA.				NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER; NCI NIH HHS [CA68064-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; BACCALAO R, 1995, HDB BIOL CONFOCAL MI, P311; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FRANCINI G, 1993, CANCER EPIDEM BIOMAR, V2, P125; GARVIN AJ, 1993, AM J PATHOL, V142, P375; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Heppner KJ, 1996, AM J PATHOL, V149, P273; Imren S, 1996, CANCER RES, V56, P2891; Jiang YF, 2001, CANCER RES, V61, P2365; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; Liu YLE, 1997, J BIOL CHEM, V272, P20479, DOI 10.1074/jbc.272.33.20479; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; Nemeth JA, 1996, EXP CELL RES, V224, P110, DOI 10.1006/excr.1996.0117; PYKE C, 1993, AM J PATHOL, V142, P359; Ritter LM, 1999, BIOCHEM BIOPH RES CO, V257, P494, DOI 10.1006/bbrc.1999.0408; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	33	51	60	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4337	4343		10.1038/sj.onc.1204508	http://dx.doi.org/10.1038/sj.onc.1204508			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466614				2022-12-28	WOS:000169912600007
J	Obexer, P; Certa, U; Kofler, R; Helmberg, A				Obexer, P; Certa, U; Kofler, R; Helmberg, A			Expression profiling of glucocorticoid-treated T-ALL cell lines: rapid repression of multiple genes involved in RNA-, protein- and nucleotide synthesis	ONCOGENE			English	Article						chemotherapy; gene chip; glucocorticoid; leukemia; pathophysiology	SPINAL MUSCULAR-ATROPHY; RECEPTOR MESSENGER-RNA; KAPPA-B ACTIVITY; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; FK506-BINDING IMMUNOPHILIN; REGULATED APOPTOSIS; DOWN-REGULATION; COMPLETE CDNA; DNA-BINDING	To arrive at a better understanding of the effects of the glucocorticoid component of chemotherapy protocols on lymphocytic leukemia cells, we analysed early responses of T-lymphocytic leukemia cell lines Jurkat and CEM-C7, both of which undergo apoptosis in response to dexamethasone, via gene chips. Among genes identified as repressed, a notable cluster seemed to be of importance for the processes of transcription, mRNA splicing and protein synthesis. Consequently, we assessed time-resolved uptake of uridine and methionine to monitor RNA and protein synthesis, along with parameters quantifying apoptosis, Repression of uptake to about 65% of that in untreated cells preceded the first sign of apoptosis by several hours in both cell lines, In addition to this general repression of RNA and protein synthesis, several genes were found to be regulated that may contribute to synergistic action of glucocorticoids with other components of frequently used chemotherapy protocols such as antimetabolites, methotrexate and alkylating agents.	Univ Innsbruck, Sch Med, Inst Pathophysiol, A-6020 Innsbruck, Austria; F Hoffmann La Roche & Co Ltd, Roche Genet, CH-4070 Basel, Switzerland	University of Innsbruck; Roche Holding	Helmberg, A (corresponding author), Univ Innsbruck, Sch Med, Inst Pathophysiol, A-6020 Innsbruck, Austria.	arno.helmberg@uibk.ac.at						ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Altmeyer A, 1997, IMMUNITY, V7, P667, DOI 10.1016/S1074-7613(00)80387-8; ANTAKLY T, 1989, CANCER RES, V49, pS2230; ASHRAF J, 1991, J STEROID BIOCHEM, V38, P561, DOI 10.1016/0960-0760(91)90313-T; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baxter J D, 2000, Adv Intern Med, V45, P317; BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Chabncr BA, 1996, PHARMACOL BASIS THER, P1233; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; Chen QF, 1998, GENOMICS, V48, P121, DOI 10.1006/geno.1997.5141; CRUZEN ME, 1994, DNA SEQUENCE, V4, P243, DOI 10.3109/10425179409020847; DAYAN A, 1995, GENE, V165, P307, DOI 10.1016/0378-1119(95)00321-V; DENTON RR, 1993, ENDOCRINOLOGY, V133, P248, DOI 10.1210/en.133.1.248; EISEN LP, 1988, J BIOL CHEM, V263, P12044; ELISEI R, 1993, J ENDOCRINOL INVEST, V16, P533, DOI 10.1007/BF03348900; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FOLEY GE, 1967, BIOCHEM PHARMACOL, V16, P659, DOI 10.1016/0006-2952(67)90078-0; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Godowski P.J., 1989, UCLA S MOL CELLULAR, P197; GOMI M, 1990, CANCER RES, V50, P1873; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HELMBERG A, 1990, J IMMUNOL, V145, P4332; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HONORE B, 1995, J BIOL CHEM, V270, P28780; HORTSCH M, 1988, NUCLEIC ACIDS RES, V16, P361, DOI 10.1093/nar/16.1.361; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; HUANG SH, 1994, DNA CELL BIOL, V13, P461, DOI 10.1089/dna.1994.13.461; Iwahana H, 1996, BIOCHEM BIOPH RES CO, V219, P249, DOI 10.1006/bbrc.1996.0213; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Lipsitt DR, 1999, GEN HOSP PSYCHIAT, V21, P1; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MITA K, 1995, GENE, V159, P285, DOI 10.1016/0378-1119(95)00081-G; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Ramdas J, 1999, CANCER RES, V59, P1378; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 1998, MOL CELL ENDOCRINOL, V146, P1, DOI 10.1016/S0303-7207(98)00208-1; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHIMMER BP, 1996, PHARMACOL BASIS THER, P1465; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; SIBLEY CH, 1974, CELL, V2, P213, DOI 10.1016/0092-8674(74)90013-0; SILLEKENS PTG, 1988, NUCLEIC ACIDS RES, V16, P8307, DOI 10.1093/nar/16.17.8307; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; THULASI R, 1993, J BIOL CHEM, V268, P18306; Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; Yoon JB, 1996, MOL CELL BIOL, V16, P1; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	74	47	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4324	4336		10.1038/sj.onc.1204573	http://dx.doi.org/10.1038/sj.onc.1204573			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466613				2022-12-28	WOS:000169912600006
J	Krueger, JS; Keshamouni, VG; Atanaskova, N; Reddy, KB				Krueger, JS; Keshamouni, VG; Atanaskova, N; Reddy, KB			Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion	ONCOGENE			English	Article						MAPK; MEK; cell motility; breast cancer; cell signaling	HUMAN BREAST-CANCER; EPIDERMAL GROWTH-FACTOR; FACTOR SCATTER FACTOR; TYROSINE KINASE; EGF RECEPTOR; SIGNAL-TRANSDUCTION; MIGRATION; EXPRESSION; LINES; RAS	We have shown that ER-negative and invasive human breast cancer cell lines MDA-MB-468 and MDA-MB-231 have constitutively higher mitogen activated protein kinase (ERK1&2/MAPK) when compared to the ER-positive and non-invasive MCF-7 human breast cancer cells. In MCF-7 cells, TGF alpha stimulation induced only transient MAPK activation, leading to a transient increase in cell migration. However, MDA 231 and MDA 468 cells, TCF alpha stimulation induced sustained MAPK activation, which correlated with enhanced cell motility and in vitro invasion, Serum stimulation activates ERK/MAPK activity persistently ire both ER-positive and ER-negative breast cancer cells, leading to enhanced and sustained cell migration. Inhibition of MAPK activation by anti-sense MEK expression in MDA-MB-468 cells significantly inhibits cell migration and in vitro invasion. In contrast, MCF-7 cells expressing constitutively activated MEK show a significant increase in MAPK activity and cell migration, but this failed to enhance in vitro invasion. The kinetic profiles of MAPK activation and inhibition show a relationship between the duration and magnitude of MAPK activation and cell migration in both ER-positive and ER-negative human breast cancer cells. These studies show that cell motility is modulated by the magnitude and the duration of MAPK activation; but increased activation of MAPK may not be sufficient to allow in vitro invasion in noninvasive MCF-7 breast cancer cells.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Reddy, KB (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.			Keshamouni, Venkateshwar/0000-0003-1947-791X	NCI NIH HHS [CA 64248, CA 83964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083964, R29CA064248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Fan W H, 1998, Cell Res, V8, P63; FRIEDL P, 1995, CANCER RES, V55, P4557; Gilhooly EM, 1999, INT J ONCOL, V15, P267; Gopalakrishna R, 1999, CANCER LETT, V136, P143, DOI 10.1016/S0304-3835(98)00315-2; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSKE M, 1994, INT REV CYTOL, V155, P49, DOI 10.1016/S0074-7696(08)62096-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MISHRA S, 1993, BIOCHEM BIOPH RES CO, V191, P1066, DOI 10.1006/bbrc.1993.1325; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Prasad KSS, 1997, J BIOL CHEM, V272, P11457; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; Reddy KB, 1999, INT J ONCOL, V15, P301; Rigot V, 1998, J CELL SCI, V111, P3119; SATO C, 1995, J INVEST DERMATOL, V104, P958, DOI 10.1111/1523-1747.ep12606221; SEGER R, 1995, J BIOL CHEM, V270, P28325; Shao ZM, 1998, ANTICANCER RES, V18, P1435; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Slack JK, 1999, J BIOL CHEM, V274, P27177, DOI 10.1074/jbc.274.38.27177; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Xie H, 1998, J CELL SCI, V111, P615; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	41	145	161	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4209	4218		10.1038/sj.onc.1204541	http://dx.doi.org/10.1038/sj.onc.1204541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464287				2022-12-28	WOS:000169857200011
